assays_assay_id,assays_assay_organism,assays_confidence_score,assays_assay_type,assays_assay_cell_type,assays_src_id,assays_description,assays_tid,assays_assay_tax_id,assays_assay_subcellular_fraction,assays_variant_id,assays_chembl_id,assays_doc_id,assays_tissue_id,assays_cell_id,assays_src_assay_id,assays_assay_tissue,assays_relationship_type,assays_curated_by,assays_bao_format
1,,8,B,,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,12052,,,,CHEMBL615117,11087,,,,,H,Autocuration,BAO_0000019
2,,0,F,,1,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,22226,,,,CHEMBL615118,684,,,,,U,Autocuration,BAO_0000219
3,,0,B,,1,,22226,,,,CHEMBL615119,15453,,,,,U,Autocuration,BAO_0000019
4,Bos taurus,4,B,,1,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,104729,9913.0,,,CHEMBL615120,17841,,,,,H,Autocuration,BAO_0000249
5,Homo sapiens,1,F,143B,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,9606.0,,,CHEMBL615121,17430,,163.0,,,N,Intermediate,BAO_0000219
6,Homo sapiens,1,F,143B,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,9606.0,,,CHEMBL615122,17430,,163.0,,,N,Intermediate,BAO_0000219
7,Mus musculus,1,F,143B,1,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,80001,10090.0,,,CHEMBL615123,13799,,163.0,,,N,Intermediate,BAO_0000219
8,Homo sapiens,1,F,143B,1,In vitro cell cytotoxicity was determined against 143B cell line,80001,9606.0,,,CHEMBL615124,17774,,163.0,,,N,Expert,BAO_0000219
9,Homo sapiens,1,F,143B,1,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,80001,9606.0,,,CHEMBL615125,3801,,163.0,,,N,Intermediate,BAO_0000219
10,Homo sapiens,1,F,143B,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,9606.0,,,CHEMBL615126,17430,,163.0,,,N,Intermediate,BAO_0000219
11,Homo sapiens,1,F,143B,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,9606.0,,,CHEMBL615127,17430,,163.0,,,N,Intermediate,BAO_0000219
12,Homo sapiens,1,F,143B,1,In vitro cell cytotoxicity was determined against 143B-LTK cell line,80001,9606.0,,,CHEMBL615128,17774,,163.0,,,N,Expert,BAO_0000219
13,Staphylococcus aureus,1,F,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,1280.0,,,CHEMBL857900,11324,,,,,N,Intermediate,BAO_0000218
14,Staphylococcus aureus,1,F,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,1280.0,,,CHEMBL615129,11324,,,,,N,Intermediate,BAO_0000218
15,Staphylococcus aureus,1,F,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,1280.0,,,CHEMBL615130,11324,,,,,N,Intermediate,BAO_0000218
16,Staphylococcus aureus,1,F,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,1280.0,,,CHEMBL615131,11324,,,,,N,Intermediate,BAO_0000218
17,Rattus norvegicus,9,A,,1,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,100122,10116.0,,,CHEMBL884521,11347,,,,,D,Expert,BAO_0000357
18,,8,B,,1,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,,CHEMBL615132,16474,,,,,H,Autocuration,BAO_0000357
19,,8,B,,1,Inhibition of partially purified 15-lipoxygenase from human leukocytes,12054,,,,CHEMBL615133,10091,,,,,H,Autocuration,BAO_0000019
20,,8,B,,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,,CHEMBL615134,16474,,,,,H,Autocuration,BAO_0000357
21,,8,B,,1,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,,CHEMBL615135,16474,,,,,H,Autocuration,BAO_0000357
22,,8,B,,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,,CHEMBL615136,16474,,,,,H,Autocuration,BAO_0000357
23,,8,B,,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,,CHEMBL615137,16474,,,,,H,Autocuration,BAO_0000357
24,,8,B,,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,,CHEMBL615138,16474,,,,,H,Autocuration,BAO_0000357
25,,0,B,,1,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",22226,,,,CHEMBL836324,14352,,,,,U,Autocuration,BAO_0000219
26,Oryctolagus cuniculus,8,B,,1,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,12054,9986.0,,,CHEMBL615139,5646,,,,,H,Autocuration,BAO_0000357
27,Oryctolagus cuniculus,8,B,,1,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),12054,9986.0,,,CHEMBL615140,5646,,,,,H,Autocuration,BAO_0000357
28,,8,B,,1,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,12426,,,,CHEMBL615141,10997,,,,,H,Autocuration,BAO_0000219
29,soya bean,8,B,,1,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,12054,3847.0,,,CHEMBL615142,6309,,,,,H,Autocuration,BAO_0000357
30,Glycine max,8,B,,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated,12054,3847.0,,,CHEMBL615143,167,,,,,H,Autocuration,BAO_0000357
31,Glycine max,8,B,,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,12054,3847.0,,,CHEMBL615144,167,,,,,H,Autocuration,BAO_0000357
32,Glycine max,8,B,,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,12054,3847.0,,,CHEMBL872867,11087,,,,,H,Autocuration,BAO_0000357
33,Glycine max,8,B,,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,12054,3847.0,,,CHEMBL615145,11087,,,,,H,Autocuration,BAO_0000357
34,Glycine max,8,B,,1,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,3847.0,,,CHEMBL615146,13622,,,,,H,Autocuration,BAO_0000357
35,Glycine max,8,B,,1,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,3847.0,,,CHEMBL615147,13622,,,,,H,Autocuration,BAO_0000357
36,Rattus norvegicus,0,A,,1,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,22226,10116.0,,,CHEMBL615148,11347,,,,,U,Autocuration,BAO_0000019
37,Escherichia coli,0,B,,1,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,22226,562.0,,,CHEMBL615149,5926,,,,,U,Autocuration,BAO_0000019
38,,0,B,,1,Dissociation constant with dimeric 16S rRNA RNA construct B,22226,,,,CHEMBL615150,4567,,,,,U,Autocuration,BAO_0000019
39,,3,B,,1,Dissociation constant towards 16S rRNA construct A,22222,,,,CHEMBL615151,3782,,,,,M,Intermediate,BAO_0000225
40,,3,B,,1,Dissociation constant towards 16S rRNA construct B,22222,,,,CHEMBL615152,3782,,,,,M,Intermediate,BAO_0000225
41,Escherichia coli,3,B,,1,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,100263,562.0,,,CHEMBL615153,4466,,,,,M,Expert,BAO_0000225
42,Escherichia coli,3,B,,1,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,100263,562.0,,,CHEMBL615154,6592,,,,,M,Expert,BAO_0000225
43,,8,B,,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,,CHEMBL615155,898,,,,,H,Autocuration,BAO_0000019
44,,8,B,,1,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,,CHEMBL615156,898,,,,,H,Autocuration,BAO_0000019
45,Homo sapiens,8,B,,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,9606.0,,,CHEMBL615157,13163,,,,,H,Autocuration,BAO_0000019
46,Homo sapiens,8,B,,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,9606.0,,,CHEMBL615158,13163,,,,,H,Autocuration,BAO_0000019
47,Rattus norvegicus,9,B,,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,10116.0,,,CHEMBL615159,10691,,,,,D,Expert,BAO_0000019
48,Rattus norvegicus,9,B,,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,10116.0,,,CHEMBL615172,10691,,,,,D,Expert,BAO_0000019
49,Rattus norvegicus,9,B,,1,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,10116.0,,,CHEMBL615173,10691,,,,,D,Expert,BAO_0000019
50,Rattus norvegicus,9,B,,1,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,10116.0,,,CHEMBL615174,10691,,,,,D,Expert,BAO_0000019
51,,8,B,,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,,CHEMBL884518,898,,,,,H,Autocuration,BAO_0000019
52,,8,B,,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),11512,,,,CHEMBL615175,912,,,,,H,Autocuration,BAO_0000357
53,,8,B,,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,11512,,,,CHEMBL615176,912,,,,,H,Autocuration,BAO_0000357
54,,8,B,,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,11512,,,,CHEMBL615177,912,,,,,H,Autocuration,BAO_0000357
55,Rattus norvegicus,5,B,,1,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,104740,10116.0,Membranes,,CHEMBL615178,15103,,,,,D,Autocuration,BAO_0000249
56,Homo sapiens,1,F,1A9,1,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,80002,9606.0,,,CHEMBL615179,5116,,506.0,,,N,Intermediate,BAO_0000219
57,Rattus norvegicus,7,F,Oocytes,1,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,104835,10116.0,,,CHEMBL615180,14578,,,,,D,Autocuration,BAO_0000219
58,Rattus norvegicus,7,F,Oocytes,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,104821,10116.0,,,CHEMBL615181,14578,,,,,D,Autocuration,BAO_0000219
59,Rattus norvegicus,7,F,Oocytes,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,104848,10116.0,,,CHEMBL615182,14578,,,,,D,Autocuration,BAO_0000219
60,Homo sapiens,1,F,1A9,1,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,80002,9606.0,,,CHEMBL615183,4787,,506.0,,,N,Expert,BAO_0000219
61,Homo sapiens,1,F,1A9,1,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,80002,9606.0,,,CHEMBL615184,4787,,506.0,,,N,Intermediate,BAO_0000219
62,Homo sapiens,1,F,1A9,1,Cytotoxic activity against human ovarian cancer (1A9) cell line,80002,9606.0,,,CHEMBL615185,3547,,506.0,,,N,Intermediate,BAO_0000219
63,Homo sapiens,1,F,1A9,1,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,80002,9606.0,,,CHEMBL615186,3547,,506.0,,,N,Intermediate,BAO_0000219
64,Homo sapiens,1,F,1A9,1,Effective dose of compound against replication of 1A9 cell line was evaluated,80002,9606.0,,,CHEMBL615187,6726,,506.0,,,N,Intermediate,BAO_0000219
65,Homo sapiens,1,F,1A9,1,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,80002,9606.0,,,CHEMBL885343,3455,,506.0,,,N,Expert,BAO_0000219
66,Homo sapiens,1,F,1A9,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),80002,9606.0,,,CHEMBL615188,5726,,506.0,,,N,Intermediate,BAO_0000219
67,Homo sapiens,1,F,1A9,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,80002,9606.0,,,CHEMBL615189,5726,,506.0,,,N,Intermediate,BAO_0000219
68,Homo sapiens,1,F,1A9,1,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,80002,9606.0,,,CHEMBL615190,5726,,506.0,,,N,Intermediate,BAO_0000219
69,Homo sapiens,1,F,1A9,1,Inhibitory activity against Taxol resistant 1A9 cell lines,80002,9606.0,,,CHEMBL615191,3395,,506.0,,,N,Intermediate,BAO_0000219
70,Homo sapiens,1,F,1A9,1,Cytotoxicity against human ovarian cancer (1A9) cell lines.,80002,9606.0,,,CHEMBL615192,3415,,506.0,,,N,Expert,BAO_0000219
71,Homo sapiens,1,F,1A9,1,Percentage inhibition of human ovarian cancer (1A9) cell lines.,80002,9606.0,,,CHEMBL827083,3415,,506.0,,,N,Expert,BAO_0000219
72,Homo sapiens,1,F,1A9,1,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,80002,9606.0,,,CHEMBL615193,17099,,506.0,,,N,Expert,BAO_0000219
73,Homo sapiens,1,F,1A9,1,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,80002,9606.0,,,CHEMBL615194,17099,,506.0,,,N,Intermediate,BAO_0000219
74,Homo sapiens,1,F,1A9,1,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,80002,9606.0,,,CHEMBL615195,17099,,506.0,,,N,Intermediate,BAO_0000219
75,Homo sapiens,1,F,1A9,1,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,80002,9606.0,,,CHEMBL615196,17099,,506.0,,,N,Intermediate,BAO_0000219
76,Homo sapiens,1,F,Jurkat,1,Inhibitory concentration against Jurkat cells,81072,9606.0,,,CHEMBL615197,17721,,503.0,,,N,Intermediate,BAO_0000219
77,,0,F,,1,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,22226,,,,CHEMBL615198,1229,,,,,U,Intermediate,BAO_0000019
78,Rattus norvegicus,9,A,,1,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,100121,10116.0,,,CHEMBL615199,11347,,,,,D,Expert,BAO_0000357
79,,8,B,,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,,CHEMBL615200,17117,,,,,H,Expert,BAO_0000357
80,,8,B,,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,,CHEMBL615201,17117,,,,,H,Expert,BAO_0000357
81,,8,B,,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",11231,,,,CHEMBL615202,17117,,,,,H,Expert,BAO_0000357
82,Candida albicans,8,B,,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11231,5476.0,Microsomes,,CHEMBL615203,11375,,,,,H,Autocuration,BAO_0000251
83,Candida albicans,8,B,,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11231,5476.0,Microsomes,,CHEMBL615204,11375,,,,,H,Autocuration,BAO_0000251
84,Saccharomyces cerevisiae,8,B,,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11231,4932.0,Microsomes,,CHEMBL615205,11375,,,,,H,Autocuration,BAO_0000251
85,Saccharomyces cerevisiae,8,B,,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11231,4932.0,Microsomes,,CHEMBL615206,11375,,,,,H,Autocuration,BAO_0000251
86,Sus scrofa,8,B,,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",12083,9823.0,Microsomes,,CHEMBL615207,11375,2107.0,,,Liver,H,Autocuration,BAO_0000251
87,Rattus norvegicus,8,B,,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",11231,10116.0,,,CHEMBL827084,791,,,,,H,Autocuration,BAO_0000019
88,Rattus norvegicus,8,B,,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",11231,10116.0,,,CHEMBL615208,791,,,,,H,Autocuration,BAO_0000019
89,Rattus norvegicus,8,B,,1,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",11231,10116.0,,,CHEMBL615209,791,,,,,H,Autocuration,BAO_0000019
90,Rattus norvegicus,9,B,,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",12083,10116.0,Microsomes,,CHEMBL615210,11375,2107.0,,,Liver,D,Autocuration,BAO_0000251
91,Rattus norvegicus,9,B,,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,10116.0,Microsomes,,CHEMBL615211,11375,2107.0,,,Liver,D,Autocuration,BAO_0000251
92,Rattus norvegicus,9,B,,1,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,10116.0,Microsomes,,CHEMBL615212,153,2107.0,,,Liver,D,Autocuration,BAO_0000251
93,,8,B,,1,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),11377,,,,CHEMBL615213,8269,,,,,H,Expert,BAO_0000357
94,,8,B,,1,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,11377,,,,CHEMBL615273,8269,,,,,H,Expert,BAO_0000357
95,Homo sapiens,1,F,HepG2,1,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,81020,9606.0,,,CHEMBL615274,17653,,726.0,,,N,Expert,BAO_0000219
96,Homo sapiens,1,F,HepG2,1,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,81020,9606.0,,,CHEMBL615275,14277,,726.0,,,N,Intermediate,BAO_0000219
97,Homo sapiens,1,F,HepG2,1,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,81020,9606.0,,,CHEMBL615276,1717,,726.0,,,N,Intermediate,BAO_0000219
98,Homo sapiens,1,F,HepG2,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,81020,9606.0,,,CHEMBL615277,14091,,726.0,,,N,Intermediate,BAO_0000219
99,Homo sapiens,1,F,HepG2,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,81020,9606.0,,,CHEMBL615326,14091,,726.0,,,N,Intermediate,BAO_0000219
100,Hepatitis B virus,1,F,,1,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,50606,10407.0,,,CHEMBL883130,17653,,,,,N,Expert,BAO_0000218
101,Homo sapiens,1,F,HepG2,1,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,81020,9606.0,,,CHEMBL884519,13105,,726.0,,,N,Intermediate,BAO_0000219
102,Homo sapiens,1,F,HepG2,1,Concentration required to inhibit 50% of 2.2.15 cell line,81020,9606.0,,,CHEMBL615327,1717,,726.0,,,N,Intermediate,BAO_0000219
103,Homo sapiens,1,A,HepG2,1,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,81020,9606.0,,,CHEMBL615328,13105,,726.0,,,N,Intermediate,BAO_0000219
104,Homo sapiens,1,F,2.2.15,1,Cytotoxic activity of compound against uninfected 2.2.15 cells.,50587,9606.0,,,CHEMBL615329,13600,,,,,N,Intermediate,BAO_0000218
105,Homo sapiens,1,F,2.2.15,1,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,50587,9606.0,,,CHEMBL615330,13467,,,,,N,Intermediate,BAO_0000218
106,Hepatitis B virus,1,F,2.2.15,1,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",50606,10407.0,,,CHEMBL615331,17477,,,,,N,Expert,BAO_0000218
107,Homo sapiens,1,F,2.2.15,1,In vitro anti-HBV activity in 2.2.15 cells,50587,9606.0,,,CHEMBL615332,1593,,,,,N,Intermediate,BAO_0000218
108,Homo sapiens,1,F,2.2.15,1,In vitro anti-HBV activity in 2.2.15 cells; Not determined,50587,9606.0,,,CHEMBL615333,1593,,,,,N,Intermediate,BAO_0000218
109,Homo sapiens,1,F,2.2.15,1,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,50587,9606.0,,,CHEMBL615334,15089,,,,,N,Intermediate,BAO_0000218
110,Homo sapiens,1,F,2.2.15,1,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,50587,9606.0,,,CHEMBL615335,15089,,,,,N,Intermediate,BAO_0000218
111,Homo sapiens,1,F,2.2.15,1,Cytotoxicity in 2.2.15 cells,50587,9606.0,,,CHEMBL615336,1593,,,,,N,Intermediate,BAO_0000218
112,Homo sapiens,1,F,2.2.15,1,Cytotoxicity in 2.2.15 cells; Not determined,50587,9606.0,,,CHEMBL615337,1593,,,,,N,Intermediate,BAO_0000218
113,Homo sapiens,1,F,2.2.15,1,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,50587,9606.0,,,CHEMBL615338,13600,,,,,N,Intermediate,BAO_0000218
114,Homo sapiens,1,F,2.2.15,1,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,50587,9606.0,,,CHEMBL615339,13467,,,,,N,Intermediate,BAO_0000218
115,Homo sapiens,1,F,2.2.15,1,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,50587,9606.0,,,CHEMBL615340,13467,,,,,N,Intermediate,BAO_0000218
116,Homo sapiens,1,F,HepG2,1,Antiviral activity against HBV was determined in 2.215 cell line,81020,9606.0,,,CHEMBL615341,14764,,726.0,,,N,Intermediate,BAO_0000219
117,Homo sapiens,0,B,,1,Inhibition of 20-HETE synthesis in human renal microsomes,22226,9606.0,Microsomes,,CHEMBL615342,6531,,,,,U,Autocuration,BAO_0000251
118,,0,B,,1,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,22226,,,,CHEMBL615343,17322,,,,,U,Autocuration,BAO_0000019
119,Homo sapiens,1,F,2008,1,Inhibitory concentration against 2008 (ovarian) cells,80612,9606.0,,,CHEMBL615344,17072,,388.0,,,N,Intermediate,BAO_0000219
120,Homo sapiens,1,F,2008,1,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,80612,9606.0,,,CHEMBL615345,16936,,388.0,,,N,Intermediate,BAO_0000219
121,Homo sapiens,1,F,2008,1,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),80612,9606.0,,,CHEMBL615346,16936,,388.0,,,N,Intermediate,BAO_0000219
122,Homo sapiens,1,F,2008,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,80612,9606.0,,,CHEMBL615347,17146,,388.0,,,N,Intermediate,BAO_0000219
123,Homo sapiens,1,F,2008,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,80612,9606.0,,,CHEMBL615348,17146,,388.0,,,N,Intermediate,BAO_0000219
124,Homo sapiens,1,F,2008/R,1,In vitro inhibition of 2008/R ovarian cancer cell line,80613,9606.0,,,CHEMBL827085,10797,,561.0,,,N,Intermediate,BAO_0000219
125,Homo sapiens,1,F,2008/R,1,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,80613,9606.0,,,CHEMBL615349,10797,,561.0,,,N,Intermediate,BAO_0000219
126,Homo sapiens,1,F,2008/S,1,In vitro inhibition of 2008/S ovarian cancer cell line,80614,9606.0,,,CHEMBL615350,10797,,389.0,,,N,Intermediate,BAO_0000219
127,Homo sapiens,1,F,2008/S,1,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,80614,9606.0,,,CHEMBL615351,10797,,389.0,,,N,Intermediate,BAO_0000219
128,Homo sapiens,2,B,,1,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,100256,9606.0,,,CHEMBL615352,4823,,,,,S,Expert,BAO_0000220
129,Homo sapiens,2,B,,1,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,100256,9606.0,,,CHEMBL615353,12912,,,,,S,Intermediate,BAO_0000220
130,,2,B,,1,Inhibition of chymotrypsin-like activity of 20S proteasome,100256,,,,CHEMBL615354,2957,,,,,S,Expert,BAO_0000220
131,,2,B,,1,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,100256,,,,CHEMBL615355,2957,,,,,S,Expert,BAO_0000220
132,,2,B,,1,Inhibitory activity against 20S proteosome,100256,,,,CHEMBL615356,3260,,,,,S,Intermediate,BAO_0000220
133,Homo sapiens,0,B,,1,Compound was tested for inhibitory activity against tryptase,22226,9606.0,,,CHEMBL615357,3451,,,,,U,Autocuration,BAO_0000019
134,Homo sapiens,1,F,HepG2,1,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,81020,9606.0,,,CHEMBL615358,13885,,726.0,,,N,Intermediate,BAO_0000219
135,Homo sapiens,1,F,HepG2,1,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,81020,9606.0,,,CHEMBL827086,13885,,726.0,,,N,Intermediate,BAO_0000219
136,,0,B,,1,Compound was tested for the inhibition of Alpha-glucosidase,22226,,,,CHEMBL615359,3676,,,,,U,Autocuration,BAO_0000019
137,,8,B,,1,Inhibitory concentration against human neutrophil elastase (HNE),235,,,,CHEMBL615360,6043,,,,,H,Autocuration,BAO_0000357
138,Rattus norvegicus,0,F,,1,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,22226,10116.0,,,CHEMBL615361,11140,948.0,,,Heart,U,Autocuration,BAO_0000218
139,,8,F,,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,,CHEMBL615362,10543,,,,,H,Autocuration,BAO_0000019
140,,8,F,,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,,CHEMBL615363,10543,,,,,H,Expert,BAO_0000019
141,,8,B,,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,,CHEMBL615364,10543,,,,,H,Autocuration,BAO_0000357
142,,8,F,,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,,CHEMBL615365,10543,,,,,H,Expert,BAO_0000019
143,Mus musculus,1,F,P338,1,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,80360,10090.0,,,CHEMBL615366,11365,,524.0,,,N,Intermediate,BAO_0000219
144,Mus musculus,1,F,P338,1,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,80360,10090.0,,,CHEMBL615367,11365,,524.0,,,N,Intermediate,BAO_0000219
145,Homo sapiens,1,F,PBL,1,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,80384,9606.0,,,CHEMBL615368,11803,,554.0,,,N,Intermediate,BAO_0000219
146,Ovis aries,0,F,,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,22226,9940.0,,,CHEMBL615369,11803,,,,,U,Autocuration,BAO_0000019
147,Ovis aries,0,F,,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,22226,9940.0,,,CHEMBL615370,11803,,,,,U,Autocuration,BAO_0000019
148,,8,B,,1,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),191,,,,CHEMBL615673,12278,,,,,H,Autocuration,BAO_0000357
149,Homo sapiens,0,F,,1,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,22226,9606.0,,,CHEMBL615674,8249,,,,,U,Autocuration,BAO_0000019
150,Homo sapiens,0,F,,1,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,22226,9606.0,,,CHEMBL615675,8249,,,,,U,Autocuration,BAO_0000019
151,Homo sapiens,0,F,CCRF-CEM,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,22226,9606.0,,,CHEMBL615676,8249,,635.0,,,U,Autocuration,BAO_0000219
152,Homo sapiens,0,F,CCRF-CEM,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,22226,9606.0,,,CHEMBL615677,8249,,635.0,,,U,Autocuration,BAO_0000219
153,Homo sapiens,0,F,CCRF-CEM,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,22226,9606.0,,,CHEMBL615678,8249,,635.0,,,U,Autocuration,BAO_0000219
154,Homo sapiens,0,F,CCRF-CEM,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,22226,9606.0,,,CHEMBL615679,8249,,635.0,,,U,Autocuration,BAO_0000219
155,Homo sapiens,0,F,,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,22226,9606.0,,,CHEMBL615680,8249,,,,,U,Autocuration,BAO_0000019
156,Homo sapiens,0,F,,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,22226,9606.0,,,CHEMBL615681,8249,,,,,U,Autocuration,BAO_0000019
157,,6,B,,1,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,104290,,,,CHEMBL857972,16992,,,,,H,Autocuration,BAO_0000249
158,Streptococcus pyogenes,1,F,,1,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,50264,1314.0,,,CHEMBL857899,10543,,,,,N,Intermediate,BAO_0000218
159,Human herpesvirus 3,1,F,,1,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),50527,10335.0,,,CHEMBL615371,17833,,,,,N,Intermediate,BAO_0000218
160,vericilla zoster virus,1,F,HEL,1,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,50527,10335.0,,,CHEMBL615372,17290,,468.0,,,N,Expert,BAO_0000218
161,vericilla zoster virus,1,F,,1,Antiviral activity against 07/1 strain of VZV; ND: No data,50527,10335.0,,,CHEMBL615373,17290,,,,,N,Intermediate,BAO_0000218
162,vericilla zoster virus,1,F,,1,Antiviral activity against 07/1 strain of VZV; ND=No data,50527,10335.0,,,CHEMBL615374,17290,,,,,N,Intermediate,BAO_0000218
163,escherichia cloac,1,F,,1,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",50145,561.0,,,CHEMBL615375,10932,,,,,N,Intermediate,BAO_0000218
164,,0,B,,1,Ratio of Ki at A2 to Ki at A1 receptors,22226,,,,CHEMBL615376,9707,,,,,U,Autocuration,BAO_0000019
165,Candida albicans,8,B,,1,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",11143,5476.0,,,CHEMBL615377,2346,,,,,H,Expert,BAO_0000249
166,Candida glabrata CBS 138,8,B,,1,"Inhibition of 1,3-beta-glucan synthase",18077,284593.0,,,CHEMBL615378,2205,,,,,H,Expert,BAO_0000357
167,Homo sapiens,1,F,1-87 tumor cell line,1,Inhibition of growth of 1-87 human tumor cell line,80609,9606.0,,,CHEMBL615379,11900,,832.0,,,N,Intermediate,BAO_0000219
168,Rattus norvegicus,9,B,,1,Inhibition of 1-lipoxygenase (LOX)in RBL cells,12166,10116.0,,,CHEMBL615380,14864,,,,,D,Expert,BAO_0000219
169,Glycine max,9,B,,1,Inhibitory activity against soybean 1-lipoxygenase (SLO),100171,3847.0,,,CHEMBL615381,16474,,,,,D,Autocuration,BAO_0000357
170,Glycine max,9,B,,1,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,100171,3847.0,,,CHEMBL615382,16474,,,,,D,Autocuration,BAO_0000357
171,Glycine max,9,B,,1,% inhibition against soybean 1-lipoxygenase (SLO),100171,3847.0,,,CHEMBL615383,16474,,,,,D,Autocuration,BAO_0000357
172,Glycine max,9,B,,1,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,100171,3847.0,,,CHEMBL615384,16474,,,,,D,Autocuration,BAO_0000357
173,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,100171,3847.0,,,CHEMBL615385,3094,,,,,D,Autocuration,BAO_0000357
174,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,100171,3847.0,,,CHEMBL615386,3094,,,,,D,Autocuration,BAO_0000357
175,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,100171,3847.0,,,CHEMBL615387,3094,,,,,D,Autocuration,BAO_0000357
176,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,100171,3847.0,,,CHEMBL615388,3094,,,,,D,Autocuration,BAO_0000357
177,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,100171,3847.0,,,CHEMBL615214,3094,,,,,D,Autocuration,BAO_0000357
178,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,100171,3847.0,,,CHEMBL827087,3094,,,,,D,Autocuration,BAO_0000357
179,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,100171,3847.0,,,CHEMBL615215,3094,,,,,D,Autocuration,BAO_0000357
180,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,100171,3847.0,,,CHEMBL615216,3094,,,,,D,Autocuration,BAO_0000357
181,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,100171,3847.0,,,CHEMBL615217,3094,,,,,D,Autocuration,BAO_0000357
182,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,100171,3847.0,,,CHEMBL615218,3094,,,,,D,Autocuration,BAO_0000357
183,Glycine max,9,B,,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,100171,3847.0,,,CHEMBL615219,3094,,,,,D,Autocuration,BAO_0000357
184,Mus musculus,0,B,,1,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,22226,10090.0,,,CHEMBL615220,10413,,,,,U,Autocuration,BAO_0000019
185,Mus musculus,1,F,C3H 10T1/2,1,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),80049,10090.0,,,CHEMBL615221,16929,,294.0,,,N,Intermediate,BAO_0000219
186,,0,F,,1,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,22226,,,,CHEMBL615222,1229,,,,,U,Intermediate,BAO_0000019
187,,8,B,,1,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11489,,,,CHEMBL615223,16587,,,,,H,Autocuration,BAO_0000357
188,,8,B,,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11862,,,,CHEMBL615224,16587,,,,,H,Autocuration,BAO_0000357
189,,8,B,,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,11862,,,,CHEMBL615225,16587,,,,,H,Autocuration,BAO_0000357
190,,8,B,,1,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,11489,,,,CHEMBL615226,16587,,,,,H,Autocuration,BAO_0000357
191,,8,B,,1,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,11862,,,,CHEMBL615227,16587,,,,,H,Autocuration,BAO_0000357
192,Bos taurus,9,F,,1,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,12347,9913.0,,,CHEMBL615228,8058,,,,,D,Expert,BAO_0000019
193,Rattus norvegicus,9,B,,1,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,100120,10116.0,,,CHEMBL615229,9065,,,,,D,Expert,BAO_0000357
194,Rattus norvegicus,9,B,,1,Inhibition of 11 beta-hydroxylase from rat adrenal gland,100120,10116.0,,,CHEMBL615230,8865,2369.0,,,Adrenal gland,D,Expert,BAO_0000357
195,Rattus norvegicus,9,B,,1,Inhibition of rat adrenal 11-beta-hydroxylase,100120,10116.0,,,CHEMBL615231,9066,,,,,D,Expert,BAO_0000357
196,Rattus norvegicus,9,B,,1,Inhibition of rat adrenal 11-beta-hydroxylase,100120,10116.0,,,CHEMBL884520,8394,,,,,D,Expert,BAO_0000357
197,Rattus norvegicus,9,B,,1,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,100120,10116.0,,,CHEMBL615232,8394,,,,,D,Expert,BAO_0000357
198,,8,B,,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,10328,,,,CHEMBL615233,6431,,,,,H,Autocuration,BAO_0000019
199,,8,B,,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,,CHEMBL827088,6431,,,,,H,Autocuration,BAO_0000357
200,,8,B,,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,,CHEMBL615234,6431,,,,,H,Autocuration,BAO_0000357
201,,8,F,,1,Compound was tested for the percent of inhibition against 12-LO at 10 uM,11134,,,,CHEMBL615235,9295,,,,,H,Autocuration,BAO_0000019
202,,8,B,,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,,CHEMBL615236,10193,,,,,H,Autocuration,BAO_0000019
203,,8,B,,1,Compound was tested in vitro for inhibition of 12-LO human platelet,11134,,,,CHEMBL615237,13622,,,,,H,Autocuration,BAO_0000019
204,,8,F,,1,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,,,CHEMBL615238,12079,,,,,H,Autocuration,BAO_0000019
205,,8,B,,1,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,11134,,,,CHEMBL615239,13622,,,,,H,Autocuration,BAO_0000019
206,Homo sapiens,9,F,,1,Inhibitory concentration against human platelet 12-lipoxygenase,11134,9606.0,,,CHEMBL615240,12079,,,,,D,Autocuration,BAO_0000019
207,,8,B,,1,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,11835,,,,CHEMBL615241,13500,,,,,H,Expert,BAO_0000019
208,,8,B,,1,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,11601,,,,CHEMBL615242,13723,,,,,H,Expert,BAO_0000357
209,,8,B,,1,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),11134,,,,CHEMBL615243,16474,,,,,H,Autocuration,BAO_0000019
210,,8,B,,1,Inhibitory activity against human platelet 12-lipoxygenase,11134,,,,CHEMBL615244,1630,,,,,H,Autocuration,BAO_0000019
211,,8,B,,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,11134,,,,CHEMBL615245,167,,,,,H,Autocuration,BAO_0000019
212,,8,B,,1,% inhibition against human platelet 12-lipoxygenase (12-HLO),11134,,,,CHEMBL615246,16474,,,,,H,Autocuration,BAO_0000019
213,,8,B,,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,11134,,,,CHEMBL615247,167,,,,,H,Autocuration,BAO_0000019
214,,8,B,,1,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,11134,,,,CHEMBL615248,16474,,,,,H,Autocuration,BAO_0000019
215,,8,B,,1,Inhibitory activity towards porcine 12-lipoxygenase,11601,,,,CHEMBL615249,10091,,,,,H,Autocuration,BAO_0000357
216,,8,B,,1,Tested for inhibition against porcine 12-LO,11601,,,,CHEMBL615250,11966,,,,,H,Autocuration,BAO_0000357
217,,8,B,,1,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,12052,,,,CHEMBL615251,951,,,,,H,Autocuration,BAO_0000019
218,,8,B,,1,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,12052,,,,CHEMBL615252,10997,,,,,H,Autocuration,BAO_0000019
219,,8,B,,1,In vitro inhibition of rat platelet 12-lipoxygenase,12052,,,,CHEMBL828340,10193,,,,,H,Expert,BAO_0000019
220,,8,B,,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,,CHEMBL615253,10193,,,,,H,Autocuration,BAO_0000019
221,,8,B,,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,12052,,,,CHEMBL615254,10193,,,,,H,Autocuration,BAO_0000019
222,,8,B,,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,12052,,,,CHEMBL615255,10193,,,,,H,Autocuration,BAO_0000019
223,,8,B,,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,,CHEMBL615256,10193,,,,,H,Autocuration,BAO_0000019
224,,8,B,,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase,12052,,,,CHEMBL615257,10193,,,,,H,Autocuration,BAO_0000019
225,,8,B,,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,12052,,,,CHEMBL615258,11087,,,,,H,Autocuration,BAO_0000019
226,Homo sapiens,1,F,41M,1,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,80007,9606.0,,,CHEMBL615259,15569,,621.0,,,N,Intermediate,BAO_0000219
227,Homo sapiens,1,F,41M,1,In vitro antitumor activity against 41M cell line.,80007,9606.0,,,CHEMBL615260,12989,,621.0,,,N,Expert,BAO_0000219
228,Homo sapiens,1,F,41M,1,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,80007,9606.0,,,CHEMBL615261,16745,,621.0,,,N,Intermediate,BAO_0000219
229,Homo sapiens,1,F,41M,1,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,80007,9606.0,,,CHEMBL615262,15569,,621.0,,,N,Intermediate,BAO_0000219
230,Homo sapiens,1,F,41M,1,In vitro antitumor activity against 41McisR cell line.,80007,9606.0,,,CHEMBL615263,12989,,621.0,,,N,Expert,BAO_0000219
231,Homo sapiens,1,F,41M,1,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,80007,9606.0,,,CHEMBL838393,12989,,621.0,,,N,Expert,BAO_0000219
232,Homo sapiens,1,F,41M,1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,80007,9606.0,,,CHEMBL615264,16745,,621.0,,,N,Intermediate,BAO_0000219
233,Homo sapiens,9,B,,1,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),84,9606.0,,,CHEMBL615265,6210,,,,,D,Expert,BAO_0000357
234,Homo sapiens,9,B,,1,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,9606.0,,,CHEMBL615266,6210,,,,,D,Expert,BAO_0000357
235,,8,B,,1,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,,,CHEMBL615267,6226,,,,,H,Expert,BAO_0000357
236,,8,B,,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,,CHEMBL615268,17855,,,,,H,Expert,BAO_0000357
237,,8,B,,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,10201,,,,CHEMBL615269,17855,,,,,H,Expert,BAO_0000357
238,,8,B,,1,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,,CHEMBL615270,17855,,,,,H,Expert,BAO_0000357
239,,8,B,,1,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,,CHEMBL615271,10413,,,,,H,Autocuration,BAO_0000357
240,Escherichia coli,8,B,,1,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,562.0,,,CHEMBL615272,10413,,,,,H,Autocuration,BAO_0000357
241,Escherichia coli,8,B,,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,562.0,,,CHEMBL615103,10413,,,,,H,Autocuration,BAO_0000357
242,Escherichia coli,8,B,,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",11303,562.0,,,CHEMBL615104,10413,,,,,H,Autocuration,BAO_0000357
243,,8,B,,1,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,,CHEMBL615105,10413,,,,,H,Autocuration,BAO_0000357
244,,8,B,,1,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",12220,,,,CHEMBL872866,10413,,,,,H,Autocuration,BAO_0000357
245,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,9823.0,,,CHEMBL615106,7587,,,,,H,Autocuration,BAO_0000357
246,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",11303,9823.0,,,CHEMBL615107,7587,,,,,H,Autocuration,BAO_0000019
247,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",11303,9823.0,,,CHEMBL615108,7587,,,,,H,Autocuration,BAO_0000357
248,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",11303,9823.0,,,CHEMBL615109,7587,,,,,H,Autocuration,BAO_0000357
249,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,9823.0,,,CHEMBL615110,7587,,,,,H,Autocuration,BAO_0000357
250,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,9823.0,,,CHEMBL840105,7587,,,,,H,Autocuration,BAO_0000019
251,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",11303,9823.0,,,CHEMBL615111,7587,,,,,H,Autocuration,BAO_0000019
252,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",11303,9823.0,,,CHEMBL615112,7587,,,,,H,Autocuration,BAO_0000019
253,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",11303,9823.0,,,CHEMBL615113,7587,,,,,H,Autocuration,BAO_0000019
254,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",11303,9823.0,,,CHEMBL615114,7587,,,,,H,Autocuration,BAO_0000019
255,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,9823.0,,,CHEMBL615115,7587,,,,,H,Autocuration,BAO_0000357
256,Sus scrofa,8,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,9823.0,,,CHEMBL615116,7587,,,,,H,Autocuration,BAO_0000019
257,,8,B,,1,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",11303,,,,CHEMBL615698,7323,,,,,H,Autocuration,BAO_0000357
258,Sus scrofa,0,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",22226,9823.0,,,CHEMBL615699,7587,,,,,U,Autocuration,BAO_0000019
259,Sus scrofa,0,B,,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",22226,9823.0,,,CHEMBL615700,7587,,,,,U,Autocuration,BAO_0000019
260,Saccharomyces cerevisiae,8,B,,1,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,100249,4932.0,,,CHEMBL615701,13750,,,,,H,Expert,BAO_0000357
261,Rattus norvegicus,0,B,,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,10116.0,,,CHEMBL615702,7662,,,,,U,Autocuration,BAO_0000019
262,Rattus norvegicus,0,B,,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,10116.0,,,CHEMBL615703,7662,,,,,U,Autocuration,BAO_0000019
263,Rattus norvegicus,0,B,,1,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",22226,10116.0,,,CHEMBL615704,7662,,,,,U,Autocuration,BAO_0000019
264,,6,F,,1,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,,CHEMBL615705,12211,,,,,H,Autocuration,BAO_0000019
265,,6,F,,1,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,,CHEMBL615706,12211,,,,,H,Autocuration,BAO_0000019
266,Cavia porcellus,9,F,,1,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,20033,10141.0,,,CHEMBL615707,12211,2116.0,,,Ileum,D,Intermediate,BAO_0000221
267,,8,F,,1,Stimulatory activity of intragastric pressure was tested in the rat,10623,,,,CHEMBL615708,12211,,,,,H,Expert,BAO_0000019
268,,8,B,,1,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,121,,,,CHEMBL615709,15453,,,,,H,Autocuration,BAO_0000357
269,Rattus norvegicus,0,F,,1,Dose to reduce neuronal firing against 5-HT cells in rats (iv),22226,10116.0,,,CHEMBL615710,11884,,,,,U,Autocuration,BAO_0000218
270,,8,F,,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,12688,,,,CHEMBL615711,7185,,,,,H,Autocuration,BAO_0000019
271,Homo sapiens,9,B,,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,121,9606.0,,,CHEMBL615712,6876,,,,,D,Expert,BAO_0000357
272,Homo sapiens,9,B,,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,121,9606.0,,,CHEMBL836325,6876,,,,,D,Expert,BAO_0000357
273,,8,F,,1,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,12198,,,,CHEMBL615713,11863,,,,,H,Autocuration,BAO_0000019
274,,8,B,,1,Inhibition constant of high-affinity 5-HT uptake,12198,,,,CHEMBL615714,11863,,,,,H,Autocuration,BAO_0000357
275,,8,F,,1,Michaelis-Menten constant was reported for high affinity transport of 5-HT,12198,,,,CHEMBL615715,11863,,,,,H,Autocuration,BAO_0000019
276,,8,F,,1,Maximum rate was determined for high affinity transport of 5-HT,12198,,,,CHEMBL615716,11863,,,,,H,Autocuration,BAO_0000019
277,,4,F,,1,Compound was tested for agonistic activity against 5-HT uptake,104714,,,,CHEMBL615717,4639,,,,,H,Autocuration,BAO_0000019
278,,8,B,,1,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,10577,,,,CHEMBL881818,15796,,,,,H,Expert,BAO_0000019
279,Bos taurus,8,B,,1,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,105,9913.0,,,CHEMBL884540,15796,,,,,H,Expert,BAO_0000357
280,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,104744,10116.0,,,CHEMBL615718,12801,,,,,D,Autocuration,BAO_0000224
281,,4,B,,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,104744,,,,CHEMBL615719,12801,,,,,H,Autocuration,BAO_0000224
282,,4,B,,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,104744,,Membranes,,CHEMBL615720,12120,,,,,H,Autocuration,BAO_0000249
283,,4,B,,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,104744,,Membranes,,CHEMBL615721,12120,,,,,H,Autocuration,BAO_0000249
284,,4,B,,1,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,,CHEMBL615722,11963,,,,,H,Autocuration,BAO_0000019
285,,8,F,,1,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,51,,,,CHEMBL615723,11701,,,,,H,Autocuration,BAO_0000019
286,,8,B,,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL615724,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
287,,8,B,,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,,CHEMBL615725,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
288,,8,B,,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL615726,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
289,,8,F,,1,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),10576,,,,CHEMBL615727,16394,,,,,H,Autocuration,BAO_0000218
290,Cavia porcellus,9,F,,1,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,105570,10141.0,,,CHEMBL615728,11574,,,,,D,Intermediate,BAO_0000019
291,,8,B,CHO,1,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,,CHEMBL857971,15779,,449.0,,,H,Autocuration,BAO_0000219
292,,8,B,,1,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL615729,15363,,,,,H,Autocuration,BAO_0000357
293,Rattus norvegicus,9,F,,1,Efficacy against 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL615730,15363,,,,,D,Expert,BAO_0000019
294,,8,F,,1,Intrinsic activity towards 5-HT2A receptor of rat tail artery,12687,,,,CHEMBL615731,15329,,,,,H,Expert,BAO_0000019
295,,8,F,,1,Relative potency towards 5-HT2A receptor of rat tail artery,12687,,,,CHEMBL615732,15329,,,,,H,Expert,BAO_0000019
296,,8,F,,1,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,,CHEMBL615733,15329,,,,,H,Expert,BAO_0000019
297,,8,F,,1,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,12687,,,,CHEMBL615734,15329,,,,,H,Expert,BAO_0000019
298,,8,F,,1,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,12687,,,,CHEMBL615735,15329,,,,,H,Autocuration,BAO_0000019
299,,8,F,,1,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,,CHEMBL615736,15329,,,,,H,Expert,BAO_0000019
300,Cavia porcellus,9,F,,1,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,10141.0,,,CHEMBL615737,273,2116.0,,,Ileum,D,Intermediate,BAO_0000221
301,Cavia porcellus,9,F,,1,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),20033,10141.0,,,CHEMBL615738,273,2116.0,,,Ileum,D,Intermediate,BAO_0000221
302,Cavia porcellus,9,F,,1,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,10141.0,,,CHEMBL615739,273,2116.0,,,Ileum,D,Intermediate,BAO_0000221
303,,8,B,,1,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,10623,,,,CHEMBL615278,12092,,,,,H,Autocuration,BAO_0000357
304,Rattus norvegicus,9,F,,1,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,10116.0,,,CHEMBL615279,1317,,,,,D,Expert,BAO_0000019
305,,8,B,,1,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL615280,12409,,,,,H,Expert,BAO_0000357
306,Gallus gallus,0,B,,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,22226,9031.0,,,CHEMBL615281,11126,,,,,U,Autocuration,BAO_0000019
307,Homo sapiens,0,F,,1,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,22226,9606.0,,,CHEMBL615282,11126,,,,,U,Autocuration,BAO_0000019
308,Homo sapiens,0,F,,1,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,9606.0,,,CHEMBL615283,11126,,,,,U,Autocuration,BAO_0000019
309,Homo sapiens,1,B,HL-60,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,80156,9606.0,,,CHEMBL615284,11126,,649.0,,,N,Autocuration,BAO_0000219
310,Homo sapiens,0,B,,1,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,22226,9606.0,,,CHEMBL615285,11126,,,,,U,Autocuration,BAO_0000019
311,Homo sapiens,0,B,,1,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,9606.0,,,CHEMBL615286,11126,,,,,U,Autocuration,BAO_0000019
312,Homo sapiens,7,B,Oocytes,1,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,104703,9606.0,,,CHEMBL615287,17807,,,,,D,Autocuration,BAO_0000219
313,,2,F,,1,Chymotryptic inhibitory activity against 26S proteasome,100256,,,,CHEMBL615288,16575,,,,,S,Intermediate,BAO_0000220
314,,2,B,,1,Inhibitory activity against 26S proteasome degradation of IkB,100256,,,,CHEMBL615289,15407,,,,,S,Intermediate,BAO_0000220
315,Homo sapiens,1,F,A2780,1,In vitro inhibition of 2780/DOX ovarian cancer cell line,81034,9606.0,,,CHEMBL615290,10797,,478.0,,,N,Intermediate,BAO_0000219
316,Homo sapiens,1,F,A2780,1,In vitro inhibition of 2780/S ovarian cancer cell line,81034,9606.0,,,CHEMBL884522,10797,,478.0,,,N,Intermediate,BAO_0000219
317,Homo sapiens,0,F,,1,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,22226,9606.0,,,CHEMBL615291,3469,,,,,U,Autocuration,BAO_0000019
318,,3,B,,1,Association constant for binding to AATT 28-mer AATT hairpin,22222,,,,CHEMBL615292,16037,,,,,M,Intermediate,BAO_0000225
319,,3,B,,1,Kinetically Defined Association Constant for 28-mer AATT hairpin.,22222,,,,CHEMBL615293,16037,,,,,M,Intermediate,BAO_0000225
320,,3,B,,1,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,,CHEMBL615294,16037,,,,,M,Intermediate,BAO_0000225
321,,3,B,,1,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,,CHEMBL615295,16037,,,,,M,Intermediate,BAO_0000225
322,Homo sapiens,0,F,,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),22226,9606.0,,,CHEMBL825021,16524,,,,,U,Autocuration,BAO_0000019
323,Homo sapiens,0,F,,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),22226,9606.0,,,CHEMBL615296,16524,,,,,U,Autocuration,BAO_0000019
324,Homo sapiens,0,F,,1,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,22226,9606.0,,,CHEMBL615297,16524,,,,,U,Autocuration,BAO_0000019
325,Cricetulus griseus,0,F,,1,Cytotoxicity against cell line 2SC/20 determined by MTT test,22226,10029.0,,,CHEMBL615298,16758,,,,,U,Autocuration,BAO_0000019
326,Cricetulus griseus,0,F,,1,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,22226,10029.0,,,CHEMBL615299,16758,,,,,U,Autocuration,BAO_0000019
327,Cricetulus griseus,0,F,,1,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,22226,10029.0,,,CHEMBL615300,16758,,,,,U,Autocuration,BAO_0000019
328,,8,B,,1,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,241,,,,CHEMBL615301,14360,,,,,H,Autocuration,BAO_0000357
329,Homo sapiens,9,B,,1,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,241,9606.0,,,CHEMBL615302,14360,,,,,D,Expert,BAO_0000357
330,Rattus norvegicus,0,B,,1,Selectivity ratio of ID50 in liver and heart,22226,10116.0,,,CHEMBL615303,9964,,,,,U,Autocuration,BAO_0000019
331,,8,B,,1,"Selectivity, ratio of relative ID50 in liver and heart",12132,,,,CHEMBL615304,9964,,,,,H,Autocuration,BAO_0000019
332,,8,B,,1,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,12132,,,,CHEMBL615305,9964,,,,,H,Autocuration,BAO_0000019
333,,8,B,,1,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615306,9964,,,,,H,Autocuration,BAO_0000218
334,,8,B,,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615307,9964,,,,,H,Autocuration,BAO_0000218
335,,8,B,,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615308,9964,,,,,H,Autocuration,BAO_0000218
336,,8,F,,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615309,9964,,,,,H,Autocuration,BAO_0000218
337,,0,B,,1,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",22226,,,,CHEMBL615310,9964,,,,,U,Autocuration,BAO_0000019
338,,8,B,,1,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,12132,,,,CHEMBL615311,9964,,,,,H,Autocuration,BAO_0000019
339,Homo sapiens,0,B,,1,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",22226,9606.0,,,CHEMBL615312,9964,,,,,U,Autocuration,BAO_0000019
340,,8,B,,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,,CHEMBL615313,9964,,,,,H,Autocuration,BAO_0000019
341,,8,F,,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,,CHEMBL615314,9964,,,,,H,Autocuration,BAO_0000019
342,,8,B,,1,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615315,9964,,,,,H,Autocuration,BAO_0000019
343,Rattus norvegicus,0,B,,1,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",22226,10116.0,,,CHEMBL615316,9964,,,,,U,Autocuration,BAO_0000218
344,,8,B,,1,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,12132,,,,CHEMBL615317,9964,,,,,H,Autocuration,BAO_0000218
345,,8,B,,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615318,9964,,,,,H,Autocuration,BAO_0000218
346,Rattus norvegicus,0,B,,1,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",22226,10116.0,,,CHEMBL615319,9964,,,,,U,Autocuration,BAO_0000218
347,,8,B,,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615320,9964,,,,,H,Autocuration,BAO_0000019
348,,8,F,,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,,CHEMBL615321,9964,,,,,H,Autocuration,BAO_0000019
349,Rattus norvegicus,0,B,,1,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",22226,10116.0,,,CHEMBL615322,3796,,,,,U,Autocuration,BAO_0000019
350,Escherichia coli,8,B,,1,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,562.0,,,CHEMBL615323,4251,,,,,H,Autocuration,BAO_0000357
351,Escherichia coli,8,B,,1,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,562.0,,,CHEMBL615407,4251,,,,,H,Autocuration,BAO_0000357
352,Escherichia coli,8,B,,1,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,562.0,,,CHEMBL857267,4251,,,,,H,Autocuration,BAO_0000357
353,Escherichia coli,8,B,,1,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,562.0,,,CHEMBL615408,4251,,,,,H,Autocuration,BAO_0000357
354,,8,B,,1,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,19690,,,,CHEMBL615409,166,,,,,H,Autocuration,BAO_0000357
355,,8,B,,1,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,19690,,,,CHEMBL615410,17861,,,,,H,Autocuration,BAO_0000357
356,,8,B,,1,Inhibition constant against 3-dehydroquinate synthase,19690,,,,CHEMBL615411,166,,,,,H,Autocuration,BAO_0000357
357,,8,B,,1,Association rate constant against 3-dehydroquinate synthase,19690,,,,CHEMBL615412,166,,,,,H,Autocuration,BAO_0000357
358,,8,B,,1,Rate constant against 3-dehydroquinate synthase,19690,,,,CHEMBL615413,166,,,,,H,Autocuration,BAO_0000357
359,,0,B,,1,Inhibitory activity against fuc-TVII,22226,,,,CHEMBL615414,3548,,,,,U,Autocuration,BAO_0000019
360,Rattus norvegicus,9,B,,1,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,10116.0,Microsomes,,CHEMBL615415,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
361,Rattus norvegicus,9,B,,1,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,10116.0,Microsomes,,CHEMBL615416,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
362,Rattus norvegicus,9,B,,1,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,10116.0,Microsomes,,CHEMBL615417,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
363,Rattus norvegicus,9,B,,1,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,10116.0,Microsomes,,CHEMBL615418,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
364,Rattus norvegicus,9,B,,1,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,10116.0,Microsomes,,CHEMBL615419,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
365,Rattus norvegicus,9,B,,1,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,12236,10116.0,Microsomes,,CHEMBL615420,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
366,Rattus norvegicus,9,B,,1,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,12236,10116.0,Microsomes,,CHEMBL615421,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
367,Rattus norvegicus,9,B,,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,12236,10116.0,Microsomes,,CHEMBL615422,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
368,Rattus norvegicus,9,B,,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,12236,10116.0,Microsomes,,CHEMBL615423,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
369,Rattus norvegicus,9,B,,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,12236,10116.0,Microsomes,,CHEMBL872868,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
370,Rattus norvegicus,9,B,,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,12236,10116.0,Microsomes,,CHEMBL615424,9877,2107.0,,,Liver,D,Autocuration,BAO_0000251
371,,4,B,,1,Inhibitory activity against 3-phosphoglycerate kinase.,104832,,,,CHEMBL825022,3003,,,,,H,Autocuration,BAO_0000224
372,,4,B,,1,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,104832,,,,CHEMBL615425,3003,,,,,H,Autocuration,BAO_0000224
373,,4,B,,1,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",104832,,,,CHEMBL615426,3003,,,,,H,Autocuration,BAO_0000224
374,Homo sapiens,9,B,,1,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,10612,9606.0,,,CHEMBL615427,17185,,,,,D,Expert,BAO_0000357
375,Homo sapiens,1,F,3677 melanoma cell line,1,Cytotoxicity on 3677 melanoma cells,80616,9606.0,,,CHEMBL615428,6072,,844.0,,,N,Intermediate,BAO_0000219
376,Homo sapiens,1,F,3677 melanoma cell line,1,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,80616,9606.0,,,CHEMBL615429,6072,,844.0,,,N,Intermediate,BAO_0000219
377,Mus musculus,1,F,MC-38,1,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,80617,10090.0,,,CHEMBL615430,5018,,700.0,,,N,Intermediate,BAO_0000219
378,Homo sapiens,0,F,,1,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,22226,9606.0,,,CHEMBL615431,2852,,,,,U,Intermediate,BAO_0000019
379,,0,F,B16,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,22226,,,,CHEMBL615432,8663,,798.0,,,U,Autocuration,BAO_0000218
380,,0,F,B16,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,22226,,,,CHEMBL615433,8663,,798.0,,,U,Autocuration,BAO_0000218
381,Human rhinovirus 14,9,F,,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12464,12131.0,,,CHEMBL615434,3245,,,,,D,Expert,BAO_0000019
382,Human rhinovirus sp.,1,F,,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,50085,169066.0,,,CHEMBL615435,3245,,,,,N,Intermediate,BAO_0000218
383,human rhinovirus type 14,1,F,,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,50679,169066.0,,,CHEMBL615436,3877,,,,,N,Intermediate,BAO_0000218
384,human rhinovirus type 14,1,F,,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,50679,169066.0,,,CHEMBL615437,3877,,,,,N,Intermediate,BAO_0000218
385,Human rhinovirus 14,9,F,,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,12131.0,,,CHEMBL615438,5861,,,,,D,Expert,BAO_0000019
386,Human rhinovirus 14,9,F,,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,12131.0,,,CHEMBL615439,5861,,,,,D,Expert,BAO_0000019
387,Human rhinovirus 14,9,F,,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,12131.0,,,CHEMBL615440,5861,,,,,D,Expert,BAO_0000019
388,Human rhinovirus 14,9,F,,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12464,12131.0,,,CHEMBL615441,5861,,,,,D,Expert,BAO_0000019
389,Enterovirus,1,F,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,50665,12059.0,,,CHEMBL615641,13748,,,,,N,Intermediate,BAO_0000218
390,Enterovirus,1,F,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,50665,12059.0,,,CHEMBL872065,13748,,,,,N,Intermediate,BAO_0000218
391,Enterovirus,1,F,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,50665,12059.0,,,CHEMBL825023,13748,,,,,N,Intermediate,BAO_0000218
392,Enterovirus,1,F,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,50665,12059.0,,,CHEMBL615642,13748,,,,,N,Intermediate,BAO_0000218
393,Human rhinovirus B,8,B,,1,Inhibition of human rhinovirus 3C protease,12464,147712.0,,,CHEMBL615643,13748,,,,,H,Expert,BAO_0000357
394,Homo sapiens,0,B,,1,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,22226,9606.0,,,CHEMBL615644,17699,,,,,U,Autocuration,BAO_0000019
395,Mus musculus,1,F,3EM 37,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),80619,10090.0,,,CHEMBL615645,7145,,833.0,,,N,Intermediate,BAO_0000218
396,Mus musculus,1,F,3EM 37,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),80619,10090.0,,,CHEMBL615646,7145,,833.0,,,N,Intermediate,BAO_0000218
397,Mus musculus,1,F,3EM 37,1,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),80619,10090.0,,,CHEMBL615647,7145,,833.0,,,N,Intermediate,BAO_0000218
398,Mus musculus,1,F,3EM 37,1,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),80619,10090.0,,,CHEMBL615648,7145,,833.0,,,N,Intermediate,BAO_0000218
399,Mus musculus,1,F,3EM 37,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,80619,10090.0,,,CHEMBL615649,7145,,833.0,,,N,Intermediate,BAO_0000218
400,Mus musculus,1,F,3EM 37,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,80619,10090.0,,,CHEMBL615650,7145,,833.0,,,N,Intermediate,BAO_0000218
401,Mus musculus,1,F,3LL cell line,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,10090.0,,,CHEMBL615651,5325,,847.0,,,N,Intermediate,BAO_0000218
402,Mus musculus,1,F,3LL cell line,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,10090.0,,,CHEMBL615652,5325,,847.0,,,N,Intermediate,BAO_0000218
403,Mus musculus,1,F,3LL cell line,1,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,80620,10090.0,,,CHEMBL615653,5325,,847.0,,,N,Expert,BAO_0000218
404,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,80620,10090.0,,,CHEMBL615654,16169,,847.0,,,N,Intermediate,BAO_0000219
405,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,80620,10090.0,,,CHEMBL615655,16169,,847.0,,,N,Intermediate,BAO_0000219
406,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,80620,10090.0,,,CHEMBL825024,16169,,847.0,,,N,Intermediate,BAO_0000219
407,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,80620,10090.0,,,CHEMBL615656,16169,,847.0,,,N,Intermediate,BAO_0000219
408,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,80620,10090.0,,,CHEMBL615657,16169,,847.0,,,N,Intermediate,BAO_0000219
409,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,80620,10090.0,,,CHEMBL615658,16169,,847.0,,,N,Intermediate,BAO_0000219
410,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,80620,10090.0,,,CHEMBL615659,16169,,847.0,,,N,Intermediate,BAO_0000219
411,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,80620,10090.0,,,CHEMBL615660,16169,,847.0,,,N,Intermediate,BAO_0000219
412,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,10090.0,,,CHEMBL615661,16169,,847.0,,,N,Intermediate,BAO_0000219
413,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,80620,10090.0,,,CHEMBL615662,16169,,847.0,,,N,Intermediate,BAO_0000219
414,Mus musculus,1,F,3LL cell line,1,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,80620,10090.0,,,CHEMBL615663,16169,,847.0,,,N,Intermediate,BAO_0000219
415,Mus musculus,1,F,3LL cell line,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,80620,10090.0,,,CHEMBL615664,16169,,847.0,,,N,Intermediate,BAO_0000219
416,Mus musculus,1,F,3LL cell line,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,80620,10090.0,,,CHEMBL615665,16169,,847.0,,,N,Intermediate,BAO_0000219
417,Mus musculus,1,F,3LL cell line,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,10090.0,,,CHEMBL615666,16169,,847.0,,,N,Intermediate,BAO_0000219
418,Mus musculus,1,F,3LL cell line,1,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,80620,10090.0,,,CHEMBL615667,16169,,847.0,,,N,Intermediate,BAO_0000219
419,Mus musculus,1,F,3LL cell line,1,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,80620,10090.0,,,CHEMBL615668,16169,,847.0,,,N,Intermediate,BAO_0000219
420,Mus musculus,1,F,3LL cell line,1,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,80620,10090.0,,,CHEMBL615669,16169,,847.0,,,N,Intermediate,BAO_0000219
421,Mus musculus,1,F,3LL cell line,1,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,80620,10090.0,,,CHEMBL615670,16169,,847.0,,,N,Intermediate,BAO_0000219
422,Mus musculus,1,F,3LL cell line,1,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,80620,10090.0,,,CHEMBL836739,16169,,847.0,,,N,Intermediate,BAO_0000219
423,Mus musculus,1,F,3LL cell line,1,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,80620,10090.0,,,CHEMBL615671,16169,,847.0,,,N,Intermediate,BAO_0000219
424,Mus musculus,1,F,3LL cell line,1,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,80620,10090.0,,,CHEMBL615672,16169,,847.0,,,N,Intermediate,BAO_0000219
425,Mus musculus,1,F,3LL cell line,1,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,80620,10090.0,,,CHEMBL615791,16169,,847.0,,,N,Intermediate,BAO_0000219
426,Mus musculus,1,F,3LL cell line,1,spermine levels in 3LL cells after the treatment of 1 uM of Compound,80620,10090.0,,,CHEMBL615792,16169,,847.0,,,N,Intermediate,BAO_0000219
427,Mus musculus,1,F,3LL cell line,1,spermine levels in 3LL cells after the treatment of 10 uM of Compound,80620,10090.0,,,CHEMBL615793,16169,,847.0,,,N,Intermediate,BAO_0000219
428,Mus musculus,1,F,3LL cell line,1,spermine levels in 3LL cells after the treatment of 250 uM of Compound,80620,10090.0,,,CHEMBL615794,16169,,847.0,,,N,Intermediate,BAO_0000219
429,Mus musculus,1,F,3LL cell line,1,spermine levels in 3LL cells after the treatment of 50 uM of Compound,80620,10090.0,,,CHEMBL615795,16169,,847.0,,,N,Intermediate,BAO_0000219
430,Homo sapiens,1,F,3LLD122,1,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,80621,9606.0,,,CHEMBL615590,15547,,971.0,,,N,Intermediate,BAO_0000219
431,,0,F,,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,22226,,,,CHEMBL615591,8663,,,,,U,Autocuration,BAO_0000218
432,,0,F,,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,22226,,,,CHEMBL615592,8663,,,,,U,Autocuration,BAO_0000218
433,,0,F,,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,22226,,,,CHEMBL615593,8663,,,,,U,Autocuration,BAO_0000218
434,,0,F,,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,22226,,,,CHEMBL615594,8663,,,,,U,Autocuration,BAO_0000218
435,Mus musculus,1,F,NIH3T3,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,10090.0,,,CHEMBL615595,4504,,723.0,,,N,Intermediate,BAO_0000219
436,Mus musculus,1,F,NIH3T3,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,10090.0,,,CHEMBL615596,4504,,723.0,,,N,Intermediate,BAO_0000219
437,,8,F,NIH3T3,1,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,11169,,,,CHEMBL615597,12695,,723.0,,,H,Expert,BAO_0000219
438,Mus musculus,1,F,NIH3T3,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,80951,10090.0,,,CHEMBL615598,12695,,723.0,,,N,Intermediate,BAO_0000219
439,Mus musculus,1,F,NIH3T3,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,80951,10090.0,,,CHEMBL615599,12695,,723.0,,,N,Intermediate,BAO_0000219
440,Mus musculus,1,F,NIH3T3,1,Effective dose against murine 3T3 fibroblasts cells,80951,10090.0,,,CHEMBL615600,17642,,723.0,,,N,Expert,BAO_0000219
441,Mus musculus,1,F,NIH3T3,1,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,80951,10090.0,,,CHEMBL615601,17642,,723.0,,,N,Expert,BAO_0000219
442,Mus musculus,1,F,NIH3T3,1,Cytotoxic effect on 3T3 cells,80951,10090.0,,,CHEMBL615602,12340,,723.0,,,N,Expert,BAO_0000219
443,Mus musculus,1,F,NIH3T3,1,Cytotoxic effect on 3T3 cells,80951,10090.0,,,CHEMBL615603,12340,,723.0,,,N,Expert,BAO_0000219
444,Mus musculus,1,F,NIH3T3,1,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,80951,10090.0,,,CHEMBL615604,12716,,723.0,,,N,Intermediate,BAO_0000219
445,Mus musculus,1,F,NIH3T3,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,10090.0,,,CHEMBL615605,6277,,723.0,,,N,Intermediate,BAO_0000219
446,Mus musculus,1,F,NIH3T3,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,80951,10090.0,,,CHEMBL615606,6277,,723.0,,,N,Intermediate,BAO_0000219
447,Mus musculus,1,F,NIH3T3,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,80951,10090.0,,,CHEMBL884526,6277,,723.0,,,N,Expert,BAO_0000219
448,Mus musculus,1,F,NIH3T3,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,80951,10090.0,,,CHEMBL615607,6277,,723.0,,,N,Expert,BAO_0000219
449,Mus musculus,1,F,NIH3T3,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,80951,10090.0,,,CHEMBL615608,6277,,723.0,,,N,Intermediate,BAO_0000219
450,Mus musculus,1,F,NIH3T3,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,80951,10090.0,,,CHEMBL615609,6277,,723.0,,,N,Expert,BAO_0000219
451,Mus musculus,1,F,NIH3T3,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,80951,10090.0,,,CHEMBL615682,6277,,723.0,,,N,Expert,BAO_0000219
452,Mus musculus,1,F,NIH3T3,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,80951,10090.0,,,CHEMBL615683,6277,,723.0,,,N,Intermediate,BAO_0000219
453,Mus musculus,1,F,NIH3T3,1,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,80951,10090.0,,,CHEMBL615684,17780,,723.0,,,N,Expert,BAO_0000218
454,Mus musculus,7,F,,1,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,104860,10090.0,,,CHEMBL615685,12751,,,,,D,Autocuration,BAO_0000219
455,Mus musculus,1,F,NIH3T3,1,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,80951,10090.0,,,CHEMBL615686,12380,,723.0,,,N,Expert,BAO_0000219
456,Mus musculus,1,F,NIH3T3,1,Inhibitory activity against 3T3 cell line,80951,10090.0,,,CHEMBL615687,14892,,723.0,,,N,Intermediate,BAO_0000219
457,Mus musculus,1,F,NIH3T3,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,80951,10090.0,,,CHEMBL884523,12695,,723.0,,,N,Intermediate,BAO_0000219
458,,8,F,,1,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,11169,,,,CHEMBL615688,12695,,,,,H,Expert,BAO_0000019
459,Mus musculus,1,F,NIH3T3,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,80951,10090.0,,,CHEMBL615689,12695,,723.0,,,N,Intermediate,BAO_0000219
460,Mus musculus,1,F,NIH3T3,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,80951,10090.0,,,CHEMBL615690,12695,,723.0,,,N,Intermediate,BAO_0000219
461,,8,F,,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,11169,,,,CHEMBL615691,12695,,,,,H,Expert,BAO_0000019
462,,8,F,,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,11169,,,,CHEMBL615692,12695,,,,,H,Expert,BAO_0000019
463,Mus musculus,1,F,NIH3T3,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,10090.0,,,CHEMBL615693,6277,,723.0,,,N,Intermediate,BAO_0000219
464,Mus musculus,1,F,NIH3T3,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,80951,10090.0,,,CHEMBL615324,6277,,723.0,,,N,Expert,BAO_0000219
465,Homo sapiens,9,F,NIH3T3,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,9606.0,,,CHEMBL615325,4959,,723.0,,,D,Expert,BAO_0000219
466,Homo sapiens,9,F,NIH3T3,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,9606.0,,,CHEMBL615490,4959,,723.0,,,D,Expert,BAO_0000219
467,Homo sapiens,9,F,NIH3T3,1,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,188,9606.0,,,CHEMBL615491,4959,,723.0,,,D,Expert,BAO_0000219
468,Homo sapiens,9,F,NIH3T3,1,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),188,9606.0,,,CHEMBL615492,4959,,723.0,,,D,Expert,BAO_0000219
469,Mus musculus,1,F,NIH3T3,1,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,80951,10090.0,,,CHEMBL615493,12082,,723.0,,,N,Intermediate,BAO_0000219
470,Mus musculus,1,F,NIH3T3,1,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,80951,10090.0,,,CHEMBL615494,12082,,723.0,,,N,Intermediate,BAO_0000219
471,Mus musculus,1,F,NIH3T3,1,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,80951,10090.0,,,CHEMBL615495,12082,,723.0,,,N,Intermediate,BAO_0000219
472,Mus musculus,1,F,NIH3T3,1,Inhibitory concentration was calculated on 3T3 cells by using growth assay,80951,10090.0,,,CHEMBL615496,12082,,723.0,,,N,Intermediate,BAO_0000219
473,Mus musculus,1,F,NIH3T3,1,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,80951,10090.0,,,CHEMBL615497,2643,,723.0,,,N,Intermediate,BAO_0000219
474,Mus musculus,1,F,NIH3T3,1,Inhibition of Swiss 3T3 mouse fibroblast proliferation,80951,10090.0,,,CHEMBL615498,11926,,723.0,,,N,Expert,BAO_0000219
475,Mus musculus,1,A,NIH3T3,1,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,80951,10090.0,,,CHEMBL615499,15204,,723.0,,,N,Intermediate,BAO_0000219
476,Mus musculus,1,F,NIH3T3,1,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,80951,10090.0,,,CHEMBL835522,15992,,723.0,,,N,Expert,BAO_0000219
477,Mus musculus,1,F,NIH3T3,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,80951,10090.0,,,CHEMBL615500,16279,,723.0,,,N,Intermediate,BAO_0000219
478,Mus musculus,1,F,NIH3T3,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,10090.0,,,CHEMBL615501,16279,,723.0,,,N,Intermediate,BAO_0000219
479,Mus musculus,1,F,NIH3T3,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,10090.0,,,CHEMBL615502,16279,,723.0,,,N,Intermediate,BAO_0000219
480,Mus musculus,1,F,NIH3T3,1,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,10090.0,,,CHEMBL615503,16279,,723.0,,,N,Intermediate,BAO_0000219
481,Mus musculus,1,F,NIH3T3,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,10090.0,,,CHEMBL615504,16279,,723.0,,,N,Intermediate,BAO_0000219
482,Mus musculus,1,F,NIH3T3,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,10090.0,,,CHEMBL615505,16279,,723.0,,,N,Intermediate,BAO_0000219
483,Mus musculus,1,F,NIH3T3,1,Inhibition of swiss 3T3 mouse fibroblast proliferation,80951,10090.0,,,CHEMBL615506,12831,,723.0,,,N,Expert,BAO_0000219
484,Mus musculus,1,F,NIH3T3,1,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,80951,10090.0,,,CHEMBL615507,13497,,723.0,,,N,Intermediate,BAO_0000219
485,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,,CHEMBL615508,13715,,620.0,,,N,Intermediate,BAO_0000218
486,Mus musculus,1,F,3T3-L1,1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,80006,10090.0,,,CHEMBL615509,13618,,620.0,,,N,Intermediate,BAO_0000219
487,Mus musculus,1,F,3T3-L1,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,80006,10090.0,,,CHEMBL615510,11902,,620.0,,,N,Intermediate,BAO_0000219
488,Mus musculus,1,F,3T3-L1,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,80006,10090.0,,,CHEMBL615511,11902,,620.0,,,N,Intermediate,BAO_0000219
489,Mus musculus,1,F,3T3-L1,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,80006,10090.0,,,CHEMBL615512,11902,,620.0,,,N,Intermediate,BAO_0000219
490,Mus musculus,1,F,3T3-L1,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",80006,10090.0,,,CHEMBL615513,14840,,620.0,,,N,Intermediate,BAO_0000218
491,Mus musculus,1,F,3T3-L1,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",80006,10090.0,,,CHEMBL615514,14840,,620.0,,,N,Intermediate,BAO_0000218
492,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,80006,,,,CHEMBL615515,13715,,620.0,,,N,Intermediate,BAO_0000219
493,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,,CHEMBL615516,13715,,620.0,,,N,Intermediate,BAO_0000219
494,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,,CHEMBL615517,13715,,620.0,,,N,Intermediate,BAO_0000219
495,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,,CHEMBL615518,13715,,620.0,,,N,Intermediate,BAO_0000219
496,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,,CHEMBL615519,13715,,620.0,,,N,Intermediate,BAO_0000219
497,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,80006,,,,CHEMBL615520,13715,,620.0,,,N,Intermediate,BAO_0000218
498,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,80006,,,,CHEMBL615521,13715,,620.0,,,N,Intermediate,BAO_0000218
499,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,,CHEMBL615522,13715,,620.0,,,N,Intermediate,BAO_0000218
500,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,,CHEMBL615523,13715,,620.0,,,N,Intermediate,BAO_0000218
501,,1,F,3T3-L1,1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,,CHEMBL615524,13715,,620.0,,,N,Expert,BAO_0000218
502,,1,F,3T3-L1,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,,CHEMBL615525,13715,,620.0,,,N,Expert,BAO_0000218
503,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,,CHEMBL615526,13715,,620.0,,,N,Intermediate,BAO_0000218
504,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,,CHEMBL615527,13715,,620.0,,,N,Intermediate,BAO_0000218
505,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,80006,,,,CHEMBL615528,13715,,620.0,,,N,Intermediate,BAO_0000218
506,,1,F,3T3-L1,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,,CHEMBL615529,13715,,620.0,,,N,Expert,BAO_0000218
507,,1,F,3T3-L1,1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,,CHEMBL615530,13715,,620.0,,,N,Expert,BAO_0000218
508,,1,F,3T3-L1,1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,,CHEMBL615531,13715,,620.0,,,N,Expert,BAO_0000218
509,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,,CHEMBL615532,13715,,620.0,,,N,Intermediate,BAO_0000219
510,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,,CHEMBL615533,13715,,620.0,,,N,Intermediate,BAO_0000219
511,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,,CHEMBL615534,13715,,620.0,,,N,Intermediate,BAO_0000219
512,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,,CHEMBL615535,13715,,620.0,,,N,Intermediate,BAO_0000218
513,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,,CHEMBL615536,13715,,620.0,,,N,Intermediate,BAO_0000218
514,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,,CHEMBL615537,13715,,620.0,,,N,Intermediate,BAO_0000218
515,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,,CHEMBL615538,13715,,620.0,,,N,Intermediate,BAO_0000218
516,,1,F,3T3-L1,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,,CHEMBL836166,13715,,620.0,,,N,Intermediate,BAO_0000218
517,,8,F,3T3-L1,1,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,11214,,,,CHEMBL615539,6411,,620.0,,,H,Expert,BAO_0000219
518,Mus musculus,1,F,3T3-L1,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,80006,10090.0,,,CHEMBL615540,6411,,620.0,,,N,Intermediate,BAO_0000219
519,,8,F,3T3-L1,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,11214,,,,CHEMBL615541,6411,,620.0,,,H,Expert,BAO_0000219
520,Mus musculus,1,F,3T3-L1,1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,80006,10090.0,,,CHEMBL615542,3966,,620.0,,,N,Expert,BAO_0000219
521,Mus musculus,1,F,3T3-L1,1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,80006,10090.0,,,CHEMBL615543,3966,,620.0,,,N,Intermediate,BAO_0000219
522,Mus musculus,1,F,3T3-L1,1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,80006,10090.0,,,CHEMBL615544,15556,,620.0,,,N,Expert,BAO_0000219
523,Mus musculus,1,F,3T3-L1,1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,10090.0,,,CHEMBL615545,5845,,620.0,,,N,Expert,BAO_0000219
524,Mus musculus,1,F,3T3-L1,1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,10090.0,,,CHEMBL615546,14422,,620.0,,,N,Expert,BAO_0000219
525,Mus musculus,1,F,3T3-L1,1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,80006,10090.0,,,CHEMBL615547,5845,,620.0,,,N,Expert,BAO_0000219
526,Mus musculus,1,F,3T3-L1,1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,80006,10090.0,,,CHEMBL615548,14508,,620.0,,,N,Expert,BAO_0000219
527,Mus musculus,1,F,3T3-L1,1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,80006,10090.0,,,CHEMBL615549,14508,,620.0,,,N,Expert,BAO_0000219
528,Mus musculus,1,F,3T3-L1,1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,80006,10090.0,,,CHEMBL615550,14508,,620.0,,,N,Expert,BAO_0000219
529,Rattus norvegicus,1,F,3Y1 cell line,1,Inhibitory activity against rat fibroblast (3Y1) cell line,80622,10116.0,,,CHEMBL615551,6349,,1118.0,,,N,Intermediate,BAO_0000219
530,Rattus norvegicus,1,F,3Y1 cell line,1,Mean concentration causing inhibition of cell growth in 3Y1 cells.,80622,10116.0,,,CHEMBL615552,15899,,1118.0,,,N,Expert,BAO_0000219
531,Rattus norvegicus,1,F,3Y1 cell line,1,Cytotoxicity in 3Y1 cells.,80622,10116.0,,,CHEMBL615553,15899,,1118.0,,,N,Expert,BAO_0000219
532,Rattus norvegicus,1,F,3Y1 cell line,1,Cytostatic effect in 3Y1 cells.,80622,10116.0,,,CHEMBL615554,15899,,1118.0,,,N,Expert,BAO_0000219
533,Rattus norvegicus,1,F,3Y1 cell line,1,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",80622,10116.0,,,CHEMBL615555,15899,,1118.0,,,N,Intermediate,BAO_0000219
534,Rattus norvegicus,1,F,3Y1 cell line,1,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,80622,10116.0,,,CHEMBL615556,17038,,1118.0,,,N,Expert,BAO_0000219
535,,0,B,,1,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,22226,,,,CHEMBL615557,12421,,,,,U,Autocuration,BAO_0000019
536,,0,B,,1,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,,CHEMBL615558,12947,,,,,U,Autocuration,BAO_0000019
537,,0,B,,1,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,,CHEMBL872066,12947,,,,,U,Autocuration,BAO_0000019
538,Sus scrofa,9,B,,1,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,11607,9823.0,,,CHEMBL615559,4896,,,,,D,Expert,BAO_0000019
539,,8,B,,1,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,11607,,,,CHEMBL615560,6148,,,,,H,Autocuration,BAO_0000019
540,,8,B,,1,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,11607,,,,CHEMBL615561,16432,,,,,H,Autocuration,BAO_0000019
541,,8,B,,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,11607,,,,CHEMBL857062,4978,,,,,H,Expert,BAO_0000019
542,,8,B,,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),11607,,,,CHEMBL615562,4978,,,,,H,Expert,BAO_0000019
543,,8,B,,1,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,11607,,,,CHEMBL615563,3723,,,,,H,Autocuration,BAO_0000019
544,,8,B,,1,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),11607,,,,CHEMBL615564,3518,,,,,H,Autocuration,BAO_0000357
545,,8,B,,1,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,11607,,,,CHEMBL615565,4164,,,,,H,Autocuration,BAO_0000019
546,,8,B,,1,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,11607,,,,CHEMBL615566,3518,,,,,H,Autocuration,BAO_0000019
547,Sus scrofa,9,B,,1,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,11607,9823.0,,,CHEMBL615567,4164,,,,,D,Expert,BAO_0000019
548,,8,B,,1,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,11607,,,,CHEMBL615568,3518,,,,,H,Autocuration,BAO_0000019
549,,8,B,,1,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),11607,,,,CHEMBL615569,3518,,,,,H,Autocuration,BAO_0000357
550,,8,B,,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,11607,,,,CHEMBL615570,4978,,,,,H,Autocuration,BAO_0000019
551,,8,B,,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),11607,,,,CHEMBL615571,4978,,,,,H,Autocuration,BAO_0000019
552,,4,B,,1,Binding affinity against melatonin (MT1) receptor (pC1),104733,,,,CHEMBL615572,6455,,,,,H,Autocuration,BAO_0000224
553,,0,B,,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,22226,,,,CHEMBL615573,2222,,,,,U,Autocuration,BAO_0000019
554,,0,B,,1,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,22226,,,,CHEMBL615574,13020,,,,,U,Autocuration,BAO_0000019
555,,0,B,,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,22226,,,,CHEMBL615575,13021,,,,,U,Autocuration,BAO_0000019
556,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,10619,,,,CHEMBL615576,14532,,,,,H,Autocuration,BAO_0000357
557,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10619,,,,CHEMBL615577,14118,,,,,H,Autocuration,BAO_0000357
558,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,51,,,,CHEMBL615578,11884,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
559,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615579,13969,,,,,H,Expert,BAO_0000357
560,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615580,13392,,,,,H,Expert,BAO_0000357
561,,8,B,,1,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,51,,,,CHEMBL615581,14430,,,,,H,Expert,BAO_0000019
562,,8,B,,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,,CHEMBL615582,12248,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
563,,8,B,,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,,CHEMBL615583,12249,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
564,,8,B,,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,,CHEMBL615584,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
565,,8,B,,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL833691,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
566,,8,B,,1,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,,CHEMBL615585,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
567,,8,B,,1,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,,CHEMBL615586,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
568,,8,B,,1,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL884524,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
569,,8,B,,1,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,,CHEMBL615587,12249,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
570,,8,B,,1,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,,,CHEMBL615588,11799,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
571,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10576,10116.0,Membranes,,CHEMBL615589,14331,,,,,D,Expert,BAO_0000249
572,Bos taurus,8,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,51,9913.0,,,CHEMBL615442,11884,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
573,,8,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,51,,,,CHEMBL615443,14331,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
574,,8,B,,1,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,51,,,,CHEMBL615444,11701,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
575,,8,B,,1,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,51,,,,CHEMBL615445,11701,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
576,,8,B,,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,51,,,,CHEMBL615446,12248,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
577,,8,B,CHO,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,51,,,,CHEMBL615447,12248,,449.0,,,H,Autocuration,BAO_0000219
578,,8,B,,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,,CHEMBL615448,12248,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
579,,8,B,,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,,CHEMBL615449,12249,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
580,,8,B,CHO,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,,CHEMBL615450,12248,,449.0,,,H,Autocuration,BAO_0000219
581,,8,B,,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,,,CHEMBL615451,11799,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
582,,8,B,,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,,CHEMBL615452,634,,,,,H,Autocuration,BAO_0000357
583,,8,B,,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,,CHEMBL615453,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
584,,8,B,,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL615454,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
585,,8,B,,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,,CHEMBL615455,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
586,,8,B,,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL615456,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
587,,8,B,,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,,CHEMBL615457,9995,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
588,,8,B,,1,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,51,,,,CHEMBL615458,12210,10000000.0,,,Hippocampus,H,Expert,BAO_0000218
589,,8,B,,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL615459,13311,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
590,Homo sapiens,9,B,CHO,1,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",51,9606.0,,,CHEMBL615460,2331,,449.0,,,D,Expert,BAO_0000219
591,Cavia porcellus,8,F,,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,51,10141.0,,,CHEMBL615461,1375,,,,,H,Autocuration,BAO_0000019
592,Cavia porcellus,8,F,,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,51,10141.0,,,CHEMBL615462,1375,,,,,H,Autocuration,BAO_0000019
593,Cavia porcellus,8,F,,1,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,51,10141.0,,,CHEMBL615463,11574,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
594,Cavia porcellus,8,B,,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,10141.0,,,CHEMBL615464,12867,2116.0,,,Ileum,H,Autocuration,BAO_0000221
595,Cavia porcellus,8,B,,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,10141.0,,,CHEMBL615465,12867,2116.0,,,Ileum,H,Autocuration,BAO_0000221
596,Cavia porcellus,8,B,,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,10141.0,,,CHEMBL615466,12867,2116.0,,,Ileum,H,Autocuration,BAO_0000221
597,Cavia porcellus,8,B,,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,10141.0,,,CHEMBL615467,12867,2116.0,,,Ileum,H,Autocuration,BAO_0000221
598,Cavia porcellus,8,B,,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,10141.0,,,CHEMBL615468,12867,2116.0,,,Ileum,H,Autocuration,BAO_0000221
599,Cavia porcellus,8,B,,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,51,10141.0,,,CHEMBL615469,12867,2116.0,,,Ileum,H,Autocuration,BAO_0000221
600,Cavia porcellus,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor,51,10141.0,,,CHEMBL615470,11574,,,,,H,Autocuration,BAO_0000357
601,Cavia porcellus,8,B,,1,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,51,10141.0,,,CHEMBL615471,13114,,,,,H,Autocuration,BAO_0000357
602,Cavia porcellus,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,51,10141.0,,,CHEMBL615472,13181,,,,,H,Autocuration,BAO_0000357
603,Cavia porcellus,8,B,,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,10141.0,,,CHEMBL883242,10639,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
604,Cavia porcellus,8,F,,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,10141.0,,,CHEMBL615473,10639,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
605,Cricetulus griseus,8,B,CHO,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11863,10029.0,,,CHEMBL615474,11883,,449.0,,,H,Autocuration,BAO_0000218
606,,8,B,,1,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615475,17785,,,,,H,Autocuration,BAO_0000357
607,,8,F,HeLa,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,51,,,,CHEMBL615476,1558,,308.0,,,H,Autocuration,BAO_0000219
608,,8,F,HeLa,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,51,,,,CHEMBL615477,1558,,308.0,,,H,Autocuration,BAO_0000219
609,,8,F,,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615478,15740,,,,,H,Autocuration,BAO_0000019
610,,8,F,CHO,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615160,17624,,449.0,,,H,Autocuration,BAO_0000219
611,,8,F,CHO,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615161,17624,,449.0,,,H,Expert,BAO_0000219
612,,8,F,CHO,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,51,,,,CHEMBL615162,17624,,449.0,,,H,Autocuration,BAO_0000219
613,,8,F,CHO,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,51,,,,CHEMBL615163,17624,,449.0,,,H,Autocuration,BAO_0000219
614,,8,B,CHO,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,,CHEMBL615164,17624,,449.0,,,H,Expert,BAO_0000219
615,,8,B,CHO,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,,CHEMBL615165,17624,,449.0,,,H,Expert,BAO_0000219
616,,8,B,CHO,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,51,,,,CHEMBL615166,17624,,449.0,,,H,Autocuration,BAO_0000219
617,,8,F,,1,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,51,,,,CHEMBL615167,14256,,,,,H,Autocuration,BAO_0000219
618,Homo sapiens,9,B,HeLa,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,9606.0,,,CHEMBL615168,3445,,308.0,,,D,Expert,BAO_0000219
619,Homo sapiens,9,B,HeLa,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,51,9606.0,,,CHEMBL615169,3445,,308.0,,,D,Expert,BAO_0000219
620,Homo sapiens,9,B,CHO,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL615170,17200,,449.0,,,D,Expert,BAO_0000219
621,Homo sapiens,9,B,CHO,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,9606.0,,,CHEMBL615171,17200,,449.0,,,D,Expert,BAO_0000219
622,,8,F,,1,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615694,15180,,,,,H,Autocuration,BAO_0000019
623,,8,F,,1,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615695,15180,,,,,H,Autocuration,BAO_0000019
624,,8,F,,1,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,,CHEMBL615696,16026,,,,,H,Autocuration,BAO_0000019
625,,8,F,CHO,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,,CHEMBL615697,2759,,449.0,,,H,Autocuration,BAO_0000219
626,Homo sapiens,9,F,CHO,1,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,9606.0,,,CHEMBL859410,2759,,449.0,,,D,Expert,BAO_0000219
627,,8,F,CHO,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,,CHEMBL615841,2759,,449.0,,,H,Autocuration,BAO_0000219
628,Homo sapiens,9,F,CHO,1,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,9606.0,,,CHEMBL615842,2759,,449.0,,,D,Expert,BAO_0000219
629,,8,F,CHO,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,,CHEMBL835003,2759,,449.0,,,H,Autocuration,BAO_0000219
630,,8,F,CHO,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),51,,,,CHEMBL615843,2759,,449.0,,,H,Autocuration,BAO_0000219
631,Homo sapiens,9,F,CHO,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,9606.0,,,CHEMBL615979,2759,,449.0,,,D,Expert,BAO_0000219
632,,8,F,CHO,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,,CHEMBL615980,2759,,449.0,,,H,Autocuration,BAO_0000219
633,Homo sapiens,9,F,CHO,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,9606.0,,,CHEMBL615981,2759,,449.0,,,D,Expert,BAO_0000219
634,Homo sapiens,9,F,,1,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,51,9606.0,,,CHEMBL615982,3445,,,,,D,Expert,BAO_0000019
635,Homo sapiens,9,F,,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,9606.0,,,CHEMBL615983,5272,,,,,D,Expert,BAO_0000019
636,Homo sapiens,9,F,,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",51,9606.0,,,CHEMBL615984,5272,,,,,D,Expert,BAO_0000019
637,Homo sapiens,9,F,,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",51,9606.0,,,CHEMBL615985,5272,,,,,D,Expert,BAO_0000019
638,,8,F,CHO,1,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,,CHEMBL615986,17624,,449.0,,,H,Autocuration,BAO_0000219
639,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,,CHEMBL615987,17624,,449.0,,,H,Autocuration,BAO_0000219
640,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,,CHEMBL615988,17624,,449.0,,,H,Autocuration,BAO_0000219
641,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,,CHEMBL615989,17624,,449.0,,,H,Expert,BAO_0000219
642,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,,CHEMBL615990,17624,,449.0,,,H,Autocuration,BAO_0000219
643,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,51,,,,CHEMBL615991,17624,,449.0,,,H,Autocuration,BAO_0000219
644,,8,F,CHO,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,,CHEMBL615992,17624,,449.0,,,H,Autocuration,BAO_0000219
645,,8,F,CHO,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,,CHEMBL615993,17624,,449.0,,,H,Autocuration,BAO_0000219
646,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,,CHEMBL615994,17624,,449.0,,,H,Expert,BAO_0000219
647,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,51,,,,CHEMBL615995,17624,,449.0,,,H,Autocuration,BAO_0000219
648,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,,CHEMBL615996,17624,,449.0,,,H,Autocuration,BAO_0000219
649,,8,F,CHO,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,,CHEMBL615997,17624,,449.0,,,H,Autocuration,BAO_0000219
650,,8,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,,CHEMBL615998,6563,,,,,H,Autocuration,BAO_0000019
651,,8,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,,CHEMBL615999,6563,,,,,H,Autocuration,BAO_0000019
652,,8,F,,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,,CHEMBL616000,6563,,,,,H,Autocuration,BAO_0000019
653,,8,F,HEK293,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,,CHEMBL616001,17296,,722.0,,,H,Autocuration,BAO_0000219
654,Homo sapiens,9,F,,1,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",51,9606.0,,,CHEMBL616002,6876,,,,,D,Expert,BAO_0000019
655,,8,F,,1,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",51,,,,CHEMBL616003,6876,,,,,H,Expert,BAO_0000019
656,Homo sapiens,9,F,,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL616004,5272,,,,,D,Expert,BAO_0000019
657,Homo sapiens,9,F,,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,51,9606.0,,,CHEMBL616005,5272,,,,,D,Expert,BAO_0000019
658,,8,F,,1,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,,CHEMBL616006,5548,,,,,H,Autocuration,BAO_0000019
659,,8,F,,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",51,,,,CHEMBL616007,5548,,,,,H,Expert,BAO_0000019
660,,8,F,,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,,CHEMBL616008,5548,,,,,H,Autocuration,BAO_0000019
661,,8,F,,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,,CHEMBL616009,5548,,,,,H,Autocuration,BAO_0000019
662,,8,F,,1,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",51,,,,CHEMBL616010,5929,,,,,H,Expert,BAO_0000019
663,Homo sapiens,9,F,,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",51,9606.0,,,CHEMBL616011,5929,,,,,D,Expert,BAO_0000019
664,Homo sapiens,9,F,,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",51,9606.0,,,CHEMBL615740,5929,,,,,D,Expert,BAO_0000019
665,,8,F,,1,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",51,,,,CHEMBL615741,16245,,,,,H,Autocuration,BAO_0000019
666,,8,F,,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,,CHEMBL615742,5640,,,,,H,Expert,BAO_0000019
667,,8,F,,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",51,,,,CHEMBL615743,5640,,,,,H,Autocuration,BAO_0000019
668,,8,F,CHO,1,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,51,,,,CHEMBL615744,14509,,449.0,,,H,Autocuration,BAO_0000219
669,,8,F,CHO,1,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,51,,,,CHEMBL615745,14509,,449.0,,,H,Expert,BAO_0000219
670,,8,B,,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,,CHEMBL615746,15331,,,,,H,Autocuration,BAO_0000357
671,,8,B,,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,,CHEMBL615747,15331,,,,,H,Autocuration,BAO_0000357
672,,8,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,,CHEMBL615748,6563,,,,,H,Autocuration,BAO_0000019
673,,8,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",51,,,,CHEMBL615749,6563,,,,,H,Autocuration,BAO_0000019
674,,8,F,,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,,CHEMBL615750,6563,,,,,H,Autocuration,BAO_0000019
675,Homo sapiens,9,F,,1,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL616259,6563,,,,,D,Expert,BAO_0000019
676,,8,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,,CHEMBL616260,6563,,,,,H,Autocuration,BAO_0000019
677,Homo sapiens,9,F,,1,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,51,9606.0,,,CHEMBL616261,5272,,,,,D,Expert,BAO_0000019
678,Homo sapiens,9,F,,1,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,9606.0,,,CHEMBL616262,5272,,,,,D,Expert,BAO_0000019
679,Homo sapiens,9,F,,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,9606.0,,,CHEMBL616263,5272,,,,,D,Expert,BAO_0000019
680,Homo sapiens,9,F,,1,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,51,9606.0,,,CHEMBL616264,5272,,,,,D,Expert,BAO_0000019
681,Homo sapiens,9,F,,1,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,51,9606.0,,,CHEMBL616265,5272,,,,,D,Expert,BAO_0000019
682,Homo sapiens,9,F,,1,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,9606.0,,,CHEMBL616266,5272,,,,,D,Expert,BAO_0000019
683,Homo sapiens,9,F,,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,9606.0,,,CHEMBL616267,5272,,,,,D,Expert,BAO_0000019
684,Homo sapiens,9,F,,1,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,51,9606.0,,,CHEMBL616268,5272,,,,,D,Expert,BAO_0000019
685,Homo sapiens,9,B,,1,Inhibition of human 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL616269,16146,,,,,D,Expert,BAO_0000357
686,,8,B,CHO,1,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,,CHEMBL884528,17624,,449.0,,,H,Autocuration,BAO_0000219
687,,9,B,HEK293,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,105,,,,CHEMBL616270,13706,,722.0,,,D,Expert,BAO_0000219
688,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,51,,,,CHEMBL616271,15250,,449.0,,,H,Autocuration,BAO_0000219
689,,8,F,CHO,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616272,17624,,449.0,,,H,Autocuration,BAO_0000219
690,,8,B,,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,51,,,,CHEMBL616273,6861,,,,,H,Expert,BAO_0000357
691,Homo sapiens,9,B,,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL616274,17200,,,,,D,Expert,BAO_0000357
692,,8,B,CHO,1,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,51,,,,CHEMBL616275,17624,,449.0,,,H,Autocuration,BAO_0000219
693,,8,B,CHO,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,,CHEMBL616276,17624,,449.0,,,H,Autocuration,BAO_0000219
694,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,10116.0,,,CHEMBL616277,12058,,,,,U,Autocuration,BAO_0000218
695,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,22226,10116.0,,,CHEMBL616278,12058,,,,,U,Autocuration,BAO_0000218
696,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,22226,10116.0,,,CHEMBL616279,12058,,,,,U,Autocuration,BAO_0000218
697,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,10116.0,,,CHEMBL616280,12058,,,,,U,Autocuration,BAO_0000218
698,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,22226,10116.0,,,CHEMBL616281,12058,,,,,U,Autocuration,BAO_0000218
699,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,10116.0,,,CHEMBL616282,12058,,,,,U,Autocuration,BAO_0000218
700,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,22226,10116.0,,,CHEMBL616283,12058,,,,,U,Autocuration,BAO_0000218
701,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,22226,10116.0,,,CHEMBL616284,12058,,,,,U,Autocuration,BAO_0000218
702,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,22226,10116.0,,,CHEMBL616285,12058,,,,,U,Autocuration,BAO_0000218
703,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,22226,10116.0,,,CHEMBL616286,12058,,,,,U,Autocuration,BAO_0000218
704,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,22226,10116.0,,,CHEMBL616287,12058,,,,,U,Autocuration,BAO_0000218
705,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,22226,10116.0,,,CHEMBL616288,12058,,,,,U,Autocuration,BAO_0000218
706,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,22226,10116.0,,,CHEMBL616289,12058,,,,,U,Autocuration,BAO_0000218
707,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,22226,10116.0,,,CHEMBL615610,12058,,,,,U,Autocuration,BAO_0000218
708,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,22226,10116.0,,,CHEMBL615611,12058,,,,,U,Autocuration,BAO_0000218
709,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,22226,10116.0,,,CHEMBL615612,12058,,,,,U,Autocuration,BAO_0000218
710,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,22226,10116.0,,,CHEMBL615613,12058,,,,,U,Autocuration,BAO_0000218
711,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,22226,10116.0,,,CHEMBL615614,12058,,,,,U,Autocuration,BAO_0000218
712,Rattus norvegicus,0,F,,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,10116.0,,,CHEMBL615615,12058,,,,,U,Autocuration,BAO_0000218
713,,4,B,,1,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,105093,,,,CHEMBL615616,11440,,,,,H,Autocuration,BAO_0000019
714,,8,B,,1,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,11923,,,,CHEMBL615617,6238,1898.0,,,Hypothalamus,H,Autocuration,BAO_0000249
715,,8,B,,1,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10577,,,,CHEMBL615618,10046,,,,,H,Autocuration,BAO_0000019
716,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10577,,,,CHEMBL615619,10046,,,,,H,Autocuration,BAO_0000019
717,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,,,CHEMBL615620,10046,,,,,H,Expert,BAO_0000019
718,,8,B,,1,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",55,,,,CHEMBL615621,167,,,,,H,Autocuration,BAO_0000357
719,,8,B,,1,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",55,,,,CHEMBL615622,167,,,,,H,Autocuration,BAO_0000357
720,,8,F,,1,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),12166,,,,CHEMBL615623,11520,,,,,H,Autocuration,BAO_0000019
721,,8,F,,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,,CHEMBL615624,11520,,,,,H,Autocuration,BAO_0000019
722,,8,F,,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,,CHEMBL615625,11520,,,,,H,Autocuration,BAO_0000019
723,,8,F,,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,,CHEMBL767045,11520,,,,,H,Autocuration,BAO_0000019
724,Cavia porcellus,8,F,,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,55,10141.0,,,CHEMBL615626,135,,,,,H,Autocuration,BAO_0000019
725,Cavia porcellus,8,F,,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,55,10141.0,,,CHEMBL615627,135,,,,,H,Autocuration,BAO_0000019
726,Cavia porcellus,8,B,,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,55,10141.0,,,CHEMBL615628,11311,,,,,H,Autocuration,BAO_0000019
727,Cavia porcellus,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,10141.0,,,CHEMBL615629,10193,,,,,H,Autocuration,BAO_0000357
728,Homo sapiens,9,B,,1,Inhibitory concentration against 5-lipoxygenase from human whole blood,55,9606.0,,,CHEMBL615630,12281,,,,,D,Expert,BAO_0000357
729,,8,B,,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,,,CHEMBL615631,11311,,,,,H,Autocuration,BAO_0000219
730,,8,F,,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,,CHEMBL615632,12576,,,,,H,Autocuration,BAO_0000218
731,,8,B,,1,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,17087,,,,CHEMBL615633,12281,,,,,H,Autocuration,BAO_0000357
732,,8,F,,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,,CHEMBL615634,12576,,,,,H,Autocuration,BAO_0000218
733,Sus scrofa,8,B,,1,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,9823.0,,,CHEMBL615635,11089,,,,,H,Expert,BAO_0000019
734,,8,B,,1,In vitro inhibition of rat 5-Lipoxygenase,12166,,,,CHEMBL615636,11006,,,,,H,Expert,BAO_0000357
735,Rattus norvegicus,9,B,,1,Inhibitory activity against 5-Lipoxygenase,12166,10116.0,,,CHEMBL615637,11481,,,,,D,Expert,BAO_0000357
736,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,12166,,,,CHEMBL615638,10864,,702.0,,,H,Expert,BAO_0000219
737,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,,CHEMBL615639,3595,,702.0,,,H,Autocuration,BAO_0000219
738,,8,B,RBL-1,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,12166,,,,CHEMBL615640,11311,,702.0,,,H,Autocuration,BAO_0000219
739,,8,B,,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,12166,,,,CHEMBL615796,11311,,,,,H,Autocuration,BAO_0000019
740,,8,B,,1,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],12166,,,,CHEMBL615845,11311,,,,,H,Autocuration,BAO_0000219
741,,8,B,,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,,CHEMBL615846,11006,,,,,H,Autocuration,BAO_0000357
742,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,,,CHEMBL615847,3595,,702.0,,,H,Autocuration,BAO_0000219
743,,8,B,,1,The compound was tested for inhibition of isolated 5-Lipoxygenase,12166,,,,CHEMBL615848,11311,,,,,H,Autocuration,BAO_0000357
744,Rattus norvegicus,0,B,,1,Ratio of IC50 against 5-LO and COX,22226,10116.0,,,CHEMBL615849,11481,,,,,U,Autocuration,BAO_0000019
745,,8,B,,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,,CHEMBL615850,11006,,,,,H,Autocuration,BAO_0000357
746,,8,B,,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,12166,,,,CHEMBL615851,11006,,,,,H,Autocuration,BAO_0000357
747,,8,B,,1,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,12166,,,,CHEMBL615852,11311,,,,,H,Autocuration,BAO_0000219
748,,8,F,,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,12166,,,,CHEMBL615853,11006,,,,,H,Autocuration,BAO_0000019
749,,8,B,,1,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,120,,,,CHEMBL884527,4288,2367.0,,,Prostate gland,H,Autocuration,BAO_0000357
750,Columba livia,0,B,,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,22226,8932.0,,,CHEMBL872871,7587,,,,,U,Autocuration,BAO_0000019
751,Columba livia,0,B,,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,22226,8932.0,,,CHEMBL615854,7587,,,,,U,Autocuration,BAO_0000019
752,Columba livia,0,B,,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,22226,8932.0,,,CHEMBL767046,7587,,,,,U,Autocuration,BAO_0000019
753,,8,B,,1,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,10732,,,,CHEMBL615855,11249,,,,,H,Autocuration,BAO_0000357
754,Rattus norvegicus,9,F,,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,12198,10116.0,,,CHEMBL615856,8003,,,,,D,Expert,BAO_0000019
755,Rattus norvegicus,9,F,,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,10116.0,,,CHEMBL615857,8003,,,,,D,Expert,BAO_0000019
756,Rattus norvegicus,9,F,,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,10116.0,,,CHEMBL615858,8003,,,,,D,Expert,BAO_0000019
757,,8,B,,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,,,CHEMBL615859,12416,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
758,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1 receptor,51,,,,CHEMBL615860,16293,,,,,H,Autocuration,BAO_0000357
759,Oryctolagus cuniculus,0,B,,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,9986.0,,,CHEMBL615861,13047,,,,,U,Autocuration,BAO_0000019
760,Oryctolagus cuniculus,0,B,,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,9986.0,,,CHEMBL615862,13047,,,,,U,Autocuration,BAO_0000019
761,Oryctolagus cuniculus,0,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,22226,9986.0,,,CHEMBL615863,13047,,,,,U,Autocuration,BAO_0000019
762,Oryctolagus cuniculus,0,B,,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,22226,9986.0,,,CHEMBL615864,13047,,,,,U,Autocuration,BAO_0000019
763,,4,B,,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,,CHEMBL615865,10085,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
764,,4,B,,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,,CHEMBL615866,10085,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
765,,4,B,,1,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,,CHEMBL615867,10085,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
766,,4,B,,1,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,104744,,Membranes,,CHEMBL615868,9841,,,,,H,Autocuration,BAO_0000249
767,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,104744,10116.0,,,CHEMBL615869,8822,,,,,D,Autocuration,BAO_0000249
768,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,104744,10116.0,,,CHEMBL615870,9806,,,,,D,Autocuration,BAO_0000019
769,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,104744,10116.0,,,CHEMBL615871,9806,,,,,D,Autocuration,BAO_0000019
770,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,104744,,,,CHEMBL615872,8868,,,,,H,Autocuration,BAO_0000224
771,,4,B,,1,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,104744,,,,CHEMBL833492,9036,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
772,,4,B,,1,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,104744,,,,CHEMBL615873,11374,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
773,,4,B,,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,104744,,,,CHEMBL615479,10881,,,,,H,Autocuration,BAO_0000224
774,,4,B,,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,104744,,,,CHEMBL615480,8822,,,,,H,Autocuration,BAO_0000019
775,Rattus norvegicus,5,B,,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,104744,10116.0,,,CHEMBL615481,9806,,,,,D,Autocuration,BAO_0000249
776,,4,B,,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,,CHEMBL872869,15463,,,,,H,Autocuration,BAO_0000019
777,,4,B,,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,,CHEMBL615482,15463,,,,,H,Autocuration,BAO_0000019
778,,4,B,,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,,CHEMBL615483,14542,955.0,,,Brain,H,Autocuration,BAO_0000221
779,,4,B,,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,,CHEMBL615484,14542,955.0,,,Brain,H,Autocuration,BAO_0000221
780,,4,B,,1,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,104744,,,,CHEMBL615485,8569,,,,,H,Autocuration,BAO_0000019
781,Rattus norvegicus,5,B,,1,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,104744,10116.0,,,CHEMBL615486,10062,,,,,D,Autocuration,BAO_0000224
782,,4,B,,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,104744,,,,CHEMBL615487,4771,,,,,H,Autocuration,BAO_0000224
783,,4,B,,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,,CHEMBL615488,10062,,,,,H,Autocuration,BAO_0000224
784,,4,B,,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,,CHEMBL615489,10062,,,,,H,Autocuration,BAO_0000224
785,,4,B,,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,,CHEMBL615389,10062,,,,,H,Autocuration,BAO_0000224
786,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,,CHEMBL615390,15463,,,,,H,Autocuration,BAO_0000019
787,,4,B,,1,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,,CHEMBL615391,15463,,,,,H,Autocuration,BAO_0000019
788,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,104744,,,,CHEMBL615392,9098,,,,,H,Autocuration,BAO_0000224
789,Rattus norvegicus,0,B,,1,Affinity for 5-hydroxytryptamine 1 receptor,22226,10116.0,,,CHEMBL615393,3070,,,,,U,Autocuration,BAO_0000019
790,,4,B,,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,104744,,,,CHEMBL615394,14542,955.0,,,Brain,H,Autocuration,BAO_0000221
791,,4,B,,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,,CHEMBL615395,14542,955.0,,,Brain,H,Autocuration,BAO_0000221
792,,4,B,,1,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,104744,,,,CHEMBL615396,6398,,,,,H,Autocuration,BAO_0000224
793,,4,B,,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,104744,,,,CHEMBL615397,1344,955.0,,,Brain,H,Autocuration,BAO_0000221
794,,4,B,,1,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,,CHEMBL615398,11963,,,,,H,Autocuration,BAO_0000019
795,Rattus norvegicus,0,B,,1,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,22226,10116.0,,,CHEMBL615399,8908,,,,,U,Autocuration,BAO_0000019
796,,4,B,,1,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,104744,,,,CHEMBL615400,9098,,,,,H,Autocuration,BAO_0000019
797,Rattus norvegicus,5,B,,1,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,104744,10116.0,,,CHEMBL615401,8841,,,,,D,Autocuration,BAO_0000019
798,Rattus norvegicus,0,B,,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,22226,10116.0,,,CHEMBL615402,8814,,,,,U,Autocuration,BAO_0000019
799,,4,B,,1,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,104744,,,,CHEMBL615403,11752,,,,,H,Autocuration,BAO_0000019
800,,4,B,,1,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,104744,,,,CHEMBL615404,11642,955.0,,,Brain,H,Autocuration,BAO_0000221
801,,4,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,104744,,,,CHEMBL615781,11642,,,,,H,Autocuration,BAO_0000019
802,,4,B,,1,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,104744,,,,CHEMBL615782,9231,955.0,,,Brain,H,Autocuration,BAO_0000220
803,,4,B,,1,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,104744,,,,CHEMBL615783,11351,955.0,,,Brain,H,Autocuration,BAO_0000221
804,,0,B,,1,Compound was tested for binding affinity against 5-HT1 receptor,22226,,,,CHEMBL873481,4639,,,,,U,Autocuration,BAO_0000019
805,,0,B,,1,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,22226,,,,CHEMBL615784,1205,,,,,U,Autocuration,BAO_0000019
806,,8,B,,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,,CHEMBL615785,10025,,,,,H,Expert,BAO_0000357
807,,8,F,,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,,CHEMBL615786,13241,,,,,H,Autocuration,BAO_0000249
808,,8,F,,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,,,CHEMBL615787,16245,,,,,H,Autocuration,BAO_0000218
809,,8,F,,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,,,CHEMBL615788,16245,,,,,H,Autocuration,BAO_0000218
810,,8,F,,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL767044,12438,,,,,H,Autocuration,BAO_0000019
811,,8,F,,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,,,CHEMBL615789,16245,,,,,H,Autocuration,BAO_0000218
812,,8,F,,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,,,CHEMBL615790,16245,,,,,H,Autocuration,BAO_0000218
813,,8,F,,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,10576,,,,CHEMBL615813,15740,,,,,H,Autocuration,BAO_0000019
814,,8,F,,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,10576,,,,CHEMBL615814,15535,,,,,H,Autocuration,BAO_0000219
815,,8,F,,1,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,51,,,,CHEMBL615815,15535,,,,,H,Expert,BAO_0000219
816,,8,F,,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,10576,,,,CHEMBL615816,15535,,,,,H,Autocuration,BAO_0000219
817,,8,B,,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,10576,,,,CHEMBL615817,9888,,,,,H,Expert,BAO_0000249
818,,8,B,,1,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,,,CHEMBL615818,10085,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
819,,8,B,,1,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,,,CHEMBL615819,10085,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
820,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,10576,,Membranes,,CHEMBL615820,17331,,,,,H,Expert,BAO_0000249
821,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10576,10116.0,,,CHEMBL615821,10845,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
822,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,10116.0,,,CHEMBL615822,10845,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
823,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615823,10845,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
824,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10576,10116.0,,,CHEMBL615824,10845,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
825,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,10116.0,,,CHEMBL615825,10845,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
826,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615826,13730,,,,,H,Expert,BAO_0000357
827,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615827,13508,,,,,H,Expert,BAO_0000249
828,,8,B,,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615828,13508,10000000.0,,,Hippocampus,H,Expert,BAO_0000249
829,,8,B,,1,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL615829,12073,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
830,,8,B,,1,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615830,4671,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
831,,8,B,,1,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10576,,,,CHEMBL615831,13631,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
832,,8,B,,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL615832,12438,,,,,H,Autocuration,BAO_0000357
833,,8,B,,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10576,,,,CHEMBL615833,10483,,,,,H,Autocuration,BAO_0000019
834,,8,B,,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10576,,,,CHEMBL615834,10483,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
835,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,10576,,,,CHEMBL615835,12352,,,,,H,Intermediate,BAO_0000249
836,,8,B,,1,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10576,,,,CHEMBL615836,14732,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000249
837,Rattus norvegicus,9,B,,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10576,10116.0,,,CHEMBL615837,11049,,,,,D,Expert,BAO_0000019
838,Rattus norvegicus,9,B,,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10576,10116.0,,,CHEMBL615838,11049,,,,,D,Expert,BAO_0000019
839,,8,B,,1,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",10576,,,,CHEMBL615839,13657,,,,,H,Expert,BAO_0000249
840,,8,B,,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,10576,,,,CHEMBL884525,11473,,,,,H,Autocuration,BAO_0000019
841,,8,B,,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,,CHEMBL615840,2014,,,,,H,Autocuration,BAO_0000249
842,,8,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL615405,3086,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
843,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10576,,,,CHEMBL615406,15854,,,,,H,Expert,BAO_0000019
844,,8,B,,1,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,,,CHEMBL615900,10922,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
845,,8,B,,1,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10576,,,,CHEMBL615901,13346,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
846,,8,B,,1,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,10576,,,,CHEMBL615902,15311,,,,,H,Expert,BAO_0000357
847,,8,B,,1,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,,,CHEMBL615903,10922,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
848,,8,B,,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10576,,,,CHEMBL615904,10025,,,,,H,Autocuration,BAO_0000357
849,,8,B,,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,,CHEMBL615905,10025,,,,,H,Expert,BAO_0000357
850,,8,B,,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,,CHEMBL615906,9742,,,,,H,Autocuration,BAO_0000019
851,,8,F,,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,,CHEMBL615907,9742,,,,,H,Autocuration,BAO_0000019
852,,8,B,,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,,CHEMBL615908,12304,,,,,H,Expert,BAO_0000019
853,,8,B,,1,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10576,,,,CHEMBL615909,15789,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
854,,8,B,,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",10576,,,,CHEMBL615910,9912,,,,,H,Autocuration,BAO_0000019
855,,8,B,,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",10576,,,,CHEMBL615911,9912,,,,,H,Autocuration,BAO_0000019
856,,8,B,,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",10576,,,,CHEMBL615912,9912,,,,,H,Autocuration,BAO_0000019
857,,8,B,,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615913,16693,,,,,H,Expert,BAO_0000019
858,,8,B,,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,,CHEMBL615914,13276,,,,,H,Expert,BAO_0000357
859,,8,B,,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,,,CHEMBL615915,12678,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
860,,8,B,,1,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,10576,,,,CHEMBL615916,11825,,,,,H,Autocuration,BAO_0000357
861,,8,B,,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,10576,,,,CHEMBL615917,12443,,,,,H,Expert,BAO_0000357
862,,8,B,,1,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL615918,13830,,,,,H,Expert,BAO_0000357
863,,8,B,,1,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10576,,,,CHEMBL615919,14286,10000000.0,,,Hippocampus,H,Expert,BAO_0000249
864,Rattus norvegicus,9,B,,1,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,10116.0,,,CHEMBL615920,14356,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
865,,8,B,,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL615921,15306,,,,,H,Autocuration,BAO_0000357
866,,8,B,,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),10576,,,,CHEMBL615922,15306,,,,,H,Expert,BAO_0000357
867,Rattus norvegicus,9,F,,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,10116.0,,,CHEMBL881290,16616,,,,,D,Expert,BAO_0000249
868,,8,B,,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10576,,,,CHEMBL615923,3651,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
869,,8,F,,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL615924,14331,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
870,,8,F,,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL615925,14331,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
871,Rattus norvegicus,9,B,,1,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL615926,14178,,,,,D,Expert,BAO_0000357
872,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL615927,10639,,,,,D,Expert,BAO_0000019
873,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,,CHEMBL615928,12306,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
874,Rattus norvegicus,9,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10576,10116.0,,,CHEMBL615929,1348,,,,,D,Expert,BAO_0000357
875,,8,B,,1,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10576,,,,CHEMBL615930,13605,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
876,,8,B,CHO,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,,CHEMBL615931,17624,,449.0,,,H,Autocuration,BAO_0000219
877,,8,F,CHO,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615932,17624,,449.0,,,H,Autocuration,BAO_0000219
878,,8,F,CHO,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615933,17624,,449.0,,,H,Autocuration,BAO_0000219
879,,8,B,,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615934,15267,,,,,H,Autocuration,BAO_0000357
880,,8,B,,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,51,,,,CHEMBL615935,16532,,,,,H,Autocuration,BAO_0000357
881,,8,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,,CHEMBL615936,6563,,,,,H,Autocuration,BAO_0000019
882,,8,B,CHO,1,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,51,,,,CHEMBL615937,4751,,449.0,,,H,Autocuration,BAO_0000219
883,,8,B,,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615938,15463,,,,,H,Autocuration,BAO_0000357
884,,8,B,,1,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),51,,,,CHEMBL615797,3805,,,,,H,Autocuration,BAO_0000357
885,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615798,5640,,,,,H,Autocuration,BAO_0000357
886,,8,B,,1,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,51,,,,CHEMBL872870,6563,,,,,H,Autocuration,BAO_0000357
887,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,51,,,,CHEMBL615799,5548,,,,,H,Autocuration,BAO_0000357
888,,8,B,,1,Percent binding affinity against 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615800,6347,,,,,H,Autocuration,BAO_0000357
889,,8,F,HEK293,1,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,,CHEMBL615801,17296,,722.0,,,H,Autocuration,BAO_0000219
890,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,51,,,,CHEMBL615802,13047,,,,,H,Autocuration,BAO_0000019
891,,8,B,,1,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,51,,,,CHEMBL615803,15740,,,,,H,Autocuration,BAO_0000357
892,,8,F,,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,,CHEMBL835002,5640,,,,,H,Expert,BAO_0000019
893,,8,F,,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",51,,,,CHEMBL615804,5640,,,,,H,Autocuration,BAO_0000019
894,,8,B,HeLa,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615805,17211,,308.0,,,H,Expert,BAO_0000219
895,,8,B,CHO,1,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615806,4751,,449.0,,,H,Autocuration,BAO_0000219
896,Homo sapiens,9,B,,1,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,51,9606.0,,,CHEMBL615807,6491,,,,,D,Expert,BAO_0000357
897,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,51,,,,CHEMBL615808,4707,,,,,H,Autocuration,BAO_0000357
898,Homo sapiens,9,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL615809,13910,,,,,D,Expert,BAO_0000357
899,,8,B,HeLa,1,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,51,,,,CHEMBL615810,16190,,308.0,,,H,Autocuration,BAO_0000219
900,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615811,16633,,,,,H,Autocuration,BAO_0000357
901,,8,B,CHO,1,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,51,,,,CHEMBL615812,11898,,449.0,,,H,Autocuration,BAO_0000219
902,,8,B,CHO,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,,CHEMBL615751,11898,,449.0,,,H,Autocuration,BAO_0000219
903,,8,B,,1,Binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615752,14331,,,,,H,Autocuration,BAO_0000357
904,,8,B,CHO,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,51,,,,CHEMBL615753,17624,,449.0,,,H,Expert,BAO_0000219
905,,8,B,CHO,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,51,,,,CHEMBL615754,17624,,449.0,,,H,Autocuration,BAO_0000219
906,,8,B,,1,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615755,3307,,,,,H,Autocuration,BAO_0000357
907,Homo sapiens,9,B,CHO,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,9606.0,,,CHEMBL615756,6563,,449.0,,,D,Expert,BAO_0000219
908,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615757,14165,,,,,H,Autocuration,BAO_0000019
909,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,,CHEMBL615758,5732,,,,,H,Autocuration,BAO_0000357
910,,8,B,,1,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,,CHEMBL615759,13366,,,,,H,Expert,BAO_0000357
911,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615760,17626,,,,,H,Autocuration,BAO_0000357
912,,8,B,HeLa,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,51,,,,CHEMBL615761,6588,,308.0,,,H,Expert,BAO_0000219
913,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,51,,,,CHEMBL872104,16209,,,,,H,Autocuration,BAO_0000357
914,,8,B,,1,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615762,15463,,,,,H,Autocuration,BAO_0000357
915,,8,B,,1,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615763,15463,,,,,H,Autocuration,BAO_0000357
916,,8,B,,1,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,51,,,,CHEMBL615764,14770,,,,,H,Autocuration,BAO_0000357
917,,8,B,Cell line,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),51,,,,CHEMBL615765,16245,,1167.0,,,H,Autocuration,BAO_0000219
918,,8,B,,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),51,,,,CHEMBL615766,16245,,,,,H,Autocuration,BAO_0000019
919,,8,B,,1,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615767,5548,,,,,H,Autocuration,BAO_0000357
920,,8,B,,1,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615768,5548,,,,,H,Expert,BAO_0000357
921,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615769,5548,,,,,H,Autocuration,BAO_0000357
922,,8,B,,1,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,51,,,,CHEMBL615770,6876,,,,,H,Expert,BAO_0000357
923,,8,B,,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615771,2598,,,,,H,Autocuration,BAO_0000357
924,,8,B,,1,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,51,,,,CHEMBL615772,17785,,,,,H,Expert,BAO_0000357
925,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL615773,6013,,,,,H,Autocuration,BAO_0000357
926,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615774,5929,,,,,H,Expert,BAO_0000357
927,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615775,16633,,,,,H,Autocuration,BAO_0000357
928,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,,CHEMBL615776,1558,,,,,H,Autocuration,BAO_0000357
929,,8,B,,1,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL615777,16026,,,,,H,Expert,BAO_0000357
930,,8,B,,1,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,51,,,,CHEMBL615778,12469,,,,,H,Autocuration,BAO_0000219
931,Homo sapiens,9,B,,1,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,9606.0,,,CHEMBL615779,15874,,,,,D,Expert,BAO_0000357
932,,8,B,,1,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,,,CHEMBL615780,15874,,,,,H,Autocuration,BAO_0000357
933,,8,B,,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616298,3935,,,,,H,Autocuration,BAO_0000357
934,,8,B,,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616299,15818,,,,,H,Autocuration,BAO_0000357
935,,8,B,CHO-K1,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,51,,,,CHEMBL616300,13706,,485.0,,,H,Autocuration,BAO_0000219
936,,8,F,CHO-K1,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,51,,,,CHEMBL616301,13729,,485.0,,,H,Expert,BAO_0000219
937,,8,B,,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616302,15413,,,,,H,Autocuration,BAO_0000019
938,,8,B,,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),51,,,,CHEMBL616117,15413,,,,,H,Autocuration,BAO_0000019
939,,8,B,,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),51,,,,CHEMBL616118,15413,,,,,H,Autocuration,BAO_0000019
940,,8,B,,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,51,,,,CHEMBL616119,15413,,,,,H,Autocuration,BAO_0000019
941,Homo sapiens,9,B,HeLa,1,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,9606.0,,,CHEMBL616120,3445,,308.0,,,D,Expert,BAO_0000219
942,,8,B,,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616121,15740,,,,,H,Autocuration,BAO_0000357
943,,8,B,,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,51,,,,CHEMBL616122,15740,,,,,H,Autocuration,BAO_0000357
944,,8,B,,1,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616123,17626,,,,,H,Autocuration,BAO_0000357
945,Homo sapiens,9,B,,1,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL616124,4234,,,,,D,Expert,BAO_0000357
946,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,,CHEMBL616125,5640,,,,,H,Expert,BAO_0000357
947,Rattus norvegicus,8,B,,1,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,51,10116.0,,,CHEMBL616126,5272,,,,,H,Expert,BAO_0000357
948,,8,B,CHO,1,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL616127,4622,,449.0,,,H,Autocuration,BAO_0000219
949,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616128,17085,,,,,H,Expert,BAO_0000019
950,,8,B,,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,,CHEMBL616129,3025,,,,,H,Autocuration,BAO_0000357
951,,8,B,,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616130,15315,,,,,H,Expert,BAO_0000357
952,,8,B,,1,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,51,,,,CHEMBL616131,15267,,,,,H,Autocuration,BAO_0000357
953,,8,B,HeLa,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,51,,,,CHEMBL616132,17158,,308.0,,,H,Autocuration,BAO_0000219
954,Homo sapiens,9,B,HeLa,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,51,9606.0,,,CHEMBL616133,14214,,308.0,,,D,Expert,BAO_0000219
955,,8,B,,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL616134,17133,,,,,H,Autocuration,BAO_0000357
956,,8,B,,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,51,,,,CHEMBL616135,16532,,,,,H,Autocuration,BAO_0000357
957,Homo sapiens,9,B,,1,Affinity for 5-hydroxytryptamine 1A receptor subtype,51,9606.0,,,CHEMBL616136,2391,,,,,D,Expert,BAO_0000357
958,,8,B,,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,51,,,,CHEMBL616137,14447,,,,,H,Autocuration,BAO_0000019
959,,8,B,,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,51,,,,CHEMBL872105,14447,,,,,H,Autocuration,BAO_0000019
960,,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,51,,,,CHEMBL616138,15086,,,,,H,Autocuration,BAO_0000357
961,Homo sapiens,9,B,,1,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL616139,13051,,,,,D,Expert,BAO_0000357
962,,8,F,,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",51,,,,CHEMBL616140,16026,,,,,H,Autocuration,BAO_0000019
963,,8,B,,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,51,,,,CHEMBL616141,17085,,,,,H,Expert,BAO_0000019
964,,8,B,,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL616142,17133,,,,,H,Autocuration,BAO_0000357
965,,8,B,,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,51,,,,CHEMBL616143,17133,,,,,H,Autocuration,BAO_0000357
966,,8,B,HeLa,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,,CHEMBL616144,17211,,308.0,,,H,Autocuration,BAO_0000219
967,,8,B,HeLa,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,51,,,,CHEMBL616145,17211,,308.0,,,H,Autocuration,BAO_0000219
968,,8,B,HeLa,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,,CHEMBL616012,17211,,308.0,,,H,Autocuration,BAO_0000219
969,,8,B,HeLa,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,,CHEMBL616013,17211,,308.0,,,H,Autocuration,BAO_0000219
970,,8,F,,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,,CHEMBL616014,16394,,,,,H,Autocuration,BAO_0000019
971,,8,F,,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,,CHEMBL616015,16394,,,,,H,Autocuration,BAO_0000019
972,,8,F,,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,,CHEMBL616016,16394,,,,,H,Autocuration,BAO_0000019
973,,8,F,,1,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,51,,,,CHEMBL616017,16394,,,,,H,Autocuration,BAO_0000218
974,,8,B,,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,51,,,,CHEMBL616018,16394,,,,,H,Autocuration,BAO_0000019
975,,8,F,,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,51,,,,CHEMBL616019,15740,,,,,H,Autocuration,BAO_0000019
976,,8,F,,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,51,,,,CHEMBL616020,15740,,,,,H,Autocuration,BAO_0000019
977,,8,B,,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL858018,15740,,,,,H,Autocuration,BAO_0000357
978,,8,F,HEK293,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,,CHEMBL616021,17296,,722.0,,,H,Autocuration,BAO_0000219
979,,8,F,,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",51,,,,CHEMBL616022,5640,,,,,H,Expert,BAO_0000019
980,,8,F,,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",51,,,,CHEMBL616023,5640,,,,,H,Autocuration,BAO_0000019
981,,8,F,,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",51,,,,CHEMBL616024,5640,,,,,H,Autocuration,BAO_0000019
982,,8,F,,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",51,,,,CHEMBL616025,5640,,,,,H,Autocuration,BAO_0000019
983,,8,F,CHO,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,,CHEMBL616026,2759,,449.0,,,H,Autocuration,BAO_0000219
984,,8,F,,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",51,,,,CHEMBL616027,16394,,,,,H,Autocuration,BAO_0000019
985,Homo sapiens,9,F,,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",51,9606.0,,,CHEMBL616028,16394,,,,,D,Expert,BAO_0000019
986,Homo sapiens,9,F,,1,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,51,9606.0,,,CHEMBL616029,3445,,,,,D,Expert,BAO_0000019
987,,8,B,CHO,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,51,,,,CHEMBL616030,4316,,449.0,,,H,Expert,BAO_0000219
988,,8,B,,1,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,51,,,,CHEMBL616031,4316,,,,,H,Expert,BAO_0000019
989,Homo sapiens,9,F,,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,9606.0,,,CHEMBL616032,15180,,,,,D,Expert,BAO_0000019
990,Homo sapiens,9,F,,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,9606.0,,,CHEMBL616033,15180,,,,,D,Expert,BAO_0000019
991,,8,F,,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,,CHEMBL616034,15042,,,,,H,Autocuration,BAO_0000019
992,,8,F,,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,,CHEMBL616035,15042,,,,,H,Autocuration,BAO_0000019
993,,8,F,,1,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616036,15042,,,,,H,Autocuration,BAO_0000019
994,,8,F,,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,,CHEMBL616037,15042,,,,,H,Autocuration,BAO_0000019
995,,8,F,,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,,CHEMBL616038,15042,,,,,H,Autocuration,BAO_0000019
996,,8,F,,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,,CHEMBL616039,15042,,,,,H,Autocuration,BAO_0000019
997,,8,F,,1,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616040,15042,,,,,H,Autocuration,BAO_0000019
998,Homo sapiens,9,F,HeLa,1,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,9606.0,,,CHEMBL616041,15180,,308.0,,,D,Expert,BAO_0000219
999,Homo sapiens,9,F,HeLa,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,9606.0,,,CHEMBL616042,15180,,308.0,,,D,Expert,BAO_0000219
1000,Homo sapiens,9,F,HeLa,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,9606.0,,,CHEMBL616043,15180,,308.0,,,D,Expert,BAO_0000219
1001,,8,F,,1,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",51,,,,CHEMBL616044,16245,,,,,H,Autocuration,BAO_0000019
1002,,8,F,,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,,CHEMBL616045,16026,,,,,H,Autocuration,BAO_0000019
1003,,8,F,HEK293,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,,CHEMBL616046,17296,,722.0,,,H,Autocuration,BAO_0000219
1004,,8,F,CHO,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,,CHEMBL616047,2759,,449.0,,,H,Autocuration,BAO_0000219
1005,,8,F,CHO,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,,CHEMBL616048,2759,,449.0,,,H,Autocuration,BAO_0000219
1006,Homo sapiens,9,F,CHO,1,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),51,9606.0,,,CHEMBL616049,2759,,449.0,,,D,Expert,BAO_0000219
1007,,8,F,CHO,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,,CHEMBL616050,2759,,449.0,,,H,Autocuration,BAO_0000219
1008,,8,F,,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,51,,,,CHEMBL616051,15419,,,,,H,Expert,BAO_0000219
1009,,8,F,,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,51,,,,CHEMBL616212,15419,,,,,H,Autocuration,BAO_0000219
1010,,8,F,,1,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,,CHEMBL616213,16026,,,,,H,Autocuration,BAO_0000019
1011,,8,B,,1,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,51,,,,CHEMBL616214,1414,,,,,H,Expert,BAO_0000219
1012,,8,B,,1,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,51,,,,CHEMBL616215,1414,,,,,H,Expert,BAO_0000219
1013,,8,B,,1,Binding activity radioligand.,51,,,,CHEMBL616216,12861,,,,,H,Autocuration,BAO_0000357
1014,,8,B,,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,51,,,,CHEMBL616217,12861,,,,,H,Autocuration,BAO_0000019
1015,,8,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616218,5104,,,,,H,Autocuration,BAO_0000357
1016,,8,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616219,5105,,,,,H,Autocuration,BAO_0000357
1017,,8,B,,1,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616220,16312,,,,,H,Autocuration,BAO_0000357
1018,Homo sapiens,9,B,,1,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL833493,15180,,,,,D,Expert,BAO_0000357
1019,,8,B,,1,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616221,5033,,,,,H,Autocuration,BAO_0000357
1020,Homo sapiens,9,B,CHO,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,9606.0,,,CHEMBL616222,16909,,449.0,,,D,Expert,BAO_0000219
1021,,8,F,,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616223,2590,,,,,H,Autocuration,BAO_0000019
1022,,8,F,,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,,,CHEMBL616224,2590,,,,,H,Autocuration,BAO_0000019
1023,,8,B,,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,51,,,,CHEMBL616225,16394,,,,,H,Expert,BAO_0000019
1024,Homo sapiens,9,B,HEK293,1,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,51,9606.0,,,CHEMBL616226,4540,,722.0,,,D,Expert,BAO_0000219
1025,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,51,,,,CHEMBL616227,17296,,722.0,,,H,Autocuration,BAO_0000219
1026,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL616228,17296,,722.0,,,H,Autocuration,BAO_0000219
1027,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,,CHEMBL616229,15779,,722.0,,,H,Autocuration,BAO_0000219
1028,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,51,,,,CHEMBL616230,15779,,722.0,,,H,Autocuration,BAO_0000219
1029,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,51,,,,CHEMBL616231,15779,,722.0,,,H,Autocuration,BAO_0000219
1030,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL616232,6166,,,,,H,Autocuration,BAO_0000357
1031,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,,CHEMBL616233,15779,,722.0,,,H,Autocuration,BAO_0000219
1032,,8,B,HEK293,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,51,,,,CHEMBL857973,4199,,722.0,,,H,Autocuration,BAO_0000219
1033,,8,B,,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,51,,,,CHEMBL616234,15316,,,,,H,Autocuration,BAO_0000219
1034,,8,B,,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616235,14875,,,,,H,Autocuration,BAO_0000357
1035,,8,B,HeLa,1,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,,CHEMBL616236,14727,,308.0,,,H,Expert,BAO_0000219
1036,,8,B,,1,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,,CHEMBL616237,14727,,,,,H,Expert,BAO_0000019
1037,,8,B,HEK293,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,51,,,,CHEMBL616238,15146,,722.0,,,H,Autocuration,BAO_0000219
1038,,8,B,HEK293,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,51,,,,CHEMBL616239,5213,,722.0,,,H,Autocuration,BAO_0000219
1039,,8,B,,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,51,,,,CHEMBL616240,16429,,,,,H,Autocuration,BAO_0000219
1040,Homo sapiens,9,B,HeLa,1,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,51,9606.0,,,CHEMBL616241,15042,,308.0,,,D,Expert,BAO_0000219
1041,,8,B,HEK293,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,51,,,,CHEMBL616242,14818,,722.0,,,H,Autocuration,BAO_0000219
1042,,8,B,HEK293,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",51,,,,CHEMBL616243,4829,,722.0,,,H,Autocuration,BAO_0000219
1043,,9,B,,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616244,17200,,,,,D,Expert,BAO_0000357
1044,Homo sapiens,9,B,,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,51,9606.0,,,CHEMBL616245,13051,,,,,D,Autocuration,BAO_0000357
1045,,8,B,,1,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,106,,,,CHEMBL616246,5486,,,,,H,Autocuration,BAO_0000357
1046,,8,B,,1,Binding affinity against 5-HT1D receptor,105,,,,CHEMBL616247,5254,,,,,H,Autocuration,BAO_0000357
1047,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor,105,,,,CHEMBL616248,5254,,,,,H,Autocuration,BAO_0000357
1048,,8,B,,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,107,,,,CHEMBL616249,15331,,,,,H,Autocuration,BAO_0000357
1049,Homo sapiens,8,B,,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,9606.0,,,CHEMBL616250,13506,,,,,H,Autocuration,BAO_0000357
1050,,8,B,,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616251,15267,,,,,H,Autocuration,BAO_0000357
1051,,8,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,11863,,,,CHEMBL616252,16616,,,,,H,Autocuration,BAO_0000218
1052,,8,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,11863,,,,CHEMBL616253,16616,,,,,H,Autocuration,BAO_0000218
1053,,8,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,11863,,,,CHEMBL616254,16616,,,,,H,Autocuration,BAO_0000218
1054,Mus musculus,9,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,11863,10090.0,,,CHEMBL616255,16616,,,,,D,Expert,BAO_0000218
1055,Mus musculus,9,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,11863,10090.0,,,CHEMBL832872,16616,,,,,D,Expert,BAO_0000218
1056,Mus musculus,9,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,11863,10090.0,,,CHEMBL616256,16616,,,,,D,Expert,BAO_0000218
1057,Mus musculus,9,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,11863,10090.0,,,CHEMBL616257,16616,,,,,D,Expert,BAO_0000218
1058,Mus musculus,9,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,11863,10090.0,,,CHEMBL616258,16616,,,,,D,Expert,BAO_0000218
1059,Mus musculus,9,F,,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,11863,10090.0,,,CHEMBL616384,16616,,,,,D,Expert,BAO_0000218
1060,,8,B,,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,,,CHEMBL616385,10297,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1061,,8,B,,1,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,11863,,,,CHEMBL616386,13704,,,,,H,Expert,BAO_0000357
1062,Mus musculus,9,B,,1,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,10090.0,,,CHEMBL616387,10297,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1063,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,,,CHEMBL616388,10297,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1064,Mus musculus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,10090.0,,,CHEMBL616389,10297,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1065,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,,,CHEMBL616390,10297,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1066,,8,B,,1,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,11863,,,,CHEMBL616391,217,,,,,H,Autocuration,BAO_0000357
1067,Mus musculus,9,B,,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,10090.0,,,CHEMBL616392,10297,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1068,Sus scrofa,8,B,,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,51,9823.0,,,CHEMBL616393,4921,,,,,H,Autocuration,BAO_0000357
1069,Sus scrofa,8,B,,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,51,9823.0,,,CHEMBL616394,4921,,,,,H,Autocuration,BAO_0000357
1070,Sus scrofa,8,B,,1,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,51,9823.0,,,CHEMBL616395,4996,,,,,H,Autocuration,BAO_0000019
1071,Sus scrofa,8,B,,1,Compound was evaluated for the binding affinity at 5- HT1A receptor,51,9823.0,,,CHEMBL616396,12918,,,,,H,Autocuration,BAO_0000357
1072,Sus scrofa,8,B,,1,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,9823.0,,,CHEMBL872907,5333,,,,,H,Autocuration,BAO_0000019
1073,Sus scrofa,8,B,,1,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,9823.0,,,CHEMBL616397,4437,,,,,H,Autocuration,BAO_0000019
1074,Sus scrofa,8,B,,1,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,51,9823.0,,,CHEMBL616398,1742,,,,,H,Autocuration,BAO_0000019
1075,Sus scrofa,8,B,,1,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,51,9823.0,,,CHEMBL616399,16688,,,,,H,Expert,BAO_0000357
1076,Sus scrofa,8,B,,1,Binding activity radioligand.,51,9823.0,,,CHEMBL857065,12861,,,,,H,Autocuration,BAO_0000357
1077,Sus scrofa,8,B,,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,9823.0,,,CHEMBL616400,12861,,,,,H,Expert,BAO_0000019
1078,Sus scrofa,8,B,,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,9823.0,,,CHEMBL616401,12861,,,,,H,Autocuration,BAO_0000019
1079,,8,B,,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,10624,,,,CHEMBL616402,12490,,,,,H,Expert,BAO_0000019
1080,Sus scrofa,8,B,,1,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,51,9823.0,,,CHEMBL616403,11828,,,,,H,Expert,BAO_0000019
1081,Sus scrofa,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,51,9823.0,,,CHEMBL616404,11866,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1082,Sus scrofa,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,51,9823.0,,,CHEMBL616405,12827,,,,,H,Autocuration,BAO_0000249
1083,Sus scrofa,8,B,,1,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,51,9823.0,,,CHEMBL616406,12918,,,,,H,Autocuration,BAO_0000019
1084,Sus scrofa,8,F,,1,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,51,9823.0,,,CHEMBL616407,12919,,,,,H,Expert,BAO_0000019
1085,Oryctolagus cuniculus,8,B,,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,51,9986.0,,,CHEMBL616408,13047,,,,,H,Autocuration,BAO_0000019
1086,Rattus norvegicus,9,B,,1,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10576,10116.0,,,CHEMBL616409,15796,,,,,D,Expert,BAO_0000249
1087,Rattus norvegicus,9,B,,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10576,10116.0,,,CHEMBL616410,3651,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1088,,8,B,,1,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,10576,,,,CHEMBL616411,188,,,,,H,Autocuration,BAO_0000357
1089,Rattus norvegicus,9,F,,1,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,10116.0,Membranes,,CHEMBL616412,16616,,,,,D,Expert,BAO_0000249
1090,Rattus norvegicus,9,F,,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,10116.0,Membranes,,CHEMBL616413,16616,10000000.0,,,Hippocampus,D,Expert,BAO_0000249
1091,,8,B,,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,,CHEMBL616414,12306,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1092,Rattus norvegicus,9,B,,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10576,10116.0,,,CHEMBL616415,17167,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1093,,8,B,,1,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,10576,,,,CHEMBL616416,14776,,,,,H,Autocuration,BAO_0000019
1094,,8,B,,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,10576,,,,CHEMBL616417,12158,,,,,H,Expert,BAO_0000357
1095,,8,B,,1,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,10576,,,,CHEMBL616418,13481,,,,,H,Autocuration,BAO_0000357
1096,,8,B,,1,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,10576,,,,CHEMBL616419,13427,,,,,H,Autocuration,BAO_0000219
1097,,8,B,,1,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10576,,,,CHEMBL616420,10210,,,,,H,Autocuration,BAO_0000357
1098,,8,B,,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,Membranes,,CHEMBL616421,10205,,,,,H,Autocuration,BAO_0000249
1099,,8,B,,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,Membranes,,CHEMBL616422,10205,,,,,H,Autocuration,BAO_0000249
1100,,8,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10576,,Membranes,,CHEMBL616423,10205,,,,,H,Expert,BAO_0000249
1101,Rattus norvegicus,9,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10576,10116.0,,,CHEMBL616424,12280,,,,,D,Expert,BAO_0000357
1102,,8,B,,1,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616425,17386,,,,,H,Expert,BAO_0000357
1103,,8,B,,1,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,10576,,,,CHEMBL616426,13654,,,,,H,Expert,BAO_0000357
1104,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10576,,,,CHEMBL616427,14423,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1105,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10576,,,,CHEMBL616428,15412,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1106,,8,B,,1,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL616290,12073,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1107,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616052,4101,,,,,D,Expert,BAO_0000357
1108,,8,B,,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616053,10062,,,,,H,Autocuration,BAO_0000357
1109,,8,B,,1,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616054,6238,,,,,H,Autocuration,BAO_0000249
1110,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616055,16273,,,,,H,Autocuration,BAO_0000357
1111,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,10576,,,,CHEMBL616056,11139,,,,,H,Autocuration,BAO_0000357
1112,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,,CHEMBL616057,16796,,,,,H,Expert,BAO_0000019
1113,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,10116.0,,,CHEMBL616058,9548,955.0,,,Brain,D,Expert,BAO_0000221
1114,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,,CHEMBL616059,10381,955.0,,,Brain,H,Autocuration,BAO_0000221
1115,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616060,13408,,,,,H,Autocuration,BAO_0000249
1116,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10576,10116.0,,,CHEMBL616061,13825,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1117,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10576,,,,CHEMBL616062,11147,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1118,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616063,10552,,,,,H,Autocuration,BAO_0000249
1119,,8,B,,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,,,CHEMBL616064,10552,2435.0,,,Striatum,H,Autocuration,BAO_0000249
1120,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10576,10116.0,Membranes,,CHEMBL616065,17136,,,,,D,Expert,BAO_0000249
1121,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10576,10116.0,Membranes,,CHEMBL616066,5778,,,,,D,Expert,BAO_0000249
1122,,8,B,,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616067,13481,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1123,,8,B,,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10576,,,,CHEMBL616068,13481,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1124,,8,B,,1,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616069,13630,10000000.0,,,Hippocampus,H,Intermediate,BAO_0000221
1125,,8,B,,1,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,,,CHEMBL616070,16245,,,,,H,Expert,BAO_0000249
1126,,8,B,,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616071,14509,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1127,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,,,CHEMBL616072,14509,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1128,,8,B,,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10576,,,,CHEMBL616073,14509,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1129,,8,B,,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10576,,,,CHEMBL616074,14509,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1130,,8,B,,1,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,10576,,,,CHEMBL616075,14256,,,,,H,Expert,BAO_0000019
1131,,8,B,,1,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616076,11139,,,,,H,Autocuration,BAO_0000357
1132,Rattus norvegicus,9,B,,1,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10576,10116.0,,,CHEMBL616077,11047,,,,,D,Expert,BAO_0000019
1133,Rattus norvegicus,9,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10576,10116.0,,,CHEMBL616078,11047,,,,,D,Expert,BAO_0000019
1134,Rattus norvegicus,9,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10576,10116.0,,,CHEMBL616079,11047,,,,,D,Expert,BAO_0000019
1135,Rattus norvegicus,9,B,CHO-K1,1,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,10116.0,,,CHEMBL616080,2395,,485.0,,,D,Expert,BAO_0000219
1136,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616081,9699,,,,,H,Autocuration,BAO_0000357
1137,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10576,10116.0,,,CHEMBL616082,12028,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1138,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,,,CHEMBL616083,12028,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1139,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,,CHEMBL616084,5815,,,,,H,Autocuration,BAO_0000019
1140,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,10576,,,,CHEMBL616085,16616,,,,,H,Expert,BAO_0000019
1141,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,10576,,,,CHEMBL616086,5815,,,,,H,Autocuration,BAO_0000019
1142,,8,B,,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10576,,,,CHEMBL616087,2761,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1143,,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,10576,,,,CHEMBL616088,13133,,,,,H,Expert,BAO_0000357
1144,,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10576,,,,CHEMBL616089,10444,,,,,H,Autocuration,BAO_0000019
1145,Rattus norvegicus,9,B,,1,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10576,10116.0,,,CHEMBL616090,13278,,,,,D,Expert,BAO_0000357
1146,,8,B,,1,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,10576,,,,CHEMBL616091,15874,,,,,H,Autocuration,BAO_0000357
1147,,8,B,,1,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,Membranes,,CHEMBL616092,10552,2435.0,,,Striatum,H,Autocuration,BAO_0000249
1148,,8,B,,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),10576,,,,CHEMBL616093,11130,,,,,H,Autocuration,BAO_0000357
1149,,8,B,,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),10576,,,,CHEMBL616094,11130,,,,,H,Autocuration,BAO_0000218
1150,,8,B,,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,10576,,,,CHEMBL616095,14542,955.0,,,Brain,H,Autocuration,BAO_0000221
1151,Rattus norvegicus,9,B,,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616096,13670,,,,,D,Expert,BAO_0000357
1152,,8,B,,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,10576,,,,CHEMBL616097,9888,,,,,H,Expert,BAO_0000249
1153,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10576,10116.0,Membranes,,CHEMBL616098,3678,,,,,D,Expert,BAO_0000249
1154,,8,B,,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616099,11332,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1155,,8,B,,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616100,11332,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1156,,8,B,,1,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616101,1185,,,,,H,Expert,BAO_0000357
1157,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,10576,,,,CHEMBL616102,2014,,,,,H,Expert,BAO_0000249
1158,,8,B,,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616103,1185,,,,,H,Autocuration,BAO_0000357
1159,,8,B,,1,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,10576,,,,CHEMBL616104,14429,,,,,H,Expert,BAO_0000019
1160,,8,B,,1,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",10576,,,,CHEMBL616105,16288,,,,,H,Expert,BAO_0000019
1161,Rattus norvegicus,9,B,,1,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616106,5432,,,,,D,Expert,BAO_0000019
1162,,8,B,,1,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,10576,,,,CHEMBL616107,14429,,,,,H,Autocuration,BAO_0000019
1163,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,10576,,,,CHEMBL616108,13672,,,,,H,Expert,BAO_0000357
1164,,8,B,,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,,CHEMBL616109,11296,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1165,,8,B,,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,10576,,,,CHEMBL616110,11296,,,,,H,Autocuration,BAO_0000357
1166,,8,B,CHO,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,10576,,,,CHEMBL616111,14749,,449.0,,,H,Expert,BAO_0000219
1167,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,10576,,,,CHEMBL616112,15086,,,,,H,Expert,BAO_0000019
1168,,8,B,,1,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10576,,,,CHEMBL616113,13462,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1169,,8,B,,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616114,15363,,,,,H,Autocuration,BAO_0000019
1170,,8,B,,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616115,15363,,,,,H,Autocuration,BAO_0000019
1171,,8,B,,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616116,10796,,,,,H,Autocuration,BAO_0000357
1172,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615844,12816,955.0,,,Brain,H,Expert,BAO_0000221
1173,,8,B,,1,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL615939,13542,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1174,,8,B,,1,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,10576,,,,CHEMBL615940,13308,,,,,H,Expert,BAO_0000019
1175,,8,B,,1,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10576,,,,CHEMBL615941,13541,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1176,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10576,,,,CHEMBL615942,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1177,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,,,CHEMBL615943,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1178,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10576,,,,CHEMBL615944,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1179,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10576,,,,CHEMBL615945,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1180,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10576,,,,CHEMBL615946,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1181,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10576,,,,CHEMBL615947,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1182,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10576,,,,CHEMBL615948,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1183,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10576,,,,CHEMBL615949,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1184,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10576,,,,CHEMBL615950,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1185,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10576,,,,CHEMBL615951,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1186,,8,B,,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10576,,,,CHEMBL615952,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1187,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10576,,,,CHEMBL615953,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1188,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10576,,,,CHEMBL615954,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1189,Rattus norvegicus,9,B,,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,10116.0,,,CHEMBL615955,10058,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1190,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10576,,,,CHEMBL615956,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1191,,8,B,,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10576,,,,CHEMBL615957,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1192,,8,B,,1,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,10576,,,,CHEMBL615958,12879,,,,,H,Expert,BAO_0000019
1193,,8,B,,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,10576,,,,CHEMBL615959,11964,,,,,H,Expert,BAO_0000019
1194,,8,B,,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),10576,,,,CHEMBL615960,11964,,,,,H,Autocuration,BAO_0000019
1195,,8,B,,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),10576,,,,CHEMBL615961,11964,,,,,H,Autocuration,BAO_0000019
1196,,8,B,,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,,CHEMBL615962,9548,955.0,,,Brain,H,Expert,BAO_0000221
1197,,8,B,,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,10576,,,,CHEMBL615963,9098,,,,,H,Expert,BAO_0000019
1198,,8,B,,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,10576,,,,CHEMBL615964,9098,,,,,H,Autocuration,BAO_0000019
1199,,8,B,,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,10576,,,,CHEMBL615965,9098,,,,,H,Autocuration,BAO_0000019
1200,,8,B,CHO,1,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,10576,,,,CHEMBL615966,13248,,449.0,,,H,Expert,BAO_0000219
1201,,8,B,,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,10576,,,,CHEMBL615967,3147,,,,,H,Expert,BAO_0000249
1202,,8,B,,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,,CHEMBL615968,13949,,,,,H,Expert,BAO_0000019
1203,,8,B,CHO,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10576,,,,CHEMBL615969,11883,,449.0,,,H,Autocuration,BAO_0000218
1204,,8,B,,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),10576,,,,CHEMBL615970,11883,,,,,H,Autocuration,BAO_0000218
1205,Rattus norvegicus,9,B,,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10576,10116.0,,,CHEMBL615971,11883,,,,,D,Expert,BAO_0000357
1206,,8,B,,1,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,Membranes,,CHEMBL615972,15535,,,,,H,Expert,BAO_0000249
1207,,8,B,,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,10576,,,,CHEMBL615973,15535,,,,,H,Autocuration,BAO_0000249
1208,,8,B,,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,10576,,,,CHEMBL615974,15535,,,,,H,Autocuration,BAO_0000249
1209,Homo sapiens,9,B,CHO,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,9606.0,,,CHEMBL615975,16372,,449.0,,,D,Expert,BAO_0000219
1210,,8,B,,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,10576,,,,CHEMBL615976,14608,,,,,H,Expert,BAO_0000249
1211,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,10116.0,,,CHEMBL872106,4795,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1212,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL615977,13863,,,,,H,Autocuration,BAO_0000357
1213,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,10576,,,,CHEMBL615978,13863,,,,,H,Autocuration,BAO_0000357
1214,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,10576,,,,CHEMBL616166,13863,,,,,H,Autocuration,BAO_0000357
1215,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,10576,,,,CHEMBL616167,13863,,,,,H,Autocuration,BAO_0000357
1216,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,10576,,,,CHEMBL616168,13863,,,,,H,Autocuration,BAO_0000357
1217,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,10576,,,,CHEMBL616169,13863,,,,,H,Autocuration,BAO_0000357
1218,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,10576,,,,CHEMBL616170,13863,,,,,H,Autocuration,BAO_0000357
1219,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,10576,,,,CHEMBL616171,13863,,,,,H,Autocuration,BAO_0000357
1220,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,10576,,,,CHEMBL616172,13863,,,,,H,Autocuration,BAO_0000357
1221,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,10576,,,,CHEMBL616173,13863,,,,,H,Autocuration,BAO_0000357
1222,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,10576,,,,CHEMBL616174,13863,,,,,H,Autocuration,BAO_0000357
1223,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,10576,,,,CHEMBL616175,13863,,,,,H,Autocuration,BAO_0000357
1224,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,10576,,,,CHEMBL616176,13863,,,,,H,Autocuration,BAO_0000357
1225,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,10576,,,,CHEMBL616177,13863,,,,,H,Autocuration,BAO_0000357
1226,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,10576,,,,CHEMBL616178,13863,,,,,H,Autocuration,BAO_0000357
1227,,8,B,,1,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,,CHEMBL616179,9742,,,,,H,Autocuration,BAO_0000019
1228,,8,B,,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616180,12073,,,,,H,Autocuration,BAO_0000357
1229,,8,B,,1,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,10576,,,,CHEMBL616181,4101,,,,,H,Autocuration,BAO_0000357
1230,,8,B,,1,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,10576,,,,CHEMBL616182,15360,,,,,H,Autocuration,BAO_0000019
1231,,8,B,,1,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616183,11576,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1232,,8,B,,1,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,10576,,,,CHEMBL615874,5834,,,,,H,Expert,BAO_0000019
1233,Rattus norvegicus,9,B,CHO-K1,1,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,10116.0,,,CHEMBL615875,2395,,485.0,,,D,Expert,BAO_0000219
1234,,8,B,,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,10576,,,,CHEMBL615876,1375,,,,,H,Autocuration,BAO_0000019
1235,,8,B,,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,10576,,,,CHEMBL615877,1375,,,,,H,Autocuration,BAO_0000019
1236,,8,B,,1,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),10576,,,,CHEMBL615878,3967,,,,,H,Autocuration,BAO_0000357
1237,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,10576,,,,CHEMBL615879,12884,,,,,H,Expert,BAO_0000357
1238,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,10576,,,,CHEMBL615880,2343,,,,,H,Expert,BAO_0000357
1239,,8,B,,1,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,,,CHEMBL615881,11511,,,,,H,Autocuration,BAO_0000019
1240,Rattus norvegicus,9,B,,1,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,10116.0,,,CHEMBL615882,11511,,,,,D,Expert,BAO_0000019
1241,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,10576,,,,CHEMBL615883,16394,,,,,H,Autocuration,BAO_0000218
1242,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),10576,,,,CHEMBL615884,16394,,,,,H,Autocuration,BAO_0000218
1243,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),10576,,,,CHEMBL615885,16394,,,,,H,Autocuration,BAO_0000218
1244,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),10576,,,,CHEMBL615886,16394,,,,,H,Autocuration,BAO_0000218
1245,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),10576,,,,CHEMBL615887,16394,,,,,H,Autocuration,BAO_0000218
1246,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),10576,,,,CHEMBL615888,16394,,,,,H,Autocuration,BAO_0000218
1247,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),10576,,,,CHEMBL615889,16394,,,,,H,Autocuration,BAO_0000218
1248,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),10576,,,,CHEMBL615890,16394,,,,,H,Autocuration,BAO_0000218
1249,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),10576,,,,CHEMBL615891,16394,,,,,H,Autocuration,BAO_0000218
1250,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),10576,,,,CHEMBL615892,16394,,,,,H,Autocuration,BAO_0000218
1251,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),10576,,,,CHEMBL615893,16394,,,,,H,Autocuration,BAO_0000218
1252,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),10576,,,,CHEMBL615894,16394,,,,,H,Autocuration,BAO_0000218
1253,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),10576,,,,CHEMBL615895,16394,,,,,H,Autocuration,BAO_0000218
1254,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),10576,,,,CHEMBL615896,16394,,,,,H,Autocuration,BAO_0000218
1255,,8,F,,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,10576,,,,CHEMBL615897,16394,,,,,H,Autocuration,BAO_0000218
1256,Rattus norvegicus,9,F,,1,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,10116.0,Membranes,,CHEMBL615898,16616,,,,,D,Expert,BAO_0000249
1257,,8,B,,1,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,10576,,,,CHEMBL615899,16796,,,,,H,Autocuration,BAO_0000019
1258,,8,B,,1,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,,CHEMBL616291,16796,,,,,H,Autocuration,BAO_0000019
1259,,8,B,,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,10576,,,,CHEMBL616292,15629,,,,,H,Autocuration,BAO_0000357
1260,,8,F,,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,,CHEMBL616293,13241,,,,,H,Autocuration,BAO_0000249
1261,,8,B,,1,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL616294,12073,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1262,,8,B,,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10576,,,,CHEMBL616295,14286,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000249
1263,,8,B,,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,10576,,,,CHEMBL616296,14542,955.0,,,Brain,H,Autocuration,BAO_0000221
1264,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,,CHEMBL616297,13630,,,,,H,Autocuration,BAO_0000019
1265,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,10576,,,,CHEMBL616605,13630,,,,,H,Autocuration,BAO_0000019
1266,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,10576,,,,CHEMBL616606,13630,,,,,H,Autocuration,BAO_0000019
1267,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,,CHEMBL616607,13630,,,,,H,Autocuration,BAO_0000019
1268,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,,CHEMBL616608,13630,,,,,H,Expert,BAO_0000019
1269,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,10576,,,,CHEMBL616609,13630,,,,,H,Autocuration,BAO_0000019
1270,Rattus norvegicus,9,F,,1,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10576,10116.0,,,CHEMBL616610,13630,,,,,D,Expert,BAO_0000019
1271,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,,CHEMBL616611,13630,,,,,H,Autocuration,BAO_0000019
1272,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,10576,,,,CHEMBL616612,13630,,,,,H,Expert,BAO_0000019
1273,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,10576,,,,CHEMBL616613,13630,,,,,H,Autocuration,BAO_0000019
1274,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,10576,,,,CHEMBL616614,13630,,,,,H,Expert,BAO_0000019
1275,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,10576,,,,CHEMBL616615,13630,,,,,H,Autocuration,BAO_0000019
1276,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,,CHEMBL616616,13630,,,,,H,Expert,BAO_0000019
1277,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,10576,,,,CHEMBL616617,13630,,,,,H,Autocuration,BAO_0000019
1278,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,,CHEMBL616618,13630,,,,,H,Autocuration,BAO_0000019
1279,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,10576,,,,CHEMBL616619,13630,,,,,H,Autocuration,BAO_0000019
1280,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,10576,,,,CHEMBL616620,13630,,,,,H,Expert,BAO_0000019
1281,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,,CHEMBL616621,13630,,,,,H,Expert,BAO_0000019
1282,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,10576,,,,CHEMBL616622,13630,,,,,H,Autocuration,BAO_0000019
1283,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,10576,,,,CHEMBL616146,13630,,,,,H,Expert,BAO_0000019
1284,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,10576,,,,CHEMBL832873,13630,,,,,H,Autocuration,BAO_0000019
1285,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,10576,,,,CHEMBL616147,13630,,,,,H,Autocuration,BAO_0000019
1286,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,,CHEMBL872872,13630,,,,,H,Autocuration,BAO_0000019
1287,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,,CHEMBL616148,13630,,,,,H,Autocuration,BAO_0000019
1288,,8,B,,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10576,,,,CHEMBL616149,9783,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1289,,8,B,,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10576,,,,CHEMBL616150,9783,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1290,Rattus norvegicus,9,B,,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10576,10116.0,Membranes,,CHEMBL616151,14331,,,,,D,Expert,BAO_0000249
1291,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10576,,,,CHEMBL872873,15260,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1292,,8,B,,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10576,,,,CHEMBL616670,15260,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1293,,8,B,,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10576,,,,CHEMBL616671,15260,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1294,Rattus norvegicus,9,F,,1,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,10116.0,,,CHEMBL884861,16616,,,,,D,Expert,BAO_0000249
1295,,8,B,,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,10576,,,,CHEMBL616672,15629,,,,,H,Autocuration,BAO_0000357
1296,,8,B,,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,,CHEMBL616673,15086,,,,,H,Autocuration,BAO_0000019
1297,,8,F,,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,,CHEMBL616674,5717,,,,,H,Expert,BAO_0000019
1298,,8,B,,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,,CHEMBL616675,12652,,,,,H,Autocuration,BAO_0000357
1299,,8,B,,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10576,,,,CHEMBL616676,14608,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1300,,8,B,,1,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,,CHEMBL616677,12306,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1301,,8,B,,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,,CHEMBL616678,12306,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1302,Rattus norvegicus,9,B,,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616679,15247,,,,,D,Expert,BAO_0000357
1303,,8,B,,1,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10576,,,,CHEMBL616680,17529,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1304,,8,B,,1,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL616681,14826,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1305,,8,B,,1,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL616682,14826,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1306,,8,B,,1,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616683,13241,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1307,,8,B,,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616684,14093,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1308,,8,B,,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10576,,,,CHEMBL616685,14093,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1309,,8,B,,1,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,10576,,,,CHEMBL616686,14442,955.0,,,Brain,H,Autocuration,BAO_0000221
1310,,8,B,,1,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,,CHEMBL616687,9919,,,,,H,Autocuration,BAO_0000357
1311,,8,B,,1,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,,CHEMBL616688,9919,,,,,H,Autocuration,BAO_0000357
1312,,8,B,,1,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10576,,,,CHEMBL616689,11440,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1313,,8,B,,1,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,10576,,,,CHEMBL616690,11257,,,,,H,Autocuration,BAO_0000357
1314,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10576,,,,CHEMBL616691,10330,,,,,H,Expert,BAO_0000357
1315,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10576,10116.0,,,CHEMBL616692,17331,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1316,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,10576,,,,CHEMBL616693,16567,,,,,H,Expert,BAO_0000249
1317,Rattus norvegicus,9,B,,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,10116.0,,,CHEMBL616694,12058,,,,,D,Expert,BAO_0000019
1318,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10576,,,,CHEMBL616695,9699,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1319,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,10576,,,,CHEMBL616696,9547,,,,,H,Autocuration,BAO_0000357
1320,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10576,,,,CHEMBL616697,10330,,,,,H,Autocuration,BAO_0000357
1321,,8,B,,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616698,14331,,,,,H,Autocuration,BAO_0000357
1322,Rattus norvegicus,9,B,,1,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616949,14060,,,,,D,Expert,BAO_0000019
1323,,8,B,,1,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10576,,,,CHEMBL616950,14744,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1324,,8,B,,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,,,CHEMBL832875,13506,,,,,H,Autocuration,BAO_0000357
1325,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,,CHEMBL616951,10862,955.0,,,Brain,H,Expert,BAO_0000221
1326,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,,CHEMBL616952,10862,955.0,,,Brain,H,Expert,BAO_0000221
1327,,8,B,,1,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10576,,,,CHEMBL616953,10062,,,,,H,Expert,BAO_0000357
1328,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,10576,,,,CHEMBL616954,12073,,,,,H,Autocuration,BAO_0000357
1329,,8,B,,1,GTPgammaS radioligand binding assay,106,,,,CHEMBL616955,14875,,,,,H,Autocuration,BAO_0000357
1330,,8,B,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,,CHEMBL616956,2391,,,,,H,Autocuration,BAO_0000357
1331,,8,F,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,106,,,,CHEMBL616957,2391,,,,,H,Autocuration,BAO_0000019
1332,,8,F,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,106,,,,CHEMBL616958,2391,,,,,H,Autocuration,BAO_0000019
1333,,8,B,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616959,2391,,,,,H,Autocuration,BAO_0000357
1334,,8,B,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,,CHEMBL616960,2391,,,,,H,Autocuration,BAO_0000357
1335,,8,F,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,106,,,,CHEMBL616961,2391,,,,,H,Autocuration,BAO_0000019
1336,,8,B,HeLa,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616962,17211,,308.0,,,H,Expert,BAO_0000219
1337,,8,B,HeLa,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,106,,,,CHEMBL616963,17211,,308.0,,,H,Autocuration,BAO_0000219
1338,Homo sapiens,9,B,,1,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,106,9606.0,,,CHEMBL616524,6491,,,,,D,Expert,BAO_0000357
1339,,8,B,CHO,1,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,,,CHEMBL616525,16190,,449.0,,,H,Autocuration,BAO_0000219
1340,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,106,,,,CHEMBL872908,14165,,,,,H,Autocuration,BAO_0000019
1341,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,106,,,,CHEMBL616526,14165,,,,,H,Autocuration,BAO_0000019
1342,Homo sapiens,9,B,,1,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL616527,4234,,,,,D,Expert,BAO_0000357
1343,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,106,,,,CHEMBL616528,6328,,,,,H,Expert,BAO_0000219
1344,,8,B,,1,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,,CHEMBL616529,14770,,,,,H,Autocuration,BAO_0000357
1345,,8,B,,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,106,,,,CHEMBL616530,2598,,,,,H,Autocuration,BAO_0000357
1346,,8,B,,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616531,6897,,,,,H,Expert,BAO_0000357
1347,,8,B,,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616532,6897,,,,,H,Autocuration,BAO_0000357
1348,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616533,6013,,,,,H,Autocuration,BAO_0000357
1349,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616534,5843,,,,,H,Expert,BAO_0000357
1350,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,106,,,,CHEMBL616535,14454,,,,,H,Expert,BAO_0000357
1351,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,106,,,,CHEMBL616536,16209,,,,,H,Autocuration,BAO_0000357
1352,,8,B,,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616537,3935,,,,,H,Autocuration,BAO_0000357
1353,,8,F,CHO-K1,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,106,,,,CHEMBL616538,13729,,485.0,,,H,Expert,BAO_0000219
1354,,8,F,,1,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616539,14251,,,,,H,Expert,BAO_0000019
1355,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616540,17085,,,,,H,Expert,BAO_0000019
1356,,8,B,,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,106,,,,CHEMBL616429,3025,,,,,H,Autocuration,BAO_0000357
1357,,8,B,,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616430,15315,,,,,H,Expert,BAO_0000357
1358,Homo sapiens,9,B,,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,106,9606.0,,,CHEMBL616431,14214,,,,,D,Expert,BAO_0000219
1359,Homo sapiens,9,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL616432,3804,,,,,D,Expert,BAO_0000357
1360,Homo sapiens,9,B,,1,Affinity for 5-hydroxytryptamine 1B receptor subtype,106,9606.0,,,CHEMBL616433,2391,,,,,D,Expert,BAO_0000357
1361,Homo sapiens,9,B,,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL616434,4175,,,,,D,Expert,BAO_0000357
1362,,8,B,CHO,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,106,,,,CHEMBL616435,17296,,449.0,,,H,Autocuration,BAO_0000219
1363,,8,B,,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,106,,,,CHEMBL616436,17085,,,,,H,Expert,BAO_0000019
1364,,8,B,HeLa,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,,CHEMBL616437,17211,,308.0,,,H,Autocuration,BAO_0000219
1365,,8,B,HeLa,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,106,,,,CHEMBL616438,17211,,308.0,,,H,Autocuration,BAO_0000219
1366,,8,B,HeLa,1,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,,CHEMBL616439,17211,,308.0,,,H,Autocuration,BAO_0000219
1367,Homo sapiens,9,B,,1,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,106,9606.0,,,CHEMBL616440,15926,,,,,D,Expert,BAO_0000357
1368,,8,B,CHO-K1,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,106,,,,CHEMBL616441,16312,,485.0,,,H,Autocuration,BAO_0000219
1369,,8,B,,1,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,106,,,,CHEMBL616442,5843,,,,,H,Expert,BAO_0000357
1370,,8,B,,1,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,106,,,,CHEMBL616443,5843,,,,,H,Autocuration,BAO_0000357
1371,,8,B,CHO-K1,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616444,16312,,485.0,,,H,Expert,BAO_0000219
1372,Homo sapiens,9,B,,1,Binding activity against human 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL616445,15926,,,,,D,Expert,BAO_0000357
1373,Homo sapiens,9,B,,1,Binding activity against human 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL616446,15926,,,,,D,Expert,BAO_0000357
1374,Homo sapiens,9,B,CHO,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,9606.0,,,CHEMBL616447,4540,,449.0,,,D,Expert,BAO_0000219
1375,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,106,,,,CHEMBL616448,6166,,,,,H,Autocuration,BAO_0000357
1376,,8,B,CHO,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,106,,,,CHEMBL616449,17296,,449.0,,,H,Autocuration,BAO_0000219
1377,,8,B,CHO,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,106,,,,CHEMBL616450,17296,,449.0,,,H,Autocuration,BAO_0000219
1378,,8,B,CHO,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,106,,,,CHEMBL857974,17296,,449.0,,,H,Autocuration,BAO_0000219
1379,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,,CHEMBL616451,15779,,449.0,,,H,Autocuration,BAO_0000219
1380,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,,CHEMBL616452,15779,,449.0,,,H,Autocuration,BAO_0000219
1381,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,106,,,,CHEMBL616453,15779,,449.0,,,H,Autocuration,BAO_0000219
1382,,8,B,CHO,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,106,,,,CHEMBL616454,4199,,449.0,,,H,Autocuration,BAO_0000219
1383,Homo sapiens,9,B,,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL616455,14875,,,,,D,Expert,BAO_0000357
1384,,8,B,CHO,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,,CHEMBL616456,15146,,449.0,,,H,Autocuration,BAO_0000219
1385,,8,B,,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,106,,,,CHEMBL616457,5213,,,,,H,Autocuration,BAO_0000357
1386,,8,B,CHO,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,,CHEMBL616458,14818,,449.0,,,H,Autocuration,BAO_0000219
1387,,8,B,CHO,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",106,,,,CHEMBL616459,4829,,449.0,,,H,Autocuration,BAO_0000219
1388,,8,F,,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,106,,,,CHEMBL616460,14454,,,,,H,Expert,BAO_0000019
1389,,8,F,,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,106,,,,CHEMBL616461,14454,,,,,H,Expert,BAO_0000019
1390,,8,F,CHO,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,,CHEMBL616462,14875,,449.0,,,H,Autocuration,BAO_0000219
1391,,8,F,CHO,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,,CHEMBL616463,14875,,449.0,,,H,Autocuration,BAO_0000219
1392,,8,F,,1,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",105,,,,CHEMBL616464,15250,,,,,H,Autocuration,BAO_0000019
1393,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,105,,,,CHEMBL616465,15250,,449.0,,,H,Autocuration,BAO_0000219
1394,,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,17105,,,,CHEMBL832874,15086,,,,,H,Autocuration,BAO_0000357
1395,Oryctolagus cuniculus,8,F,,1,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,106,9986.0,,,CHEMBL616184,3025,,,,,H,Autocuration,BAO_0000019
1396,Oryctolagus cuniculus,8,B,,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,106,9986.0,,,CHEMBL616185,14998,,,,,H,Autocuration,BAO_0000019
1397,Oryctolagus cuniculus,8,B,,1,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",106,9986.0,,,CHEMBL616186,14998,,,,,H,Intermediate,BAO_0000019
1398,Oryctolagus cuniculus,8,B,,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,106,9986.0,,,CHEMBL616187,14998,,,,,H,Autocuration,BAO_0000019
1399,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,10577,,,,CHEMBL616188,13969,,,,,H,Expert,BAO_0000357
1400,,9,B,,1,Binding affinity for 5-hydroxytryptamine 1B receptor,10577,,,,CHEMBL873475,13392,,,,,D,Intermediate,BAO_0000357
1401,Rattus norvegicus,9,B,,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10577,10116.0,,,CHEMBL616189,3651,2435.0,,,Striatum,D,Expert,BAO_0000019
1402,,8,B,,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,,CHEMBL616190,10025,,,,,H,Expert,BAO_0000357
1403,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,10576,,,,CHEMBL616191,13863,,,,,H,Autocuration,BAO_0000357
1404,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,10576,,,,CHEMBL616192,13863,,,,,H,Autocuration,BAO_0000357
1405,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,10576,,,,CHEMBL616193,13863,,,,,H,Autocuration,BAO_0000357
1406,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,10576,,,,CHEMBL616194,13863,,,,,H,Autocuration,BAO_0000357
1407,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,10576,,,,CHEMBL616195,13863,,,,,H,Autocuration,BAO_0000357
1408,,8,B,,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,10576,,,,CHEMBL616196,13863,,,,,H,Autocuration,BAO_0000357
1409,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10576,,,,CHEMBL616197,4622,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000249
1410,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616198,14911,,,,,H,Intermediate,BAO_0000019
1411,,8,B,,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,,,CHEMBL616199,12678,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1412,,8,B,,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10576,,,,CHEMBL616200,12678,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1413,,8,B,,1,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616201,14235,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1414,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,,,CHEMBL616202,14949,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1415,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,,,CHEMBL616203,14949,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1416,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10576,,,,CHEMBL616204,14949,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1417,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10576,,,,CHEMBL616205,14949,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1418,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10576,,,,CHEMBL616206,14949,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1419,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,,CHEMBL616207,16118,,,,,H,Expert,BAO_0000249
1420,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,10576,,,,CHEMBL616208,3268,,,,,H,Autocuration,BAO_0000249
1421,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,10576,,,,CHEMBL616209,3268,,,,,H,Autocuration,BAO_0000249
1422,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,10576,,,,CHEMBL616210,16117,,,,,H,Expert,BAO_0000357
1423,,8,B,,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10576,,,,CHEMBL616211,9783,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1424,,8,B,,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10576,,,,CHEMBL616504,9783,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1425,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616505,14356,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1426,,8,F,,1,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616506,15740,,,,,H,Autocuration,BAO_0000019
1427,,8,B,,1,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,,CHEMBL872107,12306,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1428,Rattus norvegicus,9,B,,1,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10576,10116.0,,,CHEMBL616507,13348,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1429,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10576,,,,CHEMBL616303,10394,,,,,H,Autocuration,BAO_0000249
1430,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10576,,,,CHEMBL616304,15260,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1431,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,,,CHEMBL616305,10046,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1432,,8,F,,1,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616306,15260,10000000.0,,,Hippocampus,H,Intermediate,BAO_0000221
1433,,8,B,,1,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616307,12851,,,,,H,Autocuration,BAO_0000357
1434,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10576,10116.0,,,CHEMBL881829,2148,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1435,,8,B,,1,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,10576,,,,CHEMBL616308,13134,,,,,H,Expert,BAO_0000357
1436,,8,B,,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,10576,,,,CHEMBL616309,12462,,,,,H,Autocuration,BAO_0000019
1437,,8,B,,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,10576,,,,CHEMBL616310,12462,,,,,H,Expert,BAO_0000019
1438,,8,B,CHO,1,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,10576,,,,CHEMBL616311,12462,,449.0,,,H,Autocuration,BAO_0000219
1439,,8,B,,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616312,11933,,,,,H,Expert,BAO_0000357
1440,,8,B,,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,10576,,,,CHEMBL616313,11933,,,,,H,Autocuration,BAO_0000357
1441,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616314,403,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1442,,8,B,,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL616315,15538,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1443,,8,B,,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10576,,,,CHEMBL616567,15538,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1444,,8,B,,1,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10576,,,,CHEMBL616568,15538,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1445,,8,B,,1,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,10576,,,,CHEMBL616569,12464,,,,,H,Intermediate,BAO_0000019
1446,,8,B,,1,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,10576,,,,CHEMBL616570,1455,,,,,H,Expert,BAO_0000357
1447,,8,B,,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,,CHEMBL616571,12652,,,,,H,Autocuration,BAO_0000357
1448,,8,B,,1,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10576,,,,CHEMBL616572,12639,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1449,,8,B,,1,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,10576,,,,CHEMBL616573,13949,,,,,H,Expert,BAO_0000249
1450,Rattus norvegicus,9,B,,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10576,10116.0,,,CHEMBL616574,12463,,,,,D,Expert,BAO_0000357
1451,,8,B,,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10576,,,,CHEMBL616575,14829,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1452,,8,B,,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10576,,,,CHEMBL872108,14829,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1453,,8,B,,1,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,10576,,,,CHEMBL616576,12092,,,,,H,Autocuration,BAO_0000357
1454,,8,B,,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,10576,,,,CHEMBL616577,403,,,,,H,Autocuration,BAO_0000249
1455,,8,B,,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,10576,,,,CHEMBL616578,403,,,,,H,Autocuration,BAO_0000249
1456,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,10576,,,,CHEMBL616579,3967,,,,,H,Expert,BAO_0000357
1457,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10576,10116.0,,,CHEMBL616580,12771,,,,,D,Expert,BAO_0000019
1458,,8,B,,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,,CHEMBL616581,15086,,,,,H,Autocuration,BAO_0000019
1459,,8,B,,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL616582,14909,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1460,,8,B,,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,,CHEMBL616583,14949,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1461,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10576,10116.0,,,CHEMBL616584,2309,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1462,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616585,4170,,,,,H,Expert,BAO_0000357
1463,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10576,10116.0,,,CHEMBL616586,11642,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1464,,8,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10576,,,,CHEMBL616587,11642,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1465,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10576,,,,CHEMBL616588,12953,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1466,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,,,CHEMBL616589,12953,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1467,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,,CHEMBL616590,12953,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1468,,8,B,CHO,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",10576,,,,CHEMBL616591,12903,,449.0,,,H,Expert,BAO_0000219
1469,,8,B,,1,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616592,12536,,,,,H,Expert,BAO_0000357
1470,,8,B,,1,The inhibition activity of 5-HT1A at 1 uM,10576,,,,CHEMBL616593,10058,,,,,H,Autocuration,BAO_0000357
1471,,8,B,CHO-K1,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",10576,,,,CHEMBL616594,12902,,485.0,,,H,Expert,BAO_0000219
1472,,8,B,,1,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,10576,,,,CHEMBL616595,14057,,,,,H,Expert,BAO_0000249
1473,,8,B,,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,10576,,,,CHEMBL616596,11296,,,,,H,Autocuration,BAO_0000357
1474,,8,B,,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,,CHEMBL616597,11296,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1475,,8,B,,1,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,,CHEMBL616598,11296,10000000.0,,,Hippocampus,H,Expert,BAO_0000221
1476,Rattus norvegicus,9,F,,1,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10576,10116.0,Membranes,,CHEMBL616599,16616,,,,,D,Expert,BAO_0000249
1477,Rattus norvegicus,9,F,,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,10116.0,Membranes,,CHEMBL616600,16616,10000000.0,,,Hippocampus,D,Expert,BAO_0000249
1478,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,10576,,,,CHEMBL616601,16567,,,,,H,Autocuration,BAO_0000019
1479,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,10576,,,,CHEMBL616602,16567,,,,,H,Autocuration,BAO_0000019
1480,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,10576,,,,CHEMBL616603,16567,,,,,H,Autocuration,BAO_0000019
1481,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,10576,,,,CHEMBL616604,16567,,,,,H,Autocuration,BAO_0000019
1482,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,10576,,,,CHEMBL616316,17136,,,,,H,Autocuration,BAO_0000249
1483,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,10576,,,,CHEMBL616317,17136,,,,,H,Autocuration,BAO_0000249
1484,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10576,10116.0,,,CHEMBL616318,16616,,,,,D,Expert,BAO_0000019
1485,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10576,,,,CHEMBL616319,17331,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1486,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10576,,,,CHEMBL616320,17331,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1487,Rattus norvegicus,9,B,,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10576,10116.0,,,CHEMBL616321,17167,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1488,,8,F,,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,,CHEMBL616322,15740,,,,,H,Autocuration,BAO_0000019
1489,,8,F,,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,10576,,,,CHEMBL616323,15740,,,,,H,Autocuration,BAO_0000019
1490,,8,B,,1,Ratio of binding affinity to 5-HT 1A and D2 receptor,10576,,,,CHEMBL616324,4671,,,,,H,Autocuration,BAO_0000357
1491,,8,B,,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,,,CHEMBL616325,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1492,,8,B,,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,,,CHEMBL616326,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1493,,8,B,,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10576,,,,CHEMBL616327,10058,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1494,,8,B,,1,Percentage inhibition against 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616328,12073,,,,,H,Autocuration,BAO_0000357
1495,,8,B,,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,,CHEMBL858110,2759,,,,,H,Autocuration,BAO_0000249
1496,,8,F,,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,,CHEMBL616329,2759,,,,,H,Autocuration,BAO_0000249
1497,,8,B,,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,,CHEMBL616330,2759,,,,,H,Autocuration,BAO_0000249
1498,,8,F,,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,,CHEMBL616331,2759,,,,,H,Autocuration,BAO_0000249
1499,,8,F,,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,,CHEMBL616332,2759,,,,,H,Autocuration,BAO_0000249
1500,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10576,,,,CHEMBL857063,9737,955.0,,,Brain,H,Autocuration,BAO_0000249
1501,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,10576,,,,CHEMBL616333,9737,,,,,H,Autocuration,BAO_0000019
1502,,8,F,,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,10576,,,,CHEMBL616334,5717,,,,,H,Expert,BAO_0000019
1503,,8,B,,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,,CHEMBL616335,12253,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1504,,8,B,,1,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,10576,,,,CHEMBL616336,14025,,,,,H,Autocuration,BAO_0000019
1505,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10576,,,,CHEMBL616337,10425,,,,,H,Expert,BAO_0000249
1506,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,10576,,,,CHEMBL616338,14998,,,,,H,Autocuration,BAO_0000019
1507,,8,B,,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10576,,,,CHEMBL616339,13694,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1508,,8,B,,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10576,,,,CHEMBL616340,13694,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1509,,8,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,10576,,,,CHEMBL616341,4342,,,,,H,Autocuration,BAO_0000357
1510,Rattus norvegicus,9,B,,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,10116.0,,,CHEMBL616342,12936,,,,,D,Expert,BAO_0000357
1511,Rattus norvegicus,9,B,,1,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10576,10116.0,,,CHEMBL616343,13144,,,,,D,Expert,BAO_0000019
1512,,8,B,,1,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,10576,,,,CHEMBL616344,13343,,,,,H,Expert,BAO_0000019
1513,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,,CHEMBL616345,12132,,,,,H,Expert,BAO_0000357
1514,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,10576,,,,CHEMBL616346,15419,,,,,H,Expert,BAO_0000019
1515,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,,CHEMBL616347,1479,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1516,,8,B,,1,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,10576,,,,CHEMBL616348,14287,,,,,H,Expert,BAO_0000019
1517,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor,10576,,,,CHEMBL616349,13116,,,,,H,Expert,BAO_0000357
1518,Rattus norvegicus,9,B,,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10576,10116.0,Membranes,,CHEMBL616152,2759,,,,,D,Expert,BAO_0000249
1519,,8,B,,1,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,,CHEMBL616153,2759,,,,,H,Autocuration,BAO_0000249
1520,,8,B,,1,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",10576,,,,CHEMBL616154,14748,,,,,H,Expert,BAO_0000019
1521,,8,B,,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,,CHEMBL616155,12304,,,,,H,Autocuration,BAO_0000019
1522,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10576,10116.0,,,CHEMBL616156,12409,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1523,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10576,10116.0,,,CHEMBL616157,12409,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
1524,,8,B,,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10576,,,,CHEMBL616158,13267,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1525,,8,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,,CHEMBL616159,15194,,,,,H,Autocuration,BAO_0000357
1526,,8,B,,1,pKi value against rat 5-hydroxytryptamine 1A receptor.,10576,,,,CHEMBL616160,14256,,,,,H,Expert,BAO_0000357
1527,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,10576,,,,CHEMBL616161,16567,,,,,H,Autocuration,BAO_0000019
1528,,8,F,,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,,CHEMBL616162,15740,,,,,H,Autocuration,BAO_0000019
1529,Rattus norvegicus,9,B,,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,10116.0,,,CHEMBL616163,13278,,,,,D,Expert,BAO_0000357
1530,,8,B,,1,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10626,,Membranes,,CHEMBL616164,1970,,,,,H,Expert,BAO_0000249
1531,,8,B,,1,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10576,,,,CHEMBL616165,10034,955.0,,,Brain,H,Autocuration,BAO_0000221
1532,Rattus norvegicus,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,51,10116.0,,,CHEMBL616355,13348,,,,,H,Autocuration,BAO_0000019
1533,,8,F,,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,,CHEMBL616356,13630,,,,,H,Autocuration,BAO_0000019
1534,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,,CHEMBL616357,10862,955.0,,,Brain,H,Autocuration,BAO_0000221
1535,,8,B,,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,,,CHEMBL616358,12058,,,,,H,Autocuration,BAO_0000019
1536,,8,B,,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616359,4639,,,,,H,Autocuration,BAO_0000357
1537,,8,B,,1,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,51,,,,CHEMBL616360,15453,,,,,H,Expert,BAO_0000357
1538,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616361,4820,,,,,H,Expert,BAO_0000357
1539,,8,B,,1,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616362,1089,,,,,H,Autocuration,BAO_0000357
1540,,8,B,,1,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,51,,Brain membranes,,CHEMBL616363,386,,,,,H,Autocuration,BAO_0000249
1541,,8,B,,1,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,51,,,,CHEMBL616364,6011,,,,,H,Autocuration,BAO_0000357
1542,,8,B,,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616365,5014,,,,,H,Autocuration,BAO_0000357
1543,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL616366,4402,,,,,H,Expert,BAO_0000357
1544,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL872906,17066,,,,,H,Expert,BAO_0000357
1545,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,51,,,,CHEMBL616367,17515,,,,,H,Autocuration,BAO_0000357
1546,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616368,2474,,,,,H,Autocuration,BAO_0000357
1547,,8,B,,1,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,51,,,,CHEMBL616369,4775,,,,,H,Autocuration,BAO_0000357
1548,Homo sapiens,9,B,,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,51,9606.0,,,CHEMBL616370,14294,,,,,D,Expert,BAO_0000357
1549,Homo sapiens,9,B,,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,51,9606.0,,,CHEMBL616371,14294,,,,,D,Expert,BAO_0000357
1550,,8,B,CHO,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,,CHEMBL616372,12249,,449.0,,,H,Autocuration,BAO_0000219
1551,,8,B,,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,51,,,,CHEMBL616373,11376,,,,,H,Expert,BAO_0000219
1552,,8,B,,1,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,,CHEMBL616374,2474,,,,,H,Autocuration,BAO_0000218
1553,,8,B,,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,,CHEMBL616375,13311,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
1554,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,51,,,,CHEMBL616376,4373,,,,,H,Autocuration,BAO_0000357
1555,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,51,,,,CHEMBL857064,1633,,,,,H,Expert,BAO_0000357
1556,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,,CHEMBL616377,11866,,,,,H,Autocuration,BAO_0000357
1557,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,,CHEMBL616378,4373,,,,,H,Autocuration,BAO_0000357
1558,,8,B,,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,51,,,,CHEMBL616379,4687,,,,,H,Autocuration,BAO_0000357
1559,,8,B,,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616380,16946,,,,,H,Autocuration,BAO_0000357
1560,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,11863,,,,CHEMBL616381,13291,,,,,H,Autocuration,BAO_0000357
1561,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616382,14159,,,,,H,Autocuration,BAO_0000357
1562,,8,B,,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,11863,,,,CHEMBL616383,10812,,,,,H,Autocuration,BAO_0000357
1563,Mus musculus,9,B,CHO,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,11863,10090.0,,,CHEMBL616350,3032,,449.0,,,D,Expert,BAO_0000219
1564,,8,B,,1,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616351,16655,,,,,H,Autocuration,BAO_0000357
1565,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,11863,,,,CHEMBL616352,14532,,,,,H,Autocuration,BAO_0000357
1566,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616353,13944,,,,,H,Autocuration,BAO_0000357
1567,,8,B,,1,Binding affinity against serotonergic 5-HT1a receptor,11863,,,,CHEMBL616354,13033,,,,,H,Autocuration,BAO_0000357
1568,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,11863,,,,CHEMBL616508,10321,,,,,H,Autocuration,BAO_0000357
1569,Mus musculus,9,B,,1,Binding affinity for 5-hydroxytryptamine 1A receptor,11863,10090.0,,,CHEMBL616559,2968,,,,,D,Expert,BAO_0000357
1570,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616560,13964,,,,,H,Autocuration,BAO_0000357
1571,,8,B,,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",11863,,,,CHEMBL616561,15527,,,,,H,Autocuration,BAO_0000357
1572,,8,B,CHO,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,,CHEMBL616562,12248,,449.0,,,H,Autocuration,BAO_0000219
1573,,8,B,CHO,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,,CHEMBL616563,12249,,449.0,,,H,Autocuration,BAO_0000219
1574,,8,B,,1,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616564,15120,,,,,H,Autocuration,BAO_0000357
1575,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,11863,,,,CHEMBL616565,13313,,,,,H,Autocuration,BAO_0000357
1576,,8,B,,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616566,2613,,,,,H,Autocuration,BAO_0000218
1577,,8,B,,1,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,11863,,,,CHEMBL616989,16700,,,,,H,Autocuration,BAO_0000357
1578,,8,B,,1,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL857975,2201,,,,,H,Autocuration,BAO_0000357
1579,Mus musculus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,10090.0,,,CHEMBL616990,1274,,,,,D,Expert,BAO_0000357
1580,,8,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,11863,,,,CHEMBL616991,1317,,,,,H,Autocuration,BAO_0000357
1581,,8,B,,1,Tested against 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616992,12146,,,,,H,Autocuration,BAO_0000357
1582,,8,B,,1,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,,CHEMBL616993,14059,,,,,H,Autocuration,BAO_0000357
1583,Oryctolagus cuniculus,8,B,,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,106,9986.0,,,CHEMBL616994,14025,,,,,H,Expert,BAO_0000019
1584,Oryctolagus cuniculus,8,B,,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,106,9986.0,,,CHEMBL616995,14025,,,,,H,Autocuration,BAO_0000019
1585,Gorilla gorilla,9,B,HEK293,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105571,9593.0,,,CHEMBL616996,14447,,722.0,,,D,Intermediate,BAO_0000219
1586,Cavia porcellus,8,F,,1,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,10141.0,,,CHEMBL616997,3025,,,,,H,Autocuration,BAO_0000218
1587,Cavia porcellus,8,F,,1,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,10141.0,,,CHEMBL616998,3025,,,,,H,Autocuration,BAO_0000218
1588,Cavia porcellus,8,F,,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,106,10141.0,,,CHEMBL616999,15329,,,,,H,Autocuration,BAO_0000019
1589,Cavia porcellus,8,F,,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,106,10141.0,,,CHEMBL617000,15329,,,,,H,Autocuration,BAO_0000019
1590,Cavia porcellus,8,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,106,10141.0,,,CHEMBL617001,15847,,,,,H,Autocuration,BAO_0000019
1591,Cavia porcellus,8,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,106,10141.0,,,CHEMBL858111,15847,,,,,H,Autocuration,BAO_0000019
1592,,8,F,,1,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,106,,,,CHEMBL617002,14165,,,,,H,Autocuration,BAO_0000019
1593,,8,F,,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),106,,,,CHEMBL617003,14214,,,,,H,Autocuration,BAO_0000019
1594,,8,F,,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),106,,,,CHEMBL617004,14214,,,,,H,Autocuration,BAO_0000019
1595,Homo sapiens,9,F,,1,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,106,9606.0,,,CHEMBL617005,14214,,,,,D,Expert,BAO_0000019
1596,Homo sapiens,9,F,CHO-K1,1,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,106,9606.0,,,CHEMBL616623,13729,,485.0,,,D,Expert,BAO_0000219
1597,,8,F,CHO,1,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,106,,,,CHEMBL616624,3025,,449.0,,,H,Autocuration,BAO_0000219
1598,,8,B,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL883243,2391,,,,,H,Autocuration,BAO_0000357
1599,,8,F,,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,106,,,,CHEMBL616625,2391,,,,,H,Autocuration,BAO_0000019
1600,,8,F,CHO,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",106,,,,CHEMBL616626,14956,,449.0,,,H,Expert,BAO_0000219
1601,,8,F,CHO,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,106,,,,CHEMBL616627,2598,,449.0,,,H,Autocuration,BAO_0000219
1602,,8,F,CHO,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,106,,,,CHEMBL616628,2598,,449.0,,,H,Autocuration,BAO_0000219
1603,,8,F,CHO,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,106,,,,CHEMBL616629,2598,,449.0,,,H,Autocuration,BAO_0000219
1604,,8,F,CHO,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,106,,,,CHEMBL616630,2598,,449.0,,,H,Autocuration,BAO_0000219
1605,,8,F,,1,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,,CHEMBL616631,14956,,,,,H,Expert,BAO_0000019
1606,,8,F,,1,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,,CHEMBL616632,14956,,,,,H,Autocuration,BAO_0000019
1607,Homo sapiens,9,B,,1,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL616633,14214,,,,,D,Expert,BAO_0000357
1608,,8,B,CHO,1,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,106,,,,CHEMBL616634,3463,,449.0,,,H,Expert,BAO_0000219
1609,,8,B,,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,106,,,,CHEMBL616635,15331,,,,,H,Autocuration,BAO_0000357
1610,Homo sapiens,9,B,,1,Binding affinity against 5-hydroxytryptamine 1B receptor,106,9606.0,,,CHEMBL885358,16146,,,,,D,Expert,BAO_0000357
1611,Homo sapiens,9,B,CHO,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,9606.0,,,CHEMBL616636,14159,,449.0,,,D,Expert,BAO_0000219
1612,,8,B,CHO,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,106,,,,CHEMBL616637,14158,,449.0,,,H,Expert,BAO_0000219
1613,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616638,14159,,,,,H,Autocuration,BAO_0000357
1614,,8,B,CHO,1,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,,CHEMBL616639,15250,,449.0,,,H,Expert,BAO_0000219
1615,,8,B,CHO,1,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,106,,,,CHEMBL616640,15250,,449.0,,,H,Expert,BAO_0000219
1616,,8,B,CHO,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,,CHEMBL616641,15331,,449.0,,,H,Expert,BAO_0000219
1617,,8,B,CHO,1,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,106,,,,CHEMBL616642,15332,,449.0,,,H,Expert,BAO_0000219
1618,,8,B,CHO,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,,,CHEMBL616643,14956,,449.0,,,H,Expert,BAO_0000219
1619,,8,B,,1,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),106,,,,CHEMBL616644,3805,,,,,H,Autocuration,BAO_0000357
1620,,8,B,,1,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,106,,,,CHEMBL616645,14875,,,,,H,Autocuration,BAO_0000357
1621,Oryctolagus cuniculus,8,F,,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,9986.0,,,CHEMBL616646,14454,,,,,H,Autocuration,BAO_0000019
1622,Oryctolagus cuniculus,8,F,,1,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,9986.0,,,CHEMBL616647,14454,,,,,H,Expert,BAO_0000019
1623,,8,B,,1,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),105,,,,CHEMBL616509,16288,,,,,H,Autocuration,BAO_0000357
1624,,8,B,,1,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),105,,,,CHEMBL616510,16288,,,,,H,Autocuration,BAO_0000357
1625,,8,B,,1,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616511,16312,,,,,H,Autocuration,BAO_0000357
1626,Bos taurus,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,105,9913.0,,,CHEMBL616512,1348,,,,,H,Expert,BAO_0000357
1627,Bos taurus,8,B,,1,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,105,9913.0,,,CHEMBL616513,5834,,,,,H,Autocuration,BAO_0000357
1628,Bos taurus,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,9913.0,,,CHEMBL616514,13366,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1629,Bos taurus,8,B,,1,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,105,9913.0,,,CHEMBL616515,1414,,,,,H,Expert,BAO_0000357
1630,Bos taurus,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,105,9913.0,,,CHEMBL616516,14998,,,,,H,Autocuration,BAO_0000019
1631,Bos taurus,8,B,,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,9913.0,,,CHEMBL616517,11473,,,,,H,Autocuration,BAO_0000357
1632,Bos taurus,8,B,,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,9913.0,,,CHEMBL616518,11473,,,,,H,Autocuration,BAO_0000357
1633,Bos taurus,8,B,,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,9913.0,,,CHEMBL616519,10639,,,,,H,Autocuration,BAO_0000357
1634,Bos taurus,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,9913.0,,,CHEMBL616520,10639,,,,,H,Autocuration,BAO_0000357
1635,Bos taurus,8,B,,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,105,9913.0,,,CHEMBL616521,1375,,,,,H,Autocuration,BAO_0000357
1636,Bos taurus,8,B,,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,105,9913.0,,,CHEMBL616522,1375,,,,,H,Autocuration,BAO_0000357
1637,Bos taurus,8,B,,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,9913.0,,,CHEMBL884531,16532,,,,,H,Autocuration,BAO_0000357
1638,Bos taurus,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,105,9913.0,,,CHEMBL616523,11147,,,,,H,Autocuration,BAO_0000357
1639,Bos taurus,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,9913.0,,,CHEMBL616731,13366,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1640,Bos taurus,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,105,9913.0,,,CHEMBL616732,10444,,,,,H,Autocuration,BAO_0000019
1641,Bos taurus,8,B,,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,105,9913.0,,,CHEMBL616733,16532,,,,,H,Autocuration,BAO_0000357
1642,Bos taurus,8,B,,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,9913.0,,,CHEMBL616734,16532,,,,,H,Autocuration,BAO_0000357
1643,Bos taurus,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,105,9913.0,,,CHEMBL616735,12827,,,,,H,Autocuration,BAO_0000249
1644,Bos taurus,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,105,9913.0,,,CHEMBL616736,12827,,,,,H,Autocuration,BAO_0000249
1645,Bos taurus,8,F,,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,9913.0,,,CHEMBL616737,12919,,,,,H,Expert,BAO_0000019
1646,Bos taurus,8,B,,1,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,105,9913.0,,,CHEMBL616738,14025,,,,,H,Autocuration,BAO_0000019
1647,Bos taurus,8,F,,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,9913.0,,,CHEMBL616739,12919,,,,,H,Expert,BAO_0000019
1648,Bos taurus,8,F,,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,9913.0,,,CHEMBL616740,12919,,,,,H,Expert,BAO_0000019
1649,Bos taurus,8,F,,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,9913.0,,,CHEMBL616741,12919,,,,,H,Expert,BAO_0000019
1650,Gorilla gorilla,8,B,HEK293,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105,9593.0,,,CHEMBL616742,14447,,722.0,,,H,Autocuration,BAO_0000219
1651,Cavia porcellus,9,B,,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,105570,10141.0,,,CHEMBL616743,1375,,,,,D,Intermediate,BAO_0000019
1652,Cavia porcellus,9,B,,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,105570,10141.0,,,CHEMBL616744,1375,,,,,D,Intermediate,BAO_0000019
1653,Cavia porcellus,9,F,,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,105570,10141.0,,,CHEMBL616745,12409,,,,,D,Intermediate,BAO_0000019
1654,Cavia porcellus,9,F,,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,10141.0,,,CHEMBL616746,12409,,,,,D,Intermediate,BAO_0000019
1655,Cavia porcellus,9,F,,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,105570,10141.0,,,CHEMBL616747,12409,,,,,D,Intermediate,BAO_0000019
1656,Cavia porcellus,9,F,,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,105570,10141.0,,,CHEMBL616748,12409,,,,,D,Intermediate,BAO_0000019
1657,Cavia porcellus,9,F,,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,105570,10141.0,,,CHEMBL616648,12409,,,,,D,Intermediate,BAO_0000019
1658,Cavia porcellus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor,105570,10141.0,,,CHEMBL616649,11574,,,,,D,Intermediate,BAO_0000357
1659,Cavia porcellus,9,B,,1,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,105570,10141.0,,,CHEMBL616650,1558,,,,,D,Intermediate,BAO_0000357
1660,Cavia porcellus,9,F,,1,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,10141.0,,,CHEMBL616651,12409,,,,,D,Intermediate,BAO_0000218
1661,Cavia porcellus,9,F,,1,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,10141.0,,,CHEMBL616652,12409,,,,,D,Intermediate,BAO_0000218
1662,Cavia porcellus,9,F,,1,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,10141.0,,,CHEMBL616653,12409,,,,,D,Intermediate,BAO_0000218
1663,Cavia porcellus,9,F,,1,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,105570,10141.0,,,CHEMBL616654,12409,,,,,D,Intermediate,BAO_0000218
1664,Cavia porcellus,9,B,,1,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,105570,10141.0,,,CHEMBL616655,12253,,,,,D,Intermediate,BAO_0000019
1665,Cavia porcellus,9,B,,1,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,105570,10141.0,,,CHEMBL616656,12936,,,,,D,Intermediate,BAO_0000357
1666,Cavia porcellus,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,105,10141.0,,,CHEMBL616657,13181,,,,,H,Autocuration,BAO_0000019
1667,Cavia porcellus,9,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,105570,10141.0,,,CHEMBL616658,12409,2435.0,,,Striatum,D,Intermediate,BAO_0000357
1668,Cavia porcellus,9,B,,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,105570,10141.0,,,CHEMBL616659,10639,,,,,D,Intermediate,BAO_0000357
1669,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor,51,,,,CHEMBL616660,5254,,,,,H,Autocuration,BAO_0000357
1670,,8,B,,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,106,,,,CHEMBL616661,13051,,,,,H,Autocuration,BAO_0000357
1671,,8,F,,1,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616662,3463,,,,,H,Expert,BAO_0000019
1672,,8,F,,1,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616663,15315,,,,,H,Autocuration,BAO_0000019
1673,,8,F,,1,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616664,6011,,,,,H,Autocuration,BAO_0000019
1674,Homo sapiens,9,F,CHO,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",105,9606.0,,,CHEMBL881820,14159,,449.0,,,D,Expert,BAO_0000219
1675,,8,F,CHO,1,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",105,,,,CHEMBL616665,14159,,449.0,,,H,Autocuration,BAO_0000219
1676,,8,B,CHO,1,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616666,15250,,449.0,,,H,Expert,BAO_0000219
1677,,8,B,CHO,1,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616667,15250,,449.0,,,H,Autocuration,BAO_0000219
1678,,8,F,CHO,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,,,CHEMBL616668,15331,,449.0,,,H,Expert,BAO_0000219
1679,Homo sapiens,9,F,CHO,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,9606.0,,,CHEMBL616669,15332,,449.0,,,D,Expert,BAO_0000219
1680,,8,F,CHO,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",105,,,,CHEMBL617040,15332,,449.0,,,H,Expert,BAO_0000219
1681,,8,F,CHO,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",105,,,,CHEMBL617041,3294,,449.0,,,H,Autocuration,BAO_0000219
1682,,8,F,CHO,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",105,,,,CHEMBL617042,14158,,449.0,,,H,Expert,BAO_0000219
1683,,8,F,CHO,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",105,,,,CHEMBL617043,14956,,449.0,,,H,Expert,BAO_0000219
1684,,8,F,,1,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL617044,12469,,,,,H,Autocuration,BAO_0000019
1685,,8,F,CHO,1,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL617045,3463,,449.0,,,H,Expert,BAO_0000219
1686,Homo sapiens,9,F,CHO,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,9606.0,,,CHEMBL617046,15250,,449.0,,,D,Expert,BAO_0000219
1687,Homo sapiens,9,F,CHO,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,9606.0,,,CHEMBL617047,15250,,449.0,,,D,Expert,BAO_0000219
1688,,8,F,,1,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",105,,,,CHEMBL617048,14956,,,,,H,Expert,BAO_0000019
1689,,8,F,,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",105,,,,CHEMBL616897,14159,,,,,H,Autocuration,BAO_0000019
1690,Homo sapiens,9,F,,1,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",105,9606.0,,,CHEMBL616898,14159,,,,,D,Expert,BAO_0000019
1691,Homo sapiens,9,F,CHO,1,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,105,9606.0,,,CHEMBL858201,14499,,449.0,,,D,Expert,BAO_0000219
1692,,8,F,,1,Intrinsic activity for 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616899,15315,,,,,H,Autocuration,BAO_0000019
1693,,8,B,,1,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),105,,,,CHEMBL616900,3294,,,,,H,Autocuration,BAO_0000219
1694,,8,B,CHO,1,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,105,,,,CHEMBL616901,3463,,449.0,,,H,Expert,BAO_0000219
1695,,8,B,,1,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,105,,,,CHEMBL616902,15331,,,,,H,Autocuration,BAO_0000357
1696,Homo sapiens,9,B,CHO,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,9606.0,,,CHEMBL616903,14159,,449.0,,,D,Expert,BAO_0000219
1697,,8,B,CHO,1,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,105,,,,CHEMBL616904,14158,,449.0,,,H,Expert,BAO_0000219
1698,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616905,14159,,,,,H,Autocuration,BAO_0000357
1699,,8,B,CHO,1,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,105,,,,CHEMBL616906,15250,,449.0,,,H,Expert,BAO_0000219
1700,,8,B,CHO,1,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,,CHEMBL616907,15250,,449.0,,,H,Expert,BAO_0000219
1701,,8,B,CHO,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,,CHEMBL616908,15331,,449.0,,,H,Expert,BAO_0000219
1702,Homo sapiens,9,B,CHO,1,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,9606.0,,,CHEMBL616909,15332,,449.0,,,D,Expert,BAO_0000219
1703,Homo sapiens,9,B,CHO,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,9606.0,,,CHEMBL616910,14499,,449.0,,,D,Expert,BAO_0000219
1704,,8,B,CHO,1,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,,CHEMBL616911,15332,,449.0,,,H,Expert,BAO_0000219
1705,,8,B,CHO,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,,CHEMBL616912,14956,,449.0,,,H,Expert,BAO_0000219
1706,,8,B,,1,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),105,,,,CHEMBL616913,3805,,,,,H,Autocuration,BAO_0000357
1707,Homo sapiens,9,B,CHO,1,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,105,9606.0,,,CHEMBL616914,6011,,449.0,,,D,Expert,BAO_0000219
1708,,8,B,CHO,1,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,,,CHEMBL616915,16190,,449.0,,,H,Autocuration,BAO_0000219
1709,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,105,,,,CHEMBL616916,14165,,,,,H,Autocuration,BAO_0000019
1710,Homo sapiens,9,B,,1,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,105,9606.0,,,CHEMBL616917,4234,,,,,D,Expert,BAO_0000357
1711,,8,B,,1,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",105,,,,CHEMBL616918,15527,,,,,H,Autocuration,BAO_0000357
1712,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,105,,,,CHEMBL616919,6328,,,,,H,Expert,BAO_0000219
1713,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,105,,,,CHEMBL616920,16209,,,,,H,Autocuration,BAO_0000357
1714,,8,B,,1,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,105,,,,CHEMBL872914,14770,,,,,H,Autocuration,BAO_0000357
1715,,8,B,,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,105,,,,CHEMBL616921,2598,,,,,H,Autocuration,BAO_0000357
1716,,8,B,,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616922,6897,,,,,H,Expert,BAO_0000357
1717,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616923,6013,,,,,H,Autocuration,BAO_0000357
1718,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616924,5843,,,,,H,Expert,BAO_0000357
1719,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,105,,,,CHEMBL875909,14454,,,,,H,Expert,BAO_0000357
1720,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,105,,,,CHEMBL616925,14454,,,,,H,Autocuration,BAO_0000357
1721,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,105,,,,CHEMBL616926,14454,,,,,H,Autocuration,BAO_0000357
1722,,8,B,,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616927,15818,,,,,H,Autocuration,BAO_0000357
1723,,8,F,CHO-K1,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,105,,,,CHEMBL616928,13729,,485.0,,,H,Expert,BAO_0000219
1724,Homo sapiens,9,B,,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),105,9606.0,,,CHEMBL616929,6011,,,,,D,Expert,BAO_0000219
1725,Homo sapiens,9,B,,1,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,105,9606.0,,,CHEMBL616930,4234,,,,,D,Expert,BAO_0000357
1726,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616931,17085,,,,,H,Expert,BAO_0000019
1727,,8,B,,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,105,,,,CHEMBL616932,3025,,,,,H,Autocuration,BAO_0000357
1728,,8,B,,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616933,15315,,,,,H,Expert,BAO_0000357
1729,Homo sapiens,9,B,,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,105,9606.0,,,CHEMBL616934,14214,,,,,D,Expert,BAO_0000219
1730,Homo sapiens,9,B,,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,9606.0,,,CHEMBL616935,3804,,,,,D,Expert,BAO_0000357
1731,,8,B,,1,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,105,,,,CHEMBL616936,16700,,,,,H,Autocuration,BAO_0000357
1732,Homo sapiens,9,B,,1,Affinity for 5-hydroxytryptamine 1D receptor subtype,105,9606.0,,,CHEMBL616937,2391,,,,,D,Expert,BAO_0000357
1733,Homo sapiens,9,B,,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,9606.0,,,CHEMBL616938,4175,,,,,D,Expert,BAO_0000357
1734,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616939,17085,,,,,H,Autocuration,BAO_0000019
1735,,8,B,,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,105,,,,CHEMBL616940,17085,,,,,H,Expert,BAO_0000019
1736,Homo sapiens,9,B,,1,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,105,9606.0,,,CHEMBL616941,15926,,,,,D,Expert,BAO_0000357
1737,,8,B,CHO-K1,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,105,,,,CHEMBL616942,16312,,485.0,,,H,Autocuration,BAO_0000219
1738,,8,B,CHO-K1,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,105,,,,CHEMBL616943,16312,,485.0,,,H,Autocuration,BAO_0000219
1739,,4,B,CHO,1,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,104802,,,,CHEMBL616944,14956,,449.0,,,H,Autocuration,BAO_0000219
1740,,8,F,,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",105,,,,CHEMBL616945,3294,,,,,H,Autocuration,BAO_0000019
1741,,8,B,,1,Binding activity radioligand.,105,,,,CHEMBL616946,12861,,,,,H,Autocuration,BAO_0000357
1742,,8,B,,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,105,,,,CHEMBL616947,12861,,,,,H,Autocuration,BAO_0000019
1743,,8,B,CHO-K1,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616948,16312,,485.0,,,H,Expert,BAO_0000219
1744,,8,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616851,5104,,,,,H,Autocuration,BAO_0000357
1745,,8,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616852,5105,,,,,H,Autocuration,BAO_0000357
1746,,8,B,,1,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616853,14499,,,,,H,Autocuration,BAO_0000357
1747,Homo sapiens,9,B,,1,Binding activity against human 5-hydroxytryptamine 1D receptor,105,9606.0,,,CHEMBL616854,15926,,,,,D,Expert,BAO_0000357
1748,Homo sapiens,9,B,CHO,1,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,9606.0,,,CHEMBL616855,4540,,449.0,,,D,Expert,BAO_0000219
1749,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,105,,,,CHEMBL616856,15779,,449.0,,,H,Autocuration,BAO_0000219
1750,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,105,,,,CHEMBL616857,15779,,449.0,,,H,Autocuration,BAO_0000219
1751,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL616858,6166,,,,,H,Autocuration,BAO_0000357
1752,,8,B,CHO,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,105,,,,CHEMBL616859,15779,,449.0,,,H,Autocuration,BAO_0000219
1753,,8,B,CHO,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,105,,,,CHEMBL616860,15779,,449.0,,,H,Autocuration,BAO_0000219
1754,,8,B,HEK293,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,,CHEMBL616861,17451,,722.0,,,H,Autocuration,BAO_0000219
1755,,8,B,HEK293,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,,CHEMBL616541,17451,,722.0,,,H,Autocuration,BAO_0000219
1756,,8,B,HEK293,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,105,,,,CHEMBL616542,17451,,722.0,,,H,Autocuration,BAO_0000219
1757,,8,B,CHO,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,105,,,,CHEMBL616543,4199,,449.0,,,H,Autocuration,BAO_0000219
1758,Homo sapiens,9,B,,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,9606.0,,,CHEMBL616544,14875,,,,,D,Expert,BAO_0000357
1759,,8,B,CHO,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,105,,,,CHEMBL616545,15146,,449.0,,,H,Autocuration,BAO_0000219
1760,,8,B,,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,105,,,,CHEMBL616546,5213,,,,,H,Autocuration,BAO_0000357
1761,,8,B,CHO,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,105,,,,CHEMBL616547,14818,,449.0,,,H,Autocuration,BAO_0000219
1762,,8,B,CHO,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",105,,,,CHEMBL616548,4829,,449.0,,,H,Autocuration,BAO_0000219
1763,,8,F,,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,105,,,,CHEMBL616549,14454,,,,,H,Expert,BAO_0000019
1764,,8,F,,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,105,,,,CHEMBL616550,14454,,,,,H,Expert,BAO_0000019
1765,,8,B,,1,Binding affinity against 5-HT2C receptor,108,,,,CHEMBL857066,5254,,,,,H,Autocuration,BAO_0000357
1766,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor,108,,,,CHEMBL616551,5254,,,,,H,Autocuration,BAO_0000357
1767,,8,B,,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,,CHEMBL616552,10639,,,,,H,Autocuration,BAO_0000357
1768,,8,F,,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,,CHEMBL832876,10639,,,,,H,Autocuration,BAO_0000019
1769,,8,B,,1,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",10577,,,,CHEMBL616553,12352,,,,,H,Expert,BAO_0000019
1770,,8,B,,1,Binding affinity towards 5-HT1B was determined,10577,,,,CHEMBL616554,9098,,,,,H,Autocuration,BAO_0000357
1771,,8,B,,1,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,10577,,,,CHEMBL616555,14430,,,,,H,Expert,BAO_0000019
1772,,8,B,,1,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",10577,,,,CHEMBL616556,13657,,,,,H,Expert,BAO_0000019
1773,,8,B,,1,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",10577,,,,CHEMBL616557,13657,,,,,H,Autocuration,BAO_0000019
1774,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10577,,,,CHEMBL616558,15854,,,,,H,Expert,BAO_0000019
1775,Rattus norvegicus,9,B,,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10577,10116.0,,,CHEMBL616749,10639,,,,,D,Expert,BAO_0000019
1776,,8,B,,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,,CHEMBL616750,10025,,,,,H,Autocuration,BAO_0000357
1777,,8,B,,1,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10577,,,,CHEMBL616751,10025,,,,,H,Autocuration,BAO_0000357
1778,,8,B,,1,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,,CHEMBL616752,14286,,,,,H,Autocuration,BAO_0000249
1779,,8,B,,1,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,10577,,,,CHEMBL616753,3651,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1780,Rattus norvegicus,9,B,,1,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10577,10116.0,,,CHEMBL616754,14178,,,,,D,Expert,BAO_0000357
1781,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10577,,,,CHEMBL616755,10639,,,,,H,Autocuration,BAO_0000019
1782,,8,B,,1,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,10577,,,,CHEMBL616756,13605,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1783,,8,B,,1,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,10577,,,,CHEMBL616757,5834,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1784,,8,B,,1,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10577,,,,CHEMBL616758,10922,2435.0,,,Striatum,H,Autocuration,BAO_0000357
1785,,8,B,,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,,CHEMBL616759,14286,,,,,H,Autocuration,BAO_0000249
1786,,8,B,,1,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,10577,,,,CHEMBL616760,11825,,,,,H,Autocuration,BAO_0000357
1787,,8,B,,1,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,10577,,,,CHEMBL616761,14826,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1788,,8,B,,1,Binding affinity against 5-HT1B serotonin receptor in rat striatum,10577,,,,CHEMBL616762,9699,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1789,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,10577,,,,CHEMBL616763,14423,,,,,H,Autocuration,BAO_0000019
1790,,8,B,,1,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10577,,,,CHEMBL872909,10062,,,,,H,Expert,BAO_0000357
1791,,8,B,,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,,CHEMBL616764,10062,,,,,H,Autocuration,BAO_0000357
1792,Rattus norvegicus,9,B,,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10577,10116.0,,,CHEMBL616765,12280,,,,,D,Expert,BAO_0000357
1793,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,10577,,,,CHEMBL616766,15412,2435.0,,,Striatum,H,Autocuration,BAO_0000357
1794,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,10577,,,,CHEMBL616767,15412,2435.0,,,Striatum,H,Autocuration,BAO_0000357
1795,,8,B,,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,,CHEMBL616768,10062,,,,,H,Autocuration,BAO_0000357
1796,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,,CHEMBL616769,11147,,,,,H,Autocuration,BAO_0000357
1797,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,10577,,,,CHEMBL616770,9547,,,,,H,Autocuration,BAO_0000019
1798,,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10577,,,,CHEMBL616771,10444,,,,,H,Autocuration,BAO_0000019
1799,,8,B,,1,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,10577,,,,CHEMBL616772,12469,2435.0,,,Striatum,H,Autocuration,BAO_0000019
1800,,8,B,,1,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,10577,,,,CHEMBL616773,9098,,,,,H,Expert,BAO_0000019
1801,,8,B,,1,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,10577,,,,CHEMBL616774,9098,,,,,H,Autocuration,BAO_0000019
1802,,8,B,,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,,,CHEMBL616775,9699,,,,,H,Autocuration,BAO_0000357
1803,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10577,,,,CHEMBL616776,10394,,,,,H,Autocuration,BAO_0000249
1804,,8,B,,1,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,10577,,,,CHEMBL616777,12092,,,,,H,Autocuration,BAO_0000357
1805,,8,B,,1,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,10577,,,,CHEMBL616778,16700,,,,,H,Autocuration,BAO_0000357
1806,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10577,10116.0,,,CHEMBL616779,403,,,,,D,Expert,BAO_0000249
1807,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,10577,10116.0,,,CHEMBL616780,12771,,,,,D,Expert,BAO_0000357
1808,,8,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,10577,,,,CHEMBL616781,11642,,,,,H,Autocuration,BAO_0000019
1809,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,10577,,,,CHEMBL616782,12953,,,,,H,Autocuration,BAO_0000357
1810,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,10577,,,,CHEMBL616783,12953,,,,,H,Autocuration,BAO_0000357
1811,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,10577,,,,CHEMBL616784,12953,2435.0,,,Striatum,H,Expert,BAO_0000019
1812,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,10577,,,,CHEMBL616785,12953,,,,,H,Autocuration,BAO_0000357
1813,,8,B,,1,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,,,CHEMBL857067,9737,955.0,,,Brain,H,Autocuration,BAO_0000249
1814,,8,B,,1,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,10577,,,,CHEMBL616786,9737,,,,,H,Autocuration,BAO_0000019
1815,,8,B,,1,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,,,CHEMBL616787,9737,955.0,,,Brain,H,Autocuration,BAO_0000249
1816,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,10577,,,,CHEMBL616788,12827,,,,,H,Autocuration,BAO_0000357
1817,,8,B,,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,10577,,,,CHEMBL616789,5033,,,,,H,Autocuration,BAO_0000357
1818,Rattus norvegicus,9,B,,1,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10577,10116.0,,,CHEMBL616790,9786,,,,,D,Expert,BAO_0000019
1819,,8,B,,1,Binding affinity at 5-hydroxytryptamine 1B receptor,10577,,,,CHEMBL616791,13116,,,,,H,Expert,BAO_0000357
1820,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,10577,,,,CHEMBL616792,16429,,,,,H,Autocuration,BAO_0000019
1821,Rattus norvegicus,9,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10577,10116.0,,,CHEMBL616793,12409,,,,,D,Expert,BAO_0000249
1822,,8,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,,CHEMBL616794,15194,,,,,H,Autocuration,BAO_0000357
1823,,8,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,10577,,,,CHEMBL616795,15194,,,,,H,Autocuration,BAO_0000357
1824,,4,B,,1,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,104686,,,,CHEMBL616796,5486,,,,,H,Autocuration,BAO_0000019
1825,,8,B,,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616797,4639,,,,,H,Autocuration,BAO_0000357
1826,,8,B,,1,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,106,,Brain membranes,,CHEMBL616798,386,,,,,H,Autocuration,BAO_0000249
1827,,8,B,,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,106,,,,CHEMBL616799,2474,,,,,H,Autocuration,BAO_0000357
1828,,8,B,,1,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,106,,,,CHEMBL616800,6011,,,,,H,Autocuration,BAO_0000357
1829,,8,B,,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616801,5014,,,,,H,Autocuration,BAO_0000357
1830,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,106,,,,CHEMBL616802,17515,,,,,H,Autocuration,BAO_0000357
1831,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,106,,,,CHEMBL616803,4373,,,,,H,Autocuration,BAO_0000357
1832,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,106,,,,CHEMBL857068,1633,,,,,H,Expert,BAO_0000357
1833,,8,B,,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,106,,,,CHEMBL616804,1633,,,,,H,Autocuration,BAO_0000357
1834,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,106,,,,CHEMBL616805,4373,,,,,H,Autocuration,BAO_0000357
1835,,8,B,,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616806,4687,,,,,H,Autocuration,BAO_0000357
1836,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,,,CHEMBL616807,11574,,,,,H,Autocuration,BAO_0000357
1837,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,106,,,,CHEMBL616808,10321,,,,,H,Autocuration,BAO_0000357
1838,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,,CHEMBL616809,15527,,,,,H,Autocuration,BAO_0000357
1839,,8,B,,1,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,106,,,,CHEMBL616810,17200,,,,,H,Autocuration,BAO_0000357
1840,,4,B,,1,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,104802,,,,CHEMBL616811,14423,,,,,H,Autocuration,BAO_0000224
1841,Bos taurus,8,B,,1,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,108,9913.0,,,CHEMBL616812,5834,,,,,H,Autocuration,BAO_0000357
1842,Sus scrofa,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,108,9823.0,,,CHEMBL616813,11473,,,,,H,Autocuration,BAO_0000357
1843,Sus scrofa,8,B,,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,108,9823.0,,,CHEMBL616814,11473,,,,,H,Autocuration,BAO_0000357
1844,Sus scrofa,8,B,,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,9823.0,,,CHEMBL616815,10639,,,,,H,Autocuration,BAO_0000357
1845,Sus scrofa,8,B,,1,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,9823.0,,,CHEMBL616816,10639,,,,,H,Autocuration,BAO_0000357
1846,Sus scrofa,8,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,108,9823.0,,,CHEMBL616817,14331,,,,,H,Autocuration,BAO_0000357
1847,Sus scrofa,8,B,,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,108,9823.0,,,CHEMBL616818,10796,,,,,H,Autocuration,BAO_0000357
1848,Sus scrofa,8,B,,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,108,9823.0,,,CHEMBL616819,9098,,,,,H,Expert,BAO_0000357
1849,Sus scrofa,8,B,,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,108,9823.0,,,CHEMBL616820,14331,,,,,H,Expert,BAO_0000357
1850,Sus scrofa,8,B,,1,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,108,9823.0,,,CHEMBL616821,11828,,,,,H,Expert,BAO_0000019
1851,Sus scrofa,8,B,,1,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,108,9823.0,,,CHEMBL616822,11866,,,,,H,Autocuration,BAO_0000357
1852,Oryctolagus cuniculus,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,108,9986.0,,,CHEMBL616823,13047,,,,,H,Autocuration,BAO_0000019
1853,Rattus norvegicus,9,B,,1,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,12689,10116.0,,,CHEMBL616824,188,,,,,D,Autocuration,BAO_0000357
1854,Rattus norvegicus,9,B,,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,10116.0,,,CHEMBL616825,11825,,,,,D,Autocuration,BAO_0000357
1855,Rattus norvegicus,9,B,,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,10116.0,,,CHEMBL616826,11825,,,,,D,Autocuration,BAO_0000357
1856,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,12689,10116.0,,,CHEMBL616827,11624,,,,,D,Expert,BAO_0000019
1857,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,12689,10116.0,,,CHEMBL616828,11139,,,,,D,Autocuration,BAO_0000357
1858,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,12689,10116.0,,,CHEMBL616829,11147,,,,,D,Autocuration,BAO_0000357
1859,Rattus norvegicus,9,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,12689,10116.0,,,CHEMBL616830,10444,,,,,D,Autocuration,BAO_0000019
1860,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,10116.0,,,CHEMBL616831,11624,,,,,D,Expert,BAO_0000357
1861,Rattus norvegicus,9,B,,1,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,10116.0,,,CHEMBL616832,11662,,,,,D,Autocuration,BAO_0000019
1862,Rattus norvegicus,9,B,,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,10116.0,,,CHEMBL616833,11662,,,,,D,Autocuration,BAO_0000019
1863,Rattus norvegicus,9,B,,1,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,10116.0,,,CHEMBL616834,11662,,,,,D,Expert,BAO_0000019
1864,Rattus norvegicus,9,B,,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,10116.0,,,CHEMBL829595,11662,,,,,D,Autocuration,BAO_0000019
1865,Rattus norvegicus,9,B,,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,12689,10116.0,,,CHEMBL616835,9098,,,,,D,Autocuration,BAO_0000357
1866,Rattus norvegicus,9,B,,1,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,12689,10116.0,,,CHEMBL872910,10394,,,,,D,Autocuration,BAO_0000249
1867,,8,B,,1,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,12689,,,,CHEMBL616836,11933,,,,,H,Expert,BAO_0000357
1868,Rattus norvegicus,9,B,,1,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12689,10116.0,,,CHEMBL616837,12092,,,,,D,Autocuration,BAO_0000357
1869,Rattus norvegicus,9,B,,1,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12689,10116.0,,,CHEMBL616466,12253,,,,,D,Autocuration,BAO_0000019
1870,Rattus norvegicus,9,B,HEK293,1,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12689,10116.0,,,CHEMBL616467,12253,,722.0,,,D,Autocuration,BAO_0000219
1871,,8,B,,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,108,,,,CHEMBL616468,1558,,,,,H,Autocuration,BAO_0000357
1872,,8,B,,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,,CHEMBL616469,2474,,,,,H,Autocuration,BAO_0000357
1873,,8,B,,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,,CHEMBL616470,2474,,,,,H,Autocuration,BAO_0000357
1874,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,,CHEMBL616471,11574,,,,,H,Autocuration,BAO_0000357
1875,,8,B,,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,12689,,,,CHEMBL616472,1558,,,,,H,Autocuration,BAO_0000357
1876,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,,CHEMBL616473,13944,,,,,H,Autocuration,BAO_0000357
1877,,8,B,,1,Binding affinity against serotonergic 5-HT1c receptor,12689,,,,CHEMBL616474,13033,,,,,H,Autocuration,BAO_0000357
1878,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,12689,,,,CHEMBL616475,10321,,,,,H,Autocuration,BAO_0000357
1879,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,12689,,,,CHEMBL616476,11866,,,,,H,Autocuration,BAO_0000357
1880,Oryctolagus cuniculus,8,B,,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,9986.0,,,CHEMBL616477,14454,,,,,H,Autocuration,BAO_0000019
1881,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,104686,,,,CHEMBL616478,11574,,,,,H,Autocuration,BAO_0000224
1882,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,104686,,,,CHEMBL616479,11574,,,,,H,Autocuration,BAO_0000224
1883,,4,B,,1,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,104686,,,,CHEMBL616480,13631,,,,,H,Autocuration,BAO_0000019
1884,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,104686,10116.0,,,CHEMBL616481,9630,,,,,D,Autocuration,BAO_0000019
1885,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,104686,10116.0,,,CHEMBL616482,8822,,,,,D,Autocuration,BAO_0000249
1886,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,104686,10116.0,,,CHEMBL884713,9064,955.0,,,Brain,D,Autocuration,BAO_0000221
1887,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,104686,,,,CHEMBL616483,8868,,,,,H,Autocuration,BAO_0000224
1888,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,104686,,,,CHEMBL616484,9064,,,,,H,Autocuration,BAO_0000224
1889,,4,B,,1,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,104686,,,,CHEMBL616485,9806,,,,,H,Autocuration,BAO_0000019
1890,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,,CHEMBL616486,9098,,,,,H,Autocuration,BAO_0000224
1891,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,104686,,,,CHEMBL616487,8868,,,,,H,Autocuration,BAO_0000224
1892,,4,B,,1,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,,CHEMBL616488,12765,,,,,H,Autocuration,BAO_0000224
1893,,4,B,,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,,CHEMBL616489,11049,,,,,H,Autocuration,BAO_0000019
1894,,4,B,,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,,CHEMBL616490,11049,,,,,H,Autocuration,BAO_0000019
1895,,4,B,,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,104686,,,,CHEMBL616491,11049,,,,,H,Autocuration,BAO_0000019
1896,,4,B,,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,104686,,,,CHEMBL616492,11049,,,,,H,Autocuration,BAO_0000019
1897,,4,B,,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,,CHEMBL616493,11049,,,,,H,Autocuration,BAO_0000019
1898,,4,B,,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,104686,,,,CHEMBL616494,11473,,,,,H,Autocuration,BAO_0000019
1899,,4,B,,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,104686,,,,CHEMBL616495,11473,,,,,H,Autocuration,BAO_0000019
1900,,4,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,104686,,,,CHEMBL616496,3086,,,,,H,Autocuration,BAO_0000019
1901,,4,B,,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,,CHEMBL616497,11049,,,,,H,Autocuration,BAO_0000019
1902,,4,B,,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,,CHEMBL616498,11049,,,,,H,Autocuration,BAO_0000019
1903,,4,B,,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,104686,,,,CHEMBL616499,10639,,,,,H,Autocuration,BAO_0000019
1904,,4,B,,1,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,104686,,,,CHEMBL616500,10922,,,,,H,Autocuration,BAO_0000019
1905,Rattus norvegicus,5,B,,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,10116.0,,,CHEMBL616501,9064,955.0,,,Brain,D,Autocuration,BAO_0000221
1906,,4,B,,1,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,104686,,,,CHEMBL616502,10748,955.0,,,Brain,H,Autocuration,BAO_0000221
1907,,4,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,Membranes,,CHEMBL884529,11614,,,,,H,Autocuration,BAO_0000249
1908,,4,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,Membranes,,CHEMBL616503,11615,,,,,H,Autocuration,BAO_0000249
1909,,4,B,,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL616964,11615,,,,,H,Autocuration,BAO_0000224
1910,,4,B,,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,Membranes,,CHEMBL616965,11614,,,,,H,Autocuration,BAO_0000249
1911,,4,B,,1,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,104686,,,,CHEMBL616966,11702,,,,,H,Autocuration,BAO_0000224
1912,,4,B,,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,,CHEMBL616967,11702,,,,,H,Autocuration,BAO_0000224
1913,Rattus norvegicus,5,B,,1,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL616968,11702,,,,,D,Autocuration,BAO_0000224
1914,,4,B,,1,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,,CHEMBL616969,11702,,,,,H,Autocuration,BAO_0000224
1915,,4,B,,1,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,104686,,,,CHEMBL884530,13346,,,,,H,Autocuration,BAO_0000019
1916,,4,B,,1,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL616970,10025,,,,,H,Autocuration,BAO_0000224
1917,,4,B,,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,,CHEMBL616971,10025,,,,,H,Autocuration,BAO_0000224
1918,,4,B,,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,,CHEMBL616972,10025,,,,,H,Autocuration,BAO_0000224
1919,,4,B,,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,104686,,,,CHEMBL616973,9036,,,,,H,Autocuration,BAO_0000224
1920,,4,B,,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,104686,,,,CHEMBL616974,9036,,,,,H,Autocuration,BAO_0000224
1921,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,104686,,,,CHEMBL616975,9161,,,,,H,Autocuration,BAO_0000019
1922,,4,B,,1,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,104686,,,,CHEMBL616976,12304,,,,,H,Autocuration,BAO_0000019
1923,,4,B,,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,104686,,,,CHEMBL616977,13276,,,,,H,Autocuration,BAO_0000224
1924,,4,B,,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,,CHEMBL616978,11825,,,,,H,Autocuration,BAO_0000224
1925,,4,B,,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,104686,,,,CHEMBL616979,12443,,,,,H,Autocuration,BAO_0000224
1926,,4,B,,1,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL616980,13830,,,,,H,Autocuration,BAO_0000224
1927,,4,B,,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,104686,,Membranes,,CHEMBL616981,9592,,,,,H,Autocuration,BAO_0000249
1928,,4,B,,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,104686,,Membranes,,CHEMBL616982,9592,,,,,H,Autocuration,BAO_0000249
1929,,4,B,,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,104686,,,,CHEMBL616983,10881,,,,,H,Autocuration,BAO_0000224
1930,,4,B,,1,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,104686,,,,CHEMBL616984,13605,,,,,H,Autocuration,BAO_0000019
1931,Rattus norvegicus,5,B,,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL616985,11624,,,,,D,Autocuration,BAO_0000224
1932,,4,B,,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,,CHEMBL616986,4101,,,,,H,Autocuration,BAO_0000224
1933,,4,B,,1,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,,CHEMBL616987,4101,,,,,H,Autocuration,BAO_0000224
1934,,4,B,,1,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,104686,,,,CHEMBL616988,15360,,,,,H,Autocuration,BAO_0000019
1935,,4,B,,1,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,,CHEMBL617243,11576,,,,,H,Autocuration,BAO_0000019
1936,,4,B,,1,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,104686,,,,CHEMBL617244,5834,,,,,H,Autocuration,BAO_0000019
1937,Rattus norvegicus,5,B,CHO-K1,1,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,10116.0,,,CHEMBL617245,2395,,485.0,,,D,Autocuration,BAO_0000219
1938,,4,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,Membranes,,CHEMBL617246,11965,,,,,H,Autocuration,BAO_0000249
1939,,4,B,,1,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),104686,,,,CHEMBL617546,3967,,,,,H,Autocuration,BAO_0000224
1940,,4,B,,1,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),104686,,Brain membranes,,CHEMBL617547,11130,,,,,H,Autocuration,BAO_0000249
1941,,4,B,,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,,,CHEMBL617548,13427,,,,,H,Autocuration,BAO_0000219
1942,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617549,9443,,,,,H,Autocuration,BAO_0000224
1943,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,,CHEMBL617550,9443,,,,,H,Autocuration,BAO_0000224
1944,,4,B,,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,,CHEMBL617551,11825,,,,,H,Autocuration,BAO_0000224
1945,,4,B,,1,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,104686,,Membranes,,CHEMBL617552,12120,,,,,H,Autocuration,BAO_0000249
1946,,4,B,,1,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,104686,,Membranes,,CHEMBL617553,12120,,,,,H,Autocuration,BAO_0000249
1947,,4,F,,1,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,104686,,,,CHEMBL617554,11963,1515.0,,,Thoracic aorta,H,Autocuration,BAO_0000019
1948,,4,B,,1,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617555,9069,,,,,H,Autocuration,BAO_0000019
1949,,4,B,,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,,CHEMBL617556,8868,,,,,H,Autocuration,BAO_0000224
1950,,8,B,,1,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,10624,,,,CHEMBL617557,17200,,,,,H,Autocuration,BAO_0000357
1951,,8,B,,1,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,10624,,,,CHEMBL617558,17200,,,,,H,Autocuration,BAO_0000357
1952,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,17106,,,,CHEMBL617559,13969,,,,,H,Expert,BAO_0000357
1953,,9,B,,1,Binding affinity for 5-hydroxytryptamine 1D receptor,17106,,,,CHEMBL617560,13392,,,,,D,Expert,BAO_0000357
1954,,8,B,,1,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,,CHEMBL617561,1742,,,,,H,Autocuration,BAO_0000249
1955,,8,B,,1,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,,CHEMBL617562,1742,,,,,H,Autocuration,BAO_0000249
1956,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,17106,,,,CHEMBL617563,14331,2435.0,,,Striatum,H,Autocuration,BAO_0000357
1957,,8,F,,1,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,17106,,,,CHEMBL617564,12861,,,,,H,Autocuration,BAO_0000019
1958,,8,B,,1,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,17106,,,,CHEMBL617565,12861,,,,,H,Expert,BAO_0000019
1959,,8,B,,1,Binding activity radioligand.,17106,,,,CHEMBL856076,12861,,,,,H,Autocuration,BAO_0000357
1960,,8,B,,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,17106,,,,CHEMBL617566,12861,,,,,H,Autocuration,BAO_0000019
1961,,8,B,,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,,CHEMBL875911,12861,,,,,H,Expert,BAO_0000019
1962,,8,B,,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,17106,,,,CHEMBL617567,12861,,,,,H,Autocuration,BAO_0000019
1963,,8,B,,1,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,,CHEMBL617568,675,,,,,H,Autocuration,BAO_0000249
1964,,8,B,,1,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,17106,,,,CHEMBL617569,12490,,,,,H,Expert,BAO_0000019
1965,,8,B,,1,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,17106,,,,CHEMBL617570,11828,,,,,H,Expert,BAO_0000249
1966,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,17106,,,,CHEMBL617571,11866,,,,,H,Autocuration,BAO_0000357
1967,Sus scrofa,8,B,,1,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,105,9823.0,,,CHEMBL617572,773,,,,,H,Autocuration,BAO_0000357
1968,Oryctolagus cuniculus,8,B,,1,The compound was tested for intrinsic activity against 5-HT1D receptor,105,9986.0,,,CHEMBL617573,13047,,,,,H,Expert,BAO_0000357
1969,Oryctolagus cuniculus,8,B,,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,105,9986.0,,,CHEMBL617574,13047,,,,,H,Autocuration,BAO_0000019
1970,Oryctolagus cuniculus,8,B,,1,The compound was tested for binding affinity against 5-HT1D receptor,105,9986.0,,,CHEMBL617575,13047,,,,,H,Expert,BAO_0000357
1971,,8,B,,1,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,10578,,,,CHEMBL617576,188,,,,,H,Autocuration,BAO_0000357
1972,,8,F,,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10578,,,,CHEMBL617577,10639,,,,,H,Autocuration,BAO_0000019
1973,,8,F,,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,10578,,,,CHEMBL617578,12438,,,,,H,Autocuration,BAO_0000019
1974,,8,B,,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,10578,,,,CHEMBL617579,12438,,,,,H,Autocuration,BAO_0000357
1975,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10578,,,,CHEMBL617580,15854,,,,,H,Expert,BAO_0000019
1976,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10578,,,,CHEMBL617581,10394,,,,,H,Autocuration,BAO_0000249
1977,,8,B,,1,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,10578,,,,CHEMBL617582,12092,,,,,H,Autocuration,BAO_0000357
1978,,8,B,,1,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,10578,,,,CHEMBL617583,3389,,,,,H,Expert,BAO_0000019
1979,,8,B,,1,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,105,,,,CHEMBL617584,6011,,,,,H,Autocuration,BAO_0000357
1980,,8,B,,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL617585,4639,,,,,H,Autocuration,BAO_0000357
1981,,8,B,,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,105,,,,CHEMBL875912,2474,,,,,H,Autocuration,BAO_0000357
1982,,8,B,,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL617586,5014,,,,,H,Autocuration,BAO_0000357
1983,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,105,,,,CHEMBL617587,17515,,,,,H,Autocuration,BAO_0000357
1984,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,105,,,,CHEMBL617588,11866,,,,,H,Autocuration,BAO_0000357
1985,,8,B,,1,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL857980,4687,,,,,H,Autocuration,BAO_0000357
1986,,8,B,,1,Tested against 5-hydroxytryptamine 1D receptor,105,,,,CHEMBL617589,12146,,,,,H,Autocuration,BAO_0000357
1987,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,105,,,,CHEMBL617590,10321,,,,,H,Autocuration,BAO_0000357
1988,,8,B,HEK293,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,105,,,,CHEMBL617591,13267,,722.0,,,H,Autocuration,BAO_0000219
1989,Homo sapiens,9,B,,1,Binding affinity against 5-Hydroxytryptamine 1D receptor,105,9606.0,,,CHEMBL617592,1274,,,,,D,Expert,BAO_0000357
1990,,8,B,,1,,105,,,,CHEMBL617593,15250,,,,,H,Autocuration,BAO_0000357
1991,,8,B,CHO-K1,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,106,,,,CHEMBL617594,13706,,485.0,,,H,Autocuration,BAO_0000219
1992,,8,B,CHO-K1,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,,CHEMBL617595,13706,,485.0,,,H,Autocuration,BAO_0000219
1993,,8,B,HEK293,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,105,,,,CHEMBL617596,13706,,722.0,,,H,Autocuration,BAO_0000219
1994,,8,B,HEK293,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,105,,,,CHEMBL617597,13706,,722.0,,,H,Autocuration,BAO_0000219
1995,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,105,,,,CHEMBL617598,13047,,,,,H,Autocuration,BAO_0000019
1996,,8,B,,1,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,105,,,,CHEMBL872916,13366,,,,,H,Autocuration,BAO_0000357
1997,,8,B,,1,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,105,,,,CHEMBL617599,13366,,,,,H,Expert,BAO_0000357
1998,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,105,,,,CHEMBL617091,1558,,,,,H,Autocuration,BAO_0000357
1999,,8,B,CHO-K1,1,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",105,,,,CHEMBL617092,12902,,485.0,,,H,Expert,BAO_0000219
2000,,8,B,CHO-K1,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,,CHEMBL617093,13706,,485.0,,,H,Autocuration,BAO_0000219
2001,,8,F,,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,105,,,,CHEMBL617094,13706,,,,,H,Autocuration,BAO_0000019
2002,,8,F,,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,105,,,,CHEMBL617095,13706,,,,,H,Autocuration,BAO_0000019
2003,,8,F,,1,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,,CHEMBL617096,14251,,,,,H,Autocuration,BAO_0000019
2004,,8,F,,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,,CHEMBL617097,14251,,,,,H,Autocuration,BAO_0000019
2005,,8,F,,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,,CHEMBL617098,14251,,,,,H,Autocuration,BAO_0000019
2006,,8,B,,1,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,105,,,,CHEMBL617301,13313,,,,,H,Autocuration,BAO_0000357
2007,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,105,,,,CHEMBL617302,13313,,,,,H,Autocuration,BAO_0000357
2008,,8,B,,1,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,105,,,,CHEMBL617303,13366,,,,,H,Autocuration,BAO_0000357
2009,,8,B,,1,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,105,,,,CHEMBL617304,13051,,,,,H,Expert,BAO_0000357
2010,,8,B,CHO,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",105,,,,CHEMBL617305,12903,,449.0,,,H,Expert,BAO_0000219
2011,Homo sapiens,9,B,,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,105,9606.0,,,CHEMBL617306,12469,,,,,D,Autocuration,BAO_0000219
2012,,8,B,,1,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,17106,,,,CHEMBL617307,5619,,,,,H,Autocuration,BAO_0000357
2013,Oryctolagus cuniculus,8,B,,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,105,9986.0,,,CHEMBL617308,13047,,,,,H,Autocuration,BAO_0000019
2014,,8,B,,1,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,105,,,,CHEMBL617309,16633,,,,,H,Autocuration,BAO_0000357
2015,,8,B,,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,,CHEMBL617310,16633,,,,,H,Autocuration,BAO_0000357
2016,,8,B,,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,,CHEMBL617311,16633,,,,,H,Autocuration,BAO_0000357
2017,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,105,,,,CHEMBL617312,16633,,,,,H,Autocuration,BAO_0000357
2018,,8,B,,1,Affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,,CHEMBL617313,3269,,,,,H,Autocuration,BAO_0000357
2019,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,,CHEMBL617314,12409,,,,,H,Expert,BAO_0000357
2020,,8,F,,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,,CHEMBL617315,13706,,,,,H,Autocuration,BAO_0000019
2021,,8,B,HEK293,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,106,,,,CHEMBL617316,13706,,722.0,,,H,Autocuration,BAO_0000219
2022,,8,B,HEK293,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,106,,,,CHEMBL617317,13706,,722.0,,,H,Autocuration,BAO_0000219
2023,,8,B,CHO,1,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,,CHEMBL617318,12903,,449.0,,,H,Autocuration,BAO_0000219
2024,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,106,,,,CHEMBL617319,13047,,,,,H,Autocuration,BAO_0000019
2025,,9,B,,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,,CHEMBL617320,13366,,,,,D,Expert,BAO_0000357
2026,,9,B,,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,,CHEMBL617321,13366,,,,,D,Expert,BAO_0000357
2027,,9,B,,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,,CHEMBL617322,13366,,,,,D,Expert,BAO_0000357
2028,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,106,,,,CHEMBL616862,13366,,,,,H,Autocuration,BAO_0000357
2029,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,106,,,,CHEMBL616863,13366,,,,,H,Autocuration,BAO_0000357
2030,,8,B,CHO,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,106,,,,CHEMBL616864,12469,,449.0,,,H,Autocuration,BAO_0000219
2031,,8,B,CHO-K1,1,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,106,,,,CHEMBL616865,13706,,485.0,,,H,Autocuration,BAO_0000219
2032,,8,B,CHO-K1,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,106,,,,CHEMBL616866,13706,,485.0,,,H,Autocuration,BAO_0000219
2033,,8,F,,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,,CHEMBL616867,13706,,,,,H,Autocuration,BAO_0000019
2034,,8,B,CHO-K1,1,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",106,,,,CHEMBL616868,12902,,485.0,,,H,Expert,BAO_0000219
2035,,8,B,,1,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,105,,,,CHEMBL616869,13051,,,,,H,Expert,BAO_0000357
2036,,8,B,CHO,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,,CHEMBL616870,12903,,449.0,,,H,Expert,BAO_0000219
2037,,8,F,CHO-K1,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,105,,,,CHEMBL616871,1558,,485.0,,,H,Autocuration,BAO_0000219
2038,,8,F,CHO-K1,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,105,,,,CHEMBL616872,1558,,485.0,,,H,Autocuration,BAO_0000219
2039,,8,F,CHO-K1,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,105,,,,CHEMBL616873,1558,,485.0,,,H,Autocuration,BAO_0000219
2040,,8,F,CHO-K1,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,105,,,,CHEMBL616838,1558,,485.0,,,H,Autocuration,BAO_0000219
2041,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,105,,,,CHEMBL616839,1558,,,,,H,Autocuration,BAO_0000357
2042,Oryctolagus cuniculus,8,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,106,9986.0,,,CHEMBL616840,13047,,,,,H,Autocuration,BAO_0000019
2043,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,105,,,,CHEMBL616841,13313,,,,,H,Autocuration,BAO_0000357
2044,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,105,,,,CHEMBL616842,13313,,,,,H,Autocuration,BAO_0000357
2045,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta,105,,,,CHEMBL857976,12409,,,,,H,Expert,BAO_0000357
2046,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,10618,,,,CHEMBL616843,15250,,449.0,,,H,Autocuration,BAO_0000219
2047,Homo sapiens,9,B,,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,10618,9606.0,,,CHEMBL616844,1348,,,,,D,Expert,BAO_0000357
2048,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,10618,,,,CHEMBL616845,1348,,,,,H,Autocuration,BAO_0000357
2049,Homo sapiens,9,B,,1,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,10618,9606.0,,,CHEMBL616846,4234,,,,,D,Expert,BAO_0000357
2050,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,10618,,,,CHEMBL616847,16209,,,,,H,Autocuration,BAO_0000357
2051,,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10618,,,,CHEMBL616848,10444,,,,,H,Autocuration,BAO_0000019
2052,,8,B,,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,10618,,,,CHEMBL616849,3935,,,,,H,Autocuration,BAO_0000357
2053,,8,B,,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,10618,,,,CHEMBL872911,15818,,,,,H,Autocuration,BAO_0000357
2054,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,10618,,,,CHEMBL616850,17085,,,,,H,Autocuration,BAO_0000019
2055,Homo sapiens,9,B,CHO,1,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,10618,9606.0,,,CHEMBL616699,12936,,449.0,,,D,Expert,BAO_0000219
2056,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,10618,,,,CHEMBL616700,6166,,,,,H,Autocuration,BAO_0000357
2057,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,10618,,,,CHEMBL616701,15779,,449.0,,,H,Autocuration,BAO_0000219
2058,,8,B,CHO,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,10618,,,,CHEMBL616702,15779,,449.0,,,H,Autocuration,BAO_0000219
2059,,8,B,CHO,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,10618,,,,CHEMBL616703,15779,,449.0,,,H,Autocuration,BAO_0000219
2060,,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,10618,,,,CHEMBL616704,13181,,,,,H,Autocuration,BAO_0000357
2061,,8,B,CHO,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,10618,,,,CHEMBL616705,4199,,449.0,,,H,Autocuration,BAO_0000219
2062,,8,B,,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,10618,,,,CHEMBL616706,14875,,,,,H,Autocuration,BAO_0000357
2063,,8,B,CHO,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,10618,,,,CHEMBL616707,15146,,449.0,,,H,Autocuration,BAO_0000219
2064,,8,B,,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,10618,,,,CHEMBL616708,5213,,,,,H,Autocuration,BAO_0000357
2065,,8,B,,1,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,10618,,,,CHEMBL616709,12146,,,,,H,Autocuration,BAO_0000357
2066,,8,B,CHO,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,10618,,,,CHEMBL616710,13267,,449.0,,,H,Autocuration,BAO_0000219
2067,,8,B,CHO,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,10618,,,,CHEMBL616711,14818,,449.0,,,H,Autocuration,BAO_0000219
2068,,8,B,CHO,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",10618,,,,CHEMBL616712,4829,,449.0,,,H,Autocuration,BAO_0000219
2069,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,10618,,,,CHEMBL616713,4373,,,,,H,Autocuration,BAO_0000357
2070,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,10618,,,,CHEMBL616714,4373,,,,,H,Autocuration,BAO_0000357
2071,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,10618,,,,CHEMBL616715,14159,,,,,H,Autocuration,BAO_0000357
2072,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1E receptor,10618,,,,CHEMBL616716,16633,,,,,H,Autocuration,BAO_0000357
2073,,8,F,,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",279,,,,CHEMBL616717,17085,,,,,H,Autocuration,BAO_0000019
2074,,8,F,,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",279,,,,CHEMBL616718,17085,,,,,H,Expert,BAO_0000019
2075,,8,F,,1,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL875905,16209,,,,,H,Autocuration,BAO_0000019
2076,,8,F,,1,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL616719,16209,,,,,H,Autocuration,BAO_0000019
2077,,8,F,,1,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",279,,,,CHEMBL616720,17085,,,,,H,Expert,BAO_0000019
2078,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL616721,14159,,,,,H,Autocuration,BAO_0000357
2079,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,279,,,,CHEMBL616722,15250,,449.0,,,H,Autocuration,BAO_0000219
2080,,8,B,,1,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),279,,,,CHEMBL616723,3805,,,,,H,Autocuration,BAO_0000357
2081,,8,B,CHO,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,279,,,,CHEMBL616724,16190,,449.0,,,H,Autocuration,BAO_0000219
2082,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,279,,,,CHEMBL616725,16190,,,,,H,Autocuration,BAO_0000357
2083,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL616726,16209,,,,,H,Autocuration,BAO_0000357
2084,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,279,,,,CHEMBL616727,16209,,,,,H,Autocuration,BAO_0000357
2085,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,279,,,,CHEMBL616728,16209,,,,,H,Autocuration,BAO_0000357
2086,,8,B,,1,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL616729,6866,,,,,H,Autocuration,BAO_0000357
2087,,8,B,,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL616730,17085,,,,,H,Expert,BAO_0000019
2088,,8,B,,1,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL617125,16312,,,,,H,Autocuration,BAO_0000357
2089,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,279,,,,CHEMBL857977,6166,,,,,H,Autocuration,BAO_0000357
2090,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,,CHEMBL617126,15779,,449.0,,,H,Autocuration,BAO_0000219
2091,,8,B,CHO,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,279,,,,CHEMBL617127,4199,,449.0,,,H,Autocuration,BAO_0000219
2092,,8,B,,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL617128,14875,,,,,H,Autocuration,BAO_0000357
2093,,8,B,CHO,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,279,,,,CHEMBL617129,15146,,449.0,,,H,Autocuration,BAO_0000219
2094,,8,B,,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,279,,,,CHEMBL617130,5213,,,,,H,Autocuration,BAO_0000357
2095,,8,B,CHO,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,279,,,,CHEMBL617131,14818,,449.0,,,H,Autocuration,BAO_0000219
2096,,8,B,CHO,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,,CHEMBL617132,4829,,449.0,,,H,Autocuration,BAO_0000219
2097,,8,B,CHO,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,,CHEMBL617133,4829,,449.0,,,H,Autocuration,BAO_0000219
2098,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,279,,,,CHEMBL617134,4373,,,,,H,Autocuration,BAO_0000357
2099,,8,B,,1,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,279,,,,CHEMBL617135,4373,,,,,H,Autocuration,BAO_0000357
2100,,8,B,,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,279,,,,CHEMBL617136,5014,,,,,H,Autocuration,BAO_0000357
2101,,4,B,,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",104686,,,,CHEMBL617137,11662,,,,,H,Autocuration,BAO_0000019
2102,,4,B,,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,,CHEMBL617138,11662,,,,,H,Autocuration,BAO_0000019
2103,,4,B,,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,,CHEMBL617139,11662,,,,,H,Autocuration,BAO_0000019
2104,,8,B,,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617140,14093,,,,,H,Autocuration,BAO_0000019
2105,,4,F,,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",104686,,,,CHEMBL617141,11200,,,,,H,Autocuration,BAO_0000218
2106,,4,F,,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,,CHEMBL858112,11200,,,,,H,Autocuration,BAO_0000019
2107,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,17005,,,,CHEMBL617142,12352,,,,,H,Intermediate,BAO_0000019
2108,Bos taurus,0,B,,1,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",22226,9913.0,,,CHEMBL617143,13657,,,,,U,Autocuration,BAO_0000019
2109,Bos taurus,0,B,,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,22226,9913.0,,,CHEMBL617144,14331,,,,,U,Autocuration,BAO_0000019
2110,Bos taurus,0,B,,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,22226,9913.0,,,CHEMBL617145,14331,,,,,U,Autocuration,BAO_0000019
2111,,0,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,22226,,,,CHEMBL617146,14331,,,,,U,Autocuration,BAO_0000019
2112,Cavia porcellus,4,B,,1,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,104784,10141.0,,,CHEMBL617147,12685,,,,,H,Autocuration,BAO_0000019
2113,Cavia porcellus,4,B,,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,104784,10141.0,,,CHEMBL617148,14389,,,,,H,Autocuration,BAO_0000019
2114,Cavia porcellus,4,B,,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,104784,10141.0,,,CHEMBL617149,14386,,,,,H,Autocuration,BAO_0000019
2115,,4,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,104784,,,,CHEMBL617150,5732,,,,,H,Autocuration,BAO_0000224
2116,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104784,,,,CHEMBL617151,16293,,,,,H,Autocuration,BAO_0000224
2117,,4,B,,1,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617201,2078,,,,,H,Autocuration,BAO_0000224
2118,,8,B,,1,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,10209,,,,CHEMBL617202,5486,,,,,H,Autocuration,BAO_0000357
2119,,4,B,,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,,,CHEMBL617203,11820,,,,,H,Autocuration,BAO_0000218
2120,,4,B,,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,,,CHEMBL617204,10297,,,,,H,Autocuration,BAO_0000019
2121,,4,B,,1,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,104826,,,,CHEMBL617205,13704,,,,,H,Autocuration,BAO_0000224
2122,Mus musculus,5,B,,1,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,104826,10090.0,,,CHEMBL617206,10297,,,,,D,Autocuration,BAO_0000019
2123,,4,B,,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,,,CHEMBL617207,11820,,,,,H,Autocuration,BAO_0000218
2124,Mus musculus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,104826,10090.0,,,CHEMBL617208,10297,,,,,D,Autocuration,BAO_0000019
2125,,4,B,,1,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,104826,,,,CHEMBL617209,11555,,,,,H,Autocuration,BAO_0000224
2126,,4,B,,1,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,104826,,,,CHEMBL617210,11555,,,,,H,Autocuration,BAO_0000224
2127,,4,B,,1,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,104826,,,,CHEMBL617211,11555,,,,,H,Autocuration,BAO_0000224
2128,Mus musculus,5,B,,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,10090.0,,,CHEMBL617212,10297,,,,,D,Autocuration,BAO_0000019
2129,Sus scrofa,4,B,,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,104784,9823.0,,,CHEMBL617213,16688,,,,,H,Autocuration,BAO_0000224
2130,Sus scrofa,4,B,,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,104784,9823.0,,,CHEMBL617214,16688,,,,,H,Autocuration,BAO_0000224
2131,,0,B,,1,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,,CHEMBL617215,5333,,,,,U,Autocuration,BAO_0000221
2132,,0,B,,1,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,,CHEMBL617216,4437,,,,,U,Autocuration,BAO_0000221
2133,Sus scrofa,8,B,,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,17005,9823.0,,,CHEMBL617217,5033,,,,,H,Autocuration,BAO_0000357
2134,,4,B,,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617218,15267,,,,,H,Autocuration,BAO_0000019
2135,,4,B,,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL872913,15267,,,,,H,Autocuration,BAO_0000019
2136,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,104826,,,,CHEMBL617219,11820,,,,,H,Autocuration,BAO_0000019
2137,,4,B,,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL873482,9069,,,,,H,Autocuration,BAO_0000224
2138,Rattus norvegicus,5,B,,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,104686,10116.0,,,CHEMBL617220,9162,,,,,D,Autocuration,BAO_0000019
2139,,4,B,,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,104686,,,,CHEMBL617221,9162,,,,,H,Autocuration,BAO_0000019
2140,,4,B,,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,104686,,,,CHEMBL617222,9162,,,,,H,Autocuration,BAO_0000019
2141,,4,F,,1,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,104686,,,,CHEMBL875906,10428,,,,,H,Autocuration,BAO_0000019
2142,,4,B,,1,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,104686,,,,CHEMBL617223,9628,,,,,H,Autocuration,BAO_0000019
2143,,4,B,,1,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617224,12704,,,,,H,Autocuration,BAO_0000224
2144,Rattus norvegicus,5,B,,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104686,10116.0,,,CHEMBL617225,15453,,,,,D,Autocuration,BAO_0000224
2145,,4,B,,1,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,104686,,,,CHEMBL617226,188,,,,,H,Autocuration,BAO_0000224
2146,,4,B,,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,104686,,,,CHEMBL617227,10349,,,,,H,Autocuration,BAO_0000224
2147,,4,B,,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,104686,,,,CHEMBL617228,10349,,,,,H,Autocuration,BAO_0000224
2148,,4,B,,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,,CHEMBL617229,8868,,,,,H,Autocuration,BAO_0000224
2149,,4,B,,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,,CHEMBL617230,10025,,,,,H,Autocuration,BAO_0000224
2150,,4,B,,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,,CHEMBL617231,10025,,,,,H,Autocuration,BAO_0000224
2151,,4,B,,1,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,104686,,,,CHEMBL617232,11702,,,,,H,Autocuration,BAO_0000224
2152,,4,B,,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617233,11702,,,,,H,Autocuration,BAO_0000224
2153,,4,B,,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,,CHEMBL617234,11702,,,,,H,Autocuration,BAO_0000224
2154,,4,F,,1,Compound was tested for the inhibition of quipazine induced head twitches in rats,104686,,,,CHEMBL617235,11702,,,,,H,Autocuration,BAO_0000019
2155,,4,F,,1,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,104686,,,,CHEMBL617236,11702,,,,,H,Autocuration,BAO_0000019
2156,,4,B,,1,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,104686,,,,CHEMBL617237,10085,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
2157,,4,B,,1,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,104686,,,,CHEMBL617238,10085,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
2158,Rattus norvegicus,5,B,,1,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,104686,10116.0,,,CHEMBL617239,9630,955.0,,,Brain,D,Autocuration,BAO_0000221
2159,,4,B,,1,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,,CHEMBL617240,11070,,,,,H,Autocuration,BAO_0000019
2160,,4,B,,1,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,Membranes,,CHEMBL617241,9841,,,,,H,Autocuration,BAO_0000249
2161,,4,B,,1,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,Membranes,,CHEMBL875907,9841,,,,,H,Autocuration,BAO_0000249
2162,,4,B,,1,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,104686,,,,CHEMBL617242,13291,,,,,H,Autocuration,BAO_0000019
2163,,4,F,,1,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,104686,,,,CHEMBL617152,10590,,,,,H,Autocuration,BAO_0000019
2164,Rattus norvegicus,5,B,,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,10116.0,,,CHEMBL617153,9064,955.0,,,Brain,D,Autocuration,BAO_0000221
2165,Rattus norvegicus,5,B,,1,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,104686,10116.0,Membranes,,CHEMBL617154,12268,,,,,D,Autocuration,BAO_0000249
2166,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,104686,,,,CHEMBL617155,13508,955.0,,,Brain,H,Autocuration,BAO_0000221
2167,,4,F,,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,,CHEMBL617156,11279,,,,,H,Autocuration,BAO_0000019
2168,,4,F,,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,104686,,,,CHEMBL617157,11200,,,,,H,Autocuration,BAO_0000019
2169,,4,F,,1,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,,CHEMBL617158,11200,,,,,H,Autocuration,BAO_0000019
2170,,4,F,,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,,CHEMBL617159,11200,,,,,H,Autocuration,BAO_0000019
2171,,4,F,,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,,CHEMBL617160,11200,,,,,H,Autocuration,BAO_0000019
2172,,4,F,,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,,CHEMBL858113,11200,,,,,H,Autocuration,BAO_0000019
2173,,4,B,,1,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,104686,,,,CHEMBL617247,9231,955.0,,,Brain,H,Autocuration,BAO_0000220
2174,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,,CHEMBL617248,9737,,,,,H,Autocuration,BAO_0000019
2175,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,104686,,,,CHEMBL617249,9737,955.0,,,Brain,H,Autocuration,BAO_0000249
2176,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,104686,,,,CHEMBL617250,9737,,,,,H,Autocuration,BAO_0000019
2177,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,,CHEMBL617251,9737,,,,,H,Autocuration,BAO_0000019
2178,Rattus norvegicus,5,B,,1,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL617252,11828,,,,,D,Autocuration,BAO_0000019
2179,,4,B,,1,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,104686,,,,CHEMBL617006,12253,,,,,H,Autocuration,BAO_0000019
2180,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,104686,,,,CHEMBL617007,12253,,,,,H,Autocuration,BAO_0000019
2181,,4,F,,1,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",104686,,,,CHEMBL617008,11279,,,,,H,Autocuration,BAO_0000019
2182,,4,B,,1,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,104686,,,,CHEMBL617009,11866,,,,,H,Autocuration,BAO_0000019
2183,Rattus norvegicus,5,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,104686,10116.0,,,CHEMBL617010,14424,,,,,D,Autocuration,BAO_0000224
2184,Rattus norvegicus,5,B,,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL857978,15180,,,,,D,Autocuration,BAO_0000019
2185,Rattus norvegicus,5,B,,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL617011,15180,,,,,D,Autocuration,BAO_0000019
2186,Rattus norvegicus,5,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,104686,10116.0,,,CHEMBL617012,9786,,,,,D,Autocuration,BAO_0000019
2187,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,104686,,,,CHEMBL617013,12132,,,,,H,Autocuration,BAO_0000224
2188,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,104686,,,,CHEMBL617014,5486,,,,,H,Autocuration,BAO_0000249
2189,,4,B,,1,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617015,15316,,,,,H,Autocuration,BAO_0000019
2190,,4,B,,1,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,104686,,,,CHEMBL617016,16429,,,,,H,Autocuration,BAO_0000019
2191,,4,B,,1,pKi value for 5-hydroxytryptamine 2 receptor binding site,104686,,,,CHEMBL617017,14617,,,,,H,Autocuration,BAO_0000224
2192,,4,B,,1,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,104686,,,,CHEMBL617018,11351,955.0,,,Brain,H,Autocuration,BAO_0000221
2193,,4,F,,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,,CHEMBL617019,11279,,,,,H,Autocuration,BAO_0000019
2194,,4,B,,1,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,,CHEMBL617020,9523,,,,,H,Autocuration,BAO_0000019
2195,,4,B,,1,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,,CHEMBL617021,9523,,,,,H,Autocuration,BAO_0000019
2196,,4,B,,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,,CHEMBL617022,9523,,,,,H,Autocuration,BAO_0000019
2197,,4,B,,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,,CHEMBL617023,9523,,,,,H,Autocuration,BAO_0000019
2198,,4,B,,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,,CHEMBL617024,9523,,,,,H,Autocuration,BAO_0000019
2199,,4,B,,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,,CHEMBL617025,9523,,,,,H,Autocuration,BAO_0000019
2200,,4,B,,1,Hill coefficient of compound was determined,105075,,,,CHEMBL617026,9523,,,,,H,Autocuration,BAO_0000224
2201,,0,B,,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,22226,,,,CHEMBL617027,4771,,,,,U,Autocuration,BAO_0000019
2202,Rattus norvegicus,5,B,,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,104686,10116.0,,,CHEMBL617028,5033,,,,,D,Autocuration,BAO_0000019
2203,,8,B,,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,12687,,,,CHEMBL617029,10845,,,,,H,Expert,BAO_0000019
2204,,8,B,,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,12687,,,,CHEMBL875908,10845,,,,,H,Expert,BAO_0000019
2205,,8,B,,1,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),12687,,,,CHEMBL617030,16288,,,,,H,Autocuration,BAO_0000357
2206,,8,B,,1,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),12687,,,,CHEMBL617031,16288,,,,,H,Autocuration,BAO_0000019
2207,,8,B,,1,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,12687,,,,CHEMBL617032,16190,,,,,H,Autocuration,BAO_0000019
2208,Rattus norvegicus,5,B,,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,104686,10116.0,,,CHEMBL617033,12463,,,,,D,Autocuration,BAO_0000224
2209,,4,B,,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",104686,,,,CHEMBL617034,9699,,,,,H,Autocuration,BAO_0000224
2210,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,104686,,,,CHEMBL617035,9699,,,,,H,Autocuration,BAO_0000224
2211,,4,B,,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,,CHEMBL617036,11662,,,,,H,Autocuration,BAO_0000019
2212,,4,B,,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617037,1205,,,,,H,Autocuration,BAO_0000224
2213,,0,B,,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,22226,,,,CHEMBL617038,11376,,,,,U,Autocuration,BAO_0000219
2214,,4,B,,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",104784,,,,CHEMBL617039,11376,,,,,H,Autocuration,BAO_0000219
2215,,4,B,,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617161,4639,,,,,H,Autocuration,BAO_0000224
2216,,4,B,,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617162,2222,,,,,H,Autocuration,BAO_0000224
2217,,4,B,,1,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617163,1558,,,,,H,Autocuration,BAO_0000224
2218,,4,B,,1,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617164,1089,,,,,H,Autocuration,BAO_0000224
2219,,4,B,,1,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,104784,,Brain membranes,,CHEMBL617165,386,,,,,H,Autocuration,BAO_0000249
2220,,4,B,,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,104784,,,,CHEMBL617166,2474,,,,,H,Autocuration,BAO_0000224
2221,,4,B,,1,Binding affinity towards 5-HT2 receptor,104784,,,,CHEMBL617167,17066,,,,,H,Autocuration,BAO_0000224
2222,,4,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL872912,959,,,,,H,Autocuration,BAO_0000224
2223,,4,B,,1,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,104784,,,,CHEMBL617168,6398,,,,,H,Autocuration,BAO_0000224
2224,,4,B,,1,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,104686,,,,CHEMBL617169,11889,,,,,H,Autocuration,BAO_0000224
2225,,4,B,,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617170,4221,,,,,H,Autocuration,BAO_0000224
2226,,4,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,104784,,,,CHEMBL617171,11026,,,,,H,Autocuration,BAO_0000224
2227,,4,B,,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,104784,,,,CHEMBL617172,11866,,,,,H,Autocuration,BAO_0000224
2228,,4,B,,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617173,4221,,,,,H,Autocuration,BAO_0000224
2229,,0,B,,1,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,22226,,,,CHEMBL617174,13950,,,,,U,Autocuration,BAO_0000019
2230,,4,B,,1,5-hydroxytryptamine 2 receptor binding affinity,104784,,,,CHEMBL617175,1263,,,,,H,Autocuration,BAO_0000224
2231,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,17005,,,,CHEMBL617176,13291,,,,,H,Autocuration,BAO_0000357
2232,,8,B,,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,17005,,,,CHEMBL617177,10812,,,,,H,Autocuration,BAO_0000357
2233,,4,B,,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,,CHEMBL617178,13020,,,,,H,Autocuration,BAO_0000224
2234,,4,B,,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,104784,,,,CHEMBL617179,13021,,,,,H,Autocuration,BAO_0000224
2235,,4,B,,1,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,,CHEMBL617180,13020,,,,,H,Autocuration,BAO_0000224
2236,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,17005,,,,CHEMBL617181,14532,,,,,H,Autocuration,BAO_0000357
2237,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,,CHEMBL617182,13944,,,,,H,Autocuration,BAO_0000357
2238,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,,CHEMBL617183,14331,,,,,H,Autocuration,BAO_0000357
2239,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,17005,,,,CHEMBL617184,14118,,,,,H,Autocuration,BAO_0000357
2240,,8,B,,1,Binding affinity against serotonergic 5-HT2 receptor,17005,,,,CHEMBL617185,13033,,,,,H,Autocuration,BAO_0000357
2241,,8,B,,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,17005,,,,CHEMBL617186,10321,,,,,H,Autocuration,BAO_0000357
2242,,8,B,,1,Compound was evaluated for the binding affinity at 5- HT2 receptor,17005,,,,CHEMBL617187,12918,,,,,H,Autocuration,BAO_0000357
2243,,8,B,,1,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,17005,,,,CHEMBL617188,15120,,,,,H,Autocuration,BAO_0000357
2244,,8,B,,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,17005,,,,CHEMBL617189,2613,,,,,H,Autocuration,BAO_0000218
2245,Homo sapiens,5,B,,1,Inhibitory activity against cloned human 5-HT2 receptor,104784,9606.0,,,CHEMBL617190,13378,,,,,D,Autocuration,BAO_0000224
2246,Homo sapiens,5,B,CHO,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",104784,9606.0,,,CHEMBL617191,2331,,449.0,,,D,Autocuration,BAO_0000219
2247,Homo sapiens,5,B,CHO,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",104784,9606.0,,,CHEMBL617192,2331,,449.0,,,D,Autocuration,BAO_0000219
2248,Homo sapiens,5,B,CHO,1,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",104784,9606.0,,,CHEMBL617193,2331,,449.0,,,D,Autocuration,BAO_0000219
2249,Homo sapiens,5,B,CHO,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",104784,9606.0,,,CHEMBL617194,2331,,449.0,,,D,Autocuration,BAO_0000219
2250,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,104784,,,,CHEMBL617195,4170,,,,,H,Autocuration,BAO_0000224
2251,,4,B,,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104784,,,,CHEMBL881830,15453,,,,,H,Autocuration,BAO_0000224
2252,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,17005,,,,CHEMBL617196,1479,,,,,H,Autocuration,BAO_0000357
2253,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,104686,,,,CHEMBL617197,11139,,,,,H,Autocuration,BAO_0000224
2254,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,17005,,,,CHEMBL617198,13969,,,,,H,Expert,BAO_0000357
2255,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,17005,,,,CHEMBL873476,13392,,,,,H,Expert,BAO_0000357
2256,,8,B,,1,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,17005,,,,CHEMBL617199,14430,,,,,H,Expert,BAO_0000019
2257,Cavia porcellus,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,107,10141.0,,,CHEMBL617200,13181,,,,,H,Autocuration,BAO_0000357
2258,,8,B,,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,,CHEMBL617484,17200,,,,,H,Autocuration,BAO_0000357
2259,,8,B,,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,,CHEMBL617485,17200,,,,,H,Autocuration,BAO_0000357
2260,,8,B,,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,,CHEMBL617486,17200,,,,,H,Autocuration,BAO_0000357
2261,,8,B,,1,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,107,,,,CHEMBL858022,13463,,,,,H,Autocuration,BAO_0000357
2262,,8,B,CHO,1,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,,CHEMBL617049,6347,,449.0,,,H,Autocuration,BAO_0000219
2263,Homo sapiens,9,F,CHO,1,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,107,9606.0,,,CHEMBL617050,6857,,449.0,,,D,Expert,BAO_0000219
2264,,8,F,,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,,CHEMBL617051,4176,,,,,H,Autocuration,BAO_0000219
2265,,8,F,,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,107,,,,CHEMBL617052,4176,,,,,H,Autocuration,BAO_0000219
2266,,8,F,,1,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,,CHEMBL617053,4176,,,,,H,Autocuration,BAO_0000219
2267,,8,B,CHO,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",107,,,,CHEMBL617054,6347,,449.0,,,H,Autocuration,BAO_0000219
2268,,8,B,CHO,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",107,,,,CHEMBL617055,6347,,449.0,,,H,Autocuration,BAO_0000219
2269,,8,B,,1,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,107,,,,CHEMBL882924,15331,,,,,H,Autocuration,BAO_0000357
2270,Homo sapiens,9,B,,1,Inhibition of human 5-hydroxytryptamine 2A receptor,107,9606.0,,,CHEMBL617056,16146,,,,,D,Expert,BAO_0000357
2271,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,,CHEMBL617057,15250,,449.0,,,H,Autocuration,BAO_0000219
2272,,8,B,,1,Inhibitory concentration against human 5-HT2A receptor in BEK cells,107,,,,CHEMBL617058,13631,,,,,H,Expert,BAO_0000219
2273,,8,B,,1,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),107,,,,CHEMBL617059,3805,,,,,H,Autocuration,BAO_0000357
2274,,8,B,CHO,1,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,107,,,,CHEMBL617060,4011,,449.0,,,H,Autocuration,BAO_0000219
2275,,8,B,CHO,1,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,107,,,,CHEMBL617061,4012,,449.0,,,H,Expert,BAO_0000219
2276,,8,B,L929,1,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,107,,,,CHEMBL617062,6366,,307.0,,,H,Expert,BAO_0000219
2277,,8,B,CHO,1,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,,CHEMBL617063,15949,,449.0,,,H,Expert,BAO_0000219
2278,,8,F,,1,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,107,,,,CHEMBL617064,14093,,,,,H,Autocuration,BAO_0000019
2279,,8,F,,1,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,,CHEMBL617065,13481,,,,,H,Autocuration,BAO_0000019
2280,,8,B,CHO,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,,CHEMBL617066,6347,,449.0,,,H,Autocuration,BAO_0000219
2281,,8,B,CHO,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,107,,,,CHEMBL617067,6347,,449.0,,,H,Autocuration,BAO_0000219
2282,,8,F,,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,107,,,,CHEMBL617068,14093,,,,,H,Autocuration,BAO_0000019
2283,,8,F,,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,107,,,,CHEMBL617069,14093,,,,,H,Autocuration,BAO_0000019
2284,,8,F,,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,,CHEMBL617070,13481,,,,,H,Autocuration,BAO_0000019
2285,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,107,,,,CHEMBL617071,14442,,,,,H,Autocuration,BAO_0000357
2286,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,,CHEMBL872915,14442,,,,,H,Autocuration,BAO_0000357
2287,,8,B,,1,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,107,,,,CHEMBL617072,14755,,,,,H,Autocuration,BAO_0000357
2288,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,107,,,,CHEMBL617073,16441,,,,,H,Autocuration,BAO_0000357
2289,,8,B,,1,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,107,,,,CHEMBL617074,14744,,,,,H,Autocuration,BAO_0000357
2290,,8,B,CHO,1,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,,CHEMBL617075,16659,,449.0,,,H,Expert,BAO_0000219
2291,,8,B,,1,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617076,3307,,,,,H,Autocuration,BAO_0000357
2292,Homo sapiens,9,B,,1,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,107,9606.0,,,CHEMBL617077,6857,,,,,D,Expert,BAO_0000019
2293,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,107,,,,CHEMBL617078,5635,,,,,H,Expert,BAO_0000357
2294,Homo sapiens,9,B,,1,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,107,9606.0,,,CHEMBL617079,4234,,,,,D,Expert,BAO_0000357
2295,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,,CHEMBL617080,15527,,,,,H,Autocuration,BAO_0000357
2296,,8,B,CHO,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,107,,,,CHEMBL617081,6588,,449.0,,,H,Expert,BAO_0000219
2297,,8,B,,1,Binding affinity towards human 5-HT2A receptor in BEK cells,107,,,,CHEMBL617082,13631,,,,,H,Expert,BAO_0000219
2298,,8,B,,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617083,17723,,,,,H,Autocuration,BAO_0000357
2299,,8,B,,1,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,,CHEMBL617084,14770,,,,,H,Autocuration,BAO_0000357
2300,Homo sapiens,9,B,,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,9606.0,,,CHEMBL617085,16293,,,,,D,Expert,BAO_0000357
2301,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,,CHEMBL617086,16209,,,,,H,Autocuration,BAO_0000357
2302,,8,B,,1,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,107,,,,CHEMBL617087,12469,,,,,H,Autocuration,BAO_0000219
2303,,8,B,,1,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617088,15363,,,,,H,Autocuration,BAO_0000357
2304,,8,B,,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617089,15363,,,,,H,Autocuration,BAO_0000357
2305,,8,B,,1,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",107,,,,CHEMBL617090,16441,,,,,H,Expert,BAO_0000019
2306,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,107,,,,CHEMBL617513,8,,,,,H,Autocuration,BAO_0000357
2307,,8,B,HEK293,1,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,107,,,,CHEMBL617514,4176,,722.0,,,H,Autocuration,BAO_0000219
2308,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617515,17085,,,,,H,Autocuration,BAO_0000019
2309,,8,B,,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,,CHEMBL617516,17200,,,,,H,Autocuration,BAO_0000357
2310,Homo sapiens,9,B,,1,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,9606.0,,,CHEMBL617517,17200,,,,,D,Expert,BAO_0000357
2311,Homo sapiens,9,B,CHO,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,107,9606.0,,,CHEMBL617518,4013,,449.0,,,D,Expert,BAO_0000219
2312,,8,B,,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617519,5088,,,,,H,Autocuration,BAO_0000357
2313,Homo sapiens,9,B,,1,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,107,9606.0,,,CHEMBL617520,5088,,,,,D,Expert,BAO_0000357
2314,,8,B,,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,107,,,,CHEMBL617521,5088,,,,,H,Autocuration,BAO_0000357
2315,Homo sapiens,9,B,,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,107,9606.0,,,CHEMBL617522,5088,,,,,D,Expert,BAO_0000357
2316,,8,B,,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,107,,,,CHEMBL617523,5088,,,,,H,Autocuration,BAO_0000357
2317,,8,B,,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,107,,,,CHEMBL617524,5088,,,,,H,Autocuration,BAO_0000357
2318,,4,B,,1,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,104686,,,,CHEMBL617525,9786,,,,,H,Autocuration,BAO_0000019
2319,Rattus norvegicus,5,B,,1,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,104686,10116.0,,,CHEMBL617526,9205,,,,,D,Autocuration,BAO_0000019
2320,,4,B,,1,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,104686,,,,CHEMBL617527,11257,,,,,H,Autocuration,BAO_0000224
2321,,4,B,,1,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,,CHEMBL617528,9362,,,,,H,Autocuration,BAO_0000019
2322,,4,B,,1,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,,CHEMBL617529,9362,,,,,H,Autocuration,BAO_0000019
2323,,4,B,,1,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,104686,,,,CHEMBL617530,10590,,,,,H,Autocuration,BAO_0000224
2324,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,,CHEMBL617531,10468,,,,,H,Autocuration,BAO_0000019
2325,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,104686,,,,CHEMBL617532,13050,,,,,H,Autocuration,BAO_0000019
2326,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,104686,,,,CHEMBL617533,11624,,,,,H,Autocuration,BAO_0000019
2327,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,,CHEMBL617534,10468,,,,,H,Autocuration,BAO_0000019
2328,,4,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,104686,,,,CHEMBL617535,10330,,,,,H,Autocuration,BAO_0000224
2329,,4,B,,1,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,,CHEMBL617536,10062,,,,,H,Autocuration,BAO_0000224
2330,,4,B,,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617537,11642,,,,,H,Autocuration,BAO_0000224
2331,,4,B,,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617538,10062,,,,,H,Autocuration,BAO_0000224
2332,,4,B,,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,,,CHEMBL617539,13427,,,,,H,Autocuration,BAO_0000219
2333,Rattus norvegicus,5,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL617540,12280,,,,,D,Autocuration,BAO_0000224
2334,Rattus norvegicus,5,B,,1,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,104686,10116.0,,,CHEMBL617541,4101,,,,,D,Autocuration,BAO_0000224
2335,,4,B,,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617542,10062,,,,,H,Autocuration,BAO_0000224
2336,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,104686,,,,CHEMBL617543,11147,,,,,H,Autocuration,BAO_0000224
2337,Rattus norvegicus,5,B,CHO-K1,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,10116.0,,,CHEMBL617544,2395,,485.0,,,D,Autocuration,BAO_0000219
2338,Rattus norvegicus,5,B,CHO-K1,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,10116.0,,,CHEMBL617545,2395,,485.0,,,D,Autocuration,BAO_0000219
2339,Rattus norvegicus,5,B,,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,104686,10116.0,,,CHEMBL617413,9098,,,,,D,Autocuration,BAO_0000019
2340,,4,B,,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,104686,,,,CHEMBL617414,9098,,,,,H,Autocuration,BAO_0000019
2341,Rattus norvegicus,5,B,,1,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,104686,10116.0,,,CHEMBL617415,9098,,,,,D,Autocuration,BAO_0000019
2342,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617416,9443,,,,,H,Autocuration,BAO_0000224
2343,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,,CHEMBL617417,9443,,,,,H,Autocuration,BAO_0000224
2344,,4,B,,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",104686,,,,CHEMBL617418,9699,,,,,H,Autocuration,BAO_0000019
2345,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,104686,,,,CHEMBL617419,9699,,,,,H,Autocuration,BAO_0000019
2346,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,,CHEMBL617420,9098,,,,,H,Autocuration,BAO_0000224
2347,Rattus norvegicus,5,B,,1,Affinity for 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL617421,3070,,,,,D,Autocuration,BAO_0000224
2348,,4,B,,1,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,104686,,,,CHEMBL617422,9547,,,,,H,Autocuration,BAO_0000224
2349,,4,B,,1,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,104686,,,,CHEMBL617423,10444,,,,,H,Autocuration,BAO_0000019
2350,,4,B,,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,104686,,,,CHEMBL617424,14617,,,,,H,Autocuration,BAO_0000019
2351,,4,B,,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,104686,,,,CHEMBL617425,14617,,,,,H,Autocuration,BAO_0000019
2352,,4,B,,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),104686,,,,CHEMBL617426,11130,,,,,H,Autocuration,BAO_0000224
2353,,4,B,,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),104686,,,,CHEMBL617427,11130,,,,,H,Autocuration,BAO_0000218
2354,,4,B,,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,104686,,,,CHEMBL617428,14542,955.0,,,Brain,H,Autocuration,BAO_0000221
2355,,4,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,104686,,,,CHEMBL617429,2797,,,,,H,Autocuration,BAO_0000224
2356,,4,B,,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,,CHEMBL617430,11332,,,,,H,Autocuration,BAO_0000019
2357,,4,B,,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,,CHEMBL617431,11332,,,,,H,Autocuration,BAO_0000019
2358,,4,B,,1,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,104686,,,,CHEMBL617432,10752,1870.0,,,Frontal cortex,H,Autocuration,BAO_0000019
2359,,4,B,,1,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617433,1185,,,,,H,Autocuration,BAO_0000224
2360,,4,B,,1,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617434,1185,,,,,H,Autocuration,BAO_0000224
2361,Rattus norvegicus,5,B,,1,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,104686,10116.0,,,CHEMBL617435,11624,,,,,D,Autocuration,BAO_0000224
2362,,4,B,,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,104686,,,,CHEMBL617436,1344,,,,,H,Autocuration,BAO_0000019
2363,Rattus norvegicus,5,B,,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,104686,10116.0,,,CHEMBL617437,15453,2435.0,,,Striatum,D,Autocuration,BAO_0000019
2364,,4,B,,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,,CHEMBL617438,11662,,,,,H,Autocuration,BAO_0000019
2365,,4,B,,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,,CHEMBL617439,11662,,,,,H,Autocuration,BAO_0000019
2366,,4,B,,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617440,10796,,,,,H,Autocuration,BAO_0000224
2367,,4,B,,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617441,9069,,,,,H,Autocuration,BAO_0000224
2368,Rattus norvegicus,5,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,104686,10116.0,,,CHEMBL872918,8814,,,,,D,Autocuration,BAO_0000019
2369,Rattus norvegicus,5,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,104686,10116.0,,,CHEMBL617442,8908,,,,,D,Autocuration,BAO_0000019
2370,,4,B,,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,,CHEMBL617443,9098,,,,,H,Autocuration,BAO_0000019
2371,,4,B,,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,104686,,,,CHEMBL617444,9098,,,,,H,Autocuration,BAO_0000019
2372,,4,B,,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,,CHEMBL617445,9098,,,,,H,Autocuration,BAO_0000019
2373,,4,B,,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,104686,,,,CHEMBL617446,9098,,,,,H,Autocuration,BAO_0000019
2374,,4,B,,1,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,104686,,,,CHEMBL617447,9098,,,,,H,Autocuration,BAO_0000249
2375,,4,B,,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,104686,,,,CHEMBL617448,9098,,,,,H,Autocuration,BAO_0000019
2376,,4,B,,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,104686,,,,CHEMBL617449,9098,,,,,H,Autocuration,BAO_0000019
2377,,4,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,104686,,,,CHEMBL617450,9161,,,,,H,Autocuration,BAO_0000019
2378,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,104686,,,,CHEMBL617451,9161,,,,,H,Autocuration,BAO_0000019
2379,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,104686,,,,CHEMBL617452,9161,,,,,H,Autocuration,BAO_0000019
2380,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,104686,,,,CHEMBL617453,9161,,,,,H,Autocuration,BAO_0000019
2381,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,104686,,,,CHEMBL617660,9161,,,,,H,Autocuration,BAO_0000019
2382,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,104686,,,,CHEMBL617661,9161,,,,,H,Autocuration,BAO_0000019
2383,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,104686,,,,CHEMBL617662,9161,,,,,H,Autocuration,BAO_0000019
2384,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,104686,,,,CHEMBL872919,9161,,,,,H,Autocuration,BAO_0000019
2385,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,104686,,,,CHEMBL617663,9161,,,,,H,Autocuration,BAO_0000019
2386,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,104686,,,,CHEMBL617664,9161,,,,,H,Autocuration,BAO_0000019
2387,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,104686,,,,CHEMBL617665,9161,,,,,H,Autocuration,BAO_0000019
2388,,4,B,,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,104686,,,,CHEMBL617666,9161,,,,,H,Autocuration,BAO_0000019
2389,,4,B,,1,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,104686,,,,CHEMBL617667,12094,,,,,H,Autocuration,BAO_0000019
2390,,4,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,104686,,,,CHEMBL617668,12018,,,,,H,Autocuration,BAO_0000249
2391,,4,B,,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,104686,,,,CHEMBL617669,10394,,,,,H,Autocuration,BAO_0000249
2392,,4,B,,1,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617670,15260,,,,,H,Autocuration,BAO_0000224
2393,Rattus norvegicus,5,B,,1,Inhibitory constant against 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL617671,11624,,,,,D,Autocuration,BAO_0000224
2394,,4,B,,1,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617672,13654,,,,,H,Autocuration,BAO_0000224
2395,,4,B,,1,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,104686,,,,CHEMBL617673,9541,,,,,H,Autocuration,BAO_0000019
2396,,4,B,,1,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,104686,,,,CHEMBL617674,11933,,,,,H,Autocuration,BAO_0000224
2397,,4,B,,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,,CHEMBL617675,15538,,,,,H,Autocuration,BAO_0000019
2398,,4,B,,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,104686,,,,CHEMBL617676,15538,,,,,H,Autocuration,BAO_0000019
2399,,4,B,,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,104686,,,,CHEMBL617677,15538,,,,,H,Autocuration,BAO_0000019
2400,,5,B,,1,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617678,8841,,,,,D,Autocuration,BAO_0000019
2401,,4,B,,1,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,104686,,,,CHEMBL617679,1455,,,,,H,Autocuration,BAO_0000224
2402,,4,B,,1,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,104686,,,,CHEMBL617680,1455,,,,,H,Autocuration,BAO_0000224
2403,,4,B,,1,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,104686,,,,CHEMBL617681,11752,,,,,H,Autocuration,BAO_0000019
2404,,4,B,,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,104686,,,,CHEMBL617682,11642,955.0,,,Brain,H,Autocuration,BAO_0000221
2405,,4,B,,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,104686,,,,CHEMBL617683,12092,,,,,H,Autocuration,BAO_0000224
2406,,4,B,,1,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,104686,,,,CHEMBL617684,3967,,,,,H,Autocuration,BAO_0000224
2407,Rattus norvegicus,5,B,,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,10116.0,,,CHEMBL617685,12771,,,,,D,Autocuration,BAO_0000224
2408,,4,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,104686,,,,CHEMBL617686,11642,,,,,H,Autocuration,BAO_0000019
2409,,4,B,,1,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,104686,,,,CHEMBL617687,11628,,,,,H,Autocuration,BAO_0000224
2410,,4,B,,1,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,,CHEMBL617688,13654,,,,,H,Autocuration,BAO_0000224
2411,,4,F,,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,,CHEMBL617689,11200,,,,,H,Autocuration,BAO_0000019
2412,,4,F,,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,,CHEMBL617690,11200,,,,,H,Autocuration,BAO_0000019
2413,,4,F,,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,,,CHEMBL617691,11200,,,,,H,Autocuration,BAO_0000218
2414,,4,F,,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,,,CHEMBL617692,11200,,,,,H,Autocuration,BAO_0000218
2415,,4,F,,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,,,CHEMBL617693,11200,,,,,H,Autocuration,BAO_0000218
2416,,4,F,,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,,,CHEMBL617694,11200,,,,,H,Autocuration,BAO_0000218
2417,,8,B,,1,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,12687,,,,CHEMBL857985,15436,955.0,,,Brain,H,Expert,BAO_0000221
2418,Rattus norvegicus,9,B,,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,10116.0,,,CHEMBL617695,15436,,,,,D,Expert,BAO_0000019
2419,,8,B,,1,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,12687,,,,CHEMBL617696,14025,,,,,H,Autocuration,BAO_0000019
2420,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,12687,,,,CHEMBL617697,4342,,,,,H,Autocuration,BAO_0000357
2421,Rattus norvegicus,9,B,,1,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,12687,10116.0,,,CHEMBL617257,13735,,,,,D,Expert,BAO_0000019
2422,Rattus norvegicus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,12687,10116.0,,,CHEMBL617258,5816,,,,,D,Expert,BAO_0000357
2423,,8,B,,1,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,12687,,,,CHEMBL617259,14287,,,,,H,Expert,BAO_0000019
2424,,8,B,,1,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,12687,,,,CHEMBL617260,15738,,,,,H,Autocuration,BAO_0000357
2425,Rattus norvegicus,9,B,,1,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL617261,15738,,,,,D,Expert,BAO_0000357
2426,,8,B,,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,12687,,,,CHEMBL617262,15026,,,,,H,Autocuration,BAO_0000019
2427,,8,B,,1,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,,CHEMBL617263,16647,,,,,H,Expert,BAO_0000019
2428,,8,B,,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,12687,,,,CHEMBL617264,16647,,,,,H,Autocuration,BAO_0000019
2429,Rattus norvegicus,9,B,,1,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL617265,13345,,,,,D,Expert,BAO_0000019
2430,,8,B,,1,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,12687,,Membranes,,CHEMBL617266,1543,,,,,H,Autocuration,BAO_0000249
2431,,8,B,,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12687,,,,CHEMBL617267,12444,,,,,H,Autocuration,BAO_0000019
2432,,8,B,,1,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,12687,,,,CHEMBL617268,16404,,,,,H,Expert,BAO_0000019
2433,,8,B,CHO,1,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,12687,,,,CHEMBL617269,16404,,449.0,,,H,Autocuration,BAO_0000219
2434,,8,B,,1,Kinetic inhibition constant evaluated by measuring serotonergic activity,12687,,,,CHEMBL617323,15577,,,,,H,Expert,BAO_0000357
2435,,8,B,,1,Serotonergic activity of the compound.,12687,,,,CHEMBL617324,15577,,,,,H,Autocuration,BAO_0000357
2436,,8,B,,1,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,12687,,,,CHEMBL617325,2495,,,,,H,Autocuration,BAO_0000249
2437,Rattus norvegicus,9,B,,1,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,12687,10116.0,,,CHEMBL617326,15042,,,,,D,Expert,BAO_0000019
2438,,8,B,,1,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,12687,,,,CHEMBL617327,15026,,,,,H,Expert,BAO_0000249
2439,Rattus norvegicus,9,F,,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,10116.0,,,CHEMBL617328,12919,,,,,D,Expert,BAO_0000019
2440,Rattus norvegicus,9,F,,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,10116.0,,,CHEMBL617329,12919,,,,,D,Expert,BAO_0000019
2441,Rattus norvegicus,9,F,,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,10116.0,,,CHEMBL617330,12919,,,,,D,Expert,BAO_0000019
2442,,8,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,,CHEMBL617331,15194,,,,,H,Autocuration,BAO_0000357
2443,,8,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,12687,,,,CHEMBL617332,15194,,,,,H,Autocuration,BAO_0000357
2444,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617333,4820,,,,,H,Expert,BAO_0000357
2445,,8,B,,1,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,107,,,,CHEMBL617334,6736,,,,,H,Autocuration,BAO_0000357
2446,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,107,,,,CHEMBL617335,5163,,,,,H,Autocuration,BAO_0000357
2447,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,107,,,,CHEMBL617336,5163,,,,,H,Autocuration,BAO_0000357
2448,,8,B,,1,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,107,,,,CHEMBL617337,6011,,,,,H,Autocuration,BAO_0000357
2449,Homo sapiens,9,B,,1,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,107,9606.0,,,CHEMBL617338,14294,,,,,D,Expert,BAO_0000357
2450,,8,B,,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617339,5014,,,,,H,Autocuration,BAO_0000357
2451,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617340,17066,,,,,H,Expert,BAO_0000357
2452,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,107,,,,CHEMBL617341,17515,,,,,H,Autocuration,BAO_0000357
2453,,8,B,,1,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617342,6736,,,,,H,Expert,BAO_0000357
2454,,8,B,,1,Affinity for 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617343,5163,,,,,H,Expert,BAO_0000357
2455,,8,B,NIH3T3,1,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,107,,,,CHEMBL617344,16911,,723.0,,,H,Expert,BAO_0000219
2456,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,107,,,,CHEMBL617345,6841,,,,,H,Expert,BAO_0000357
2457,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,107,,,,CHEMBL617346,6119,,,,,H,Expert,BAO_0000357
2458,,8,B,,1,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617347,3962,,,,,H,Autocuration,BAO_0000357
2459,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,107,,,,CHEMBL617348,4373,,,,,H,Autocuration,BAO_0000357
2460,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,107,,,,CHEMBL617349,4373,,,,,H,Autocuration,BAO_0000357
2461,,8,F,,1,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617350,3962,,,,,H,Autocuration,BAO_0000019
2462,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,107,,,,CHEMBL872339,1633,,,,,H,Expert,BAO_0000357
2463,,8,B,,1,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,107,,,,CHEMBL617351,4373,,,,,H,Autocuration,BAO_0000357
2464,,8,B,,1,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617352,6576,,,,,H,Expert,BAO_0000357
2465,,8,B,,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617353,4687,,,,,H,Autocuration,BAO_0000357
2466,,8,B,,1,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617354,16946,,,,,H,Autocuration,BAO_0000357
2467,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617355,14159,,,,,H,Autocuration,BAO_0000357
2468,Mus musculus,8,B,CHO,1,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,107,10090.0,,,CHEMBL617356,3032,,449.0,,,H,Expert,BAO_0000219
2469,,8,B,,1,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617357,16655,,,,,H,Autocuration,BAO_0000357
2470,,8,B,,1,Binding affinity at 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617358,13964,,,,,H,Autocuration,BAO_0000357
2471,,8,B,,1,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617359,16989,,,,,H,Expert,BAO_0000357
2472,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,107,,,,CHEMBL617360,16117,,,,,H,Autocuration,BAO_0000357
2473,,8,B,,1,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,107,,,,CHEMBL875913,16700,,,,,H,Autocuration,BAO_0000357
2474,,8,B,,1,Affinity against 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617361,3269,,,,,H,Autocuration,BAO_0000357
2475,Homo sapiens,9,B,,1,Binding affinity against 5-Hydroxytryptamine 2A receptor,107,9606.0,,,CHEMBL617362,1274,,,,,D,Expert,BAO_0000357
2476,,8,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,107,,,,CHEMBL617363,1317,,,,,H,Autocuration,BAO_0000357
2477,,8,B,,1,Tested against 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617364,12146,,,,,H,Autocuration,BAO_0000357
2478,,4,B,,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,,CHEMBL617365,12652,,,,,H,Autocuration,BAO_0000224
2479,,4,B,,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,105075,,,,CHEMBL617366,12652,,,,,H,Autocuration,BAO_0000224
2480,,4,B,,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,105075,,,,CHEMBL617367,12652,,,,,H,Autocuration,BAO_0000224
2481,,4,B,,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,,CHEMBL617368,12652,,,,,H,Autocuration,BAO_0000224
2482,,8,B,,1,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),107,,,,CHEMBL617369,16647,,,,,H,Autocuration,BAO_0000357
2483,Homo sapiens,9,B,HEK293,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,227,9606.0,,,CHEMBL617370,15851,,722.0,,,D,Expert,BAO_0000219
2484,Homo sapiens,9,F,CHO,1,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,227,9606.0,,,CHEMBL617371,6857,,449.0,,,D,Expert,BAO_0000219
2485,,8,B,,1,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),227,,,,CHEMBL617372,3805,,,,,H,Autocuration,BAO_0000357
2486,Homo sapiens,9,B,,1,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,227,9606.0,,,CHEMBL617373,6491,,,,,D,Expert,BAO_0000357
2487,,8,F,,1,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,227,,,,CHEMBL617374,14093,,,,,H,Autocuration,BAO_0000019
2488,,8,F,,1,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,227,,,,CHEMBL617375,13481,,,,,H,Autocuration,BAO_0000019
2489,,8,F,,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,227,,,,CHEMBL617376,14093,,,,,H,Autocuration,BAO_0000019
2490,,8,F,,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,227,,,,CHEMBL617377,14093,,,,,H,Autocuration,BAO_0000019
2491,,8,F,,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,227,,,,CHEMBL617378,14093,,,,,H,Autocuration,BAO_0000019
2492,,8,F,,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,,CHEMBL617379,13481,,,,,H,Autocuration,BAO_0000019
2493,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,227,,,,CHEMBL617380,14442,,,,,H,Autocuration,BAO_0000357
2494,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,227,,,,CHEMBL617381,14442,,,,,H,Autocuration,BAO_0000357
2495,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,,CHEMBL617382,14442,,,,,H,Autocuration,BAO_0000357
2496,,8,B,,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617383,12369,,,,,H,Autocuration,BAO_0000357
2497,,8,B,,1,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,107,,,,CHEMBL617384,12369,,,,,H,Expert,BAO_0000357
2498,,8,B,,1,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,107,,,,CHEMBL617385,12369,,,,,H,Expert,BAO_0000357
2499,,8,B,,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,107,,,,CHEMBL617386,14447,,,,,H,Autocuration,BAO_0000019
2500,,8,B,,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,107,,,,CHEMBL617387,14447,,,,,H,Autocuration,BAO_0000019
2501,,8,B,NIH3T3,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,,CHEMBL617388,17451,,723.0,,,H,Autocuration,BAO_0000219
2502,,8,F,CHO,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,,,CHEMBL617389,6857,,449.0,,,H,Autocuration,BAO_0000219
2503,Homo sapiens,9,F,CHO,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,9606.0,,,CHEMBL617390,6857,,449.0,,,D,Expert,BAO_0000219
2504,,4,B,,1,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,104817,,,,CHEMBL617391,5635,,,,,H,Autocuration,BAO_0000224
2505,,8,B,,1,Binding activity radioligand.,107,,,,CHEMBL617392,12861,,,,,H,Autocuration,BAO_0000357
2506,,8,B,,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,107,,,,CHEMBL617393,12861,,,,,H,Autocuration,BAO_0000019
2507,,8,B,L929,1,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,,CHEMBL617394,5105,,307.0,,,H,Autocuration,BAO_0000219
2508,,8,B,L929,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,,CHEMBL617395,5104,,307.0,,,H,Expert,BAO_0000219
2509,,8,B,L929,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,107,,,,CHEMBL617396,5105,,307.0,,,H,Expert,BAO_0000219
2510,,8,B,L929,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,107,,,,CHEMBL617397,5105,,307.0,,,H,Autocuration,BAO_0000219
2511,,8,B,,1,Binding affinity against 5-HT2A receptor,107,,,,CHEMBL617398,5254,,,,,H,Autocuration,BAO_0000357
2512,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor,107,,,,CHEMBL617399,5254,,,,,H,Autocuration,BAO_0000357
2513,,8,B,HEK293,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,107,,,,CHEMBL617400,13267,,722.0,,,H,Autocuration,BAO_0000219
2514,,8,B,HEK293,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,107,,,,CHEMBL617401,13267,,722.0,,,H,Autocuration,BAO_0000219
2515,Homo sapiens,9,B,HEK293,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,107,9606.0,,,CHEMBL617402,14157,,722.0,,,D,Expert,BAO_0000219
2516,Homo sapiens,9,B,HEK293,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,9606.0,,,CHEMBL617403,12936,,722.0,,,D,Expert,BAO_0000219
2517,,8,B,,1,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,107,,,,CHEMBL617404,14068,,,,,H,Expert,BAO_0000357
2518,Homo sapiens,9,B,HEK293,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,9606.0,,,CHEMBL857981,12936,,722.0,,,D,Expert,BAO_0000219
2519,Homo sapiens,9,B,HEK293,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,9606.0,,,CHEMBL617405,12936,,722.0,,,D,Expert,BAO_0000219
2520,Homo sapiens,9,B,HEK293,1,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,107,9606.0,,,CHEMBL617253,4540,,722.0,,,D,Expert,BAO_0000219
2521,,8,B,,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,107,,,,CHEMBL617254,6166,,,,,H,Expert,BAO_0000357
2522,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,,CHEMBL617255,17296,,722.0,,,H,Autocuration,BAO_0000219
2523,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,,CHEMBL617256,17296,,722.0,,,H,Autocuration,BAO_0000219
2524,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,107,,,,CHEMBL616874,17296,,722.0,,,H,Autocuration,BAO_0000219
2525,Homo sapiens,9,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,107,9606.0,,,CHEMBL616875,15779,,722.0,,,D,Expert,BAO_0000219
2526,,8,B,HEK293,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,107,,,,CHEMBL616876,14391,,722.0,,,H,Expert,BAO_0000219
2527,,8,B,HEK293,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",107,,,,CHEMBL616877,15851,,722.0,,,H,Expert,BAO_0000219
2528,Homo sapiens,9,B,HEK293,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,107,9606.0,,,CHEMBL616878,15851,,722.0,,,D,Expert,BAO_0000219
2529,,8,B,HEK293,1,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,107,,,,CHEMBL616879,3832,,722.0,,,H,Expert,BAO_0000219
2530,,8,B,HEK293,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,107,,,,CHEMBL616880,3833,,722.0,,,H,Expert,BAO_0000219
2531,Homo sapiens,9,B,HEK293,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,9606.0,,,CHEMBL616881,12936,,722.0,,,D,Expert,BAO_0000219
2532,,8,B,NIH3T3,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,107,,,,CHEMBL616882,17451,,723.0,,,H,Autocuration,BAO_0000219
2533,,8,B,NIH3T3,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,,CHEMBL616883,17451,,723.0,,,H,Autocuration,BAO_0000219
2534,,8,B,NIH3T3,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,,CHEMBL616884,17451,,723.0,,,H,Autocuration,BAO_0000219
2535,,8,B,HEK293,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,107,,,,CHEMBL616885,4199,,722.0,,,H,Autocuration,BAO_0000219
2536,,8,B,CHO-K1,1,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,107,,,,CHEMBL616886,1883,,485.0,,,H,Autocuration,BAO_0000219
2537,,8,B,CHO-K1,1,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,107,,,,CHEMBL616887,1883,,485.0,,,H,Expert,BAO_0000219
2538,Homo sapiens,9,B,,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,9606.0,,,CHEMBL616888,14875,,,,,D,Expert,BAO_0000357
2539,,8,B,HEK293,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,107,,,,CHEMBL616889,15146,,722.0,,,H,Autocuration,BAO_0000219
2540,,8,B,HEK293,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,107,,,,CHEMBL616890,5213,,722.0,,,H,Autocuration,BAO_0000219
2541,Homo sapiens,9,B,CHO,1,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,107,9606.0,,,CHEMBL616891,16404,,449.0,,,D,Expert,BAO_0000219
2542,,8,B,HEK293,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,107,,,,CHEMBL616892,14818,,722.0,,,H,Autocuration,BAO_0000219
2543,,8,B,HEK293,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",107,,,,CHEMBL616893,4829,,722.0,,,H,Autocuration,BAO_0000219
2544,,8,F,NIH3T3,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,10620,,,,CHEMBL616894,12652,,723.0,,,H,Autocuration,BAO_0000219
2545,,8,B,NIH3T3,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,107,,,,CHEMBL616895,4682,,723.0,,,H,Expert,BAO_0000219
2546,,8,F,,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,10620,,,,CHEMBL616896,12652,,,,,H,Autocuration,BAO_0000019
2547,,8,B,,1,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,10621,,,,CHEMBL617099,4921,,,,,H,Autocuration,BAO_0000357
2548,,8,B,,1,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,10621,,,,CHEMBL617100,4921,,,,,H,Autocuration,BAO_0000357
2549,Oryctolagus cuniculus,8,B,,1,Binding affinity against rabbit aorta 5-HT2A receptor,107,9986.0,,,CHEMBL884532,16312,,,,,H,Autocuration,BAO_0000357
2550,Oryctolagus cuniculus,8,B,,1,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,107,9986.0,,,CHEMBL617101,14998,,,,,H,Expert,BAO_0000357
2551,Oryctolagus cuniculus,8,B,,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,107,9986.0,,,CHEMBL617102,14025,,,,,H,Expert,BAO_0000357
2552,Oryctolagus cuniculus,8,B,,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,107,9986.0,,,CHEMBL617103,13047,,,,,H,Autocuration,BAO_0000019
2553,Oryctolagus cuniculus,8,B,,1,The compound was tested for binding affinity against 5-HT2A receptor,107,9986.0,,,CHEMBL617104,13047,,,,,H,Expert,BAO_0000357
2554,,8,B,CHO-K1,1,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,10576,,,,CHEMBL857979,1883,,485.0,,,H,Autocuration,BAO_0000219
2555,,8,B,,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein,12687,,,,CHEMBL857502,13463,,,,,H,Autocuration,BAO_0000019
2556,,8,B,,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,,CHEMBL617105,13463,,,,,H,Autocuration,BAO_0000019
2557,,8,B,,1,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,12687,,,,CHEMBL858021,13463,945.0,,,Stomach,H,Autocuration,BAO_0000019
2558,Rattus norvegicus,9,B,,1,Binding affinity for 5-HT 2A in rat stomach fundus,12687,10116.0,,,CHEMBL875910,13463,945.0,,,Stomach,D,Expert,BAO_0000019
2559,,8,B,,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,,CHEMBL617106,13463,,,,,H,Autocuration,BAO_0000019
2560,,8,B,NIH3T3,1,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617107,16326,,723.0,,,H,Expert,BAO_0000219
2561,,8,F,,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617108,14093,,,,,H,Autocuration,BAO_0000019
2562,,8,F,,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617109,14093,,,,,H,Autocuration,BAO_0000019
2563,,8,B,,1,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617110,15740,,,,,H,Autocuration,BAO_0000357
2564,,8,B,,1,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,12687,,,,CHEMBL617111,16633,,,,,H,Autocuration,BAO_0000357
2565,Rattus norvegicus,9,F,,1,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,12687,10116.0,,,CHEMBL617112,17200,,,,,D,Expert,BAO_0000019
2566,,8,B,,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617113,17133,,,,,H,Autocuration,BAO_0000357
2567,,8,B,,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617114,17133,,,,,H,Autocuration,BAO_0000357
2568,,8,B,,1,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617115,17133,,,,,H,Autocuration,BAO_0000357
2569,,8,F,,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,,CHEMBL617116,17200,,,,,H,Autocuration,BAO_0000219
2570,,8,F,,1,Efficacy at 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617117,15363,,,,,H,Autocuration,BAO_0000019
2571,,8,B,,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,,,CHEMBL617118,17200,,,,,H,Autocuration,BAO_0000357
2572,Rattus norvegicus,9,B,,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,10116.0,,,CHEMBL617119,17200,,,,,D,Expert,BAO_0000357
2573,Rattus norvegicus,9,B,,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),12687,10116.0,,,CHEMBL617120,17200,,,,,D,Expert,BAO_0000357
2574,Rattus norvegicus,9,F,,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,10116.0,,,CHEMBL617121,17200,,,,,D,Expert,BAO_0000219
2575,,8,F,,1,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,,CHEMBL617122,17200,,,,,H,Autocuration,BAO_0000219
2576,,8,B,,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617123,17211,,,,,H,Autocuration,BAO_0000019
2577,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,,CHEMBL617124,17331,,,,,H,Expert,BAO_0000019
2578,,8,B,,1,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,12687,,,,CHEMBL617600,13565,,,,,H,Expert,BAO_0000249
2579,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,12687,,,,CHEMBL617601,13730,,,,,H,Expert,BAO_0000357
2580,,8,B,,1,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12687,,,,CHEMBL882923,12416,,,,,H,Expert,BAO_0000019
2581,,8,B,,1,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617602,15295,,,,,H,Autocuration,BAO_0000357
2582,,8,B,,1,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,12687,,,,CHEMBL617603,1742,,,,,H,Autocuration,BAO_0000019
2583,,8,B,,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617604,15295,,,,,H,Autocuration,BAO_0000357
2584,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,12687,,,,CHEMBL617605,14970,,,,,H,Expert,BAO_0000019
2585,,8,B,,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,12687,,,,CHEMBL617606,16693,,,,,H,Expert,BAO_0000019
2586,Rattus norvegicus,9,B,,1,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL617607,14776,,,,,D,Expert,BAO_0000019
2587,,8,B,,1,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,,CHEMBL617455,14286,,,,,H,Autocuration,BAO_0000249
2588,Rattus norvegicus,9,B,,1,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,10116.0,,,CHEMBL617456,17200,,,,,D,Expert,BAO_0000019
2589,,8,B,,1,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),12687,,,,CHEMBL617457,15306,,,,,H,Expert,BAO_0000357
2590,Rattus norvegicus,9,B,,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL617458,14178,,,,,D,Expert,BAO_0000357
2591,Rattus norvegicus,9,B,,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,12687,10116.0,,,CHEMBL617459,14229,,,,,D,Expert,BAO_0000019
2592,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12687,,,,CHEMBL617460,12884,,,,,H,Expert,BAO_0000357
2593,,8,B,,1,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",12687,,,,CHEMBL617461,13149,,,,,H,Expert,BAO_0000357
2594,Rattus norvegicus,9,B,,1,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,12687,10116.0,,,CHEMBL617462,15295,,,,,D,Expert,BAO_0000019
2595,,8,B,,1,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,12687,,,,CHEMBL617463,15740,,,,,H,Autocuration,BAO_0000357
2596,,8,B,,1,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",12687,,,,CHEMBL617464,15185,,,,,H,Autocuration,BAO_0000019
2597,,8,B,,1,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",12687,,,,CHEMBL617465,15185,,,,,H,Autocuration,BAO_0000019
2598,,8,B,,1,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,12687,,,,CHEMBL617466,17529,,,,,H,Expert,BAO_0000019
2599,,8,B,,1,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,,CHEMBL617467,14826,,,,,H,Autocuration,BAO_0000019
2600,,8,B,,1,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,12687,,,,CHEMBL617468,17211,,,,,H,Expert,BAO_0000019
2601,,8,B,,1,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,,CHEMBL617469,14826,,,,,H,Autocuration,BAO_0000019
2602,,8,B,,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617470,14093,,,,,H,Autocuration,BAO_0000019
2603,,8,B,,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,12687,,,,CHEMBL617471,14093,,,,,H,Autocuration,BAO_0000019
2604,,8,B,NIH3T3,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,12687,,,,CHEMBL617472,13246,,723.0,,,H,Expert,BAO_0000219
2605,,8,B,,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,12687,,,,CHEMBL617473,13246,,,,,H,Expert,BAO_0000357
2606,Rattus norvegicus,9,B,,1,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,10116.0,,,CHEMBL617474,15436,,,,,D,Expert,BAO_0000019
2607,Rattus norvegicus,9,B,,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,10116.0,,,CHEMBL617475,15436,,,,,D,Expert,BAO_0000019
2608,,8,B,,1,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,12687,,,,CHEMBL617476,14442,955.0,,,Brain,H,Autocuration,BAO_0000221
2609,,8,B,,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617477,12457,,,,,H,Expert,BAO_0000357
2610,,8,B,NIH3T3,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617478,12457,,723.0,,,H,Expert,BAO_0000219
2611,,8,F,,1,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",12687,,,,CHEMBL617479,14755,,,,,H,Autocuration,BAO_0000221
2612,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,12687,,,,CHEMBL617480,4707,,,,,H,Autocuration,BAO_0000357
2613,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617481,13297,,,,,H,Expert,BAO_0000357
2614,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,,CHEMBL617482,17331,,,,,H,Expert,BAO_0000019
2615,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,12687,,,,CHEMBL617483,4664,,,,,H,Autocuration,BAO_0000019
2616,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,,CHEMBL621528,16633,,,,,H,Autocuration,BAO_0000357
2617,Rattus norvegicus,9,B,NIH3T3,1,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,12687,10116.0,,,CHEMBL621529,4664,,723.0,,,D,Expert,BAO_0000219
2618,,8,B,,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,,CHEMBL621530,16133,,,,,H,Expert,BAO_0000357
2619,,8,B,,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,,CHEMBL621531,16133,,,,,H,Expert,BAO_0000357
2620,Rattus norvegicus,9,B,,1,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL621532,14060,,,,,D,Expert,BAO_0000019
2621,,8,B,,1,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,,CHEMBL621533,16326,,,,,H,Expert,BAO_0000357
2622,,8,B,CHO,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,12687,,,,CHEMBL621534,16659,,449.0,,,H,Expert,BAO_0000219
2623,,8,B,,1,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,12687,,,,CHEMBL621535,14776,,,,,H,Autocuration,BAO_0000019
2624,,8,B,,1,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,12687,,,,CHEMBL621536,13481,,,,,H,Autocuration,BAO_0000357
2625,,8,B,,1,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL621537,17386,,,,,H,Autocuration,BAO_0000357
2626,Rattus norvegicus,9,B,,1,Binding affinity for 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL621538,6611,,,,,D,Expert,BAO_0000357
2627,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,12687,,,,CHEMBL621539,14423,,,,,H,Autocuration,BAO_0000019
2628,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,12687,,,,CHEMBL621540,15412,,,,,H,Autocuration,BAO_0000019
2629,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,12687,,,,CHEMBL621541,15412,,,,,H,Autocuration,BAO_0000019
2630,,8,B,,1,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,12687,,,,CHEMBL621542,6238,,,,,H,Autocuration,BAO_0000019
2631,,8,B,,1,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,12687,,,,CHEMBL621543,6648,,,,,H,Expert,BAO_0000357
2632,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,12687,,,,CHEMBL621544,5667,,,,,H,Expert,BAO_0000357
2633,Rattus norvegicus,9,B,,1,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,12687,10116.0,,,CHEMBL621545,6611,,,,,D,Expert,BAO_0000357
2634,,8,B,,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,,CHEMBL621546,13481,,,,,H,Autocuration,BAO_0000357
2635,,8,B,,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,12687,,,,CHEMBL621547,13481,,,,,H,Autocuration,BAO_0000357
2636,,8,B,NIH3T3,1,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL618692,15558,,723.0,,,H,Expert,BAO_0000219
2637,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL618693,6013,,,,,H,Autocuration,BAO_0000357
2638,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,,CHEMBL872922,16633,,,,,H,Autocuration,BAO_0000357
2639,,8,B,,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,12687,,,,CHEMBL618694,6013,,,,,H,Autocuration,BAO_0000357
2640,Rattus norvegicus,9,B,,1,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,12687,10116.0,,,CHEMBL618695,6013,,,,,D,Expert,BAO_0000357
2641,,8,B,,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,12687,,,,CHEMBL618696,6013,,,,,H,Autocuration,BAO_0000357
2642,,8,B,,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,12687,,,,CHEMBL618697,6013,,,,,H,Expert,BAO_0000357
2643,,8,B,,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,12687,,,,CHEMBL618892,6013,,,,,H,Autocuration,BAO_0000357
2644,,8,B,,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,12687,,,,CHEMBL618893,6013,,,,,H,Autocuration,BAO_0000357
2645,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL618894,16293,,,,,H,Autocuration,BAO_0000357
2646,,8,B,NIH3T3,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,12687,,,,CHEMBL618895,17175,,723.0,,,H,Expert,BAO_0000219
2647,Rattus norvegicus,9,B,,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,10116.0,,,CHEMBL618896,13278,,,,,D,Expert,BAO_0000357
2648,,8,B,,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,12687,,,,CHEMBL618897,3682,5383.0,,,Caudate-putamen,H,Autocuration,BAO_0000019
2649,,8,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,12687,,,,CHEMBL618898,2014,,,,,H,Autocuration,BAO_0000357
2650,,8,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,12687,,,,CHEMBL618899,2014,,,,,H,Autocuration,BAO_0000357
2651,,8,B,,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,12687,,,,CHEMBL618900,4932,,,,,H,Autocuration,BAO_0000357
2652,,8,B,,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,12687,,,,CHEMBL618901,4932,,,,,H,Autocuration,BAO_0000019
2653,,8,B,,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL618902,3935,,,,,H,Autocuration,BAO_0000357
2654,Rattus norvegicus,9,B,,1,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL618903,5432,10000000.0,,,Hippocampus,D,Expert,BAO_0000221
2655,,8,B,,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL618904,15818,,,,,H,Autocuration,BAO_0000357
2656,,8,B,,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,12687,,,,CHEMBL618905,13672,,,,,H,Autocuration,BAO_0000357
2657,,8,B,,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,12687,,,,CHEMBL618906,13672,,,,,H,Autocuration,BAO_0000357
2658,,8,B,NIH3T3,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,12687,,,,CHEMBL618907,14749,,723.0,,,H,Expert,BAO_0000219
2659,,8,B,,1,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,12687,,,,CHEMBL618908,13462,,,,,H,Autocuration,BAO_0000019
2660,,8,B,,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617909,15740,,,,,H,Autocuration,BAO_0000357
2661,,8,B,,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,,CHEMBL617910,16647,,,,,H,Expert,BAO_0000019
2662,,8,B,,1,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,12687,,,,CHEMBL617911,13345,955.0,,,Brain,H,Autocuration,BAO_0000221
2663,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,,CHEMBL872923,16740,,,,,H,Autocuration,BAO_0000249
2664,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,,CHEMBL617912,16740,,,,,H,Autocuration,BAO_0000249
2665,Rattus norvegicus,9,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,12687,10116.0,,,CHEMBL617913,15535,,,,,D,Expert,BAO_0000019
2666,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,,CHEMBL617914,16740,,,,,H,Expert,BAO_0000249
2667,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,,CHEMBL617915,16740,,,,,H,Autocuration,BAO_0000249
2668,,8,B,,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,,CHEMBL617916,16740,,,,,H,Autocuration,BAO_0000249
2669,Rattus norvegicus,9,B,,1,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,12687,10116.0,,,CHEMBL617917,4795,,,,,D,Expert,BAO_0000019
2670,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,12687,,,,CHEMBL617918,8,,,,,H,Expert,BAO_0000019
2671,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,12687,,,,CHEMBL617919,8,,,,,H,Autocuration,BAO_0000019
2672,Rattus norvegicus,9,B,,1,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,10116.0,,,CHEMBL617920,17200,,,,,D,Expert,BAO_0000019
2673,Rattus norvegicus,9,B,,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,12687,10116.0,,,CHEMBL617921,2148,,,,,D,Expert,BAO_0000019
2674,Rattus norvegicus,5,B,,1,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",105102,10116.0,,,CHEMBL617922,13345,,,,,D,Expert,BAO_0000224
2675,,8,B,,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,,CHEMBL617923,5088,,,,,H,Autocuration,BAO_0000357
2676,,8,B,,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,,CHEMBL617924,5088,,,,,H,Autocuration,BAO_0000357
2677,,8,B,,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,12687,,,,CHEMBL617925,17133,,,,,H,Autocuration,BAO_0000357
2678,Rattus norvegicus,9,B,,1,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,12687,10116.0,,,CHEMBL617926,17133,,,,,D,Expert,BAO_0000357
2679,,8,B,,1,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,12687,,,,CHEMBL617927,16532,,,,,H,Autocuration,BAO_0000357
2680,,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,,CHEMBL617928,15086,,,,,H,Autocuration,BAO_0000357
2681,Rattus norvegicus,9,B,,1,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,10116.0,,,CHEMBL617929,2309,,,,,D,Expert,BAO_0000019
2682,,8,B,,1,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12687,,,,CHEMBL617930,12953,,,,,H,Expert,BAO_0000019
2683,,8,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12687,,,,CHEMBL617931,12953,,,,,H,Autocuration,BAO_0000019
2684,,8,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12687,,,,CHEMBL617932,12953,,,,,H,Autocuration,BAO_0000019
2685,,8,B,CHO,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,12687,,,,CHEMBL617933,16659,,449.0,,,H,Autocuration,BAO_0000219
2686,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,,CHEMBL617934,16740,,,,,H,Autocuration,BAO_0000019
2687,,8,B,,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,,CHEMBL617935,16740,,,,,H,Autocuration,BAO_0000019
2688,,8,B,,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,12687,,,,CHEMBL617936,17133,,,,,H,Autocuration,BAO_0000357
2689,,8,B,,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,12687,,,,CHEMBL617937,17211,,,,,H,Autocuration,BAO_0000019
2690,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,12687,,,,CHEMBL617938,17331,,,,,H,Autocuration,BAO_0000019
2691,,8,B,,1,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,12687,,,,CHEMBL617939,16633,,,,,H,Autocuration,BAO_0000218
2692,,8,B,,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,12687,,,,CHEMBL617940,16633,,,,,H,Autocuration,BAO_0000218
2693,,8,B,,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,12687,,,,CHEMBL617941,16633,,,,,H,Autocuration,BAO_0000218
2694,,8,B,,1,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,12687,,,,CHEMBL617942,15026,,,,,H,Expert,BAO_0000357
2695,,8,B,,1,Ratio of pKi of 5-HT2A to that of D2 receptor,12687,,,,CHEMBL617943,15026,,,,,H,Expert,BAO_0000357
2696,,4,B,,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,,CHEMBL617944,16404,,,,,H,Expert,BAO_0000224
2697,,4,B,,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,,CHEMBL617945,16404,,,,,H,Expert,BAO_0000224
2698,,4,B,,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,105075,,,,CHEMBL617946,16404,,,,,H,Expert,BAO_0000224
2699,,8,B,,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,12687,,,,CHEMBL617947,16404,,,,,H,Autocuration,BAO_0000357
2700,,8,B,,1,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,12687,,,,CHEMBL617948,16326,,,,,H,Expert,BAO_0000357
2701,,8,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,12687,,,,CHEMBL858116,15847,,,,,H,Autocuration,BAO_0000019
2702,,8,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,12687,,,,CHEMBL617949,15847,,,,,H,Autocuration,BAO_0000019
2703,,8,F,,1,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,12687,,,,CHEMBL617950,15329,,,,,H,Autocuration,BAO_0000019
2704,,8,F,,1,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,12687,,,,CHEMBL617951,16404,1515.0,,,Thoracic aorta,H,Expert,BAO_0000019
2705,,8,F,,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,12687,,,,CHEMBL617952,16404,1515.0,,,Thoracic aorta,H,Expert,BAO_0000019
2706,,8,F,,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,12687,,,,CHEMBL617953,16404,1515.0,,,Thoracic aorta,H,Autocuration,BAO_0000019
2707,,8,B,,1,Binding activity radioligand.,12687,,,,CHEMBL617954,12861,,,,,H,Autocuration,BAO_0000357
2708,,8,B,,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,,CHEMBL617955,12861,,,,,H,Expert,BAO_0000019
2709,,8,B,,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12687,,,,CHEMBL857071,12861,,,,,H,Autocuration,BAO_0000019
2710,,8,B,,1,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12687,,,,CHEMBL617270,12490,,,,,H,Expert,BAO_0000019
2711,,8,B,N1E-115,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12687,,,,CHEMBL617271,12827,,339.0,,,H,Autocuration,BAO_0000219
2712,,8,B,N1E-115,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12687,,,,CHEMBL617272,12827,,339.0,,,H,Autocuration,BAO_0000219
2713,,8,B,,1,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12687,,,,CHEMBL617273,12918,,,,,H,Autocuration,BAO_0000019
2714,Rattus norvegicus,9,F,,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12687,10116.0,,,CHEMBL617274,12919,,,,,D,Expert,BAO_0000019
2715,,8,B,,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617275,17723,,,,,H,Autocuration,BAO_0000357
2716,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617276,6013,,,,,H,Autocuration,BAO_0000357
2717,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617277,16293,,,,,H,Autocuration,BAO_0000357
2718,,8,B,,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617278,3857,,,,,H,Expert,BAO_0000019
2719,,8,B,,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,108,,,,CHEMBL617279,3857,,,,,H,Expert,BAO_0000019
2720,,8,B,,1,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617280,3857,,,,,H,Expert,BAO_0000019
2721,,8,B,,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617281,15363,,,,,H,Autocuration,BAO_0000357
2722,,8,B,,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617282,15363,,,,,H,Autocuration,BAO_0000357
2723,,8,B,,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,108,,,,CHEMBL617283,16441,,,,,H,Expert,BAO_0000019
2724,,8,B,,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,108,,,,CHEMBL617284,16441,,,,,H,Expert,BAO_0000019
2725,,8,B,HEK293,1,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,108,,,,CHEMBL617285,4176,,722.0,,,H,Autocuration,BAO_0000219
2726,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617286,17085,,,,,H,Autocuration,BAO_0000019
2727,Homo sapiens,9,B,,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,108,9606.0,,,CHEMBL617287,17200,,,,,D,Expert,BAO_0000357
2728,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,108,,,,CHEMBL617288,5088,,,,,H,Expert,BAO_0000357
2729,,8,B,,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,108,,,,CHEMBL617289,5088,,,,,H,Autocuration,BAO_0000357
2730,,8,B,,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,,CHEMBL872917,5088,,,,,H,Autocuration,BAO_0000357
2731,,8,B,,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,108,,,,CHEMBL617290,5088,,,,,H,Autocuration,BAO_0000357
2732,,8,B,CHO,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,,CHEMBL617291,16659,,449.0,,,H,Autocuration,BAO_0000219
2733,,8,B,CHO,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,108,,,,CHEMBL617292,16659,,449.0,,,H,Autocuration,BAO_0000219
2734,,8,B,NIH3T3,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,108,,,,CHEMBL617293,17451,,723.0,,,H,Autocuration,BAO_0000219
2735,Homo sapiens,9,F,CHO,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,108,9606.0,,,CHEMBL617294,6857,,449.0,,,D,Expert,BAO_0000219
2736,,8,B,,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,,CHEMBL617295,3857,,,,,H,Expert,BAO_0000019
2737,,8,B,,1,Binding activity radioligand.,108,,,,CHEMBL617296,12861,,,,,H,Autocuration,BAO_0000357
2738,,8,B,,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,108,,,,CHEMBL617297,12861,,,,,H,Autocuration,BAO_0000019
2739,,8,B,CHO,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,108,,,,CHEMBL617298,5104,,449.0,,,H,Expert,BAO_0000219
2740,,8,B,CHO,1,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,108,,,,CHEMBL617299,5105,,449.0,,,H,Expert,BAO_0000219
2741,,8,B,CHO,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,108,,,,CHEMBL617300,5105,,449.0,,,H,Autocuration,BAO_0000219
2742,,8,B,,1,Binding affinity against 5-HT2C receptor,108,,,,CHEMBL617454,5254,,,,,H,Autocuration,BAO_0000357
2743,,8,B,HEK293,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,108,,,,CHEMBL617505,13267,,722.0,,,H,Autocuration,BAO_0000219
2744,Homo sapiens,9,B,HEK293,1,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,108,9606.0,,,CHEMBL617506,14157,,722.0,,,D,Expert,BAO_0000219
2745,Homo sapiens,9,B,HEK293,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,9606.0,,,CHEMBL617507,12936,,722.0,,,D,Expert,BAO_0000219
2746,,8,B,,1,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,108,,,,CHEMBL617508,14068,,,,,H,Expert,BAO_0000357
2747,Homo sapiens,9,B,HEK293,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,9606.0,,,CHEMBL857982,12936,,722.0,,,D,Expert,BAO_0000219
2748,Homo sapiens,9,B,HEK293,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,108,9606.0,,,CHEMBL617509,4540,,722.0,,,D,Expert,BAO_0000219
2749,Homo sapiens,9,B,HEK293,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,108,9606.0,,,CHEMBL617510,4540,,722.0,,,D,Expert,BAO_0000219
2750,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,108,,,,CHEMBL617511,6166,,,,,H,Autocuration,BAO_0000357
2751,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,108,,,,CHEMBL617512,17296,,722.0,,,H,Autocuration,BAO_0000219
2752,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,108,,,,CHEMBL617749,17296,,722.0,,,H,Autocuration,BAO_0000219
2753,,8,B,HEK293,1,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,,CHEMBL617750,15779,,722.0,,,H,Autocuration,BAO_0000219
2754,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,,CHEMBL617751,15779,,722.0,,,H,Autocuration,BAO_0000219
2755,,8,B,HEK293,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,108,,,,CHEMBL617752,14391,,722.0,,,H,Expert,BAO_0000219
2756,,8,B,HEK293,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",108,,,,CHEMBL617753,15779,,722.0,,,H,Autocuration,BAO_0000219
2757,,8,B,HEK293,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",108,,,,CHEMBL617754,15851,,722.0,,,H,Expert,BAO_0000219
2758,Homo sapiens,9,B,HEK293,1,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,108,9606.0,,,CHEMBL617755,15851,,722.0,,,D,Expert,BAO_0000219
2759,,8,B,HEK293,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",108,,,,CHEMBL617756,15779,,722.0,,,H,Autocuration,BAO_0000219
2760,,8,B,HEK293,1,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,108,,,,CHEMBL617757,3832,,722.0,,,H,Expert,BAO_0000219
2761,,8,B,HEK293,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,108,,,,CHEMBL617758,3833,,722.0,,,H,Expert,BAO_0000219
2762,,8,B,NIH3T3,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,108,,,,CHEMBL617759,17451,,723.0,,,H,Autocuration,BAO_0000219
2763,,8,B,HEK293,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,108,,,,CHEMBL617760,4199,,722.0,,,H,Autocuration,BAO_0000219
2764,,8,B,CHO-K1,1,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,108,,,,CHEMBL617761,1883,,485.0,,,H,Expert,BAO_0000219
2765,Homo sapiens,9,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor,108,9606.0,,,CHEMBL617762,4321,,,,,D,Expert,BAO_0000357
2766,,8,B,,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617763,14875,,,,,H,Autocuration,BAO_0000357
2767,,8,B,HEK293,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,108,,,,CHEMBL857983,15146,,722.0,,,H,Autocuration,BAO_0000219
2768,,8,B,HEK293,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,108,,,,CHEMBL617764,5213,,722.0,,,H,Autocuration,BAO_0000219
2769,,8,B,HeLa,1,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,108,,,,CHEMBL617765,16404,,308.0,,,H,Autocuration,BAO_0000219
2770,,8,F,,1,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,108,,,,CHEMBL617766,13267,,,,,H,Autocuration,BAO_0000019
2771,,8,F,,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,108,,,,CHEMBL617767,13267,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
2772,,8,B,HEK293,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,108,,,,CHEMBL617768,14818,,722.0,,,H,Autocuration,BAO_0000219
2773,,8,B,HEK293,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",108,,,,CHEMBL617769,4829,,722.0,,,H,Autocuration,BAO_0000219
2774,,8,B,,1,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,11864,,,,CHEMBL858023,13463,,,,,H,Autocuration,BAO_0000357
2775,,8,B,,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus,11864,,,,CHEMBL617770,13463,945.0,,,Stomach,H,Autocuration,BAO_0000019
2776,,8,B,,1,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,11864,,,,CHEMBL617771,13463,945.0,,,Stomach,H,Autocuration,BAO_0000019
2777,,8,F,A9,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,11864,,,,CHEMBL617772,12652,,625.0,,,H,Autocuration,BAO_0000219
2778,,8,B,NIH3T3,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,,CHEMBL617773,4682,,723.0,,,H,Autocuration,BAO_0000219
2779,,8,B,NIH3T3,1,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,11864,,,,CHEMBL617850,4682,,723.0,,,H,Autocuration,BAO_0000219
2780,,8,B,NIH3T3,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,,CHEMBL617851,4682,,723.0,,,H,Autocuration,BAO_0000219
2781,,8,F,,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,11864,,,,CHEMBL617852,12652,,,,,H,Autocuration,BAO_0000019
2782,Mus musculus,8,B,,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,12689,10090.0,,,CHEMBL858024,13463,945.0,,,Stomach,H,Autocuration,BAO_0000019
2783,Rattus norvegicus,9,B,,1,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,12689,10116.0,,,CHEMBL617853,13463,945.0,,,Stomach,D,Expert,BAO_0000019
2784,,8,B,,1,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,108,,,,CHEMBL617854,13969,,,,,H,Expert,BAO_0000357
2785,Sus scrofa,8,B,,1,Binding affinity for 5-hydroxytryptamine 2C receptor,108,9823.0,,,CHEMBL873477,13392,,,,,H,Expert,BAO_0000357
2786,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617855,13392,,,,,H,Expert,BAO_0000357
2787,,8,B,,1,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,108,,,,CHEMBL617856,14430,,,,,H,Expert,BAO_0000019
2788,,8,B,,1,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,108,,,,CHEMBL617857,1742,,,,,H,Autocuration,BAO_0000019
2789,,8,B,,1,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,108,,,,CHEMBL617858,14286,,,,,H,Autocuration,BAO_0000249
2790,,8,B,,1,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617859,5619,,,,,H,Autocuration,BAO_0000357
2791,,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617860,15086,,,,,H,Autocuration,BAO_0000357
2792,,8,B,,1,Binding activity radioligand.,108,,,,CHEMBL617861,12861,,,,,H,Autocuration,BAO_0000357
2793,,8,B,,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,108,,,,CHEMBL617862,12861,,,,,H,Expert,BAO_0000019
2794,,8,B,,1,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,108,,,,CHEMBL617863,12861,,,,,H,Autocuration,BAO_0000019
2795,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,108,,,,CHEMBL617864,12827,,,,,H,Autocuration,BAO_0000249
2796,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,108,,,,CHEMBL617649,12827,,,,,H,Autocuration,BAO_0000249
2797,Sus scrofa,8,F,,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,9823.0,,,CHEMBL617650,12919,,,,,H,Expert,BAO_0000019
2798,Sus scrofa,8,F,,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,9823.0,,,CHEMBL617651,12919,,,,,H,Expert,BAO_0000019
2799,Sus scrofa,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,108,9823.0,,,CHEMBL617652,16429,,,,,H,Autocuration,BAO_0000357
2800,Sus scrofa,8,B,,1,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,108,9823.0,,,CHEMBL857072,773,,,,,H,Autocuration,BAO_0000019
2801,Sus scrofa,8,B,,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,108,9823.0,,,CHEMBL617653,5033,,,,,H,Autocuration,BAO_0000357
2802,,8,B,,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,,CHEMBL617654,12861,,,,,H,Autocuration,BAO_0000019
2803,,8,F,,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL617655,14093,,,,,H,Autocuration,BAO_0000019
2804,,8,B,,1,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,12689,,,,CHEMBL617656,14970,,,,,H,Expert,BAO_0000357
2805,,8,B,,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,12689,,,,CHEMBL617657,14970,,,,,H,Autocuration,BAO_0000357
2806,,8,B,,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,12689,,,,CHEMBL617658,14970,,,,,H,Autocuration,BAO_0000357
2807,Rattus norvegicus,9,B,,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,12689,10116.0,,,CHEMBL617659,14178,,,,,D,Expert,BAO_0000357
2808,Rattus norvegicus,9,B,,1,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,12689,10116.0,,,CHEMBL617838,14178,,,,,D,Expert,BAO_0000357
2809,Rattus norvegicus,9,B,,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,12689,10116.0,Brain membranes,,CHEMBL617839,14229,,,,,D,Expert,BAO_0000249
2810,,8,B,,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,12689,,,,CHEMBL617840,16532,,,,,H,Autocuration,BAO_0000357
2811,,8,B,,1,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,12689,,,,CHEMBL617841,14826,,,,,H,Autocuration,BAO_0000019
2812,,8,B,,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,12689,,,,CHEMBL875915,17211,,,,,H,Autocuration,BAO_0000019
2813,,8,B,,1,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,12689,,,,CHEMBL617842,17211,,,,,H,Expert,BAO_0000219
2814,,8,B,NIH3T3,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,12689,,,,CHEMBL617843,13246,,723.0,,,H,Expert,BAO_0000219
2815,,8,B,,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,12689,,,,CHEMBL617844,13246,,,,,H,Expert,BAO_0000357
2816,,8,B,,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL617845,12457,,,,,H,Expert,BAO_0000357
2817,,8,B,NIH3T3,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL617846,12457,,723.0,,,H,Expert,BAO_0000219
2818,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,12689,,,,CHEMBL617847,4707,,,,,H,Autocuration,BAO_0000357
2819,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL617848,13297,,,,,H,Expert,BAO_0000357
2820,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,,CHEMBL617849,16633,,,,,H,Autocuration,BAO_0000357
2821,,8,B,,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,,CHEMBL621507,16133,,,,,H,Expert,BAO_0000357
2822,,8,B,,1,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,12689,,,,CHEMBL621508,16326,,,,,H,Expert,BAO_0000357
2823,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,12689,,,,CHEMBL621509,14423,,,,,H,Autocuration,BAO_0000019
2824,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,12689,,,,CHEMBL621510,15412,,,,,H,Autocuration,BAO_0000019
2825,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,12689,,,,CHEMBL621511,15412,,,,,H,Autocuration,BAO_0000019
2826,,8,B,A9,1,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL621512,15558,,625.0,,,H,Expert,BAO_0000219
2827,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,,CHEMBL621513,16633,,,,,H,Autocuration,BAO_0000357
2828,,8,B,,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,12689,,,,CHEMBL621514,6013,,,,,H,Expert,BAO_0000357
2829,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,12689,,,,CHEMBL621515,17175,,,,,H,Expert,BAO_0000219
2830,,8,B,,1,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12689,,,,CHEMBL621516,12469,,,,,H,Autocuration,BAO_0000219
2831,,8,B,,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,12689,,,,CHEMBL621517,3682,5383.0,,,Caudate-putamen,H,Autocuration,BAO_0000019
2832,,8,B,,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,12689,,,,CHEMBL621518,4932,,,,,H,Autocuration,BAO_0000357
2833,,8,B,,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,12689,,,,CHEMBL621519,4932,,,,,H,Autocuration,BAO_0000019
2834,,8,B,,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL621520,3935,,,,,H,Autocuration,BAO_0000357
2835,,8,B,,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL621521,15818,,,,,H,Autocuration,BAO_0000357
2836,,8,B,,1,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL621522,15818,,,,,H,Autocuration,BAO_0000357
2837,,8,B,,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,12689,,,,CHEMBL621523,14749,,,,,H,Expert,BAO_0000219
2838,,8,B,,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL621524,15740,,,,,H,Autocuration,BAO_0000357
2839,Rattus norvegicus,9,B,,1,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,12689,10116.0,,,CHEMBL621525,17133,,,,,D,Expert,BAO_0000357
2840,,8,B,,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,12689,,,,CHEMBL872921,16532,,,,,H,Autocuration,BAO_0000357
2841,,8,B,,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL621526,12369,,,,,H,Autocuration,BAO_0000357
2842,,8,B,,1,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12689,,,,CHEMBL621527,12369,,,,,H,Expert,BAO_0000219
2843,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,12689,10116.0,,,CHEMBL617865,2309,,,,,D,Expert,BAO_0000019
2844,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL617866,12953,,,,,H,Autocuration,BAO_0000357
2845,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12689,,,,CHEMBL617867,12953,,,,,H,Autocuration,BAO_0000019
2846,,8,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12689,,,,CHEMBL617487,12953,,,,,H,Autocuration,BAO_0000357
2847,,8,B,,1,Binding affinity for 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL617488,12953,,,,,H,Expert,BAO_0000357
2848,,8,B,,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,12689,,,,CHEMBL617489,17133,,,,,H,Autocuration,BAO_0000357
2849,,8,B,,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,12689,,,,CHEMBL617490,17211,,,,,H,Autocuration,BAO_0000019
2850,,8,B,,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,12689,,,,CHEMBL617491,17211,,,,,H,Autocuration,BAO_0000019
2851,,8,B,,1,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,12689,,,,CHEMBL617492,14025,,,,,H,Autocuration,BAO_0000019
2852,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,12689,,,,CHEMBL617493,14998,,,,,H,Autocuration,BAO_0000019
2853,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,12689,,,,CHEMBL617494,4342,,,,,H,Autocuration,BAO_0000357
2854,Rattus norvegicus,9,B,,1,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,12689,10116.0,,,CHEMBL617495,13735,,,,,D,Expert,BAO_0000019
2855,,8,B,,1,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,12689,,,,CHEMBL617496,13181,,,,,H,Autocuration,BAO_0000357
2856,,8,B,CHO-K1,1,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,12689,,,,CHEMBL617497,1883,,485.0,,,H,Autocuration,BAO_0000219
2857,,8,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,,CHEMBL617498,15194,,,,,H,Autocuration,BAO_0000357
2858,,8,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,12689,,,,CHEMBL617499,15194,,,,,H,Autocuration,BAO_0000357
2859,,8,F,,1,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,12689,,,,CHEMBL617500,14579,,,,,H,Autocuration,BAO_0000019
2860,,8,B,,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617501,4639,,,,,H,Autocuration,BAO_0000357
2861,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617502,4820,,,,,H,Expert,BAO_0000357
2862,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,227,,,,CHEMBL617503,14442,,,,,H,Autocuration,BAO_0000357
2863,,8,B,,1,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,227,,,,CHEMBL617504,14755,,,,,H,Autocuration,BAO_0000357
2864,,8,B,,1,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,227,,,,CHEMBL617406,14744,,,,,H,Autocuration,BAO_0000357
2865,Homo sapiens,9,B,,1,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,227,9606.0,,,CHEMBL617407,6857,,,,,D,Expert,BAO_0000019
2866,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,227,,,,CHEMBL617408,16209,,,,,H,Autocuration,BAO_0000357
2867,,8,B,,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617409,15363,,,,,H,Autocuration,BAO_0000357
2868,,8,B,,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617410,15363,,,,,H,Autocuration,BAO_0000357
2869,,8,B,,1,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617411,15363,,,,,H,Autocuration,BAO_0000357
2870,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617412,17085,,,,,H,Autocuration,BAO_0000019
2871,Homo sapiens,9,B,,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,227,9606.0,,,CHEMBL617774,17200,,,,,D,Expert,BAO_0000357
2872,Homo sapiens,9,B,HEK293,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,9606.0,,,CHEMBL617775,15851,,722.0,,,D,Expert,BAO_0000219
2873,Homo sapiens,9,B,HEK293,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,9606.0,,,CHEMBL617776,15851,,722.0,,,D,Expert,BAO_0000219
2874,Homo sapiens,9,F,CHO,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,9606.0,,,CHEMBL617777,6857,,449.0,,,D,Expert,BAO_0000219
2875,Homo sapiens,9,F,CHO,1,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,9606.0,,,CHEMBL617778,6857,,449.0,,,D,Expert,BAO_0000219
2876,,8,B,HEK293,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,,CHEMBL617779,15779,,722.0,,,H,Autocuration,BAO_0000219
2877,,8,B,HEK293,1,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,227,,,,CHEMBL617780,15851,,722.0,,,H,Expert,BAO_0000219
2878,,8,B,HEK293,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",227,,,,CHEMBL617781,15779,,722.0,,,H,Autocuration,BAO_0000219
2879,Homo sapiens,9,B,HEK293,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,227,9606.0,,,CHEMBL617782,14157,,722.0,,,D,Expert,BAO_0000219
2880,Homo sapiens,9,B,HEK293,1,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,227,9606.0,,,CHEMBL617783,4540,,722.0,,,D,Expert,BAO_0000219
2881,,8,B,,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,227,,,,CHEMBL617784,6166,,,,,H,Autocuration,BAO_0000357
2882,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,227,,,,CHEMBL617785,15779,,722.0,,,H,Autocuration,BAO_0000219
2883,,8,B,HEK293,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,227,,,,CHEMBL857984,14391,,722.0,,,H,Expert,BAO_0000219
2884,,8,B,HEK293,1,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,227,,,,CHEMBL617786,3832,,722.0,,,H,Expert,BAO_0000219
2885,,8,B,HEK293,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,227,,,,CHEMBL617787,3833,,722.0,,,H,Expert,BAO_0000219
2886,Homo sapiens,9,B,HEK293,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,227,9606.0,,,CHEMBL617788,15851,,722.0,,,D,Expert,BAO_0000219
2887,Homo sapiens,9,B,HEK293,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,227,9606.0,,,CHEMBL617789,15851,,722.0,,,D,Expert,BAO_0000219
2888,,8,B,HEK293,1,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,227,,,,CHEMBL617790,4199,,722.0,,,H,Autocuration,BAO_0000219
2889,,8,B,CHO-K1,1,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,227,,,,CHEMBL617791,1883,,485.0,,,H,Expert,BAO_0000219
2890,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617608,4321,,,,,H,Expert,BAO_0000357
2891,,8,B,HEK293,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,227,,,,CHEMBL617609,15146,,722.0,,,H,Autocuration,BAO_0000219
2892,,8,B,HEK293,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,227,,,,CHEMBL617610,5213,,722.0,,,H,Autocuration,BAO_0000219
2893,,8,B,HEK293,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,227,,,,CHEMBL617611,14818,,722.0,,,H,Autocuration,BAO_0000219
2894,,8,B,HEK293,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,,CHEMBL617612,4829,,722.0,,,H,Autocuration,BAO_0000219
2895,,8,B,HEK293,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,,CHEMBL617613,4829,,722.0,,,H,Autocuration,BAO_0000219
2896,Oryctolagus cuniculus,8,B,,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,227,9986.0,,,CHEMBL617614,14025,,,,,H,Autocuration,BAO_0000019
2897,,8,B,,1,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,12688,,,,CHEMBL617615,13463,945.0,,,Stomach,H,Expert,BAO_0000019
2898,,8,B,,1,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,12688,,,,CHEMBL858114,7259,945.0,,,Stomach,H,Expert,BAO_0000357
2899,,8,B,,1,Affinity against serotonergic receptor in the isolated rat stomach fundus,12688,,,,CHEMBL617616,7259,945.0,,,Stomach,H,Autocuration,BAO_0000357
2900,Rattus norvegicus,9,F,,1,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,12688,10116.0,,,CHEMBL617617,7185,945.0,,,Stomach,D,Expert,BAO_0000019
2901,Rattus norvegicus,9,F,,1,Antagonistic against 5-hydroxytryptamine 2B receptor,12688,10116.0,,,CHEMBL875914,7185,,,,,D,Expert,BAO_0000019
2902,,8,F,,1,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,12688,,,,CHEMBL617618,13267,945.0,,,Stomach,H,Autocuration,BAO_0000019
2903,Rattus norvegicus,9,B,,1,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,12688,10116.0,,,CHEMBL617619,13735,945.0,,,Stomach,D,Expert,BAO_0000357
2904,,8,F,,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,12688,,,,CHEMBL617620,15738,,,,,H,Autocuration,BAO_0000019
2905,,8,F,,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,12688,,,,CHEMBL617621,15738,,,,,H,Autocuration,BAO_0000019
2906,,8,F,,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,12688,,,,CHEMBL617622,15738,,,,,H,Autocuration,BAO_0000019
2907,Rattus norvegicus,9,B,,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,10116.0,,,CHEMBL617623,12936,945.0,,,Stomach,D,Expert,BAO_0000357
2908,Rattus norvegicus,9,B,,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,10116.0,,,CHEMBL617624,12936,945.0,,,Stomach,D,Expert,BAO_0000357
2909,Rattus norvegicus,9,B,,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,10116.0,,,CHEMBL617625,12936,945.0,,,Stomach,D,Expert,BAO_0000357
2910,Rattus norvegicus,9,B,,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,10116.0,,,CHEMBL617626,12936,945.0,,,Stomach,D,Expert,BAO_0000357
2911,,8,F,,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,,CHEMBL617627,16404,945.0,,,Stomach,H,Autocuration,BAO_0000019
2912,,8,F,,1,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,,CHEMBL617628,16404,945.0,,,Stomach,H,Expert,BAO_0000019
2913,,8,F,,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,12688,,,,CHEMBL617629,16404,945.0,,,Stomach,H,Autocuration,BAO_0000019
2914,,8,F,,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,12688,,,,CHEMBL858115,16404,945.0,,,Stomach,H,Autocuration,BAO_0000019
2915,Rattus norvegicus,9,F,,1,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,12688,10116.0,,,CHEMBL617630,16404,945.0,,,Stomach,D,Expert,BAO_0000019
2916,,8,F,,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,12688,,,,CHEMBL617631,16404,1515.0,,,Thoracic aorta,H,Autocuration,BAO_0000019
2917,,8,B,,1,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,,CHEMBL617632,7483,,,,,H,Autocuration,BAO_0000357
2918,,8,B,,1,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,12688,,,,CHEMBL617633,7483,,,,,H,Expert,BAO_0000357
2919,,8,B,,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,,CHEMBL617634,7483,,,,,H,Autocuration,BAO_0000357
2920,,8,B,,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,,CHEMBL617635,7483,,,,,H,Autocuration,BAO_0000357
2922,Rattus norvegicus,9,F,,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,10116.0,,,CHEMBL617637,16404,945.0,,,Stomach,D,Autocuration,BAO_0000019
2923,,8,B,,1,Binding affinity against 5-hydroxytryptamine 1A receptor,227,,,,CHEMBL617638,6347,,,,,H,Autocuration,BAO_0000357
2924,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,227,,,,CHEMBL617639,4373,,,,,H,Autocuration,BAO_0000357
2925,,8,B,,1,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,227,,,,CHEMBL617640,4373,,,,,H,Autocuration,BAO_0000357
2926,,8,B,,1,Evaluated for the binding affinity to 5-HT 2B receptor,227,,,,CHEMBL617641,4687,,,,,H,Autocuration,BAO_0000357
2927,,8,B,,1,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617642,16946,,,,,H,Autocuration,BAO_0000357
2928,,8,B,,1,Binding affinities against 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617643,16633,,,,,H,Autocuration,BAO_0000357
2929,,8,B,,1,Binding affinities towards 5-hydroxytryptamine 2B receptor,227,,,,CHEMBL617644,16633,,,,,H,Autocuration,BAO_0000357
2930,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,227,,,,CHEMBL617645,16633,,,,,H,Autocuration,BAO_0000357
2931,,8,B,,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,,,CHEMBL617646,15026,,,,,H,Expert,BAO_0000357
2932,Bos taurus,8,B,,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,9913.0,,,CHEMBL617647,15738,,,,,H,Autocuration,BAO_0000357
2933,Bos taurus,8,B,,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,108,9913.0,,,CHEMBL617648,15738,,,,,H,Autocuration,BAO_0000357
2934,Bos taurus,8,B,,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,108,9913.0,,,CHEMBL617875,15738,,,,,H,Autocuration,BAO_0000357
2935,Bos taurus,8,B,,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,108,9913.0,,,CHEMBL617876,15738,,,,,H,Autocuration,BAO_0000357
2936,Bos taurus,8,B,,1,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,108,9913.0,,,CHEMBL617877,16404,,,,,H,Expert,BAO_0000357
2937,Bos taurus,8,B,,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,9913.0,,,CHEMBL617878,15026,,,,,H,Expert,BAO_0000357
2938,Bos taurus,8,B,,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,9913.0,,,CHEMBL617879,15738,,,,,H,Autocuration,BAO_0000357
2939,Cavia porcellus,8,B,,1,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,108,10141.0,,,CHEMBL617880,16312,,,,,H,Autocuration,BAO_0000019
2940,Cavia porcellus,9,B,,1,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,20033,10141.0,,,CHEMBL617881,5486,2435.0,,,Striatum,D,Intermediate,BAO_0000357
2941,,8,B,,1,Binding affinity against 5-HT1A receptor,51,,,,CHEMBL857073,5254,,,,,H,Autocuration,BAO_0000357
2942,,8,F,CHO,1,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,108,,,,CHEMBL617882,3857,,449.0,,,H,Expert,BAO_0000219
2943,Homo sapiens,9,F,CHO,1,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,108,9606.0,,,CHEMBL617883,6857,,449.0,,,D,Expert,BAO_0000219
2944,,8,F,,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,108,,,,CHEMBL617884,4176,,,,,H,Autocuration,BAO_0000219
2945,,8,B,CHO,1,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,108,,,,CHEMBL617885,6347,,449.0,,,H,Autocuration,BAO_0000219
2946,,8,B,CHO,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",108,,,,CHEMBL617886,6347,,449.0,,,H,Autocuration,BAO_0000219
2947,Homo sapiens,9,B,,1,Inhibition of human 5-hydroxytryptamine 2C receptor,108,9606.0,,,CHEMBL617887,16146,,,,,D,Expert,BAO_0000357
2948,,8,B,,1,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),108,,,,CHEMBL617888,3805,,,,,H,Autocuration,BAO_0000357
2949,,8,B,,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,,CHEMBL617889,3857,,,,,H,Autocuration,BAO_0000019
2950,,8,B,,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617890,5635,,,,,H,Autocuration,BAO_0000357
2951,,8,B,,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,,CHEMBL617891,5635,,,,,H,Autocuration,BAO_0000357
2952,,8,B,,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,,CHEMBL617892,5635,,,,,H,Autocuration,BAO_0000357
2953,,8,B,CHO,1,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,108,,,,CHEMBL617893,4012,,449.0,,,H,Expert,BAO_0000219
2954,,8,B,CHO,1,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,108,,,,CHEMBL617894,6366,,449.0,,,H,Expert,BAO_0000219
2955,,8,B,CHO,1,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,,CHEMBL617895,15949,,449.0,,,H,Expert,BAO_0000219
2956,,8,B,CHO,1,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL617896,17211,,449.0,,,H,Autocuration,BAO_0000219
2957,Homo sapiens,9,B,,1,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,108,9606.0,,,CHEMBL617897,6491,,,,,D,Expert,BAO_0000357
2958,,8,F,,1,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,108,,,,CHEMBL617898,14093,,,,,H,Autocuration,BAO_0000019
2959,,8,F,,1,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,108,,,,CHEMBL617899,13481,,,,,H,Autocuration,BAO_0000019
2960,Rattus norvegicus,8,B,CHO,1,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,108,10116.0,,,CHEMBL617900,6347,,449.0,,,H,Expert,BAO_0000219
2961,,8,F,,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,108,,,,CHEMBL617901,14093,,,,,H,Autocuration,BAO_0000019
2962,,8,F,,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,108,,,,CHEMBL617902,14093,,,,,H,Autocuration,BAO_0000019
2963,,8,F,,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,,CHEMBL617903,13481,,,,,H,Autocuration,BAO_0000019
2964,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,108,,,,CHEMBL617904,14442,,,,,H,Autocuration,BAO_0000357
2965,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,108,,,,CHEMBL617905,14442,,,,,H,Autocuration,BAO_0000357
2966,,8,B,,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,108,,,,CHEMBL617906,14442,,,,,H,Autocuration,BAO_0000357
2967,,8,B,,1,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,108,,,,CHEMBL617907,14755,,,,,H,Autocuration,BAO_0000357
2968,,8,B,,1,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,108,,,,CHEMBL617908,14744,,,,,H,Autocuration,BAO_0000357
2969,,8,B,CHO,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,,CHEMBL620617,16659,,449.0,,,H,Expert,BAO_0000219
2970,Homo sapiens,9,B,,1,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,108,9606.0,,,CHEMBL620618,6857,,,,,D,Expert,BAO_0000019
2971,,8,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,108,,,,CHEMBL620619,5635,,,,,H,Expert,BAO_0000357
2972,Homo sapiens,9,B,,1,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,108,9606.0,,,CHEMBL620620,4234,,,,,D,Expert,BAO_0000357
2973,,8,B,,1,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,108,,,,CHEMBL620621,16209,,,,,H,Autocuration,BAO_0000357
2974,Rattus norvegicus,7,B,,1,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,104698,10116.0,Membranes,,CHEMBL872920,5778,,,,,D,Autocuration,BAO_0000249
2975,,6,B,,1,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,104698,,,,CHEMBL620622,5094,,,,,H,Autocuration,BAO_0000223
2976,Rattus norvegicus,7,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,104698,10116.0,,,CHEMBL620623,809,,,,,D,Autocuration,BAO_0000019
2977,,6,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,104698,,,,CHEMBL620624,1578,,,,,H,Autocuration,BAO_0000019
2978,,6,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,104698,,,,CHEMBL620625,809,,,,,H,Autocuration,BAO_0000019
2979,,6,B,,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,104698,,,,CHEMBL620626,12469,,,,,H,Autocuration,BAO_0000219
2980,,6,B,,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,104698,,,,CHEMBL621307,14290,,,,,H,Autocuration,BAO_0000019
2981,,6,B,,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,104698,,,,CHEMBL621308,14290,,,,,H,Autocuration,BAO_0000019
2982,,6,B,,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,104698,,,,CHEMBL621309,10609,,,,,H,Autocuration,BAO_0000223
2983,,6,B,,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,104698,,,,CHEMBL621310,10609,,,,,H,Autocuration,BAO_0000223
2984,,6,B,,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,104698,,,,CHEMBL621311,10609,,,,,H,Autocuration,BAO_0000223
2985,,6,B,,1,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,,CHEMBL621502,15253,,,,,H,Autocuration,BAO_0000249
2986,,6,B,,1,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,,CHEMBL621503,15253,,,,,H,Autocuration,BAO_0000249
2987,,6,B,,1,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,104698,,Membranes,,CHEMBL621504,11683,,,,,H,Autocuration,BAO_0000249
2988,,6,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,104698,,,,CHEMBL621505,12092,,,,,H,Autocuration,BAO_0000223
2989,,6,B,,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,,CHEMBL621506,1946,,,,,H,Autocuration,BAO_0000019
2990,,6,B,,1,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,104698,,,,CHEMBL619781,11623,,,,,H,Autocuration,BAO_0000223
2991,,6,B,,1,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,104698,,,,CHEMBL619782,11623,,,,,H,Autocuration,BAO_0000223
2992,,6,B,,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,104698,,,,CHEMBL619783,14788,,,,,H,Autocuration,BAO_0000019
2993,Rattus norvegicus,7,B,,1,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,104698,10116.0,,,CHEMBL619784,5432,,,,,D,Autocuration,BAO_0000019
2994,,6,B,,1,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,,CHEMBL619785,14826,,,,,H,Autocuration,BAO_0000249
2995,,6,B,,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,104698,,,,CHEMBL619786,2222,,,,,H,Autocuration,BAO_0000223
2996,,6,B,,1,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,104698,,,,CHEMBL619787,11963,,,,,H,Autocuration,BAO_0000019
2997,,6,B,,1,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,104698,,,,CHEMBL872925,14145,,,,,H,Autocuration,BAO_0000019
2998,,6,B,,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,104698,,,,CHEMBL619788,17819,,,,,H,Autocuration,BAO_0000019
2999,,6,B,,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,,CHEMBL619789,10394,,,,,H,Autocuration,BAO_0000249
3000,,6,B,,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,,CHEMBL619790,10394,,,,,H,Autocuration,BAO_0000249
3001,,6,B,,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,,CHEMBL619791,15034,,,,,H,Autocuration,BAO_0000019
3002,,6,B,,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,,CHEMBL619792,691,,,,,H,Autocuration,BAO_0000019
3003,,6,B,,1,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,104698,,Membranes,,CHEMBL619793,12092,,,,,H,Autocuration,BAO_0000249
3004,Rattus norvegicus,7,B,,1,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL619794,11752,,,,,D,Autocuration,BAO_0000223
3005,,6,B,,1,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,104698,,,,CHEMBL619795,11752,955.0,,,Brain,H,Autocuration,BAO_0000221
3006,,6,B,,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,104698,,,,CHEMBL619796,301,,,,,H,Autocuration,BAO_0000019
3007,,6,B,,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,104698,,,,CHEMBL620448,16532,,,,,H,Autocuration,BAO_0000223
3008,,6,B,,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,,CHEMBL620449,16532,,,,,H,Autocuration,BAO_0000223
3009,,6,B,,1,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,104698,,,,CHEMBL620450,12092,,,,,H,Autocuration,BAO_0000223
3010,,6,B,,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,104698,,,,CHEMBL620451,11684,,,,,H,Autocuration,BAO_0000223
3011,,6,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,104698,,,,CHEMBL620631,11684,,,,,H,Autocuration,BAO_0000223
3012,,6,B,,1,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,104698,,,,CHEMBL620632,12953,,,,,H,Autocuration,BAO_0000019
3013,,6,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,104698,,,,CHEMBL620633,12953,,,,,H,Autocuration,BAO_0000019
3014,,6,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,104698,,,,CHEMBL620634,12953,,,,,H,Autocuration,BAO_0000223
3015,,6,B,,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,104698,,,,CHEMBL620635,12861,,,,,H,Autocuration,BAO_0000019
3016,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,,CHEMBL620636,11454,,,,,H,Autocuration,BAO_0000218
3017,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,,CHEMBL620637,11454,,,,,H,Autocuration,BAO_0000218
3018,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,,CHEMBL620638,11454,,,,,H,Autocuration,BAO_0000218
3019,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,,CHEMBL620639,11454,,,,,H,Autocuration,BAO_0000218
3020,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,,CHEMBL620640,11454,,,,,H,Autocuration,BAO_0000218
3021,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,,CHEMBL620641,11454,,,,,H,Autocuration,BAO_0000218
3022,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,104698,,,,CHEMBL620642,11454,,,,,H,Autocuration,BAO_0000218
3023,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,,CHEMBL620643,11454,,,,,H,Autocuration,BAO_0000218
3024,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,,CHEMBL620644,11454,,,,,H,Autocuration,BAO_0000218
3025,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,,CHEMBL620645,11454,,,,,H,Autocuration,BAO_0000218
3026,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,,CHEMBL620646,11454,,,,,H,Autocuration,BAO_0000218
3027,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,,CHEMBL620647,11454,,,,,H,Autocuration,BAO_0000218
3028,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,,CHEMBL620648,11454,,,,,H,Autocuration,BAO_0000218
3029,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,,CHEMBL620649,11454,,,,,H,Autocuration,BAO_0000218
3030,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,,CHEMBL620650,11454,,,,,H,Autocuration,BAO_0000218
3031,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,,CHEMBL620651,11454,,,,,H,Autocuration,BAO_0000218
3032,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,,CHEMBL872875,11454,,,,,H,Autocuration,BAO_0000218
3033,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,,CHEMBL620652,11454,,,,,H,Autocuration,BAO_0000218
3034,,6,F,,1,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,104698,,,,CHEMBL620653,10609,,,,,H,Autocuration,BAO_0000019
3035,,6,B,,1,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,104698,,,,CHEMBL857076,12861,,,,,H,Autocuration,BAO_0000019
3036,Rattus norvegicus,7,B,,1,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL620654,12861,,,,,D,Autocuration,BAO_0000019
3037,,6,B,,1,Binding activity radioligand.,104698,,,,CHEMBL620655,12861,,,,,H,Autocuration,BAO_0000223
3038,,6,B,,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,104698,,Brain membranes,,CHEMBL620656,10728,,,,,H,Autocuration,BAO_0000249
3039,,6,B,,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,104698,,Brain membranes,,CHEMBL620657,10728,,,,,H,Autocuration,BAO_0000249
3040,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,108,,,,CHEMBL620658,5163,,,,,H,Autocuration,BAO_0000357
3041,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,108,,,,CHEMBL620659,5163,,,,,H,Autocuration,BAO_0000357
3042,,8,B,,1,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,108,,,,CHEMBL620660,6011,,,,,H,Autocuration,BAO_0000357
3043,,8,B,,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL620661,5014,,,,,H,Autocuration,BAO_0000357
3044,,8,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL620662,5635,,,,,H,Autocuration,BAO_0000357
3045,,8,B,,1,Affinity for 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL620663,5163,,,,,H,Expert,BAO_0000357
3046,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,,CHEMBL620664,6841,,,,,H,Autocuration,BAO_0000357
3047,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,108,,,,CHEMBL620665,6119,,,,,H,Expert,BAO_0000357
3048,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,108,,,,CHEMBL620666,4373,,,,,H,Autocuration,BAO_0000357
3049,,8,B,,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,108,,,,CHEMBL620667,1633,,,,,H,Autocuration,BAO_0000357
3050,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,108,,,,CHEMBL620668,1633,,,,,H,Expert,BAO_0000357
3051,,8,B,,1,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,108,,,,CHEMBL620669,4373,,,,,H,Autocuration,BAO_0000357
3052,,8,B,,1,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL620670,6576,,,,,H,Expert,BAO_0000357
3053,,8,B,,1,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL620671,4687,,,,,H,Autocuration,BAO_0000357
3054,,8,B,,1,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,108,,,,CHEMBL620672,12146,,,,,H,Autocuration,BAO_0000357
3055,,8,B,,1,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,108,,,,CHEMBL620673,12146,,,,,H,Autocuration,BAO_0000357
3056,,8,B,,1,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL620674,16946,,,,,H,Autocuration,BAO_0000357
3057,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL620675,14159,,,,,H,Autocuration,BAO_0000357
3058,,8,B,,1,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,108,,,,CHEMBL620676,16700,,,,,H,Autocuration,BAO_0000357
3059,,8,B,,1,Affinity against 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL621382,3269,,,,,H,Autocuration,BAO_0000357
3060,Homo sapiens,9,B,,1,Binding affinity against 5-hydroxytryptamine 2C receptor,108,9606.0,,,CHEMBL621383,1274,,,,,D,Expert,BAO_0000357
3061,,8,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,108,,,,CHEMBL621384,1317,,,,,H,Autocuration,BAO_0000357
3062,Bos taurus,8,B,,1,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,144,9913.0,,,CHEMBL621385,5834,,,,,H,Autocuration,BAO_0000357
3063,Bos taurus,8,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,144,9913.0,,,CHEMBL617989,11147,,,,,H,Autocuration,BAO_0000357
3064,Cavia porcellus,4,F,,1,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,104714,10141.0,,,CHEMBL617990,14145,,,,,H,Expert,BAO_0000019
3065,Cavia porcellus,4,B,,1,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,10141.0,,,CHEMBL875085,10561,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3066,Cavia porcellus,4,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,104714,10141.0,,,CHEMBL617991,15847,,,,,H,Autocuration,BAO_0000019
3067,Cavia porcellus,4,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,104714,10141.0,,,CHEMBL617992,15847,,,,,H,Autocuration,BAO_0000019
3068,Cavia porcellus,4,B,,1,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,10141.0,,,CHEMBL617993,10561,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3069,Cavia porcellus,4,B,,1,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,104714,10141.0,,,CHEMBL617994,11454,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3070,Cavia porcellus,4,F,,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,104714,10141.0,,,CHEMBL617995,4639,,,,,H,Autocuration,BAO_0000019
3071,Cavia porcellus,4,F,,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,104714,10141.0,,,CHEMBL617996,4639,,,,,H,Autocuration,BAO_0000019
3072,Cavia porcellus,4,F,,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,104714,10141.0,,,CHEMBL617997,4639,,,,,H,Autocuration,BAO_0000019
3073,Cavia porcellus,4,F,,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,104714,10141.0,,,CHEMBL617998,4639,,,,,H,Autocuration,BAO_0000019
3074,Cavia porcellus,4,F,,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,104714,10141.0,,,CHEMBL617999,4639,,,,,H,Autocuration,BAO_0000019
3075,Cavia porcellus,4,F,,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,104714,10141.0,,,CHEMBL618000,4639,,,,,H,Autocuration,BAO_0000019
3076,Cavia porcellus,4,F,,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",104714,10141.0,,,CHEMBL617815,15253,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3077,Cavia porcellus,4,F,,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",104714,10141.0,,,CHEMBL617816,15253,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3078,Cavia porcellus,4,F,,1,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,104714,10141.0,,,CHEMBL617817,11963,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3079,Cavia porcellus,4,B,,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,104714,10141.0,,,CHEMBL617818,1946,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3080,Cavia porcellus,4,B,,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,104714,10141.0,,,CHEMBL617819,1946,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3081,Cavia porcellus,4,B,,1,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,104714,10141.0,,,CHEMBL617820,12045,,,,,H,Autocuration,BAO_0000223
3082,Cavia porcellus,4,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,10141.0,,,CHEMBL617821,1559,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3083,Cavia porcellus,4,F,,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,10141.0,,,CHEMBL617822,273,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3084,Cavia porcellus,4,F,,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),104714,10141.0,,,CHEMBL617823,273,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3085,Cavia porcellus,4,F,,1,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,104714,10141.0,,,CHEMBL617824,188,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3086,Cavia porcellus,4,F,,1,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,104714,10141.0,,,CHEMBL617825,12919,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3087,Cavia porcellus,4,F,,1,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,104714,10141.0,,,CHEMBL617826,12918,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3088,Cavia porcellus,4,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,10141.0,,,CHEMBL617827,1559,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3089,Cavia porcellus,4,F,,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,10141.0,,,CHEMBL617828,273,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3090,Cavia porcellus,4,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,10141.0,,,CHEMBL617829,1559,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3091,Cavia porcellus,4,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,104714,10141.0,,,CHEMBL617830,1559,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3092,Cavia porcellus,4,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,104714,10141.0,,,CHEMBL617831,1559,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3093,Cavia porcellus,4,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,104714,10141.0,,,CHEMBL617832,14424,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3094,Cavia porcellus,0,B,,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,22226,10141.0,,,CHEMBL617833,13181,,,,,U,Autocuration,BAO_0000019
3095,,8,B,,1,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,51,,,,CHEMBL617834,5486,,,,,H,Autocuration,BAO_0000357
3096,Homo sapiens,5,B,,1,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,104714,9606.0,,,CHEMBL617835,6491,,,,,D,Expert,BAO_0000223
3097,,4,B,,1,Binding affinity towards 5-HT3 receptor,104714,,,,CHEMBL617836,6013,,,,,H,Autocuration,BAO_0000223
3098,,4,B,,1,Binding activity radioligand.,104714,,,,CHEMBL617837,12861,,,,,H,Autocuration,BAO_0000223
3099,,4,B,,1,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,104714,,,,CHEMBL620392,12861,,,,,H,Autocuration,BAO_0000019
3100,,4,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL620393,5104,,,,,H,Autocuration,BAO_0000223
3101,,4,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL620394,5105,,,,,H,Autocuration,BAO_0000223
3102,,4,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,104714,,,,CHEMBL620395,5104,,,,,H,Autocuration,BAO_0000223
3103,,0,B,,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,22226,,,,CHEMBL620396,3935,,,,,U,Autocuration,BAO_0000019
3104,,4,B,NG108-15,1,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,105030,,,,CHEMBL620582,13657,,433.0,,,H,Expert,BAO_0000219
3105,,4,B,,1,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",105030,,,,CHEMBL620583,10369,,,,,H,Autocuration,BAO_0000218
3106,,4,B,,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,,CHEMBL620584,10369,,,,,H,Autocuration,BAO_0000019
3107,,4,B,,1,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,105030,,,,CHEMBL620585,12918,,,,,H,Autocuration,BAO_0000224
3108,,4,B,,1,Compound was evaluated for the binding affinity at 5- HT3 receptor,105030,,,,CHEMBL620586,12918,,,,,H,Autocuration,BAO_0000224
3109,,4,B,,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,,CHEMBL620587,10369,,,,,H,Autocuration,BAO_0000019
3110,,4,B,,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,105030,,,,CHEMBL620588,773,,,,,H,Autocuration,BAO_0000019
3111,,4,F,,1,5-hydroxytryptamine 3 receptor agonism in mouse,105030,,,,CHEMBL620589,12918,,,,,H,Autocuration,BAO_0000218
3112,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,105030,,,,CHEMBL620590,10561,,,,,H,Autocuration,BAO_0000219
3113,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,,CHEMBL617956,12827,,,,,H,Autocuration,BAO_0000019
3114,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,,CHEMBL617957,12827,,,,,H,Autocuration,BAO_0000019
3115,,4,B,,1,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,105030,,,,CHEMBL617958,12918,,,,,H,Autocuration,BAO_0000224
3116,,4,B,,1,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,,CHEMBL617959,273,,,,,H,Autocuration,BAO_0000219
3117,,4,B,,1,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,,CHEMBL617960,273,,,,,H,Autocuration,BAO_0000219
3118,,4,B,,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,105030,,,,CHEMBL617961,10561,,,,,H,Autocuration,BAO_0000224
3119,,4,B,,1,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,105030,,,,CHEMBL617962,5033,,,,,H,Autocuration,BAO_0000219
3120,,4,B,N1E-115,1,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,105030,,,,CHEMBL617963,16429,,339.0,,,H,Autocuration,BAO_0000219
3121,,8,B,,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,11765,,,,CHEMBL617964,10322,,,,,H,Autocuration,BAO_0000019
3122,,8,B,,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,11765,,,,CHEMBL617965,14331,,,,,H,Autocuration,BAO_0000219
3123,Mus musculus,9,B,,1,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10630,10090.0,,,CHEMBL617966,13462,,,,,D,Autocuration,BAO_0000357
3124,,8,B,,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,,CHEMBL857074,12861,,,,,H,Autocuration,BAO_0000019
3125,Sus scrofa,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,144,9823.0,,,CHEMBL617967,15086,,,,,H,Autocuration,BAO_0000357
3126,Sus scrofa,8,B,,1,Binding activity radioligand.,144,9823.0,,,CHEMBL617968,12861,,,,,H,Autocuration,BAO_0000357
3127,Oryctolagus cuniculus,4,B,,1,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,104714,9986.0,,,CHEMBL617969,10561,,,,,H,Autocuration,BAO_0000223
3128,Oryctolagus cuniculus,4,B,,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,104714,9986.0,,,CHEMBL617970,10561,,,,,H,Autocuration,BAO_0000223
3129,Oryctolagus cuniculus,4,B,,1,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,104714,9986.0,,,CHEMBL617971,10561,,,,,H,Autocuration,BAO_0000223
3130,Oryctolagus cuniculus,4,B,,1,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104714,9986.0,,,CHEMBL617972,10561,,,,,H,Autocuration,BAO_0000019
3131,Oryctolagus cuniculus,4,F,,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,9986.0,,,CHEMBL617973,273,,,,,H,Autocuration,BAO_0000019
3132,Oryctolagus cuniculus,4,F,,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,9986.0,,,CHEMBL617974,273,,,,,H,Autocuration,BAO_0000019
3133,Oryctolagus cuniculus,4,F,,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,9986.0,,,CHEMBL617975,273,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3134,Oryctolagus cuniculus,4,F,,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,9986.0,,,CHEMBL617976,273,,,,,H,Autocuration,BAO_0000019
3135,Oryctolagus cuniculus,4,F,,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,9986.0,,,CHEMBL617977,273,,,,,H,Autocuration,BAO_0000019
3136,Oryctolagus cuniculus,4,F,,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,9986.0,,,CHEMBL617978,273,,,,,H,Autocuration,BAO_0000019
3137,Oryctolagus cuniculus,4,F,,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,9986.0,,,CHEMBL617979,273,,,,,H,Autocuration,BAO_0000019
3138,Oryctolagus cuniculus,4,B,CHO,1,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,104714,9986.0,,,CHEMBL617980,13047,,449.0,,,H,Autocuration,BAO_0000219
3139,Rattus norvegicus,7,B,,1,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL617981,1650,,,,,D,Autocuration,BAO_0000019
3140,,8,B,,1,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),12020,,,,CHEMBL617982,16288,,,,,H,Autocuration,BAO_0000019
3141,,8,B,,1,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),12020,,,,CHEMBL617983,16288,,,,,H,Autocuration,BAO_0000357
3142,Rattus norvegicus,7,B,,1,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,104698,10116.0,,,CHEMBL617984,10254,,,,,D,Autocuration,BAO_0000019
3143,,6,B,,1,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",104698,,,,CHEMBL617985,14532,,,,,H,Autocuration,BAO_0000019
3144,,6,F,,1,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,,,CHEMBL617986,13392,948.0,,,Heart,H,Autocuration,BAO_0000218
3145,,6,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,,,CHEMBL617987,13392,948.0,,,Heart,H,Autocuration,BAO_0000019
3146,,6,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,,,CHEMBL617988,13392,948.0,,,Heart,H,Autocuration,BAO_0000019
3147,,6,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",104698,,,,CHEMBL617792,13392,948.0,,,Heart,H,Autocuration,BAO_0000019
3148,,6,F,,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,,,CHEMBL617793,13392,948.0,,,Heart,H,Autocuration,BAO_0000019
3149,,6,F,,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,,CHEMBL617794,13392,,,,,H,Autocuration,BAO_0000019
3150,,6,F,,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,,CHEMBL617795,13392,,,,,H,Autocuration,BAO_0000019
3151,,6,F,,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,,CHEMBL617796,13392,,,,,H,Autocuration,BAO_0000019
3152,,6,F,,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,,CHEMBL617797,13392,,,,,H,Autocuration,BAO_0000019
3153,Rattus norvegicus,7,F,,1,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),104698,10116.0,,,CHEMBL617798,1089,,,,,D,Autocuration,BAO_0000218
3154,,6,F,,1,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),104698,,,,CHEMBL617799,1089,,,,,H,Autocuration,BAO_0000218
3155,Rattus norvegicus,7,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,10116.0,,,CHEMBL617800,11454,,,,,D,Autocuration,BAO_0000218
3156,Rattus norvegicus,7,F,,1,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,104698,10116.0,,,CHEMBL617801,11454,,,,,D,Autocuration,BAO_0000019
3157,Rattus norvegicus,7,F,,1,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,104698,10116.0,,,CHEMBL617802,12205,,,,,D,Autocuration,BAO_0000218
3158,Rattus norvegicus,7,F,,1,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),104698,10116.0,,,CHEMBL617803,1089,,,,,D,Autocuration,BAO_0000019
3159,,6,B,,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,,CHEMBL617804,5094,,,,,H,Autocuration,BAO_0000019
3160,Rattus norvegicus,7,B,,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL617805,2622,,,,,D,Autocuration,BAO_0000019
3161,,6,B,,1,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,104698,,,,CHEMBL617806,245,,,,,H,Autocuration,BAO_0000223
3162,,6,B,,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,104698,,,,CHEMBL617807,14788,,,,,H,Autocuration,BAO_0000019
3163,,6,B,,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,104698,,,,CHEMBL617808,14788,,,,,H,Autocuration,BAO_0000019
3164,,6,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,104698,,,,CHEMBL617809,3020,,,,,H,Autocuration,BAO_0000249
3165,,6,B,,1,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,104698,,,,CHEMBL617810,1742,,,,,H,Autocuration,BAO_0000019
3166,,6,B,,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,104698,,,,CHEMBL617811,17394,955.0,,,Brain,H,Autocuration,BAO_0000249
3167,,6,B,,1,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,104698,,,,CHEMBL617812,17394,955.0,,,Brain,H,Autocuration,BAO_0000221
3168,,6,B,,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,,CHEMBL617813,17394,,,,,H,Autocuration,BAO_0000249
3169,,6,B,,1,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,,CHEMBL617814,14286,,,,,H,Autocuration,BAO_0000249
3170,,6,B,,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,104698,,,,CHEMBL617698,14178,,,,,H,Autocuration,BAO_0000019
3171,Rattus norvegicus,7,B,,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,104698,10116.0,,,CHEMBL617699,14178,,,,,D,Autocuration,BAO_0000019
3172,Rattus norvegicus,7,B,,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,104698,10116.0,,,CHEMBL617700,14178,,,,,D,Autocuration,BAO_0000019
3173,Rattus norvegicus,7,B,,1,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL617701,14178,,,,,D,Autocuration,BAO_0000223
3174,,6,B,,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,,CHEMBL617702,15034,,,,,H,Autocuration,BAO_0000019
3175,,6,B,,1,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",104698,,Membranes,,CHEMBL617703,1089,,,,,H,Autocuration,BAO_0000249
3176,Rattus norvegicus,7,B,,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,104698,10116.0,,,CHEMBL617704,1089,,,,,D,Autocuration,BAO_0000019
3177,,6,B,,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,,CHEMBL617705,16532,,,,,H,Autocuration,BAO_0000223
3178,Rattus norvegicus,7,B,,1,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL617706,12801,,,,,D,Autocuration,BAO_0000223
3179,,6,B,NG108-15,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),104698,,,,CHEMBL617707,15194,,433.0,,,H,Autocuration,BAO_0000219
3180,,6,B,NG108-15,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,104698,,,,CHEMBL617708,15194,,433.0,,,H,Autocuration,BAO_0000219
3181,,6,B,,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,104698,,,,CHEMBL617709,15194,,,,,H,Autocuration,BAO_0000019
3182,,6,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,104698,,,,CHEMBL617710,15194,,,,,H,Autocuration,BAO_0000019
3183,,6,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,104698,,,,CHEMBL882925,15194,,,,,H,Autocuration,BAO_0000019
3184,,6,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,104698,,,,CHEMBL617711,15194,,,,,H,Autocuration,BAO_0000019
3185,,6,F,,1,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,104698,,,,CHEMBL617712,10610,,,,,H,Autocuration,BAO_0000019
3186,Rattus norvegicus,7,F,,1,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,104698,10116.0,,,CHEMBL617713,10355,,,,,D,Autocuration,BAO_0000019
3187,,6,F,,1,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",104698,,,,CHEMBL617714,691,,,,,H,Autocuration,BAO_0000019
3188,,6,F,,1,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,104698,,,,CHEMBL617715,10611,,,,,H,Autocuration,BAO_0000218
3189,,6,F,,1,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,104698,,,,CHEMBL617716,12801,,,,,H,Autocuration,BAO_0000218
3190,,6,F,,1,Inhibition of 5-HT evoked reflex bradycardia in rat.,104698,,,,CHEMBL617717,10609,,,,,H,Autocuration,BAO_0000218
3191,,6,F,,1,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617718,11454,,,,,H,Autocuration,BAO_0000218
3192,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617719,11454,,,,,H,Autocuration,BAO_0000218
3193,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),104698,,,,CHEMBL617720,11454,,,,,H,Autocuration,BAO_0000218
3194,Rattus norvegicus,7,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,104698,10116.0,,,CHEMBL617721,11454,,,,,D,Autocuration,BAO_0000218
3195,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617722,11454,,,,,H,Autocuration,BAO_0000218
3196,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,104698,,,,CHEMBL617723,11454,,,,,H,Autocuration,BAO_0000218
3197,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617724,11454,,,,,H,Autocuration,BAO_0000218
3198,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617725,11454,,,,,H,Autocuration,BAO_0000218
3199,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617726,11454,,,,,H,Autocuration,BAO_0000218
3200,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617727,11454,,,,,H,Autocuration,BAO_0000218
3201,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617728,11454,,,,,H,Autocuration,BAO_0000218
3202,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617729,11454,,,,,H,Autocuration,BAO_0000218
3203,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617730,11454,,,,,H,Autocuration,BAO_0000218
3204,,6,F,,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617731,11454,,,,,H,Autocuration,BAO_0000218
3205,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617732,11454,,,,,H,Autocuration,BAO_0000218
3206,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617733,11454,,,,,H,Autocuration,BAO_0000218
3207,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617734,11454,,,,,H,Autocuration,BAO_0000218
3208,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,104698,,,,CHEMBL872874,11454,,,,,H,Autocuration,BAO_0000218
3209,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,104698,,,,CHEMBL617735,11454,,,,,H,Autocuration,BAO_0000218
3210,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,104698,,,,CHEMBL617736,11454,,,,,H,Autocuration,BAO_0000218
3211,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,104698,,,,CHEMBL617737,11454,,,,,H,Autocuration,BAO_0000218
3212,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,104698,,,,CHEMBL617738,11454,,,,,H,Autocuration,BAO_0000218
3213,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617739,11454,,,,,H,Autocuration,BAO_0000218
3214,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617740,11454,,,,,H,Autocuration,BAO_0000218
3215,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617741,11454,,,,,H,Autocuration,BAO_0000218
3216,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617742,11454,,,,,H,Autocuration,BAO_0000218
3217,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617743,11454,,,,,H,Autocuration,BAO_0000218
3218,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617744,11454,,,,,H,Autocuration,BAO_0000218
3219,,6,F,,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,,,CHEMBL617745,11454,,,,,H,Autocuration,BAO_0000218
3220,,6,F,,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",104698,,,,CHEMBL617746,670,,,,,H,Autocuration,BAO_0000218
3221,,6,F,,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",104698,,,,CHEMBL617747,670,,,,,H,Autocuration,BAO_0000218
3222,,6,F,,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,104698,,,,CHEMBL617748,10321,,,,,H,Autocuration,BAO_0000218
3223,,6,F,,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,104698,,,,CHEMBL618909,10321,,,,,H,Autocuration,BAO_0000218
3224,,6,F,,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,104698,,,,CHEMBL618910,10321,,,,,H,Autocuration,BAO_0000218
3225,,6,F,,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,104698,,,,CHEMBL618911,10321,,,,,H,Autocuration,BAO_0000218
3226,,6,F,,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,104698,,,,CHEMBL618912,10321,,,,,H,Autocuration,BAO_0000218
3227,,6,F,,1,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),104698,,,,CHEMBL618913,10322,,,,,H,Autocuration,BAO_0000218
3228,,6,F,,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,,CHEMBL618914,15412,,,,,H,Autocuration,BAO_0000019
3229,,6,F,,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,,CHEMBL618915,15412,,,,,H,Autocuration,BAO_0000019
3230,Rattus norvegicus,7,B,,1,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL618916,15412,,,,,D,Autocuration,BAO_0000223
3231,,6,F,,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,104698,,,,CHEMBL618917,15412,,,,,H,Autocuration,BAO_0000019
3232,,7,B,,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,104698,,,,CHEMBL618918,15412,10000000.0,,,Hippocampus,D,Intermediate,BAO_0000221
3233,Rattus norvegicus,7,B,,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,104698,10116.0,,,CHEMBL618919,15412,,,,,D,Autocuration,BAO_0000019
3234,Rattus norvegicus,7,B,,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL618920,17394,,,,,D,Autocuration,BAO_0000019
3235,,6,B,,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,104698,,,,CHEMBL618921,12457,,,,,H,Autocuration,BAO_0000223
3236,,6,B,,1,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,104698,,,,CHEMBL618922,12457,,,,,H,Autocuration,BAO_0000019
3237,,6,B,,1,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,104698,,,,CHEMBL618923,12205,,,,,H,Autocuration,BAO_0000019
3238,,6,B,,1,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,104698,,,,CHEMBL618924,14532,,,,,H,Autocuration,BAO_0000019
3239,,6,B,,1,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,104698,,,,CHEMBL618925,1122,,,,,H,Autocuration,BAO_0000019
3240,,6,B,,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,,CHEMBL618926,5094,,,,,H,Autocuration,BAO_0000019
3241,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,20033,10141.0,,,CHEMBL618927,809,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3242,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,20033,10141.0,,,CHEMBL618928,809,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3243,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",20033,10141.0,,,CHEMBL618929,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3244,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",20033,10141.0,,,CHEMBL618930,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3245,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,10141.0,,,CHEMBL618931,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3246,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,10141.0,,,CHEMBL619594,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3247,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",20033,10141.0,,,CHEMBL619595,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3248,Cavia porcellus,9,F,,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,20033,10141.0,,,CHEMBL619596,13961,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3249,Cavia porcellus,9,F,,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,20033,10141.0,,,CHEMBL619755,13961,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3250,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,20033,10141.0,,,CHEMBL619756,809,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3251,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,20033,10141.0,,,CHEMBL619757,809,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3252,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,20033,10141.0,,,CHEMBL619758,809,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3253,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",20033,10141.0,,,CHEMBL619759,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3254,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",20033,10141.0,,,CHEMBL619760,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3255,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",20033,10141.0,,,CHEMBL619761,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3256,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,20033,10141.0,,,CHEMBL619762,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3257,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,10141.0,,,CHEMBL619763,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3258,Cavia porcellus,9,F,,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,10141.0,,,CHEMBL617868,14290,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3259,Cavia porcellus,9,B,,1,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,10141.0,,,CHEMBL617869,15034,,,,,D,Intermediate,BAO_0000357
3260,Cavia porcellus,9,B,,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,10141.0,,,CHEMBL882926,5094,2435.0,,,Striatum,D,Intermediate,BAO_0000249
3261,Cavia porcellus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,10141.0,,,CHEMBL617870,5094,2435.0,,,Striatum,D,Intermediate,BAO_0000249
3262,Cavia porcellus,9,B,,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,20033,10141.0,,,CHEMBL617871,5399,2435.0,,,Striatum,D,Intermediate,BAO_0000357
3263,Cavia porcellus,9,B,,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,10141.0,,,CHEMBL617872,17394,2435.0,,,Striatum,D,Intermediate,BAO_0000357
3264,Cavia porcellus,9,B,,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,10141.0,,,CHEMBL617873,17394,2435.0,,,Striatum,D,Intermediate,BAO_0000357
3265,Cavia porcellus,9,B,,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,10141.0,,,CHEMBL617874,17394,2435.0,,,Striatum,D,Intermediate,BAO_0000357
3266,Cavia porcellus,9,F,,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,20033,10141.0,,,CHEMBL619067,13961,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3267,Cavia porcellus,9,F,,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,20033,10141.0,,,CHEMBL619068,13961,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3268,Cavia porcellus,9,F,,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,10141.0,,,CHEMBL619069,13961,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3269,Cavia porcellus,9,B,,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,20033,10141.0,,,CHEMBL619070,16946,,,,,D,Intermediate,BAO_0000357
3270,Cavia porcellus,9,B,,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,20033,10141.0,,,CHEMBL619071,16946,,,,,D,Intermediate,BAO_0000357
3271,Cavia porcellus,9,F,,1,Agonistic activity against 5-hydroxytryptamine 4 receptor,20033,10141.0,,,CHEMBL619072,15034,,,,,D,Intermediate,BAO_0000019
3272,Cavia porcellus,9,F,,1,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,20033,10141.0,,,CHEMBL619073,15034,,,,,D,Intermediate,BAO_0000019
3273,Cavia porcellus,9,F,,1,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,20033,10141.0,,,CHEMBL619074,12918,,,,,D,Intermediate,BAO_0000019
3274,Cavia porcellus,9,B,,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,20033,10141.0,,,CHEMBL619075,16946,,,,,D,Intermediate,BAO_0000357
3275,Cavia porcellus,9,B,,1,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,10141.0,,,CHEMBL619076,17394,2435.0,,,Striatum,D,Intermediate,BAO_0000357
3276,Cavia porcellus,9,B,,1,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,20033,10141.0,,,CHEMBL619077,15034,2435.0,,,Striatum,D,Intermediate,BAO_0000357
3277,Cavia porcellus,9,B,,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,10141.0,,,CHEMBL619078,5094,2435.0,,,Striatum,D,Intermediate,BAO_0000249
3278,Cavia porcellus,9,B,,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,10141.0,,,CHEMBL619079,5094,2435.0,,,Striatum,D,Intermediate,BAO_0000249
3279,Cavia porcellus,9,B,,1,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,20033,10141.0,,,CHEMBL619080,17358,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3280,Cavia porcellus,9,B,,1,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,20033,10141.0,,,CHEMBL619081,12953,,,,,D,Expert,BAO_0000357
3281,Cavia porcellus,9,B,,1,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,10141.0,,,CHEMBL619082,12953,,,,,D,Intermediate,BAO_0000357
3282,Cavia porcellus,9,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,20033,10141.0,,,CHEMBL619083,12953,,,,,D,Intermediate,BAO_0000357
3283,Cavia porcellus,9,B,,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,10141.0,,,CHEMBL619084,12953,,,,,D,Intermediate,BAO_0000357
3284,Cavia porcellus,9,F,,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,10141.0,,,CHEMBL859397,273,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3285,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,20033,10141.0,,,CHEMBL619085,12918,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3286,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,20033,10141.0,,,CHEMBL619086,12919,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3287,Cavia porcellus,9,F,,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,20033,10141.0,,,CHEMBL619087,273,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3288,Cavia porcellus,9,F,,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,10141.0,,,CHEMBL619088,273,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3289,Cavia porcellus,9,B,,1,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,20033,10141.0,,,CHEMBL619089,13181,,,,,D,Intermediate,BAO_0000357
3290,Cavia porcellus,8,B,,1,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,168,10141.0,,,CHEMBL619090,13181,,,,,H,Autocuration,BAO_0000357
3291,Cavia porcellus,9,F,,1,Antagonistic activity against 5-hydroxytryptamine 4 receptor,20033,10141.0,,,CHEMBL619091,15034,,,,,D,Intermediate,BAO_0000019
3292,Cavia porcellus,9,B,,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,10141.0,,,CHEMBL619092,5033,,,,,D,Intermediate,BAO_0000357
3293,Cavia porcellus,9,B,,1,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,20033,10141.0,,,CHEMBL619093,1980,,,,,D,Intermediate,BAO_0000019
3294,Cavia porcellus,8,B,HEK293,1,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,168,10141.0,,,CHEMBL619094,13181,,722.0,,,H,Autocuration,BAO_0000219
3295,Cavia porcellus,9,B,,1,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,20033,10141.0,,,CHEMBL619095,14287,,,,,D,Intermediate,BAO_0000019
3296,Cavia porcellus,9,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,20033,10141.0,,,CHEMBL857988,1317,,,,,D,Intermediate,BAO_0000357
3297,Cavia porcellus,9,B,,1,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,20033,10141.0,,,CHEMBL619096,15316,,,,,D,Intermediate,BAO_0000357
3298,Cavia porcellus,9,B,,1,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,20033,10141.0,,,CHEMBL619097,16429,2435.0,,,Striatum,D,Intermediate,BAO_0000357
3299,Cavia porcellus,9,B,,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,20033,10141.0,,,CHEMBL619098,14818,10000000.0,,,Hippocampus,D,Intermediate,BAO_0000221
3300,Cavia porcellus,9,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,20033,10141.0,,,CHEMBL619751,15194,,,,,D,Intermediate,BAO_0000357
3301,Cavia porcellus,9,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,20033,10141.0,,,CHEMBL619752,15194,,,,,D,Intermediate,BAO_0000357
3302,Cavia porcellus,9,F,,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,10141.0,,,CHEMBL875096,13961,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3303,,8,B,,1,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,108,,,,CHEMBL619004,5486,,,,,H,Autocuration,BAO_0000357
3304,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,168,,,,CHEMBL619005,16209,,,,,H,Autocuration,BAO_0000357
3305,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL619006,17085,,,,,H,Autocuration,BAO_0000019
3306,,8,B,HeLa,1,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,168,,,,CHEMBL619007,4199,,308.0,,,H,Autocuration,BAO_0000219
3307,,8,B,,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL619008,15146,,,,,H,Autocuration,BAO_0000357
3308,,8,B,,1,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL619009,5213,,,,,H,Autocuration,BAO_0000357
3309,,8,B,HeLa,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",168,,,,CHEMBL619010,4829,,308.0,,,H,Autocuration,BAO_0000219
3310,,8,B,,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,10622,,,,CHEMBL619011,17358,,,,,H,Autocuration,BAO_0000357
3311,,8,B,,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,10622,,,,CHEMBL619012,17358,,,,,H,Autocuration,BAO_0000357
3312,,8,B,,1,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,10622,,,,CHEMBL619013,16946,,,,,H,Autocuration,BAO_0000219
3313,,8,B,,1,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,10622,,,,CHEMBL619014,17358,,,,,H,Autocuration,BAO_0000357
3314,,8,F,,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,11249,,,,CHEMBL857503,268,2081.0,,,Cardiac atrium,H,Autocuration,BAO_0000019
3315,,8,F,,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,11249,,,,CHEMBL619015,268,2081.0,,,Cardiac atrium,H,Autocuration,BAO_0000019
3316,,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,11249,,,,CHEMBL619016,15086,,,,,H,Autocuration,BAO_0000357
3317,,8,B,,1,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,11249,,,,CHEMBL619017,14875,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
3318,Sus scrofa,8,B,,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,168,9823.0,,,CHEMBL619018,13267,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
3319,Oryctolagus cuniculus,8,B,,1,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,168,9986.0,,,CHEMBL619019,13047,,,,,H,Autocuration,BAO_0000019
3320,Rattus norvegicus,9,B,,1,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10623,10116.0,,,CHEMBL619020,1650,,,,,D,Expert,BAO_0000357
3321,,8,F,,1,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,,CHEMBL619021,567,,,,,H,Autocuration,BAO_0000019
3322,,8,B,,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,10623,,,,CHEMBL619022,17358,,,,,H,Autocuration,BAO_0000357
3323,,8,B,,1,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,10623,,,,CHEMBL619023,188,,,,,H,Autocuration,BAO_0000357
3324,,8,F,,1,lntrinsic activity relative to 5-HT receptor,10623,,,,CHEMBL619024,670,,,,,H,Autocuration,BAO_0000019
3325,,8,F,,1,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,10623,,,,CHEMBL619025,204,,,,,H,Autocuration,BAO_0000019
3326,,8,F,,1,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,10623,,,,CHEMBL619026,1946,,,,,H,Expert,BAO_0000019
3327,,8,F,,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,10623,,,,CHEMBL619027,6398,,,,,H,Autocuration,BAO_0000019
3328,,8,F,,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,10623,,,,CHEMBL619028,6398,,,,,H,Autocuration,BAO_0000019
3329,,8,F,,1,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,10623,,,,CHEMBL619029,17358,,,,,H,Autocuration,BAO_0000019
3330,,8,F,,1,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,10623,,,,CHEMBL619030,6398,,,,,H,Autocuration,BAO_0000019
3331,,8,B,,1,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,10623,,,,CHEMBL619031,11752,,,,,H,Expert,BAO_0000357
3332,,8,F,,1,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,10623,,,,CHEMBL619032,809,,,,,H,Autocuration,BAO_0000019
3333,Rattus norvegicus,9,B,,1,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10623,10116.0,,,CHEMBL619033,14178,,,,,D,Expert,BAO_0000357
3334,,8,B,,1,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,,CHEMBL619034,567,,,,,H,Autocuration,BAO_0000357
3335,,8,B,,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,10623,,,,CHEMBL619035,1946,,,,,H,Autocuration,BAO_0000357
3336,,8,B,,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,10623,,,,CHEMBL619036,1946,,,,,H,Autocuration,BAO_0000357
3337,Rattus norvegicus,9,B,,1,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10623,10116.0,,,CHEMBL619037,13961,,,,,D,Expert,BAO_0000019
3338,,8,B,,1,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,10623,,,,CHEMBL619038,6238,2435.0,,,Striatum,H,Autocuration,BAO_0000249
3339,,8,B,,1,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,10623,,,,CHEMBL619039,14290,,,,,H,Autocuration,BAO_0000249
3340,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,10623,,,,CHEMBL619040,14290,,,,,H,Expert,BAO_0000249
3341,Rattus norvegicus,9,B,,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,10116.0,,,CHEMBL619041,809,2435.0,,,Striatum,D,Expert,BAO_0000019
3342,,8,B,,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,,,CHEMBL619042,1578,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3343,,8,B,,1,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,10623,,,,CHEMBL619043,16709,2435.0,,,Striatum,H,Expert,BAO_0000249
3344,,8,B,,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,10623,,,,CHEMBL619044,1946,2435.0,,,Striatum,H,Expert,BAO_0000019
3345,,8,B,,1,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,10623,,,,CHEMBL619045,15253,2435.0,,,Striatum,H,Expert,BAO_0000249
3346,,8,B,,1,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,,,CHEMBL619046,4535,2435.0,,,Striatum,H,Expert,BAO_0000249
3347,,8,B,,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,10623,,,,CHEMBL619047,13961,,,,,H,Expert,BAO_0000249
3348,,8,F,,1,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,10623,,,,CHEMBL619048,17358,955.0,,,Brain,H,Autocuration,BAO_0000221
3349,,8,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,10623,,,,CHEMBL859398,15847,,,,,H,Autocuration,BAO_0000019
3350,,8,F,,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,10623,,,,CHEMBL619049,15847,,,,,H,Autocuration,BAO_0000019
3351,,8,F,,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,10623,,,,CHEMBL857886,670,,,,,H,Autocuration,BAO_0000019
3352,,8,F,,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,10623,,,,CHEMBL619050,670,,,,,H,Autocuration,BAO_0000019
3353,,8,F,,1,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,,,CHEMBL620591,1317,,,,,H,Autocuration,BAO_0000019
3354,Rattus norvegicus,9,B,,1,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10623,10116.0,,,CHEMBL620592,12936,,,,,D,Expert,BAO_0000357
3355,,8,B,,1,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,,,CHEMBL620593,4535,2435.0,,,Striatum,H,Expert,BAO_0000249
3356,Rattus norvegicus,9,F,,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10623,10116.0,,,CHEMBL620594,14424,,,,,D,Expert,BAO_0000019
3357,,8,F,,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,10623,,,,CHEMBL875079,14424,,,,,H,Expert,BAO_0000019
3358,,8,F,,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,,CHEMBL620595,14424,,,,,H,Expert,BAO_0000019
3359,Rattus norvegicus,9,F,,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10623,10116.0,,,CHEMBL620596,14424,,,,,D,Expert,BAO_0000019
3360,,8,F,,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,10623,,,,CHEMBL620597,14424,,,,,H,Autocuration,BAO_0000019
3361,,8,F,,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,10623,,,,CHEMBL620598,14424,,,,,H,Expert,BAO_0000019
3362,,8,F,,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),10623,,,,CHEMBL620599,14424,,,,,H,Expert,BAO_0000218
3363,,8,F,,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,,CHEMBL620600,14424,,,,,H,Autocuration,BAO_0000019
3364,Rattus norvegicus,8,F,,1,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,168,10116.0,,,CHEMBL620601,1980,,,,,H,Autocuration,BAO_0000019
3365,,8,F,,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,168,,,,CHEMBL620602,4639,,,,,H,Autocuration,BAO_0000019
3366,,8,B,,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL620603,17358,,,,,H,Autocuration,BAO_0000357
3367,,8,B,,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,168,,,,CHEMBL620604,17358,,,,,H,Autocuration,BAO_0000357
3368,,8,B,,1,Compound was tested for 5-hydroxytryptamine 4 binding affinity,168,,,,CHEMBL620605,17358,,,,,H,Autocuration,BAO_0000357
3369,,8,B,,1,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL620606,1558,,,,,H,Autocuration,BAO_0000357
3370,,8,F,,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,,CHEMBL620607,17358,,,,,H,Autocuration,BAO_0000019
3371,,8,B,,1,In vitro binding affinity towards 5-HT4 receptor was determined,168,,,,CHEMBL620608,16117,,,,,H,Autocuration,BAO_0000357
3372,,8,F,,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,,CHEMBL620609,17358,,,,,H,Autocuration,BAO_0000019
3373,,8,F,,1,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL620610,17358,,,,,H,Autocuration,BAO_0000019
3374,,8,B,,1,Tested for selectivity for 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL620611,17358,,,,,H,Autocuration,BAO_0000357
3375,,8,B,,1,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,168,,,,CHEMBL620612,17358,,,,,H,Autocuration,BAO_0000357
3376,,8,B,,1,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,168,,,,CHEMBL620613,17358,,,,,H,Autocuration,BAO_0000357
3377,,8,B,,1,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,168,,,,CHEMBL620614,17358,,,,,H,Autocuration,BAO_0000357
3378,,8,B,,1,Binding affinity against 5-Hydroxytryptamine 4 receptor,168,,,,CHEMBL620615,1274,,,,,H,Expert,BAO_0000357
3379,,6,B,,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,104698,,Brain membranes,,CHEMBL857075,10728,,,,,H,Autocuration,BAO_0000249
3380,,6,B,,1,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,104698,,Brain membranes,,CHEMBL620616,11695,,,,,H,Autocuration,BAO_0000249
3381,,6,B,,1,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,104698,,Brain membranes,,CHEMBL619411,11695,,,,,H,Autocuration,BAO_0000249
3382,,6,B,,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,104698,,,,CHEMBL619412,12490,,,,,H,Autocuration,BAO_0000019
3383,Rattus norvegicus,7,B,,1,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL619413,11828,,,,,D,Autocuration,BAO_0000019
3384,,6,B,,1,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,104698,,,,CHEMBL619414,12253,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
3385,,6,B,,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104698,,,,CHEMBL619415,10561,,,,,H,Autocuration,BAO_0000019
3386,,6,B,,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,104698,,,,CHEMBL619416,10561,,,,,H,Autocuration,BAO_0000019
3387,,6,F,,1,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,104698,,,,CHEMBL619417,14432,,,,,H,Autocuration,BAO_0000019
3388,Rattus norvegicus,7,B,,1,Binding affinity against rat 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL619418,12936,,,,,D,Autocuration,BAO_0000223
3389,Rattus norvegicus,7,B,,1,Binding affinity against 5-Hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL619419,1274,,,,,D,Autocuration,BAO_0000223
3390,,6,B,,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,104698,,,,CHEMBL619420,1980,,,,,H,Autocuration,BAO_0000019
3391,,6,B,,1,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,104698,,,,CHEMBL619421,670,,,,,H,Autocuration,BAO_0000249
3392,Rattus norvegicus,7,B,,1,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,104698,10116.0,,,CHEMBL619422,968,,,,,D,Autocuration,BAO_0000019
3393,,6,B,,1,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,104698,,,,CHEMBL619423,14287,,,,,H,Autocuration,BAO_0000019
3394,,6,B,,1,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,104698,,,,CHEMBL875080,567,,,,,H,Autocuration,BAO_0000019
3395,,6,B,,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,104698,,,,CHEMBL619424,13267,,,,,H,Autocuration,BAO_0000019
3396,,6,B,,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,104698,,,,CHEMBL619425,14826,,,,,H,Autocuration,BAO_0000249
3397,,6,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,104698,,,,CHEMBL619426,15194,,,,,H,Autocuration,BAO_0000223
3398,,6,B,,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,104698,,,,CHEMBL619427,15194,,,,,H,Autocuration,BAO_0000223
3399,Rattus norvegicus,7,B,,1,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,104698,10116.0,,,CHEMBL619645,10394,,,,,D,Autocuration,BAO_0000223
3400,,9,B,,1,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",10576,,,,CHEMBL619646,13657,,,,,D,Expert,BAO_0000249
3401,,8,F,,1,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,12020,,,,CHEMBL619647,1879,955.0,,,Brain,H,Autocuration,BAO_0000221
3402,,8,F,,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,12020,,,,CHEMBL619648,1879,,,,,H,Autocuration,BAO_0000019
3403,,8,F,,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,12020,,,,CHEMBL619165,1879,,,,,H,Autocuration,BAO_0000019
3404,,8,F,,1,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,12020,,,,CHEMBL620719,204,,,,,H,Autocuration,BAO_0000218
3405,,8,B,,1,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,,CHEMBL872924,1879,,,,,H,Autocuration,BAO_0000019
3406,,8,B,,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,12020,,,,CHEMBL620720,1879,,,,,H,Autocuration,BAO_0000357
3407,,8,B,,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,,CHEMBL620721,1879,,,,,H,Autocuration,BAO_0000019
3408,,8,B,,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,12020,,,,CHEMBL620722,1879,,,,,H,Autocuration,BAO_0000019
3409,,6,B,,1,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",104698,,,,CHEMBL620723,10641,,,,,H,Autocuration,BAO_0000019
3410,,8,B,,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,12020,,,,CHEMBL620724,773,,,,,H,Autocuration,BAO_0000019
3411,,6,B,,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,104698,,,,CHEMBL620725,11952,,,,,H,Autocuration,BAO_0000249
3412,Rattus norvegicus,9,F,,1,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,12020,10116.0,,,CHEMBL620726,14145,,,,,D,Autocuration,BAO_0000019
3413,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,,CHEMBL620727,17066,,,,,H,Expert,BAO_0000357
3414,,4,B,,1,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,104714,,,,CHEMBL620728,6398,,,,,H,Autocuration,BAO_0000223
3415,,0,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,22226,,,,CHEMBL620729,10321,,,,,U,Autocuration,BAO_0000019
3416,,4,F,,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,104714,,,,CHEMBL858288,511,,,,,H,Autocuration,BAO_0000019
3417,,4,B,,1,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL620730,4639,,,,,H,Autocuration,BAO_0000223
3418,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL620731,4639,,,,,H,Autocuration,BAO_0000223
3419,Cavia porcellus,4,F,,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,104714,10141.0,,,CHEMBL620732,4639,,,,,H,Autocuration,BAO_0000019
3420,Cavia porcellus,4,F,,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,10141.0,,,CHEMBL618042,4639,,,,,H,Autocuration,BAO_0000019
3421,Cavia porcellus,4,F,,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,104714,10141.0,,,CHEMBL618043,4639,,,,,H,Autocuration,BAO_0000019
3422,,4,B,,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL618044,1558,,,,,H,Autocuration,BAO_0000223
3423,,4,F,,1,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,104714,,,,CHEMBL618045,268,,,,,H,Autocuration,BAO_0000019
3424,,4,B,,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,104714,,,,CHEMBL618046,2474,,,,,H,Autocuration,BAO_0000223
3425,,4,F,,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,104714,,,,CHEMBL618047,5067,,,,,H,Autocuration,BAO_0000019
3426,,4,F,,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,104714,,,,CHEMBL875084,5067,,,,,H,Autocuration,BAO_0000019
3427,,4,F,,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,104714,,,,CHEMBL618048,5067,,,,,H,Autocuration,BAO_0000019
3428,,4,B,,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,104714,,,,CHEMBL618049,5067,,,,,H,Autocuration,BAO_0000223
3429,,4,F,,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,104714,,,,CHEMBL619764,5067,,,,,H,Autocuration,BAO_0000019
3430,,4,F,,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,104714,,,,CHEMBL619765,5067,,,,,H,Autocuration,BAO_0000019
3431,,4,F,,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,104714,,,,CHEMBL619766,5067,,,,,H,Autocuration,BAO_0000019
3432,,4,B,,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,104714,,,,CHEMBL619767,5067,,,,,H,Autocuration,BAO_0000223
3433,,4,B,,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,104714,,,,CHEMBL619768,5067,,,,,H,Autocuration,BAO_0000223
3434,,4,F,,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,104714,,,,CHEMBL619769,5067,,,,,H,Autocuration,BAO_0000019
3435,,4,B,,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,104714,,,,CHEMBL619770,5067,,,,,H,Autocuration,BAO_0000223
3436,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL619771,5067,,,,,H,Autocuration,BAO_0000223
3437,,4,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,104714,,,,CHEMBL619772,14331,,,,,H,Autocuration,BAO_0000219
3438,,4,B,,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,104714,,,,CHEMBL619773,5067,,,,,H,Autocuration,BAO_0000223
3439,,4,B,NG108-15,1,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,104714,,,,CHEMBL619774,6179,,433.0,,,H,Autocuration,BAO_0000219
3440,,4,B,,1,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,104714,,,,CHEMBL875083,4265,,,,,H,Autocuration,BAO_0000019
3441,,4,B,NG108-15,1,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,104714,,,,CHEMBL620718,4265,,433.0,,,H,Autocuration,BAO_0000219
3442,,4,B,,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,104714,,,,CHEMBL618127,17358,,,,,H,Autocuration,BAO_0000223
3443,,4,B,,1,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,104714,,,,CHEMBL618128,17358,,,,,H,Autocuration,BAO_0000223
3444,,4,B,,1,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,104714,,,,CHEMBL618129,13628,,,,,H,Autocuration,BAO_0000219
3445,,4,B,,1,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,104714,,,,CHEMBL618130,4612,,,,,H,Autocuration,BAO_0000223
3446,,4,F,,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,104714,,,,CHEMBL618131,17358,,,,,H,Autocuration,BAO_0000019
3447,Cavia porcellus,4,F,,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,104714,10141.0,,,CHEMBL618132,4639,,,,,H,Autocuration,BAO_0000019
3448,Cavia porcellus,4,F,,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,104714,10141.0,,,CHEMBL618133,4639,,,,,H,Autocuration,BAO_0000019
3449,Cavia porcellus,4,F,,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,104714,10141.0,,,CHEMBL618134,4639,,,,,H,Autocuration,BAO_0000019
3450,Cavia porcellus,4,F,,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,10141.0,,,CHEMBL618135,4639,,,,,H,Autocuration,BAO_0000019
3451,,4,B,,1,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,104714,,,,CHEMBL618136,511,,,,,H,Autocuration,BAO_0000223
3452,,4,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL618137,1479,,,,,H,Autocuration,BAO_0000223
3453,,4,B,,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,104714,,,,CHEMBL618138,1317,,,,,H,Autocuration,BAO_0000223
3454,,4,B,,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,104714,,,,CHEMBL618139,12146,,,,,H,Autocuration,BAO_0000223
3455,,4,B,,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,104714,,,,CHEMBL618140,12146,,,,,H,Autocuration,BAO_0000223
3456,,4,B,,1,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,104714,,,,CHEMBL618141,13969,,,,,H,Autocuration,BAO_0000223
3457,,8,B,,1,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,,,CHEMBL873478,13392,,,,,H,Expert,BAO_0000357
3458,,6,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,104698,,,,CHEMBL618142,13392,,,,,H,Autocuration,BAO_0000223
3459,,8,B,,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,144,,,,CHEMBL618143,14159,,,,,H,Autocuration,BAO_0000357
3460,,8,B,,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,144,,,,CHEMBL618144,1558,,,,,H,Autocuration,BAO_0000357
3461,,8,B,,1,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,144,,,,CHEMBL618145,16655,,,,,H,Autocuration,BAO_0000357
3462,,4,B,,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,,CHEMBL618146,13020,,,,,H,Autocuration,BAO_0000223
3463,,4,B,,1,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,104714,,,,CHEMBL618147,13021,,,,,H,Autocuration,BAO_0000223
3464,,4,B,,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,,CHEMBL618148,13020,,,,,H,Autocuration,BAO_0000223
3465,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,144,,,,CHEMBL618149,10321,,,,,H,Autocuration,BAO_0000019
3466,,8,B,,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,,CHEMBL872927,15818,,,,,H,Autocuration,BAO_0000357
3467,,8,B,,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,,CHEMBL618150,15818,,,,,H,Autocuration,BAO_0000357
3468,,8,B,,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,144,,,,CHEMBL618151,17358,,,,,H,Autocuration,BAO_0000357
3469,,8,B,,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,144,,,,CHEMBL875094,2222,,,,,H,Autocuration,BAO_0000357
3470,,8,B,,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,144,,,,CHEMBL618152,10322,,,,,H,Autocuration,BAO_0000019
3471,,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,144,,,,CHEMBL618153,16117,,,,,H,Autocuration,BAO_0000357
3472,,8,B,,1,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,144,,,,CHEMBL618888,17200,,,,,H,Autocuration,BAO_0000357
3473,,8,F,,1,Tested for 5-hydroxytryptamine 3 receptor agonist activity,144,,,,CHEMBL618889,17358,,,,,H,Autocuration,BAO_0000019
3474,,8,B,,1,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,144,,,,CHEMBL618890,16700,,,,,H,Autocuration,BAO_0000357
3475,,8,B,,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,144,,,,CHEMBL618891,1980,,,,,H,Autocuration,BAO_0000019
3476,,8,B,,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,144,,,,CHEMBL619054,1980,,,,,H,Autocuration,BAO_0000019
3477,,4,B,,1,Binding affinity against the 5-hydroxytryptamine 3 receptor,104714,,,,CHEMBL619055,12409,,,,,H,Autocuration,BAO_0000223
3478,,8,B,,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,,CHEMBL619056,4365,,,,,H,Autocuration,BAO_0000357
3479,,8,F,,1,Percent efficacy against 5-hydroxytryptamine 3A receptor,144,,,,CHEMBL619057,4365,,,,,H,Autocuration,BAO_0000019
3480,,8,B,,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,,CHEMBL619058,4365,,,,,H,Autocuration,BAO_0000357
3481,Rattus norvegicus,9,F,Oocytes,1,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,12020,10116.0,,,CHEMBL619059,6769,,,,,D,Expert,BAO_0000219
3482,Rattus norvegicus,9,F,Oocytes,1,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,12020,10116.0,,,CHEMBL619060,6769,,,,,D,Expert,BAO_0000219
3483,Rattus norvegicus,9,F,Oocytes,1,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,12020,10116.0,,,CHEMBL875095,6769,,,,,D,Expert,BAO_0000219
3484,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,20033,10141.0,,,CHEMBL619061,809,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3485,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,20033,10141.0,,,CHEMBL619062,809,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3486,Cavia porcellus,9,F,,1,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,20033,10141.0,,,CHEMBL619063,14290,,,,,D,Intermediate,BAO_0000019
3487,Cavia porcellus,9,B,,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,20033,10141.0,,,CHEMBL619064,17358,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3488,Cavia porcellus,9,B,,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,20033,10141.0,,,CHEMBL619065,17358,,,,,D,Intermediate,BAO_0000357
3489,Cavia porcellus,9,B,,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,20033,10141.0,,,CHEMBL619066,17358,2116.0,,,Ileum,D,Intermediate,BAO_0000221
3490,,8,B,,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,10209,,,,CHEMBL619775,17386,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3491,,8,B,,1,Affinity against 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL619776,3269,,,,,H,Autocuration,BAO_0000357
3492,Cavia porcellus,4,B,,1,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,10141.0,,,CHEMBL619777,7721,,,,,H,Autocuration,BAO_0000224
3493,Cavia porcellus,4,B,,1,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,10141.0,,,CHEMBL619778,7721,,,,,H,Autocuration,BAO_0000224
3494,Cavia porcellus,4,B,,1,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,104841,10141.0,,,CHEMBL619779,9117,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3495,Cavia porcellus,4,B,,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,10141.0,,,CHEMBL619780,7721,,,,,H,Autocuration,BAO_0000224
3496,Cavia porcellus,4,B,,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,10141.0,,,CHEMBL619166,7721,,,,,H,Autocuration,BAO_0000224
3497,Cavia porcellus,4,F,,1,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,10141.0,,,CHEMBL619167,15796,,,,,H,Autocuration,BAO_0000019
3498,Cavia porcellus,4,F,,1,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,10141.0,,,CHEMBL619168,15796,,,,,H,Autocuration,BAO_0000019
3499,Homo sapiens,9,B,,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,168,9606.0,,,CHEMBL619169,15650,2081.0,,,Cardiac atrium,D,Expert,BAO_0000219
3500,Homo sapiens,9,B,,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,168,9606.0,,,CHEMBL619170,15650,2081.0,,,Cardiac atrium,D,Expert,BAO_0000219
3501,Homo sapiens,5,F,,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",104841,9606.0,,,CHEMBL619171,6866,,,,,D,Autocuration,BAO_0000019
3502,Homo sapiens,9,F,,1,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",168,9606.0,,,CHEMBL619172,15650,2081.0,,,Cardiac atrium,D,Expert,BAO_0000219
3503,Mus musculus,0,B,,1,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,22226,10090.0,,,CHEMBL619173,10063,,,,,U,Autocuration,BAO_0000019
3504,Mus musculus,0,B,,1,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,22226,10090.0,,,CHEMBL619174,12665,,,,,U,Autocuration,BAO_0000019
3505,,4,B,,1,5-hydroxytryptamine receptor binding affinity was determined in rats,104705,,,,CHEMBL619175,7504,,,,,H,Autocuration,BAO_0000019
3506,,4,B,,1,Binding affinity at rat 5-hydroxytryptamine receptor.,104705,,,,CHEMBL619176,7504,,,,,H,Autocuration,BAO_0000224
3507,,4,B,,1,Affinity against 5-hydroxytryptamine receptors in rat fundus model,104705,,,,CHEMBL619177,7038,,,,,H,Autocuration,BAO_0000019
3508,,4,B,,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,104705,,,,CHEMBL619178,7626,,,,,H,Autocuration,BAO_0000224
3509,,4,B,,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,104705,,,,CHEMBL619179,7626,,,,,H,Autocuration,BAO_0000224
3510,,4,F,,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,104705,,,,CHEMBL619180,7185,945.0,,,Stomach,H,Autocuration,BAO_0000019
3511,,4,F,,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,104705,,,,CHEMBL619181,7185,945.0,,,Stomach,H,Autocuration,BAO_0000019
3512,,4,F,,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,104705,,,,CHEMBL619182,7185,,,,,H,Autocuration,BAO_0000019
3513,,4,B,,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,104705,,,,CHEMBL619183,6960,,,,,H,Autocuration,BAO_0000224
3514,,4,B,,1,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",104705,,,,CHEMBL619184,6960,,,,,H,Autocuration,BAO_0000224
3515,,8,B,,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,,,CHEMBL619185,12416,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
3516,,8,B,,1,Binding affinity for rat 5-hydroxytryptamine transporter.,12198,,,,CHEMBL619186,15753,,,,,H,Expert,BAO_0000357
3517,,4,B,,1,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,104705,,,,CHEMBL619187,8062,,,,,H,Autocuration,BAO_0000019
3518,Rattus norvegicus,5,B,,1,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,104705,10116.0,,,CHEMBL619188,9036,,,,,D,Autocuration,BAO_0000019
3519,Rattus norvegicus,5,B,,1,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,104705,10116.0,,,CHEMBL619189,15067,,,,,D,Autocuration,BAO_0000224
3520,Rattus norvegicus,9,F,,1,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,12198,10116.0,,,CHEMBL619190,15753,955.0,,,Brain,D,Expert,BAO_0000019
3521,Rattus norvegicus,9,F,,1,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,12198,10116.0,,,CHEMBL619191,15753,2037.0,,,Cerebellum,D,Expert,BAO_0000221
3522,Rattus norvegicus,5,B,,1,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,104705,10116.0,,,CHEMBL619192,15295,,,,,D,Autocuration,BAO_0000019
3523,Rattus norvegicus,5,B,,1,Percent binding affinity against 5-hydroxytryptamine receptor,104705,10116.0,,,CHEMBL619193,6347,,,,,D,Autocuration,BAO_0000224
3524,,0,B,,1,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,22226,,,,CHEMBL619194,6763,,,,,U,Autocuration,BAO_0000019
3525,Rattus norvegicus,5,B,,1,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,104705,10116.0,,,CHEMBL619195,12092,,,,,D,Autocuration,BAO_0000224
3526,Rattus norvegicus,5,B,,1,Affinity against 5-hydroxytryptamine receptor was determined,104705,10116.0,,,CHEMBL619196,1579,,,,,D,Autocuration,BAO_0000224
3527,Rattus norvegicus,5,B,,1,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,104705,10116.0,,,CHEMBL619197,1579,945.0,,,Stomach,D,Autocuration,BAO_0000019
3528,Homo sapiens,9,B,,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,9606.0,,,CHEMBL619198,5963,,,,,D,Expert,BAO_0000219
3529,Homo sapiens,9,B,,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,9606.0,,,CHEMBL875081,5963,,,,,D,Expert,BAO_0000219
3530,,8,B,,1,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,18065,,,,CHEMBL884712,5030,,,,,H,Autocuration,BAO_0000357
3531,,8,B,,1,Inhibition of 5-hydroxytryptamine reuptake,121,,,,CHEMBL884710,15796,,,,,H,Expert,BAO_0000357
3532,,8,F,,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",18065,,,,CHEMBL619199,15413,,,,,H,Autocuration,BAO_0000019
3533,,8,F,,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",18065,,,,CHEMBL619200,15413,,,,,H,Autocuration,BAO_0000019
3534,,8,F,,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",18065,,,,CHEMBL619201,15413,,,,,H,Autocuration,BAO_0000019
3535,,8,F,,1,Tested for 5-hydroxytryptamine receptor uptake,18065,,,,CHEMBL619202,12409,,,,,H,Autocuration,BAO_0000019
3536,Homo sapiens,9,B,CHO,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,9606.0,,,CHEMBL619203,16909,,449.0,,,D,Expert,BAO_0000219
3537,Homo sapiens,9,F,,1,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,51,9606.0,,,CHEMBL619204,16909,,,,,D,Expert,BAO_0000019
3538,Homo sapiens,8,B,,1,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,10576,9606.0,,,CHEMBL619205,15629,,,,,H,Autocuration,BAO_0000249
3539,,8,B,,1,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,10576,,,,CHEMBL619206,15629,,,,,H,Autocuration,BAO_0000357
3540,,8,B,,1,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,10576,,,,CHEMBL619207,15629,,,,,H,Expert,BAO_0000249
3541,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10825,,,,CHEMBL619208,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3542,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10825,,,,CHEMBL619209,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3543,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10825,,,,CHEMBL619210,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3544,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,,,CHEMBL619211,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3545,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10825,,,,CHEMBL619212,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3546,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10825,,,,CHEMBL620681,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3547,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10825,,,,CHEMBL620682,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3548,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10825,,,,CHEMBL620683,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3549,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10825,,,,CHEMBL620684,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3550,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,,,CHEMBL620685,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3551,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10825,,,,CHEMBL620686,10034,2435.0,,,Striatum,H,Autocuration,BAO_0000019
3552,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10825,,,,CHEMBL620687,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3553,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,,,CHEMBL620688,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3554,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10825,,,,CHEMBL620689,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3555,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10825,,,,CHEMBL620690,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3556,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10825,,,,CHEMBL620691,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3557,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10825,,,,CHEMBL620692,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3558,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10825,,,,CHEMBL620693,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3559,,8,B,,1,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL620694,1274,,,,,H,Expert,BAO_0000357
3560,,8,F,,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,,CHEMBL857986,17358,,,,,H,Autocuration,BAO_0000019
3561,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,168,,,,CHEMBL620695,14532,,,,,H,Autocuration,BAO_0000357
3562,,8,B,,1,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL620696,16989,,,,,H,Expert,BAO_0000357
3563,,8,B,,1,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,168,,,,CHEMBL620697,17200,,,,,H,Autocuration,BAO_0000357
3564,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 4 receptor,168,,,,CHEMBL620698,15779,,,,,H,Autocuration,BAO_0000357
3565,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,,CHEMBL620699,15779,,,,,H,Autocuration,BAO_0000357
3566,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,,CHEMBL620700,15779,,,,,H,Autocuration,BAO_0000357
3567,,8,B,COS-7,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,168,,,,CHEMBL620701,15650,,643.0,,,H,Autocuration,BAO_0000219
3568,,8,B,COS-7,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,168,,,,CHEMBL875082,15650,,643.0,,,H,Autocuration,BAO_0000219
3569,,8,B,COS-7,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,168,,,,CHEMBL620702,15650,,643.0,,,H,Autocuration,BAO_0000219
3570,,8,B,COS-7,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,168,,,,CHEMBL620703,15650,,643.0,,,H,Autocuration,BAO_0000219
3571,,8,B,C6,1,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,,CHEMBL620704,17046,,673.0,,,H,Autocuration,BAO_0000219
3572,,8,B,C6,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,,CHEMBL620705,17046,,673.0,,,H,Expert,BAO_0000219
3573,,8,B,C6,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,168,,,,CHEMBL620706,15650,,673.0,,,H,Expert,BAO_0000219
3574,,8,B,C6,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,168,,,,CHEMBL620707,17046,,673.0,,,H,Expert,BAO_0000219
3575,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 5 receptor,10624,,,,CHEMBL620708,17066,,,,,H,Expert,BAO_0000357
3576,,8,B,,1,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,105,,,,CHEMBL620709,17200,,,,,H,Autocuration,BAO_0000357
3577,Homo sapiens,9,B,,1,Binding affinity against 5-hydroxytryptamine 5A receptor,10624,9606.0,,,CHEMBL620710,16146,,,,,D,Expert,BAO_0000357
3578,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,10624,,,,CHEMBL620711,15250,,449.0,,,H,Autocuration,BAO_0000219
3579,Homo sapiens,9,B,,1,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,10624,9606.0,,,CHEMBL620712,6491,,,,,D,Expert,BAO_0000357
3580,Homo sapiens,9,B,,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,9606.0,,,CHEMBL620713,17066,,,,,D,Expert,BAO_0000357
3581,Homo sapiens,9,B,,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,10624,9606.0,,,CHEMBL620714,17066,,,,,D,Expert,BAO_0000357
3582,Homo sapiens,9,B,,1,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,10624,9606.0,,,CHEMBL620715,4234,,,,,D,Expert,BAO_0000357
3583,,8,B,,1,Binding affinity towards 5-HT5A receptor,10624,,,,CHEMBL620716,6013,,,,,H,Autocuration,BAO_0000357
3584,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,10624,,,,CHEMBL620717,17175,,,,,H,Expert,BAO_0000357
3585,,8,B,,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,,,CHEMBL618072,15818,,,,,H,Autocuration,BAO_0000357
3586,,8,B,,1,Binding affinity towards cloned human 5-HT5A receptor was determined,10624,,,,CHEMBL857987,6166,,,,,H,Autocuration,BAO_0000357
3587,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10624,,,,CHEMBL618073,15779,,722.0,,,H,Autocuration,BAO_0000219
3588,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10624,,,,CHEMBL618074,15779,,722.0,,,H,Autocuration,BAO_0000219
3589,,8,B,HEK293,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),10624,,,,CHEMBL618075,5213,,722.0,,,H,Autocuration,BAO_0000219
3590,Mus musculus,9,B,,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10625,10090.0,,,CHEMBL618076,17066,,,,,D,Expert,BAO_0000357
3591,Mus musculus,9,B,,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10625,10090.0,,,CHEMBL618077,17066,,,,,D,Expert,BAO_0000357
3592,Mus musculus,9,B,,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10625,10090.0,,,CHEMBL618078,17066,,,,,D,Expert,BAO_0000357
3593,Mus musculus,9,B,,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10625,10090.0,,,CHEMBL881821,17066,,,,,D,Expert,BAO_0000357
3594,Mus musculus,9,B,,1,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10625,10090.0,,,CHEMBL618079,17066,,,,,D,Expert,BAO_0000357
3595,,8,B,,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,10625,,,,CHEMBL618080,17175,,,,,H,Expert,BAO_0000357
3596,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10576,,,,CHEMBL618081,16190,,722.0,,,H,Autocuration,BAO_0000219
3597,,8,B,HEK293,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10626,,,,CHEMBL618082,16190,,722.0,,,H,Autocuration,BAO_0000219
3598,,8,B,,1,Binding affinity towards 5-HT5a receptor,10624,,,,CHEMBL618083,4820,,,,,H,Expert,BAO_0000357
3599,Homo sapiens,9,B,,1,Binding affinity towards 5-hydroxytryptamine 5A receptor,10624,9606.0,,,CHEMBL618084,17066,,,,,D,Expert,BAO_0000357
3600,,8,B,,1,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,10624,,,,CHEMBL618085,17066,,,,,H,Expert,BAO_0000357
3601,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,10624,,,,CHEMBL618086,17175,,,,,H,Expert,BAO_0000357
3602,,8,B,,1,Binding affinities against 5-hydroxytryptamine 5A receptor,10624,,,,CHEMBL875092,16633,,,,,H,Autocuration,BAO_0000357
3603,,8,B,,1,Binding affinities towards 5-hydroxytryptamine 5A receptor,10624,,,,CHEMBL618087,16633,,,,,H,Autocuration,BAO_0000357
3604,,8,B,,1,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,10624,,,,CHEMBL872926,16700,,,,,H,Autocuration,BAO_0000357
3605,Cavia porcellus,4,F,,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,104714,10141.0,,,CHEMBL618088,4639,,,,,H,Autocuration,BAO_0000019
3606,,4,B,,1,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,104714,,,,CHEMBL618089,5486,,,,,H,Autocuration,BAO_0000223
3607,Homo sapiens,9,B,,1,Inhibition of human 5-hydroxytryptamine 6 receptor,10627,9606.0,,,CHEMBL618090,16146,,,,,D,Expert,BAO_0000357
3608,Homo sapiens,9,B,,1,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,10627,9606.0,,,CHEMBL618091,17273,,,,,D,Expert,BAO_0000357
3609,,8,B,,1,Inhibition against human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL618092,17687,,,,,H,Autocuration,BAO_0000357
3610,Homo sapiens,9,B,,1,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,10627,9606.0,,,CHEMBL618093,6491,,,,,D,Expert,BAO_0000357
3611,,8,B,HeLa,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,10627,,,,CHEMBL618094,16190,,308.0,,,H,Expert,BAO_0000219
3612,Homo sapiens,9,B,,1,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,10627,9606.0,,,CHEMBL618095,17066,,,,,D,Expert,BAO_0000357
3613,Homo sapiens,9,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,9606.0,,,CHEMBL875093,17066,,,,,D,Expert,BAO_0000357
3614,Homo sapiens,9,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,10627,9606.0,,,CHEMBL618096,17066,,,,,D,Expert,BAO_0000357
3615,Homo sapiens,9,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,10627,9606.0,,,CHEMBL618118,17066,,,,,D,Expert,BAO_0000357
3616,Homo sapiens,9,B,,1,Binding affinity against 5-hydroxytryptamine 6 receptor,10627,9606.0,,,CHEMBL618119,3555,,,,,D,Expert,BAO_0000357
3617,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL618120,5808,,,,,H,Expert,BAO_0000357
3618,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL618121,6013,,,,,H,Autocuration,BAO_0000357
3619,,8,B,HEK293,1,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",10627,,,,CHEMBL618122,15818,,722.0,,,H,Expert,BAO_0000219
3620,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,10627,,,,CHEMBL618123,16209,,,,,H,Autocuration,BAO_0000357
3621,,8,B,HEK293,1,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,10627,,,,CHEMBL618124,3935,,722.0,,,H,Expert,BAO_0000219
3622,,8,B,,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL618125,15818,,,,,H,Autocuration,BAO_0000357
3623,Homo sapiens,9,B,HEK293,1,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,9606.0,,,CHEMBL618126,3805,,722.0,,,D,Expert,BAO_0000219
3624,,8,B,,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,10627,,,,CHEMBL618236,16441,,,,,H,Expert,BAO_0000019
3625,,8,B,,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10627,,,,CHEMBL618237,16441,,,,,H,Expert,BAO_0000019
3626,,8,B,COS-7,1,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,10627,,,,CHEMBL618238,6786,,643.0,,,H,Expert,BAO_0000219
3627,Homo sapiens,9,B,,1,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,10627,9606.0,,,CHEMBL618239,4234,,,,,D,Expert,BAO_0000357
3628,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL618240,17085,,,,,H,Autocuration,BAO_0000019
3629,,8,B,,1,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,10627,,,,CHEMBL618241,17200,,,,,H,Autocuration,BAO_0000357
3630,,8,B,HEK293,1,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,,,CHEMBL859399,17451,,722.0,,,H,Autocuration,BAO_0000219
3631,,8,F,,1,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,10627,,,,CHEMBL618242,3935,,,,,H,Autocuration,BAO_0000019
3632,,8,B,,1,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL857991,5033,,,,,H,Autocuration,BAO_0000357
3633,,8,B,,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL619951,4540,,,,,H,Expert,BAO_0000357
3634,Homo sapiens,9,B,HeLa,1,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,9606.0,,,CHEMBL619952,4540,,308.0,,,D,Expert,BAO_0000219
3635,Homo sapiens,9,B,HeLa,1,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,9606.0,,,CHEMBL619953,4540,,308.0,,,D,Expert,BAO_0000219
3636,,8,B,HeLa,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,10627,,,,CHEMBL619954,17296,,308.0,,,H,Autocuration,BAO_0000219
3637,,8,B,HeLa,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,,CHEMBL619955,17296,,308.0,,,H,Autocuration,BAO_0000219
3638,,8,B,HeLa,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,,CHEMBL619956,17296,,308.0,,,H,Autocuration,BAO_0000219
3639,,8,B,CHO,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,10627,,,,CHEMBL619957,15779,,449.0,,,H,Autocuration,BAO_0000219
3640,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10627,,,,CHEMBL619958,15779,,722.0,,,H,Autocuration,BAO_0000219
3641,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,10627,,,,CHEMBL620627,15779,,722.0,,,H,Autocuration,BAO_0000219
3642,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10627,,,,CHEMBL620628,15779,,722.0,,,H,Autocuration,BAO_0000219
3643,,8,B,HeLa,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,10627,,,,CHEMBL620629,15779,,308.0,,,H,Autocuration,BAO_0000219
3644,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620630,6166,,,,,H,Autocuration,BAO_0000357
3645,,8,B,HeLa,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,10627,,,,CHEMBL620782,17451,,308.0,,,H,Autocuration,BAO_0000219
3646,,8,B,,1,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620783,15316,,,,,H,Autocuration,BAO_0000357
3647,,8,B,,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620784,4199,,,,,H,Expert,BAO_0000357
3648,,8,B,HeLa,1,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,10627,,,,CHEMBL620785,15146,,308.0,,,H,Expert,BAO_0000219
3649,,8,B,,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),10627,,,,CHEMBL857992,5213,,,,,H,Autocuration,BAO_0000357
3650,,8,B,,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,10627,,,,CHEMBL620786,16429,,,,,H,Autocuration,BAO_0000219
3651,,8,B,HeLa,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,10627,,,,CHEMBL620787,14818,,308.0,,,H,Autocuration,BAO_0000219
3652,,8,B,HeLa,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",10627,,,,CHEMBL620788,4829,,308.0,,,H,Autocuration,BAO_0000219
3653,,8,B,HeLa,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",10627,,,,CHEMBL620789,4829,,308.0,,,H,Autocuration,BAO_0000219
3654,,8,B,HeLa,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",10627,,,,CHEMBL620790,4829,,308.0,,,H,Autocuration,BAO_0000219
3655,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,10628,,,,CHEMBL620791,15250,,449.0,,,H,Autocuration,BAO_0000219
3656,,8,B,,1,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,10628,,,,CHEMBL620792,14423,,,,,H,Autocuration,BAO_0000019
3657,,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,10628,,,,CHEMBL620793,15086,,,,,H,Autocuration,BAO_0000357
3658,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,10628,,,,CHEMBL620794,4342,,,,,H,Autocuration,BAO_0000357
3659,Homo sapiens,9,B,HeLa,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,10627,9606.0,,,CHEMBL620795,16190,,308.0,,,D,Autocuration,BAO_0000219
3660,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620796,4820,,,,,H,Expert,BAO_0000357
3661,,8,B,,1,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,10627,,,,CHEMBL620797,4639,,,,,H,Autocuration,BAO_0000357
3662,Homo sapiens,9,F,,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,9606.0,,,CHEMBL620798,17066,,,,,D,Expert,BAO_0000019
3663,,8,B,,1,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,10627,,,,CHEMBL620799,6011,,,,,H,Autocuration,BAO_0000357
3664,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620800,17066,,,,,H,Expert,BAO_0000357
3665,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,10627,,,,CHEMBL620801,17515,,,,,H,Autocuration,BAO_0000357
3666,,8,B,,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL875100,5014,,,,,H,Autocuration,BAO_0000357
3667,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,10627,,,,CHEMBL620802,4373,,,,,H,Autocuration,BAO_0000357
3668,,8,F,,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620803,17066,,,,,H,Expert,BAO_0000019
3669,,8,F,,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,,,CHEMBL620804,17066,,,,,H,Expert,BAO_0000019
3670,,8,B,,1,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,10627,,,,CHEMBL620805,4373,,,,,H,Autocuration,BAO_0000357
3671,,8,B,,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620806,4687,,,,,H,Autocuration,BAO_0000357
3672,,8,B,,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,10627,,,,CHEMBL620807,16946,,,,,H,Autocuration,BAO_0000357
3673,,8,B,,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,10627,,,,CHEMBL620808,16946,,,,,H,Autocuration,BAO_0000357
3674,,8,B,,1,Binding affinities against 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620809,16633,,,,,H,Autocuration,BAO_0000357
3675,,8,B,,1,Binding affinities towards 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620810,16633,,,,,H,Autocuration,BAO_0000357
3676,Homo sapiens,9,B,,1,Binding affinity towards 5-hydroxytryptamine 6 receptor,10627,9606.0,,,CHEMBL620811,17066,,,,,D,Expert,BAO_0000357
3677,,8,B,,1,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,10627,,,,CHEMBL620812,16700,,,,,H,Autocuration,BAO_0000357
3678,,8,B,,1,Affinity against 5-hydroxytryptamine 6 receptor,10627,,,,CHEMBL620813,3269,,,,,H,Autocuration,BAO_0000357
3679,,8,B,,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],10627,,,,CHEMBL620814,5486,,,,,H,Autocuration,BAO_0000357
3680,Homo sapiens,9,B,,1,Inhibition of human 5-hydroxytryptamine 7 receptor,10209,9606.0,,,CHEMBL620815,16146,,,,,D,Expert,BAO_0000357
3681,,8,B,HEK293,1,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,10209,,,,CHEMBL620816,5014,,722.0,,,H,Autocuration,BAO_0000219
3682,,8,B,,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL620817,15463,,,,,H,Autocuration,BAO_0000357
3683,,8,B,,1,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),10209,,,,CHEMBL620818,3805,,,,,H,Autocuration,BAO_0000357
3684,,8,B,HEK293,1,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,10209,,,,CHEMBL620819,5014,,722.0,,,H,Expert,BAO_0000219
3685,Homo sapiens,9,B,,1,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,10209,9606.0,,,CHEMBL620820,6491,,,,,D,Expert,BAO_0000357
3686,,8,B,CHO,1,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,10209,,,,CHEMBL620821,16190,,449.0,,,H,Autocuration,BAO_0000219
3687,Homo sapiens,9,B,,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,9606.0,,,CHEMBL620822,17066,,,,,D,Expert,BAO_0000357
3688,Homo sapiens,9,B,,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,10209,9606.0,,,CHEMBL620823,17066,,,,,D,Expert,BAO_0000357
3689,Homo sapiens,9,B,,1,Binding affinity against 5-hydroxytryptamine 7 receptor,10209,9606.0,,,CHEMBL620824,3555,,,,,D,Expert,BAO_0000357
3690,,8,B,CHO,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,10209,,,,CHEMBL620825,6588,,449.0,,,H,Expert,BAO_0000219
3691,,8,B,,1,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,10209,,,,CHEMBL872930,15463,,,,,H,Autocuration,BAO_0000357
3692,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL620826,6013,,,,,H,Autocuration,BAO_0000357
3693,,8,B,,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,10209,,,,CHEMBL620827,16209,,,,,H,Autocuration,BAO_0000357
3694,,8,B,,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL620828,3935,,,,,H,Autocuration,BAO_0000357
3695,,8,B,,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL620829,15818,,,,,H,Autocuration,BAO_0000357
3696,,8,B,HEK293,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,10209,,,,CHEMBL620830,5014,,722.0,,,H,Expert,BAO_0000219
3697,,8,B,,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,10209,,,,CHEMBL620831,16441,,,,,H,Expert,BAO_0000019
3698,,8,B,,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10209,,,,CHEMBL620832,16441,,,,,H,Expert,BAO_0000019
3699,Homo sapiens,9,B,,1,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,10209,9606.0,,,CHEMBL621548,4234,,,,,D,Expert,BAO_0000357
3700,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL621549,17085,,,,,H,Autocuration,BAO_0000019
3701,,8,B,,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,10209,,,,CHEMBL621550,17200,,,,,H,Autocuration,BAO_0000357
3702,,8,B,CHO,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,10209,,,,CHEMBL621551,17451,,449.0,,,H,Autocuration,BAO_0000219
3703,,8,B,,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,10209,,,,CHEMBL621552,17085,,,,,H,Autocuration,BAO_0000019
3704,,8,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL857077,5104,,,,,H,Autocuration,BAO_0000357
3705,,8,B,,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,10209,,,,CHEMBL618158,5104,,,,,H,Autocuration,BAO_0000357
3706,Homo sapiens,9,B,COS-7,1,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,9606.0,,,CHEMBL618159,5033,,643.0,,,D,Expert,BAO_0000219
3707,,8,B,COS-7,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,,,CHEMBL875101,5486,,643.0,,,H,Autocuration,BAO_0000219
3708,Homo sapiens,9,B,HEK293,1,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,10209,9606.0,,,CHEMBL618160,4540,,722.0,,,D,Expert,BAO_0000219
3709,,8,B,,1,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,10209,,,,CHEMBL618161,6166,,,,,H,Expert,BAO_0000357
3710,,8,B,HEK293,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,10209,,,,CHEMBL618162,17342,,722.0,,,H,Expert,BAO_0000219
3711,,8,B,,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,10209,,,,CHEMBL618163,17342,,,,,H,Expert,BAO_0000357
3712,,8,B,,1,Binding affinity against 5-hydroxytryptamine 7 human receptors,10209,,,,CHEMBL618164,17296,,,,,H,Autocuration,BAO_0000357
3713,,8,B,,1,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,10209,,,,CHEMBL618165,16429,,,,,H,Expert,BAO_0000219
3714,,8,B,HEK293,1,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,10209,,,,CHEMBL618166,15779,,722.0,,,H,Autocuration,BAO_0000219
3715,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,,CHEMBL857989,15779,,722.0,,,H,Autocuration,BAO_0000219
3716,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,,CHEMBL619888,15779,,722.0,,,H,Autocuration,BAO_0000219
3717,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,,CHEMBL619889,15779,,722.0,,,H,Autocuration,BAO_0000219
3718,,8,B,HEK293,1,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,,CHEMBL619890,15779,,722.0,,,H,Autocuration,BAO_0000219
3719,,8,B,CHO,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,10209,,,,CHEMBL619891,17451,,449.0,,,H,Autocuration,BAO_0000219
3720,,8,B,HEK293,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),10209,,,,CHEMBL619892,4199,,722.0,,,H,Autocuration,BAO_0000219
3721,,9,B,HEK293,1,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,10209,,,,CHEMBL619893,4199,,722.0,,,D,Expert,BAO_0000219
3722,,8,B,HEK293,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),10209,,,,CHEMBL619894,4199,,722.0,,,H,Autocuration,BAO_0000219
3723,,9,B,HEK293,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,10209,,,,CHEMBL619895,3680,,722.0,,,D,Intermediate,BAO_0000219
3724,,9,B,,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,10209,,,,CHEMBL619896,3680,,,,,D,Intermediate,BAO_0000357
3725,,8,B,COS-7,1,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,10209,,,,CHEMBL619897,15316,,643.0,,,H,Autocuration,BAO_0000219
3726,,8,B,HEK293,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,10209,,,,CHEMBL619898,15146,,722.0,,,H,Autocuration,BAO_0000219
3727,,8,B,HEK293,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,10209,,,,CHEMBL619899,5213,,722.0,,,H,Expert,BAO_0000219
3728,,8,B,HEK293,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),10209,,,,CHEMBL619900,5213,,722.0,,,H,Autocuration,BAO_0000219
3729,Homo sapiens,9,B,HEK293,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,10209,9606.0,,,CHEMBL619901,14818,,722.0,,,D,Expert,BAO_0000219
3730,,8,B,HEK293,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,10209,,,,CHEMBL620580,14818,,722.0,,,H,Autocuration,BAO_0000219
3731,,8,B,HEK293,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,10209,,,,CHEMBL620581,14818,,722.0,,,H,Autocuration,BAO_0000219
3732,,8,B,HEK293,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",10209,,,,CHEMBL620733,4829,,722.0,,,H,Autocuration,BAO_0000219
3733,Homo sapiens,9,B,,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,10209,9606.0,,,CHEMBL620734,17200,,,,,D,Autocuration,BAO_0000357
3734,Mus musculus,9,B,,1,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10022,10090.0,,,CHEMBL620735,17066,,,,,D,Expert,BAO_0000357
3735,Oryctolagus cuniculus,8,B,,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,10209,9986.0,,,CHEMBL620736,14025,,,,,H,Autocuration,BAO_0000019
3736,,8,B,CHO,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,11923,,,,CHEMBL620737,15250,,449.0,,,H,Autocuration,BAO_0000219
3737,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,11923,,,,CHEMBL620738,16372,,449.0,,,H,Autocuration,BAO_0000219
3738,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,11923,,,,CHEMBL620739,16372,,449.0,,,H,Autocuration,BAO_0000219
3739,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,11923,,,,CHEMBL620740,16372,,449.0,,,H,Autocuration,BAO_0000219
3740,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,11923,,,,CHEMBL620741,16372,,449.0,,,H,Autocuration,BAO_0000219
3741,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,11923,,,,CHEMBL620742,16372,,449.0,,,H,Autocuration,BAO_0000219
3742,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,11923,,,,CHEMBL620743,16372,,449.0,,,H,Autocuration,BAO_0000219
3743,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,11923,,,,CHEMBL620744,16372,,449.0,,,H,Autocuration,BAO_0000219
3744,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,11923,,,,CHEMBL620745,16372,,449.0,,,H,Autocuration,BAO_0000219
3745,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,11923,,,,CHEMBL620746,16372,,449.0,,,H,Autocuration,BAO_0000219
3746,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,11923,,,,CHEMBL620747,16372,,449.0,,,H,Autocuration,BAO_0000219
3747,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,11923,,,,CHEMBL620748,16372,,449.0,,,H,Autocuration,BAO_0000219
3748,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,11923,,,,CHEMBL620749,16372,,449.0,,,H,Autocuration,BAO_0000219
3749,,8,B,,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,11923,,,,CHEMBL620750,17066,,,,,H,Expert,BAO_0000357
3750,Rattus norvegicus,9,B,,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,11923,10116.0,,,CHEMBL620751,17066,,,,,D,Expert,BAO_0000357
3751,,8,B,,1,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,11923,,,,CHEMBL620752,17386,,,,,H,Expert,BAO_0000357
3752,,8,B,,1,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,11923,,,,CHEMBL872929,14423,,,,,H,Autocuration,BAO_0000019
3753,Rattus norvegicus,9,B,,1,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,11923,10116.0,,,CHEMBL620753,15874,,,,,D,Expert,BAO_0000357
3754,Rattus norvegicus,9,B,,1,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,11923,10116.0,,,CHEMBL620754,15874,,,,,D,Expert,BAO_0000357
3755,Rattus norvegicus,9,B,CHO,1,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,11923,10116.0,,,CHEMBL620755,16372,,449.0,,,D,Expert,BAO_0000219
3756,,8,B,,1,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,11923,,,,CHEMBL620756,4622,,,,,H,Autocuration,BAO_0000357
3757,,8,B,,1,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,11923,,,,CHEMBL620757,15086,,,,,H,Autocuration,BAO_0000357
3758,,8,B,CHO,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",11923,,,,CHEMBL620758,16372,,449.0,,,H,Autocuration,BAO_0000219
3759,,8,B,CHO,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",11923,,,,CHEMBL620759,16372,,449.0,,,H,Autocuration,BAO_0000219
3760,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,11923,,,,CHEMBL620760,16372,,449.0,,,H,Autocuration,BAO_0000219
3761,,8,B,CHO,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,11923,,,,CHEMBL620761,16372,,449.0,,,H,Autocuration,BAO_0000219
3762,,8,F,,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,11923,,,,CHEMBL620762,17386,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3763,,8,F,,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,11923,,,,CHEMBL620763,17386,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3764,,8,F,,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,11923,,,,CHEMBL620764,17386,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3765,Rattus norvegicus,9,B,,1,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,11923,10116.0,Membranes,,CHEMBL857990,5831,,,,,D,Expert,BAO_0000249
3766,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,11923,,,,CHEMBL620765,4342,,,,,H,Autocuration,BAO_0000357
3767,,8,B,,1,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,11923,,,,CHEMBL620766,17319,,,,,H,Expert,BAO_0000357
3768,,8,B,,1,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,11923,,,,CHEMBL620767,17342,1898.0,,,Hypothalamus,H,Expert,BAO_0000019
3769,,8,B,,1,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,11923,,,,CHEMBL620768,17342,,,,,H,Autocuration,BAO_0000357
3770,,8,B,,1,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,11923,,,,CHEMBL619051,3680,1898.0,,,Hypothalamus,H,Expert,BAO_0000249
3771,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,11923,,,,CHEMBL619052,3680,,,,,H,Expert,BAO_0000357
3772,Rattus norvegicus,9,F,HEK293,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,11923,10116.0,,,CHEMBL619053,17319,,722.0,,,D,Expert,BAO_0000219
3773,Rattus norvegicus,9,F,HEK293,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,11923,10116.0,,,CHEMBL619703,17319,,722.0,,,D,Expert,BAO_0000219
3774,Rattus norvegicus,9,F,HEK293,1,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,11923,10116.0,,,CHEMBL619704,17319,,722.0,,,D,Autocuration,BAO_0000219
3775,,8,B,,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL619851,4820,,,,,H,Expert,BAO_0000357
3776,,8,B,,1,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,10209,,,,CHEMBL619852,4639,,,,,H,Autocuration,BAO_0000357
3777,,8,B,,1,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,10209,,,,CHEMBL619853,6011,,,,,H,Autocuration,BAO_0000357
3778,Homo sapiens,9,B,,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,9606.0,,,CHEMBL619854,17066,,,,,D,Expert,BAO_0000357
3779,,8,B,,1,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL619855,17066,,,,,H,Expert,BAO_0000357
3780,,8,B,,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,10209,,,,CHEMBL619856,17515,,,,,H,Autocuration,BAO_0000357
3781,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,,,CHEMBL619857,4373,,,,,H,Autocuration,BAO_0000357
3782,,8,F,,1,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,10209,,,,CHEMBL619858,17066,,,,,H,Expert,BAO_0000019
3783,,8,B,,1,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,10209,,,,CHEMBL619859,4373,,,,,H,Autocuration,BAO_0000357
3784,,8,B,,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,,,CHEMBL619860,4373,,,,,H,Autocuration,BAO_0000357
3785,,8,B,,1,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL619861,4687,,,,,H,Autocuration,BAO_0000357
3786,,8,B,,1,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL619862,17342,,,,,H,Expert,BAO_0000357
3787,,8,B,,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,10209,,,,CHEMBL619863,16946,,,,,H,Autocuration,BAO_0000357
3788,,8,B,,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,10209,,,,CHEMBL619864,16946,,,,,H,Autocuration,BAO_0000357
3789,,8,B,,1,Binding affinities against 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL872928,16633,,,,,H,Autocuration,BAO_0000357
3790,,8,B,,1,Binding affinities towards 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL619865,16633,,,,,H,Autocuration,BAO_0000357
3791,,8,B,,1,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,10209,,,,CHEMBL619866,17066,,,,,H,Expert,BAO_0000357
3792,,8,B,,1,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,10209,,,,CHEMBL619867,16700,,,,,H,Autocuration,BAO_0000357
3793,,8,B,,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,10209,,,,CHEMBL619868,17386,2116.0,,,Ileum,H,Autocuration,BAO_0000221
3794,,8,F,,1,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,55,,,,CHEMBL619869,14080,,,,,H,Autocuration,BAO_0000019
3795,Homo sapiens,9,F,,1,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,55,9606.0,,,CHEMBL619870,14080,,,,,D,Expert,BAO_0000019
3796,,8,B,,1,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,55,,,,CHEMBL619871,409,,,,,H,Autocuration,BAO_0000357
3797,,8,B,,1,In vitro inhibition of human recombinant lipoxygenase enzyme,55,,,,CHEMBL619872,409,,,,,H,Autocuration,BAO_0000357
3798,,8,B,,1,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,55,,,,CHEMBL619873,409,,,,,H,Autocuration,BAO_0000357
3799,,8,B,,1,Inhibition of 5-lipoxygenase in human whole blood.,55,,,,CHEMBL619874,11090,178.0,,,Blood,H,Expert,BAO_0000357
3800,,8,B,,1,Inhibition of 5-lipoxygenase in human whole blood.,55,,,,CHEMBL619875,11090,178.0,,,Blood,H,Expert,BAO_0000357
3801,,8,B,,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,55,,,,CHEMBL619876,948,,,,,H,Autocuration,BAO_0000357
3802,,8,B,,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),55,,,,CHEMBL619877,948,,,,,H,Autocuration,BAO_0000357
3803,,8,F,,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,55,,,,CHEMBL619878,13622,,,,,H,Expert,BAO_0000219
3804,,8,F,,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,55,,,,CHEMBL619879,13622,178.0,,,Blood,H,Autocuration,BAO_0000019
3805,,8,B,,1,In vitro inhibition of 5-lipoxygenase from human polymorphs,55,,,,CHEMBL619880,9637,,,,,H,Autocuration,BAO_0000357
3806,,8,B,,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),55,,,,CHEMBL619881,11320,,,,,H,Autocuration,BAO_0000357
3807,,8,B,,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,55,,,,CHEMBL619882,11320,,,,,H,Expert,BAO_0000357
3808,,8,B,,1,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,55,,,,CHEMBL619883,6838,,,,,H,Autocuration,BAO_0000357
3809,Homo sapiens,9,B,,1,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),55,9606.0,,,CHEMBL619884,17667,178.0,,,Blood,D,Expert,BAO_0000357
3810,,8,B,,1,In vitro potency against human 5-Lipoxygenase,55,,,,CHEMBL619885,12703,,,,,H,Autocuration,BAO_0000357
3811,Homo sapiens,9,F,,1,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,55,9606.0,,,CHEMBL619886,14312,,,,,D,Expert,BAO_0000019
3812,,8,F,,1,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,55,,,,CHEMBL619887,14312,178.0,,,Blood,H,Autocuration,BAO_0000019
3813,,8,F,,1,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,,,CHEMBL875097,5364,,,,,H,Autocuration,BAO_0000019
3814,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,55,,,,CHEMBL618001,951,,,,,H,Autocuration,BAO_0000219
3815,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,55,,,,CHEMBL618002,951,,,,,H,Autocuration,BAO_0000219
3816,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,55,,,,CHEMBL618003,951,,,,,H,Autocuration,BAO_0000219
3817,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,55,,,,CHEMBL618004,951,,,,,H,Autocuration,BAO_0000219
3818,,8,B,,1,Inhibition of human 5-lipoxygenase in human cells,55,,,,CHEMBL618005,12365,,,,,H,Autocuration,BAO_0000219
3819,,8,B,,1,Inhibition of human neutrophil 5-lipoxygenase,55,,,,CHEMBL618006,10603,,,,,H,Expert,BAO_0000357
3820,,8,B,,1,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,55,,,,CHEMBL875086,10501,,,,,H,Autocuration,BAO_0000019
3821,,8,B,,1,Inhibition of 5-lipoxygenase from human whole blood,55,,,,CHEMBL618007,12281,178.0,,,Blood,H,Expert,BAO_0000357
3822,,8,B,,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,,,CHEMBL618008,2567,,,,,H,Autocuration,BAO_0000357
3823,,8,B,,1,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,55,,,,CHEMBL618009,2567,,,,,H,Autocuration,BAO_0000219
3824,,8,B,,1,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,55,,,,CHEMBL618010,10193,,,,,H,Expert,BAO_0000357
3825,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,,CHEMBL618011,10193,,,,,H,Autocuration,BAO_0000357
3826,,8,B,,1,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,55,,,,CHEMBL618012,13623,,,,,H,Expert,BAO_0000357
3827,,8,B,,1,Tested against 5-lipoxygenase,55,,,,CHEMBL882927,12780,,,,,H,Autocuration,BAO_0000357
3828,,8,B,,1,Tested for activity against 5-Lipoxygenase (5-LO),55,,,,CHEMBL618013,12780,,,,,H,Autocuration,BAO_0000357
3829,,8,B,,1,Tested for activity against 5-lipoxygenase,55,,,,CHEMBL618014,12780,,,,,H,Autocuration,BAO_0000357
3830,,8,B,,1,Tested for inhibition of 5-HPETE production by human 5-LO,55,,,,CHEMBL618015,11966,,,,,H,Autocuration,BAO_0000357
3831,,8,F,,1,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,,,CHEMBL618016,5364,,,,,H,Autocuration,BAO_0000019
3832,,8,B,,1,Inhibition of Human 5-lipoxygenase,55,,,,CHEMBL618017,13165,,,,,H,Expert,BAO_0000357
3833,,8,B,,1,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,55,,,,CHEMBL618018,5364,,,,,H,Autocuration,BAO_0000019
3834,,8,B,,1,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,,,CHEMBL875087,11311,,,,,H,Autocuration,BAO_0000219
3835,,8,B,,1,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],55,,,,CHEMBL618019,11311,,,,,H,Autocuration,BAO_0000219
3836,,8,B,,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,55,,,,CHEMBL618020,14863,,,,,H,Autocuration,BAO_0000019
3837,,8,B,,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,55,,,,CHEMBL618021,14863,,,,,H,Autocuration,BAO_0000019
3838,,8,B,,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),55,,,,CHEMBL618022,11087,178.0,,,Blood,H,Autocuration,BAO_0000357
3839,,8,B,,1,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,55,,,,CHEMBL618023,455,,,,,H,Autocuration,BAO_0000357
3840,,8,B,,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,,CHEMBL618024,13183,,,,,H,Autocuration,BAO_0000357
3841,,8,B,,1,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,55,,,,CHEMBL873950,10319,,,,,H,Expert,BAO_0000019
3842,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,,CHEMBL618025,10193,,,,,H,Autocuration,BAO_0000357
3843,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,55,,,,CHEMBL618026,951,,,,,H,Autocuration,BAO_0000219
3844,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,55,,,,CHEMBL618027,951,,,,,H,Autocuration,BAO_0000219
3845,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,55,,,,CHEMBL618028,951,,,,,H,Autocuration,BAO_0000219
3846,,8,B,,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,55,,,,CHEMBL618029,951,,,,,H,Autocuration,BAO_0000219
3847,,8,B,,1,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,55,,,,CHEMBL618030,9859,,,,,H,Expert,BAO_0000357
3848,,8,B,,1,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,55,,,,CHEMBL618031,9859,,,,,H,Expert,BAO_0000357
3849,,8,B,,1,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,55,,,,CHEMBL618032,9859,,,,,H,Autocuration,BAO_0000357
3850,,8,B,,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,,,CHEMBL618033,2567,,,,,H,Autocuration,BAO_0000357
3851,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,55,,,,CHEMBL618034,10193,,,,,H,Autocuration,BAO_0000357
3852,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,,CHEMBL875088,10193,,,,,H,Autocuration,BAO_0000357
3853,,8,B,,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,55,,,,CHEMBL618035,949,,,,,H,Autocuration,BAO_0000019
3854,,8,B,,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,55,,,,CHEMBL618036,949,,,,,H,Autocuration,BAO_0000019
3855,,8,B,,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,55,,,,CHEMBL618037,10603,,,,,H,Expert,BAO_0000357
3856,,8,B,,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,,,CHEMBL618038,10603,,,,,H,Expert,BAO_0000357
3857,,8,F,,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,,,CHEMBL618761,10603,,,,,H,Autocuration,BAO_0000019
3858,,8,B,,1,Inhibition of lipoxygenase at the concentration of 0.1 uM,55,,,,CHEMBL618762,10603,,,,,H,Expert,BAO_0000357
3859,,8,B,,1,Inhibition of lipoxygenase at the concentration of 1 uM,55,,,,CHEMBL618763,10603,,,,,H,Expert,BAO_0000357
3860,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,55,,,,CHEMBL618764,10193,,,,,H,Autocuration,BAO_0000357
3861,Homo sapiens,9,B,,1,Inhibition of 5-Lipoxygenase (5-LOX),55,9606.0,,,CHEMBL618765,14580,,,,,D,Expert,BAO_0000357
3862,,8,B,,1,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,,,CHEMBL618766,11090,,,,,H,Expert,BAO_0000357
3863,,8,B,,1,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,,,CHEMBL618767,11090,,,,,H,Expert,BAO_0000357
3864,,8,B,,1,Inhibitory activity against lipoxygenase-2 in mice,17087,,,,CHEMBL619380,6339,,,,,H,Autocuration,BAO_0000357
3865,,8,B,,1,Inhibitory activity against murine lipoxygenase-2.,17087,,,,CHEMBL619381,6339,,,,,H,Expert,BAO_0000357
3866,Mus musculus,9,B,,1,Inhibition of 5-lipoxygenase from mouse macrophage,17087,10090.0,,,CHEMBL619382,12281,,,,,D,Expert,BAO_0000357
3867,,8,B,,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,17087,,,,CHEMBL619383,11311,,,,,H,Autocuration,BAO_0000357
3868,Sus scrofa,8,B,,1,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,9823.0,,,CHEMBL619384,11089,,,,,H,Autocuration,BAO_0000019
3869,Sus scrofa,8,B,,1,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,55,9823.0,,,CHEMBL619385,10091,,,,,H,Autocuration,BAO_0000019
3870,Oryctolagus cuniculus,8,B,,1,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,55,9986.0,,,CHEMBL882928,14352,,,,,H,Autocuration,BAO_0000019
3871,Rattus norvegicus,9,B,,1,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,12166,10116.0,,,CHEMBL619386,13329,,,,,D,Expert,BAO_0000019
3872,,8,B,,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",12166,,,,CHEMBL619387,13329,,,,,H,Autocuration,BAO_0000019
3873,,8,B,,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,,,CHEMBL619388,13329,,,,,H,Autocuration,BAO_0000019
3874,,8,B,,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",12166,,,,CHEMBL619389,13329,,,,,H,Autocuration,BAO_0000019
3875,,8,B,,1,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),12166,,,,CHEMBL619390,13329,,,,,H,Expert,BAO_0000019
3876,,8,B,,1,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",12166,,,,CHEMBL619391,13329,,,,,H,Expert,BAO_0000019
3877,,8,B,,1,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,12166,,,,CHEMBL619392,13329,,,,,H,Autocuration,BAO_0000019
3878,,8,B,,1,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),12166,,,,CHEMBL619393,11311,,,,,H,Autocuration,BAO_0000019
3879,,8,B,,1,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,12166,,,,CHEMBL619394,11311,,,,,H,Autocuration,BAO_0000019
3880,,8,B,RBL-1,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,,,CHEMBL619395,105,,702.0,,,H,Autocuration,BAO_0000219
3881,,8,B,RBL-1,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,,,CHEMBL619396,105,,702.0,,,H,Autocuration,BAO_0000219
3882,,8,B,,1,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),12166,,,,CHEMBL619397,9138,,,,,H,Autocuration,BAO_0000357
3883,,8,B,,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",12166,,,,CHEMBL619398,9138,,,,,H,Autocuration,BAO_0000357
3884,,8,B,,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",12166,,,,CHEMBL619399,9138,,,,,H,Autocuration,BAO_0000357
3885,,8,B,,1,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,,,CHEMBL619400,14427,,,,,H,Autocuration,BAO_0000357
3886,,8,B,,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,,,CHEMBL619401,13329,,,,,H,Autocuration,BAO_0000019
3887,,8,B,,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",12166,,,,CHEMBL619402,13329,,,,,H,Autocuration,BAO_0000019
3888,Rattus norvegicus,9,B,RBL-2H3,1,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,12166,10116.0,,,CHEMBL619403,14427,,663.0,,,D,Expert,BAO_0000219
3889,,8,B,,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,,,CHEMBL619404,14427,,,,,H,Autocuration,BAO_0000357
3890,,8,B,,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,12166,,,,CHEMBL619405,14427,,,,,H,Autocuration,BAO_0000357
3891,,8,B,RBL-1,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,12166,,,,CHEMBL619406,10293,,702.0,,,H,Expert,BAO_0000219
3892,Rattus norvegicus,9,B,RBL-1,1,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,12166,10116.0,,,CHEMBL619407,338,,702.0,,,D,Expert,BAO_0000219
3893,,8,B,,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),12166,,,,CHEMBL619408,303,,,,,H,Autocuration,BAO_0000357
3894,,8,B,RBL-1,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,12166,,,,CHEMBL619409,303,,702.0,,,H,Autocuration,BAO_0000219
3895,,8,B,RBL-1,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,12166,,,,CHEMBL619410,9247,,702.0,,,H,Expert,BAO_0000219
3896,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,,,CHEMBL619753,9247,,702.0,,,H,Autocuration,BAO_0000219
3897,,8,B,RBL-1,1,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,12166,,,,CHEMBL619754,137,,702.0,,,H,Autocuration,BAO_0000219
3898,,8,B,,1,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,12166,,,,CHEMBL619903,11481,,,,,H,Expert,BAO_0000357
3899,,8,B,,1,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",12166,,,,CHEMBL619904,11481,,,,,H,Expert,BAO_0000357
3900,,8,B,,1,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,12166,,,,CHEMBL619905,9029,,,,,H,Expert,BAO_0000357
3901,,8,B,,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,12166,,,,CHEMBL619906,1701,,,,,H,Autocuration,BAO_0000019
3902,,8,B,,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,12166,,,,CHEMBL619907,1701,,,,,H,Autocuration,BAO_0000019
3903,,8,B,,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,12166,,,,CHEMBL619908,1701,,,,,H,Autocuration,BAO_0000019
3904,,8,B,,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,12166,,,,CHEMBL619909,1701,,,,,H,Autocuration,BAO_0000019
3905,,8,F,RBL-1,1,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,12166,,,,CHEMBL619910,13358,,702.0,,,H,Expert,BAO_0000219
3906,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,12166,,,,CHEMBL882929,1175,,702.0,,,H,Expert,BAO_0000219
3907,,8,B,RBL-1,1,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,12166,,,,CHEMBL619911,8797,,702.0,,,H,Expert,BAO_0000219
3908,,8,B,,1,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,12166,,,,CHEMBL619912,8797,,,,,H,Autocuration,BAO_0000019
3909,Rattus norvegicus,9,B,,1,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,12166,10116.0,,,CHEMBL619913,577,,,,,D,Expert,BAO_0000357
3910,,8,B,RBL-1,1,In vitro inhibitory activity against RBL-1 5-LO,12166,,,,CHEMBL619914,9295,,702.0,,,H,Expert,BAO_0000219
3911,,8,B,RBL-1,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),12166,,,,CHEMBL619915,9295,,702.0,,,H,Autocuration,BAO_0000219
3912,,8,B,RBL-1,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),12166,,,,CHEMBL619916,9295,,702.0,,,H,Autocuration,BAO_0000219
3913,,8,B,,1,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,12166,,,,CHEMBL619917,9295,,,,,H,Autocuration,BAO_0000218
3914,,8,B,,1,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,12166,,,,CHEMBL619918,9295,,,,,H,Autocuration,BAO_0000357
3915,,8,B,,1,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,12166,,,,CHEMBL619919,216,,,,,H,Autocuration,BAO_0000218
3916,,8,B,RBL-1,1,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,12166,,,,CHEMBL883710,11090,,702.0,,,H,Autocuration,BAO_0000219
3917,,8,B,,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,12166,,,,CHEMBL619920,11090,178.0,,,Blood,H,Autocuration,BAO_0000019
3918,,8,B,,1,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,12166,,,,CHEMBL619921,10091,,,,,H,Expert,BAO_0000357
3919,,8,F,,1,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,12166,,,,CHEMBL619922,10274,,,,,H,Autocuration,BAO_0000019
3920,,8,F,,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,12166,,,,CHEMBL619923,13622,,,,,H,Autocuration,BAO_0000219
3921,,8,B,RBL-1,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12166,,,,CHEMBL619924,12118,,702.0,,,H,Expert,BAO_0000219
3922,,8,B,,1,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12166,,,,CHEMBL619925,12576,,,,,H,Expert,BAO_0000357
3923,,8,B,RBL-1,1,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,12166,,,,CHEMBL619926,9546,,702.0,,,H,Expert,BAO_0000219
3924,,8,B,RBL-1,1,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,12166,,,,CHEMBL619927,9521,,702.0,,,H,Autocuration,BAO_0000219
3925,,8,B,RBL-1,1,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,12166,,,,CHEMBL619928,10626,,702.0,,,H,Expert,BAO_0000219
3926,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase,12166,,,,CHEMBL619929,9225,,702.0,,,H,Autocuration,BAO_0000219
3927,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,12166,,,,CHEMBL875089,9225,,702.0,,,H,Autocuration,BAO_0000219
3928,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,12166,,,,CHEMBL619930,9225,,702.0,,,H,Autocuration,BAO_0000219
3929,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,12166,,,,CHEMBL619931,9225,,702.0,,,H,Autocuration,BAO_0000219
3930,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,12166,,,,CHEMBL619932,9225,,702.0,,,H,Autocuration,BAO_0000219
3931,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,12166,,,,CHEMBL619933,9225,,702.0,,,H,Autocuration,BAO_0000219
3932,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,12166,,,,CHEMBL619934,9225,,702.0,,,H,Autocuration,BAO_0000219
3933,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,12166,,,,CHEMBL619935,9225,,702.0,,,H,Autocuration,BAO_0000219
3934,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,12166,,,,CHEMBL619936,9225,,702.0,,,H,Autocuration,BAO_0000219
3935,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,12166,,,,CHEMBL619937,9225,,702.0,,,H,Autocuration,BAO_0000219
3936,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,12166,,,,CHEMBL619938,9225,,702.0,,,H,Autocuration,BAO_0000219
3937,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,12166,,,,CHEMBL619939,9225,,702.0,,,H,Autocuration,BAO_0000219
3938,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,12166,,,,CHEMBL619940,9225,,702.0,,,H,Autocuration,BAO_0000219
3939,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,12166,,,,CHEMBL875090,9225,,702.0,,,H,Autocuration,BAO_0000219
3940,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,12166,,,,CHEMBL619941,9225,,702.0,,,H,Autocuration,BAO_0000219
3941,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,12166,,,,CHEMBL619942,9225,,702.0,,,H,Autocuration,BAO_0000219
3942,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,12166,,,,CHEMBL883711,9225,,702.0,,,H,Autocuration,BAO_0000219
3943,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,12166,,,,CHEMBL619943,9225,,702.0,,,H,Autocuration,BAO_0000219
3944,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,12166,,,,CHEMBL619944,9225,,702.0,,,H,Autocuration,BAO_0000219
3945,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,12166,,,,CHEMBL619945,9225,,702.0,,,H,Autocuration,BAO_0000219
3946,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,12166,,,,CHEMBL619946,9225,,702.0,,,H,Autocuration,BAO_0000219
3947,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,12166,,,,CHEMBL619947,9225,,702.0,,,H,Autocuration,BAO_0000219
3948,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,12166,,,,CHEMBL619948,9225,,702.0,,,H,Autocuration,BAO_0000219
3949,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,12166,,,,CHEMBL619949,9225,,702.0,,,H,Autocuration,BAO_0000219
3950,,8,B,,1,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,12166,,,,CHEMBL619950,9401,,,,,H,Expert,BAO_0000019
3951,,8,B,,1,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,12166,,,,CHEMBL618050,10325,,,,,H,Autocuration,BAO_0000019
3952,,8,F,RBL-2H3,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,12166,,,,CHEMBL875091,1556,,663.0,,,H,Expert,BAO_0000219
3953,,8,F,RBL-2H3,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,12166,,,,CHEMBL618051,1556,,663.0,,,H,Expert,BAO_0000219
3954,Rattus norvegicus,9,B,RBL-1,1,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,12166,10116.0,,,CHEMBL618052,961,,702.0,,,D,Expert,BAO_0000219
3955,,8,B,,1,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,12166,,,,CHEMBL618053,6838,,,,,H,Autocuration,BAO_0000019
3956,,8,B,,1,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),12166,,,,CHEMBL618054,10325,,,,,H,Expert,BAO_0000019
3957,Rattus norvegicus,9,B,RBL-1,1,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,10116.0,,,CHEMBL618055,9209,,702.0,,,D,Expert,BAO_0000219
3958,,8,B,RBL-1,1,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,12166,,,,CHEMBL618056,11520,,702.0,,,H,Expert,BAO_0000219
3959,,8,B,,1,In vitro inhibitory activity against 5-lipoxygenase was determined,12166,,,,CHEMBL618057,137,,,,,H,Autocuration,BAO_0000357
3960,,8,B,RBL-1,1,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,12166,,,,CHEMBL618058,4717,,702.0,,,H,Autocuration,BAO_0000219
3961,,8,B,RBL-1,1,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,12166,,,,CHEMBL618059,10636,,702.0,,,H,Expert,BAO_0000219
3962,Rattus norvegicus,9,F,,1,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,12166,10116.0,,,CHEMBL618060,14312,,,,,D,Expert,BAO_0000019
3963,,8,B,RBL-1,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,12166,,,,CHEMBL618061,1203,,702.0,,,H,Autocuration,BAO_0000219
3964,,8,B,,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,12166,,,,CHEMBL618062,1203,,,,,H,Autocuration,BAO_0000019
3965,,8,B,RBL-1,1,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,12166,,,,CHEMBL618063,13622,,702.0,,,H,Expert,BAO_0000219
3966,,8,B,,1,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,12166,,,,CHEMBL618064,9793,,,,,H,Autocuration,BAO_0000357
3967,Rattus norvegicus,9,B,RBL-1,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,12166,10116.0,,,CHEMBL618065,1143,,702.0,,,D,Expert,BAO_0000219
3968,Rattus norvegicus,9,B,RBL-1,1,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,12166,10116.0,,,CHEMBL618066,11854,,702.0,,,D,Expert,BAO_0000219
3969,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,,CHEMBL618067,3595,,702.0,,,H,Autocuration,BAO_0000219
3970,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,,,CHEMBL618068,3595,,702.0,,,H,Autocuration,BAO_0000219
3971,Rattus norvegicus,9,B,RBL-1,1,Inhibition of 5-lipoxygenase in rat RBL-1 cells,12166,10116.0,,,CHEMBL618069,10501,,702.0,,,D,Expert,BAO_0000219
3972,,8,B,RBL-1,1,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,,CHEMBL618070,12526,,702.0,,,H,Expert,BAO_0000219
3973,,8,F,,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10825,,,,CHEMBL618071,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3974,,8,F,,1,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,,,CHEMBL619247,10034,349.0,,,Limbic system,H,Autocuration,BAO_0000019
3975,,8,F,,1,Approximate dose levels for a half maximal reduction of 5-HTP levels,10825,,,,CHEMBL619248,10034,,,,,H,Autocuration,BAO_0000019
3976,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,,,CHEMBL619249,10046,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
3977,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,,,CHEMBL619250,10046,10000000.0,,,Hippocampus,H,Autocuration,BAO_0000221
3978,,8,B,,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,,,CHEMBL619251,10046,,,,,H,Autocuration,BAO_0000019
3979,Canis lupus familiaris,8,F,,1,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,55,9615.0,,,CHEMBL619252,12079,178.0,,,Blood,H,Autocuration,BAO_0000019
3980,,8,F,,1,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,55,,,,CHEMBL619253,12079,178.0,,,Blood,H,Autocuration,BAO_0000019
3981,,8,B,,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,,,CHEMBL619254,11311,,,,,H,Autocuration,BAO_0000219
3982,,8,B,,1,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,17140,,,,CHEMBL619255,12338,,,,,H,Expert,BAO_0000219
3983,,8,B,,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,17140,,,,CHEMBL619256,12143,,,,,H,Expert,BAO_0000219
3984,,8,B,,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),17140,,,,CHEMBL875418,12143,,,,,H,Autocuration,BAO_0000219
3985,,8,B,,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,,,CHEMBL619257,12143,,,,,H,Expert,BAO_0000219
3986,,8,B,,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,,,CHEMBL619258,12143,,,,,H,Autocuration,BAO_0000219
3987,,8,B,,1,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,17140,,,,CHEMBL619259,12365,,,,,H,Expert,BAO_0000357
3988,,8,B,,1,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,17140,,,,CHEMBL619260,13500,,,,,H,Expert,BAO_0000357
3989,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619261,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3990,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619263,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3991,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619264,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3992,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619265,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3993,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619266,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3994,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619902,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3995,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620058,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3996,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620059,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3997,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620060,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3998,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620061,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
3999,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",55,9615.0,,,CHEMBL620062,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4000,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620063,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4001,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",55,9615.0,,,CHEMBL620064,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4002,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620065,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4003,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",55,9615.0,,,CHEMBL620066,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4004,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620067,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4005,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",55,9615.0,,,CHEMBL620068,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4006,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620069,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4007,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",55,9615.0,,,CHEMBL620070,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4008,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620071,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4009,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",55,9615.0,,,CHEMBL620072,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4010,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620036,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4011,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",55,9615.0,,,CHEMBL857702,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4012,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620037,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4013,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",55,9615.0,,,CHEMBL620038,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4014,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620039,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4015,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",55,9615.0,,,CHEMBL620040,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4016,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620041,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4017,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",55,9615.0,,,CHEMBL620042,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4018,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620043,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4019,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",55,9615.0,,,CHEMBL620044,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4020,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620045,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4021,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",55,9615.0,,,CHEMBL620046,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4022,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620047,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4023,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",55,9615.0,,,CHEMBL620048,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4024,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL857703,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4025,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",55,9615.0,,,CHEMBL620049,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4026,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620050,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4027,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL620051,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4028,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619213,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4029,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619214,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4030,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619804,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4031,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619805,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4032,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619806,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4033,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619807,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4034,Canis lupus familiaris,8,F,,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,9615.0,,,CHEMBL619808,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4035,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,55,9615.0,,,CHEMBL619809,3595,,,,,H,Autocuration,BAO_0000218
4036,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,55,9615.0,,,CHEMBL619810,3595,,,,,H,Autocuration,BAO_0000218
4037,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,55,9615.0,,,CHEMBL619811,3595,,,,,H,Autocuration,BAO_0000218
4038,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,55,9615.0,,,CHEMBL620769,3595,,,,,H,Autocuration,BAO_0000218
4039,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,55,9615.0,,,CHEMBL620770,3595,,,,,H,Autocuration,BAO_0000218
4040,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,55,9615.0,,,CHEMBL620771,3595,,,,,H,Autocuration,BAO_0000218
4041,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,55,9615.0,,,CHEMBL620772,3595,,,,,H,Autocuration,BAO_0000218
4042,Canis lupus familiaris,8,B,,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,55,9615.0,,,CHEMBL620773,3595,,,,,H,Autocuration,BAO_0000218
4043,Cavia porcellus,8,B,,1,Ability to inhibit 5-lipoxygenase in guinea pig,55,10141.0,,,CHEMBL620774,9203,,,,,H,Autocuration,BAO_0000357
4044,Cavia porcellus,8,B,,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),55,10141.0,,,CHEMBL620775,82,,,,,H,Expert,BAO_0000357
4045,Cavia porcellus,8,B,,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,55,10141.0,,,CHEMBL620776,11090,,,,,H,Autocuration,BAO_0000357
4046,Cavia porcellus,8,B,,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",55,10141.0,,,CHEMBL620777,12832,178.0,,,Blood,H,Autocuration,BAO_0000218
4047,Cavia porcellus,8,B,,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,55,10141.0,,,CHEMBL620778,1065,,,,,H,Autocuration,BAO_0000357
4048,Cavia porcellus,8,B,,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,55,10141.0,,,CHEMBL620779,1065,,,,,H,Autocuration,BAO_0000357
4049,Cavia porcellus,8,B,,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,55,10141.0,,,CHEMBL621500,12832,,,,,H,Expert,BAO_0000019
4050,Cavia porcellus,8,B,,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,10141.0,,,CHEMBL621501,12832,,,,,H,Expert,BAO_0000019
4051,Cavia porcellus,8,B,,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,10141.0,,,CHEMBL618098,12832,,,,,H,Autocuration,BAO_0000019
4052,Cavia porcellus,8,B,,1,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,10141.0,,,CHEMBL618099,10504,,,,,H,Autocuration,BAO_0000019
4053,Cavia porcellus,8,B,,1,Inhibitory activity against 5-lipoxygenase,55,10141.0,,,CHEMBL618100,7788,,,,,H,Autocuration,BAO_0000357
4054,Cavia porcellus,8,B,,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,55,10141.0,,,CHEMBL618101,10001,,,,,H,Autocuration,BAO_0000357
4055,Cavia porcellus,8,B,,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,55,10141.0,,,CHEMBL618102,10193,,,,,H,Autocuration,BAO_0000357
4056,Cavia porcellus,8,B,,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,55,10141.0,,,CHEMBL618103,13243,,,,,H,Autocuration,BAO_0000357
4057,Cavia porcellus,8,B,,1,Inhibitory activity uM,55,10141.0,,,CHEMBL618104,13243,,,,,H,Autocuration,BAO_0000357
4058,Cavia porcellus,8,B,,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,55,10141.0,,,CHEMBL883712,969,,,,,H,Autocuration,BAO_0000219
4059,Cavia porcellus,8,B,,1,Inhibitory activity against 5-lipoxygenase at 10 uM,55,10141.0,,,CHEMBL618105,10001,,,,,H,Autocuration,BAO_0000357
4060,Cavia porcellus,8,B,,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,10141.0,,,CHEMBL618106,7788,,,,,H,Autocuration,BAO_0000357
4061,Cavia porcellus,8,B,,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,55,10141.0,,,CHEMBL618107,10001,,,,,H,Autocuration,BAO_0000357
4062,Cavia porcellus,8,B,,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,10141.0,,,CHEMBL618108,10193,,,,,H,Autocuration,BAO_0000357
4063,Cavia porcellus,8,B,,1,Inhibitory activity uM,55,10141.0,,,CHEMBL618109,13243,,,,,H,Autocuration,BAO_0000357
4064,Cavia porcellus,8,B,,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,55,10141.0,,,CHEMBL618110,13243,,,,,H,Autocuration,BAO_0000357
4065,Cavia porcellus,8,B,,1,Inhibitory activity uM,55,10141.0,,,CHEMBL618111,13243,,,,,H,Expert,BAO_0000357
4066,Cavia porcellus,8,F,,1,Inhibitory activity uM,55,10141.0,,,CHEMBL618112,13243,,,,,H,Autocuration,BAO_0000019
4067,Cavia porcellus,8,B,,1,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,10141.0,,,CHEMBL618113,10504,,,,,H,Autocuration,BAO_0000019
4068,Cavia porcellus,8,B,,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,10141.0,,,CHEMBL618114,7788,,,,,H,Autocuration,BAO_0000357
4069,Cavia porcellus,8,F,,1,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,55,10141.0,,,CHEMBL620871,10546,2116.0,,,Ileum,H,Expert,BAO_0000221
4070,,8,B,,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,,CHEMBL620872,13183,,,,,H,Autocuration,BAO_0000357
4071,,8,B,,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,,CHEMBL620873,13183,,,,,H,Autocuration,BAO_0000357
4072,,8,B,,1,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),55,,,,CHEMBL620874,2578,,,,,H,Autocuration,BAO_0000357
4073,,8,B,,1,In vitro inhibition of human 5-Lipoxygenase.,55,,,,CHEMBL620875,12780,,,,,H,Expert,BAO_0000357
4074,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,10116.0,Microsomes,,CHEMBL620876,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4075,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,10116.0,Microsomes,,CHEMBL620877,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4076,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,10116.0,Microsomes,,CHEMBL857854,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4077,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,22226,10116.0,Microsomes,,CHEMBL620878,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4078,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,10116.0,Microsomes,,CHEMBL620879,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4079,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,10116.0,Microsomes,,CHEMBL620880,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4080,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,10116.0,Microsomes,,CHEMBL620881,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4081,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,10116.0,Microsomes,,CHEMBL620882,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4082,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,10116.0,Microsomes,,CHEMBL620883,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4083,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,10116.0,Microsomes,,CHEMBL620884,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4084,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,10116.0,Microsomes,,CHEMBL620885,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4085,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,22226,10116.0,Microsomes,,CHEMBL620886,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4086,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,10116.0,Microsomes,,CHEMBL620887,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4087,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,10116.0,Microsomes,,CHEMBL618039,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4088,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,10116.0,Microsomes,,CHEMBL618040,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4089,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,22226,10116.0,Microsomes,,CHEMBL618041,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4090,Rattus norvegicus,0,B,,1,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,10116.0,Microsomes,,CHEMBL618216,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4091,Rattus norvegicus,0,B,,1,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,10116.0,Microsomes,,CHEMBL618217,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4092,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,22226,10116.0,Microsomes,,CHEMBL618218,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4093,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,22226,10116.0,Microsomes,,CHEMBL618219,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4094,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,22226,10116.0,Microsomes,,CHEMBL618220,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4095,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,22226,10116.0,Microsomes,,CHEMBL618221,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4096,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,22226,10116.0,Microsomes,,CHEMBL618222,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4097,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,10116.0,Microsomes,,CHEMBL618223,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4098,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,10116.0,Microsomes,,CHEMBL618224,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4099,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,22226,10116.0,Microsomes,,CHEMBL618225,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4100,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,22226,10116.0,Microsomes,,CHEMBL618226,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4101,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,10116.0,Microsomes,,CHEMBL618227,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4102,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,10116.0,Microsomes,,CHEMBL618228,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4103,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,10116.0,Microsomes,,CHEMBL618229,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4104,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,10116.0,Microsomes,,CHEMBL618230,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4105,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,10116.0,Microsomes,,CHEMBL618231,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4106,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,10116.0,Microsomes,,CHEMBL618232,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4107,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,10116.0,Microsomes,,CHEMBL618233,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4108,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,10116.0,Microsomes,,CHEMBL618234,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4109,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,10116.0,Microsomes,,CHEMBL618235,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4110,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,10116.0,Microsomes,,CHEMBL618115,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4111,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,10116.0,Microsomes,,CHEMBL618116,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4112,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,10116.0,Microsomes,,CHEMBL618117,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4113,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,10116.0,Microsomes,,CHEMBL619968,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4114,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,10116.0,Microsomes,,CHEMBL619969,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4115,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,10116.0,Microsomes,,CHEMBL619970,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4116,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,22226,10116.0,Microsomes,,CHEMBL619971,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4117,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,22226,10116.0,Microsomes,,CHEMBL619972,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4118,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,22226,10116.0,Microsomes,,CHEMBL619973,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4119,Rattus norvegicus,0,B,,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,22226,10116.0,Microsomes,,CHEMBL619974,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4120,Rattus norvegicus,0,B,,1,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,10116.0,Microsomes,,CHEMBL619975,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4121,Rattus norvegicus,0,B,,1,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,22226,10116.0,Microsomes,,CHEMBL619976,7411,,,,,U,Autocuration,BAO_0000251
4122,Rattus norvegicus,0,B,,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,10116.0,Microsomes,,CHEMBL619977,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4123,Rattus norvegicus,0,B,,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,10116.0,Microsomes,,CHEMBL619978,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4124,Rattus norvegicus,0,B,,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",22226,10116.0,Microsomes,,CHEMBL619979,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4125,Rattus norvegicus,0,B,,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,10116.0,Microsomes,,CHEMBL619980,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4126,Rattus norvegicus,0,B,,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,10116.0,Microsomes,,CHEMBL619981,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4127,Homo sapiens,1,F,RPMI-8226,1,In vitro inhibition of 7226/S myeloma cancer cell line,80433,9606.0,,,CHEMBL619982,10797,,741.0,,,N,Intermediate,BAO_0000219
4128,Homo sapiens,1,F,BEL-7404 tumor cell line,1,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),80698,9606.0,,,CHEMBL619983,6881,,993.0,,,N,Intermediate,BAO_0000219
4129,Homo sapiens,1,F,786-0,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,9606.0,,,CHEMBL620031,3838,,391.0,,,N,Intermediate,BAO_0000219
4130,Homo sapiens,1,F,786-0,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,9606.0,,,CHEMBL620032,3838,,391.0,,,N,Intermediate,BAO_0000219
4131,Cricetulus griseus,1,F,V79,1,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,81264,10029.0,,,CHEMBL620033,12981,,505.0,,,N,Expert,BAO_0000219
4132,Cricetulus griseus,1,F,V79,1,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,81264,10029.0,,,CHEMBL620034,12981,,505.0,,,N,Expert,BAO_0000219
4133,Rattus norvegicus,1,F,7800C1 cell line,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,80635,10116.0,,,CHEMBL620035,7653,,1119.0,,,N,Intermediate,BAO_0000219
4134,Rattus norvegicus,1,F,7800C1 cell line,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,80635,10116.0,,,CHEMBL618318,7653,,1119.0,,,N,Intermediate,BAO_0000219
4135,Rattus norvegicus,1,F,7800C1 cell line,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,80635,10116.0,,,CHEMBL618319,7653,,1119.0,,,N,Intermediate,BAO_0000219
4136,Rattus norvegicus,1,F,7800C1 cell line,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,80635,10116.0,,,CHEMBL618320,7653,,1119.0,,,N,Intermediate,BAO_0000219
4137,Rattus norvegicus,1,F,7800C1 cell line,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,80635,10116.0,,,CHEMBL618321,7653,,1119.0,,,N,Intermediate,BAO_0000219
4138,Rattus norvegicus,1,F,7800C1 cell line,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,80635,10116.0,,,CHEMBL883118,7653,,1119.0,,,N,Intermediate,BAO_0000219
4139,Homo sapiens,1,F,786-0,1,In vitro antitumor activity against renal 786-0 tumor cell lines,80640,9606.0,,,CHEMBL883795,17229,,391.0,,,N,Intermediate,BAO_0000219
4140,Homo sapiens,1,F,786-0,1,Cytotoxic activity against 786-0 Renal cancer cell line,80640,9606.0,,,CHEMBL618322,12858,,391.0,,,N,Intermediate,BAO_0000219
4141,Homo sapiens,1,F,786-0,1,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,80640,9606.0,,,CHEMBL618323,16325,,391.0,,,N,Intermediate,BAO_0000219
4142,Homo sapiens,1,F,786-0,1,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,80640,9606.0,,,CHEMBL618324,16325,,391.0,,,N,Intermediate,BAO_0000219
4143,Homo sapiens,1,F,786-0,1,In vitro antitumor activity against human renal 786-0 cell line,80640,9606.0,,,CHEMBL618325,5858,,391.0,,,N,Intermediate,BAO_0000219
4144,Homo sapiens,1,F,786-0,1,Inhibition of Renal cancer in 786-0 cancer cell lines,80640,9606.0,,,CHEMBL875416,16325,,391.0,,,N,Intermediate,BAO_0000219
4145,Homo sapiens,1,F,786-0,1,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,80640,9606.0,,,CHEMBL618326,14696,,391.0,,,N,Intermediate,BAO_0000219
4146,Homo sapiens,1,F,786-0,1,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,80640,9606.0,,,CHEMBL618327,3786,,391.0,,,N,Intermediate,BAO_0000219
4147,Homo sapiens,1,F,786-0,1,inhibition of the growth of renal cancer(786-0) cell line,80640,9606.0,,,CHEMBL619215,14696,,391.0,,,N,Intermediate,BAO_0000219
4148,Homo sapiens,1,F,786-0,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,9606.0,,,CHEMBL619216,14769,,391.0,,,N,Intermediate,BAO_0000219
4149,Homo sapiens,1,F,786-0,1,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,80640,9606.0,,,CHEMBL619217,15354,,391.0,,,N,Intermediate,BAO_0000219
4150,Homo sapiens,1,F,786-0,1,The IC50 value was measured on 786-0 cell line in ovarian tumor,80640,9606.0,,,CHEMBL619218,14255,,391.0,,,N,Intermediate,BAO_0000219
4151,Homo sapiens,1,F,786-0,1,The IC50 value was measured on 786-0 cell line in ovarian tumor t,80640,9606.0,,,CHEMBL619219,14255,,391.0,,,N,Intermediate,BAO_0000219
4152,Homo sapiens,1,F,786-0,1,The IC50 value was measured on 786-0 cell line in renal tumor type.,80640,9606.0,,,CHEMBL619220,14255,,391.0,,,N,Intermediate,BAO_0000219
4153,Homo sapiens,1,F,786-0,1,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,80640,9606.0,,,CHEMBL619221,14696,,391.0,,,N,Intermediate,BAO_0000219
4154,Homo sapiens,1,F,786-0,1,Tested for cytotoxic activity against renal cancer 786-0 cell line,80640,9606.0,,,CHEMBL619222,12016,,391.0,,,N,Intermediate,BAO_0000219
4155,Homo sapiens,1,F,786-0,1,Compound was tested for growth inhibitory activity against 786-0 cell line,80640,9606.0,,,CHEMBL857454,2597,,391.0,,,N,Intermediate,BAO_0000219
4156,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12166,,,,CHEMBL619223,12526,,702.0,,,H,Autocuration,BAO_0000219
4157,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12166,,,,CHEMBL619224,12526,,702.0,,,H,Autocuration,BAO_0000219
4158,,8,B,,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,,,,CHEMBL619225,14799,,,,,H,Autocuration,BAO_0000019
4159,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,,CHEMBL619226,3595,,702.0,,,H,Expert,BAO_0000219
4160,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,,,CHEMBL619227,3595,,702.0,,,H,Expert,BAO_0000219
4161,,8,B,,1,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12166,,,,CHEMBL619228,12767,,,,,H,Autocuration,BAO_0000357
4162,,8,B,,1,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,12166,,,,CHEMBL619229,10997,,,,,H,Autocuration,BAO_0000219
4163,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,12166,,,,CHEMBL619230,11388,,702.0,,,H,Autocuration,BAO_0000219
4164,,8,B,,1,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,12166,,,,CHEMBL619231,167,,,,,H,Autocuration,BAO_0000357
4165,,8,B,,1,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",12166,,,,CHEMBL619232,167,,,,,H,Autocuration,BAO_0000357
4166,,8,B,,1,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,12166,,,,CHEMBL619233,13744,,,,,H,Expert,BAO_0000357
4167,,8,B,,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,12166,,,,CHEMBL619234,1630,,,,,H,Autocuration,BAO_0000357
4168,,8,B,,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),12166,,,,CHEMBL619235,1630,,,,,H,Autocuration,BAO_0000357
4169,Rattus norvegicus,9,B,,1,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",12166,10116.0,,,CHEMBL619236,969,,,,,D,Expert,BAO_0000019
4170,,8,B,RBL-1,1,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,12166,,,,CHEMBL619237,13621,,702.0,,,H,Autocuration,BAO_0000219
4171,,8,B,,1,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,12166,,,,CHEMBL619238,10089,,,,,H,Autocuration,BAO_0000357
4172,,8,B,,1,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,12166,,,,CHEMBL619239,10193,,,,,H,Expert,BAO_0000357
4173,,8,B,,1,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,12166,,,,CHEMBL619240,11966,,,,,H,Autocuration,BAO_0000357
4174,,8,B,,1,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,,,CHEMBL875417,12251,,,,,H,Autocuration,BAO_0000019
4175,,8,B,RBL-1,1,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),12166,,,,CHEMBL619241,211,,702.0,,,H,Autocuration,BAO_0000219
4176,,8,F,,1,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,,,CHEMBL619242,12251,,,,,H,Expert,BAO_0000019
4177,,8,B,RBL-1,1,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12166,,,,CHEMBL883796,12495,,702.0,,,H,Autocuration,BAO_0000219
4178,,8,B,,1,Tested for its inhibitory activity against 5-lipoxygenase,12166,,,,CHEMBL619243,414,,,,,H,Autocuration,BAO_0000357
4179,,8,B,,1,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,12166,,,,CHEMBL619244,414,,,,,H,Autocuration,BAO_0000357
4180,,8,B,,1,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",12166,,,,CHEMBL619245,10325,,,,,H,Expert,BAO_0000019
4181,,8,B,,1,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,,,CHEMBL619246,11966,,,,,H,Expert,BAO_0000019
4182,,8,B,RBL-1,1,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,,CHEMBL619984,165,,702.0,,,H,Expert,BAO_0000219
4183,,8,B,RBL-1,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,12166,,,,CHEMBL619985,165,,702.0,,,H,Autocuration,BAO_0000219
4184,,8,B,RBL-1,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,,CHEMBL619986,165,,702.0,,,H,Autocuration,BAO_0000219
4185,,8,B,RBL-1,1,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,,CHEMBL619987,165,,702.0,,,H,Expert,BAO_0000219
4186,,8,B,,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,12166,,,,CHEMBL619988,11311,,,,,H,Autocuration,BAO_0000218
4187,,8,B,RBL-1,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,12166,,,,CHEMBL619989,11311,,702.0,,,H,Autocuration,BAO_0000219
4188,,8,B,RBL-1,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,,,,CHEMBL619990,11311,,702.0,,,H,Autocuration,BAO_0000219
4189,,8,B,,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,,,CHEMBL619991,11311,,,,,H,Autocuration,BAO_0000219
4190,,8,B,,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),12166,,,,CHEMBL619992,11311,,,,,H,Autocuration,BAO_0000219
4191,,8,B,,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),12166,,,,CHEMBL619993,11311,,,,,H,Autocuration,BAO_0000218
4192,,8,F,RBL-2H3,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,12166,,,,CHEMBL619994,11311,,663.0,,,H,Autocuration,BAO_0000219
4193,,8,F,RBL-2H3,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,12166,,,,CHEMBL619995,11311,,663.0,,,H,Autocuration,BAO_0000219
4194,,8,B,,1,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],12166,,,,CHEMBL619996,11311,,,,,H,Autocuration,BAO_0000019
4195,,8,B,,1,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,12166,,,,CHEMBL619997,11732,,,,,H,Autocuration,BAO_0000019
4196,,8,B,,1,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,12166,,,,CHEMBL619998,11732,,,,,H,Expert,BAO_0000019
4197,,8,B,,1,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,12166,,,,CHEMBL619999,11087,,,,,H,Expert,BAO_0000019
4198,,8,B,,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,12166,,,,CHEMBL620000,11087,,,,,H,Autocuration,BAO_0000019
4199,,8,B,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,12166,,,,CHEMBL620001,11087,,702.0,,,H,Autocuration,BAO_0000219
4200,Rattus norvegicus,9,B,,1,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,12166,10116.0,,,CHEMBL620002,11087,,,,,D,Expert,BAO_0000357
4201,,8,B,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,12166,,,,CHEMBL620003,496,,702.0,,,H,Autocuration,BAO_0000219
4202,,8,F,RBL-1,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,12166,,,,CHEMBL620004,13986,,702.0,,,H,Expert,BAO_0000219
4203,,8,B,,1,Compound was evaluated for the inhibition of 5-lipoxygenase,12166,,,,CHEMBL874063,11520,,,,,H,Autocuration,BAO_0000357
4204,,8,B,RBL-1,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,12166,,,,CHEMBL620005,10293,,702.0,,,H,Autocuration,BAO_0000219
4205,,8,B,RBL-1,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,12166,,,,CHEMBL620006,303,,702.0,,,H,Autocuration,BAO_0000219
4206,,8,B,RBL-1,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,12166,,,,CHEMBL620007,303,,702.0,,,H,Autocuration,BAO_0000219
4207,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,12166,,,,CHEMBL620008,9247,,702.0,,,H,Autocuration,BAO_0000219
4208,Rattus norvegicus,9,B,RBL-1,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,12166,10116.0,,,CHEMBL620009,9247,,702.0,,,D,Expert,BAO_0000219
4209,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,,,CHEMBL620010,9247,,702.0,,,H,Autocuration,BAO_0000219
4210,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,12166,,,,CHEMBL620011,9247,,702.0,,,H,Autocuration,BAO_0000219
4211,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,12166,,,,CHEMBL620677,9247,,702.0,,,H,Autocuration,BAO_0000219
4212,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,12166,,,,CHEMBL620678,9247,,702.0,,,H,Autocuration,BAO_0000219
4213,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,12166,,,,CHEMBL620679,9247,,702.0,,,H,Autocuration,BAO_0000219
4214,,8,B,RBL-1,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,12166,,,,CHEMBL620680,9247,,702.0,,,H,Autocuration,BAO_0000219
4215,Rattus norvegicus,9,B,,1,Inhibitory activity against 5-lipoxygenase at 10 uM,12166,10116.0,,,CHEMBL620838,11481,,,,,D,Expert,BAO_0000357
4216,,8,B,,1,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,12166,,,,CHEMBL620839,105,,,,,H,Autocuration,BAO_0000357
4217,,8,B,,1,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,12166,,,,CHEMBL620840,9029,,,,,H,Expert,BAO_0000357
4218,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,12166,,,,CHEMBL620841,1175,,702.0,,,H,Expert,BAO_0000219
4219,,8,B,RBL-1,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12166,,,,CHEMBL620842,12118,,702.0,,,H,Autocuration,BAO_0000219
4220,,8,B,RBL-1,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12166,,,,CHEMBL620843,12118,,702.0,,,H,Autocuration,BAO_0000219
4221,,8,B,RBL-1,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12166,,,,CHEMBL620844,12118,,702.0,,,H,Autocuration,BAO_0000219
4222,,8,B,RBL-1,1,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,12166,,,,CHEMBL620845,9225,,702.0,,,H,Autocuration,BAO_0000219
4223,,8,B,,1,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,12166,,,,CHEMBL620846,9401,,,,,H,Autocuration,BAO_0000019
4224,,8,B,,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,,,CHEMBL873951,137,,,,,H,Autocuration,BAO_0000357
4225,,8,B,,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,,,CHEMBL620847,137,,,,,H,Autocuration,BAO_0000357
4226,,8,B,RBL-1,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,,,CHEMBL620848,4717,,702.0,,,H,Autocuration,BAO_0000219
4227,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,,,CHEMBL620849,3595,,702.0,,,H,Autocuration,BAO_0000219
4228,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,12166,,,,CHEMBL620850,10501,,702.0,,,H,Autocuration,BAO_0000219
4229,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,12166,,,,CHEMBL620851,10501,,702.0,,,H,Autocuration,BAO_0000219
4230,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,12166,,,,CHEMBL620852,10501,,702.0,,,H,Autocuration,BAO_0000219
4231,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,,CHEMBL875098,12526,,702.0,,,H,Autocuration,BAO_0000219
4232,Rattus norvegicus,9,B,RBL-1,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,12166,10116.0,,,CHEMBL620853,14799,,702.0,,,D,Expert,BAO_0000219
4233,,8,B,,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,12166,,,,CHEMBL620854,14799,,,,,H,Autocuration,BAO_0000019
4234,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,,,CHEMBL620855,3595,,702.0,,,H,Autocuration,BAO_0000219
4235,,8,B,RBL-1,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,,,CHEMBL839884,3595,,702.0,,,H,Expert,BAO_0000219
4236,,8,B,RBL-1,1,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,,CHEMBL620856,12526,,702.0,,,H,Autocuration,BAO_0000219
4237,,8,B,RBL-1,1,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,,CHEMBL620857,12526,,702.0,,,H,Autocuration,BAO_0000219
4238,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,,,CHEMBL620858,10193,,,,,H,Autocuration,BAO_0000019
4239,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,,,CHEMBL620859,10193,,,,,H,Autocuration,BAO_0000019
4240,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,,,CHEMBL620860,10193,,,,,H,Autocuration,BAO_0000019
4241,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,12166,,,,CHEMBL620861,10193,,,,,H,Autocuration,BAO_0000019
4242,,8,B,,1,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),12166,,,,CHEMBL620862,9138,,,,,H,Expert,BAO_0000357
4243,,8,B,,1,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,12166,,,,CHEMBL620863,9138,,,,,H,Autocuration,BAO_0000357
4244,,8,B,,1,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,,,CHEMBL620864,11966,,,,,H,Autocuration,BAO_0000019
4245,,8,B,RBL-1,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,12166,,,,CHEMBL620865,165,,702.0,,,H,Autocuration,BAO_0000219
4246,,8,B,RBL-1,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,12166,,,,CHEMBL620866,165,,702.0,,,H,Autocuration,BAO_0000219
4247,,8,B,RBL-2H3,1,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,12166,,,,CHEMBL620867,11311,,663.0,,,H,Autocuration,BAO_0000219
4248,,8,B,RBL-2H3,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,,,CHEMBL620868,11311,,663.0,,,H,Autocuration,BAO_0000219
4249,,8,F,RBL-2H3,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,,,CHEMBL620869,11311,,663.0,,,H,Autocuration,BAO_0000219
4250,,8,F,,1,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,12166,,,,CHEMBL873952,11311,,,,,H,Autocuration,BAO_0000019
4251,,8,B,,1,The compound was tested for inhibition of isolated 5-lipoxygenase,12166,,,,CHEMBL875099,11311,,,,,H,Autocuration,BAO_0000357
4252,,8,F,RBL-2H3,1,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,12166,,,,CHEMBL620870,11311,,663.0,,,H,Autocuration,BAO_0000219
4253,,8,B,,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,12166,,,,CHEMBL618261,11087,,,,,H,Autocuration,BAO_0000019
4254,,8,B,,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,12166,,,,CHEMBL618262,11087,,,,,H,Autocuration,BAO_0000019
4255,,8,B,,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,12166,,,,CHEMBL619428,11087,,,,,H,Autocuration,BAO_0000019
4256,,8,B,,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,,,CHEMBL619429,11087,,,,,H,Autocuration,BAO_0000019
4257,,8,B,,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,,,CHEMBL619430,11087,,,,,H,Autocuration,BAO_0000019
4258,,8,B,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,12166,,,,CHEMBL620017,496,,702.0,,,H,Autocuration,BAO_0000219
4259,,8,B,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,12166,,,,CHEMBL620018,496,,702.0,,,H,Autocuration,BAO_0000219
4260,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,12166,,,,CHEMBL620019,13986,,702.0,,,H,Autocuration,BAO_0000219
4261,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,12166,,,,CHEMBL620020,13986,,702.0,,,H,Autocuration,BAO_0000219
4262,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,12166,,,,CHEMBL620021,13986,,702.0,,,H,Autocuration,BAO_0000219
4263,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,12166,,,,CHEMBL620022,13986,,702.0,,,H,Autocuration,BAO_0000219
4264,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,12166,,,,CHEMBL620023,13986,,702.0,,,H,Autocuration,BAO_0000219
4265,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,12166,,,,CHEMBL620024,13986,,702.0,,,H,Autocuration,BAO_0000219
4266,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,12166,,,,CHEMBL620025,13986,,702.0,,,H,Autocuration,BAO_0000219
4267,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,12166,,,,CHEMBL620026,13986,,702.0,,,H,Autocuration,BAO_0000219
4268,,8,F,RBL-1,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,12166,,,,CHEMBL620027,13986,,702.0,,,H,Autocuration,BAO_0000219
4269,Rattus norvegicus,9,F,,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,12166,10116.0,,,CHEMBL620028,13986,,,,,D,Expert,BAO_0000019
4270,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,12166,,,,CHEMBL620029,10193,,,,,H,Autocuration,BAO_0000357
4271,,8,B,,1,Compound was tested for the percent of inhibition against 5-LO at 10 uM,12166,,,,CHEMBL620030,9295,,,,,H,Autocuration,BAO_0000357
4272,,8,B,RBL-1,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,12166,,,,CHEMBL875415,4717,,702.0,,,H,Autocuration,BAO_0000219
4273,,8,B,RBL-1,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,,,CHEMBL618256,4717,,702.0,,,H,Autocuration,BAO_0000219
4274,,8,B,RBL-1,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,12166,,,,CHEMBL618257,11854,,702.0,,,H,Autocuration,BAO_0000219
4275,,8,B,RBL-1,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,12166,,,,CHEMBL618258,11854,,702.0,,,H,Autocuration,BAO_0000219
4276,,8,B,RBL-1,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,12166,,,,CHEMBL618259,11854,,702.0,,,H,Autocuration,BAO_0000219
4277,,8,B,,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,,,CHEMBL618260,10193,,,,,H,Autocuration,BAO_0000019
4278,,8,B,RBL-1,1,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,12166,,,,CHEMBL618215,9295,,702.0,,,H,Autocuration,BAO_0000219
4279,,8,B,RBL-1,1,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,12166,,,,CHEMBL618390,9295,,702.0,,,H,Autocuration,BAO_0000219
4280,,8,B,RBL-1,1,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,12166,,,,CHEMBL618391,9295,,702.0,,,H,Autocuration,BAO_0000219
4281,,8,B,RBL-1,1,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,12166,,,,CHEMBL618392,9295,,702.0,,,H,Autocuration,BAO_0000219
4282,,8,B,RBL-1,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,12166,,,,CHEMBL618393,165,,702.0,,,H,Autocuration,BAO_0000219
4283,,8,B,,1,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,12166,,,,CHEMBL618394,11311,,,,,H,Autocuration,BAO_0000219
4284,Homo sapiens,8,B,RBL-1,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,9606.0,,,CHEMBL618395,10489,,702.0,,,H,Expert,BAO_0000219
4285,Rattus norvegicus,9,B,RBL-1,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,10116.0,,,CHEMBL618396,10489,,702.0,,,D,Expert,BAO_0000219
4286,Rattus norvegicus,9,B,RBL-1,1,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),12166,10116.0,,,CHEMBL858253,10489,,702.0,,,D,Expert,BAO_0000219
4287,Rattus norvegicus,9,B,,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,10116.0,,,CHEMBL618397,14799,,,,,D,Autocuration,BAO_0000019
4288,Glycine max,8,B,,1,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),12054,3847.0,,,CHEMBL618398,9295,,,,,H,Autocuration,BAO_0000357
4289,,0,B,,1,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",22226,,,,CHEMBL618399,16811,,,,,U,Autocuration,BAO_0000019
4290,,8,B,,1,In vitro inhibition of 5-Lipoxygenase; Inactive.,55,,,,CHEMBL618400,168,,,,,H,Expert,BAO_0000357
4291,,8,B,,1,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,55,,,,CHEMBL618401,6309,,,,,H,Autocuration,BAO_0000357
4292,,8,B,,1,Inhibitory concentration against 5-lipoxygenase; No inhibition,55,,,,CHEMBL618402,6309,,,,,H,Autocuration,BAO_0000357
4293,,8,B,RBL-1,1,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,55,,,,CHEMBL876400,3092,,702.0,,,H,Autocuration,BAO_0000219
4294,,8,B,,1,Inhibitory activity against 5-lipoxygenase.,55,,,,CHEMBL618403,168,,,,,H,Expert,BAO_0000357
4295,,8,B,,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,55,,,,CHEMBL618404,168,,,,,H,Autocuration,BAO_0000357
4296,,8,B,,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,55,,,,CHEMBL618405,168,,,,,H,Autocuration,BAO_0000357
4297,,8,B,,1,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,55,,,,CHEMBL618406,168,,,,,H,Autocuration,BAO_0000357
4298,,8,F,,1,Inhibitory concentration against arachidonic acid 5-lipoxygenation,55,,,,CHEMBL618407,12338,,,,,H,Expert,BAO_0000019
4299,,8,B,,1,Tested for the inhibitory activity against 5-lipoxygenase,55,,,,CHEMBL618408,4501,,,,,H,Autocuration,BAO_0000357
4300,,8,B,,1,Compound was tested for its inhibitory activity against 5-lipoxygenase,55,,,,CHEMBL618409,1132,,,,,H,Autocuration,BAO_0000357
4301,,8,B,,1,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,55,,,,CHEMBL618410,2117,,,,,H,Autocuration,BAO_0000357
4302,,8,B,,1,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,55,,,,CHEMBL618411,168,,,,,H,Autocuration,BAO_0000357
4303,,8,B,,1,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,55,,,,CHEMBL618412,168,,,,,H,Autocuration,BAO_0000357
4304,,8,B,RBL-1,1,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,12166,,,,CHEMBL618413,13575,,702.0,,,H,Autocuration,BAO_0000219
4305,,8,B,,1,,12166,,,,CHEMBL618414,11089,,,,,H,Autocuration,BAO_0000357
4306,,8,B,,1,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),10102,,,,CHEMBL618415,216,,,,,H,Autocuration,BAO_0000357
4307,,8,B,,1,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,10102,,,,CHEMBL618416,13165,,,,,H,Autocuration,BAO_0000019
4308,,8,B,,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,10102,,,,CHEMBL876401,3278,,,,,H,Autocuration,BAO_0000357
4309,,8,B,,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,10102,,,,CHEMBL618417,3278,,,,,H,Expert,BAO_0000357
4310,,8,B,,1,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,10102,,,,CHEMBL618418,11966,,,,,H,Autocuration,BAO_0000357
4311,,8,B,,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",10102,,,,CHEMBL618419,175,,,,,H,Autocuration,BAO_0000357
4312,,8,B,,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",10102,,,,CHEMBL618420,175,,,,,H,Autocuration,BAO_0000357
4313,,8,B,,1,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,10102,,,,CHEMBL618421,13449,,,,,H,Autocuration,BAO_0000357
4314,,8,B,,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,11238,,,,CHEMBL618422,12014,,,,,H,Autocuration,BAO_0000019
4315,,8,B,,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),11238,,,,CHEMBL618423,12014,,,,,H,Autocuration,BAO_0000019
4316,,8,B,,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),11238,,,,CHEMBL618424,12014,,,,,H,Autocuration,BAO_0000019
4317,,2,B,,1,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,100284,,,,CHEMBL618425,99,,,,,S,Intermediate,BAO_0000220
4318,Homo sapiens,0,F,,1,The dark toxicity against 543 human galactophore carcinoma cells,22226,9606.0,,,CHEMBL618426,4349,,,,,U,Autocuration,BAO_0000019
4319,Homo sapiens,1,F,Panel (56 tumour cell lines),1,Tested in vitro for cytotoxicity against 56 human tumor cell lines,80623,9606.0,,,CHEMBL618427,4071,,390.0,,,N,Expert,BAO_0000219
4320,Homo sapiens,1,F,5637,1,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,80008,9606.0,,,CHEMBL618428,17589,,345.0,,,N,Expert,BAO_0000219
4321,Homo sapiens,1,F,5637,1,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,80008,9606.0,,,CHEMBL618429,15002,,345.0,,,N,Intermediate,BAO_0000219
4322,Homo sapiens,1,F,5637,1,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",80008,9606.0,,,CHEMBL618430,13958,,345.0,,,N,Intermediate,BAO_0000219
4323,Homo sapiens,1,F,5637,1,Growth inhibition against human 5637 cell lines,80008,9606.0,,,CHEMBL618431,17589,,345.0,,,N,Expert,BAO_0000219
4324,Homo sapiens,1,F,5637,1,Antitumor activity against human bladder carcinoma 5637 cells.,80008,9606.0,,,CHEMBL883799,16748,,345.0,,,N,Expert,BAO_0000219
4325,Homo sapiens,1,F,5637,1,Antitumor activity against human bladder carcinoma 5637 cells,80008,9606.0,,,CHEMBL618432,16747,,345.0,,,N,Intermediate,BAO_0000219
4326,Homo sapiens,1,F,5637,1,Antitumor activity against human bladder carcinoma 5637 cells,80008,9606.0,,,CHEMBL618433,16747,,345.0,,,N,Intermediate,BAO_0000219
4327,Bos taurus,9,B,,1,In vitro inhibition of bovine trypsin(Trp).,10443,9913.0,,,CHEMBL618434,15285,,,,,D,Expert,BAO_0000357
4328,Cercopithecidae,8,B,CV-1,1,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,240,9527.0,,,CHEMBL618435,3726,,407.0,,,H,Expert,BAO_0000219
4329,,8,B,,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,10577,,,,CHEMBL876402,5033,,,,,H,Autocuration,BAO_0000357
4330,,6,F,,1,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,104698,,,,CHEMBL618436,11756,,,,,H,Autocuration,BAO_0000019
4331,,0,F,,1,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,22226,,,,CHEMBL618437,11953,,,,,U,Autocuration,BAO_0000218
4332,Cavia porcellus,9,B,,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,20033,10141.0,,,CHEMBL618438,5033,,,,,D,Intermediate,BAO_0000357
4333,Rattus norvegicus,8,A,,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,10116.0,Microsomes,,CHEMBL883800,11347,,,,,H,Expert,BAO_0000251
4334,Rattus norvegicus,8,A,,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,10116.0,Microsomes,,CHEMBL618439,11347,,,,,H,Expert,BAO_0000251
4335,,0,F,,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,,,CHEMBL618440,1229,,,,,U,Intermediate,BAO_0000019
4336,,0,F,,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,,,CHEMBL618441,1229,,,,,U,Intermediate,BAO_0000019
4337,Trypanosoma brucei,8,B,,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,11938,5691.0,,,CHEMBL618442,17588,,,,,H,Expert,BAO_0000019
4338,Trypanosoma brucei,8,B,,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,11938,5691.0,,,CHEMBL618443,17588,,,,,H,Autocuration,BAO_0000019
4339,Ovis aries,8,B,,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,11938,9940.0,,,CHEMBL619158,17588,,,,,H,Expert,BAO_0000019
4340,Ovis aries,8,B,,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,11938,9940.0,,,CHEMBL620974,17588,,,,,H,Autocuration,BAO_0000019
4341,,8,B,,1,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,11938,,,,CHEMBL620975,16485,,,,,H,Autocuration,BAO_0000357
4342,Homo sapiens,0,F,,1,Average inhibitory concentration against 60 human cell lines was reported,22226,9606.0,,,CHEMBL620976,4337,,,,,U,Intermediate,BAO_0000019
4343,Homo sapiens,0,F,,1,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,22226,9606.0,,,CHEMBL620977,4112,,,,,U,Expert,BAO_0000019
4344,Homo sapiens,1,F,Panel NCI-60 (60 carcinoma cell lines),1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,80315,9606.0,,,CHEMBL620978,16160,,542.0,,,N,Intermediate,BAO_0000219
4345,Homo sapiens,1,F,Panel NCI-60 (60 carcinoma cell lines),1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,80315,9606.0,,,CHEMBL620979,16160,,542.0,,,N,Intermediate,BAO_0000219
4346,,1,F,Panel NCI-60 (60 carcinoma cell lines),1,In vitro mean growth inhibitory activity against 60-cell panel,80315,,,,CHEMBL620980,17376,,542.0,,,N,Expert,BAO_0000219
4347,,1,F,Panel NCI-60 (60 carcinoma cell lines),1,In vitro mean growth lethal concentration against 60-cell panel,80315,,,,CHEMBL620981,17376,,542.0,,,N,Expert,BAO_0000219
4348,,1,F,Panel NCI-60 (60 carcinoma cell lines),1,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,80315,,,,CHEMBL620982,17376,,542.0,,,N,Expert,BAO_0000219
4349,,1,F,Panel NCI-60 (60 carcinoma cell lines),1,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,80315,,,,CHEMBL620983,17376,,542.0,,,N,Expert,BAO_0000219
4350,,4,F,,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,,,CHEMBL620984,3241,,,,,H,Autocuration,BAO_0000019
4351,,4,F,,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,,,CHEMBL620985,3241,,,,,H,Autocuration,BAO_0000019
4352,,8,B,,1,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,275,,,,CHEMBL620986,3725,,,,,H,Expert,BAO_0000357
4353,Plasmodium falciparum,1,F,,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,50425,5833.0,,,CHEMBL620987,10805,,,,,N,Expert,BAO_0000218
4354,Plasmodium falciparum,1,F,,1,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,50425,5833.0,,,CHEMBL620988,10805,,,,,N,Expert,BAO_0000218
4355,Plasmodium falciparum,1,F,,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,50425,5833.0,,,CHEMBL620989,10805,,,,,N,Expert,BAO_0000218
4356,Plasmodium falciparum,1,F,,1,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,50425,5833.0,,,CHEMBL620990,10805,,,,,N,Expert,BAO_0000218
4357,Plasmodium falciparum,1,F,,1,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,50425,5833.0,,,CHEMBL620991,10805,,,,,N,Intermediate,BAO_0000218
4358,Mus musculus,1,F,6C3HED,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,80628,10090.0,,,CHEMBL620992,10144,,850.0,,,N,Intermediate,BAO_0000218
4359,Mus musculus,1,F,6C3HED,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,80628,10090.0,,,CHEMBL620993,10144,,850.0,,,N,Intermediate,BAO_0000218
4360,Mus musculus,1,F,6C3HED,1,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,80628,10090.0,,,CHEMBL620994,10144,,850.0,,,N,Intermediate,BAO_0000218
4361,Mus musculus,1,F,6C3HED,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,80628,10090.0,,,CHEMBL620995,10144,,850.0,,,N,Intermediate,BAO_0000218
4362,Mus musculus,1,F,6C3HED,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,80628,10090.0,,,CHEMBL620996,10144,,850.0,,,N,Intermediate,BAO_0000218
4363,Mus musculus,1,F,6C3HED,1,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,80628,10090.0,,,CHEMBL875581,10144,,850.0,,,N,Intermediate,BAO_0000218
4364,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,22224,10090.0,,,CHEMBL620997,10685,,,,,U,Autocuration,BAO_0000218
4365,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,22224,10090.0,,,CHEMBL620998,10685,,,,,U,Autocuration,BAO_0000218
4366,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),22224,10090.0,,,CHEMBL620999,10685,,,,,U,Autocuration,BAO_0000218
4367,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,22224,10090.0,,,CHEMBL621000,10685,,,,,U,Autocuration,BAO_0000218
4368,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,22224,10090.0,,,CHEMBL621001,10685,,,,,U,Autocuration,BAO_0000218
4369,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,22224,10090.0,,,CHEMBL621002,10685,,,,,U,Autocuration,BAO_0000218
4370,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,22224,10090.0,,,CHEMBL621003,10685,,,,,U,Autocuration,BAO_0000218
4371,Mus musculus,0,F,,1,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",22224,10090.0,,,CHEMBL621004,10685,,,,,U,Autocuration,BAO_0000218
4372,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),22224,10090.0,,,CHEMBL621005,10685,,,,,U,Autocuration,BAO_0000218
4373,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),22224,10090.0,,,CHEMBL621006,10685,,,,,U,Autocuration,BAO_0000218
4374,Mus musculus,0,F,,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,22224,10090.0,,,CHEMBL621007,10685,,,,,U,Autocuration,BAO_0000218
4375,Mus musculus,0,F,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,22224,10090.0,,,CHEMBL621008,10144,,,,,U,Autocuration,BAO_0000218
4376,Mus musculus,0,F,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,22224,10090.0,,,CHEMBL621009,10144,,,,,U,Autocuration,BAO_0000218
4377,Mus musculus,0,F,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,22224,10090.0,,,CHEMBL857705,10144,,,,,U,Autocuration,BAO_0000218
4378,Mus musculus,0,F,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,22224,10090.0,,,CHEMBL619828,10144,,,,,U,Autocuration,BAO_0000218
4379,Mus musculus,0,F,,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,22224,10090.0,,,CHEMBL619829,10685,,,,,U,Autocuration,BAO_0000218
4380,Mus musculus,0,F,,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,22224,10090.0,,,CHEMBL619830,10685,,,,,U,Autocuration,BAO_0000218
4381,Mus musculus,0,F,,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,22224,10090.0,,,CHEMBL619831,10685,,,,,U,Autocuration,BAO_0000218
4382,Mus musculus,0,F,,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,22224,10090.0,,,CHEMBL619832,10685,,,,,U,Autocuration,BAO_0000218
4383,Mus musculus,0,A,,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,22224,10090.0,,,CHEMBL619833,10685,,,,,U,Autocuration,BAO_0000218
4384,Mus musculus,0,A,,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,22224,10090.0,,,CHEMBL619834,10685,,,,,U,Autocuration,BAO_0000218
4385,Mus musculus,0,A,,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,22224,10090.0,,,CHEMBL619835,10685,,,,,U,Autocuration,BAO_0000218
4386,Mus musculus,0,A,,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,22224,10090.0,,,CHEMBL619836,10685,,,,,U,Autocuration,BAO_0000218
4387,Mus musculus,1,F,6C3HED,1,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",80628,10090.0,,,CHEMBL619837,8831,,850.0,,,N,Intermediate,BAO_0000218
4388,,0,F,,1,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,22224,,,,CHEMBL619838,11704,,,,,U,Autocuration,BAO_0000218
4389,Mus musculus,1,A,,1,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,50594,10090.0,,,CHEMBL619839,11704,,,,,N,Intermediate,BAO_0000218
4390,Mus musculus,1,F,6C3HED,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,80628,10090.0,,,CHEMBL619840,10685,,850.0,,,N,Intermediate,BAO_0000218
4391,Mus musculus,1,F,6C3HED,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,80628,10090.0,,,CHEMBL619841,10685,,850.0,,,N,Intermediate,BAO_0000218
4392,Mus musculus,1,F,6C3HED,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),80628,10090.0,,,CHEMBL857704,11368,,850.0,,,N,Expert,BAO_0000218
4393,Mus musculus,1,F,6C3HED,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),80628,10090.0,,,CHEMBL619842,11368,,850.0,,,N,Intermediate,BAO_0000218
4394,Mus musculus,1,F,6C3HED,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),80628,10090.0,,,CHEMBL619843,11368,,850.0,,,N,Expert,BAO_0000218
4395,Staphylococcus aureus,0,B,,1,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",22226,1280.0,,,CHEMBL619844,17763,,,,,U,Autocuration,BAO_0000019
4396,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,22226,10116.0,Microsomes,,CHEMBL857855,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4397,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,10116.0,Microsomes,,CHEMBL619845,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4398,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,22226,10116.0,Microsomes,,CHEMBL619846,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4399,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,22226,10116.0,Microsomes,,CHEMBL619847,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4400,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,22226,10116.0,Microsomes,,CHEMBL619848,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4401,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,22226,10116.0,Microsomes,,CHEMBL620893,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4402,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,22226,10116.0,Microsomes,,CHEMBL620894,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4403,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,22226,10116.0,Microsomes,,CHEMBL620895,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4404,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,10116.0,Microsomes,,CHEMBL620896,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4405,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,10116.0,Microsomes,,CHEMBL620897,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4406,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,10116.0,Microsomes,,CHEMBL620898,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4407,Rattus norvegicus,0,B,,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,10116.0,Microsomes,,CHEMBL620899,7411,2107.0,,,Liver,U,Autocuration,BAO_0000251
4408,Cercopithecidae,0,A,,1,The apparent total plasma clearance in monkey,22224,9527.0,,,CHEMBL620900,347,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4409,Cercopithecidae,0,A,,1,Compound was evaluated for Hepatic clearance in monkey,22224,9527.0,,,CHEMBL620901,3341,,,,,U,Autocuration,BAO_0000218
4410,Cercopithecidae,0,A,,1,Lower clearance in monkey (i.v.) at 0.5 mpk,22224,9527.0,,,CHEMBL620902,17853,,,,,U,Autocuration,BAO_0000218
4411,Cercopithecidae,0,A,,1,Plasma clearance in rhesus monkey,22224,9527.0,,,CHEMBL620903,4514,,,,,U,Autocuration,BAO_0000218
4412,Cercopithecidae,0,A,,1,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,22224,9527.0,,,CHEMBL620904,6062,,,,,U,Autocuration,BAO_0000218
4413,Cercopithecidae,0,A,,1,Plasma clearance of compound was determined in monkey,22224,9527.0,,,CHEMBL620905,6821,,,,,U,Autocuration,BAO_0000218
4414,Cercopithecidae,0,A,,1,Plasma clearance was calculated in rhesus monkey,22224,9527.0,,,CHEMBL620906,6057,,,,,U,Autocuration,BAO_0000218
4415,Cercopithecidae,0,A,,1,Plasma clearance in rhesus monkey,22224,9527.0,,,CHEMBL875420,5145,,,,,U,Autocuration,BAO_0000218
4416,Cercopithecidae,0,A,,1,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,9527.0,,,CHEMBL620907,6641,,,,,U,Autocuration,BAO_0000218
4417,Cercopithecidae,0,A,,1,Plasma clearance was evaluated in rhesus,22224,9527.0,,,CHEMBL620908,5472,,,,,U,Autocuration,BAO_0000218
4418,Cercopithecidae,0,A,,1,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,22224,9527.0,,,CHEMBL620909,4257,,,,,U,Autocuration,BAO_0000218
4419,Cercopithecidae,0,A,,1,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,9527.0,,,CHEMBL620910,5546,,,,,U,Autocuration,BAO_0000218
4420,Cercopithecidae,0,A,,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,9527.0,,,CHEMBL620911,5334,,,,,U,Autocuration,BAO_0000218
4421,Cercopithecidae,0,A,,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,9527.0,,,CHEMBL620912,5334,,,,,U,Autocuration,BAO_0000218
4422,Cercopithecidae,0,A,,1,Cmax 24 hr after 2 mg/kg oral administration in monkeys,22224,9527.0,,,CHEMBL620913,17509,,,,,U,Autocuration,BAO_0000218
4423,Cercopithecidae,0,A,,1,Cmax in monkey after administration of 1 mg/kg iv,22224,9527.0,,,CHEMBL620914,6535,,,,,U,Autocuration,BAO_0000218
4424,Cercopithecidae,0,A,,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,22224,9527.0,,,CHEMBL620915,5668,,,,,U,Autocuration,BAO_0000218
4425,Cercopithecidae,0,A,,1,Cmax in cynomolgus monkey by iv administration,22224,9527.0,,,CHEMBL620916,5922,,,,,U,Autocuration,BAO_0000218
4426,Cercopithecidae,0,A,,1,Cmax in cynomolgus monkey by po administration,22224,9527.0,,,CHEMBL620917,5922,,,,,U,Autocuration,BAO_0000218
4427,Cercopithecidae,0,A,,1,Cmax value evaluated in monkey,22224,9527.0,,,CHEMBL620918,6078,,,,,U,Autocuration,BAO_0000218
4428,Cercopithecidae,0,A,,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL620919,2661,,,,,U,Autocuration,BAO_0000218
4429,Cercopithecidae,0,A,,1,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,22224,9527.0,,,CHEMBL620920,3249,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4430,Cercopithecidae,0,A,,1,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,22224,9527.0,,,CHEMBL620921,3249,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4431,Cercopithecidae,0,A,,1,Maximal plasma concentration in squirrel monkeys,22224,9527.0,,,CHEMBL620922,5553,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4432,Cercopithecidae,0,A,,1,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,9527.0,,,CHEMBL620923,1916,,,,,U,Autocuration,BAO_0000218
4433,Cercopithecidae,0,A,,1,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,22224,9527.0,,,CHEMBL620924,6227,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4434,Cercopithecidae,0,A,,1,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,9527.0,,,CHEMBL620925,4809,,,,,U,Autocuration,BAO_0000218
4435,Cercopithecidae,0,A,,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,9527.0,,,CHEMBL620926,5355,,,,,U,Autocuration,BAO_0000218
4436,Cercopithecidae,0,A,,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,9527.0,,,CHEMBL620927,5355,,,,,U,Autocuration,BAO_0000218
4437,Cercopithecidae,0,A,,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,22224,9527.0,,,CHEMBL620928,5355,,,,,U,Autocuration,BAO_0000218
4438,Cercopithecidae,0,A,,1,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL620929,5355,,,,,U,Autocuration,BAO_0000218
4439,Cercopithecidae,0,A,,1,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,22224,9527.0,,,CHEMBL620930,6221,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4440,Cercopithecidae,0,A,,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,22224,9527.0,,,CHEMBL620931,167,,,,,U,Autocuration,BAO_0000218
4441,Cercopithecidae,0,A,,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,22224,9527.0,,,CHEMBL620932,167,,,,,U,Autocuration,BAO_0000218
4442,monkey,0,A,,1,Absolute bioavailability was evaluated in monkey,22224,9443.0,,,CHEMBL620933,4257,,,,,U,Autocuration,BAO_0000218
4443,monkey,0,A,,1,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,22224,9443.0,,,CHEMBL620934,6221,,,,,U,Autocuration,BAO_0000218
4444,monkey,0,A,,1,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,22224,9443.0,,,CHEMBL620935,17667,,,,,U,Autocuration,BAO_0000218
4445,Macaca mulatta,0,A,,1,Bioavailability of compound was determined in rhesus monkey,22224,9544.0,,,CHEMBL620936,17267,,,,,U,Autocuration,BAO_0000218
4446,marmosets,0,A,,1,Bioavailability determined after oral administration in marmoset,22224,38020.0,,,CHEMBL620937,4256,,,,,U,Autocuration,BAO_0000218
4447,Macaca fascicularis,0,A,,1,Oral bioavailability in cynomolgus monkey,22224,9541.0,,,CHEMBL620938,4256,,,,,U,Autocuration,BAO_0000218
4448,monkey,0,A,,1,Bioavailability in monkey (p.o.) at 2.0 mpk,22224,9443.0,,,CHEMBL620939,17853,,,,,U,Autocuration,BAO_0000218
4449,monkey,0,A,,1,Bioavailability was evaluated after oral administration in monkey,22224,9443.0,,,CHEMBL620940,16365,,,,,U,Autocuration,BAO_0000218
4450,Macaca fascicularis,0,A,,1,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,9541.0,,,CHEMBL620941,1916,,,,,U,Autocuration,BAO_0000218
4451,Macaca mulatta,0,A,,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,9544.0,,,CHEMBL620942,5334,,,,,U,Autocuration,BAO_0000218
4452,Macaca mulatta,0,A,,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,9544.0,,,CHEMBL620943,5334,,,,,U,Autocuration,BAO_0000218
4453,monkey,0,A,,1,Bioavailability of the compound was determined in monkey,22224,9443.0,,,CHEMBL620944,17592,,,,,U,Autocuration,BAO_0000218
4454,Saimiri sciureus,0,A,,1,Bioavailability in squirrel monkey (dose 5 mg/kg),22224,9521.0,,,CHEMBL620945,1399,,,,,U,Autocuration,BAO_0000218
4455,monkey,0,A,,1,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,9443.0,,,CHEMBL620946,4809,,,,,U,Autocuration,BAO_0000218
4456,monkey,0,A,,1,Oral bioavailability in monkey,22224,9443.0,,,CHEMBL620947,3341,,,,,U,Autocuration,BAO_0000218
4457,Saimiri sciureus,0,A,,1,Compound was tested for bioavailability in squirrel monkey,22224,9521.0,,,CHEMBL620948,64,,,,,U,Autocuration,BAO_0000218
4458,Macaca mulatta,0,A,,1,Oral bioavailability in Rhesus monkey,22224,9544.0,,,CHEMBL620949,5005,,,,,U,Autocuration,BAO_0000218
4459,Macaca mulatta,0,A,,1,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),22224,9544.0,,,CHEMBL620950,5005,,,,,U,Autocuration,BAO_0000218
4460,Macaca fascicularis,0,A,,1,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,22224,9541.0,,,CHEMBL620951,5237,,,,,U,Autocuration,BAO_0000218
4461,Macaca fascicularis,0,A,,1,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,22224,9541.0,,,CHEMBL620952,5237,,,,,U,Autocuration,BAO_0000218
4462,monkey,0,A,,1,Oral bioavailability in monkey (dose 5 mg/kg),22224,9443.0,,,CHEMBL875421,5302,,,,,U,Autocuration,BAO_0000218
4463,monkey,0,A,,1,Oral bioavailability of compound at 5 mg/kg in monkey,22224,9443.0,,,CHEMBL620953,17667,,,,,U,Autocuration,BAO_0000218
4464,Canis lupus familiaris,1,A,,1,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,9615.0,,,CHEMBL873491,6161,,,,,N,Intermediate,BAO_0000218
4465,Canis lupus familiaris,1,A,,1,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,50588,9615.0,,,CHEMBL620954,6161,,,,,N,Intermediate,BAO_0000218
4466,Canis lupus familiaris,1,A,,1,Plasma half life determined,50588,9615.0,,,CHEMBL620955,3854,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4467,Canis lupus familiaris,1,A,,1,Plasma half life in dog,50588,9615.0,,,CHEMBL618097,993,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4468,Canis lupus familiaris,1,A,,1,Plasma half-life in Beagle dogs,50588,9615.0,,,CHEMBL618268,4514,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4469,Canis lupus familiaris,1,A,,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,9615.0,,,CHEMBL618269,5334,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4470,Canis lupus familiaris,1,A,,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),50588,9615.0,,,CHEMBL618270,5334,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4471,Canis lupus familiaris,1,A,,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,50588,9615.0,,,CHEMBL618271,1466,,,,,N,Intermediate,BAO_0000218
4472,Canis lupus familiaris,1,A,,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,50588,9615.0,,,CHEMBL873493,1466,,,,,N,Intermediate,BAO_0000218
4473,Canis lupus familiaris,1,A,,1,Tested for the half life period in dog,50588,9615.0,,,CHEMBL621031,5313,,,,,N,Intermediate,BAO_0000218
4474,Canis lupus familiaris,1,A,,1,Tested for the half life period in dog at dosage of 10 mpk,50588,9615.0,,,CHEMBL621032,5313,,,,,N,Intermediate,BAO_0000218
4475,Canis lupus familiaris,1,A,,1,The compound was tested for half life in dog,50588,9615.0,,,CHEMBL621033,3880,,,,,N,Intermediate,BAO_0000218
4476,Canis lupus familiaris,1,A,,1,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",50588,9615.0,,,CHEMBL621034,3639,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4477,Canis lupus familiaris,1,A,,1,The half life was determined,50588,9615.0,,,CHEMBL621035,3880,,,,,N,Intermediate,BAO_0000218
4478,Canis lupus familiaris,1,A,,1,The plasma half-life in dogs,50588,9615.0,,,CHEMBL621036,3918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4479,Canis lupus familiaris,1,A,,1,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,50588,9615.0,,,CHEMBL621037,16452,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4480,Canis lupus familiaris,1,A,,1,Half life in dog,50588,9615.0,,,CHEMBL619812,17796,,,,,N,Intermediate,BAO_0000218
4481,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,9615.0,,,CHEMBL619813,5983,,,,,N,Intermediate,BAO_0000218
4482,Canis lupus familiaris,1,A,,1,tmax upon peroral administration of 10.0 mg/Kg dose in dog,50588,9615.0,,,CHEMBL873335,1466,,,,,N,Intermediate,BAO_0000218
4483,Canis lupus familiaris,1,A,,1,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL619814,16456,,,,,N,Intermediate,BAO_0000218
4484,Mustela putorius furo,1,A,,1,Cmax in ferrets after 30 mg/kg oral dose,50506,9669.0,,,CHEMBL619815,6113,,,,,N,Expert,BAO_0000218
4485,Mustela putorius furo,1,F,,1,Emesis in ferrets at 30 mg/kg oral dose,50506,9669.0,,,CHEMBL619816,6113,,,,,N,Expert,BAO_0000218
4486,Macaca fascicularis,0,A,,1,Bioavailability in cynomolgus monkey,22224,9541.0,,,CHEMBL619817,17796,,,,,U,Autocuration,BAO_0000218
4487,Macaca fascicularis,1,A,,1,Volume of distribution in cynomolgus,100710,9541.0,,,CHEMBL619818,17796,,,,,N,Intermediate,BAO_0000218
4488,Cavia porcellus,0,A,,1,AUC tested in guinea pig when 3 mg/kg dose was given perorally,22224,10141.0,,,CHEMBL619819,5308,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4489,Cavia porcellus,0,A,,1,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,10141.0,,,CHEMBL619820,4877,,,,,U,Autocuration,BAO_0000218
4490,Cavia porcellus,0,A,,1,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",22224,10141.0,,,CHEMBL875419,4876,,,,,U,Autocuration,BAO_0000218
4491,Cavia porcellus,0,A,,1,AUC in guinea pig after 3mg/kg oral dose,22224,10141.0,,,CHEMBL619821,4878,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4492,Cavia porcellus,0,A,,1,Bioavailability in guinea pig was tested,22224,10141.0,,,CHEMBL619822,5308,,,,,U,Autocuration,BAO_0000218
4493,Cavia porcellus,0,A,,1,Tested for oral bioavailability in guinea pig at 5 mg/kg,22224,10141.0,,,CHEMBL619823,4877,,,,,U,Autocuration,BAO_0000218
4494,Cavia porcellus,0,A,,1,Tested for the oral bioavailability of the compound,22224,10141.0,,,CHEMBL619824,4876,,,,,U,Autocuration,BAO_0000218
4495,Cavia porcellus,0,A,,1,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,22224,10141.0,,,CHEMBL619825,4876,,,,,U,Autocuration,BAO_0000218
4496,Cavia porcellus,0,A,,1,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,22224,10141.0,,,CHEMBL619826,5308,,,,,U,Autocuration,BAO_0000218
4497,Cavia porcellus,0,A,,1,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,10141.0,,,CHEMBL619827,4877,2048.0,,,Lung,U,Autocuration,BAO_0000218
4498,Cavia porcellus,0,A,,1,Cmax in guinea pig after 3mg/kg oral dose,22224,10141.0,,,CHEMBL618167,4878,,,,,U,Autocuration,BAO_0000218
4499,Cavia porcellus,0,A,,1,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL618168,5689,178.0,,,Blood,U,Autocuration,BAO_0000019
4500,Cavia porcellus,0,A,,1,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL618169,5689,955.0,,,Brain,U,Autocuration,BAO_0000019
4501,Cavia porcellus,0,A,,1,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL618170,5689,,,,,U,Autocuration,BAO_0000019
4502,Cavia porcellus,0,A,,1,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL618171,5689,160.0,,,Intestine,U,Autocuration,BAO_0000019
4503,Cavia porcellus,0,A,,1,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL618172,5689,2113.0,,,Kidney,U,Autocuration,BAO_0000019
4504,Cavia porcellus,0,A,,1,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL618173,5689,2107.0,,,Liver,U,Autocuration,BAO_0000019
4505,Cavia porcellus,0,A,,1,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL618174,5689,,,,,U,Autocuration,BAO_0000019
4506,Cavia porcellus,0,A,,1,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,22224,10141.0,,,CHEMBL875408,5689,2106.0,,,Spleen,U,Autocuration,BAO_0000019
4507,Cavia porcellus,0,A,,1,Elimination T1/2 in Guinea pig (PO dose),22224,10141.0,,,CHEMBL839827,14465,,,,,U,Autocuration,BAO_0000218
4508,Cavia porcellus,0,A,,1,Partition coefficient was measured as -log (counts per min ),22224,10141.0,,,CHEMBL618175,5689,,,,,U,Autocuration,BAO_0000019
4509,Cavia porcellus,0,A,,1,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,10141.0,,,CHEMBL618176,611,,,,,U,Autocuration,BAO_0000218
4510,Cavia porcellus,0,A,,1,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,10141.0,,,CHEMBL618177,611,,,,,U,Autocuration,BAO_0000218
4511,Cavia porcellus,0,A,,1,Elimination T1/2 in Guinea pig (PO dose),22224,10141.0,,,CHEMBL618178,14465,,,,,U,Autocuration,BAO_0000218
4512,Cavia porcellus,0,A,,1,"Tested for the half life period of the compound, intravenously",22224,10141.0,,,CHEMBL618179,4876,,,,,U,Autocuration,BAO_0000218
4513,Cavia porcellus,0,A,,1,Half-life was measured,22224,10141.0,,,CHEMBL873489,5689,,,,,U,Autocuration,BAO_0000019
4514,Cavia porcellus,0,A,,1,The time required for onset of inotropy after addition of a single dose of delta F75,22224,10141.0,,,CHEMBL618180,7515,,,,,U,Autocuration,BAO_0000019
4515,Cavia porcellus,0,A,,1,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,22224,10141.0,,,CHEMBL618181,17667,,,,,U,Autocuration,BAO_0000218
4516,Cavia porcellus,0,A,,1,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,22224,10141.0,,,CHEMBL618182,17667,,,,,U,Autocuration,BAO_0000218
4517,Cricetulus griseus,0,A,,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,10029.0,,,CHEMBL618183,4727,,,,,U,Autocuration,BAO_0000218
4518,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL618184,10107,,,,,N,Intermediate,BAO_0000218
4519,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL618185,10107,,,,,N,Intermediate,BAO_0000218
4520,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL618186,10107,,,,,N,Intermediate,BAO_0000218
4521,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL618187,10107,,,,,N,Intermediate,BAO_0000218
4522,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,50594,10090.0,,,CHEMBL618188,10107,,,,,N,Intermediate,BAO_0000218
4523,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL875409,10107,,,,,N,Intermediate,BAO_0000218
4524,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL618189,10107,,,,,N,Intermediate,BAO_0000218
4525,Mus musculus,1,A,,1,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618190,3655,178.0,,,Blood,N,Intermediate,BAO_0000218
4526,Mus musculus,1,A,,1,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618191,3655,178.0,,,Blood,N,Intermediate,BAO_0000218
4527,Mus musculus,1,A,,1,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618192,3655,178.0,,,Blood,N,Intermediate,BAO_0000218
4528,Mus musculus,1,A,,1,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618193,3655,10000001.0,,,Bone,N,Intermediate,BAO_0000218
4529,Mus musculus,1,A,,1,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618194,3655,10000001.0,,,Bone,N,Intermediate,BAO_0000218
4530,Mus musculus,1,A,,1,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618195,3655,10000001.0,,,Bone,N,Intermediate,BAO_0000218
4531,Mus musculus,1,A,,1,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618196,3655,955.0,,,Brain,N,Intermediate,BAO_0000218
4532,Mus musculus,1,A,,1,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618197,3655,955.0,,,Brain,N,Intermediate,BAO_0000218
4533,Mus musculus,1,A,,1,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618198,3655,955.0,,,Brain,N,Intermediate,BAO_0000218
4534,Mus musculus,1,A,,1,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618199,3655,948.0,,,Heart,N,Intermediate,BAO_0000218
4535,Mus musculus,1,A,,1,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618200,3655,948.0,,,Heart,N,Intermediate,BAO_0000218
4536,Mus musculus,1,A,,1,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618201,3655,948.0,,,Heart,N,Intermediate,BAO_0000218
4537,Mus musculus,1,A,,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618202,3655,160.0,,,Intestine,N,Intermediate,BAO_0000218
4538,Mus musculus,1,A,,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618203,3655,160.0,,,Intestine,N,Intermediate,BAO_0000218
4539,Mus musculus,1,A,,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618204,3655,160.0,,,Intestine,N,Intermediate,BAO_0000218
4540,Mus musculus,1,A,,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618205,3655,2113.0,,,Kidney,N,Intermediate,BAO_0000218
4541,Mus musculus,1,A,,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618206,3655,2113.0,,,Kidney,N,Intermediate,BAO_0000218
4542,Mus musculus,1,A,,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618207,3655,2113.0,,,Kidney,N,Intermediate,BAO_0000218
4543,Mus musculus,1,A,,1,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618208,3655,2107.0,,,Liver,N,Intermediate,BAO_0000218
4544,Mus musculus,1,A,,1,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618932,3655,2107.0,,,Liver,N,Intermediate,BAO_0000218
4545,Mus musculus,1,A,,1,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618933,3655,2107.0,,,Liver,N,Intermediate,BAO_0000218
4546,Mus musculus,1,A,,1,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618934,3655,2048.0,,,Lung,N,Intermediate,BAO_0000218
4547,Mus musculus,1,A,,1,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618935,3655,2048.0,,,Lung,N,Intermediate,BAO_0000218
4548,Mus musculus,1,A,,1,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL618936,3655,2048.0,,,Lung,N,Intermediate,BAO_0000218
4549,Mus musculus,1,A,,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL618937,3655,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
4550,Mus musculus,1,A,,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL618938,3655,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
4551,Mus musculus,1,A,,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL619104,3655,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
4552,Mus musculus,1,A,,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL619105,3655,2106.0,,,Spleen,N,Intermediate,BAO_0000218
4553,Mus musculus,1,A,,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL619106,3655,2106.0,,,Spleen,N,Intermediate,BAO_0000218
4554,Mus musculus,1,A,,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL619107,3655,2106.0,,,Spleen,N,Intermediate,BAO_0000218
4555,Mus musculus,1,A,,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,50594,10090.0,,,CHEMBL875410,3655,945.0,,,Stomach,N,Intermediate,BAO_0000218
4556,Mus musculus,1,A,,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,50594,10090.0,,,CHEMBL619108,3655,945.0,,,Stomach,N,Intermediate,BAO_0000218
4557,Mus musculus,1,A,,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,50594,10090.0,,,CHEMBL619109,3655,945.0,,,Stomach,N,Intermediate,BAO_0000218
4558,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,10090.0,,,CHEMBL619110,16597,,,,,N,Intermediate,BAO_0000218
4559,Mus musculus,1,F,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,10090.0,,,CHEMBL619111,16597,,,,,N,Intermediate,BAO_0000218
4560,Mus musculus,1,A,,1,MRT value at a dose of 10 mg/kg intravenous administration in mice.,50594,10090.0,,,CHEMBL619112,16597,,,,,N,Intermediate,BAO_0000218
4561,Mus musculus,1,A,,1,MRT value at a dose of 10 mg/kg peroral administration in mice.,50594,10090.0,,,CHEMBL619113,16597,,,,,N,Intermediate,BAO_0000218
4562,Mus musculus,1,A,,1,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,50594,10090.0,,,CHEMBL619114,17764,,,,,N,Intermediate,BAO_0000218
4563,Mus musculus,1,F,,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,10090.0,,,CHEMBL619115,17764,,,,,N,Intermediate,BAO_0000218
4564,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,81034,9606.0,,,CHEMBL619116,3830,,478.0,,,N,Intermediate,BAO_0000219
4565,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,81034,9606.0,,,CHEMBL619117,3829,,478.0,,,N,Intermediate,BAO_0000219
4566,Homo sapiens,1,F,A2780,1,Compound was evaluated for cytotoxicity against A2780 cell lines.,81034,9606.0,,,CHEMBL619118,2040,,478.0,,,N,Intermediate,BAO_0000219
4567,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,81034,9606.0,,,CHEMBL619119,15684,,478.0,,,N,Intermediate,BAO_0000219
4568,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,9606.0,,,CHEMBL619120,15684,,478.0,,,N,Intermediate,BAO_0000219
4569,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,9606.0,,,CHEMBL619121,15684,,478.0,,,N,Intermediate,BAO_0000219
4570,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,9606.0,,,CHEMBL619122,15684,,478.0,,,N,Intermediate,BAO_0000219
4571,Homo sapiens,1,F,A2780,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,9606.0,,,CHEMBL619123,15684,,478.0,,,N,Intermediate,BAO_0000219
4572,Homo sapiens,1,F,A2780,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,9606.0,,,CHEMBL619124,15684,,478.0,,,N,Intermediate,BAO_0000219
4573,Homo sapiens,1,F,A2780,1,Compound was evaluated for cytotoxicity against A2780 cell line,81034,9606.0,,,CHEMBL619125,2859,,478.0,,,N,Intermediate,BAO_0000219
4574,Homo sapiens,1,F,A2780,1,In vitro inhibitory activity against human tumor cell line A2780,81034,9606.0,,,CHEMBL875411,5618,,478.0,,,N,Intermediate,BAO_0000219
4575,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,81034,9606.0,,,CHEMBL619126,15684,,478.0,,,N,Intermediate,BAO_0000219
4576,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,9606.0,,,CHEMBL619127,15684,,478.0,,,N,Intermediate,BAO_0000219
4577,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,9606.0,,,CHEMBL619128,15684,,478.0,,,N,Intermediate,BAO_0000219
4578,Homo sapiens,1,F,A2780,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,9606.0,,,CHEMBL619129,15684,,478.0,,,N,Intermediate,BAO_0000219
4579,Homo sapiens,1,F,A2780,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,81034,9606.0,,,CHEMBL619130,2113,,478.0,,,N,Intermediate,BAO_0000219
4580,Homo sapiens,1,F,A2780,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,81034,9606.0,,,CHEMBL619131,2113,,478.0,,,N,Intermediate,BAO_0000219
4581,Homo sapiens,1,F,A2780,1,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,81034,9606.0,,,CHEMBL619132,16745,,478.0,,,N,Intermediate,BAO_0000219
4582,Homo sapiens,1,F,A2780,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,9606.0,,,CHEMBL619133,16597,,478.0,,,N,Expert,BAO_0000218
4583,Homo sapiens,1,F,A2780,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,9606.0,,,CHEMBL619134,15684,,478.0,,,N,Intermediate,BAO_0000219
4584,Homo sapiens,1,F,A2780,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,9606.0,,,CHEMBL619135,15684,,478.0,,,N,Intermediate,BAO_0000219
4585,Homo sapiens,1,F,A2780,1,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,81034,9606.0,,,CHEMBL619136,2040,,478.0,,,N,Intermediate,BAO_0000219
4586,Homo sapiens,1,F,A2780,1,Relative resistance factor in A2780 cisplatin-resistant line,81034,9606.0,,,CHEMBL619137,2040,,478.0,,,N,Intermediate,BAO_0000219
4587,Homo sapiens,1,F,A2780,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,81034,9606.0,,,CHEMBL883713,16165,,478.0,,,N,Intermediate,BAO_0000219
4588,Homo sapiens,1,F,A2780,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,81034,9606.0,,,CHEMBL875412,16165,,478.0,,,N,Intermediate,BAO_0000219
4589,Homo sapiens,1,F,A2780,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,9606.0,,,CHEMBL619138,16597,,478.0,,,N,Expert,BAO_0000218
4590,Homo sapiens,1,F,A2780,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,9606.0,,,CHEMBL619262,16597,,478.0,,,N,Expert,BAO_0000218
4591,Homo sapiens,1,F,A2780,1,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,81034,9606.0,,,CHEMBL619139,3992,,478.0,,,N,Intermediate,BAO_0000219
4592,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,81034,9606.0,,,CHEMBL619140,10553,,478.0,,,N,Intermediate,BAO_0000219
4593,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,81034,9606.0,,,CHEMBL619141,15608,,478.0,,,N,Intermediate,BAO_0000219
4594,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,81034,9606.0,,,CHEMBL619142,15608,,478.0,,,N,Intermediate,BAO_0000219
4595,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,81034,9606.0,,,CHEMBL619143,15608,,478.0,,,N,Intermediate,BAO_0000219
4596,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,81034,9606.0,,,CHEMBL619144,15608,,478.0,,,N,Intermediate,BAO_0000219
4597,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,81034,9606.0,,,CHEMBL619145,15608,,478.0,,,N,Intermediate,BAO_0000219
4598,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,81034,9606.0,,,CHEMBL619146,15608,,478.0,,,N,Intermediate,BAO_0000219
4599,Homo sapiens,1,F,A2780,1,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,81034,9606.0,,,CHEMBL619147,15569,,478.0,,,N,Intermediate,BAO_0000219
4600,Homo sapiens,1,F,A2780,1,Antiproliferative effect of compound on A2780/DX cell line,81034,9606.0,,,CHEMBL619148,17420,,478.0,,,N,Intermediate,BAO_0000219
4601,Homo sapiens,1,F,A2780,1,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,81034,9606.0,,,CHEMBL619149,17420,,478.0,,,N,Intermediate,BAO_0000219
4602,Homo sapiens,1,F,A2780,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),81034,9606.0,,,CHEMBL619150,15099,,478.0,,,N,Intermediate,BAO_0000219
4603,Homo sapiens,1,F,A2780,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),81034,9606.0,,,CHEMBL619151,15099,,478.0,,,N,Intermediate,BAO_0000219
4604,Homo sapiens,1,F,A2780,1,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,81034,9606.0,,,CHEMBL883794,17672,,478.0,,,N,Intermediate,BAO_0000219
4605,Homo sapiens,1,F,A2780,1,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,81034,9606.0,,,CHEMBL619152,17672,,478.0,,,N,Intermediate,BAO_0000219
4606,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against A2780ADR cell line,81034,9606.0,,,CHEMBL619153,17270,,478.0,,,N,Intermediate,BAO_0000219
4607,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against A2780CIS cell line,81034,9606.0,,,CHEMBL619154,17270,,478.0,,,N,Intermediate,BAO_0000219
4608,Homo sapiens,1,F,A2780,1,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,81034,9606.0,,,CHEMBL619155,5574,,478.0,,,N,Intermediate,BAO_0000219
4609,Homo sapiens,1,F,A2780,1,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,81034,9606.0,,,CHEMBL619156,2113,,478.0,,,N,Intermediate,BAO_0000219
4610,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,9606.0,,,CHEMBL619157,16913,,478.0,,,N,Intermediate,BAO_0000219
4611,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,9606.0,,,CHEMBL619797,16913,,478.0,,,N,Intermediate,BAO_0000219
4612,Macaca mulatta,0,A,,1,Oral bioavailability of compound in rhesus macaques,22224,9544.0,,,CHEMBL619798,17839,,,,,U,Autocuration,BAO_0000218
4613,monkey,0,A,,1,Oral bioavailability in monkey,22224,9443.0,,,CHEMBL619799,6821,,,,,U,Autocuration,BAO_0000218
4614,monkey,0,A,,1,Oral bioavailability evaluated in monkey,22224,9443.0,,,CHEMBL619800,6078,,,,,U,Autocuration,BAO_0000218
4615,monkey,0,A,,1,Oral bioavailability in monkey (dose 1 mg/kg p.o.),22224,9443.0,,,CHEMBL619801,6535,,,,,U,Autocuration,BAO_0000218
4616,Macaca mulatta,0,A,,1,Oral bioavailability in Rhesus monkey,22224,9544.0,,,CHEMBL619802,4449,,,,,U,Autocuration,BAO_0000218
4617,Macaca mulatta,0,A,,1,Oral bioavailability was calculated in rhesus monkey,22224,9544.0,,,CHEMBL619803,6057,,,,,U,Autocuration,BAO_0000218
4618,Macaca fascicularis,0,A,,1,Oral bioavailability in cynomolgus monkey,22224,9541.0,,,CHEMBL619965,5922,,,,,U,Autocuration,BAO_0000218
4619,monkey,0,A,,1,Oral bioavailability in monkey,22224,9443.0,,,CHEMBL619966,5940,,,,,U,Autocuration,BAO_0000218
4620,monkey,0,A,,1,Oral bioavailability in monkey,22224,9443.0,,,CHEMBL619967,6265,,,,,U,Autocuration,BAO_0000218
4621,monkey,0,A,,1,Oral bioavailability in monkey (dose 1 mg/kg),22224,9443.0,,,CHEMBL620073,6265,,,,,U,Autocuration,BAO_0000218
4622,monkey,0,A,,1,Oral bioavailability in monkey (dose 5 mg/kg),22224,9443.0,,,CHEMBL620074,6265,,,,,U,Autocuration,BAO_0000218
4623,monkey,0,A,,1,Oral bioavailability in monkey,22224,9443.0,,,CHEMBL620075,5940,,,,,U,Autocuration,BAO_0000218
4624,monkey,0,A,,1,Oral bioavailability in monkey,22224,9443.0,,,CHEMBL620076,5940,,,,,U,Autocuration,BAO_0000218
4625,Macaca mulatta,0,A,,1,Oral bioavailability in rhesus monkey,22224,9544.0,,,CHEMBL620077,4514,,,,,U,Autocuration,BAO_0000218
4626,Macaca mulatta,0,A,,1,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,22224,9544.0,,,CHEMBL620078,5546,,,,,U,Autocuration,BAO_0000218
4627,Saimiri sciureus,0,A,,1,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,22224,9521.0,,,CHEMBL620079,5553,,,,,U,Autocuration,BAO_0000218
4628,monkey,0,A,,1,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,9443.0,,,CHEMBL620080,6641,,,,,U,Autocuration,BAO_0000218
4629,Macaca mulatta,0,A,,1,Oral bioavailability in Rhesus monkey,22224,9544.0,,,CHEMBL620081,5472,,,,,U,Autocuration,BAO_0000218
4630,Macaca mulatta,0,A,,1,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),22224,9544.0,,,CHEMBL620082,5668,,,,,U,Autocuration,BAO_0000218
4631,monkey,0,A,,1,Oral bioavailability in monkey at 10 mg/kg of the compound,22224,9443.0,,,CHEMBL620083,5711,,,,,U,Autocuration,BAO_0000218
4632,Macaca mulatta,0,A,,1,Bioavailability in Rhesus monkey,22224,9544.0,,,CHEMBL620084,5145,,,,,U,Autocuration,BAO_0000218
4633,Cercopithecidae,0,A,,1,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL620085,3443,,,,,U,Autocuration,BAO_0000218
4634,Cercopithecidae,0,A,,1,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL874595,3443,,,,,U,Autocuration,BAO_0000218
4635,Cercopithecidae,0,A,,1,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,22224,9527.0,,,CHEMBL873352,3249,,,,,U,Autocuration,BAO_0000218
4636,Cercopithecidae,0,A,,1,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,22224,9527.0,,,CHEMBL620086,3249,,,,,U,Autocuration,BAO_0000218
4637,Cercopithecidae,0,A,,1,Mean residence time was determined after intravenous administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL620087,5355,,,,,U,Autocuration,BAO_0000218
4638,Cercopithecidae,0,A,,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,9527.0,,,CHEMBL620088,5355,,,,,U,Autocuration,BAO_0000218
4639,Cercopithecidae,0,A,,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,9527.0,,,CHEMBL620089,5355,,,,,U,Autocuration,BAO_0000218
4640,Cercopithecidae,0,A,,1,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,9527.0,,,CHEMBL620090,4809,,,,,U,Autocuration,BAO_0000218
4641,Cercopithecidae,0,A,,1,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,9527.0,,,CHEMBL620091,4809,,,,,U,Autocuration,BAO_0000218
4642,Cercopithecidae,0,A,,1,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),22224,9527.0,Microsomes,,CHEMBL620092,14294,,,,,U,Autocuration,BAO_0000251
4643,Cercopithecidae,0,A,,1,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),22224,9527.0,Microsomes,,CHEMBL620093,14294,,,,,U,Autocuration,BAO_0000251
4644,Cercopithecidae,0,A,,1,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),22224,9527.0,Microsomes,,CHEMBL620094,14294,,,,,U,Autocuration,BAO_0000251
4645,Cercopithecidae,0,A,,1,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),22224,9527.0,Microsomes,,CHEMBL620095,14294,,,,,U,Autocuration,BAO_0000251
4646,Cercopithecidae,0,A,,1,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL620096,3443,,,,,U,Autocuration,BAO_0000218
4647,Cercopithecidae,0,A,,1,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL620097,3443,,,,,U,Autocuration,BAO_0000218
4648,Cercopithecidae,0,A,,1,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,22224,9527.0,,,CHEMBL620098,11271,,,,,U,Autocuration,BAO_0000019
4649,Cercopithecidae,0,A,,1,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL620099,3443,,,,,U,Autocuration,BAO_0000218
4650,Cercopithecidae,0,A,,1,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL620100,3443,,,,,U,Autocuration,BAO_0000218
4651,Cercopithecidae,0,A,,1,Elimination Half-life of compound was determined in monkey,22224,9527.0,,,CHEMBL620101,6821,,,,,U,Autocuration,BAO_0000019
4652,Cercopithecidae,0,A,,1,Half life of compound was determined in rhesus monkey,22224,9527.0,,,CHEMBL620102,17267,,,,,U,Autocuration,BAO_0000019
4653,Cercopithecidae,0,A,,1,Half life in monkey plasma,22224,9527.0,,,CHEMBL620103,5819,1969.0,,,Plasma,U,Autocuration,BAO_0000366
4654,Cercopithecidae,0,A,,1,Half life in monkey plasma; Not detected,22224,9527.0,,,CHEMBL620104,5819,1969.0,,,Plasma,U,Autocuration,BAO_0000366
4655,Cercopithecidae,0,A,,1,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,9527.0,,,CHEMBL874596,1916,,,,,U,Autocuration,BAO_0000218
4656,Cercopithecidae,0,A,,1,Half-life 24 hr after 2 mg/kg iv administration in monkeys,22224,9527.0,,,CHEMBL873490,17509,,,,,U,Autocuration,BAO_0000218
4657,Cercopithecidae,0,A,,1,Terminal half life of the compound.,22224,9527.0,,,CHEMBL620105,1399,,,,,U,Autocuration,BAO_0000019
4658,Cercopithecidae,0,A,,1,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,9527.0,,,CHEMBL620780,1916,,,,,U,Autocuration,BAO_0000218
4659,Cercopithecidae,0,A,,1,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,9527.0,,,CHEMBL620781,4809,,,,,U,Autocuration,BAO_0000218
4660,Cercopithecidae,0,A,,1,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,9527.0,,,CHEMBL620956,5546,,,,,U,Autocuration,BAO_0000218
4661,Cercopithecidae,0,A,,1,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL620957,3443,1088.0,,,Urine,U,Autocuration,BAO_0000218
4662,Cercopithecidae,0,A,,1,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL620958,3443,1088.0,,,Urine,U,Autocuration,BAO_0000218
4663,Cercopithecidae,0,A,,1,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,22224,9527.0,,,CHEMBL620959,4257,,,,,U,Autocuration,BAO_0000218
4664,Cercopithecidae,0,A,,1,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,22224,9527.0,,,CHEMBL620960,6221,,,,,U,Autocuration,BAO_0000218
4665,Cercopithecidae,0,A,,1,Volume of distribution was evaluated in rhesus,22224,9527.0,,,CHEMBL620961,5472,,,,,U,Autocuration,BAO_0000218
4666,Cricetulus griseus,0,A,,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,10029.0,,,CHEMBL620962,4727,,,,,U,Autocuration,BAO_0000218
4667,Cricetulus griseus,0,A,,1,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,22224,10029.0,,,CHEMBL620963,4727,,,,,U,Autocuration,BAO_0000218
4668,Cricetulus griseus,0,A,,1,Bioavailability in hamster was determined,22224,10029.0,,,CHEMBL620964,4727,,,,,U,Autocuration,BAO_0000218
4669,Cricetulus griseus,0,A,,1,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,22224,10029.0,,,CHEMBL620965,4727,,,,,U,Autocuration,BAO_0000218
4670,Cricetulus griseus,0,A,,1,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,22224,10029.0,,,CHEMBL620966,4727,,,,,U,Autocuration,BAO_0000218
4671,Cricetulus griseus,0,A,,1,Half life of compound was determined in hamster blood,22224,10029.0,,,CHEMBL620967,4727,178.0,,,Blood,U,Autocuration,BAO_0000221
4672,Sus scrofa,0,A,,1,Michaelis-Menten constant of the compound.,22224,9823.0,,,CHEMBL620968,1452,,,,,U,Autocuration,BAO_0000019
4673,Sus scrofa,0,A,,1,Vmax value was measured at 0 uM concentration of silyl ether.,22224,9823.0,,,CHEMBL874597,1452,,,,,U,Autocuration,BAO_0000019
4674,Sus scrofa,0,A,,1,Vmax value was measured at 10 uM concentration of silyl ether.,22224,9823.0,,,CHEMBL620969,1452,,,,,U,Autocuration,BAO_0000019
4675,Sus scrofa,0,A,,1,Vmax value was measured at 5 uM concentration of silyl ether.,22224,9823.0,,,CHEMBL620970,1452,,,,,U,Autocuration,BAO_0000019
4676,Homo sapiens,9,B,,1,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,235,9606.0,,,CHEMBL620971,11706,,,,,D,Expert,BAO_0000357
4677,Homo sapiens,0,A,,1,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,22224,9606.0,,,CHEMBL620972,1916,,,,,U,Autocuration,BAO_0000218
4678,Homo sapiens,0,A,,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),22224,9606.0,,,CHEMBL620973,17791,,,,,U,Autocuration,BAO_0000019
4679,Homo sapiens,0,A,,1,Active metabolite of ifosfamide determined in humans; A-Active,22224,9606.0,,,CHEMBL618243,7766,,,,,U,Autocuration,BAO_0000019
4680,Homo sapiens,0,A,,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,22224,9606.0,,,CHEMBL618244,6567,,,,,U,Autocuration,BAO_0000019
4681,Homo sapiens,0,A,,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,22224,9606.0,,,CHEMBL618245,6567,,,,,U,Autocuration,BAO_0000019
4682,Homo sapiens,0,A,,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,22224,9606.0,,,CHEMBL618246,6567,,,,,U,Autocuration,BAO_0000019
4683,Homo sapiens,0,A,,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,22224,9606.0,,,CHEMBL618247,6567,,,,,U,Autocuration,BAO_0000019
4684,Homo sapiens,0,A,,1,Compound was evaluated for oral bioavailability in human,22224,9606.0,,,CHEMBL618248,17791,,,,,U,Autocuration,BAO_0000218
4685,Homo sapiens,0,A,,1,Metabolite of ifosfamide determined in urine; NF-Not found,22224,9606.0,,,CHEMBL618249,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4686,Homo sapiens,0,A,,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),22224,9606.0,,,CHEMBL618250,6852,,,,,U,Autocuration,BAO_0000019
4687,Homo sapiens,0,A,,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,22224,9606.0,,,CHEMBL874598,6852,,,,,U,Autocuration,BAO_0000019
4688,Homo sapiens,0,A,,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,22224,9606.0,,,CHEMBL618251,6852,,,,,U,Autocuration,BAO_0000019
4689,Homo sapiens,0,A,,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,22224,9606.0,,,CHEMBL618252,6852,,,,,U,Autocuration,BAO_0000019
4690,Homo sapiens,0,A,,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,22224,9606.0,,,CHEMBL618253,6852,,,,,U,Autocuration,BAO_0000019
4691,Homo sapiens,0,A,,1,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),22224,9606.0,,,CHEMBL618254,6852,,,,,U,Autocuration,BAO_0000019
4692,Homo sapiens,0,A,,1,Percent of compound in healthy individuals (Group D),22224,9606.0,,,CHEMBL618255,6852,,,,,U,Autocuration,BAO_0000019
4693,Homo sapiens,0,A,,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,9606.0,Microsomes,,CHEMBL618983,4397,2107.0,,,Liver,U,Autocuration,BAO_0000251
4694,Homo sapiens,0,A,,1,Binding towards human plasma protein at 10 uM,22224,9606.0,,,CHEMBL618984,17409,,,,,U,Autocuration,BAO_0000019
4695,Homo sapiens,0,A,,1,Binding towards human plasma protein at 100 uM,22224,9606.0,,,CHEMBL618985,17409,,,,,U,Autocuration,BAO_0000019
4696,Homo sapiens,0,A,,1,Human plasma protein binding activity was determined,22224,9606.0,,,CHEMBL618986,17176,,,,,U,Autocuration,BAO_0000019
4697,Homo sapiens,0,A,,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,9606.0,,,CHEMBL618987,15444,,,,,U,Autocuration,BAO_0000019
4698,Homo sapiens,0,A,,1,Percent binding of compound towards human plasma protein was determined,22224,9606.0,,,CHEMBL618988,17267,,,,,U,Autocuration,BAO_0000019
4699,Homo sapiens,0,A,,1,Plasma clearance in human liver microsomes,22224,9606.0,Microsomes,,CHEMBL618989,5944,2107.0,,,Liver,U,Autocuration,BAO_0000251
4700,Homo sapiens,0,A,,1,In vitro intrinsic clearance in human liver microsome,22224,9606.0,Microsomes,,CHEMBL618990,5668,2107.0,,,Liver,U,Autocuration,BAO_0000251
4701,Homo sapiens,0,A,,1,In vitro intrinsic clearance in human liver microsome,22224,9606.0,Microsomes,,CHEMBL618991,5669,2107.0,,,Liver,U,Autocuration,BAO_0000251
4702,Homo sapiens,0,A,,1,In vitro microsome metabolism clearance in human was determined,22224,9606.0,Microsomes,,CHEMBL876725,5041,,,,,U,Autocuration,BAO_0000251
4703,Homo sapiens,0,A,,1,In vitro microsome metabolism clearance in human was determined; High,22224,9606.0,Microsomes,,CHEMBL618992,5041,,,,,U,Autocuration,BAO_0000251
4704,Homo sapiens,0,A,,1,In vitro microsome metabolism clearance in human was determined; ND denotes no data,22224,9606.0,Microsomes,,CHEMBL618993,5041,,,,,U,Autocuration,BAO_0000251
4705,Homo sapiens,0,A,,1,Pharmacokinetic property (clearance) in human liver microsome,22224,9606.0,Microsomes,,CHEMBL618994,5676,2107.0,,,Liver,U,Autocuration,BAO_0000251
4706,Homo sapiens,0,A,,1,Plasma clearance in human liver microsomes,22224,9606.0,Microsomes,,CHEMBL618995,5944,2107.0,,,Liver,U,Autocuration,BAO_0000251
4707,Homo sapiens,0,A,,1,In vitro clearance in human liver microsomes,22224,9606.0,Microsomes,,CHEMBL618996,17538,2107.0,,,Liver,U,Autocuration,BAO_0000251
4708,Homo sapiens,0,A,,1,Intrinsic clearance in human liver microsomes was determined,22224,9606.0,Microsomes,,CHEMBL618997,6331,2107.0,,,Liver,U,Autocuration,BAO_0000251
4709,Homo sapiens,0,A,,1,Intrinsic clearance in human liver microsomes was determined,22224,9606.0,Microsomes,,CHEMBL618998,5948,2107.0,,,Liver,U,Autocuration,BAO_0000251
4710,Homo sapiens,0,A,,1,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,22224,9606.0,,,CHEMBL618999,5965,,,,,U,Autocuration,BAO_0000218
4711,Homo sapiens,0,A,,1,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,22224,9606.0,,,CHEMBL620223,1916,,,,,U,Autocuration,BAO_0000218
4712,Homo sapiens,0,A,,1,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,22224,9606.0,,,CHEMBL620224,5965,,,,,U,Autocuration,BAO_0000218
4713,Homo sapiens,0,A,,1,Stability in human plasma 2 hr after incubation expressed as percent concentration,22224,9606.0,,,CHEMBL620225,1299,,,,,U,Autocuration,BAO_0000019
4714,Homo sapiens,0,A,,1,Stability in human plasma 4 hr after incubation expressed as percent concentration,22224,9606.0,,,CHEMBL620226,1299,,,,,U,Autocuration,BAO_0000019
4715,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL620227,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4716,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL876726,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4717,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL620228,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4718,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL620229,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4719,Mus musculus,1,F,,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,10090.0,,,CHEMBL620230,17764,,,,,N,Intermediate,BAO_0000218
4720,Mus musculus,1,F,,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,10090.0,,,CHEMBL620231,17764,,,,,N,Intermediate,BAO_0000218
4721,Mus musculus,1,F,,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,10090.0,,,CHEMBL620232,17764,,,,,N,Intermediate,BAO_0000218
4722,Mus musculus,1,F,,1,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,50594,10090.0,,,CHEMBL620233,17764,,,,,N,Intermediate,BAO_0000218
4723,Mus musculus,1,A,,1,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),50594,10090.0,,,CHEMBL620234,14294,,,,,N,Intermediate,BAO_0000218
4724,Mus musculus,1,A,,1,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),50594,10090.0,,,CHEMBL620235,14294,,,,,N,Intermediate,BAO_0000218
4725,Mus musculus,1,A,,1,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),50594,10090.0,,,CHEMBL620236,14294,,,,,N,Intermediate,BAO_0000218
4726,Mus musculus,1,A,,1,In vitro metabolic potential in mouse liver microsomes,50594,10090.0,,,CHEMBL620237,6251,2107.0,,,Liver,N,Intermediate,BAO_0000218
4727,Mus musculus,1,A,,1,Ability of compound to bind to plasma protein was evaluated in HSA cells,50594,10090.0,,,CHEMBL620238,17582,,,,,N,Intermediate,BAO_0000218
4728,Mus musculus,1,A,,1,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),50594,10090.0,,,CHEMBL620239,17811,2369.0,,,Adrenal gland,N,Intermediate,BAO_0000218
4729,Mus musculus,1,A,,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,50594,10090.0,,,CHEMBL620240,17811,955.0,,,Brain,N,Intermediate,BAO_0000218
4730,Mus musculus,1,A,,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,50594,10090.0,,,CHEMBL620241,17811,955.0,,,Brain,N,Intermediate,BAO_0000218
4731,Mus musculus,1,A,,1,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),50594,10090.0,,,CHEMBL876727,17811,,,,,N,Intermediate,BAO_0000218
4732,Mus musculus,1,A,,1,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),50594,10090.0,,,CHEMBL620242,17811,2113.0,,,Kidney,N,Intermediate,BAO_0000218
4733,Mus musculus,1,A,,1,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),50594,10090.0,,,CHEMBL620243,17811,,,,,N,Intermediate,BAO_0000218
4734,Mus musculus,1,A,,1,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,50594,10090.0,,,CHEMBL620244,5288,,,,,N,Intermediate,BAO_0000218
4735,Mus musculus,1,A,,1,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,50594,10090.0,,,CHEMBL620245,2717,1977.0,,,Serum,N,Intermediate,BAO_0000218
4736,Mus musculus,1,A,,1,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,50594,10090.0,,,CHEMBL620246,2717,1977.0,,,Serum,N,Intermediate,BAO_0000218
4737,Mus musculus,1,A,,1,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,50594,10090.0,,,CHEMBL620247,2717,1977.0,,,Serum,N,Intermediate,BAO_0000218
4738,Mus musculus,1,A,,1,Half life of compound was determined in plasma of mice at 24 mg/Kg,50594,10090.0,,,CHEMBL620248,17753,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4739,Mus musculus,1,A,,1,Half life of compound was determined in plasma of mice at 40 mg/Kg,50594,10090.0,,,CHEMBL873497,17753,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4740,Mus musculus,1,A,,1,Half life of compound was determined in plasma of mice at 5 mg/Kg,50594,10090.0,,,CHEMBL620249,17753,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4741,Mus musculus,1,F,,1,Half life after intraperitoneal administration in mice at 18 uM/kg,50594,10090.0,,,CHEMBL620250,17764,,,,,N,Intermediate,BAO_0000218
4742,Mus musculus,1,F,,1,Half life after intraperitoneal administration in mice at 23 uM/kg,50594,10090.0,,,CHEMBL620251,17764,,,,,N,Intermediate,BAO_0000218
4743,Mus musculus,1,F,,1,Half life after intraperitoneal administration in mice at 25 uM/kg,50594,10090.0,,,CHEMBL620252,17764,,,,,N,Intermediate,BAO_0000218
4744,Mus musculus,1,F,,1,Half life after intraperitoneal administration in mice at 26 uM/kg,50594,10090.0,,,CHEMBL620253,17764,,,,,N,Intermediate,BAO_0000218
4745,Mus musculus,1,F,,1,Half life after intravenous administration in mice at 23 uM/kg,50594,10090.0,,,CHEMBL620254,17764,,,,,N,Intermediate,BAO_0000218
4746,Mus musculus,1,A,,1,Half life after intravenous administration in mice at 24 uM/kg,50594,10090.0,,,CHEMBL620255,17764,,,,,N,Intermediate,BAO_0000218
4747,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,10090.0,,,CHEMBL620256,16597,,,,,N,Intermediate,BAO_0000218
4748,Mus musculus,1,A,,1,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,50594,10090.0,,,CHEMBL876728,2675,,,,,N,Intermediate,BAO_0000218
4749,Mus musculus,1,A,,1,Maximum time required to reach Cp max was evaluated in mice after oral administration,50594,10090.0,,,CHEMBL620257,2675,,,,,N,Intermediate,BAO_0000218
4750,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,10090.0,,,CHEMBL620258,16597,,,,,N,Intermediate,BAO_0000218
4751,Mus musculus,1,A,,1,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",50594,10090.0,,,CHEMBL620259,4890,,,,,N,Intermediate,BAO_0000218
4752,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,50594,10090.0,,,CHEMBL620260,429,,,,,N,Intermediate,BAO_0000218
4753,Mus musculus,1,A,,1,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,50594,10090.0,,,CHEMBL620261,17837,178.0,,,Blood,N,Intermediate,BAO_0000218
4754,Mus musculus,1,A,,1,Half life at a dose of 10 mg/kg intravenous administration in mice.,50594,10090.0,,,CHEMBL620262,16597,,,,,N,Intermediate,BAO_0000218
4755,Mus musculus,1,A,,1,Half life at a dose of 10 mg/kg peroral administration in mice.,50594,10090.0,,,CHEMBL620263,16597,,,,,N,Intermediate,BAO_0000218
4756,Mus musculus,1,A,,1,Half life in ob/ob mice,50594,10090.0,,,CHEMBL620264,6619,,,,,N,Intermediate,BAO_0000218
4757,Mus musculus,1,A,,1,Half-life at a single subcutaneous administration of 40 mg/kg in mice,50594,10090.0,,,CHEMBL620265,4066,,,,,N,Intermediate,BAO_0000218
4758,Mus musculus,1,A,,1,Half-life was measured in mouse,50594,10090.0,,,CHEMBL620266,4239,,,,,N,Intermediate,BAO_0000218
4759,Mus musculus,1,A,,1,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,50594,10090.0,,,CHEMBL620267,5969,,,,,N,Intermediate,BAO_0000218
4760,Mus musculus,1,A,,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,50594,10090.0,,,CHEMBL619364,8999,,,,,N,Intermediate,BAO_0000218
4761,Mus musculus,1,A,,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,50594,10090.0,,,CHEMBL619365,8999,,,,,N,Intermediate,BAO_0000218
4762,Mus musculus,1,A,,1,T2 in brain of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL619366,17641,955.0,,,Brain,N,Intermediate,BAO_0000218
4763,Mus musculus,1,A,,1,T2 in kidney of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL619367,17641,2113.0,,,Kidney,N,Intermediate,BAO_0000218
4764,Mus musculus,1,A,,1,T2 in liver of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL619368,17641,2107.0,,,Liver,N,Intermediate,BAO_0000218
4765,Mus musculus,1,A,,1,T2 in lungs of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL619369,17641,2048.0,,,Lung,N,Intermediate,BAO_0000218
4766,Mus musculus,1,A,,1,T2 in spleen of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL876729,17641,2106.0,,,Spleen,N,Intermediate,BAO_0000218
4767,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,10090.0,,,CHEMBL619370,16597,,,,,N,Intermediate,BAO_0000218
4768,Mus musculus,1,A,,1,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",50594,10090.0,,,CHEMBL619371,4890,,,,,N,Intermediate,BAO_0000218
4769,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,50594,10090.0,,,CHEMBL619372,429,,,,,N,Intermediate,BAO_0000218
4770,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,50594,10090.0,,,CHEMBL620012,429,,,,,N,Intermediate,BAO_0000218
4771,Mus musculus,1,A,,1,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,50594,10090.0,,,CHEMBL620013,5969,,,,,N,Intermediate,BAO_0000218
4772,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,9606.0,,,CHEMBL620014,16913,,478.0,,,N,Intermediate,BAO_0000219
4773,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,9606.0,,,CHEMBL620015,16913,,478.0,,,N,Intermediate,BAO_0000219
4774,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,9606.0,,,CHEMBL621010,16913,,478.0,,,N,Intermediate,BAO_0000219
4775,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,9606.0,,,CHEMBL621011,16913,,478.0,,,N,Intermediate,BAO_0000219
4776,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,9606.0,,,CHEMBL621012,16913,,478.0,,,N,Intermediate,BAO_0000219
4777,Homo sapiens,1,F,A2780,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,9606.0,,,CHEMBL621013,16913,,478.0,,,N,Intermediate,BAO_0000219
4778,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against A2780TAX cell line,81034,9606.0,,,CHEMBL621014,17270,,478.0,,,N,Intermediate,BAO_0000219
4779,Homo sapiens,1,F,A2780cisR,1,In vitro inhibitory activity against human tumor cell line A2780cis,80017,9606.0,,,CHEMBL618154,5618,,481.0,,,N,Intermediate,BAO_0000219
4780,Homo sapiens,1,F,A2780,1,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,81034,9606.0,,,CHEMBL618155,17777,,478.0,,,N,Expert,BAO_0000219
4781,Homo sapiens,1,F,A2780cisR,1,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,80017,9606.0,,,CHEMBL618156,16112,,481.0,,,N,Intermediate,BAO_0000219
4782,Homo sapiens,1,F,A2780cisR,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,9606.0,,,CHEMBL618157,15748,,481.0,,,N,Intermediate,BAO_0000219
4783,Homo sapiens,1,F,A2780,1,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,81034,9606.0,,,CHEMBL618328,6633,,478.0,,,N,Intermediate,BAO_0000219
4784,Homo sapiens,1,F,A2780,1,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,81034,9606.0,,,CHEMBL618329,16930,,478.0,,,N,Intermediate,BAO_0000219
4785,Homo sapiens,1,F,A2780,1,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,81034,9606.0,,,CHEMBL618330,17496,,478.0,,,N,Intermediate,BAO_0000219
4786,Homo sapiens,1,F,A2780,1,In vitro antitumor activity against A2780cisR cell line.,81034,9606.0,,,CHEMBL618331,12989,,478.0,,,N,Expert,BAO_0000219
4787,Homo sapiens,1,F,A2780,1,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),81034,9606.0,,,CHEMBL618332,4840,,478.0,,,N,Intermediate,BAO_0000219
4788,Homo sapiens,1,F,A2780,1,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,81034,9606.0,,,CHEMBL618333,12989,,478.0,,,N,Expert,BAO_0000219
4789,Homo sapiens,1,F,A2780cisR,1,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,80017,9606.0,,,CHEMBL618334,16745,,481.0,,,N,Intermediate,BAO_0000219
4790,Homo sapiens,1,F,A2780,1,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,81034,9606.0,,,CHEMBL618335,16597,,478.0,,,N,Expert,BAO_0000219
4791,Rattus norvegicus,9,B,,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,11736,10116.0,,,CHEMBL618336,16547,,,,,D,Expert,BAO_0000019
4792,,8,F,,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,,,,CHEMBL618337,16547,,,,,H,Expert,BAO_0000019
4793,Rattus norvegicus,9,F,,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,10116.0,,,CHEMBL618338,16547,,,,,D,Expert,BAO_0000019
4794,Homo sapiens,9,F,HEK293,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,278,9606.0,,,CHEMBL618339,15856,,722.0,,,D,Expert,BAO_0000219
4795,Homo sapiens,9,F,HEK293,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,278,9606.0,,,CHEMBL618340,15856,,722.0,,,D,Expert,BAO_0000219
4796,Mus musculus,9,B,,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,11831,10090.0,,,CHEMBL618341,16547,,,,,D,Expert,BAO_0000019
4797,,8,F,,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,,,,CHEMBL618342,16547,,,,,H,Expert,BAO_0000019
4798,Mus musculus,9,F,,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,10090.0,,,CHEMBL618343,16547,,,,,D,Expert,BAO_0000019
4799,,8,B,,1,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,280,,,,CHEMBL621038,17402,,,,,H,Expert,BAO_0000357
4800,Homo sapiens,0,F,T-cells,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),22226,9606.0,,,CHEMBL621039,11746,,574.0,,,U,Autocuration,BAO_0000219
4801,Homo sapiens,0,F,T-cells,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,22226,9606.0,,,CHEMBL621040,11746,,574.0,,,U,Autocuration,BAO_0000219
4802,Homo sapiens,1,F,A-375,1,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,80018,9606.0,,,CHEMBL621041,5455,,455.0,,,N,Intermediate,BAO_0000219
4803,Homo sapiens,1,F,A-375,1,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,80018,9606.0,,,CHEMBL621042,2068,,455.0,,,N,Intermediate,BAO_0000219
4804,Homo sapiens,1,F,A-375,1,In vitro antitumor activity against A375cell line extracted form melanoma,80018,9606.0,,,CHEMBL621043,2683,,455.0,,,N,Intermediate,BAO_0000219
4805,Homo sapiens,1,F,A-375,1,Inhibition of cell growth in (A375) melan cell line,80018,9606.0,,,CHEMBL621044,15313,,455.0,,,N,Expert,BAO_0000219
4806,Homo sapiens,1,F,A-375,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,80018,9606.0,,,CHEMBL621045,13739,,455.0,,,N,Intermediate,BAO_0000219
4807,Homo sapiens,1,F,A-375,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,80018,9606.0,,,CHEMBL621046,13739,,455.0,,,N,Intermediate,BAO_0000219
4808,Homo sapiens,1,F,A-375,1,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,80018,9606.0,,,CHEMBL621047,14750,,455.0,,,N,Intermediate,BAO_0000219
4809,Homo sapiens,1,F,A-427,1,Antiproliferative activity measured against A427 human lung carcinoma,80019,9606.0,,,CHEMBL621048,14777,,797.0,,,N,Intermediate,BAO_0000219
4810,Homo sapiens,1,F,A-427,1,Antiproliferative activity measured against A427 human lung carcinoma,80019,9606.0,,,CHEMBL883798,14777,,797.0,,,N,Intermediate,BAO_0000219
4811,Homo sapiens,1,F,A-427,1,Cytotoxicity against lung carcinoma A427 tumor cell lines,80019,9606.0,,,CHEMBL621049,17672,,797.0,,,N,Intermediate,BAO_0000219
4812,Homo sapiens,1,F,A-427,1,Inhibition of large cell lung carcinoma (A427),80019,9606.0,,,CHEMBL621050,14368,,797.0,,,N,Intermediate,BAO_0000219
4813,Homo sapiens,1,F,A-427,1,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,80019,9606.0,,,CHEMBL621051,14368,,797.0,,,N,Intermediate,BAO_0000219
4814,Homo sapiens,1,F,A-427,1,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80019,9606.0,,,CHEMBL621052,13866,,797.0,,,N,Intermediate,BAO_0000219
4815,Homo sapiens,1,F,A-427,1,Inhibitory concentration in human lung carcinoma A427 cell line,80019,9606.0,,,CHEMBL621053,2545,,797.0,,,N,Intermediate,BAO_0000219
4816,Homo sapiens,1,F,A-427,1,Inhibitory concentration in human lung carcinoma A427/VCR cell line,80019,9606.0,,,CHEMBL621054,2545,,797.0,,,N,Intermediate,BAO_0000219
4817,Cercopithecidae,0,A,,1,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,9527.0,,,CHEMBL621055,6062,,,,,U,Autocuration,BAO_0000218
4818,Cercopithecidae,0,A,,1,Tested for volume of distribution upon iv administration to african green monkey,22224,9527.0,,,CHEMBL876398,4578,,,,,U,Autocuration,BAO_0000218
4819,Cercopithecidae,0,A,,1,Volume of distribution in monkey,22224,9527.0,,,CHEMBL621056,17592,,,,,U,Autocuration,BAO_0000218
4820,Macaca mulatta,0,A,,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,9544.0,,,CHEMBL621057,5005,,,,,U,Autocuration,BAO_0000218
4821,Macaca mulatta,0,A,,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,9544.0,,,CHEMBL621058,5005,,,,,U,Autocuration,BAO_0000218
4822,Cercopithecidae,0,A,,1,Pharmacokinetic property(Vdss) in cynomolgus monkey,22224,9527.0,,,CHEMBL621059,5922,,,,,U,Autocuration,BAO_0000218
4823,Cercopithecidae,0,A,,1,The distribution volume after intravenous administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL621060,5355,,,,,U,Autocuration,BAO_0000218
4824,Cercopithecidae,0,A,,1,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,22224,9527.0,,,CHEMBL621061,5355,,,,,U,Autocuration,BAO_0000218
4825,Cercopithecidae,0,A,,1,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,22224,9527.0,,,CHEMBL621062,5355,,,,,U,Autocuration,BAO_0000218
4826,Cercopithecidae,0,A,,1,Volume displacement was calculated in rhesus monkey,22224,9527.0,,,CHEMBL621063,6057,,,,,U,Autocuration,BAO_0000218
4827,Cercopithecidae,0,A,,1,Volume of distribution in steady state was determined in rhesus monkey,22224,9527.0,,,CHEMBL621064,5145,,,,,U,Autocuration,BAO_0000218
4828,Cercopithecidae,0,A,,1,Volume of distribution of compound was determined in monkey,22224,9527.0,,,CHEMBL621065,6821,,,,,U,Autocuration,BAO_0000218
4829,Cercopithecidae,0,A,,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,9527.0,,,CHEMBL621066,5334,,,,,U,Autocuration,BAO_0000218
4830,Cercopithecidae,0,A,,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,9527.0,,,CHEMBL621067,5334,,,,,U,Autocuration,BAO_0000218
4831,Cercopithecidae,0,A,,1,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,9527.0,,,CHEMBL621068,6641,,,,,U,Autocuration,BAO_0000218
4832,Cercopithecidae,0,A,,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL876399,2661,,,,,U,Autocuration,BAO_0000218
4833,Cercopithecidae,0,A,,1,Volume distribution in monkey after administration of 1 mg/kg iv,22224,9527.0,,,CHEMBL621069,6535,,,,,U,Autocuration,BAO_0000218
4834,Cercopithecidae,0,A,,1,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,9527.0,,,CHEMBL621070,4809,,,,,U,Autocuration,BAO_0000218
4835,Cercopithecidae,0,A,,1,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,9527.0,,,CHEMBL621071,6062,,,,,U,Autocuration,BAO_0000218
4836,Cercopithecidae,0,A,,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL621072,3443,,,,,U,Autocuration,BAO_0000218
4837,Cercopithecidae,0,A,,1,Oral systemic bioavailability upon iv administration to african green monkey,22224,9527.0,,,CHEMBL618209,4578,,,,,U,Autocuration,BAO_0000218
4838,Cercopithecidae,0,A,,1,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,9527.0,,,CHEMBL618210,4809,,,,,U,Autocuration,BAO_0000218
4839,Cercopithecidae,0,A,,1,Baboon plasma free fraction. ,22224,9527.0,,,CHEMBL618211,11271,,,,,U,Autocuration,BAO_0000019
4840,Cercopithecidae,0,A,,1,Area under the curve was calculated in rhesus monkey after iv administration,22224,9527.0,,,CHEMBL618212,6057,,,,,U,Autocuration,BAO_0000218
4841,Cercopithecidae,0,A,,1,Area under the curve was calculated in rhesus monkey after peroral administration,22224,9527.0,,,CHEMBL618213,6057,,,,,U,Autocuration,BAO_0000019
4842,Cercopithecidae,0,A,,1,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,22224,9527.0,,,CHEMBL618214,17853,,,,,U,Autocuration,BAO_0000019
4843,Cercopithecidae,0,A,,1,Half life period in monkey after 5 mg/kg dose,22224,9527.0,,,CHEMBL873492,5302,,,,,U,Autocuration,BAO_0000218
4844,Cercopithecidae,0,A,,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose,22224,9527.0,,,CHEMBL618272,4257,,,,,U,Autocuration,BAO_0000218
4845,Cercopithecidae,0,A,,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,22224,9527.0,,,CHEMBL618273,4257,,,,,U,Autocuration,BAO_0000218
4846,Cercopithecidae,0,A,,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,9527.0,,,CHEMBL618274,13501,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4847,Cercopithecidae,0,A,,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,22224,9527.0,,,CHEMBL618275,5394,,,,,U,Autocuration,BAO_0000218
4848,Cercopithecidae,0,A,,1,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL618276,2661,,,,,U,Autocuration,BAO_0000218
4849,Cercopithecidae,0,A,,1,Compound was evaluated for terminal half life in monkey,22224,9527.0,,,CHEMBL618277,3341,,,,,U,Autocuration,BAO_0000019
4850,Cercopithecidae,0,A,,1,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,22224,9527.0,,,CHEMBL618278,3045,,,,,U,Autocuration,BAO_0000218
4851,Macaca mulatta,0,A,,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,9544.0,,,CHEMBL618279,5005,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4852,Cercopithecidae,0,A,,1,Half life of compound was determined in squirrel monkey,22224,9527.0,,,CHEMBL618280,4847,,,,,U,Autocuration,BAO_0000019
4853,Macaca fascicularis,0,A,,1,Half life after iv administration in cynomolgus monkey,22224,9541.0,,,CHEMBL618281,4256,,,,,U,Autocuration,BAO_0000218
4854,Cercopithecidae,0,A,,1,Half life in monkey plasma after administration of 1 mg/kg iv,22224,9527.0,,,CHEMBL618282,6535,1969.0,,,Plasma,U,Autocuration,BAO_0000218
4855,Cercopithecidae,0,A,,1,Half life was calculated in rhesus monkey,22224,9527.0,,,CHEMBL618283,6057,,,,,U,Autocuration,BAO_0000019
4856,Cercopithecidae,0,A,,1,Half life in monkey,22224,9527.0,,,CHEMBL618284,17592,,,,,U,Autocuration,BAO_0000019
4857,Cercopithecidae,0,A,,1,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,9527.0,,,CHEMBL618285,6641,,,,,U,Autocuration,BAO_0000218
4858,Cercopithecidae,0,A,,1,Half life was evaluated in rhesus,22224,9527.0,,,CHEMBL618286,5472,,,,,U,Autocuration,BAO_0000019
4859,Cercopithecidae,0,A,,1,Half life period after oral administration (2.5 mg/kg) in monkey was determined,22224,9527.0,,,CHEMBL618287,6221,,,,,U,Autocuration,BAO_0000218
4860,Cercopithecidae,0,A,,1,Half life period was determine after peroral administration at 10 mpk in Rhesus,22224,9527.0,,,CHEMBL618288,5668,,,,,U,Autocuration,BAO_0000218
4861,Cercopithecidae,0,A,,1,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,9527.0,,,CHEMBL876393,4809,,,,,U,Autocuration,BAO_0000218
4862,Cercopithecidae,0,A,,1,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,9527.0,,,CHEMBL618289,5546,,,,,U,Autocuration,BAO_0000218
4863,Cercopithecidae,0,A,,1,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,22224,9527.0,,,CHEMBL618290,5553,,,,,U,Autocuration,BAO_0000218
4864,Cercopithecidae,0,A,,1,Half-life was calculated in monkey,22224,9527.0,,,CHEMBL618291,6078,,,,,U,Autocuration,BAO_0000019
4865,Cercopithecidae,0,A,,1,Half-life in Squirrel monkey,22224,9527.0,,,CHEMBL618292,5147,,,,,U,Autocuration,BAO_0000019
4866,Cercopithecidae,0,A,,1,Half-life in rhesus monkey,22224,9527.0,,,CHEMBL618293,5145,,,,,U,Autocuration,BAO_0000019
4867,Cercopithecidae,0,A,,1,Half-life was measured in monkey after an iv dose of 1 mg/kg,22224,9527.0,,,CHEMBL618294,6062,,,,,U,Autocuration,BAO_0000218
4868,Cercopithecidae,0,A,,1,Half-life period after intravenous administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL618295,5355,,,,,U,Autocuration,BAO_0000218
4869,Cercopithecidae,0,A,,1,Half-life period after oral administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL618296,5355,,,,,U,Autocuration,BAO_0000218
4870,Cercopithecidae,0,A,,1,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,22224,9527.0,,,CHEMBL618297,5355,,,,,U,Autocuration,BAO_0000218
4871,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL618298,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4872,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL618299,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4873,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL618300,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4874,Homo sapiens,0,A,,1,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,9606.0,,,CHEMBL618301,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4875,Homo sapiens,0,A,,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,9606.0,,,CHEMBL618302,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4876,Homo sapiens,0,A,,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,9606.0,,,CHEMBL876394,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4877,Homo sapiens,0,A,,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,9606.0,,,CHEMBL618303,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4878,Homo sapiens,0,A,,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,9606.0,,,CHEMBL618304,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4879,Homo sapiens,0,A,,1,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,22224,9606.0,,,CHEMBL618305,1916,,,,,U,Autocuration,BAO_0000218
4880,Homo sapiens,0,A,,1,Oral bioavailability in human,22224,9606.0,,,CHEMBL618306,16643,,,,,U,Autocuration,BAO_0000218
4881,Homo sapiens,0,A,,1,Compound was tested for human plasma protein binding,22224,9606.0,,,CHEMBL618307,17248,,,,,U,Autocuration,BAO_0000019
4882,Homo sapiens,0,A,,1,Compound was tested for human plasma protein binding; Not determined,22224,9606.0,,,CHEMBL618308,17248,,,,,U,Autocuration,BAO_0000019
4883,Homo sapiens,0,A,,1,Protein binding activity of compound in human plasma; % Free,22224,9606.0,,,CHEMBL618309,6241,,,,,U,Autocuration,BAO_0000019
4884,Homo sapiens,0,A,,1,Unbound fraction (plasma),22224,9606.0,,,CHEMBL618310,17716,,,,,U,Autocuration,BAO_0000019
4885,Homo sapiens,0,A,,1,Half life for the hydrolysis of compound in human blood serum,22224,9606.0,,,CHEMBL873353,17605,1969.0,,,Plasma,U,Autocuration,BAO_0000366
4886,Homo sapiens,0,A,,1,Half life period in human plasma using phosphate buffer (0.08 M),22224,9606.0,,,CHEMBL618311,17625,1969.0,,,Plasma,U,Autocuration,BAO_0000366
4887,Homo sapiens,0,A,,1,Half life period in human plasma using phosphate buffer (0.1 M),22224,9606.0,,,CHEMBL618312,17625,1969.0,,,Plasma,U,Autocuration,BAO_0000366
4888,Homo sapiens,0,A,,1,Half-life in human plasma was determined,22224,9606.0,,,CHEMBL618313,17747,1969.0,,,Plasma,U,Autocuration,BAO_0000366
4889,Homo sapiens,0,A,,1,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,22224,9606.0,,,CHEMBL618314,15613,,,,,U,Autocuration,BAO_0000019
4890,Homo sapiens,0,A,,1,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),22224,9606.0,,,CHEMBL618315,354,,,,,U,Autocuration,BAO_0000019
4891,Homo sapiens,0,A,,1,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,9606.0,,,CHEMBL618316,3741,,,,,U,Autocuration,BAO_0000019
4892,Homo sapiens,0,A,,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,9606.0,,,CHEMBL618317,3741,,,,,U,Autocuration,BAO_0000019
4893,Homo sapiens,0,A,,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,9606.0,,,CHEMBL620138,3741,,,,,U,Autocuration,BAO_0000019
4894,Homo sapiens,0,A,,1,Partition coefficient (logP),22224,9606.0,,,CHEMBL858280,17599,,,,,U,Autocuration,BAO_0000019
4895,Homo sapiens,0,A,,1,In vitro metabolic stability in human was measured as pmol/min/mg/protein,22224,9606.0,,,CHEMBL620139,5486,,,,,U,Autocuration,BAO_0000019
4896,Homo sapiens,0,A,,1,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,22224,9606.0,Microsomes,,CHEMBL620140,5600,,,,,U,Autocuration,BAO_0000251
4897,Homo sapiens,0,A,,1,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),22224,9606.0,,,CHEMBL620141,14294,,,,,U,Autocuration,BAO_0000019
4898,Homo sapiens,0,A,,1,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),22224,9606.0,,,CHEMBL620142,14294,,,,,U,Autocuration,BAO_0000019
4899,Homo sapiens,0,A,,1,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),22224,9606.0,,,CHEMBL620143,14294,,,,,U,Autocuration,BAO_0000019
4900,Homo sapiens,0,A,,1,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),22224,9606.0,Microsomes,,CHEMBL620144,14294,,,,,U,Autocuration,BAO_0000251
4901,Homo sapiens,0,A,,1,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),22224,9606.0,Microsomes,,CHEMBL620145,14294,,,,,U,Autocuration,BAO_0000251
4902,Homo sapiens,0,A,,1,Metabolism of compound in human microsomes; Trace,22224,9606.0,Microsomes,,CHEMBL620146,14294,,,,,U,Autocuration,BAO_0000251
4903,Homo sapiens,0,A,,1,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,22224,9606.0,Microsomes,,CHEMBL620147,6260,2107.0,,,Liver,U,Autocuration,BAO_0000251
4904,Homo sapiens,0,A,,1,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,22224,9606.0,Microsomes,,CHEMBL620148,6187,,,,,U,Autocuration,BAO_0000251
4905,Homo sapiens,0,A,,1,In vitro metabolic potential in human liver microsomes,22224,9606.0,Microsomes,,CHEMBL620149,6251,2107.0,,,Liver,U,Autocuration,BAO_0000251
4906,Homo sapiens,0,A,,1,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,22224,9606.0,,,CHEMBL876412,3246,,,,,U,Autocuration,BAO_0000019
4907,Homo sapiens,0,A,,1,Tested for human plasma protein binding of the compound; Not tested,22224,9606.0,,,CHEMBL619352,17313,,,,,U,Autocuration,BAO_0000019
4908,Homo sapiens,0,A,,1,Compound was tested for percent protein binding (PB) in human,22224,9606.0,,,CHEMBL619353,6227,,,,,U,Autocuration,BAO_0000019
4909,Homo sapiens,0,A,,1,Protein binding in human plasma,22224,9606.0,,,CHEMBL619354,5530,1969.0,,,Plasma,U,Autocuration,BAO_0000019
4910,Homo sapiens,0,A,,1,Permeability coefficient (B to A) in Caco-2 cell,22224,9606.0,,,CHEMBL619355,6108,,,,,U,Autocuration,BAO_0000019
4911,Homo sapiens,0,A,,1,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,22224,9606.0,,,CHEMBL619356,6108,,,,,U,Autocuration,BAO_0000019
4912,Homo sapiens,0,A,,1,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),22224,9606.0,,,CHEMBL619357,2774,,,,,U,Autocuration,BAO_0000019
4913,Homo sapiens,0,A,,1,In vitro rate of absorption observed as Caco-2 permeability in humans,22224,9606.0,,,CHEMBL619358,16643,,,,,U,Autocuration,BAO_0000019
4914,Homo sapiens,0,A,Caco-2,1,Cellular permeability of compound was determined in Caco-2 cells; High,22224,9606.0,,,CHEMBL619359,17582,,495.0,,,U,Autocuration,BAO_0000219
4915,Homo sapiens,0,A,Caco-2,1,Permeability in Caco-2 cells of compound,22224,9606.0,,,CHEMBL619360,6838,,495.0,,,U,Autocuration,BAO_0000219
4916,Homo sapiens,0,A,,1,Permeability coefficient (A to B) in Caco-2 cell,22224,9606.0,,,CHEMBL619361,6108,,,,,U,Autocuration,BAO_0000019
4917,Homo sapiens,0,A,,1,Permeability coefficient (B to A) in Caco-2 cell,22224,9606.0,,,CHEMBL619362,6108,,,,,U,Autocuration,BAO_0000019
4918,Homo sapiens,0,A,,1,Permeability coefficient (Papp) (Caco-2 cell monolayer),22224,9606.0,,,CHEMBL619363,6108,,,,,U,Autocuration,BAO_0000019
4919,Homo sapiens,0,A,,1,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,22224,9606.0,,,CHEMBL618942,2146,,,,,U,Autocuration,BAO_0000019
4920,Homo sapiens,0,A,,1,Compound was tested for protein binding in human plasma,22224,9606.0,,,CHEMBL618943,4514,,,,,U,Autocuration,BAO_0000019
4921,Homo sapiens,0,A,,1,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,22224,9606.0,,,CHEMBL618944,6108,,,,,U,Autocuration,BAO_0000019
4922,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,22224,9606.0,,,CHEMBL618945,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
4923,Mus musculus,1,A,,1,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,50594,10090.0,,,CHEMBL618946,5969,,,,,N,Intermediate,BAO_0000218
4924,Mus musculus,1,A,,1,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,10090.0,,,CHEMBL876413,3277,,,,,N,Intermediate,BAO_0000218
4925,Mus musculus,1,A,,1,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,10090.0,,,CHEMBL618947,3802,,,,,N,Intermediate,BAO_0000218
4926,Mus musculus,1,A,,1,Time taken to reach maximum concentration in plasma upon oral administration in mouse,50594,10090.0,,,CHEMBL618948,2862,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4927,Mus musculus,1,A,,1,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,10090.0,,,CHEMBL618949,6348,1969.0,,,Plasma,N,Intermediate,BAO_0000218
4928,Mus musculus,1,F,,1,Tmax after intraperitoneal administration in mice at 23 uM/kg,50594,10090.0,,,CHEMBL618950,17764,,,,,N,Intermediate,BAO_0000218
4929,Mus musculus,1,A,,1,Tmax after oral administration at 30 mg/kg in ICR mouse,50594,10090.0,,,CHEMBL618951,5781,,,,,N,Intermediate,BAO_0000218
4930,Mus musculus,1,A,,1,Tmax after peroral administration in mice at 2.4 uM/kg,50594,10090.0,,,CHEMBL618952,17764,,,,,N,Intermediate,BAO_0000218
4931,Mus musculus,1,A,,1,Tmax at a single subcutaneous administration of 40 mg/kg in mice,50594,10090.0,,,CHEMBL618953,4066,,,,,N,Intermediate,BAO_0000218
4932,Mus musculus,1,A,,1,Tmax in brain of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL618954,17641,955.0,,,Brain,N,Intermediate,BAO_0000218
4933,Mus musculus,1,A,,1,Tmax in kidney of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL618955,17641,2113.0,,,Kidney,N,Intermediate,BAO_0000218
4934,Mus musculus,1,A,,1,Tmax in liver of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL618956,17641,2107.0,,,Liver,N,Intermediate,BAO_0000218
4935,Mus musculus,1,A,,1,Tmax in lungs of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL618957,17641,2048.0,,,Lung,N,Intermediate,BAO_0000218
4936,Mus musculus,1,F,,1,Tmax in mice at 18 uM/kg i.p. administration,50594,10090.0,,,CHEMBL618958,17764,,,,,N,Intermediate,BAO_0000218
4937,Mus musculus,1,F,,1,Tmax in mice at 23 uM/kg i.v. administration,50594,10090.0,,,CHEMBL618959,17764,,,,,N,Intermediate,BAO_0000218
4938,Mus musculus,1,F,,1,Tmax in mice at 25 uM/kg i.p. administration,50594,10090.0,,,CHEMBL618960,17764,,,,,N,Intermediate,BAO_0000218
4939,Mus musculus,1,F,,1,Tmax in mice at 26 uM/kg i.p. administration,50594,10090.0,,,CHEMBL876723,17764,,,,,N,Intermediate,BAO_0000218
4940,Mus musculus,1,A,,1,Tmax in spleen of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL618961,17641,2106.0,,,Spleen,N,Intermediate,BAO_0000218
4941,Mus musculus,1,A,,1,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,10090.0,,,CHEMBL618962,16597,,,,,N,Intermediate,BAO_0000218
4942,Mus musculus,1,A,,1,Tmax value at a dose of 10 mg/kg peroral administration in mice.,50594,10090.0,,,CHEMBL618963,16597,,,,,N,Intermediate,BAO_0000218
4943,Mus musculus,1,A,,1,Tmax value in IRC mice,50594,10090.0,,,CHEMBL618964,5951,,,,,N,Intermediate,BAO_0000218
4944,Mus musculus,1,A,,1,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,10090.0,,,CHEMBL618965,5506,,,,,N,Intermediate,BAO_0000218
4945,Mus musculus,1,A,,1,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,10090.0,,,CHEMBL618966,5506,,,,,N,Intermediate,BAO_0000218
4946,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),50594,10090.0,,,CHEMBL618967,429,1088.0,,,Urine,N,Intermediate,BAO_0000218
4947,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),50594,10090.0,,,CHEMBL618968,429,1088.0,,,Urine,N,Intermediate,BAO_0000218
4948,Mus musculus,1,A,,1,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),50594,10090.0,,,CHEMBL618969,4066,1088.0,,,Urine,N,Intermediate,BAO_0000218
4949,Mus musculus,1,A,,1,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL618970,17734,,,,,N,Intermediate,BAO_0000218
4950,Mus musculus,1,A,,1,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL618971,17734,,,,,N,Intermediate,BAO_0000218
4951,Mus musculus,1,A,,1,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,10090.0,,,CHEMBL618972,6062,,,,,N,Intermediate,BAO_0000218
4952,Mus musculus,1,A,,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,50594,10090.0,,,CHEMBL618973,5969,,,,,N,Intermediate,BAO_0000218
4953,Mus musculus,1,A,,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,50594,10090.0,,,CHEMBL618974,5969,,,,,N,Intermediate,BAO_0000218
4954,Mus musculus,1,A,,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,10090.0,,,CHEMBL618975,5969,,,,,N,Intermediate,BAO_0000218
4955,Mus musculus,1,A,,1,Vd in mice,50594,10090.0,,,CHEMBL618976,5980,,,,,N,Intermediate,BAO_0000218
4956,Mus musculus,1,A,,1,Volume of distribution in mouse,50594,10090.0,,,CHEMBL618977,17592,,,,,N,Intermediate,BAO_0000218
4957,Mus musculus,1,A,,1,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,10090.0,,,CHEMBL876724,6348,,,,,N,Intermediate,BAO_0000218
4958,Mus musculus,1,A,,1,Volume of distribution of compound in plasma was determined at 24 mg/Kg,50594,10090.0,,,CHEMBL618978,17753,,,,,N,Intermediate,BAO_0000218
4959,Mus musculus,1,A,,1,Volume of distribution of compound in plasma was determined at 40 mg/Kg,50594,10090.0,,,CHEMBL618979,17753,,,,,N,Intermediate,BAO_0000218
4960,Mus musculus,1,A,,1,Volume of distribution of compound in plasma was determined at 5 mg/Kg,50594,10090.0,,,CHEMBL618980,17753,,,,,N,Intermediate,BAO_0000218
4961,Mus musculus,1,A,,1,Pharmacokinetic property (vdss) was measured in mouse,50594,10090.0,,,CHEMBL618981,4239,,,,,N,Intermediate,BAO_0000218
4962,Mus musculus,1,A,,1,Value distribution upon iv administration in mouse,50594,10090.0,,,CHEMBL618982,2862,,,,,N,Intermediate,BAO_0000218
4963,Mus musculus,1,A,,1,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL620150,17734,,,,,N,Intermediate,BAO_0000218
4964,Mus musculus,1,A,,1,Volume of distribution was evaluated in mice after intravenous administration,50594,10090.0,,,CHEMBL620151,2675,,,,,N,Intermediate,BAO_0000218
4965,Mus musculus,1,A,,1,Volume of distribution was evaluated in mice after oral administration,50594,10090.0,,,CHEMBL620152,2675,,,,,N,Intermediate,BAO_0000218
4966,Mus musculus,1,A,,1,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,50594,10090.0,,,CHEMBL620153,17837,,,,,N,Intermediate,BAO_0000218
4967,Mus musculus,1,A,,1,Steady state volume of distribution was determined in mice,50594,10090.0,,,CHEMBL876395,5727,,,,,N,Intermediate,BAO_0000218
4968,Mus musculus,1,A,,1,Volume distribution (steady state) of compound was determined in mouse,50594,10090.0,,,CHEMBL620154,17852,,,,,N,Intermediate,BAO_0000218
4969,Mus musculus,1,A,,1,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,50594,10090.0,,,CHEMBL620155,17764,,,,,N,Intermediate,BAO_0000218
4970,Mus musculus,1,A,,1,Vss value at a dose of 10 mg/kg intravenous administration in mice.,50594,10090.0,,,CHEMBL620156,16597,,,,,N,Intermediate,BAO_0000218
4971,Mus musculus,1,A,,1,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,10090.0,,,CHEMBL620157,6062,,,,,N,Intermediate,BAO_0000218
4972,Mus musculus,1,A,,1,Biodistribution of compound (oxidized form) in in kidney tissue,50594,10090.0,,,CHEMBL620158,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
4973,Mus musculus,1,A,,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,10090.0,,,CHEMBL620159,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
4974,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,10090.0,,,CHEMBL620160,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
4975,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL620161,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
4976,Homo sapiens,1,F,A-427,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,80019,9606.0,,,CHEMBL620162,10708,,797.0,,,N,Intermediate,BAO_0000219
4977,Homo sapiens,1,F,A-431,1,Inhibition of A431 human squamous cell carcinoma cell proliferation,80852,9606.0,,,CHEMBL620163,16597,,500.0,,,N,Expert,BAO_0000219
4978,Homo sapiens,1,F,A-431,1,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,80852,9606.0,,,CHEMBL620833,16062,,500.0,,,N,Expert,BAO_0000219
4979,Homo sapiens,1,F,A-431,1,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,80852,9606.0,,,CHEMBL876396,16062,,500.0,,,N,Expert,BAO_0000219
4980,Homo sapiens,1,F,A-431,1,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,80852,9606.0,,,CHEMBL620834,16958,,500.0,,,N,Expert,BAO_0000219
4981,Homo sapiens,1,F,A-431,1,Inhibition of A431 human carcinoma cell proliferation,80852,9606.0,,,CHEMBL620835,6700,,500.0,,,N,Expert,BAO_0000219
4982,Homo sapiens,1,F,A-431,1,In vitro inhibition of A431 (human carcinoma) cell basal growth.,80852,9606.0,,,CHEMBL620836,17226,,500.0,,,N,Expert,BAO_0000219
4983,Homo sapiens,1,F,A-431,1,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,80852,9606.0,,,CHEMBL620837,6828,,500.0,,,N,Intermediate,BAO_0000219
4984,Homo sapiens,1,F,A-431,1,In vitro cytotoxicity against epidermoid carcinoma cell line,80852,9606.0,,,CHEMBL621017,12314,,500.0,,,N,Intermediate,BAO_0000219
4985,Homo sapiens,9,F,A-431,1,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9,9606.0,,,CHEMBL621018,13412,,500.0,,,D,Expert,BAO_0000218
4986,Homo sapiens,1,F,A-431,1,Antiproliferative activity of compound was measured on human tumor cell line A431.,80852,9606.0,,,CHEMBL621019,13299,,500.0,,,N,Intermediate,BAO_0000219
4987,Homo sapiens,1,F,A-431,1,Antiproliferative effect of compound on A431 cell line expressing mutant p53,80852,9606.0,,,CHEMBL621020,17420,,500.0,,,N,Intermediate,BAO_0000219
4988,Homo sapiens,1,F,A-431,1,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,80852,9606.0,,,CHEMBL621021,13678,,500.0,,,N,Intermediate,BAO_0000219
4989,,8,F,A-431,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,9,,,,CHEMBL621022,14171,,500.0,,,H,Expert,BAO_0000219
4990,Homo sapiens,1,F,A-431,1,Tested for antiproliferative activity against human A431 cells,80852,9606.0,,,CHEMBL621023,6333,,500.0,,,N,Expert,BAO_0000219
4991,Homo sapiens,9,F,A-431,1,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9,9606.0,,,CHEMBL621024,2356,,500.0,,,D,Expert,BAO_0000219
4992,Homo sapiens,1,F,A-431,1,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,80852,9606.0,,,CHEMBL621025,15578,,500.0,,,N,Expert,BAO_0000219
4993,Homo sapiens,1,F,A-431,1,Inhibition of A431 cell proliferation,80852,9606.0,,,CHEMBL621026,5126,,500.0,,,N,Expert,BAO_0000219
4994,Homo sapiens,1,F,A-431,1,Cytotoxic effect on A431 human epidermoid carcinoma cells,80852,9606.0,,,CHEMBL621027,6844,,500.0,,,N,Expert,BAO_0000219
4995,Homo sapiens,1,F,A-431,1,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),80852,9606.0,,,CHEMBL876397,6844,,500.0,,,N,Expert,BAO_0000219
4996,Homo sapiens,1,F,A-431,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,80852,9606.0,,,CHEMBL883797,4925,,500.0,,,N,Intermediate,BAO_0000219
4997,Homo sapiens,1,F,A-431,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,80852,9606.0,,,CHEMBL621028,4925,,500.0,,,N,Intermediate,BAO_0000219
4998,Homo sapiens,1,F,A-431,1,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,80852,9606.0,,,CHEMBL621029,13978,,500.0,,,N,Intermediate,BAO_0000219
4999,Homo sapiens,1,F,A-431,1,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,80852,9606.0,,,CHEMBL621030,16786,,500.0,,,N,Intermediate,BAO_0000219
5000,,8,F,A-431,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,,CHEMBL621147,13412,,500.0,,,H,Expert,BAO_0000219
5001,Homo sapiens,1,F,A-431,1,In vivo antiproliferative activity against A431 cell line,80852,9606.0,,,CHEMBL621148,17824,,500.0,,,N,Intermediate,BAO_0000218
5002,Homo sapiens,9,F,A-431,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9,9606.0,,,CHEMBL621149,12751,,500.0,,,D,Expert,BAO_0000219
5003,Homo sapiens,1,F,A-431,1,Inhibition of A431 human epidermoid carcinoma cell proliferation,80852,9606.0,,,CHEMBL621150,12380,,500.0,,,N,Expert,BAO_0000219
5004,Homo sapiens,9,F,A-431,1,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9,9606.0,,,CHEMBL621151,4959,,500.0,,,D,Expert,BAO_0000219
5005,Homo sapiens,1,F,A-431,1,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),80852,9606.0,,,CHEMBL621152,6333,,500.0,,,N,Intermediate,BAO_0000219
5006,Homo sapiens,1,F,A-431,1,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),80852,9606.0,,,CHEMBL621153,6333,,500.0,,,N,Intermediate,BAO_0000219
5007,Homo sapiens,1,F,A-431,1,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),80852,9606.0,,,CHEMBL884000,6333,,500.0,,,N,Intermediate,BAO_0000219
5008,Homo sapiens,9,F,,1,Inhibition of EGFR overexpressing A431 cell proliferation,9,9606.0,,,CHEMBL621154,5296,,,,,D,Expert,BAO_0000019
5009,Homo sapiens,1,F,A-431,1,Inhibition of A431 cell proliferation,80852,9606.0,,,CHEMBL621155,12624,,500.0,,,N,Expert,BAO_0000219
5010,Homo sapiens,9,F,A-431,1,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9,9606.0,,,CHEMBL621156,14926,,500.0,,,D,Expert,BAO_0000219
5011,Homo sapiens,9,F,A-431,1,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9,9606.0,,,CHEMBL621157,14926,,500.0,,,D,Expert,BAO_0000219
5012,,8,F,A-431,1,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),9,,,,CHEMBL621158,14926,,500.0,,,H,Expert,BAO_0000219
5013,Homo sapiens,1,F,A-431,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,9606.0,,,CHEMBL621159,15144,,500.0,,,N,Intermediate,BAO_0000219
5014,Homo sapiens,1,F,A-431,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,9606.0,,,CHEMBL621160,15144,,500.0,,,N,Intermediate,BAO_0000219
5015,Homo sapiens,1,F,A-431,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,80852,9606.0,,,CHEMBL621161,5245,,500.0,,,N,Intermediate,BAO_0000219
5016,Homo sapiens,1,F,A-431,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,80852,9606.0,,,CHEMBL621162,5245,,500.0,,,N,Intermediate,BAO_0000219
5017,Homo sapiens,1,F,A-431,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,9606.0,,,CHEMBL621163,5245,,500.0,,,N,Intermediate,BAO_0000219
5018,Homo sapiens,1,F,A-431,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,80852,9606.0,,,CHEMBL621164,5245,,500.0,,,N,Intermediate,BAO_0000219
5019,Homo sapiens,1,F,A-431,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,80852,9606.0,,,CHEMBL621165,5245,,500.0,,,N,Intermediate,BAO_0000219
5020,Cercopithecidae,0,A,,1,Half-life period in cynomolgus monkey,22224,9527.0,,,CHEMBL619159,5922,,,,,U,Autocuration,BAO_0000019
5021,Cercopithecidae,0,A,,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",22224,9527.0,,,CHEMBL619160,1116,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5022,Cercopithecidae,0,A,,1,Longer half-life in monkey (i.v.) at 0.5 mpk,22224,9527.0,,,CHEMBL619161,17853,,,,,U,Autocuration,BAO_0000218
5023,Cercopithecidae,0,A,,1,Plasma half life in monkey,22224,9527.0,,,CHEMBL619162,993,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5024,Cercopithecidae,0,A,,1,Plasma half-life in rhesus monkey,22224,9527.0,,,CHEMBL619163,4514,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5025,Cercopithecidae,0,A,,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,9527.0,,,CHEMBL619164,5334,1969.0,,,Plasma,U,Autocuration,BAO_0000218
5026,Cercopithecidae,0,A,,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,9527.0,,,CHEMBL619320,5334,1969.0,,,Plasma,U,Autocuration,BAO_0000218
5027,Cercopithecidae,0,A,,1,Tested for half life upon iv administration to african green monkey,22224,9527.0,,,CHEMBL619321,4578,,,,,U,Autocuration,BAO_0000218
5028,Cercopithecidae,0,A,,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL873336,2661,,,,,U,Autocuration,BAO_0000218
5029,Cercopithecidae,0,A,,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,9527.0,,,CHEMBL619322,5355,,,,,U,Autocuration,BAO_0000218
5030,Cercopithecidae,0,A,,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,9527.0,,,CHEMBL619323,5355,,,,,U,Autocuration,BAO_0000218
5031,Cercopithecidae,0,A,,1,The time for peak concentration value after oral administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL619324,5355,,,,,U,Autocuration,BAO_0000218
5032,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,22224,9527.0,,,CHEMBL619325,11271,,,,,U,Autocuration,BAO_0000019
5033,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,22224,9527.0,,,CHEMBL876411,11271,,,,,U,Autocuration,BAO_0000019
5034,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,22224,9527.0,,,CHEMBL619326,11271,,,,,U,Autocuration,BAO_0000019
5035,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,22224,9527.0,,,CHEMBL619327,11271,,,,,U,Autocuration,BAO_0000019
5036,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,22224,9527.0,,,CHEMBL619328,11271,,,,,U,Autocuration,BAO_0000019
5037,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,22224,9527.0,,,CHEMBL619329,11271,,,,,U,Autocuration,BAO_0000019
5038,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,22224,9527.0,,,CHEMBL619330,11271,,,,,U,Autocuration,BAO_0000019
5039,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,22224,9527.0,,,CHEMBL619331,11271,,,,,U,Autocuration,BAO_0000019
5040,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,22224,9527.0,,,CHEMBL619332,11271,,,,,U,Autocuration,BAO_0000019
5041,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,22224,9527.0,,,CHEMBL619333,11271,,,,,U,Autocuration,BAO_0000019
5042,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,22224,9527.0,,,CHEMBL619334,11271,,,,,U,Autocuration,BAO_0000019
5043,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,22224,9527.0,,,CHEMBL619335,11271,,,,,U,Autocuration,BAO_0000019
5044,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,22224,9527.0,,,CHEMBL619336,11271,,,,,U,Autocuration,BAO_0000019
5045,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,22224,9527.0,,,CHEMBL619337,11271,,,,,U,Autocuration,BAO_0000019
5046,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,22224,9527.0,,,CHEMBL619338,11271,,,,,U,Autocuration,BAO_0000019
5047,Cercopithecidae,0,A,,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,22224,9527.0,,,CHEMBL619339,11271,,,,,U,Autocuration,BAO_0000019
5048,Rattus norvegicus,1,A,,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,10116.0,,,CHEMBL619340,5809,,,,,N,Intermediate,BAO_0000218
5049,Rattus norvegicus,1,A,,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL873496,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5050,Rattus norvegicus,1,A,,1,AUC value in rat after IV administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619341,3546,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5051,Rattus norvegicus,1,A,,1,AUC value in rat after oral administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619342,3546,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5052,Rattus norvegicus,1,A,,1,Cmax value in rat after oral administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619343,3546,,,,,N,Intermediate,BAO_0000218
5053,Rattus norvegicus,1,A,,1,Bioavailability in rat after oral administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619344,3546,,,,,N,Intermediate,BAO_0000218
5054,Rattus norvegicus,1,A,,1,Tmax value in rat after oral administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619345,3546,,,,,N,Intermediate,BAO_0000218
5055,Rattus norvegicus,1,A,,1,Vc value in rat after IV administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619346,3546,,,,,N,Intermediate,BAO_0000218
5056,Rattus norvegicus,1,A,,1,Half life period in rat after IV administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619347,3546,,,,,N,Intermediate,BAO_0000218
5057,Papio hamadryas,0,A,,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,9557.0,,,CHEMBL619348,10625,,,,,U,Autocuration,BAO_0000019
5058,Papio hamadryas,0,A,,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),22224,9557.0,,,CHEMBL619349,10625,,,,,U,Autocuration,BAO_0000019
5059,Papio hamadryas,0,A,,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),22224,9557.0,,,CHEMBL619350,10625,,,,,U,Autocuration,BAO_0000019
5060,Papio hamadryas,0,A,,1,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,22224,9557.0,,,CHEMBL619351,10625,,,,,U,Autocuration,BAO_0000019
5061,Papio hamadryas,0,A,,1,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,22224,9557.0,,,CHEMBL875953,10625,,,,,U,Autocuration,BAO_0000019
5062,Papio hamadryas,0,A,,1,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,22224,9557.0,,,CHEMBL621716,10625,,,,,U,Autocuration,BAO_0000019
5063,Papio hamadryas,0,A,,1,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,22224,9557.0,,,CHEMBL621717,10625,,,,,U,Autocuration,BAO_0000019
5064,Papio hamadryas,0,A,,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,9557.0,,,CHEMBL621718,10625,,,,,U,Autocuration,BAO_0000019
5065,beagle,0,A,,1,Area under curve after 1 mpk peroral administration to beagles,22224,9615.0,,,CHEMBL621719,3510,,,,,U,Autocuration,BAO_0000019
5066,beagle,0,A,,1,Area under curve after 2 mpk peroral administration to beagles,22224,9615.0,,,CHEMBL621720,3510,,,,,U,Autocuration,BAO_0000019
5067,beagle,0,A,,1,Cmax value after 1 mpk peroral administration to beagles,22224,9615.0,,,CHEMBL621721,3510,,,,,U,Autocuration,BAO_0000218
5068,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,22224,9606.0,,,CHEMBL621722,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
5069,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,22224,9606.0,,,CHEMBL621723,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
5070,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,22224,9606.0,,,CHEMBL621724,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
5071,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,22224,9606.0,,,CHEMBL623443,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
5072,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,22224,9606.0,,,CHEMBL623444,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
5073,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,22224,9606.0,,,CHEMBL623445,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
5074,Homo sapiens,0,A,,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,22224,9606.0,,,CHEMBL623446,7766,1088.0,,,Urine,U,Autocuration,BAO_0000019
5075,Homo sapiens,0,A,,1,Metabolic stability observed at 30 min after administration in human liver microsomes,22224,9606.0,Microsomes,,CHEMBL623447,16643,2107.0,,,Liver,U,Autocuration,BAO_0000251
5076,Homo sapiens,0,A,,1,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,22224,9606.0,,,CHEMBL623448,6852,,,,,U,Autocuration,BAO_0000019
5077,Homo sapiens,0,A,,1,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,22224,9606.0,,,CHEMBL623449,6852,,,,,U,Autocuration,BAO_0000019
5078,Homo sapiens,0,A,,1,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,22224,9606.0,,,CHEMBL623450,6852,,,,,U,Autocuration,BAO_0000019
5079,Homo sapiens,0,A,,1,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",22224,9606.0,Microsomes,,CHEMBL623451,6567,2107.0,,,Liver,U,Autocuration,BAO_0000251
5080,Homo sapiens,0,A,,1,Metabolic stability (% remaining at 30 mins) in human S9.,22224,9606.0,,,CHEMBL623452,6570,,,,,U,Autocuration,BAO_0000019
5081,Homo sapiens,0,A,,1,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,22224,9606.0,,,CHEMBL623453,6570,,,,,U,Autocuration,BAO_0000019
5082,Homo sapiens,0,A,,1,Percent parent compound remaining after 20 min incubation with human liver microsomes,22224,9606.0,Microsomes,,CHEMBL623454,5237,2107.0,,,Liver,U,Autocuration,BAO_0000251
5083,Homo sapiens,0,A,,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,22224,9606.0,Microsomes,,CHEMBL623455,5237,2107.0,,,Liver,U,Autocuration,BAO_0000251
5084,Homo sapiens,0,A,,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,22224,9606.0,Microsomes,,CHEMBL624371,5237,2107.0,,,Liver,U,Autocuration,BAO_0000251
5085,Homo sapiens,0,A,,1,First pass metabolism and metabolic bioavailability using human hepatic microsomes,22224,9606.0,,,CHEMBL624372,5202,,,,,U,Autocuration,BAO_0000218
5086,Homo sapiens,0,A,,1,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,22224,9606.0,,,CHEMBL624373,5481,,,,,U,Autocuration,BAO_0000019
5087,Homo sapiens,0,A,,1,Percent remaining in human plasma after incubation for 60 min at 37 C.,22224,9606.0,,,CHEMBL624374,5481,,,,,U,Autocuration,BAO_0000019
5088,Homo sapiens,0,A,,1,The percent remaining in human plasma after 30 min was determined,22224,9606.0,,,CHEMBL624556,3956,,,,,U,Autocuration,BAO_0000019
5089,Homo sapiens,0,A,,1,Conversion rate of the prodrug in human plasma,22224,9606.0,,,CHEMBL624557,5074,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5090,Homo sapiens,0,A,,1,Conversion rate of the prodrug in human plasma; ND means no data,22224,9606.0,,,CHEMBL624558,5074,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5091,Homo sapiens,0,A,,1,Half life of compound was determined in human blood,22224,9606.0,,,CHEMBL624559,4727,178.0,,,Blood,U,Autocuration,BAO_0000221
5092,Homo sapiens,0,A,,1,Half life of compound was determined in man with once daily dosing,22224,9606.0,,,CHEMBL624560,5965,,,,,U,Autocuration,BAO_0000019
5093,Homo sapiens,0,A,,1,Half life in human microsomes,22224,9606.0,Microsomes,,CHEMBL624561,5732,,,,,U,Autocuration,BAO_0000251
5094,Homo sapiens,0,A,,1,Half life in human plasma,22224,9606.0,,,CHEMBL624562,5819,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5095,Homo sapiens,0,A,,1,Half life in human plasma; Not detected,22224,9606.0,,,CHEMBL624563,5819,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5096,Homo sapiens,0,A,,1,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,22224,9606.0,,,CHEMBL624564,1916,,,,,U,Autocuration,BAO_0000218
5097,Homo sapiens,0,A,,1,Half-life for oxidative metabolic stability was determined using rat liver microsomes,22224,9606.0,Microsomes,,CHEMBL624565,6597,2107.0,,,Liver,U,Autocuration,BAO_0000251
5098,Homo sapiens,0,A,,1,Half-life in human plasma,22224,9606.0,,,CHEMBL875152,5229,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5099,Homo sapiens,0,A,,1,Half-life of the parent prodrug in plasma,22224,9606.0,,,CHEMBL624566,5229,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5100,Homo sapiens,0,A,,1,In vitro half life in human plasma was determined,22224,9606.0,,,CHEMBL873805,2192,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5101,Homo sapiens,0,A,,1,The compound was tested In Vitro for half life in human liver microsomes.,22224,9606.0,Microsomes,,CHEMBL624567,3032,2107.0,,,Liver,U,Autocuration,BAO_0000251
5102,Homo sapiens,0,A,,1,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,22224,9606.0,,,CHEMBL624568,1916,,,,,U,Autocuration,BAO_0000218
5103,Homo sapiens,0,A,,1,Observed volume of distribution,22224,9606.0,,,CHEMBL624569,17716,,,,,U,Autocuration,BAO_0000218
5104,Homo sapiens,0,A,,1,Oral bioavailability in human,22224,9606.0,,,CHEMBL624570,15778,,,,,U,Autocuration,BAO_0000218
5105,Homo sapiens,0,A,,1,Tested for human plasma protein binding of the compound,22224,9606.0,,,CHEMBL624571,17313,,,,,U,Autocuration,BAO_0000019
5106,Homo sapiens,0,A,,1,"First order rate constant, k was determined in human plasma",22224,9606.0,,,CHEMBL624572,4231,,,,,U,Autocuration,BAO_0000019
5107,Homo sapiens,0,A,,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,9606.0,,,CHEMBL624573,4755,,,,,U,Autocuration,BAO_0000019
5108,Homo sapiens,0,A,,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,9606.0,,,CHEMBL875153,4755,,,,,U,Autocuration,BAO_0000019
5109,Homo sapiens,0,A,,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,22224,9606.0,Microsomes,,CHEMBL624574,16907,2107.0,,,Liver,U,Autocuration,BAO_0000251
5110,Homo sapiens,0,A,,1,The compound was tested for the plasma binding in human,22224,9606.0,,,CHEMBL624575,10839,,,,,U,Autocuration,BAO_0000019
5111,Homo sapiens,0,A,,1,Plasma protein binding (human),22224,9606.0,,,CHEMBL624576,10839,,,,,U,Autocuration,BAO_0000019
5112,Homo sapiens,0,A,,1,Compound was evaluated for half-life in human liver microsomes,22224,9606.0,Microsomes,,CHEMBL624577,3199,2107.0,,,Liver,U,Autocuration,BAO_0000251
5113,Homo sapiens,0,A,,1,Half life measured in vitro for its stability in human blood,22224,9606.0,,,CHEMBL624578,1345,178.0,,,Blood,U,Autocuration,BAO_0000221
5114,Homo sapiens,0,A,,1,Half life in human serum,22224,9606.0,,,CHEMBL622796,4297,1977.0,,,Serum,U,Autocuration,BAO_0000019
5115,Homo sapiens,0,A,,1,Half life in human serum; ND=not determined,22224,9606.0,,,CHEMBL622797,4297,1977.0,,,Serum,U,Autocuration,BAO_0000019
5116,Homo sapiens,0,A,,1,Half life were determined in CEM-SS cell extract in decomposition step 1,22224,9606.0,,,CHEMBL622798,4297,,,,,U,Autocuration,BAO_0000019
5117,Homo sapiens,0,A,,1,Half life were determined in CEM-SS cell extract in decomposition step 2,22224,9606.0,,,CHEMBL622799,4297,,,,,U,Autocuration,BAO_0000019
5118,Homo sapiens,0,A,,1,Half life of the in human plasma,22224,9606.0,,,CHEMBL622800,4231,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5119,Homo sapiens,0,A,,1,Half life period in human hepatic S9 fraction was determined,22224,9606.0,S9,,CHEMBL622801,5633,,,,,U,Autocuration,BAO_0000220
5120,Homo sapiens,0,A,,1,Half life period in human liver microsome was determined,22224,9606.0,Microsomes,,CHEMBL622802,5633,2107.0,,,Liver,U,Autocuration,BAO_0000251
5121,Homo sapiens,0,A,,1,Half life period was determined; 6-7,22224,9606.0,,,CHEMBL622803,17791,,,,,U,Autocuration,BAO_0000019
5122,Homo sapiens,0,A,,1,Half life period was evaluated in human,22224,9606.0,,,CHEMBL875154,17791,,,,,U,Autocuration,BAO_0000019
5123,Homo sapiens,0,A,,1,Half life time in human plasma,22224,9606.0,,,CHEMBL622804,3160,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5124,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622805,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5125,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622611,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5126,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622612,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5127,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL875160,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5128,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,10090.0,,,CHEMBL622613,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5129,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622614,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5130,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622615,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
5131,Mus musculus,1,A,,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,10090.0,,,CHEMBL622616,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
5132,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622617,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
5133,Mus musculus,1,A,,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,10090.0,,,CHEMBL622618,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
5134,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,10090.0,,,CHEMBL622619,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
5135,Mus musculus,1,A,,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622620,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
5136,Mus musculus,1,A,,1,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622621,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5137,Mus musculus,1,A,,1,Biodistribution of compound (oxidized form) in blood tissue,50594,10090.0,,,CHEMBL622622,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
5138,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622623,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
5139,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL622624,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
5140,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622625,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
5141,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622626,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
5142,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL622627,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
5143,Mus musculus,1,A,,1,Biodistribution of compound (oxidized form) in brain tissue of mice,50594,10090.0,,,CHEMBL622628,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5144,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622629,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5145,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622630,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5146,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622631,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5147,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL622632,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5148,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL622633,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
5149,Mus musculus,1,A,,1,Biodistribution of compound (oxidized form) in heart tissue of mice,50594,10090.0,,,CHEMBL622634,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5150,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL622635,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5151,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL875161,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5152,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622636,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5153,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL623335,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5154,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL623336,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
5155,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL623337,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5156,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL623338,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5157,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL623339,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5158,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL623524,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5159,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL623525,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5160,Mus musculus,1,A,,1,Biodistribution of compound (oxidized form) in liver tissue,50594,10090.0,,,CHEMBL623526,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
5161,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL623527,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
5162,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL623528,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
5163,Homo sapiens,1,F,A-431,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,80852,9606.0,,,CHEMBL624615,5245,,500.0,,,N,Intermediate,BAO_0000219
5164,Homo sapiens,1,F,A-431,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,9606.0,,,CHEMBL621672,5245,,500.0,,,N,Intermediate,BAO_0000219
5165,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",80852,,,,CHEMBL621673,16289,,500.0,,,N,Expert,BAO_0000218
5166,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",80852,,,,CHEMBL621674,16289,,500.0,,,N,Expert,BAO_0000218
5167,Homo sapiens,9,F,A-431,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,9606.0,,,CHEMBL884002,16093,,500.0,,,D,Expert,BAO_0000219
5168,Homo sapiens,1,F,A-431,1,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",80852,9606.0,,,CHEMBL621850,16825,,500.0,,,N,Intermediate,BAO_0000219
5169,Homo sapiens,1,F,A-431,1,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,80852,9606.0,,,CHEMBL621851,4848,,500.0,,,N,Intermediate,BAO_0000219
5170,Homo sapiens,9,F,A-431,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9,9606.0,,,CHEMBL621852,14827,,500.0,,,D,Expert,BAO_0000219
5171,Homo sapiens,9,F,A-431,1,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9,9606.0,,,CHEMBL621853,14827,,500.0,,,D,Expert,BAO_0000219
5172,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",80852,,,,CHEMBL621854,16289,,500.0,,,N,Expert,BAO_0000218
5173,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,,,CHEMBL621855,16289,,500.0,,,N,Expert,BAO_0000218
5174,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,,,CHEMBL623724,16289,,500.0,,,N,Expert,BAO_0000218
5175,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",80852,,,,CHEMBL623725,16289,,500.0,,,N,Expert,BAO_0000218
5176,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",80852,,,,CHEMBL623726,16289,,500.0,,,N,Expert,BAO_0000218
5177,Homo sapiens,9,F,A-431,1,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9,9606.0,,,CHEMBL623727,16289,,500.0,,,D,Expert,BAO_0000219
5178,,8,F,A-431,1,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,9,,,,CHEMBL623728,16289,,500.0,,,H,Expert,BAO_0000219
5179,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",80852,,,,CHEMBL623729,16289,,500.0,,,N,Expert,BAO_0000218
5180,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,,,CHEMBL623730,16289,,500.0,,,N,Expert,BAO_0000218
5181,,1,F,A-431,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,,,CHEMBL623731,16289,,500.0,,,N,Expert,BAO_0000218
5182,Mus musculus,1,F,A-431,1,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,10090.0,,,CHEMBL623732,14555,,500.0,,,N,Expert,BAO_0000218
5183,Mus musculus,1,F,A-431,1,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,10090.0,,,CHEMBL623733,14555,,500.0,,,N,Expert,BAO_0000218
5184,Mus musculus,1,F,A-431,1,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,10090.0,,,CHEMBL623734,14555,,500.0,,,N,Expert,BAO_0000218
5185,Mus musculus,1,F,A-431,1,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,10090.0,,,CHEMBL623735,14555,,500.0,,,N,Expert,BAO_0000218
5186,Homo sapiens,1,F,A-431,1,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,80852,9606.0,,,CHEMBL623736,1937,,500.0,,,N,Expert,BAO_0000219
5187,Homo sapiens,1,F,A-431,1,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,80852,9606.0,,,CHEMBL623737,13739,,500.0,,,N,Intermediate,BAO_0000219
5188,Homo sapiens,1,F,A-431,1,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,80852,9606.0,,,CHEMBL623738,3558,,500.0,,,N,Intermediate,BAO_0000219
5189,Homo sapiens,1,F,A-431,1,Dose giving a 50% decrease in the living cell number (A437 cells),80852,9606.0,,,CHEMBL875168,3558,,500.0,,,N,Intermediate,BAO_0000219
5190,Homo sapiens,1,F,A549,1,In vitro inhibitory concentration against proliferation of A459 cell line.,80682,9606.0,,,CHEMBL623739,17686,,646.0,,,N,Expert,BAO_0000219
5191,Homo sapiens,1,F,A549,1,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,80682,9606.0,,,CHEMBL623740,5305,,646.0,,,N,Intermediate,BAO_0000219
5192,Homo sapiens,1,F,A549,1,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,80682,9606.0,,,CHEMBL624424,3614,,646.0,,,N,Intermediate,BAO_0000219
5193,Homo sapiens,1,F,A498,1,In vitro antitumor activity against renal A498 tumor cell lines,80021,9606.0,,,CHEMBL624425,17229,,624.0,,,N,Intermediate,BAO_0000219
5194,Homo sapiens,1,F,A498,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",80021,9606.0,,,CHEMBL624426,15935,,624.0,,,N,Intermediate,BAO_0000219
5195,Homo sapiens,1,F,A498,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",80021,9606.0,,,CHEMBL624427,15935,,624.0,,,N,Intermediate,BAO_0000219
5196,Homo sapiens,1,F,A498,1,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,80021,9606.0,,,CHEMBL624428,15560,,624.0,,,N,Intermediate,BAO_0000219
5197,Homo sapiens,1,F,A498,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,80021,9606.0,,,CHEMBL624429,13891,,624.0,,,N,Intermediate,BAO_0000219
5198,Homo sapiens,1,F,A498,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,80021,9606.0,,,CHEMBL624620,13891,,624.0,,,N,Intermediate,BAO_0000219
5199,Homo sapiens,1,F,A498,1,Cytotoxicity on kidney carcinoma (A-498) cell line,80021,9606.0,,,CHEMBL624621,13788,,624.0,,,N,Intermediate,BAO_0000219
5200,Homo sapiens,1,F,A498,1,Compound was evaluated against Human cell line renal A498,80021,9606.0,,,CHEMBL624622,15403,,624.0,,,N,Intermediate,BAO_0000219
5201,Homo sapiens,1,F,A498,1,Compound was tested for inhibition of A498 human renal cancer cell line,80021,9606.0,,,CHEMBL624623,1009,,624.0,,,N,Intermediate,BAO_0000219
5202,Homo sapiens,1,F,A498,1,Growth inhibitory activity against A498 human cancer cell line,80021,9606.0,,,CHEMBL874365,1043,,624.0,,,N,Intermediate,BAO_0000219
5203,Homo sapiens,1,F,A498,1,In vitro antitumor activity against human renal A498 cell line,80021,9606.0,,,CHEMBL624624,5858,,624.0,,,N,Intermediate,BAO_0000219
5204,Homo sapiens,1,F,A498,1,In vitro cytotoxic activity against renal (A498) cell line,80021,9606.0,,,CHEMBL624625,5958,,624.0,,,N,Intermediate,BAO_0000219
5205,Homo sapiens,1,F,A498,1,In vitro cytotoxic activity against human renal cancer (A498) cell line,80021,9606.0,,,CHEMBL624626,5506,,624.0,,,N,Intermediate,BAO_0000219
5206,Homo sapiens,1,F,A498,1,Tested for cytostatic activity against renal A498 cell line,80021,9606.0,,,CHEMBL624627,12781,,624.0,,,N,Intermediate,BAO_0000219
5207,Homo sapiens,1,F,A498,1,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,80021,9606.0,,,CHEMBL883157,14399,,624.0,,,N,Intermediate,BAO_0000219
5208,Homo sapiens,1,F,A498,1,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,80021,9606.0,,,CHEMBL624628,5958,,624.0,,,N,Expert,BAO_0000219
5209,beagle,0,A,,1,Cmax value after 2 mpk peroral administration to beagles,22224,9615.0,,,CHEMBL624629,3510,,,,,U,Autocuration,BAO_0000218
5210,Canis lupus familiaris,0,A,,1,Bioavailability,22224,9615.0,,,CHEMBL623551,3510,,,,,U,Autocuration,BAO_0000218
5211,Canis lupus familiaris,0,A,,1,Bioavailability after 1 mpk peroral administration to beagles,22224,9615.0,,,CHEMBL623552,3510,,,,,U,Autocuration,BAO_0000218
5212,Canis lupus familiaris,0,A,,1,Bioavailability after 2 mpk peroral administration to beagles,22224,9615.0,,,CHEMBL623553,3510,,,,,U,Autocuration,BAO_0000218
5213,Bos taurus,0,A,,1,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,22224,9913.0,,,CHEMBL623554,3085,,,,,U,Autocuration,BAO_0000019
5214,Bos taurus,0,A,,1,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,22224,9913.0,,,CHEMBL623555,3085,,,,,U,Autocuration,BAO_0000019
5215,Bos taurus,0,A,,1,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,22224,9913.0,,,CHEMBL623556,3085,,,,,U,Autocuration,BAO_0000019
5216,Bos taurus,0,A,,1,Solubility against bovine alpha-chymotrypsin,22224,9913.0,,,CHEMBL623557,9372,,,,,U,Autocuration,BAO_0000019
5217,Bos taurus,0,A,,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,9913.0,,,CHEMBL623558,3085,,,,,U,Autocuration,BAO_0000019
5218,Bos taurus,0,A,,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,9913.0,,,CHEMBL623559,3085,,,,,U,Autocuration,BAO_0000019
5219,Bos taurus,0,A,,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,22224,9913.0,,,CHEMBL623560,1469,2106.0,,,Spleen,U,Autocuration,BAO_0000221
5220,Bos taurus,0,A,,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum,22224,9913.0,,,CHEMBL623561,4297,,,,,U,Autocuration,BAO_0000019
5221,Bos taurus,0,A,,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,22224,9913.0,,,CHEMBL623562,4297,,,,,U,Autocuration,BAO_0000019
5222,Bos taurus,0,A,,1,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,22224,9913.0,,,CHEMBL623563,17585,,,,,U,Autocuration,BAO_0000019
5223,Bos taurus,0,A,,1,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,22224,9913.0,,,CHEMBL623564,1336,2106.0,,,Spleen,U,Autocuration,BAO_0000221
5224,Bos taurus,0,A,,1,Half life in presence of 2 mg/mL BSA at pH 8.8,22224,9913.0,,,CHEMBL873806,3085,,,,,U,Autocuration,BAO_0000019
5225,Bos taurus,0,A,,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,22224,9913.0,,,CHEMBL623565,2857,,,,,U,Autocuration,BAO_0000019
5226,Bos taurus,0,A,,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,22224,9913.0,,,CHEMBL623566,2857,,,,,U,Autocuration,BAO_0000019
5227,Bos taurus,0,A,,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,22224,9913.0,,,CHEMBL623567,2857,,,,,U,Autocuration,BAO_0000019
5228,Bos taurus,0,A,,1,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),22224,9913.0,,,CHEMBL623568,1540,,,,,U,Autocuration,BAO_0000019
5229,Canis lupus familiaris,1,A,,1,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,50588,9615.0,,,CHEMBL623569,6316,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5230,Canis lupus familiaris,1,A,,1,AUC after administration at 100 mg/kg/day in dogs,50588,9615.0,,,CHEMBL623570,17594,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5231,Canis lupus familiaris,1,A,,1,AUC in dog at 0-24 hr by peroral administration at 3 mpk,50588,9615.0,,,CHEMBL624254,4953,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5232,Canis lupus familiaris,1,A,,1,AUC value after 15 mg/kg iv dose in Dogs,50588,9615.0,,,CHEMBL624255,16907,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5233,Canis lupus familiaris,1,A,,1,AUC value after 30 mg/kg po dose in Dogs,50588,9615.0,,,CHEMBL624256,16907,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5234,Canis lupus familiaris,1,A,,1,AUC value after administration of 4 mg/Kg oral dose in dog,50588,9615.0,,,CHEMBL624257,2959,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5235,Canis lupus familiaris,1,A,,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,50588,9615.0,,,CHEMBL624258,17594,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5236,Canis lupus familiaris,1,A,,1,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,50588,9615.0,,,CHEMBL875277,5356,,,,,N,Intermediate,BAO_0000218
5237,Canis lupus familiaris,1,A,,1,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,50588,9615.0,,,CHEMBL622667,16807,,,,,N,Intermediate,BAO_0000218
5238,Canis lupus familiaris,1,A,,1,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,50588,9615.0,,,CHEMBL622668,4527,,,,,N,Intermediate,BAO_0000218
5239,Canis lupus familiaris,1,A,,1,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,50588,9615.0,,,CHEMBL622669,4527,,,,,N,Intermediate,BAO_0000218
5240,Canis lupus familiaris,1,A,,1,Area under curve determined in dogs after intravenous administration of 3 mg/kg,50588,9615.0,,,CHEMBL622670,15660,,,,,N,Intermediate,BAO_0000218
5241,Canis lupus familiaris,1,A,,1,Area under curve determined in dogs after oral administration of 10 mg/kg,50588,9615.0,,,CHEMBL622671,15660,,,,,N,Intermediate,BAO_0000218
5242,Canis lupus familiaris,1,A,,1,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,9615.0,,,CHEMBL622672,5802,,,,,N,Intermediate,BAO_0000218
5243,Canis lupus familiaris,1,A,,1,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL622673,3598,,,,,N,Expert,BAO_0000218
5244,Canis lupus familiaris,1,A,,1,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL622674,3598,,,,,N,Expert,BAO_0000218
5245,Canis lupus familiaris,1,A,,1,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,9615.0,,,CHEMBL622675,5944,,,,,N,Intermediate,BAO_0000218
5246,Canis lupus familiaris,1,A,,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,50588,9615.0,,,CHEMBL622676,5944,,,,,N,Intermediate,BAO_0000218
5247,Canis lupus familiaris,1,A,,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,9615.0,,,CHEMBL622677,5944,,,,,N,Intermediate,BAO_0000218
5248,Canis lupus familiaris,1,A,,1,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,50588,9615.0,,,CHEMBL622678,5944,,,,,N,Intermediate,BAO_0000218
5249,Canis lupus familiaris,1,A,,1,Area under curve in dog after administration of 20 mg/kg dose through peroral route,50588,9615.0,,,CHEMBL622679,4186,,,,,N,Intermediate,BAO_0000218
5250,Canis lupus familiaris,1,A,,1,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,9615.0,,,CHEMBL622680,5007,,,,,N,Intermediate,BAO_0000218
5251,Canis lupus familiaris,1,A,,1,Area under curve was determine after peroral administration at 10 mpk in dog,50588,9615.0,,,CHEMBL622681,5668,,,,,N,Intermediate,BAO_0000218
5252,Canis lupus familiaris,1,A,,1,Area under curve was determine after peroral administration at 5 mpk in dog,50588,9615.0,,,CHEMBL875278,5668,,,,,N,Intermediate,BAO_0000218
5253,Canis lupus familiaris,1,A,,1,Area under curve was determined,50588,9615.0,,,CHEMBL622682,5006,,,,,N,Intermediate,BAO_0000218
5254,Canis lupus familiaris,1,A,,1,Area under curve in dogs,50588,9615.0,,,CHEMBL622683,5006,,,,,N,Intermediate,BAO_0000218
5255,Canis lupus familiaris,1,A,,1,Area under curve in dogs at 10 mg/kg dose fo oral administration,50588,9615.0,,,CHEMBL622684,3771,,,,,N,Intermediate,BAO_0000218
5256,Canis lupus familiaris,1,A,,1,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),50588,9615.0,,,CHEMBL622685,3771,,,,,N,Intermediate,BAO_0000218
5257,Canis lupus familiaris,1,A,,1,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,50588,9615.0,,,CHEMBL622686,3771,,,,,N,Intermediate,BAO_0000218
5258,Canis lupus familiaris,1,A,,1,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,9615.0,,,CHEMBL618344,1916,,,,,N,Intermediate,BAO_0000218
5259,Canis lupus familiaris,1,A,,1,Area under curve value in dog at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL875582,5302,,,,,N,Intermediate,BAO_0000218
5260,Canis lupus familiaris,1,A,,1,Area under curve was determined after 0.1 mg/kg iv administration in dog,50588,9615.0,,,CHEMBL618345,5600,,,,,N,Intermediate,BAO_0000218
5261,Canis lupus familiaris,1,A,,1,Area under curve was determined after 0.3 mg/kg po administration in dog,50588,9615.0,,,CHEMBL618346,5600,,,,,N,Intermediate,BAO_0000218
5262,Canis lupus familiaris,1,A,,1,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,50588,9615.0,,,CHEMBL618347,17764,,,,,N,Intermediate,BAO_0000218
5263,Canis lupus familiaris,1,A,,1,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,50588,9615.0,,,CHEMBL618348,4368,,,,,N,Intermediate,BAO_0000218
5264,Homo sapiens,0,A,,1,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,22224,9606.0,,,CHEMBL618349,5318,,,,,U,Autocuration,BAO_0000019
5265,Homo sapiens,0,A,,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,9606.0,,,CHEMBL618350,5318,,,,,U,Autocuration,BAO_0000019
5266,Homo sapiens,0,A,,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,22224,9606.0,,,CHEMBL618351,5318,,,,,U,Autocuration,BAO_0000019
5267,Homo sapiens,0,A,,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,22224,9606.0,,,CHEMBL618352,5318,,,,,U,Autocuration,BAO_0000019
5268,Homo sapiens,0,A,,1,Time taken to reduce 50% of the concentration of compound in blood plasma,22224,9606.0,,,CHEMBL873494,14518,178.0,,,Blood,U,Autocuration,BAO_0000221
5269,Homo sapiens,0,A,,1,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,9606.0,,,CHEMBL618353,2209,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5270,Homo sapiens,0,A,,1,Half life in human plasma,22224,9606.0,,,CHEMBL618354,6787,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5271,Homo sapiens,0,A,,1,Half life in human plasma was reported,22224,9606.0,,,CHEMBL875583,4898,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5272,Homo sapiens,0,A,,1,Half life in human serum,22224,9606.0,,,CHEMBL618355,6072,1977.0,,,Serum,U,Autocuration,BAO_0000019
5273,Homo sapiens,0,A,,1,Half life upon exposure to human plasma,22224,9606.0,,,CHEMBL618356,16907,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5274,Homo sapiens,0,A,,1,t1/2 in human microsomes,22224,9606.0,Microsomes,,CHEMBL618357,5656,,,,,U,Autocuration,BAO_0000251
5275,Homo sapiens,0,A,,1,Half life period in 80% human plasma at 37 degree Centigrade,22224,9606.0,,,CHEMBL618358,4755,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5276,Homo sapiens,0,A,,1,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),22224,9606.0,,,CHEMBL618359,17503,14.0,,,Zone of skin,U,Autocuration,BAO_0000221
5277,Homo sapiens,0,A,,1,Half-life measured in in vitro Cathepsin B assay in human plasma,22224,9606.0,,,CHEMBL618360,12357,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5278,Homo sapiens,0,A,,1,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,22224,9606.0,,,CHEMBL618361,3076,,,,,U,Autocuration,BAO_0000019
5279,Homo sapiens,0,A,,1,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,22224,9606.0,Microsomes,,CHEMBL618362,6410,2107.0,,,Liver,U,Autocuration,BAO_0000251
5280,Homo sapiens,0,A,,1,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,9606.0,,,CHEMBL618363,3741,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5281,Homo sapiens,0,A,,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,9606.0,,,CHEMBL618364,3741,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5282,Homo sapiens,0,A,,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,9606.0,,,CHEMBL875584,3741,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5283,Homo sapiens,0,A,,1,Half-life in the CEM cell extracts,22224,9606.0,,,CHEMBL618365,1540,,,,,U,Autocuration,BAO_0000019
5284,Homo sapiens,0,A,,1,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,22224,9606.0,,,CHEMBL873495,2905,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5285,Homo sapiens,0,A,,1,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,22224,9606.0,,,CHEMBL618366,2905,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5286,Homo sapiens,0,A,,1,Half-life was determined,22224,9606.0,,,CHEMBL618367,5523,,,,,U,Autocuration,BAO_0000019
5287,Homo sapiens,0,A,,1,Half-life (human blood stability),22224,9606.0,,,CHEMBL618368,1499,178.0,,,Blood,U,Autocuration,BAO_0000221
5288,Homo sapiens,0,A,,1,Half-life (human blood stability); no data,22224,9606.0,,,CHEMBL618369,1499,178.0,,,Blood,U,Autocuration,BAO_0000221
5289,Homo sapiens,0,A,,1,Half-life in human plasma,22224,9606.0,,,CHEMBL618370,17065,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5290,Homo sapiens,0,A,,1,CYP3A4 metabolism half-life (t1/2),22224,9606.0,,,CHEMBL618371,6861,,,,,U,Autocuration,BAO_0000019
5291,Homo sapiens,0,A,,1,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),22224,9606.0,,,CHEMBL618372,1499,178.0,,,Blood,U,Autocuration,BAO_0000221
5292,Homo sapiens,0,A,,1,In vitro half life in human plasma,22224,9606.0,,,CHEMBL618373,530,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5293,Homo sapiens,0,A,,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",22224,9606.0,,,CHEMBL618374,1116,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5294,Homo sapiens,0,A,,1,In vitro hydrolysis in human plasma,22224,9606.0,,,CHEMBL618375,6695,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5295,Homo sapiens,0,A,,1,In vitro hydrolysis in human plasma; no data,22224,9606.0,,,CHEMBL618376,6695,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5296,Homo sapiens,0,A,,1,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,22224,9606.0,Microsomes,,CHEMBL618377,10,2107.0,,,Liver,U,Autocuration,BAO_0000251
5297,Homo sapiens,0,A,,1,Plasma half life in human,22224,9606.0,,,CHEMBL618378,993,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5298,Homo sapiens,0,A,,1,Stability after incubation with human plasma (at 37 degree C),22224,9606.0,,,CHEMBL618379,15429,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5299,Homo sapiens,0,A,,1,T1/2 was evaluated in human plasma,22224,9606.0,,,CHEMBL618380,1675,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5300,Homo sapiens,0,A,,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,9606.0,,,CHEMBL618381,2209,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5301,Homo sapiens,0,A,,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",22224,9606.0,,,CHEMBL618382,2209,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5302,Homo sapiens,0,A,,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,9606.0,,,CHEMBL618383,5318,,,,,U,Autocuration,BAO_0000019
5303,Homo sapiens,0,A,,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,22224,9606.0,,,CHEMBL618384,2412,,,,,U,Autocuration,BAO_0000019
5304,Homo sapiens,0,A,,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,22224,9606.0,,,CHEMBL618385,2412,,,,,U,Autocuration,BAO_0000019
5305,Homo sapiens,0,A,,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,22224,9606.0,,,CHEMBL619099,2906,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5306,Homo sapiens,0,A,,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,22224,9606.0,,,CHEMBL619100,2906,1969.0,,,Plasma,U,Autocuration,BAO_0000366
5307,Homo sapiens,0,A,,1,Time taken for 50% to be consumed by serum PON1 was determined,22224,9606.0,,,CHEMBL619101,5495,,,,,U,Autocuration,BAO_0000019
5308,Homo sapiens,0,A,,1,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,22224,9606.0,,,CHEMBL619102,5495,,,,,U,Autocuration,BAO_0000019
5309,Homo sapiens,0,A,,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,9606.0,Microsomes,,CHEMBL619103,4397,2107.0,,,Liver,U,Autocuration,BAO_0000251
5310,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL619268,2413,,,,,U,Autocuration,BAO_0000218
5311,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL619269,2413,,,,,U,Autocuration,BAO_0000218
5312,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL619270,2413,,,,,U,Autocuration,BAO_0000218
5313,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL619271,2413,,,,,U,Autocuration,BAO_0000218
5314,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL875585,2413,,,,,U,Autocuration,BAO_0000218
5315,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,10095.0,,,CHEMBL619272,2413,,,,,U,Autocuration,BAO_0000218
5316,Homo sapiens,1,F,786-0,1,Compound tested for growth inhibition of renal cancer cell line 786-0,80640,9606.0,,,CHEMBL619273,6058,,391.0,,,N,Intermediate,BAO_0000219
5317,Homo sapiens,1,F,786-0,1,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,80640,9606.0,,,CHEMBL619274,17708,,391.0,,,N,Intermediate,BAO_0000219
5318,Homo sapiens,1,F,786-0,1,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,80640,9606.0,,,CHEMBL619275,14017,,391.0,,,N,Expert,BAO_0000219
5319,Homo sapiens,1,F,786-0,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",80640,9606.0,,,CHEMBL619276,16818,,391.0,,,N,Intermediate,BAO_0000219
5320,Homo sapiens,1,F,786-0,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",80640,9606.0,,,CHEMBL619277,16818,,391.0,,,N,Intermediate,BAO_0000219
5321,Homo sapiens,1,F,786-0,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",80640,9606.0,,,CHEMBL619278,16818,,391.0,,,N,Intermediate,BAO_0000219
5322,Homo sapiens,1,F,786-0,1,Tested for cytotoxicity against 786-0 cell lines in renal cancer,80640,9606.0,,,CHEMBL619279,11970,,391.0,,,N,Intermediate,BAO_0000219
5323,Homo sapiens,1,F,786-0,1,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,80640,9606.0,,,CHEMBL858458,12400,,391.0,,,N,Intermediate,BAO_0000219
5324,Homo sapiens,1,F,786-0,1,Cytotoxic effect on renal cancer line 786-0,80640,9606.0,,,CHEMBL619280,12888,,391.0,,,N,Expert,BAO_0000219
5325,Homo sapiens,1,F,786-0,1,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,80640,9606.0,,,CHEMBL619281,15300,,391.0,,,N,Intermediate,BAO_0000219
5326,Homo sapiens,1,F,786-0,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,9606.0,,,CHEMBL619282,14769,,391.0,,,N,Intermediate,BAO_0000219
5327,Homo sapiens,1,F,786-0,1,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",80640,9606.0,,,CHEMBL619283,15895,,391.0,,,N,Intermediate,BAO_0000219
5328,Homo sapiens,1,F,786-0,1,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,80640,9606.0,,,CHEMBL619284,17376,,391.0,,,N,Intermediate,BAO_0000219
5329,Homo sapiens,1,F,786-0,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80640,9606.0,,,CHEMBL619285,14882,,391.0,,,N,Intermediate,BAO_0000219
5330,Homo sapiens,1,F,786-0,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),80640,9606.0,,,CHEMBL619286,14882,,391.0,,,N,Intermediate,BAO_0000219
5331,Homo sapiens,1,F,786-0,1,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,80640,9606.0,,,CHEMBL619287,15176,,391.0,,,N,Intermediate,BAO_0000219
5332,Homo sapiens,1,F,786-0,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80640,9606.0,,,CHEMBL857455,12696,,391.0,,,N,Intermediate,BAO_0000219
5333,Homo sapiens,1,F,786-0,1,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),80640,9606.0,,,CHEMBL883801,2496,,391.0,,,N,Intermediate,BAO_0000219
5334,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,80641,9606.0,,,CHEMBL619288,11831,,972.0,,,N,Intermediate,BAO_0000219
5335,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),80641,9606.0,,,CHEMBL619289,11831,,972.0,,,N,Intermediate,BAO_0000219
5336,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,80641,9606.0,,,CHEMBL619290,11831,,972.0,,,N,Intermediate,BAO_0000219
5337,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),80641,9606.0,,,CHEMBL619291,11831,,972.0,,,N,Intermediate,BAO_0000219
5338,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),80641,9606.0,,,CHEMBL619292,11831,,972.0,,,N,Intermediate,BAO_0000219
5339,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,9606.0,,,CHEMBL619293,11831,,972.0,,,N,Intermediate,BAO_0000219
5340,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),80641,9606.0,,,CHEMBL619294,11831,,972.0,,,N,Intermediate,BAO_0000219
5341,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),80641,9606.0,,,CHEMBL619295,11831,,972.0,,,N,Intermediate,BAO_0000219
5342,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),80641,9606.0,,,CHEMBL619296,11831,,972.0,,,N,Intermediate,BAO_0000219
5343,Homo sapiens,1,F,791T cell line,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,9606.0,,,CHEMBL619297,11831,,972.0,,,N,Intermediate,BAO_0000219
5344,Homo sapiens,1,F,786-0,1,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,80640,9606.0,,,CHEMBL619298,12782,,391.0,,,N,Intermediate,BAO_0000219
5345,,0,F,,1,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,22226,,,,CHEMBL619299,1229,,,,,U,Intermediate,BAO_0000019
5346,Homo sapiens,1,F,RPMI-8226,1,Inhibition of cell growth in drug resistant 8226 myeloma cell line,80433,9606.0,,,CHEMBL619300,15313,,741.0,,,N,Expert,BAO_0000219
5347,Homo sapiens,1,F,RPMI-8226,1,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,80433,9606.0,,,CHEMBL619301,15313,,741.0,,,N,Expert,BAO_0000219
5348,Homo sapiens,1,F,RPMI-8226,1,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,80433,9606.0,,,CHEMBL619302,11544,,741.0,,,N,Intermediate,BAO_0000219
5349,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,9606.0,,,CHEMBL619303,9424,,741.0,,,N,Intermediate,BAO_0000219
5350,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,9606.0,,,CHEMBL619304,9424,,741.0,,,N,Intermediate,BAO_0000219
5351,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,9606.0,,,CHEMBL857706,9424,,741.0,,,N,Intermediate,BAO_0000219
5352,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,9606.0,,,CHEMBL619305,9424,,741.0,,,N,Intermediate,BAO_0000219
5353,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,9606.0,,,CHEMBL619306,9424,,741.0,,,N,Intermediate,BAO_0000219
5354,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,9606.0,,,CHEMBL619307,9424,,741.0,,,N,Intermediate,BAO_0000219
5355,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,9606.0,,,CHEMBL619308,9424,,741.0,,,N,Intermediate,BAO_0000219
5356,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,9606.0,,,CHEMBL619309,9424,,741.0,,,N,Intermediate,BAO_0000219
5357,Homo sapiens,1,F,RPMI-8226,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,9606.0,,,CHEMBL619310,9424,,741.0,,,N,Intermediate,BAO_0000219
5358,Homo sapiens,1,F,A498,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,9606.0,,,CHEMBL619311,14769,,624.0,,,N,Intermediate,BAO_0000219
5359,Homo sapiens,1,F,A498,1,Compound was tested for the growth inhibition of A498 renal tumor cell line,80021,9606.0,,,CHEMBL619312,15354,,624.0,,,N,Intermediate,BAO_0000219
5360,Homo sapiens,1,F,A498,1,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),80021,9606.0,,,CHEMBL619313,17445,,624.0,,,N,Intermediate,BAO_0000219
5361,Homo sapiens,1,F,A498,1,In vitro inhibitory concentration against renal cancer cell line A498,80021,9606.0,,,CHEMBL619314,4337,,624.0,,,N,Intermediate,BAO_0000219
5362,Homo sapiens,1,F,A498,1,Cytotoxicity against A 498 tumor cell line,80021,9606.0,,,CHEMBL619959,15277,,624.0,,,N,Intermediate,BAO_0000219
5363,Homo sapiens,1,F,A498,1,In vitro antitumor activity against A498 human cancer cell line,80021,9606.0,,,CHEMBL619960,4812,,624.0,,,N,Intermediate,BAO_0000219
5364,Homo sapiens,1,F,A498,1,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),80021,9606.0,,,CHEMBL619961,4812,,624.0,,,N,Intermediate,BAO_0000219
5365,Homo sapiens,1,F,A498,1,Inhibitory dose required against A498 human tumor cell lines,80021,9606.0,,,CHEMBL619962,4995,,624.0,,,N,Intermediate,BAO_0000219
5366,Homo sapiens,1,F,A498,1,Anticancer activity against one renal cancer (A498 cell line),80021,9606.0,,,CHEMBL875586,5847,,624.0,,,N,Intermediate,BAO_0000219
5367,Homo sapiens,1,F,A498,1,In vitro cytotoxicity against melanoma A498 cell line,80021,9606.0,,,CHEMBL619963,6557,,624.0,,,N,Intermediate,BAO_0000219
5368,Homo sapiens,1,F,A498,1,Compound was tested for growth inhibitory activity against A498 cell line,80021,9606.0,,,CHEMBL619964,2597,,624.0,,,N,Intermediate,BAO_0000219
5369,Homo sapiens,1,F,A498,1,Compound tested for growth inhibition of renal cancer cell line A498,80021,9606.0,,,CHEMBL620108,6058,,624.0,,,N,Intermediate,BAO_0000219
5370,Homo sapiens,1,F,A498,1,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,80021,9606.0,,,CHEMBL620109,17708,,624.0,,,N,Intermediate,BAO_0000219
5371,Homo sapiens,1,F,A498,1,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,80021,9606.0,,,CHEMBL620110,15176,,624.0,,,N,Intermediate,BAO_0000219
5372,Homo sapiens,1,F,A498,1,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,80021,9606.0,,,CHEMBL620111,15300,,624.0,,,N,Intermediate,BAO_0000219
5373,Homo sapiens,1,F,A498,1,Tested for cytotoxicity against A498 cell lines in renal cancer,80021,9606.0,,,CHEMBL620112,11970,,624.0,,,N,Intermediate,BAO_0000219
5374,Homo sapiens,1,F,A498,1,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,80021,9606.0,,,CHEMBL620113,12400,,624.0,,,N,Intermediate,BAO_0000219
5375,Homo sapiens,1,F,A498,1,Cytotoxic effect on renal cancer lines A498,80021,9606.0,,,CHEMBL620114,12888,,624.0,,,N,Expert,BAO_0000219
5376,Homo sapiens,1,F,A498,1,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,80021,9606.0,,,CHEMBL620115,3030,,624.0,,,N,Intermediate,BAO_0000219
5377,Homo sapiens,1,F,A498,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,9606.0,,,CHEMBL620116,14769,,624.0,,,N,Intermediate,BAO_0000219
5378,Homo sapiens,1,F,A498,1,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,80021,9606.0,,,CHEMBL620117,17376,,624.0,,,N,Intermediate,BAO_0000219
5379,Homo sapiens,1,F,A498,1,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,80021,9606.0,,,CHEMBL620118,16558,,624.0,,,N,Intermediate,BAO_0000219
5380,Homo sapiens,1,F,A498,1,Cytotoxicity against human kidney carcinoma cell lines A4982LM,80021,9606.0,,,CHEMBL620119,5194,,624.0,,,N,Intermediate,BAO_0000219
5381,Homo sapiens,1,F,A498,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,80021,9606.0,,,CHEMBL620120,10708,,624.0,,,N,Intermediate,BAO_0000219
5382,Homo sapiens,1,F,A549,1,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,80682,9606.0,,,CHEMBL620121,16880,,646.0,,,N,Expert,BAO_0000219
5383,Homo sapiens,1,F,A549,1,Antitumor activity against A549 human lung carcinoma cell line,80682,9606.0,,,CHEMBL620122,10196,,646.0,,,N,Intermediate,BAO_0000219
5384,Homo sapiens,1,F,A549,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,80682,9606.0,,,CHEMBL620123,10196,,646.0,,,N,Intermediate,BAO_0000219
5385,Homo sapiens,1,F,A549,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,80682,9606.0,,,CHEMBL620124,10196,,646.0,,,N,Intermediate,BAO_0000219
5386,Homo sapiens,1,F,A549,1,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",80682,9606.0,,,CHEMBL620125,12083,,646.0,,,N,Intermediate,BAO_0000219
5387,Homo sapiens,1,F,A549,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,80682,9606.0,,,CHEMBL620126,16464,,646.0,,,N,Expert,BAO_0000219
5388,Homo sapiens,1,F,A549,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,9606.0,,,CHEMBL883027,16464,,646.0,,,N,Intermediate,BAO_0000219
5389,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against human lung A549 cell line,80682,9606.0,,,CHEMBL620127,16470,,646.0,,,N,Expert,BAO_0000219
5390,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),80682,9606.0,,,CHEMBL620128,16470,,646.0,,,N,Intermediate,BAO_0000219
5391,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against human lung A549 cell line),80682,9606.0,,,CHEMBL620129,16470,,646.0,,,N,Intermediate,BAO_0000219
5392,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,80682,9606.0,,,CHEMBL620130,16470,,646.0,,,N,Intermediate,BAO_0000219
5393,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human non small-cell-lung cell line A549.,80682,9606.0,,,CHEMBL620131,16582,,646.0,,,N,Expert,BAO_0000219
5394,Homo sapiens,1,F,A549,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",80682,9606.0,,,CHEMBL620132,15935,,646.0,,,N,Intermediate,BAO_0000219
5395,Homo sapiens,1,F,A549,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",80682,9606.0,,,CHEMBL620133,15935,,646.0,,,N,Intermediate,BAO_0000219
5396,Homo sapiens,1,F,A549,1,Inhibition of A549 human lung carcinoma cell proliferation,80682,9606.0,,,CHEMBL620134,16597,,646.0,,,N,Expert,BAO_0000219
5397,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,9606.0,,,CHEMBL620135,17376,,646.0,,,N,Intermediate,BAO_0000219
5398,Homo sapiens,1,F,A549,1,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,80682,9606.0,,,CHEMBL620136,16496,,646.0,,,N,Intermediate,BAO_0000219
5399,Homo sapiens,1,F,A549,1,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,80682,9606.0,,,CHEMBL620137,16152,,646.0,,,N,Intermediate,BAO_0000219
5400,Homo sapiens,1,F,A549,1,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,80682,9606.0,,,CHEMBL620268,16152,,646.0,,,N,Intermediate,BAO_0000219
5401,Homo sapiens,1,F,A549,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,9606.0,,,CHEMBL620269,16464,,646.0,,,N,Intermediate,BAO_0000219
5402,Homo sapiens,1,F,A549,1,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,80682,9606.0,,,CHEMBL620270,2288,,646.0,,,N,Intermediate,BAO_0000219
5403,Homo sapiens,1,F,A549,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,9606.0,,,CHEMBL620271,17350,,646.0,,,N,Intermediate,BAO_0000219
5404,Homo sapiens,1,F,A549,1,Inhibition of A549 cancer cell proliferation,80682,9606.0,,,CHEMBL620272,4090,,646.0,,,N,Expert,BAO_0000219
5405,Homo sapiens,1,F,A549,1,Inhibition of A549 cancer cell proliferation (Not tested),80682,9606.0,,,CHEMBL620273,4090,,646.0,,,N,Expert,BAO_0000219
5406,Homo sapiens,1,F,A549,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,9606.0,,,CHEMBL620274,17350,,646.0,,,N,Intermediate,BAO_0000219
5407,Homo sapiens,1,F,A549,1,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,80682,9606.0,,,CHEMBL620275,4197,,646.0,,,N,Intermediate,BAO_0000219
5408,Homo sapiens,1,F,A549,1,Antiproliferative potency determined as inhibitory concentration against A549 cells,80682,9606.0,,,CHEMBL620276,17072,,646.0,,,N,Intermediate,BAO_0000219
5409,Homo sapiens,1,F,A549,1,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,80682,9606.0,,,CHEMBL620277,17072,,646.0,,,N,Intermediate,BAO_0000219
5410,Homo sapiens,1,F,A549,1,Cytotoxicity against Renal cell lines A549 was determined,80682,9606.0,,,CHEMBL620278,5194,,646.0,,,N,Intermediate,BAO_0000219
5411,Canis lupus familiaris,1,A,,1,Area under curve was determined in dog after a 3 mg/kg of oral dose,50588,9615.0,,,CHEMBL620279,4257,,,,,N,Intermediate,BAO_0000218
5412,Canis lupus familiaris,1,A,,1,Area under curve was determined in dog after oral administration at 1 mg/kg,50588,9615.0,,,CHEMBL620280,6123,,,,,N,Intermediate,BAO_0000218
5413,Canis lupus familiaris,1,A,,1,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL620281,1337,,,,,N,Intermediate,BAO_0000218
5414,Canis lupus familiaris,1,A,,1,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL620282,1337,,,,,N,Intermediate,BAO_0000218
5415,Canis lupus familiaris,1,A,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),50588,9615.0,,,CHEMBL621134,8833,,,,,N,Intermediate,BAO_0000218
5416,Canis lupus familiaris,1,A,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),50588,9615.0,,,CHEMBL621135,8833,,,,,N,Intermediate,BAO_0000218
5417,Canis lupus familiaris,1,A,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),50588,9615.0,,,CHEMBL621136,8833,,,,,N,Intermediate,BAO_0000218
5418,Canis lupus familiaris,1,A,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),50588,9615.0,,,CHEMBL621137,8833,,,,,N,Intermediate,BAO_0000218
5419,Canis lupus familiaris,1,A,,1,Area under plasma concentration time curve in dog upon oral administration,50588,9615.0,,,CHEMBL621138,17657,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5420,Canis lupus familiaris,1,A,,1,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,50588,9615.0,,,CHEMBL875587,17650,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5421,Canis lupus familiaris,1,A,,1,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,50588,9615.0,,,CHEMBL621139,1977,,,,,N,Intermediate,BAO_0000218
5422,Canis lupus familiaris,1,A,,1,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,50588,9615.0,,,CHEMBL621140,1977,,,,,N,Intermediate,BAO_0000218
5423,Canis lupus familiaris,1,A,,1,Area under the curve for the compound was obtained when tested in dog,50588,9615.0,,,CHEMBL621141,3132,,,,,N,Intermediate,BAO_0000218
5424,Canis lupus familiaris,1,A,,1,Area under the curve at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL621142,5473,,,,,N,Intermediate,BAO_0000218
5425,Canis lupus familiaris,1,A,,1,Area under the curve at a dose of 1 mg/kg (oral),50588,9615.0,,,CHEMBL621143,5474,,,,,N,Intermediate,BAO_0000218
5426,Canis lupus familiaris,1,A,,1,Area under the curve at i.v. dose of 0.2 mg/kg,50588,9615.0,,,CHEMBL621144,5474,,,,,N,Intermediate,BAO_0000218
5427,Canis lupus familiaris,1,A,,1,Area under the curve was measured in dog after an iv dose of 1 mg/kg,50588,9615.0,,,CHEMBL621145,6062,,,,,N,Intermediate,BAO_0000218
5428,Canis lupus familiaris,1,A,,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,50588,9615.0,,,CHEMBL621146,4709,,,,,N,Intermediate,BAO_0000218
5429,Canis lupus familiaris,1,A,,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,50588,9615.0,,,CHEMBL622567,2652,,,,,N,Intermediate,BAO_0000218
5430,Canis lupus familiaris,1,A,,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,50588,9615.0,,,CHEMBL622568,2652,,,,,N,Intermediate,BAO_0000218
5431,Canis lupus familiaris,1,A,,1,Compound was evaluated for area under the curve in dog blood.,50588,9615.0,,,CHEMBL622569,2877,,,,,N,Intermediate,BAO_0000218
5432,Canis lupus familiaris,1,A,,1,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,50588,9615.0,,,CHEMBL622570,5444,,,,,N,Intermediate,BAO_0000218
5433,Canis lupus familiaris,1,A,,1,AUC in dog after oral dose (1 mg/kg),50588,9615.0,,,CHEMBL622571,5130,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5434,Canis lupus familiaris,1,A,,1,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,50588,9615.0,,,CHEMBL622572,6265,,,,,N,Intermediate,BAO_0000218
5435,Canis lupus familiaris,1,A,,1,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",50588,9615.0,,,CHEMBL622573,4657,,,,,N,Intermediate,BAO_0000218
5436,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC after intravenous administration to dogs,50588,9615.0,,,CHEMBL622574,16367,,,,,N,Intermediate,BAO_0000218
5437,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC after oral administration to dogs,50588,9615.0,,,CHEMBL622575,16367,,,,,N,Intermediate,BAO_0000218
5438,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,50588,9615.0,,,CHEMBL622576,9579,,,,,N,Intermediate,BAO_0000218
5439,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,50588,9615.0,,,CHEMBL622577,9579,,,,,N,Intermediate,BAO_0000218
5440,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,9615.0,,,CHEMBL622578,5983,,,,,N,Intermediate,BAO_0000218
5441,Canis lupus familiaris,1,A,,1,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,50588,9615.0,,,CHEMBL622579,6241,,,,,N,Intermediate,BAO_0000218
5442,Canis lupus familiaris,1,A,,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",50588,9615.0,,,CHEMBL622580,5313,,,,,N,Intermediate,BAO_0000218
5443,Canis lupus familiaris,1,A,,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",50588,9615.0,,,CHEMBL622581,5313,,,,,N,Intermediate,BAO_0000218
5444,Canis lupus familiaris,1,A,,1,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,9615.0,,,CHEMBL622582,6642,,,,,N,Intermediate,BAO_0000218
5445,Canis lupus familiaris,1,A,,1,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,9615.0,,,CHEMBL622583,6642,,,,,N,Intermediate,BAO_0000218
5446,Canis lupus familiaris,1,A,,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,9615.0,,,CHEMBL622584,6641,,,,,N,Intermediate,BAO_0000218
5447,Canis lupus familiaris,1,A,,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,9615.0,,,CHEMBL622585,6642,,,,,N,Intermediate,BAO_0000218
5448,Canis lupus familiaris,1,A,,1,Compound was evaluated for oral bioavailability in dog; 90-100,50588,9615.0,,,CHEMBL622586,17791,,,,,N,Intermediate,BAO_0000218
5449,Canis lupus familiaris,1,A,,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,50588,9615.0,,,CHEMBL623281,17655,,,,,N,Intermediate,BAO_0000218
5450,Canis lupus familiaris,1,A,,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,50588,9615.0,,,CHEMBL623282,17655,,,,,N,Intermediate,BAO_0000218
5451,Canis lupus familiaris,1,A,,1,PAPP (membrane permeability) in dog kidney cell monolayer assay,50588,9615.0,,,CHEMBL623283,6596,,,,,N,Intermediate,BAO_0000218
5452,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623284,3880,,,,,N,Intermediate,BAO_0000218
5453,Canis lupus familiaris,1,A,,1,Bioavailability administered orally at a dose of 10 mg/kg to dogs,50588,9615.0,,,CHEMBL623285,16367,,,,,N,Intermediate,BAO_0000218
5454,Canis lupus familiaris,1,A,,1,Plasma protein binding towards dog plasma at 10 uM,50588,9615.0,,,CHEMBL623463,17409,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5455,Canis lupus familiaris,1,A,,1,Plasma protein binding towards dog plasma at 100 uM,50588,9615.0,,,CHEMBL875952,17409,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5456,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 4 mg/kg p.o.),50588,9615.0,,,CHEMBL621705,2959,,,,,N,Intermediate,BAO_0000218
5457,Canis lupus familiaris,1,A,,1,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,50588,9615.0,,,CHEMBL621706,13501,,,,,N,Intermediate,BAO_0000218
5458,Canis lupus familiaris,1,A,,1,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,50588,9615.0,,,CHEMBL621707,4527,,,,,N,Intermediate,BAO_0000218
5459,Canis lupus familiaris,1,A,,1,Bioavailability in dogs,50588,9615.0,,,CHEMBL621708,15145,,,,,N,Intermediate,BAO_0000218
5460,Canis lupus familiaris,1,A,,1,Bioavailability,50588,9615.0,,,CHEMBL621709,4219,,,,,N,Intermediate,BAO_0000218
5461,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 10 mg/kg),50588,9615.0,,,CHEMBL621710,17538,,,,,N,Intermediate,BAO_0000218
5462,Canis lupus familiaris,1,A,,1,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,50588,9615.0,,,CHEMBL621711,17538,,,,,N,Intermediate,BAO_0000218
5463,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 10.0 mg/kg p.o.),50588,9615.0,,,CHEMBL621712,1466,,,,,N,Intermediate,BAO_0000218
5464,Canis lupus familiaris,1,A,,1,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,50588,9615.0,,,CHEMBL621713,17650,,,,,N,Intermediate,BAO_0000218
5465,Canis lupus familiaris,1,A,,1,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,50588,9615.0,,,CHEMBL621714,3132,,,,,N,Intermediate,BAO_0000218
5466,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL621715,2413,,,,,U,Autocuration,BAO_0000218
5467,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL623717,2413,2107.0,,,Liver,U,Autocuration,BAO_0000218
5468,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,10095.0,,,CHEMBL623718,2413,2107.0,,,Liver,U,Autocuration,BAO_0000218
5469,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL623719,2413,2107.0,,,Liver,U,Autocuration,BAO_0000218
5470,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL623720,2413,,,,,U,Autocuration,BAO_0000218
5471,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL623721,2413,,,,,U,Autocuration,BAO_0000218
5472,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL623722,2413,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
5473,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,10095.0,,,CHEMBL623723,2413,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
5474,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL618543,2413,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
5475,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL618544,2413,2106.0,,,Spleen,U,Autocuration,BAO_0000218
5476,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL875155,2413,2106.0,,,Spleen,U,Autocuration,BAO_0000218
5477,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,10095.0,,,CHEMBL618545,2413,,,,,U,Autocuration,BAO_0000218
5478,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,10095.0,,,CHEMBL618546,2413,,,,,U,Autocuration,BAO_0000218
5479,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL623529,2413,,,,,U,Autocuration,BAO_0000218
5480,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,10095.0,,,CHEMBL623530,2413,,,,,U,Autocuration,BAO_0000218
5481,Mus sp.,0,A,,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,10095.0,,,CHEMBL621764,2413,,,,,U,Autocuration,BAO_0000218
5482,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,9527.0,,,CHEMBL621765,17827,,,,,U,Autocuration,BAO_0000019
5483,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,9527.0,,,CHEMBL621766,17827,2037.0,,,Cerebellum,U,Autocuration,BAO_0000019
5484,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,9527.0,,,CHEMBL621767,17827,1870.0,,,Frontal cortex,U,Autocuration,BAO_0000019
5485,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),22224,9527.0,,,CHEMBL621768,17827,,,,,U,Autocuration,BAO_0000019
5486,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),22224,9527.0,,,CHEMBL621769,17827,2435.0,,,Striatum,U,Autocuration,BAO_0000019
5487,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,9527.0,,,CHEMBL621770,17827,,,,,U,Autocuration,BAO_0000019
5488,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,9527.0,,,CHEMBL621771,17827,2037.0,,,Cerebellum,U,Autocuration,BAO_0000019
5489,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,9527.0,,,CHEMBL621772,17827,1870.0,,,Frontal cortex,U,Autocuration,BAO_0000019
5490,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),22224,9527.0,,,CHEMBL621773,17827,,,,,U,Autocuration,BAO_0000019
5491,Cercopithecidae,0,A,,1,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),22224,9527.0,,,CHEMBL621774,17827,2435.0,,,Striatum,U,Autocuration,BAO_0000019
5492,Cercopithecidae,0,A,,1,Compound was evaluated for oral bioavailability in rats,22224,9527.0,,,CHEMBL621775,17791,,,,,U,Autocuration,BAO_0000218
5493,Cercopithecidae,0,A,,1,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,22224,9527.0,,,CHEMBL621776,17667,1969.0,,,Plasma,U,Autocuration,BAO_0000218
5494,Cercopithecidae,0,A,,1,Half life period was evaluated in monkey,22224,9527.0,,,CHEMBL621777,17791,,,,,U,Autocuration,BAO_0000019
5495,Cercopithecidae,0,A,,1,Half-life in rhesus monkeys by intravenous administration of dose,22224,9527.0,,,CHEMBL875162,110,,,,,U,Autocuration,BAO_0000218
5496,Mus musculus,1,A,,1,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,50594,10090.0,,,CHEMBL621778,5781,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5497,Mus musculus,1,A,,1,AUC after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL621779,17734,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5498,Mus musculus,1,A,,1,AUC value was determined after oral administration,50594,10090.0,,,CHEMBL622479,17718,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5499,Mus musculus,1,A,,1,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,10090.0,,,CHEMBL622480,4573,,,,,N,Intermediate,BAO_0000218
5500,Mus musculus,1,A,,1,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,10090.0,,,CHEMBL622481,3277,,,,,N,Intermediate,BAO_0000218
5501,Mus musculus,1,A,,1,Area under curve by ioral administration in mouse,50594,10090.0,,,CHEMBL622482,2862,,,,,N,Intermediate,BAO_0000218
5502,Mus musculus,1,A,,1,Area under curve by iv administration in mouse,50594,10090.0,,,CHEMBL622483,2862,,,,,N,Intermediate,BAO_0000218
5503,Mus musculus,1,A,,1,Area under curve at 0-8 hr in IRC mice after peroral administration,50594,10090.0,,,CHEMBL622484,5951,,,,,N,Intermediate,BAO_0000218
5504,Mus musculus,1,A,,1,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,50594,10090.0,,,CHEMBL622641,17729,,,,,N,Intermediate,BAO_0000218
5505,Mus musculus,1,A,,1,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,50594,10090.0,,,CHEMBL622642,17728,,,,,N,Intermediate,BAO_0000218
5506,Mus musculus,1,A,,1,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,50594,10090.0,,,CHEMBL622643,17728,,,,,N,Intermediate,BAO_0000218
5507,Mus musculus,1,A,,1,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,50594,10090.0,,,CHEMBL622644,17729,,,,,N,Intermediate,BAO_0000218
5508,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,9606.0,,,CHEMBL622645,9424,,741.0,,,N,Intermediate,BAO_0000219
5509,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,9606.0,,,CHEMBL622646,9424,,741.0,,,N,Intermediate,BAO_0000219
5510,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,9606.0,,,CHEMBL621238,9424,,741.0,,,N,Intermediate,BAO_0000219
5511,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,9606.0,,,CHEMBL621239,9424,,741.0,,,N,Intermediate,BAO_0000219
5512,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,9606.0,,,CHEMBL621240,9424,,741.0,,,N,Intermediate,BAO_0000219
5513,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,9606.0,,,CHEMBL621241,9424,,741.0,,,N,Intermediate,BAO_0000219
5514,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,9606.0,,,CHEMBL621242,9424,,741.0,,,N,Intermediate,BAO_0000219
5515,Homo sapiens,1,F,RPMI-8226,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,9606.0,,,CHEMBL620350,9424,,741.0,,,N,Intermediate,BAO_0000219
5516,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,9606.0,,,CHEMBL620351,9424,,741.0,,,N,Intermediate,BAO_0000219
5517,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,9606.0,,,CHEMBL620352,9424,,741.0,,,N,Intermediate,BAO_0000219
5518,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,9606.0,,,CHEMBL620353,9424,,741.0,,,N,Intermediate,BAO_0000219
5519,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,9606.0,,,CHEMBL620354,9424,,741.0,,,N,Intermediate,BAO_0000219
5520,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,9606.0,,,CHEMBL620355,9424,,741.0,,,N,Intermediate,BAO_0000219
5521,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,9606.0,,,CHEMBL620356,9424,,741.0,,,N,Intermediate,BAO_0000219
5522,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,9606.0,,,CHEMBL620357,9424,,741.0,,,N,Intermediate,BAO_0000219
5523,Homo sapiens,1,F,RPMI-8226,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,9606.0,,,CHEMBL620358,9424,,741.0,,,N,Intermediate,BAO_0000219
5524,Homo sapiens,1,F,RPMI-8226,1,In vitro inhibition of human 8226 myeloma tumor cell line growth.,80433,9606.0,,,CHEMBL620359,9424,,741.0,,,N,Expert,BAO_0000219
5525,Homo sapiens,1,F,RPMI-8226,1,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,80433,9606.0,,,CHEMBL620360,11544,,741.0,,,N,Intermediate,BAO_0000219
5526,Homo sapiens,1,F,RPMI-8226,1,Cytotoxicity of compound against 8226/DOX1V cells,80433,9606.0,,,CHEMBL620361,17378,,741.0,,,N,Intermediate,BAO_0000219
5527,Homo sapiens,1,F,RPMI-8226,1,Cytotoxicity of compound against 8226/S cells,80433,9606.0,,,CHEMBL620362,17378,,741.0,,,N,Intermediate,BAO_0000219
5528,Homo sapiens,1,F,RPMI-8226,1,Inhibitory concentration against 8226 myeloma cancer cell line,80433,9606.0,,,CHEMBL620363,17079,,741.0,,,N,Intermediate,BAO_0000219
5529,Homo sapiens,1,F,RPMI-8226,1,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,80433,9606.0,,,CHEMBL620364,17079,,741.0,,,N,Intermediate,BAO_0000219
5530,Homo sapiens,1,F,833K,1,Inhibition of cell growth was studied in human teratocarcinoma (833K).,80647,9606.0,,,CHEMBL620365,13466,,854.0,,,N,Intermediate,BAO_0000219
5531,Homo sapiens,1,F,833K,1,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',80647,9606.0,,,CHEMBL620366,13466,,854.0,,,N,Intermediate,BAO_0000219
5532,Homo sapiens,1,F,833K,1,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,80647,9606.0,,,CHEMBL620367,2392,,854.0,,,N,Expert,BAO_0000219
5533,Homo sapiens,1,F,833K,1,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,80647,9606.0,,,CHEMBL620368,2392,,854.0,,,N,Intermediate,BAO_0000219
5534,,0,B,,1,Inhibitory activity against caspase-1,22226,,,,CHEMBL620369,6608,,,,,U,Autocuration,BAO_0000019
5535,Enterococcus faecalis,8,B,,1,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,45,1351.0,,,CHEMBL620370,10199,,,,,H,Autocuration,BAO_0000357
5536,Homo sapiens,1,F,8701-BC,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,80648,9606.0,,,CHEMBL620371,17749,,705.0,,,N,Intermediate,BAO_0000219
5537,Homo sapiens,1,F,8701-BC,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,80648,9606.0,,,CHEMBL620372,17749,,705.0,,,N,Intermediate,BAO_0000219
5538,,0,F,,1,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,22226,,,,CHEMBL876492,1229,,,,,U,Intermediate,BAO_0000019
5539,,0,F,,1,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,22226,,,,CHEMBL620373,1229,,,,,U,Intermediate,BAO_0000019
5540,,0,F,,1,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,22226,,,,CHEMBL620374,1229,,,,,U,Intermediate,BAO_0000019
5541,,0,B,,1,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,22226,,,,CHEMBL620375,6390,,,,,U,Autocuration,BAO_0000019
5542,Streptococcus pyogenes,0,F,,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,1314.0,,,CHEMBL857902,16219,,,,,U,Autocuration,BAO_0000019
5543,Streptococcus pyogenes,0,F,,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,1314.0,,,CHEMBL620376,16219,,,,,U,Autocuration,BAO_0000019
5544,,8,B,,1,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,11922,,,,CHEMBL620377,17043,,,,,H,Autocuration,BAO_0000357
5545,Homo sapiens,1,F,KB ,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,9606.0,,,CHEMBL620378,6929,,324.0,,,N,Intermediate,BAO_0000219
5546,Homo sapiens,1,A,KB ,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,9606.0,,,CHEMBL620379,6929,,324.0,,,N,Intermediate,BAO_0000219
5547,Homo sapiens,0,F,,1,In vitro cytotoxicity of compound was tested against 9KB cells.,22226,9606.0,,,CHEMBL620380,7083,,,,,U,Autocuration,BAO_0000219
5548,Rattus norvegicus,1,F,9L,1,Cytotoxic concentration against 9L cells was determined on day 3,80653,10116.0,,,CHEMBL884006,12446,,392.0,,,N,Intermediate,BAO_0000219
5549,Rattus norvegicus,1,F,9L,1,Tested in vitro for anticancer activity against 9L cells,80653,10116.0,,,CHEMBL620381,15345,,392.0,,,N,Expert,BAO_0000219
5550,Rattus norvegicus,1,F,9L,1,Tested in vitro for anticancer activity against 9L cells; Not determined,80653,10116.0,,,CHEMBL620382,15345,,392.0,,,N,Expert,BAO_0000219
5551,Homo sapiens,1,F,A549,1,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,80682,9606.0,,,CHEMBL620383,6301,,646.0,,,N,Intermediate,BAO_0000219
5552,Homo sapiens,1,F,A549,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,80682,9606.0,,,CHEMBL876493,4833,,646.0,,,N,Intermediate,BAO_0000219
5553,Homo sapiens,1,F,A549,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,80682,9606.0,,,CHEMBL620384,4833,,646.0,,,N,Intermediate,BAO_0000219
5554,Homo sapiens,1,F,A549,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,80682,9606.0,,,CHEMBL620385,4833,,646.0,,,N,Intermediate,BAO_0000219
5555,Homo sapiens,1,F,A549,1,Cytotoxicity against human lung carcinoma A549 cell line,80682,9606.0,,,CHEMBL620386,13330,,646.0,,,N,Expert,BAO_0000219
5556,Homo sapiens,9,F,A549,1,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,25,9606.0,,,CHEMBL620387,17517,,646.0,,,D,Expert,BAO_0000219
5557,Homo sapiens,9,F,A549,1,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",25,9606.0,,,CHEMBL621404,17517,,646.0,,,D,Expert,BAO_0000219
5558,Homo sapiens,1,F,A549,1,"In vitro growth inhibition of A549, lung carcinoma",80682,9606.0,,,CHEMBL621405,14425,,646.0,,,N,Intermediate,BAO_0000219
5559,Homo sapiens,1,F,A549,1,"In vitro growth inhibition of A549, lung carcinoma.",80682,9606.0,,,CHEMBL621406,14425,,646.0,,,N,Intermediate,BAO_0000219
5560,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL621407,5228,,646.0,,,N,Expert,BAO_0000219
5561,Homo sapiens,1,F,A549,1,Cytotoxic activity against human lung cancer A549 cell line was determined,80682,9606.0,,,CHEMBL621408,5351,,646.0,,,N,Intermediate,BAO_0000219
5562,Homo sapiens,1,F,A549,1,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,80682,9606.0,,,CHEMBL885345,12198,,646.0,,,N,Expert,BAO_0000219
5563,Homo sapiens,1,F,A549,1,Cytotoxicity concentration against human lung carcinoma A-549 cell line,80682,9606.0,,,CHEMBL621409,13891,,646.0,,,N,Intermediate,BAO_0000219
5564,Homo sapiens,1,F,A549,1,Cytotoxicity in A549 (human carcinoma) cell line.,80682,9606.0,,,CHEMBL876034,5677,,646.0,,,N,Expert,BAO_0000219
5565,Homo sapiens,1,F,A549,1,Cytotoxicity on lung carcinoma (A-549) cell line,80682,9606.0,,,CHEMBL621410,13788,,646.0,,,N,Intermediate,BAO_0000219
5566,Homo sapiens,1,F,A549,1,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,80682,9606.0,,,CHEMBL621411,13384,,646.0,,,N,Expert,BAO_0000219
5567,Homo sapiens,1,F,A549,1,Effective dose of compound against replication of A549 cell line was evaluated,80682,9606.0,,,CHEMBL621412,6726,,646.0,,,N,Intermediate,BAO_0000219
5568,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,80682,9606.0,,,CHEMBL621413,3455,,646.0,,,N,Expert,BAO_0000219
5569,Homo sapiens,1,F,A549,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),80682,9606.0,,,CHEMBL621414,5726,,646.0,,,N,Intermediate,BAO_0000219
5570,Homo sapiens,1,F,A549,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,80682,9606.0,,,CHEMBL621415,5726,,646.0,,,N,Intermediate,BAO_0000219
5571,Homo sapiens,1,F,A549,1,The compound was evaluated for antiproliferative activity against A549 cell line,80682,9606.0,,,CHEMBL621416,3936,,646.0,,,N,Intermediate,BAO_0000219
5572,Homo sapiens,1,F,A549,1,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,80682,9606.0,,,CHEMBL621417,14991,,646.0,,,N,Intermediate,BAO_0000219
5573,Homo sapiens,1,F,A549,1,Concentration required for growth inhibition of human lung carcinoma cell line A549,80682,9606.0,,,CHEMBL621418,5243,,646.0,,,N,Intermediate,BAO_0000219
5574,Homo sapiens,1,F,A549,1,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,80682,9606.0,,,CHEMBL621419,12858,,646.0,,,N,Intermediate,BAO_0000219
5575,Homo sapiens,1,F,A549,1,Growth inhibition against A549 cell line was evaluated,80682,9606.0,,,CHEMBL621420,6776,,646.0,,,N,Intermediate,BAO_0000219
5576,Homo sapiens,1,F,A549,1,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,80682,9606.0,,,CHEMBL875823,16558,,646.0,,,N,Intermediate,BAO_0000219
5577,Homo sapiens,1,F,A549,1,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,80682,9606.0,,,CHEMBL621421,4583,,646.0,,,N,Expert,BAO_0000219
5578,Homo sapiens,1,F,A549,1,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,80682,9606.0,,,CHEMBL621422,13514,,646.0,,,N,Intermediate,BAO_0000219
5579,Homo sapiens,1,F,A549,1,Chemosensitivity against DT-diaphorase rich A549 cell lines,80682,9606.0,,,CHEMBL884014,15166,,646.0,,,N,Expert,BAO_0000219
5580,Homo sapiens,1,F,A549,1,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,9606.0,,,CHEMBL621423,13873,,646.0,,,N,Intermediate,BAO_0000219
5581,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human A549 (lung cancer) cell line.,80682,9606.0,,,CHEMBL621424,6447,,646.0,,,N,Expert,BAO_0000219
5582,Homo sapiens,1,F,A549,1,In vitro antitumor activity against A549 (lung) human tumor cell lines.,80682,9606.0,,,CHEMBL621425,2068,,646.0,,,N,Intermediate,BAO_0000219
5583,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against human lung carcinoma A549 cell line,80682,9606.0,,,CHEMBL621426,1863,,646.0,,,N,Expert,BAO_0000219
5584,Homo sapiens,1,F,A549,1,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,80682,9606.0,,,CHEMBL621427,13873,,646.0,,,N,Intermediate,BAO_0000219
5585,Homo sapiens,1,F,A549,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,9606.0,,,CHEMBL621428,13873,,646.0,,,N,Intermediate,BAO_0000219
5586,Homo sapiens,1,F,A549,1,Tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,9606.0,,,CHEMBL621429,13873,,646.0,,,N,Expert,BAO_0000219
5587,Homo sapiens,1,F,A549,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),80682,9606.0,,,CHEMBL621430,579,,646.0,,,N,Intermediate,BAO_0000219
5588,Homo sapiens,1,F,A549,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,80682,9606.0,,,CHEMBL621431,579,,646.0,,,N,Intermediate,BAO_0000219
5589,Homo sapiens,1,F,A549,1,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,80682,9606.0,,,CHEMBL621432,4584,,646.0,,,N,Intermediate,BAO_0000219
5590,Homo sapiens,1,F,A549,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,80682,9606.0,,,CHEMBL621433,5421,,646.0,,,N,Expert,BAO_0000219
5591,Homo sapiens,1,F,A549,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,9606.0,,,CHEMBL875824,5421,,646.0,,,N,Intermediate,BAO_0000219
5592,Homo sapiens,1,F,A549,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,9606.0,,,CHEMBL621434,5421,,646.0,,,N,Intermediate,BAO_0000219
5593,Homo sapiens,1,F,A549,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,80682,9606.0,,,CHEMBL621435,5421,,646.0,,,N,Intermediate,BAO_0000219
5594,Homo sapiens,1,F,A549,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,80682,9606.0,,,CHEMBL621436,14188,,646.0,,,N,Intermediate,BAO_0000219
5595,Homo sapiens,1,F,A549,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,80682,9606.0,,,CHEMBL621437,14188,,646.0,,,N,Intermediate,BAO_0000219
5596,Homo sapiens,1,F,A549,1,Compound was tested for the growth inhibition of A549 lung tumor cell line,80682,9606.0,,,CHEMBL621438,15354,,646.0,,,N,Intermediate,BAO_0000219
5597,Homo sapiens,1,F,A549,1,Growth inhibition of human non-small-lung carcinoma (A549) cell line,80682,9606.0,,,CHEMBL621439,14253,,646.0,,,N,Expert,BAO_0000219
5598,Homo sapiens,1,F,A549,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,9606.0,,,CHEMBL621440,13873,,646.0,,,N,Intermediate,BAO_0000219
5599,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (conscious),50588,9615.0,,,CHEMBL621441,3043,,,,,N,Intermediate,BAO_0000218
5600,Canis lupus familiaris,1,A,,1,Compound was evaluated for the oral bioavailability after oral administration in dog.,50588,9615.0,,,CHEMBL621442,3045,,,,,N,Intermediate,BAO_0000218
5601,Canis lupus familiaris,1,A,,1,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,50588,9615.0,,,CHEMBL621443,3022,,,,,N,Intermediate,BAO_0000218
5602,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621444,4453,,,,,N,Intermediate,BAO_0000218
5603,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL625133,1696,,,,,N,Intermediate,BAO_0000218
5604,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL625134,5045,,,,,N,Intermediate,BAO_0000218
5605,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (fasted),50588,9615.0,,,CHEMBL625135,5356,,,,,N,Intermediate,BAO_0000218
5606,Canis lupus familiaris,1,A,,1,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,50588,9615.0,,,CHEMBL625136,17764,,,,,N,Intermediate,BAO_0000218
5607,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL625137,6448,,,,,N,Intermediate,BAO_0000218
5608,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL625138,1475,,,,,N,Intermediate,BAO_0000218
5609,Canis lupus familiaris,1,A,,1,Percent bioavailability in dog,50588,9615.0,,,CHEMBL625139,3788,,,,,N,Intermediate,BAO_0000218
5610,Canis lupus familiaris,1,A,,1,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,50588,9615.0,,,CHEMBL872264,3639,,,,,N,Intermediate,BAO_0000218
5611,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL625140,13397,,,,,N,Intermediate,BAO_0000218
5612,Canis lupus familiaris,1,A,,1,The compound was evaluated for bioavailability in dogs; 34-44,50588,9615.0,,,CHEMBL624436,2137,,,,,N,Intermediate,BAO_0000218
5613,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 4 mg/kg p.o.),50588,9615.0,,,CHEMBL624437,2959,,,,,N,Intermediate,BAO_0000218
5614,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL872261,6448,,,,,N,Intermediate,BAO_0000218
5615,Canis lupus familiaris,1,A,,1,8 hour trough Blood level in dog was measured after administration of compound,50588,9615.0,,,CHEMBL624438,6084,,,,,N,Intermediate,BAO_0000218
5616,Canis lupus familiaris,1,A,,1,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,50588,9615.0,,,CHEMBL624439,3639,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5617,Canis lupus familiaris,1,A,,1,C24 after oral administration at 5 mg/kg,50588,9615.0,,,CHEMBL624440,6316,,,,,N,Intermediate,BAO_0000218
5618,Canis lupus familiaris,1,A,,1,Clearance after oral and iv dosing in dogs,50588,9615.0,,,CHEMBL624441,5238,,,,,N,Intermediate,BAO_0000218
5619,Canis lupus familiaris,1,A,,1,Clearance of the drug was measured in the plasma of dog,50588,9615.0,,,CHEMBL624442,17796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5620,Canis lupus familiaris,1,A,,1,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,50588,9615.0,,,CHEMBL624443,2652,,,,,N,Intermediate,BAO_0000218
5621,Canis lupus familiaris,1,A,,1,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL624444,5654,,,,,N,Intermediate,BAO_0000218
5622,Canis lupus familiaris,1,A,,1,Clearance of compound was determined in dogs,50588,9615.0,,,CHEMBL624445,6621,,,,,N,Intermediate,BAO_0000218
5623,Canis lupus familiaris,1,A,,1,Clearance on i.v. administration of 2 mg/kg was measured in dog,50588,9615.0,,,CHEMBL624446,6505,,,,,N,Intermediate,BAO_0000218
5624,Canis lupus familiaris,1,A,,1,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,9615.0,,,CHEMBL624447,5802,,,,,N,Intermediate,BAO_0000218
5625,Canis lupus familiaris,1,A,,1,Plasma clearance in dog was determined,50588,9615.0,,,CHEMBL624448,17267,,,,,N,Intermediate,BAO_0000218
5626,Canis lupus familiaris,1,A,,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,9615.0,,,CHEMBL624449,4521,,,,,N,Intermediate,BAO_0000218
5627,Canis lupus familiaris,1,A,,1,Plasma clearance in dog after administration of 0.25 mg/kg iv,50588,9615.0,,,CHEMBL624450,6535,,,,,N,Intermediate,BAO_0000218
5628,Canis lupus familiaris,1,A,,1,Plasma clearance in dog after administration of 1 mg/kg iv,50588,9615.0,,,CHEMBL875942,6535,,,,,N,Intermediate,BAO_0000218
5629,Canis lupus familiaris,1,A,,1,Plasma clearance in dogs,50588,9615.0,,,CHEMBL624451,6535,,,,,N,Intermediate,BAO_0000218
5630,Canis lupus familiaris,1,A,,1,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,50588,9615.0,,,CHEMBL624452,5542,,,,,N,Intermediate,BAO_0000218
5631,Canis lupus familiaris,1,A,,1,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,9615.0,,,CHEMBL624453,5199,,,,,N,Intermediate,BAO_0000218
5632,Canis lupus familiaris,1,A,,1,Plasma clearance after 15 mg/kg iv dose in Dogs,50588,9615.0,,,CHEMBL624454,16907,,,,,N,Intermediate,BAO_0000218
5633,Canis lupus familiaris,1,A,,1,Plasma clearance after 30 mg/kg po dose in Dogs,50588,9615.0,,,CHEMBL624455,16907,,,,,N,Intermediate,BAO_0000218
5634,Canis lupus familiaris,1,A,,1,Plasma administration to dogs,50588,9615.0,,,CHEMBL624456,16367,,,,,N,Intermediate,BAO_0000218
5635,Canis lupus familiaris,1,A,,1,Plasma clearance was determined,50588,9615.0,,,CHEMBL624457,5505,,,,,N,Intermediate,BAO_0000218
5636,Canis lupus familiaris,1,A,,1,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL624458,6215,,,,,N,Intermediate,BAO_0000218
5637,Canis lupus familiaris,1,A,,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,50588,9615.0,,,CHEMBL624459,1466,,,,,N,Intermediate,BAO_0000218
5638,Homo sapiens,2,A,,1,Intrinsic clearance in human liver microsomes,102164,9606.0,Microsomes,,CHEMBL624460,5007,2107.0,,,Liver,S,Intermediate,BAO_0000251
5639,Homo sapiens,2,A,,1,Intrinsic clearance in human liver microsomes,102164,9606.0,Microsomes,,CHEMBL624461,5007,2107.0,,,Liver,S,Intermediate,BAO_0000251
5640,Canis lupus familiaris,1,A,,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,9615.0,,,CHEMBL875943,16452,,,,,N,Intermediate,BAO_0000218
5641,Canis lupus familiaris,1,A,,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,9615.0,,,CHEMBL624462,16452,,,,,N,Intermediate,BAO_0000218
5642,Canis lupus familiaris,1,A,,1,Clearance in dog (dose 1 mg/kg i.v.),50588,9615.0,,,CHEMBL624463,16452,,,,,N,Intermediate,BAO_0000218
5643,Canis lupus familiaris,1,A,,1,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,50588,9615.0,,,CHEMBL624464,6221,,,,,N,Intermediate,BAO_0000218
5644,Canis lupus familiaris,1,A,,1,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,9615.0,,,CHEMBL624465,5007,,,,,N,Intermediate,BAO_0000218
5645,Canis lupus familiaris,1,A,,1,Plasma clearance after peroral administration at 10 mpk in dog,50588,9615.0,,,CHEMBL624466,5668,,,,,N,Intermediate,BAO_0000218
5646,Canis lupus familiaris,1,A,,1,Plasma clearance after peroral administration at 5 mpk in dog,50588,9615.0,,,CHEMBL624467,5668,,,,,N,Intermediate,BAO_0000218
5647,Canis lupus familiaris,1,A,,1,Plasma clearance after peroral administration at 5 mg/kg in dog,50588,9615.0,,,CHEMBL624468,5668,,,,,N,Intermediate,BAO_0000218
5648,Canis lupus familiaris,1,A,,1,Plasma clearance was measured in dog,50588,9615.0,,,CHEMBL624469,15660,,,,,N,Intermediate,BAO_0000218
5649,Canis lupus familiaris,1,A,,1,Plasma clearance was measured in dog,50588,9615.0,,,CHEMBL624470,15660,,,,,N,Intermediate,BAO_0000218
5650,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,9615.0,,,CHEMBL624471,5983,,,,,N,Intermediate,BAO_0000218
5651,Canis lupus familiaris,1,A,,1,Total clearance was determined after 0.1 mg/kg iv administration in dog,50588,9615.0,,,CHEMBL624472,5600,,,,,N,Intermediate,BAO_0000218
5652,Canis lupus familiaris,1,A,,1,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,50588,9615.0,,,CHEMBL622775,17764,,,,,N,Intermediate,BAO_0000218
5653,Canis lupus familiaris,1,A,,1,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,50588,9615.0,,,CHEMBL622776,6039,,,,,N,Intermediate,BAO_0000218
5654,Canis lupus familiaris,1,A,,1,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,50588,9615.0,,,CHEMBL622777,6039,,,,,N,Intermediate,BAO_0000218
5655,Canis lupus familiaris,1,A,,1,Clearance after peroral administration of 0.2 mg/kg in dog was determined,50588,9615.0,,,CHEMBL622778,6039,,,,,N,Intermediate,BAO_0000218
5656,Canis lupus familiaris,1,A,,1,Clearance by intravenous administration of 1.2 mg/kg in dog,50588,9615.0,,,CHEMBL622779,4368,,,,,N,Intermediate,BAO_0000218
5657,Canis lupus familiaris,1,A,,1,Clearance by iv administration in dogs at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL622780,4305,,,,,N,Intermediate,BAO_0000218
5658,Canis lupus familiaris,1,A,,1,Clearance value was evaluated in dog plasma,50588,9615.0,,,CHEMBL622781,1918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5659,Canis lupus familiaris,1,A,,1,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL622782,6005,,,,,N,Intermediate,BAO_0000218
5660,Canis lupus familiaris,1,A,,1,Compound was tested for plasma clearance in dog,50588,9615.0,,,CHEMBL622783,4839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5661,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (Plasma clearance) was measured in dog,50588,9615.0,,,CHEMBL622784,4239,,,,,N,Intermediate,BAO_0000218
5662,Mus musculus,1,A,,1,Area under curve when injected perorally in mice at a dose of 50 mg/kg,50594,10090.0,,,CHEMBL622785,17729,,,,,N,Intermediate,BAO_0000218
5663,Mus musculus,1,A,,1,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,50594,10090.0,,,CHEMBL622786,17728,,,,,N,Intermediate,BAO_0000218
5664,Mus musculus,1,A,,1,Area under curve value in mouse at a dose of 10 mg/kg,50594,10090.0,,,CHEMBL622787,5302,,,,,N,Intermediate,BAO_0000218
5665,Mus musculus,1,A,,1,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,10090.0,,,CHEMBL875949,5506,,,,,N,Intermediate,BAO_0000218
5666,Mus musculus,1,A,,1,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,10090.0,,,CHEMBL622788,5506,,,,,N,Intermediate,BAO_0000218
5667,Mus musculus,1,F,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,10090.0,,,CHEMBL622789,17764,,,,,N,Intermediate,BAO_0000218
5668,Mus musculus,1,F,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,10090.0,,,CHEMBL622790,17764,,,,,N,Intermediate,BAO_0000218
5669,Mus musculus,1,F,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,10090.0,,,CHEMBL622791,17764,,,,,N,Intermediate,BAO_0000218
5670,Mus musculus,1,F,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,10090.0,,,CHEMBL622792,17764,,,,,N,Intermediate,BAO_0000218
5671,Mus musculus,1,A,,1,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,50594,10090.0,,,CHEMBL622793,17764,,,,,N,Intermediate,BAO_0000218
5672,Mus musculus,1,A,,1,Area under curve was determined for the compound at 24 mg/Kg,50594,10090.0,,,CHEMBL622794,17753,,,,,N,Intermediate,BAO_0000218
5673,Mus musculus,1,A,,1,Area under curve was determined for the compound at 40 mg/Kg,50594,10090.0,,,CHEMBL622795,17753,,,,,N,Intermediate,BAO_0000218
5674,Mus musculus,1,A,,1,Area under curve was determined for the compound at 5 mg/Kg,50594,10090.0,,,CHEMBL621803,17753,,,,,N,Intermediate,BAO_0000218
5675,Mus musculus,1,A,,1,Area under the curve for the compound is obtained at dose 25 mg/kg,50594,10090.0,,,CHEMBL621804,3132,,,,,N,Intermediate,BAO_0000218
5676,Mus musculus,1,A,,1,Area under the curve for the compound was obtained when tested in mouse,50594,10090.0,,,CHEMBL621805,3132,,,,,N,Intermediate,BAO_0000218
5677,Mus musculus,1,A,,1,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,50594,10090.0,,,CHEMBL621806,17837,,,,,N,Intermediate,BAO_0000218
5678,Mus musculus,1,A,,1,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,50594,10090.0,,,CHEMBL621807,17837,,,,,N,Intermediate,BAO_0000218
5679,Mus musculus,1,A,,1,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,50594,10090.0,,,CHEMBL621808,6062,,,,,N,Intermediate,BAO_0000218
5680,Mus musculus,1,A,,1,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,50594,10090.0,,,CHEMBL621809,4066,,,,,N,Intermediate,BAO_0000218
5681,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,10090.0,,,CHEMBL621810,16597,,,,,N,Intermediate,BAO_0000218
5682,Mus musculus,1,A,,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,10090.0,,,CHEMBL875164,14239,,,,,N,Intermediate,BAO_0000218
5683,Mus musculus,1,A,,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,10090.0,,,CHEMBL621811,14239,,,,,N,Intermediate,BAO_0000218
5684,Mus musculus,1,A,,1,"Compound was evaluated for the pharmacokinetic parameter, area under curve",50594,10090.0,,,CHEMBL621812,4890,,,,,N,Intermediate,BAO_0000218
5685,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),50594,10090.0,,,CHEMBL621813,429,,,,,N,Intermediate,BAO_0000218
5686,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),50594,10090.0,,,CHEMBL621814,429,,,,,N,Intermediate,BAO_0000218
5687,Mus musculus,1,A,,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,50594,10090.0,,,CHEMBL621815,5969,,,,,N,Intermediate,BAO_0000218
5688,Mus musculus,1,A,,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,50594,10090.0,,,CHEMBL621816,5969,,,,,N,Intermediate,BAO_0000218
5689,Mus musculus,1,A,,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,10090.0,,,CHEMBL621817,5969,,,,,N,Intermediate,BAO_0000218
5690,Mus musculus,1,A,,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,50594,10090.0,,,CHEMBL621818,6091,,,,,N,Intermediate,BAO_0000218
5691,Mus musculus,1,A,,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,50594,10090.0,,,CHEMBL621819,6091,,,,,N,Intermediate,BAO_0000218
5692,Mus musculus,1,A,,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,50594,10090.0,,,CHEMBL621820,6091,,,,,N,Intermediate,BAO_0000218
5693,Mus musculus,1,A,,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,50594,10090.0,,,CHEMBL621821,6091,,,,,N,Intermediate,BAO_0000218
5694,Mus musculus,1,A,,1,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,50594,10090.0,,,CHEMBL621822,6178,,,,,N,Intermediate,BAO_0000218
5695,Mus musculus,1,A,,1,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,50594,10090.0,,,CHEMBL619474,6178,,,,,N,Intermediate,BAO_0000218
5696,Mus musculus,1,A,,1,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,10090.0,,,CHEMBL619475,6619,,,,,N,Intermediate,BAO_0000218
5697,Mus musculus,1,A,,1,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,10090.0,,,CHEMBL619476,6619,,,,,N,Intermediate,BAO_0000218
5698,Mus musculus,1,A,,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",50594,10090.0,,,CHEMBL619477,3760,,,,,N,Intermediate,BAO_0000218
5699,Mus musculus,1,A,,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",50594,10090.0,,,CHEMBL619478,3760,,,,,N,Intermediate,BAO_0000218
5700,Mus musculus,1,A,,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",50594,10090.0,,,CHEMBL619479,3760,,,,,N,Intermediate,BAO_0000218
5701,Mus musculus,1,A,,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",50594,10090.0,,,CHEMBL619480,3760,,,,,N,Intermediate,BAO_0000218
5702,Mus musculus,1,A,,1,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,50594,10090.0,,,CHEMBL619481,3192,,,,,N,Intermediate,BAO_0000218
5703,Mus musculus,1,A,,1,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,50594,10090.0,,,CHEMBL619482,3192,,,,,N,Intermediate,BAO_0000218
5704,Mus musculus,1,A,,1,Area under the curve was evaluated in mice after intravenous administration,50594,10090.0,,,CHEMBL619483,2675,,,,,N,Intermediate,BAO_0000218
5705,Mus musculus,1,A,,1,Area under the curve was evaluated in mice after oral administration,50594,10090.0,,,CHEMBL619484,2675,,,,,N,Intermediate,BAO_0000218
5706,Mus musculus,1,A,,1,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,50594,10090.0,,,CHEMBL619485,16597,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5707,Mus musculus,1,A,,1,AUC total value at a dose of 10 mg/kg peroral administration in mice.,50594,10090.0,,,CHEMBL619486,16597,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5708,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,10090.0,,,CHEMBL619487,16597,,,,,N,Intermediate,BAO_0000218
5709,Mus musculus,1,A,,1,AUMC after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL619488,17734,,,,,N,Intermediate,BAO_0000218
5710,Mus musculus,1,A,,1,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620106,7767,178.0,,,Blood,N,Intermediate,BAO_0000218
5711,,1,F,9L,1,The compound was tested in vitro for anticancer activity against 9L cells,80653,,,,CHEMBL620107,15345,,392.0,,,N,Intermediate,BAO_0000219
5712,Rattus norvegicus,0,F,,1,Anti proliferation activity determined; Weak effect,22226,10116.0,,,CHEMBL620283,2181,,,,,U,Autocuration,BAO_0000019
5713,Rattus norvegicus,0,F,,1,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,22226,10116.0,,,CHEMBL875176,2181,,,,,U,Autocuration,BAO_0000219
5714,Rattus norvegicus,0,F,,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,22226,10116.0,,,CHEMBL620284,2181,,,,,U,Autocuration,BAO_0000219
5715,Rattus norvegicus,0,F,,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,22226,10116.0,,,CHEMBL623515,2181,,,,,U,Autocuration,BAO_0000219
5716,Mus musculus,0,F,,1,The cytotoxic activity was in vitro tested by 9PS assay method,22226,10090.0,,,CHEMBL623516,10486,,,,,U,Autocuration,BAO_0000019
5717,Mus musculus,0,F,,1,The cytotoxic activity was in vitro tested by 9PS assay method.,22226,10090.0,,,CHEMBL623517,10486,,,,,U,Autocuration,BAO_0000019
5718,,0,A,,1,Partition coefficient (logD6.5),22224,,,,CHEMBL857878,15508,,,,,U,Autocuration,BAO_0000019
5719,Homo sapiens,1,F,A2780,1,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,81034,9606.0,,,CHEMBL623518,5242,,478.0,,,N,Expert,BAO_0000219
5720,Homo sapiens,1,F,A-375,1,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),80018,9606.0,,,CHEMBL624195,16167,,455.0,,,N,Intermediate,BAO_0000219
5721,Homo sapiens,1,F,A-431,1,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,80852,9606.0,,,CHEMBL624196,4782,,500.0,,,N,Expert,BAO_0000219
5722,Homo sapiens,9,F,A-431,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,9606.0,,,CHEMBL624197,16093,,500.0,,,D,Expert,BAO_0000219
5723,Homo sapiens,1,F,A498,1,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,80021,9606.0,,,CHEMBL624198,2596,,624.0,,,N,Intermediate,BAO_0000219
5724,Homo sapiens,1,F,A498,1,in vitro cytotoxicity against A 498 cancer cell line,80021,9606.0,,,CHEMBL621287,2596,,624.0,,,N,Intermediate,BAO_0000219
5725,Homo sapiens,1,F,A498,1,In vitro cytotoxic activity against renal (A 498) cancer cell line.,80021,9606.0,,,CHEMBL621288,3239,,624.0,,,N,Intermediate,BAO_0000219
5726,Homo sapiens,1,F,A498,1,Cytotoxic activity against A 498 renal cancer cell lines.,80021,9606.0,,,CHEMBL876496,1847,,624.0,,,N,Intermediate,BAO_0000219
5727,Homo sapiens,1,F,A498,1,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,80021,9606.0,,,CHEMBL621289,10553,,624.0,,,N,Intermediate,BAO_0000219
5728,Staphylococcus aureus,0,F,,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,1280.0,,,CHEMBL621290,16219,,,,,U,Autocuration,BAO_0000019
5729,Staphylococcus aureus,0,F,,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,1280.0,,,CHEMBL621291,16219,,,,,U,Autocuration,BAO_0000019
5730,Staphylococcus aureus,0,F,,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,1280.0,,,CHEMBL621292,16219,,,,,U,Autocuration,BAO_0000019
5731,Staphylococcus aureus,0,F,,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,1280.0,,,CHEMBL621293,16219,,,,,U,Autocuration,BAO_0000019
5732,Homo sapiens,1,F,A549,1,Inhibitory concentration required against A 549 lung cancer cell line,80682,9606.0,,,CHEMBL621294,4782,,646.0,,,N,Intermediate,BAO_0000219
5733,Homo sapiens,1,F,A549,1,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,80682,9606.0,,,CHEMBL621295,11805,,646.0,,,N,Intermediate,BAO_0000219
5734,Homo sapiens,1,F,A549,1,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,80682,9606.0,,,CHEMBL884007,11805,,646.0,,,N,Intermediate,BAO_0000219
5735,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against lung cancer A 549 cell lines,80682,9606.0,,,CHEMBL621296,2007,,646.0,,,N,Intermediate,BAO_0000219
5736,Homo sapiens,1,F,A549,1,Compound was tested for its cytotoxicity against A 549 cell line,80682,9606.0,,,CHEMBL621297,4594,,646.0,,,N,Intermediate,BAO_0000219
5737,Homo sapiens,1,F,A549,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",80682,9606.0,,,CHEMBL839828,6018,,646.0,,,N,Expert,BAO_0000219
5738,Homo sapiens,1,F,A549,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",80682,9606.0,,,CHEMBL620397,6018,,646.0,,,N,Intermediate,BAO_0000219
5739,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,80682,9606.0,,,CHEMBL620398,3599,,646.0,,,N,Expert,BAO_0000219
5740,Homo sapiens,1,F,A549,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,9606.0,,,CHEMBL620399,2551,,646.0,,,N,Intermediate,BAO_0000219
5741,Homo sapiens,1,F,A549,1,In vitro inhibition of A549 (human lung cancer) cell growth.,80682,9606.0,,,CHEMBL620400,16132,,646.0,,,N,Expert,BAO_0000219
5742,Homo sapiens,1,F,A549,1,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,80682,9606.0,,,CHEMBL620401,16132,,646.0,,,N,Intermediate,BAO_0000219
5743,Homo sapiens,1,F,A549,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,9606.0,,,CHEMBL620402,2551,,646.0,,,N,Expert,BAO_0000219
5744,Homo sapiens,1,F,A549,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),80682,9606.0,,,CHEMBL620403,2551,,646.0,,,N,Expert,BAO_0000219
5745,,0,F,,1,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,22226,,,,CHEMBL620404,11913,,,,,U,Autocuration,BAO_0000218
5746,,4,F,,1,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,104694,,,,CHEMBL620405,12621,,,,,H,Autocuration,BAO_0000218
5747,,4,F,,1,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,104694,,,,CHEMBL620406,12621,,,,,H,Autocuration,BAO_0000218
5748,,4,F,,1,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,104694,,,,CHEMBL620407,12621,,,,,H,Autocuration,BAO_0000218
5749,,4,F,,1,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,104694,,,,CHEMBL620408,12621,,,,,H,Autocuration,BAO_0000218
5750,,4,F,,1,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,104694,,,,CHEMBL620409,12621,,,,,H,Autocuration,BAO_0000218
5751,Homo sapiens,1,F,A498,1,Inhibition of A-498 human Renal cell proliferation,80021,9606.0,,,CHEMBL620410,3600,,624.0,,,N,Expert,BAO_0000219
5752,Rattus norvegicus,0,F,,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",22226,10116.0,,,CHEMBL620411,1796,,,,,U,Autocuration,BAO_0000019
5753,Rattus norvegicus,0,F,,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",22226,10116.0,,,CHEMBL620412,1796,,,,,U,Autocuration,BAO_0000019
5754,Rattus norvegicus,0,F,,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",22226,10116.0,,,CHEMBL876596,1796,,,,,U,Autocuration,BAO_0000019
5755,Homo sapiens,1,F,A 172,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,80012,9606.0,,,CHEMBL620413,16464,,622.0,,,N,Expert,BAO_0000219
5756,Homo sapiens,1,F,A 172,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,9606.0,,,CHEMBL620414,16464,,622.0,,,N,Intermediate,BAO_0000219
5757,Homo sapiens,1,F,A 172,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,9606.0,,,CHEMBL620415,16464,,622.0,,,N,Intermediate,BAO_0000219
5758,Homo sapiens,1,F,A549,1,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,80682,9606.0,,,CHEMBL620416,13617,,646.0,,,N,Expert,BAO_0000219
5759,Homo sapiens,1,F,A549,1,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,80682,9606.0,,,CHEMBL620417,4584,,646.0,,,N,Intermediate,BAO_0000219
5760,Homo sapiens,1,F,A549,1,Cytotoxic activity evaluated against A549 tumor cells,80682,9606.0,,,CHEMBL620418,13799,,646.0,,,N,Expert,BAO_0000219
5761,Homo sapiens,1,F,A549,1,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,80682,9606.0,,,CHEMBL620419,16726,,646.0,,,N,Intermediate,BAO_0000219
5762,Homo sapiens,1,F,A549,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,80682,9606.0,,,CHEMBL620420,16109,,646.0,,,N,Intermediate,BAO_0000219
5763,Homo sapiens,1,F,A549,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,80682,9606.0,,,CHEMBL620421,16109,,646.0,,,N,Intermediate,BAO_0000219
5764,Homo sapiens,1,F,A549,1,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,80682,9606.0,,,CHEMBL620422,15474,,646.0,,,N,Intermediate,BAO_0000219
5765,Homo sapiens,1,F,A549,1,Cytotoxicity of compound against A549 cell line,80682,9606.0,,,CHEMBL620423,6851,,646.0,,,N,Intermediate,BAO_0000219
5766,Homo sapiens,1,F,A549,1,Cytotoxicity against human lung cell carcinoma A549 cell line,80682,9606.0,,,CHEMBL620424,17534,,646.0,,,N,Expert,BAO_0000219
5767,Homo sapiens,1,F,A549,1,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,80682,9606.0,,,CHEMBL620425,2621,,646.0,,,N,Intermediate,BAO_0000219
5768,Homo sapiens,1,F,A549,1,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,80682,9606.0,,,CHEMBL620426,830,,646.0,,,N,Intermediate,BAO_0000219
5769,Homo sapiens,1,F,A549,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,80682,9606.0,,,CHEMBL620427,14255,,646.0,,,N,Intermediate,BAO_0000219
5770,Homo sapiens,1,F,A549,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,80682,9606.0,,,CHEMBL620428,14255,,646.0,,,N,Intermediate,BAO_0000219
5771,Homo sapiens,1,F,A549,1,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,80682,9606.0,,,CHEMBL620429,1590,,646.0,,,N,Intermediate,BAO_0000219
5772,Homo sapiens,1,F,A549,1,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,80682,9606.0,,,CHEMBL620430,6146,,646.0,,,N,Expert,BAO_0000219
5773,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL839887,17427,,646.0,,,N,Expert,BAO_0000219
5774,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,80682,9606.0,,,CHEMBL620431,5280,,646.0,,,N,Intermediate,BAO_0000219
5775,Homo sapiens,1,F,A549,1,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,80682,9606.0,,,CHEMBL884010,16786,,646.0,,,N,Intermediate,BAO_0000219
5776,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A549 (human lung cancer),80682,9606.0,,,CHEMBL620538,5895,,646.0,,,N,Intermediate,BAO_0000219
5777,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL620539,14297,,646.0,,,N,Expert,BAO_0000219
5778,Homo sapiens,1,F,A549,1,In vivo antiproliferative activity against A549 cell line,80682,9606.0,,,CHEMBL623373,17824,,646.0,,,N,Intermediate,BAO_0000218
5779,Homo sapiens,1,F,A549,1,Inhibition of non-small-cell lung adenocarcinoma (A549),80682,9606.0,,,CHEMBL623374,14368,,646.0,,,N,Intermediate,BAO_0000219
5780,Homo sapiens,1,F,A549,1,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,80682,9606.0,,,CHEMBL623375,14368,,646.0,,,N,Intermediate,BAO_0000219
5781,Homo sapiens,1,F,A549,1,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,80682,9606.0,,,CHEMBL623376,14254,,646.0,,,N,Intermediate,BAO_0000219
5782,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),80682,9606.0,,,CHEMBL623377,15897,,646.0,,,N,Intermediate,BAO_0000219
5783,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80682,9606.0,,,CHEMBL623378,13866,,646.0,,,N,Intermediate,BAO_0000219
5784,Homo sapiens,1,F,A549,1,Inhibitory activity of compound against human A549 lung carcinoma cell line.,80682,9606.0,,,CHEMBL623379,13370,,646.0,,,N,Intermediate,BAO_0000219
5785,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 lung cancer cell line,80682,9606.0,,,CHEMBL623380,4862,,646.0,,,N,Intermediate,BAO_0000219
5786,Homo sapiens,1,F,A549,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,80682,9606.0,,,CHEMBL623381,4862,,646.0,,,N,Intermediate,BAO_0000219
5787,Homo sapiens,1,F,A549,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,80682,9606.0,,,CHEMBL623382,4862,,646.0,,,N,Intermediate,BAO_0000219
5788,Homo sapiens,1,F,A549,1,Inhibitory concentration against A549 (lung cancer) cell line,80682,9606.0,,,CHEMBL623383,15970,,646.0,,,N,Intermediate,BAO_0000219
5789,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL623384,17713,,646.0,,,N,Expert,BAO_0000219
5790,Homo sapiens,1,F,A549,1,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,80682,9606.0,,,CHEMBL623385,4833,,646.0,,,N,Intermediate,BAO_0000219
5791,Homo sapiens,1,F,A549,1,Activity against A549 cancer cell line.,80682,9606.0,,,CHEMBL623386,13736,,646.0,,,N,Expert,BAO_0000219
5792,Homo sapiens,1,F,A549,1,The compound was evaluated for cytotoxicity against A549 cell line,80682,9606.0,,,CHEMBL884105,4312,,646.0,,,N,Intermediate,BAO_0000219
5793,Homo sapiens,1,F,A549,1,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,80682,9606.0,,,CHEMBL623387,5421,,646.0,,,N,Intermediate,BAO_0000219
5794,Homo sapiens,1,F,A549,1,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,9606.0,,,CHEMBL621568,5421,,646.0,,,N,Intermediate,BAO_0000219
5795,Homo sapiens,1,F,A549,1,Growth inhibitory activity was measured for human A549 tumor cell line.,80682,9606.0,,,CHEMBL621569,14717,,646.0,,,N,Intermediate,BAO_0000219
5796,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 lung cancer cell line,80682,9606.0,,,CHEMBL621570,4634,,646.0,,,N,Intermediate,BAO_0000219
5797,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 cell line; inactive,80682,9606.0,,,CHEMBL621571,1149,,646.0,,,N,Intermediate,BAO_0000219
5798,Homo sapiens,1,F,A549,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,9606.0,,,CHEMBL621572,5421,,646.0,,,N,Expert,BAO_0000219
5799,Homo sapiens,1,F,A549,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,9606.0,,,CHEMBL621573,5421,,646.0,,,N,Expert,BAO_0000219
5800,Homo sapiens,1,F,A549,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,9606.0,,,CHEMBL621574,5421,,646.0,,,N,Intermediate,BAO_0000219
5801,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),80682,9606.0,,,CHEMBL621575,3320,,646.0,,,N,Intermediate,BAO_0000219
5802,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),80682,9606.0,,,CHEMBL621576,3320,,646.0,,,N,Intermediate,BAO_0000219
5803,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),80682,9606.0,,,CHEMBL621577,3320,,646.0,,,N,Intermediate,BAO_0000219
5804,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),80682,9606.0,,,CHEMBL621578,3320,,646.0,,,N,Intermediate,BAO_0000219
5805,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),80682,9606.0,,,CHEMBL621579,3320,,646.0,,,N,Intermediate,BAO_0000219
5806,Homo sapiens,1,F,A549,1,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,80682,9606.0,,,CHEMBL621580,5726,,646.0,,,N,Intermediate,BAO_0000219
5807,Canis lupus familiaris,1,A,,1,Plasma clearance (in vivo) in mongrel dogs was determined,50588,9615.0,,,CHEMBL621581,17800,,,,,N,Intermediate,BAO_0000218
5808,Canis lupus familiaris,1,A,,1,Plasma clearance was measured in dog,50588,9615.0,,,CHEMBL621582,5985,,,,,N,Intermediate,BAO_0000218
5809,Canis lupus familiaris,1,A,,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,9615.0,,,CHEMBL621583,5530,,,,,N,Intermediate,BAO_0000218
5810,Canis lupus familiaris,1,A,,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL621584,5530,,,,,N,Intermediate,BAO_0000218
5811,Canis lupus familiaris,1,A,,1,Tested for plasma clearance in dog,50588,9615.0,,,CHEMBL621585,4839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5812,Canis lupus familiaris,1,A,,1,The compound was tested for clearance in dog plasma.,50588,9615.0,,,CHEMBL621586,3639,,,,,N,Intermediate,BAO_0000218
5813,Canis lupus familiaris,1,A,,1,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",50588,9615.0,,,CHEMBL875835,4838,,,,,N,Intermediate,BAO_0000218
5814,Canis lupus familiaris,1,A,,1,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,50588,9615.0,,,CHEMBL621587,4137,,,,,N,Intermediate,BAO_0000218
5815,Canis lupus familiaris,1,A,,1,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,9615.0,,,CHEMBL621588,5017,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5816,Canis lupus familiaris,1,A,,1,In vitro clearance in dog liver microsomes,50588,9615.0,Microsomes,,CHEMBL621589,17538,2107.0,,,Liver,N,Intermediate,BAO_0000218
5817,Canis lupus familiaris,1,A,,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,9615.0,,,CHEMBL621590,6161,,,,,N,Intermediate,BAO_0000218
5818,Canis lupus familiaris,1,A,,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,50588,9615.0,,,CHEMBL621591,6161,,,,,N,Intermediate,BAO_0000218
5819,Canis lupus familiaris,1,A,,1,Plasma clearance in dog,50588,9615.0,,,CHEMBL621592,1696,,,,,N,Intermediate,BAO_0000218
5820,Canis lupus familiaris,1,A,,1,Clearance rate in dog,50588,9615.0,,,CHEMBL621593,6762,,,,,N,Intermediate,BAO_0000218
5821,Canis lupus familiaris,1,A,,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,9615.0,,,CHEMBL621594,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5822,Canis lupus familiaris,1,A,,1,Clearance in dogs,50588,9615.0,,,CHEMBL621595,6305,,,,,N,Intermediate,BAO_0000218
5823,Canis lupus familiaris,1,A,,1,Plasma clearance in dogs,50588,9615.0,,,CHEMBL621596,4942,,,,,N,Intermediate,BAO_0000218
5824,Canis lupus familiaris,1,A,,1,Plasma clearance was determined,50588,9615.0,,,CHEMBL621597,4219,,,,,N,Intermediate,BAO_0000218
5825,Canis lupus familiaris,1,A,,1,Lower clearance in dog (i.v.) at 0.5 mpk,50588,9615.0,,,CHEMBL621598,17853,,,,,N,Intermediate,BAO_0000218
5826,Canis lupus familiaris,1,A,,1,Plasma clearance in Beagle dogs,50588,9615.0,,,CHEMBL621599,4514,,,,,N,Intermediate,BAO_0000218
5827,Canis lupus familiaris,1,A,,1,Plasma clearance (Clp) in dog,50588,9615.0,,,CHEMBL875836,6448,,,,,N,Intermediate,BAO_0000218
5828,Canis lupus familiaris,1,A,,1,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL621600,6227,,,,,N,Intermediate,BAO_0000218
5829,Canis lupus familiaris,1,A,,1,Plasma clearance (pharmacokinetic parameter) in dog was determined,50588,9615.0,,,CHEMBL621601,6227,,,,,N,Intermediate,BAO_0000218
5830,Canis lupus familiaris,1,A,,1,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,50588,9615.0,,,CHEMBL618474,6062,,,,,N,Intermediate,BAO_0000218
5831,Canis lupus familiaris,1,A,,1,Plasma clearance of compound was determined in dog,50588,9615.0,,,CHEMBL618475,6821,,,,,N,Intermediate,BAO_0000218
5832,Canis lupus familiaris,1,A,,1,Plasma clearance after intravenous administration of 1 mg/kg in dog,50588,9615.0,,,CHEMBL624524,4709,,,,,N,Intermediate,BAO_0000218
5833,Canis lupus familiaris,1,A,,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,9615.0,,,CHEMBL624525,4521,,,,,N,Intermediate,BAO_0000218
5834,Canis lupus familiaris,1,A,,1,Plasma clearance in dog was determined,50588,9615.0,,,CHEMBL624526,5374,,,,,N,Intermediate,BAO_0000218
5835,Canis lupus familiaris,1,A,,1,Plasma clearance was calculated in dog,50588,9615.0,,,CHEMBL624527,6057,,,,,N,Intermediate,BAO_0000218
5836,Canis lupus familiaris,1,A,,1,Plasma clearance at the dose of 2 mg/kg in dog,50588,9615.0,,,CHEMBL624528,4727,,,,,N,Intermediate,BAO_0000218
5837,Canis lupus familiaris,1,A,,1,Plasma clearance in dog,50588,9615.0,,,CHEMBL624529,5145,,,,,N,Intermediate,BAO_0000218
5838,Canis lupus familiaris,1,A,,1,Plasma clearance in dog,50588,9615.0,,,CHEMBL624530,17657,,,,,N,Intermediate,BAO_0000218
5839,Canis lupus familiaris,1,A,,1,Plasma clearance in dog; Unable to calculate,50588,9615.0,,,CHEMBL624531,17657,,,,,N,Intermediate,BAO_0000218
5840,Canis lupus familiaris,1,A,,1,Plasma clearance in rhesus monkey,50588,9615.0,,,CHEMBL624532,5145,,,,,N,Intermediate,BAO_0000218
5841,Canis lupus familiaris,1,A,,1,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,9615.0,,,CHEMBL624533,6642,,,,,N,Intermediate,BAO_0000218
5842,Canis lupus familiaris,1,A,,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,9615.0,,,CHEMBL624534,6641,,,,,N,Intermediate,BAO_0000218
5843,Canis lupus familiaris,1,A,,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,9615.0,,,CHEMBL624535,6642,,,,,N,Intermediate,BAO_0000218
5844,Canis lupus familiaris,1,A,,1,Plasma clearance was evaluated in dog,50588,9615.0,,,CHEMBL624536,5472,,,,,N,Intermediate,BAO_0000218
5845,Canis lupus familiaris,1,A,,1,Plasma clearance was evaluated in dog; Not tested,50588,9615.0,,,CHEMBL624537,5472,,,,,N,Intermediate,BAO_0000218
5846,Canis lupus familiaris,1,A,,1,Plasma clearance was evaluated in rhesus,50588,9615.0,,,CHEMBL624538,5472,,,,,N,Intermediate,BAO_0000218
5847,Canis lupus familiaris,1,A,,1,Plasma clearance was evaluated in rhesus; Not tested,50588,9615.0,,,CHEMBL624539,5472,,,,,N,Intermediate,BAO_0000218
5848,Canis lupus familiaris,1,A,,1,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,50588,9615.0,,,CHEMBL624540,4257,,,,,N,Intermediate,BAO_0000218
5849,Canis lupus familiaris,1,A,,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,9615.0,,,CHEMBL624541,6679,,,,,N,Intermediate,BAO_0000218
5850,Canis lupus familiaris,1,A,,1,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,9615.0,,,CHEMBL624542,5546,,,,,N,Intermediate,BAO_0000218
5851,Canis lupus familiaris,1,A,,1,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,9615.0,,,CHEMBL624543,6348,,,,,N,Intermediate,BAO_0000218
5852,Canis lupus familiaris,1,A,,1,Clearance value at a dose of 0.2 mg/kg i.v.,50588,9615.0,,,CHEMBL624544,5474,,,,,N,Intermediate,BAO_0000218
5853,Canis lupus familiaris,1,A,,1,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,50588,9615.0,,,CHEMBL624545,6316,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5854,Canis lupus familiaris,1,A,,1,Cmax after oral dose of compound at 3 mg/kg in dogs,50588,9615.0,,,CHEMBL624546,17594,,,,,N,Intermediate,BAO_0000218
5855,Canis lupus familiaris,1,A,,1,Cmax after single intravenous bolus of 1 mg/kg in dogs,50588,9615.0,,,CHEMBL875957,17594,,,,,N,Intermediate,BAO_0000218
5856,Canis lupus familiaris,1,A,,1,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,9615.0,,,CHEMBL624547,5802,,,,,N,Intermediate,BAO_0000218
5857,Canis lupus familiaris,1,A,,1,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,9615.0,,,CHEMBL624548,6535,,,,,N,Intermediate,BAO_0000218
5858,Canis lupus familiaris,1,A,,1,Cmax in dog after administration of 1 mg/kg iv,50588,9615.0,,,CHEMBL624549,6535,,,,,N,Intermediate,BAO_0000218
5859,Canis lupus familiaris,1,A,,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,50588,9615.0,,,CHEMBL624550,1466,1969.0,,,Plasma,N,Intermediate,BAO_0000218
5860,Canis lupus familiaris,1,A,,1,Cmax on p.o. administration of 10 mg/kg was measured in dog,50588,9615.0,,,CHEMBL621613,6505,,,,,N,Intermediate,BAO_0000218
5861,Canis lupus familiaris,1,A,,1,Cmax was determine after peroral administration at 10 mpk in dog,50588,9615.0,,,CHEMBL621614,5668,,,,,N,Intermediate,BAO_0000218
5862,Canis lupus familiaris,1,A,,1,Cmax was determine after peroral administration at 5 mpk in dog,50588,9615.0,,,CHEMBL623431,5668,,,,,N,Intermediate,BAO_0000218
5863,Canis lupus familiaris,1,A,,1,Cmax was determine after peroral administration at 5 mg/kg in dog,50588,9615.0,,,CHEMBL623432,5668,,,,,N,Intermediate,BAO_0000218
5864,Canis lupus familiaris,1,A,,1,Cmax after 0.3 mg/kg po administration in dog,50588,9615.0,,,CHEMBL623433,5600,,,,,N,Intermediate,BAO_0000218
5865,Canis lupus familiaris,1,A,,1,Cmax after peroral administration in dogs at 2.4 uM/kg,50588,9615.0,,,CHEMBL623434,17764,,,,,N,Intermediate,BAO_0000218
5866,Canis lupus familiaris,1,A,,1,Cmax in dog after oral administration at 1 mg/kg,50588,9615.0,,,CHEMBL623435,6123,,,,,N,Intermediate,BAO_0000218
5867,Canis lupus familiaris,1,A,,1,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,50588,9615.0,,,CHEMBL623436,6123,,,,,N,Intermediate,BAO_0000218
5868,Canis lupus familiaris,1,A,,1,Cmax upon oral administration in male Beagle dog at 10 mg/kg,50588,9615.0,,,CHEMBL875958,6757,,,,,N,Intermediate,BAO_0000218
5869,Canis lupus familiaris,1,A,,1,Cmax value after 15 mg/kg iv dose in Dogs,50588,9615.0,,,CHEMBL623437,16907,,,,,N,Intermediate,BAO_0000218
5870,Mus musculus,1,A,,1,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623438,7767,178.0,,,Blood,N,Intermediate,BAO_0000218
5871,Mus musculus,1,A,,1,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623439,7767,178.0,,,Blood,N,Intermediate,BAO_0000218
5872,Mus musculus,1,A,,1,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623440,7767,10000001.0,,,Bone,N,Intermediate,BAO_0000218
5873,Mus musculus,1,A,,1,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623441,7767,10000001.0,,,Bone,N,Intermediate,BAO_0000218
5874,Mus musculus,1,A,,1,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623442,7767,10000001.0,,,Bone,N,Intermediate,BAO_0000218
5875,Mus musculus,1,A,,1,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623469,7767,,,,,N,Intermediate,BAO_0000218
5876,Mus musculus,1,A,,1,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623470,7767,,,,,N,Intermediate,BAO_0000218
5877,Mus musculus,1,A,,1,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623471,7767,,,,,N,Intermediate,BAO_0000218
5878,Mus musculus,1,A,,1,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623472,7767,948.0,,,Heart,N,Intermediate,BAO_0000218
5879,Mus musculus,1,A,,1,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623473,7767,948.0,,,Heart,N,Intermediate,BAO_0000218
5880,Mus musculus,1,A,,1,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623474,7767,948.0,,,Heart,N,Intermediate,BAO_0000218
5881,Mus musculus,1,A,,1,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623475,7767,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5882,Mus musculus,1,A,,1,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623476,7767,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5883,Mus musculus,1,A,,1,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL623477,7767,2113.0,,,Kidney,N,Intermediate,BAO_0000218
5884,Mus musculus,1,A,,1,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621896,7767,160.0,,,Intestine,N,Intermediate,BAO_0000218
5885,Mus musculus,1,A,,1,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621897,7767,160.0,,,Intestine,N,Intermediate,BAO_0000218
5886,Mus musculus,1,A,,1,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621898,7767,160.0,,,Intestine,N,Intermediate,BAO_0000218
5887,Mus musculus,1,A,,1,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621899,7767,2107.0,,,Liver,N,Intermediate,BAO_0000218
5888,Mus musculus,1,A,,1,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621900,7767,2107.0,,,Liver,N,Intermediate,BAO_0000218
5889,Mus musculus,1,A,,1,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621901,7767,2107.0,,,Liver,N,Intermediate,BAO_0000218
5890,Mus musculus,1,A,,1,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621902,7767,2048.0,,,Lung,N,Intermediate,BAO_0000218
5891,Mus musculus,1,A,,1,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL621903,7767,2048.0,,,Lung,N,Intermediate,BAO_0000218
5892,Mus musculus,1,A,,1,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL622587,7767,2048.0,,,Lung,N,Intermediate,BAO_0000218
5893,Mus musculus,1,A,,1,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620285,7767,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
5894,Mus musculus,1,A,,1,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL875285,7767,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
5895,Mus musculus,1,A,,1,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620286,7767,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
5896,Mus musculus,1,A,,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620287,7767,,,,,N,Intermediate,BAO_0000218
5897,Mus musculus,1,A,,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620288,7767,,,,,N,Intermediate,BAO_0000218
5898,Mus musculus,1,A,,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620289,7767,,,,,N,Intermediate,BAO_0000218
5899,Mus musculus,1,A,,1,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620290,7767,160.0,,,Intestine,N,Intermediate,BAO_0000218
5900,Mus musculus,1,A,,1,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620291,7767,160.0,,,Intestine,N,Intermediate,BAO_0000218
5901,Mus musculus,1,A,,1,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620292,7767,160.0,,,Intestine,N,Intermediate,BAO_0000218
5902,Mus musculus,1,A,,1,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620293,7767,2106.0,,,Spleen,N,Intermediate,BAO_0000218
5903,Mus musculus,1,A,,1,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL620294,7767,2106.0,,,Spleen,N,Intermediate,BAO_0000218
5904,Mus musculus,1,A,,1,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL618614,7767,2106.0,,,Spleen,N,Intermediate,BAO_0000218
5905,Mus musculus,1,A,,1,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL618615,7767,945.0,,,Stomach,N,Intermediate,BAO_0000218
5906,Mus musculus,1,A,,1,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL618616,7767,945.0,,,Stomach,N,Intermediate,BAO_0000218
5907,Homo sapiens,1,F,A 172,1,Cytotoxicity against A-172 human tumor cell lines,80012,9606.0,,,CHEMBL618617,2036,,622.0,,,N,Expert,BAO_0000219
5908,Homo sapiens,1,F,A 172,1,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,80012,9606.0,,,CHEMBL618618,2357,,622.0,,,N,Intermediate,BAO_0000219
5909,Homo sapiens,1,F,A204,1,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,80014,9606.0,,,CHEMBL618619,1457,,623.0,,,N,Intermediate,BAO_0000219
5910,Homo sapiens,1,F,A2780,1,Tested for antiproliferative activity against A-2780 tumoral cell line,81034,9606.0,,,CHEMBL618620,4379,,478.0,,,N,Intermediate,BAO_0000219
5911,Homo sapiens,1,F,A-375,1,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,80018,9606.0,,,CHEMBL618621,1093,,455.0,,,N,Intermediate,BAO_0000219
5912,Homo sapiens,1,F,A-375,1,Tested in vitro against A-375 cell line human melanoma,80018,9606.0,,,CHEMBL618622,12152,,455.0,,,N,Intermediate,BAO_0000219
5913,Homo sapiens,1,F,A-427,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,80019,9606.0,,,CHEMBL618623,16464,,797.0,,,N,Expert,BAO_0000219
5914,Homo sapiens,1,F,A-427,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,9606.0,,,CHEMBL618624,16464,,797.0,,,N,Intermediate,BAO_0000219
5915,Homo sapiens,1,F,A-427,1,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,80019,9606.0,,,CHEMBL618625,16582,,797.0,,,N,Expert,BAO_0000219
5916,Homo sapiens,1,F,A-427,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,9606.0,,,CHEMBL618626,16464,,797.0,,,N,Intermediate,BAO_0000219
5917,Homo sapiens,1,F,A-427,1,Antitumor activity on A-427 lung carcinoma cell lines,80019,9606.0,,,CHEMBL618627,10413,,797.0,,,N,Intermediate,BAO_0000219
5918,Homo sapiens,1,F,A-427,1,Cytotoxic activity against human A-427 lung tumor cell line,80019,9606.0,,,CHEMBL618628,6418,,797.0,,,N,Intermediate,BAO_0000219
5919,Homo sapiens,1,F,A-427,1,In vitro antitumor effects against human A-427 cell lines.,80019,9606.0,,,CHEMBL618629,17134,,797.0,,,N,Expert,BAO_0000219
5920,Homo sapiens,1,F,A-427,1,In vitro inhibition of A-427 (human lung cancer) cell growth.,80019,9606.0,,,CHEMBL618630,16132,,797.0,,,N,Expert,BAO_0000219
5921,Homo sapiens,1,F,A-427,1,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,80019,9606.0,,,CHEMBL618631,16132,,797.0,,,N,Intermediate,BAO_0000219
5922,Homo sapiens,1,F,A-427,1,Cytotoxic activity of compound against A-427 lung human tumor cell line,80019,9606.0,,,CHEMBL618632,16780,,797.0,,,N,Intermediate,BAO_0000219
5923,Homo sapiens,1,F,A-431,1,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,80852,9606.0,,,CHEMBL618633,4085,,500.0,,,N,Expert,BAO_0000219
5924,Homo sapiens,1,F,A498,1,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,80021,9606.0,,,CHEMBL619315,1276,,624.0,,,N,Intermediate,BAO_0000219
5925,Homo sapiens,1,F,A498,1,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,80021,9606.0,,,CHEMBL619316,3498,,624.0,,,N,Expert,BAO_0000219
5926,Homo sapiens,1,F,A498,1,Cytotoxicity against human kidney carcinoma A-498cell lines,80021,9606.0,,,CHEMBL619317,1169,,624.0,,,N,Intermediate,BAO_0000219
5927,Homo sapiens,1,F,A498,1,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,80021,9606.0,,,CHEMBL619318,4450,,624.0,,,N,Intermediate,BAO_0000219
5928,Homo sapiens,1,F,A498,1,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,80021,9606.0,,,CHEMBL619319,3311,,624.0,,,N,Intermediate,BAO_0000219
5929,Homo sapiens,1,F,A498,1,Antitumor cytotoxic activity against A-498 cell line was determined,80021,9606.0,,,CHEMBL619739,4461,,624.0,,,N,Intermediate,BAO_0000219
5930,Homo sapiens,1,F,A498,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,80021,9606.0,,,CHEMBL619740,3311,,624.0,,,N,Intermediate,BAO_0000219
5931,Homo sapiens,1,F,A498,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,80021,9606.0,,,CHEMBL883158,3311,,624.0,,,N,Intermediate,BAO_0000219
5932,Homo sapiens,1,F,A498,1,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,80021,9606.0,,,CHEMBL884012,1457,,624.0,,,N,Intermediate,BAO_0000219
5933,Homo sapiens,1,F,A498,1,In vitro inhibitory activity against A-498 ovarian cancer cell lines,80021,9606.0,,,CHEMBL619741,3664,,624.0,,,N,Intermediate,BAO_0000219
5934,Homo sapiens,1,F,A498,1,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",80021,9606.0,,,CHEMBL619742,15895,,624.0,,,N,Intermediate,BAO_0000219
5935,Homo sapiens,1,F,A549,1,Inhibition of growth lung non-small cell carcinoma A-549 cell line,80682,9606.0,,,CHEMBL876610,11843,,646.0,,,N,Intermediate,BAO_0000219
5936,Homo sapiens,1,F,A549,1,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,80682,9606.0,,,CHEMBL619743,11843,,646.0,,,N,Intermediate,BAO_0000219
5937,Homo sapiens,1,F,A549,1,In vitro antiproliferative activity against human A-549 NSCL cell line,80682,9606.0,,,CHEMBL619744,17705,,646.0,,,N,Intermediate,BAO_0000219
5938,Homo sapiens,1,F,A549,1,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,80682,9606.0,,,CHEMBL619745,17705,,646.0,,,N,Intermediate,BAO_0000219
5939,Homo sapiens,1,F,A549,1,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,80682,9606.0,,,CHEMBL619746,4369,,646.0,,,N,Intermediate,BAO_0000219
5940,Homo sapiens,1,F,A549,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,80682,9606.0,,,CHEMBL619747,4369,,646.0,,,N,Intermediate,BAO_0000219
5941,Homo sapiens,1,F,A549,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,80682,9606.0,,,CHEMBL619748,4369,,646.0,,,N,Intermediate,BAO_0000219
5942,Homo sapiens,1,F,A549,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,80682,9606.0,,,CHEMBL619749,4369,,646.0,,,N,Intermediate,BAO_0000219
5943,Homo sapiens,1,F,A549,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,80682,9606.0,,,CHEMBL619750,4369,,646.0,,,N,Intermediate,BAO_0000219
5944,Homo sapiens,1,F,A549,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,80682,9606.0,,,CHEMBL624014,4369,,646.0,,,N,Intermediate,BAO_0000219
5945,Homo sapiens,1,F,A549,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,80682,9606.0,,,CHEMBL624015,4369,,646.0,,,N,Intermediate,BAO_0000219
5946,Homo sapiens,1,F,A549,1,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,80682,9606.0,,,CHEMBL885344,4787,,646.0,,,N,Expert,BAO_0000219
5947,Homo sapiens,1,F,A549,1,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,80682,9606.0,,,CHEMBL623224,4787,,646.0,,,N,Intermediate,BAO_0000219
5948,Homo sapiens,1,F,A549,1,Cytotoxic activity against A-549 cell line,80682,9606.0,,,CHEMBL623225,6513,,646.0,,,N,Intermediate,BAO_0000219
5949,Homo sapiens,1,F,A549,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,80682,9606.0,,,CHEMBL622698,6690,,646.0,,,N,Intermediate,BAO_0000219
5950,Homo sapiens,1,F,A549,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,80682,9606.0,,,CHEMBL622699,6690,,646.0,,,N,Intermediate,BAO_0000219
5951,Homo sapiens,1,F,A549,1,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",80682,9606.0,,,CHEMBL622700,12263,,646.0,,,N,Expert,BAO_0000219
5952,Homo sapiens,1,F,A549,1,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),80682,9606.0,,,CHEMBL622701,1054,,646.0,,,N,Intermediate,BAO_0000219
5953,Homo sapiens,1,F,A549,1,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),80682,9606.0,,,CHEMBL622702,1359,,646.0,,,N,Intermediate,BAO_0000219
5954,Homo sapiens,1,F,A549,1,Cytotoxic activity against human lung carcinoma (A-549) cell line,80682,9606.0,,,CHEMBL622703,3547,,646.0,,,N,Intermediate,BAO_0000219
5955,Homo sapiens,1,F,A549,1,Cytotoxic activity towards A-549 cells,80682,9606.0,,,CHEMBL622704,5771,,646.0,,,N,Expert,BAO_0000219
5956,Homo sapiens,1,F,A549,1,"In vitro percent inhibition of A549, lung carcinoma.",80682,9606.0,,,CHEMBL622705,14425,,646.0,,,N,Intermediate,BAO_0000219
5957,Homo sapiens,1,F,A549,1,"In vitro percent inhibition of A549, lung carcinoma",80682,9606.0,,,CHEMBL622706,14425,,646.0,,,N,Intermediate,BAO_0000219
5958,Homo sapiens,1,F,A549,1,"In vitro percent inhibition of A549, lung carcinoma.",80682,9606.0,,,CHEMBL622707,14425,,646.0,,,N,Intermediate,BAO_0000219
5959,Homo sapiens,1,F,A549,1,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",80682,9606.0,,,CHEMBL622708,14425,,646.0,,,N,Intermediate,BAO_0000219
5960,Homo sapiens,1,F,A549,1,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,80682,9606.0,,,CHEMBL622709,5280,,646.0,,,N,Intermediate,BAO_0000219
5961,Homo sapiens,1,F,A549,1,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,80682,9606.0,,,CHEMBL622710,15176,,646.0,,,N,Intermediate,BAO_0000219
5962,Homo sapiens,1,F,A549,1,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,80682,9606.0,,,CHEMBL622711,15300,,646.0,,,N,Intermediate,BAO_0000219
5963,Homo sapiens,1,F,A549,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,9606.0,,,CHEMBL622712,17824,,646.0,,,N,Intermediate,BAO_0000218
5964,Homo sapiens,1,F,A549,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,9606.0,,,CHEMBL622713,17824,,646.0,,,N,Intermediate,BAO_0000218
5965,Homo sapiens,1,F,A549,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,9606.0,,,CHEMBL622714,17824,,646.0,,,N,Intermediate,BAO_0000218
5966,Homo sapiens,1,F,A549,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,9606.0,,,CHEMBL622715,17824,,646.0,,,N,Intermediate,BAO_0000218
5967,Homo sapiens,1,F,A549,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,9606.0,,,CHEMBL622716,17824,,646.0,,,N,Intermediate,BAO_0000218
5968,Homo sapiens,1,F,A549,1,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",80682,9606.0,,,CHEMBL622717,17824,,646.0,,,N,Intermediate,BAO_0000219
5969,Homo sapiens,1,F,A549,1,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),80682,9606.0,,,CHEMBL622718,17528,,646.0,,,N,Intermediate,BAO_0000218
5970,Homo sapiens,1,F,A549,1,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,80682,9606.0,,,CHEMBL622719,6870,,646.0,,,N,Expert,BAO_0000219
5971,Homo sapiens,1,F,A549,1,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,9606.0,,,CHEMBL622720,6870,,646.0,,,N,Intermediate,BAO_0000219
5972,Homo sapiens,1,F,A549,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,80682,9606.0,,,CHEMBL622721,6870,,646.0,,,N,Intermediate,BAO_0000219
5973,Homo sapiens,1,F,A549,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,9606.0,,,CHEMBL622722,6870,,646.0,,,N,Intermediate,BAO_0000219
5974,Homo sapiens,1,F,A549,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,9606.0,,,CHEMBL876030,16726,,646.0,,,N,Intermediate,BAO_0000219
5975,Homo sapiens,1,F,A549,1,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",80682,9606.0,,,CHEMBL620206,6170,,646.0,,,N,Intermediate,BAO_0000219
5976,Homo sapiens,1,F,A549,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,80682,9606.0,,,CHEMBL620207,6583,,646.0,,,N,Expert,BAO_0000219
5977,Homo sapiens,1,F,A549,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,80682,9606.0,,,CHEMBL620208,6583,,646.0,,,N,Expert,BAO_0000219
5978,Homo sapiens,1,F,A549,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,80682,9606.0,,,CHEMBL620209,6583,,646.0,,,N,Expert,BAO_0000219
5979,Homo sapiens,1,F,A549,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,80682,9606.0,,,CHEMBL620210,6583,,646.0,,,N,Expert,BAO_0000219
5980,Homo sapiens,1,F,A549,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,80682,9606.0,,,CHEMBL621639,6583,,646.0,,,N,Expert,BAO_0000219
5981,Homo sapiens,1,F,A549,1,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,80682,9606.0,,,CHEMBL621640,17321,,646.0,,,N,Intermediate,BAO_0000219
5982,Homo sapiens,1,F,A549,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,80682,9606.0,,,CHEMBL621641,17528,,646.0,,,N,Expert,BAO_0000219
5983,Homo sapiens,1,F,A549,1,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,80682,9606.0,,,CHEMBL621642,12888,,646.0,,,N,Expert,BAO_0000219
5984,Homo sapiens,1,F,A549,1,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,80682,9606.0,,,CHEMBL621643,4312,,646.0,,,N,Intermediate,BAO_0000219
5985,Homo sapiens,1,F,A549,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,80682,9606.0,,,CHEMBL621644,4312,,646.0,,,N,Intermediate,BAO_0000219
5986,Homo sapiens,1,F,A549,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,80682,9606.0,,,CHEMBL621645,4312,,646.0,,,N,Intermediate,BAO_0000219
5987,Mus musculus,1,F,A549,1,In vitro antiproliferative activity against A549 cell line,80682,10090.0,,,CHEMBL621646,17737,,646.0,,,N,Intermediate,BAO_0000219
5988,,1,F,A549,1,Synergism with indomethacin in A549 cells,80682,,,,CHEMBL621647,6630,,646.0,,,N,Intermediate,BAO_0000219
5989,,1,F,A549,1,Synergism with tolmetin in A549 cells,80682,,,,CHEMBL621648,6630,,646.0,,,N,Intermediate,BAO_0000219
5990,,1,F,A549,1,Synergism with sulindac in A549 cells,80682,,,,CHEMBL621649,6630,,646.0,,,N,Intermediate,BAO_0000219
5991,,1,F,A549,1,Antagonism of indomethacin in A549 cells,80682,,,,CHEMBL621650,6630,,646.0,,,N,Intermediate,BAO_0000219
5992,,1,F,A549,1,Antagonism of sulindac in A549 cells,80682,,,,CHEMBL621651,6630,,646.0,,,N,Intermediate,BAO_0000219
5993,,1,F,A549,1,Antagonism of tolmetin in A549 cells,80682,,,,CHEMBL621652,6630,,646.0,,,N,Intermediate,BAO_0000219
5994,,1,F,A549,1,Synergism with indomethacin in A549 cells,80682,,,,CHEMBL621653,6630,,646.0,,,N,Intermediate,BAO_0000219
5995,,1,F,A549,1,Synergism with sulindac in A549 cells,80682,,,,CHEMBL621654,6630,,646.0,,,N,Intermediate,BAO_0000219
5996,,1,F,A549,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,80682,,,,CHEMBL621655,6630,,646.0,,,N,Intermediate,BAO_0000219
5997,Canis lupus familiaris,1,A,,1,Cmax value after 30 mg/kg po dose in Dogs,50588,9615.0,,,CHEMBL621656,16907,,,,,N,Intermediate,BAO_0000218
5998,Canis lupus familiaris,1,A,,1,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,9615.0,,,CHEMBL621657,5944,,,,,N,Intermediate,BAO_0000218
5999,Canis lupus familiaris,1,A,,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,50588,9615.0,,,CHEMBL621658,5944,,,,,N,Intermediate,BAO_0000218
6000,Canis lupus familiaris,1,A,,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,9615.0,,,CHEMBL621659,5944,,,,,N,Intermediate,BAO_0000218
6001,Canis lupus familiaris,1,A,,1,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,50588,9615.0,,,CHEMBL621660,5944,,,,,N,Intermediate,BAO_0000218
6002,Canis lupus familiaris,1,A,,1,Cmax value after administration of 4 mg/Kg oral dose in dog,50588,9615.0,,,CHEMBL621661,2959,,,,,N,Intermediate,BAO_0000218
6003,Canis lupus familiaris,1,A,,1,Cmax value in dog,50588,9615.0,,,CHEMBL621662,6241,,,,,N,Intermediate,BAO_0000218
6004,Canis lupus familiaris,1,A,,1,Cmax value in dogs after oral administration at 1 mg/kg,50588,9615.0,,,CHEMBL621663,6241,,,,,N,Intermediate,BAO_0000218
6005,Canis lupus familiaris,1,A,,1,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,50588,9615.0,,,CHEMBL621664,2652,,,,,N,Intermediate,BAO_0000218
6006,Canis lupus familiaris,1,A,,1,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,50588,9615.0,,,CHEMBL621665,1806,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6007,Canis lupus familiaris,1,A,,1,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,50588,9615.0,,,CHEMBL621666,1806,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6008,Canis lupus familiaris,1,A,,1,Concentration maxima after oral dosing in dogs,50588,9615.0,,,CHEMBL621667,1021,,,,,N,Intermediate,BAO_0000218
6009,Canis lupus familiaris,1,A,,1,Concentration maxima after oral dosing in dogs; not available,50588,9615.0,,,CHEMBL876738,1021,,,,,N,Intermediate,BAO_0000218
6010,Canis lupus familiaris,1,A,,1,Concentration maxima after oral dosing in dogs; not available,50588,9615.0,,,CHEMBL621668,1021,,,,,N,Intermediate,BAO_0000218
6011,Canis lupus familiaris,1,A,,1,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,50588,9615.0,,,CHEMBL621669,5444,,,,,N,Intermediate,BAO_0000218
6012,Canis lupus familiaris,1,A,,1,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,50588,9615.0,,,CHEMBL621670,5444,,,,,N,Intermediate,BAO_0000218
6013,Canis lupus familiaris,1,A,,1,In vivo maximal concentration was calculated at 1 mg/kg in dog,50588,9615.0,,,CHEMBL621671,5444,,,,,N,Intermediate,BAO_0000218
6014,Canis lupus familiaris,1,A,,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,50588,9615.0,,,CHEMBL622360,5444,,,,,N,Intermediate,BAO_0000218
6015,Canis lupus familiaris,1,A,,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,50588,9615.0,,,CHEMBL622361,5444,,,,,N,Intermediate,BAO_0000218
6016,Canis lupus familiaris,1,A,,1,Cmax in dog plasma after oral dose (1 mg/kg),50588,9615.0,,,CHEMBL622362,5130,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6017,Canis lupus familiaris,1,A,,1,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL622363,3249,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6018,Canis lupus familiaris,1,A,,1,Maximal plasma concentration at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL622364,5473,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6019,Canis lupus familiaris,1,A,,1,Maximal plasma concentration at a dose of 1 mg/kg (oral),50588,9615.0,,,CHEMBL622365,5474,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6020,Canis lupus familiaris,1,A,,1,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,50588,9615.0,,,CHEMBL622533,4657,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6021,Canis lupus familiaris,1,A,,1,Maximum concentration of compound in dog was evaluated.,50588,9615.0,,,CHEMBL622534,3031,,,,,N,Intermediate,BAO_0000218
6022,Canis lupus familiaris,1,A,,1,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,50588,9615.0,,,CHEMBL622535,4527,,,,,N,Intermediate,BAO_0000218
6023,Canis lupus familiaris,1,A,,1,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,50588,9615.0,,,CHEMBL876739,4186,,,,,N,Intermediate,BAO_0000218
6024,Canis lupus familiaris,1,A,,1,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,9615.0,,,CHEMBL622536,5007,,,,,N,Intermediate,BAO_0000218
6025,Canis lupus familiaris,1,A,,1,Maximum concentration obtained in dog plasma was determined,50588,9615.0,,,CHEMBL622537,3132,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6026,Canis lupus familiaris,1,A,,1,Maximum concentration was determined,50588,9615.0,,,CHEMBL622538,5006,,,,,N,Intermediate,BAO_0000218
6027,Canis lupus familiaris,1,A,,1,Maximum concentration at the dose of 2 mg/kg in dog,50588,9615.0,,,CHEMBL627867,4727,,,,,N,Intermediate,BAO_0000218
6028,Canis lupus familiaris,1,A,,1,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,9615.0,,,CHEMBL627868,1916,,,,,N,Intermediate,BAO_0000218
6029,Canis lupus familiaris,1,A,,1,Maximum concentration was evaluated in dog plasma,50588,9615.0,,,CHEMBL627869,1918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6030,Canis lupus familiaris,1,A,,1,Maximum concentration was evaluated after 75 min after administration in dog,50588,9615.0,,,CHEMBL627870,3045,,,,,N,Intermediate,BAO_0000218
6031,Canis lupus familiaris,1,A,,1,Maximum plasma concentration determined in dog after oral administration of 17b,50588,9615.0,,,CHEMBL627871,9579,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6032,Canis lupus familiaris,1,A,,1,Maximum plasma concentration determined in dog after oral administration of 2b,50588,9615.0,,,CHEMBL627872,9579,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6033,Canis lupus familiaris,1,A,,1,Maximum plasma concentration in dog,50588,9615.0,,,CHEMBL627873,933,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6034,Canis lupus familiaris,1,A,,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,50588,9615.0,,,CHEMBL627874,17839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6035,Canis lupus familiaris,1,A,,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,50588,9615.0,,,CHEMBL627875,17839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6036,Canis lupus familiaris,1,A,,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,50588,9615.0,,,CHEMBL627876,17839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6037,Canis lupus familiaris,1,A,,1,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,50588,9615.0,,,CHEMBL627877,17839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6038,Canis lupus familiaris,1,A,,1,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,9615.0,,,CHEMBL627878,6348,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6039,Canis lupus familiaris,1,A,,1,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL627879,16367,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6040,Canis lupus familiaris,1,A,,1,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL875355,1337,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6041,Canis lupus familiaris,1,A,,1,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL627880,1337,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6042,Canis lupus familiaris,1,A,,1,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,9615.0,,,CHEMBL627881,5199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6043,Canis lupus familiaris,1,A,,1,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,9615.0,,,CHEMBL627882,17650,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6044,Canis lupus familiaris,1,A,,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50588,9615.0,,,CHEMBL627883,6679,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6045,Canis lupus familiaris,1,A,,1,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,50588,9615.0,,,CHEMBL628526,5356,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6046,Canis lupus familiaris,1,A,,1,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,50588,9615.0,,,CHEMBL628527,5356,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6047,Canis lupus familiaris,1,A,,1,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL628528,6227,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6048,Canis lupus familiaris,1,A,,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,50588,9615.0,,,CHEMBL628529,6227,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6049,Canis lupus familiaris,1,A,,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,50588,9615.0,,,CHEMBL628530,6227,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6050,Canis lupus familiaris,1,A,,1,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL625243,6227,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6051,Canis lupus familiaris,1,A,,1,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL625244,3598,1969.0,,,Plasma,N,Expert,BAO_0000218
6052,Canis lupus familiaris,1,A,,1,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,50588,9615.0,,,CHEMBL625245,4368,,,,,N,Intermediate,BAO_0000218
6053,Canis lupus familiaris,1,A,,1,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,50588,9615.0,,,CHEMBL625246,6265,,,,,N,Intermediate,BAO_0000218
6054,Mus musculus,1,A,,1,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL625247,7767,945.0,,,Stomach,N,Intermediate,BAO_0000218
6055,Mus musculus,1,A,,1,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,10090.0,,,CHEMBL625248,7767,1088.0,,,Urine,N,Intermediate,BAO_0000218
6056,Mus musculus,1,A,,1,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,50594,10090.0,,,CHEMBL625249,7767,1088.0,,,Urine,N,Intermediate,BAO_0000218
6057,Mus musculus,1,A,,1,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,50594,10090.0,,,CHEMBL625250,7767,1088.0,,,Urine,N,Intermediate,BAO_0000218
6058,Mus musculus,1,A,,1,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,50594,10090.0,,,CHEMBL625251,17811,,,,,N,Intermediate,BAO_0000218
6059,Mus musculus,1,A,,1,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,50594,10090.0,,,CHEMBL875356,17811,,,,,N,Intermediate,BAO_0000218
6060,Mus musculus,1,A,,1,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),50594,10090.0,,,CHEMBL625252,17827,,,,,N,Intermediate,BAO_0000218
6061,Mus musculus,1,A,,1,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,10090.0,,,CHEMBL625253,17827,178.0,,,Blood,N,Intermediate,BAO_0000218
6062,Mus musculus,1,A,,1,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),50594,10090.0,,,CHEMBL625254,17827,,,,,N,Intermediate,BAO_0000218
6063,Mus musculus,1,A,,1,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),50594,10090.0,,,CHEMBL625255,17827,,,,,N,Intermediate,BAO_0000218
6064,Mus musculus,1,A,,1,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),50594,10090.0,,,CHEMBL625256,17827,,,,,N,Intermediate,BAO_0000218
6065,Mus musculus,1,A,,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,10090.0,,,CHEMBL625257,17827,178.0,,,Blood,N,Intermediate,BAO_0000218
6066,Mus musculus,1,A,,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),50594,10090.0,,,CHEMBL625258,17827,178.0,,,Blood,N,Intermediate,BAO_0000218
6067,Mus musculus,1,A,,1,Compound was evaluated for washout rate in mice (Radiolabeled compound),50594,10090.0,,,CHEMBL625259,17827,,,,,N,Intermediate,BAO_0000218
6068,Mus musculus,1,A,,1,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,50594,10090.0,,,CHEMBL625260,17827,,,,,N,Intermediate,BAO_0000218
6069,Mus musculus,1,A,,1,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,10090.0,,,CHEMBL625261,17827,,,,,N,Intermediate,BAO_0000218
6070,Mus musculus,1,A,,1,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,10090.0,,,CHEMBL625262,17827,,,,,N,Intermediate,BAO_0000218
6071,Mus musculus,1,A,,1,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,10090.0,,,CHEMBL622639,17827,,,,,N,Intermediate,BAO_0000218
6072,Mus musculus,1,A,,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,50594,10090.0,,,CHEMBL622640,17257,,,,,N,Intermediate,BAO_0000218
6073,Mus musculus,1,A,,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,50594,10090.0,,,CHEMBL622812,17257,,,,,N,Intermediate,BAO_0000218
6074,Mus musculus,1,A,,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,50594,10090.0,,,CHEMBL622813,17257,,,,,N,Intermediate,BAO_0000218
6075,Mus musculus,1,A,,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,50594,10090.0,,,CHEMBL622814,17257,,,,,N,Intermediate,BAO_0000218
6076,Mus musculus,1,A,,1,Time at maximum activity in mice (Radiolabeled compound),50594,10090.0,,,CHEMBL622815,17827,,,,,N,Intermediate,BAO_0000218
6077,Mus musculus,1,A,,1,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,50594,10090.0,,,CHEMBL625342,3760,,,,,N,Intermediate,BAO_0000218
6078,Mus musculus,1,A,,1,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,50594,10090.0,,,CHEMBL625343,3760,,,,,N,Intermediate,BAO_0000218
6079,Mus musculus,1,A,,1,Binding towards mouse plasma protein at 10 uM,50594,10090.0,,,CHEMBL877591,17409,,,,,N,Intermediate,BAO_0000218
6080,Mus musculus,1,A,,1,Binding towards mouse plasma protein at 100 uM,50594,10090.0,,,CHEMBL625344,17409,,,,,N,Intermediate,BAO_0000218
6081,Mus musculus,1,A,,1,Bioavailability was evaluated in mice after intravenous administration,50594,10090.0,,,CHEMBL625345,2675,,,,,N,Intermediate,BAO_0000218
6082,Mus musculus,1,A,,1,Bioavailability was evaluated in mice after oral administration,50594,10090.0,,,CHEMBL625346,2675,,,,,N,Intermediate,BAO_0000218
6083,Mus musculus,1,A,,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,50594,10090.0,,,CHEMBL625347,3132,,,,,N,Intermediate,BAO_0000218
6084,Mus musculus,1,A,,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,50594,10090.0,,,CHEMBL625348,3132,,,,,N,Intermediate,BAO_0000218
6085,Mus musculus,1,A,,1,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,50594,10090.0,,,CHEMBL625349,16597,,,,,N,Intermediate,BAO_0000218
6086,Mus musculus,1,A,,1,Oral bioavailability in mouse,50594,10090.0,,,CHEMBL625350,2862,,,,,N,Intermediate,BAO_0000218
6087,Mus musculus,1,A,,1,Oral bioavailability after intravenous administration in mice at 24 uM/kg,50594,10090.0,,,CHEMBL882952,17764,,,,,N,Intermediate,BAO_0000218
6088,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL625351,846,955.0,,,Brain,N,Intermediate,BAO_0000218
6089,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL625352,846,955.0,,,Brain,N,Intermediate,BAO_0000218
6090,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL877592,846,955.0,,,Brain,N,Intermediate,BAO_0000218
6091,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL625353,846,955.0,,,Brain,N,Intermediate,BAO_0000218
6092,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL625354,846,955.0,,,Brain,N,Intermediate,BAO_0000218
6093,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL626019,846,955.0,,,Brain,N,Intermediate,BAO_0000218
6094,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL626020,846,948.0,,,Heart,N,Intermediate,BAO_0000218
6095,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL626021,846,948.0,,,Heart,N,Intermediate,BAO_0000218
6096,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL626022,846,948.0,,,Heart,N,Intermediate,BAO_0000218
6097,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL626192,846,948.0,,,Heart,N,Intermediate,BAO_0000218
6098,Homo sapiens,1,F,A549,1,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),80682,9606.0,,,CHEMBL626193,1276,,646.0,,,N,Intermediate,BAO_0000219
6099,Homo sapiens,1,F,A549,1,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,80682,9606.0,,,CHEMBL626194,3498,,646.0,,,N,Expert,BAO_0000219
6100,Homo sapiens,1,F,A549,1,Cytotoxicity against human lung carcinoma A-549 cell lines,80682,9606.0,,,CHEMBL626195,1169,,646.0,,,N,Intermediate,BAO_0000219
6101,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,80682,9606.0,,,CHEMBL626196,4450,,646.0,,,N,Intermediate,BAO_0000219
6102,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma cell line A-549,80682,9606.0,,,CHEMBL626197,358,,646.0,,,N,Intermediate,BAO_0000219
6103,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,80682,9606.0,,,CHEMBL626198,358,,646.0,,,N,Intermediate,BAO_0000219
6104,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,80682,9606.0,,,CHEMBL626199,358,,646.0,,,N,Intermediate,BAO_0000219
6105,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,80682,9606.0,,,CHEMBL626200,358,,646.0,,,N,Intermediate,BAO_0000219
6106,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,80682,9606.0,,,CHEMBL626201,358,,646.0,,,N,Intermediate,BAO_0000219
6107,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,80682,9606.0,,,CHEMBL626202,358,,646.0,,,N,Intermediate,BAO_0000219
6108,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,80682,9606.0,,,CHEMBL626203,358,,646.0,,,N,Intermediate,BAO_0000219
6109,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A-549 human lung cancer cells,80682,9606.0,,,CHEMBL626204,15167,,646.0,,,N,Intermediate,BAO_0000219
6110,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,80682,9606.0,,,CHEMBL624701,4139,,646.0,,,N,Intermediate,BAO_0000219
6111,Homo sapiens,1,F,A549,1,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,80682,9606.0,,,CHEMBL624702,833,,646.0,,,N,Intermediate,BAO_0000219
6112,Homo sapiens,1,F,A549,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,9606.0,,,CHEMBL624703,15718,,646.0,,,N,Expert,BAO_0000219
6113,Homo sapiens,1,F,A549,1,Tested in vitro for cytotoxicity against A-549 lung cancer cells,80682,9606.0,,,CHEMBL624704,12373,,646.0,,,N,Intermediate,BAO_0000219
6114,Homo sapiens,1,F,A549,1,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,80682,9606.0,,,CHEMBL624705,637,,646.0,,,N,Intermediate,BAO_0000219
6115,Homo sapiens,1,F,A549,1,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,80682,9606.0,,,CHEMBL624706,14867,,646.0,,,N,Expert,BAO_0000219
6116,Homo sapiens,1,F,A549,1,Antitumor cytotoxic activity against A-549 cell line was determined,80682,9606.0,,,CHEMBL624707,4461,,646.0,,,N,Intermediate,BAO_0000219
6117,Homo sapiens,1,F,A549,1,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",80682,9606.0,,,CHEMBL624708,5406,,646.0,,,N,Intermediate,BAO_0000219
6118,Homo sapiens,1,F,A549,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,9606.0,,,CHEMBL624709,4457,,646.0,,,N,Intermediate,BAO_0000219
6119,Homo sapiens,1,F,A549,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL884107,1386,,646.0,,,N,Expert,BAO_0000219
6120,Homo sapiens,1,F,A549,1,Antitumoral activity was assayed against A-549 cell line,80682,9606.0,,,CHEMBL624710,3265,,646.0,,,N,Intermediate,BAO_0000219
6121,Homo sapiens,1,F,A549,1,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,80682,9606.0,,,CHEMBL624711,2359,,646.0,,,N,Intermediate,BAO_0000219
6122,Homo sapiens,1,F,A549,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,9606.0,,,CHEMBL624712,4457,,646.0,,,N,Intermediate,BAO_0000219
6123,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL624713,12454,,646.0,,,N,Expert,BAO_0000219
6124,Homo sapiens,1,F,A549,1,Compound was tested for inhibition of cell growth of A-549 cells,80682,9606.0,,,CHEMBL624714,1481,,646.0,,,N,Intermediate,BAO_0000219
6125,Homo sapiens,1,F,A549,1,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,80682,9606.0,,,CHEMBL624715,1750,,646.0,,,N,Intermediate,BAO_0000219
6126,Homo sapiens,1,F,A549,1,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,80682,9606.0,,,CHEMBL624716,5065,,646.0,,,N,Intermediate,BAO_0000219
6127,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A549-human lung carcinoma cells.,80682,9606.0,,,CHEMBL619505,808,,646.0,,,N,Expert,BAO_0000219
6128,Homo sapiens,1,F,A549,1,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,80682,9606.0,,,CHEMBL619506,16364,,646.0,,,N,Expert,BAO_0000219
6129,Homo sapiens,1,F,A549,1,Cytotoxic activity against A-549 cell lines.,80682,9606.0,,,CHEMBL619507,1847,,646.0,,,N,Intermediate,BAO_0000219
6130,Homo sapiens,1,F,A549,1,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,80682,9606.0,,,CHEMBL619508,1747,,646.0,,,N,Expert,BAO_0000219
6131,Homo sapiens,1,F,A549,1,Cytotoxicity against human A549 non small cell lung cell lines,80682,9606.0,,,CHEMBL619509,1003,,646.0,,,N,Intermediate,BAO_0000219
6132,Homo sapiens,1,F,A549,1,Inhibition of cell growth in (A-549) lung cell line,80682,9606.0,,,CHEMBL619510,15313,,646.0,,,N,Expert,BAO_0000219
6133,Homo sapiens,1,F,A549,1,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,80682,9606.0,,,CHEMBL619511,3122,,646.0,,,N,Intermediate,BAO_0000219
6134,Homo sapiens,1,F,A549,1,In vitro antitumor activity against A-549 tumor cells.,80682,9606.0,,,CHEMBL619512,16049,,646.0,,,N,Intermediate,BAO_0000219
6135,Homo sapiens,1,F,A549,1,In vitro antitumor effects against human A-549 cell lines.,80682,9606.0,,,CHEMBL619513,17134,,646.0,,,N,Expert,BAO_0000219
6136,Homo sapiens,1,F,A549,1,In vitro cytotoxic activity of compound against A-549 cell line,80682,9606.0,,,CHEMBL619514,6406,,646.0,,,N,Intermediate,BAO_0000219
6137,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human lung carcinoma A-549 cell line,80682,9606.0,,,CHEMBL619515,627,,646.0,,,N,Intermediate,BAO_0000219
6138,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human non-small cell lung carcinoma A549,80682,9606.0,,,CHEMBL619516,12307,,646.0,,,N,Intermediate,BAO_0000219
6139,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,80682,9606.0,,,CHEMBL884005,17861,,646.0,,,N,Intermediate,BAO_0000219
6140,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,80682,9606.0,,,CHEMBL619517,6682,,646.0,,,N,Expert,BAO_0000219
6141,Homo sapiens,1,F,A549,1,Inhibitory concentration of compound against A-549 cell line,80682,9606.0,,,CHEMBL619518,6663,,646.0,,,N,Intermediate,BAO_0000219
6142,Homo sapiens,1,F,A549,1,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,80682,9606.0,,,CHEMBL619519,2454,,646.0,,,N,Intermediate,BAO_0000219
6143,Homo sapiens,1,F,A549,1,cytotoxic activity against leukemia (A-549) cancer cell line,80682,9606.0,,,CHEMBL876489,14709,,646.0,,,N,Intermediate,BAO_0000219
6144,Homo sapiens,1,F,A549,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,9606.0,,,CHEMBL619520,15718,,646.0,,,N,Expert,BAO_0000219
6145,Homo sapiens,1,F,A549,1,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,80682,9606.0,,,CHEMBL619521,15718,,646.0,,,N,Intermediate,BAO_0000219
6146,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),80682,9606.0,,,CHEMBL619522,17130,,646.0,,,N,Intermediate,BAO_0000219
6147,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),80682,9606.0,,,CHEMBL619523,17130,,646.0,,,N,Intermediate,BAO_0000219
6148,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),80682,9606.0,,,CHEMBL619524,17130,,646.0,,,N,Intermediate,BAO_0000219
6149,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),80682,9606.0,,,CHEMBL619525,17130,,646.0,,,N,Intermediate,BAO_0000219
6150,,1,F,A549,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,80682,,,,CHEMBL619526,6630,,646.0,,,N,Intermediate,BAO_0000219
6151,Homo sapiens,1,F,A549,1,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,80682,9606.0,,,CHEMBL619527,16726,,646.0,,,N,Intermediate,BAO_0000219
6152,Homo sapiens,1,F,A549,1,Cytotoxicity against A549 cells; No cytotoxicity,80682,9606.0,,,CHEMBL619528,17846,,646.0,,,N,Intermediate,BAO_0000219
6153,Homo sapiens,1,F,A549,1,Cytotoxicity against human lung carcinoma (A549) cell lines,80682,9606.0,,,CHEMBL619529,3415,,646.0,,,N,Expert,BAO_0000219
6154,Homo sapiens,1,F,A549,1,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,80682,9606.0,,,CHEMBL619530,3415,,646.0,,,N,Expert,BAO_0000219
6155,Homo sapiens,1,F,A549,1,In vitro anticancer activity against human lung (A549) cell line,80682,9606.0,,,CHEMBL876490,5609,,646.0,,,N,Intermediate,BAO_0000219
6156,Homo sapiens,1,F,A549,1,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,80682,9606.0,,,CHEMBL619531,17206,,646.0,,,N,Intermediate,BAO_0000219
6157,Homo sapiens,1,F,A549,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619532,17206,,646.0,,,N,Intermediate,BAO_0000219
6158,Homo sapiens,1,F,A549,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619533,17206,,646.0,,,N,Intermediate,BAO_0000219
6159,Homo sapiens,1,F,A549,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619534,17206,,646.0,,,N,Intermediate,BAO_0000219
6160,Homo sapiens,1,F,A549,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL620164,17206,,646.0,,,N,Intermediate,BAO_0000219
6161,Homo sapiens,1,F,A549,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL620165,17206,,646.0,,,N,Intermediate,BAO_0000219
6162,Homo sapiens,1,F,A549,1,Inhibition of A549 human lung tumor cell proliferation,80682,9606.0,,,CHEMBL620166,16295,,646.0,,,N,Expert,BAO_0000219
6163,Homo sapiens,1,F,A549,1,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",80682,9606.0,,,CHEMBL620167,16825,,646.0,,,N,Intermediate,BAO_0000219
6164,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human tumor cell line A549,80682,9606.0,,,CHEMBL620168,3439,,646.0,,,N,Expert,BAO_0000219
6165,Homo sapiens,1,F,A549,1,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,80682,9606.0,,,CHEMBL620338,10870,,646.0,,,N,Intermediate,BAO_0000219
6166,Homo sapiens,1,F,A549,1,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,80682,9606.0,,,CHEMBL620339,4845,,646.0,,,N,Intermediate,BAO_0000219
6167,Homo sapiens,1,F,A549,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,80682,9606.0,,,CHEMBL620340,5822,,646.0,,,N,Intermediate,BAO_0000219
6168,Homo sapiens,1,F,A549,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,80682,9606.0,,,CHEMBL620341,5822,,646.0,,,N,Intermediate,BAO_0000219
6169,Homo sapiens,1,F,A549,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,80682,9606.0,,,CHEMBL876491,5822,,646.0,,,N,Intermediate,BAO_0000219
6170,Homo sapiens,1,F,A549,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,9606.0,,,CHEMBL620342,16381,,646.0,,,N,Intermediate,BAO_0000219
6171,Homo sapiens,1,F,A549,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,9606.0,,,CHEMBL620343,16381,,646.0,,,N,Intermediate,BAO_0000219
6172,Homo sapiens,1,F,A549,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,9606.0,,,CHEMBL620344,16381,,646.0,,,N,Intermediate,BAO_0000219
6173,Homo sapiens,1,F,A549,1,In vitro anticancer activity against human lung (A549) cell line,80682,9606.0,,,CHEMBL620345,5609,,646.0,,,N,Intermediate,BAO_0000219
6174,Homo sapiens,1,F,A549,1,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,80682,9606.0,,,CHEMBL620346,4644,,646.0,,,N,Intermediate,BAO_0000219
6175,Homo sapiens,1,F,A549,1,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,80682,9606.0,,,CHEMBL620347,4644,,646.0,,,N,Intermediate,BAO_0000219
6176,Homo sapiens,1,F,A549,1,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,80682,9606.0,,,CHEMBL620348,4644,,646.0,,,N,Intermediate,BAO_0000219
6177,Homo sapiens,1,F,A549,1,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,80682,9606.0,,,CHEMBL620349,4644,,646.0,,,N,Intermediate,BAO_0000219
6178,Homo sapiens,1,F,A549,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,80682,9606.0,,,CHEMBL618667,5822,,646.0,,,N,Intermediate,BAO_0000219
6179,Homo sapiens,1,F,A549,1,Percentage inhibition of human lung carcinoma (A549) cell lines,80682,9606.0,,,CHEMBL618668,3415,,646.0,,,N,Expert,BAO_0000219
6180,Homo sapiens,1,F,A549,1,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,80682,9606.0,,,CHEMBL876031,16726,,646.0,,,N,Intermediate,BAO_0000219
6181,Homo sapiens,1,F,A549,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",80682,9606.0,,,CHEMBL618759,17206,,646.0,,,N,Intermediate,BAO_0000219
6182,Homo sapiens,1,F,A549,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,9606.0,,,CHEMBL618760,17206,,646.0,,,N,Intermediate,BAO_0000219
6183,Homo sapiens,1,F,A549,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,9606.0,,,CHEMBL619000,17206,,646.0,,,N,Intermediate,BAO_0000219
6184,Homo sapiens,1,F,A549,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",80682,9606.0,,,CHEMBL619001,17206,,646.0,,,N,Intermediate,BAO_0000219
6185,Homo sapiens,1,F,A549,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",80682,9606.0,,,CHEMBL619002,17206,,646.0,,,N,Intermediate,BAO_0000219
6186,Homo sapiens,1,F,A549,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",80682,9606.0,,,CHEMBL619003,17206,,646.0,,,N,Intermediate,BAO_0000219
6187,Homo sapiens,1,F,A549,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",80682,9606.0,,,CHEMBL619597,17206,,646.0,,,N,Intermediate,BAO_0000219
6188,Homo sapiens,1,F,A549,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",80682,9606.0,,,CHEMBL619598,17206,,646.0,,,N,Intermediate,BAO_0000219
6189,Homo sapiens,1,F,A549,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,80682,9606.0,,,CHEMBL619599,17206,,646.0,,,N,Intermediate,BAO_0000219
6190,Homo sapiens,1,F,A549,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,80682,9606.0,,,CHEMBL619600,17206,,646.0,,,N,Intermediate,BAO_0000219
6191,Homo sapiens,1,F,A549,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,9606.0,,,CHEMBL619601,16726,,646.0,,,N,Intermediate,BAO_0000219
6192,Homo sapiens,1,F,A549,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619602,17206,,646.0,,,N,Intermediate,BAO_0000219
6193,Homo sapiens,1,F,A549,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619603,17206,,646.0,,,N,Intermediate,BAO_0000219
6194,Homo sapiens,1,F,A549,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619604,17206,,646.0,,,N,Intermediate,BAO_0000219
6195,Homo sapiens,1,F,A549,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619605,17206,,646.0,,,N,Intermediate,BAO_0000219
6196,Canis lupus familiaris,1,A,,1,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL619606,6084,,,,,N,Intermediate,BAO_0000218
6197,Canis lupus familiaris,1,A,,1,Pharmacokinetic activity (Cmax) in dog,50588,9615.0,,,CHEMBL876032,6084,,,,,N,Intermediate,BAO_0000218
6198,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,9615.0,,,CHEMBL619607,4809,,,,,N,Intermediate,BAO_0000218
6199,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,50588,9615.0,,,CHEMBL619608,5983,,,,,N,Intermediate,BAO_0000218
6200,Canis lupus familiaris,1,A,,1,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,50588,9615.0,,,CHEMBL619609,6251,,,,,N,Intermediate,BAO_0000218
6201,Canis lupus familiaris,1,A,,1,Cmax in dog plasma after 30mg/kg oral dose,50588,9615.0,,,CHEMBL619610,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6202,Canis lupus familiaris,1,A,,1,Tested for the peak blood level in dog,50588,9615.0,,,CHEMBL619611,4273,178.0,,,Blood,N,Intermediate,BAO_0000218
6203,Canis lupus familiaris,1,A,,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",50588,9615.0,,,CHEMBL619612,5313,,,,,N,Intermediate,BAO_0000218
6204,Canis lupus familiaris,1,A,,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",50588,9615.0,,,CHEMBL619613,5313,,,,,N,Intermediate,BAO_0000218
6205,Canis lupus familiaris,1,A,,1,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,50588,9615.0,,,CHEMBL619614,6221,178.0,,,Blood,N,Intermediate,BAO_0000218
6206,Canis lupus familiaris,1,A,,1,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,50588,9615.0,,,CHEMBL619615,4709,,,,,N,Intermediate,BAO_0000218
6207,Canis lupus familiaris,1,A,,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,50588,9615.0,,,CHEMBL619616,167,,,,,N,Intermediate,BAO_0000218
6208,Canis lupus familiaris,1,A,,1,Final plasma concentration in dogs after oral administration at 1 mg/kg,50588,9615.0,,,CHEMBL619617,6241,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6209,Canis lupus familiaris,1,A,,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,50588,9615.0,,,CHEMBL619618,344,,,,,N,Intermediate,BAO_0000218
6210,Canis lupus familiaris,1,A,,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,50588,9615.0,,,CHEMBL876033,344,,,,,N,Intermediate,BAO_0000218
6211,Canis lupus familiaris,1,A,,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,50588,9615.0,,,CHEMBL619619,344,,,,,N,Intermediate,BAO_0000218
6212,Canis lupus familiaris,1,A,,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,50588,9615.0,,,CHEMBL619620,2189,,,,,N,Intermediate,BAO_0000218
6213,Canis lupus familiaris,1,A,,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,50588,9615.0,,,CHEMBL619621,2189,1088.0,,,Urine,N,Intermediate,BAO_0000218
6214,Canis lupus familiaris,1,A,,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,50588,9615.0,,,CHEMBL619622,2189,1088.0,,,Urine,N,Intermediate,BAO_0000218
6215,Canis lupus familiaris,1,A,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,50588,9615.0,,,CHEMBL618874,2189,1088.0,,,Urine,N,Intermediate,BAO_0000218
6216,Canis lupus familiaris,1,A,,1,Absolute bioavailability was evaluated in dog,50588,9615.0,,,CHEMBL618875,4257,,,,,N,Intermediate,BAO_0000218
6217,Canis lupus familiaris,1,A,,1,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,50588,9615.0,,,CHEMBL618876,6221,,,,,N,Intermediate,BAO_0000218
6218,Canis lupus familiaris,1,A,,1,Bioavailability after peroral administration (1 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL618877,6215,,,,,N,Intermediate,BAO_0000218
6219,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL618878,17267,,,,,N,Intermediate,BAO_0000218
6220,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL618879,6621,,,,,N,Intermediate,BAO_0000218
6221,Canis lupus familiaris,1,A,,1,Bioavailability after intravenous administration in dogs,50588,9615.0,,,CHEMBL618880,3854,,,,,N,Intermediate,BAO_0000218
6222,Canis lupus familiaris,1,A,,1,Bioavailability after peroral administration in dogs,50588,9615.0,,,CHEMBL618881,3854,,,,,N,Intermediate,BAO_0000218
6223,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,9615.0,,,CHEMBL618882,5007,,,,,N,Intermediate,BAO_0000218
6224,Canis lupus familiaris,1,A,,1,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,50588,9615.0,,,CHEMBL624226,4333,,,,,N,Intermediate,BAO_0000218
6225,Canis lupus familiaris,1,A,,1,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,50588,9615.0,,,CHEMBL624227,4333,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6226,Canis lupus familiaris,1,A,,1,Bioavailability,50588,9615.0,,,CHEMBL624228,5006,,,,,N,Intermediate,BAO_0000218
6227,Canis lupus familiaris,1,A,,1,Bioavailability,50588,9615.0,,,CHEMBL624229,5199,,,,,N,Intermediate,BAO_0000218
6228,Canis lupus familiaris,1,A,,1,Bioavailability by intravenous administration of 1.2 mg/kg in dog,50588,9615.0,,,CHEMBL624230,4368,,,,,N,Intermediate,BAO_0000218
6229,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL624231,3771,,,,,N,Intermediate,BAO_0000218
6230,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL624232,4953,,,,,N,Intermediate,BAO_0000218
6231,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL625127,5064,,,,,N,Intermediate,BAO_0000218
6232,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL625128,17657,,,,,N,Intermediate,BAO_0000218
6233,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL621675,17796,,,,,N,Intermediate,BAO_0000218
6234,Canis lupus familiaris,1,A,,1,Bioavailability in dog (p.o.) at 2.0 mpk,50588,9615.0,,,CHEMBL621676,17853,,,,,N,Intermediate,BAO_0000218
6235,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),50588,9615.0,,,CHEMBL621677,4521,,,,,N,Intermediate,BAO_0000218
6236,Canis lupus familiaris,1,A,,1,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,9615.0,,,CHEMBL621678,4521,,,,,N,Intermediate,BAO_0000218
6237,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL621679,5006,,,,,N,Intermediate,BAO_0000218
6238,Canis lupus familiaris,1,A,,1,Bioavailability was evaluated after oral administration in dog,50588,9615.0,,,CHEMBL621680,16365,,,,,N,Intermediate,BAO_0000218
6239,Canis lupus familiaris,1,A,,1,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,9615.0,,,CHEMBL621681,1916,,,,,N,Intermediate,BAO_0000218
6240,Canis lupus familiaris,1,A,,1,Bioavailability was evaluated in dog,50588,9615.0,,,CHEMBL876740,1918,,,,,N,Intermediate,BAO_0000218
6241,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL621682,4239,,,,,N,Intermediate,BAO_0000218
6242,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL621683,6505,,,,,N,Intermediate,BAO_0000218
6243,Canis lupus familiaris,1,A,,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,9615.0,,,CHEMBL621684,5334,,,,,N,Intermediate,BAO_0000218
6244,Canis lupus familiaris,1,A,,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,9615.0,,,CHEMBL621685,5334,,,,,N,Intermediate,BAO_0000218
6245,Canis lupus familiaris,1,A,,1,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,9615.0,,,CHEMBL621686,4809,,,,,N,Intermediate,BAO_0000218
6246,Canis lupus familiaris,1,A,,1,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,9615.0,,,CHEMBL621687,6348,,,,,N,Intermediate,BAO_0000218
6247,Canis lupus familiaris,1,A,,1,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL621688,6005,,,,,N,Intermediate,BAO_0000218
6248,Canis lupus familiaris,1,A,,1,Bioavailability of compound in dog was determined after peroral administration,50588,9615.0,,,CHEMBL621689,17804,,,,,N,Intermediate,BAO_0000218
6249,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621690,3184,,,,,N,Intermediate,BAO_0000218
6250,Canis lupus familiaris,1,A,,1,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,50588,9615.0,,,CHEMBL621691,1806,,,,,N,Intermediate,BAO_0000218
6251,Canis lupus familiaris,1,A,,1,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,50588,9615.0,,,CHEMBL875941,1806,,,,,N,Intermediate,BAO_0000218
6252,Canis lupus familiaris,1,A,,1,Compound was evaluated for oral bioavailability in dogs; 37-38 %,50588,9615.0,,,CHEMBL621692,1806,,,,,N,Intermediate,BAO_0000218
6253,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL621693,4839,,,,,N,Intermediate,BAO_0000218
6254,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),50588,9615.0,,,CHEMBL621694,5017,,,,,N,Intermediate,BAO_0000218
6255,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL621695,846,948.0,,,Heart,N,Intermediate,BAO_0000218
6256,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL621696,846,948.0,,,Heart,N,Intermediate,BAO_0000218
6257,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL621697,846,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6258,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL621698,846,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6259,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623420,846,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6260,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623421,846,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6261,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623422,846,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6262,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623423,846,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6263,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623424,846,2107.0,,,Liver,N,Intermediate,BAO_0000218
6264,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623425,846,2107.0,,,Liver,N,Intermediate,BAO_0000218
6265,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623426,846,2107.0,,,Liver,N,Intermediate,BAO_0000218
6266,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623427,846,2107.0,,,Liver,N,Intermediate,BAO_0000218
6267,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623428,846,2107.0,,,Liver,N,Intermediate,BAO_0000218
6268,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL875947,846,2107.0,,,Liver,N,Intermediate,BAO_0000218
6269,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623429,846,2048.0,,,Lung,N,Intermediate,BAO_0000218
6270,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL623430,846,2048.0,,,Lung,N,Intermediate,BAO_0000218
6271,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL622588,846,2048.0,,,Lung,N,Intermediate,BAO_0000218
6272,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL622589,846,2048.0,,,Lung,N,Intermediate,BAO_0000218
6273,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL622751,846,2048.0,,,Lung,N,Intermediate,BAO_0000218
6274,Mus musculus,1,A,,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,10090.0,,,CHEMBL622752,846,2048.0,,,Lung,N,Intermediate,BAO_0000218
6275,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL622753,6599,,42.0,,,N,Intermediate,BAO_0000218
6276,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL622647,6599,,42.0,,,N,Intermediate,BAO_0000218
6277,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL875163,6599,,42.0,,,N,Intermediate,BAO_0000218
6278,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL622648,6599,,42.0,,,N,Intermediate,BAO_0000218
6279,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL622649,6599,,42.0,,,N,Intermediate,BAO_0000218
6280,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL622650,6599,955.0,42.0,,Brain,N,Intermediate,BAO_0000218
6281,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL622651,6599,955.0,42.0,,Brain,N,Intermediate,BAO_0000218
6282,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL622652,6599,955.0,42.0,,Brain,N,Intermediate,BAO_0000218
6283,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL622653,6599,955.0,42.0,,Brain,N,Intermediate,BAO_0000218
6284,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL622654,6599,955.0,42.0,,Brain,N,Intermediate,BAO_0000218
6285,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL622655,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6286,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL622656,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6287,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL622657,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6288,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL622658,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6289,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL622659,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6290,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL624630,6599,2113.0,42.0,,Kidney,N,Intermediate,BAO_0000218
6291,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL624631,6599,2113.0,42.0,,Kidney,N,Intermediate,BAO_0000218
6292,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL624632,6599,2113.0,42.0,,Kidney,N,Intermediate,BAO_0000218
6293,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,80682,9606.0,,,CHEMBL624633,17130,,646.0,,,N,Intermediate,BAO_0000219
6294,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,80682,9606.0,,,CHEMBL624634,17130,,646.0,,,N,Intermediate,BAO_0000219
6295,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),80682,9606.0,,,CHEMBL624635,17130,,646.0,,,N,Intermediate,BAO_0000219
6296,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),80682,9606.0,,,CHEMBL624636,17130,,646.0,,,N,Intermediate,BAO_0000219
6297,Homo sapiens,1,F,A549,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL857055,3263,,646.0,,,N,Expert,BAO_0000219
6298,Homo sapiens,1,F,A549,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,80682,9606.0,,,CHEMBL624637,6663,,646.0,,,N,Expert,BAO_0000219
6299,Homo sapiens,1,F,A549,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,80682,9606.0,,,CHEMBL624638,6663,,646.0,,,N,Expert,BAO_0000219
6300,Homo sapiens,1,F,A549,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,80682,9606.0,,,CHEMBL874366,6663,,646.0,,,N,Expert,BAO_0000219
6301,Homo sapiens,1,F,A549,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,80682,9606.0,,,CHEMBL624639,6663,,646.0,,,N,Expert,BAO_0000219
6302,Homo sapiens,1,F,A549,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,80682,9606.0,,,CHEMBL624640,6663,,646.0,,,N,Expert,BAO_0000219
6303,Homo sapiens,1,F,A549,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,80682,9606.0,,,CHEMBL624641,6663,,646.0,,,N,Intermediate,BAO_0000219
6304,Homo sapiens,1,F,A549,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,80682,9606.0,,,CHEMBL624642,6663,,646.0,,,N,Intermediate,BAO_0000219
6305,Homo sapiens,1,F,A549,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,80682,9606.0,,,CHEMBL624643,6663,,646.0,,,N,Intermediate,BAO_0000219
6306,Homo sapiens,1,F,A549,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,80682,9606.0,,,CHEMBL624644,6663,,646.0,,,N,Intermediate,BAO_0000219
6307,Homo sapiens,1,F,A549,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,80682,9606.0,,,CHEMBL624645,6663,,646.0,,,N,Intermediate,BAO_0000219
6308,Homo sapiens,1,F,A549,1,The compound was evaluated for its cytotoxic potency against A-549 cell line,80682,9606.0,,,CHEMBL619445,3983,,646.0,,,N,Intermediate,BAO_0000219
6309,Homo sapiens,1,F,A549,1,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,80682,9606.0,,,CHEMBL839886,11141,,646.0,,,N,Expert,BAO_0000219
6310,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 tumor cell line.,80682,9606.0,,,CHEMBL619446,5076,,646.0,,,N,Intermediate,BAO_0000219
6311,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,80682,9606.0,,,CHEMBL619447,3311,,646.0,,,N,Intermediate,BAO_0000219
6312,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,80682,9606.0,,,CHEMBL619448,3311,,646.0,,,N,Intermediate,BAO_0000219
6313,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,80682,9606.0,,,CHEMBL619449,3311,,646.0,,,N,Intermediate,BAO_0000219
6314,Homo sapiens,1,F,A549,1,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,80682,9606.0,,,CHEMBL619450,5076,,646.0,,,N,Intermediate,BAO_0000219
6315,Homo sapiens,1,F,A549,1,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),80682,9606.0,,,CHEMBL619451,4150,,646.0,,,N,Intermediate,BAO_0000219
6316,Homo sapiens,1,F,A549,1,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,80682,9606.0,,,CHEMBL619452,2150,,646.0,,,N,Expert,BAO_0000219
6317,Homo sapiens,1,F,A549,1,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,80682,9606.0,,,CHEMBL619453,4644,,646.0,,,N,Intermediate,BAO_0000219
6318,Homo sapiens,1,F,A549,1,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,80682,9606.0,,,CHEMBL874367,263,,646.0,,,N,Intermediate,BAO_0000219
6319,Homo sapiens,1,F,A549,1,Cytotoxic concentration against A-549 tumor cells.,80682,9606.0,,,CHEMBL619454,11333,,646.0,,,N,Intermediate,BAO_0000219
6320,Homo sapiens,1,F,A549,1,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,80682,9606.0,,,CHEMBL619455,11333,,646.0,,,N,Intermediate,BAO_0000219
6321,Homo sapiens,1,F,A549,1,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",80682,9606.0,,,CHEMBL619456,15895,,646.0,,,N,Intermediate,BAO_0000219
6322,Acinetobacter baumannii,1,F,,1,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,50191,470.0,,,CHEMBL619457,16677,,,,,N,Expert,BAO_0000218
6323,Acinetobacter calcoaceticus,1,F,,1,Activity against Acinetobacter calcoaceticus (AC54),50192,471.0,,,CHEMBL619458,10624,,,,,N,Intermediate,BAO_0000218
6324,Aspergillus flavus,1,F,,1,In vitro antifungal activity against Aspergillus flavus CM74,50274,5059.0,,,CHEMBL619459,16717,,,,,N,Expert,BAO_0000218
6325,Aspergillus flavus,1,F,,1,In vitro antifungal activity against Aspergillus flavus CM74,50274,5059.0,,,CHEMBL619460,16717,,,,,N,Expert,BAO_0000218
6326,Aspergillus fumigatus,1,F,,1,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,50416,746128.0,,,CHEMBL619461,5513,,,,,N,Intermediate,BAO_0000218
6327,Aspergillus fumigatus,1,F,,1,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),50416,746128.0,,,CHEMBL619462,15962,,,,,N,Intermediate,BAO_0000218
6328,Aspergillus fumigatus,1,F,,1,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,746128.0,,,CHEMBL620388,15962,,,,,N,Intermediate,BAO_0000218
6329,Aspergillus fumigatus,1,F,,1,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,746128.0,,,CHEMBL620389,15962,,,,,N,Intermediate,BAO_0000218
6330,Aspergillus fumigatus,1,F,,1,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),50416,746128.0,,,CHEMBL620390,15962,,,,,N,Intermediate,BAO_0000218
6331,Aspergillus fumigatus,1,F,,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,746128.0,,,CHEMBL620391,16717,,,,,N,Expert,BAO_0000218
6332,Aspergillus fumigatus,1,F,,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,746128.0,,,CHEMBL621073,16717,,,,,N,Expert,BAO_0000218
6333,Actinomyces naeslundii,1,F,,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,50296,1655.0,,,CHEMBL621074,8117,,,,,N,Intermediate,BAO_0000218
6334,Actinomyces viscosus,1,F,,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,50366,1656.0,,,CHEMBL621075,8117,,,,,N,Intermediate,BAO_0000218
6335,Acanthocheilonema viteae,1,F,,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,6277.0,,,CHEMBL619554,15472,,,,,N,Intermediate,BAO_0000218
6336,Acanthocheilonema viteae,1,F,,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,6277.0,,,CHEMBL619555,15472,,,,,N,Intermediate,BAO_0000218
6337,Aggregatibacter actinomycetemcomitans,1,F,,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,50169,714.0,,,CHEMBL619556,16443,,,,,N,Intermediate,BAO_0000218
6338,Aggregatibacter actinomycetemcomitans,1,F,,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,50169,714.0,,,CHEMBL619557,16443,,,,,N,Intermediate,BAO_0000218
6339,Aggregatibacter actinomycetemcomitans,1,F,,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,50169,714.0,,,CHEMBL619558,16443,,,,,N,Intermediate,BAO_0000218
6340,Homo sapiens,1,F,A549,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619559,17206,,646.0,,,N,Intermediate,BAO_0000219
6341,Homo sapiens,1,F,A549,1,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619560,17206,,646.0,,,N,Intermediate,BAO_0000219
6342,Homo sapiens,1,F,A549,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,9606.0,,,CHEMBL619561,16381,,646.0,,,N,Intermediate,BAO_0000219
6343,Homo sapiens,1,F,A549,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,9606.0,,,CHEMBL619562,16381,,646.0,,,N,Intermediate,BAO_0000219
6344,Homo sapiens,1,F,A549,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,9606.0,,,CHEMBL619563,16381,,646.0,,,N,Intermediate,BAO_0000219
6345,Homo sapiens,1,F,A549,1,GI values against A549 cells (lung cancer),80682,9606.0,,,CHEMBL857457,16381,,646.0,,,N,Intermediate,BAO_0000219
6346,Homo sapiens,1,F,A549,1,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,80682,9606.0,,,CHEMBL619564,17206,,646.0,,,N,Intermediate,BAO_0000219
6347,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 human adenocarcinoma,80682,9606.0,,,CHEMBL619565,16325,,646.0,,,N,Intermediate,BAO_0000219
6348,Homo sapiens,1,F,A549,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,80682,9606.0,,,CHEMBL619566,10708,,646.0,,,N,Intermediate,BAO_0000218
6349,Homo sapiens,1,F,A549,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,80682,9606.0,,,CHEMBL619567,10708,,646.0,,,N,Intermediate,BAO_0000218
6350,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,9606.0,,,CHEMBL619568,17376,,646.0,,,N,Intermediate,BAO_0000219
6351,Homo sapiens,1,F,A549,1,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,80682,9606.0,,,CHEMBL619569,17376,,646.0,,,N,Intermediate,BAO_0000219
6352,Homo sapiens,1,F,A549,1,Cytotoxicity against human A549 lung cells,80682,9606.0,,,CHEMBL619570,17488,,646.0,,,N,Intermediate,BAO_0000219
6353,Homo sapiens,1,F,A549,1,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,80682,9606.0,,,CHEMBL619571,17404,,646.0,,,N,Intermediate,BAO_0000218
6354,Homo sapiens,1,F,A549,1,Growth inhibition of A549 (human lung carcinoma) cell line.,80682,9606.0,,,CHEMBL619572,10958,,646.0,,,N,Expert,BAO_0000219
6355,Homo sapiens,1,F,A549,1,Effective dose required for inhibitory activity against A549 human tumor cell line.,80682,9606.0,,,CHEMBL619573,17099,,646.0,,,N,Expert,BAO_0000219
6356,Homo sapiens,1,F,A549,1,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,80682,9606.0,,,CHEMBL619574,17099,,646.0,,,N,Intermediate,BAO_0000219
6357,Homo sapiens,1,F,A549,1,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,80682,9606.0,,,CHEMBL619575,4096,,646.0,,,N,Intermediate,BAO_0000219
6358,Homo sapiens,1,F,A549,1,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,80682,9606.0,,,CHEMBL619576,4096,,646.0,,,N,Expert,BAO_0000219
6359,Homo sapiens,1,F,A549,1,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,80682,9606.0,,,CHEMBL619577,4096,,646.0,,,N,Intermediate,BAO_0000219
6360,Homo sapiens,1,F,A549,1,In vitro inhibitory activity against A549 tumor cell culture,80682,9606.0,,,CHEMBL619578,2525,,646.0,,,N,Intermediate,BAO_0000219
6361,Homo sapiens,1,F,A549,1,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,80682,9606.0,,,CHEMBL884009,2525,,646.0,,,N,Intermediate,BAO_0000219
6362,Homo sapiens,1,F,A549,1,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),80682,9606.0,,,CHEMBL619579,5302,,646.0,,,N,Intermediate,BAO_0000219
6363,Homo sapiens,1,F,A549,1,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,80682,9606.0,,,CHEMBL619580,16325,,646.0,,,N,Intermediate,BAO_0000219
6364,Homo sapiens,1,F,A549,1,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,80682,9606.0,,,CHEMBL619581,16939,,646.0,,,N,Intermediate,BAO_0000219
6365,Homo sapiens,1,F,A549,1,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,80682,9606.0,,,CHEMBL619582,17229,,646.0,,,N,Intermediate,BAO_0000219
6366,Homo sapiens,1,F,A549,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,80682,9606.0,,,CHEMBL619583,17380,,646.0,,,N,Intermediate,BAO_0000219
6367,Homo sapiens,1,F,A549,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,80682,9606.0,,,CHEMBL876502,17380,,646.0,,,N,Intermediate,BAO_0000219
6368,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,80682,9606.0,,,CHEMBL619584,1903,,646.0,,,N,Intermediate,BAO_0000219
6369,Homo sapiens,1,F,A549,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,9606.0,,,CHEMBL619585,3838,,646.0,,,N,Intermediate,BAO_0000219
6370,Homo sapiens,1,F,A549,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,9606.0,,,CHEMBL619586,14696,,646.0,,,N,Intermediate,BAO_0000219
6371,Homo sapiens,1,F,A549,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,9606.0,,,CHEMBL619587,3838,,646.0,,,N,Intermediate,BAO_0000219
6372,Homo sapiens,1,F,A549,1,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,80682,9606.0,,,CHEMBL619588,1522,,646.0,,,N,Intermediate,BAO_0000219
6373,Homo sapiens,1,F,A549,1,Tested in vitro for cytotoxicity in A549/ATCC cell lines,80682,9606.0,,,CHEMBL619589,12400,,646.0,,,N,Intermediate,BAO_0000219
6374,Homo sapiens,1,F,A549,1,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,9606.0,,,CHEMBL619590,14696,,646.0,,,N,Intermediate,BAO_0000219
6375,Homo sapiens,1,F,A549,1,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),80682,9606.0,,,CHEMBL619591,14769,,646.0,,,N,Intermediate,BAO_0000219
6376,Homo sapiens,1,F,A549,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,80682,9606.0,,,CHEMBL619592,14696,,646.0,,,N,Intermediate,BAO_0000219
6377,Homo sapiens,1,F,A549,1,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,80682,9606.0,,,CHEMBL619593,1888,,646.0,,,N,Intermediate,BAO_0000219
6378,Homo sapiens,1,F,A549,1,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,80682,9606.0,,,CHEMBL620217,12016,,646.0,,,N,Intermediate,BAO_0000219
6379,Homo sapiens,1,F,A549,1,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,80682,9606.0,,,CHEMBL620218,6058,,646.0,,,N,Intermediate,BAO_0000219
6380,Homo sapiens,1,F,A549,1,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,80682,9606.0,,,CHEMBL620219,17708,,646.0,,,N,Intermediate,BAO_0000219
6381,Homo sapiens,1,F,A549,1,Antitumor activity against A549/ATCC cell line,80682,9606.0,,,CHEMBL620220,12301,,646.0,,,N,Intermediate,BAO_0000219
6382,Homo sapiens,1,F,A549,1,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,80682,9606.0,,,CHEMBL625141,11970,,646.0,,,N,Intermediate,BAO_0000219
6383,Homo sapiens,1,F,A549,1,In vitro cytotoxicity against A549/ATCC cell line.,80682,9606.0,,,CHEMBL625142,11818,,646.0,,,N,Expert,BAO_0000219
6384,Homo sapiens,1,F,A549,1,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,80682,9606.0,,,CHEMBL625143,12400,,646.0,,,N,Intermediate,BAO_0000219
6385,Homo sapiens,1,F,A549,1,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,80682,9606.0,,,CHEMBL625144,3381,,646.0,,,N,Intermediate,BAO_0000219
6386,Homo sapiens,1,F,A549,1,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,80682,9606.0,,,CHEMBL622474,17376,,646.0,,,N,Intermediate,BAO_0000219
6387,Homo sapiens,1,F,A549,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,80682,9606.0,,,CHEMBL884104,10708,,646.0,,,N,Intermediate,BAO_0000219
6388,Homo sapiens,0,F,,1,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,22226,9606.0,,,CHEMBL622475,2964,,,,,U,Autocuration,BAO_0000219
6389,Canis lupus familiaris,0,A,,1,Compound was tested for oral bioavailability in dogs,22224,9615.0,,,CHEMBL622476,5005,,,,,U,Intermediate,BAO_0000218
6390,Canis lupus familiaris,1,A,,1,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,50588,9615.0,,,CHEMBL875831,6229,,,,,N,Intermediate,BAO_0000218
6391,Canis lupus familiaris,1,A,,1,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,50588,9615.0,,,CHEMBL622477,6229,,,,,N,Intermediate,BAO_0000218
6392,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL622478,5374,,,,,N,Intermediate,BAO_0000218
6393,Canis lupus familiaris,1,A,,1,Compound was tested for the oral bioavailability in dog; No availability,50588,9615.0,,,CHEMBL623172,5374,,,,,N,Intermediate,BAO_0000218
6394,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 5 mg/kg),50588,9615.0,,,CHEMBL623173,6265,,,,,N,Intermediate,BAO_0000218
6395,Canis lupus familiaris,1,A,,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,9615.0,,,CHEMBL623174,5654,,,,,N,Intermediate,BAO_0000218
6396,Canis lupus familiaris,1,A,,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,9615.0,,,CHEMBL623175,5654,,,,,N,Intermediate,BAO_0000218
6397,Canis lupus familiaris,1,A,,1,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),50588,9615.0,,,CHEMBL623340,16456,,,,,N,Intermediate,BAO_0000218
6398,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 5 mg/kg),50588,9615.0,,,CHEMBL623341,5302,,,,,N,Intermediate,BAO_0000218
6399,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),50588,9615.0,,,CHEMBL623342,3624,,,,,N,Intermediate,BAO_0000218
6400,Canis lupus familiaris,1,A,,1,Oral bioavailability of active FTIs in dogs,50588,9615.0,,,CHEMBL623343,16452,,,,,N,Intermediate,BAO_0000218
6401,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,9615.0,,,CHEMBL623344,5802,,,,,N,Intermediate,BAO_0000218
6402,Canis lupus familiaris,1,A,,1,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL623345,3598,,,,,N,Expert,BAO_0000218
6403,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL875832,17839,,,,,N,Intermediate,BAO_0000218
6404,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623346,6762,,,,,N,Intermediate,BAO_0000218
6405,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623347,6821,,,,,N,Intermediate,BAO_0000218
6406,Canis lupus familiaris,1,A,,1,Oral bioavailability of compound was determined in dog; Not tested,50588,9615.0,,,CHEMBL623348,6821,,,,,N,Intermediate,BAO_0000218
6407,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623349,5210,,,,,N,Intermediate,BAO_0000218
6408,Canis lupus familiaris,1,A,,1,Oral bioavailability (10 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL623350,6227,,,,,N,Intermediate,BAO_0000218
6409,Canis lupus familiaris,1,A,,1,Oral bioavailability,50588,9615.0,,,CHEMBL623351,761,,,,,N,Intermediate,BAO_0000218
6410,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),50588,9615.0,,,CHEMBL623352,761,,,,,N,Intermediate,BAO_0000218
6411,Canis lupus familiaris,1,A,,1,Oral bioavailability administered in solution in rats,50588,9615.0,,,CHEMBL623353,761,,,,,N,Intermediate,BAO_0000218
6412,Canis lupus familiaris,1,A,,1,Oral bioavailability after 30 mg/kg po dose in Dogs,50588,9615.0,,,CHEMBL875833,16907,,,,,N,Intermediate,BAO_0000218
6413,Canis lupus familiaris,1,A,,1,Oral bioavailability at a dose of 1 mg/kg in dogs,50588,9615.0,,,CHEMBL623354,5474,,,,,N,Intermediate,BAO_0000218
6414,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 1 mg/kg p.o.),50588,9615.0,,,CHEMBL623355,6535,,,,,N,Intermediate,BAO_0000218
6415,Canis lupus familiaris,1,A,,1,Oral bioavailability in Dog; ND = not determined,50588,9615.0,,,CHEMBL623356,6535,,,,,N,Intermediate,BAO_0000218
6416,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623357,3352,,,,,N,Intermediate,BAO_0000218
6417,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623358,6168,,,,,N,Intermediate,BAO_0000218
6418,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623359,5988,,,,,N,Intermediate,BAO_0000218
6419,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623360,4942,,,,,N,Intermediate,BAO_0000218
6420,Canis lupus familiaris,1,A,,1,Oral bioavailability in dogs; No data,50588,9615.0,,,CHEMBL623361,4942,,,,,N,Intermediate,BAO_0000218
6421,Canis lupus familiaris,1,A,,1,Oral bioavailability measured in dogs,50588,9615.0,,,CHEMBL623362,14541,,,,,N,Intermediate,BAO_0000218
6422,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623363,4449,,,,,N,Intermediate,BAO_0000218
6423,Canis lupus familiaris,1,A,,1,Oral bioavailability was calculated in dog,50588,9615.0,,,CHEMBL623364,6057,,,,,N,Intermediate,BAO_0000218
6424,Canis lupus familiaris,1,A,,1,Oral bioavailability after 0.3 mg/kg po administration in dog,50588,9615.0,,,CHEMBL875834,5600,,,,,N,Intermediate,BAO_0000218
6425,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (i.v. dosing),50588,9615.0,,,CHEMBL623365,5542,,,,,N,Intermediate,BAO_0000218
6426,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623366,5542,,,,,N,Intermediate,BAO_0000218
6427,Canis lupus familiaris,1,A,,1,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,50588,9615.0,,,CHEMBL623367,5546,,,,,N,Intermediate,BAO_0000218
6428,Canis lupus familiaris,1,A,,1,Oral bioavailability in Beagle dogs,50588,9615.0,,,CHEMBL623368,4514,,,,,N,Intermediate,BAO_0000218
6429,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623369,3624,,,,,N,Intermediate,BAO_0000218
6430,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623370,3854,,,,,N,Intermediate,BAO_0000218
6431,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623371,5836,,,,,N,Intermediate,BAO_0000218
6432,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL623372,5940,,,,,N,Intermediate,BAO_0000218
6433,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621351,6168,,,,,N,Intermediate,BAO_0000218
6434,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621352,6227,,,,,N,Intermediate,BAO_0000218
6435,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621353,6251,,,,,N,Intermediate,BAO_0000218
6436,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621354,6448,,,,,N,Intermediate,BAO_0000218
6437,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621355,6647,,,,,N,Intermediate,BAO_0000218
6438,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621356,5940,,,,,N,Intermediate,BAO_0000218
6439,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621357,933,,,,,N,Intermediate,BAO_0000218
6440,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621358,5210,,,,,N,Intermediate,BAO_0000218
6441,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),50588,9615.0,,,CHEMBL621359,6642,,,,,N,Intermediate,BAO_0000218
6442,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,9615.0,,,CHEMBL621360,6641,,,,,N,Intermediate,BAO_0000218
6443,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,9615.0,,,CHEMBL621361,6642,,,,,N,Intermediate,BAO_0000218
6444,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621362,5472,,,,,N,Intermediate,BAO_0000218
6445,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621363,5985,,,,,N,Intermediate,BAO_0000218
6446,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621364,15660,,,,,N,Intermediate,BAO_0000218
6447,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),50588,9615.0,,,CHEMBL621166,5530,,,,,N,Intermediate,BAO_0000218
6448,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 1 mg/kg i.v.),50588,9615.0,,,CHEMBL621167,5530,,,,,N,Intermediate,BAO_0000218
6449,Canis lupus familiaris,1,A,,1,Oral bioavailability (F) in dogs,50588,9615.0,,,CHEMBL621168,6305,,,,,N,Intermediate,BAO_0000218
6450,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL621169,5210,,,,,N,Intermediate,BAO_0000218
6451,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL875950,5238,,,,,N,Intermediate,BAO_0000218
6452,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 10 mg/kg),50588,9615.0,,,CHEMBL621170,5668,,,,,N,Intermediate,BAO_0000218
6453,Canis lupus familiaris,1,A,,1,Oral bioavailability after peroral administration at 5 mpk in Dog,50588,9615.0,,,CHEMBL621171,5668,,,,,N,Intermediate,BAO_0000218
6454,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 5 mg/kg),50588,9615.0,,,CHEMBL621172,5668,,,,,N,Intermediate,BAO_0000218
6455,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 10 mg/kg),50588,9615.0,,,CHEMBL621173,6084,,,,,N,Intermediate,BAO_0000218
6456,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621174,6599,2113.0,42.0,,Kidney,N,Intermediate,BAO_0000218
6457,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621175,6599,2113.0,42.0,,Kidney,N,Intermediate,BAO_0000218
6458,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL621176,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6459,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL621177,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6460,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL621178,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6461,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621179,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6462,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621180,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6463,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL875951,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6464,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL621181,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6465,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL621182,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6466,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621183,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6467,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621184,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6468,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL621185,6599,,42.0,,,N,Intermediate,BAO_0000218
6469,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL621186,6599,,42.0,,,N,Intermediate,BAO_0000218
6470,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL621187,6599,,42.0,,,N,Intermediate,BAO_0000218
6471,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621188,6599,,42.0,,,N,Intermediate,BAO_0000218
6472,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621189,6599,,42.0,,,N,Intermediate,BAO_0000218
6473,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL621190,6599,2106.0,42.0,,Spleen,N,Intermediate,BAO_0000218
6474,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL618520,6599,2106.0,42.0,,Spleen,N,Intermediate,BAO_0000218
6475,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL621739,6599,2106.0,42.0,,Spleen,N,Intermediate,BAO_0000218
6476,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621740,6599,2106.0,42.0,,Spleen,N,Intermediate,BAO_0000218
6477,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621741,6599,2106.0,42.0,,Spleen,N,Intermediate,BAO_0000218
6478,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL621742,6599,,42.0,,,N,Intermediate,BAO_0000218
6479,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL621743,6599,,42.0,,,N,Intermediate,BAO_0000218
6480,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL621744,6599,,42.0,,,N,Intermediate,BAO_0000218
6481,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621745,6599,,42.0,,,N,Intermediate,BAO_0000218
6482,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621746,6599,,42.0,,,N,Intermediate,BAO_0000218
6483,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL621747,6599,,42.0,,,N,Intermediate,BAO_0000218
6484,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL621748,6599,,42.0,,,N,Intermediate,BAO_0000218
6485,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL621749,6599,,42.0,,,N,Intermediate,BAO_0000218
6486,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621750,6599,,42.0,,,N,Intermediate,BAO_0000218
6487,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621751,6599,,42.0,,,N,Intermediate,BAO_0000218
6488,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL621752,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6489,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL621753,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6490,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL875955,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6491,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL621754,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6492,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL621755,6599,948.0,42.0,,Heart,N,Intermediate,BAO_0000218
6493,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL621756,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6494,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL624199,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6495,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL624200,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6496,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL624375,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6497,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL624376,6599,2107.0,42.0,,Liver,N,Intermediate,BAO_0000218
6498,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL624377,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6499,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL624378,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6500,aeinetobacter anitrotap,1,F,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,107673.0,,,CHEMBL857901,12269,,,,,N,Intermediate,BAO_0000218
6501,Acinetobacter calcoaceticus subsp. anitratus,1,F,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,107673.0,,,CHEMBL875274,12269,,,,,N,Intermediate,BAO_0000218
6502,Acinetobacter calcoaceticus subsp. anitratus,1,F,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,107673.0,,,CHEMBL624379,12269,,,,,N,Intermediate,BAO_0000218
6503,aeinetobacter anitrotap,1,F,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,107673.0,,,CHEMBL624380,12269,,,,,N,Intermediate,BAO_0000218
6504,Acinetobacter calcoaceticus,1,F,,1,Activity against Acinetobacter calcoaceticus (AC54),50192,471.0,,,CHEMBL624381,10624,,,,,N,Intermediate,BAO_0000218
6505,Anolis carolinensis,1,F,,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,50714,28377.0,,,CHEMBL624382,17216,,,,,N,Intermediate,BAO_0000218
6506,Anolis carolinensis,1,F,,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,50714,28377.0,,,CHEMBL624383,17216,,,,,N,Intermediate,BAO_0000218
6507,Actinomyces naeslundii,1,F,,1,Chlorohexidine coefficient for Actinomyces naeslundii 631,50296,1655.0,,,CHEMBL624384,9560,,,,,N,Intermediate,BAO_0000218
6508,Actinomyces naeslundii,1,F,,1,Chlorohexidine coefficient for Actinomyces naeslundii B74,50296,1655.0,,,CHEMBL624385,9560,,,,,N,Intermediate,BAO_0000218
6509,Actinomyces naeslundii,1,F,,1,Chlorohexidine coefficient for Actinomyces naeslundii N/3,50296,1655.0,,,CHEMBL624386,9560,,,,,N,Intermediate,BAO_0000218
6510,Actinomyces naeslundii,1,F,,1,Chlorohexidine coefficient for Actinomyces naeslundii N/9,50296,1655.0,,,CHEMBL624387,9560,,,,,N,Intermediate,BAO_0000218
6511,Actinomyces naeslundii,1,F,,1,Plaque bactericidal index against Actinomyces naeslundii 631,50296,1655.0,,,CHEMBL624388,9560,,,,,N,Intermediate,BAO_0000218
6512,Actinomyces naeslundii,1,F,,1,Plaque bactericidal index against Actinomyces naeslundii N/9,50296,1655.0,,,CHEMBL624389,9560,,,,,N,Intermediate,BAO_0000218
6513,Actinomyces naeslundii,1,F,,1,Plaque bactericidal index against Actinomyces naeslundii B74,50296,1655.0,,,CHEMBL624390,9560,,,,,N,Intermediate,BAO_0000218
6514,Actinomyces naeslundii,1,F,,1,Plaque bactericidal index against Actinomyces naeslundii N/3,50296,1655.0,,,CHEMBL875275,9560,,,,,N,Intermediate,BAO_0000218
6515,Artemia salina,1,F,,1,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,50056,85549.0,,,CHEMBL624391,114,,,,,N,Intermediate,BAO_0000218
6516,Artemia salina,1,F,,1,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",50056,85549.0,,,CHEMBL623636,114,,,,,N,Intermediate,BAO_0000218
6517,Ascaris suum,1,F,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,6253.0,,,CHEMBL623637,10841,,,,,N,Intermediate,BAO_0000218
6518,Ascaris suum,1,F,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,6253.0,,,CHEMBL623638,10841,,,,,N,Intermediate,BAO_0000218
6519,Ascaris suum,1,F,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,6253.0,,,CHEMBL623639,10841,,,,,N,Intermediate,BAO_0000218
6520,Ascaris suum,1,F,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,6253.0,,,CHEMBL623640,10841,,,,,N,Intermediate,BAO_0000218
6521,Ascaris suum,1,F,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,6253.0,,,CHEMBL623641,10841,,,,,N,Intermediate,BAO_0000218
6522,Ascaris suum,1,F,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,50532,6253.0,,,CHEMBL623642,10841,,,,,N,Intermediate,BAO_0000218
6523,Ascaris suum,1,F,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,6253.0,,,CHEMBL623643,10841,,,,,N,Intermediate,BAO_0000218
6524,Ascaris suum,1,F,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,6253.0,,,CHEMBL623644,10841,,,,,N,Intermediate,BAO_0000218
6525,Ascaris suum,1,F,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,6253.0,,,CHEMBL623645,10841,,,,,N,Intermediate,BAO_0000218
6526,Ascaris suum,1,F,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,6253.0,,,CHEMBL623646,10841,,,,,N,Intermediate,BAO_0000218
6527,Ascaris suum,1,F,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,6253.0,,,CHEMBL623647,10841,,,,,N,Intermediate,BAO_0000218
6528,Ascaris suum,1,F,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,50532,6253.0,,,CHEMBL623648,10841,,,,,N,Intermediate,BAO_0000218
6529,Actinomyces viscosus,1,F,,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,1656.0,,,CHEMBL623649,8117,,,,,N,Intermediate,BAO_0000218
6530,Actinomyces viscosus,1,F,,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,1656.0,,,CHEMBL623650,8117,,,,,N,Intermediate,BAO_0000218
6531,Actinomyces viscosus,1,F,,1,Chlorohexidine coefficient for Actinomyces viscosus 8A06,50366,1656.0,,,CHEMBL623651,9560,,,,,N,Intermediate,BAO_0000218
6532,Actinomyces viscosus,1,F,,1,Chlorohexidine coefficient for Actinomyces viscosus M-100,50366,1656.0,,,CHEMBL623652,9560,,,,,N,Expert,BAO_0000218
6533,Actinomyces viscosus,1,F,,1,Chlorohexidine coefficient for Actinomyces viscosus M-626,50366,1656.0,,,CHEMBL623653,9560,,,,,N,Intermediate,BAO_0000218
6534,Actinomyces viscosus,1,F,,1,Chlorohexidine coefficient for Actinomyces viscosus T14V,50366,1656.0,,,CHEMBL623654,9560,,,,,N,Intermediate,BAO_0000218
6535,Actinomyces viscosus,1,F,,1,Plaque bactericidal index against Actinomyces viscosus 8A06,50366,1656.0,,,CHEMBL623655,9560,,,,,N,Intermediate,BAO_0000218
6536,Actinomyces viscosus,1,F,,1,Plaque bactericidal index against Actinomyces viscosus M-100,50366,1656.0,,,CHEMBL623656,9560,,,,,N,Intermediate,BAO_0000218
6537,Actinomyces viscosus,1,F,,1,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,50366,1656.0,,,CHEMBL623657,9560,,,,,N,Expert,BAO_0000218
6538,Actinomyces viscosus,1,F,,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,1656.0,,,CHEMBL623658,9560,,,,,N,Intermediate,BAO_0000218
6539,Actinomyces viscosus,1,F,,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,1656.0,,,CHEMBL623659,9560,,,,,N,Intermediate,BAO_0000218
6540,Actinomyces viscosus,1,F,,1,Plaque bactericidal index against Actinomyces viscosus 626,50366,1656.0,,,CHEMBL623660,9560,,,,,N,Intermediate,BAO_0000218
6541,Actinomyces viscosus,1,F,,1,Plaque bactericidal index against Actinomyces viscosus T14V,50366,1656.0,,,CHEMBL623661,9560,,,,,N,Intermediate,BAO_0000218
6542,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL875281,10986,,,,,N,Intermediate,BAO_0000218
6543,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL623662,10986,,,,,N,Intermediate,BAO_0000218
6544,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL623663,10986,,,,,N,Intermediate,BAO_0000218
6545,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL623664,10986,,,,,N,Intermediate,BAO_0000218
6546,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL623665,10986,,,,,N,Intermediate,BAO_0000218
6547,Homo sapiens,1,F,A673,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,80023,9606.0,,,CHEMBL621856,10708,,165.0,,,N,Intermediate,BAO_0000219
6548,Homo sapiens,1,F,A704,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,80661,9606.0,,,CHEMBL620432,10708,,645.0,,,N,Intermediate,BAO_0000219
6549,Rattus norvegicus,0,F,,1,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,22226,10116.0,,,CHEMBL620433,416,,,,,U,Autocuration,BAO_0000219
6550,Mus musculus,1,F,A9,1,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,10090.0,,,CHEMBL620434,14354,,625.0,,,N,Intermediate,BAO_0000219
6551,Mus musculus,1,F,A9,1,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,10090.0,,,CHEMBL620435,14354,,625.0,,,N,Intermediate,BAO_0000219
6552,Homo sapiens,1,F,A9,1,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,80024,9606.0,,,CHEMBL620436,5116,,625.0,,,N,Intermediate,BAO_0000219
6553,Homo sapiens,1,F,A9,1,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,80024,9606.0,,,CHEMBL876597,5116,,625.0,,,N,Intermediate,BAO_0000219
6554,Homo sapiens,1,F,Human ovarian carcinoma cell line,1,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,81037,9606.0,,,CHEMBL620437,15694,,874.0,,,N,Expert,BAO_0000219
6555,Mus musculus,1,F,A9,1,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",80024,10090.0,,,CHEMBL620438,13038,,625.0,,,N,Expert,BAO_0000219
6556,Mus musculus,1,F,A9,1,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,80024,10090.0,,,CHEMBL620439,13038,,625.0,,,N,Expert,BAO_0000219
6557,Mus musculus,1,F,A9,1,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,80024,10090.0,,,CHEMBL619657,10923,,625.0,,,N,Expert,BAO_0000219
6558,Mus musculus,1,F,A9,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,80024,10090.0,,,CHEMBL619658,10923,,625.0,,,N,Intermediate,BAO_0000219
6559,Mus musculus,1,F,A9,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,80024,10090.0,,,CHEMBL619659,10923,,625.0,,,N,Intermediate,BAO_0000219
6560,,8,F,,1,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10649,,,,CHEMBL619660,10923,,,,,H,Expert,BAO_0000019
6561,Mus musculus,1,F,A9,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,80024,10090.0,,,CHEMBL619661,10923,,625.0,,,N,Intermediate,BAO_0000219
6562,Mus musculus,1,F,A9,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,80024,10090.0,,,CHEMBL619662,10923,,625.0,,,N,Intermediate,BAO_0000219
6563,Cricetulus griseus,1,F,AA6,1,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,80663,10029.0,,,CHEMBL619663,8158,,975.0,,,N,Intermediate,BAO_0000219
6564,Homo sapiens,0,F,,1,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,22226,9606.0,,,CHEMBL619664,15494,,,,,U,Autocuration,BAO_0000219
6565,Homo sapiens,0,F,,1,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",22226,9606.0,,,CHEMBL619665,15494,,,,,U,Autocuration,BAO_0000219
6566,Homo sapiens,1,F,AA5,1,Anti -HIV activity was measured against AA5/HIV-1(IIIB),80662,9606.0,,,CHEMBL883244,12348,,974.0,,,N,Intermediate,BAO_0000219
6567,Homo sapiens,1,F,AA5,1,Cytotoxicity was measured against AA5/HIV-1(IIIB),80662,9606.0,,,CHEMBL884011,12348,,974.0,,,N,Intermediate,BAO_0000219
6568,Homo sapiens,1,F,AA5,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,80662,9606.0,,,CHEMBL619666,2726,,974.0,,,N,Intermediate,BAO_0000219
6569,Homo sapiens,1,F,U-937,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,80566,9606.0,,,CHEMBL619667,2726,,379.0,,,N,Intermediate,BAO_0000219
6570,Cricetulus griseus,1,F,UV4,1,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,80578,10029.0,,,CHEMBL619668,10747,,274.0,,,N,Intermediate,BAO_0000219
6571,Cricetulus griseus,1,F,CHO-AA8,1,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",80089,10029.0,,,CHEMBL619669,11005,,185.0,,,N,Expert,BAO_0000219
6572,Cricetulus griseus,1,F,CHO-AA8,1,Average intracellular compound concentration when the hypoxic SER=1.6,80089,10029.0,,,CHEMBL876608,12687,,185.0,,,N,Intermediate,BAO_0000219
6573,Cricetulus griseus,1,F,CHO-AA8,1,Average intracellular compound concentration when the hypoxic SER=1.6.,80089,10029.0,,,CHEMBL619670,12687,,185.0,,,N,Intermediate,BAO_0000219
6574,Cricetulus griseus,1,F,CHO-AA8,1,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,80089,10029.0,,,CHEMBL619671,12687,,185.0,,,N,Intermediate,BAO_0000219
6575,Cricetulus griseus,1,F,CHO-AA8,1,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,80089,10029.0,,,CHEMBL619672,12687,,185.0,,,N,Intermediate,BAO_0000219
6576,Cricetulus griseus,1,F,CHO-AA8,1,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,80089,10029.0,,,CHEMBL619673,12687,,185.0,,,N,Intermediate,BAO_0000219
6577,Cricetulus griseus,1,F,CHO-AA8,1,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",80089,10029.0,,,CHEMBL619674,13436,,185.0,,,N,Intermediate,BAO_0000219
6578,Cricetulus griseus,1,F,CHO-AA8,1,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",80089,10029.0,,,CHEMBL619675,13435,,185.0,,,N,Intermediate,BAO_0000219
6579,Cricetulus griseus,1,F,CHO-AA8,1,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,80089,10029.0,,,CHEMBL619676,13302,,185.0,,,N,Intermediate,BAO_0000219
6580,Cricetulus griseus,1,F,CHO-AA8,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,10029.0,,,CHEMBL619677,12687,,185.0,,,N,Intermediate,BAO_0000219
6581,Cricetulus griseus,1,A,CHO-AA8,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,10029.0,,,CHEMBL619678,12687,,185.0,,,N,Intermediate,BAO_0000219
6582,Cricetulus griseus,1,A,CHO-AA8,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,80089,10029.0,,,CHEMBL619679,12687,,185.0,,,N,Intermediate,BAO_0000219
6583,Cricetulus griseus,1,A,CHO-AA8,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,80089,10029.0,,,CHEMBL619680,12878,,185.0,,,N,Expert,BAO_0000219
6584,Cricetulus griseus,1,A,CHO-AA8,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,80089,10029.0,,,CHEMBL621457,12878,,185.0,,,N,Intermediate,BAO_0000219
6585,Cricetulus griseus,1,F,CHO-AA8,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,80089,10029.0,,,CHEMBL876609,14367,,185.0,,,N,Expert,BAO_0000219
6586,Cricetulus griseus,1,F,CHO-AA8,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,80089,10029.0,,,CHEMBL621458,14367,,185.0,,,N,Intermediate,BAO_0000219
6587,hampster,1,F,CHO-AA8,1,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,80089,36483.0,,,CHEMBL621459,12398,,185.0,,,N,Expert,BAO_0000219
6588,Cricetulus griseus,1,F,CHO-AA8,1,Aerobic growth inhibition in Chinese hamster cell line AA8,80089,10029.0,,,CHEMBL621460,12878,,185.0,,,N,Expert,BAO_0000219
6589,Cricetulus griseus,1,F,CHO-AA8,1,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,80089,10029.0,,,CHEMBL621461,13820,,185.0,,,N,Expert,BAO_0000219
6590,Cricetulus griseus,1,F,CHO-AA8,1,Inhibition of growth under aerobic conditions in AA8 cells,80089,10029.0,,,CHEMBL621462,13436,,185.0,,,N,Expert,BAO_0000219
6591,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 10 mg/kg),50588,9615.0,,,CHEMBL621463,6084,,,,,N,Intermediate,BAO_0000218
6592,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog at 10 mg/kg of the compound,50588,9615.0,,,CHEMBL621464,5711,,,,,N,Intermediate,BAO_0000218
6593,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 5 uM/kg),50588,9615.0,,,CHEMBL621465,4353,,,,,N,Intermediate,BAO_0000218
6594,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 5 uM/kg),50588,9615.0,,,CHEMBL621466,4353,,,,,N,Intermediate,BAO_0000218
6595,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (mongrel),50588,9615.0,,,CHEMBL621467,17800,,,,,N,Intermediate,BAO_0000218
6596,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 10 mg/kg),50588,9615.0,,,CHEMBL621468,3994,,,,,N,Intermediate,BAO_0000218
6597,Canis lupus familiaris,1,F,,1,Oral bioavailability in dog (dose 10 mg/kg),50588,9615.0,,,CHEMBL876734,3994,,,,,N,Intermediate,BAO_0000218
6598,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL618476,5145,,,,,N,Intermediate,BAO_0000218
6599,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 1 mg/kg i.v.),50588,9615.0,,,CHEMBL618477,16452,,,,,N,Intermediate,BAO_0000218
6600,Canis lupus familiaris,1,A,,1,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),50588,9615.0,,,CHEMBL618478,16452,,,,,N,Intermediate,BAO_0000218
6601,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,50588,9615.0,,,CHEMBL618479,5983,,,,,N,Intermediate,BAO_0000218
6602,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL618480,4273,,,,,N,Intermediate,BAO_0000218
6603,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 3-10 mg/kg),50588,9615.0,,,CHEMBL618481,12500,,,,,N,Intermediate,BAO_0000218
6604,Canis lupus familiaris,1,A,,1,The compound was tested for bioavailability of compound in plasma of dog; Complete,50588,9615.0,,,CHEMBL618482,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6605,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL618483,3639,,,,,N,Intermediate,BAO_0000218
6606,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL618484,3880,,,,,N,Intermediate,BAO_0000218
6607,Canis lupus familiaris,1,A,,1,Bioavailability in dog,50588,9615.0,,,CHEMBL618485,4838,,,,,N,Intermediate,BAO_0000218
6608,Canis lupus familiaris,1,A,,1,oral bioavailability was measured in dogs,50588,9615.0,,,CHEMBL618486,15600,,,,,N,Intermediate,BAO_0000218
6609,Canis lupus familiaris,1,A,,1,Compound was tested for plasma protein binding in dog; Not determined,50588,9615.0,,,CHEMBL618487,17248,,,,,N,Intermediate,BAO_0000218
6610,Canis lupus familiaris,1,A,,1,Compound was tested for plasma protein binding of dog,50588,9615.0,,,CHEMBL618488,17248,,,,,N,Intermediate,BAO_0000218
6611,Canis lupus familiaris,1,A,,1,Compound was tested for plasma protein binding of dog; Not determined,50588,9615.0,,,CHEMBL876735,17248,,,,,N,Intermediate,BAO_0000218
6612,Canis lupus familiaris,1,A,,1,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,50588,9615.0,,,CHEMBL618489,17443,,,,,N,Intermediate,BAO_0000218
6613,Canis lupus familiaris,1,A,,1,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,50588,9615.0,,,CHEMBL618490,4186,,,,,N,Intermediate,BAO_0000218
6614,Canis lupus familiaris,1,A,,1,Half life was determined,50588,9615.0,,,CHEMBL618491,3749,,,,,N,Intermediate,BAO_0000218
6615,Canis lupus familiaris,1,A,,1,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL618492,3249,,,,,N,Intermediate,BAO_0000218
6616,Canis lupus familiaris,1,A,,1,Half life was evaluated in dog,50588,9615.0,,,CHEMBL873354,3022,,,,,N,Intermediate,BAO_0000218
6617,Canis lupus familiaris,1,A,,1,Half life was determined,50588,9615.0,,,CHEMBL618493,3749,,,,,N,Intermediate,BAO_0000218
6618,Canis lupus familiaris,1,A,,1,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,9615.0,,,CHEMBL618494,2517,,,,,N,Intermediate,BAO_0000218
6619,Canis lupus familiaris,1,A,,1,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,9615.0,,,CHEMBL618495,2517,948.0,,,Heart,N,Intermediate,BAO_0000218
6620,Canis lupus familiaris,1,A,,1,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,9615.0,,,CHEMBL618496,2517,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6621,Canis lupus familiaris,1,A,,1,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,9615.0,,,CHEMBL618497,2517,2107.0,,,Liver,N,Intermediate,BAO_0000218
6622,Canis lupus familiaris,1,A,,1,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,9615.0,,,CHEMBL618498,2517,2048.0,,,Lung,N,Intermediate,BAO_0000218
6623,Canis lupus familiaris,1,A,,1,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,9615.0,,,CHEMBL618499,2517,2106.0,,,Spleen,N,Intermediate,BAO_0000218
6624,Canis lupus familiaris,1,A,,1,LogP in dog,50588,9615.0,,,CHEMBL876736,3639,,,,,N,Intermediate,BAO_0000218
6625,Canis lupus familiaris,1,A,,1,Partition coefficient (logP),50588,9615.0,,,CHEMBL618500,6227,,,,,N,Intermediate,BAO_0000218
6626,Canis lupus familiaris,1,A,,1,Partition coefficient in dog,50588,9615.0,,,CHEMBL857831,6227,,,,,N,Intermediate,BAO_0000218
6627,Canis lupus familiaris,1,A,,1,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,50588,9615.0,,,CHEMBL618501,17764,,,,,N,Intermediate,BAO_0000218
6628,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),50588,9615.0,,,CHEMBL618502,4809,,,,,N,Intermediate,BAO_0000218
6629,Canis lupus familiaris,1,A,,1,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,50588,9615.0,,,CHEMBL618503,5600,,,,,N,Intermediate,BAO_0000218
6630,Canis lupus familiaris,1,A,,1,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),50588,9615.0,,,CHEMBL618504,14294,,,,,N,Intermediate,BAO_0000218
6631,Canis lupus familiaris,1,A,,1,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),50588,9615.0,,,CHEMBL618505,14294,,,,,N,Intermediate,BAO_0000218
6632,Canis lupus familiaris,1,A,,1,Metabolism of compound in dog S9 microsomes; Trace,50588,9615.0,,,CHEMBL618506,14294,,,,,N,Intermediate,BAO_0000218
6633,Canis lupus familiaris,1,A,,1,In vitro metabolic potential in dog liver microsomes,50588,9615.0,,,CHEMBL618507,6251,2107.0,,,Liver,N,Intermediate,BAO_0000218
6634,Canis lupus familiaris,1,A,,1,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,50588,9615.0,,,CHEMBL876737,3748,,,,,N,Intermediate,BAO_0000218
6635,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL618508,2713,,,,,N,Intermediate,BAO_0000218
6636,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL618509,6512,,,,,N,Intermediate,BAO_0000218
6637,Canis lupus familiaris,1,A,,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,9615.0,,,CHEMBL618510,6679,,,,,N,Intermediate,BAO_0000218
6638,Canis lupus familiaris,1,A,,1,The compound was tested for bioavailability in dogs,50588,9615.0,,,CHEMBL618511,3749,,,,,N,Intermediate,BAO_0000218
6639,Canis lupus familiaris,1,A,,1,The compound was tested for oral bioavailability in dogs,50588,9615.0,,,CHEMBL618512,3749,,,,,N,Intermediate,BAO_0000218
6640,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog,50588,9615.0,,,CHEMBL618513,6742,,,,,N,Intermediate,BAO_0000218
6641,Canis lupus familiaris,1,A,,1,Compound was tested for percent protein binding (PB) in dog,50588,9615.0,,,CHEMBL618514,6227,,,,,N,Intermediate,BAO_0000218
6642,Canis lupus familiaris,1,A,,1,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,50588,9615.0,,,CHEMBL620052,6874,,,,,N,Intermediate,BAO_0000218
6643,Canis lupus familiaris,1,A,,1,Compound was evaluated for plasma clearance.,50588,9615.0,,,CHEMBL620053,2877,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6644,Canis lupus familiaris,1,A,,1,The compound was tested for plasma clearance in dog,50588,9615.0,,,CHEMBL620054,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6645,Canis lupus familiaris,1,A,,1,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,50588,9615.0,,,CHEMBL620055,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6646,Canis lupus familiaris,1,A,,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,50588,9615.0,,,CHEMBL620056,4709,,,,,N,Intermediate,BAO_0000218
6647,Canis lupus familiaris,1,A,,1,In vitro relative rate of metabolism was determined in dog liver microsomes,50588,9615.0,,,CHEMBL620057,5542,2107.0,,,Liver,N,Intermediate,BAO_0000218
6648,Canis lupus familiaris,1,A,,1,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,50588,9615.0,,,CHEMBL618939,17594,,,,,N,Intermediate,BAO_0000218
6649,Canis lupus familiaris,1,A,,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,9615.0,,,CHEMBL618940,2652,,,,,N,Intermediate,BAO_0000218
6650,Canis lupus familiaris,1,A,,1,Half life after intravenous administration in dogs at 1.2 uM/kg,50588,9615.0,,,CHEMBL618941,17764,,,,,N,Intermediate,BAO_0000218
6651,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL624473,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6652,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL624474,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6653,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL624475,6599,2048.0,42.0,,Lung,N,Intermediate,BAO_0000218
6654,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,50594,10090.0,,,CHEMBL624476,6599,,42.0,,,N,Intermediate,BAO_0000218
6655,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,50594,10090.0,,,CHEMBL623478,6599,,42.0,,,N,Intermediate,BAO_0000218
6656,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,50594,10090.0,,,CHEMBL623479,6599,,42.0,,,N,Intermediate,BAO_0000218
6657,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,50594,10090.0,,,CHEMBL623480,6599,,42.0,,,N,Intermediate,BAO_0000218
6658,Mus musculus,1,A,CCRF S-180,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,50594,10090.0,,,CHEMBL623481,6599,,42.0,,,N,Intermediate,BAO_0000218
6659,Mus musculus,1,A,,1,C2 in brain of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623482,17641,955.0,,,Brain,N,Intermediate,BAO_0000218
6660,Mus musculus,1,A,,1,C2 in kidney of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623483,17641,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6661,Mus musculus,1,A,,1,C2 in liver of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623484,17641,2107.0,,,Liver,N,Intermediate,BAO_0000218
6662,Mus musculus,1,A,,1,C2 in lungs of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623485,17641,2048.0,,,Lung,N,Intermediate,BAO_0000218
6663,Mus musculus,1,A,,1,C2 in spleen of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623486,17641,2106.0,,,Spleen,N,Intermediate,BAO_0000218
6664,Mus musculus,1,A,,1,Plasma clearance in mouse,50594,10090.0,,,CHEMBL623487,17852,,,,,N,Intermediate,BAO_0000218
6665,Mus musculus,1,A,,1,Clearance of compound after intravenous administration in mice at 24 uM/kg,50594,10090.0,,,CHEMBL623488,17764,,,,,N,Intermediate,BAO_0000218
6666,Mus musculus,1,A,,1,Clearance from mouse blood following i.v. administration of 10 mg/kg,50594,10090.0,,,CHEMBL623489,17837,,,,,N,Intermediate,BAO_0000218
6667,Mus musculus,1,A,,1,Clearance was evaluated in mice after intravenous administration,50594,10090.0,,,CHEMBL875157,2675,,,,,N,Intermediate,BAO_0000218
6668,Mus musculus,1,A,,1,Clearance was evaluated in mice after oral administration,50594,10090.0,,,CHEMBL623490,2675,,,,,N,Intermediate,BAO_0000218
6669,Mus musculus,1,A,,1,Pharmacokinetic property (Plasma clearance) was measured in mouse,50594,10090.0,,,CHEMBL623491,4239,,,,,N,Intermediate,BAO_0000218
6670,Mus musculus,1,A,,1,Plasma clearance of compound was determined at 40 mg/Kg,50594,10090.0,,,CHEMBL623492,17753,,,,,N,Intermediate,BAO_0000218
6671,Mus musculus,1,A,,1,Plasma clearance of at 24 mg/Kg,50594,10090.0,,,CHEMBL623493,17753,,,,,N,Intermediate,BAO_0000218
6672,Mus musculus,1,A,,1,Plasma clearance at 24 mg/Kg,50594,10090.0,,,CHEMBL623494,17753,,,,,N,Intermediate,BAO_0000218
6673,Mus musculus,1,A,,1,Plasma clearance at 5 mg/Kg,50594,10090.0,,,CHEMBL623495,17753,,,,,N,Intermediate,BAO_0000218
6674,Mus musculus,1,A,,1,Plasma clearance in mice,50594,10090.0,,,CHEMBL623496,5727,,,,,N,Intermediate,BAO_0000218
6675,Mus musculus,1,A,,1,Plasma clearance value upon iv administration in mouse,50594,10090.0,,,CHEMBL623497,2862,,,,,N,Intermediate,BAO_0000218
6676,Mus musculus,1,A,,1,Total plasma clearance in mice,50594,10090.0,,,CHEMBL623498,5980,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6677,Mus musculus,1,A,,1,Clearance in mouse,50594,10090.0,,,CHEMBL623499,17592,,,,,N,Intermediate,BAO_0000218
6678,Mus musculus,1,A,,1,Clearance value was determined,50594,10090.0,,,CHEMBL623500,17718,,,,,N,Intermediate,BAO_0000218
6679,Mus musculus,1,A,,1,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,50594,10090.0,,,CHEMBL623501,16597,,,,,N,Intermediate,BAO_0000218
6680,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL875158,17384,,,,,U,Intermediate,BAO_0000100
6681,Mus musculus,1,A,,1,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,50594,10090.0,,,CHEMBL623502,6062,,,,,N,Intermediate,BAO_0000218
6682,Mus musculus,1,A,,1,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL623503,17734,,,,,N,Intermediate,BAO_0000218
6683,Mus musculus,1,A,,1,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,10090.0,,,CHEMBL623504,6348,,,,,N,Intermediate,BAO_0000218
6684,Mus musculus,1,A,,1,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,50594,10090.0,,,CHEMBL623505,5969,,,,,N,Intermediate,BAO_0000218
6685,Mus musculus,1,A,,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,50594,10090.0,,,CHEMBL623506,5969,,,,,N,Intermediate,BAO_0000218
6686,Mus musculus,1,A,,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,10090.0,,,CHEMBL623507,5969,,,,,N,Intermediate,BAO_0000218
6687,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,50594,10090.0,,,CHEMBL623508,16597,,,,,N,Intermediate,BAO_0000218
6688,Mus musculus,1,A,,1,Cmax after oral administration at 30 mg/kg in ICR mouse,50594,10090.0,,,CHEMBL623509,5781,,,,,N,Intermediate,BAO_0000218
6689,Mus musculus,1,A,,1,Cmax after peroral administration in mice at 2.4 uM/kg,50594,10090.0,,,CHEMBL875159,17764,,,,,N,Intermediate,BAO_0000218
6690,Mus musculus,1,A,,1,Cmax in brain of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623510,17641,955.0,,,Brain,N,Intermediate,BAO_0000218
6691,Mus musculus,1,A,,1,Cmax in kidney of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623511,17641,2113.0,,,Kidney,N,Intermediate,BAO_0000218
6692,Mus musculus,1,A,,1,Cmax in liver of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623512,17641,2107.0,,,Liver,N,Intermediate,BAO_0000218
6693,Mus musculus,1,A,,1,Cmax in lungs of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL623513,17641,2048.0,,,Lung,N,Intermediate,BAO_0000218
6694,Mus musculus,1,F,,1,Cmax in mice at 18 uM/kg i.p. administration,50594,10090.0,,,CHEMBL623514,17764,,,,,N,Intermediate,BAO_0000218
6695,Mus musculus,1,F,,1,Cmax in mice at 23 uM/kg i.v. administration,50594,10090.0,,,CHEMBL622609,17764,,,,,N,Intermediate,BAO_0000218
6696,Mus musculus,1,F,,1,Cmax in mice at 24 uM/kg i.p. administration,50594,10090.0,,,CHEMBL622610,17764,,,,,N,Intermediate,BAO_0000218
6697,Mus musculus,1,F,,1,Cmax in mice at 25 uM/kg i.p. administration,50594,10090.0,,,CHEMBL621823,17764,,,,,N,Intermediate,BAO_0000218
6698,Mus musculus,1,F,,1,Cmax in mice at 26 uM/kg i.p. administration,50594,10090.0,,,CHEMBL621824,17764,,,,,N,Intermediate,BAO_0000218
6699,Mus musculus,1,A,,1,Cmax in spleen of mice at the oral dose of 50 mg/kg,50594,10090.0,,,CHEMBL621825,17641,2106.0,,,Spleen,N,Intermediate,BAO_0000218
6700,Mus musculus,1,A,,1,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,10090.0,,,CHEMBL621826,16597,,,,,N,Intermediate,BAO_0000218
6701,Mus musculus,1,A,,1,Cmax value at a dose of 10 mg/kg peroral administration in mice.,50594,10090.0,,,CHEMBL621827,16597,,,,,N,Intermediate,BAO_0000218
6702,Mus musculus,1,A,,1,Cmax value was determined,50594,10090.0,,,CHEMBL621828,5727,,,,,N,Intermediate,BAO_0000218
6703,Mus musculus,1,A,,1,Cmax value in IRC mice,50594,10090.0,,,CHEMBL621829,5951,,,,,N,Intermediate,BAO_0000218
6704,Mus musculus,1,A,,1,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,10090.0,,,CHEMBL621830,5506,,,,,N,Intermediate,BAO_0000218
6705,Mus musculus,1,A,,1,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,10090.0,,,CHEMBL621831,5506,,,,,N,Intermediate,BAO_0000218
6706,Mus musculus,1,A,,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,10090.0,,,CHEMBL621832,14239,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6707,Mus musculus,1,A,,1,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",50594,10090.0,,,CHEMBL624579,4890,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6708,Mus musculus,1,A,,1,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,50594,10090.0,,,CHEMBL624580,429,,,,,N,Intermediate,BAO_0000218
6709,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL624581,10986,,,,,N,Intermediate,BAO_0000218
6710,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL624582,10986,,,,,N,Intermediate,BAO_0000218
6711,Acanthocheilonema viteae,1,F,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,50535,6277.0,,,CHEMBL624583,10986,,,,,N,Intermediate,BAO_0000218
6712,Homo sapiens,1,F,A-375,1,Inhibitory activity against human tumor cell line A0375 melanoma.,80018,9606.0,,,CHEMBL624584,13227,,455.0,,,N,Intermediate,BAO_0000219
6713,Rattus norvegicus,9,B,,1,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,12512,10116.0,Brain membranes,,CHEMBL624585,4481,,,,,D,Expert,BAO_0000249
6714,Homo sapiens,9,F,,1,Forskolin-induced cAMP production at human A1 adenosine receptor,114,9606.0,,,CHEMBL875165,16931,,,,,D,Expert,BAO_0000019
6715,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,114,,,,CHEMBL619490,3850,,449.0,,,H,Autocuration,BAO_0000219
6716,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,,,,CHEMBL619491,3850,,449.0,,,H,Autocuration,BAO_0000219
6717,,8,F,CHO,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,114,,,,CHEMBL619492,3850,,449.0,,,H,Expert,BAO_0000219
6718,,8,F,CHO,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,114,,,,CHEMBL619493,3850,,449.0,,,H,Expert,BAO_0000219
6719,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,114,,,,CHEMBL619494,3850,,449.0,,,H,Autocuration,BAO_0000219
6720,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,114,,,,CHEMBL619495,3850,,449.0,,,H,Autocuration,BAO_0000219
6721,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,114,,,,CHEMBL619496,3850,,449.0,,,H,Autocuration,BAO_0000219
6722,Homo sapiens,9,F,CHO,1,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,9606.0,,,CHEMBL619497,3850,,449.0,,,D,Expert,BAO_0000219
6723,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,114,,,,CHEMBL619498,3850,,449.0,,,H,Autocuration,BAO_0000219
6724,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,114,,,,CHEMBL619499,3850,,449.0,,,H,Autocuration,BAO_0000219
6725,,8,F,CHO,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,114,,,,CHEMBL619500,3850,,449.0,,,H,Expert,BAO_0000219
6726,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,114,,,,CHEMBL619501,3850,,449.0,,,H,Autocuration,BAO_0000219
6727,,8,F,CHO,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,114,,,,CHEMBL619502,3850,,449.0,,,H,Expert,BAO_0000219
6728,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,114,,,,CHEMBL619503,3850,,449.0,,,H,Autocuration,BAO_0000219
6729,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,,,CHEMBL619504,3850,,449.0,,,H,Autocuration,BAO_0000219
6730,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,114,,,,CHEMBL621298,3850,,449.0,,,H,Autocuration,BAO_0000219
6731,,8,F,CHO,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,114,,,,CHEMBL621299,3850,,449.0,,,H,Expert,BAO_0000219
6732,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,114,,,,CHEMBL621300,3850,,449.0,,,H,Autocuration,BAO_0000219
6733,,8,F,CHO,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,114,,,,CHEMBL621301,3850,,449.0,,,H,Autocuration,BAO_0000219
6734,,8,F,CHO,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,,,CHEMBL621302,3850,,449.0,,,H,Expert,BAO_0000219
6735,Oryctolagus cuniculus,1,F,A10,1,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,80013,9986.0,,,CHEMBL621303,12680,,164.0,,,N,Intermediate,BAO_0000219
6736,Rattus norvegicus,0,F,A10,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells,22226,10116.0,,,CHEMBL621304,1313,,164.0,,,U,Autocuration,BAO_0000219
6737,Rattus norvegicus,0,F,A10,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,22226,10116.0,,,CHEMBL621305,1313,,164.0,,,U,Autocuration,BAO_0000219
6738,Rattus norvegicus,1,F,A10,1,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,80013,10116.0,,,CHEMBL621306,17567,,164.0,,,N,Intermediate,BAO_0000219
6739,Rattus norvegicus,1,F,A10,1,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,80013,10116.0,,,CHEMBL618444,17567,,164.0,,,N,Intermediate,BAO_0000219
6740,Rattus norvegicus,1,F,A10,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,80013,10116.0,,,CHEMBL618445,11819,,164.0,,,N,Intermediate,BAO_0000219
6741,Cricetulus griseus,1,F,CHO-AA8,1,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,80089,10029.0,,,CHEMBL618446,13436,,185.0,,,N,Intermediate,BAO_0000219
6742,Cricetulus griseus,1,F,CHO-AA8,1,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,80089,10029.0,,,CHEMBL618447,12687,,185.0,,,N,Intermediate,BAO_0000219
6743,Cricetulus griseus,1,F,CHO-AA8,1,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,80089,10029.0,,,CHEMBL618448,12651,,185.0,,,N,Intermediate,BAO_0000219
6744,Cricetulus griseus,1,F,CHO-AA8,1,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,80089,10029.0,,,CHEMBL618449,13300,,185.0,,,N,Intermediate,BAO_0000219
6745,Cricetulus griseus,1,F,CHO-AA8,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,80089,10029.0,,,CHEMBL618637,15296,,185.0,,,N,Intermediate,BAO_0000219
6746,Cricetulus griseus,1,F,CHO-AA8,1,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",80089,10029.0,,,CHEMBL618638,15328,,185.0,,,N,Intermediate,BAO_0000219
6747,Cricetulus griseus,1,F,CHO-AA8,1,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),80089,10029.0,,,CHEMBL618639,13302,,185.0,,,N,Intermediate,BAO_0000219
6748,Cricetulus griseus,1,F,CHO-AA8,1,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",80089,10029.0,,,CHEMBL618640,14367,,185.0,,,N,Expert,BAO_0000219
6749,Cricetulus griseus,1,F,CHO-AA8,1,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,80089,10029.0,,,CHEMBL618641,17002,,185.0,,,N,Expert,BAO_0000219
6750,Cricetulus griseus,1,F,CHO-AA8,1,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,80089,10029.0,,,CHEMBL618642,13436,,185.0,,,N,Intermediate,BAO_0000219
6751,Cricetulus griseus,1,F,CHO-AA8,1,Inhibitory activity against aerobic growth of AA8 cells.,80089,10029.0,,,CHEMBL618643,13435,,185.0,,,N,Intermediate,BAO_0000219
6752,Cricetulus griseus,1,A,CHO-AA8,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,10029.0,,,CHEMBL884013,10503,,185.0,,,N,Intermediate,BAO_0000219
6753,Cricetulus griseus,1,F,CHO-AA8,1,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,10029.0,,,CHEMBL622723,10503,,185.0,,,N,Expert,BAO_0000219
6754,Cricetulus griseus,1,F,CHO-AA8,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,10029.0,,,CHEMBL622724,10503,,185.0,,,N,Intermediate,BAO_0000219
6755,Cricetulus griseus,1,F,CHO-AA8,1,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,80089,10029.0,,,CHEMBL622725,15090,,185.0,,,N,Expert,BAO_0000219
6756,Cricetulus griseus,1,F,CHO-AA8,1,Cytotoxicity against AA8 cell line,80089,10029.0,,,CHEMBL622726,10368,,185.0,,,N,Expert,BAO_0000219
6757,Cricetulus griseus,1,F,CHO-AA8,1,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),80089,10029.0,,,CHEMBL622727,12651,,185.0,,,N,Intermediate,BAO_0000219
6758,Cricetulus griseus,1,A,CHO-AA8,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,10029.0,,,CHEMBL622728,12687,,185.0,,,N,Intermediate,BAO_0000219
6759,Cricetulus griseus,1,F,CHO-AA8,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,10029.0,,,CHEMBL622729,12687,,185.0,,,N,Intermediate,BAO_0000219
6760,Cricetulus griseus,1,A,CHO-AA8,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,10029.0,,,CHEMBL622730,12687,,185.0,,,N,Intermediate,BAO_0000219
6761,Cricetulus griseus,1,F,CHO-AA8,1,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,80089,10029.0,,,CHEMBL622731,1890,,185.0,,,N,Intermediate,BAO_0000219
6762,Cricetulus griseus,1,F,CHO-AA8,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,10029.0,,,CHEMBL622732,10747,,185.0,,,N,Intermediate,BAO_0000219
6763,Cricetulus griseus,1,F,CHO-AA8,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,10029.0,,,CHEMBL622733,10747,,185.0,,,N,Intermediate,BAO_0000219
6764,Cricetulus griseus,0,F,,1,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),22224,10029.0,,,CHEMBL622734,11616,,,,,U,Autocuration,BAO_0000218
6765,Cricetulus griseus,1,F,CHO-AA8,1,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,80089,10029.0,,,CHEMBL622735,11616,,185.0,,,N,Expert,BAO_0000219
6766,Cricetulus griseus,0,F,CHO-AA8,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,22224,10029.0,,,CHEMBL618746,3471,,185.0,,,U,Autocuration,BAO_0000219
6767,Cricetulus griseus,0,F,CHO-AA8,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,22224,10029.0,,,CHEMBL618747,3471,,185.0,,,U,Autocuration,BAO_0000219
6768,Cricetulus griseus,0,F,CHO-AA8,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,22224,10029.0,,,CHEMBL620540,3471,,185.0,,,U,Autocuration,BAO_0000219
6769,Cricetulus griseus,0,F,CHO-AA8,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,22224,10029.0,,,CHEMBL620541,3471,,185.0,,,U,Autocuration,BAO_0000219
6770,Cricetulus griseus,0,F,CHO-AA8,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,22224,10029.0,,,CHEMBL620542,3471,,185.0,,,U,Autocuration,BAO_0000219
6771,Cricetulus griseus,0,F,CHO-AA8,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,22224,10029.0,,,CHEMBL620543,3471,,185.0,,,U,Autocuration,BAO_0000219
6772,Cricetulus griseus,0,F,CHO-AA8,1,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,22224,10029.0,,,CHEMBL618832,3471,,185.0,,,U,Autocuration,BAO_0000219
6773,Cricetulus griseus,1,F,CHO-AA8,1,Concentration required to reduce AA8 cell survival by 10%,80089,10029.0,,,CHEMBL618833,11616,,185.0,,,N,Expert,BAO_0000219
6774,Cricetulus griseus,0,F,CHO-AA8,1,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",22224,10029.0,,,CHEMBL618834,2656,,185.0,,,U,Autocuration,BAO_0000219
6775,Cricetulus griseus,0,F,CHO-AA8,1,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,10029.0,,,CHEMBL618835,10518,,185.0,,,U,Autocuration,BAO_0000219
6776,Cricetulus griseus,0,F,CHO-AA8,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,10029.0,,,CHEMBL618836,10518,,185.0,,,U,Autocuration,BAO_0000219
6777,Cricetulus griseus,0,F,CHO-AA8,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,22224,10029.0,,,CHEMBL618837,10518,,185.0,,,U,Autocuration,BAO_0000219
6778,Cricetulus griseus,0,F,CHO-AA8,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,22224,10029.0,,,CHEMBL618838,10518,,185.0,,,U,Autocuration,BAO_0000219
6779,Cricetulus griseus,0,F,CHO-AA8,1,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,22224,10029.0,,,CHEMBL618839,16156,,185.0,,,U,Autocuration,BAO_0000219
6780,Cricetulus griseus,0,F,CHO-AA8,1,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,22224,10029.0,,,CHEMBL618840,2656,,185.0,,,U,Autocuration,BAO_0000219
6781,Cricetulus griseus,0,F,,1,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",22224,10029.0,,,CHEMBL618841,11005,,,,,U,Autocuration,BAO_0000019
6782,Cricetulus griseus,0,F,CHO-AA8,1,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,22224,10029.0,,,CHEMBL618842,11942,,185.0,,,U,Autocuration,BAO_0000219
6783,Cricetulus griseus,0,F,CHO-AA8,1,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,22224,10029.0,,,CHEMBL618843,2128,,185.0,,,U,Autocuration,BAO_0000219
6784,Canis lupus familiaris,1,A,,1,Half life period after 15 mg/kg iv dose in Dogs,50588,9615.0,,,CHEMBL618844,16907,,,,,N,Intermediate,BAO_0000218
6785,Canis lupus familiaris,1,A,,1,Half life period after 30 mg/kg po dose in Dogs,50588,9615.0,,,CHEMBL618845,16907,,,,,N,Intermediate,BAO_0000218
6786,Canis lupus familiaris,1,A,,1,Half life was measured after oral 2b administration (tested in 6 dogs),50588,9615.0,,,CHEMBL618846,9579,,,,,N,Intermediate,BAO_0000218
6787,Canis lupus familiaris,1,A,,1,Half life was measured in dog after oral 17b administration,50588,9615.0,,,CHEMBL618847,9579,,,,,N,Intermediate,BAO_0000218
6788,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,50588,9615.0,,,CHEMBL618848,9579,,,,,N,Intermediate,BAO_0000218
6789,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,50588,9615.0,,,CHEMBL618849,9579,,,,,N,Intermediate,BAO_0000218
6790,Canis lupus familiaris,1,A,,1,Tmax value after 15 mg/kg iv dose in Dogs,50588,9615.0,,,CHEMBL618850,16907,,,,,N,Intermediate,BAO_0000218
6791,Canis lupus familiaris,1,A,,1,Tmax value after 30 mg/kg po dose in Dogs,50588,9615.0,,,CHEMBL618851,16907,,,,,N,Intermediate,BAO_0000218
6792,Canis lupus familiaris,1,A,,1,Compound was evaluated for its half life when administered intravenously in dog,50588,9615.0,,,CHEMBL873815,3184,,,,,N,Intermediate,BAO_0000218
6793,Canis lupus familiaris,1,A,,1,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,9615.0,,,CHEMBL618852,5017,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6794,Canis lupus familiaris,1,A,,1,Elimination Half-life of compound was determined in dog,50588,9615.0,,,CHEMBL618853,6821,,,,,N,Intermediate,BAO_0000218
6795,Canis lupus familiaris,1,A,,1,Half life of compound in dog following oral administration,50588,9615.0,,,CHEMBL618854,17839,,,,,N,Intermediate,BAO_0000218
6796,Canis lupus familiaris,1,A,,1,Half life of compound was determined in dog,50588,9615.0,,,CHEMBL618855,17267,,,,,N,Intermediate,BAO_0000218
6797,Canis lupus familiaris,1,A,,1,Half life of compound was determined in dog blood,50588,9615.0,,,CHEMBL618856,4727,178.0,,,Blood,N,Intermediate,BAO_0000218
6798,Canis lupus familiaris,1,A,,1,Half life after oral and iv dosing in dogs,50588,9615.0,,,CHEMBL875827,5238,,,,,N,Intermediate,BAO_0000218
6799,Canis lupus familiaris,1,A,,1,Half life in dogs in hours,50588,9615.0,,,CHEMBL618857,4942,,,,,N,Intermediate,BAO_0000218
6800,Canis lupus familiaris,1,A,,1,Half life on i.v. administration of 2 mg/kg was measured in dog,50588,9615.0,,,CHEMBL618858,6505,,,,,N,Intermediate,BAO_0000218
6801,Canis lupus familiaris,1,A,,1,t1/2 in dog after oral dose (1 mg/kg),50588,9615.0,,,CHEMBL618859,5130,,,,,N,Intermediate,BAO_0000218
6802,Canis lupus familiaris,1,A,,1,Half life was evaluated in dog,50588,9615.0,,,CHEMBL618860,1475,,,,,N,Intermediate,BAO_0000218
6803,Canis lupus familiaris,1,A,,1,Half life period of compound was determined after intravenous administration at 2 mg/kg,50588,9615.0,,,CHEMBL618861,17804,,,,,N,Intermediate,BAO_0000218
6804,Canis lupus familiaris,1,A,,1,Half life period of compound was determined after peroral administration at 2 mg/kg,50588,9615.0,,,CHEMBL622539,17804,,,,,N,Intermediate,BAO_0000218
6805,Canis lupus familiaris,1,A,,1,Half life period (10 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL622540,6084,,,,,N,Intermediate,BAO_0000218
6806,Canis lupus familiaris,1,A,,1,Half life period (10 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL873803,6084,,,,,N,Intermediate,BAO_0000218
6807,Canis lupus familiaris,1,A,,1,Half life period by iv administration in dog at a dose of 0.3 mg/kg,50588,9615.0,,,CHEMBL873804,5542,,,,,N,Intermediate,BAO_0000218
6808,Canis lupus familiaris,1,A,,1,Half life period by po administration in dog at a dose of 0.3 mg/kg,50588,9615.0,,,CHEMBL624311,5542,,,,,N,Intermediate,BAO_0000218
6809,Canis lupus familiaris,1,A,,1,Half life period in dog,50588,9615.0,,,CHEMBL624312,6084,,,,,N,Intermediate,BAO_0000218
6810,Canis lupus familiaris,1,A,,1,Half life period in dogs after oral administration at 1 mg/kg,50588,9615.0,,,CHEMBL624313,6241,,,,,N,Intermediate,BAO_0000218
6811,Canis lupus familiaris,1,A,,1,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,9615.0,,,CHEMBL624314,1916,,,,,N,Intermediate,BAO_0000218
6812,Canis lupus familiaris,1,A,,1,Half-life of compound was determined in dogs,50588,9615.0,,,CHEMBL624315,6621,,,,,N,Intermediate,BAO_0000218
6813,Canis lupus familiaris,1,A,,1,Half-life in dog plasma,50588,9615.0,,,CHEMBL624316,1696,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6814,Canis lupus familiaris,1,A,,1,Half-life in mongrel dogs was determined,50588,9615.0,,,CHEMBL624317,17800,,,,,N,Intermediate,BAO_0000218
6815,Canis lupus familiaris,1,A,,1,Half-life in dog upon oral administration,50588,9615.0,,,CHEMBL624318,17657,,,,,N,Intermediate,BAO_0000218
6816,Canis lupus familiaris,1,A,,1,Half-life in dog upon oral administration; Unable to calculate,50588,9615.0,,,CHEMBL624319,17657,,,,,N,Intermediate,BAO_0000218
6817,Canis lupus familiaris,1,A,,1,Half-life was measured in dog,50588,9615.0,,,CHEMBL624496,4239,,,,,N,Intermediate,BAO_0000218
6818,Canis lupus familiaris,1,A,,1,Half-life was measured in dog,50588,9615.0,,,CHEMBL624497,5985,,,,,N,Intermediate,BAO_0000218
6819,Canis lupus familiaris,1,A,,1,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,50588,9615.0,,,CHEMBL624498,9932,,,,,N,Intermediate,BAO_0000218
6820,Canis lupus familiaris,1,A,,1,Oral half life was determined,50588,9615.0,,,CHEMBL624499,5199,,,,,N,Intermediate,BAO_0000218
6821,Canis lupus familiaris,1,A,,1,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,50588,9615.0,,,CHEMBL624500,5199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6822,Canis lupus familiaris,1,A,,1,Plasma half life was evaluated,50588,9615.0,,,CHEMBL624501,1475,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6823,Canis lupus familiaris,1,A,,1,Plasma half life was evaluated in Dog,50588,9615.0,,,CHEMBL623666,1475,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6824,Canis lupus familiaris,1,A,,1,Plasma half life was evaluated in dog,50588,9615.0,,,CHEMBL623667,1475,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6825,Canis lupus familiaris,1,A,,1,T1/2 (Half-life) was after oral administration at 5 mg/kg,50588,9615.0,,,CHEMBL623668,6316,,,,,N,Intermediate,BAO_0000218
6826,Canis lupus familiaris,1,A,,1,Tested for the half life value in dog,50588,9615.0,,,CHEMBL623669,4883,,,,,N,Intermediate,BAO_0000218
6827,Canis lupus familiaris,1,A,,1,Maximum time at the dose of 2 mg/kg in dog,50588,9615.0,,,CHEMBL623670,4727,,,,,N,Intermediate,BAO_0000218
6828,Canis lupus familiaris,1,A,,1,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,9615.0,,,CHEMBL623671,1916,,,,,N,Intermediate,BAO_0000218
6829,Canis lupus familiaris,1,A,,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL875945,1337,178.0,,,Blood,N,Intermediate,BAO_0000218
6830,Canis lupus familiaris,1,A,,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL623672,1337,178.0,,,Blood,N,Intermediate,BAO_0000218
6831,Canis lupus familiaris,1,A,,1,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,50588,9615.0,,,CHEMBL623673,6265,,,,,N,Intermediate,BAO_0000218
6832,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,9615.0,,,CHEMBL623674,4809,,,,,N,Intermediate,BAO_0000218
6833,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,9615.0,,,CHEMBL623675,5983,,,,,N,Intermediate,BAO_0000218
6834,Canis lupus familiaris,1,A,,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",50588,9615.0,,,CHEMBL872526,5313,,,,,N,Intermediate,BAO_0000218
6835,Canis lupus familiaris,1,A,,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",50588,9615.0,,,CHEMBL623676,5313,,,,,N,Intermediate,BAO_0000218
6836,Canis lupus familiaris,1,A,,1,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,9615.0,,,CHEMBL623677,17650,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6837,Canis lupus familiaris,1,A,,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,9615.0,,,CHEMBL623678,5199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6838,Canis lupus familiaris,1,A,,1,Time taken for maximum plasma concentration in dog,50588,9615.0,,,CHEMBL623679,933,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6839,Canis lupus familiaris,1,A,,1,Time to reach Cmax after oral administration to dogs,50588,9615.0,,,CHEMBL623680,16367,,,,,N,Intermediate,BAO_0000218
6840,Canis lupus familiaris,1,A,,1,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,9615.0,,,CHEMBL623681,6348,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6841,Canis lupus familiaris,1,A,,1,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,50588,9615.0,,,CHEMBL623682,6316,,,,,N,Intermediate,BAO_0000218
6842,Canis lupus familiaris,1,A,,1,Tmax after peroral administration (1 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL623683,6215,,,,,N,Intermediate,BAO_0000218
6843,Canis lupus familiaris,1,A,,1,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL623684,3598,,,,,N,Expert,BAO_0000218
6844,Canis lupus familiaris,1,A,,1,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,50588,9615.0,,,CHEMBL622745,4527,,,,,N,Intermediate,BAO_0000218
6845,Canis lupus familiaris,1,A,,1,Tmax after peroral administration in dogs at 2.4 uM/kg,50588,9615.0,,,CHEMBL622746,17764,,,,,N,Intermediate,BAO_0000218
6846,Mus musculus,1,A,,1,In vivo Cmax in mice at dose of 100 mg/kg,50594,10090.0,,,CHEMBL622747,5969,,,,,N,Intermediate,BAO_0000218
6847,Mus musculus,1,A,,1,In vivo Cmax in mice at dose of 50 mg/kg,50594,10090.0,,,CHEMBL622748,5969,,,,,N,Intermediate,BAO_0000218
6848,Mus musculus,1,A,,1,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,10090.0,,,CHEMBL622749,4573,,,,,N,Intermediate,BAO_0000218
6849,Mus musculus,1,A,,1,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,10090.0,,,CHEMBL622750,3277,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6850,Mus musculus,1,A,,1,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL623411,17734,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6851,Mus musculus,1,A,,1,Maximum concentration obtained in mouse plasma was determined,50594,10090.0,,,CHEMBL875946,3132,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6852,Mus musculus,1,A,,1,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,50594,10090.0,,,CHEMBL623412,3132,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6853,Mus musculus,1,A,,1,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,10090.0,,,CHEMBL623413,6348,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6854,Mus musculus,1,A,,1,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,50594,10090.0,,,CHEMBL623414,17729,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6855,Mus musculus,1,A,,1,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,50594,10090.0,,,CHEMBL623415,17729,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6856,Mus musculus,1,A,,1,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,50594,10090.0,,,CHEMBL623416,17729,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6857,Mus musculus,1,A,,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,50594,10090.0,,,CHEMBL623417,17728,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6858,Mus musculus,1,A,,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,50594,10090.0,,,CHEMBL623418,17728,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6859,Mus musculus,1,A,,1,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,50594,10090.0,,,CHEMBL623419,17728,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6860,Mus musculus,1,A,,1,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,50594,10090.0,,,CHEMBL622816,4066,,,,,N,Intermediate,BAO_0000218
6861,Mus musculus,1,A,,1,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,50594,10090.0,,,CHEMBL623313,6178,,,,,N,Intermediate,BAO_0000218
6862,Mus musculus,1,A,,1,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,50594,10090.0,,,CHEMBL623314,6178,,,,,N,Intermediate,BAO_0000218
6863,Mus musculus,1,A,,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,50594,10090.0,,,CHEMBL876788,3760,,,,,N,Intermediate,BAO_0000218
6864,Mus musculus,1,A,,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,50594,10090.0,,,CHEMBL623315,3760,,,,,N,Intermediate,BAO_0000218
6865,Mus musculus,1,A,,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,50594,10090.0,,,CHEMBL623316,3760,,,,,N,Intermediate,BAO_0000218
6866,Mus musculus,1,A,,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,50594,10090.0,,,CHEMBL623317,3760,,,,,N,Intermediate,BAO_0000218
6868,Mus musculus,1,A,,1,Cmax in male mice after 2 mg/kg oral dose,50594,10090.0,,,CHEMBL623319,5961,,,,,N,Intermediate,BAO_0000218
6869,Mus musculus,1,A,,1,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,50594,10090.0,,,CHEMBL623320,6137,,,,,N,Intermediate,BAO_0000218
6870,Mus musculus,1,A,,1,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,10090.0,,,CHEMBL623321,3802,,,,,N,Intermediate,BAO_0000218
6871,Mus musculus,1,A,,1,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,50594,10090.0,,,CHEMBL623322,3535,,,,,N,Intermediate,BAO_0000218
6872,Mus musculus,1,A,,1,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,50594,10090.0,,,CHEMBL623323,3535,,,,,N,Intermediate,BAO_0000218
6873,Mus musculus,1,A,,1,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,50594,10090.0,,,CHEMBL623324,3535,,,,,N,Intermediate,BAO_0000218
6874,Mus musculus,1,A,,1,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,50594,10090.0,,,CHEMBL623325,3535,,,,,N,Intermediate,BAO_0000218
6875,Mus musculus,1,A,,1,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,50594,10090.0,,,CHEMBL623326,3535,,,,,N,Intermediate,BAO_0000218
6876,Mus musculus,1,A,,1,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,50594,10090.0,,,CHEMBL623327,3535,,,,,N,Intermediate,BAO_0000218
6877,Mus musculus,1,A,,1,Maximum concentration in plasma upon oral administration in mouse,50594,10090.0,,,CHEMBL623328,2862,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6878,Mus musculus,1,A,,1,Maximum plasma concentration was evaluated in mice after oral administration,50594,10090.0,,,CHEMBL623329,2675,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6879,Mus musculus,1,A,,1,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,50594,10090.0,,,CHEMBL623330,2675,1969.0,,,Plasma,N,Intermediate,BAO_0000218
6880,Mus musculus,1,A,,1,Dose at which the compound induced fecal excretion in mice,50594,10090.0,,,CHEMBL876789,5399,,,,,N,Intermediate,BAO_0000218
6893,Rattus norvegicus,1,F,A10,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,80013,10116.0,,,CHEMBL623333,11819,,164.0,,,N,Expert,BAO_0000219
6894,Rattus norvegicus,1,F,A10,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,80013,10116.0,,,CHEMBL623334,11819,,164.0,,,N,Expert,BAO_0000219
6895,Rattus norvegicus,1,F,A10,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,80013,10116.0,,,CHEMBL627536,11819,,164.0,,,N,Expert,BAO_0000219
6896,Rattus norvegicus,1,F,A10,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,80013,10116.0,,,CHEMBL627537,11819,,164.0,,,N,Expert,BAO_0000219
6897,Rattus norvegicus,1,F,A10,1,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),80013,10116.0,,,CHEMBL627538,16361,,164.0,,,N,Intermediate,BAO_0000219
6898,Homo sapiens,1,F,A121,1,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,80655,9606.0,,,CHEMBL884106,2288,,393.0,,,N,Intermediate,BAO_0000219
6899,Homo sapiens,1,F,A121,1,Anticancer activity against human ovarian carcinoma A121 cells,80655,9606.0,,,CHEMBL625294,10404,,393.0,,,N,Intermediate,BAO_0000219
6900,Homo sapiens,1,F,A121,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,80655,9606.0,,,CHEMBL625295,14790,,393.0,,,N,Intermediate,BAO_0000219
6901,Homo sapiens,1,F,A121,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,80655,9606.0,,,CHEMBL625296,14790,,393.0,,,N,Intermediate,BAO_0000219
6902,Homo sapiens,1,F,A121,1,Growth inhibition of human ovarian carcinoma (A121) cell line,80655,9606.0,,,CHEMBL625297,14253,,393.0,,,N,Expert,BAO_0000219
6903,Homo sapiens,1,F,A121,1,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,80655,9606.0,,,CHEMBL625298,13617,,393.0,,,N,Expert,BAO_0000219
6904,Homo sapiens,1,F,A121,1,Cytotoxicity against human A121 ovarian cells,80655,9606.0,,,CHEMBL625960,1003,,393.0,,,N,Intermediate,BAO_0000219
6905,Homo sapiens,1,F,A121,1,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,80655,9606.0,,,CHEMBL625961,830,,393.0,,,N,Intermediate,BAO_0000219
6906,Homo sapiens,1,F,A121,1,In vitro cytotoxicity against human ovarian carcinoma A21,80655,9606.0,,,CHEMBL625962,12307,,393.0,,,N,Intermediate,BAO_0000219
6907,Homo sapiens,1,F,A121,1,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,80655,9606.0,,,CHEMBL624717,14254,,393.0,,,N,Intermediate,BAO_0000219
6908,Homo sapiens,1,F,A121,1,Inhibitory activity of compound against human A121 ovarian cell line.,80655,9606.0,,,CHEMBL624718,13370,,393.0,,,N,Intermediate,BAO_0000219
6909,Homo sapiens,1,F,A121,1,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,80655,9606.0,,,CHEMBL624719,14790,,393.0,,,N,Intermediate,BAO_0000219
6910,Homo sapiens,1,F,A121,1,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,80655,9606.0,,,CHEMBL624720,3614,,393.0,,,N,Intermediate,BAO_0000219
6911,Homo sapiens,1,F,A 172,1,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,80012,9606.0,,,CHEMBL624721,2664,,622.0,,,N,Intermediate,BAO_0000219
6912,Homo sapiens,1,F,A 172,1,In vitro cytotoxicity against A172 human tumor cell lines.,80012,9606.0,,,CHEMBL624722,2037,,622.0,,,N,Expert,BAO_0000219
6913,Homo sapiens,1,F,A 172,1,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,80012,9606.0,,,CHEMBL877597,14539,,622.0,,,N,Intermediate,BAO_0000219
6914,Homo sapiens,1,F,A 172,1,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,80012,9606.0,,,CHEMBL624723,2836,,622.0,,,N,Intermediate,BAO_0000219
6915,Homo sapiens,1,F,A 172,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,80012,9606.0,,,CHEMBL624724,10708,,622.0,,,N,Intermediate,BAO_0000219
6916,Canis lupus familiaris,4,B,,1,Association constant against A2 adenosine receptor,104729,9615.0,,,CHEMBL624725,8975,,,,,H,Autocuration,BAO_0000224
6917,fish,1,F,A2,1,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,80656,,,,CHEMBL624726,7645,,1085.0,,,N,Intermediate,BAO_0000219
6918,Rattus norvegicus,5,B,,1,Ratio of Ki for adenosine A2 and A1 receptor binding,104713,10116.0,,,CHEMBL857535,11377,,,,,D,Autocuration,BAO_0000224
6919,Homo sapiens,1,F,A204,1,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,80014,9606.0,,,CHEMBL624727,13528,,623.0,,,N,Expert,BAO_0000219
6920,Homo sapiens,1,F,A204,1,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,80014,9606.0,,,CHEMBL624728,10160,,623.0,,,N,Expert,BAO_0000219
6921,Homo sapiens,1,F,A2058,1,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,80015,9606.0,,,CHEMBL624729,15144,,404.0,,,N,Intermediate,BAO_0000219
6922,Homo sapiens,1,F,A253 cell line,1,Growth inhibition against Human squamous cell line(A 253),80657,9606.0,,,CHEMBL624730,13160,,973.0,,,N,Intermediate,BAO_0000219
6923,Homo sapiens,1,F,A253 cell line,1,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,80657,9606.0,,,CHEMBL624731,12898,,973.0,,,N,Intermediate,BAO_0000219
6924,Homo sapiens,1,F,A253 cell line,1,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,80657,9606.0,,,CHEMBL624732,13069,,973.0,,,N,Intermediate,BAO_0000219
6925,Homo sapiens,1,F,A253 cell line,1,Growth inhibition of A253 cell lines.,80657,9606.0,,,CHEMBL883245,15984,,973.0,,,N,Intermediate,BAO_0000219
6926,Homo sapiens,1,F,A253 cell line,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),80657,9606.0,,,CHEMBL624733,15564,,973.0,,,N,Intermediate,BAO_0000219
6927,Homo sapiens,1,F,A253 cell line,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,9606.0,,,CHEMBL624734,15564,,973.0,,,N,Intermediate,BAO_0000219
6928,Homo sapiens,1,F,A253 cell line,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,9606.0,,,CHEMBL624735,15564,,973.0,,,N,Intermediate,BAO_0000219
6929,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,81034,9606.0,,,CHEMBL621780,4720,,478.0,,,N,Intermediate,BAO_0000219
6930,Homo sapiens,1,F,A2780,1,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,81034,9606.0,,,CHEMBL877598,16112,,478.0,,,N,Intermediate,BAO_0000219
6931,Homo sapiens,1,F,A2780,1,Cytotoxic activity against A2780 human ovarian carcinoma cell line,81034,9606.0,,,CHEMBL621781,16597,,478.0,,,N,Expert,BAO_0000219
6932,Homo sapiens,1,F,A2780,1,Cytotoxicity against human cancer cell lines A2780 (ovarian),81034,9606.0,,,CHEMBL621782,16378,,478.0,,,N,Intermediate,BAO_0000219
6933,Homo sapiens,1,F,A2780,1,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,81034,9606.0,,,CHEMBL621783,16085,,478.0,,,N,Expert,BAO_0000219
6934,Homo sapiens,1,F,A2780,1,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,81034,9606.0,,,CHEMBL621784,16317,,478.0,,,N,Intermediate,BAO_0000219
6935,Homo sapiens,1,F,A2780,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,9606.0,,,CHEMBL621785,15748,,478.0,,,N,Intermediate,BAO_0000219
6936,Homo sapiens,1,F,A2780,1,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,81034,9606.0,,,CHEMBL621968,16597,,478.0,,,N,Expert,BAO_0000219
6937,Homo sapiens,1,F,A2780,1,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,81034,9606.0,,,CHEMBL621969,16597,,478.0,,,N,Expert,BAO_0000219
6938,Homo sapiens,1,F,A2780,1,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,81034,9606.0,,,CHEMBL621970,16597,,478.0,,,N,Expert,BAO_0000219
6939,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,81034,9606.0,,,CHEMBL621971,15608,,478.0,,,N,Intermediate,BAO_0000219
6940,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,81034,9606.0,,,CHEMBL621972,15608,,478.0,,,N,Intermediate,BAO_0000219
6941,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,81034,9606.0,,,CHEMBL884108,15608,,478.0,,,N,Intermediate,BAO_0000219
6942,Cricetulus griseus,0,F,,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,22224,10029.0,,,CHEMBL623826,15296,,,,,U,Autocuration,BAO_0000019
6943,Cricetulus griseus,0,A,CHO-AA8,1,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,22224,10029.0,,,CHEMBL623827,10251,,185.0,,,U,Autocuration,BAO_0000219
6944,Cricetulus griseus,0,F,CHO-AA8,1,Evaluated for growth inhibition of AA8 cells under aerobic conditions,22224,10029.0,,,CHEMBL623828,10251,,185.0,,,U,Autocuration,BAO_0000219
6945,Cricetulus griseus,0,F,CHO-AA8,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,22224,10029.0,,,CHEMBL623829,10251,,185.0,,,U,Autocuration,BAO_0000219
6946,Cricetulus griseus,0,F,CHO-AA8,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),22224,10029.0,,,CHEMBL623830,10251,,185.0,,,U,Autocuration,BAO_0000219
6947,Cricetulus griseus,0,F,,1,Growth inhibition against CHO-derived cell line AA8,22224,10029.0,,,CHEMBL623831,11858,,,,,U,Autocuration,BAO_0000019
6948,Cricetulus griseus,0,F,CHO-AA8,1,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],22224,10029.0,,,CHEMBL623832,11858,,185.0,,,U,Autocuration,BAO_0000219
6949,hampster,1,F,CHO-AA8,1,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,80089,36483.0,,,CHEMBL623833,11616,,185.0,,,N,Expert,BAO_0000219
6950,Cricetulus griseus,1,F,CHO-AA8,1,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,80089,10029.0,,,CHEMBL623834,11616,,185.0,,,N,Expert,BAO_0000219
6951,Cricetulus griseus,0,F,CHO-AA8,1,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,22224,10029.0,,,CHEMBL623835,10518,,185.0,,,U,Autocuration,BAO_0000219
6952,Cricetulus griseus,0,F,CHO-AA8,1,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,22224,10029.0,,,CHEMBL623836,11396,,185.0,,,U,Autocuration,BAO_0000219
6953,Cricetulus griseus,0,F,CHO-AA8,1,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,22224,10029.0,,,CHEMBL623837,10518,,185.0,,,U,Autocuration,BAO_0000219
6954,Cricetulus griseus,1,F,CHO-AA8,1,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,80089,10029.0,,,CHEMBL623838,11616,,185.0,,,N,Expert,BAO_0000219
6955,,8,F,,1,compound was evaluated for association constant (Ka) of isolated serum protein AAG,12675,,,,CHEMBL623839,14837,,,,,H,Autocuration,BAO_0000019
6956,,8,F,,1,Number of binding sites (n) of isolated serum protein AAG,12675,,,,CHEMBL623840,14837,,,,,H,Autocuration,BAO_0000019
6957,,3,B,,1,Association constant for binding to AATT duplex,22222,,,,CHEMBL623841,16037,,,,,M,Intermediate,BAO_0000225
6958,Homo sapiens,1,F,ABAE,1,Inhibition of ABAE human fibroblast cell proliferation,100090,9606.0,,,CHEMBL623842,16597,,416.0,,,N,Expert,BAO_0000219
6959,Mus musculus,1,F,AC755,1,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",80668,10090.0,,,CHEMBL623843,8831,,1064.0,,,N,Intermediate,BAO_0000218
6960,Oryctolagus cuniculus,9,F,,1,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,102444,9986.0,,,CHEMBL618669,13419,,,,,D,Expert,BAO_0000218
6961,Oryctolagus cuniculus,9,F,,1,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,102444,9986.0,,,CHEMBL618670,13419,,,,,D,Expert,BAO_0000218
6962,,8,B,,1,Inhibitory activity against angiotensin-converting enzyme (ACE).,69,,,,CHEMBL618671,15778,,,,,H,Autocuration,BAO_0000357
6963,,8,B,,1,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,69,,,,CHEMBL618672,15778,,,,,H,Autocuration,BAO_0000357
6964,Homo sapiens,1,F,ACH-2 cell line,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,80669,9606.0,,,CHEMBL618673,12988,,978.0,,,N,Intermediate,BAO_0000219
6965,Homo sapiens,1,F,ACH-2 cell line,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),80669,9606.0,,,CHEMBL618674,12988,,978.0,,,N,Intermediate,BAO_0000219
6966,Human immunodeficiency virus 1,0,F,T cell line,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,22224,11676.0,,,CHEMBL618675,12988,,998.0,,,U,Autocuration,BAO_0000219
6967,Human immunodeficiency virus 1,0,F,T cell line,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),22224,11676.0,,,CHEMBL618676,12988,,998.0,,,U,Autocuration,BAO_0000219
6968,Human immunodeficiency virus 1,0,F,T cell line,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),22224,11676.0,,,CHEMBL618677,12988,,998.0,,,U,Autocuration,BAO_0000219
6969,Homo sapiens,1,F,ACHN,1,Inhibition of growth of renal cancer ACHN cell line,80025,9606.0,,,CHEMBL618678,11843,,626.0,,,N,Intermediate,BAO_0000219
6970,Homo sapiens,1,F,ACHN,1,Inhibition of growth of ACHN renal cancer cell line,80025,9606.0,,,CHEMBL618679,16939,,626.0,,,N,Intermediate,BAO_0000219
6971,Homo sapiens,1,F,ACHN,1,Inhibitory concentration required against ACHN renal cancer cell line,80025,9606.0,,,CHEMBL618680,4782,,626.0,,,N,Intermediate,BAO_0000219
6972,Homo sapiens,1,F,ACHN,1,Concentration required to inhibit growth of human renal (ACHN) cell line,80025,9606.0,,,CHEMBL618681,6310,,626.0,,,N,Expert,BAO_0000219
6973,Homo sapiens,1,F,ACHN,1,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,80025,9606.0,,,CHEMBL618682,6310,,626.0,,,N,Intermediate,BAO_0000219
6974,Homo sapiens,1,F,ACHN,1,Cytotoxic activity against ACHN Renal cancer cell line,80025,9606.0,,,CHEMBL618683,12858,,626.0,,,N,Intermediate,BAO_0000219
6975,Homo sapiens,1,F,ACHN,1,Cytotoxicity evaluation against ACHN renal cancer cells,80025,9606.0,,,CHEMBL618684,17380,,626.0,,,N,Intermediate,BAO_0000219
6976,Homo sapiens,1,F,ACHN,1,In vitro antitumor activity against human renal ACHN cell line,80025,9606.0,,,CHEMBL618685,5858,,626.0,,,N,Intermediate,BAO_0000219
6977,Homo sapiens,1,F,ACHN,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,9606.0,,,CHEMBL876499,3838,,626.0,,,N,Intermediate,BAO_0000219
6978,Homo sapiens,1,F,ACHN,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,9606.0,,,CHEMBL618686,3838,,626.0,,,N,Intermediate,BAO_0000219
6979,Homo sapiens,1,F,ACHN,1,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",80025,9606.0,,,CHEMBL618687,5406,,626.0,,,N,Intermediate,BAO_0000219
6980,Homo sapiens,1,F,ACHN,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,9606.0,,,CHEMBL618688,4071,,626.0,,,N,Intermediate,BAO_0000219
6981,Homo sapiens,1,F,ACHN,1,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,9606.0,,,CHEMBL618689,4071,,626.0,,,N,Expert,BAO_0000219
6982,Homo sapiens,1,F,ACHN,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,80025,9606.0,,,CHEMBL618690,4071,,626.0,,,N,Intermediate,BAO_0000219
6983,Homo sapiens,1,F,ACHN,1,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,80025,9606.0,,,CHEMBL618691,15002,,626.0,,,N,Intermediate,BAO_0000219
6984,Homo sapiens,1,F,ACHN,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,9606.0,,,CHEMBL619373,14769,,626.0,,,N,Intermediate,BAO_0000219
6985,Homo sapiens,1,F,ACHN,1,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",80025,9606.0,,,CHEMBL884008,13958,,626.0,,,N,Intermediate,BAO_0000219
6986,Homo sapiens,1,F,ACHN,1,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,80025,9606.0,,,CHEMBL619374,1665,,626.0,,,N,Intermediate,BAO_0000219
6987,Homo sapiens,1,F,ACHN,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line,80025,9606.0,,,CHEMBL619375,15354,,626.0,,,N,Intermediate,BAO_0000219
6988,Homo sapiens,1,F,ACHN,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,80025,9606.0,,,CHEMBL619376,15354,,626.0,,,N,Intermediate,BAO_0000219
6989,Homo sapiens,1,F,ACHN,1,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,80025,9606.0,,,CHEMBL619377,13978,,626.0,,,N,Intermediate,BAO_0000219
6990,Homo sapiens,1,F,ACHN,1,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,80025,9606.0,,,CHEMBL619378,6798,,626.0,,,N,Intermediate,BAO_0000219
6991,Canis lupus familiaris,1,A,,1,Tmax value after administration of 4 mg/Kg oral dose in dog,50588,9615.0,,,CHEMBL872527,2959,,,,,N,Intermediate,BAO_0000218
6992,Canis lupus familiaris,1,A,,1,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",50588,9615.0,,,CHEMBL876500,9932,,,,,N,Intermediate,BAO_0000218
6993,Canis lupus familiaris,1,A,,1,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,9615.0,,,CHEMBL619379,5546,,,,,N,Intermediate,BAO_0000218
6994,Canis lupus familiaris,1,A,,1,Volume distribution after 15 mg/kg iv dose in Dogs,50588,9615.0,,,CHEMBL619538,16907,,,,,N,Intermediate,BAO_0000218
6995,Canis lupus familiaris,1,A,,1,Volume distribution after 30 mg/kg po dose in Dogs,50588,9615.0,,,CHEMBL619539,16907,,,,,N,Intermediate,BAO_0000218
6996,Canis lupus familiaris,1,A,,1,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,50588,9615.0,,,CHEMBL619540,4257,,,,,N,Intermediate,BAO_0000218
6997,Canis lupus familiaris,1,A,,1,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL619541,4305,,,,,N,Intermediate,BAO_0000218
6998,Canis lupus familiaris,1,A,,1,Volume of distribution was evaluated in dog,50588,9615.0,,,CHEMBL619542,5472,,,,,N,Intermediate,BAO_0000218
6999,Canis lupus familiaris,1,A,,1,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,9615.0,,,CHEMBL619543,6062,,,,,N,Intermediate,BAO_0000218
7000,Canis lupus familiaris,1,A,,1,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL619544,3598,,,,,N,Expert,BAO_0000218
7001,Canis lupus familiaris,1,A,,1,The compound was tested for volume of distribution in dog,50588,9615.0,,,CHEMBL619545,12500,,,,,N,Intermediate,BAO_0000218
7002,Canis lupus familiaris,1,A,,1,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,50588,9615.0,,,CHEMBL619546,12500,,,,,N,Intermediate,BAO_0000218
7003,Canis lupus familiaris,1,A,,1,Vd (1 mg/kg) was determined in dog (in vivo),50588,9615.0,,,CHEMBL619547,6227,,,,,N,Intermediate,BAO_0000218
7004,Canis lupus familiaris,1,A,,1,Vd in dog,50588,9615.0,,,CHEMBL619548,6227,,,,,N,Intermediate,BAO_0000218
7005,Canis lupus familiaris,1,A,,1,Volume distribution was determined,50588,9615.0,,,CHEMBL619549,4219,,,,,N,Intermediate,BAO_0000218
7006,Canis lupus familiaris,1,A,,1,Volume of distribution in dog,50588,9615.0,,,CHEMBL619550,1696,,,,,N,Intermediate,BAO_0000218
7007,Canis lupus familiaris,1,A,,1,Volume of distribution by as 4 fold increase by iv administration in dogs,50588,9615.0,,,CHEMBL876501,5542,,,,,N,Intermediate,BAO_0000218
7008,Canis lupus familiaris,1,A,,1,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,9615.0,,,CHEMBL619551,5199,,,,,N,Intermediate,BAO_0000218
7009,Canis lupus familiaris,1,A,,1,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,9615.0,,,CHEMBL619552,6348,,,,,N,Intermediate,BAO_0000218
7010,Canis lupus familiaris,1,A,,1,Volume distribution at the dose of 2 mg/kg in dog,50588,9615.0,,,CHEMBL619553,4727,,,,,N,Intermediate,BAO_0000218
7011,Canis lupus familiaris,1,A,,1,Steady state volume of distribution was determined,50588,9615.0,,,CHEMBL618722,16367,,,,,N,Intermediate,BAO_0000218
7012,Canis lupus familiaris,1,A,,1,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,50588,9615.0,,,CHEMBL618723,2652,,,,,N,Intermediate,BAO_0000218
7013,Canis lupus familiaris,1,A,,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,9615.0,,,CHEMBL618724,16452,,,,,N,Intermediate,BAO_0000218
7014,Canis lupus familiaris,1,A,,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,9615.0,,,CHEMBL618725,16452,,,,,N,Intermediate,BAO_0000218
7015,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 1 mg/kg i.v.),50588,9615.0,,,CHEMBL618726,16452,,,,,N,Intermediate,BAO_0000218
7016,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,9615.0,,,CHEMBL618727,5334,,,,,N,Intermediate,BAO_0000218
7017,Canis lupus familiaris,1,A,,1,Pharmacokinetic property (vdss) was measured in dog,50588,9615.0,,,CHEMBL624233,4239,,,,,N,Intermediate,BAO_0000218
7018,Canis lupus familiaris,1,A,,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,50588,9615.0,,,CHEMBL624234,4709,,,,,N,Intermediate,BAO_0000218
7019,Canis lupus familiaris,1,A,,1,Vdss was determined after iv 0.1 mg/kg administration in dog,50588,9615.0,,,CHEMBL624235,5600,,,,,N,Intermediate,BAO_0000218
7020,Canis lupus familiaris,1,A,,1,Volume displacement was calculated in dog,50588,9615.0,,,CHEMBL624236,6057,,,,,N,Intermediate,BAO_0000218
7021,Canis lupus familiaris,1,A,,1,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL624237,5654,,,,,N,Intermediate,BAO_0000218
7022,Canis lupus familiaris,1,A,,1,Volume distribution constant was determined,50588,9615.0,,,CHEMBL624238,5505,,,,,N,Intermediate,BAO_0000218
7023,Canis lupus familiaris,1,A,,1,Volume distribution at a dose of 1 uM/kg in dog was determined,50588,9615.0,,,CHEMBL624239,4527,,,,,N,Intermediate,BAO_0000218
7024,Canis lupus familiaris,1,A,,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,9615.0,,,CHEMBL875829,4521,,,,,N,Intermediate,BAO_0000218
7025,Canis lupus familiaris,1,A,,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,9615.0,,,CHEMBL624240,4521,,,,,N,Intermediate,BAO_0000218
7026,Canis lupus familiaris,1,A,,1,Volume distribution (Vdss) was measured in dog,50588,9615.0,,,CHEMBL624241,15660,,,,,N,Intermediate,BAO_0000218
7027,Canis lupus familiaris,1,A,,1,Volume distribution (Vdss) was measured in dog,50588,9615.0,,,CHEMBL624242,15660,,,,,N,Intermediate,BAO_0000218
7028,Canis lupus familiaris,1,A,,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,9615.0,,,CHEMBL624243,6679,,,,,N,Intermediate,BAO_0000218
7029,Canis lupus familiaris,1,A,,1,Volume of distribution in steady state was determined in dog,50588,9615.0,,,CHEMBL624244,5145,,,,,N,Intermediate,BAO_0000218
7030,Canis lupus familiaris,1,A,,1,Volume of distribution of compound was determined in dog,50588,9615.0,,,CHEMBL624245,6821,,,,,N,Intermediate,BAO_0000218
7031,Canis lupus familiaris,1,A,,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,50588,9615.0,,,CHEMBL624246,4137,,,,,N,Intermediate,BAO_0000218
7032,Canis lupus familiaris,1,A,,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,9615.0,,,CHEMBL624247,5334,,,,,N,Intermediate,BAO_0000218
7033,Canis lupus familiaris,1,A,,1,Volume of distribution (Vdss) was measured in dog,50588,9615.0,,,CHEMBL624248,15660,,,,,N,Intermediate,BAO_0000218
7034,Canis lupus familiaris,1,A,,1,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,9615.0,,,CHEMBL624249,6642,,,,,N,Intermediate,BAO_0000218
7035,Canis lupus familiaris,1,A,,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,9615.0,,,CHEMBL624250,6641,,,,,N,Intermediate,BAO_0000218
7036,Canis lupus familiaris,1,A,,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,9615.0,,,CHEMBL624251,6642,,,,,N,Intermediate,BAO_0000218
7037,Canis lupus familiaris,1,A,,1,Maximum rate of depolarization of the upstroke of the action potential,50588,9615.0,,,CHEMBL624252,11659,,,,,N,Intermediate,BAO_0000218
7038,Canis lupus familiaris,1,A,,1,Steady state volume distribution in dog,50588,9615.0,,,CHEMBL624253,6448,,,,,N,Intermediate,BAO_0000218
7039,Canis lupus familiaris,1,A,,1,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,50588,9615.0,,,CHEMBL624950,5474,,,,,N,Intermediate,BAO_0000218
7040,Canis lupus familiaris,1,A,,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,50588,9615.0,,,CHEMBL624951,1466,,,,,N,Intermediate,BAO_0000218
7041,Canis lupus familiaris,1,A,,1,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,9615.0,,,CHEMBL875830,6535,,,,,N,Intermediate,BAO_0000218
7042,Canis lupus familiaris,1,A,,1,Volume distribution in dog after administration of 1 mg/kg iv,50588,9615.0,,,CHEMBL624952,6535,,,,,N,Intermediate,BAO_0000218
7043,Canis lupus familiaris,1,A,,1,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,50588,9615.0,,,CHEMBL624953,17764,,,,,N,Intermediate,BAO_0000218
7044,Canis lupus familiaris,1,A,,1,Vss after intravenous administration (0.5 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL624954,6215,,,,,N,Intermediate,BAO_0000218
7045,Canis lupus familiaris,1,A,,1,Vss on i.v. administration of 2 mg/kg was measured in dog,50588,9615.0,,,CHEMBL624955,6505,,,,,N,Intermediate,BAO_0000218
7046,Canis lupus familiaris,1,A,,1,Vss was determined,50588,9615.0,,,CHEMBL624956,3639,,,,,N,Intermediate,BAO_0000218
7047,Canis lupus familiaris,1,A,,1,Vss in dog,50588,9615.0,,,CHEMBL625129,3639,,,,,N,Intermediate,BAO_0000218
7048,Canis lupus familiaris,1,A,,1,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,9615.0,,,CHEMBL625130,6062,,,,,N,Intermediate,BAO_0000218
7049,Canis lupus familiaris,1,A,,1,Volume distribution in dogs,50588,9615.0,,,CHEMBL625131,4942,,,,,N,Intermediate,BAO_0000218
7050,Canis lupus familiaris,1,A,,1,Volume of distribution in dog,50588,9615.0,,,CHEMBL625132,17796,,,,,N,Intermediate,BAO_0000218
7051,Canis lupus familiaris,1,A,,1,Tested for the oral bioavailability in dog,50588,9615.0,,,CHEMBL872263,4883,,,,,N,Intermediate,BAO_0000218
7060,Mus musculus,1,A,,1,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,50594,10090.0,,,CHEMBL624336,17837,,,,,N,Intermediate,BAO_0000218
7061,Mus musculus,1,A,,1,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,50594,10090.0,,,CHEMBL624337,17729,,,,,N,Intermediate,BAO_0000218
7062,Mus musculus,1,A,,1,Bioavailability after peroral administration of 50 mg/kg of dose in mice,50594,10090.0,,,CHEMBL624338,17729,,,,,N,Intermediate,BAO_0000218
7063,Mus musculus,1,A,,1,Bioavailability was measured in mouse,50594,10090.0,,,CHEMBL624339,4239,,,,,N,Intermediate,BAO_0000218
7064,Mus musculus,1,A,,1,Bioavailability in mouse,50594,10090.0,,,CHEMBL624340,17592,,,,,N,Intermediate,BAO_0000218
7065,Mus musculus,1,A,,1,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,10090.0,,,CHEMBL624341,6348,,,,,N,Intermediate,BAO_0000218
7066,Mus musculus,1,A,,1,Bioavailability in mouse,50594,10090.0,,,CHEMBL624342,2801,,,,,N,Intermediate,BAO_0000218
7067,Mus musculus,1,A,,1,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,50594,10090.0,,,CHEMBL624343,2801,,,,,N,Intermediate,BAO_0000218
7068,Mus musculus,1,A,,1,Oral bioavailability in mouse,50594,10090.0,,,CHEMBL624344,17718,,,,,N,Intermediate,BAO_0000218
7069,Mus musculus,1,A,,1,Oral availability at 50 mg/kg po in male mice,50594,10090.0,,,CHEMBL624345,5727,,,,,N,Intermediate,BAO_0000218
7070,Mus musculus,1,A,,1,Oral bioavailability in mouse (dose 10 mg/kg),50594,10090.0,,,CHEMBL624346,5302,,,,,N,Intermediate,BAO_0000218
7071,Mus musculus,1,A,,1,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,50594,10090.0,,,CHEMBL624347,3598,,,,,N,Expert,BAO_0000218
7072,Mus musculus,1,A,,1,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",50594,10090.0,,,CHEMBL624348,5961,,,,,N,Intermediate,BAO_0000218
7074,Mus musculus,1,A,,1,Oral bioavailability in mouse,50594,10090.0,,,CHEMBL622754,6091,,,,,N,Intermediate,BAO_0000218
7075,Mus musculus,1,A,,1,Oral bioavailability in vivo in mice;ND=Not determined,50594,10090.0,,,CHEMBL622755,6091,,,,,N,Intermediate,BAO_0000218
7076,Mus musculus,1,A,,1,Oral bioavailability in mouse at 10 mg/kg of the compound,50594,10090.0,,,CHEMBL622756,5711,,,,,N,Intermediate,BAO_0000218
7077,Mus musculus,1,A,,1,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),50594,10090.0,,,CHEMBL622757,17728,,,,,N,Intermediate,BAO_0000218
7078,Mus musculus,1,A,,1,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),50594,10090.0,,,CHEMBL622758,17728,,,,,N,Intermediate,BAO_0000218
7079,Mus musculus,1,A,,1,Tested for bioavailability of the compound,50594,10090.0,,,CHEMBL622759,3802,,,,,N,Intermediate,BAO_0000218
7080,Mus musculus,1,A,,1,Tested for half life at the dose of 10 mg/kg when administered intravenously,50594,10090.0,,,CHEMBL622760,3802,,,,,N,Intermediate,BAO_0000218
7081,Mus musculus,1,A,,1,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,50594,10090.0,,,CHEMBL622761,14029,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7082,Mus musculus,1,A,,1,The plasma half life of compound was determined on heparin prepared by human plasma. ,50594,10090.0,,,CHEMBL622762,14029,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7083,Mus musculus,1,A,,1,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,50594,10090.0,,,CHEMBL622763,14029,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7084,Mus musculus,1,A,,1,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,50594,10090.0,,,CHEMBL622764,14029,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7085,Mus musculus,1,A,,1,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,50594,10090.0,,,CHEMBL622765,14029,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7086,Mus musculus,1,F,,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,50594,10090.0,,,CHEMBL622766,17753,,,,,N,Intermediate,BAO_0000218
7087,Mus musculus,1,A,,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,50594,10090.0,,,CHEMBL622767,17753,,,,,N,Intermediate,BAO_0000218
7088,Mus musculus,1,A,,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,50594,10090.0,,,CHEMBL622768,17753,,,,,N,Intermediate,BAO_0000218
7089,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL875948,10107,178.0,,,Blood,N,Intermediate,BAO_0000218
7090,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL622769,10107,178.0,,,Blood,N,Intermediate,BAO_0000218
7091,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL622770,10107,178.0,,,Blood,N,Intermediate,BAO_0000218
7092,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL622771,10107,178.0,,,Blood,N,Intermediate,BAO_0000218
7093,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL622772,10107,178.0,,,Blood,N,Intermediate,BAO_0000218
7094,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL622773,10107,178.0,,,Blood,N,Intermediate,BAO_0000218
7095,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL622774,10107,178.0,,,Blood,N,Intermediate,BAO_0000218
7096,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL621725,10107,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7097,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,10090.0,,,CHEMBL621726,10107,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7098,Homo sapiens,1,F,A2780,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,81034,9606.0,,,CHEMBL621727,15608,,478.0,,,N,Intermediate,BAO_0000219
7099,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,81034,9606.0,,,CHEMBL622413,3290,,478.0,,,N,Expert,BAO_0000219
7100,Homo sapiens,1,F,A2780,1,Compound was evaluated for cytotoxicity against A2780 cell line,81034,9606.0,,,CHEMBL622414,2859,,478.0,,,N,Intermediate,BAO_0000219
7101,Homo sapiens,1,F,A2780,1,Inhibition of A2780 cell clonogenic assay,81034,9606.0,,,CHEMBL622415,15688,,478.0,,,N,Expert,BAO_0000219
7102,Homo sapiens,1,F,A2780,1,Cytotoxic effect on ovarian cancer cell line (A2780),81034,9606.0,,,CHEMBL884001,5642,,478.0,,,N,Expert,BAO_0000219
7103,Homo sapiens,1,F,A2780,1,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,81034,9606.0,,,CHEMBL622416,6633,,478.0,,,N,Intermediate,BAO_0000219
7104,Homo sapiens,1,F,A2780,1,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",81034,9606.0,,,CHEMBL622417,3906,,478.0,,,N,Intermediate,BAO_0000219
7105,Homo sapiens,1,F,A2780,1,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,81034,9606.0,,,CHEMBL622590,6788,,478.0,,,N,Expert,BAO_0000219
7106,Homo sapiens,1,F,A2780,1,Antiproliferative activity against human A2780 cells,81034,9606.0,,,CHEMBL622591,17582,,478.0,,,N,Expert,BAO_0000219
7107,Homo sapiens,1,F,A2780,1,Inhibition of human A2780 cell proliferation,81034,9606.0,,,CHEMBL622592,17764,,478.0,,,N,Expert,BAO_0000219
7108,Homo sapiens,1,F,A2780,1,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,81034,9606.0,,,CHEMBL622593,17764,,478.0,,,N,Expert,BAO_0000219
7109,Homo sapiens,1,F,A2780,1,Inhibition of human A2780 cell proliferation (No data),81034,9606.0,,,CHEMBL622594,17764,,478.0,,,N,Expert,BAO_0000219
7110,Homo sapiens,1,F,A2780,1,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,81034,9606.0,,,CHEMBL622595,2815,,478.0,,,N,Intermediate,BAO_0000219
7111,Homo sapiens,1,F,A2780,1,Compound was evaluated against human Ovarian carcinoma cell line A2780,81034,9606.0,,,CHEMBL622596,16930,,478.0,,,N,Intermediate,BAO_0000219
7112,Homo sapiens,1,F,A2780,1,Growth inhibition against A2780 wild-type ovarian cell lines,81034,9606.0,,,CHEMBL622597,17777,,478.0,,,N,Expert,BAO_0000219
7113,Homo sapiens,1,F,A2780,1,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,81034,9606.0,,,CHEMBL622598,17777,,478.0,,,N,Intermediate,BAO_0000219
7114,Homo sapiens,5,F,,1,Inhibition of tubulin polymerization in human ovarian cancer cell lines,104766,9606.0,,,CHEMBL622599,16936,,,,,D,Autocuration,BAO_0000019
7115,Homo sapiens,1,F,A2780,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,9606.0,,,CHEMBL622600,13759,,478.0,,,N,Intermediate,BAO_0000219
7116,Homo sapiens,1,F,A2780,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,9606.0,,,CHEMBL622601,13759,,478.0,,,N,Intermediate,BAO_0000219
7117,Homo sapiens,1,F,A2780,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,9606.0,,,CHEMBL622602,13759,,478.0,,,N,Intermediate,BAO_0000219
7118,Homo sapiens,1,F,A2780,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,9606.0,,,CHEMBL622603,13759,,478.0,,,N,Intermediate,BAO_0000219
7119,Homo sapiens,1,F,A2780,1,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,9606.0,,,CHEMBL622604,15292,,478.0,,,N,Intermediate,BAO_0000219
7120,Homo sapiens,1,F,A2780,1,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,9606.0,,,CHEMBL622605,15292,,478.0,,,N,Intermediate,BAO_0000219
7121,Homo sapiens,1,F,A2780,1,In vitro inhibition of human ovarian cell line A2780,81034,9606.0,,,CHEMBL622606,15069,,478.0,,,N,Expert,BAO_0000219
7122,Homo sapiens,1,F,A2780,1,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",81034,9606.0,,,CHEMBL619463,15069,,478.0,,,N,Expert,BAO_0000219
7123,Homo sapiens,1,F,A2780,1,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),81034,9606.0,,,CHEMBL619464,14073,,478.0,,,N,Intermediate,BAO_0000219
7124,Homo sapiens,1,F,A2780,1,Concentration required to inhibit A2780-cell growth by 50%,81034,9606.0,,,CHEMBL619465,14553,,478.0,,,N,Expert,BAO_0000219
7125,Homo sapiens,1,F,A2780,1,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,81034,9606.0,,,CHEMBL619466,13040,,478.0,,,N,Expert,BAO_0000219
7126,Homo sapiens,1,F,A2780,1,Cytotoxic effect on human ovarian (A2780) cancer cell line,81034,9606.0,,,CHEMBL619467,6891,,478.0,,,N,Expert,BAO_0000219
7127,Homo sapiens,1,F,A2780,1,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,81034,9606.0,,,CHEMBL619468,15569,,478.0,,,N,Intermediate,BAO_0000219
7128,Homo sapiens,1,F,A2780,1,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,81034,9606.0,,,CHEMBL619469,14190,,478.0,,,N,Expert,BAO_0000219
7129,Homo sapiens,1,F,A2780,1,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,9606.0,,,CHEMBL619470,15014,,478.0,,,N,Expert,BAO_0000219
7130,Homo sapiens,1,F,A2780,1,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,9606.0,,,CHEMBL619471,15014,,478.0,,,N,Intermediate,BAO_0000219
7131,Homo sapiens,1,F,A2780,1,Cytotoxicity against human ovarian carcinoma A2780 cell line,81034,9606.0,,,CHEMBL619472,17496,,478.0,,,N,Intermediate,BAO_0000219
7132,Homo sapiens,1,F,A2780,1,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",81034,9606.0,,,CHEMBL619473,13617,,478.0,,,N,Intermediate,BAO_0000219
7133,Homo sapiens,1,F,A2780,1,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",81034,9606.0,,,CHEMBL874368,13617,,478.0,,,N,Intermediate,BAO_0000219
7134,Homo sapiens,1,F,A2780,1,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",81034,9606.0,,,CHEMBL884003,13617,,478.0,,,N,Intermediate,BAO_0000219
7135,Homo sapiens,1,F,A2780,1,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",81034,9606.0,,,CHEMBL622690,13617,,478.0,,,N,Intermediate,BAO_0000219
7136,Homo sapiens,1,F,A2780,1,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,81034,9606.0,,,CHEMBL622691,17672,,478.0,,,N,Intermediate,BAO_0000219
7137,Homo sapiens,1,F,A2780,1,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,9606.0,,,CHEMBL622692,4544,,478.0,,,N,Intermediate,BAO_0000219
7138,Homo sapiens,1,F,A2780,1,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,9606.0,,,CHEMBL623406,4544,,478.0,,,N,Intermediate,BAO_0000219
7139,Homo sapiens,1,F,A2780,1,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",81034,9606.0,,,CHEMBL884004,16317,,478.0,,,N,Intermediate,BAO_0000219
7140,Homo sapiens,1,F,A2780,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,81034,9606.0,,,CHEMBL623407,15099,,478.0,,,N,Intermediate,BAO_0000219
7141,Homo sapiens,1,F,A2780,1,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,81034,9606.0,,,CHEMBL623408,13978,,478.0,,,N,Intermediate,BAO_0000219
7142,Homo sapiens,1,F,A2780,1,In vitro antitumor activity against A2780 cell line.,81034,9606.0,,,CHEMBL623409,12989,,478.0,,,N,Expert,BAO_0000219
7143,Homo sapiens,1,F,A2780,1,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,81034,9606.0,,,CHEMBL623410,5574,,478.0,,,N,Intermediate,BAO_0000219
7144,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against A2780 human ovarian cancer cell line,81034,9606.0,,,CHEMBL623576,13528,,478.0,,,N,Expert,BAO_0000219
7145,Homo sapiens,1,F,ACHN,1,Inhibitory activity against kidney A-CHN tumor cell growth in culture,80025,9606.0,,,CHEMBL623577,12782,,626.0,,,N,Intermediate,BAO_0000219
7146,Homo sapiens,1,F,ACHN,1,The IC50 value was measured on ACHN cell line in renal tumor type.,80025,9606.0,,,CHEMBL623578,14255,,626.0,,,N,Intermediate,BAO_0000219
7147,Homo sapiens,1,F,ACHN,1,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,80025,9606.0,,,CHEMBL623579,16364,,626.0,,,N,Intermediate,BAO_0000219
7148,Homo sapiens,1,F,ACHN,1,In vitro lethal concentration against most sensitive ACHN cell line,80025,9606.0,,,CHEMBL623580,17376,,626.0,,,N,Expert,BAO_0000219
7149,Homo sapiens,1,F,ACHN,1,Tested for cytotoxic activity against renal cancer ACHN cell line,80025,9606.0,,,CHEMBL623581,12016,,626.0,,,N,Intermediate,BAO_0000219
7150,Homo sapiens,1,F,ACHN,1,Compound tested for growth inhibition of renal cancer cell line ACHN,80025,9606.0,,,CHEMBL857456,6058,,626.0,,,N,Intermediate,BAO_0000219
7151,Homo sapiens,1,F,ACHN,1,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,80025,9606.0,,,CHEMBL623582,17708,,626.0,,,N,Intermediate,BAO_0000219
7152,Homo sapiens,1,F,ACHN,1,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,80025,9606.0,,,CHEMBL623583,15176,,626.0,,,N,Intermediate,BAO_0000219
7153,Homo sapiens,1,F,ACHN,1,In vitro anticancer activity against ACHN renal cancer cell line,80025,9606.0,,,CHEMBL623584,2806,,626.0,,,N,Intermediate,BAO_0000219
7154,Homo sapiens,1,F,ACHN,1,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,80025,9606.0,,,CHEMBL623585,15300,,626.0,,,N,Intermediate,BAO_0000219
7155,Homo sapiens,1,F,ACHN,1,Percent selectivity was evaluated in renal ACHN cell lines,80025,9606.0,,,CHEMBL623586,16364,,626.0,,,N,Intermediate,BAO_0000219
7156,Homo sapiens,1,F,ACHN,1,In vitro inhibitory activity against renal ACHN cancer cell line,80025,9606.0,,,CHEMBL623587,13859,,626.0,,,N,Intermediate,BAO_0000219
7157,Homo sapiens,1,F,ACHN,1,Tested for cytotoxicity against ACHN cell lines in renal cancer,80025,9606.0,,,CHEMBL875279,11970,,626.0,,,N,Intermediate,BAO_0000219
7158,Homo sapiens,1,F,ACHN,1,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,80025,9606.0,,,CHEMBL623588,2450,,626.0,,,N,Intermediate,BAO_0000219
7159,Homo sapiens,1,F,ACHN,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80025,9606.0,,,CHEMBL623589,12696,,626.0,,,N,Intermediate,BAO_0000219
7160,Homo sapiens,1,F,ACHN,1,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,80025,9606.0,,,CHEMBL623590,12400,,626.0,,,N,Intermediate,BAO_0000219
7161,Homo sapiens,1,F,ACHN,1,Cytotoxic effect on renal cancer line ACHN,80025,9606.0,,,CHEMBL623591,12888,,626.0,,,N,Expert,BAO_0000219
7162,Homo sapiens,1,F,ACHN,1,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,80025,9606.0,,,CHEMBL623592,3156,,626.0,,,N,Intermediate,BAO_0000219
7163,Homo sapiens,1,F,ACHN,1,In vitro inhibition of Renal Cancer ACHN cell lines,80025,9606.0,,,CHEMBL623593,3381,,626.0,,,N,Intermediate,BAO_0000219
7164,Homo sapiens,1,F,ACHN,1,Antitumor activity against human renal adenocarcinoma ACHN cells,80025,9606.0,,,CHEMBL623594,16747,,626.0,,,N,Intermediate,BAO_0000219
7165,Homo sapiens,1,F,ACHN,1,Antitumor activity against human renal adenocarcinoma ACHN cells.,80025,9606.0,,,CHEMBL621833,16748,,626.0,,,N,Expert,BAO_0000219
7166,Homo sapiens,1,F,ACHN,1,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,80025,9606.0,,,CHEMBL621834,12062,,626.0,,,N,Intermediate,BAO_0000219
7167,Homo sapiens,1,F,ACHN,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,9606.0,,,CHEMBL621835,14769,,626.0,,,N,Intermediate,BAO_0000219
7168,Homo sapiens,1,F,ACHN,1,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",80025,9606.0,,,CHEMBL621836,15895,,626.0,,,N,Intermediate,BAO_0000219
7169,Homo sapiens,1,F,ACHN,1,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,80025,9606.0,,,CHEMBL621837,17376,,626.0,,,N,Intermediate,BAO_0000219
7170,Homo sapiens,1,F,ACHN,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80025,9606.0,,,CHEMBL875280,14882,,626.0,,,N,Intermediate,BAO_0000219
7171,Homo sapiens,1,F,ACHN,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,80025,9606.0,,,CHEMBL621838,14882,,626.0,,,N,Intermediate,BAO_0000219
7172,Homo sapiens,1,F,ACHN,1,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,80025,9606.0,,,CHEMBL621839,15661,,626.0,,,N,Intermediate,BAO_0000219
7173,,0,A,,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,,CHEMBL621840,9680,,,,,U,Autocuration,BAO_0000019
7174,,8,F,,1,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,10647,,,,CHEMBL621841,14579,,,,,H,Autocuration,BAO_0000019
7175,Cytomegalovirus,1,F,HEL,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,50529,10358.0,,,CHEMBL622979,17290,,468.0,,,N,Expert,BAO_0000218
7176,Cytomegalovirus,1,F,,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,50529,10358.0,,,CHEMBL876595,17290,,,,,N,Intermediate,BAO_0000218
7177,,8,B,,1,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),12159,,,,CHEMBL620221,15891,,,,,H,Autocuration,BAO_0000357
7178,,8,B,,1,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),12159,,,,CHEMBL620222,15890,,,,,H,Autocuration,BAO_0000357
7179,Bos taurus,1,F,ADDP cell line,1,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,80670,9913.0,,,CHEMBL620506,3801,,979.0,,,N,Intermediate,BAO_0000219
7180,Mus musculus,1,F,ADJ/PC6,1,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,10090.0,,,CHEMBL620507,9222,,980.0,,,N,Intermediate,BAO_0000219
7181,Mus musculus,1,F,ADJ/PC6,1,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,10090.0,,,CHEMBL620508,9222,,980.0,,,N,Intermediate,BAO_0000219
7182,Mus musculus,1,F,ADJ/PC6,1,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",80671,10090.0,,,CHEMBL620509,7257,,980.0,,,N,Intermediate,BAO_0000219
7183,Mus musculus,1,F,ADJ/PC6,1,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,80671,10090.0,,,CHEMBL620510,7257,,980.0,,,N,Intermediate,BAO_0000219
7184,Mus musculus,1,A,ADJ/PC6,1,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,80671,10090.0,,,CHEMBL620511,7257,,980.0,,,N,Intermediate,BAO_0000219
7185,Mus musculus,1,F,ADJ/PC6,1,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,80671,10090.0,,,CHEMBL620512,8084,,980.0,,,N,Intermediate,BAO_0000219
7186,Mus musculus,0,F,,1,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,22224,10090.0,,,CHEMBL620513,14943,,,,,U,Autocuration,BAO_0000019
7187,Mus musculus,0,F,,1,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,22224,10090.0,,,CHEMBL620514,14943,,,,,U,Autocuration,BAO_0000019
7188,Mus musculus,0,F,,1,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,22224,10090.0,,,CHEMBL620515,14943,,,,,U,Autocuration,BAO_0000019
7189,Bacillus subtilis,0,A,,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),22224,1423.0,,,CHEMBL620516,10524,,,,,U,Autocuration,BAO_0000218
7190,Canis lupus familiaris,1,A,,1,AUC value in dog after IV administration at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL620517,3546,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7191,Canis lupus familiaris,1,A,,1,AUC value in dog after oral administration at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL620518,3546,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7192,Canis lupus familiaris,1,A,,1,Cmax value in dog after oral administration at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL620519,3546,,,,,N,Intermediate,BAO_0000218
7193,Canis lupus familiaris,1,A,,1,Bioavailability in dog after oral administration at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL621386,3546,,,,,N,Intermediate,BAO_0000218
7194,Canis lupus familiaris,1,A,,1,Tmax value in dog after oral administration at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL621387,3546,,,,,N,Intermediate,BAO_0000218
7195,Canis lupus familiaris,1,A,,1,Compound was evaluated for its clearance when administered intravenously in dog,50588,9615.0,,,CHEMBL621388,3184,,,,,N,Intermediate,BAO_0000218
7196,Canis lupus familiaris,1,A,,1,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL621389,16456,,,,,N,Intermediate,BAO_0000218
7197,Canis lupus familiaris,1,A,,1,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,9615.0,,,CHEMBL621390,4809,,,,,N,Intermediate,BAO_0000218
7198,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL621391,4219,,,,,U,Intermediate,BAO_0000100
7199,Canis lupus familiaris,1,A,,1,Half life in dog,50588,9615.0,,,CHEMBL621392,3748,,,,,N,Intermediate,BAO_0000218
7200,Canis lupus familiaris,1,A,,1,Time taken for EC90 was determined when tested in dog,50588,9615.0,,,CHEMBL621393,3132,,,,,N,Intermediate,BAO_0000218
7201,Canis lupus familiaris,1,A,,1,Half life (iv) was determined,50588,9615.0,,,CHEMBL621394,4219,,,,,N,Intermediate,BAO_0000218
7202,Canis lupus familiaris,1,A,,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,50588,9615.0,,,CHEMBL621395,16907,2107.0,,,Liver,N,Intermediate,BAO_0000218
7203,Canis lupus familiaris,1,A,,1,Area under the curve was calculated in dog after iv administration,50588,9615.0,,,CHEMBL621396,6057,,,,,N,Intermediate,BAO_0000218
7204,Canis lupus familiaris,1,A,,1,Area under the curve was calculated in dog after peroral administration,50588,9615.0,,,CHEMBL621397,6057,,,,,N,Intermediate,BAO_0000218
7205,Canis lupus familiaris,1,A,,1,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,50588,9615.0,,,CHEMBL621398,17853,,,,,N,Intermediate,BAO_0000218
7206,Canis lupus familiaris,1,A,,1,pKa was evaluated in dog,50588,9615.0,,,CHEMBL618818,3639,,,,,N,Intermediate,BAO_0000218
7207,Canis lupus familiaris,1,A,,1,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,50588,9615.0,,,CHEMBL618819,14541,,,,,N,Intermediate,BAO_0000218
7208,Canis lupus familiaris,1,A,,1,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL618820,16456,,,,,N,Intermediate,BAO_0000218
7209,Canis lupus familiaris,1,A,,1,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,9615.0,,,CHEMBL873810,16456,,,,,N,Intermediate,BAO_0000218
7210,Canis lupus familiaris,1,A,,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,9615.0,,,CHEMBL876606,2652,,,,,N,Intermediate,BAO_0000218
7211,Canis lupus familiaris,1,A,,1,Compound was evaluated for the half-life (t 1/2) in hours,50588,9615.0,,,CHEMBL618821,3624,,,,,N,Intermediate,BAO_0000218
7212,Canis lupus familiaris,1,A,,1,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL618822,1337,178.0,,,Blood,N,Intermediate,BAO_0000218
7213,Canis lupus familiaris,1,A,,1,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,9615.0,,,CHEMBL618823,1337,178.0,,,Blood,N,Intermediate,BAO_0000218
7214,Canis lupus familiaris,1,A,,1,Half life after intravenous administration of 1 mg/kg in dog,50588,9615.0,,,CHEMBL618824,4709,,,,,N,Intermediate,BAO_0000218
7215,Canis lupus familiaris,1,A,,1,Half life was measured in dog,50588,9615.0,,,CHEMBL618825,15660,,,,,N,Intermediate,BAO_0000218
7216,Canis lupus familiaris,1,A,,1,Half life period in dog after 5 mg/kg dose,50588,9615.0,,,CHEMBL618826,5302,,,,,N,Intermediate,BAO_0000218
7217,Canis lupus familiaris,1,A,,1,Half life period was evaluated in dog; 4-4.8,50588,9615.0,,,CHEMBL618827,17791,,,,,N,Intermediate,BAO_0000218
7218,Canis lupus familiaris,1,A,,1,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,9615.0,,,CHEMBL618828,6348,,,,,N,Intermediate,BAO_0000218
7219,Canis lupus familiaris,1,A,,1,Half-life was determined in dog after a3 mg/kg of iv dose,50588,9615.0,,,CHEMBL618829,4257,,,,,N,Intermediate,BAO_0000218
7220,Canis lupus familiaris,1,A,,1,Half-life was determined,50588,9615.0,,,CHEMBL618830,3771,,,,,N,Intermediate,BAO_0000218
7221,Canis lupus familiaris,1,A,,1,Half life in dogs,50588,9615.0,,,CHEMBL618831,6305,,,,,N,Intermediate,BAO_0000218
7222,Canis lupus familiaris,1,A,,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,50588,9615.0,,,CHEMBL619489,13501,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7223,Canis lupus familiaris,1,A,,1,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,50588,9615.0,,,CHEMBL619649,17594,,,,,N,Intermediate,BAO_0000218
7224,Canis lupus familiaris,1,A,,1,Compound was evaluated for the half life period after iv administration in Beagle dog.,50588,9615.0,,,CHEMBL876607,3045,,,,,N,Intermediate,BAO_0000218
7225,Canis lupus familiaris,1,A,,1,Compound was evaluated for the half life period after oral administration in conscious dog.,50588,9615.0,,,CHEMBL619650,3043,,,,,N,Intermediate,BAO_0000218
7226,Canis lupus familiaris,1,A,,1,Compound was tested for half life in dog,50588,9615.0,,,CHEMBL619651,4839,,,,,N,Intermediate,BAO_0000218
7227,Canis lupus familiaris,1,A,,1,Compound was tested for its half life in dog,50588,9615.0,,,CHEMBL619652,4839,,,,,N,Intermediate,BAO_0000218
7228,Canis lupus familiaris,1,A,,1,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,9615.0,,,CHEMBL619653,5802,,,,,N,Intermediate,BAO_0000218
7229,Canis lupus familiaris,1,A,,1,Half life of compound in dog was determined,50588,9615.0,,,CHEMBL619654,17839,,,,,N,Intermediate,BAO_0000218
7230,Canis lupus familiaris,1,A,,1,Half life (iv) was determined,50588,9615.0,,,CHEMBL619655,4219,,,,,N,Intermediate,BAO_0000218
7231,Canis lupus familiaris,1,A,,1,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),50588,9615.0,,,CHEMBL619656,13966,178.0,,,Blood,N,Intermediate,BAO_0000218
7232,Canis lupus familiaris,1,A,,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,9615.0,,,CHEMBL873812,3994,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7233,Canis lupus familiaris,1,F,,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,9615.0,,,CHEMBL621365,3994,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7234,Canis lupus familiaris,1,A,,1,Half life in dog,50588,9615.0,,,CHEMBL621366,4453,,,,,N,Intermediate,BAO_0000218
7235,Canis lupus familiaris,1,A,,1,Half life in dog plasma,50588,9615.0,,,CHEMBL621367,6535,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7236,Canis lupus familiaris,1,A,,1,Half life in dog plasma after administration of 0.25 mg/kg iv,50588,9615.0,,,CHEMBL621368,6535,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7237,Canis lupus familiaris,1,A,,1,Half life in dog plasma after administration of 1 mg/kg iv,50588,9615.0,,,CHEMBL621369,6535,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7238,Canis lupus familiaris,1,A,,1,Half life in dog plasma was determined at dose 10 mg/kg,50588,9615.0,,,CHEMBL621370,3132,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7239,Canis lupus familiaris,1,A,,1,Half life in dog was determined,50588,9615.0,,,CHEMBL621371,5374,,,,,N,Intermediate,BAO_0000218
7240,Canis lupus familiaris,1,A,,1,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,9615.0,,,CHEMBL621372,5007,,,,,N,Intermediate,BAO_0000218
7241,Canis lupus familiaris,1,A,,1,Half life upon exposure to human plasma,50588,9615.0,,,CHEMBL621373,16907,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7242,Canis lupus familiaris,1,A,,1,Half life was calculated in dog,50588,9615.0,,,CHEMBL621374,6057,,,,,N,Intermediate,BAO_0000218
7243,Canis lupus familiaris,1,A,,1,Half life was determined,50588,9615.0,,,CHEMBL621375,5006,,,,,N,Intermediate,BAO_0000218
7244,Canis lupus familiaris,1,A,,1,Half life was determined,50588,9615.0,,,CHEMBL621376,5473,,,,,N,Intermediate,BAO_0000218
7245,Canis lupus familiaris,1,A,,1,Half life by intravenous administration of 1.2 mg/kg in dog,50588,9615.0,,,CHEMBL619624,4368,,,,,N,Intermediate,BAO_0000218
7246,Canis lupus familiaris,1,A,,1,Half life in dog,50588,9615.0,,,CHEMBL875840,6448,,,,,N,Intermediate,BAO_0000218
7247,Canis lupus familiaris,1,A,,1,Half life in dog after intra venous administration of the compound,50588,9615.0,,,CHEMBL619625,4353,,,,,N,Intermediate,BAO_0000218
7248,Canis lupus familiaris,1,A,,1,Half life in dog after intra venous administration of the compound; ND means Not determined,50588,9615.0,,,CHEMBL619626,4353,,,,,N,Intermediate,BAO_0000218
7249,Canis lupus familiaris,1,A,,1,Half life in dog after po administration of the compound,50588,9615.0,,,CHEMBL619627,4353,,,,,N,Intermediate,BAO_0000218
7250,Canis lupus familiaris,1,A,,1,Half life in dog after po administration of the compound; ND means Not determined,50588,9615.0,,,CHEMBL873817,4353,,,,,N,Intermediate,BAO_0000218
7251,Canis lupus familiaris,1,A,,1,Half life in dog at the single oral dose of 1 mg/kg,50588,9615.0,,,CHEMBL619628,6265,,,,,N,Intermediate,BAO_0000218
7252,Canis lupus familiaris,1,A,,1,Half life in dogs,50588,9615.0,,,CHEMBL619629,5006,,,,,N,Intermediate,BAO_0000218
7253,Canis lupus familiaris,1,A,,1,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,50588,9615.0,,,CHEMBL619630,5356,,,,,N,Intermediate,BAO_0000218
7254,Canis lupus familiaris,1,A,,1,Half life in rat,50588,9615.0,,,CHEMBL619631,405,,,,,N,Intermediate,BAO_0000218
7255,Canis lupus familiaris,1,A,,1,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,9615.0,,,CHEMBL619632,6642,,,,,N,Intermediate,BAO_0000218
7256,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL619633,10107,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7257,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL875841,10107,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7258,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL619634,10107,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7259,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL619635,10107,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7260,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL619636,10107,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7261,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL619637,10107,10000004.0,,,Gut,N,Intermediate,BAO_0000218
7262,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL619638,10107,10000004.0,,,Gut,N,Intermediate,BAO_0000218
7263,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL619639,10107,10000004.0,,,Gut,N,Intermediate,BAO_0000218
7264,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL619640,10107,10000004.0,,,Gut,N,Intermediate,BAO_0000218
7265,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL619641,10107,10000004.0,,,Gut,N,Intermediate,BAO_0000218
7266,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL619642,10107,10000004.0,,,Gut,N,Intermediate,BAO_0000218
7267,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL619643,10107,10000004.0,,,Gut,N,Intermediate,BAO_0000218
7268,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL619644,10107,948.0,,,Heart,N,Intermediate,BAO_0000218
7269,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL621112,10107,948.0,,,Heart,N,Intermediate,BAO_0000218
7270,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL621113,10107,948.0,,,Heart,N,Intermediate,BAO_0000218
7271,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL621114,10107,948.0,,,Heart,N,Intermediate,BAO_0000218
7272,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL621115,10107,948.0,,,Heart,N,Intermediate,BAO_0000218
7273,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL621116,10107,948.0,,,Heart,N,Intermediate,BAO_0000218
7274,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL621117,10107,948.0,,,Heart,N,Intermediate,BAO_0000218
7275,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL621118,10107,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7276,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,10090.0,,,CHEMBL621119,10107,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7277,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL621120,10107,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7278,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL621757,10107,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7279,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL621758,10107,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7280,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL621759,10107,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7281,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL621760,10107,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7282,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL621761,10107,2107.0,,,Liver,N,Intermediate,BAO_0000218
7283,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL621762,10107,2107.0,,,Liver,N,Intermediate,BAO_0000218
7284,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL621763,10107,2107.0,,,Liver,N,Intermediate,BAO_0000218
7285,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL624502,10107,2107.0,,,Liver,N,Intermediate,BAO_0000218
7286,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL624503,10107,2107.0,,,Liver,N,Intermediate,BAO_0000218
7287,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL624504,10107,2107.0,,,Liver,N,Intermediate,BAO_0000218
7288,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL624505,10107,2107.0,,,Liver,N,Intermediate,BAO_0000218
7289,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL624506,10107,2048.0,,,Lung,N,Intermediate,BAO_0000218
7290,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against A2780 (human ovarian cancer),81034,9606.0,,,CHEMBL624507,5895,,478.0,,,N,Intermediate,BAO_0000219
7291,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,81034,9606.0,,,CHEMBL624508,6338,,478.0,,,N,Intermediate,BAO_0000219
7292,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,81034,9606.0,,,CHEMBL624509,15163,,478.0,,,N,Intermediate,BAO_0000219
7293,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,81034,9606.0,,,CHEMBL624510,15163,,478.0,,,N,Intermediate,BAO_0000219
7294,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,81034,9606.0,,,CHEMBL875956,15000,,478.0,,,N,Expert,BAO_0000219
7295,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,81034,9606.0,,,CHEMBL839885,15000,,478.0,,,N,Expert,BAO_0000219
7296,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,81034,9606.0,,,CHEMBL624511,14729,,478.0,,,N,Expert,BAO_0000219
7297,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity against A2780 cell line,81034,9606.0,,,CHEMBL624512,17270,,478.0,,,N,Intermediate,BAO_0000219
7298,Homo sapiens,1,F,A2780,1,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,81034,9606.0,,,CHEMBL624513,5685,,478.0,,,N,Intermediate,BAO_0000219
7299,Homo sapiens,1,F,A2780,1,In vitro inhibitory activity against human ovarian cancer A2780 cell line,81034,9606.0,,,CHEMBL624514,3563,,478.0,,,N,Intermediate,BAO_0000219
7300,Homo sapiens,1,F,A2780,1,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,81034,9606.0,,,CHEMBL618547,17753,,478.0,,,N,Intermediate,BAO_0000218
7301,Homo sapiens,1,F,A2780,1,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",81034,9606.0,,,CHEMBL618548,16317,,478.0,,,N,Intermediate,BAO_0000219
7302,Homo sapiens,1,F,A2780,1,Inhibition of tubulin polymerization in analogy of ca.,81034,9606.0,,,CHEMBL618549,16936,,478.0,,,N,Intermediate,BAO_0000219
7303,Homo sapiens,1,F,A2780,1,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,81034,9606.0,,,CHEMBL618550,3801,,478.0,,,N,Intermediate,BAO_0000219
7304,Homo sapiens,1,F,A2780,1,Cytotoxic effect in ovarian cancer cell line (A2780),81034,9606.0,,,CHEMBL618551,6181,,478.0,,,N,Expert,BAO_0000219
7305,Homo sapiens,1,F,A2780,1,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,81034,9606.0,,,CHEMBL618552,5318,,478.0,,,N,Intermediate,BAO_0000219
7306,Homo sapiens,1,F,A2780,1,Tested for the cytotoxicity in A2780 ovarian cell line,81034,9606.0,,,CHEMBL618553,4840,,478.0,,,N,Intermediate,BAO_0000219
7307,Homo sapiens,1,F,A2780,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,9606.0,,,CHEMBL618554,15748,,478.0,,,N,Intermediate,BAO_0000219
7308,Homo sapiens,1,F,A2780,1,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,81034,9606.0,,,CHEMBL618555,15748,,478.0,,,N,Intermediate,BAO_0000219
7309,,1,F,A2780cisR,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,80017,,,,CHEMBL618556,15748,,481.0,,,N,Intermediate,BAO_0000219
7310,,1,F,A2780cisR,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,,,,CHEMBL618557,15748,,481.0,,,N,Intermediate,BAO_0000219
7311,,1,F,A2780cisR,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,80017,,,,CHEMBL618558,15748,,481.0,,,N,Intermediate,BAO_0000219
7312,,1,F,A2780cisR,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),80017,,,,CHEMBL618559,15748,,481.0,,,N,Intermediate,BAO_0000219
7313,Homo sapiens,1,F,A2780,1,In vivo log of cells killed after administration of compound in A2780 cell line,81034,9606.0,,,CHEMBL618560,17753,,478.0,,,N,Intermediate,BAO_0000218
7314,Homo sapiens,1,F,A2780,1,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,81034,9606.0,,,CHEMBL618561,17753,,478.0,,,N,Intermediate,BAO_0000218
7315,Homo sapiens,1,F,A2780,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,81034,9606.0,,,CHEMBL618562,16936,,478.0,,,N,Intermediate,BAO_0000219
7316,Homo sapiens,1,F,A2780,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,81034,9606.0,,,CHEMBL618563,16936,,478.0,,,N,Intermediate,BAO_0000219
7317,Homo sapiens,1,F,A2780,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,81034,9606.0,,,CHEMBL618564,16936,,478.0,,,N,Intermediate,BAO_0000219
7318,Homo sapiens,1,F,A2780,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,81034,9606.0,,,CHEMBL618565,16936,,478.0,,,N,Intermediate,BAO_0000219
7319,Homo sapiens,1,F,A2780,1,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),81034,9606.0,,,CHEMBL618566,17528,,478.0,,,N,Intermediate,BAO_0000218
7320,Homo sapiens,1,F,A2780,1,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,81034,9606.0,,,CHEMBL618567,6633,,478.0,,,N,Intermediate,BAO_0000219
7321,Homo sapiens,1,F,A2780,1,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,81034,9606.0,,,CHEMBL618568,15000,,478.0,,,N,Expert,BAO_0000219
7322,Homo sapiens,1,F,A2780,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,81034,9606.0,,,CHEMBL618569,17528,,478.0,,,N,Expert,BAO_0000219
7323,Homo sapiens,1,F,A2780,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,81034,9606.0,,,CHEMBL621857,16936,,478.0,,,N,Intermediate,BAO_0000219
7324,Homo sapiens,1,F,A2780,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,81034,9606.0,,,CHEMBL621858,16936,,478.0,,,N,Intermediate,BAO_0000219
7325,Homo sapiens,1,F,A2780,1,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,81034,9606.0,,,CHEMBL621859,16936,,478.0,,,N,Intermediate,BAO_0000219
7326,Homo sapiens,1,F,A2780,1,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",81034,9606.0,,,CHEMBL621860,16936,,478.0,,,N,Intermediate,BAO_0000219
7327,Homo sapiens,1,F,A2780,1,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),81034,9606.0,,,CHEMBL621861,16936,,478.0,,,N,Intermediate,BAO_0000219
7328,Homo sapiens,1,F,A2780,1,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",81034,9606.0,,,CHEMBL621862,16936,,478.0,,,N,Expert,BAO_0000219
7329,Homo sapiens,1,F,A2780,1,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,9606.0,,,CHEMBL621863,16936,,478.0,,,N,Intermediate,BAO_0000219
7330,Homo sapiens,1,F,A2780,1,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,9606.0,,,CHEMBL621864,16936,,478.0,,,N,Intermediate,BAO_0000219
7331,Homo sapiens,1,F,A2780,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,9606.0,,,CHEMBL621865,16936,,478.0,,,N,Intermediate,BAO_0000219
7332,Mus musculus,1,F,A2780,1,In vitro antiproliferative activity against A2780 cell line,81034,10090.0,,,CHEMBL621866,17737,,478.0,,,N,Intermediate,BAO_0000219
7333,Mus musculus,1,F,A2780,1,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,81034,10090.0,,,CHEMBL621867,17764,,478.0,,,N,Expert,BAO_0000219
7334,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,81034,9606.0,,,CHEMBL621868,3830,,478.0,,,N,Intermediate,BAO_0000219
7335,Homo sapiens,1,F,A2780,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,81034,9606.0,,,CHEMBL875282,3829,,478.0,,,N,Intermediate,BAO_0000219
7336,Canis lupus familiaris,1,A,,1,Vc value in dog after IV administration at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL621869,3546,,,,,N,Intermediate,BAO_0000218
7337,Canis lupus familiaris,1,A,,1,Half life period in dog after IV administration at a dose of 5 mg/kg,50588,9615.0,,,CHEMBL621870,3546,,,,,N,Intermediate,BAO_0000218
7338,Cercopithecidae,0,A,,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,22224,9527.0,,,CHEMBL621871,5668,,,,,U,Autocuration,BAO_0000019
7339,Cercopithecidae,0,A,,1,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL621243,3443,1969.0,,,Plasma,U,Autocuration,BAO_0000218
7340,Cercopithecidae,0,A,,1,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL621244,3443,1969.0,,,Plasma,U,Autocuration,BAO_0000218
7341,Macaca fascicularis,0,A,,1,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,9541.0,,,CHEMBL621245,4256,,,,,U,Autocuration,BAO_0000218
7342,Macaca fascicularis,0,A,,1,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,22224,9541.0,,,CHEMBL621246,4256,,,,,U,Autocuration,BAO_0000218
7343,Macaca fascicularis,0,A,,1,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,22224,9541.0,,,CHEMBL621247,4256,,,,,U,Autocuration,BAO_0000218
7344,Rattus norvegicus,0,A,,1,Oral Bioavailability in rat,22224,10116.0,,,CHEMBL618386,4256,,,,,U,Autocuration,BAO_0000218
7345,Cercopithecidae,0,A,,1,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,9527.0,,,CHEMBL618387,1916,,,,,U,Autocuration,BAO_0000218
7346,Cercopithecidae,0,A,,1,Area under curve value in monkey at a dose of 5 mg/kg,22224,9527.0,,,CHEMBL618388,5302,,,,,U,Autocuration,BAO_0000218
7347,Cercopithecidae,0,A,,1,Area under curve was determined in monkey after a 3 mg/kg of oral dose,22224,9527.0,,,CHEMBL618389,4257,,,,,U,Autocuration,BAO_0000218
7348,Cercopithecidae,0,A,,1,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL618574,5355,,,,,U,Autocuration,BAO_0000019
7349,Cercopithecidae,0,A,,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL618575,5355,,,,,U,Autocuration,BAO_0000019
7350,Cercopithecidae,0,A,,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,22224,9527.0,,,CHEMBL618576,5355,,,,,U,Autocuration,BAO_0000019
7351,Cercopithecidae,0,A,,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,22224,9527.0,,,CHEMBL618577,6078,,,,,U,Autocuration,BAO_0000218
7352,Cercopithecidae,0,A,,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,22224,9527.0,,,CHEMBL876487,6078,,,,,U,Autocuration,BAO_0000218
7353,Cercopithecidae,0,A,,1,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,22224,9527.0,,,CHEMBL618578,6062,,,,,U,Autocuration,BAO_0000218
7354,Cercopithecidae,0,A,,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL618579,2661,,,,,U,Autocuration,BAO_0000218
7355,Cercopithecidae,0,A,,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL618580,2661,,,,,U,Autocuration,BAO_0000019
7356,Cercopithecidae,0,A,,1,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,22224,9527.0,,,CHEMBL618581,5394,,,,,U,Autocuration,BAO_0000218
7357,Cercopithecidae,0,A,,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,22224,9527.0,,,CHEMBL618582,4397,,,,,U,Autocuration,BAO_0000218
7358,Cercopithecidae,0,A,,1,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,22224,9527.0,,,CHEMBL618583,17509,,,,,U,Autocuration,BAO_0000218
7359,Cercopithecidae,0,A,,1,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,22224,9527.0,,,CHEMBL618584,17509,,,,,U,Autocuration,BAO_0000218
7360,Cercopithecidae,0,A,,1,Oral AUCN in monkey (dosed at 0.5 mpk iv ),22224,9527.0,,,CHEMBL618585,6641,,,,,U,Autocuration,BAO_0000218
7361,Cercopithecidae,0,A,,1,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),22224,9527.0,,,CHEMBL618586,5355,,,,,U,Autocuration,BAO_0000218
7362,Cercopithecidae,0,A,,1,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL618587,3443,,,,,U,Autocuration,BAO_0000218
7363,Cercopithecidae,0,A,,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,9527.0,,,CHEMBL618588,3443,,,,,U,Autocuration,BAO_0000218
7364,Cercopithecidae,0,A,,1,Binding towards monkey plasma protein at 10 uM,22224,9527.0,,,CHEMBL618589,17409,,,,,U,Autocuration,BAO_0000019
7365,Cercopithecidae,0,A,,1,Binding towards monkey plasma protein at 100 uM,22224,9527.0,,,CHEMBL618590,17409,,,,,U,Autocuration,BAO_0000019
7366,Cercopithecidae,0,A,,1,Apparent bioavailability in squirrel monkey was determined,22224,9527.0,,,CHEMBL872262,1052,,,,,U,Autocuration,BAO_0000218
7367,Cercopithecidae,0,A,,1,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,9527.0,,,CHEMBL618591,13501,,,,,U,Autocuration,BAO_0000218
7368,monkey,0,A,,1,Bioavailability in monkey (dose 2 mg/kg),22224,9443.0,,,CHEMBL618592,17509,,,,,U,Autocuration,BAO_0000218
7369,Cercopithecidae,0,A,,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,22224,9527.0,,,CHEMBL876488,5394,,,,,U,Autocuration,BAO_0000218
7370,Cercopithecidae,0,A,,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL618593,2661,,,,,U,Autocuration,BAO_0000218
7371,monkey,0,A,,1,Bioavailability in monkey (i.d. dosing),22224,9443.0,,,CHEMBL618594,11219,,,,,U,Autocuration,BAO_0000218
7372,Cercopithecidae,0,A,,1,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,22224,9527.0,,,CHEMBL618595,3045,,,,,U,Autocuration,BAO_0000218
7373,Cercopithecidae,0,A,,1,Clearance of the drug was measured in cynomolgus,22224,9527.0,,,CHEMBL621469,17796,,,,,U,Autocuration,BAO_0000019
7374,Cercopithecidae,0,A,,1,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,22224,9527.0,,,CHEMBL621470,1399,,,,,U,Autocuration,BAO_0000218
7375,Cercopithecidae,0,A,,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,9527.0,,,CHEMBL621471,2661,,,,,U,Autocuration,BAO_0000218
7376,Macaca mulatta,0,A,,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,9544.0,,,CHEMBL621472,5005,1969.0,,,Plasma,U,Autocuration,BAO_0000218
7377,Cercopithecidae,0,A,,1,Plasma clearance in rhesus monkey was determined,22224,9527.0,,,CHEMBL621473,17267,,,,,U,Autocuration,BAO_0000218
7378,Cercopithecidae,0,A,,1,Plasma clearance in monkey after administration of 1 mg/kg iv,22224,9527.0,,,CHEMBL621474,6535,,,,,U,Autocuration,BAO_0000218
7379,Cercopithecidae,0,A,,1,Plasma clearance in cynomolgus monkey,22224,9527.0,,,CHEMBL621475,5922,,,,,U,Autocuration,BAO_0000218
7380,Cercopithecidae,0,A,,1,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,22224,9527.0,,,CHEMBL621476,6221,,,,,U,Autocuration,BAO_0000218
7381,Cercopithecidae,0,A,,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,22224,9527.0,,,CHEMBL624290,5668,,,,,U,Autocuration,BAO_0000218
7382,Cercopithecidae,0,A,,1,The total clearance was determined after intravenous administration in cynomolgus monkeys,22224,9527.0,,,CHEMBL624291,5355,,,,,U,Autocuration,BAO_0000218
7383,Cercopithecidae,0,A,,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,9527.0,,,CHEMBL624292,5355,,,,,U,Autocuration,BAO_0000218
7384,Cercopithecidae,0,A,,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,9527.0,,,CHEMBL624293,5355,,,,,U,Autocuration,BAO_0000218
7385,Cercopithecidae,0,A,,1,Tested for Clearance upon iv administration to african green monkey,22224,9527.0,,,CHEMBL624294,4578,,,,,U,Autocuration,BAO_0000218
7386,Cercopithecidae,0,A,,1,Clearance in monkey,22224,9527.0,,,CHEMBL624295,17592,,,,,U,Autocuration,BAO_0000218
7387,Canis lupus familiaris,1,A,,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,9615.0,,,CHEMBL624296,6641,,,,,N,Intermediate,BAO_0000218
7388,Canis lupus familiaris,1,A,,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,9615.0,,,CHEMBL624297,6642,,,,,N,Intermediate,BAO_0000218
7389,Canis lupus familiaris,1,A,,1,Half life was evaluated after intravenous administration to dogs,50588,9615.0,,,CHEMBL624298,16367,,,,,N,Intermediate,BAO_0000218
7390,Canis lupus familiaris,1,A,,1,Half life was evaluated in dog,50588,9615.0,,,CHEMBL624299,5472,,,,,N,Intermediate,BAO_0000218
7391,Canis lupus familiaris,1,A,,1,Half life was evaluated in dog,50588,9615.0,,,CHEMBL624300,5474,,,,,N,Intermediate,BAO_0000218
7392,Canis lupus familiaris,1,A,,1,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL624301,5654,,,,,N,Intermediate,BAO_0000218
7393,Canis lupus familiaris,1,A,,1,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),50588,9615.0,,,CHEMBL624302,6227,,,,,N,Intermediate,BAO_0000218
7394,Canis lupus familiaris,1,A,,1,Half life period after intravenous administration in dog,50588,9615.0,,,CHEMBL876026,6227,,,,,N,Intermediate,BAO_0000218
7395,Canis lupus familiaris,1,A,,1,Half life period after oral administration (2.5 mg/kg) in dog was determined,50588,9615.0,,,CHEMBL624303,6221,,,,,N,Intermediate,BAO_0000218
7396,Canis lupus familiaris,1,A,,1,Half life period at a dose of 1 uM/kg in dog was determined,50588,9615.0,,,CHEMBL624304,4527,,,,,N,Intermediate,BAO_0000218
7397,Canis lupus familiaris,1,A,,1,Half life period was determine after peroral administration at 10 mpk in dog,50588,9615.0,,,CHEMBL624305,5668,,,,,N,Intermediate,BAO_0000218
7398,Canis lupus familiaris,1,A,,1,Half life period was determine after peroral administration at 5 mpk in dog,50588,9615.0,,,CHEMBL624306,5668,,,,,N,Intermediate,BAO_0000218
7399,Canis lupus familiaris,1,A,,1,Half life period was determined,50588,9615.0,,,CHEMBL624307,3854,,,,,N,Intermediate,BAO_0000218
7400,Canis lupus familiaris,1,A,,1,Half life period was determined,50588,9615.0,,,CHEMBL624308,5505,,,,,N,Intermediate,BAO_0000218
7401,Canis lupus familiaris,1,A,,1,Half life period by iv administration in dog at a dose of 6 mg/kg,50588,9615.0,,,CHEMBL624309,6251,,,,,N,Intermediate,BAO_0000218
7402,Canis lupus familiaris,1,A,,1,Half life period was evaluated in dog,50588,9615.0,,,CHEMBL624310,1918,,,,,N,Intermediate,BAO_0000218
7403,Canis lupus familiaris,1,A,,1,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,9615.0,,,CHEMBL625003,5546,,,,,N,Intermediate,BAO_0000218
7404,Canis lupus familiaris,1,A,,1,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,9615.0,,,CHEMBL625004,4809,,,,,N,Intermediate,BAO_0000218
7405,Canis lupus familiaris,1,A,,1,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,50588,9615.0,,,CHEMBL625005,6215,,,,,N,Intermediate,BAO_0000218
7406,Canis lupus familiaris,1,A,,1,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,50588,9615.0,,,CHEMBL873813,4527,,,,,N,Intermediate,BAO_0000218
7407,Canis lupus familiaris,1,A,,1,Half-life after oral dose of compound at 3 mg/kg in dogs,50588,9615.0,,,CHEMBL625006,17594,,,,,N,Intermediate,BAO_0000218
7408,Canis lupus familiaris,1,A,,1,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,50588,9615.0,,,CHEMBL625007,17839,,,,,N,Intermediate,BAO_0000218
7409,Canis lupus familiaris,1,A,,1,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,50588,9615.0,,,CHEMBL876027,17839,,,,,N,Intermediate,BAO_0000218
7410,Canis lupus familiaris,1,A,,1,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,50588,9615.0,,,CHEMBL625008,17839,,,,,N,Intermediate,BAO_0000218
7411,Canis lupus familiaris,1,A,,1,Half-life of compound in dog following p.o. administration of 1 mg/kg,50588,9615.0,,,CHEMBL625009,17839,,,,,N,Intermediate,BAO_0000218
7412,Canis lupus familiaris,1,A,,1,Half-life of compound in plasma of dog was determined,50588,9615.0,,,CHEMBL625010,5210,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7413,Canis lupus familiaris,1,A,,1,Half-life of compound was determined in dogs,50588,9615.0,,,CHEMBL625011,5210,,,,,N,Intermediate,BAO_0000218
7414,Canis lupus familiaris,1,A,,1,Half-life after administration of 4 mg/Kg oral dose in dog,50588,9615.0,,,CHEMBL621553,2959,,,,,N,Intermediate,BAO_0000218
7415,Canis lupus familiaris,1,A,,1,Half-life after intravenous administration of 1 mg/kg/h in dog,50588,9615.0,,,CHEMBL621554,4137,,,,,N,Intermediate,BAO_0000218
7416,Canis lupus familiaris,1,A,,1,Half-life in Dog,50588,9615.0,,,CHEMBL621555,5064,,,,,N,Intermediate,BAO_0000218
7417,Canis lupus familiaris,1,A,,1,Half-life in Dog,50588,9615.0,,,CHEMBL621556,5147,,,,,N,Intermediate,BAO_0000218
7418,Canis lupus familiaris,1,A,,1,Half-life in dog,50588,9615.0,,,CHEMBL621557,5145,,,,,N,Intermediate,BAO_0000218
7419,Canis lupus familiaris,1,A,,1,Half-life in dog after oral administration at 1 mg/kg,50588,9615.0,,,CHEMBL621558,6123,,,,,N,Intermediate,BAO_0000218
7420,Canis lupus familiaris,1,A,,1,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,50588,9615.0,,,CHEMBL621559,6123,,,,,N,Intermediate,BAO_0000218
7421,Canis lupus familiaris,1,A,,1,Half-life in dogs,50588,9615.0,,,CHEMBL621560,4333,,,,,N,Intermediate,BAO_0000218
7422,Canis lupus familiaris,1,A,,1,Half-life in dogs; ND indicates not determined,50588,9615.0,,,CHEMBL876028,4333,,,,,N,Intermediate,BAO_0000218
7423,Canis lupus familiaris,1,A,,1,Half-life in plasma of dog,50588,9615.0,,,CHEMBL621561,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7424,Canis lupus familiaris,1,A,,1,Half-life in plasma of dog at dose of 3-10 mgkg,50588,9615.0,,,CHEMBL621562,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7425,Canis lupus familiaris,1,A,,1,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL621563,6005,,,,,N,Intermediate,BAO_0000218
7426,Canis lupus familiaris,1,A,,1,Half-life was measured in dog after an iv dose of 1 mg/kg,50588,9615.0,,,CHEMBL621564,6062,,,,,N,Intermediate,BAO_0000218
7427,Canis lupus familiaris,1,A,,1,Half-life was measured in dogs after an oral dose of 10 uM/kg,50588,9615.0,,,CHEMBL621565,17650,,,,,N,Intermediate,BAO_0000218
7428,Canis lupus familiaris,1,A,,1,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,9615.0,,,CHEMBL621566,5530,,,,,N,Intermediate,BAO_0000218
7429,Canis lupus familiaris,1,A,,1,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,9615.0,,,CHEMBL621567,5530,,,,,N,Intermediate,BAO_0000218
7430,Canis lupus familiaris,1,A,,1,Half-life of the compound after 0.3 mg/kg po administration in dog,50588,9615.0,,,CHEMBL622978,5600,,,,,N,Intermediate,BAO_0000218
7431,Canis lupus familiaris,1,A,,1,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,50588,9615.0,,,CHEMBL873814,6039,,,,,N,Intermediate,BAO_0000218
7432,Canis lupus familiaris,1,A,,1,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,50588,9615.0,,,CHEMBL623219,6039,,,,,N,Intermediate,BAO_0000218
7433,Canis lupus familiaris,1,A,,1,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,50588,9615.0,,,CHEMBL624477,6039,,,,,N,Intermediate,BAO_0000218
7434,Canis lupus familiaris,1,A,,1,t1/2 in dog,50588,9615.0,,,CHEMBL624478,6227,,,,,N,Intermediate,BAO_0000218
7435,Canis lupus familiaris,1,A,,1,Half-life period measured in dogs,50588,9615.0,,,CHEMBL624479,14541,,,,,N,Intermediate,BAO_0000218
7436,Canis lupus familiaris,1,A,,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,9615.0,,,CHEMBL624480,4521,,,,,N,Intermediate,BAO_0000218
7437,Canis lupus familiaris,1,A,,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,9615.0,,,CHEMBL623595,4521,,,,,N,Intermediate,BAO_0000218
7438,Canis lupus familiaris,1,A,,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,9615.0,,,CHEMBL623596,6679,,,,,N,Intermediate,BAO_0000218
7439,Canis lupus familiaris,1,A,,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",50588,9615.0,,,CHEMBL623597,1116,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7440,Canis lupus familiaris,1,A,,1,In vivo half life period was calculated at 1 mg/kg in dog,50588,9615.0,,,CHEMBL623598,5444,,,,,N,Intermediate,BAO_0000218
7441,Canis lupus familiaris,1,A,,1,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,50588,9615.0,,,CHEMBL623599,5444,,,,,N,Intermediate,BAO_0000218
7442,Canis lupus familiaris,1,A,,1,Longer half-life in dog (i.v.) at 0.5 mpk,50588,9615.0,,,CHEMBL623600,17853,,,,,N,Intermediate,BAO_0000218
7443,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog (dose 5 uM/kg),50588,9615.0,,,CHEMBL623601,4353,,,,,N,Intermediate,BAO_0000218
7444,Canis lupus familiaris,1,A,,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,9615.0,,,CHEMBL623602,16452,,,,,N,Intermediate,BAO_0000218
7445,Canis lupus familiaris,1,A,,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,9615.0,,,CHEMBL623603,16452,,,,,N,Intermediate,BAO_0000218
7446,Canis lupus familiaris,1,A,,1,Bioavailability in dog (dose 1 mg/kg i.v.),50588,9615.0,,,CHEMBL623604,16452,,,,,N,Intermediate,BAO_0000218
7447,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,10090.0,,,CHEMBL623605,10107,2048.0,,,Lung,N,Intermediate,BAO_0000218
7448,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL623606,10107,2048.0,,,Lung,N,Intermediate,BAO_0000218
7449,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL623607,10107,2048.0,,,Lung,N,Intermediate,BAO_0000218
7450,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL623608,10107,2048.0,,,Lung,N,Intermediate,BAO_0000218
7451,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL623609,10107,2048.0,,,Lung,N,Intermediate,BAO_0000218
7452,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL623610,10107,2048.0,,,Lung,N,Intermediate,BAO_0000218
7453,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL623611,10107,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7454,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,10090.0,,,CHEMBL623612,10107,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7455,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL623613,10107,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7456,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL623614,10107,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7457,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL623615,10107,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7458,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL623616,10107,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7459,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL623617,10107,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7460,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL875944,10107,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
7461,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL623618,10107,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
7462,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL623619,10107,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
7463,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL623620,10107,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
7464,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL623621,10107,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
7465,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL623622,10107,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
7466,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL623623,10107,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
7467,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL623624,10107,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7468,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL618521,10107,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7469,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL618522,10107,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7470,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL618523,10107,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7471,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL618524,10107,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7472,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL618525,10107,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7473,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL624586,10107,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7474,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,10090.0,,,CHEMBL624587,10107,945.0,,,Stomach,N,Intermediate,BAO_0000218
7475,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,10090.0,,,CHEMBL624588,10107,945.0,,,Stomach,N,Intermediate,BAO_0000218
7476,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,10090.0,,,CHEMBL624589,10107,945.0,,,Stomach,N,Intermediate,BAO_0000218
7477,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,10090.0,,,CHEMBL624590,10107,945.0,,,Stomach,N,Intermediate,BAO_0000218
7478,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,10090.0,,,CHEMBL624591,10107,945.0,,,Stomach,N,Intermediate,BAO_0000218
7479,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,10090.0,,,CHEMBL624592,10107,945.0,,,Stomach,N,Intermediate,BAO_0000218
7480,Mus musculus,1,A,,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,10090.0,,,CHEMBL624593,10107,945.0,,,Stomach,N,Intermediate,BAO_0000218
7481,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL624594,4689,,,,,N,Intermediate,BAO_0000218
7482,Rattus norvegicus,1,A,,1,Tested for the bioavailability in rat,50597,10116.0,,,CHEMBL624595,4950,,,,,N,Intermediate,BAO_0000218
7483,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,10116.0,,,CHEMBL624596,5328,,,,,N,Intermediate,BAO_0000218
7484,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL624597,406,,,,,N,Intermediate,BAO_0000218
7485,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL624598,12500,,,,,N,Intermediate,BAO_0000218
7486,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 3-10 mg/kg),50597,10116.0,,,CHEMBL624599,12500,,,,,N,Intermediate,BAO_0000218
7487,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL875166,5247,,,,,N,Intermediate,BAO_0000218
7488,Rattus norvegicus,1,A,,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,10116.0,,,CHEMBL624600,4186,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7489,Rattus norvegicus,1,A,,1,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,10116.0,,,CHEMBL624601,4186,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7490,Rattus norvegicus,1,A,,1,Half life after oral administration was determined in rats at 6 mg/kg,50597,10116.0,,,CHEMBL624602,6647,,,,,N,Intermediate,BAO_0000218
7491,Rattus norvegicus,1,A,,1,Half life was determined,50597,10116.0,,,CHEMBL624603,6484,,,,,N,Intermediate,BAO_0000218
7492,Rattus norvegicus,1,A,,1,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL624604,3249,,,,,N,Intermediate,BAO_0000218
7493,Rattus norvegicus,1,A,,1,Plasma half life in rat at oral dose 2.8 mg/mk body weight,50597,10116.0,,,CHEMBL624605,6281,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7494,Rattus norvegicus,1,A,,1,Half life in rats,50597,10116.0,,,CHEMBL624606,3307,,,,,N,Intermediate,BAO_0000218
7495,Rattus norvegicus,1,A,,1,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,50597,10116.0,,,CHEMBL624607,12058,178.0,,,Blood,N,Intermediate,BAO_0000218
7496,Rattus norvegicus,1,A,,1,Hill coefficient of the compound,50597,10116.0,,,CHEMBL624608,8833,,,,,N,Intermediate,BAO_0000218
7497,Rattus norvegicus,1,A,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,50597,10116.0,,,CHEMBL624609,3193,178.0,,,Blood,N,Intermediate,BAO_0000218
7498,Rattus norvegicus,1,A,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,50597,10116.0,,,CHEMBL624610,3193,178.0,,,Blood,N,Intermediate,BAO_0000218
7499,Rattus norvegicus,1,A,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,50597,10116.0,,,CHEMBL624611,3193,178.0,,,Blood,N,Intermediate,BAO_0000218
7500,Rattus norvegicus,1,A,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,50597,10116.0,,,CHEMBL624612,3193,178.0,,,Blood,N,Intermediate,BAO_0000218
7501,Rattus norvegicus,1,A,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,50597,10116.0,,,CHEMBL875167,3193,178.0,,,Blood,N,Intermediate,BAO_0000218
7502,Rattus norvegicus,1,A,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,50597,10116.0,,,CHEMBL624613,3193,178.0,,,Blood,N,Intermediate,BAO_0000218
7503,Rattus norvegicus,1,A,,1,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",50597,10116.0,,,CHEMBL624614,3193,178.0,,,Blood,N,Intermediate,BAO_0000218
7504,Rattus norvegicus,1,A,,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,10116.0,,,CHEMBL624392,5960,,,,,N,Intermediate,BAO_0000218
7505,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624393,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
7506,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624394,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
7507,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624395,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
7508,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624396,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
7509,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624397,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
7510,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624398,13950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7511,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624399,13950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7512,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624400,13950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7513,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624401,13950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7514,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,50597,10116.0,,,CHEMBL624402,13950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7515,Rattus norvegicus,1,A,,1,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL624403,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7516,Rattus norvegicus,1,A,,1,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL624404,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7517,Rattus norvegicus,1,A,,1,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL624405,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7518,Rattus norvegicus,1,A,,1,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL624406,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7519,Rattus norvegicus,1,A,,1,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL624407,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7520,Rattus norvegicus,1,A,,1,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL624408,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7521,Rattus norvegicus,1,A,,1,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL618644,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7522,Rattus norvegicus,1,A,,1,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL618645,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7523,Rattus norvegicus,1,A,,1,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL618646,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7524,Rattus norvegicus,1,A,,1,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL618647,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7525,Rattus norvegicus,1,A,,1,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL618648,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7526,Rattus norvegicus,1,A,,1,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL618649,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7527,Rattus norvegicus,1,A,,1,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL618650,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7528,Rattus norvegicus,1,A,,1,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL618651,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7529,Rattus norvegicus,1,A,,1,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL876497,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7530,Rattus norvegicus,1,A,,1,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL618652,9866,2048.0,,,Lung,N,Intermediate,BAO_0000218
7531,Rattus norvegicus,1,A,,1,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL618653,9866,2048.0,,,Lung,N,Intermediate,BAO_0000218
7532,Rattus norvegicus,1,A,,1,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL618654,9866,2048.0,,,Lung,N,Intermediate,BAO_0000218
7533,Rattus norvegicus,1,A,,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,50597,10116.0,,,CHEMBL618655,6351,,,,,N,Intermediate,BAO_0000218
7534,Rattus norvegicus,1,A,,1,Compound was tested for solubility in water,50597,10116.0,,,CHEMBL618656,1465,,,,,N,Intermediate,BAO_0000218
7535,,0,P,,1,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),22229,,,,CHEMBL618657,5182,,,,,U,Intermediate,BAO_0000100
7536,Rattus norvegicus,1,A,,1,Solubility was determined,50597,10116.0,,,CHEMBL618658,17847,,,,,N,Intermediate,BAO_0000218
7537,Rattus norvegicus,1,A,,1,solubility in water (ug/mL) at 37 degree C.,50597,10116.0,,,CHEMBL618659,15339,,,,,N,Intermediate,BAO_0000218
7538,Rattus norvegicus,1,A,,1,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,50597,10116.0,,,CHEMBL618660,5202,,,,,N,Intermediate,BAO_0000218
7539,Rattus norvegicus,1,A,,1,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,50597,10116.0,,,CHEMBL618661,1088,,,,,N,Intermediate,BAO_0000218
7540,Rattus norvegicus,1,A,,1,Half life in rats,50597,10116.0,,,CHEMBL873807,3169,,,,,N,Intermediate,BAO_0000218
7541,Rattus norvegicus,1,A,,1,Half life in Dawley rat,50597,10116.0,,,CHEMBL618662,5353,,,,,N,Intermediate,BAO_0000218
7542,Rattus norvegicus,1,A,,1,Half life period after 3 mg/kg iv administration,50597,10116.0,,,CHEMBL618663,2864,,,,,N,Intermediate,BAO_0000218
7543,Rattus norvegicus,1,A,,1,Half life period after 3 mg/kg iv administration in rat,50597,10116.0,,,CHEMBL618664,2864,,,,,N,Intermediate,BAO_0000218
7544,Rattus norvegicus,1,A,,1,Half life period after 3 mg/kg iv administration in the rat,50597,10116.0,,,CHEMBL618665,2864,,,,,N,Intermediate,BAO_0000218
7545,Rattus norvegicus,1,A,,1,Half life period in female Sprague-Dawley rats,50597,10116.0,,,CHEMBL876498,6362,,,,,N,Intermediate,BAO_0000218
7546,Rattus norvegicus,1,A,,1,Half life period in rat,50597,10116.0,,,CHEMBL618666,6249,,,,,N,Intermediate,BAO_0000218
7547,Rattus norvegicus,1,A,,1,Half-life in rats was determined,50597,10116.0,,,CHEMBL620440,3169,,,,,N,Intermediate,BAO_0000218
7548,Rattus norvegicus,1,A,,1,Half-life in rats with metabolic oxidation,50597,10116.0,,,CHEMBL620441,3169,,,,,N,Intermediate,BAO_0000218
7549,Rattus norvegicus,1,A,,1,Half-life in rats,50597,10116.0,,,CHEMBL620442,3169,,,,,N,Intermediate,BAO_0000218
7550,Rattus norvegicus,1,A,,1,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,10116.0,,,CHEMBL620443,17260,,,,,N,Intermediate,BAO_0000218
7551,Rattus norvegicus,1,A,,1,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,10116.0,,,CHEMBL620444,17260,,,,,N,Intermediate,BAO_0000218
7552,Rattus norvegicus,1,A,,1,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,10116.0,,,CHEMBL620445,17260,,,,,N,Intermediate,BAO_0000218
7553,Rattus norvegicus,1,A,,1,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,10116.0,,,CHEMBL620446,17260,,,,,N,Intermediate,BAO_0000218
7554,Rattus norvegicus,1,A,,1,Biological half-life measured in plasma of rat,50597,10116.0,,,CHEMBL620447,2879,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7555,Rattus norvegicus,1,A,,1,Biological half-life measured in plasma of rat; 22-25,50597,10116.0,,,CHEMBL621129,2879,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7556,Rattus norvegicus,1,A,,1,Biological half-life measured in plasma of rat; 9-16,50597,10116.0,,,CHEMBL621130,2879,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7557,Rattus norvegicus,1,A,,1,Compound was evaluated for its half life when administered intravenously in rat,50597,10116.0,,,CHEMBL873808,3184,,,,,N,Intermediate,BAO_0000218
7558,Rattus norvegicus,1,A,,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,50597,10116.0,,,CHEMBL876598,4891,,,,,N,Intermediate,BAO_0000218
7559,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,50597,10116.0,,,CHEMBL621131,429,,,,,N,Intermediate,BAO_0000218
7560,Rattus norvegicus,1,A,,1,Half life (T1/2) after oral administration in rat,50597,10116.0,,,CHEMBL621132,5656,,,,,N,Intermediate,BAO_0000218
7561,Rattus norvegicus,1,A,,1,Half life of compound after iv administration of 20 mg/kg dose in rat,50597,10116.0,,,CHEMBL621133,4413,,,,,N,Intermediate,BAO_0000218
7562,Rattus norvegicus,1,A,,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL621312,3598,,,,,N,Expert,BAO_0000218
7563,Rattus norvegicus,1,A,,1,Half life of compound was determined in rat,50597,10116.0,,,CHEMBL621313,17267,,,,,N,Intermediate,BAO_0000218
7564,Rattus norvegicus,1,A,,1,Half life of compound was determined in rat blood,50597,10116.0,,,CHEMBL621314,4727,178.0,,,Blood,N,Intermediate,BAO_0000218
7565,Rattus norvegicus,1,A,,1,Half life at 1 mg/kg was determined in rat,50597,10116.0,,,CHEMBL621315,17651,,,,,N,Intermediate,BAO_0000218
7566,Rattus norvegicus,1,A,,1,Half life at 10 mg/kg was determined in rat,50597,10116.0,,,CHEMBL621316,17651,,,,,N,Intermediate,BAO_0000218
7567,Rattus norvegicus,1,A,,1,Half life in rats,50597,10116.0,,,CHEMBL621317,401,,,,,N,Intermediate,BAO_0000218
7568,Rattus norvegicus,1,A,,1,Half life in rats in hours,50597,10116.0,,,CHEMBL621318,4942,,,,,N,Intermediate,BAO_0000218
7569,Rattus norvegicus,1,A,,1,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,10116.0,,,CHEMBL621319,17735,,,,,N,Intermediate,BAO_0000218
7570,Rattus norvegicus,1,A,,1,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,50597,10116.0,,,CHEMBL621377,6056,,,,,N,Intermediate,BAO_0000218
7571,Rattus norvegicus,1,A,,1,Half life was determined,50597,10116.0,,,CHEMBL621378,5213,,,,,N,Intermediate,BAO_0000218
7572,Rattus norvegicus,1,A,,1,Half life after i.v. administration,50597,10116.0,,,CHEMBL876599,6616,,,,,N,Intermediate,BAO_0000218
7573,Rattus norvegicus,1,A,,1,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,50597,10116.0,,,CHEMBL621379,5937,,,,,N,Intermediate,BAO_0000218
7574,Rattus norvegicus,1,A,,1,Half life in rat plasma,50597,10116.0,,,CHEMBL621380,5819,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7575,Rattus norvegicus,1,A,,1,Half life in rat plasma; Not detected,50597,10116.0,,,CHEMBL621381,5819,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7576,Rattus norvegicus,1,A,,1,Half life in rats,50597,10116.0,,,CHEMBL618515,6803,,,,,N,Intermediate,BAO_0000218
7577,Rattus norvegicus,1,A,,1,Half life period of compound was determined after peroral administration,50597,10116.0,,,CHEMBL618516,17804,,,,,N,Intermediate,BAO_0000218
7578,Rattus norvegicus,1,A,,1,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,50597,10116.0,,,CHEMBL618517,17804,,,,,N,Intermediate,BAO_0000218
7579,Rattus norvegicus,1,A,,1,Half life period in rat,50597,10116.0,,,CHEMBL618518,5948,,,,,N,Intermediate,BAO_0000218
7580,Rattus norvegicus,1,A,,1,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,10116.0,,,CHEMBL618519,1916,,,,,N,Intermediate,BAO_0000218
7581,Rattus norvegicus,1,A,,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,10116.0,,,CHEMBL618698,1916,,,,,N,Intermediate,BAO_0000218
7582,Rattus norvegicus,1,A,,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,50597,10116.0,,,CHEMBL618862,1916,,,,,N,Intermediate,BAO_0000218
7583,Rattus norvegicus,1,A,,1,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL618863,4890,,,,,N,Intermediate,BAO_0000218
7584,Rattus norvegicus,1,A,,1,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,50597,10116.0,,,CHEMBL618864,17764,,,,,N,Intermediate,BAO_0000218
7585,Rattus norvegicus,1,A,,1,Half life time in rat the dose of 2 mg/kg,50597,10116.0,,,CHEMBL618865,4727,,,,,N,Intermediate,BAO_0000218
7586,Rattus norvegicus,1,A,,1,Half-life 24 hr after 10 mg/kg iv administration in rats,50597,10116.0,,,CHEMBL618866,17509,,,,,N,Intermediate,BAO_0000218
7587,Rattus norvegicus,1,A,,1,Half-life 24 hr after 2 mg/kg iv administration in rats,50597,10116.0,,,CHEMBL618867,17509,,,,,N,Intermediate,BAO_0000218
7588,Rattus norvegicus,1,A,,1,Half-life consistent with the observed metabolic steady state in rats,50597,10116.0,,,CHEMBL875828,6597,,,,,N,Intermediate,BAO_0000218
7589,Rattus norvegicus,1,A,,1,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,10116.0,,,CHEMBL618868,17735,,,,,N,Intermediate,BAO_0000218
7590,Rattus norvegicus,1,A,,1,Half-life for oxidative metabolic stability was determined using male human,50597,10116.0,,,CHEMBL618869,6597,,,,,N,Intermediate,BAO_0000218
7591,Rattus norvegicus,1,A,,1,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",50597,10116.0,,,CHEMBL618870,17670,,,,,N,Intermediate,BAO_0000218
7592,Rattus norvegicus,1,A,,1,Half-life in rat plasma,50597,10116.0,,,CHEMBL618871,1696,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7593,Rattus norvegicus,1,A,,1,Half-life in rat plasma was determined,50597,10116.0,,,CHEMBL618872,1742,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7594,Rattus norvegicus,1,A,,1,Half-life in rats was determined,50597,10116.0,,,CHEMBL873816,17800,,,,,N,Intermediate,BAO_0000218
7595,,0,A,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,22224,,,,CHEMBL618873,12923,,,,,U,Autocuration,BAO_0000218
7596,,0,A,,1,Area under curve after oral dose of 0.1 mg//kg,22224,,,,CHEMBL621602,11954,,,,,U,Autocuration,BAO_0000019
7597,,0,A,,1,Area under curve after oral dose of 0.3 mg/kg,22224,,,,CHEMBL621603,11954,,,,,U,Autocuration,BAO_0000218
7598,,0,A,,1,Area under curve after oral dose of 1 mg/kg,22224,,,,CHEMBL621604,11954,,,,,U,Autocuration,BAO_0000218
7599,,0,A,,1,Area under curve after oral dose of 10 mg/kg,22224,,,,CHEMBL621605,11954,,,,,U,Autocuration,BAO_0000218
7600,,0,A,,1,Area under curve after oral dose of 23.4 mg/kg,22224,,,,CHEMBL621606,11954,,,,,U,Autocuration,BAO_0000218
7601,,0,A,,1,Area under curve after oral dose of 3 mg/kg,22224,,,,CHEMBL621607,11954,,,,,U,Autocuration,BAO_0000218
7602,,0,A,,1,Area under curve after oral dose of 3.87 mg/kg,22224,,,,CHEMBL621608,11954,,,,,U,Autocuration,BAO_0000218
7603,,0,A,,1,Area under curve was determined,22224,,,,CHEMBL621609,5237,,,,,U,Autocuration,BAO_0000019
7604,,0,A,,1,Area under curve at a dose of 10 mg/kg,22224,,,,CHEMBL621610,4026,,,,,U,Autocuration,BAO_0000218
7605,Rattus norvegicus,1,A,,1,Area under curve was determined; ND=No data,50597,10116.0,,,CHEMBL621611,5237,,,,,N,Intermediate,BAO_0000218
7606,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL621612,14793,,,,,N,Intermediate,BAO_0000218
7607,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,10116.0,,,CHEMBL622308,14793,,,,,N,Intermediate,BAO_0000218
7608,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL622309,14793,,,,,N,Intermediate,BAO_0000218
7609,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,10116.0,,,CHEMBL622310,14793,,,,,N,Intermediate,BAO_0000218
7610,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL622311,14793,,,,,N,Intermediate,BAO_0000218
7611,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,50597,10116.0,,,CHEMBL622312,14793,,,,,N,Intermediate,BAO_0000218
7612,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL622931,14793,,,,,N,Intermediate,BAO_0000218
7613,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,50597,10116.0,,,CHEMBL622932,14793,,,,,N,Intermediate,BAO_0000218
7614,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL622736,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7615,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,10116.0,,,CHEMBL622737,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7616,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL622738,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7617,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,10116.0,,,CHEMBL622739,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7618,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL622740,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7619,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,50597,10116.0,,,CHEMBL622741,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7620,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,10116.0,,,CHEMBL622742,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7621,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,50597,10116.0,,,CHEMBL622743,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7622,Mus musculus,1,A,,1,AUC in mice,50594,10090.0,,,CHEMBL622744,11637,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7623,,0,A,,1,Area under curve was measured from the graph obtained from concentration Vs time,22224,,,,CHEMBL624134,11149,,,,,U,Autocuration,BAO_0000019
7624,,0,A,,1,Area under curve value of compound per hour after oral administration,22224,,,,CHEMBL624135,10016,,,,,U,Autocuration,BAO_0000019
7625,Rattus norvegicus,1,A,,1,Area under curve was determined after oral administration in rats,50597,10116.0,,,CHEMBL624136,17796,,,,,N,Intermediate,BAO_0000218
7626,Rattus norvegicus,1,A,,1,Area under curve was determined after oral administration in rats; No data,50597,10116.0,,,CHEMBL624137,17796,,,,,N,Intermediate,BAO_0000218
7627,Rattus norvegicus,1,A,,1,Area under curve was determined after oral administration in rats;No data,50597,10116.0,,,CHEMBL624320,17796,,,,,N,Intermediate,BAO_0000218
7628,Canis lupus familiaris,1,A,,1,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,9615.0,,,CHEMBL624321,12923,,,,,N,Intermediate,BAO_0000218
7629,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,10116.0,,,CHEMBL624322,15372,,,,,N,Intermediate,BAO_0000218
7630,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound after iv dose of 5.06 in rats,50597,10116.0,,,CHEMBL624323,15372,,,,,N,Intermediate,BAO_0000218
7631,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,50597,10116.0,,,CHEMBL624324,15372,,,,,N,Intermediate,BAO_0000218
7632,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,50597,10116.0,,,CHEMBL624325,15372,,,,,N,Intermediate,BAO_0000218
7633,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,50597,10116.0,,,CHEMBL624326,15372,,,,,N,Intermediate,BAO_0000218
7634,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,50597,10116.0,,,CHEMBL624327,15372,,,,,N,Intermediate,BAO_0000218
7635,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,50597,10116.0,,,CHEMBL624328,15372,,,,,N,Intermediate,BAO_0000218
7636,Canis lupus familiaris,1,A,,1,Area under curve was determined in Dogs after peroral administration,50588,9615.0,,,CHEMBL627848,14169,,,,,N,Intermediate,BAO_0000218
7637,Rattus norvegicus,1,A,,1,Area under curve was determined in Rats after peroral administration,50597,10116.0,,,CHEMBL627849,14169,,,,,N,Intermediate,BAO_0000218
7638,Rattus norvegicus,1,A,,1,Area under curve was determined in carotid blood of rat when administered intradermally,50597,10116.0,,,CHEMBL627850,14258,,,,,N,Intermediate,BAO_0000218
7639,Rattus norvegicus,1,A,,1,Area under curve was determined in portal blood of rat when administered intradermally,50597,10116.0,,,CHEMBL627851,14258,,,,,N,Intermediate,BAO_0000218
7640,Mus musculus,1,A,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL627852,15011,,,,,N,Intermediate,BAO_0000218
7641,Mus musculus,1,A,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL627853,15011,,,,,N,Intermediate,BAO_0000218
7642,Mus musculus,1,A,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,10090.0,,,CHEMBL627854,15011,,,,,N,Intermediate,BAO_0000218
7643,Mus musculus,1,A,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL627855,15011,,,,,N,Intermediate,BAO_0000218
7644,Mus musculus,1,A,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,10090.0,,,CHEMBL627856,15011,,,,,N,Intermediate,BAO_0000218
7645,Mus musculus,1,A,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL875339,15011,,,,,N,Intermediate,BAO_0000218
7646,Mus musculus,1,A,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),50594,10090.0,,,CHEMBL627857,15011,,,,,N,Intermediate,BAO_0000218
7647,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,50597,10116.0,,,CHEMBL627858,11195,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7648,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627859,10130,178.0,,,Blood,N,Intermediate,BAO_0000218
7649,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627860,10130,955.0,,,Brain,N,Intermediate,BAO_0000218
7650,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627019,10130,948.0,,,Heart,N,Intermediate,BAO_0000218
7651,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627020,10130,2107.0,,,Liver,N,Intermediate,BAO_0000218
7652,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627021,10130,2048.0,,,Lung,N,Intermediate,BAO_0000218
7653,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627022,10130,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7654,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627023,10130,,,,,N,Intermediate,BAO_0000218
7655,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627024,10130,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7656,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627025,10130,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7657,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627026,10130,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7658,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627027,10130,178.0,,,Blood,N,Intermediate,BAO_0000218
7659,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627028,10130,955.0,,,Brain,N,Intermediate,BAO_0000218
7660,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627029,10130,948.0,,,Heart,N,Intermediate,BAO_0000218
7661,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627030,10130,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7662,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627031,10130,2107.0,,,Liver,N,Intermediate,BAO_0000218
7663,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627032,10130,2048.0,,,Lung,N,Intermediate,BAO_0000218
7664,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627033,10130,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7665,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627034,10130,,,,,N,Intermediate,BAO_0000218
7666,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627035,10130,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7667,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627036,10130,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7668,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL875340,10130,178.0,,,Blood,N,Intermediate,BAO_0000218
7669,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627037,10130,948.0,,,Heart,N,Intermediate,BAO_0000218
7670,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627038,10130,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7671,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627039,10130,2107.0,,,Liver,N,Intermediate,BAO_0000218
7672,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL627040,10130,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7673,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL624663,10130,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7674,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL625963,10130,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
7675,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL876799,10130,955.0,,,Brain,N,Intermediate,BAO_0000218
7676,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL626133,10130,2048.0,,,Lung,N,Intermediate,BAO_0000218
7677,Rattus norvegicus,1,A,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,50597,10116.0,,,CHEMBL626134,10130,,,,,N,Intermediate,BAO_0000218
7678,Rattus norvegicus,1,A,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL626135,6295,,,,,N,Intermediate,BAO_0000218
7679,Rattus norvegicus,1,A,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL626136,6296,,,,,N,Intermediate,BAO_0000218
7680,Rattus norvegicus,1,A,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,50597,10116.0,,,CHEMBL626137,6296,,,,,N,Intermediate,BAO_0000218
7681,Rattus norvegicus,1,A,,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL626138,6295,,,,,N,Intermediate,BAO_0000218
7682,Rattus norvegicus,1,A,,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL626139,6296,,,,,N,Intermediate,BAO_0000218
7683,Rattus norvegicus,1,A,,1,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,10116.0,,,CHEMBL626140,17260,,,,,N,Intermediate,BAO_0000218
7684,Rattus norvegicus,1,A,,1,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,10116.0,,,CHEMBL626141,17260,,,,,N,Intermediate,BAO_0000218
7685,Rattus norvegicus,1,A,,1,C24h in rat p.o. at 20 mg/kg concentration,50597,10116.0,,,CHEMBL626142,17686,,,,,N,Intermediate,BAO_0000218
7686,Rattus norvegicus,1,A,,1,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL627930,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7687,Rattus norvegicus,1,A,,1,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL627931,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7688,Rattus norvegicus,1,A,,1,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL627932,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
7689,Rattus norvegicus,1,A,,1,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL627933,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7690,Rattus norvegicus,1,A,,1,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,50597,10116.0,,,CHEMBL627934,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7691,Rattus norvegicus,1,A,,1,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,50597,10116.0,,,CHEMBL627935,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
7692,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,10116.0,,,CHEMBL627936,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7693,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,50597,10116.0,,,CHEMBL627937,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7694,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,10116.0,,,CHEMBL627938,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7695,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,50597,10116.0,,,CHEMBL627939,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7696,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,50597,10116.0,,,CHEMBL627940,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7697,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,10116.0,,,CHEMBL627941,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7698,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL876800,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7699,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,50597,10116.0,,,CHEMBL627942,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7700,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,10116.0,,,CHEMBL627943,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7701,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,50597,10116.0,,,CHEMBL627944,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7702,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,50597,10116.0,,,CHEMBL627945,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7703,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,50597,10116.0,,,CHEMBL628584,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7704,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA at 15 min,50597,10116.0,,,CHEMBL628585,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7705,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,50597,10116.0,,,CHEMBL628586,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7706,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA at 30 min,50597,10116.0,,,CHEMBL628587,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7707,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,50597,10116.0,,,CHEMBL628588,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7708,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,50597,10116.0,,,CHEMBL628589,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7709,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,50597,10116.0,,,CHEMBL625304,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7710,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,50597,10116.0,,,CHEMBL625305,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7711,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,50597,10116.0,,,CHEMBL625306,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7712,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,50597,10116.0,,,CHEMBL625307,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7713,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,50597,10116.0,,,CHEMBL625308,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7714,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,50597,10116.0,,,CHEMBL627740,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7715,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,50597,10116.0,,,CHEMBL627741,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7716,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL627742,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7717,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,50597,10116.0,,,CHEMBL627743,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7718,Rattus norvegicus,1,A,,1,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,50597,10116.0,,,CHEMBL627744,9866,178.0,,,Blood,N,Intermediate,BAO_0000218
7719,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,50597,10116.0,,,CHEMBL627745,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7720,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,10116.0,,,CHEMBL627746,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7721,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,10116.0,,,CHEMBL627747,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7722,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,50597,10116.0,,,CHEMBL876810,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7723,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,50597,10116.0,,,CHEMBL627748,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7724,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,10116.0,,,CHEMBL627749,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7725,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL627750,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7726,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,50597,10116.0,,,CHEMBL618728,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7727,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,10116.0,,,CHEMBL618729,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7728,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA at 15 min,50597,10116.0,,,CHEMBL618730,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7729,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,50597,10116.0,,,CHEMBL618731,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7730,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA at 30 min,50597,10116.0,,,CHEMBL618732,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7731,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,50597,10116.0,,,CHEMBL618733,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7732,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,50597,10116.0,,,CHEMBL618734,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7733,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,50597,10116.0,,,CHEMBL618735,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7734,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,50597,10116.0,,,CHEMBL876602,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7735,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,50597,10116.0,,,CHEMBL618736,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7736,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,50597,10116.0,,,CHEMBL618737,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7737,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,50597,10116.0,,,CHEMBL618738,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7738,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,50597,10116.0,,,CHEMBL618739,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7739,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,50597,10116.0,,,CHEMBL618740,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7740,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL618741,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7741,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,50597,10116.0,,,CHEMBL618742,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7742,Rattus norvegicus,1,A,,1,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,50597,10116.0,,,CHEMBL618743,9866,10000001.0,,,Bone,N,Intermediate,BAO_0000218
7743,Rattus norvegicus,1,A,,1,Half-life from rat plasma at a single oral dose of 25 mg/kg,50597,10116.0,,,CHEMBL618744,17752,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7744,Rattus norvegicus,1,A,,1,Half-life in male rat,50597,10116.0,,,CHEMBL618745,5610,,,,,N,Intermediate,BAO_0000218
7745,Rattus norvegicus,1,A,,1,Half-life in rat after peroral administration at 10 mg/kg concentration,50597,10116.0,,,CHEMBL620479,5939,,,,,N,Intermediate,BAO_0000218
7746,Rattus norvegicus,1,A,,1,Half-life in rat after peroral administration at 5 mg/kg concentration,50597,10116.0,,,CHEMBL620480,5939,,,,,N,Intermediate,BAO_0000218
7747,Rattus norvegicus,1,A,,1,Half-life in rat at a dose of 3 mg/kg,50597,10116.0,,,CHEMBL620481,17771,,,,,N,Intermediate,BAO_0000218
7748,Rattus norvegicus,1,A,,1,Half-life was evaluated in rats,50597,10116.0,,,CHEMBL620482,1974,,,,,N,Intermediate,BAO_0000218
7749,Rattus norvegicus,1,A,,1,Half-life was measured in rat,50597,10116.0,,,CHEMBL876603,4239,,,,,N,Intermediate,BAO_0000218
7750,Rattus norvegicus,1,A,,1,Half-life period for the compound was determined in rats at 50 mg/kg dose,50597,10116.0,,,CHEMBL620483,6681,,,,,N,Intermediate,BAO_0000218
7751,Rattus norvegicus,1,A,,1,Half-life period in rats after intravenous administration at 5 mg/kg,50597,10116.0,,,CHEMBL620484,17752,,,,,N,Intermediate,BAO_0000218
7752,Rattus norvegicus,1,A,,1,Half-life period in rat at 10 mg/kg,50597,10116.0,,,CHEMBL620485,6046,,,,,N,Intermediate,BAO_0000218
7753,Rattus norvegicus,1,A,,1,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL620486,6685,,,,,N,Intermediate,BAO_0000218
7754,Rattus norvegicus,1,A,,1,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",50597,10116.0,,,CHEMBL620487,6685,,,,,N,Intermediate,BAO_0000218
7755,Rattus norvegicus,1,A,,1,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",50597,10116.0,,,CHEMBL620488,6685,,,,,N,Intermediate,BAO_0000218
7756,Rattus norvegicus,1,A,,1,Half-life time in rat the dose of 2 mg/kg,50597,10116.0,,,CHEMBL620489,4727,,,,,N,Intermediate,BAO_0000218
7757,Rattus norvegicus,1,A,,1,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,50597,10116.0,,,CHEMBL620490,1088,,,,,N,Intermediate,BAO_0000218
7758,Rattus norvegicus,1,A,,1,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,50597,10116.0,,,CHEMBL620491,5610,,,,,N,Intermediate,BAO_0000218
7759,Rattus norvegicus,1,A,,1,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,10116.0,,,CHEMBL876604,3032,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7760,Rattus norvegicus,1,A,,1,Oral half life was determined,50597,10116.0,,,CHEMBL620492,5199,,,,,N,Intermediate,BAO_0000218
7761,Rattus norvegicus,1,A,,1,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",50597,10116.0,,,CHEMBL620493,14941,,,,,N,Intermediate,BAO_0000218
7762,Rattus norvegicus,1,A,,1,Pharmacokinetic property (t1/2) in rat,50597,10116.0,,,CHEMBL620494,4408,,,,,N,Intermediate,BAO_0000218
7763,Rattus norvegicus,1,A,,1,Plasma elimination half-life was determined,50597,10116.0,,,CHEMBL620495,2552,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7764,Rattus norvegicus,1,A,,1,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,10116.0,,,CHEMBL620496,5199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7765,Rattus norvegicus,1,A,,1,Plasma half life was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL620497,15662,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7766,Rattus norvegicus,1,A,,1,Plasma half-life was determined,50597,10116.0,,,CHEMBL620498,1465,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7767,Rattus norvegicus,1,A,,1,Plasma half-life following oral administration in Fisher rats,50597,10116.0,,,CHEMBL620499,1446,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7768,Rattus norvegicus,1,A,,1,Plasma half-life in rat,50597,10116.0,,,CHEMBL620500,6824,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7769,Rattus norvegicus,1,A,,1,Plasmatic Half-life after intravenous administration to rat,50597,10116.0,,,CHEMBL873809,17533,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7770,Rattus norvegicus,1,A,,1,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,10116.0,,,CHEMBL620501,5979,,,,,N,Intermediate,BAO_0000218
7771,Rattus norvegicus,1,A,,1,Terminal half life after intravenous administration (1 mg/kg) in rat,50597,10116.0,,,CHEMBL620502,4689,,,,,N,Intermediate,BAO_0000218
7772,Rattus norvegicus,1,A,,1,Terminal half life in Rat at a oral dose of 5 mg/kg,50597,10116.0,,,CHEMBL620503,4689,,,,,N,Intermediate,BAO_0000218
7773,Rattus norvegicus,1,A,,1,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,10116.0,,,CHEMBL620504,2463,,,,,N,Intermediate,BAO_0000218
7774,Rattus norvegicus,1,A,,1,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,50597,10116.0,,,CHEMBL876605,4883,,,,,N,Intermediate,BAO_0000218
7775,Rattus norvegicus,1,A,,1,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,50597,10116.0,,,CHEMBL620505,4883,,,,,N,Intermediate,BAO_0000218
7776,Rattus norvegicus,1,A,,1,plasma half life was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL873811,15662,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7777,Rattus norvegicus,1,A,,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL624016,3598,,,,,N,Expert,BAO_0000218
7778,Rattus norvegicus,1,A,,1,Half life of compound determined in rat,50597,10116.0,,,CHEMBL624017,4576,,,,,N,Intermediate,BAO_0000218
7779,Rattus norvegicus,1,A,,1,Mean residence time determined in rat,50597,10116.0,,,CHEMBL624018,4576,,,,,N,Intermediate,BAO_0000218
7780,Rattus norvegicus,1,A,,1,Plasma half life determined in rat,50597,10116.0,,,CHEMBL624019,4576,,,,,N,Intermediate,BAO_0000218
7781,Rattus norvegicus,1,A,,1,Compound was evaluated for Tmax in brain after intravenous administration in male rats,50597,10116.0,,,CHEMBL624020,4910,955.0,,,Brain,N,Intermediate,BAO_0000218
7782,Rattus norvegicus,1,A,,1,Compound was evaluated for pharmacokinetic parameter maximum time period,50597,10116.0,,,CHEMBL624201,4891,,,,,N,Intermediate,BAO_0000218
7783,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,10116.0,,,CHEMBL872528,429,,,,,N,Intermediate,BAO_0000218
7784,Rattus norvegicus,1,A,,1,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL624202,5974,,,,,N,Intermediate,BAO_0000218
7785,Rattus norvegicus,1,A,,1,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL624203,5974,,,,,N,Intermediate,BAO_0000218
7786,Rattus norvegicus,1,A,,1,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL624350,5974,,,,,N,Intermediate,BAO_0000218
7787,Rattus norvegicus,1,A,,1,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL621320,5974,,,,,N,Intermediate,BAO_0000218
7788,Rattus norvegicus,1,A,,1,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,10116.0,,,CHEMBL621321,17582,,,,,N,Intermediate,BAO_0000218
7789,Rattus norvegicus,1,A,,1,Maximum time (Tmax) required to reach Cmax in rats,50597,10116.0,,,CHEMBL621322,4026,,,,,N,Intermediate,BAO_0000218
7790,Rattus norvegicus,1,A,,1,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL621323,4890,,,,,N,Intermediate,BAO_0000218
7791,Rattus norvegicus,1,A,,1,Maximum time of clearance of compound in rats after peroral administration,50597,10116.0,,,CHEMBL621324,6571,,,,,N,Intermediate,BAO_0000218
7792,Rattus norvegicus,1,A,,1,Maximum time at the dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL621325,4727,,,,,N,Intermediate,BAO_0000218
7793,Rattus norvegicus,1,A,,1,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,50597,10116.0,,,CHEMBL875837,17651,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7794,Rattus norvegicus,1,A,,1,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,50597,10116.0,,,CHEMBL621326,17651,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7795,Rattus norvegicus,1,A,,1,Tmax in Guinea pig (PO dose),50597,10116.0,,,CHEMBL621327,14465,,,,,N,Intermediate,BAO_0000218
7796,Rattus norvegicus,1,A,,1,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",50597,10116.0,,,CHEMBL621328,14941,,,,,N,Intermediate,BAO_0000218
7797,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (Tmax) in rat,50597,10116.0,,,CHEMBL621329,5960,,,,,N,Intermediate,BAO_0000218
7798,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (Tmax) was estimated,50597,10116.0,,,CHEMBL621330,5022,,,,,N,Intermediate,BAO_0000218
7799,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Tmax) in rat,50597,10116.0,,,CHEMBL621331,4408,,,,,N,Intermediate,BAO_0000218
7800,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,10116.0,,,CHEMBL621332,5983,,,,,N,Intermediate,BAO_0000218
7801,Rattus norvegicus,1,A,,1,T max in Rat at a oral dose of 5 mg/kg,50597,10116.0,,,CHEMBL621333,4689,,,,,N,Intermediate,BAO_0000218
7802,Rattus norvegicus,1,A,,1,T max was determined at 10 mg/kg po dose in rats,50597,10116.0,,,CHEMBL621334,2792,,,,,N,Intermediate,BAO_0000218
7803,Mus musculus,1,A,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,10090.0,,,CHEMBL621335,15011,,,,,N,Intermediate,BAO_0000218
7804,Canis lupus familiaris,1,A,,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,50588,9615.0,,,CHEMBL621336,14180,,,,,N,Intermediate,BAO_0000218
7805,Rattus norvegicus,1,A,,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,50597,10116.0,,,CHEMBL621337,14180,,,,,N,Intermediate,BAO_0000218
7806,Canis lupus familiaris,1,A,,1,Area under curve was measured after i.v. administration into Beagle dog.,50588,9615.0,,,CHEMBL621338,14599,,,,,N,Intermediate,BAO_0000218
7807,Canis lupus familiaris,1,A,,1,Area under curve was measured after iv administration into Beagle dog,50588,9615.0,,,CHEMBL875838,14599,,,,,N,Intermediate,BAO_0000218
7808,Canis lupus familiaris,1,A,,1,Area under curve was measured after po administration into Beagle dog,50588,9615.0,,,CHEMBL621339,14599,,,,,N,Intermediate,BAO_0000218
7809,Canis lupus familiaris,1,A,,1,Area under curve was measured after po administration into Beagle dog.,50588,9615.0,,,CHEMBL621340,14599,,,,,N,Intermediate,BAO_0000218
7810,,0,A,,1,Area under curve was measured at peroral dose of 3 mg/kg,22224,,,,CHEMBL621341,15675,,,,,U,Autocuration,BAO_0000218
7811,,0,A,,1,Area under curve was measured by using concentration Vs time,22224,,,,CHEMBL621342,12706,,,,,U,Autocuration,BAO_0000019
7812,,0,A,,1,Area under curve was measured by using concentration Vs time; not tested,22224,,,,CHEMBL621343,12706,,,,,U,Autocuration,BAO_0000019
7813,Mus musculus,1,A,,1,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),50594,10090.0,,,CHEMBL621344,9750,,,,,N,Intermediate,BAO_0000218
7814,Mus musculus,1,A,,1,Area under curve(AUC) was measured in mice after oral administration.,50594,10090.0,,,CHEMBL621345,9750,,,,,N,Intermediate,BAO_0000218
7815,,0,A,,1,Area under curve(AUC) value of the compound,22224,,,,CHEMBL621346,14691,,,,,U,Autocuration,BAO_0000019
7816,,0,A,,1,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,22224,,,,CHEMBL621347,14691,,,,,U,Autocuration,BAO_0000218
7817,Canis lupus familiaris,1,A,,1,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,50588,9615.0,,,CHEMBL621348,14691,,,,,N,Intermediate,BAO_0000218
7818,,0,A,,1,Area under curve(carotid artery) was determined by the availability in blood,22224,,,,CHEMBL621349,2939,178.0,,,Blood,U,Autocuration,BAO_0000019
7819,,0,A,,1,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,22224,,,,CHEMBL621350,2939,178.0,,,Blood,U,Autocuration,BAO_0000019
7820,,0,A,,1,Area under curve(carotid artery) was determined by the availability in blood; No data,22224,,,,CHEMBL875839,2939,178.0,,,Blood,U,Autocuration,BAO_0000019
7821,,0,A,,1,Area under curve(portal vein) was determined by the availability in blood,22224,,,,CHEMBL620211,2939,178.0,,,Blood,U,Autocuration,BAO_0000019
7822,,0,A,,1,Area under curve(portal vein) was determined by the availability in blood; ND means no data,22224,,,,CHEMBL620212,2939,178.0,,,Blood,U,Autocuration,BAO_0000019
7823,,0,A,,1,Area under curve(portal vein) was determined by the availability in blood; No data,22224,,,,CHEMBL620213,2939,178.0,,,Blood,U,Autocuration,BAO_0000019
7824,Macaca mulatta,1,A,,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,9544.0,,,CHEMBL620214,9552,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7825,Macaca mulatta,1,A,,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,9544.0,,,CHEMBL620215,9552,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7826,Macaca mulatta,1,A,,1,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,50797,9544.0,,,CHEMBL620216,9552,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7827,Canis lupus familiaris,1,A,,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",50588,9615.0,,,CHEMBL620888,9552,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7828,Canis lupus familiaris,1,A,,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",50588,9615.0,,,CHEMBL620889,9552,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7829,,0,A,,1,Area under plasma concentration vs time curve observed in rats for 0-3 h,22224,,,,CHEMBL620890,9552,1969.0,,,Plasma,U,Autocuration,BAO_0000019
7830,Rattus norvegicus,1,A,,1,Area under plasma time curve determined in male rat,50597,10116.0,,,CHEMBL620891,11911,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7831,,0,A,,1,Area under the MAP curve measured over 5 min.,22224,,,,CHEMBL620892,16618,,,,,U,Autocuration,BAO_0000019
7832,Mus musculus,1,A,,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,50594,10090.0,,,CHEMBL621079,14387,,,,,N,Intermediate,BAO_0000218
7833,Mus musculus,1,A,,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,50594,10090.0,,,CHEMBL621080,14387,,,,,N,Intermediate,BAO_0000218
7834,Canis lupus familiaris,1,A,,1,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,50588,9615.0,,,CHEMBL621081,12836,,,,,N,Intermediate,BAO_0000218
7835,Cricetinae,1,A,,1,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,100712,10026.0,,,CHEMBL621082,12836,,,,,N,Intermediate,BAO_0000218
7836,Rattus norvegicus,1,A,,1,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,50597,10116.0,,,CHEMBL621083,12836,,,,,N,Intermediate,BAO_0000218
7837,Canis lupus familiaris,1,A,,1,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,50588,9615.0,,,CHEMBL621084,14339,,,,,N,Intermediate,BAO_0000218
7838,Canis lupus familiaris,1,A,,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,50588,9615.0,,,CHEMBL621085,14339,,,,,N,Intermediate,BAO_0000218
7839,Canis lupus familiaris,1,A,,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,50588,9615.0,,,CHEMBL621086,14339,,,,,N,Intermediate,BAO_0000218
7840,Canis lupus familiaris,1,A,,1,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50588,9615.0,,,CHEMBL621087,10524,,,,,N,Intermediate,BAO_0000218
7841,Canis lupus familiaris,1,A,,1,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),50588,9615.0,,,CHEMBL622607,9994,,,,,N,Intermediate,BAO_0000218
7842,Canis lupus familiaris,1,A,,1,Serum AUC in marmosets (IV dose),50588,9615.0,,,CHEMBL622608,11325,,,,,N,Intermediate,BAO_0000218
7843,,0,A,,1,Area under the curve after intravenous administration at a dose of 10 umol/kg,22224,,,,CHEMBL624481,12536,,,,,U,Autocuration,BAO_0000019
7844,,0,A,,1,Area under the curve after intravenous administration at a dose of 2 umol/kg,22224,,,,CHEMBL624482,12536,,,,,U,Autocuration,BAO_0000019
7845,,0,A,,1,Area under the curve after intravenous administration at a dose of 4 umol/kg,22224,,,,CHEMBL624483,12536,,,,,U,Autocuration,BAO_0000019
7846,,0,A,,1,Area under the curve after intravenous administration at a dose of 40 umol/kg,22224,,,,CHEMBL624484,12536,,,,,U,Autocuration,BAO_0000019
7847,,0,A,,1,Area under the curve after intravenous administration at a dose of 5 umol/kg,22224,,,,CHEMBL624485,12536,,,,,U,Autocuration,BAO_0000019
7848,Rattus norvegicus,1,A,,1,Area under the curve for fumarate salt was evaluated in F344 Rats.,50597,10116.0,,,CHEMBL624486,15556,,,,,N,Intermediate,BAO_0000218
7849,,0,A,,1,Area under the curve for the compound was calculated.,22224,,,,CHEMBL624487,2809,,,,,U,Autocuration,BAO_0000019
7850,,0,A,,1,Area under the curve in concentration/ time,22224,,,,CHEMBL624488,9511,,,,,U,Autocuration,BAO_0000019
7851,Rattus norvegicus,1,A,,1,Area under the curve administered intraintestinal in rats.,50597,10116.0,,,CHEMBL624489,12818,,,,,N,Intermediate,BAO_0000218
7852,Rattus norvegicus,1,A,,1,Area under the curve administered intravenously in rats.,50597,10116.0,,,CHEMBL625184,12818,,,,,N,Intermediate,BAO_0000218
7853,,0,A,,1,Area under the curve during intravenous administration,22224,,,,CHEMBL625185,15118,,,,,U,Autocuration,BAO_0000019
7854,,0,A,,1,Area under the curve during intravenous administration; Not determined,22224,,,,CHEMBL875954,15118,,,,,U,Autocuration,BAO_0000019
7855,,0,A,,1,Area under the curve during systemic administration,22224,,,,CHEMBL625186,15118,,,,,U,Autocuration,BAO_0000019
7856,,0,A,,1,Area under the curve during systemic administration; Not determined,22224,,,,CHEMBL625187,15118,,,,,U,Autocuration,BAO_0000019
7857,,0,A,,1,Area under the curve was calculated for the compound.,22224,,,,CHEMBL625188,2632,,,,,U,Autocuration,BAO_0000019
7858,Canis lupus familiaris,1,A,,1,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,50588,9615.0,,,CHEMBL625189,14346,,,,,N,Intermediate,BAO_0000218
7859,Canis lupus familiaris,1,A,,1,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,50588,9615.0,,,CHEMBL625190,14346,,,,,N,Intermediate,BAO_0000218
7860,Rattus norvegicus,1,A,,1,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL621733,14346,,,,,N,Intermediate,BAO_0000218
7861,Rattus norvegicus,1,A,,1,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL621734,14346,,,,,N,Intermediate,BAO_0000218
7862,Rattus norvegicus,1,A,,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,50597,10116.0,,,CHEMBL621735,11149,,,,,N,Intermediate,BAO_0000218
7863,Rattus norvegicus,1,A,,1,Clearance of the drug was measured in the plasma of rat; No data,50597,10116.0,,,CHEMBL621736,17796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7864,Rattus norvegicus,1,A,,1,The pharmacokinetic parameter plasma clearance in vivo in rats,50597,10116.0,,,CHEMBL621737,5247,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7865,Rattus norvegicus,1,A,,1,Plasma clearance at the dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL621738,4727,,,,,N,Intermediate,BAO_0000218
7866,Rattus norvegicus,1,A,,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,10116.0,,,CHEMBL622806,5654,,,,,N,Intermediate,BAO_0000218
7867,Rattus norvegicus,1,A,,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,10116.0,,,CHEMBL623519,5654,,,,,N,Intermediate,BAO_0000218
7868,Rattus norvegicus,1,A,,1,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,10116.0,,,CHEMBL623520,17260,,,,,N,Intermediate,BAO_0000218
7869,Rattus norvegicus,1,A,,1,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,10116.0,,,CHEMBL623521,17065,,,,,N,Intermediate,BAO_0000218
7870,Rattus norvegicus,1,A,,1,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,10116.0,,,CHEMBL623522,17671,,,,,N,Intermediate,BAO_0000218
7871,Rattus norvegicus,1,A,,1,Clearance rate in rat,50597,10116.0,,,CHEMBL623523,6672,,,,,N,Intermediate,BAO_0000218
7872,Rattus norvegicus,1,A,,1,Clearance rate in rat,50597,10116.0,,,CHEMBL623690,6673,,,,,N,Intermediate,BAO_0000218
7873,Rattus norvegicus,1,A,,1,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL623691,5978,,,,,N,Intermediate,BAO_0000218
7874,Rattus norvegicus,1,A,,1,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL623692,5978,,,,,N,Intermediate,BAO_0000218
7875,Rattus norvegicus,1,A,,1,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL623693,5978,,,,,N,Intermediate,BAO_0000218
7876,Rattus norvegicus,1,A,,1,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL623694,5978,,,,,N,Intermediate,BAO_0000218
7877,Rattus norvegicus,1,A,,1,Clearance of compound after iv administration of 20 mg/kg dose in rat,50597,10116.0,,,CHEMBL623695,4413,,,,,N,Intermediate,BAO_0000218
7878,Rattus norvegicus,1,A,,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,50597,10116.0,,,CHEMBL623696,2661,,,,,N,Intermediate,BAO_0000218
7879,Rattus norvegicus,1,A,,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,50597,10116.0,,,CHEMBL623697,2661,,,,,N,Intermediate,BAO_0000218
7880,Macaca mulatta,0,A,,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,9544.0,,,CHEMBL623698,5005,1969.0,,,Plasma,U,Intermediate,BAO_0000218
7881,Rattus norvegicus,0,A,,1,Compound was tested for its plasma clearance rate in Sprague Dawley rats,22224,10116.0,,,CHEMBL623699,5005,1969.0,,,Plasma,U,Intermediate,BAO_0000218
7882,Rattus norvegicus,1,A,,1,Mean (%CV) PK parameters for CL(mL/min/kg).,50597,10116.0,,,CHEMBL623700,15765,,,,,N,Intermediate,BAO_0000218
7883,Rattus norvegicus,1,A,,1,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,50597,10116.0,,,CHEMBL623701,3747,,,,,N,Intermediate,BAO_0000218
7884,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,50597,10116.0,,,CHEMBL623702,16366,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7885,Rattus norvegicus,1,A,,1,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,50597,10116.0,,,CHEMBL623703,4199,,,,,N,Intermediate,BAO_0000218
7886,Rattus norvegicus,1,A,,1,Plasma clearance in rat was determined,50597,10116.0,,,CHEMBL623704,17267,,,,,N,Intermediate,BAO_0000218
7887,Rattus norvegicus,1,A,,1,Plasma clearance in rat after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL623705,6535,,,,,N,Intermediate,BAO_0000218
7888,Rattus norvegicus,1,A,,1,Plasma clearance in rat after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL623706,6535,,,,,N,Intermediate,BAO_0000218
7889,Rattus norvegicus,1,A,,1,Plasma clearance was determined,50597,10116.0,,,CHEMBL623707,5041,,,,,N,Intermediate,BAO_0000218
7890,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL623708,5960,,,,,N,Intermediate,BAO_0000218
7891,Rattus norvegicus,1,A,,1,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,50597,10116.0,,,CHEMBL623709,5937,,,,,N,Intermediate,BAO_0000218
7892,Rattus norvegicus,1,A,,1,Plasma clearance in rat by iv administration,50597,10116.0,,,CHEMBL623710,5871,,,,,N,Intermediate,BAO_0000218
7893,Rattus norvegicus,1,A,,1,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,50597,10116.0,,,CHEMBL623711,5874,,,,,N,Intermediate,BAO_0000218
7894,Rattus norvegicus,1,A,,1,Plasma clearance in rat p.o.,50597,10116.0,,,CHEMBL623712,6504,,,,,N,Intermediate,BAO_0000218
7895,Rattus norvegicus,1,A,,1,Plasma clearance in rats,50597,10116.0,,,CHEMBL623713,6803,,,,,N,Intermediate,BAO_0000218
7896,Rattus norvegicus,1,A,,1,Plasma clearance was determined; ND denotes no data,50597,10116.0,,,CHEMBL623714,5041,,,,,N,Intermediate,BAO_0000218
7897,Rattus norvegicus,1,A,,1,Plasma clearance was determined; ND denotes not determined,50597,10116.0,,,CHEMBL623715,5041,,,,,N,Intermediate,BAO_0000218
7898,Rattus norvegicus,1,A,,1,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,10116.0,,,CHEMBL623716,1916,,,,,N,Intermediate,BAO_0000218
7899,Rattus norvegicus,1,A,,1,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,10116.0,,,CHEMBL622980,5199,,,,,N,Intermediate,BAO_0000218
7900,Rattus norvegicus,1,A,,1,Plasma administration to rats,50597,10116.0,,,CHEMBL622981,16367,,,,,N,Intermediate,BAO_0000218
7901,Rattus norvegicus,1,A,,1,Plasma clearance of the compound in female Sprague-Dawley rats,50597,10116.0,,,CHEMBL622982,6362,,,,,N,Intermediate,BAO_0000218
7902,Rattus norvegicus,1,A,,1,Plasma clearance was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL622983,15662,,,,,N,Intermediate,BAO_0000218
7903,Rattus norvegicus,1,A,,1,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,50597,10116.0,,,CHEMBL622984,6215,,,,,N,Intermediate,BAO_0000218
7904,Rattus norvegicus,1,A,,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,50597,10116.0,,,CHEMBL622985,1466,,,,,N,Intermediate,BAO_0000218
7905,Rattus norvegicus,1,A,,1,plasma clearance was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL623631,15662,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7906,Rattus norvegicus,1,A,,1,In vivo CL/F determined,50597,10116.0,,,CHEMBL623632,4723,,,,,N,Intermediate,BAO_0000218
7907,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL623633,2792,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7908,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL623634,2792,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7909,Rattus norvegicus,1,A,,1,Compound was tested for the lower blood clearance in rat,50597,10116.0,,,CHEMBL623635,5213,,,,,N,Intermediate,BAO_0000218
7910,Rattus norvegicus,1,A,,1,Evaluated for the low clearance in rat (in vivo),50597,10116.0,,,CHEMBL621195,4687,,,,,N,Intermediate,BAO_0000218
7911,Rattus norvegicus,1,A,,1,Pharmacokinetic property (CLb)of the compound was determined in rat,50597,10116.0,,,CHEMBL621196,3371,,,,,N,Intermediate,BAO_0000218
7912,Rattus norvegicus,1,A,,1,Rapid clearance after intravenous administration in rat was determined,50597,10116.0,,,CHEMBL875287,4690,,,,,N,Intermediate,BAO_0000218
7913,Rattus norvegicus,1,A,,1,Clearance measured in rat,50597,10116.0,,,CHEMBL621197,5702,,,,,N,Intermediate,BAO_0000218
7914,Rattus norvegicus,1,A,,1,Compound was evaluated for plasma clearance in rat,50597,10116.0,,,CHEMBL621198,740,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7915,Rattus norvegicus,1,A,,1,Low plasma clearance was calculated in rat,50597,10116.0,,,CHEMBL621199,4853,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7916,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Clp) in rat,50597,10116.0,,,CHEMBL621200,5789,,,,,N,Intermediate,BAO_0000218
7917,Rattus norvegicus,1,A,,1,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,50597,10116.0,,,CHEMBL621201,4527,,,,,N,Intermediate,BAO_0000218
7918,Rattus norvegicus,1,A,,1,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,50597,10116.0,,,CHEMBL621202,4527,,,,,N,Intermediate,BAO_0000218
7919,Rattus norvegicus,1,A,,1,Plasma clearance after IV dosing at 0.5 mg/kg in rat,50597,10116.0,,,CHEMBL621203,6518,,,,,N,Intermediate,BAO_0000218
7920,Rattus norvegicus,1,A,,1,Plasma clearance after IV dosing at 1 mg/kg in rat,50597,10116.0,,,CHEMBL621204,6518,,,,,N,Intermediate,BAO_0000218
7921,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,50597,10116.0,,,CHEMBL621205,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7922,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621206,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7923,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,10116.0,,,CHEMBL621207,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7924,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,50597,10116.0,,,CHEMBL621208,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7925,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,50597,10116.0,,,CHEMBL621209,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7926,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,50597,10116.0,,,CHEMBL876484,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7927,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL621210,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7928,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621211,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7929,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,10116.0,,,CHEMBL621212,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7930,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA at 15 min,50597,10116.0,,,CHEMBL621213,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7931,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,50597,10116.0,,,CHEMBL621214,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7932,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA at 30 min,50597,10116.0,,,CHEMBL621215,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7933,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,50597,10116.0,,,CHEMBL621216,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7934,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,50597,10116.0,,,CHEMBL621217,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7935,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,50597,10116.0,,,CHEMBL621218,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7936,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,50597,10116.0,,,CHEMBL621219,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7937,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,50597,10116.0,,,CHEMBL621220,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7938,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,50597,10116.0,,,CHEMBL621221,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7939,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,50597,10116.0,,,CHEMBL621222,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7940,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,50597,10116.0,,,CHEMBL621223,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7941,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,50597,10116.0,,,CHEMBL876485,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7942,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL621224,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7943,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,50597,10116.0,,,CHEMBL621225,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7944,Rattus norvegicus,1,A,,1,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,50597,10116.0,,,CHEMBL621226,9866,948.0,,,Heart,N,Intermediate,BAO_0000218
7945,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621227,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7946,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,10116.0,,,CHEMBL621228,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7947,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,10116.0,,,CHEMBL621229,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7948,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,50597,10116.0,,,CHEMBL621230,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7949,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,10116.0,,,CHEMBL621231,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7950,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,10116.0,,,CHEMBL621232,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7951,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL621233,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7952,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621234,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7953,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,10116.0,,,CHEMBL621235,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7954,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL621236,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7955,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,50597,10116.0,,,CHEMBL621237,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7956,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,50597,10116.0,,,CHEMBL876486,9866,2113.0,,,Kidney,N,Intermediate,BAO_0000218
7957,Rattus norvegicus,1,A,,1,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,50597,10116.0,,,CHEMBL622436,9866,160.0,,,Intestine,N,Intermediate,BAO_0000218
7958,Rattus norvegicus,1,A,,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,50597,10116.0,,,CHEMBL622437,9866,160.0,,,Intestine,N,Intermediate,BAO_0000218
7959,Rattus norvegicus,1,A,,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,50597,10116.0,,,CHEMBL622438,9866,160.0,,,Intestine,N,Intermediate,BAO_0000218
7960,Rattus norvegicus,1,A,,1,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,50597,10116.0,,,CHEMBL622439,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7961,Rattus norvegicus,1,A,,1,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,50597,10116.0,,,CHEMBL622440,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7962,Rattus norvegicus,1,A,,1,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,50597,10116.0,,,CHEMBL622441,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7963,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,10116.0,,,CHEMBL622442,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7964,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,50597,10116.0,,,CHEMBL622443,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7965,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,10116.0,,,CHEMBL622444,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7966,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,50597,10116.0,,,CHEMBL622445,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7967,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,10116.0,,,CHEMBL622446,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7968,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL622447,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7969,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,50597,10116.0,,,CHEMBL622448,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7970,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,10116.0,,,CHEMBL622449,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7971,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,50597,10116.0,,,CHEMBL622450,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7972,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,50597,10116.0,,,CHEMBL622451,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7973,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA at 15 min,50597,10116.0,,,CHEMBL622452,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7974,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,50597,10116.0,,,CHEMBL622453,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7975,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA at 30 min,50597,10116.0,,,CHEMBL622454,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7976,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,50597,10116.0,,,CHEMBL622455,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7977,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,50597,10116.0,,,CHEMBL876024,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
7978,Rattus norvegicus,1,A,,1,T max was determined at 3 mg/kg po dose in rats,50597,10116.0,,,CHEMBL622456,2792,,,,,N,Intermediate,BAO_0000218
7979,Rattus norvegicus,1,A,,1,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL622457,15078,,,,,N,Intermediate,BAO_0000218
7980,Rattus norvegicus,1,A,,1,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL622458,15078,,,,,N,Intermediate,BAO_0000218
7981,Rattus norvegicus,1,A,,1,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,50597,10116.0,,,CHEMBL622459,15022,,,,,N,Intermediate,BAO_0000218
7982,Rattus norvegicus,1,A,,1,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,50597,10116.0,,,CHEMBL873343,15022,,,,,N,Intermediate,BAO_0000218
7983,Rattus norvegicus,1,A,,1,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,50597,10116.0,,,CHEMBL622460,15022,,,,,N,Intermediate,BAO_0000218
7984,Rattus norvegicus,1,A,,1,Time for maximum plasma concentration determined in rat,50597,10116.0,,,CHEMBL622461,4576,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7985,Rattus norvegicus,1,A,,1,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,10116.0,,,CHEMBL622462,6681,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7986,Rattus norvegicus,1,A,,1,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL622463,16365,,,,,N,Intermediate,BAO_0000218
7987,Rattus norvegicus,1,A,,1,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL622464,16365,,,,,N,Intermediate,BAO_0000218
7988,Rattus norvegicus,1,A,,1,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,50597,10116.0,,,CHEMBL622465,16365,,,,,N,Intermediate,BAO_0000218
7989,Rattus norvegicus,1,A,,1,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL622466,16365,,,,,N,Intermediate,BAO_0000218
7990,Rattus norvegicus,1,A,,1,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,50597,10116.0,,,CHEMBL622467,16365,,,,,N,Intermediate,BAO_0000218
7991,Rattus norvegicus,1,A,,1,Time of maximum plasma concentration in rat,50597,10116.0,,,CHEMBL622468,6824,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7992,Rattus norvegicus,1,A,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL876025,6685,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7993,Rattus norvegicus,1,A,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,10116.0,,,CHEMBL622469,6685,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7994,Rattus norvegicus,1,A,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,10116.0,,,CHEMBL622470,6685,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7995,Rattus norvegicus,1,A,,1,Time required to reach maximum concentration (Cmax) after oral administration in rat,50597,10116.0,,,CHEMBL622471,15662,,,,,N,Intermediate,BAO_0000218
7996,Rattus norvegicus,1,A,,1,Time required to reach maximum concentration in rat plasma,50597,10116.0,,,CHEMBL622472,1742,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7997,Rattus norvegicus,1,A,,1,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,10116.0,,,CHEMBL622473,2774,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7998,Rattus norvegicus,1,A,,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,10116.0,,,CHEMBL624282,5199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
7999,Rattus norvegicus,1,A,,1,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,10116.0,,,CHEMBL624283,12873,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8000,Rattus norvegicus,1,A,,1,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,10116.0,,,CHEMBL624284,12873,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8001,Rattus norvegicus,1,A,,1,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,10116.0,,,CHEMBL624285,1916,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8002,Rattus norvegicus,1,A,,1,Time to reach Cmax after oral administration to rats,50597,10116.0,,,CHEMBL624286,16367,,,,,N,Intermediate,BAO_0000218
8003,Rattus norvegicus,1,A,,1,Time to reach Cmax when a dose of 1 mg/kg is administered orally,50597,10116.0,,,CHEMBL624287,16366,,,,,N,Intermediate,BAO_0000218
8004,Rattus norvegicus,1,A,,1,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,50597,10116.0,,,CHEMBL624288,216,,,,,N,Intermediate,BAO_0000218
8005,Rattus norvegicus,1,A,,1,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,50597,10116.0,,,CHEMBL624289,6410,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8006,Rattus norvegicus,1,A,,1,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,50597,10116.0,,,CHEMBL873344,6410,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8007,Rattus norvegicus,1,A,,1,Tmax after peroral administration (10 mg/kg) was determined in rat,50597,10116.0,,,CHEMBL619623,6215,,,,,N,Intermediate,BAO_0000218
8008,Rattus norvegicus,1,A,,1,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL621399,3598,,,,,N,Expert,BAO_0000218
8009,Rattus norvegicus,1,A,,1,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,50597,10116.0,,,CHEMBL621400,4527,,,,,N,Intermediate,BAO_0000218
8010,Rattus norvegicus,1,A,,1,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",50597,10116.0,,,CHEMBL621401,17670,,,,,N,Intermediate,BAO_0000218
8011,Rattus norvegicus,1,A,,1,Tmax was determined,50597,10116.0,,,CHEMBL621402,1465,,,,,N,Intermediate,BAO_0000218
8012,Rattus norvegicus,1,A,,1,Tmax was determined,50597,10116.0,,,CHEMBL621403,2552,,,,,N,Intermediate,BAO_0000218
8013,Rattus norvegicus,1,A,,1,Tmax after oral administration in rat,50597,10116.0,,,CHEMBL621121,5656,,,,,N,Intermediate,BAO_0000218
8014,Rattus norvegicus,1,A,,1,Tmax after peroral administration in rats at 2.4 uM/kg,50597,10116.0,,,CHEMBL872525,17764,,,,,N,Intermediate,BAO_0000218
8015,Rattus norvegicus,1,A,,1,Tmax in male rat,50597,10116.0,,,CHEMBL621122,5610,,,,,N,Intermediate,BAO_0000218
8016,Rattus norvegicus,1,A,,1,Tmax in rat at 10 mg/kg,50597,10116.0,,,CHEMBL621123,6046,,,,,N,Intermediate,BAO_0000218
8017,Rattus norvegicus,1,A,,1,Tmax in rat by po administration at a dose of 40 mg/kg,50597,10116.0,,,CHEMBL621124,5874,,,,,N,Intermediate,BAO_0000218
8018,Rattus norvegicus,1,A,,1,Tmax in rats,50597,10116.0,,,CHEMBL621125,17596,,,,,N,Intermediate,BAO_0000218
8019,Rattus norvegicus,1,A,,1,Tmax was measured in rats after peroral administration at 5 mg/kg,50597,10116.0,,,CHEMBL621126,17804,,,,,N,Intermediate,BAO_0000218
8020,Rattus norvegicus,1,A,,1,Tmax value after oral dose at a dose of 10 mg/kg in rats.,50597,10116.0,,,CHEMBL621127,1908,,,,,N,Intermediate,BAO_0000218
8021,Rattus norvegicus,1,A,,1,Tmax value after administration of 20 mg/Kg oral dose in rat,50597,10116.0,,,CHEMBL621128,2959,,,,,N,Intermediate,BAO_0000218
8022,Rattus norvegicus,1,A,,1,Tmax value at a dose of 10 mg/kg in male SD rats,50597,10116.0,,,CHEMBL618263,6757,,,,,N,Intermediate,BAO_0000218
8023,Rattus norvegicus,1,A,,1,Tmax value at a dose of 100 mg/kg in male SD rats,50597,10116.0,,,CHEMBL618264,6757,,,,,N,Intermediate,BAO_0000218
8024,Rattus norvegicus,1,A,,1,Tmax value at a dose of 50 mg/kg in male SD rats,50597,10116.0,,,CHEMBL618265,6757,,,,,N,Intermediate,BAO_0000218
8025,Rattus norvegicus,1,A,,1,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,10116.0,,,CHEMBL618266,4186,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8026,Rattus norvegicus,1,A,,1,time required to reach maximum concentration (Cmax) after oral administration in rat,50597,10116.0,,,CHEMBL618267,15662,,,,,N,Intermediate,BAO_0000218
8027,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),50597,10116.0,,,CHEMBL618450,429,1088.0,,,Urine,N,Intermediate,BAO_0000218
8028,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),50597,10116.0,,,CHEMBL618451,429,1088.0,,,Urine,N,Intermediate,BAO_0000218
8029,Rattus norvegicus,1,A,,1,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,10116.0,,,CHEMBL618452,5546,,,,,N,Intermediate,BAO_0000218
8030,Rattus norvegicus,1,A,,1,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,50597,10116.0,,,CHEMBL618453,3173,1088.0,,,Urine,N,Intermediate,BAO_0000218
8031,Rattus norvegicus,1,A,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,50597,10116.0,,,CHEMBL618454,3173,1088.0,,,Urine,N,Intermediate,BAO_0000218
8032,Rattus norvegicus,1,A,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,50597,10116.0,,,CHEMBL618455,3173,1088.0,,,Urine,N,Intermediate,BAO_0000218
8033,Rattus norvegicus,1,A,,1,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,50597,10116.0,,,CHEMBL618456,4257,,,,,N,Intermediate,BAO_0000218
8034,Rattus norvegicus,1,A,,1,Compound distribution in rat tissues was determined,50597,10116.0,,,CHEMBL618457,6011,,,,,N,Intermediate,BAO_0000218
8035,Rattus norvegicus,1,A,,1,Volume of distribution was evaluated in rat,50597,10116.0,,,CHEMBL618458,5472,,,,,N,Intermediate,BAO_0000218
8036,Rattus norvegicus,1,A,,1,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL618459,14346,,,,,N,Intermediate,BAO_0000218
8037,Rattus norvegicus,1,A,,1,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL876733,14346,,,,,N,Intermediate,BAO_0000218
8038,Canis lupus familiaris,1,A,,1,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,50588,9615.0,,,CHEMBL618460,14346,,,,,N,Intermediate,BAO_0000218
8039,Rattus norvegicus,1,A,,1,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL618461,14346,,,,,N,Intermediate,BAO_0000218
8040,,0,A,,1,Area under the curve was determined after oral administration (300 uM/Kg),22224,,,,CHEMBL618462,15469,,,,,U,Autocuration,BAO_0000019
8041,Rattus norvegicus,1,A,,1,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL618463,14346,,,,,N,Intermediate,BAO_0000218
8042,Rattus norvegicus,1,A,,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,50597,10116.0,,,CHEMBL618464,14346,,,,,N,Intermediate,BAO_0000218
8043,Rattus norvegicus,1,A,,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL618465,14346,,,,,N,Intermediate,BAO_0000218
8044,Rattus norvegicus,1,A,,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,50597,10116.0,,,CHEMBL618466,14346,,,,,N,Intermediate,BAO_0000218
8045,Rattus norvegicus,1,A,,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,50597,10116.0,,,CHEMBL618467,14346,,,,,N,Intermediate,BAO_0000218
8046,Rattus norvegicus,1,A,,1,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,10116.0,,,CHEMBL618468,15372,,,,,N,Intermediate,BAO_0000218
8047,Canis lupus familiaris,1,A,,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,50588,9615.0,,,CHEMBL618469,12935,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8048,Canis lupus familiaris,1,A,,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,50588,9615.0,,,CHEMBL618470,12935,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8049,,0,A,,1,Plasma drug AUC in rat (PO dose),22224,,,,CHEMBL618471,14813,,,,,U,Autocuration,BAO_0000218
8050,Mus musculus,1,A,,1,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,50594,10090.0,,,CHEMBL618472,15792,,,,,N,Intermediate,BAO_0000218
8051,,0,A,,1,Area under was determined at a dose of 30 mg/kg,22224,,,,CHEMBL618473,3579,,,,,U,Autocuration,BAO_0000218
8052,Mustela putorius furo,1,A,,1,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,50506,9669.0,,,CHEMBL621699,12487,,,,,N,Intermediate,BAO_0000218
8053,Rattus norvegicus,1,A,,1,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,50597,10116.0,,,CHEMBL621700,12487,,,,,N,Intermediate,BAO_0000218
8054,Rattus norvegicus,1,A,,1,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,50597,10116.0,,,CHEMBL621701,12487,,,,,N,Intermediate,BAO_0000218
8055,Mustela putorius furo,1,A,,1,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,50506,9669.0,,,CHEMBL621702,12487,,,,,N,Intermediate,BAO_0000218
8056,Canis lupus familiaris,1,A,,1,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,50588,9615.0,,,CHEMBL621703,12487,,,,,N,Intermediate,BAO_0000218
8057,Canis lupus familiaris,1,A,,1,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,50588,9615.0,,,CHEMBL621704,12487,,,,,N,Intermediate,BAO_0000218
8058,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",50597,10116.0,,,CHEMBL624259,12902,,,,,N,Intermediate,BAO_0000218
8059,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",50597,10116.0,,,CHEMBL624260,12902,,,,,N,Intermediate,BAO_0000218
8060,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",50597,10116.0,,,CHEMBL624430,12902,,,,,N,Intermediate,BAO_0000218
8061,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",50597,10116.0,,,CHEMBL624431,12902,,,,,N,Intermediate,BAO_0000218
8062,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",50597,10116.0,,,CHEMBL624432,12902,,,,,N,Intermediate,BAO_0000218
8063,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",50597,10116.0,,,CHEMBL624433,12902,,,,,N,Intermediate,BAO_0000218
8064,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",50597,10116.0,,,CHEMBL624434,12902,,,,,N,Intermediate,BAO_0000218
8065,Rattus norvegicus,1,A,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",50597,10116.0,,,CHEMBL624435,12902,,,,,N,Intermediate,BAO_0000218
8066,Mus musculus,1,A,,1,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,50594,10090.0,,,CHEMBL618570,12745,,,,,N,Intermediate,BAO_0000218
8067,Mus musculus,1,A,,1,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,10090.0,,,CHEMBL618571,12745,,,,,N,Intermediate,BAO_0000218
8068,Mus musculus,1,A,,1,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,50594,10090.0,,,CHEMBL618572,12745,,,,,N,Intermediate,BAO_0000218
8069,Mus musculus,1,A,,1,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,10090.0,,,CHEMBL618573,12745,,,,,N,Intermediate,BAO_0000218
8070,Mus musculus,1,A,,1,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,50594,10090.0,,,CHEMBL619267,12745,,,,,N,Intermediate,BAO_0000218
8071,Mus musculus,1,A,,1,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,10090.0,,,CHEMBL619431,12745,,,,,N,Intermediate,BAO_0000218
8072,Mus musculus,1,A,,1,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,50594,10090.0,,,CHEMBL619432,12745,,,,,N,Intermediate,BAO_0000218
8073,Mus musculus,1,A,,1,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,10090.0,,,CHEMBL619433,12745,,,,,N,Intermediate,BAO_0000218
8074,,0,A,,1,AUC in mice after oral dose (50 mg/kg),22224,,,,CHEMBL619434,13298,1969.0,,,Plasma,U,Autocuration,BAO_0000218
8075,Mus musculus,1,A,,1,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,50594,10090.0,,,CHEMBL619435,12226,1977.0,,,Serum,N,Intermediate,BAO_0000218
8076,,0,A,,1,AUC (0-4 hr) ug/ml/h,22224,,,,CHEMBL619436,12634,1969.0,,,Plasma,U,Autocuration,BAO_0000019
8077,Rattus norvegicus,1,A,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,50597,10116.0,,,CHEMBL619437,14810,,,,,N,Intermediate,BAO_0000218
8078,,0,A,,1,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,22224,,,,CHEMBL619438,13889,,,,,U,Autocuration,BAO_0000218
8079,Mus musculus,1,A,,1,Compound was evaluated for Area under curve in mice,50594,10090.0,,,CHEMBL619439,10018,,,,,N,Intermediate,BAO_0000218
8080,Rattus norvegicus,1,A,,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,10116.0,,,CHEMBL619440,8758,,,,,N,Intermediate,BAO_0000218
8081,,0,F,,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,22224,,,,CHEMBL619441,8758,,,,,U,Autocuration,BAO_0000218
8082,Rattus norvegicus,1,A,,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,10116.0,,,CHEMBL619442,8758,,,,,N,Intermediate,BAO_0000218
8083,,0,A,,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,22224,,,,CHEMBL875156,2249,,,,,U,Autocuration,BAO_0000019
8084,,0,A,,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,22224,,,,CHEMBL619443,2249,,,,,U,Autocuration,BAO_0000019
8085,,0,A,,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,22224,,,,CHEMBL619444,2249,,,,,U,Autocuration,BAO_0000019
8086,,0,A,,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,22224,,,,CHEMBL623464,2249,,,,,U,Autocuration,BAO_0000019
8087,Mus musculus,1,A,,1,Compound was evaluated for area under curve when administered through oral route in mouse,50594,10090.0,,,CHEMBL623465,15115,,,,,N,Intermediate,BAO_0000218
8088,Rattus norvegicus,1,A,,1,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,50597,10116.0,,,CHEMBL623466,6518,,,,,N,Intermediate,BAO_0000218
8089,Rattus norvegicus,1,A,,1,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,50597,10116.0,,,CHEMBL623467,6518,,,,,N,Intermediate,BAO_0000218
8090,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL623468,6249,,,,,N,Intermediate,BAO_0000218
8091,Rattus norvegicus,1,A,,1,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,10116.0,,,CHEMBL622660,2463,,,,,N,Intermediate,BAO_0000218
8092,Rattus norvegicus,1,A,,1,Plasma clearance rate in Sprague-Dawley rats,50597,10116.0,,,CHEMBL622661,4969,,,,,N,Intermediate,BAO_0000218
8093,Rattus norvegicus,1,F,,1,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL622662,17720,,,,,N,Intermediate,BAO_0000218
8094,Rattus norvegicus,1,A,,1,Pharmacokinetic property (total body clearance) in rat,50597,10116.0,,,CHEMBL622663,3457,,,,,N,Intermediate,BAO_0000218
8095,Rattus norvegicus,1,A,,1,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,50597,10116.0,,,CHEMBL622664,5983,,,,,N,Intermediate,BAO_0000218
8096,Rattus norvegicus,1,A,,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL622665,6295,,,,,N,Intermediate,BAO_0000218
8097,Rattus norvegicus,1,A,,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL622666,6296,,,,,N,Intermediate,BAO_0000218
8098,Rattus norvegicus,1,A,,1,Cl in rat i.v. at 2 mg/kg concentration,50597,10116.0,,,CHEMBL621615,17686,,,,,N,Intermediate,BAO_0000218
8099,Rattus norvegicus,1,A,,1,Clearance of compound after intravenous administration in rats at 24 uM/kg,50597,10116.0,,,CHEMBL621616,17764,,,,,N,Intermediate,BAO_0000218
8100,Rattus norvegicus,1,A,,1,Clearance was determined,50597,10116.0,,,CHEMBL621617,5503,,,,,N,Intermediate,BAO_0000218
8101,Rattus norvegicus,1,A,,1,Clearance by intravenous administration of 3.4 mg/kg in rat,50597,10116.0,,,CHEMBL621618,4368,,,,,N,Intermediate,BAO_0000218
8102,Rattus norvegicus,1,A,,1,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,10116.0,,,CHEMBL621619,6005,,,,,N,Intermediate,BAO_0000218
8103,Rattus norvegicus,1,A,,1,Clearance rate after i.v. administration in rats,50597,10116.0,,,CHEMBL621620,5031,,,,,N,Intermediate,BAO_0000218
8104,Rattus norvegicus,1,A,,1,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL621786,4890,,,,,N,Intermediate,BAO_0000218
8105,Rattus norvegicus,1,A,,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,10116.0,,,CHEMBL621787,5182,,,,,N,Intermediate,BAO_0000218
8106,Rattus norvegicus,1,A,,1,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,50597,10116.0,,,CHEMBL621788,5979,,,,,N,Intermediate,BAO_0000218
8107,Rattus norvegicus,1,A,,1,Clearance (Cl) after oral administration in rat,50597,10116.0,,,CHEMBL621789,5656,,,,,N,Intermediate,BAO_0000218
8108,Rattus norvegicus,1,A,,1,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,50597,10116.0,,,CHEMBL621790,17804,,,,,N,Intermediate,BAO_0000218
8109,Rattus norvegicus,1,A,,1,Compound was tested for plasma clearance in rat,50597,10116.0,,,CHEMBL621791,4839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8110,Rattus norvegicus,1,A,,1,In vitro microsome metabolism clearance in rat was determined,50597,10116.0,Microsomes,,CHEMBL621792,5041,,,,,N,Intermediate,BAO_0000218
8111,Rattus norvegicus,1,A,,1,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,50597,10116.0,Microsomes,,CHEMBL621793,5041,,,,,N,Intermediate,BAO_0000218
8112,Rattus norvegicus,1,A,,1,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL621794,5974,,,,,N,Intermediate,BAO_0000218
8113,Rattus norvegicus,1,A,,1,In vivo plasma clearance was determined,50597,10116.0,,,CHEMBL621795,5496,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8114,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,50597,10116.0,,,CHEMBL621796,5739,,,,,N,Intermediate,BAO_0000218
8115,Rattus norvegicus,1,A,Hepatocyte,1,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,50597,10116.0,,,CHEMBL621797,5676,2107.0,401.0,,Liver,N,Intermediate,BAO_0000218
8116,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Plasma clearance) was measured in rat,50597,10116.0,,,CHEMBL621798,4239,,,,,N,Intermediate,BAO_0000218
8117,Rattus norvegicus,1,A,,1,Pharmacokinetic property (clearance) in rat i.v.,50597,10116.0,,,CHEMBL621799,5676,,,,,N,Intermediate,BAO_0000218
8118,Rattus norvegicus,1,A,,1,"Plasma Clearance was evaluated in rats, iv",50597,10116.0,,,CHEMBL621800,1918,,,,,N,Intermediate,BAO_0000218
8119,Rattus norvegicus,1,A,,1,Plasma clearance (in vivo) in rats was determined,50597,10116.0,,,CHEMBL621801,17800,,,,,N,Intermediate,BAO_0000218
8120,Rattus norvegicus,1,A,,1,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,50597,10116.0,,,CHEMBL621802,6056,,,,,N,Intermediate,BAO_0000218
8121,Rattus norvegicus,1,A,,1,Plasma clearance was determined,50597,10116.0,,,CHEMBL618596,5496,,,,,N,Intermediate,BAO_0000218
8122,Rattus norvegicus,1,A,,1,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,50597,10116.0,,,CHEMBL618597,5939,,,,,N,Intermediate,BAO_0000218
8123,Rattus norvegicus,1,A,,1,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,50597,10116.0,,,CHEMBL618598,5939,,,,,N,Intermediate,BAO_0000218
8124,Rattus norvegicus,1,A,,1,Plasma clearance in rats,50597,10116.0,,,CHEMBL618599,17752,,,,,N,Intermediate,BAO_0000218
8125,Rattus norvegicus,1,A,,1,Plasma clearance rate determined in rat,50597,10116.0,,,CHEMBL618600,4576,,,,,N,Intermediate,BAO_0000218
8126,Rattus norvegicus,1,A,,1,Plasma clearance was determined in rat,50597,10116.0,,,CHEMBL618601,6011,,,,,N,Intermediate,BAO_0000218
8127,Rattus norvegicus,1,A,,1,Plasma clearance was determined,50597,10116.0,,,CHEMBL618602,5510,,,,,N,Intermediate,BAO_0000218
8128,Rattus norvegicus,1,A,,1,Plasma clearance value in rat,50597,10116.0,,,CHEMBL618603,5948,,,,,N,Intermediate,BAO_0000218
8129,Rattus norvegicus,1,A,,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,10116.0,,,CHEMBL618604,6125,2107.0,,,Liver,N,Intermediate,BAO_0000218
8130,Rattus norvegicus,1,A,,1,Clearance in rat,50597,10116.0,,,CHEMBL618605,4839,,,,,N,Intermediate,BAO_0000218
8131,Rattus norvegicus,1,A,,1,Total body clearance in rat i.v. at 2 mg/kg concentration,50597,10116.0,,,CHEMBL618606,17686,,,,,N,Intermediate,BAO_0000218
8132,Rattus norvegicus,1,A,,1,Clearance of compound in rats after intravenous administration,50597,10116.0,,,CHEMBL618607,6571,,,,,N,Intermediate,BAO_0000218
8133,Rattus norvegicus,1,A,,1,Clearance after iv administration to rats,50597,10116.0,,,CHEMBL618608,3364,,,,,N,Intermediate,BAO_0000218
8134,Rattus norvegicus,1,A,,1,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,10116.0,,,CHEMBL618609,13569,,,,,N,Intermediate,BAO_0000218
8135,Rattus norvegicus,1,A,,1,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,10116.0,,,CHEMBL618610,13569,,,,,N,Intermediate,BAO_0000218
8136,Rattus norvegicus,1,A,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,50597,10116.0,,,CHEMBL618611,13569,,,,,N,Intermediate,BAO_0000218
8137,Rattus norvegicus,1,A,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,10116.0,,,CHEMBL618612,13569,,,,,N,Intermediate,BAO_0000218
8138,Rattus norvegicus,1,A,,1,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,10116.0,,,CHEMBL618613,13569,,,,,N,Intermediate,BAO_0000218
8139,Rattus norvegicus,1,A,,1,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,10116.0,,,CHEMBL621076,13569,,,,,N,Intermediate,BAO_0000218
8140,Rattus norvegicus,1,A,,1,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,10116.0,,,CHEMBL621077,13569,,,,,N,Intermediate,BAO_0000218
8141,Rattus norvegicus,1,A,,1,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",50597,10116.0,,,CHEMBL621078,17670,,,,,N,Intermediate,BAO_0000218
8142,Rattus norvegicus,1,A,,1,Clearance in rat,50597,10116.0,,,CHEMBL621251,5970,,,,,N,Intermediate,BAO_0000218
8143,Rattus norvegicus,1,A,,1,Clearance in rat after oral administration at 10 mg/kg,50597,10116.0,,,CHEMBL621252,6495,,,,,N,Intermediate,BAO_0000218
8144,Rattus norvegicus,1,A,,1,Clearance in rat.,50597,10116.0,,,CHEMBL621253,4590,,,,,N,Intermediate,BAO_0000218
8145,Rattus norvegicus,1,A,,1,Clearance rate following an oral dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL621254,6193,,,,,N,Intermediate,BAO_0000218
8146,Rattus norvegicus,1,A,,1,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,50597,10116.0,,,CHEMBL621255,2832,,,,,N,Intermediate,BAO_0000218
8147,Rattus norvegicus,1,A,,1,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,50597,10116.0,,,CHEMBL621256,1052,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8148,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,50597,10116.0,,,CHEMBL621257,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8149,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,50597,10116.0,,,CHEMBL621258,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8150,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,50597,10116.0,,,CHEMBL621259,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8151,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,50597,10116.0,,,CHEMBL621260,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8152,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,50597,10116.0,,,CHEMBL876494,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8153,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,50597,10116.0,,,CHEMBL621261,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8154,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,50597,10116.0,,,CHEMBL621262,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8155,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,10116.0,,,CHEMBL621263,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8156,Rattus norvegicus,1,A,,1,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,50597,10116.0,,,CHEMBL621264,9866,2107.0,,,Liver,N,Intermediate,BAO_0000218
8157,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621265,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8158,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,50597,10116.0,,,CHEMBL621266,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8159,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621267,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8160,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621268,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8161,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,50597,10116.0,,,CHEMBL621269,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8162,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,50597,10116.0,,,CHEMBL621270,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8163,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,50597,10116.0,,,CHEMBL621271,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8164,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,50597,10116.0,,,CHEMBL621272,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8165,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,50597,10116.0,,,CHEMBL621273,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8166,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,50597,10116.0,,,CHEMBL621274,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8167,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,50597,10116.0,,,CHEMBL876495,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8168,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,50597,10116.0,,,CHEMBL621275,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8169,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,50597,10116.0,,,CHEMBL621276,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8170,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,50597,10116.0,,,CHEMBL621277,9866,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8171,Rattus norvegicus,1,A,,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,50597,10116.0,,,CHEMBL621278,9866,160.0,,,Intestine,N,Intermediate,BAO_0000218
8172,Rattus norvegicus,1,A,,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,50597,10116.0,,,CHEMBL621279,9866,160.0,,,Intestine,N,Intermediate,BAO_0000218
8173,Rattus norvegicus,1,A,,1,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),50597,10116.0,,,CHEMBL621280,9866,160.0,,,Intestine,N,Intermediate,BAO_0000218
8174,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621281,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8175,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,50597,10116.0,,,CHEMBL621282,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8176,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,10116.0,,,CHEMBL621283,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8177,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,50597,10116.0,,,CHEMBL621284,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8178,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,50597,10116.0,,,CHEMBL621285,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8179,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,50597,10116.0,,,CHEMBL621286,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8180,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,50597,10116.0,,,CHEMBL623220,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8181,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,50597,10116.0,,,CHEMBL623221,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8182,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,50597,10116.0,,,CHEMBL876029,9866,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8183,Rattus norvegicus,1,A,,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,50597,10116.0,,,CHEMBL623222,9866,945.0,,,Stomach,N,Intermediate,BAO_0000218
8184,Rattus norvegicus,1,A,,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,50597,10116.0,,,CHEMBL623223,9866,945.0,,,Stomach,N,Intermediate,BAO_0000218
8185,Rattus norvegicus,1,A,,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,50597,10116.0,,,CHEMBL621445,9866,945.0,,,Stomach,N,Intermediate,BAO_0000218
8186,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621446,13950,178.0,,,Blood,N,Intermediate,BAO_0000218
8187,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621447,13950,178.0,,,Blood,N,Intermediate,BAO_0000218
8188,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619681,13950,178.0,,,Blood,N,Intermediate,BAO_0000218
8189,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619682,13950,178.0,,,Blood,N,Intermediate,BAO_0000218
8190,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619683,13950,178.0,,,Blood,N,Intermediate,BAO_0000218
8191,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619684,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
8192,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619685,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
8193,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619686,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
8194,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619687,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
8195,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619688,13950,955.0,,,Brain,N,Intermediate,BAO_0000218
8196,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619689,13950,948.0,,,Heart,N,Intermediate,BAO_0000218
8197,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619690,13950,948.0,,,Heart,N,Intermediate,BAO_0000218
8198,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619691,13950,948.0,,,Heart,N,Intermediate,BAO_0000218
8199,Rattus norvegicus,1,A,,1,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,10116.0,,,CHEMBL619692,6062,,,,,N,Intermediate,BAO_0000218
8200,Rattus norvegicus,1,A,,1,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL619693,3598,,,,,N,Expert,BAO_0000218
8201,Rattus norvegicus,1,A,,1,Vc value after IV dose at a dose of 5 mg/kg in rats.,50597,10116.0,,,CHEMBL619694,1908,,,,,N,Intermediate,BAO_0000218
8202,Rattus norvegicus,1,A,,1,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,50597,10116.0,,,CHEMBL619695,17596,,,,,N,Intermediate,BAO_0000218
8203,Rattus norvegicus,1,A,,1,Compound was evaluated for pharmacokinetic parameter volume of distribution,50597,10116.0,,,CHEMBL619696,4891,,,,,N,Intermediate,BAO_0000218
8204,Rattus norvegicus,1,A,,1,Compound was evaluated for volume of distribution in rat,50597,10116.0,,,CHEMBL619697,740,,,,,N,Intermediate,BAO_0000218
8205,Rattus norvegicus,1,A,,1,Steady state volume distribution was determined; steady state(ss),50597,10116.0,,,CHEMBL619698,16366,,,,,N,Intermediate,BAO_0000218
8206,Rattus norvegicus,1,A,,1,Steady state volume of distribution after iv administration to rats,50597,10116.0,,,CHEMBL619699,3364,,,,,N,Intermediate,BAO_0000218
8207,Rattus norvegicus,1,A,,1,Steady state volume of distribution dosing at 3 mg/kg iv,50597,10116.0,,,CHEMBL619700,2552,,,,,N,Intermediate,BAO_0000218
8208,Rattus norvegicus,1,A,,1,The compound was evaluated for volume of distribution in rat,50597,10116.0,,,CHEMBL619701,406,,,,,N,Intermediate,BAO_0000218
8209,Rattus norvegicus,1,A,,1,The compound was tested for volume of distribution in rat,50597,10116.0,,,CHEMBL619702,12500,,,,,N,Intermediate,BAO_0000218
8210,Rattus norvegicus,1,A,,1,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,50597,10116.0,,,CHEMBL620335,12500,,,,,N,Intermediate,BAO_0000218
8211,Rattus norvegicus,1,A,,1,Volume distribution (VD) after oral administration in rat,50597,10116.0,,,CHEMBL620336,5656,,,,,N,Intermediate,BAO_0000218
8212,Rattus norvegicus,1,A,,1,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,10116.0,,,CHEMBL620337,17671,,,,,N,Intermediate,BAO_0000218
8213,Rattus norvegicus,1,A,,1,Volume distribution in rat,50597,10116.0,,,CHEMBL620520,1094,,,,,N,Intermediate,BAO_0000218
8214,Rattus norvegicus,1,A,,1,Volume distribution in rat,50597,10116.0,,,CHEMBL620521,5833,,,,,N,Intermediate,BAO_0000218
8215,Rattus norvegicus,1,A,,1,Volume distribution in rat after peroral administration at 10 mg/kg,50597,10116.0,,,CHEMBL875825,5939,,,,,N,Intermediate,BAO_0000218
8216,Rattus norvegicus,1,A,,1,Volume distribution in rat after peroral administration at 5 mg/kg,50597,10116.0,,,CHEMBL620522,5939,,,,,N,Intermediate,BAO_0000218
8217,Rattus norvegicus,1,A,,1,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,10116.0,,,CHEMBL620523,6005,,,,,N,Intermediate,BAO_0000218
8218,Rattus norvegicus,1,A,,1,Volume of distribution in rat.,50597,10116.0,,,CHEMBL620524,1696,,,,,N,Intermediate,BAO_0000218
8219,Rattus norvegicus,1,A,,1,Volume of distribution in rat,50597,10116.0,,,CHEMBL620525,6672,,,,,N,Intermediate,BAO_0000218
8220,Rattus norvegicus,1,A,,1,Volume of distribution in rat,50597,10116.0,,,CHEMBL620526,6673,,,,,N,Intermediate,BAO_0000218
8221,Rattus norvegicus,1,A,,1,Volume of distribution in rat by iv administration,50597,10116.0,,,CHEMBL620527,5871,,,,,N,Intermediate,BAO_0000218
8222,Rattus norvegicus,1,A,,1,Volume of distribution in rats,50597,10116.0,,,CHEMBL620528,6803,,,,,N,Intermediate,BAO_0000218
8223,Rattus norvegicus,1,A,,1,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,10116.0,,,CHEMBL620529,5199,,,,,N,Intermediate,BAO_0000218
8224,Rattus norvegicus,1,A,,1,Volume distribution at the dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL620530,4727,,,,,N,Intermediate,BAO_0000218
8225,Rattus norvegicus,1,A,,1,Steady state volume of distribution was determined,50597,10116.0,,,CHEMBL620531,16367,,,,,N,Intermediate,BAO_0000218
8226,Macaca mulatta,0,A,,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,9544.0,,,CHEMBL620532,5005,,,,,U,Intermediate,BAO_0000218
8227,Rattus norvegicus,0,A,,1,Compound was tested for its plasma volume distribution in Sprague Dawley rats,22224,10116.0,,,CHEMBL620533,5005,,,,,U,Intermediate,BAO_0000218
8228,Rattus norvegicus,0,A,,1,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,22224,10116.0,,,CHEMBL620534,5005,,,,,U,Intermediate,BAO_0000218
8229,Rattus norvegicus,1,A,,1,Mean (%CV) PK parameters for Vdss(mL/kg).,50597,10116.0,,,CHEMBL620535,15765,,,,,N,Intermediate,BAO_0000218
8230,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL875826,2792,,,,,N,Intermediate,BAO_0000218
8231,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL620536,2792,,,,,N,Intermediate,BAO_0000218
8232,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,10116.0,,,CHEMBL620537,5334,,,,,N,Intermediate,BAO_0000218
8233,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,50597,10116.0,,,CHEMBL618526,5334,,,,,N,Intermediate,BAO_0000218
8234,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,50597,10116.0,,,CHEMBL618527,5739,,,,,N,Intermediate,BAO_0000218
8235,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Vdss) in rat,50597,10116.0,,,CHEMBL618528,5789,,,,,N,Intermediate,BAO_0000218
8236,Rattus norvegicus,1,A,,1,Pharmacokinetic property (vdss) was measured in rat,50597,10116.0,,,CHEMBL618529,4239,,,,,N,Intermediate,BAO_0000218
8237,Rattus norvegicus,1,A,,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,50597,10116.0,,,CHEMBL618530,4709,,,,,N,Intermediate,BAO_0000218
8238,Rattus norvegicus,1,A,,1,Volume of distribution in rat,50597,10116.0,,,CHEMBL618531,6642,,,,,N,Intermediate,BAO_0000218
8239,Rattus norvegicus,1,A,,1,The pharmacokinetic parameter volume of distribution in vivo in rats,50597,10116.0,,,CHEMBL618532,5247,,,,,N,Intermediate,BAO_0000218
8240,Rattus norvegicus,1,F,,1,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL618533,17720,,,,,N,Intermediate,BAO_0000218
8241,Rattus norvegicus,1,A,,1,Vdss in rat i.v. at 2 mg/kg concentration,50597,10116.0,,,CHEMBL618534,17686,,,,,N,Intermediate,BAO_0000218
8242,Rattus norvegicus,1,A,,1,Volume distribution after intravenous administration (1 mg/kg) in rat,50597,10116.0,,,CHEMBL618535,4689,,,,,N,Intermediate,BAO_0000218
8243,Rattus norvegicus,1,A,,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,10116.0,,,CHEMBL618536,5654,,,,,N,Intermediate,BAO_0000218
8244,Rattus norvegicus,1,A,,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,10116.0,,,CHEMBL618537,5654,,,,,N,Intermediate,BAO_0000218
8245,Rattus norvegicus,1,A,,1,Volume distribution at a dose of 10 uM/kg in rat was determined,50597,10116.0,,,CHEMBL618538,4527,,,,,N,Intermediate,BAO_0000218
8246,Rattus norvegicus,1,A,,1,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,10116.0,,,CHEMBL618539,4521,,,,,N,Intermediate,BAO_0000218
8247,Rattus norvegicus,1,A,,1,Volume distribution was calculated in rat,50597,10116.0,,,CHEMBL618540,6057,,,,,N,Intermediate,BAO_0000218
8248,Rattus norvegicus,1,A,,1,Volume distribution was determined,50597,10116.0,,,CHEMBL618541,5510,,,,,N,Intermediate,BAO_0000218
8249,Rattus norvegicus,1,A,,1,Volume of distribution after intravenous administration was evaluated in rat,50597,10116.0,,,CHEMBL618542,2938,,,,,N,Intermediate,BAO_0000218
8250,Rattus norvegicus,1,A,,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,10116.0,,,CHEMBL622544,6679,,,,,N,Intermediate,BAO_0000218
8251,Rattus norvegicus,1,A,,1,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",50597,10116.0,,,CHEMBL622545,6685,,,,,N,Intermediate,BAO_0000218
8252,Rattus norvegicus,1,A,,1,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,10116.0,,,CHEMBL622546,6685,,,,,N,Intermediate,BAO_0000218
8253,Rattus norvegicus,1,A,,1,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",50597,10116.0,,,CHEMBL622547,6685,,,,,N,Intermediate,BAO_0000218
8254,Rattus norvegicus,1,A,,1,Volume of distribution in steady state was determined in rat,50597,10116.0,,,CHEMBL622548,5145,,,,,N,Intermediate,BAO_0000218
8255,Rattus norvegicus,1,A,,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,50597,10116.0,,,CHEMBL622549,6467,,,,,N,Intermediate,BAO_0000218
8256,Rattus norvegicus,1,A,,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,10116.0,,,CHEMBL622550,6467,,,,,N,Intermediate,BAO_0000218
8257,Mus musculus,1,A,,1,Compound was evaluated for area under curve when administered through oral route to mouse,50594,10090.0,,,CHEMBL622551,15115,,,,,N,Intermediate,BAO_0000218
8258,Rattus norvegicus,1,A,,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,10116.0,,,CHEMBL622552,8758,,,,,N,Intermediate,BAO_0000218
8259,Rattus norvegicus,1,A,,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,10116.0,,,CHEMBL622553,8758,,,,,N,Intermediate,BAO_0000218
8260,,0,F,,1,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,22224,,,,CHEMBL622554,8267,,,,,U,Autocuration,BAO_0000218
8261,Canis lupus familiaris,1,A,,1,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,50588,9615.0,,,CHEMBL622555,8267,,,,,N,Intermediate,BAO_0000218
8262,Mus musculus,1,A,,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,10090.0,,,CHEMBL622556,14239,,,,,N,Intermediate,BAO_0000218
8263,Mus musculus,1,A,,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,10090.0,,,CHEMBL622557,14239,,,,,N,Intermediate,BAO_0000218
8264,Mus musculus,1,A,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,50594,10090.0,,,CHEMBL622558,10754,178.0,,,Blood,N,Intermediate,BAO_0000218
8265,Mus musculus,1,A,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,50594,10090.0,,,CHEMBL622559,10754,178.0,,,Blood,N,Intermediate,BAO_0000218
8266,Canis lupus familiaris,1,A,,1,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,50588,9615.0,,,CHEMBL622560,10754,,,,,N,Intermediate,BAO_0000218
8267,Rattus norvegicus,1,A,,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,10116.0,,,CHEMBL622561,14681,,,,,N,Intermediate,BAO_0000218
8268,Rattus norvegicus,1,A,,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,50597,10116.0,,,CHEMBL622562,14681,,,,,N,Intermediate,BAO_0000218
8269,Rattus norvegicus,1,A,,1,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,10116.0,,,CHEMBL622563,14681,,,,,N,Intermediate,BAO_0000218
8270,,0,A,,1,Concentration of compound in Central nervous system,22224,,,,CHEMBL622564,13118,,,,,U,Autocuration,BAO_0000019
8271,,0,A,,1,Concentration of compound in Central nervous system; Not detectable,22224,,,,CHEMBL622565,13118,,,,,U,Autocuration,BAO_0000019
8272,Mus musculus,1,A,,1,"Concentration of diester in the blood, following oral administration in mice",50594,10090.0,,,CHEMBL622566,13318,,,,,N,Intermediate,BAO_0000218
8273,Mus musculus,1,A,,1,"Concentration of monoester in the blood, following oral administration in mice",50594,10090.0,,,CHEMBL624515,13318,,,,,N,Intermediate,BAO_0000218
8274,Mus musculus,1,A,,1,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,50594,10090.0,,,CHEMBL624516,13318,,,,,N,Intermediate,BAO_0000218
8275,,0,A,,1,Evaluated for Pharmacokinetic property: Area under the curve,22224,,,,CHEMBL624517,15692,,,,,U,Autocuration,BAO_0000019
8276,Mus musculus,1,A,,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,50594,10090.0,,,CHEMBL624518,14839,,,,,N,Intermediate,BAO_0000218
8277,Macaca fascicularis,1,A,,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,100710,9541.0,,,CHEMBL624519,14839,,,,,N,Intermediate,BAO_0000218
8278,Macaca fascicularis,1,A,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,100710,9541.0,,,CHEMBL624520,14839,,,,,N,Intermediate,BAO_0000218
8279,Macaca fascicularis,1,A,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,100710,9541.0,,,CHEMBL624521,14839,,,,,N,Intermediate,BAO_0000218
8280,Macaca fascicularis,1,A,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,100710,9541.0,,,CHEMBL624522,14839,,,,,N,Intermediate,BAO_0000218
8281,Macaca fascicularis,1,A,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,100710,9541.0,,,CHEMBL624523,14839,,,,,N,Intermediate,BAO_0000218
8282,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,9541.0,,,CHEMBL624409,14839,,,,,N,Intermediate,BAO_0000218
8283,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",100710,9541.0,,,CHEMBL624410,14839,,,,,N,Intermediate,BAO_0000218
8284,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,9541.0,,,CHEMBL624411,14839,,,,,N,Intermediate,BAO_0000218
8285,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",100710,9541.0,,,CHEMBL623531,14839,,,,,N,Intermediate,BAO_0000218
8286,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",100710,9541.0,,,CHEMBL623532,14839,,,,,N,Intermediate,BAO_0000218
8287,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",100710,9541.0,,,CHEMBL623533,14839,,,,,N,Intermediate,BAO_0000218
8288,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,9541.0,,,CHEMBL623534,14839,,,,,N,Intermediate,BAO_0000218
8289,Mus musculus,1,A,,1,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,50594,10090.0,,,CHEMBL623535,14839,,,,,N,Intermediate,BAO_0000218
8290,Mus musculus,1,A,,1,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,50594,10090.0,,,CHEMBL623536,14839,,,,,N,Intermediate,BAO_0000218
8291,Mus musculus,1,A,,1,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,50594,10090.0,,,CHEMBL623537,14839,,,,,N,Intermediate,BAO_0000218
8292,Mus musculus,1,A,,1,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,50594,10090.0,,,CHEMBL623538,14839,,,,,N,Intermediate,BAO_0000218
8293,Mus musculus,1,A,,1,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,50594,10090.0,,,CHEMBL623539,14839,,,,,N,Intermediate,BAO_0000218
8294,Mus musculus,1,A,,1,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,50594,10090.0,,,CHEMBL623540,14839,,,,,N,Intermediate,BAO_0000218
8295,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",50594,10090.0,,,CHEMBL623541,14839,,,,,N,Intermediate,BAO_0000218
8296,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",50594,10090.0,,,CHEMBL623542,14839,,,,,N,Intermediate,BAO_0000218
8297,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",50594,10090.0,,,CHEMBL623543,14839,,,,,N,Intermediate,BAO_0000218
8298,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",50594,10090.0,,,CHEMBL623544,14839,,,,,N,Intermediate,BAO_0000218
8299,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",50594,10090.0,,,CHEMBL623545,14839,,,,,N,Intermediate,BAO_0000218
8300,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",50594,10090.0,,,CHEMBL623546,14839,,,,,N,Intermediate,BAO_0000218
8301,Rattus norvegicus,1,A,,1,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL623547,5408,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8302,Rattus norvegicus,1,A,,1,High i.v. clearance in Dawley rats,50597,10116.0,,,CHEMBL623548,6827,,,,,N,Intermediate,BAO_0000218
8303,Rattus norvegicus,1,A,,1,In vitro clearance in rat liver microsomes,50597,10116.0,Microsomes,,CHEMBL623549,17538,2107.0,,,Liver,N,Intermediate,BAO_0000218
8304,Rattus norvegicus,1,A,,1,Intrinsic clearance in rat liver microsomes was determined,50597,10116.0,Microsomes,,CHEMBL623550,6331,2107.0,,,Liver,N,Intermediate,BAO_0000218
8305,Rattus norvegicus,1,A,Hepatocyte,1,Intrinsic clearance in rat hepatocytes was determined,50597,10116.0,,,CHEMBL875276,5948,2107.0,401.0,,Liver,N,Intermediate,BAO_0000218
8306,Rattus norvegicus,1,A,,1,Plasma Clearance was determined,50597,10116.0,,,CHEMBL621872,4026,,,,,N,Intermediate,BAO_0000218
8307,Rattus norvegicus,1,A,,1,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,50597,10116.0,,,CHEMBL621873,6647,,,,,N,Intermediate,BAO_0000218
8308,Rattus norvegicus,1,A,,1,Plasma clearance in rat.,50597,10116.0,,,CHEMBL621874,1696,,,,,N,Intermediate,BAO_0000218
8309,Rattus norvegicus,1,A,,1,Plasma clearance in rats,50597,10116.0,,,CHEMBL621875,6597,,,,,N,Intermediate,BAO_0000218
8310,Rattus norvegicus,1,A,,1,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,50597,10116.0,,,CHEMBL621876,347,,,,,N,Intermediate,BAO_0000218
8311,Rattus norvegicus,1,A,,1,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,50597,10116.0,,,CHEMBL621877,16423,,,,,N,Intermediate,BAO_0000218
8312,Rattus norvegicus,1,A,,1,Plasma clearance was measured in rat,50597,10116.0,,,CHEMBL621878,2879,,,,,N,Intermediate,BAO_0000218
8313,Rattus norvegicus,1,A,,1,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,10116.0,,,CHEMBL621879,4883,,,,,N,Intermediate,BAO_0000218
8314,Rattus norvegicus,1,A,,1,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",50597,10116.0,,,CHEMBL621880,5328,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8315,Rattus norvegicus,1,A,,1,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,50597,10116.0,,,CHEMBL621881,5160,,,,,N,Intermediate,BAO_0000218
8316,Rattus norvegicus,1,A,,1,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,10116.0,,,CHEMBL621882,17582,,,,,N,Intermediate,BAO_0000218
8317,Rattus norvegicus,1,A,,1,Total clearance at 1 mg/kg was determined in rat,50597,10116.0,,,CHEMBL875283,17651,,,,,N,Intermediate,BAO_0000218
8318,Rattus norvegicus,1,A,,1,Total clearance at 10 mg/kg was determined in rat,50597,10116.0,,,CHEMBL621883,17651,,,,,N,Intermediate,BAO_0000218
8319,Rattus norvegicus,1,A,,1,Clearance in rat,50597,10116.0,,,CHEMBL621884,6596,,,,,N,Intermediate,BAO_0000218
8320,Rattus norvegicus,1,A,,1,Plasma clearance rate determined in rats,50597,10116.0,,,CHEMBL621885,4796,,,,,N,Intermediate,BAO_0000218
8321,Rattus norvegicus,1,A,,1,Clearance of compound in rat was evaluated,50597,10116.0,,,CHEMBL621886,6850,,,,,N,Intermediate,BAO_0000218
8322,Rattus norvegicus,1,A,,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,10116.0,,,CHEMBL621887,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8323,Rattus norvegicus,1,A,,1,Pharmacokinetic property (blood clearance) in rat,50597,10116.0,,,CHEMBL621888,3371,,,,,N,Intermediate,BAO_0000218
8324,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL621889,2083,,,,,N,Intermediate,BAO_0000218
8325,Rattus norvegicus,1,A,,1,Plasma clearance in rats,50597,10116.0,,,CHEMBL621890,4942,,,,,N,Intermediate,BAO_0000218
8326,Rattus norvegicus,1,A,,1,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,50597,10116.0,Microsomes,,CHEMBL621891,6838,2107.0,,,Liver,N,Intermediate,BAO_0000218
8327,Rattus norvegicus,1,A,,1,Clearance in Dawley rat,50597,10116.0,,,CHEMBL621892,5353,,,,,N,Intermediate,BAO_0000218
8328,Rattus norvegicus,1,A,,1,Clearance rat,50597,10116.0,,,CHEMBL621893,6641,,,,,N,Intermediate,BAO_0000218
8329,Rattus norvegicus,1,A,,1,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),50597,10116.0,,,CHEMBL621894,6641,,,,,N,Intermediate,BAO_0000218
8330,Rattus norvegicus,1,A,,1,Clearance rat; Not determined,50597,10116.0,,,CHEMBL621895,6641,,,,,N,Intermediate,BAO_0000218
8331,Rattus norvegicus,1,A,,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.,50597,10116.0,,,CHEMBL875284,6444,,,,,N,Intermediate,BAO_0000218
8332,Rattus norvegicus,1,A,,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,10116.0,,,CHEMBL618699,6444,,,,,N,Intermediate,BAO_0000218
8333,Rattus norvegicus,1,A,,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,10116.0,,,CHEMBL618700,6444,,,,,N,Intermediate,BAO_0000218
8334,Rattus norvegicus,1,A,,1,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,10116.0,,,CHEMBL618701,6211,,,,,N,Intermediate,BAO_0000218
8335,Rattus norvegicus,1,A,,1,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,10116.0,,,CHEMBL876600,12873,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8336,Rattus norvegicus,1,A,,1,Clearance of compound in rat after 1 mg/kg i.v. administration,50597,10116.0,,,CHEMBL618702,6570,,,,,N,Intermediate,BAO_0000218
8337,Rattus norvegicus,1,A,,1,Compound was evaluated for Hepatic clearance in rat,50597,10116.0,,,CHEMBL618703,3341,,,,,N,Intermediate,BAO_0000218
8338,Rattus norvegicus,1,A,,1,In vivo clearance after 5 mg/kg dose,50597,10116.0,,,CHEMBL618704,4891,,,,,N,Intermediate,BAO_0000218
8339,Rattus norvegicus,1,A,,1,Compound was tested for plasma clearance in rats,50597,10116.0,,,CHEMBL618705,1094,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8340,Rattus norvegicus,1,A,,1,Hepatic clearance after intravenous administration was evaluated in rat,50597,10116.0,,,CHEMBL618706,2938,,,,,N,Intermediate,BAO_0000218
8341,Rattus norvegicus,1,A,,1,Lower clearance in rat (i.v.) at 0.5 mpk,50597,10116.0,,,CHEMBL618707,17853,,,,,N,Intermediate,BAO_0000218
8342,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter expressed as plasma clearance in rat,50597,10116.0,,,CHEMBL618708,6049,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8343,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Clp) in rat,50597,10116.0,,,CHEMBL618709,5789,,,,,N,Intermediate,BAO_0000218
8344,Rattus norvegicus,1,A,,1,Plasma clearance in Sprague-Dawley rats,50597,10116.0,,,CHEMBL618710,4514,,,,,N,Intermediate,BAO_0000218
8345,Rattus norvegicus,1,A,,1,Plasma clearance (Clp) in rat,50597,10116.0,,,CHEMBL618711,6448,,,,,N,Intermediate,BAO_0000218
8346,Rattus norvegicus,1,A,,1,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,50597,10116.0,,,CHEMBL618712,6062,,,,,N,Intermediate,BAO_0000218
8347,Rattus norvegicus,1,A,,1,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,50597,10116.0,,,CHEMBL618713,5710,,,,,N,Intermediate,BAO_0000218
8348,Rattus norvegicus,1,A,,1,Plasma clearance after intravenous administration of 1 mg/kg in rat,50597,10116.0,,,CHEMBL618714,4709,,,,,N,Intermediate,BAO_0000218
8349,Rattus norvegicus,1,A,,1,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,10116.0,,,CHEMBL618715,4521,,,,,N,Intermediate,BAO_0000218
8350,Rattus norvegicus,1,A,,1,Plasma clearance in rat was determined,50597,10116.0,,,CHEMBL618716,1742,,,,,N,Intermediate,BAO_0000218
8351,Rattus norvegicus,1,A,,1,Plasma clearance measured in rat,50597,10116.0,,,CHEMBL876601,6057,,,,,N,Intermediate,BAO_0000218
8352,Rattus norvegicus,1,A,,1,Plasma clearance was calculated in rat,50597,10116.0,,,CHEMBL618717,6057,,,,,N,Intermediate,BAO_0000218
8353,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL618718,5145,,,,,N,Intermediate,BAO_0000218
8354,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL618719,5833,,,,,N,Intermediate,BAO_0000218
8355,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL618720,6453,,,,,N,Intermediate,BAO_0000218
8356,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL618721,6640,,,,,N,Intermediate,BAO_0000218
8357,Rattus norvegicus,1,A,,1,Plasma clearance in rats,50597,10116.0,,,CHEMBL621477,6305,,,,,N,Intermediate,BAO_0000218
8358,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL621478,6642,,,,,N,Intermediate,BAO_0000218
8359,Rattus norvegicus,1,A,,1,Plasma clearance was evaluated in rat,50597,10116.0,,,CHEMBL621479,5472,,,,,N,Intermediate,BAO_0000218
8360,Rattus norvegicus,1,A,,1,Plasma clearance was evaluated in rat; Not tested,50597,10116.0,,,CHEMBL621480,5472,,,,,N,Intermediate,BAO_0000218
8361,Rattus norvegicus,1,A,,1,Plasma clearance rate was determined for the compound in rat,50597,10116.0,,,CHEMBL621481,5144,,,,,N,Intermediate,BAO_0000218
8362,Rattus norvegicus,1,A,,1,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",50597,10116.0,,,CHEMBL621482,6685,,,,,N,Intermediate,BAO_0000218
8363,Rattus norvegicus,1,A,,1,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,10116.0,,,CHEMBL621483,6685,,,,,N,Intermediate,BAO_0000218
8364,Rattus norvegicus,1,A,,1,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",50597,10116.0,,,CHEMBL621484,6685,,,,,N,Intermediate,BAO_0000218
8365,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621485,13950,948.0,,,Heart,N,Intermediate,BAO_0000218
8366,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621486,13950,948.0,,,Heart,N,Intermediate,BAO_0000218
8367,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621487,13950,160.0,,,Intestine,N,Intermediate,BAO_0000218
8368,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621488,13950,160.0,,,Intestine,N,Intermediate,BAO_0000218
8369,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621489,13950,160.0,,,Intestine,N,Intermediate,BAO_0000218
8370,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621490,13950,160.0,,,Intestine,N,Intermediate,BAO_0000218
8371,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621491,13950,160.0,,,Intestine,N,Intermediate,BAO_0000218
8372,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621492,13950,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8373,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621493,13950,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8374,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621494,13950,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8375,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621495,13950,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8376,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621496,13950,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8377,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621497,13950,2107.0,,,Liver,N,Intermediate,BAO_0000218
8378,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621498,13950,2107.0,,,Liver,N,Intermediate,BAO_0000218
8379,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL621499,13950,2107.0,,,Liver,N,Intermediate,BAO_0000218
8380,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL618634,13950,2107.0,,,Liver,N,Intermediate,BAO_0000218
8381,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL618635,13950,2107.0,,,Liver,N,Intermediate,BAO_0000218
8382,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL618636,13950,2048.0,,,Lung,N,Intermediate,BAO_0000218
8383,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619737,13950,2048.0,,,Lung,N,Intermediate,BAO_0000218
8384,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL619738,13950,2048.0,,,Lung,N,Intermediate,BAO_0000218
8385,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL624329,13950,2048.0,,,Lung,N,Intermediate,BAO_0000218
8386,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL624330,13950,2048.0,,,Lung,N,Intermediate,BAO_0000218
8387,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL624331,13950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8388,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL624332,13950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8389,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL624333,13950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8390,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL624334,13950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8391,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL624335,13950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8392,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620016,13950,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8393,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620169,13950,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8394,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620170,13950,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8395,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620171,13950,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8396,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620172,13950,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8397,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620173,13950,945.0,,,Stomach,N,Intermediate,BAO_0000218
8398,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620174,13950,945.0,,,Stomach,N,Intermediate,BAO_0000218
8399,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620175,13950,945.0,,,Stomach,N,Intermediate,BAO_0000218
8400,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620176,13950,945.0,,,Stomach,N,Intermediate,BAO_0000218
8401,Rattus norvegicus,1,A,,1,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620177,13950,945.0,,,Stomach,N,Intermediate,BAO_0000218
8402,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620178,13950,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
8403,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620179,13950,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
8404,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620180,13950,,,,,N,Intermediate,BAO_0000218
8405,Rattus norvegicus,1,A,,1,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,50597,10116.0,,,CHEMBL620181,6570,,,,,N,Intermediate,BAO_0000218
8406,Rattus norvegicus,1,A,,1,Volume of distribution of compound in rats after intravenous administration,50597,10116.0,,,CHEMBL620182,6571,,,,,N,Intermediate,BAO_0000218
8407,Rattus norvegicus,1,A,,1,Volume of distribution in rat,50597,10116.0,,,CHEMBL620183,6453,,,,,N,Intermediate,BAO_0000218
8408,Rattus norvegicus,1,A,,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,50597,10116.0,,,CHEMBL620184,6444,,,,,N,Intermediate,BAO_0000218
8409,Rattus norvegicus,1,A,,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,10116.0,,,CHEMBL620185,6444,,,,,N,Intermediate,BAO_0000218
8410,Rattus norvegicus,1,A,,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,10116.0,,,CHEMBL620186,6444,,,,,N,Intermediate,BAO_0000218
8411,Rattus norvegicus,1,A,,1,Volume of distribution was determined in Dawley rat,50597,10116.0,,,CHEMBL620187,5353,,,,,N,Intermediate,BAO_0000218
8412,Rattus norvegicus,1,A,,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,10116.0,,,CHEMBL620188,5334,,,,,N,Intermediate,BAO_0000218
8413,Rattus norvegicus,1,A,,1,Volume of distribution was reported in Sprague-Dawley rat,50597,10116.0,,,CHEMBL620189,5334,,,,,N,Intermediate,BAO_0000218
8414,Rattus norvegicus,1,A,,1,Volumes of distribution in rat after peroral administration,50597,10116.0,,,CHEMBL620190,6641,,,,,N,Intermediate,BAO_0000218
8415,Rattus norvegicus,1,A,,1,Volumes of distribution in rat after po administration,50597,10116.0,,,CHEMBL620191,6641,,,,,N,Intermediate,BAO_0000218
8416,Rattus norvegicus,1,A,,1,Volumes of distribution in rat after po administration; Not determined,50597,10116.0,,,CHEMBL620192,6641,,,,,N,Intermediate,BAO_0000218
8417,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Volume) in rat i.v.,50597,10116.0,,,CHEMBL620193,5676,,,,,N,Intermediate,BAO_0000218
8418,Rattus norvegicus,1,A,,1,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,50597,10116.0,,,CHEMBL620194,6410,,,,,N,Intermediate,BAO_0000218
8419,Rattus norvegicus,1,A,,1,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",50597,10116.0,,,CHEMBL876730,17670,,,,,N,Intermediate,BAO_0000218
8420,Rattus norvegicus,1,A,,1,Volume distribution in rat after oral administration at 10 mg/kg,50597,10116.0,,,CHEMBL620195,6495,,,,,N,Intermediate,BAO_0000218
8421,Rattus norvegicus,1,A,,1,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL620196,5408,,,,,N,Intermediate,BAO_0000218
8422,Rattus norvegicus,1,A,,1,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,10116.0,,,CHEMBL620197,4883,,,,,N,Intermediate,BAO_0000218
8423,Rattus norvegicus,1,A,,1,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,50597,10116.0,,,CHEMBL620198,6647,,,,,N,Intermediate,BAO_0000218
8424,Rattus norvegicus,1,A,,1,Volume of distribution in rats,50597,10116.0,,,CHEMBL620199,6495,,,,,N,Intermediate,BAO_0000218
8425,Rattus norvegicus,1,A,,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,50597,10116.0,,,CHEMBL620200,2661,,,,,N,Intermediate,BAO_0000218
8426,Rattus norvegicus,1,A,,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,50597,10116.0,,,CHEMBL620201,2661,,,,,N,Intermediate,BAO_0000218
8427,Rattus norvegicus,1,A,,1,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL620202,5974,,,,,N,Intermediate,BAO_0000218
8428,Rattus norvegicus,1,A,,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL620203,5974,,,,,N,Intermediate,BAO_0000218
8429,Rattus norvegicus,1,A,,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,50597,10116.0,,,CHEMBL620204,5974,,,,,N,Intermediate,BAO_0000218
8430,Rattus norvegicus,1,A,,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL620205,5974,,,,,N,Intermediate,BAO_0000218
8431,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (Vss) in rat,50597,10116.0,,,CHEMBL624664,5960,,,,,N,Intermediate,BAO_0000218
8432,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Volume) in rat i.v.,50597,10116.0,,,CHEMBL624665,5676,,,,,N,Intermediate,BAO_0000218
8433,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Vss) in rat,50597,10116.0,,,CHEMBL624666,5948,,,,,N,Intermediate,BAO_0000218
8434,Rattus norvegicus,1,A,,1,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,10116.0,,,CHEMBL624667,5979,,,,,N,Intermediate,BAO_0000218
8435,Rattus norvegicus,1,A,,1,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL624668,5978,,,,,N,Intermediate,BAO_0000218
8436,Rattus norvegicus,1,A,,1,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL624669,5978,,,,,N,Intermediate,BAO_0000218
8437,Rattus norvegicus,1,A,,1,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL624670,5978,,,,,N,Intermediate,BAO_0000218
8438,Rattus norvegicus,1,A,,1,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL624671,5978,,,,,N,Intermediate,BAO_0000218
8439,Rattus norvegicus,1,A,,1,Steady state volume distribution in rat,50597,10116.0,,,CHEMBL624672,6448,,,,,N,Intermediate,BAO_0000218
8440,Rattus norvegicus,1,A,,1,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",50597,10116.0,,,CHEMBL624673,12873,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8441,Rattus norvegicus,1,A,,1,Steady state volume of distribution determined in rat,50597,10116.0,,,CHEMBL624674,4576,,,,,N,Intermediate,BAO_0000218
8442,Rattus norvegicus,1,A,,1,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,10116.0,,,CHEMBL624675,17582,,,,,N,Intermediate,BAO_0000218
8443,Rattus norvegicus,1,A,,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,50597,10116.0,,,CHEMBL621728,1466,,,,,N,Intermediate,BAO_0000218
8444,Rattus norvegicus,1,A,,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,50597,10116.0,,,CHEMBL621729,5182,,,,,N,Intermediate,BAO_0000218
8445,Rattus norvegicus,1,A,,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,50597,10116.0,,,CHEMBL621730,5182,,,,,N,Intermediate,BAO_0000218
8446,Rattus norvegicus,1,A,,1,Volume distribution in rat after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL621731,6535,,,,,N,Intermediate,BAO_0000218
8447,Rattus norvegicus,1,A,,1,Volume distribution in rat after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL621732,6535,,,,,N,Intermediate,BAO_0000218
8448,Rattus norvegicus,1,A,,1,Volume in steady state distribution value was determined,50597,10116.0,,,CHEMBL621908,5041,,,,,N,Intermediate,BAO_0000218
8449,Rattus norvegicus,1,A,,1,Volume in steady state distribution value was determined; ND denotes no data,50597,10116.0,,,CHEMBL875347,5041,,,,,N,Intermediate,BAO_0000218
8450,Rattus norvegicus,1,A,,1,Volume in steady state distribution value was determined; ND denotes not determined,50597,10116.0,,,CHEMBL621909,5041,,,,,N,Intermediate,BAO_0000218
8451,Rattus norvegicus,1,A,,1,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,10116.0,,,CHEMBL621910,17065,,,,,N,Intermediate,BAO_0000218
8452,Rattus norvegicus,1,A,,1,Volume of distribution at steady state was evaluated in rats,50597,10116.0,,,CHEMBL621911,6597,,,,,N,Intermediate,BAO_0000218
8453,Rattus norvegicus,1,A,,1,Volume of distribution at steady state was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL621912,15662,,,,,N,Intermediate,BAO_0000218
8454,Rattus norvegicus,1,A,,1,Volume of distribution in steady state was determined in rat,50597,10116.0,,,CHEMBL621913,6485,,,,,N,Intermediate,BAO_0000218
8455,Rattus norvegicus,1,A,,1,Volume of distribution in steady state was determined in rat,50597,10116.0,,,CHEMBL621914,17655,,,,,N,Intermediate,BAO_0000218
8456,Rattus norvegicus,1,A,,1,Volume of distribution after i.v. administration,50597,10116.0,,,CHEMBL621915,6616,,,,,N,Intermediate,BAO_0000218
8457,Rattus norvegicus,1,A,,1,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,10116.0,,,CHEMBL621916,1916,,,,,N,Intermediate,BAO_0000218
8458,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL621917,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
8459,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL621918,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
8460,Mus musculus,1,A,,1,Biodistribution of compound (oxidized form) in spleen tissue,50594,10090.0,,,CHEMBL621919,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8461,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL621920,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8462,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL621921,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8463,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622401,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8464,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,10090.0,,,CHEMBL875348,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8465,Mus musculus,1,A,,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,10090.0,,,CHEMBL622402,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8466,Mus musculus,1,A,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,50594,10090.0,,,CHEMBL622403,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
8467,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622404,16438,178.0,,,Blood,N,Intermediate,BAO_0000218
8468,Mus musculus,1,A,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,50594,10090.0,,,CHEMBL622405,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
8469,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622406,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
8470,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622407,16438,955.0,,,Brain,N,Intermediate,BAO_0000218
8471,Mus musculus,1,A,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,50594,10090.0,,,CHEMBL622408,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
8472,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622409,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
8473,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL622410,16438,948.0,,,Heart,N,Intermediate,BAO_0000218
8474,Mus musculus,1,A,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,50594,10090.0,,,CHEMBL622411,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8475,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,10090.0,,,CHEMBL627864,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8476,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL627865,16438,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8477,Mus musculus,1,A,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,50594,10090.0,,,CHEMBL627866,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
8478,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL627751,16438,2107.0,,,Liver,N,Intermediate,BAO_0000218
8479,Mus musculus,1,A,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,50594,10090.0,,,CHEMBL627752,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8480,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,10090.0,,,CHEMBL627753,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8481,Mus musculus,1,A,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,10090.0,,,CHEMBL627754,16438,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8482,Mus musculus,1,A,,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,50594,10090.0,,,CHEMBL627755,12467,,,,,N,Intermediate,BAO_0000218
8483,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627756,17208,955.0,,,Brain,N,Intermediate,BAO_0000218
8484,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627757,17208,955.0,,,Brain,N,Intermediate,BAO_0000218
8485,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627758,17208,955.0,,,Brain,N,Intermediate,BAO_0000218
8486,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627759,17208,955.0,,,Brain,N,Intermediate,BAO_0000218
8487,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627760,17208,955.0,,,Brain,N,Intermediate,BAO_0000218
8488,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627761,17208,955.0,,,Brain,N,Intermediate,BAO_0000218
8489,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL876811,17208,948.0,,,Heart,N,Intermediate,BAO_0000218
8490,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627762,17208,948.0,,,Heart,N,Intermediate,BAO_0000218
8491,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627763,17208,948.0,,,Heart,N,Intermediate,BAO_0000218
8492,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627764,17208,948.0,,,Heart,N,Intermediate,BAO_0000218
8493,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627765,17208,948.0,,,Heart,N,Intermediate,BAO_0000218
8494,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627766,17208,948.0,,,Heart,N,Intermediate,BAO_0000218
8495,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627767,17208,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8496,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627768,17208,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8497,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL628422,17208,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8498,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL628423,17208,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8499,Rattus norvegicus,1,A,,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,50597,10116.0,,,CHEMBL628424,5089,,,,,N,Intermediate,BAO_0000218
8500,Rattus norvegicus,1,A,,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,50597,10116.0,,,CHEMBL628425,5089,,,,,N,Intermediate,BAO_0000218
8501,Rattus norvegicus,1,A,,1,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,50597,10116.0,,,CHEMBL628426,4257,,,,,N,Intermediate,BAO_0000218
8502,Rattus norvegicus,1,A,,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,10116.0,,,CHEMBL628427,6679,,,,,N,Intermediate,BAO_0000218
8503,Rattus norvegicus,1,A,,1,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,10116.0,,,CHEMBL626938,5546,,,,,N,Intermediate,BAO_0000218
8504,Rattus norvegicus,1,A,,1,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,10116.0,,,CHEMBL626939,6141,,,,,N,Intermediate,BAO_0000218
8505,Rattus norvegicus,1,A,,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,10116.0,,,CHEMBL626940,5334,,,,,N,Intermediate,BAO_0000218
8506,Rattus norvegicus,1,A,,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,10116.0,,,CHEMBL626941,5334,,,,,N,Intermediate,BAO_0000218
8507,Rattus norvegicus,1,A,,1,Plasma clearance was reported in Sprague-Dawley rat,50597,10116.0,,,CHEMBL626942,5334,,,,,N,Intermediate,BAO_0000218
8508,Rattus norvegicus,1,A,,1,Plasma clearance after intravenous administration (1 mg/kg) in rat,50597,10116.0,,,CHEMBL876812,4689,,,,,N,Intermediate,BAO_0000218
8509,Rattus norvegicus,1,A,,1,Plasma clearance of compound in rats was evaluated,50597,10116.0,,,CHEMBL626943,6848,,,,,N,Intermediate,BAO_0000218
8510,Rattus norvegicus,1,A,,1,Plasma clearance of compound in rats was evaluated; ND indicates not determined,50597,10116.0,,,CHEMBL626944,6848,,,,,N,Intermediate,BAO_0000218
8511,Rattus norvegicus,1,A,,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,50597,10116.0,,,CHEMBL626945,6467,,,,,N,Intermediate,BAO_0000218
8512,Rattus norvegicus,1,A,,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,10116.0,,,CHEMBL626946,6467,,,,,N,Intermediate,BAO_0000218
8513,Rattus norvegicus,1,A,,1,Plasma clearance rate in Sprague-Dawley rats,50597,10116.0,,,CHEMBL626856,4956,,,,,N,Intermediate,BAO_0000218
8514,Rattus norvegicus,1,A,,1,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),50597,10116.0,,,CHEMBL626857,5529,,,,,N,Intermediate,BAO_0000218
8515,Rattus norvegicus,1,A,,1,The compound was evaluated for plasma clearance in rat,50597,10116.0,,,CHEMBL626858,406,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8516,Rattus norvegicus,1,A,,1,Total plasma clearance in rat,50597,10116.0,,,CHEMBL627018,17655,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8517,Rattus norvegicus,1,A,,1,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,50597,10116.0,,,CHEMBL625331,3293,178.0,,,Blood,N,Intermediate,BAO_0000218
8518,Rattus norvegicus,1,A,,1,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,50597,10116.0,,,CHEMBL625332,4075,178.0,,,Blood,N,Intermediate,BAO_0000218
8519,Rattus norvegicus,1,A,,1,C max was determined at 10 mg/kg po dose in rats,50597,10116.0,,,CHEMBL877590,2792,,,,,N,Intermediate,BAO_0000218
8520,Rattus norvegicus,1,A,,1,C max was determined at 3 mg/kg po dose in rats,50597,10116.0,,,CHEMBL625333,2792,,,,,N,Intermediate,BAO_0000218
8521,Rattus norvegicus,1,A,,1,Cmax after repeated oral dose of compound at 1 mg/kg in rats,50597,10116.0,,,CHEMBL625334,17594,,,,,N,Intermediate,BAO_0000218
8522,Rattus norvegicus,1,A,,1,Cmax after single intravenous bolus of 1 mg/kg in rats,50597,10116.0,,,CHEMBL625335,17594,,,,,N,Intermediate,BAO_0000218
8523,Rattus norvegicus,1,A,,1,Cmax of compound at 5 mg/kg after po administration was determined in rat,50597,10116.0,,,CHEMBL625336,4762,,,,,N,Intermediate,BAO_0000218
8524,Rattus norvegicus,1,A,,1,Cmax 24 hr after 10 mg/kg oral administration in rats,50597,10116.0,,,CHEMBL625337,17509,,,,,N,Intermediate,BAO_0000218
8525,Rattus norvegicus,1,A,,1,Cmax 24 hr after 2 mg/kg oral administration in rats,50597,10116.0,,,CHEMBL625338,17509,,,,,N,Intermediate,BAO_0000218
8526,Rattus norvegicus,1,A,,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,50597,10116.0,,,CHEMBL625339,1466,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8527,Rattus norvegicus,1,A,,1,Cmax in rat after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL625340,6535,,,,,N,Intermediate,BAO_0000218
8528,Rattus norvegicus,1,A,,1,Cmax in rat after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL625341,6535,,,,,N,Intermediate,BAO_0000218
8529,Rattus norvegicus,1,A,,1,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,50597,10116.0,,,CHEMBL622687,3169,,,,,N,Intermediate,BAO_0000218
8530,Rattus norvegicus,1,A,,1,Cmax wa determined in rat plasma at 30 mg/kg after po administration,50597,10116.0,,,CHEMBL622688,6515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8531,Rattus norvegicus,1,A,,1,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,50597,10116.0,,,CHEMBL622689,11149,178.0,,,Blood,N,Intermediate,BAO_0000218
8532,Rattus norvegicus,1,A,,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,50597,10116.0,,,CHEMBL620295,11149,178.0,,,Blood,N,Intermediate,BAO_0000218
8533,Rattus norvegicus,1,A,,1,Cmax after 10 mg/kg oral administration in rat,50597,10116.0,,,CHEMBL620296,17858,,,,,N,Intermediate,BAO_0000218
8534,Rattus norvegicus,1,A,,1,Cmax after IV dosing at 0.5 mg/kg in rat; no data,50597,10116.0,,,CHEMBL620297,6518,,,,,N,Intermediate,BAO_0000218
8535,Rattus norvegicus,1,A,,1,Cmax after IV dosing at 1 mg/kg in rat; no data,50597,10116.0,,,CHEMBL620298,6518,,,,,N,Intermediate,BAO_0000218
8536,Rattus norvegicus,1,A,,1,Cmax after oral administration at 20 mpk in rats,50597,10116.0,,,CHEMBL620299,4426,,,,,N,Intermediate,BAO_0000218
8537,Rattus norvegicus,1,A,,1,Cmax after oral administration at 20 mpk in rats; Not performed.,50597,10116.0,,,CHEMBL620300,4426,,,,,N,Intermediate,BAO_0000218
8538,Rattus norvegicus,1,A,,1,Cmax after oral administration at 20 mpk in rats d; Not performed.,50597,10116.0,,,CHEMBL620301,4426,,,,,N,Intermediate,BAO_0000218
8539,Rattus norvegicus,1,A,,1,Cmax after oral administration in rat,50597,10116.0,,,CHEMBL620302,5656,,,,,N,Intermediate,BAO_0000218
8540,Rattus norvegicus,1,A,,1,Cmax after oral administration at a dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL620303,6518,,,,,N,Intermediate,BAO_0000218
8541,Rattus norvegicus,1,A,,1,Cmax after oral administration at a dose of 4 mg/kg in rat,50597,10116.0,,,CHEMBL620304,6518,,,,,N,Intermediate,BAO_0000218
8542,Rattus norvegicus,1,A,,1,Cmax in rats after 20 mg/kg oral dose,50597,10116.0,,,CHEMBL620305,6113,,,,,N,Intermediate,BAO_0000218
8543,Rattus norvegicus,1,A,,1,Cmax after peroral administration in rats at 2.4 uM/kg,50597,10116.0,,,CHEMBL620306,17764,,,,,N,Intermediate,BAO_0000218
8544,Rattus norvegicus,1,A,,1,Cmax at the dose of 2 mg/Kg administered perorally in rats,50597,10116.0,,,CHEMBL620307,4756,,,,,N,Intermediate,BAO_0000218
8545,Rattus norvegicus,1,A,,1,Cmax at the dose of 5 mg/Kg administered perorally in rats,50597,10116.0,,,CHEMBL620308,4756,,,,,N,Intermediate,BAO_0000218
8546,Rattus norvegicus,1,A,,1,Cmax by administering at 20 mg/kg p.o. in rats,50597,10116.0,,,CHEMBL620309,6402,,,,,N,Intermediate,BAO_0000218
8547,Rattus norvegicus,1,A,,1,Cmax in male rat,50597,10116.0,,,CHEMBL620310,5610,,,,,N,Intermediate,BAO_0000218
8548,Rattus norvegicus,1,A,,1,Cmax in rat,50597,10116.0,,,CHEMBL620311,5207,,,,,N,Intermediate,BAO_0000218
8549,Rattus norvegicus,1,A,,1,Cmax in rat,50597,10116.0,,,CHEMBL620312,6011,,,,,N,Intermediate,BAO_0000218
8550,Rattus norvegicus,1,A,,1,Cmax in rat,50597,10116.0,,,CHEMBL620313,6504,,,,,N,Intermediate,BAO_0000218
8551,Rattus norvegicus,1,A,,1,Cmax in rat at 10 mg/kg,50597,10116.0,,,CHEMBL620314,6046,,,,,N,Intermediate,BAO_0000218
8552,Rattus norvegicus,1,A,,1,Cmax in rat at the dose of 1 mg/kg i.v.,50597,10116.0,,,CHEMBL620315,6504,,,,,N,Intermediate,BAO_0000218
8553,Rattus norvegicus,1,A,,1,Cmax in rat by po administration at a dose of 40 mg/kg,50597,10116.0,,,CHEMBL620316,5874,,,,,N,Intermediate,BAO_0000218
8554,Rattus norvegicus,1,A,,1,Cmax in rat p.o. at 20 mg/kg concentration,50597,10116.0,,,CHEMBL620317,17686,,,,,N,Intermediate,BAO_0000218
8555,Rattus norvegicus,1,A,,1,Cmax in rats,50597,10116.0,,,CHEMBL620318,5836,,,,,N,Intermediate,BAO_0000218
8556,Rattus norvegicus,1,A,,1,Cmax in rats,50597,10116.0,,,CHEMBL620319,17596,,,,,N,Intermediate,BAO_0000218
8557,Rattus norvegicus,1,A,,1,Cmax was evaluated after 20 uM/kg of peroral administration,50597,10116.0,,,CHEMBL620320,16423,,,,,N,Intermediate,BAO_0000218
8558,Rattus norvegicus,1,A,,1,Cmax was measured in rats after peroral administration at 3 mg/kg,50597,10116.0,,,CHEMBL620321,17804,,,,,N,Intermediate,BAO_0000218
8559,Rattus norvegicus,1,A,,1,Cmax value after oral dose at a dose of 10 mg/kg in rats.,50597,10116.0,,,CHEMBL620322,1908,,,,,N,Intermediate,BAO_0000218
8560,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620323,13950,,,,,N,Intermediate,BAO_0000218
8561,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620324,13950,1870.0,,,Frontal cortex,N,Intermediate,BAO_0000218
8562,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620325,13950,1870.0,,,Frontal cortex,N,Intermediate,BAO_0000218
8563,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620326,13950,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
8564,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620327,13950,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
8565,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620328,13950,,,,,N,Intermediate,BAO_0000218
8566,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620329,13950,,,,,N,Intermediate,BAO_0000218
8567,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620330,13950,1891.0,,,Midbrain,N,Intermediate,BAO_0000218
8568,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL875286,13950,1891.0,,,Midbrain,N,Intermediate,BAO_0000218
8569,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620331,13950,,,,,N,Intermediate,BAO_0000218
8570,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620332,13950,,,,,N,Intermediate,BAO_0000218
8571,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620333,13950,2435.0,,,Striatum,N,Intermediate,BAO_0000218
8572,Rattus norvegicus,1,A,,1,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,10116.0,,,CHEMBL620334,13950,2435.0,,,Striatum,N,Intermediate,BAO_0000218
8573,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL621015,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8574,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL621016,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8575,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL621191,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8576,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL621192,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8577,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL621193,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8578,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL621194,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8579,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL624204,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8580,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL624205,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8581,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL624206,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8582,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL624207,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8583,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL624208,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8584,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL624209,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8585,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL624210,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8586,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL624211,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8587,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL624212,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8588,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL624213,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8589,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL876611,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8590,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL624214,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8591,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL624215,16434,178.0,,,Blood,N,Intermediate,BAO_0000218
8592,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL624216,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8593,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL624217,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8594,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL624218,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8595,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL624219,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8596,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL624220,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8597,Rattus norvegicus,1,A,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL624221,16435,178.0,,,Blood,N,Intermediate,BAO_0000218
8598,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL624222,16434,,,,,N,Intermediate,BAO_0000218
8599,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL624223,16434,,,,,N,Intermediate,BAO_0000218
8600,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL624224,16434,,,,,N,Intermediate,BAO_0000218
8601,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL624225,16434,,,,,N,Intermediate,BAO_0000218
8602,Rattus norvegicus,1,A,,1,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,50597,10116.0,,,CHEMBL622420,17764,,,,,N,Intermediate,BAO_0000218
8603,Rattus norvegicus,1,A,,1,Volume of steady state distribution after i.v. administration in rats,50597,10116.0,,,CHEMBL622421,5031,,,,,N,Intermediate,BAO_0000218
8604,Rattus norvegicus,1,A,,1,Vss after intravenous administration (5.0 mg/kg) was determined in rat,50597,10116.0,,,CHEMBL622422,6215,,,,,N,Intermediate,BAO_0000218
8605,Rattus norvegicus,1,A,,1,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,10116.0,,,CHEMBL622423,17671,,,,,N,Intermediate,BAO_0000218
8606,Rattus norvegicus,1,A,,1,Vss was determined,50597,10116.0,,,CHEMBL622424,17752,,,,,N,Intermediate,BAO_0000218
8607,Rattus norvegicus,1,A,,1,Vss in rat,50597,10116.0,,,CHEMBL622425,6596,,,,,N,Intermediate,BAO_0000218
8608,Rattus norvegicus,1,A,,1,Vss was evaluated after 10 uM/kg of intra arterial administration,50597,10116.0,,,CHEMBL876612,16423,,,,,N,Intermediate,BAO_0000218
8609,Rattus norvegicus,1,A,,1,volume of distribution at steady state was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL622426,15662,,,,,N,Intermediate,BAO_0000218
8610,Rattus norvegicus,1,A,,1,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,10116.0,,,CHEMBL622427,6062,,,,,N,Intermediate,BAO_0000218
8611,Rattus norvegicus,1,A,,1,Pharmacokinetic (PK) parameter Vz in rat,50597,10116.0,,,CHEMBL622428,5874,,,,,N,Intermediate,BAO_0000218
8612,Rattus norvegicus,1,A,,1,Volume distribution in rats,50597,10116.0,,,CHEMBL622429,4942,,,,,N,Intermediate,BAO_0000218
8613,Rattus norvegicus,1,A,,1,Volume of distribution in rat; No data,50597,10116.0,,,CHEMBL622430,17796,,,,,N,Intermediate,BAO_0000218
8614,Rattus norvegicus,1,A,,1,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL622431,4890,,,,,N,Intermediate,BAO_0000218
8615,Rattus norvegicus,1,A,,1,% absorption predicted from in vitro rat ileum transport studies,50597,10116.0,,,CHEMBL622432,15765,2116.0,,,Ileum,N,Intermediate,BAO_0000218
8616,Rattus norvegicus,1,A,,1,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,10116.0,,,CHEMBL622433,13569,,,,,N,Intermediate,BAO_0000218
8617,Rattus norvegicus,1,A,,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,10116.0,,,CHEMBL622434,13569,,,,,N,Intermediate,BAO_0000218
8618,Rattus norvegicus,1,A,,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,50597,10116.0,,,CHEMBL622435,13569,,,,,N,Intermediate,BAO_0000218
8619,Rattus norvegicus,1,A,,1,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),50597,10116.0,,,CHEMBL618748,13569,,,,,N,Intermediate,BAO_0000218
8620,Rattus norvegicus,1,A,,1,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,10116.0,,,CHEMBL618749,13569,,,,,N,Intermediate,BAO_0000218
8621,Rattus norvegicus,1,A,,1,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,10116.0,,,CHEMBL618750,13569,,,,,N,Intermediate,BAO_0000218
8622,Rattus norvegicus,1,A,,1,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,10116.0,,,CHEMBL618751,13569,,,,,N,Intermediate,BAO_0000218
8623,Rattus norvegicus,1,A,,1,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,10116.0,,,CHEMBL618752,13569,,,,,N,Intermediate,BAO_0000218
8624,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL618753,4576,,,,,N,Intermediate,BAO_0000218
8625,Rattus norvegicus,1,A,,1,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,50597,10116.0,,,CHEMBL618754,750,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8626,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL618755,750,,,,,N,Intermediate,BAO_0000218
8627,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL618756,4590,,,,,N,Intermediate,BAO_0000218
8628,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL618757,1716,,,,,N,Intermediate,BAO_0000218
8629,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL618758,1974,,,,,N,Intermediate,BAO_0000218
8630,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 30 mg/kg),50597,10116.0,,,CHEMBL621088,4502,,,,,N,Intermediate,BAO_0000218
8631,Rattus norvegicus,1,A,,1,Pharmacokinetic property (cLogP) in rat,50597,10116.0,,,CHEMBL621089,3371,,,,,N,Intermediate,BAO_0000218
8632,Rattus norvegicus,1,F,,1,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,50597,10116.0,,,CHEMBL621090,9099,178.0,,,Blood,N,Intermediate,BAO_0000218
8633,Rattus norvegicus,1,F,,1,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,50597,10116.0,,,CHEMBL621091,9099,178.0,,,Blood,N,Intermediate,BAO_0000218
8634,Rattus norvegicus,1,A,,1,Clearance in rat.,50597,10116.0,,,CHEMBL876731,4590,,,,,N,Intermediate,BAO_0000218
8635,Rattus norvegicus,1,A,,1,Compound was evaluated for its clearance when administered intravenously in rat,50597,10116.0,,,CHEMBL621092,3184,,,,,N,Intermediate,BAO_0000218
8636,Rattus norvegicus,1,A,,1,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL621093,16456,,,,,N,Intermediate,BAO_0000218
8637,Rattus norvegicus,1,A,,1,Blood: Brain distribution ratio is determined in rat,50597,10116.0,,,CHEMBL621094,4199,,,,,N,Intermediate,BAO_0000218
8638,Rattus norvegicus,1,A,,1,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,50597,10116.0,,,CHEMBL621095,4199,,,,,N,Intermediate,BAO_0000218
8639,Rattus norvegicus,1,A,,1,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,50597,10116.0,,,CHEMBL621096,4199,,,,,N,Intermediate,BAO_0000218
8640,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL621097,8677,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8641,Rattus norvegicus,1,F,,1,Percent dose excreted in 0-48 hours administered ip to male rat,50597,10116.0,,,CHEMBL621098,7449,,,,,N,Intermediate,BAO_0000218
8642,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621099,11977,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
8643,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621100,11977,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
8644,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL621101,11977,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
8645,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621102,11977,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
8646,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL876732,11977,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
8647,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621103,11977,,,,,N,Intermediate,BAO_0000218
8648,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621104,11977,,,,,N,Intermediate,BAO_0000218
8649,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL621105,11977,,,,,N,Intermediate,BAO_0000218
8650,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621106,11977,,,,,N,Intermediate,BAO_0000218
8651,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621107,11977,,,,,N,Intermediate,BAO_0000218
8652,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621108,11977,,,,,N,Intermediate,BAO_0000218
8653,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621109,11977,,,,,N,Intermediate,BAO_0000218
8654,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL621110,17208,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8655,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL621111,17208,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8656,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL622541,17208,2107.0,,,Liver,N,Intermediate,BAO_0000218
8657,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL622542,17208,2107.0,,,Liver,N,Intermediate,BAO_0000218
8658,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL622543,17208,2107.0,,,Liver,N,Intermediate,BAO_0000218
8659,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624412,17208,2107.0,,,Liver,N,Intermediate,BAO_0000218
8660,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624413,17208,2107.0,,,Liver,N,Intermediate,BAO_0000218
8661,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624414,17208,2107.0,,,Liver,N,Intermediate,BAO_0000218
8662,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624415,17208,2048.0,,,Lung,N,Intermediate,BAO_0000218
8663,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624416,17208,2048.0,,,Lung,N,Intermediate,BAO_0000218
8664,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624417,17208,2048.0,,,Lung,N,Intermediate,BAO_0000218
8665,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624418,17208,2048.0,,,Lung,N,Intermediate,BAO_0000218
8666,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624419,17208,2048.0,,,Lung,N,Intermediate,BAO_0000218
8667,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624420,17208,2048.0,,,Lung,N,Intermediate,BAO_0000218
8668,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624421,17208,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8669,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624422,17208,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8670,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL624423,17208,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8671,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL625123,17208,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8672,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL625124,17208,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8673,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL625125,17208,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8674,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL625126,17208,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
8675,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626947,17208,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
8676,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626948,17208,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
8677,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626949,17208,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
8678,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626950,17208,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
8679,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626951,17208,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
8680,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626952,17208,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8681,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626953,17208,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8682,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626954,17208,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8683,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626955,17208,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8684,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626956,17208,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8685,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626957,17208,2106.0,,,Spleen,N,Intermediate,BAO_0000218
8686,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626958,17208,178.0,,,Blood,N,Intermediate,BAO_0000218
8687,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626959,17208,178.0,,,Blood,N,Intermediate,BAO_0000218
8688,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626960,17208,178.0,,,Blood,N,Intermediate,BAO_0000218
8689,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL626961,17208,178.0,,,Blood,N,Intermediate,BAO_0000218
8690,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627589,17208,178.0,,,Blood,N,Intermediate,BAO_0000218
8691,Mus musculus,1,A,,1,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),50594,10090.0,,,CHEMBL627590,17208,178.0,,,Blood,N,Intermediate,BAO_0000218
8692,Mus musculus,1,A,,1,Time taken for EC90 was determined when tested in mouse,50594,10090.0,,,CHEMBL627591,3132,,,,,N,Intermediate,BAO_0000218
8693,Mus musculus,1,A,,1,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,50594,10090.0,,,CHEMBL627592,3132,,,,,N,Intermediate,BAO_0000218
8694,Mus musculus,1,A,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,10090.0,,,CHEMBL627593,16597,,,,,N,Intermediate,BAO_0000218
8695,Mus musculus,1,A,,1,Half life in mice,50594,10090.0,,,CHEMBL627594,5727,,,,,N,Intermediate,BAO_0000218
8696,Mus musculus,1,A,,1,Half life period in mouse after 10 mg/Kg dose,50594,10090.0,,,CHEMBL876813,5302,,,,,N,Intermediate,BAO_0000218
8697,Mus musculus,1,A,,1,Half life period in mouse after 10 mg/kg dose,50594,10090.0,,,CHEMBL627595,5302,,,,,N,Intermediate,BAO_0000218
8698,Mus musculus,1,A,,1,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,10090.0,,,CHEMBL627596,6348,,,,,N,Intermediate,BAO_0000218
8699,Rattus norvegicus,1,A,,1,Cmax value at 5 mg/kg po was determined in rat,50597,10116.0,,,CHEMBL627597,5964,,,,,N,Intermediate,BAO_0000218
8700,Rattus norvegicus,1,A,,1,Cmax value evaluated in rat,50597,10116.0,,,CHEMBL627598,6078,,,,,N,Intermediate,BAO_0000218
8701,Rattus norvegicus,1,A,,1,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,50597,10116.0,,,CHEMBL627599,5206,955.0,,,Brain,N,Intermediate,BAO_0000218
8702,Rattus norvegicus,1,A,,1,Cmax value after administration of 20 mg/Kg oral dose in rat,50597,10116.0,,,CHEMBL627600,2959,,,,,N,Intermediate,BAO_0000218
8703,Rattus norvegicus,1,A,,1,Cmax value at 1 mg/kg po in rat,50597,10116.0,,,CHEMBL627601,5964,,,,,N,Intermediate,BAO_0000218
8704,Rattus norvegicus,1,A,,1,Cmax value at 5 mg/kg po in rat,50597,10116.0,,,CHEMBL627776,5964,,,,,N,Intermediate,BAO_0000218
8705,Rattus norvegicus,1,A,,1,Cmax value at a dose of 10 mg/kg in male SD rats,50597,10116.0,,,CHEMBL627777,6757,,,,,N,Intermediate,BAO_0000218
8706,Rattus norvegicus,1,A,,1,Cmax value at a dose of 100 mg/kg in male SD rats,50597,10116.0,,,CHEMBL627778,6757,,,,,N,Intermediate,BAO_0000218
8707,Rattus norvegicus,1,A,,1,Cmax value at a dose of 50 mg/kg in male SD rats,50597,10116.0,,,CHEMBL627779,6757,,,,,N,Intermediate,BAO_0000218
8708,Rattus norvegicus,1,A,,1,Cmax value in rats at 10 mg/kg,50597,10116.0,,,CHEMBL876814,17617,,,,,N,Intermediate,BAO_0000218
8709,Rattus norvegicus,1,A,,1,Cmax value was evaluated in rats at a dose of 20 mg/kg,50597,10116.0,,,CHEMBL627780,1445,,,,,N,Intermediate,BAO_0000218
8710,Rattus norvegicus,1,A,,1,Cmax value was determined after peroral administration of 20 mg/kg in rat,50597,10116.0,,,CHEMBL627781,6082,,,,,N,Intermediate,BAO_0000218
8711,Rattus norvegicus,1,A,,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,10116.0,,,CHEMBL627782,1446,,,,,N,Intermediate,BAO_0000218
8712,Rattus norvegicus,1,A,,1,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,50597,10116.0,,,CHEMBL627783,5407,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8713,Rattus norvegicus,1,A,,1,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,50597,10116.0,,,CHEMBL627784,2690,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8714,Rattus norvegicus,1,A,,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,50597,10116.0,,,CHEMBL627785,2661,,,,,N,Intermediate,BAO_0000218
8715,Rattus norvegicus,1,A,,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,50597,10116.0,,,CHEMBL627786,2661,,,,,N,Intermediate,BAO_0000218
8716,Rattus norvegicus,1,A,,1,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,50597,10116.0,,,CHEMBL627787,4891,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8717,Rattus norvegicus,1,A,,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,50597,10116.0,,,CHEMBL627788,2807,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8718,Rattus norvegicus,1,A,,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,50597,10116.0,,,CHEMBL626579,2807,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8719,Rattus norvegicus,1,A,,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,50597,10116.0,,,CHEMBL626580,2807,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8720,Rattus norvegicus,1,A,,1,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,50597,10116.0,,,CHEMBL876815,3634,,,,,N,Intermediate,BAO_0000218
8721,Rattus norvegicus,1,A,,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,50597,10116.0,,,CHEMBL626581,1881,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8722,Rattus norvegicus,1,A,,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,50597,10116.0,,,CHEMBL626582,1881,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8723,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,50597,10116.0,,,CHEMBL626583,429,,,,,N,Intermediate,BAO_0000218
8724,Rattus norvegicus,1,A,,1,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL626205,5974,,,,,N,Intermediate,BAO_0000218
8725,Rattus norvegicus,1,A,,1,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL626206,5974,,,,,N,Intermediate,BAO_0000218
8726,Rattus norvegicus,1,A,,1,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL626207,5974,,,,,N,Intermediate,BAO_0000218
8727,Rattus norvegicus,1,A,,1,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL623882,5974,,,,,N,Intermediate,BAO_0000218
8728,Rattus norvegicus,1,A,,1,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,50597,10116.0,,,CHEMBL623883,17582,,,,,N,Intermediate,BAO_0000218
8729,Rattus norvegicus,1,A,,1,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,50597,10116.0,,,CHEMBL623884,17582,,,,,N,Intermediate,BAO_0000218
8730,Rattus norvegicus,1,A,,1,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,10116.0,,,CHEMBL623885,3032,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8731,Rattus norvegicus,1,A,,1,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL623886,6295,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8732,Rattus norvegicus,1,A,,1,Maximal concentration in rat was determined,50597,10116.0,,,CHEMBL623887,6619,,,,,N,Intermediate,BAO_0000218
8733,Rattus norvegicus,1,A,,1,Maximal concentration after i.v. administration,50597,10116.0,,,CHEMBL623888,6616,,,,,N,Intermediate,BAO_0000218
8734,Rattus norvegicus,1,A,,1,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL623889,3249,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8735,Rattus norvegicus,1,A,,1,Maximal plasma concentration in rat after oral administration at 50 mg/kg,50597,10116.0,,,CHEMBL623890,17791,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8736,Rattus norvegicus,1,A,,1,Cmax in rat plasma after oral dose (50 mg/Kg),50597,10116.0,,,CHEMBL623891,17791,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8737,Rattus norvegicus,1,A,,1,Maximal plasma concentration was determined.,50597,10116.0,,,CHEMBL623892,1360,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8738,Rattus norvegicus,1,A,,1,Maximal plasma drug concentration was determined,50597,10116.0,,,CHEMBL623893,2552,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8739,Rattus norvegicus,1,A,,1,Maximal concentration in rats after peroral administration,50597,10116.0,,,CHEMBL877616,6571,,,,,N,Intermediate,BAO_0000218
8740,Rattus norvegicus,1,A,,1,Maximum concentration in rat after 2 mg/kg peroral administration,50597,10116.0,,,CHEMBL623894,6570,,,,,N,Intermediate,BAO_0000218
8741,Rattus norvegicus,1,A,,1,Maximum concentration in rat plasma after 5 mg/kg oral gavage,50597,10116.0,,,CHEMBL623895,6567,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8742,Rattus norvegicus,1,A,,1,Maximum concentration of compound in rat was evaluated.,50597,10116.0,,,CHEMBL623896,3031,,,,,N,Intermediate,BAO_0000218
8743,Rattus norvegicus,1,A,,1,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL623897,3436,,,,,N,Intermediate,BAO_0000218
8744,Rattus norvegicus,1,A,,1,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL623898,3436,,,,,N,Intermediate,BAO_0000218
8745,Rattus norvegicus,1,A,,1,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,10116.0,,,CHEMBL623899,2083,,,,,N,Intermediate,BAO_0000218
8746,Rattus norvegicus,1,A,,1,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL623900,3436,,,,,N,Intermediate,BAO_0000218
8747,Rattus norvegicus,1,A,,1,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,50597,10116.0,,,CHEMBL623901,4527,,,,,N,Intermediate,BAO_0000218
8748,Rattus norvegicus,1,A,,1,Maximum concentration was evaluated in rats,50597,10116.0,,,CHEMBL623902,1974,,,,,N,Intermediate,BAO_0000218
8749,Rattus norvegicus,1,A,,1,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,50597,10116.0,,,CHEMBL623903,3307,1359.0,,,Cerebrospinal fluid,N,Intermediate,BAO_0000218
8750,Rattus norvegicus,1,A,,1,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,50597,10116.0,,,CHEMBL623904,3307,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8751,Rattus norvegicus,1,A,,1,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,10116.0,,,CHEMBL877617,1916,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8752,Rattus norvegicus,1,A,,1,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,50597,10116.0,,,CHEMBL623905,1500,,,,,N,Intermediate,BAO_0000218
8753,Rattus norvegicus,1,A,,1,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,50597,10116.0,,,CHEMBL623906,1500,,,,,N,Intermediate,BAO_0000218
8754,Rattus norvegicus,1,A,,1,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,10116.0,,,CHEMBL623907,4186,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8755,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL623908,16434,,,,,N,Intermediate,BAO_0000218
8756,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL623909,16434,,,,,N,Intermediate,BAO_0000218
8757,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL623910,16434,,,,,N,Intermediate,BAO_0000218
8758,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL623911,16434,,,,,N,Intermediate,BAO_0000218
8759,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL623912,16435,,,,,N,Intermediate,BAO_0000218
8760,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL624616,16435,,,,,N,Intermediate,BAO_0000218
8761,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL624617,16435,,,,,N,Intermediate,BAO_0000218
8762,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL624618,16435,,,,,N,Intermediate,BAO_0000218
8763,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL624619,16435,,,,,N,Intermediate,BAO_0000218
8764,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL624794,16435,,,,,N,Intermediate,BAO_0000218
8765,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL624795,16435,,,,,N,Intermediate,BAO_0000218
8766,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL623921,16435,,,,,N,Intermediate,BAO_0000218
8767,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL623922,16434,,,,,N,Intermediate,BAO_0000218
8768,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL623923,16434,,,,,N,Intermediate,BAO_0000218
8769,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL623924,16434,,,,,N,Intermediate,BAO_0000218
8770,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL623925,16435,,,,,N,Intermediate,BAO_0000218
8771,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL623926,16435,,,,,N,Intermediate,BAO_0000218
8772,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL623927,16435,,,,,N,Intermediate,BAO_0000218
8773,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL623928,16435,,,,,N,Intermediate,BAO_0000218
8774,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL623929,16435,,,,,N,Intermediate,BAO_0000218
8775,Rattus norvegicus,1,A,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL623930,16435,,,,,N,Intermediate,BAO_0000218
8776,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL623931,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8777,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL622165,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8778,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL621249,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8779,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL621250,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8780,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL621448,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8781,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL621449,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8782,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL621450,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8783,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL621451,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8784,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL621452,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8785,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL621453,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8786,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL621454,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8787,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL621455,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8788,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL621456,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8789,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL625145,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8790,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL875847,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8791,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL625146,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8792,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL625147,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8793,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL625148,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8794,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL625149,16434,955.0,,,Brain,N,Intermediate,BAO_0000218
8795,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL625150,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8796,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL625151,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8797,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL625152,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8798,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL625153,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8799,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL625154,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8800,Rattus norvegicus,1,A,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL625155,16435,955.0,,,Brain,N,Intermediate,BAO_0000218
8801,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL625156,11977,,,,,N,Intermediate,BAO_0000218
8802,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624354,11977,,,,,N,Intermediate,BAO_0000218
8803,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624355,11977,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
8804,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624356,11977,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
8805,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624357,11977,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
8806,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624358,11977,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
8807,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624359,11977,2435.0,,,Striatum,N,Intermediate,BAO_0000218
8808,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624360,11977,2435.0,,,Striatum,N,Intermediate,BAO_0000218
8809,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL624361,11977,2435.0,,,Striatum,N,Intermediate,BAO_0000218
8810,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624362,11977,2435.0,,,Striatum,N,Intermediate,BAO_0000218
8811,Rattus norvegicus,1,A,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624363,11977,2435.0,,,Striatum,N,Intermediate,BAO_0000218
8812,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624364,11977,178.0,,,Blood,N,Intermediate,BAO_0000218
8813,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624365,11977,178.0,,,Blood,N,Intermediate,BAO_0000218
8814,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624366,11977,178.0,,,Blood,N,Intermediate,BAO_0000218
8815,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624367,11977,178.0,,,Blood,N,Intermediate,BAO_0000218
8816,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624368,11977,955.0,,,Brain,N,Intermediate,BAO_0000218
8817,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL624369,11977,955.0,,,Brain,N,Intermediate,BAO_0000218
8818,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL624370,11977,955.0,,,Brain,N,Intermediate,BAO_0000218
8819,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625069,11977,955.0,,,Brain,N,Intermediate,BAO_0000218
8820,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625070,11977,955.0,,,Brain,N,Intermediate,BAO_0000218
8821,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626051,11977,948.0,,,Heart,N,Intermediate,BAO_0000218
8822,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626052,11977,948.0,,,Heart,N,Intermediate,BAO_0000218
8823,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL626053,11977,948.0,,,Heart,N,Intermediate,BAO_0000218
8824,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626054,11977,948.0,,,Heart,N,Intermediate,BAO_0000218
8825,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626055,11977,948.0,,,Heart,N,Intermediate,BAO_0000218
8826,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626056,11977,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8827,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626057,11977,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8828,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625193,11977,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8829,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625194,11977,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8830,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625195,11977,2107.0,,,Liver,N,Intermediate,BAO_0000218
8831,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625196,11977,2107.0,,,Liver,N,Intermediate,BAO_0000218
8832,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL625197,11977,2107.0,,,Liver,N,Intermediate,BAO_0000218
8833,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625198,11977,2107.0,,,Liver,N,Intermediate,BAO_0000218
8834,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL627929,11977,2107.0,,,Liver,N,Intermediate,BAO_0000218
8835,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL627074,11977,2048.0,,,Lung,N,Intermediate,BAO_0000218
8836,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL627075,11977,2048.0,,,Lung,N,Intermediate,BAO_0000218
8837,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL627076,11977,2048.0,,,Lung,N,Intermediate,BAO_0000218
8838,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL627077,11977,2048.0,,,Lung,N,Intermediate,BAO_0000218
8839,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL627078,11977,2048.0,,,Lung,N,Intermediate,BAO_0000218
8840,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL627079,11977,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8841,Mus musculus,1,A,,1,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,10090.0,,,CHEMBL873824,4573,,,,,N,Intermediate,BAO_0000218
8842,Mus musculus,1,A,,1,Half life in mouse plasma was determined at dose 25 mg/kg,50594,10090.0,,,CHEMBL627080,3132,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8843,Mus musculus,1,A,,1,Half life was determined,50594,10090.0,,,CHEMBL627081,17718,,,,,N,Intermediate,BAO_0000218
8844,Mus musculus,1,A,,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,10090.0,,,CHEMBL627082,17728,,,,,N,Intermediate,BAO_0000218
8845,Mus musculus,1,A,,1,Half-life in male mice after 1 mg/kg intravenous dose,50594,10090.0,,,CHEMBL627083,5961,,,,,N,Intermediate,BAO_0000218
8847,Mus musculus,1,A,,1,Half life in mice plasma,50594,10090.0,,,CHEMBL627085,17731,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8848,Mus musculus,1,A,,1,Half life in mouse,50594,10090.0,,,CHEMBL627086,17592,,,,,N,Intermediate,BAO_0000218
8849,Mus musculus,1,A,,1,Half life in mouse plasma at dose 25 mg/kg,50594,10090.0,,,CHEMBL627087,3132,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8850,Mus musculus,1,A,,1,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,50594,10090.0,,,CHEMBL627088,17729,,,,,N,Intermediate,BAO_0000218
8851,Mus musculus,1,A,,1,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,50594,10090.0,,,CHEMBL627089,17729,,,,,N,Intermediate,BAO_0000218
8852,Mus musculus,1,A,,1,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,50594,10090.0,,,CHEMBL627090,17729,,,,,N,Intermediate,BAO_0000218
8853,Mus musculus,1,A,,1,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,10090.0,,,CHEMBL627091,3277,,,,,N,Intermediate,BAO_0000218
8854,Mus musculus,1,A,,1,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",50594,10090.0,,,CHEMBL627092,3760,,,,,N,Intermediate,BAO_0000218
8855,Mus musculus,1,A,,1,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",50594,10090.0,,,CHEMBL876785,3760,,,,,N,Intermediate,BAO_0000218
8856,Mus musculus,1,A,,1,Half-life by iv administration in mouse,50594,10090.0,,,CHEMBL627093,2862,,,,,N,Intermediate,BAO_0000218
8857,Mus musculus,1,A,,1,Half-life by oral administration in mouse,50594,10090.0,,,CHEMBL627094,2862,,,,,N,Intermediate,BAO_0000218
8858,Mus musculus,1,A,,1,Half-life in mice,50594,10090.0,,,CHEMBL627095,5980,,,,,N,Intermediate,BAO_0000218
8859,Mus musculus,1,A,,1,Half-life using mouse brain homogenate,50594,10090.0,,,CHEMBL627096,6159,955.0,,,Brain,N,Intermediate,BAO_0000218
8860,Mus musculus,1,A,,1,Half-life was measured in mice,50594,10090.0,,,CHEMBL627097,6254,,,,,N,Intermediate,BAO_0000218
8861,Mus musculus,1,A,,1,Half-life was measured in mouse after an iv dose of 1 mg/kg,50594,10090.0,,,CHEMBL627098,6062,,,,,N,Intermediate,BAO_0000218
8862,Mus musculus,1,A,,1,Half-life period was determined in mouse blood,50594,10090.0,,,CHEMBL627099,1574,178.0,,,Blood,N,Intermediate,BAO_0000218
8863,Mus musculus,1,A,,1,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",50594,10090.0,,,CHEMBL627100,56,955.0,,,Brain,N,Intermediate,BAO_0000218
8864,Mus musculus,1,A,,1,Plasma half life in mouse,50594,10090.0,,,CHEMBL627101,993,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8865,Mus musculus,1,A,,1,Stability of the peptide in the presence of mouse serum,50594,10090.0,,,CHEMBL627102,6652,,,,,N,Intermediate,BAO_0000218
8866,Mus musculus,1,A,,1,Terminal half life of compound was determined in mouse,50594,10090.0,,,CHEMBL627103,17852,,,,,N,Intermediate,BAO_0000218
8867,Mus musculus,1,A,,1,Terminal half life was evaluated in mice after intravenous administration,50594,10090.0,,,CHEMBL627104,2675,,,,,N,Intermediate,BAO_0000218
8868,Mus musculus,1,A,,1,Terminal half life was evaluated in mice after oral administration,50594,10090.0,,,CHEMBL627105,2675,,,,,N,Intermediate,BAO_0000218
8869,Mus musculus,1,A,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,50594,10090.0,,,CHEMBL876786,499,,,,,N,Intermediate,BAO_0000218
8870,Mus musculus,1,A,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,50594,10090.0,,,CHEMBL873825,499,,,,,N,Intermediate,BAO_0000218
8871,Mus musculus,1,A,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,50594,10090.0,,,CHEMBL627106,499,,,,,N,Intermediate,BAO_0000218
8872,Mus musculus,1,A,,1,half life period is evaluated by administering intravenously at 25 mg/kg in mice,50594,10090.0,,,CHEMBL626336,14239,,,,,N,Intermediate,BAO_0000218
8873,Mus musculus,1,A,,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",50594,10090.0,,,CHEMBL877462,5506,,,,,N,Intermediate,BAO_0000218
8874,Mus musculus,1,A,,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",50594,10090.0,,,CHEMBL626337,5506,,,,,N,Intermediate,BAO_0000218
8875,Mus musculus,1,A,,1,Half life after intraperitoneal administration of 100 mg/kg in mice,50594,10090.0,,,CHEMBL626338,17734,,,,,N,Intermediate,BAO_0000218
8876,Mus musculus,1,A,,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,50594,10090.0,,,CHEMBL626339,17728,,,,,N,Intermediate,BAO_0000218
8877,Mus musculus,1,A,,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,10090.0,,,CHEMBL626340,17728,,,,,N,Intermediate,BAO_0000218
8878,Mus musculus,1,A,,1,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,50594,10090.0,,,CHEMBL625377,17728,,,,,N,Intermediate,BAO_0000218
8879,Mus musculus,1,A,,1,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,50594,10090.0,,,CHEMBL625378,17728,,,,,N,Intermediate,BAO_0000218
8880,Mus musculus,1,A,,1,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,50594,10090.0,,,CHEMBL625379,17728,,,,,N,Intermediate,BAO_0000218
8881,Sus scrofa,0,A,,1,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),22224,9823.0,Microsomes,,CHEMBL625380,14294,,,,,U,Autocuration,BAO_0000251
8882,Sus scrofa,0,A,,1,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),22224,9823.0,Microsomes,,CHEMBL625381,14294,,,,,U,Autocuration,BAO_0000251
8883,Sus scrofa,0,A,,1,Stability to porcine renal DHP-I,22224,9823.0,,,CHEMBL625382,6056,,,,,U,Autocuration,BAO_0000019
8884,Sus scrofa,0,A,,1,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,22224,9823.0,,,CHEMBL873828,1317,,,,,U,Autocuration,BAO_0000218
8885,Sus scrofa,0,A,,1,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,22224,9823.0,,,CHEMBL625383,1317,,,,,U,Autocuration,BAO_0000218
8886,Sus scrofa,0,A,,1,Half-life of the parent prodrug in porcine esterase solution,22224,9823.0,,,CHEMBL625384,5229,,,,,U,Autocuration,BAO_0000019
8887,Sus scrofa,0,A,,1,"First order rate constant, k was determined in in pig liver Esterase",22224,9823.0,,,CHEMBL625385,4231,,,,,U,Autocuration,BAO_0000019
8888,Sus scrofa,0,A,,1,Half life of the in pig liver Esterase,22224,9823.0,,,CHEMBL625386,4231,2107.0,,,Liver,U,Autocuration,BAO_0000221
8889,Sus scrofa,0,A,,1,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,22224,9823.0,,,CHEMBL623571,5318,2107.0,,,Liver,U,Autocuration,BAO_0000221
8890,Sus scrofa,0,A,,1,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,22224,9823.0,,,CHEMBL623572,5318,2107.0,,,Liver,U,Autocuration,BAO_0000221
8891,Sus scrofa,0,A,,1,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,22224,9823.0,,,CHEMBL623573,5318,2107.0,,,Liver,U,Autocuration,BAO_0000221
8892,Sus scrofa,0,A,,1,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,22224,9823.0,,,CHEMBL623574,3305,2107.0,,,Liver,U,Autocuration,BAO_0000221
8893,Sus scrofa,0,A,,1,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,22224,9823.0,,,CHEMBL623575,3305,2107.0,,,Liver,U,Autocuration,BAO_0000221
8894,Sus scrofa,0,A,,1,Half-life in the presence of pig liver esterase(PLE) was evaluated.,22224,9823.0,,,CHEMBL623749,2842,2107.0,,,Liver,U,Autocuration,BAO_0000221
8895,Sus scrofa,0,A,,1,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,22224,9823.0,,,CHEMBL623750,2842,2107.0,,,Liver,U,Autocuration,BAO_0000221
8896,Sus scrofa,0,A,,1,Half-life in vitro in pig liver,22224,9823.0,,,CHEMBL623751,889,2107.0,,,Liver,U,Autocuration,BAO_0000221
8897,Sus scrofa,0,A,,1,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,22224,9823.0,,,CHEMBL623752,1904,2107.0,,,Liver,U,Autocuration,BAO_0000221
8898,Rattus norvegicus,1,A,,1,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,10116.0,,,CHEMBL623753,4186,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8899,Rattus norvegicus,1,A,,1,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,10116.0,,,CHEMBL623754,2774,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8900,Rattus norvegicus,1,A,,1,Maximum concentration in rat plasma was determined,50597,10116.0,,,CHEMBL623755,1742,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8901,Rattus norvegicus,1,A,,1,Maximum concentration in rats,50597,10116.0,,,CHEMBL623756,3169,,,,,N,Intermediate,BAO_0000218
8902,Rattus norvegicus,1,A,,1,Maximum concentration in rats at 1-2 hours,50597,10116.0,,,CHEMBL623757,3169,,,,,N,Intermediate,BAO_0000218
8903,Rattus norvegicus,1,A,,1,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,50597,10116.0,,,CHEMBL623758,2081,,,,,N,Intermediate,BAO_0000218
8904,Rattus norvegicus,1,A,,1,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,50597,10116.0,,,CHEMBL623759,3307,955.0,,,Brain,N,Intermediate,BAO_0000218
8905,Rattus norvegicus,1,A,,1,Maximum concentration at the dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL623760,4727,,,,,N,Intermediate,BAO_0000218
8906,Rattus norvegicus,1,A,,1,Maximum concentration was evaluated in rats,50597,10116.0,,,CHEMBL623761,6597,,,,,N,Intermediate,BAO_0000218
8907,Rattus norvegicus,1,A,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL623762,16365,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8908,Rattus norvegicus,1,A,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL877594,16365,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8909,Rattus norvegicus,1,A,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,50597,10116.0,,,CHEMBL623763,16365,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8910,Rattus norvegicus,1,A,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,50597,10116.0,,,CHEMBL623764,16365,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8911,Rattus norvegicus,1,A,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL623765,16365,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8912,Rattus norvegicus,1,A,,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,50597,10116.0,,,CHEMBL623766,2591,178.0,,,Blood,N,Intermediate,BAO_0000218
8913,Rattus norvegicus,1,A,,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,50597,10116.0,,,CHEMBL623767,2591,178.0,,,Blood,N,Intermediate,BAO_0000218
8914,Rattus norvegicus,1,A,,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,50597,10116.0,,,CHEMBL623768,2591,178.0,,,Blood,N,Intermediate,BAO_0000218
8915,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,50597,10116.0,,,CHEMBL623769,5978,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8916,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,50597,10116.0,,,CHEMBL623770,5978,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8917,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,50597,10116.0,,,CHEMBL623771,5978,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8918,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,50597,10116.0,,,CHEMBL623772,5978,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8919,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,10116.0,,,CHEMBL623773,5978,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8920,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,10116.0,,,CHEMBL623774,5978,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8921,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,10116.0,,,CHEMBL623775,5978,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8922,Rattus norvegicus,1,A,,1,Cmax in rat (PO dose),50597,10116.0,,,CHEMBL623776,14465,,,,,N,Intermediate,BAO_0000218
8923,Rattus norvegicus,1,A,,1,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL622191,4723,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8924,Rattus norvegicus,1,A,,1,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL622192,4723,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8925,Rattus norvegicus,1,A,,1,Maximum plasma concentration determined in rat,50597,10116.0,,,CHEMBL622193,4576,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8926,Rattus norvegicus,1,A,,1,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,10116.0,,,CHEMBL622194,12873,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8927,Rattus norvegicus,1,A,,1,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,10116.0,,,CHEMBL622195,12873,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8928,Rattus norvegicus,1,A,,1,Maximum plasma concentration in rat,50597,10116.0,,,CHEMBL622196,6824,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8929,Rattus norvegicus,1,A,,1,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,10116.0,,,CHEMBL622197,17065,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8930,Rattus norvegicus,1,A,,1,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,50597,10116.0,,,CHEMBL622198,2932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8931,Rattus norvegicus,1,A,,1,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,50597,10116.0,,,CHEMBL622199,2932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8932,Rattus norvegicus,1,A,,1,Maximum plasma concentration of compound was measured in rat,50597,10116.0,,,CHEMBL622200,2879,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8933,Rattus norvegicus,1,A,,1,Maximum plasma concentration after 20 mg/kg oral administration in rat,50597,10116.0,,,CHEMBL622201,2864,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8934,Rattus norvegicus,1,A,,1,Maximum plasma concentration after oral administration to rats,50597,10116.0,,,CHEMBL623990,16367,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8935,Rattus norvegicus,1,A,,1,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,10116.0,,,CHEMBL623991,17717,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8936,Rattus norvegicus,1,A,,1,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",50597,10116.0,,,CHEMBL623992,17717,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8937,Rattus norvegicus,1,A,,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,10116.0,,,CHEMBL623993,17717,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8938,Rattus norvegicus,1,A,,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,50597,10116.0,,,CHEMBL623994,17717,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8939,Rattus norvegicus,1,F,,1,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL623995,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8940,Rattus norvegicus,1,F,,1,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL623996,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8941,Rattus norvegicus,1,F,,1,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL623997,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8942,Rattus norvegicus,1,A,,1,Maximum plasma concentration dosed orally in rats,50597,10116.0,,,CHEMBL623998,4516,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8943,Rattus norvegicus,1,A,,1,Maximum plasma concentration dosed orally in rats after 6 hours,50597,10116.0,,,CHEMBL623999,4516,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8944,Rattus norvegicus,1,A,,1,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,50597,10116.0,,,CHEMBL624000,4516,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8945,Rattus norvegicus,1,A,,1,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,10116.0,,,CHEMBL624001,5199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8946,Rattus norvegicus,1,A,,1,Maximum plasma concentration in rat after po administration,50597,10116.0,,,CHEMBL624002,17538,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8947,Rattus norvegicus,1,A,,1,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL624003,6685,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8948,Rattus norvegicus,1,A,,1,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",50597,10116.0,,,CHEMBL624004,6685,1969.0,,,Plasma,N,Intermediate,BAO_0000218
8949,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL624005,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8950,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL624006,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8951,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL624007,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8952,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL624008,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8953,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL624009,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8954,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL874387,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8955,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL624010,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8956,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL624011,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8957,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL624012,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8958,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL624013,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8959,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL624736,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8960,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL624737,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8961,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL624738,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8962,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL624739,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8963,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL624740,16434,948.0,,,Heart,N,Intermediate,BAO_0000218
8964,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL624896,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8965,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL624897,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8966,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL624108,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8967,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL624109,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8968,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL624110,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8969,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL624111,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8970,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL624112,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8971,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL624113,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8972,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL619709,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8973,Rattus norvegicus,1,A,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL619710,16435,948.0,,,Heart,N,Intermediate,BAO_0000218
8974,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL619711,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8975,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL619712,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8976,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL619713,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8977,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL619714,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8978,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL619715,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8979,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL619716,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8980,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL619717,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8981,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL619718,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8982,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL619719,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8983,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL875329,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8984,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL619720,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8985,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL619721,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8986,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL619722,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8987,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL619723,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8988,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL619724,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8989,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL619725,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8990,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL619726,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8991,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL619727,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8992,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL619728,16434,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8993,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL619729,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
8994,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL619730,11977,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8995,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL619731,11977,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8996,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL619732,11977,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8997,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL619733,11977,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8998,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL619734,11977,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
8999,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL619735,11977,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9000,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL875330,11977,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9001,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL628465,11977,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9002,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL628466,11977,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9003,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL628467,11977,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9004,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL628468,11977,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9005,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL628469,11977,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9006,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL628470,11977,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9007,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL628471,11977,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9008,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL628472,11977,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9009,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625191,11977,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9010,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL625192,11977,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9011,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,10116.0,,,CHEMBL875337,11977,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9012,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626341,11977,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9013,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL626342,11977,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9014,Rattus norvegicus,1,A,,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,10116.0,,,CHEMBL621943,11977,2107.0,,,Liver,N,Intermediate,BAO_0000218
9015,Rattus norvegicus,1,A,,1,Half life in rats,50597,10116.0,,,CHEMBL621944,3748,,,,,N,Intermediate,BAO_0000218
9016,Rattus norvegicus,1,A,,1,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,50597,10116.0,,,CHEMBL621945,15765,,,,,N,Intermediate,BAO_0000218
9017,Rattus norvegicus,1,A,,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),50597,10116.0,,,CHEMBL621946,4871,,,,,N,Intermediate,BAO_0000218
9018,Rattus norvegicus,1,A,,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,10116.0,,,CHEMBL621947,4871,,,,,N,Intermediate,BAO_0000218
9019,Rattus norvegicus,1,A,,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),50597,10116.0,,,CHEMBL621948,4872,,,,,N,Intermediate,BAO_0000218
9020,Rattus norvegicus,1,A,,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,10116.0,,,CHEMBL621949,4872,,,,,N,Intermediate,BAO_0000218
9021,Rattus norvegicus,1,A,,1,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),50597,10116.0,,,CHEMBL621950,5413,,,,,N,Intermediate,BAO_0000218
9022,Rattus norvegicus,1,A,,1,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,50597,10116.0,,,CHEMBL621951,5413,,,,,N,Intermediate,BAO_0000218
9023,Rattus norvegicus,1,A,,1,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,50597,10116.0,,,CHEMBL621952,15272,178.0,,,Blood,N,Intermediate,BAO_0000218
9024,Rattus norvegicus,1,A,,1,Stability (%) in rat liver microsomes,50597,10116.0,,,CHEMBL621953,4689,2107.0,,,Liver,N,Intermediate,BAO_0000218
9025,Rattus norvegicus,1,A,,1,Area under curve was calculated after intravenous administration,50597,10116.0,,,CHEMBL621954,6057,,,,,N,Intermediate,BAO_0000218
9026,Rattus norvegicus,1,A,,1,Area under the curve was calculated after iv administration in rat,50597,10116.0,,,CHEMBL621955,6057,,,,,N,Intermediate,BAO_0000218
9027,Rattus norvegicus,1,A,,1,Area under the curve was calculated in rat after peroral administration,50597,10116.0,,,CHEMBL621956,6057,,,,,N,Intermediate,BAO_0000218
9028,Rattus norvegicus,1,A,,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,10116.0,,,CHEMBL621957,6211,,,,,N,Intermediate,BAO_0000218
9029,Rattus norvegicus,1,A,,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,50597,10116.0,,,CHEMBL621958,5710,,,,,N,Intermediate,BAO_0000218
9030,Rattus norvegicus,1,A,,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,50597,10116.0,,,CHEMBL621959,5710,,,,,N,Intermediate,BAO_0000218
9031,Rattus norvegicus,1,A,,1,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,50597,10116.0,,,CHEMBL621960,17853,,,,,N,Intermediate,BAO_0000218
9032,Rattus norvegicus,1,A,,1,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,50597,10116.0,,,CHEMBL621961,17853,,,,,N,Intermediate,BAO_0000218
9033,Rattus norvegicus,1,A,,1,p value of the compound,50597,10116.0,,,CHEMBL621962,15765,,,,,N,Intermediate,BAO_0000218
9034,Rattus norvegicus,1,F,,1,p value of the compound,50597,10116.0,,,CHEMBL876787,15765,,,,,N,Intermediate,BAO_0000218
9035,Rattus norvegicus,1,A,,1,p value of the compound,50597,10116.0,,,CHEMBL621963,15765,,,,,N,Intermediate,BAO_0000218
9036,Rattus norvegicus,1,A,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,10116.0,,,CHEMBL622637,6175,945.0,,,Stomach,N,Intermediate,BAO_0000218
9037,Rattus norvegicus,1,A,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,10116.0,,,CHEMBL622638,6175,945.0,,,Stomach,N,Intermediate,BAO_0000218
9038,Rattus norvegicus,1,A,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,10116.0,,,CHEMBL626561,6175,945.0,,,Stomach,N,Intermediate,BAO_0000218
9039,Oryctolagus cuniculus,0,F,,1,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),22224,9986.0,,,CHEMBL626562,7991,,,,,U,Autocuration,BAO_0000019
9040,Oryctolagus cuniculus,0,A,,1,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),22224,9986.0,,,CHEMBL626563,429,,,,,U,Autocuration,BAO_0000218
9041,Oryctolagus cuniculus,0,A,,1,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),22224,9986.0,,,CHEMBL626564,429,,,,,U,Autocuration,BAO_0000218
9042,Oryctolagus cuniculus,0,A,,1,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,9986.0,,,CHEMBL626565,6253,,,,,U,Autocuration,BAO_0000218
9043,Oryctolagus cuniculus,0,A,,1,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,9986.0,,,CHEMBL626566,6253,,,,,U,Autocuration,BAO_0000218
9044,Oryctolagus cuniculus,0,A,,1,Clearance rate in rabbits,22224,9986.0,,,CHEMBL626567,3615,,,,,U,Autocuration,BAO_0000218
9045,Oryctolagus cuniculus,0,A,,1,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,9986.0,,,CHEMBL626568,4059,,,,,U,Autocuration,BAO_0000218
9046,Oryctolagus cuniculus,0,A,,1,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,9986.0,,,CHEMBL626569,5124,,,,,U,Autocuration,BAO_0000218
9047,Oryctolagus cuniculus,0,A,,1,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,9986.0,,,CHEMBL626570,5124,,,,,U,Autocuration,BAO_0000218
9048,Oryctolagus cuniculus,0,A,,1,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,9986.0,,,CHEMBL626571,5124,,,,,U,Autocuration,BAO_0000218
9049,Oryctolagus cuniculus,0,A,,1,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,22224,9986.0,,,CHEMBL626572,429,,,,,U,Autocuration,BAO_0000218
9050,Oryctolagus cuniculus,0,A,,1,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,9986.0,,,CHEMBL626573,4059,1969.0,,,Plasma,U,Autocuration,BAO_0000218
9051,Oryctolagus cuniculus,0,A,,1,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,22224,9986.0,Microsomes,,CHEMBL626574,9659,2107.0,,,Liver,U,Autocuration,BAO_0000251
9052,Oryctolagus cuniculus,0,A,,1,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,22224,9986.0,Microsomes,,CHEMBL626575,9659,2107.0,,,Liver,U,Autocuration,BAO_0000251
9053,Oryctolagus cuniculus,0,A,,1,Dose at which bioavailability of intravenously administered compound was tested in rabbit,22224,9986.0,,,CHEMBL626576,3639,,,,,U,Autocuration,BAO_0000218
9054,Oryctolagus cuniculus,0,A,,1,Dose at which bioavailability of perorally administered compound was tested in rabbit,22224,9986.0,,,CHEMBL626577,3639,,,,,U,Autocuration,BAO_0000218
9055,Oryctolagus cuniculus,0,A,,1,The compound was tested for its bioavailability in rabbit (by oral dosage).,22224,9986.0,,,CHEMBL626578,3639,,,,,U,Autocuration,BAO_0000218
9056,Oryctolagus cuniculus,0,A,,1,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,9986.0,,,CHEMBL625263,5124,,,,,U,Autocuration,BAO_0000218
9057,Oryctolagus cuniculus,0,A,,1,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,9986.0,,,CHEMBL625264,5124,,,,,U,Autocuration,BAO_0000218
9058,Oryctolagus cuniculus,0,A,,1,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,9986.0,,,CHEMBL625265,5124,,,,,U,Autocuration,BAO_0000218
9059,Oryctolagus cuniculus,0,A,,1,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),22224,9986.0,Microsomes,,CHEMBL625266,14294,,,,,U,Autocuration,BAO_0000251
9060,Oryctolagus cuniculus,0,A,,1,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),22224,9986.0,Microsomes,,CHEMBL876796,14294,,,,,U,Autocuration,BAO_0000251
9061,Oryctolagus cuniculus,0,A,,1,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,22224,9986.0,,,CHEMBL625267,429,,,,,U,Autocuration,BAO_0000218
9062,Oryctolagus cuniculus,0,A,,1,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,9986.0,,,CHEMBL625268,5124,1969.0,,,Plasma,U,Autocuration,BAO_0000218
9063,Oryctolagus cuniculus,0,A,,1,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,9986.0,,,CHEMBL625269,5124,1969.0,,,Plasma,U,Autocuration,BAO_0000218
9064,Oryctolagus cuniculus,0,A,,1,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,9986.0,,,CHEMBL624689,5124,1969.0,,,Plasma,U,Autocuration,BAO_0000218
9065,Oryctolagus cuniculus,0,A,,1,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,22224,9986.0,,,CHEMBL624690,429,,,,,U,Autocuration,BAO_0000218
9066,Oryctolagus cuniculus,0,A,,1,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),22224,9986.0,,,CHEMBL624691,429,1088.0,,,Urine,U,Autocuration,BAO_0000218
9067,Oryctolagus cuniculus,0,A,,1,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),22224,9986.0,,,CHEMBL624692,429,1088.0,,,Urine,U,Autocuration,BAO_0000218
9068,Oryctolagus cuniculus,0,A,,1,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,9986.0,,,CHEMBL624693,4059,,,,,U,Autocuration,BAO_0000218
9069,Oryctolagus cuniculus,0,A,,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,22224,9986.0,,,CHEMBL624694,4137,,,,,U,Autocuration,BAO_0000218
9070,Oryctolagus cuniculus,0,A,,1,In vitro Biological half-life in crude homogenate of rabbit renal cortex,22224,9986.0,,,CHEMBL877596,11672,,,,,U,Autocuration,BAO_0000221
9071,Oryctolagus cuniculus,0,A,,1,Time within which only 10% of the drug was degraded,22224,9986.0,,,CHEMBL624695,12886,,,,,U,Autocuration,BAO_0000019
9072,Oryctolagus cuniculus,0,A,,1,Half life period in rabbit liver homogenate,22224,9986.0,,,CHEMBL624696,3853,2107.0,,,Liver,U,Autocuration,BAO_0000221
9073,Oryctolagus cuniculus,0,A,,1,Half life value in rabbits,22224,9986.0,,,CHEMBL624697,3615,,,,,U,Autocuration,BAO_0000019
9074,Oryctolagus cuniculus,0,A,,1,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,9986.0,,,CHEMBL624698,6253,178.0,,,Blood,U,Autocuration,BAO_0000218
9075,Oryctolagus cuniculus,0,A,,1,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,9986.0,,,CHEMBL624699,6253,178.0,,,Blood,U,Autocuration,BAO_0000218
9076,Oryctolagus cuniculus,0,A,,1,Half-life period in rabbits following intravenous administration at 2 mg/kg,22224,9986.0,,,CHEMBL624700,6077,,,,,U,Autocuration,BAO_0000218
9077,Rattus norvegicus,1,A,,1,AUC 0-8 hr value in rats at 10 mg/kg,50597,10116.0,,,CHEMBL622903,17617,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9078,Rattus norvegicus,1,A,,1,AUC after administration at 2000 mg/kg/day in rats,50597,10116.0,,,CHEMBL622904,17594,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9079,Rattus norvegicus,1,A,,1,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,50597,10116.0,,,CHEMBL622905,6149,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9080,Rattus norvegicus,1,A,,1,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,10116.0,,,CHEMBL622906,17260,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9081,Rattus norvegicus,1,A,,1,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,10116.0,,,CHEMBL622907,17260,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9082,Rattus norvegicus,1,A,,1,AUC in rat after oral administration at 10.5 mg/kg dose,50597,10116.0,,,CHEMBL622908,6644,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9083,Rattus norvegicus,1,A,,1,AUC in rat after oral administration at 11.2 mg/kg dose,50597,10116.0,,,CHEMBL622909,6644,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9084,Rattus norvegicus,1,A,,1,AUC in rat after oral administration at 9.7 mg/kg dose,50597,10116.0,,,CHEMBL622910,6644,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9085,Rattus norvegicus,1,A,,1,AUC in rat brain after oral administration at 10 mg/kg,50597,10116.0,,,CHEMBL622911,6495,955.0,,,Brain,N,Intermediate,BAO_0000218
9086,Rattus norvegicus,1,A,,1,AUC in rat p.o.,50597,10116.0,,,CHEMBL622912,6504,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9087,Rattus norvegicus,1,A,,1,AUC in rat p.o. at 20 mg/kg concentration,50597,10116.0,,,CHEMBL622913,17686,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9088,Rattus norvegicus,1,A,,1,AUC in rat plasma after oral administration at 10 mg/kg,50597,10116.0,,,CHEMBL622914,6495,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9089,Rattus norvegicus,1,A,,1,AUC in rats,50597,10116.0,,,CHEMBL622915,216,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9090,Rattus norvegicus,1,A,,1,AUC value after IV dose at a dose of 5 mg/kg in rats.,50597,10116.0,,,CHEMBL622916,1908,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9091,Rattus norvegicus,1,A,,1,AUC value after oral dose at a dose of 10 mg/kg in rats.,50597,10116.0,,,CHEMBL622917,1908,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9092,Rattus norvegicus,1,A,,1,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,10116.0,,,CHEMBL622918,6685,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9093,Rattus norvegicus,1,A,,1,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,50597,10116.0,,,CHEMBL622919,216,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9094,Rattus norvegicus,1,A,,1,Maximum plasma concentration was evaluated in rat,50597,10116.0,,,CHEMBL622920,6049,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9095,Rattus norvegicus,1,A,,1,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,10116.0,,,CHEMBL622921,2463,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9096,Rattus norvegicus,1,A,,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50597,10116.0,,,CHEMBL622922,6679,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9097,Rattus norvegicus,1,A,,1,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,10116.0,,,CHEMBL622923,6681,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9098,Rattus norvegicus,1,A,,1,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL877604,4890,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9099,Rattus norvegicus,1,A,,1,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,50597,10116.0,,,CHEMBL622924,6410,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9100,Rattus norvegicus,1,A,,1,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,50597,10116.0,,,CHEMBL622925,6410,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9101,Rattus norvegicus,1,A,,1,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,50597,10116.0,,,CHEMBL622926,16366,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9102,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL623625,6227,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9103,Rattus norvegicus,1,A,,1,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL623626,3598,1969.0,,,Plasma,N,Expert,BAO_0000218
9104,Rattus norvegicus,1,A,,1,Maximum plasma drug concentration was determined,50597,10116.0,,,CHEMBL623627,1465,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9105,Rattus norvegicus,1,A,,1,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,50597,10116.0,,,CHEMBL623628,4368,,,,,N,Intermediate,BAO_0000218
9106,Rattus norvegicus,1,A,,1,Mean peak plasma concentration was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL623629,15662,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9107,Rattus norvegicus,1,A,,1,Mean peak plasma concentration was observed after oral administration in rat,50597,10116.0,,,CHEMBL623630,15662,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9108,Rattus norvegicus,1,A,,1,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,50597,10116.0,,,CHEMBL623804,5355,,,,,N,Intermediate,BAO_0000218
9109,Rattus norvegicus,1,A,,1,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL623805,5355,,,,,N,Intermediate,BAO_0000218
9110,Rattus norvegicus,1,A,,1,Peak oral plasma concentration was determined in rats by oral administration,50597,10116.0,,,CHEMBL623806,1567,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9111,Rattus norvegicus,1,A,,1,Peak plasma concentration (Cmax) was determined,50597,10116.0,,,CHEMBL623807,4026,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9112,Rattus norvegicus,1,A,,1,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL623808,6193,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9113,Rattus norvegicus,1,A,,1,Peak plasma concentration (Cmax) in rats,50597,10116.0,,,CHEMBL623809,4026,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9114,Rattus norvegicus,1,A,,1,Peak plasma concentration at 1 mg/kg peroral administration,50597,10116.0,,,CHEMBL623810,6485,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9115,Rattus norvegicus,1,A,,1,Peak plasma concentration in rat,50597,10116.0,,,CHEMBL623811,17655,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9116,Rattus norvegicus,1,A,,1,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",50597,10116.0,,,CHEMBL623812,14941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9117,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,50597,10116.0,,,CHEMBL877605,5394,,,,,N,Intermediate,BAO_0000218
9118,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Cmax) in rat,50597,10116.0,,,CHEMBL623813,4408,,,,,N,Intermediate,BAO_0000218
9119,Rattus norvegicus,1,A,,1,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,10116.0,,,CHEMBL623814,5983,,,,,N,Intermediate,BAO_0000218
9120,Rattus norvegicus,1,A,,1,Cmax in rat after 3mg/kg oral dose,50597,10116.0,,,CHEMBL623815,4878,,,,,N,Intermediate,BAO_0000218
9121,Rattus norvegicus,1,A,,1,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,50597,10116.0,,,CHEMBL623816,5862,,,,,N,Intermediate,BAO_0000218
9122,Rattus norvegicus,1,A,,1,Cmax in rats after 20 mg/kg oral dose,50597,10116.0,,,CHEMBL623145,4517,,,,,N,Intermediate,BAO_0000218
9123,Rattus norvegicus,1,A,,1,Cmax in rat plasma after 30mg/kg oral dose,50597,10116.0,,,CHEMBL623146,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9124,Rattus norvegicus,1,A,,1,Plasma concentration after oral administration of 100 mg/kg to rats,50597,10116.0,,,CHEMBL623147,5436,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9125,Rattus norvegicus,1,A,,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,10116.0,,,CHEMBL623042,4910,955.0,,,Brain,N,Intermediate,BAO_0000218
9126,Rattus norvegicus,1,A,,1,Tested for the Cmax in rat at 10 mg/kg per orally,50597,10116.0,,,CHEMBL623043,4950,,,,,N,Intermediate,BAO_0000218
9127,Rattus norvegicus,1,A,,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL623044,15078,,,,,N,Intermediate,BAO_0000218
9128,Rattus norvegicus,1,A,,1,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL623045,15078,,,,,N,Intermediate,BAO_0000218
9129,Rattus norvegicus,1,A,,1,Bioavailability as oral Cmax in rats at 30 mins,50597,10116.0,,,CHEMBL623046,3360,,,,,N,Intermediate,BAO_0000218
9130,Rattus norvegicus,1,A,,1,Bioavailability as oral Cmax in rats at 6hr,50597,10116.0,,,CHEMBL623226,3360,,,,,N,Intermediate,BAO_0000218
9131,Rattus norvegicus,1,A,,1,The maximum concentration of compound was measured at the dose of 100 umol/kg,50597,10116.0,,,CHEMBL623227,15022,,,,,N,Intermediate,BAO_0000218
9132,Rattus norvegicus,1,A,,1,The maximum concentration of compound was measured at the dose of 300 umol/kg,50597,10116.0,,,CHEMBL623228,15022,,,,,N,Intermediate,BAO_0000218
9133,Rattus norvegicus,1,A,,1,The maximum concentration of compound was measured at the dose of 30 umol/kg,50597,10116.0,,,CHEMBL623229,15022,,,,,N,Intermediate,BAO_0000218
9134,Rattus norvegicus,1,A,,1,The maximum plasma levels for the compounds were determined by LC-MS.,50597,10116.0,,,CHEMBL623230,5160,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9135,Rattus norvegicus,1,A,,1,mean peak plasma concentration was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL623231,15662,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9136,Rattus norvegicus,1,A,,1,mean peak plasma concentration was observed after oral administration in rat,50597,10116.0,,,CHEMBL623232,15662,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9137,Rattus norvegicus,1,A,,1,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,50597,10116.0,,,CHEMBL623233,4709,,,,,N,Intermediate,BAO_0000218
9138,Rattus norvegicus,1,A,,1,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,50597,10116.0,,,CHEMBL623234,3535,,,,,N,Intermediate,BAO_0000218
9139,Rattus norvegicus,1,A,,1,Concentration in plasma (portal) following oral dose in rats at 1 hr,50597,10116.0,,,CHEMBL623235,3535,,,,,N,Intermediate,BAO_0000218
9140,Rattus norvegicus,1,A,,1,Concentration in plasma (portal) following oral dose in rats at 2 hr,50597,10116.0,,,CHEMBL623236,3535,,,,,N,Intermediate,BAO_0000218
9141,Rattus norvegicus,1,A,,1,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,50597,10116.0,,,CHEMBL623237,3535,,,,,N,Intermediate,BAO_0000218
9142,Rattus norvegicus,1,A,,1,Concentration in plasma (systemic) following oral dose in rats at 1 hr,50597,10116.0,,,CHEMBL623238,3535,,,,,N,Intermediate,BAO_0000218
9143,Rattus norvegicus,1,A,,1,Concentration in plasma (systemic) following oral dose in rats at 2 hr,50597,10116.0,,,CHEMBL623239,3535,,,,,N,Intermediate,BAO_0000218
9144,Rattus norvegicus,0,A,,1,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,22224,10116.0,,,CHEMBL623240,5005,1969.0,,,Plasma,U,Intermediate,BAO_0000218
9145,Rattus norvegicus,1,A,,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",50597,10116.0,,,CHEMBL623241,6326,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
9146,Rattus norvegicus,1,A,,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",50597,10116.0,,,CHEMBL623242,6326,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
9147,Rattus norvegicus,1,A,,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",50597,10116.0,,,CHEMBL874394,6326,,,,,N,Intermediate,BAO_0000218
9148,Rattus norvegicus,1,A,,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",50597,10116.0,,,CHEMBL623243,6326,,,,,N,Intermediate,BAO_0000218
9149,Rattus norvegicus,1,A,,1,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL623244,17411,,,,,N,Intermediate,BAO_0000218
9150,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL623245,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9151,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL623246,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9152,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL623247,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9153,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL623248,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9154,Rattus norvegicus,1,A,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL623249,16435,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9155,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL625072,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9156,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL625073,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9157,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL625074,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9158,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL625075,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9159,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL625076,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9160,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL625077,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9161,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL625078,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9162,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL874395,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9163,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL625079,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9164,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL625080,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9165,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL625081,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9166,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL625082,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9167,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL625083,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9168,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL625084,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9169,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL625085,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9170,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL625086,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9171,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL625087,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9172,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL625088,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9173,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL622205,16434,2107.0,,,Liver,N,Intermediate,BAO_0000218
9174,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL622206,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9175,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL622207,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9176,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL622366,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9177,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL622367,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9178,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL875331,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9179,Rattus norvegicus,1,A,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL622368,16435,2107.0,,,Liver,N,Intermediate,BAO_0000218
9180,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL622369,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9181,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL622370,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9182,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL622371,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9183,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL622372,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9184,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL622373,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9185,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL622374,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9186,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL622375,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9187,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL622376,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9188,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL622377,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9189,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL622378,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9190,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL622379,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9191,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL622380,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9192,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL622381,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9193,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL622382,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9194,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL622383,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9195,Rattus norvegicus,1,A,,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,10116.0,,,CHEMBL875332,6175,945.0,,,Stomach,N,Intermediate,BAO_0000218
9196,Rattus norvegicus,1,A,,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,10116.0,,,CHEMBL622384,6175,945.0,,,Stomach,N,Intermediate,BAO_0000218
9197,Rattus norvegicus,1,A,,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,10116.0,,,CHEMBL622385,6175,945.0,,,Stomach,N,Intermediate,BAO_0000218
9198,Rattus norvegicus,1,A,,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,10116.0,,,CHEMBL622386,6175,945.0,,,Stomach,N,Intermediate,BAO_0000218
9199,Rattus norvegicus,1,A,,1,The compound was tested for the plasma binding in rat,50597,10116.0,,,CHEMBL622387,10839,,,,,N,Intermediate,BAO_0000218
9200,Rattus norvegicus,1,A,,1,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",50597,10116.0,,,CHEMBL622388,16459,,,,,N,Intermediate,BAO_0000218
9201,Rattus norvegicus,1,A,,1,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",50597,10116.0,,,CHEMBL622389,16459,,,,,N,Intermediate,BAO_0000218
9202,Rattus norvegicus,1,A,,1,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",50597,10116.0,,,CHEMBL622390,16459,,,,,N,Intermediate,BAO_0000218
9203,Rattus norvegicus,1,A,,1,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),50597,10116.0,,,CHEMBL622391,16459,,,,,N,Intermediate,BAO_0000218
9204,Rattus norvegicus,1,A,,1,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),50597,10116.0,,,CHEMBL622392,16459,,,,,N,Intermediate,BAO_0000218
9205,Rattus norvegicus,1,A,,1,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),50597,10116.0,,,CHEMBL622393,16459,,,,,N,Intermediate,BAO_0000218
9206,Rattus norvegicus,1,A,,1,Plasma level at 2 hr after administration of the compound,50597,10116.0,,,CHEMBL622394,3278,,,,,N,Intermediate,BAO_0000218
9207,Rattus norvegicus,1,A,,1,plasma level at 2 hr after administration of the compound,50597,10116.0,,,CHEMBL622395,3278,,,,,N,Intermediate,BAO_0000218
9208,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 1 min,50597,10116.0,,,CHEMBL622396,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9209,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 10 min,50597,10116.0,,,CHEMBL624894,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9210,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 10 mins,50597,10116.0,,,CHEMBL624895,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9211,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 2 hr,50597,10116.0,,,CHEMBL624058,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9212,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 3 min,50597,10116.0,,,CHEMBL624059,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9213,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 3 mins,50597,10116.0,,,CHEMBL624060,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9214,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 5 min,50597,10116.0,,,CHEMBL624061,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9215,Rattus norvegicus,1,A,,1,Stability in rat serum measured as % recovery at 5 mins,50597,10116.0,,,CHEMBL624062,4684,1977.0,,,Serum,N,Intermediate,BAO_0000218
9216,Rattus norvegicus,1,A,,1,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL624063,16456,,,,,N,Intermediate,BAO_0000218
9217,Rattus norvegicus,1,A,,1,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL624064,16456,,,,,N,Intermediate,BAO_0000218
9218,Rattus norvegicus,1,A,,1,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,50597,10116.0,,,CHEMBL624065,723,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9219,Rattus norvegicus,1,A,,1,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,50597,10116.0,,,CHEMBL624066,723,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9220,Rattus norvegicus,1,A,,1,Half life tested in mature male rat at a dose of 30 mg/kg,50597,10116.0,,,CHEMBL877490,5160,,,,,N,Intermediate,BAO_0000218
9221,Rattus norvegicus,1,A,,1,Half life after intravenous administration of 1 mg/kg in rat,50597,10116.0,,,CHEMBL874442,4709,,,,,N,Intermediate,BAO_0000218
9222,Rattus norvegicus,1,A,,1,Half life period after administration (30 mg/kg) in rat,50597,10116.0,,,CHEMBL626890,5633,,,,,N,Intermediate,BAO_0000218
9223,Rattus norvegicus,1,A,,1,Half life period in rat after 5 mg/Kg dose,50597,10116.0,,,CHEMBL626891,5302,,,,,N,Intermediate,BAO_0000218
9224,Rattus norvegicus,1,A,,1,Half life period in rat after 5 mg/kg dose,50597,10116.0,,,CHEMBL626892,5302,,,,,N,Intermediate,BAO_0000218
9225,Rattus norvegicus,1,A,,1,Half life period was determined,50597,10116.0,,,CHEMBL626893,17791,,,,,N,Intermediate,BAO_0000218
9226,Rattus norvegicus,1,A,,1,Half life period was evaluated in rat,50597,10116.0,,,CHEMBL626894,17791,,,,,N,Intermediate,BAO_0000218
9227,Rattus norvegicus,1,A,,1,Half life period was evaluated in rat; 0.5-1.0,50597,10116.0,,,CHEMBL626895,17791,,,,,N,Intermediate,BAO_0000218
9228,Rattus norvegicus,1,A,,1,Half life period was evaluated in rat; 5.9-7.5,50597,10116.0,,,CHEMBL626896,17791,,,,,N,Intermediate,BAO_0000218
9229,Rattus norvegicus,1,A,,1,Half-life in rat plasma,50597,10116.0,,,CHEMBL626897,14512,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9230,Rattus norvegicus,1,A,,1,Half-life time in rat was determined,50597,10116.0,,,CHEMBL626898,6230,,,,,N,Intermediate,BAO_0000218
9231,Rattus norvegicus,1,A,,1,Terminal half-life after iv administration to rats,50597,10116.0,,,CHEMBL626899,3364,,,,,N,Intermediate,BAO_0000218
9232,Rattus norvegicus,1,A,,1,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,50597,10116.0,,,CHEMBL626900,6874,,,,,N,Intermediate,BAO_0000218
9233,Rattus norvegicus,1,A,,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,50597,10116.0,,,CHEMBL626901,857,,,,,N,Intermediate,BAO_0000218
9234,Rattus norvegicus,1,A,,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),50597,10116.0,,,CHEMBL626902,858,,,,,N,Intermediate,BAO_0000218
9235,Rattus norvegicus,1,A,,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),50597,10116.0,,,CHEMBL626903,858,,,,,N,Intermediate,BAO_0000218
9236,Rattus norvegicus,1,A,,1,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,50597,10116.0,,,CHEMBL874443,5355,,,,,N,Intermediate,BAO_0000218
9237,Rattus norvegicus,1,A,,1,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL626904,5355,,,,,N,Intermediate,BAO_0000218
9238,Rattus norvegicus,1,A,,1,Half life in rats,50597,10116.0,,,CHEMBL626905,6305,,,,,N,Intermediate,BAO_0000218
9239,Rattus norvegicus,1,A,,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,10116.0,,,CHEMBL873830,13501,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9240,Rattus norvegicus,1,A,,1,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,50597,10116.0,,,CHEMBL626906,17594,,,,,N,Intermediate,BAO_0000218
9241,Rattus norvegicus,1,A,,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,10116.0,,,CHEMBL631076,4186,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9242,Rattus norvegicus,1,A,,1,Biological half-life was measured in plasma of rats,50597,10116.0,,,CHEMBL631077,2932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9243,Rattus norvegicus,1,A,,1,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,10116.0,,,CHEMBL631078,17065,,,,,N,Intermediate,BAO_0000218
9244,Rattus norvegicus,1,A,,1,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,50597,10116.0,,,CHEMBL631079,15765,,,,,N,Intermediate,BAO_0000218
9245,Rattus norvegicus,1,A,,1,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,50597,10116.0,,,CHEMBL631080,2713,,,,,N,Intermediate,BAO_0000218
9246,Rattus norvegicus,1,A,,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,50597,10116.0,,,CHEMBL631081,2661,,,,,N,Intermediate,BAO_0000218
9247,Rattus norvegicus,1,A,,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,50597,10116.0,,,CHEMBL631239,2661,,,,,N,Intermediate,BAO_0000218
9248,Rattus norvegicus,1,A,,1,Compound was evaluated for plasma half life in rat,50597,10116.0,,,CHEMBL631240,740,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9249,Rattus norvegicus,1,A,,1,AUC value at a dose of 5 mg/kg (p.o.) in rats,50597,10116.0,,,CHEMBL631241,6597,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9250,Rattus norvegicus,1,A,,1,AUC value after administration of 20 mg/Kg oral dose in rat,50597,10116.0,,,CHEMBL631242,2959,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9251,Rattus norvegicus,1,A,,1,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,50597,10116.0,,,CHEMBL631243,17594,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9252,Rattus norvegicus,1,A,,1,AUC0-96 after administration at 50 mg/kg,50597,10116.0,,,CHEMBL874444,17596,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9253,Rattus norvegicus,1,A,,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,50597,10116.0,,,CHEMBL631244,17594,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9254,Rattus norvegicus,1,A,,1,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",50597,10116.0,,,CHEMBL631245,3293,,,,,N,Intermediate,BAO_0000218
9255,Rattus norvegicus,1,A,,1,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,50597,10116.0,,,CHEMBL627162,6757,,,,,N,Intermediate,BAO_0000218
9256,Rattus norvegicus,1,A,,1,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,50597,10116.0,,,CHEMBL627163,6757,,,,,N,Intermediate,BAO_0000218
9257,Rattus norvegicus,1,A,,1,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,50597,10116.0,,,CHEMBL627164,6757,,,,,N,Intermediate,BAO_0000218
9258,Rattus norvegicus,1,A,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,50597,10116.0,,,CHEMBL627165,5979,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9259,Rattus norvegicus,1,A,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,50597,10116.0,,,CHEMBL627166,5979,,,,,N,Intermediate,BAO_0000218
9260,Rattus norvegicus,1,A,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,50597,10116.0,,,CHEMBL627167,5979,,,,,N,Intermediate,BAO_0000218
9261,Rattus norvegicus,1,A,,1,Area under curve (AUC) at a dose of 30 mg/kg in rats,50597,10116.0,,,CHEMBL627822,4026,,,,,N,Intermediate,BAO_0000218
9262,Rattus norvegicus,1,A,,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL627823,5355,,,,,N,Intermediate,BAO_0000218
9263,Rattus norvegicus,1,A,,1,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,50597,10116.0,,,CHEMBL627824,5355,,,,,N,Intermediate,BAO_0000218
9264,Rattus norvegicus,1,A,,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,10116.0,,,CHEMBL627825,5355,,,,,N,Intermediate,BAO_0000218
9265,Rattus norvegicus,1,A,,1,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,50597,10116.0,,,CHEMBL627826,5633,,,,,N,Intermediate,BAO_0000218
9266,Rattus norvegicus,1,A,,1,Area under curve (Pharmacokinetic property) was determined,50597,10116.0,,,CHEMBL627827,1716,,,,,N,Intermediate,BAO_0000218
9267,Rattus norvegicus,1,A,,1,Area under curve (Pharmacokinetic property) of the compound; Not determined,50597,10116.0,,,CHEMBL627828,1716,,,,,N,Intermediate,BAO_0000218
9268,Rattus norvegicus,1,A,,1,Area under curve after intravenous administration (1 mg/kg) in rat,50597,10116.0,,,CHEMBL627829,4689,,,,,N,Intermediate,BAO_0000218
9269,Rattus norvegicus,1,A,,1,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,50597,10116.0,,,CHEMBL627830,4527,,,,,N,Intermediate,BAO_0000218
9270,Rattus norvegicus,1,A,,1,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,50597,10116.0,,,CHEMBL627831,4527,,,,,N,Intermediate,BAO_0000218
9271,Rattus norvegicus,1,A,,1,Area under curve in male SD rats was observed after oral administration in rat,50597,10116.0,,,CHEMBL627832,15662,,,,,N,Intermediate,BAO_0000218
9272,Rattus norvegicus,1,A,,1,Area under curve of compound after iv administration of 20 mg/kg dose in rat,50597,10116.0,,,CHEMBL627833,4413,,,,,N,Intermediate,BAO_0000218
9273,Rattus norvegicus,1,A,,1,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL627834,3598,,,,,N,Expert,BAO_0000218
9274,Rattus norvegicus,1,A,,1,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL628004,3598,,,,,N,Expert,BAO_0000218
9275,Rattus norvegicus,1,A,,1,Area under curve at 5 mg/kg po was determined in rat,50597,10116.0,,,CHEMBL628005,5964,,,,,N,Intermediate,BAO_0000218
9276,Rattus norvegicus,1,A,,1,Area under curve in Rat at a oral dose of 5 mg/kg,50597,10116.0,,,CHEMBL628006,4689,,,,,N,Intermediate,BAO_0000218
9277,Rattus norvegicus,1,A,,1,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,10116.0,,,CHEMBL628007,4186,,,,,N,Intermediate,BAO_0000218
9278,Rattus norvegicus,1,A,,1,Area under curve was determined,50597,10116.0,,,CHEMBL625676,5510,,,,,N,Intermediate,BAO_0000218
9279,Rattus norvegicus,1,A,,1,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,50597,10116.0,,,CHEMBL631309,17858,,,,,N,Intermediate,BAO_0000218
9280,Rattus norvegicus,1,A,,1,Area under curve after intravenous administration at 3 mg/kg,50597,10116.0,,,CHEMBL631310,17804,,,,,N,Intermediate,BAO_0000218
9281,Rattus norvegicus,1,A,,1,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,50597,10116.0,,,CHEMBL631311,6106,,,,,N,Intermediate,BAO_0000218
9282,Rattus norvegicus,1,A,,1,Area under curve at 4 hr in rat,50597,10116.0,,,CHEMBL631312,5964,,,,,N,Intermediate,BAO_0000218
9283,Rattus norvegicus,1,A,,1,Area under curve at a dose of 30 mg/kg,50597,10116.0,,,CHEMBL631313,4026,,,,,N,Intermediate,BAO_0000218
9284,Rattus norvegicus,1,A,,1,Area under curve at the dose of 2 mg/Kg administered perorally in rats,50597,10116.0,,,CHEMBL631314,4756,,,,,N,Intermediate,BAO_0000218
9285,Rattus norvegicus,1,A,,1,Area under curve at the dose of 5 mg/Kg administered perorally in rats,50597,10116.0,,,CHEMBL631315,4756,,,,,N,Intermediate,BAO_0000218
9286,Rattus norvegicus,1,A,,1,Area under curve for a 2-mpk po dose in SD rats,50597,10116.0,,,CHEMBL631316,5862,,,,,N,Intermediate,BAO_0000218
9287,Rattus norvegicus,1,A,,1,Area under curve in SD rats,50597,10116.0,,,CHEMBL631317,5862,,,,,N,Intermediate,BAO_0000218
9288,Rattus norvegicus,1,A,,1,Area under curve in rat after oral administration at 13 mg/kg dose,50597,10116.0,,,CHEMBL874471,6644,,,,,N,Intermediate,BAO_0000218
9289,Rattus norvegicus,1,A,,1,Area under curve in rat by po administration at 0-24 hr,50597,10116.0,,,CHEMBL631318,5871,,,,,N,Intermediate,BAO_0000218
9290,Rattus norvegicus,1,A,,1,Area under curve in rat plasma,50597,10116.0,,,CHEMBL631319,5919,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9291,Rattus norvegicus,1,A,,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,50597,10116.0,,,CHEMBL631320,5939,,,,,N,Intermediate,BAO_0000218
9292,Rattus norvegicus,1,A,,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,50597,10116.0,,,CHEMBL631321,5939,,,,,N,Intermediate,BAO_0000218
9293,Rattus norvegicus,1,A,,1,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,50597,10116.0,,,CHEMBL631322,10,,,,,N,Intermediate,BAO_0000218
9294,Rattus norvegicus,1,A,,1,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,50597,10116.0,,,CHEMBL631323,11149,,,,,N,Intermediate,BAO_0000218
9295,Rattus norvegicus,1,A,,1,Area under curve value in rat at a dose of 5 mg/kg,50597,10116.0,,,CHEMBL631324,5302,,,,,N,Intermediate,BAO_0000218
9296,Rattus norvegicus,1,A,,1,Area under curve was determined after oral administration in rats,50597,10116.0,,,CHEMBL631325,17796,,,,,N,Intermediate,BAO_0000218
9297,Rattus norvegicus,1,A,,1,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL631326,4890,,,,,N,Intermediate,BAO_0000218
9298,Rattus norvegicus,1,A,,1,Area under curve was determined after peroral administration in rat,50597,10116.0,,,CHEMBL631327,6011,,,,,N,Intermediate,BAO_0000218
9299,Rattus norvegicus,1,A,,1,Area under curve was determined at a dose 30 mpk administered orally.,50597,10116.0,,,CHEMBL631328,5375,,,,,N,Intermediate,BAO_0000218
9300,Rattus norvegicus,1,A,,1,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,50597,10116.0,,,CHEMBL631329,17764,,,,,N,Intermediate,BAO_0000218
9301,Rattus norvegicus,1,A,,1,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,50597,10116.0,,,CHEMBL627217,4368,,,,,N,Intermediate,BAO_0000218
9302,Rattus norvegicus,1,A,,1,Area under curve was determined in male rat,50597,10116.0,,,CHEMBL626352,5610,,,,,N,Intermediate,BAO_0000218
9303,Rattus norvegicus,1,A,,1,Area under curve was determined in rat after PO administration,50597,10116.0,,,CHEMBL626353,5833,,,,,N,Intermediate,BAO_0000218
9304,Rattus norvegicus,1,A,,1,Area under curve was determined in rat after a 3 mg/kg of oral dose,50597,10116.0,,,CHEMBL626354,4257,,,,,N,Intermediate,BAO_0000218
9305,Rattus norvegicus,1,A,,1,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,50597,10116.0,,,CHEMBL626355,5937,,,,,N,Intermediate,BAO_0000218
9306,Rattus norvegicus,1,A,,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,50597,10116.0,,,CHEMBL626356,5932,,,,,N,Intermediate,BAO_0000218
9307,Rattus norvegicus,1,A,,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,50597,10116.0,,,CHEMBL626357,5932,,,,,N,Intermediate,BAO_0000218
9308,Rattus norvegicus,1,A,,1,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL626358,17411,,,,,N,Intermediate,BAO_0000218
9309,Rattus norvegicus,1,A,,1,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL626359,17411,,,,,N,Intermediate,BAO_0000218
9310,Rattus norvegicus,1,A,,1,Peak plasma concentration in rat at a dose of 3 mg/kg,50597,10116.0,,,CHEMBL626360,17771,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9311,Rattus norvegicus,1,A,,1,Plasma concentration at 2 hr in rats was evaluated.,50597,10116.0,,,CHEMBL626361,1628,,,,,N,Intermediate,BAO_0000218
9312,Rattus norvegicus,1,A,,1,Plasma concentration at 2 hr in rats was evaluated; Not available,50597,10116.0,,,CHEMBL626362,1628,,,,,N,Intermediate,BAO_0000218
9313,Rattus norvegicus,1,A,,1,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL626363,17411,,,,,N,Intermediate,BAO_0000218
9314,Rattus norvegicus,1,A,,1,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL626970,4910,,,,,N,Intermediate,BAO_0000218
9315,Rattus norvegicus,1,A,,1,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL626971,4910,,,,,N,Intermediate,BAO_0000218
9316,Rattus norvegicus,1,A,,1,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL626972,4910,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9317,Rattus norvegicus,1,A,,1,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL626973,4910,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9318,Rattus norvegicus,1,A,,1,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL626974,4910,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9319,Rattus norvegicus,1,A,,1,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL874592,4910,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9320,Rattus norvegicus,1,A,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,50597,10116.0,,,CHEMBL626975,5510,,,,,N,Intermediate,BAO_0000218
9321,Rattus norvegicus,1,A,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,50597,10116.0,,,CHEMBL626976,5510,,,,,N,Intermediate,BAO_0000218
9322,Rattus norvegicus,1,A,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,50597,10116.0,,,CHEMBL626977,5510,,,,,N,Intermediate,BAO_0000218
9323,Rattus norvegicus,1,A,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,50597,10116.0,,,CHEMBL626978,5510,,,,,N,Intermediate,BAO_0000218
9324,Rattus norvegicus,1,A,,1,PK study was carried to determine the relative absorption ranking in rat.,50597,10116.0,,,CHEMBL626979,16427,,,,,N,Intermediate,BAO_0000218
9325,Rattus norvegicus,1,A,,1,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,50597,10116.0,,,CHEMBL626980,4689,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9326,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",50597,10116.0,,,CHEMBL626981,11450,178.0,,,Blood,N,Intermediate,BAO_0000218
9327,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",50597,10116.0,,,CHEMBL626982,11450,178.0,,,Blood,N,Intermediate,BAO_0000218
9328,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",50597,10116.0,,,CHEMBL626983,11450,178.0,,,Blood,N,Intermediate,BAO_0000218
9329,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",50597,10116.0,,,CHEMBL622522,11450,178.0,,,Blood,N,Intermediate,BAO_0000218
9330,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",50597,10116.0,,,CHEMBL622523,11450,178.0,,,Blood,N,Intermediate,BAO_0000218
9331,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",50597,10116.0,,,CHEMBL622524,11450,178.0,,,Blood,N,Intermediate,BAO_0000218
9332,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",50597,10116.0,,,CHEMBL622525,11450,955.0,,,Brain,N,Intermediate,BAO_0000218
9333,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",50597,10116.0,,,CHEMBL622526,11450,955.0,,,Brain,N,Intermediate,BAO_0000218
9334,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",50597,10116.0,,,CHEMBL619849,11450,955.0,,,Brain,N,Intermediate,BAO_0000218
9335,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",50597,10116.0,,,CHEMBL619850,11450,955.0,,,Brain,N,Intermediate,BAO_0000218
9336,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",50597,10116.0,,,CHEMBL623864,11450,955.0,,,Brain,N,Intermediate,BAO_0000218
9337,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",50597,10116.0,,,CHEMBL623865,11450,955.0,,,Brain,N,Intermediate,BAO_0000218
9338,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",50597,10116.0,,,CHEMBL623866,11450,948.0,,,Heart,N,Intermediate,BAO_0000218
9339,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",50597,10116.0,,,CHEMBL623867,11450,948.0,,,Heart,N,Intermediate,BAO_0000218
9340,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",50597,10116.0,,,CHEMBL877615,11450,948.0,,,Heart,N,Intermediate,BAO_0000218
9341,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",50597,10116.0,,,CHEMBL623868,11450,948.0,,,Heart,N,Intermediate,BAO_0000218
9342,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",50597,10116.0,,,CHEMBL623869,11450,948.0,,,Heart,N,Intermediate,BAO_0000218
9343,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",50597,10116.0,,,CHEMBL623870,11450,948.0,,,Heart,N,Intermediate,BAO_0000218
9344,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL623871,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9345,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL623872,16434,2048.0,,,Lung,N,Intermediate,BAO_0000218
9346,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL622129,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9347,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL622130,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9348,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL622131,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9349,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL622132,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9350,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL622133,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9351,Rattus norvegicus,1,A,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL622134,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9352,Rattus norvegicus,1,A,,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL622135,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9353,Rattus norvegicus,1,A,,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL622136,16435,2048.0,,,Lung,N,Intermediate,BAO_0000218
9354,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL622137,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9355,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL622138,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9356,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL623017,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9357,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL623018,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9358,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL623019,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9359,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL623020,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9360,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL623021,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9361,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL623022,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9362,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL623023,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9363,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL623024,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9364,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL623025,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9365,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL620545,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9366,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL620546,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9367,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL620547,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9368,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL620548,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9369,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL620549,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9370,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL620550,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9371,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL620551,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9372,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL620552,16434,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9373,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL620553,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9374,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL620554,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9375,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL875845,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9376,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL620555,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9377,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL620556,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9378,Rattus norvegicus,1,A,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL620557,16435,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9379,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL620558,16434,,,,,N,Intermediate,BAO_0000218
9380,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL620559,16434,,,,,N,Intermediate,BAO_0000218
9381,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL622939,16434,,,,,N,Intermediate,BAO_0000218
9382,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL622940,16434,,,,,N,Intermediate,BAO_0000218
9383,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL622941,16434,,,,,N,Intermediate,BAO_0000218
9384,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL622942,16434,,,,,N,Intermediate,BAO_0000218
9385,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL622943,16434,,,,,N,Intermediate,BAO_0000218
9386,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL622944,16434,,,,,N,Intermediate,BAO_0000218
9387,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL622945,16435,,,,,N,Intermediate,BAO_0000218
9388,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL622946,16435,,,,,N,Intermediate,BAO_0000218
9389,Rattus norvegicus,1,A,,1,Compound was evaluated for terminal half life in rat,50597,10116.0,,,CHEMBL622947,3341,,,,,N,Intermediate,BAO_0000218
9390,Rattus norvegicus,1,A,,1,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,50597,10116.0,,,CHEMBL622948,3634,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9391,Rattus norvegicus,1,A,,1,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,50597,10116.0,,,CHEMBL622949,3634,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9392,Rattus norvegicus,1,A,,1,Compound was tested for its half life in rat,50597,10116.0,,,CHEMBL622950,4839,,,,,N,Intermediate,BAO_0000218
9393,Macaca mulatta,0,A,,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,9544.0,,,CHEMBL622951,5005,1969.0,,,Plasma,U,Intermediate,BAO_0000218
9394,Rattus norvegicus,0,A,,1,Compound was tested for its plasma half life in Sprague Dawley rats,22224,10116.0,,,CHEMBL622952,5005,1969.0,,,Plasma,U,Intermediate,BAO_0000366
9395,Rattus norvegicus,0,A,,1,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,22224,10116.0,,,CHEMBL622953,5005,1969.0,,,Plasma,U,Intermediate,BAO_0000366
9396,Rattus norvegicus,1,A,,1,Compound was tested for plasma half-life period in rat,50597,10116.0,,,CHEMBL873818,1094,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9397,Rattus norvegicus,1,A,,1,Elimination half life after i.v. administration of compound in rats,50597,10116.0,,,CHEMBL622954,5031,,,,,N,Intermediate,BAO_0000218
9398,Rattus norvegicus,1,A,,1,Elimination half-life after IV dosing at 0.5 mg/kg in rat,50597,10116.0,,,CHEMBL622955,6518,,,,,N,Intermediate,BAO_0000218
9399,Rattus norvegicus,1,A,,1,Elimination half-life after IV dosing at 1 mg/kg in rat,50597,10116.0,,,CHEMBL875229,6518,,,,,N,Intermediate,BAO_0000218
9400,Rattus norvegicus,1,A,,1,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL622956,6518,,,,,N,Intermediate,BAO_0000218
9401,Rattus norvegicus,1,A,,1,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,50597,10116.0,,,CHEMBL622957,6518,,,,,N,Intermediate,BAO_0000218
9402,Rattus norvegicus,1,A,,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,10116.0,,,CHEMBL622958,5408,955.0,,,Brain,N,Intermediate,BAO_0000218
9403,Rattus norvegicus,1,A,,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,10116.0,,,CHEMBL622959,5408,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9404,Rattus norvegicus,1,A,,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,10116.0,,,CHEMBL622960,5408,955.0,,,Brain,N,Intermediate,BAO_0000218
9405,Rattus norvegicus,1,A,,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,10116.0,,,CHEMBL622961,5408,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9406,Rattus norvegicus,1,A,,1,Evaluated for the half life in rat (in vivo),50597,10116.0,,,CHEMBL622962,4687,,,,,N,Intermediate,BAO_0000218
9407,Rattus norvegicus,1,A,,1,Hafl life in rat,50597,10116.0,,,CHEMBL622963,6640,,,,,N,Intermediate,BAO_0000218
9408,Rattus norvegicus,1,A,,1,Hafl life rat,50597,10116.0,,,CHEMBL622964,6640,,,,,N,Intermediate,BAO_0000218
9409,Rattus norvegicus,1,A,,1,Hafl life rat,50597,10116.0,,,CHEMBL622965,6641,,,,,N,Intermediate,BAO_0000218
9410,Rattus norvegicus,1,A,,1,Hafl life rat; Not determined,50597,10116.0,,,CHEMBL622966,6640,,,,,N,Intermediate,BAO_0000218
9411,Rattus norvegicus,1,A,,1,Hafl life rat; Not determined,50597,10116.0,,,CHEMBL622967,6641,,,,,N,Intermediate,BAO_0000218
9412,Rattus norvegicus,1,A,,1,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL622968,17411,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9413,Rattus norvegicus,1,A,,1,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL622969,17411,2107.0,,,Liver,N,Intermediate,BAO_0000218
9414,Rattus norvegicus,1,A,,1,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL875327,17411,2048.0,,,Lung,N,Intermediate,BAO_0000218
9415,Rattus norvegicus,1,A,,1,Half life in rat after 1 mg/kg i.v. administration,50597,10116.0,,,CHEMBL628638,6570,,,,,N,Intermediate,BAO_0000218
9416,Rattus norvegicus,1,A,,1,Half life in rat after 2 mg/kg peroral administration,50597,10116.0,,,CHEMBL628639,6570,,,,,N,Intermediate,BAO_0000218
9417,Rattus norvegicus,1,A,,1,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL625840,17411,,,,,N,Intermediate,BAO_0000218
9418,Rattus norvegicus,1,A,,1,Half life of 10 mg/kg oral dose determined in rats,50597,10116.0,,,CHEMBL625841,4722,,,,,N,Intermediate,BAO_0000218
9419,Rattus norvegicus,1,A,,1,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL625842,5978,,,,,N,Intermediate,BAO_0000218
9420,Rattus norvegicus,1,A,,1,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL625843,5978,,,,,N,Intermediate,BAO_0000218
9421,Rattus norvegicus,1,A,,1,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL625844,5978,,,,,N,Intermediate,BAO_0000218
9422,Rattus norvegicus,1,A,,1,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL873822,5978,,,,,N,Intermediate,BAO_0000218
9423,Rattus norvegicus,1,A,,1,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL625845,5978,,,,,N,Intermediate,BAO_0000218
9424,Rattus norvegicus,1,A,,1,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL627059,5978,,,,,N,Intermediate,BAO_0000218
9425,Rattus norvegicus,1,A,,1,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL627060,5978,,,,,N,Intermediate,BAO_0000218
9426,Rattus norvegicus,1,A,,1,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL627061,5978,,,,,N,Intermediate,BAO_0000218
9427,Rattus norvegicus,1,A,,1,Half life of compound at 5 mg/kg after po administration was determined in rat,50597,10116.0,,,CHEMBL627709,4762,,,,,N,Intermediate,BAO_0000218
9428,Rattus norvegicus,1,A,,1,Half life of compound determined after intravenous administration to rat,50597,10116.0,,,CHEMBL627710,5327,,,,,N,Intermediate,BAO_0000218
9429,Rattus norvegicus,1,A,,1,Half life of compound was determined in rat,50597,10116.0,,,CHEMBL627711,4847,,,,,N,Intermediate,BAO_0000218
9430,Rattus norvegicus,1,A,,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL627712,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9431,Rattus norvegicus,1,A,,1,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL627713,4723,,,,,N,Intermediate,BAO_0000218
9432,Rattus norvegicus,1,A,,1,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL627714,4723,,,,,N,Intermediate,BAO_0000218
9433,Macaca fascicularis,0,A,,1,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,9541.0,,,CHEMBL627889,4256,,,,,U,Intermediate,BAO_0000218
9434,Rattus norvegicus,0,A,,1,Half life determined in rat by intravenous administration,22224,10116.0,,,CHEMBL627890,4256,,,,,U,Intermediate,BAO_0000218
9435,Rattus norvegicus,1,A,,1,Half life determined in rats after iv administration,50597,10116.0,,,CHEMBL627891,4722,,,,,N,Intermediate,BAO_0000218
9436,Rattus norvegicus,1,A,,1,Half life in rat plasma after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL627892,6535,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9437,Rattus norvegicus,1,A,,1,Half life in rat plasma after administration of 2 mg/kg iv,50597,10116.0,,,CHEMBL627893,6535,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9438,Rattus norvegicus,1,A,,1,Half life in rat plasma was determined,50597,10116.0,,,CHEMBL627894,1435,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9439,Rattus norvegicus,1,A,,1,Half life in rat plasma was determined; NA means not applicable,50597,10116.0,,,CHEMBL627895,1435,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9440,Rattus norvegicus,1,A,,1,Half life in rat was tested,50597,10116.0,,,CHEMBL627896,5206,,,,,N,Intermediate,BAO_0000218
9441,Rattus norvegicus,1,A,,1,Half life measured in rat plasma,50597,10116.0,,,CHEMBL627897,6080,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9442,Rattus norvegicus,1,A,,1,Half life recorded in rats,50597,10116.0,,,CHEMBL627898,4449,,,,,N,Intermediate,BAO_0000218
9443,Rattus norvegicus,1,A,,1,Half life was calculated,50597,10116.0,,,CHEMBL627899,6057,,,,,N,Intermediate,BAO_0000218
9444,Rattus norvegicus,1,A,,1,Half life was calculated in rat,50597,10116.0,,,CHEMBL873823,6057,,,,,N,Intermediate,BAO_0000218
9445,Rattus norvegicus,1,A,,1,Half life was determined,50597,10116.0,,,CHEMBL627900,3747,,,,,N,Intermediate,BAO_0000218
9446,Rattus norvegicus,1,A,,1,Half life after 10 mg/kg oral administration in rat,50597,10116.0,,,CHEMBL627901,17858,,,,,N,Intermediate,BAO_0000218
9447,Rattus norvegicus,1,A,,1,Half life after administering orally a dose of 10 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL627902,16365,,,,,N,Intermediate,BAO_0000218
9448,Rattus norvegicus,1,A,,1,Half life after administering orally a dose of 30 mg/kg,50597,10116.0,,,CHEMBL627903,16365,,,,,N,Intermediate,BAO_0000218
9449,Rattus norvegicus,1,A,,1,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,50597,10116.0,,,CHEMBL627904,5031,,,,,N,Intermediate,BAO_0000218
9450,Rattus norvegicus,1,A,,1,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,50597,10116.0,,,CHEMBL627905,4722,,,,,N,Intermediate,BAO_0000218
9451,Rattus norvegicus,1,A,,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,50597,10116.0,,,CHEMBL627906,6078,,,,,N,Intermediate,BAO_0000218
9452,Rattus norvegicus,1,A,,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,50597,10116.0,,,CHEMBL627907,6078,,,,,N,Intermediate,BAO_0000218
9453,Rattus norvegicus,1,A,,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL876783,6078,,,,,N,Intermediate,BAO_0000218
9454,Rattus norvegicus,1,A,,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,50597,10116.0,,,CHEMBL627908,6078,,,,,N,Intermediate,BAO_0000218
9455,Rattus norvegicus,1,A,,1,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,10116.0,,,CHEMBL627909,17065,,,,,N,Intermediate,BAO_0000218
9456,Rattus norvegicus,1,A,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,50597,10116.0,,,CHEMBL627910,1353,,,,,N,Intermediate,BAO_0000218
9457,Rattus norvegicus,1,A,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),50597,10116.0,,,CHEMBL627911,1353,,,,,N,Intermediate,BAO_0000218
9458,Rattus norvegicus,1,A,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),50597,10116.0,,,CHEMBL627912,1353,,,,,N,Intermediate,BAO_0000218
9459,Rattus norvegicus,1,A,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),50597,10116.0,,,CHEMBL627913,1353,,,,,N,Intermediate,BAO_0000218
9460,Rattus norvegicus,1,A,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),50597,10116.0,,,CHEMBL627914,1353,,,,,N,Intermediate,BAO_0000218
9461,Rattus norvegicus,1,A,,1,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,50597,10116.0,,,CHEMBL627915,16423,,,,,N,Intermediate,BAO_0000218
9462,Rattus norvegicus,1,A,,1,Area under the curve was evaluated after 20 uM/kg of peroral administration,50597,10116.0,,,CHEMBL627916,16423,,,,,N,Intermediate,BAO_0000218
9463,Rattus norvegicus,1,A,,1,Area under the curve was measured in rat after an iv dose of 1 mg/kg,50597,10116.0,,,CHEMBL627917,6062,,,,,N,Intermediate,BAO_0000218
9464,Rattus norvegicus,1,A,,1,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,50597,10116.0,,,CHEMBL627918,6056,,,,,N,Intermediate,BAO_0000218
9465,Rattus norvegicus,1,A,,1,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,50597,10116.0,,,CHEMBL627919,5182,,,,,N,Intermediate,BAO_0000218
9466,Rattus norvegicus,1,A,,1,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,50597,10116.0,,,CHEMBL627920,6410,,,,,N,Intermediate,BAO_0000218
9467,Rattus norvegicus,1,A,,1,Area under the curve was evaluated at an oral dose of 30 mg/kg,50597,10116.0,,,CHEMBL627921,6410,,,,,N,Intermediate,BAO_0000218
9468,Rattus norvegicus,1,A,,1,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL627922,4723,,,,,N,Intermediate,BAO_0000218
9469,Rattus norvegicus,1,A,,1,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL876784,4723,,,,,N,Intermediate,BAO_0000218
9470,Rattus norvegicus,1,A,,1,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL627923,4723,,,,,N,Intermediate,BAO_0000218
9471,Rattus norvegicus,1,A,,1,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL626208,4723,,,,,N,Intermediate,BAO_0000218
9472,Rattus norvegicus,1,A,,1,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL626209,4723,,,,,N,Intermediate,BAO_0000218
9473,Rattus norvegicus,1,A,,1,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL626210,4723,,,,,N,Intermediate,BAO_0000218
9474,Rattus norvegicus,1,A,,1,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,10116.0,,,CHEMBL627994,2463,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9475,Rattus norvegicus,1,A,,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,50597,10116.0,,,CHEMBL627995,4709,,,,,N,Intermediate,BAO_0000218
9476,Rattus norvegicus,1,A,,1,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,50597,10116.0,,,CHEMBL627996,4075,,,,,N,Intermediate,BAO_0000218
9477,Rattus norvegicus,1,A,,1,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,50597,10116.0,,,CHEMBL627997,5394,,,,,N,Intermediate,BAO_0000218
9478,Rattus norvegicus,1,A,,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,50597,10116.0,,,CHEMBL627998,2661,,,,,N,Intermediate,BAO_0000218
9479,Rattus norvegicus,1,A,,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,50597,10116.0,,,CHEMBL628640,2661,,,,,N,Intermediate,BAO_0000218
9480,Rattus norvegicus,1,A,,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,50597,10116.0,,,CHEMBL628641,2661,,,,,N,Intermediate,BAO_0000218
9481,Rattus norvegicus,1,A,,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,50597,10116.0,,,CHEMBL628642,2661,,,,,N,Intermediate,BAO_0000218
9482,Rattus norvegicus,1,A,,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),50597,10116.0,,,CHEMBL628643,17791,,,,,N,Intermediate,BAO_0000218
9483,Rattus norvegicus,1,A,,1,Compound was tested for area under curve in rat,50597,10116.0,,,CHEMBL628644,2591,,,,,N,Intermediate,BAO_0000218
9484,Rattus norvegicus,1,A,,1,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,50597,10116.0,,,CHEMBL628645,6567,,,,,N,Intermediate,BAO_0000218
9485,Rattus norvegicus,1,A,,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,10116.0,,,CHEMBL628646,6211,,,,,N,Intermediate,BAO_0000218
9486,Rattus norvegicus,1,A,,1,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),50597,10116.0,,,CHEMBL628647,5529,,,,,N,Intermediate,BAO_0000218
9487,Rattus norvegicus,1,A,,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,10116.0,,,CHEMBL628648,5408,,,,,N,Intermediate,BAO_0000218
9488,Rattus norvegicus,1,A,,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,10116.0,,,CHEMBL625358,5408,,,,,N,Intermediate,BAO_0000218
9489,Rattus norvegicus,1,A,,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,10116.0,,,CHEMBL625359,5408,,,,,N,Intermediate,BAO_0000218
9490,Rattus norvegicus,1,A,,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,10116.0,,,CHEMBL625360,5408,,,,,N,Intermediate,BAO_0000218
9491,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),50597,10116.0,,,CHEMBL625361,429,,,,,N,Intermediate,BAO_0000218
9492,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),50597,10116.0,,,CHEMBL625362,429,,,,,N,Intermediate,BAO_0000218
9493,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),50597,10116.0,,,CHEMBL625363,429,,,,,N,Intermediate,BAO_0000218
9494,Rattus norvegicus,1,A,,1,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,10116.0,,,CHEMBL625364,4796,,,,,N,Intermediate,BAO_0000218
9495,Rattus norvegicus,1,A,,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL625365,5974,,,,,N,Intermediate,BAO_0000218
9496,Rattus norvegicus,1,A,,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL625366,5974,,,,,N,Intermediate,BAO_0000218
9497,Rattus norvegicus,1,A,,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL625367,5974,,,,,N,Intermediate,BAO_0000218
9498,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",50597,10116.0,,,CHEMBL625368,11450,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9499,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",50597,10116.0,,,CHEMBL625369,11450,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9500,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",50597,10116.0,,,CHEMBL625370,11450,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9501,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",50597,10116.0,,,CHEMBL625371,11450,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9502,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",50597,10116.0,,,CHEMBL625372,11450,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9503,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",50597,10116.0,,,CHEMBL625373,11450,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9504,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",50597,10116.0,,,CHEMBL625374,11450,2107.0,,,Liver,N,Intermediate,BAO_0000218
9505,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",50597,10116.0,,,CHEMBL877593,11450,2107.0,,,Liver,N,Intermediate,BAO_0000218
9506,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",50597,10116.0,,,CHEMBL625375,11450,2107.0,,,Liver,N,Intermediate,BAO_0000218
9507,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",50597,10116.0,,,CHEMBL625376,11450,2107.0,,,Liver,N,Intermediate,BAO_0000218
9508,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",50597,10116.0,,,CHEMBL621973,11450,2107.0,,,Liver,N,Intermediate,BAO_0000218
9509,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",50597,10116.0,,,CHEMBL621974,11450,2107.0,,,Liver,N,Intermediate,BAO_0000218
9510,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",50597,10116.0,,,CHEMBL621975,11450,2048.0,,,Lung,N,Intermediate,BAO_0000218
9511,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",50597,10116.0,,,CHEMBL622166,11450,2048.0,,,Lung,N,Intermediate,BAO_0000218
9512,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",50597,10116.0,,,CHEMBL622167,11450,2048.0,,,Lung,N,Intermediate,BAO_0000218
9513,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",50597,10116.0,,,CHEMBL622168,11450,2048.0,,,Lung,N,Intermediate,BAO_0000218
9514,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",50597,10116.0,,,CHEMBL622169,11450,2048.0,,,Lung,N,Intermediate,BAO_0000218
9515,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",50597,10116.0,,,CHEMBL622170,11450,2048.0,,,Lung,N,Intermediate,BAO_0000218
9516,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",50597,10116.0,,,CHEMBL622171,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9517,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",50597,10116.0,,,CHEMBL622172,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9518,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",50597,10116.0,,,CHEMBL622173,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9519,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",50597,10116.0,,,CHEMBL622174,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9520,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",50597,10116.0,,,CHEMBL622175,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9521,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",50597,10116.0,,,CHEMBL622176,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9522,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",50597,10116.0,,,CHEMBL622177,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9523,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",50597,10116.0,,,CHEMBL622178,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9524,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",50597,10116.0,,,CHEMBL622179,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9525,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",50597,10116.0,,,CHEMBL622180,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9526,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL622181,16435,,,,,N,Intermediate,BAO_0000218
9527,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL622182,16435,,,,,N,Intermediate,BAO_0000218
9528,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL622183,16435,,,,,N,Intermediate,BAO_0000218
9529,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL622184,16435,,,,,N,Intermediate,BAO_0000218
9530,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL622185,16435,,,,,N,Intermediate,BAO_0000218
9531,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL622186,16435,,,,,N,Intermediate,BAO_0000218
9532,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL622187,16434,,,,,N,Intermediate,BAO_0000218
9533,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL625002,16434,,,,,N,Intermediate,BAO_0000218
9534,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL622090,16434,,,,,N,Intermediate,BAO_0000218
9535,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL622091,16435,,,,,N,Intermediate,BAO_0000218
9536,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL622092,16435,,,,,N,Intermediate,BAO_0000218
9537,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL622093,16435,,,,,N,Intermediate,BAO_0000218
9538,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL622094,16435,,,,,N,Intermediate,BAO_0000218
9539,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL622095,16435,,,,,N,Intermediate,BAO_0000218
9540,Rattus norvegicus,1,A,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL622264,16435,,,,,N,Intermediate,BAO_0000218
9541,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL622265,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9542,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL622266,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9543,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL622267,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9544,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL622268,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9545,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL622269,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9546,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL625071,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9547,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL621621,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9548,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL621622,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9549,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL621623,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9550,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL621624,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9551,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL621625,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9552,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL621626,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9553,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL621627,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9554,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL621628,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9555,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL875328,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9556,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL621629,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9557,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL621630,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9558,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL621631,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9559,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL621632,16434,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9560,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL621633,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9561,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL621634,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9562,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL621635,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9563,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL621636,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9564,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL621637,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9565,Rattus norvegicus,1,A,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL621638,16435,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9566,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL618883,16434,,,,,N,Intermediate,BAO_0000218
9567,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,10116.0,,,CHEMBL618884,16434,,,,,N,Intermediate,BAO_0000218
9568,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL628627,16434,,,,,N,Intermediate,BAO_0000218
9569,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL628628,16434,,,,,N,Intermediate,BAO_0000218
9570,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,10116.0,,,CHEMBL628629,16434,,,,,N,Intermediate,BAO_0000218
9571,Rattus norvegicus,1,A,,1,Half life after administering orally a dose of 3 mg/kg,50597,10116.0,,,CHEMBL628630,16365,,,,,N,Intermediate,BAO_0000218
9572,Rattus norvegicus,1,A,,1,Half life after administering orally a dose of 3 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL628631,16365,,,,,N,Intermediate,BAO_0000218
9573,Rattus norvegicus,1,A,,1,Half life after administering intravenously a dose of 1 mg/kg,50597,10116.0,,,CHEMBL628632,16365,,,,,N,Intermediate,BAO_0000218
9574,Rattus norvegicus,1,A,,1,Half life after oral dosing in rats,50597,10116.0,,,CHEMBL628633,526,,,,,N,Intermediate,BAO_0000218
9575,Rattus norvegicus,1,A,,1,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,50597,10116.0,,,CHEMBL628634,16365,,,,,N,Intermediate,BAO_0000218
9576,Rattus norvegicus,1,A,,1,Half life by intravenous administration of 3.4 mg/kg in rat,50597,10116.0,,,CHEMBL627789,4368,,,,,N,Intermediate,BAO_0000218
9577,Rattus norvegicus,1,A,,1,Half life in rat,50597,10116.0,,,CHEMBL627790,3371,,,,,N,Intermediate,BAO_0000218
9578,Rattus norvegicus,1,A,,1,Half life in rat,50597,10116.0,,,CHEMBL627791,6448,,,,,N,Intermediate,BAO_0000218
9579,Rattus norvegicus,1,A,,1,Half life in rat,50597,10116.0,,,CHEMBL627792,6453,,,,,N,Intermediate,BAO_0000218
9580,Rattus norvegicus,1,A,,1,Half life in rat after intravenous administration of the compound,50597,10116.0,,,CHEMBL627793,4353,,,,,N,Intermediate,BAO_0000218
9581,Rattus norvegicus,1,A,,1,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,50597,10116.0,,,CHEMBL627794,4353,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9582,Rattus norvegicus,1,A,,1,Half life in rat after po administration of the compound,50597,10116.0,,,CHEMBL627795,4353,,,,,N,Intermediate,BAO_0000218
9583,Rattus norvegicus,1,A,,1,Half life in rat after po administration of the compound; ND means Not determined,50597,10116.0,,,CHEMBL627796,4353,,,,,N,Intermediate,BAO_0000218
9584,Rattus norvegicus,1,A,,1,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,50597,10116.0,,,CHEMBL875335,4353,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9585,Rattus norvegicus,1,A,,1,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,50597,10116.0,,,CHEMBL627797,4353,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9586,Rattus norvegicus,1,A,,1,Half life in rat i.v.,50597,10116.0,,,CHEMBL627798,5789,,,,,N,Intermediate,BAO_0000218
9587,Rattus norvegicus,1,A,,1,Half life in rat i.v. at 2 mg/kg concentration,50597,10116.0,,,CHEMBL627799,17686,,,,,N,Intermediate,BAO_0000218
9588,Rattus norvegicus,1,A,,1,Half life in rats,50597,10116.0,,,CHEMBL627800,6495,,,,,N,Intermediate,BAO_0000218
9589,Rattus norvegicus,1,A,,1,Half life in rats after intravenous administration,50597,10116.0,,,CHEMBL627801,484,,,,,N,Intermediate,BAO_0000218
9590,Rattus norvegicus,1,A,,1,Half life in rats at the dose of 1.0 mpk by i.v. administration,50597,10116.0,,,CHEMBL627802,6467,,,,,N,Intermediate,BAO_0000218
9591,Rattus norvegicus,1,A,,1,Half life in rat,50597,10116.0,,,CHEMBL627803,6642,,,,,N,Expert,BAO_0000218
9592,Rattus norvegicus,1,A,,1,Half life was evaluated after intravenous administration to rats,50597,10116.0,,,CHEMBL873820,16367,,,,,N,Intermediate,BAO_0000218
9593,Rattus norvegicus,1,A,,1,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),50597,10116.0,,,CHEMBL627804,1369,,,,,N,Intermediate,BAO_0000218
9594,Rattus norvegicus,1,A,,1,Half life was evaluated in rat,50597,10116.0,,,CHEMBL627805,5472,,,,,N,Intermediate,BAO_0000218
9595,Rattus norvegicus,1,A,,1,Half life was evaluated in rat,50597,10116.0,,,CHEMBL627806,6049,,,,,N,Intermediate,BAO_0000218
9596,Rattus norvegicus,1,A,,1,Half life was evaluated in rat; Not tested,50597,10116.0,,,CHEMBL627107,5472,,,,,N,Intermediate,BAO_0000218
9597,Rattus norvegicus,1,A,,1,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,50597,10116.0,,,CHEMBL627108,16366,,,,,N,Intermediate,BAO_0000218
9598,Rattus norvegicus,1,A,,1,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,50597,10116.0,,,CHEMBL627109,11149,,,,,N,Intermediate,BAO_0000218
9599,Rattus norvegicus,1,A,,1,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,50597,10116.0,,,CHEMBL627110,11149,178.0,,,Blood,N,Intermediate,BAO_0000218
9600,Primates,0,A,,1,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,9443.0,,,CHEMBL627111,2891,,,,,U,Intermediate,BAO_0000218
9601,Primates,0,A,,1,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,9443.0,,,CHEMBL627112,2891,,,,,U,Intermediate,BAO_0000218
9602,Rattus norvegicus,0,A,,1,Half life was measured in rat at dose of 30 mg/kg by iv administration,22224,10116.0,,,CHEMBL627113,2891,,,,,U,Intermediate,BAO_0000218
9603,Rattus norvegicus,0,A,,1,Half life was measured in rat at dose of 30 mg/kg by po administration,22224,10116.0,,,CHEMBL627114,2891,,,,,U,Intermediate,BAO_0000218
9604,Rattus norvegicus,1,A,,1,Half life (t1/2) was determined,50597,10116.0,,,CHEMBL627115,4026,,,,,N,Intermediate,BAO_0000218
9605,Rattus norvegicus,1,A,,1,Half life period at a dose of 10 uM/kg in rat was determined,50597,10116.0,,,CHEMBL627116,4527,,,,,N,Intermediate,BAO_0000218
9606,Rattus norvegicus,1,A,,1,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,50597,10116.0,,,CHEMBL627117,4527,,,,,N,Intermediate,BAO_0000218
9607,Rattus norvegicus,1,A,,1,Half life period was determined,50597,10116.0,,,CHEMBL627118,5503,,,,,N,Intermediate,BAO_0000218
9608,Rattus norvegicus,1,A,,1,Half life period after intravenous administration at 20 mpk in rats,50597,10116.0,,,CHEMBL627119,4426,,,,,N,Intermediate,BAO_0000218
9609,Rattus norvegicus,1,A,,1,Half life period after intravenous administration at 20 mpk in rats; Not performed.,50597,10116.0,,,CHEMBL627120,4426,,,,,N,Intermediate,BAO_0000218
9610,Rattus norvegicus,1,A,,1,Half life period after intravenous administration in rat,50597,10116.0,,,CHEMBL626922,6109,,,,,N,Intermediate,BAO_0000218
9611,Rattus norvegicus,1,A,,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,10116.0,,,CHEMBL626923,5654,,,,,N,Intermediate,BAO_0000218
9612,Rattus norvegicus,1,A,,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,10116.0,,,CHEMBL626924,5654,,,,,N,Intermediate,BAO_0000218
9613,Rattus norvegicus,1,A,,1,Half life period in 80% rat plasma at 37 degree Centigrade,50597,10116.0,,,CHEMBL626925,4755,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9614,Rattus norvegicus,1,A,,1,Half life period in SD rats,50597,10116.0,,,CHEMBL626926,5862,,,,,N,Intermediate,BAO_0000218
9615,Rattus norvegicus,1,A,,1,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),50597,10116.0,,,CHEMBL626927,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9616,Rattus norvegicus,1,A,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),50597,10116.0,,,CHEMBL626928,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9617,Rattus norvegicus,1,A,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,10116.0,,,CHEMBL626929,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9618,Rattus norvegicus,1,A,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,10116.0,,,CHEMBL626930,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9619,Rattus norvegicus,1,A,,1,Half life period in rat,50597,10116.0,,,CHEMBL626931,5960,,,,,N,Intermediate,BAO_0000218
9620,Rattus norvegicus,1,A,,1,Half life period in rat,50597,10116.0,,,CHEMBL626932,6103,,,,,N,Intermediate,BAO_0000218
9621,Rattus norvegicus,1,A,,1,Half life period in rat,50597,10116.0,,,CHEMBL626933,6317,,,,,N,Intermediate,BAO_0000218
9622,Rattus norvegicus,1,A,,1,Half life period in rat after oral administration at 10.5 mg/kg dose,50597,10116.0,,,CHEMBL873826,6644,,,,,N,Intermediate,BAO_0000218
9623,Rattus norvegicus,1,A,,1,Half life period in rat after oral administration at 11.2 mg/kg dose,50597,10116.0,,,CHEMBL626934,6644,,,,,N,Intermediate,BAO_0000218
9624,Rattus norvegicus,1,A,,1,Half life period in rat after oral administration at 13 mg/kg dose,50597,10116.0,,,CHEMBL626935,6644,,,,,N,Intermediate,BAO_0000218
9625,Rattus norvegicus,1,A,,1,Half life period in rat after oral administration at 9.7 mg/kg dose,50597,10116.0,,,CHEMBL626936,6644,,,,,N,Intermediate,BAO_0000218
9626,Rattus norvegicus,1,A,,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL626937,5974,,,,,N,Intermediate,BAO_0000218
9627,Rattus norvegicus,1,A,,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL625906,6295,,,,,N,Intermediate,BAO_0000218
9628,Rattus norvegicus,1,A,,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,10116.0,,,CHEMBL625907,6296,,,,,N,Intermediate,BAO_0000218
9629,Rattus norvegicus,1,A,,1,PK study was carried to determine AUC (area under curve) value in rat,50597,10116.0,,,CHEMBL625908,16427,,,,,N,Intermediate,BAO_0000218
9630,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC after intravenous administration to rats,50597,10116.0,,,CHEMBL625909,16367,,,,,N,Intermediate,BAO_0000218
9631,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC after oral administration to rats,50597,10116.0,,,CHEMBL625910,16367,,,,,N,Intermediate,BAO_0000218
9632,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,50597,10116.0,,,CHEMBL625911,16365,,,,,N,Intermediate,BAO_0000218
9633,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,50597,10116.0,,,CHEMBL625912,16365,,,,,N,Intermediate,BAO_0000218
9634,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,50597,10116.0,,,CHEMBL626538,16365,,,,,N,Intermediate,BAO_0000218
9635,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,50597,10116.0,,,CHEMBL876794,16365,,,,,N,Intermediate,BAO_0000218
9636,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,50597,10116.0,,,CHEMBL626539,16365,,,,,N,Intermediate,BAO_0000218
9637,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,50597,10116.0,,,CHEMBL626540,16365,,,,,N,Intermediate,BAO_0000218
9638,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,50597,10116.0,,,CHEMBL626541,5394,,,,,N,Intermediate,BAO_0000218
9639,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,50597,10116.0,,,CHEMBL626542,5394,,,,,N,Intermediate,BAO_0000218
9640,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,50597,10116.0,,,CHEMBL626543,2792,,,,,N,Intermediate,BAO_0000218
9641,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL626544,2792,,,,,N,Intermediate,BAO_0000218
9642,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,50597,10116.0,,,CHEMBL626545,2792,,,,,N,Intermediate,BAO_0000218
9643,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL626546,2792,,,,,N,Intermediate,BAO_0000218
9644,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter area under curve was reported,50597,10116.0,,,CHEMBL626547,5334,,,,,N,Intermediate,BAO_0000218
9645,Rattus norvegicus,1,A,,1,Pharmacokinetic property (AUC) in rat,50597,10116.0,,,CHEMBL626548,4408,,,,,N,Intermediate,BAO_0000218
9646,Rattus norvegicus,1,A,,1,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,10116.0,,,CHEMBL626549,5983,,,,,N,Intermediate,BAO_0000218
9647,Rattus norvegicus,1,A,,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,50597,10116.0,,,CHEMBL626550,4397,,,,,N,Intermediate,BAO_0000218
9648,Rattus norvegicus,1,A,,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,50597,10116.0,,,CHEMBL626551,4397,,,,,N,Intermediate,BAO_0000218
9649,Rattus norvegicus,1,A,,1,Pharmacokinetic property was determined,50597,10116.0,,,CHEMBL623777,5491,,,,,N,Intermediate,BAO_0000218
9650,Rattus norvegicus,1,A,,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,50597,10116.0,,,CHEMBL623778,5491,,,,,N,Intermediate,BAO_0000218
9651,Rattus norvegicus,1,A,,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,50597,10116.0,,,CHEMBL623779,5491,,,,,N,Intermediate,BAO_0000218
9652,Rattus norvegicus,1,A,,1,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,10116.0,,,CHEMBL623780,4199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9653,Rattus norvegicus,1,A,,1,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,50597,10116.0,,,CHEMBL622015,4199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9654,Rattus norvegicus,1,A,,1,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,50597,10116.0,,,CHEMBL622016,4199,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9655,Rattus norvegicus,1,A,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",50597,10116.0,,,CHEMBL622017,5173,,,,,N,Intermediate,BAO_0000218
9656,Rattus norvegicus,1,A,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",50597,10116.0,,,CHEMBL622018,5173,,,,,N,Intermediate,BAO_0000218
9657,Rattus norvegicus,1,A,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",50597,10116.0,,,CHEMBL622019,5173,,,,,N,Intermediate,BAO_0000218
9658,Rattus norvegicus,1,A,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",50597,10116.0,,,CHEMBL622020,5173,,,,,N,Intermediate,BAO_0000218
9659,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,50597,10116.0,,,CHEMBL622021,16366,,,,,N,Intermediate,BAO_0000218
9660,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,50597,10116.0,,,CHEMBL622022,16366,,,,,N,Intermediate,BAO_0000218
9661,Rattus norvegicus,1,A,,1,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,50597,10116.0,,,CHEMBL622023,5327,,,,,N,Intermediate,BAO_0000218
9662,Rattus norvegicus,1,A,,1,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,50597,10116.0,,,CHEMBL622024,6681,,,,,N,Intermediate,BAO_0000218
9663,Rattus norvegicus,1,A,,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),50597,10116.0,,,CHEMBL622693,12873,,,,,N,Intermediate,BAO_0000218
9664,Rattus norvegicus,1,A,,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),50597,10116.0,,,CHEMBL622694,12873,,,,,N,Intermediate,BAO_0000218
9665,Rattus norvegicus,1,A,,1,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL622695,6685,,,,,N,Intermediate,BAO_0000218
9666,Rattus norvegicus,1,A,,1,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,10116.0,,,CHEMBL622696,6685,,,,,N,Intermediate,BAO_0000218
9667,Rattus norvegicus,1,A,,1,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",50597,10116.0,,,CHEMBL622697,6685,,,,,N,Intermediate,BAO_0000218
9668,Rattus norvegicus,1,A,,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",50597,10116.0,,,CHEMBL622874,6619,,,,,N,Intermediate,BAO_0000218
9669,Rattus norvegicus,1,A,,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",50597,10116.0,,,CHEMBL622875,6619,,,,,N,Intermediate,BAO_0000218
9670,Rattus norvegicus,1,A,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,10116.0,,,CHEMBL622876,10363,,,,,N,Intermediate,BAO_0000218
9671,Rattus norvegicus,1,A,,1,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,10116.0,,,CHEMBL622877,4796,,,,,N,Intermediate,BAO_0000218
9672,Rattus norvegicus,1,A,,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,10116.0,,,CHEMBL622878,4910,,,,,N,Intermediate,BAO_0000218
9673,Rattus norvegicus,1,A,,1,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,50597,10116.0,,,CHEMBL622879,4910,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9674,Rattus norvegicus,1,A,,1,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,50597,10116.0,,,CHEMBL877602,4839,,,,,N,Intermediate,BAO_0000218
9675,Rattus norvegicus,1,A,,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL622880,15078,,,,,N,Intermediate,BAO_0000218
9676,Rattus norvegicus,1,A,,1,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL622881,15078,,,,,N,Intermediate,BAO_0000218
9677,Rattus norvegicus,1,A,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL622882,15078,,,,,N,Intermediate,BAO_0000218
9678,Rattus norvegicus,1,A,,1,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL622883,15078,,,,,N,Intermediate,BAO_0000218
9679,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",50597,10116.0,,,CHEMBL622884,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9680,Rattus norvegicus,1,A,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",50597,10116.0,,,CHEMBL622885,11450,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9681,Rattus norvegicus,1,A,,1,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,10116.0,,,CHEMBL622886,8151,,,,,N,Intermediate,BAO_0000218
9682,Rattus norvegicus,1,A,,1,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,10116.0,,,CHEMBL622887,8151,,,,,N,Intermediate,BAO_0000218
9683,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,10116.0,,,CHEMBL622888,8151,1088.0,,,Urine,N,Intermediate,BAO_0000218
9684,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622889,8677,178.0,,,Blood,N,Intermediate,BAO_0000218
9685,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622890,8677,178.0,,,Blood,N,Intermediate,BAO_0000218
9686,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622891,8677,178.0,,,Blood,N,Intermediate,BAO_0000218
9687,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL877603,8677,178.0,,,Blood,N,Intermediate,BAO_0000218
9688,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622892,8677,955.0,,,Brain,N,Intermediate,BAO_0000218
9689,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622893,8677,955.0,,,Brain,N,Intermediate,BAO_0000218
9690,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622894,8677,955.0,,,Brain,N,Intermediate,BAO_0000218
9691,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622895,8677,955.0,,,Brain,N,Intermediate,BAO_0000218
9692,Rattus norvegicus,1,A,,1,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,50597,10116.0,,,CHEMBL622896,8677,955.0,,,Brain,N,Intermediate,BAO_0000218
9693,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622897,8677,948.0,,,Heart,N,Intermediate,BAO_0000218
9694,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622898,8677,948.0,,,Heart,N,Intermediate,BAO_0000218
9695,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622899,8677,948.0,,,Heart,N,Intermediate,BAO_0000218
9696,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622900,8677,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9697,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624114,8677,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9698,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624115,8677,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9699,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624116,8677,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9700,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624117,8677,2107.0,,,Liver,N,Intermediate,BAO_0000218
9701,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624118,8677,2107.0,,,Liver,N,Intermediate,BAO_0000218
9702,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624119,8677,2107.0,,,Liver,N,Intermediate,BAO_0000218
9703,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624120,8677,2107.0,,,Liver,N,Intermediate,BAO_0000218
9704,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624121,8677,2048.0,,,Lung,N,Intermediate,BAO_0000218
9705,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624122,8677,2048.0,,,Lung,N,Intermediate,BAO_0000218
9706,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624123,8677,2048.0,,,Lung,N,Intermediate,BAO_0000218
9707,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624124,8677,2048.0,,,Lung,N,Intermediate,BAO_0000218
9708,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624125,8677,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9709,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624126,8677,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9710,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624127,8677,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9711,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624128,8677,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9712,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL624129,8677,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9713,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL624130,8677,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9714,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622340,8677,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9715,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622341,8677,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
9716,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622342,8677,160.0,,,Intestine,N,Intermediate,BAO_0000218
9717,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622343,8677,160.0,,,Intestine,N,Intermediate,BAO_0000218
9718,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622344,8677,160.0,,,Intestine,N,Intermediate,BAO_0000218
9719,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622345,8677,160.0,,,Intestine,N,Intermediate,BAO_0000218
9720,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622346,8677,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9721,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622347,8677,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9722,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622348,8677,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9723,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622349,8677,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9724,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,10116.0,,,CHEMBL622350,16434,,,,,N,Intermediate,BAO_0000218
9725,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,10116.0,,,CHEMBL622351,16434,,,,,N,Intermediate,BAO_0000218
9726,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,10116.0,,,CHEMBL622352,16434,,,,,N,Intermediate,BAO_0000218
9727,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,10116.0,,,CHEMBL622353,16435,,,,,N,Intermediate,BAO_0000218
9728,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,10116.0,,,CHEMBL622354,16435,,,,,N,Intermediate,BAO_0000218
9729,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,10116.0,,,CHEMBL622355,16435,,,,,N,Intermediate,BAO_0000218
9730,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,10116.0,,,CHEMBL622356,16435,,,,,N,Intermediate,BAO_0000218
9731,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,10116.0,,,CHEMBL622357,16435,,,,,N,Intermediate,BAO_0000218
9732,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,10116.0,,,CHEMBL622358,16435,,,,,N,Intermediate,BAO_0000218
9733,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,10116.0,,,CHEMBL622359,16435,,,,,N,Intermediate,BAO_0000218
9734,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,10116.0,,,CHEMBL874393,16435,,,,,N,Intermediate,BAO_0000218
9735,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL622872,16434,,,,,N,Intermediate,BAO_0000218
9736,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL622873,16434,,,,,N,Intermediate,BAO_0000218
9737,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL623047,16434,,,,,N,Intermediate,BAO_0000218
9738,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL623048,16435,,,,,N,Intermediate,BAO_0000218
9739,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL623049,16435,,,,,N,Intermediate,BAO_0000218
9740,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL623050,16435,,,,,N,Intermediate,BAO_0000218
9741,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL623051,16435,,,,,N,Intermediate,BAO_0000218
9742,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL623052,16435,,,,,N,Intermediate,BAO_0000218
9743,Rattus norvegicus,1,A,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL626343,16435,,,,,N,Intermediate,BAO_0000218
9744,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,10116.0,,,CHEMBL626344,16434,,,,,N,Intermediate,BAO_0000218
9745,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,10116.0,,,CHEMBL626345,16434,,,,,N,Intermediate,BAO_0000218
9746,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,10116.0,,,CHEMBL626346,16434,,,,,N,Intermediate,BAO_0000218
9747,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,10116.0,,,CHEMBL626347,16434,,,,,N,Intermediate,BAO_0000218
9748,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,10116.0,,,CHEMBL626348,16434,,,,,N,Intermediate,BAO_0000218
9749,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,10116.0,,,CHEMBL626349,16434,,,,,N,Intermediate,BAO_0000218
9750,Rattus norvegicus,1,F,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,10116.0,,,CHEMBL626350,16435,,,,,N,Intermediate,BAO_0000218
9751,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,10116.0,,,CHEMBL626351,16435,,,,,N,Intermediate,BAO_0000218
9752,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,10116.0,,,CHEMBL627650,16435,,,,,N,Intermediate,BAO_0000218
9753,Rattus norvegicus,1,F,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,10116.0,,,CHEMBL627651,16435,,,,,N,Intermediate,BAO_0000218
9754,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,10116.0,,,CHEMBL627652,16435,,,,,N,Intermediate,BAO_0000218
9755,Rattus norvegicus,1,A,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,10116.0,,,CHEMBL627653,16435,,,,,N,Intermediate,BAO_0000218
9756,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,50597,10116.0,,,CHEMBL627654,13091,,,,,N,Intermediate,BAO_0000218
9757,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,50597,10116.0,,,CHEMBL627835,13091,,,,,N,Intermediate,BAO_0000218
9758,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,50597,10116.0,,,CHEMBL627836,13091,,,,,N,Intermediate,BAO_0000218
9759,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,50597,10116.0,,,CHEMBL627837,13091,,,,,N,Intermediate,BAO_0000218
9760,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,50597,10116.0,,,CHEMBL627838,13091,,,,,N,Intermediate,BAO_0000218
9761,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,50597,10116.0,,,CHEMBL875338,13091,,,,,N,Intermediate,BAO_0000218
9762,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,50597,10116.0,,,CHEMBL627839,13091,,,,,N,Intermediate,BAO_0000218
9763,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,50597,10116.0,,,CHEMBL627840,13091,,,,,N,Intermediate,BAO_0000218
9764,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,50597,10116.0,,,CHEMBL627841,13091,,,,,N,Intermediate,BAO_0000218
9765,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,50597,10116.0,,,CHEMBL627842,13091,,,,,N,Intermediate,BAO_0000218
9766,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,50597,10116.0,,,CHEMBL627843,13091,,,,,N,Intermediate,BAO_0000218
9767,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,50597,10116.0,,,CHEMBL627844,13091,,,,,N,Intermediate,BAO_0000218
9768,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,50597,10116.0,,,CHEMBL627845,13091,,,,,N,Intermediate,BAO_0000218
9769,Rattus norvegicus,1,A,,1,Half life period in rat by iv administration at a dose of 3 mg/kg,50597,10116.0,,,CHEMBL627846,5874,,,,,N,Intermediate,BAO_0000218
9770,Rattus norvegicus,1,A,,1,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),50597,10116.0,,,CHEMBL627847,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9771,Rattus norvegicus,1,A,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),50597,10116.0,,,CHEMBL873821,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9772,Rattus norvegicus,1,A,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,10116.0,,,CHEMBL626079,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9773,Rattus norvegicus,1,A,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,10116.0,,,CHEMBL626080,1515,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9774,Rattus norvegicus,1,A,,1,Half life period was evaluated in rat plasma,50597,10116.0,,,CHEMBL626081,5491,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9775,Rattus norvegicus,1,A,,1,Half life period was evaluated in rat plasma; Not tested,50597,10116.0,,,CHEMBL875344,5491,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9776,Rattus norvegicus,1,A,,1,Half life period was evaluated in rats,50597,10116.0,,,CHEMBL626082,1918,,,,,N,Intermediate,BAO_0000218
9777,Rattus norvegicus,1,A,,1,"Half life period was evaluated in rats, iv",50597,10116.0,,,CHEMBL626250,1918,,,,,N,Intermediate,BAO_0000218
9778,Rattus norvegicus,1,A,,1,Half life period after intravenous administration at 5 mg/kg in rat,50597,10116.0,,,CHEMBL626251,6113,,,,,N,Intermediate,BAO_0000218
9779,Rattus norvegicus,1,A,,1,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,10116.0,,,CHEMBL626252,5546,,,,,N,Intermediate,BAO_0000218
9780,Rattus norvegicus,1,A,,1,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,50597,10116.0,,,CHEMBL626253,5553,,,,,N,Intermediate,BAO_0000218
9781,Rattus norvegicus,1,A,,1,Half life stability of compound was evaluated in rat plasma,50597,10116.0,,,CHEMBL626254,4188,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9782,Rattus norvegicus,1,A,,1,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,50597,10116.0,,,CHEMBL626255,6215,,,,,N,Intermediate,BAO_0000218
9783,Rattus norvegicus,1,A,,1,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,10116.0,,,CHEMBL626256,6141,,,,,N,Intermediate,BAO_0000218
9784,Rattus norvegicus,1,A,,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,10116.0,,,CHEMBL626257,5182,,,,,N,Intermediate,BAO_0000218
9785,Rattus norvegicus,1,A,,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,50597,10116.0,,,CHEMBL626258,5182,,,,,N,Intermediate,BAO_0000218
9786,Rattus norvegicus,1,A,,1,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,50597,10116.0,,,CHEMBL626259,5710,,,,,N,Intermediate,BAO_0000218
9787,Rattus norvegicus,1,A,,1,Half in rat i.v.,50597,10116.0,,,CHEMBL626260,5789,,,,,N,Intermediate,BAO_0000218
9788,Rattus norvegicus,1,A,,1,Half period in rat after intravenous administration,50597,10116.0,,,CHEMBL875345,6011,,,,,N,Intermediate,BAO_0000218
9789,Rattus norvegicus,1,A,,1,Half-life after repeated oral dose of compound at 1 mg/kg in rats,50597,10116.0,,,CHEMBL626261,17594,,,,,N,Intermediate,BAO_0000218
9790,Rattus norvegicus,1,A,,1,Half-life measured in in vitro Cathepsin B assay in rat liver,50597,10116.0,,,CHEMBL626262,12357,2107.0,,,Liver,N,Intermediate,BAO_0000218
9791,Rattus norvegicus,1,A,,1,Half-life of compound was determined in rats,50597,10116.0,,,CHEMBL626263,5210,,,,,N,Intermediate,BAO_0000218
9792,Rattus norvegicus,1,A,,1,Half-life at 10 mg/kg in rat upon intravenous administration,50597,10116.0,,,CHEMBL625270,17596,,,,,N,Intermediate,BAO_0000218
9793,Rattus norvegicus,1,A,,1,Half-life determined in rat,50597,10116.0,,,CHEMBL625271,6672,,,,,N,Intermediate,BAO_0000218
9794,Rattus norvegicus,1,A,,1,Half-life determined in rat,50597,10116.0,,,CHEMBL625272,6673,,,,,N,Intermediate,BAO_0000218
9795,Rattus norvegicus,1,A,,1,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,50597,10116.0,,,CHEMBL625273,4910,955.0,,,Brain,N,Intermediate,BAO_0000218
9796,Rattus norvegicus,1,A,,1,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",50597,10116.0,,,CHEMBL625274,3741,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9797,Rattus norvegicus,1,A,,1,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,10116.0,,,CHEMBL625275,17671,,,,,N,Intermediate,BAO_0000218
9798,Rattus norvegicus,1,A,,1,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,50597,10116.0,,,CHEMBL625276,4910,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9799,Rattus norvegicus,1,A,,1,Half-life in rat plasma,50597,10116.0,,,CHEMBL625277,17537,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9800,Rattus norvegicus,1,A,,1,Half-life in rat plasma was determined,50597,10116.0,,,CHEMBL625278,4965,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9801,Rattus norvegicus,1,A,,1,Half-life in rat plasma; Not tested,50597,10116.0,,,CHEMBL625279,17537,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9802,Rattus norvegicus,1,A,,1,Half-life in rat serum,50597,10116.0,,,CHEMBL625280,6124,1977.0,,,Serum,N,Intermediate,BAO_0000218
9803,Rattus norvegicus,1,A,,1,Half-life in rat serum; na is not available,50597,10116.0,,,CHEMBL876797,6124,1977.0,,,Serum,N,Intermediate,BAO_0000218
9804,Rattus norvegicus,1,A,,1,Half-life was calculated in rat,50597,10116.0,,,CHEMBL625281,6078,,,,,N,Intermediate,BAO_0000218
9805,Rattus norvegicus,1,A,,1,Half-life was calculated in rat plasma,50597,10116.0,,,CHEMBL873827,17668,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9806,Rattus norvegicus,1,A,,1,Half-life was determined,50597,10116.0,,,CHEMBL625282,3185,,,,,N,Intermediate,BAO_0000218
9807,Rattus norvegicus,1,A,,1,Half-life was determined,50597,10116.0,,,CHEMBL625283,4883,,,,,N,Intermediate,BAO_0000218
9808,Rattus norvegicus,1,A,,1,Half-life after administration of 20 mg/Kg oral dose in rat,50597,10116.0,,,CHEMBL625284,2959,,,,,N,Intermediate,BAO_0000218
9809,Rattus norvegicus,1,A,,1,Half-life after administration of 3.2 mg/kg intravenously in male rat,50597,10116.0,,,CHEMBL625285,4029,,,,,N,Intermediate,BAO_0000218
9810,Rattus norvegicus,1,A,,1,Half-life after intravenous administration in female rat,50597,10116.0,,,CHEMBL625286,4029,,,,,N,Intermediate,BAO_0000218
9811,Rattus norvegicus,1,A,,1,Half-life after intravenous administration in male rat,50597,10116.0,,,CHEMBL625287,4029,,,,,N,Intermediate,BAO_0000218
9812,Rattus norvegicus,1,A,,1,Half-life after intravenous dose in rat,50597,10116.0,,,CHEMBL625288,6180,,,,,N,Intermediate,BAO_0000218
9813,Rattus norvegicus,1,A,,1,Half-life in a rat liver homogenate preparation,50597,10116.0,,,CHEMBL625289,1557,2107.0,,,Liver,N,Intermediate,BAO_0000218
9814,Rattus norvegicus,1,A,,1,Half-life in plasma of rat,50597,10116.0,,,CHEMBL625290,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9815,Rattus norvegicus,1,A,,1,Half-life in plasma of rat at dose of 3-10 mgkg,50597,10116.0,,,CHEMBL876798,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9816,Rattus norvegicus,1,A,,1,Half-life in rat,50597,10116.0,,,CHEMBL625291,5064,,,,,N,Intermediate,BAO_0000218
9817,Rattus norvegicus,1,A,,1,Half-life in rat,50597,10116.0,,,CHEMBL625292,5145,,,,,N,Intermediate,BAO_0000218
9818,Rattus norvegicus,1,A,,1,Half-life in rat,50597,10116.0,,,CHEMBL625293,5147,,,,,N,Intermediate,BAO_0000218
9819,Rattus norvegicus,1,A,,1,Half-life in rat,50597,10116.0,,,CHEMBL622832,5833,,,,,N,Intermediate,BAO_0000218
9820,Rattus norvegicus,1,A,,1,Half-life in rat,50597,10116.0,,,CHEMBL622833,6596,,,,,N,Intermediate,BAO_0000218
9821,Rattus norvegicus,1,A,,1,Half-life in rat,50597,10116.0,,,CHEMBL622834,17655,,,,,N,Intermediate,BAO_0000218
9822,Rattus norvegicus,1,A,,1,Half-life in rat after oral administration at 10 mg/kg,50597,10116.0,,,CHEMBL622835,6495,,,,,N,Intermediate,BAO_0000218
9823,Rattus norvegicus,1,A,,1,Half-life in rat after po administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL622836,17538,,,,,N,Intermediate,BAO_0000218
9824,Rattus norvegicus,1,A,,1,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,10116.0,,,CHEMBL622837,17538,,,,,N,Intermediate,BAO_0000218
9825,Rattus norvegicus,1,A,,1,Half-life in rat at 3 mg/kg dose administered intravenously,50597,10116.0,,,CHEMBL622838,10,,,,,N,Intermediate,BAO_0000218
9826,Rattus norvegicus,1,A,,1,Half-life in rat brain homogenate,50597,10116.0,,,CHEMBL622839,17669,955.0,,,Brain,N,Intermediate,BAO_0000218
9827,Rattus norvegicus,1,A,,1,Half-life in rat plasma,50597,10116.0,,,CHEMBL622840,17065,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9828,Rattus norvegicus,1,A,,1,Half-life in rats,50597,10116.0,,,CHEMBL622841,4333,,,,,N,Intermediate,BAO_0000218
9829,Rattus norvegicus,1,A,,1,Half-life in Dawley rats,50597,10116.0,,,CHEMBL622842,6827,,,,,N,Intermediate,BAO_0000218
9830,Rattus norvegicus,1,A,,1,Half-life in vitro in rat plasma,50597,10116.0,,,CHEMBL622843,889,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9831,Rattus norvegicus,1,A,,1,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,50597,10116.0,,,CHEMBL622844,889,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9832,Rattus norvegicus,1,A,,1,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",50597,10116.0,,,CHEMBL622845,3747,,,,,N,Intermediate,BAO_0000218
9833,Rattus norvegicus,1,A,,1,The area under the curve of compound was measured at the dose of 100 umol/kg,50597,10116.0,,,CHEMBL622846,15022,,,,,N,Intermediate,BAO_0000218
9834,Rattus norvegicus,1,A,,1,The area under the curve of compound was measured at the dose of 300 umol/kg,50597,10116.0,,,CHEMBL622847,15022,,,,,N,Intermediate,BAO_0000218
9835,Rattus norvegicus,1,A,,1,The area under the curve of compound was measured at the dose of 30 umol/kg,50597,10116.0,,,CHEMBL622848,15022,,,,,N,Intermediate,BAO_0000218
9836,Rattus norvegicus,1,A,,1,Bioavailability as oral AUC in rats,50597,10116.0,,,CHEMBL622849,3360,,,,,N,Intermediate,BAO_0000218
9837,Rattus norvegicus,1,A,,1,The plasma concentration versus time curve (AUC) was determined,50597,10116.0,,,CHEMBL622850,5334,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9838,Rattus norvegicus,1,A,,1,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL876807,17411,,,,,N,Intermediate,BAO_0000218
9839,Rattus norvegicus,1,A,,1,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL622851,17411,,,,,N,Intermediate,BAO_0000218
9840,Rattus norvegicus,1,A,,1,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL622852,17411,,,,,N,Intermediate,BAO_0000218
9841,Rattus norvegicus,1,A,,1,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,50597,10116.0,,,CHEMBL622853,6570,,,,,N,Intermediate,BAO_0000218
9842,Rattus norvegicus,1,A,,1,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,50597,10116.0,,,CHEMBL622854,6570,,,,,N,Intermediate,BAO_0000218
9843,Rattus norvegicus,1,A,,1,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,10116.0,,,CHEMBL622855,17411,,,,,N,Intermediate,BAO_0000218
9844,Rattus norvegicus,1,A,,1,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",50597,10116.0,,,CHEMBL622856,14941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9845,Rattus norvegicus,1,A,,1,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",50597,10116.0,,,CHEMBL622857,14941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9846,Rattus norvegicus,1,A,,1,AUC in rat after po administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL622858,17538,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9847,Rattus norvegicus,1,A,,1,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,50597,10116.0,,,CHEMBL622859,17752,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9848,Rattus norvegicus,1,A,,1,Area under curve value 24 hr after 10 mg/kg iv administration in rats,50597,10116.0,,,CHEMBL622860,17509,,,,,N,Intermediate,BAO_0000218
9849,Rattus norvegicus,1,A,,1,Area under curve value 24 hr after 10 mg/kg oral administration in rats,50597,10116.0,,,CHEMBL622861,17509,,,,,N,Intermediate,BAO_0000218
9850,Rattus norvegicus,1,A,,1,Area under curve value 24 hr after 2 mg/kg iv administration in rats,50597,10116.0,,,CHEMBL622862,17509,,,,,N,Intermediate,BAO_0000218
9851,Rattus norvegicus,1,A,,1,Area under curve value 24 hr after 2 mg/kg oral administration in rats,50597,10116.0,,,CHEMBL622863,17509,,,,,N,Intermediate,BAO_0000218
9852,Rattus norvegicus,1,A,,1,Area under curve value 6 hr after po administration in rat,50597,10116.0,,,CHEMBL623817,17509,,,,,N,Intermediate,BAO_0000218
9853,Rattus norvegicus,1,A,,1,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,10116.0,,,CHEMBL623818,17717,,,,,N,Intermediate,BAO_0000218
9854,Rattus norvegicus,1,A,,1,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",50597,10116.0,,,CHEMBL623819,17717,,,,,N,Intermediate,BAO_0000218
9855,Rattus norvegicus,1,A,,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,10116.0,,,CHEMBL623820,17717,,,,,N,Intermediate,BAO_0000218
9856,Rattus norvegicus,1,A,,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,50597,10116.0,,,CHEMBL623821,17717,,,,,N,Intermediate,BAO_0000218
9857,Rattus norvegicus,1,A,,1,AUC normalized for dose (AUCN) in rat,50597,10116.0,,,CHEMBL623822,6642,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9858,Rattus norvegicus,1,A,,1,Area under curve in rat after p.o. administration,50597,10116.0,,,CHEMBL623823,6640,,,,,N,Intermediate,BAO_0000218
9859,Rattus norvegicus,1,A,,1,Area under curve in rat after p.o. administration,50597,10116.0,,,CHEMBL623824,6641,,,,,N,Intermediate,BAO_0000218
9860,Rattus norvegicus,1,A,,1,Area under curve in rat after p.o. administration; Not determined,50597,10116.0,,,CHEMBL623825,6641,,,,,N,Intermediate,BAO_0000218
9861,Rattus norvegicus,1,A,,1,Area under curve in rat after peroral administration,50597,10116.0,,,CHEMBL622070,6641,,,,,N,Intermediate,BAO_0000218
9862,Rattus norvegicus,1,A,,1,Area under curve (carotid artery) value of the compound,50597,10116.0,,,CHEMBL622071,3603,,,,,N,Intermediate,BAO_0000218
9863,Rattus norvegicus,1,A,,1,Bioavailability expressed as the area under curve of rat carotid artery,50597,10116.0,,,CHEMBL622072,3550,,,,,N,Intermediate,BAO_0000218
9864,Rattus norvegicus,1,A,,1,Area under curve in male SD rats was observed after intravenous administration in rat,50597,10116.0,,,CHEMBL622073,15662,,,,,N,Intermediate,BAO_0000218
9865,Rattus norvegicus,1,A,,1,Area under curve of the compound was determined,50597,10116.0,,,CHEMBL622074,17720,,,,,N,Intermediate,BAO_0000218
9866,Rattus norvegicus,1,A,,1,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,50597,10116.0,,,CHEMBL622075,5407,,,,,N,Intermediate,BAO_0000218
9867,Rattus norvegicus,1,A,,1,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,50597,10116.0,,,CHEMBL622076,17752,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9868,Rattus norvegicus,1,A,,1,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,50597,10116.0,,,CHEMBL622077,17752,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9869,Rattus norvegicus,1,A,,1,Area under curve (portal vein) value of the compound,50597,10116.0,,,CHEMBL622078,3603,,,,,N,Intermediate,BAO_0000218
9870,Rattus norvegicus,1,A,,1,Bioavailability expressed as the area under curve of rat portal vein,50597,10116.0,,,CHEMBL622079,3550,,,,,N,Intermediate,BAO_0000218
9871,Rattus norvegicus,1,A,,1,Area Under plasma concentration time curve in rat upon peroral administration,50597,10116.0,,,CHEMBL622080,17655,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9872,Rattus norvegicus,1,A,,1,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,50597,10116.0,,,CHEMBL877612,17582,,,,,N,Intermediate,BAO_0000218
9873,Rattus norvegicus,1,A,,1,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,50597,10116.0,,,CHEMBL622081,17582,,,,,N,Intermediate,BAO_0000218
9874,Rattus norvegicus,1,A,,1,Compound was evaluated for oral bioavailability in rats,50597,10116.0,,,CHEMBL622082,17791,,,,,N,Intermediate,BAO_0000218
9875,Rattus norvegicus,1,A,,1,Compound was evaluated for oral bioavailability in rats after iv administration,50597,10116.0,,,CHEMBL622083,17791,,,,,N,Intermediate,BAO_0000218
9876,Rattus norvegicus,1,A,,1,Compound was evaluated for oral bioavailability in rats; 30-80,50597,10116.0,,,CHEMBL622084,17791,,,,,N,Intermediate,BAO_0000218
9877,Rattus norvegicus,1,A,,1,Compound was evaluated for oral bioavailability in rats; 50-60,50597,10116.0,,,CHEMBL622085,17791,,,,,N,Intermediate,BAO_0000218
9878,Rattus norvegicus,1,A,,1,Compound was evaluated for oral bioavailability in rats; no data,50597,10116.0,,,CHEMBL622086,17791,,,,,N,Intermediate,BAO_0000218
9879,Rattus norvegicus,1,A,,1,Compound was evaluated for oral bioavailability in rats; peptide,50597,10116.0,,,CHEMBL622087,17791,,,,,N,Intermediate,BAO_0000218
9880,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",50597,10116.0,,,CHEMBL622088,7768,178.0,,,Blood,N,Intermediate,BAO_0000218
9881,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",50597,10116.0,,,CHEMBL622089,7768,178.0,,,Blood,N,Intermediate,BAO_0000218
9882,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",50597,10116.0,,,CHEMBL623685,7768,178.0,,,Blood,N,Intermediate,BAO_0000218
9883,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",50597,10116.0,,,CHEMBL623686,7768,178.0,,,Blood,N,Intermediate,BAO_0000218
9884,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL623687,8677,945.0,,,Stomach,N,Intermediate,BAO_0000218
9885,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL623688,8677,945.0,,,Stomach,N,Intermediate,BAO_0000218
9886,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL623689,8677,945.0,,,Stomach,N,Intermediate,BAO_0000218
9887,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622485,8677,945.0,,,Stomach,N,Intermediate,BAO_0000218
9888,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622486,8677,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9889,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL877613,8677,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9890,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622487,8677,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9891,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622488,8677,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
9892,Rattus norvegicus,1,A,,1,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,10116.0,,,CHEMBL622489,8677,948.0,,,Heart,N,Intermediate,BAO_0000218
9893,Rattus norvegicus,1,A,,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,10116.0,,,CHEMBL622490,6899,1088.0,,,Urine,N,Intermediate,BAO_0000218
9894,Rattus norvegicus,1,A,,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,10116.0,,,CHEMBL622491,6899,1088.0,,,Urine,N,Intermediate,BAO_0000218
9895,Rattus norvegicus,1,A,,1,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,50597,10116.0,,,CHEMBL622492,6899,2107.0,,,Liver,N,Intermediate,BAO_0000218
9896,Rattus norvegicus,1,A,,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,10116.0,,,CHEMBL622493,6899,1088.0,,,Urine,N,Intermediate,BAO_0000218
9897,Rattus norvegicus,1,A,,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,10116.0,,,CHEMBL622494,6899,1088.0,,,Urine,N,Intermediate,BAO_0000218
9898,Rattus norvegicus,1,A,,1,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,10116.0,,,CHEMBL622495,8677,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9899,Rattus norvegicus,1,A,,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,50597,10116.0,,,CHEMBL622496,6899,,,,,N,Intermediate,BAO_0000218
9900,Rattus norvegicus,1,A,,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,10116.0,,,CHEMBL622497,6899,1088.0,,,Urine,N,Intermediate,BAO_0000218
9901,Rattus norvegicus,1,A,,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,50597,10116.0,,,CHEMBL622498,2189,,,,,N,Intermediate,BAO_0000218
9902,Rattus norvegicus,1,A,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,50597,10116.0,,,CHEMBL624918,2189,1088.0,,,Urine,N,Intermediate,BAO_0000218
9903,Rattus norvegicus,1,A,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,50597,10116.0,,,CHEMBL624919,2189,1088.0,,,Urine,N,Intermediate,BAO_0000218
9904,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat blood after 5 min of administration,50597,10116.0,,,CHEMBL624920,10839,178.0,,,Blood,N,Intermediate,BAO_0000218
9905,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat blood after 5 min of administration.,50597,10116.0,,,CHEMBL624921,10839,178.0,,,Blood,N,Intermediate,BAO_0000218
9906,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat brain after 5 min of administration,50597,10116.0,,,CHEMBL624922,10839,955.0,,,Brain,N,Intermediate,BAO_0000218
9907,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat heart after 5 min of administration,50597,10116.0,,,CHEMBL624923,10839,948.0,,,Heart,N,Intermediate,BAO_0000218
9908,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat heart after 5 min of administration.,50597,10116.0,,,CHEMBL624924,10839,948.0,,,Heart,N,Intermediate,BAO_0000218
9909,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat kidney after 5 min of administration,50597,10116.0,,,CHEMBL624925,10839,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9910,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat kidney after 5 min of administration.,50597,10116.0,,,CHEMBL624926,10839,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9911,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat liver after 5 min of administration,50597,10116.0,,,CHEMBL624927,10839,2107.0,,,Liver,N,Intermediate,BAO_0000218
9912,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat liver after 5 min of administration.,50597,10116.0,,,CHEMBL874402,10839,2107.0,,,Liver,N,Intermediate,BAO_0000218
9913,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat lung after 5 min of administration,50597,10116.0,,,CHEMBL624928,10839,2048.0,,,Lung,N,Intermediate,BAO_0000218
9914,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat lung after 5 min of administration.,50597,10116.0,,,CHEMBL624929,10839,2048.0,,,Lung,N,Intermediate,BAO_0000218
9915,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat muscle after 5 min of administration,50597,10116.0,,,CHEMBL624930,10839,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9916,Rattus norvegicus,1,A,,1,Biodistribution of compound in rat muscle after 5 min of administration.,50597,10116.0,,,CHEMBL624931,10839,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9917,Rattus norvegicus,1,A,,1,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624932,4043,948.0,,,Heart,N,Intermediate,BAO_0000218
9918,Rattus norvegicus,1,A,,1,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624933,4043,948.0,,,Heart,N,Intermediate,BAO_0000218
9919,Rattus norvegicus,1,A,,1,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624934,4043,2107.0,,,Liver,N,Intermediate,BAO_0000218
9920,Rattus norvegicus,1,A,,1,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624935,4043,2107.0,,,Liver,N,Intermediate,BAO_0000218
9921,Rattus norvegicus,1,A,,1,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624936,4043,,,,,N,Intermediate,BAO_0000218
9922,Rattus norvegicus,1,A,,1,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624937,4043,,,,,N,Intermediate,BAO_0000218
9923,Rattus norvegicus,1,A,,1,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624938,4043,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9924,Rattus norvegicus,1,A,,1,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624939,4043,2106.0,,,Spleen,N,Intermediate,BAO_0000218
9925,Rattus norvegicus,1,A,,1,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL624940,4043,,,,,N,Intermediate,BAO_0000218
9926,Rattus norvegicus,1,A,,1,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,10116.0,,,CHEMBL874403,4043,,,,,N,Intermediate,BAO_0000218
9927,Rattus norvegicus,1,A,,1,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,50597,10116.0,,,CHEMBL624941,1446,,,,,N,Intermediate,BAO_0000218
9928,Rattus norvegicus,1,A,,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat,50597,10116.0,,,CHEMBL624942,9971,1088.0,,,Urine,N,Intermediate,BAO_0000218
9929,Rattus norvegicus,1,A,,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,50597,10116.0,,,CHEMBL624943,9971,1088.0,,,Urine,N,Intermediate,BAO_0000218
9930,Rattus norvegicus,1,A,,1,% Bioavailability after 1 day of the drug administration in rats,50597,10116.0,,,CHEMBL624944,5765,,,,,N,Intermediate,BAO_0000218
9931,Rattus norvegicus,1,A,,1,% Bioavailability after 4 day of the drug administration in rats,50597,10116.0,,,CHEMBL624945,5765,,,,,N,Intermediate,BAO_0000218
9932,Rattus norvegicus,1,A,,1,Absolute bioavailability was evaluated in rat,50597,10116.0,,,CHEMBL624946,4257,,,,,N,Intermediate,BAO_0000218
9933,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,50597,10116.0,,,CHEMBL624947,13091,,,,,N,Intermediate,BAO_0000218
9934,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,50597,10116.0,,,CHEMBL624948,13091,,,,,N,Intermediate,BAO_0000218
9935,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,50597,10116.0,,,CHEMBL624949,13091,,,,,N,Intermediate,BAO_0000218
9936,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,50597,10116.0,,,CHEMBL622025,13091,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9937,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,50597,10116.0,,,CHEMBL622026,13091,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9938,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,50597,10116.0,,,CHEMBL622027,13091,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9939,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,50597,10116.0,,,CHEMBL622028,13091,2113.0,,,Kidney,N,Intermediate,BAO_0000218
9940,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,50597,10116.0,,,CHEMBL622029,13091,2107.0,,,Liver,N,Intermediate,BAO_0000218
9941,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,50597,10116.0,,,CHEMBL622208,13091,2107.0,,,Liver,N,Intermediate,BAO_0000218
9942,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,50597,10116.0,,,CHEMBL622209,13091,2107.0,,,Liver,N,Intermediate,BAO_0000218
9943,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,50597,10116.0,,,CHEMBL622210,13091,2107.0,,,Liver,N,Intermediate,BAO_0000218
9944,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,50597,10116.0,,,CHEMBL622211,13091,,,,,N,Intermediate,BAO_0000218
9945,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,50597,10116.0,,,CHEMBL622212,13091,,,,,N,Intermediate,BAO_0000218
9946,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,50597,10116.0,,,CHEMBL622213,13091,,,,,N,Intermediate,BAO_0000218
9947,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,50597,10116.0,,,CHEMBL874404,13091,,,,,N,Intermediate,BAO_0000218
9948,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,50597,10116.0,,,CHEMBL620452,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9949,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,50597,10116.0,,,CHEMBL620453,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9950,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,50597,10116.0,,,CHEMBL620454,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9951,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,50597,10116.0,,,CHEMBL624067,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9952,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,50597,10116.0,,,CHEMBL624068,13091,,,,,N,Intermediate,BAO_0000218
9953,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,50597,10116.0,,,CHEMBL624069,13091,992.0,,,Female gonad,N,Intermediate,BAO_0000218
9954,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,50597,10116.0,,,CHEMBL624070,13091,992.0,,,Female gonad,N,Intermediate,BAO_0000218
9955,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,50597,10116.0,,,CHEMBL624071,13091,992.0,,,Female gonad,N,Intermediate,BAO_0000218
9956,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,50597,10116.0,,,CHEMBL624072,13091,995.0,,,Uterus,N,Intermediate,BAO_0000218
9957,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,50597,10116.0,,,CHEMBL624073,13091,995.0,,,Uterus,N,Intermediate,BAO_0000218
9958,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,50597,10116.0,,,CHEMBL624788,13091,995.0,,,Uterus,N,Intermediate,BAO_0000218
9959,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,50597,10116.0,,,CHEMBL624789,13091,995.0,,,Uterus,N,Intermediate,BAO_0000218
9960,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,50597,10116.0,,,CHEMBL624790,13091,,,,,N,Intermediate,BAO_0000218
9961,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,50597,10116.0,,,CHEMBL624791,13091,,,,,N,Intermediate,BAO_0000218
9962,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,50597,10116.0,,,CHEMBL624792,13091,,,,,N,Intermediate,BAO_0000218
9963,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,50597,10116.0,,,CHEMBL624793,13091,,,,,N,Intermediate,BAO_0000218
9964,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,50597,10116.0,,,CHEMBL877491,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9965,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,50597,10116.0,,,CHEMBL624957,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9966,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,50597,10116.0,,,CHEMBL624958,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9967,Rattus norvegicus,1,A,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,50597,10116.0,,,CHEMBL624959,13091,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
9968,Rattus norvegicus,1,A,,1,Dissociation constant was determined,50597,10116.0,,,CHEMBL624960,11977,,,,,N,Intermediate,BAO_0000218
9969,Rattus norvegicus,1,A,,1,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",50597,10116.0,,,CHEMBL624961,14941,,,,,N,Intermediate,BAO_0000218
9970,Rattus norvegicus,1,A,,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL624962,15078,,,,,N,Intermediate,BAO_0000218
9971,Rattus norvegicus,1,A,,1,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL624963,15078,,,,,N,Intermediate,BAO_0000218
9972,Rattus norvegicus,1,A,,1,Observed rate constant in 80% rat plasma at 37 degree Centigrade,50597,10116.0,,,CHEMBL624964,4755,,,,,N,Intermediate,BAO_0000218
9973,Rattus norvegicus,1,A,,1,LogP value was evaluated in the in situ rat gut perfusion assay,50597,10116.0,,,CHEMBL624965,589,,,,,N,Intermediate,BAO_0000218
9974,Rattus norvegicus,1,A,,1,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,10116.0,,,CHEMBL624966,17582,,,,,N,Intermediate,BAO_0000218
9975,Rattus norvegicus,1,A,,1,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,50597,10116.0,,,CHEMBL624967,5031,,,,,N,Intermediate,BAO_0000218
9976,Rattus norvegicus,1,A,,1,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,50597,10116.0,,,CHEMBL624968,17764,,,,,N,Intermediate,BAO_0000218
9977,Rattus norvegicus,1,A,,1,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL624969,17720,,,,,N,Intermediate,BAO_0000218
9978,Rattus norvegicus,1,F,,1,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,50597,10116.0,,,CHEMBL624970,2862,,,,,N,Expert,BAO_0000218
9979,Rattus norvegicus,1,A,,1,Half-life was evaluated after 10 uM/kg of intra arterial administration,50597,10116.0,,,CHEMBL624971,16423,,,,,N,Intermediate,BAO_0000218
9980,Rattus norvegicus,1,A,,1,Half-life was evaluated after 20 uM/kg of peroral administration,50597,10116.0,,,CHEMBL624972,16423,,,,,N,Intermediate,BAO_0000218
9981,Rattus norvegicus,1,A,,1,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,10116.0,,,CHEMBL624973,6005,,,,,N,Intermediate,BAO_0000218
9982,Rattus norvegicus,1,A,,1,Half-life was evaluated in plasma of rat,50597,10116.0,,,CHEMBL624974,2938,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9983,Rattus norvegicus,1,A,,1,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,50597,10116.0,,,CHEMBL624975,6410,,,,,N,Intermediate,BAO_0000218
9984,Rattus norvegicus,1,A,,1,Half-life was evaluated in rats at an oral dose of 30 mg/kg,50597,10116.0,,,CHEMBL877492,6410,,,,,N,Intermediate,BAO_0000218
9985,Rattus norvegicus,1,A,,1,Half-life was measured in rat after an iv dose of 1 mg/kg,50597,10116.0,,,CHEMBL624976,6062,,,,,N,Intermediate,BAO_0000218
9986,Rattus norvegicus,1,A,,1,Half-life period of compound in rats after peroral administration,50597,10116.0,,,CHEMBL624977,6571,,,,,N,Intermediate,BAO_0000218
9987,Rattus norvegicus,1,A,,1,Half-life period of compound was measured in rat plasma.,50597,10116.0,,,CHEMBL626848,3136,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9988,Rattus norvegicus,1,A,,1,Half-life period of compound was measured in rat plasma; ND is not determined,50597,10116.0,,,CHEMBL626849,3136,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9989,Rattus norvegicus,1,A,,1,Half-life period of compound was measured in rat plasma; not determined,50597,10116.0,,,CHEMBL626850,3136,1969.0,,,Plasma,N,Intermediate,BAO_0000218
9990,Rattus norvegicus,1,A,,1,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,10116.0,,,CHEMBL626851,4521,,,,,N,Intermediate,BAO_0000218
9991,Rattus norvegicus,1,A,,1,Half-life period in rat by iv administration,50597,10116.0,,,CHEMBL626852,5871,,,,,N,Intermediate,BAO_0000218
9992,Rattus norvegicus,1,A,,1,Half-life period in rats following intravenous administration at 2 mg/kg,50597,10116.0,,,CHEMBL626853,6077,,,,,N,Intermediate,BAO_0000218
9993,Rattus norvegicus,1,A,,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,10116.0,,,CHEMBL626854,6679,,,,,N,Intermediate,BAO_0000218
9994,Rattus norvegicus,1,A,,1,Half-life period was determined for the compound in rat,50597,10116.0,,,CHEMBL627486,5144,,,,,N,Intermediate,BAO_0000218
9995,Rattus norvegicus,1,A,,1,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",50597,10116.0,,,CHEMBL627487,4498,,,,,N,Intermediate,BAO_0000218
9996,Rattus norvegicus,1,A,,1,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",50597,10116.0,,,CHEMBL627488,4498,,,,,N,Intermediate,BAO_0000218
9997,Rattus norvegicus,1,A,,1,Half-life value after IV dose at a dose of 5 mg/kg in rats.,50597,10116.0,,,CHEMBL627489,1908,,,,,N,Intermediate,BAO_0000218
9998,Rattus norvegicus,1,A,,1,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,10116.0,,,CHEMBL627490,6211,,,,,N,Intermediate,BAO_0000218
9999,Rattus norvegicus,1,A,,1,Half-life was determined in rat after intravenous administration (0.5 mg/kg),50597,10116.0,,,CHEMBL873829,5529,,,,,N,Intermediate,BAO_0000218
10000,Rattus norvegicus,1,A,,1,Half-life was determined in rat at a dose of 1 mpk i.v.,50597,10116.0,,,CHEMBL627655,6444,,,,,N,Intermediate,BAO_0000218
10001,Rattus norvegicus,1,A,,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,10116.0,,,CHEMBL625994,6444,,,,,N,Intermediate,BAO_0000218
10002,Rattus norvegicus,1,A,,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,10116.0,,,CHEMBL625995,6444,,,,,N,Intermediate,BAO_0000218
10003,Rattus norvegicus,1,A,,1,Half-life in rat,50597,10116.0,,,CHEMBL625996,5207,,,,,N,Intermediate,BAO_0000218
10004,Rattus norvegicus,1,A,,1,In vitro half life in rat plasma,50597,10116.0,,,CHEMBL625850,530,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10005,Rattus norvegicus,1,A,,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",50597,10116.0,,,CHEMBL625851,1116,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10006,Rattus norvegicus,1,A,,1,In vitro half life in rat,50597,10116.0,,,CHEMBL625852,3219,,,,,N,Intermediate,BAO_0000218
10007,Rattus norvegicus,1,A,,1,In vivo half life period after intravenous administration in rat,50597,10116.0,,,CHEMBL625853,6109,,,,,N,Intermediate,BAO_0000218
10008,Rattus norvegicus,1,A,,1,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,10116.0,,,CHEMBL625854,17582,,,,,N,Intermediate,BAO_0000218
10009,Rattus norvegicus,1,A,,1,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,10116.0,,,CHEMBL874450,17582,,,,,N,Intermediate,BAO_0000218
10010,Rattus norvegicus,1,A,,1,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL625855,5974,,,,,N,Intermediate,BAO_0000218
10011,Rattus norvegicus,1,A,,1,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL625856,5974,,,,,N,Intermediate,BAO_0000218
10012,Rattus norvegicus,1,A,,1,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL625857,5974,,,,,N,Intermediate,BAO_0000218
10013,Rattus norvegicus,1,A,,1,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL873831,5974,,,,,N,Intermediate,BAO_0000218
10014,Rattus norvegicus,1,A,,1,Longer half-life in rat (i.v.) at 0.5 mpk,50597,10116.0,,,CHEMBL625858,17853,,,,,N,Intermediate,BAO_0000218
10015,Rattus norvegicus,1,A,,1,Longer half-life in rat (p.o.) at 2.0 mpk,50597,10116.0,,,CHEMBL625859,17853,,,,,N,Intermediate,BAO_0000218
10016,Rattus norvegicus,1,A,,1,Pharmacokinetic property (half life) in rat,50597,10116.0,,,CHEMBL625860,3457,,,,,N,Intermediate,BAO_0000218
10017,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,50597,10116.0,,,CHEMBL625861,2792,,,,,N,Intermediate,BAO_0000218
10018,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL625862,2792,,,,,N,Intermediate,BAO_0000218
10019,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,50597,10116.0,,,CHEMBL625863,2792,,,,,N,Intermediate,BAO_0000218
10020,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,50597,10116.0,,,CHEMBL625864,2792,,,,,N,Intermediate,BAO_0000218
10021,Rattus norvegicus,1,A,,1,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,50597,10116.0,,,CHEMBL625865,5739,,,,,N,Intermediate,BAO_0000218
10022,Rattus norvegicus,1,A,,1,Pharmacokinetic half time was determined intravenously in rats.,50597,10116.0,,,CHEMBL625866,15765,,,,,N,Intermediate,BAO_0000218
10023,Rattus norvegicus,1,A,,1,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,50597,10116.0,,,CHEMBL625867,6567,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10024,Rattus norvegicus,1,A,,1,Plasma half life of hydrolysis of the compound,50597,10116.0,,,CHEMBL625868,2448,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10025,Rattus norvegicus,1,A,,1,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,50597,10116.0,,,CHEMBL625869,5423,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10026,Rattus norvegicus,1,A,,1,Plasma half life period was calculated in rat,50597,10116.0,,,CHEMBL874451,4853,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10027,Rattus norvegicus,1,A,,1,Plasma half-life in Sprague-Dawley rats,50597,10116.0,,,CHEMBL625870,4514,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10028,Rattus norvegicus,1,A,,1,Plasma half-life in Sprague-Dawley rats; Not determined,50597,10116.0,,,CHEMBL625871,4514,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10029,Rattus norvegicus,1,A,,1,Plasma half-life in rats,50597,10116.0,,,CHEMBL625872,1500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10030,Rattus norvegicus,1,A,,1,Plasma half-life in rats; <MQL,50597,10116.0,,,CHEMBL625873,1500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10031,Rattus norvegicus,1,A,,1,Plasma half-life period (0-8 h) was determined,50597,10116.0,,,CHEMBL625874,5334,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10032,Rattus norvegicus,1,A,,1,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL625875,5334,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10033,Rattus norvegicus,1,A,,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,10116.0,,,CHEMBL625876,5334,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10034,Rattus norvegicus,1,A,,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,10116.0,,,CHEMBL631258,5334,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10035,Rattus norvegicus,1,A,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,50597,10116.0,,,CHEMBL631259,4956,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10036,Rattus norvegicus,1,A,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,50597,10116.0,,,CHEMBL631260,4956,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10037,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",50597,10116.0,,,CHEMBL631261,7768,178.0,,,Blood,N,Intermediate,BAO_0000218
10038,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",50597,10116.0,,,CHEMBL631262,7768,178.0,,,Blood,N,Intermediate,BAO_0000218
10039,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",50597,10116.0,,,CHEMBL631263,7768,178.0,,,Blood,N,Intermediate,BAO_0000218
10040,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",50597,10116.0,,,CHEMBL631264,7768,,,,,N,Intermediate,BAO_0000218
10041,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",50597,10116.0,,,CHEMBL631265,7768,,,,,N,Intermediate,BAO_0000218
10042,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",50597,10116.0,,,CHEMBL631266,7768,,,,,N,Intermediate,BAO_0000218
10043,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",50597,10116.0,,,CHEMBL631267,7768,,,,,N,Intermediate,BAO_0000218
10044,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",50597,10116.0,,,CHEMBL631268,7768,,,,,N,Intermediate,BAO_0000218
10045,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",50597,10116.0,,,CHEMBL631269,7768,,,,,N,Intermediate,BAO_0000218
10046,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",50597,10116.0,,,CHEMBL631270,7768,,,,,N,Intermediate,BAO_0000218
10047,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,10116.0,,,CHEMBL631271,7768,948.0,,,Heart,N,Intermediate,BAO_0000218
10048,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",50597,10116.0,,,CHEMBL631272,7768,948.0,,,Heart,N,Intermediate,BAO_0000218
10049,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",50597,10116.0,,,CHEMBL631273,7768,948.0,,,Heart,N,Intermediate,BAO_0000218
10050,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",50597,10116.0,,,CHEMBL631274,7768,948.0,,,Heart,N,Intermediate,BAO_0000218
10051,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",50597,10116.0,,,CHEMBL631275,7768,948.0,,,Heart,N,Intermediate,BAO_0000218
10052,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",50597,10116.0,,,CHEMBL626984,7768,948.0,,,Heart,N,Intermediate,BAO_0000218
10053,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",50597,10116.0,,,CHEMBL626985,7768,948.0,,,Heart,N,Intermediate,BAO_0000218
10054,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,10116.0,,,CHEMBL626986,7768,2107.0,,,Liver,N,Intermediate,BAO_0000218
10055,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",50597,10116.0,,,CHEMBL626987,7768,2107.0,,,Liver,N,Intermediate,BAO_0000218
10056,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",50597,10116.0,,,CHEMBL626988,7768,2107.0,,,Liver,N,Intermediate,BAO_0000218
10057,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",50597,10116.0,,,CHEMBL626989,7768,2107.0,,,Liver,N,Intermediate,BAO_0000218
10058,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",50597,10116.0,,,CHEMBL626990,7768,2107.0,,,Liver,N,Intermediate,BAO_0000218
10059,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",50597,10116.0,,,CHEMBL626991,7768,2107.0,,,Liver,N,Intermediate,BAO_0000218
10060,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",50597,10116.0,,,CHEMBL626992,7768,2107.0,,,Liver,N,Intermediate,BAO_0000218
10061,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",50597,10116.0,,,CHEMBL626993,7768,2048.0,,,Lung,N,Intermediate,BAO_0000218
10062,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",50597,10116.0,,,CHEMBL874593,7768,2048.0,,,Lung,N,Intermediate,BAO_0000218
10063,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",50597,10116.0,,,CHEMBL626994,7768,2048.0,,,Lung,N,Intermediate,BAO_0000218
10064,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",50597,10116.0,,,CHEMBL626995,7768,2048.0,,,Lung,N,Intermediate,BAO_0000218
10065,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",50597,10116.0,,,CHEMBL626190,7768,2048.0,,,Lung,N,Intermediate,BAO_0000218
10066,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",50597,10116.0,,,CHEMBL626191,7768,2048.0,,,Lung,N,Intermediate,BAO_0000218
10067,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",50597,10116.0,,,CHEMBL626364,7768,2048.0,,,Lung,N,Intermediate,BAO_0000218
10068,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",50597,10116.0,,,CHEMBL626365,7768,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
10069,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",50597,10116.0,,,CHEMBL626366,7768,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
10070,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",50597,10116.0,,,CHEMBL626367,7768,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
10071,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",50597,10116.0,,,CHEMBL626368,7768,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
10072,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",50597,10116.0,,,CHEMBL626369,7768,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
10073,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",50597,10116.0,,,CHEMBL626370,7768,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
10074,Rattus norvegicus,1,A,,1,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",50597,10116.0,,,CHEMBL626371,4498,,,,,N,Intermediate,BAO_0000218
10075,Rattus norvegicus,1,A,,1,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",50597,10116.0,,,CHEMBL626372,4498,,,,,N,Intermediate,BAO_0000218
10076,Rattus norvegicus,1,A,,1,Bioavailability after a dose of 10 mg/kg p.o.,50597,10116.0,,,CHEMBL626373,3603,,,,,N,Intermediate,BAO_0000218
10077,Rattus norvegicus,1,A,,1,Bioavailability after peroral administration (10 mg/kg) was determined in rat,50597,10116.0,,,CHEMBL626374,6215,,,,,N,Intermediate,BAO_0000218
10078,Rattus norvegicus,1,A,,1,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,50597,10116.0,,,CHEMBL626375,5710,,,,,N,Intermediate,BAO_0000218
10079,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),50597,10116.0,,,CHEMBL626376,5710,,,,,N,Intermediate,BAO_0000218
10080,Rattus norvegicus,1,A,,1,Bioavailability in rat po was determined,50597,10116.0,,,CHEMBL626377,5676,,,,,N,Intermediate,BAO_0000218
10081,Rattus norvegicus,1,A,,1,Bioavailability of compound at 10 mg/kg in rat after oral administration,50597,10116.0,,,CHEMBL626378,17667,,,,,N,Intermediate,BAO_0000218
10082,Rattus norvegicus,1,A,,1,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,50597,10116.0,,,CHEMBL626379,17667,,,,,N,Intermediate,BAO_0000218
10083,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,10116.0,,,CHEMBL626380,6848,,,,,N,Intermediate,BAO_0000218
10084,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,10116.0,,,CHEMBL626381,6848,,,,,N,Intermediate,BAO_0000218
10085,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL626382,17267,,,,,N,Intermediate,BAO_0000218
10086,Rattus norvegicus,1,A,,1,Bioavailability in rat (Sprague-Dawley) (female),50597,10116.0,,,CHEMBL626383,6362,,,,,N,Intermediate,BAO_0000218
10087,Rattus norvegicus,1,A,,1,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,10116.0,,,CHEMBL874652,17671,,,,,N,Intermediate,BAO_0000218
10088,Rattus norvegicus,1,A,,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),50597,10116.0,,,CHEMBL626384,17671,,,,,N,Intermediate,BAO_0000218
10089,Rattus norvegicus,1,A,,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,50597,10116.0,,,CHEMBL626385,4333,,,,,N,Intermediate,BAO_0000218
10090,Rattus norvegicus,1,A,,1,Bioavailability in rat at an oral dose of 2 mg/kg,50597,10116.0,,,CHEMBL626386,6077,,,,,N,Intermediate,BAO_0000218
10091,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL626387,3278,,,,,N,Intermediate,BAO_0000218
10092,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL626388,5964,,,,,N,Intermediate,BAO_0000218
10093,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL626389,4884,,,,,N,Intermediate,BAO_0000218
10094,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL626390,4905,,,,,N,Intermediate,BAO_0000218
10095,Rattus norvegicus,1,A,,1,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,50597,10116.0,,,CHEMBL626391,4884,,,,,N,Intermediate,BAO_0000218
10096,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL626392,6850,,,,,N,Intermediate,BAO_0000218
10097,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL626393,2864,,,,,N,Intermediate,BAO_0000218
10098,Rattus norvegicus,1,A,,1,Bioavailability was determined in rat,50597,10116.0,,,CHEMBL623026,5780,,,,,N,Intermediate,BAO_0000218
10099,Rattus norvegicus,1,A,,1,Bioavailability,50597,10116.0,,,CHEMBL623027,1465,,,,,N,Intermediate,BAO_0000218
10100,Rattus norvegicus,1,A,,1,Bioavailability,50597,10116.0,,,CHEMBL623028,5199,,,,,N,Intermediate,BAO_0000218
10101,Rattus norvegicus,1,A,,1,Bioavailability in rat after 1 day dosing,50597,10116.0,,,CHEMBL623029,5765,,,,,N,Intermediate,BAO_0000218
10102,Rattus norvegicus,1,A,,1,Bioavailability in rat after 4 day dosing,50597,10116.0,,,CHEMBL623030,5765,,,,,N,Intermediate,BAO_0000218
10103,Rattus norvegicus,1,A,,1,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,50597,10116.0,,,CHEMBL623031,6518,,,,,N,Intermediate,BAO_0000218
10104,Rattus norvegicus,1,A,,1,Bioavailability after IV dosing at 1 mg/kg in rat; no data,50597,10116.0,,,CHEMBL623032,6518,,,,,N,Intermediate,BAO_0000218
10105,Rattus norvegicus,1,A,,1,Bioavailability after oral administration at a dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL623033,6518,,,,,N,Intermediate,BAO_0000218
10106,Rattus norvegicus,1,A,,1,Bioavailability after oral administration at a dose of 4 mg/kg in rat,50597,10116.0,,,CHEMBL623034,6518,,,,,N,Intermediate,BAO_0000218
10107,Rattus norvegicus,1,A,,1,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,10116.0,,,CHEMBL623035,2083,,,,,N,Intermediate,BAO_0000218
10108,Rattus norvegicus,1,A,,1,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,10116.0,,,CHEMBL623036,17260,,,,,N,Intermediate,BAO_0000218
10109,Rattus norvegicus,1,A,,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,10116.0,,,CHEMBL623037,4956,,,,,N,Intermediate,BAO_0000218
10110,Rattus norvegicus,1,A,,1,Bioavailability by intravenous administration of 3.4 mg/kg in rat,50597,10116.0,,,CHEMBL623038,4368,,,,,N,Intermediate,BAO_0000218
10111,Rattus norvegicus,1,A,,1,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,50597,10116.0,,,CHEMBL874385,17752,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10112,Rattus norvegicus,1,A,,1,Bioavailability in rat (Fisher) (fasted),50597,10116.0,,,CHEMBL623039,1446,,,,,N,Intermediate,BAO_0000218
10113,Primates,0,A,,1,Bioavailability in monkey after po administration of 10 mg/kg dose,22224,9443.0,,,CHEMBL623040,2891,,,,,U,Intermediate,BAO_0000218
10114,Primates,0,A,,1,Oral bioavailability in monkey (dose 10 mg/kg),22224,9443.0,,,CHEMBL623041,2891,,,,,U,Intermediate,BAO_0000218
10115,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL623741,6672,,,,,N,Intermediate,BAO_0000218
10116,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL623742,6673,,,,,N,Intermediate,BAO_0000218
10117,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL623743,17655,,,,,N,Intermediate,BAO_0000218
10118,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL623744,17796,,,,,N,Intermediate,BAO_0000218
10119,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 2.0 mg/kg p.o.),50597,10116.0,,,CHEMBL623745,17853,,,,,N,Intermediate,BAO_0000218
10120,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),50597,10116.0,,,CHEMBL623746,4521,,,,,N,Intermediate,BAO_0000218
10121,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 5 mg/kg p.o.),50597,10116.0,,,CHEMBL623747,4940,,,,,N,Intermediate,BAO_0000218
10122,Rattus norvegicus,0,A,,1,Bioavailability in rat after po administration of 30 mg/kg dose,22224,10116.0,,,CHEMBL623748,2891,,,,,U,Intermediate,BAO_0000218
10123,Rattus norvegicus,0,A,,1,Bioavailability in rat after po administration of 30 mg/kg dose,22224,10116.0,,,CHEMBL623916,2891,,,,,U,Intermediate,BAO_0000218
10124,Rattus norvegicus,1,A,,1,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,10116.0,,,CHEMBL623917,4521,,,,,N,Intermediate,BAO_0000218
10125,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 2 mg/kg i.v.),50597,10116.0,,,CHEMBL623918,17686,,,,,N,Intermediate,BAO_0000218
10126,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL874386,17796,,,,,N,Intermediate,BAO_0000218
10127,Rattus norvegicus,1,A,,1,Bioavailability in rat; Only traces detected in rat plasma,50597,10116.0,,,CHEMBL623919,17796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10128,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL623920,5064,,,,,N,Intermediate,BAO_0000218
10129,Rattus norvegicus,1,A,,1,Bioavailability upon oral administration of compound,50597,10116.0,,,CHEMBL623148,5147,,,,,N,Intermediate,BAO_0000218
10130,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),50597,10116.0,,,CHEMBL623149,1916,,,,,N,Intermediate,BAO_0000218
10131,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL623150,6049,,,,,N,Intermediate,BAO_0000218
10132,Rattus norvegicus,1,A,,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",50597,10116.0,,,CHEMBL623151,1445,,,,,N,Intermediate,BAO_0000218
10133,Rattus norvegicus,1,A,,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",50597,10116.0,,,CHEMBL623152,1445,,,,,N,Intermediate,BAO_0000218
10134,Rattus norvegicus,1,F,,1,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,50597,10116.0,,,CHEMBL623153,2862,,,,,N,Expert,BAO_0000218
10135,Rattus norvegicus,1,F,,1,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,50597,10116.0,,,CHEMBL623154,2862,,,,,N,Expert,BAO_0000218
10136,Rattus norvegicus,1,A,,1,In vitro and metabolic stability was determined,50597,10116.0,,,CHEMBL623155,4194,,,,,N,Intermediate,BAO_0000218
10137,Rattus norvegicus,1,A,,1,In vitro metabolic stability in rat hepatocytes,50597,10116.0,,,CHEMBL623156,4194,,,,,N,Intermediate,BAO_0000218
10138,Rattus norvegicus,1,A,,1,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,50597,10116.0,,,CHEMBL623157,5486,,,,,N,Intermediate,BAO_0000218
10139,Rattus norvegicus,1,A,Hepatocyte,1,Metabolic rate for compound was observed in rat hepatocytes,50597,10116.0,,,CHEMBL623158,17582,2107.0,401.0,,Liver,N,Intermediate,BAO_0000218
10140,Rattus norvegicus,1,A,,1,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,50597,10116.0,,,CHEMBL623159,5600,,,,,N,Intermediate,BAO_0000218
10141,Rattus norvegicus,1,A,,1,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),50597,10116.0,,,CHEMBL874390,14294,,,,,N,Intermediate,BAO_0000218
10142,Rattus norvegicus,1,A,,1,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),50597,10116.0,,,CHEMBL623160,14294,,,,,N,Intermediate,BAO_0000218
10143,Rattus norvegicus,1,A,,1,Metabolism of compound in rat S9 microsomes; Trace,50597,10116.0,,,CHEMBL623161,14294,,,,,N,Intermediate,BAO_0000218
10144,Rattus norvegicus,1,A,,1,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,50597,10116.0,,,CHEMBL623162,17847,,,,,N,Intermediate,BAO_0000218
10145,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,50597,10116.0,,,CHEMBL623163,11020,,,,,N,Intermediate,BAO_0000218
10146,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,50597,10116.0,,,CHEMBL623164,11020,,,,,N,Intermediate,BAO_0000218
10147,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,50597,10116.0,,,CHEMBL623165,11020,,,,,N,Intermediate,BAO_0000218
10148,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,50597,10116.0,,,CHEMBL623166,11020,,,,,N,Intermediate,BAO_0000218
10149,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,50597,10116.0,,,CHEMBL624983,11020,,,,,N,Intermediate,BAO_0000218
10150,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,50597,10116.0,,,CHEMBL624984,11020,,,,,N,Intermediate,BAO_0000218
10151,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,50597,10116.0,,,CHEMBL624985,11020,,,,,N,Intermediate,BAO_0000218
10152,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,50597,10116.0,,,CHEMBL622970,11020,,,,,N,Intermediate,BAO_0000218
10153,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,50597,10116.0,,,CHEMBL622971,11020,,,,,N,Intermediate,BAO_0000218
10154,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,50597,10116.0,,,CHEMBL622972,11020,,,,,N,Intermediate,BAO_0000218
10155,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,50597,10116.0,,,CHEMBL622973,11020,,,,,N,Intermediate,BAO_0000218
10156,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,50597,10116.0,,,CHEMBL622974,11020,,,,,N,Intermediate,BAO_0000218
10157,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,50597,10116.0,,,CHEMBL622975,11020,,,,,N,Intermediate,BAO_0000218
10158,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,50597,10116.0,,,CHEMBL622976,11020,,,,,N,Intermediate,BAO_0000218
10159,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,50597,10116.0,,,CHEMBL622977,11020,,,,,N,Intermediate,BAO_0000218
10160,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,10116.0,,,CHEMBL624351,11020,,,,,N,Intermediate,BAO_0000218
10161,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,10116.0,,,CHEMBL624352,11020,,,,,N,Intermediate,BAO_0000218
10162,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,10116.0,,,CHEMBL624353,11020,,,,,N,Intermediate,BAO_0000218
10163,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,10116.0,,,CHEMBL622397,11020,,,,,N,Intermediate,BAO_0000218
10164,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,50597,10116.0,,,CHEMBL622398,11020,,,,,N,Intermediate,BAO_0000218
10165,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,50597,10116.0,,,CHEMBL622399,11020,,,,,N,Intermediate,BAO_0000218
10166,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,10116.0,,,CHEMBL622400,11020,,,,,N,Intermediate,BAO_0000218
10167,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,10116.0,,,CHEMBL628428,11020,,,,,N,Intermediate,BAO_0000218
10168,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,50597,10116.0,,,CHEMBL628590,11020,,,,,N,Intermediate,BAO_0000218
10169,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,10116.0,,,CHEMBL628591,11020,,,,,N,Intermediate,BAO_0000218
10170,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,50597,10116.0,,,CHEMBL628592,11020,,,,,N,Intermediate,BAO_0000218
10171,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,10116.0,,,CHEMBL628593,11020,,,,,N,Intermediate,BAO_0000218
10172,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,50597,10116.0,,,CHEMBL875333,11020,,,,,N,Intermediate,BAO_0000218
10173,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,10116.0,,,CHEMBL628594,11020,,,,,N,Intermediate,BAO_0000218
10174,Rattus norvegicus,1,A,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,50597,10116.0,,,CHEMBL628595,4969,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10175,Rattus norvegicus,1,A,,1,Stability in rat plasma was determined,50597,10116.0,,,CHEMBL628596,6737,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10176,Rattus norvegicus,1,A,,1,Stability in rat plasma was determined; ND= no data,50597,10116.0,,,CHEMBL628597,6737,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10177,Rattus norvegicus,1,A,,1,Tested for plasma half life period in rat (0-8 hr),50597,10116.0,,,CHEMBL628598,5089,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10178,Rattus norvegicus,1,A,,1,Tested for plasma half life period in rat (0-8 hr); Not determined,50597,10116.0,,,CHEMBL628599,5089,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10179,Rattus norvegicus,1,A,,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,50597,10116.0,,,CHEMBL628600,1466,,,,,N,Intermediate,BAO_0000218
10180,Rattus norvegicus,1,A,,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,50597,10116.0,,,CHEMBL628601,1466,,,,,N,Intermediate,BAO_0000218
10181,Rattus norvegicus,1,A,,1,Tested for the half life in rat,50597,10116.0,,,CHEMBL628602,4950,,,,,N,Intermediate,BAO_0000218
10182,Rattus norvegicus,1,A,,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,50597,10116.0,,,CHEMBL628603,2412,,,,,N,Intermediate,BAO_0000218
10183,Rattus norvegicus,1,A,,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,50597,10116.0,,,CHEMBL628604,2412,,,,,N,Intermediate,BAO_0000218
10184,Rattus norvegicus,1,A,,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,50597,10116.0,,,CHEMBL628605,2412,,,,,N,Intermediate,BAO_0000218
10185,Rattus norvegicus,1,A,,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,50597,10116.0,,,CHEMBL628606,2412,,,,,N,Intermediate,BAO_0000218
10186,Rattus norvegicus,1,A,,1,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,50597,10116.0,,,CHEMBL628607,2412,,,,,N,Intermediate,BAO_0000218
10187,Rattus norvegicus,1,A,,1,The biological half life the compound was measured at the dose of 100 umol/kg,50597,10116.0,,,CHEMBL628608,15022,,,,,N,Intermediate,BAO_0000218
10188,Rattus norvegicus,1,A,,1,The biological half life the compound was measured at the dose of 30 umol/kg,50597,10116.0,,,CHEMBL628609,15022,,,,,N,Intermediate,BAO_0000218
10189,Rattus norvegicus,1,A,,1,The compound was evaluated for plasma half life period in rat,50597,10116.0,,,CHEMBL628610,406,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10190,Rattus norvegicus,1,A,,1,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL873819,15078,,,,,N,Intermediate,BAO_0000218
10191,Rattus norvegicus,1,A,,1,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL628611,15078,,,,,N,Intermediate,BAO_0000218
10192,Rattus norvegicus,1,A,,1,The pharmacokinetic parameter half-life period in vivo in rats,50597,10116.0,,,CHEMBL628612,5247,,,,,N,Intermediate,BAO_0000218
10193,Rattus norvegicus,1,A,,1,"The pharmacokinetic property, Half-life was determined",50597,10116.0,,,CHEMBL628613,5041,,,,,N,Intermediate,BAO_0000218
10194,Rattus norvegicus,1,A,,1,"The pharmacokinetic property, Half-life in rat in vivo",50597,10116.0,,,CHEMBL628614,5041,,,,,N,Intermediate,BAO_0000218
10195,Rattus norvegicus,1,A,,1,"The pharmacokinetic property, Half-life was determined; ND denotes no data",50597,10116.0,,,CHEMBL628615,5041,,,,,N,Intermediate,BAO_0000218
10196,Rattus norvegicus,1,A,,1,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",50597,10116.0,,,CHEMBL628616,5041,,,,,N,Intermediate,BAO_0000218
10197,Rattus norvegicus,1,A,,1,The plasma half life period in rats,50597,10116.0,,,CHEMBL627924,3918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10198,Rattus norvegicus,1,A,,1,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,50597,10116.0,,,CHEMBL627925,2906,2107.0,,,Liver,N,Intermediate,BAO_0000218
10199,Rattus norvegicus,1,A,,1,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,10116.0,,,CHEMBL627926,6467,,,,,N,Intermediate,BAO_0000218
10200,Rattus norvegicus,1,A,,1,t1/2 (apparent elimination)of the compound was determined,50597,10116.0,,,CHEMBL627927,5510,,,,,N,Intermediate,BAO_0000218
10201,Rattus norvegicus,1,A,,1,t1/2 value in rat,50597,10116.0,,,CHEMBL627928,3788,,,,,N,Intermediate,BAO_0000218
10202,Rattus norvegicus,1,A,,1,Half life in rat,50597,10116.0,,,CHEMBL627539,17796,,,,,N,Intermediate,BAO_0000218
10203,Rattus norvegicus,1,A,,1,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,10116.0,,,CHEMBL876790,12873,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10204,Rattus norvegicus,1,A,,1,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,50597,10116.0,,,CHEMBL858186,5983,,,,,N,Intermediate,BAO_0000218
10205,Rattus norvegicus,1,A,,1,Half-life period in fasted rats,50597,10116.0,,,CHEMBL627540,15765,,,,,N,Intermediate,BAO_0000218
10206,Rattus norvegicus,1,A,,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,50597,10116.0,,,CHEMBL627541,2661,,,,,N,Intermediate,BAO_0000218
10207,Rattus norvegicus,1,A,,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,50597,10116.0,,,CHEMBL627715,2661,,,,,N,Intermediate,BAO_0000218
10208,Rattus norvegicus,1,A,,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,10116.0,,,CHEMBL627716,429,,,,,N,Intermediate,BAO_0000218
10209,Rattus norvegicus,1,A,,1,Maximum time required to achieve Cmax was determined in rat,50597,10116.0,,,CHEMBL627717,17655,,,,,N,Intermediate,BAO_0000218
10210,Rattus norvegicus,1,A,,1,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,10116.0,,,CHEMBL627718,17717,,,,,N,Intermediate,BAO_0000218
10211,Rattus norvegicus,1,A,,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,10116.0,,,CHEMBL627719,17717,,,,,N,Intermediate,BAO_0000218
10212,Rattus norvegicus,1,A,,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,50597,10116.0,,,CHEMBL627720,17717,,,,,N,Intermediate,BAO_0000218
10213,Rattus norvegicus,1,A,,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,50597,10116.0,,,CHEMBL627721,6570,,,,,N,Intermediate,BAO_0000218
10214,Rattus norvegicus,1,A,,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,50597,10116.0,,,CHEMBL627722,6570,,,,,N,Intermediate,BAO_0000218
10215,Rattus norvegicus,1,A,,1,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL627723,5978,,,,,N,Intermediate,BAO_0000218
10216,Rattus norvegicus,1,A,,1,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL626058,5978,,,,,N,Intermediate,BAO_0000218
10217,Rattus norvegicus,1,A,,1,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL626059,5978,,,,,N,Intermediate,BAO_0000218
10218,Rattus norvegicus,1,A,,1,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL626060,5978,,,,,N,Intermediate,BAO_0000218
10219,Rattus norvegicus,1,A,,1,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL626061,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10220,Rattus norvegicus,1,A,,1,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL876791,4723,,,,,N,Intermediate,BAO_0000218
10221,Rattus norvegicus,1,A,,1,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,10116.0,,,CHEMBL626062,4723,,,,,N,Intermediate,BAO_0000218
10222,Rattus norvegicus,1,A,,1,Tmax at the dose of 2 mg/Kg administered perorally in rats,50597,10116.0,,,CHEMBL626063,4756,,,,,N,Intermediate,BAO_0000218
10223,Rattus norvegicus,1,A,,1,Tmax at the dose of 5 mg/Kg administered perorally in rats,50597,10116.0,,,CHEMBL626064,4756,,,,,N,Intermediate,BAO_0000218
10224,Rattus norvegicus,1,A,,1,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL626065,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10225,Rattus norvegicus,1,A,,1,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,10116.0,,,CHEMBL626066,17720,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10226,Rattus norvegicus,1,A,,1,tmax upon peroral administration of 10.0 mg/Kg dose in rat,50597,10116.0,,,CHEMBL626067,1466,,,,,N,Intermediate,BAO_0000218
10227,Rattus norvegicus,1,F,,1,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,50597,10116.0,,,CHEMBL626068,7449,,,,,N,Intermediate,BAO_0000218
10228,Rattus norvegicus,1,F,,1,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,50597,10116.0,,,CHEMBL626069,7449,,,,,N,Intermediate,BAO_0000218
10229,Rattus norvegicus,1,F,,1,Percent total excretion of 3-methoxyacetaminophen glucuronide,50597,10116.0,,,CHEMBL626070,7449,,,,,N,Intermediate,BAO_0000218
10230,Rattus norvegicus,1,F,,1,Percent total excretion of N-methoxyacetaminophen glucuronide,50597,10116.0,,,CHEMBL626071,7449,,,,,N,Intermediate,BAO_0000218
10231,Rattus norvegicus,1,F,,1,Percent total excretion of N-methoxyacetaminophen sulfate,50597,10116.0,,,CHEMBL626072,7449,,,,,N,Intermediate,BAO_0000218
10232,Rattus norvegicus,1,F,,1,Percent total excretion of acetaminophen,50597,10116.0,,,CHEMBL626073,7449,,,,,N,Intermediate,BAO_0000218
10233,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",50597,10116.0,,,CHEMBL626741,7768,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
10234,Rattus norvegicus,1,A,,1,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",50597,10116.0,,,CHEMBL626742,17655,,,,,N,Intermediate,BAO_0000218
10235,Rattus norvegicus,1,A,,1,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,50597,10116.0,,,CHEMBL626743,17735,,,,,N,Intermediate,BAO_0000218
10236,Rattus norvegicus,1,A,,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,10116.0,,,CHEMBL876792,5960,,,,,N,Intermediate,BAO_0000218
10237,Rattus norvegicus,1,A,,1,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,10116.0,,,CHEMBL626744,17735,,,,,N,Intermediate,BAO_0000218
10238,Rattus norvegicus,1,A,,1,Compound was tested for antidiuretic activity in rats,50597,10116.0,,,CHEMBL626745,7116,,,,,N,Intermediate,BAO_0000218
10239,Rattus norvegicus,1,A,,1,AUC in rat after 3mg/kg oral dose,50597,10116.0,,,CHEMBL626746,4878,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10240,Rattus norvegicus,1,A,,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,50597,10116.0,,,CHEMBL626747,5939,,,,,N,Intermediate,BAO_0000218
10241,Rattus norvegicus,1,A,,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,50597,10116.0,,,CHEMBL626748,5939,,,,,N,Intermediate,BAO_0000218
10242,Rattus norvegicus,1,A,,1,Bioavailability administered orally at a dose of 10 mg/kg to rats,50597,10116.0,,,CHEMBL626749,16367,,,,,N,Intermediate,BAO_0000218
10243,Rattus norvegicus,1,A,,1,Oral Bioavailability was determined,50597,10116.0,,,CHEMBL626750,16366,,,,,N,Intermediate,BAO_0000218
10244,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL626751,4426,,,,,N,Intermediate,BAO_0000218
10245,Rattus norvegicus,1,A,,1,Oral bioavailability in rat; Not performed.,50597,10116.0,,,CHEMBL626913,4426,,,,,N,Intermediate,BAO_0000218
10246,Rattus norvegicus,1,A,,1,Bioavailability,50597,10116.0,,,CHEMBL626914,5041,,,,,N,Intermediate,BAO_0000218
10247,Rattus norvegicus,1,A,,1,Bioavailability was determined; ND denotes no data,50597,10116.0,,,CHEMBL626915,5041,,,,,N,Intermediate,BAO_0000218
10248,Rattus norvegicus,1,A,,1,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,50597,10116.0,,,CHEMBL626916,1500,,,,,N,Intermediate,BAO_0000218
10249,Rattus norvegicus,1,A,,1,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,50597,10116.0,,,CHEMBL626917,1500,,,,,N,Intermediate,BAO_0000218
10250,Rattus norvegicus,1,A,,1,Binding towards rat plasma protein at 10 uM,50597,10116.0,,,CHEMBL626918,17409,,,,,N,Intermediate,BAO_0000218
10251,Rattus norvegicus,1,A,,1,Binding towards rat plasma protein at 100 uM,50597,10116.0,,,CHEMBL626919,17409,,,,,N,Intermediate,BAO_0000218
10252,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 20 mg/kg p.o.),50597,10116.0,,,CHEMBL626920,2959,,,,,N,Intermediate,BAO_0000218
10253,Rattus norvegicus,1,A,,1,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,10116.0,,,CHEMBL621976,13501,,,,,N,Intermediate,BAO_0000218
10254,Rattus norvegicus,1,A,,1,Bioavailability in rat after 5 mg/kg oral gavage,50597,10116.0,,,CHEMBL877599,6567,,,,,N,Intermediate,BAO_0000218
10255,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL621977,6571,,,,,N,Intermediate,BAO_0000218
10256,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 1 mg/kg i.v.),50597,10116.0,,,CHEMBL621978,6715,,,,,N,Intermediate,BAO_0000218
10257,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 3 mg/kg p.o.),50597,10116.0,,,CHEMBL621979,6715,,,,,N,Intermediate,BAO_0000218
10258,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL621980,2932,,,,,N,Intermediate,BAO_0000218
10259,Rattus norvegicus,1,A,,1,Bioavailability of the compound in rats after administration of 30 mg/kg,50597,10116.0,,,CHEMBL621981,4171,,,,,N,Intermediate,BAO_0000218
10260,Rattus norvegicus,1,A,,1,Bioavailability after administration of 10 mg/kg in rats,50597,10116.0,,,CHEMBL621982,17509,,,,,N,Intermediate,BAO_0000218
10261,Rattus norvegicus,1,A,,1,Bioavailability after administration of 2 mg/kg in rats,50597,10116.0,,,CHEMBL882953,17509,,,,,N,Intermediate,BAO_0000218
10262,Rattus norvegicus,1,A,,1,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,50597,10116.0,,,CHEMBL621983,4527,,,,,N,Intermediate,BAO_0000218
10263,Rattus norvegicus,1,A,,1,Bioavailability in dogs was determined; high,50597,10116.0,,,CHEMBL621984,4026,,,,,N,Intermediate,BAO_0000218
10264,Rattus norvegicus,1,A,,1,Bioavailability in monkey after intravenous administration at 1 mpk,50597,10116.0,,,CHEMBL621985,6659,,,,,N,Intermediate,BAO_0000218
10265,Rattus norvegicus,1,A,,1,Bioavailability in monkey after peroral administration at 10 mpk,50597,10116.0,,,CHEMBL621986,6659,,,,,N,Intermediate,BAO_0000218
10266,Rattus norvegicus,1,A,,1,Bioavailability in rat after intravenous administration at 1 mpk,50597,10116.0,,,CHEMBL621987,6659,,,,,N,Intermediate,BAO_0000218
10267,Rattus norvegicus,1,F,,1,Bioavailability in rat after intravenous administration at 2 mpk,50597,10116.0,,,CHEMBL877600,6659,,,,,N,Intermediate,BAO_0000218
10268,Rattus norvegicus,1,A,,1,Bioavailability in rat after peroral administration at 30 mpk,50597,10116.0,,,CHEMBL621988,6659,,,,,N,Intermediate,BAO_0000218
10269,Rattus norvegicus,1,F,,1,Bioavailability in rat after peroral administration at at 100 mpk,50597,10116.0,,,CHEMBL621989,6659,,,,,N,Intermediate,BAO_0000218
10270,Rattus norvegicus,1,A,,1,Bioavailability in rats was evaluated,50597,10116.0,,,CHEMBL621990,6597,,,,,N,Intermediate,BAO_0000218
10271,Rattus norvegicus,1,A,,1,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,50597,10116.0,,,CHEMBL621991,1202,,,,,N,Intermediate,BAO_0000218
10272,Rattus norvegicus,1,A,,1,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,50597,10116.0,,,CHEMBL621992,1202,,,,,N,Intermediate,BAO_0000218
10273,Rattus norvegicus,1,A,,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,50597,10116.0,,,CHEMBL621993,1202,,,,,N,Intermediate,BAO_0000218
10274,Rattus norvegicus,1,A,,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,50597,10116.0,,,CHEMBL621994,1202,,,,,N,Intermediate,BAO_0000218
10275,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL621995,5207,,,,,N,Intermediate,BAO_0000218
10276,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL621996,5970,,,,,N,Intermediate,BAO_0000218
10277,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 10 mg/kg),50597,10116.0,,,CHEMBL621997,17538,,,,,N,Intermediate,BAO_0000218
10278,Rattus norvegicus,1,A,,1,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,10116.0,,,CHEMBL621998,17538,,,,,N,Intermediate,BAO_0000218
10279,Rattus norvegicus,1,A,,1,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,50597,10116.0,,,CHEMBL621999,1466,,,,,N,Intermediate,BAO_0000218
10280,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622000,2879,,,,,N,Intermediate,BAO_0000218
10281,Rattus norvegicus,1,A,,1,Bioavailability was measured in rat after oral administration; 2-4,50597,10116.0,,,CHEMBL622001,2879,,,,,N,Intermediate,BAO_0000218
10282,Rattus norvegicus,1,A,,1,Bioavailability was measured in rat after oral administration; 3-7,50597,10116.0,,,CHEMBL622002,2879,,,,,N,Intermediate,BAO_0000218
10283,Rattus norvegicus,1,A,,1,Bioavailability in rat (intraduodenal administration),50597,10116.0,,,CHEMBL622003,3777,,,,,N,Intermediate,BAO_0000218
10284,Rattus norvegicus,1,A,,1,Bioavailability in rat (intraduodenal administration),50597,10116.0,,,CHEMBL877601,3777,,,,,N,Intermediate,BAO_0000218
10285,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL624871,3777,,,,,N,Intermediate,BAO_0000218
10286,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622004,3777,,,,,N,Intermediate,BAO_0000218
10287,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),50597,10116.0,,,CHEMBL882954,5423,,,,,N,Intermediate,BAO_0000218
10288,Rattus norvegicus,1,A,,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,50597,10116.0,,,CHEMBL622005,16365,,,,,N,Intermediate,BAO_0000218
10289,Rattus norvegicus,1,A,,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,50597,10116.0,,,CHEMBL622006,16365,,,,,N,Intermediate,BAO_0000218
10290,Rattus norvegicus,1,A,,1,Bioavailability was measured in rat,50597,10116.0,,,CHEMBL622007,4239,,,,,N,Intermediate,BAO_0000218
10291,Rattus norvegicus,1,A,,1,Bioavailability was reported,50597,10116.0,,,CHEMBL622008,5438,,,,,N,Intermediate,BAO_0000218
10292,Rattus norvegicus,1,A,,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,10116.0,,,CHEMBL622009,5334,,,,,N,Intermediate,BAO_0000218
10293,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,10116.0,,,CHEMBL622010,5334,,,,,N,Intermediate,BAO_0000218
10294,Rattus norvegicus,1,A,,1,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,10116.0,,,CHEMBL622011,4199,,,,,N,Intermediate,BAO_0000218
10295,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),50597,10116.0,,,CHEMBL622012,4199,,,,,N,Intermediate,BAO_0000218
10296,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),50597,10116.0,,,CHEMBL622013,4199,,,,,N,Intermediate,BAO_0000218
10297,Rattus norvegicus,1,A,,1,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,10116.0,,,CHEMBL622014,4890,,,,,N,Intermediate,BAO_0000218
10298,Rattus norvegicus,1,A,,1,Bioavailability was determined at 3 mg/kg po dose in rats,50597,10116.0,,,CHEMBL624749,2792,,,,,N,Intermediate,BAO_0000218
10299,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 2 mg/kg),50597,10116.0,,,CHEMBL624750,5529,,,,,N,Intermediate,BAO_0000218
10300,Rattus norvegicus,1,A,,1,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL624751,6685,,,,,N,Intermediate,BAO_0000218
10301,Rattus norvegicus,1,A,,1,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,10116.0,,,CHEMBL624752,6685,,,,,N,Intermediate,BAO_0000218
10302,Rattus norvegicus,1,A,,1,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,10116.0,,,CHEMBL624753,6685,,,,,N,Intermediate,BAO_0000218
10303,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,50597,10116.0,,,CHEMBL624754,6005,,,,,N,Intermediate,BAO_0000218
10304,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,10116.0,,,CHEMBL624755,6410,,,,,N,Intermediate,BAO_0000218
10305,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,10116.0,,,CHEMBL624756,6410,,,,,N,Intermediate,BAO_0000218
10306,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL624757,6103,,,,,N,Intermediate,BAO_0000218
10307,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,10116.0,,,CHEMBL624758,6410,,,,,N,Intermediate,BAO_0000218
10308,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,10116.0,,,CHEMBL622270,6410,,,,,N,Intermediate,BAO_0000218
10309,Rattus norvegicus,1,A,,1,Bioavailability in rat (Sprague-Dawley),50597,10116.0,,,CHEMBL622271,5353,,,,,N,Intermediate,BAO_0000218
10310,Rattus norvegicus,1,A,,1,Bioavailability in rat at the dose of 2 mg/kg,50597,10116.0,,,CHEMBL622272,4727,,,,,N,Intermediate,BAO_0000218
10311,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622273,17804,,,,,N,Intermediate,BAO_0000218
10312,Rattus norvegicus,1,A,,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,10116.0,,,CHEMBL622274,5809,,,,,N,Intermediate,BAO_0000218
10313,Rattus norvegicus,1,A,,1,Bioavailability value of compound in rats was determined after peroral administration,50597,10116.0,,,CHEMBL622275,17804,,,,,N,Intermediate,BAO_0000218
10314,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 20 mg/kg),50597,10116.0,,,CHEMBL622276,3634,,,,,N,Intermediate,BAO_0000218
10315,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622277,3341,,,,,N,Intermediate,BAO_0000218
10316,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 5 mg/kg),50597,10116.0,,,CHEMBL622278,2690,,,,,N,Intermediate,BAO_0000218
10317,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622279,3184,,,,,N,Intermediate,BAO_0000218
10318,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622280,740,,,,,N,Intermediate,BAO_0000218
10319,Rattus norvegicus,1,A,,1,Compound was evaluated for oral bioavailability in rats; 15-27 %,50597,10116.0,,,CHEMBL624083,1806,,,,,N,Intermediate,BAO_0000218
10320,Rattus norvegicus,1,A,,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,50597,10116.0,,,CHEMBL624084,4891,,,,,N,Intermediate,BAO_0000218
10321,Rattus norvegicus,1,A,,1,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),50597,10116.0,,,CHEMBL624085,3634,,,,,N,Intermediate,BAO_0000218
10322,Rattus norvegicus,1,A,,1,Compound was tested for bioavailability in rats,50597,10116.0,,,CHEMBL624086,64,,,,,N,Intermediate,BAO_0000218
10323,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL624087,4839,,,,,N,Intermediate,BAO_0000218
10324,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL624088,1094,,,,,N,Intermediate,BAO_0000218
10325,Macaca mulatta,0,A,,1,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,22224,9544.0,,,CHEMBL624089,5005,,,,,U,Intermediate,BAO_0000218
10326,Rattus norvegicus,0,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),22224,10116.0,,,CHEMBL624090,5005,,,,,U,Intermediate,BAO_0000218
10327,Rattus norvegicus,1,A,,1,Evaluated for the bioavailability in rat (in vivo),50597,10116.0,,,CHEMBL624091,4687,,,,,N,Intermediate,BAO_0000218
10328,Rattus norvegicus,1,A,,1,F value of compound in rats was determined after peroral administration,50597,10116.0,,,CHEMBL624092,17804,,,,,N,Intermediate,BAO_0000218
10329,Rattus norvegicus,1,A,,1,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL624093,5974,,,,,N,Intermediate,BAO_0000218
10330,Rattus norvegicus,1,A,,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL624094,5974,,,,,N,Intermediate,BAO_0000218
10331,Rattus norvegicus,1,A,,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL624095,5974,,,,,N,Intermediate,BAO_0000218
10332,Rattus norvegicus,1,A,,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,10116.0,,,CHEMBL624096,5974,,,,,N,Intermediate,BAO_0000218
10333,Rattus norvegicus,1,A,,1,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",50597,10116.0,,,CHEMBL624097,1088,,,,,N,Intermediate,BAO_0000218
10334,Rattus norvegicus,1,A,,1,Maximum fall in carotid flow in rat,50597,10116.0,,,CHEMBL624098,1742,,,,,N,Intermediate,BAO_0000218
10335,Rattus norvegicus,1,A,,1,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,50597,10116.0,,,CHEMBL874392,4689,,,,,N,Intermediate,BAO_0000218
10336,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 5 mg/kg),50597,10116.0,,,CHEMBL624099,2463,,,,,N,Intermediate,BAO_0000218
10337,Rattus norvegicus,1,A,,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,10116.0,,,CHEMBL624100,5654,,,,,N,Intermediate,BAO_0000218
10338,Rattus norvegicus,1,A,,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,10116.0,,,CHEMBL624101,5654,,,,,N,Intermediate,BAO_0000218
10339,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (male Wistar),50597,10116.0,,,CHEMBL624102,6874,,,,,N,Intermediate,BAO_0000218
10340,Rattus norvegicus,1,A,,1,Oral bioavailability after administration (30 mg/kg) in rat; good,50597,10116.0,,,CHEMBL624103,5633,,,,,N,Intermediate,BAO_0000218
10341,Rattus norvegicus,1,A,,1,Oral bioavailability at the dose of 2 mg/kg in rat,50597,10116.0,,,CHEMBL624104,5496,,,,,N,Intermediate,BAO_0000218
10342,Rattus norvegicus,1,A,,1,Oral bioavailability determined in rats,50597,10116.0,,,CHEMBL624105,2358,,,,,N,Intermediate,BAO_0000218
10343,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),50597,10116.0,,,CHEMBL624106,16456,,,,,N,Intermediate,BAO_0000218
10344,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose single 10 mg/kg),50597,10116.0,,,CHEMBL624107,5302,,,,,N,Intermediate,BAO_0000218
10345,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose single 10 mg/kg),50597,10116.0,,,CHEMBL623943,5302,,,,,N,Intermediate,BAO_0000218
10346,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 5 mg/kg,50597,10116.0,,,CHEMBL623944,5302,,,,,N,Intermediate,BAO_0000218
10347,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,50597,10116.0,,,CHEMBL623945,11020,,,,,N,Intermediate,BAO_0000218
10348,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,50597,10116.0,,,CHEMBL623946,11020,,,,,N,Intermediate,BAO_0000218
10349,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,50597,10116.0,,,CHEMBL623947,11020,,,,,N,Intermediate,BAO_0000218
10350,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,50597,10116.0,,,CHEMBL623948,11020,,,,,N,Intermediate,BAO_0000218
10351,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,50597,10116.0,,,CHEMBL623949,11020,,,,,N,Intermediate,BAO_0000218
10352,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,50597,10116.0,,,CHEMBL623950,11020,,,,,N,Intermediate,BAO_0000218
10353,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,50597,10116.0,,,CHEMBL874398,11020,,,,,N,Intermediate,BAO_0000218
10354,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,50597,10116.0,,,CHEMBL623951,11020,,,,,N,Intermediate,BAO_0000218
10355,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,50597,10116.0,,,CHEMBL623952,11020,,,,,N,Intermediate,BAO_0000218
10356,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,50597,10116.0,,,CHEMBL623953,11020,,,,,N,Intermediate,BAO_0000218
10357,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,50597,10116.0,,,CHEMBL623954,11020,,,,,N,Intermediate,BAO_0000218
10358,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,50597,10116.0,,,CHEMBL623955,11020,,,,,N,Intermediate,BAO_0000218
10359,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,50597,10116.0,,,CHEMBL623956,11020,,,,,N,Intermediate,BAO_0000218
10360,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,50597,10116.0,,,CHEMBL627807,11020,,,,,N,Intermediate,BAO_0000218
10361,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,50597,10116.0,,,CHEMBL627808,11020,,,,,N,Intermediate,BAO_0000218
10362,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,50597,10116.0,,,CHEMBL627809,11020,,,,,N,Intermediate,BAO_0000218
10363,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,50597,10116.0,,,CHEMBL627810,11020,,,,,N,Intermediate,BAO_0000218
10364,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",50597,10116.0,,,CHEMBL627811,11020,,,,,N,Intermediate,BAO_0000218
10365,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",50597,10116.0,,,CHEMBL627812,11020,,,,,N,Intermediate,BAO_0000218
10366,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",50597,10116.0,,,CHEMBL627813,11020,,,,,N,Intermediate,BAO_0000218
10367,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",50597,10116.0,,,CHEMBL627814,11020,,,,,N,Intermediate,BAO_0000218
10368,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",50597,10116.0,,,CHEMBL875336,11020,,,,,N,Intermediate,BAO_0000218
10369,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",50597,10116.0,,,CHEMBL627815,11020,,,,,N,Intermediate,BAO_0000218
10370,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",50597,10116.0,,,CHEMBL627816,11020,,,,,N,Intermediate,BAO_0000218
10371,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",50597,10116.0,,,CHEMBL627817,11020,,,,,N,Intermediate,BAO_0000218
10372,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",50597,10116.0,,,CHEMBL627818,11020,,,,,N,Intermediate,BAO_0000218
10373,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",50597,10116.0,,,CHEMBL627819,11020,,,,,N,Intermediate,BAO_0000218
10374,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",50597,10116.0,,,CHEMBL627820,11020,,,,,N,Intermediate,BAO_0000218
10375,Rattus norvegicus,1,A,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",50597,10116.0,,,CHEMBL627821,11020,,,,,N,Intermediate,BAO_0000218
10376,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,10116.0,,,CHEMBL628464,11020,,,,,N,Intermediate,BAO_0000218
10377,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,10116.0,,,CHEMBL626239,11020,,,,,N,Intermediate,BAO_0000218
10378,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,50597,10116.0,,,CHEMBL626240,11020,,,,,N,Intermediate,BAO_0000218
10379,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,10116.0,,,CHEMBL626241,11020,,,,,N,Intermediate,BAO_0000218
10380,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,50597,10116.0,,,CHEMBL626242,11020,,,,,N,Intermediate,BAO_0000218
10381,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,50597,10116.0,,,CHEMBL626243,11020,,,,,N,Intermediate,BAO_0000218
10382,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,10116.0,,,CHEMBL626244,11020,,,,,N,Intermediate,BAO_0000218
10383,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,50597,10116.0,,,CHEMBL626907,11020,,,,,N,Intermediate,BAO_0000218
10384,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,10116.0,,,CHEMBL626908,11020,,,,,N,Intermediate,BAO_0000218
10385,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,10116.0,,,CHEMBL626909,11020,,,,,N,Intermediate,BAO_0000218
10386,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,10116.0,,,CHEMBL626910,11020,,,,,N,Intermediate,BAO_0000218
10387,Rattus norvegicus,1,F,,1,Percent total excretion of acetaminophen cysteine conjugate,50597,10116.0,,,CHEMBL875342,7449,,,,,N,Intermediate,BAO_0000218
10388,Rattus norvegicus,1,F,,1,Percent total excretion of acetaminophen glucuronide,50597,10116.0,,,CHEMBL626911,7449,,,,,N,Intermediate,BAO_0000218
10389,Rattus norvegicus,1,F,,1,Percent total excretion of acetaminophen sulfate,50597,10116.0,,,CHEMBL626912,7449,,,,,N,Intermediate,BAO_0000218
10390,Rattus norvegicus,1,F,,1,Percent total excretion of acetaminophen-mercapturic acid,50597,10116.0,,,CHEMBL627065,7449,,,,,N,Intermediate,BAO_0000218
10391,Rattus norvegicus,1,A,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,50597,10116.0,,,CHEMBL627066,3172,1088.0,,,Urine,N,Intermediate,BAO_0000218
10392,Rattus norvegicus,1,A,,1,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL627067,16456,,,,,N,Intermediate,BAO_0000218
10393,ratrat,0,A,,1,Biodistribution of compound in rat muscle after 5 min of administration,22224,8656.0,,,CHEMBL627068,10839,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
10394,ratrat,0,A,,1,Biodistribution of compound in rat muscle after 5 min of administration.,22224,8656.0,,,CHEMBL627069,10839,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
10395,Ovis aries,0,A,,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL627070,5334,,,,,U,Autocuration,BAO_0000218
10396,Ovis aries,0,A,,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL627071,5334,,,,,U,Autocuration,BAO_0000218
10397,Ovis aries,0,A,,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL627072,5334,,,,,U,Autocuration,BAO_0000218
10398,Ovis aries,0,A,,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL627073,5334,,,,,U,Autocuration,BAO_0000218
10399,Ovis aries,0,A,,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL625387,5334,,,,,U,Autocuration,BAO_0000218
10400,Ovis aries,0,A,,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL625388,5334,,,,,U,Autocuration,BAO_0000218
10401,Ovis aries,0,A,,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL625389,5334,1969.0,,,Plasma,U,Autocuration,BAO_0000218
10402,Ovis aries,0,A,,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,9940.0,,,CHEMBL875343,5334,1969.0,,,Plasma,U,Autocuration,BAO_0000218
10403,Serpentes,1,A,,1,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),50497,8570.0,,,CHEMBL876795,1735,,,,,N,Intermediate,BAO_0000218
10404,Serpentes,1,A,,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,50497,8570.0,,,CHEMBL626552,1469,,,,,N,Intermediate,BAO_0000218
10405,Serpentes,1,A,,1,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,50497,8570.0,,,CHEMBL626553,1336,,,,,N,Intermediate,BAO_0000218
10406,Homo sapiens,0,A,,1,The human biological plasma half life of the compound,22224,9606.0,,,CHEMBL626554,12403,1969.0,,,Plasma,U,Autocuration,BAO_0000366
10407,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,10116.0,,,CHEMBL626555,8151,1088.0,,,Urine,N,Intermediate,BAO_0000218
10408,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,50597,10116.0,,,CHEMBL626556,8004,,,,,N,Intermediate,BAO_0000218
10409,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,50597,10116.0,,,CHEMBL626557,8004,,,,,N,Intermediate,BAO_0000218
10410,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,50597,10116.0,,,CHEMBL626558,8004,,,,,N,Intermediate,BAO_0000218
10411,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,10116.0,,,CHEMBL626559,8004,,,,,N,Intermediate,BAO_0000218
10412,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,10116.0,,,CHEMBL626560,8004,,,,,N,Intermediate,BAO_0000218
10413,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,10116.0,,,CHEMBL876803,8004,,,,,N,Intermediate,BAO_0000218
10414,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,50597,10116.0,,,CHEMBL627964,8004,,,,,N,Intermediate,BAO_0000218
10415,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,50597,10116.0,,,CHEMBL627965,8004,,,,,N,Intermediate,BAO_0000218
10416,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,50597,10116.0,,,CHEMBL627966,8004,,,,,N,Intermediate,BAO_0000218
10417,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,10116.0,,,CHEMBL627967,8004,,,,,N,Intermediate,BAO_0000218
10418,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,10116.0,,,CHEMBL627968,8004,,,,,N,Intermediate,BAO_0000218
10419,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,10116.0,,,CHEMBL627969,8004,,,,,N,Intermediate,BAO_0000218
10420,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,10116.0,,,CHEMBL627970,8004,,,,,N,Intermediate,BAO_0000218
10421,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,50597,10116.0,,,CHEMBL627971,8004,178.0,,,Blood,N,Intermediate,BAO_0000218
10422,Rattus norvegicus,1,A,,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,50597,10116.0,,,CHEMBL627972,8004,178.0,,,Blood,N,Intermediate,BAO_0000218
10423,Homo sapiens,9,B,,1,Dissociation constant against binding to human cyclophilin A,180,9606.0,,,CHEMBL856029,15917,,,,,D,Expert,BAO_0000357
10424,Bos taurus,8,B,,1,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,11591,9913.0,,,CHEMBL627973,12396,,,,,H,Expert,BAO_0000019
10425,,0,A,,1,-Log C was determined by performing the electroshock minimum test,22224,,,,CHEMBL627974,7065,,,,,U,Autocuration,BAO_0000019
10426,,0,A,,1,-Log C was determined by performing the foot shock test,22224,,,,CHEMBL627975,7065,,,,,U,Autocuration,BAO_0000019
10427,,0,A,,1,-Log C was determined by performing the incl screen test,22224,,,,CHEMBL627976,7065,,,,,U,Autocuration,BAO_0000019
10428,,0,A,,1,-Log C was determined by performing the maximum electroshock test,22224,,,,CHEMBL627977,7065,,,,,U,Autocuration,BAO_0000019
10429,,0,A,,1,-Log C was determined by performing the pentylenetetrazole test,22224,,,,CHEMBL627978,7065,,,,,U,Autocuration,BAO_0000019
10430,,0,A,,1,Tested for experimental arotinoid inhibitory dose,22224,,,,CHEMBL627979,12415,,,,,U,Autocuration,BAO_0000019
10431,,0,A,,1,Negative log transformed activity,22224,,,,CHEMBL876804,10256,,,,,U,Autocuration,BAO_0000019
10432,,0,A,,1,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",22224,,,,CHEMBL627980,7991,,,,,U,Autocuration,BAO_0000019
10433,Cavia porcellus,1,A,,1,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,50512,10141.0,,,CHEMBL627981,14342,,,,,N,Intermediate,BAO_0000218
10434,Cavia porcellus,1,A,,1,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,50512,10141.0,,,CHEMBL627982,14342,,,,,N,Intermediate,BAO_0000218
10435,Cavia porcellus,1,A,,1,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,50512,10141.0,,,CHEMBL627983,14342,,,,,N,Intermediate,BAO_0000218
10436,Cavia porcellus,1,A,,1,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,50512,10141.0,,,CHEMBL627984,14342,2116.0,,,Ileum,N,Intermediate,BAO_0000218
10437,,0,P,,1,Solubility in water was determined; values expressed as -log,22229,,,,CHEMBL627985,6047,,,,,U,Autocuration,BAO_0000100
10438,,0,A,,1,Ratio of Kcat to that of Km was determined,22224,,,,CHEMBL627986,17269,,,,,U,Autocuration,BAO_0000019
10439,,0,A,,1,Observed first order rate constant,22224,,,,CHEMBL627987,10026,,,,,U,Autocuration,BAO_0000019
10440,,0,A,,1,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,22224,,,,CHEMBL627988,14583,,,,,U,Autocuration,BAO_0000019
10441,Rattus norvegicus,1,A,,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,50597,10116.0,,,CHEMBL627989,2661,,,,,N,Intermediate,BAO_0000218
10442,Rattus norvegicus,1,A,,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,50597,10116.0,,,CHEMBL627990,2661,,,,,N,Intermediate,BAO_0000218
10443,Rattus norvegicus,1,A,,1,Oral Bioavailability after administration of 10 mg/kg in male rat,50597,10116.0,,,CHEMBL876805,4029,,,,,N,Intermediate,BAO_0000218
10444,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),50597,10116.0,,,CHEMBL627991,17735,,,,,N,Intermediate,BAO_0000218
10445,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL627992,4576,,,,,N,Intermediate,BAO_0000218
10446,Rattus norvegicus,1,A,,1,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,10116.0,,,CHEMBL627993,17582,,,,,N,Intermediate,BAO_0000218
10447,Rattus norvegicus,1,A,,1,Oral bioavailability at 1 mg/kg was determined in rat,50597,10116.0,,,CHEMBL622817,17651,,,,,N,Intermediate,BAO_0000218
10448,Rattus norvegicus,1,A,,1,Oral bioavailability at 10 mg/kg was determined in rat,50597,10116.0,,,CHEMBL622818,17651,,,,,N,Intermediate,BAO_0000218
10449,Rattus norvegicus,1,A,,1,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",50597,10116.0,,,CHEMBL622819,17670,,,,,N,Intermediate,BAO_0000218
10450,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL872267,5045,,,,,N,Intermediate,BAO_0000218
10451,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622820,1696,,,,,N,Intermediate,BAO_0000218
10452,Rattus norvegicus,1,A,,1,Oral bioavailability after intravenous administration in rats at 24 uM/kg,50597,10116.0,,,CHEMBL622821,17764,,,,,N,Intermediate,BAO_0000218
10453,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622822,6448,,,,,N,Intermediate,BAO_0000218
10454,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622823,6596,,,,,N,Intermediate,BAO_0000218
10455,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622824,17547,,,,,N,Intermediate,BAO_0000218
10456,Rattus norvegicus,1,A,,1,Oral bioavailability in rat at a dose of 3 mg/kg,50597,10116.0,,,CHEMBL622825,17771,,,,,N,Intermediate,BAO_0000218
10457,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after oral administration at 10 mg/kg,50597,10116.0,,,CHEMBL622901,6495,,,,,N,Intermediate,BAO_0000218
10458,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622902,4558,,,,,N,Intermediate,BAO_0000218
10459,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL621844,17596,,,,,N,Intermediate,BAO_0000218
10460,Rattus norvegicus,1,A,,1,Oral bioavailability in Dawley rats,50597,10116.0,,,CHEMBL621845,6827,,,,,N,Intermediate,BAO_0000218
10461,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL621846,4026,,,,,N,Intermediate,BAO_0000218
10462,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 30 mg/kg),50597,10116.0,,,CHEMBL621847,10,,,,,N,Intermediate,BAO_0000218
10463,Rattus norvegicus,1,A,,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,10116.0,,,CHEMBL877609,17717,,,,,N,Intermediate,BAO_0000218
10464,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 3 mg/kg i.v.),50597,10116.0,,,CHEMBL621848,17717,,,,,N,Intermediate,BAO_0000218
10465,Rattus norvegicus,1,A,,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,10116.0,,,CHEMBL621849,17717,,,,,N,Intermediate,BAO_0000218
10466,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,10116.0,,,CHEMBL622030,17717,,,,,N,Intermediate,BAO_0000218
10467,Rattus norvegicus,1,A,,1,Percent oral bioavailability determined in rats,50597,10116.0,,,CHEMBL622031,4796,,,,,N,Intermediate,BAO_0000218
10468,Rattus norvegicus,1,A,,1,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,10116.0,,,CHEMBL622032,4883,,,,,N,Intermediate,BAO_0000218
10469,Rattus norvegicus,1,A,,1,The compound was evaluated for bioavailability in rats; 32-51,50597,10116.0,,,CHEMBL622033,2137,,,,,N,Intermediate,BAO_0000218
10470,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 20 mg/kg p.o.),50597,10116.0,,,CHEMBL622034,2959,,,,,N,Intermediate,BAO_0000218
10471,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622035,1361,,,,,N,Intermediate,BAO_0000218
10472,Rattus norvegicus,1,A,,1,Bioavailability percent in rat at the dose of 2 mg/kg,50597,10116.0,,,CHEMBL882966,4727,,,,,N,Intermediate,BAO_0000218
10473,Rattus norvegicus,1,A,,1,Bioavailability was evaluated after 20 uM/kg of peroral administration,50597,10116.0,,,CHEMBL622036,16423,,,,,N,Intermediate,BAO_0000218
10474,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622037,5206,,,,,N,Intermediate,BAO_0000218
10475,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622038,6448,,,,,N,Intermediate,BAO_0000218
10476,Rattus norvegicus,1,A,,1,Bioavailability in rats,50597,10116.0,,,CHEMBL622039,17723,,,,,N,Intermediate,BAO_0000218
10477,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622040,17738,178.0,,,Blood,N,Intermediate,BAO_0000218
10478,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622041,17738,178.0,,,Blood,N,Intermediate,BAO_0000218
10479,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622042,17738,178.0,,,Blood,N,Intermediate,BAO_0000218
10480,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622043,17738,178.0,,,Blood,N,Intermediate,BAO_0000218
10481,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622044,17738,178.0,,,Blood,N,Intermediate,BAO_0000218
10482,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622045,17738,10000001.0,,,Bone,N,Intermediate,BAO_0000218
10483,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622046,17738,10000001.0,,,Bone,N,Intermediate,BAO_0000218
10484,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622047,17738,10000001.0,,,Bone,N,Intermediate,BAO_0000218
10485,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL877610,17738,10000001.0,,,Bone,N,Intermediate,BAO_0000218
10486,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622048,17738,955.0,,,Brain,N,Intermediate,BAO_0000218
10487,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622049,17738,955.0,,,Brain,N,Intermediate,BAO_0000218
10488,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622050,17738,955.0,,,Brain,N,Intermediate,BAO_0000218
10489,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622051,17738,955.0,,,Brain,N,Intermediate,BAO_0000218
10490,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622052,17738,,,,,N,Intermediate,BAO_0000218
10491,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622053,17738,,,,,N,Intermediate,BAO_0000218
10492,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622054,17738,,,,,N,Intermediate,BAO_0000218
10493,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622055,17738,,,,,N,Intermediate,BAO_0000218
10494,Rattus norvegicus,1,A,,1,Oral bioavailability in rats was determined; High,50597,10116.0,,,CHEMBL622056,5237,,,,,N,Intermediate,BAO_0000218
10495,Rattus norvegicus,1,A,,1,Oral bioavailability in the rat was determined,50597,10116.0,,,CHEMBL622057,5503,,,,,N,Intermediate,BAO_0000218
10496,Rattus norvegicus,1,A,,1,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,50597,10116.0,,,CHEMBL628008,15765,,,,,N,Intermediate,BAO_0000218
10497,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),50597,10116.0,,,CHEMBL622058,15660,,,,,N,Intermediate,BAO_0000218
10498,Rattus norvegicus,1,A,,1,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL622059,5978,,,,,N,Intermediate,BAO_0000218
10499,Rattus norvegicus,1,A,,1,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL622060,5978,,,,,N,Intermediate,BAO_0000218
10500,Rattus norvegicus,1,A,,1,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL622061,5978,,,,,N,Intermediate,BAO_0000218
10501,Rattus norvegicus,1,A,,1,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,10116.0,,,CHEMBL622062,5978,,,,,N,Intermediate,BAO_0000218
10502,Rattus norvegicus,1,A,,1,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,50597,10116.0,,,CHEMBL622063,5656,,,,,N,Intermediate,BAO_0000218
10503,Rattus norvegicus,1,A,,1,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL877611,3598,,,,,N,Expert,BAO_0000218
10504,Rattus norvegicus,1,A,,1,Oral bioavailability of compound in Sprague Dawley rats,50597,10116.0,,,CHEMBL622064,4216,,,,,N,Intermediate,BAO_0000218
10505,Rattus norvegicus,1,A,,1,Oral bioavailability of compound in rat,50597,10116.0,,,CHEMBL622065,17839,,,,,N,Intermediate,BAO_0000218
10506,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 2 mg/kg),50597,10116.0,,,CHEMBL622066,6570,,,,,N,Intermediate,BAO_0000218
10507,Rattus norvegicus,1,A,,1,Oral bioavailability of compound in rat was determined,50597,10116.0,,,CHEMBL622067,5334,,,,,N,Intermediate,BAO_0000218
10508,Rattus norvegicus,1,A,,1,Oral bioavailability of compound in rats,50597,10116.0,,,CHEMBL622068,6886,,,,,N,Intermediate,BAO_0000218
10509,Rattus norvegicus,1,A,,1,Oral bioavailability of compound was determined in rats,50597,10116.0,,,CHEMBL622069,5210,,,,,N,Intermediate,BAO_0000218
10510,Rattus norvegicus,1,A,,1,Oral bioavailability at a dose of 30 mg/kg in rats,50597,10116.0,,,CHEMBL624796,4170,,,,,N,Intermediate,BAO_0000218
10511,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 10 mg/kg),50597,10116.0,,,CHEMBL624797,6028,,,,,N,Intermediate,BAO_0000218
10512,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 10 mg/kg),50597,10116.0,,,CHEMBL623053,6028,,,,,N,Intermediate,BAO_0000218
10513,Rattus norvegicus,1,A,,1,Oral bioavailability evaluated in rat,50597,10116.0,,,CHEMBL623054,6078,,,,,N,Intermediate,BAO_0000218
10514,Rattus norvegicus,1,A,,1,Oral bioavailability in fasted rat,50597,10116.0,,,CHEMBL623055,6168,,,,,N,Intermediate,BAO_0000218
10515,Rattus norvegicus,1,A,,1,Oral bioavailability in fed rat,50597,10116.0,,,CHEMBL623056,6168,,,,,N,Intermediate,BAO_0000218
10516,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (mature male) (dose 30 mg/kg),50597,10116.0,,,CHEMBL623057,5160,,,,,N,Intermediate,BAO_0000218
10517,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623058,6057,,,,,N,Intermediate,BAO_0000218
10518,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,10116.0,,,CHEMBL623059,6535,,,,,N,Intermediate,BAO_0000218
10519,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after administration of 10 mg/kg po,50597,10116.0,,,CHEMBL623060,6535,,,,,N,Intermediate,BAO_0000218
10520,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623061,4194,,,,,N,Intermediate,BAO_0000218
10521,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623062,6230,,,,,N,Intermediate,BAO_0000218
10522,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623063,6619,,,,,N,Intermediate,BAO_0000218
10523,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623064,17607,,,,,N,Intermediate,BAO_0000218
10524,Rattus norvegicus,1,A,,1,Oral bioavailability in ratrs,50597,10116.0,,,CHEMBL623065,4942,,,,,N,Intermediate,BAO_0000218
10525,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623066,4942,,,,,N,Intermediate,BAO_0000218
10526,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623067,6646,,,,,N,Intermediate,BAO_0000218
10527,Rattus norvegicus,1,A,,1,Oral bioavailability in rats was determined; High,50597,10116.0,,,CHEMBL623068,5237,,,,,N,Intermediate,BAO_0000218
10528,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623069,6646,,,,,N,Intermediate,BAO_0000218
10529,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623070,4449,,,,,N,Intermediate,BAO_0000218
10530,Rattus norvegicus,1,A,,1,Oral bioavailability was calculated in rat,50597,10116.0,,,CHEMBL623071,6057,,,,,N,Intermediate,BAO_0000218
10531,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL623072,2552,,,,,N,Intermediate,BAO_0000218
10532,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL623073,5496,,,,,N,Intermediate,BAO_0000218
10533,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL623074,6484,,,,,N,Intermediate,BAO_0000218
10534,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL623075,6485,,,,,N,Intermediate,BAO_0000218
10535,Rattus norvegicus,1,A,,1,Oral bioavailability after i.v. administration,50597,10116.0,,,CHEMBL623076,6616,,,,,N,Intermediate,BAO_0000218
10536,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,10116.0,,,CHEMBL623077,4969,,,,,N,Intermediate,BAO_0000218
10537,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley),50597,10116.0,,,CHEMBL623078,5862,,,,,N,Intermediate,BAO_0000218
10538,Rattus norvegicus,1,A,,1,Oral bioavailability in Sprague-Dawley rats,50597,10116.0,,,CHEMBL623079,4514,,,,,N,Intermediate,BAO_0000218
10539,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,10116.0,,,CHEMBL623080,4514,,,,,N,Intermediate,BAO_0000218
10540,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,10116.0,,,CHEMBL623081,4514,,,,,N,Intermediate,BAO_0000218
10541,Rattus norvegicus,1,A,,1,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,50597,10116.0,,,CHEMBL623082,5546,,,,,N,Intermediate,BAO_0000218
10542,Rattus norvegicus,1,A,,1,Oral bioavailability in fasted rat,50597,10116.0,,,CHEMBL874400,6168,,,,,N,Intermediate,BAO_0000218
10543,Rattus norvegicus,1,A,,1,Oral bioavailability in fed rat,50597,10116.0,,,CHEMBL623083,6168,,,,,N,Intermediate,BAO_0000218
10544,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623084,3624,,,,,N,Intermediate,BAO_0000218
10545,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623085,5213,,,,,N,Intermediate,BAO_0000218
10546,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623086,5496,,,,,N,Intermediate,BAO_0000218
10547,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623087,5553,,,,,N,Intermediate,BAO_0000218
10548,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623088,5833,,,,,N,Intermediate,BAO_0000218
10549,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623089,5836,,,,,N,Intermediate,BAO_0000218
10550,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623090,5865,,,,,N,Intermediate,BAO_0000218
10551,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623091,5960,,,,,N,Intermediate,BAO_0000218
10552,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623092,6249,,,,,N,Intermediate,BAO_0000218
10553,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623093,6448,,,,,N,Intermediate,BAO_0000218
10554,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL874401,6453,,,,,N,Intermediate,BAO_0000218
10555,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623094,6640,,,,,N,Intermediate,BAO_0000218
10556,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL623095,17607,,,,,N,Intermediate,BAO_0000218
10557,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after peroral administration at 10 mg/kg,50597,10116.0,,,CHEMBL623096,5939,,,,,N,Intermediate,BAO_0000218
10558,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after peroral administration at 5 mg/kg,50597,10116.0,,,CHEMBL624913,5939,,,,,N,Intermediate,BAO_0000218
10559,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),50597,10116.0,,,CHEMBL624914,6281,,,,,N,Intermediate,BAO_0000218
10560,Rattus norvegicus,1,A,,1,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,50597,10116.0,,,CHEMBL624915,5874,,,,,N,Intermediate,BAO_0000218
10561,Rattus norvegicus,1,A,,1,Oral bioavailability in rat; Not measured,50597,10116.0,,,CHEMBL624916,5213,,,,,N,Intermediate,BAO_0000218
10562,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL624917,4964,,,,,N,Intermediate,BAO_0000218
10563,Rattus norvegicus,1,A,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,50597,10116.0,,,CHEMBL625157,11020,,,,,N,Intermediate,BAO_0000218
10564,Rattus norvegicus,1,A,,1,In vitro metabolic potential in rat liver microsomes,50597,10116.0,,,CHEMBL625158,6251,2107.0,,,Liver,N,Intermediate,BAO_0000218
10565,Rattus norvegicus,1,A,,1,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",50597,10116.0,,,CHEMBL625159,1568,,,,,N,Intermediate,BAO_0000218
10566,Rattus norvegicus,1,A,,1,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",50597,10116.0,,,CHEMBL625160,3032,,,,,N,Intermediate,BAO_0000218
10567,Rattus norvegicus,1,A,,1,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,50597,10116.0,,,CHEMBL625161,3748,,,,,N,Intermediate,BAO_0000218
10568,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL625162,401,,,,,N,Intermediate,BAO_0000218
10569,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL625163,6512,,,,,N,Intermediate,BAO_0000218
10570,Rattus norvegicus,1,A,,1,Oral bioavailability in rats at 10 mg/kg,50597,10116.0,,,CHEMBL625164,17617,,,,,N,Intermediate,BAO_0000218
10571,Rattus norvegicus,1,A,,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,10116.0,,,CHEMBL625165,6679,,,,,N,Intermediate,BAO_0000218
10572,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL625166,6742,,,,,N,Intermediate,BAO_0000218
10573,Rattus norvegicus,1,A,,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,50597,10116.0,,,CHEMBL625167,589,,,,,N,Intermediate,BAO_0000218
10574,Rattus norvegicus,1,A,,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,50597,10116.0,,,CHEMBL625168,589,,,,,N,Intermediate,BAO_0000218
10575,Rattus norvegicus,1,A,,1,Plasma clearance of the compound,50597,10116.0,,,CHEMBL625169,3185,,,,,N,Intermediate,BAO_0000218
10576,Rattus norvegicus,1,A,,1,Plasma clearance at 10 mg/kg in rat upon intravenous administration,50597,10116.0,,,CHEMBL626264,17596,,,,,N,Intermediate,BAO_0000218
10577,Rattus norvegicus,1,A,,1,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,50597,10116.0,,,CHEMBL626265,2713,,,,,N,Intermediate,BAO_0000218
10578,Rattus norvegicus,1,A,,1,The compound was tested for plasma clearance in rat,50597,10116.0,,,CHEMBL626266,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10579,Rattus norvegicus,1,A,,1,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,50597,10116.0,,,CHEMBL626267,12500,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10580,Rattus norvegicus,1,A,,1,Plasma concentration upon oral administration of 1 mg/Kg in rats,50597,10116.0,,,CHEMBL626268,2713,,,,,N,Intermediate,BAO_0000218
10581,Rattus norvegicus,1,A,,1,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,50597,10116.0,,,CHEMBL626269,1446,,,,,N,Intermediate,BAO_0000218
10582,Rattus norvegicus,1,A,,1,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,50597,10116.0,,,CHEMBL626270,6227,,,,,N,Intermediate,BAO_0000218
10583,Rattus norvegicus,1,A,,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,50597,10116.0,,,CHEMBL626271,4709,,,,,N,Intermediate,BAO_0000218
10584,Rattus norvegicus,1,A,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",50597,10116.0,,,CHEMBL626272,5510,,,,,N,Intermediate,BAO_0000218
10585,Rattus norvegicus,1,A,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,10116.0,,,CHEMBL626273,5510,,,,,N,Intermediate,BAO_0000218
10586,Rattus norvegicus,1,A,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,10116.0,,,CHEMBL875346,5510,,,,,N,Intermediate,BAO_0000218
10587,Rattus norvegicus,1,A,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",50597,10116.0,,,CHEMBL626274,5510,,,,,N,Intermediate,BAO_0000218
10588,Rattus norvegicus,1,A,,1,Compound was tested for protein binding in rat plasma,50597,10116.0,,,CHEMBL626275,4514,,,,,N,Intermediate,BAO_0000218
10589,Rattus norvegicus,1,A,,1,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,50597,10116.0,,,CHEMBL624646,2713,,,,,N,Intermediate,BAO_0000218
10590,Rattus norvegicus,1,A,,1,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,50597,10116.0,,,CHEMBL624647,2713,,,,,N,Intermediate,BAO_0000218
10591,Rattus norvegicus,1,A,,1,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,50597,10116.0,,,CHEMBL624648,5340,2107.0,,,Liver,N,Intermediate,BAO_0000218
10592,Rattus norvegicus,1,A,,1,Area under curve ratio was determined (po/iv) in rat,50597,10116.0,,,CHEMBL624649,12058,,,,,N,Intermediate,BAO_0000218
10593,Rattus norvegicus,1,A,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,50597,10116.0,,,CHEMBL624650,11195,,,,,N,Intermediate,BAO_0000218
10594,Rattus norvegicus,1,A,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,50597,10116.0,,,CHEMBL624651,11195,,,,,N,Intermediate,BAO_0000218
10595,Rattus norvegicus,1,A,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,50597,10116.0,,,CHEMBL624652,11195,,,,,N,Intermediate,BAO_0000218
10596,Rattus norvegicus,1,A,,1,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,50597,10116.0,,,CHEMBL624653,6495,,,,,N,Intermediate,BAO_0000218
10597,Rattus norvegicus,1,A,,1,Ratio of AUCbrain to AUCplasma,50597,10116.0,,,CHEMBL624654,6078,,,,,N,Intermediate,BAO_0000218
10598,Rattus norvegicus,1,A,,1,Ratio of brain to plasma,50597,10116.0,,,CHEMBL624655,5656,,,,,N,Intermediate,BAO_0000218
10599,Rattus norvegicus,1,A,,1,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,50597,10116.0,,,CHEMBL624656,4910,,,,,N,Intermediate,BAO_0000218
10600,Rattus norvegicus,1,A,,1,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,10116.0,,,CHEMBL624657,4910,,,,,N,Intermediate,BAO_0000218
10601,Rattus norvegicus,1,A,,1,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,10116.0,,,CHEMBL624658,4910,,,,,N,Intermediate,BAO_0000218
10602,Rattus norvegicus,1,A,,1,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,50597,10116.0,,,CHEMBL624659,10130,,,,,N,Intermediate,BAO_0000218
10603,Rattus norvegicus,1,A,,1,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,50597,10116.0,,,CHEMBL624660,10130,,,,,N,Intermediate,BAO_0000218
10604,Rattus norvegicus,1,A,,1,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,50597,10116.0,,,CHEMBL624661,10130,,,,,N,Intermediate,BAO_0000218
10605,Rattus norvegicus,1,A,,1,Steady state brain :blood ratio was determined,50597,10116.0,,,CHEMBL624662,5213,,,,,N,Intermediate,BAO_0000218
10606,Rattus norvegicus,1,A,,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL625199,4910,,,,,N,Intermediate,BAO_0000218
10607,Rattus norvegicus,1,A,,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,10116.0,,,CHEMBL625200,4910,,,,,N,Intermediate,BAO_0000218
10608,Rattus norvegicus,1,A,,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,10116.0,,,CHEMBL625201,4910,,,,,N,Intermediate,BAO_0000218
10609,Rattus norvegicus,1,A,,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,10116.0,,,CHEMBL625202,4910,,,,,N,Intermediate,BAO_0000218
10610,Rattus norvegicus,1,A,,1,Percentage recovery after 3h incubation with rat hapatocytes was determined,50597,10116.0,,,CHEMBL625203,2083,,,,,N,Intermediate,BAO_0000218
10611,Rattus norvegicus,1,A,,1,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,50597,10116.0,,,CHEMBL625204,2082,,,,,N,Intermediate,BAO_0000218
10612,Rattus norvegicus,1,A,,1,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,50597,10116.0,,,CHEMBL625205,2082,,,,,N,Intermediate,BAO_0000218
10613,Rattus norvegicus,1,A,,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,50597,10116.0,,,CHEMBL625206,6351,,,,,N,Intermediate,BAO_0000218
10614,,0,A,,1,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",22224,,,,CHEMBL625207,14583,,,,,U,Autocuration,BAO_0000019
10615,,0,A,,1,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,22224,,,,CHEMBL625208,14583,,,,,U,Autocuration,BAO_0000019
10616,Homo sapiens,1,A,Caco-2,1,In vivo absorption in Caco-2 cell line monolayers was determined,50587,9606.0,,,CHEMBL625209,4608,,495.0,,,N,Intermediate,BAO_0000218
10617,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625210,13668,,,,,U,Autocuration,BAO_0000100
10618,Rattus norvegicus,1,A,,1,Area under curve was determine after peroral administration at 10 mpk in Rat,50597,10116.0,,,CHEMBL625211,5669,,,,,N,Intermediate,BAO_0000218
10619,Macaca mulatta,1,A,,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,50797,9544.0,,,CHEMBL625212,5669,,,,,N,Intermediate,BAO_0000218
10620,Rattus norvegicus,1,A,,1,Area under curve was determine after peroral administration at 160 mpk in Rat,50597,10116.0,,,CHEMBL625213,5669,,,,,N,Intermediate,BAO_0000218
10621,Rattus norvegicus,1,A,,1,Area under curve was determine after peroral administration at 20 mpk in Rat,50597,10116.0,,,CHEMBL625214,5669,,,,,N,Intermediate,BAO_0000218
10622,Rattus norvegicus,1,A,,1,Area under curve was determine after peroral administration at 50 mpk in Rat,50597,10116.0,,,CHEMBL874542,5669,,,,,N,Intermediate,BAO_0000218
10623,,0,P,,1,Calculated partition coefficient (clogP) (AlogP),22229,,,,CHEMBL625215,6472,,,,,U,Autocuration,BAO_0000100
10624,,0,A,,1,Activated partial thromboplastin time measured,22224,,,,CHEMBL625216,15106,,,,,U,Autocuration,BAO_0000019
10625,,0,P,,1,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),22224,,,,CHEMBL625217,15207,,,,,U,Autocuration,BAO_0000100
10626,,0,P,,1,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),22224,,,,CHEMBL625218,15207,,,,,U,Autocuration,BAO_0000100
10627,Canis lupus familiaris,1,A,,1,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,50588,9615.0,,,CHEMBL622864,13941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10628,Rattus norvegicus,1,A,,1,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,50597,10116.0,,,CHEMBL622865,13941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10629,Rattus norvegicus,1,A,,1,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,50597,10116.0,,,CHEMBL622866,13941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10630,Canis lupus familiaris,1,A,,1,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,50588,9615.0,,,CHEMBL622867,13941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10631,Cavia porcellus,1,A,,1,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,50512,10141.0,,,CHEMBL876808,15240,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10632,,0,A,,1,AUC in brain,22224,,,,CHEMBL627725,10655,955.0,,,Brain,U,Autocuration,BAO_0000019
10633,,0,A,,1,AUC in serum,22224,,,,CHEMBL627726,10655,1977.0,,,Serum,U,Autocuration,BAO_0000019
10634,,0,A,,1,AUC was determined,22224,,,,CHEMBL627727,6504,1969.0,,,Plasma,U,Autocuration,BAO_0000019
10635,,0,A,,1,AUC of the compound.,22224,,,,CHEMBL627728,10615,1969.0,,,Plasma,U,Autocuration,BAO_0000019
10636,,0,A,,1,AUC value (0-4 hr),22224,,,,CHEMBL627729,10353,1969.0,,,Plasma,U,Autocuration,BAO_0000019
10637,,0,A,,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",22224,,,,CHEMBL627730,14907,1969.0,,,Plasma,U,Autocuration,BAO_0000019
10638,,0,A,,1,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,22224,,,,CHEMBL627731,14907,1969.0,,,Plasma,U,Autocuration,BAO_0000019
10639,,0,A,,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",22224,,,,CHEMBL627732,14907,1969.0,,,Plasma,U,Autocuration,BAO_0000019
10640,,0,A,,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",22224,,,,CHEMBL627733,14907,1969.0,,,Plasma,U,Autocuration,BAO_0000019
10641,Rattus norvegicus,1,A,,1,AUC(area under curve) was determined after intravenous administration in rats,50597,10116.0,,,CHEMBL627734,16359,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10642,Rattus norvegicus,1,A,,1,AUC(area under curve) was determined after oral administration in rats,50597,10116.0,,,CHEMBL627735,16359,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10643,Cavia porcellus,1,A,,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,50512,10141.0,,,CHEMBL627736,15240,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10644,Rattus norvegicus,1,A,,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,50597,10116.0,,,CHEMBL876809,15240,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10645,,0,A,,1,Area Under Curve after oral dosing of 100 uM/Kg,22224,,,,CHEMBL627737,15469,,,,,U,Autocuration,BAO_0000019
10646,,0,A,,1,Area Under Curve after oral dosing of 30 uM/Kg,22224,,,,CHEMBL627738,15469,,,,,U,Autocuration,BAO_0000019
10647,,0,A,,1,Area Under Curve was measured by ploting the graph between concentration verses time,22224,,,,CHEMBL627739,13520,,,,,U,Autocuration,BAO_0000019
10648,Canis lupus familiaris,1,A,,1,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,50588,9615.0,,,CHEMBL626143,17025,,,,,N,Intermediate,BAO_0000218
10649,Simiiformes,0,A,,1,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,22224,314293.0,,,CHEMBL626144,17025,,,,,U,Autocuration,BAO_0000218
10650,Oryctolagus cuniculus,1,A,,1,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,50592,9986.0,,,CHEMBL626145,17025,,,,,N,Intermediate,BAO_0000218
10651,Rattus norvegicus,1,A,,1,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,50597,10116.0,,,CHEMBL626146,17025,,,,,N,Intermediate,BAO_0000218
10652,Rattus norvegicus,1,A,,1,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,50597,10116.0,,,CHEMBL626147,12032,178.0,,,Blood,N,Intermediate,BAO_0000218
10653,,0,A,,1,Area under curve (AUC) was determined,22224,,,,CHEMBL626148,10291,,,,,U,Autocuration,BAO_0000019
10654,,0,A,,1,Area under curve (AUC) following ip administration at 1 mg/kg,22224,,,,CHEMBL626149,5767,,,,,U,Autocuration,BAO_0000218
10655,,0,A,,1,Area under curve (AUC) was determined; ND is Not determined,22224,,,,CHEMBL626150,1434,,,,,U,Autocuration,BAO_0000019
10656,Canis lupus familiaris,1,A,,1,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,50588,9615.0,,,CHEMBL626151,14925,,,,,N,Intermediate,BAO_0000218
10657,Canis lupus familiaris,1,A,,1,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,50588,9615.0,,,CHEMBL626152,14925,,,,,N,Intermediate,BAO_0000218
10658,Canis lupus familiaris,1,A,,1,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,50588,9615.0,,,CHEMBL626153,14925,,,,,N,Intermediate,BAO_0000218
10659,,0,A,,1,Area under curve (AUR) was determined,22224,,,,CHEMBL626154,1434,,,,,U,Autocuration,BAO_0000019
10660,,0,A,,1,Area under curve at 1 uM/dg administered intravenously,22224,,,,CHEMBL626155,11883,,,,,U,Autocuration,BAO_0000019
10661,,0,A,,1,Area under curve at 10 uM/dg administered perorally,22224,,,,CHEMBL626156,11883,,,,,U,Autocuration,BAO_0000019
10662,,0,A,,1,Area under curve at 2 uM/dg administered intravenously,22224,,,,CHEMBL626157,11883,,,,,U,Autocuration,BAO_0000019
10663,,0,A,,1,Area under curve at 20 uM/dg administered perorally,22224,,,,CHEMBL626158,11883,,,,,U,Autocuration,BAO_0000019
10664,Canis lupus familiaris,1,A,,1,Area under curve at a peroral dose of 3 mg/kg in dog,50588,9615.0,,,CHEMBL626159,15233,,,,,N,Intermediate,BAO_0000218
10665,Rattus norvegicus,1,A,,1,Area under curve at a peroral dose of 3 mg/kg in rat,50597,10116.0,,,CHEMBL626160,15233,,,,,N,Intermediate,BAO_0000218
10666,Canis lupus familiaris,1,A,,1,Area under curve at an iv dose of 1 mg/kg in dog,50588,9615.0,,,CHEMBL626161,15233,,,,,N,Intermediate,BAO_0000218
10667,Rattus norvegicus,1,A,,1,Area under curve at an iv dose of 1 mg/kg in rat,50597,10116.0,,,CHEMBL626162,15233,,,,,N,Intermediate,BAO_0000218
10668,,0,A,,1,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,22224,,,,CHEMBL626163,12978,,,,,U,Autocuration,BAO_0000019
10669,,0,A,,1,Area under curve gives the effective duration for the angiotensin II antagonist effect.,22224,,,,CHEMBL626164,12978,,,,,U,Autocuration,BAO_0000019
10670,Mus musculus,1,A,,1,Area under curve measured as conc vs time after intravenous administration to mice.,50594,10090.0,,,CHEMBL626165,11355,,,,,N,Intermediate,BAO_0000218
10671,Mus musculus,1,A,,1,Area under curve measured as conc vs time after peroral administration to mice.,50594,10090.0,,,CHEMBL626166,11355,,,,,N,Intermediate,BAO_0000218
10672,Canis lupus familiaris,1,A,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,9615.0,,,CHEMBL626167,12923,,,,,N,Intermediate,BAO_0000218
10673,Canis lupus familiaris,1,A,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,50588,9615.0,,,CHEMBL626168,12923,,,,,N,Intermediate,BAO_0000218
10674,Canis lupus familiaris,1,A,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,50588,9615.0,,,CHEMBL877463,12923,,,,,N,Intermediate,BAO_0000218
10675,Canis lupus familiaris,1,A,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,50588,9615.0,,,CHEMBL626169,12923,,,,,N,Intermediate,BAO_0000218
10676,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626170,17738,948.0,,,Heart,N,Intermediate,BAO_0000218
10677,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626171,17738,948.0,,,Heart,N,Intermediate,BAO_0000218
10678,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626172,17738,948.0,,,Heart,N,Intermediate,BAO_0000218
10679,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626173,17738,948.0,,,Heart,N,Intermediate,BAO_0000218
10680,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626174,17738,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10681,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626175,17738,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10682,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626176,17738,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10683,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL626177,17738,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10684,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622499,17738,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10685,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622500,17738,2107.0,,,Liver,N,Intermediate,BAO_0000218
10686,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622501,17738,2107.0,,,Liver,N,Intermediate,BAO_0000218
10687,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622502,17738,2107.0,,,Liver,N,Intermediate,BAO_0000218
10688,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL622503,17738,2107.0,,,Liver,N,Intermediate,BAO_0000218
10689,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL877614,17738,2107.0,,,Liver,N,Intermediate,BAO_0000218
10690,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL624839,17738,2048.0,,,Lung,N,Intermediate,BAO_0000218
10691,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL624840,17738,2048.0,,,Lung,N,Intermediate,BAO_0000218
10692,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL624841,17738,2048.0,,,Lung,N,Intermediate,BAO_0000218
10693,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL624842,17738,2048.0,,,Lung,N,Intermediate,BAO_0000218
10694,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL624843,17738,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
10695,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL624844,17738,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
10696,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL624845,17738,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
10697,Rattus norvegicus,1,A,,1,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,50597,10116.0,,,CHEMBL621904,17738,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
10698,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,50597,10116.0,,,CHEMBL621905,11195,178.0,,,Blood,N,Intermediate,BAO_0000218
10699,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,50597,10116.0,,,CHEMBL874382,11195,178.0,,,Blood,N,Intermediate,BAO_0000218
10700,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,50597,10116.0,,,CHEMBL621906,11195,178.0,,,Blood,N,Intermediate,BAO_0000218
10701,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,50597,10116.0,,,CHEMBL621907,11195,955.0,,,Brain,N,Intermediate,BAO_0000218
10702,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622096,11195,955.0,,,Brain,N,Intermediate,BAO_0000218
10703,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,50597,10116.0,,,CHEMBL622097,11195,955.0,,,Brain,N,Intermediate,BAO_0000218
10704,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,50597,10116.0,,,CHEMBL622098,11195,948.0,,,Heart,N,Intermediate,BAO_0000218
10705,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622099,11195,948.0,,,Heart,N,Intermediate,BAO_0000218
10706,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,50597,10116.0,,,CHEMBL622100,11195,948.0,,,Heart,N,Intermediate,BAO_0000218
10707,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,50597,10116.0,,,CHEMBL622101,11195,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10708,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622102,11195,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10709,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,50597,10116.0,,,CHEMBL622103,11195,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10710,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,50597,10116.0,,,CHEMBL622104,11195,2107.0,,,Liver,N,Intermediate,BAO_0000218
10711,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622105,11195,2107.0,,,Liver,N,Intermediate,BAO_0000218
10712,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,50597,10116.0,,,CHEMBL622106,11195,2107.0,,,Liver,N,Intermediate,BAO_0000218
10713,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,50597,10116.0,,,CHEMBL622107,11195,2048.0,,,Lung,N,Intermediate,BAO_0000218
10714,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622108,11195,2048.0,,,Lung,N,Intermediate,BAO_0000218
10715,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,50597,10116.0,,,CHEMBL622109,11195,2048.0,,,Lung,N,Intermediate,BAO_0000218
10716,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,50597,10116.0,,,CHEMBL622110,11195,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
10717,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622111,11195,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
10718,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,50597,10116.0,,,CHEMBL874383,11195,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
10719,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,50597,10116.0,,,CHEMBL622112,11195,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
10720,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622113,11195,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
10721,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,50597,10116.0,,,CHEMBL622114,11195,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
10722,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,50597,10116.0,,,CHEMBL622115,11195,2106.0,,,Spleen,N,Intermediate,BAO_0000218
10723,Rattus norvegicus,1,A,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,50597,10116.0,,,CHEMBL622116,11195,2106.0,,,Spleen,N,Intermediate,BAO_0000218
10724,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622117,6193,,,,,N,Intermediate,BAO_0000218
10725,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622118,6803,,,,,N,Intermediate,BAO_0000218
10726,Rattus norvegicus,1,A,,1,Oral bioavailability in rats at 6 mg/kg,50597,10116.0,,,CHEMBL622119,6647,,,,,N,Intermediate,BAO_0000218
10727,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 6 mg/kg),50597,10116.0,,,CHEMBL622120,6647,,,,,N,Intermediate,BAO_0000218
10728,Rattus norvegicus,1,A,,1,Oral bioavailability in rats at 6 mg/kg dose; Not tested,50597,10116.0,,,CHEMBL622121,6647,,,,,N,Intermediate,BAO_0000218
10729,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622122,6640,,,,,N,Intermediate,BAO_0000218
10730,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622123,6641,,,,,N,Intermediate,BAO_0000218
10731,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL622124,6641,,,,,N,Intermediate,BAO_0000218
10732,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL622125,6642,,,,,N,Intermediate,BAO_0000218
10733,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL622126,5472,,,,,N,Intermediate,BAO_0000218
10734,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,10116.0,,,CHEMBL620455,6141,,,,,N,Intermediate,BAO_0000218
10735,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL620456,4390,,,,,N,Intermediate,BAO_0000218
10736,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL620457,5472,,,,,N,Intermediate,BAO_0000218
10737,Rattus norvegicus,1,A,,1,Oral bioavailability was evaluated; Not tested,50597,10116.0,,,CHEMBL620458,5472,,,,,N,Intermediate,BAO_0000218
10738,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL620459,5438,,,,,N,Intermediate,BAO_0000218
10739,Rattus norvegicus,1,A,,1,Oral bioavailability in rat by oral dosing,50597,10116.0,,,CHEMBL620460,4883,,,,,N,Intermediate,BAO_0000218
10740,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,10116.0,,,CHEMBL620461,1908,,,,,N,Intermediate,BAO_0000218
10741,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley),50597,10116.0,,,CHEMBL620462,4853,,,,,N,Intermediate,BAO_0000218
10742,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,10116.0,,,CHEMBL620463,4853,,,,,N,Intermediate,BAO_0000218
10743,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,10116.0,,,CHEMBL620464,4853,,,,,N,Intermediate,BAO_0000218
10744,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,10116.0,,,CHEMBL620465,4853,,,,,N,Intermediate,BAO_0000218
10745,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),50597,10116.0,,,CHEMBL620466,4853,,,,,N,Intermediate,BAO_0000218
10746,Rattus norvegicus,1,A,,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,50597,10116.0,,,CHEMBL620467,4853,,,,,N,Intermediate,BAO_0000218
10747,Rattus norvegicus,1,A,,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,50597,10116.0,,,CHEMBL620468,4853,,,,,N,Intermediate,BAO_0000218
10748,Rattus norvegicus,1,A,,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,50597,10116.0,,,CHEMBL620469,12873,,,,,N,Intermediate,BAO_0000218
10749,Rattus norvegicus,1,A,,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,50597,10116.0,,,CHEMBL620470,12873,,,,,N,Intermediate,BAO_0000218
10750,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL620471,3169,,,,,N,Intermediate,BAO_0000218
10751,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL620472,6305,,,,,N,Intermediate,BAO_0000218
10752,Rattus norvegicus,1,A,,1,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,50597,10116.0,,,CHEMBL620473,4762,,,,,N,Intermediate,BAO_0000218
10753,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL620474,17847,,,,,N,Intermediate,BAO_0000218
10754,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),50597,10116.0,,,CHEMBL620475,6211,,,,,N,Intermediate,BAO_0000218
10755,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL620476,6011,,,,,N,Intermediate,BAO_0000218
10756,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL620477,6317,,,,,N,Intermediate,BAO_0000218
10757,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,50597,10116.0,,,CHEMBL620478,6644,,,,,N,Intermediate,BAO_0000218
10758,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,50597,10116.0,,,CHEMBL618768,6644,,,,,N,Intermediate,BAO_0000218
10759,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after oral administration at 13 mg/kg dose,50597,10116.0,,,CHEMBL618769,6644,,,,,N,Intermediate,BAO_0000218
10760,Rattus norvegicus,1,A,,1,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,50597,10116.0,,,CHEMBL618770,6644,,,,,N,Intermediate,BAO_0000218
10761,Rattus norvegicus,1,A,,1,Oral bioavailability (dose 20 mg/kg p.o.),50597,10116.0,,,CHEMBL618771,6113,,,,,N,Intermediate,BAO_0000218
10762,Rattus norvegicus,1,A,,1,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,50597,10116.0,,,CHEMBL618772,5937,,,,,N,Intermediate,BAO_0000218
10763,Rattus norvegicus,1,A,,1,Oral bioavailability in rat at 10 mg/kg of the compound,50597,10116.0,,,CHEMBL618773,5711,,,,,N,Intermediate,BAO_0000218
10764,Rattus norvegicus,1,A,,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,10116.0,,,CHEMBL875842,17717,,,,,N,Intermediate,BAO_0000218
10765,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 3 mg/kg i.v.),50597,10116.0,,,CHEMBL618774,17717,,,,,N,Intermediate,BAO_0000218
10766,Rattus norvegicus,1,A,,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,10116.0,,,CHEMBL618775,17717,,,,,N,Intermediate,BAO_0000218
10767,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,10116.0,,,CHEMBL618776,17717,,,,,N,Intermediate,BAO_0000218
10768,Rattus norvegicus,1,A,,1,Percent bioavailability (F) in rats after iv administration,50597,10116.0,,,CHEMBL618777,4722,,,,,N,Intermediate,BAO_0000218
10769,Rattus norvegicus,1,A,,1,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,50597,10116.0,,,CHEMBL618778,4722,,,,,N,Intermediate,BAO_0000218
10770,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 5 uM/kg p.o.),50597,10116.0,,,CHEMBL618779,4353,,,,,N,Intermediate,BAO_0000218
10771,Rattus norvegicus,1,A,,1,Oral bioavailability,50597,10116.0,,,CHEMBL618780,15662,,,,,N,Intermediate,BAO_0000218
10772,Rattus norvegicus,1,A,,1,Bioavailability in rat (dose 2 mg/kg p.o.),50597,10116.0,,,CHEMBL618781,4756,,,,,N,Intermediate,BAO_0000218
10773,Rattus norvegicus,1,A,,1,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,50597,10116.0,,,CHEMBL618782,4756,,,,,N,Intermediate,BAO_0000218
10774,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 20 mg/kg),50597,10116.0,,,CHEMBL618783,3436,,,,,N,Intermediate,BAO_0000218
10775,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL618784,17800,,,,,N,Intermediate,BAO_0000218
10776,Rattus norvegicus,1,A,,1,Percent oral bioavailability evaluated in rat,50597,10116.0,,,CHEMBL618785,15762,,,,,N,Intermediate,BAO_0000218
10777,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL618786,5089,,,,,N,Intermediate,BAO_0000218
10778,Rattus norvegicus,1,A,,1,Percent oral bioavailability in rat; Not determined,50597,10116.0,,,CHEMBL618787,5089,,,,,N,Intermediate,BAO_0000218
10779,Rattus norvegicus,1,A,,1,Oral bioavailability in rat,50597,10116.0,,,CHEMBL618788,3185,,,,,N,Intermediate,BAO_0000218
10780,Rattus norvegicus,1,A,,1,Bioavailability in rat,50597,10116.0,,,CHEMBL618789,5145,,,,,N,Intermediate,BAO_0000218
10781,Rattus norvegicus,1,A,,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),50597,10116.0,,,CHEMBL618790,3457,,,,,N,Intermediate,BAO_0000218
10782,Rattus norvegicus,1,A,,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),50597,10116.0,,,CHEMBL618791,3457,,,,,N,Intermediate,BAO_0000218
10783,Rattus norvegicus,1,A,,1,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,50597,10116.0,,,CHEMBL875843,5983,,,,,N,Intermediate,BAO_0000218
10784,Rattus norvegicus,1,A,,1,Oral bioavailability in rat (dose 20 mg/kg p.o.),50597,10116.0,,,CHEMBL618792,5739,,,,,N,Intermediate,BAO_0000218
10785,Rattus norvegicus,1,A,,1,Cmax at a dose of 30 mg/kg in rat,50597,10116.0,,,CHEMBL623395,3579,,,,,N,Intermediate,BAO_0000218
10786,Simiiformes,0,A,,1,Cmax in monkeys at a dose of 1 mg/kg,22224,314293.0,,,CHEMBL623396,17788,,,,,U,Autocuration,BAO_0000218
10787,Rattus norvegicus,1,A,,1,Cmax in rat,50597,10116.0,,,CHEMBL623397,14956,,,,,N,Intermediate,BAO_0000218
10788,Rattus norvegicus,1,A,,1,Cmax in rats at a dose of 1 mg/kg,50597,10116.0,,,CHEMBL623398,17788,,,,,N,Intermediate,BAO_0000218
10789,Mus musculus,1,A,,1,Cmax was measured in mice after an oral dose of 50 mg/kg.,50594,10090.0,,,CHEMBL623399,9750,,,,,N,Intermediate,BAO_0000218
10790,,0,A,,1,"Cmax value at a dose of 12.7 uM/kg, po",22224,,,,CHEMBL623400,12767,,,,,U,Autocuration,BAO_0000218
10791,,0,A,,1,"Cmax value at a dose of 6.3 uM/kg, iv",22224,,,,CHEMBL623401,12767,,,,,U,Autocuration,BAO_0000218
10792,,0,A,,1,"Cmax value at a dose of 7.1 uM/kg, iv",22224,,,,CHEMBL623402,12767,,,,,U,Autocuration,BAO_0000218
10793,,0,A,,1,Cmax value of compound was determined after 1 hr,22224,,,,CHEMBL623403,12703,,,,,U,Autocuration,BAO_0000218
10794,,0,A,,1,Cmax value of the compound,22224,,,,CHEMBL623404,15778,,,,,U,Autocuration,BAO_0000218
10795,Rattus norvegicus,1,A,,1,Cmax value administered intraintestinal in rats.,50597,10116.0,,,CHEMBL625997,12818,,,,,N,Intermediate,BAO_0000218
10796,Rattus norvegicus,1,A,,1,Cmax value administered perorally was determined in rat; Not determined,50597,10116.0,,,CHEMBL625998,14964,,,,,N,Intermediate,BAO_0000218
10797,,0,A,,1,Cmax value at the dose of 2.3 mg/kg,22224,,,,CHEMBL625999,15808,,,,,U,Autocuration,BAO_0000218
10798,,0,A,,1,Cmax value at the dose of 5 mg/kg,22224,,,,CHEMBL626000,15808,,,,,U,Autocuration,BAO_0000218
10799,,0,A,,1,Cmax value in the period of 8 hr after dosing. ,22224,,,,CHEMBL626001,15778,,,,,U,Autocuration,BAO_0000218
10800,,0,A,,1,Cmax value at a oral dose of 20 mg/kg; Not tested,22224,,,,CHEMBL626002,3715,,,,,U,Autocuration,BAO_0000218
10801,,0,A,,1,Cmax value at a oral dose of 20 mg/kg,22224,,,,CHEMBL626003,3715,,,,,U,Autocuration,BAO_0000218
10802,Rattus norvegicus,1,A,,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,10116.0,,,CHEMBL626004,1446,,,,,N,Intermediate,BAO_0000218
10803,Cavia porcellus,1,A,,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,50512,10141.0,,,CHEMBL626005,15240,,,,,N,Intermediate,BAO_0000218
10804,Rattus norvegicus,1,A,,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,50597,10116.0,,,CHEMBL626006,15240,,,,,N,Intermediate,BAO_0000218
10805,Rattus norvegicus,1,A,,1,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,50597,10116.0,,,CHEMBL626007,14810,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10806,Mus musculus,1,A,,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,10090.0,,,CHEMBL626008,14239,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10807,Canis lupus familiaris,1,A,,1,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,50588,9615.0,,,CHEMBL626009,12555,2107.0,,,Liver,N,Intermediate,BAO_0000218
10808,Canis lupus familiaris,1,A,,1,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,50588,9615.0,,,CHEMBL626010,10754,,,,,N,Intermediate,BAO_0000218
10809,Mus musculus,1,A,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,50594,10090.0,,,CHEMBL626011,10754,178.0,,,Blood,N,Intermediate,BAO_0000218
10810,Mus musculus,1,A,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,50594,10090.0,,,CHEMBL626012,10754,178.0,,,Blood,N,Intermediate,BAO_0000218
10811,Mus musculus,1,A,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,50594,10090.0,,,CHEMBL626013,10754,178.0,,,Blood,N,Intermediate,BAO_0000218
10812,Mus musculus,1,A,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,50594,10090.0,,,CHEMBL626014,10754,178.0,,,Blood,N,Intermediate,BAO_0000218
10813,Mus musculus,1,A,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,50594,10090.0,,,CHEMBL877496,10754,178.0,,,Blood,N,Intermediate,BAO_0000218
10814,Canis lupus familiaris,1,F,,1,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,50588,9615.0,,,CHEMBL626015,14600,,,,,N,Intermediate,BAO_0000218
10815,Canis lupus familiaris,1,F,,1,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,50588,9615.0,,,CHEMBL626016,14600,,,,,N,Intermediate,BAO_0000218
10816,Canis lupus familiaris,1,F,,1,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,50588,9615.0,,,CHEMBL626017,14600,,,,,N,Intermediate,BAO_0000218
10817,Canis lupus familiaris,1,A,,1,Bioavailability as maximal plasma concentration in dogs,50588,9615.0,,,CHEMBL626018,13543,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10818,Canis lupus familiaris,1,A,,1,Bioavailability as maximal plasma concentration in dogs,50588,9615.0,,,CHEMBL626692,13543,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10819,Rattus norvegicus,1,A,,1,Bioavailability as maximal plasma concentration in rats,50597,10116.0,,,CHEMBL626693,13543,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10820,Rattus norvegicus,0,A,,1,Bioavailability as maximal plasma concentration in rats,22224,10116.0,,,CHEMBL626694,13543,1969.0,,,Plasma,U,Autocuration,BAO_0000218
10821,Canis lupus familiaris,1,A,,1,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,9615.0,,,CHEMBL626695,14600,178.0,,,Blood,N,Intermediate,BAO_0000218
10822,Canis lupus familiaris,1,A,,1,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,9615.0,,,CHEMBL626696,14600,178.0,,,Blood,N,Intermediate,BAO_0000218
10823,Canis lupus familiaris,1,A,,1,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,9615.0,,,CHEMBL626697,14600,178.0,,,Blood,N,Intermediate,BAO_0000218
10824,Canis lupus familiaris,1,A,,1,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,50588,9615.0,,,CHEMBL626859,14600,178.0,,,Blood,N,Intermediate,BAO_0000218
10825,Canis lupus familiaris,1,A,,1,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,9615.0,,,CHEMBL626860,14600,178.0,,,Blood,N,Intermediate,BAO_0000218
10826,Canis lupus familiaris,1,A,,1,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,9615.0,,,CHEMBL626861,14600,178.0,,,Blood,N,Intermediate,BAO_0000218
10827,Rattus norvegicus,1,A,,1,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,10116.0,,,CHEMBL626296,14681,,,,,N,Intermediate,BAO_0000218
10828,,0,A,,1,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,22224,,,,CHEMBL626297,15905,,,,,U,Autocuration,BAO_0000218
10829,,0,A,,1,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,22224,,,,CHEMBL626298,15905,1969.0,,,Plasma,U,Autocuration,BAO_0000218
10830,Rattus norvegicus,1,A,,1,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",50597,10116.0,,,CHEMBL626299,13304,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10831,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,50597,10116.0,,,CHEMBL626300,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10832,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,50597,10116.0,,,CHEMBL626301,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10833,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,50597,10116.0,,,CHEMBL626962,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10834,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,50597,10116.0,,,CHEMBL626963,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10835,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,50597,10116.0,,,CHEMBL626964,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10836,Macaca fascicularis,1,A,,1,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,100710,9541.0,,,CHEMBL626965,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10837,Mus musculus,1,A,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,10090.0,,,CHEMBL626966,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10838,Mus musculus,1,A,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,10090.0,,,CHEMBL626967,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10839,Macaca fascicularis,1,A,,1,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,100710,9541.0,,,CHEMBL626968,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10840,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,50597,10116.0,,,CHEMBL626969,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10841,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,50597,10116.0,,,CHEMBL627126,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10842,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,50597,10116.0,,,CHEMBL631276,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10843,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,50597,10116.0,,,CHEMBL631277,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10844,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,50597,10116.0,,,CHEMBL631278,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10845,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,50597,10116.0,,,CHEMBL874457,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10846,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,50597,10116.0,,,CHEMBL631279,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10847,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,50597,10116.0,,,CHEMBL631280,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10848,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,50597,10116.0,,,CHEMBL631281,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10849,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,50597,10116.0,,,CHEMBL631968,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10850,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,50597,10116.0,,,CHEMBL631969,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10851,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,50597,10116.0,,,CHEMBL631970,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10852,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,50597,10116.0,,,CHEMBL631971,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10853,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,50597,10116.0,,,CHEMBL631972,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10854,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,50597,10116.0,,,CHEMBL630435,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10855,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,50597,10116.0,,,CHEMBL630436,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10856,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,50597,10116.0,,,CHEMBL630437,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10857,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,50597,10116.0,,,CHEMBL630438,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10858,Rattus norvegicus,1,A,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,50597,10116.0,,,CHEMBL630439,8418,948.0,,,Heart,N,Intermediate,BAO_0000218
10859,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,50597,10116.0,,,CHEMBL630440,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10860,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,50597,10116.0,,,CHEMBL630441,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10861,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,50597,10116.0,,,CHEMBL630442,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10862,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,50597,10116.0,,,CHEMBL625234,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10863,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,50597,10116.0,,,CHEMBL625235,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10864,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,50597,10116.0,,,CHEMBL625236,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10865,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,50597,10116.0,,,CHEMBL625237,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10866,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,50597,10116.0,,,CHEMBL626125,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10867,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,50597,10116.0,,,CHEMBL626126,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10868,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,50597,10116.0,,,CHEMBL626127,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10869,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,50597,10116.0,,,CHEMBL626128,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10870,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,50597,10116.0,,,CHEMBL626129,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10871,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,50597,10116.0,,,CHEMBL626130,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10872,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,50597,10116.0,,,CHEMBL626131,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10873,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,50597,10116.0,,,CHEMBL626132,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10874,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,50597,10116.0,,,CHEMBL626752,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10875,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,50597,10116.0,,,CHEMBL626753,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10876,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,50597,10116.0,,,CHEMBL626754,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10877,Rattus norvegicus,1,A,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,50597,10116.0,,,CHEMBL626755,8418,2113.0,,,Kidney,N,Intermediate,BAO_0000218
10878,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,50597,10116.0,,,CHEMBL626756,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
10879,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,50597,10116.0,,,CHEMBL626757,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
10880,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,50597,10116.0,,,CHEMBL626758,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
10881,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,50597,10116.0,,,CHEMBL626759,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
10882,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,50597,10116.0,,,CHEMBL626760,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
10883,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL626394,6996,,,,,N,Intermediate,BAO_0000218
10884,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,50588,9615.0,,,CHEMBL626395,6996,,,,,N,Intermediate,BAO_0000218
10885,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL626396,6996,,,,,N,Intermediate,BAO_0000218
10886,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL626397,6996,,,,,N,Intermediate,BAO_0000218
10887,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,9615.0,,,CHEMBL626398,6996,,,,,N,Intermediate,BAO_0000218
10888,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL626399,6996,,,,,N,Intermediate,BAO_0000218
10889,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,50597,10116.0,,,CHEMBL874653,6996,,,,,N,Intermediate,BAO_0000218
10890,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL626400,6996,,,,,N,Intermediate,BAO_0000218
10891,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL626401,6996,,,,,N,Intermediate,BAO_0000218
10892,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL626402,6996,,,,,N,Intermediate,BAO_0000218
10893,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL626403,6996,,,,,N,Intermediate,BAO_0000218
10894,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL626404,6996,,,,,N,Intermediate,BAO_0000218
10895,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,50597,10116.0,,,CHEMBL626405,6996,,,,,N,Intermediate,BAO_0000218
10896,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL625529,6996,,,,,N,Intermediate,BAO_0000218
10897,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL625530,6996,,,,,N,Intermediate,BAO_0000218
10898,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL625531,6996,,,,,N,Intermediate,BAO_0000218
10899,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL625532,6996,,,,,N,Intermediate,BAO_0000218
10900,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL625533,6996,,,,,N,Intermediate,BAO_0000218
10901,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,50597,10116.0,,,CHEMBL875474,6996,,,,,N,Intermediate,BAO_0000218
10902,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL625534,6996,,,,,N,Intermediate,BAO_0000218
10903,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL625535,6996,,,,,N,Intermediate,BAO_0000218
10904,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL625536,6996,,,,,N,Intermediate,BAO_0000218
10905,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL625537,6996,,,,,N,Intermediate,BAO_0000218
10906,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL625538,6996,,,,,N,Intermediate,BAO_0000218
10907,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,50597,10116.0,,,CHEMBL625539,6996,,,,,N,Intermediate,BAO_0000218
10908,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL625540,6996,,,,,N,Intermediate,BAO_0000218
10909,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL625541,6996,,,,,N,Intermediate,BAO_0000218
10910,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL625542,6996,,,,,N,Intermediate,BAO_0000218
10911,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL625543,6996,,,,,N,Intermediate,BAO_0000218
10912,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL625544,6996,,,,,N,Intermediate,BAO_0000218
10913,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,50588,9615.0,,,CHEMBL625545,6996,,,,,N,Intermediate,BAO_0000218
10914,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL625546,6996,,,,,N,Intermediate,BAO_0000218
10915,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,50588,9615.0,,,CHEMBL625547,6996,,,,,N,Intermediate,BAO_0000218
10916,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL625548,6996,,,,,N,Intermediate,BAO_0000218
10917,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL625549,6996,,,,,N,Intermediate,BAO_0000218
10918,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL625550,6996,,,,,N,Intermediate,BAO_0000218
10919,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL625551,6996,,,,,N,Intermediate,BAO_0000218
10920,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL875475,6996,,,,,N,Intermediate,BAO_0000218
10921,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL625552,6996,,,,,N,Intermediate,BAO_0000218
10922,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL625553,6996,,,,,N,Intermediate,BAO_0000218
10923,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL625554,6996,,,,,N,Intermediate,BAO_0000218
10924,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,9615.0,,,CHEMBL625555,6996,,,,,N,Intermediate,BAO_0000218
10925,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL625556,6996,,,,,N,Intermediate,BAO_0000218
10926,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,50588,9615.0,,,CHEMBL624986,6996,,,,,N,Intermediate,BAO_0000218
10927,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL624987,6996,,,,,N,Intermediate,BAO_0000218
10928,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL624988,6996,,,,,N,Intermediate,BAO_0000218
10929,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,50588,9615.0,,,CHEMBL624989,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10930,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,50588,9615.0,,,CHEMBL624990,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10931,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,50588,9615.0,,,CHEMBL874391,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10932,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,50588,9615.0,,,CHEMBL624991,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10933,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,50588,9615.0,,,CHEMBL624992,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10934,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,50588,9615.0,,,CHEMBL624993,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10935,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,50588,9615.0,,,CHEMBL624994,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10936,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,50588,9615.0,,,CHEMBL624995,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10937,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,50588,9615.0,,,CHEMBL624996,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10938,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,50588,9615.0,,,CHEMBL624997,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10939,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,50588,9615.0,,,CHEMBL624998,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10940,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,50588,9615.0,,,CHEMBL624999,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10941,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,50588,9615.0,,,CHEMBL882955,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10942,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,50588,9615.0,,,CHEMBL625000,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10943,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,50588,9615.0,,,CHEMBL625001,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10944,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,50588,9615.0,,,CHEMBL625089,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10945,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,50588,9615.0,,,CHEMBL625090,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10946,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,50588,9615.0,,,CHEMBL625091,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10947,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,50588,9615.0,,,CHEMBL625092,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10948,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,50588,9615.0,,,CHEMBL625093,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10949,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,50588,9615.0,,,CHEMBL625094,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10950,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,50588,9615.0,,,CHEMBL625095,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
10951,Canis lupus familiaris,1,A,,1,Compound was evaluated for its bioavailability in the dogs,50588,9615.0,,,CHEMBL625096,2249,,,,,N,Intermediate,BAO_0000218
10952,Rattus norvegicus,1,A,,1,Compound was evaluated for its bioavailability in the rats,50597,10116.0,,,CHEMBL625097,2249,,,,,N,Intermediate,BAO_0000218
10953,,0,A,,1,Compound was evaluated for oral bioavailability,22224,,,,CHEMBL882956,17515,,,,,U,Autocuration,BAO_0000218
10954,Rattus norvegicus,1,A,,1,Compound was evaluated for percentage of Oral bioavailability in rats,50597,10116.0,,,CHEMBL625098,14541,,,,,N,Intermediate,BAO_0000218
10955,Cavia porcellus,0,A,,1,Bioavailability in guinea pig,22224,10141.0,,,CHEMBL625099,12797,,,,,U,Autocuration,BAO_0000218
10956,Rattus norvegicus,1,A,,1,Compound was evaluated for the oral bioavailability in rat,50597,10116.0,,,CHEMBL625100,12797,,,,,N,Intermediate,BAO_0000218
10957,Canis lupus familiaris,1,A,,1,Compound was evaluated for the oral bioavailability in dog,50588,9615.0,,,CHEMBL625101,12797,,,,,N,Intermediate,BAO_0000218
10958,Rattus norvegicus,1,A,,1,Compound was evaluated for the oral bioavailability in rat,50597,10116.0,,,CHEMBL874396,12797,,,,,N,Intermediate,BAO_0000218
10959,Canis lupus familiaris,0,F,,1,Bioavailability in dog (dosed i.v.),22224,9615.0,,,CHEMBL625102,11727,,,,,U,Autocuration,BAO_0000218
10960,Canis lupus familiaris,1,A,,1,Compound was tested for in vivo bioavailability in dog,50588,9615.0,,,CHEMBL625103,13249,,,,,N,Intermediate,BAO_0000218
10961,Cricetinae,1,A,,1,Compound was tested for in vivo bioavailability in hamsters,100712,10026.0,,,CHEMBL625104,13249,,,,,N,Intermediate,BAO_0000218
10962,Simiiformes,0,A,,1,Compound was tested for in vivo bioavailability in monkey,22224,314293.0,,,CHEMBL625105,13249,,,,,U,Autocuration,BAO_0000218
10963,Rattus norvegicus,1,A,,1,Compound was tested for in vivo bioavailability in rat,50597,10116.0,,,CHEMBL625106,13249,,,,,N,Intermediate,BAO_0000218
10964,Mus musculus,0,A,,1,Oral bioavailability in mouse,22224,10090.0,,,CHEMBL625107,9552,,,,,U,Autocuration,BAO_0000218
10965,Mus musculus,1,A,,1,Compound was tested for percent of oral bioavailability in mice; 56-74,50594,10090.0,,,CHEMBL625108,9552,,,,,N,Intermediate,BAO_0000218
10966,Mus musculus,0,A,,1,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),22224,10090.0,,,CHEMBL625109,14839,,,,,U,Autocuration,BAO_0000218
10967,Macaca fascicularis,0,A,,1,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),22224,9541.0,,,CHEMBL625110,14839,,,,,U,Autocuration,BAO_0000218
10968,Macaca fascicularis,0,A,,1,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),22224,9541.0,,,CHEMBL625111,14839,,,,,U,Autocuration,BAO_0000218
10969,Mus musculus,1,A,,1,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),50594,10090.0,,,CHEMBL625112,14839,,,,,N,Intermediate,BAO_0000218
10970,Mus musculus,1,A,,1,Oral bioavailability in nude mice,50594,10090.0,,,CHEMBL875334,14839,,,,,N,Intermediate,BAO_0000218
10971,Primates,0,A,,1,Bioavailability in monkey (i.d. dosing),22224,9443.0,,,CHEMBL628617,11219,,,,,U,Autocuration,BAO_0000218
10972,Rattus norvegicus,0,A,,1,Bioavailability in rat,22224,10116.0,,,CHEMBL628618,9552,,,,,U,Autocuration,BAO_0000218
10973,,0,A,,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,22224,,,,CHEMBL628619,11732,,,,,U,Autocuration,BAO_0000218
10974,,0,A,,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,22224,,,,CHEMBL628620,11732,,,,,U,Autocuration,BAO_0000218
10975,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,9541.0,,,CHEMBL628621,14839,,,,,N,Intermediate,BAO_0000218
10976,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,9541.0,,,CHEMBL628622,14839,,,,,N,Intermediate,BAO_0000218
10977,Macaca fascicularis,1,A,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,9541.0,,,CHEMBL628623,14839,,,,,N,Intermediate,BAO_0000218
10978,Macaca fascicularis,1,A,,1,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,100710,9541.0,,,CHEMBL628624,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10979,Mus musculus,1,A,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,10090.0,,,CHEMBL628625,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10980,Macaca fascicularis,1,A,,1,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,100710,9541.0,,,CHEMBL628626,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10981,Mus musculus,1,A,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,10090.0,,,CHEMBL627041,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10982,Mus musculus,1,A,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,10090.0,,,CHEMBL627042,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10983,Mus musculus,1,A,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,10090.0,,,CHEMBL627043,14839,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10984,,0,A,,1,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,22224,,,,CHEMBL627044,13932,1969.0,,,Plasma,U,Autocuration,BAO_0000218
10985,Mus musculus,1,A,,1,Cmax in mouse plasma,50594,10090.0,,,CHEMBL627045,11637,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10986,,0,A,,1,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,22224,,,,CHEMBL627046,11637,1969.0,,,Plasma,U,Autocuration,BAO_0000218
10987,Rattus norvegicus,1,A,,1,Maximal plasma concentration in rat,50597,10116.0,,,CHEMBL627047,13960,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10988,Rattus norvegicus,1,A,,1,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,50597,10116.0,,,CHEMBL627048,15905,1969.0,,,Plasma,N,Intermediate,BAO_0000218
10989,Rattus norvegicus,1,A,,1,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,50597,10116.0,,,CHEMBL627049,14062,,,,,N,Intermediate,BAO_0000218
10990,Rattus norvegicus,1,A,,1,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,50597,10116.0,,,CHEMBL627050,14062,,,,,N,Intermediate,BAO_0000218
10991,Rattus norvegicus,1,A,,1,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,50597,10116.0,,,CHEMBL627051,14062,,,,,N,Intermediate,BAO_0000218
10992,Rattus norvegicus,1,A,,1,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,50597,10116.0,,,CHEMBL627052,14062,,,,,N,Intermediate,BAO_0000218
10993,Rattus norvegicus,1,A,,1,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,50597,10116.0,,,CHEMBL627053,14062,,,,,N,Intermediate,BAO_0000218
10994,Rattus norvegicus,1,A,,1,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,50597,10116.0,,,CHEMBL627054,14062,,,,,N,Intermediate,BAO_0000218
10995,Mus musculus,1,A,,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL627055,15011,,,,,N,Intermediate,BAO_0000218
10996,Mus musculus,1,A,,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL627056,15011,,,,,N,Intermediate,BAO_0000218
10997,Mus musculus,1,A,,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,10090.0,,,CHEMBL627057,15011,,,,,N,Intermediate,BAO_0000218
10998,Mus musculus,1,A,,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL627058,15011,,,,,N,Intermediate,BAO_0000218
10999,Mus musculus,1,A,,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,10090.0,,,CHEMBL626211,15011,,,,,N,Intermediate,BAO_0000218
11000,,0,A,,1,Maximum Concentration of the compound.,22224,,,,CHEMBL626212,10291,,,,,U,Autocuration,BAO_0000218
11001,Canis lupus familiaris,1,A,,1,Maximum Concentration was measured after iv administration into Beagle dog,50588,9615.0,,,CHEMBL626213,14599,,,,,N,Intermediate,BAO_0000218
11002,Canis lupus familiaris,1,A,,1,Maximum Concentration was measured after iv administration into Beagle dog.,50588,9615.0,,,CHEMBL626214,14599,,,,,N,Intermediate,BAO_0000218
11003,Canis lupus familiaris,1,A,,1,Maximum Concentration was measured after po administration into Beagle dog,50588,9615.0,,,CHEMBL626215,14599,,,,,N,Intermediate,BAO_0000218
11004,Canis lupus familiaris,1,A,,1,Maximum Concentration was measured after po administration into Beagle dog.,50588,9615.0,,,CHEMBL626216,14599,,,,,N,Intermediate,BAO_0000218
11005,,0,A,,1,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,22224,,,,CHEMBL626217,12767,178.0,,,Blood,U,Autocuration,BAO_0000218
11006,,0,A,,1,Maximum blood level reached after an iv dose of 12.2 uM/kg,22224,,,,CHEMBL626218,12767,178.0,,,Blood,U,Autocuration,BAO_0000218
11007,,0,A,,1,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,22224,,,,CHEMBL626219,12767,178.0,,,Blood,U,Autocuration,BAO_0000218
11008,,0,A,,1,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,22224,,,,CHEMBL626220,12767,178.0,,,Blood,U,Autocuration,BAO_0000218
11009,,0,A,,1,Maximum blood level reached after an oral dose of 5.0 mg/kg,22224,,,,CHEMBL626221,12767,178.0,,,Blood,U,Autocuration,BAO_0000218
11010,,0,A,,1,Maximum blood level reached at dose of 10.6 uM/kg orally,22224,,,,CHEMBL626222,12767,178.0,,,Blood,U,Autocuration,BAO_0000218
11011,Cavia porcellus,1,A,,1,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,50512,10141.0,,,CHEMBL626223,14706,,,,,N,Intermediate,BAO_0000218
11012,Cavia porcellus,1,A,,1,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,50512,10141.0,,,CHEMBL626224,14706,,,,,N,Intermediate,BAO_0000218
11013,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL626225,14793,955.0,,,Brain,N,Intermediate,BAO_0000218
11014,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL626226,14793,955.0,,,Brain,N,Intermediate,BAO_0000218
11015,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,50597,10116.0,,,CHEMBL626227,14793,955.0,,,Brain,N,Intermediate,BAO_0000218
11016,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL626228,14793,955.0,,,Brain,N,Intermediate,BAO_0000218
11017,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL626229,14793,,,,,N,Intermediate,BAO_0000218
11018,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL626921,14793,,,,,N,Intermediate,BAO_0000218
11019,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,50597,10116.0,,,CHEMBL876793,14793,,,,,N,Intermediate,BAO_0000218
11020,Rattus norvegicus,1,A,,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL625309,14793,,,,,N,Intermediate,BAO_0000218
11021,Bacillus subtilis,1,A,,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50278,1423.0,,,CHEMBL625310,10524,,,,,N,Intermediate,BAO_0000218
11022,Simiiformes,0,A,,1,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,22224,314293.0,,,CHEMBL625311,11871,,,,,U,Autocuration,BAO_0000218
11023,Rattus norvegicus,1,A,,1,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,50597,10116.0,,,CHEMBL625312,11871,,,,,N,Intermediate,BAO_0000218
11024,,0,A,,1,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,22224,,,,CHEMBL625313,3437,,,,,U,Autocuration,BAO_0000218
11025,Mus musculus,1,A,,1,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,50594,10090.0,,,CHEMBL625314,12038,,,,,N,Intermediate,BAO_0000218
11026,Rattus norvegicus,1,A,,1,Maximum concentration in male rats after iv administration of 20 mg/kg,50597,10116.0,,,CHEMBL625315,12038,,,,,N,Intermediate,BAO_0000218
11027,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,50597,10116.0,,,CHEMBL625316,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11028,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,50597,10116.0,,,CHEMBL625317,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11029,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,50597,10116.0,,,CHEMBL625318,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11030,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,50597,10116.0,,,CHEMBL625319,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11031,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,50597,10116.0,,,CHEMBL625320,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11032,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,50597,10116.0,,,CHEMBL625321,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11033,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,50597,10116.0,,,CHEMBL625322,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11034,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,50597,10116.0,,,CHEMBL876801,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11035,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,50597,10116.0,,,CHEMBL625323,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11036,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,50597,10116.0,,,CHEMBL625324,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11037,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,50597,10116.0,,,CHEMBL625325,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11038,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,50597,10116.0,,,CHEMBL625326,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11039,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,50597,10116.0,,,CHEMBL625327,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11040,Rattus norvegicus,1,A,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,50597,10116.0,,,CHEMBL625328,8418,2107.0,,,Liver,N,Intermediate,BAO_0000218
11041,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,50597,10116.0,,,CHEMBL625329,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11042,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,50597,10116.0,,,CHEMBL625330,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11043,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,50597,10116.0,,,CHEMBL627774,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11044,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,50597,10116.0,,,CHEMBL627775,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11045,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,50597,10116.0,,,CHEMBL627949,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11046,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,50597,10116.0,,,CHEMBL627950,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11047,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,50597,10116.0,,,CHEMBL627951,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11048,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,50597,10116.0,,,CHEMBL627952,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11049,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,50597,10116.0,,,CHEMBL627953,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11050,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,50597,10116.0,,,CHEMBL627954,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11051,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,50597,10116.0,,,CHEMBL627955,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11052,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,50597,10116.0,,,CHEMBL627956,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11053,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,50597,10116.0,,,CHEMBL876802,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11054,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,50597,10116.0,,,CHEMBL627957,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11055,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,50597,10116.0,,,CHEMBL627958,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11056,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,50597,10116.0,,,CHEMBL627959,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11057,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,50597,10116.0,,,CHEMBL627960,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11058,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,50597,10116.0,,,CHEMBL627961,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11059,Rattus norvegicus,1,A,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,50597,10116.0,,,CHEMBL627962,8418,2048.0,,,Lung,N,Intermediate,BAO_0000218
11060,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL627963,9796,,,,,N,Intermediate,BAO_0000218
11061,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624759,9796,,,,,N,Intermediate,BAO_0000218
11062,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624760,9796,,,,,N,Intermediate,BAO_0000218
11063,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624761,9796,,,,,N,Intermediate,BAO_0000218
11064,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL877607,9796,,,,,N,Intermediate,BAO_0000218
11065,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624762,9796,2107.0,,,Liver,N,Intermediate,BAO_0000218
11066,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624763,9796,2107.0,,,Liver,N,Intermediate,BAO_0000218
11067,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624764,9796,2107.0,,,Liver,N,Intermediate,BAO_0000218
11068,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624765,9796,2107.0,,,Liver,N,Intermediate,BAO_0000218
11069,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL624766,9796,2107.0,,,Liver,N,Intermediate,BAO_0000218
11070,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL624767,6996,,,,,N,Intermediate,BAO_0000218
11071,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,50588,9615.0,,,CHEMBL624768,6996,,,,,N,Intermediate,BAO_0000218
11072,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL624769,6996,,,,,N,Intermediate,BAO_0000218
11073,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL624770,6996,,,,,N,Intermediate,BAO_0000218
11074,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,9615.0,,,CHEMBL624771,6996,,,,,N,Intermediate,BAO_0000218
11075,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL624772,6996,,,,,N,Intermediate,BAO_0000218
11076,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,50597,10116.0,,,CHEMBL624773,6996,,,,,N,Intermediate,BAO_0000218
11077,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL624774,6996,,,,,N,Intermediate,BAO_0000218
11078,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL624775,6996,,,,,N,Intermediate,BAO_0000218
11079,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL624776,6996,,,,,N,Intermediate,BAO_0000218
11080,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL624777,6996,,,,,N,Intermediate,BAO_0000218
11081,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL624778,6996,,,,,N,Intermediate,BAO_0000218
11082,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,50597,10116.0,,,CHEMBL624779,6996,,,,,N,Intermediate,BAO_0000218
11083,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL624780,6996,,,,,N,Intermediate,BAO_0000218
11084,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL624781,6996,,,,,N,Intermediate,BAO_0000218
11085,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL877608,6996,,,,,N,Intermediate,BAO_0000218
11086,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL624782,6996,,,,,N,Intermediate,BAO_0000218
11087,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL624783,6996,,,,,N,Intermediate,BAO_0000218
11088,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,50597,10116.0,,,CHEMBL624784,6996,,,,,N,Intermediate,BAO_0000218
11089,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL624785,6996,,,,,N,Intermediate,BAO_0000218
11090,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL624786,6996,,,,,N,Intermediate,BAO_0000218
11091,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL624787,6996,,,,,N,Intermediate,BAO_0000218
11092,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL628676,6996,,,,,N,Intermediate,BAO_0000218
11093,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,50597,10116.0,,,CHEMBL621842,6996,,,,,N,Intermediate,BAO_0000218
11094,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL621843,6996,,,,,N,Intermediate,BAO_0000218
11095,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL623873,6996,,,,,N,Intermediate,BAO_0000218
11096,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL623874,6996,,,,,N,Intermediate,BAO_0000218
11097,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL623875,6996,,,,,N,Intermediate,BAO_0000218
11098,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL623876,6996,,,,,N,Intermediate,BAO_0000218
11099,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,50588,9615.0,,,CHEMBL623877,6996,,,,,N,Intermediate,BAO_0000218
11100,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL623878,6996,,,,,N,Intermediate,BAO_0000218
11101,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,50588,9615.0,,,CHEMBL623879,6996,,,,,N,Intermediate,BAO_0000218
11102,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL623880,6996,,,,,N,Intermediate,BAO_0000218
11103,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL623881,6996,,,,,N,Intermediate,BAO_0000218
11104,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL623957,6996,,,,,N,Intermediate,BAO_0000218
11105,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL623958,6996,,,,,N,Intermediate,BAO_0000218
11106,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL623959,6996,,,,,N,Intermediate,BAO_0000218
11107,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL623960,6996,,,,,N,Intermediate,BAO_0000218
11108,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL623961,6996,,,,,N,Intermediate,BAO_0000218
11109,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL623962,6996,,,,,N,Intermediate,BAO_0000218
11110,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,9615.0,,,CHEMBL624676,6996,,,,,N,Intermediate,BAO_0000218
11111,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL624677,6996,,,,,N,Intermediate,BAO_0000218
11112,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,50588,9615.0,,,CHEMBL624678,6996,,,,,N,Intermediate,BAO_0000218
11113,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL624679,6996,,,,,N,Intermediate,BAO_0000218
11114,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL624680,6996,,,,,N,Intermediate,BAO_0000218
11115,,0,A,,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,22224,,,,CHEMBL624849,11732,,,,,U,Autocuration,BAO_0000218
11116,,0,A,,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,22224,,,,CHEMBL624850,11732,,,,,U,Autocuration,BAO_0000218
11117,,0,A,,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,22224,,,,CHEMBL874399,11732,,,,,U,Autocuration,BAO_0000218
11118,,0,A,,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,22224,,,,CHEMBL624851,11732,,,,,U,Autocuration,BAO_0000218
11119,,0,A,,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,22224,,,,CHEMBL624852,11732,,,,,U,Autocuration,BAO_0000218
11120,Rattus norvegicus,0,A,,1,Oral bioavailability in rat (dose 10 mg/kg),22224,10116.0,,,CHEMBL624853,13359,,,,,U,Autocuration,BAO_0000218
11121,Rattus norvegicus,0,A,,1,Oral bioavailability in rat (Sprague-Dawley),22224,10116.0,,,CHEMBL624854,16618,,,,,U,Autocuration,BAO_0000218
11122,Rattus norvegicus,0,A,,1,Oral bioavailability in rat,22224,10116.0,,,CHEMBL624855,13960,,,,,U,Autocuration,BAO_0000218
11123,Rattus norvegicus,0,A,,1,Oral bioavailability in rats was determined in vivo,22224,10116.0,,,CHEMBL624856,13917,,,,,U,Autocuration,BAO_0000218
11124,Canis lupus familiaris,0,A,,1,Oral bioavailability in dog,22224,9615.0,,,CHEMBL882957,14266,,,,,U,Autocuration,BAO_0000218
11125,Simiiformes,0,A,,1,Oral bioavailability of compound in monkey,22224,314293.0,,,CHEMBL624857,12359,,,,,U,Autocuration,BAO_0000218
11126,Rattus norvegicus,1,A,,1,Oral bioavailability of compound in rat,50597,10116.0,,,CHEMBL622202,12359,,,,,N,Intermediate,BAO_0000218
11127,Rattus norvegicus,0,A,,1,Bioavailability in rat of PMEA prodrug,22224,10116.0,,,CHEMBL622203,12359,,,,,U,Autocuration,BAO_0000218
11128,Rattus norvegicus,1,A,,1,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,50597,10116.0,,,CHEMBL625522,12359,,,,,N,Intermediate,BAO_0000218
11129,Macaca mulatta,0,A,,1,Serum conc at 3 hours following 25 mg/kg dose,22224,9544.0,,,CHEMBL622868,10791,,,,,U,Autocuration,BAO_0000218
11130,Macaca mulatta,0,A,,1,Urine conc 0-5 hours following 25 mg/kg dose,22224,9544.0,,,CHEMBL622869,10791,1088.0,,,Urine,U,Autocuration,BAO_0000218
11131,Macaca mulatta,0,A,,1,Urine conc 0-24 hours following 25 mg/kg dose,22224,9544.0,,,CHEMBL622870,10791,1088.0,,,Urine,U,Autocuration,BAO_0000218
11132,Chlorocebus aethiops,0,A,,1,Oral bioavailability in African green monkeys; 20-25,22224,9534.0,,,CHEMBL622871,138,,,,,U,Autocuration,BAO_0000218
11133,Macaca fascicularis,1,A,,1,Oral bioavailability in cynomolgus monkey.,100710,9541.0,,,CHEMBL620560,14521,,,,,N,Intermediate,BAO_0000218
11134,Canis lupus familiaris,0,A,,1,Oral bioavailability in dog,22224,9615.0,,,CHEMBL620561,13953,,,,,U,Autocuration,BAO_0000218
11135,Canis lupus familiaris,1,A,,1,Oral bioavailability in dog at 10 mg/kg oral dose,50588,9615.0,,,CHEMBL620562,12836,,,,,N,Intermediate,BAO_0000218
11136,Cricetinae,1,A,,1,Oral bioavailability in hamster at 10 mg/kg oral dose,100712,10026.0,,,CHEMBL620563,12836,,,,,N,Intermediate,BAO_0000218
11137,Rattus norvegicus,1,A,,1,Oral bioavailability in rat at 10 mg/kg oral dose,50597,10116.0,,,CHEMBL620564,12836,,,,,N,Intermediate,BAO_0000218
11138,Rattus norvegicus,0,A,,1,Oral bioavailability in rat,22224,10116.0,,,CHEMBL872265,14521,,,,,U,Autocuration,BAO_0000218
11139,Rattus norvegicus,0,A,,1,Oral bioavailability in rat,22224,10116.0,,,CHEMBL620565,13953,,,,,U,Autocuration,BAO_0000218
11140,Eutheria,0,A,,1,Oral bioavailability,22224,9347.0,,,CHEMBL620566,6799,,,,,U,Autocuration,BAO_0000218
11141,,0,A,,1,Oral bioavailability was determined; range 49-102%,22224,,,,CHEMBL620567,11311,,,,,U,Autocuration,BAO_0000218
11142,Canis lupus familiaris,1,A,,1,Oral bioavailability was determined in dogs,50588,9615.0,,,CHEMBL620568,4013,,,,,N,Intermediate,BAO_0000218
11143,Rattus norvegicus,0,A,,1,Oral bioavailability in rat,22224,10116.0,,,CHEMBL620569,4013,,,,,U,Autocuration,BAO_0000218
11144,Eutheria,0,A,,1,Oral bioavailability,22224,9347.0,,,CHEMBL620570,17591,,,,,U,Autocuration,BAO_0000218
11145,,0,A,,1,Oral bioavailability was determined; Not orally available,22224,,,,CHEMBL620571,17591,,,,,U,Autocuration,BAO_0000218
11146,Mus musculus,1,A,,1,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),50594,10090.0,,,CHEMBL620572,15011,,,,,N,Intermediate,BAO_0000218
11147,Mus musculus,0,A,,1,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),22224,10090.0,,,CHEMBL620573,15011,,,,,U,Autocuration,BAO_0000218
11148,Mus musculus,0,A,,1,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,22224,10090.0,,,CHEMBL620574,15011,,,,,U,Autocuration,BAO_0000218
11149,Macaca mulatta,0,A,,1,Oral bioavailability in Rhesus monkey,22224,9544.0,,,CHEMBL620575,9552,,,,,U,Autocuration,BAO_0000218
11150,Canis lupus familiaris,0,A,,1,Oral bioavailability in dog (female mongrel),22224,9615.0,,,CHEMBL620576,9552,,,,,U,Autocuration,BAO_0000218
11151,,0,A,,1,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,22224,,,,CHEMBL875846,3639,,,,,U,Autocuration,BAO_0000218
11152,Canis lupus familiaris,0,A,,1,Oral bioavailability in dog,22224,9615.0,,,CHEMBL620577,13397,,,,,U,Autocuration,BAO_0000218
11153,,0,A,,1,Percentage Bioavailability was evaluated.,22224,,,,CHEMBL620578,3031,,,,,U,Autocuration,BAO_0000218
11154,Rattus norvegicus,0,A,,1,Bioavailability in rat administered i.d.,22224,10116.0,,,CHEMBL620579,12818,,,,,U,Autocuration,BAO_0000218
11155,Eutheria,0,A,,1,Bioavailability,22224,9347.0,,,CHEMBL621248,4847,,,,,U,Autocuration,BAO_0000218
11156,Canis lupus familiaris,0,A,,1,Bioavailability in dog (male Beagle) i.v. administration,22224,9615.0,,,CHEMBL625390,12421,,,,,U,Autocuration,BAO_0000218
11157,Rattus norvegicus,0,A,,1,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",22224,10116.0,,,CHEMBL625391,11966,,,,,U,Autocuration,BAO_0000218
11158,Primates,0,A,,1,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),22224,9443.0,,,CHEMBL872266,11218,,,,,U,Autocuration,BAO_0000218
11159,Rattus norvegicus,0,A,,1,Oral bioavailability in rat (Sprague-Dawley) (male),22224,10116.0,,,CHEMBL625392,13129,,,,,U,Autocuration,BAO_0000218
11160,Rattus norvegicus,1,A,,1,The oral bioavailability was measured on rats after oral administration,50597,10116.0,,,CHEMBL625393,12350,,,,,N,Intermediate,BAO_0000218
11161,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,10116.0,,,CHEMBL625394,2231,,,,,N,Intermediate,BAO_0000218
11162,Macaca mulatta,1,A,,1,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,9544.0,,,CHEMBL625395,2231,,,,,N,Intermediate,BAO_0000218
11163,Rattus norvegicus,0,A,,1,Bioavailability in rat (dose 10 mg/kg i.d.),22224,10116.0,,,CHEMBL625396,12187,,,,,U,Autocuration,BAO_0000218
11164,Canis lupus familiaris,0,A,,1,Bioavailability in dog (male Beagle) i.v. administration,22224,9615.0,,,CHEMBL625397,12421,,,,,U,Autocuration,BAO_0000218
11165,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625398,13256,,,,,N,Intermediate,BAO_0000218
11166,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625399,13256,178.0,,,Blood,N,Intermediate,BAO_0000218
11167,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL626074,13256,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11168,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL626075,13256,,,,,N,Intermediate,BAO_0000218
11169,Rattus norvegicus,1,A,,1,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,10116.0,,,CHEMBL626076,2231,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11170,Macaca mulatta,1,A,,1,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,9544.0,,,CHEMBL626077,2231,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11171,Rattus norvegicus,1,A,,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),50597,10116.0,,,CHEMBL626078,12178,178.0,,,Blood,N,Intermediate,BAO_0000218
11172,,0,A,,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),22224,,,,CHEMBL625846,12178,178.0,,,Blood,U,Autocuration,BAO_0000218
11173,,0,A,,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),22224,,,,CHEMBL625847,12178,178.0,,,Blood,U,Autocuration,BAO_0000218
11174,Rattus norvegicus,1,A,,1,Maximum concentration observed in rats at an oral dose of 50 mg/kg,50597,10116.0,,,CHEMBL625848,15633,,,,,N,Expert,BAO_0000218
11175,Rattus norvegicus,1,A,,1,Maximum concentration of compound in plasma administered orally to rats,50597,10116.0,,,CHEMBL625849,14258,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11176,Canis lupus familiaris,1,A,,1,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",50588,9615.0,,,CHEMBL626023,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11177,Canis lupus familiaris,1,A,,1,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",50588,9615.0,,,CHEMBL626024,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11178,Canis lupus familiaris,1,A,,1,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",50588,9615.0,,,CHEMBL626025,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11179,,0,A,,1,Maximum concentration after 10 mg/kg by oral administration,22224,,,,CHEMBL626026,5566,,,,,U,Autocuration,BAO_0000218
11180,,0,A,,1,Maximum concentration at a dose of 1.5 mg/kg,22224,,,,CHEMBL626027,16935,,,,,U,Autocuration,BAO_0000218
11181,,0,A,,1,Maximum concentration at a dose of 2.0 mg/kg,22224,,,,CHEMBL626028,16935,,,,,U,Autocuration,BAO_0000218
11182,Canis lupus familiaris,1,A,,1,Maximum concentration in dog plasma,50588,9615.0,,,CHEMBL626029,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11183,,0,A,,1,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,22224,,,,CHEMBL626030,12536,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11184,,0,A,,1,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,22224,,,,CHEMBL626031,12536,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11185,,0,A,,1,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,22224,,,,CHEMBL626032,12536,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11186,,0,A,,1,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,22224,,,,CHEMBL626033,12536,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11187,,0,A,,1,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,22224,,,,CHEMBL626034,12536,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11188,Canis lupus familiaris,1,A,,1,Maximum concentration in plasma after oral administration in dog (25 mg/kg),50588,9615.0,,,CHEMBL626035,9994,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11189,,0,A,,1,Maximum concentration in plasma at Tmax,22224,,,,CHEMBL626036,1434,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11190,Canis lupus familiaris,1,A,,1,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,50588,9615.0,,,CHEMBL626037,12836,1969.0,,,Plasma,N,Expert,BAO_0000218
11191,Cricetinae,1,A,,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,100712,10026.0,,,CHEMBL626038,12836,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11192,Rattus norvegicus,1,A,,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,50597,10116.0,,,CHEMBL626039,12836,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11193,Rattus norvegicus,1,A,,1,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,50597,10116.0,,,CHEMBL626040,12545,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11194,Oryctolagus cuniculus,1,A,,1,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,50592,9986.0,,,CHEMBL626041,13856,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11195,,0,A,,1,Maximum concentration was calculated,22224,,,,CHEMBL626042,3550,,,,,U,Autocuration,BAO_0000218
11196,,0,A,,1,Maximum concentration was calculated.,22224,,,,CHEMBL626043,2632,,,,,U,Autocuration,BAO_0000218
11197,,0,A,,1,Maximum concentration at a peroral dose of 10 mg/kg,22224,,,,CHEMBL626044,5566,,,,,U,Autocuration,BAO_0000218
11198,,0,A,,1,Maximum concentration of the drug at 10 uM/dg administered perorally,22224,,,,CHEMBL626045,11883,,,,,U,Autocuration,BAO_0000218
11199,,0,A,,1,Maximum concentration of the drug at 2 uM/dg administered intravenously,22224,,,,CHEMBL626046,11883,,,,,U,Autocuration,BAO_0000218
11200,Canis lupus familiaris,1,A,,1,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",50588,9615.0,,,CHEMBL626047,14122,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11201,Cricetinae,1,A,,1,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",100712,10026.0,,,CHEMBL626048,14122,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11202,Rattus norvegicus,1,A,,1,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",50597,10116.0,,,CHEMBL626049,14122,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11203,Rattus norvegicus,1,A,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,50597,10116.0,,,CHEMBL626050,12542,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11204,Canis lupus familiaris,1,A,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,50588,9615.0,,,CHEMBL874541,12542,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11205,Cricetinae,1,A,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,100712,10026.0,,,CHEMBL622826,12542,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11206,Cricetinae,1,A,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,100712,10026.0,,,CHEMBL622827,12542,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11207,Rattus norvegicus,1,A,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,50597,10116.0,,,CHEMBL622828,12542,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11208,Rattus norvegicus,1,A,,1,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,50597,10116.0,,,CHEMBL622829,14080,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11209,Rattus norvegicus,1,A,,1,Maximum concentration reached following intravenous administration in male rat,50597,10116.0,,,CHEMBL876806,11911,,,,,N,Intermediate,BAO_0000218
11210,Canis lupus familiaris,1,A,,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,50588,9615.0,,,CHEMBL622830,13204,,,,,N,Intermediate,BAO_0000218
11211,Rattus norvegicus,1,A,,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,50597,10116.0,,,CHEMBL622831,13204,,,,,N,Intermediate,BAO_0000218
11212,Canis lupus familiaris,1,A,,1,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,50588,9615.0,,,CHEMBL626794,14346,,,,,N,Intermediate,BAO_0000218
11213,Rattus norvegicus,1,A,,1,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL626795,14346,,,,,N,Intermediate,BAO_0000218
11214,Rattus norvegicus,1,A,,1,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL626796,14346,,,,,N,Intermediate,BAO_0000218
11215,Rattus norvegicus,1,A,,1,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL626797,14346,,,,,N,Intermediate,BAO_0000218
11216,Rattus norvegicus,1,A,,1,Maximum drug concentration is determined after oral dosing in rats.,50597,10116.0,,,CHEMBL626798,14127,,,,,N,Intermediate,BAO_0000218
11217,Canis lupus familiaris,1,A,,1,Maximum observed concentration in oral (5 mg/kg) fasted dogs,50588,9615.0,,,CHEMBL626799,14339,,,,,N,Intermediate,BAO_0000218
11218,Canis lupus familiaris,1,A,,1,Maximum observed concentration in oral (5 mg/kg) fed dogs,50588,9615.0,,,CHEMBL626800,14339,,,,,N,Intermediate,BAO_0000218
11219,,0,A,,1,Maximum plasma concentration,22224,,,,CHEMBL626801,13494,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11220,Rattus norvegicus,1,A,,1,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,50597,10116.0,,,CHEMBL876816,14925,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11221,Rattus norvegicus,1,A,,1,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,50597,10116.0,,,CHEMBL626802,14474,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11222,Canis lupus familiaris,1,A,,1,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,50588,9615.0,,,CHEMBL626803,14474,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11223,,0,A,,1,Maximum plasma concentration following oral administration of 30 umol/kg,22224,,,,CHEMBL626804,13917,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11224,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,50597,10116.0,,,CHEMBL626805,9796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11225,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626309,9796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11226,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626310,9796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11227,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626311,9796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11228,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626312,9796,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11229,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626313,9796,995.0,,,Uterus,N,Intermediate,BAO_0000218
11230,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626314,9796,995.0,,,Uterus,N,Intermediate,BAO_0000218
11231,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626315,9796,995.0,,,Uterus,N,Intermediate,BAO_0000218
11232,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626316,9796,995.0,,,Uterus,N,Intermediate,BAO_0000218
11233,Rattus norvegicus,1,A,,1,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,10116.0,,,CHEMBL626317,9796,995.0,,,Uterus,N,Intermediate,BAO_0000218
11234,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),50597,10116.0,,,CHEMBL626318,8363,,,,,N,Intermediate,BAO_0000218
11235,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),50597,10116.0,,,CHEMBL626319,8363,,,,,N,Intermediate,BAO_0000218
11236,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),50597,10116.0,,,CHEMBL626320,8363,,,,,N,Intermediate,BAO_0000218
11237,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),50597,10116.0,,,CHEMBL875053,8363,,,,,N,Intermediate,BAO_0000218
11238,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),50597,10116.0,,,CHEMBL626321,8363,,,,,N,Intermediate,BAO_0000218
11239,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),50597,10116.0,,,CHEMBL626322,8363,,,,,N,Intermediate,BAO_0000218
11240,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),50597,10116.0,,,CHEMBL626323,8363,,,,,N,Intermediate,BAO_0000218
11241,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),50597,10116.0,,,CHEMBL626324,8363,,,,,N,Intermediate,BAO_0000218
11242,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),50597,10116.0,,,CHEMBL626325,8363,,,,,N,Intermediate,BAO_0000218
11243,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),50597,10116.0,,,CHEMBL626326,8363,,,,,N,Intermediate,BAO_0000218
11244,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),50597,10116.0,,,CHEMBL626327,8363,,,,,N,Intermediate,BAO_0000218
11245,Rattus norvegicus,1,A,,1,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),50597,10116.0,,,CHEMBL626328,8363,,,,,N,Intermediate,BAO_0000218
11246,Rattus norvegicus,1,A,,1,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL626329,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11247,Rattus norvegicus,1,A,,1,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL626330,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11248,Rattus norvegicus,1,A,,1,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL626331,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11249,Rattus norvegicus,1,A,,1,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL626332,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11250,Rattus norvegicus,1,A,,1,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL626333,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11251,Rattus norvegicus,1,A,,1,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL626334,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11252,Rattus norvegicus,1,A,,1,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL626335,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11253,Rattus norvegicus,1,A,,1,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624798,8684,178.0,,,Blood,N,Intermediate,BAO_0000218
11254,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624799,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11255,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624800,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11256,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624801,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11257,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624802,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11258,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624803,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11259,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624804,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11260,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624805,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11261,Rattus norvegicus,1,A,,1,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",50597,10116.0,,,CHEMBL624806,8684,955.0,,,Brain,N,Intermediate,BAO_0000218
11262,Rattus norvegicus,1,A,,1,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624807,8684,,,,,N,Intermediate,BAO_0000218
11263,Rattus norvegicus,1,A,,1,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624808,8684,,,,,N,Intermediate,BAO_0000218
11264,Rattus norvegicus,1,A,,1,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624809,8684,,,,,N,Intermediate,BAO_0000218
11265,Rattus norvegicus,1,A,,1,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624810,8684,,,,,N,Intermediate,BAO_0000218
11266,Rattus norvegicus,1,A,,1,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL877618,8684,,,,,N,Intermediate,BAO_0000218
11267,Rattus norvegicus,1,A,,1,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624811,8684,,,,,N,Intermediate,BAO_0000218
11268,Rattus norvegicus,1,A,,1,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624812,8684,,,,,N,Intermediate,BAO_0000218
11269,Rattus norvegicus,1,A,,1,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624813,8684,,,,,N,Intermediate,BAO_0000218
11270,Rattus norvegicus,1,A,,1,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624814,8684,,,,,N,Intermediate,BAO_0000218
11271,Rattus norvegicus,1,A,,1,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624815,8684,,,,,N,Intermediate,BAO_0000218
11272,Rattus norvegicus,1,A,,1,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624816,8684,,,,,N,Intermediate,BAO_0000218
11273,Rattus norvegicus,1,A,,1,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624817,8684,,,,,N,Intermediate,BAO_0000218
11274,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL624818,6996,,,,,N,Intermediate,BAO_0000218
11275,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,50588,9615.0,,,CHEMBL624819,6996,,,,,N,Intermediate,BAO_0000218
11276,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL624820,6996,,,,,N,Intermediate,BAO_0000218
11277,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL624821,6996,,,,,N,Intermediate,BAO_0000218
11278,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,9615.0,,,CHEMBL624822,6996,,,,,N,Intermediate,BAO_0000218
11279,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL624823,6996,,,,,N,Intermediate,BAO_0000218
11280,Escherichia coli,1,A,,1,Observed diffusion coefficient in organic solvent for Escherichia coli,50212,562.0,,,CHEMBL624824,15599,,,,,N,Intermediate,BAO_0000218
11281,Rattus norvegicus,1,A,,1,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,10116.0,,,CHEMBL624825,9614,178.0,,,Blood,N,Intermediate,BAO_0000218
11282,Rattus norvegicus,1,A,,1,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,10116.0,,,CHEMBL624826,9614,178.0,,,Blood,N,Intermediate,BAO_0000218
11283,Rattus norvegicus,1,A,,1,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,10116.0,,,CHEMBL876817,9614,2081.0,,,Cardiac atrium,N,Intermediate,BAO_0000218
11284,Rattus norvegicus,1,A,,1,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,10116.0,,,CHEMBL624827,9614,2081.0,,,Cardiac atrium,N,Intermediate,BAO_0000218
11285,Rattus norvegicus,1,A,,1,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,10116.0,,,CHEMBL624828,9614,,,,,N,Intermediate,BAO_0000218
11286,Rattus norvegicus,1,A,,1,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,10116.0,,,CHEMBL624829,9614,,,,,N,Intermediate,BAO_0000218
11287,Rattus norvegicus,1,A,,1,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,10116.0,,,CHEMBL624830,9614,2107.0,,,Liver,N,Intermediate,BAO_0000218
11288,Rattus norvegicus,1,A,,1,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,10116.0,,,CHEMBL624831,9614,2107.0,,,Liver,N,Intermediate,BAO_0000218
11289,Rattus norvegicus,1,A,,1,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,10116.0,,,CHEMBL624832,9614,2081.0,,,Cardiac atrium,N,Intermediate,BAO_0000218
11290,Rattus norvegicus,1,A,,1,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,10116.0,,,CHEMBL624833,9614,2081.0,,,Cardiac atrium,N,Intermediate,BAO_0000218
11291,Rattus norvegicus,1,A,,1,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,10116.0,,,CHEMBL624834,9614,,,,,N,Intermediate,BAO_0000218
11292,Rattus norvegicus,1,A,,1,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,10116.0,,,CHEMBL624835,9614,,,,,N,Intermediate,BAO_0000218
11293,Rattus norvegicus,1,A,,1,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,10116.0,,,CHEMBL624836,9614,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11294,Rattus norvegicus,1,A,,1,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,10116.0,,,CHEMBL624837,9614,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11295,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,50597,10116.0,,,CHEMBL624838,9071,178.0,,,Blood,N,Intermediate,BAO_0000218
11296,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,50597,10116.0,,,CHEMBL622188,9071,178.0,,,Blood,N,Intermediate,BAO_0000218
11297,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,50597,10116.0,,,CHEMBL622189,9071,948.0,,,Heart,N,Intermediate,BAO_0000218
11298,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,50597,10116.0,,,CHEMBL622190,9071,948.0,,,Heart,N,Intermediate,BAO_0000218
11299,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,50597,10116.0,,,CHEMBL625170,9071,948.0,,,Heart,N,Intermediate,BAO_0000218
11300,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,50597,10116.0,,,CHEMBL625171,9071,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11301,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,50597,10116.0,,,CHEMBL625172,9071,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11302,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,50597,10116.0,,,CHEMBL625173,9071,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11303,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,50597,10116.0,,,CHEMBL625174,9071,2107.0,,,Liver,N,Intermediate,BAO_0000218
11304,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,50597,10116.0,,,CHEMBL625175,9071,2107.0,,,Liver,N,Intermediate,BAO_0000218
11305,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,50597,10116.0,,,CHEMBL625176,9071,2107.0,,,Liver,N,Intermediate,BAO_0000218
11306,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,50597,10116.0,,,CHEMBL625177,9071,2048.0,,,Lung,N,Intermediate,BAO_0000218
11307,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,50597,10116.0,,,CHEMBL625178,9071,2048.0,,,Lung,N,Intermediate,BAO_0000218
11308,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,50597,10116.0,,,CHEMBL625179,9071,2048.0,,,Lung,N,Intermediate,BAO_0000218
11309,Rattus norvegicus,1,A,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,50597,10116.0,,,CHEMBL625180,9071,2048.0,,,Lung,N,Intermediate,BAO_0000218
11310,,0,A,,1,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",22224,,,,CHEMBL625181,10677,,,,,U,Autocuration,BAO_0000218
11311,Mus musculus,1,A,,1,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,50594,10090.0,,,CHEMBL625182,9750,1088.0,,,Urine,N,Intermediate,BAO_0000218
11312,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL625183,8319,,,,,N,Intermediate,BAO_0000218
11313,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL875848,8319,,,,,N,Intermediate,BAO_0000218
11314,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL622260,8319,,,,,N,Intermediate,BAO_0000218
11315,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL622261,8319,,,,,N,Intermediate,BAO_0000218
11316,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL622262,8319,,,,,N,Intermediate,BAO_0000218
11317,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL622263,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11318,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL622418,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11319,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL622419,8319,2107.0,,,Liver,N,Intermediate,BAO_0000218
11320,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL623388,13256,,,,,N,Intermediate,BAO_0000218
11321,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL623389,13256,2107.0,,,Liver,N,Intermediate,BAO_0000218
11322,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL623390,13256,,,,,N,Intermediate,BAO_0000218
11323,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL623391,13256,,,,,N,Intermediate,BAO_0000218
11324,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL623392,13256,178.0,,,Blood,N,Intermediate,BAO_0000218
11325,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL623393,13256,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11326,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL623394,13256,,,,,N,Intermediate,BAO_0000218
11327,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL618885,13256,,,,,N,Intermediate,BAO_0000218
11328,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL618886,13256,2107.0,,,Liver,N,Intermediate,BAO_0000218
11329,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL618887,13256,,,,,N,Intermediate,BAO_0000218
11330,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL619535,13256,,,,,N,Intermediate,BAO_0000218
11331,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL619536,13256,178.0,,,Blood,N,Intermediate,BAO_0000218
11332,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL619537,13256,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11333,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL619705,13256,,,,,N,Intermediate,BAO_0000218
11334,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL619706,13256,,,,,N,Intermediate,BAO_0000218
11335,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL619707,13256,2107.0,,,Liver,N,Intermediate,BAO_0000218
11336,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL619708,13256,,,,,N,Intermediate,BAO_0000218
11337,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625219,13256,,,,,N,Intermediate,BAO_0000218
11338,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625220,13256,178.0,,,Blood,N,Intermediate,BAO_0000218
11339,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625221,13256,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11340,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625222,13256,,,,,N,Intermediate,BAO_0000218
11341,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625223,13256,,,,,N,Intermediate,BAO_0000218
11342,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625224,13256,2107.0,,,Liver,N,Intermediate,BAO_0000218
11343,Mus musculus,1,A,,1,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,10090.0,,,CHEMBL625225,13256,,,,,N,Intermediate,BAO_0000218
11344,Rattus norvegicus,1,A,,1,Biodistribution in Rat blood after 24 hours of iv administration,50597,10116.0,,,CHEMBL625226,8829,178.0,,,Blood,N,Intermediate,BAO_0000218
11345,Rattus norvegicus,1,A,,1,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,50597,10116.0,,,CHEMBL625227,8829,178.0,,,Blood,N,Intermediate,BAO_0000218
11346,Rattus norvegicus,1,A,,1,Biodistribution in Rat blood after 30 minutes of iv administration,50597,10116.0,,,CHEMBL625228,8829,178.0,,,Blood,N,Intermediate,BAO_0000218
11347,Rattus norvegicus,1,A,,1,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL875354,8829,178.0,,,Blood,N,Intermediate,BAO_0000218
11348,Rattus norvegicus,1,A,,1,Biodistribution in Rat blood after 5 minutes of iv administration,50597,10116.0,,,CHEMBL625229,8829,178.0,,,Blood,N,Intermediate,BAO_0000218
11349,Rattus norvegicus,1,A,,1,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL625230,8829,178.0,,,Blood,N,Intermediate,BAO_0000218
11350,Rattus norvegicus,1,A,,1,Biodistribution in Rat heart after 24 hours of iv administration,50597,10116.0,,,CHEMBL625231,8829,948.0,,,Heart,N,Intermediate,BAO_0000218
11351,Rattus norvegicus,1,A,,1,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,50597,10116.0,,,CHEMBL625900,8829,948.0,,,Heart,N,Intermediate,BAO_0000218
11352,Rattus norvegicus,1,A,,1,Biodistribution in Rat heart after 30 minutes of iv administration,50597,10116.0,,,CHEMBL625901,8829,948.0,,,Heart,N,Intermediate,BAO_0000218
11353,Rattus norvegicus,1,A,,1,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL625902,8829,948.0,,,Heart,N,Intermediate,BAO_0000218
11354,Rattus norvegicus,1,A,,1,Biodistribution in Rat heart after 5 minutes of iv administration,50597,10116.0,,,CHEMBL625903,8829,948.0,,,Heart,N,Intermediate,BAO_0000218
11355,Rattus norvegicus,1,A,,1,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL625904,8829,948.0,,,Heart,N,Intermediate,BAO_0000218
11356,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 24 hours of iv administration,50597,10116.0,,,CHEMBL625905,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11357,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,50597,10116.0,,,CHEMBL627861,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11358,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 30 minutes of iv administration,50597,10116.0,,,CHEMBL627862,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11359,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL627863,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11360,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 30 minutes of iv administration,50597,10116.0,,,CHEMBL627769,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11361,Canis lupus familiaris,1,A,,1,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,50588,9615.0,,,CHEMBL627770,13249,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11362,Macaca fascicularis,1,A,,1,Cmax in cynomolgus monkey (PO dose),100710,9541.0,,,CHEMBL627771,13622,,,,,N,Intermediate,BAO_0000218
11363,Rattus norvegicus,1,A,,1,Cmax in rat (PO dose),50597,10116.0,,,CHEMBL627772,13622,,,,,N,Intermediate,BAO_0000218
11364,Rattus norvegicus,1,A,,1,Cmax in rat (PO dose),50597,10116.0,,,CHEMBL627773,13622,,,,,N,Intermediate,BAO_0000218
11365,Rattus norvegicus,1,A,,1,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,50597,10116.0,,,CHEMBL621922,13494,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11366,Rattus norvegicus,1,A,,1,Cmax in rat plasma after oral dose (10 mg/kg),50597,10116.0,,,CHEMBL621923,12170,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11367,,0,A,,1,Cmax in plasma after oral dose (10 mg/kg),22224,,,,CHEMBL621924,12170,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11368,Canis lupus familiaris,1,A,,1,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,50588,9615.0,,,CHEMBL621925,17025,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11369,Simiiformes,0,A,,1,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,22224,314293.0,,,CHEMBL621926,17025,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11370,Oryctolagus cuniculus,1,A,,1,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,50592,9986.0,,,CHEMBL621927,17025,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11371,Rattus norvegicus,1,A,,1,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,50597,10116.0,,,CHEMBL621928,17025,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11372,Rattus norvegicus,1,A,,1,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,50597,10116.0,,,CHEMBL621929,14187,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11373,Mus musculus,1,A,,1,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,50594,10090.0,,,CHEMBL621930,14816,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11374,Rattus norvegicus,1,A,,1,Maximum plasma concentration after oral dosing in rat,50597,10116.0,,,CHEMBL621931,17820,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11375,,0,A,,1,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL621932,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11376,,0,A,,1,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL621933,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11377,Canis lupus familiaris,1,A,,1,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,50588,9615.0,,,CHEMBL621934,14691,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11378,Canis lupus familiaris,1,A,,1,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,50588,9615.0,,,CHEMBL621935,14691,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11379,Rattus norvegicus,1,A,,1,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,50597,10116.0,,,CHEMBL621936,13375,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11380,,0,A,,1,Maximum plasma concentration was determined,22224,,,,CHEMBL621937,6236,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11381,,0,A,,1,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,,CHEMBL621938,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11382,,0,A,,1,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,,CHEMBL621939,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11383,,0,A,,1,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,22224,,,,CHEMBL621940,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11384,,0,A,,1,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL621941,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11385,,0,A,,1,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL621942,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11386,,0,A,,1,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL626178,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11387,,0,A,,1,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL626179,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11388,,0,A,,1,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL626180,14380,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11389,Rattus norvegicus,1,A,,1,Plasma Cmax in rat (PO dose),50597,10116.0,,,CHEMBL626181,13622,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11390,Rattus norvegicus,1,A,,1,Maximum serum concentration after po dose of 5.22 mg/kg in rats,50597,10116.0,,,CHEMBL626182,15372,,,,,N,Intermediate,BAO_0000218
11391,Rattus norvegicus,1,A,,1,Maximum serum concentration after po dose of 5.46 mg/kg in rats,50597,10116.0,,,CHEMBL626183,15372,,,,,N,Intermediate,BAO_0000218
11392,Rattus norvegicus,1,A,,1,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,50597,10116.0,,,CHEMBL626184,15372,,,,,N,Intermediate,BAO_0000218
11393,Rattus norvegicus,1,A,,1,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,50597,10116.0,,,CHEMBL626185,15372,,,,,N,Intermediate,BAO_0000218
11394,Canis lupus familiaris,1,A,,1,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,50588,9615.0,,,CHEMBL626186,14925,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11395,Canis lupus familiaris,1,A,,1,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,50588,9615.0,,,CHEMBL877589,14925,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11396,,0,A,,1,Maximum concentration of the drug at 1 uM/dg administered intravenously,22224,,,,CHEMBL626187,11883,,,,,U,Autocuration,BAO_0000218
11397,,0,A,,1,Maximum concentration of the drug at 20 uM/dg administered perorally,22224,,,,CHEMBL626188,11883,,,,,U,Autocuration,BAO_0000218
11398,,0,A,,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,22224,,,,CHEMBL626189,13391,,,,,U,Autocuration,BAO_0000218
11399,,0,A,,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,,CHEMBL626855,13391,178.0,,,Blood,U,Autocuration,BAO_0000218
11400,,0,A,,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,22224,,,,CHEMBL623781,13391,178.0,,,Blood,U,Autocuration,BAO_0000218
11401,,0,A,,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,,CHEMBL623782,13391,178.0,,,Blood,U,Autocuration,BAO_0000218
11402,Rattus norvegicus,1,A,,1,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,50597,10116.0,,,CHEMBL623783,16360,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11403,Canis lupus familiaris,1,A,,1,Cmax in dog plasma after 1mg/kg oral dose,50588,9615.0,,,CHEMBL623784,3673,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11404,Canis lupus familiaris,1,A,,1,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,50588,9615.0,,,CHEMBL623785,14431,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11405,Rattus norvegicus,1,A,,1,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,50597,10116.0,,,CHEMBL623786,14431,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11406,Rattus norvegicus,1,A,,1,Oral maximum concentration in rat,50597,10116.0,,,CHEMBL623787,14964,,,,,N,Intermediate,BAO_0000218
11407,Rattus norvegicus,1,A,,1,Oral maximum concentration in rat,50597,10116.0,,,CHEMBL623788,14964,,,,,N,Intermediate,BAO_0000218
11408,Mus musculus,1,A,,1,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,50594,10090.0,,,CHEMBL623789,14209,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11409,Mus musculus,1,A,,1,Peak concentration in blood after intravenous administration to mice,50594,10090.0,,,CHEMBL623790,11355,178.0,,,Blood,N,Intermediate,BAO_0000218
11410,Mus musculus,1,A,,1,Peak concentration in blood after peroral administration to mice,50594,10090.0,,,CHEMBL623791,11355,178.0,,,Blood,N,Intermediate,BAO_0000218
11411,Rattus norvegicus,1,A,,1,Peak concentration in rat plasma was determined,50597,10116.0,,,CHEMBL623792,11966,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11412,Simiiformes,0,A,,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,22224,314293.0,,,CHEMBL623793,8918,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11413,Mus musculus,1,A,,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,50594,10090.0,,,CHEMBL623794,8918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11414,Rattus norvegicus,1,A,,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,50597,10116.0,,,CHEMBL623795,8918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11415,Rattus norvegicus,1,A,,1,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623796,8684,,,,,N,Intermediate,BAO_0000218
11416,Rattus norvegicus,1,A,,1,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623797,8684,,,,,N,Intermediate,BAO_0000218
11417,Rattus norvegicus,1,A,,1,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623798,8684,,,,,N,Intermediate,BAO_0000218
11418,Rattus norvegicus,1,A,,1,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623799,8684,,,,,N,Intermediate,BAO_0000218
11419,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624490,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11420,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624491,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11421,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624492,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11422,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624493,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11423,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL877595,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11424,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624494,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11425,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624495,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11426,Rattus norvegicus,1,A,,1,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624681,8684,160.0,,,Intestine,N,Intermediate,BAO_0000218
11427,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624682,8684,,,,,N,Intermediate,BAO_0000218
11428,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624683,8684,,,,,N,Intermediate,BAO_0000218
11429,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624684,8684,,,,,N,Intermediate,BAO_0000218
11430,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624685,8684,,,,,N,Intermediate,BAO_0000218
11431,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624686,8684,,,,,N,Intermediate,BAO_0000218
11432,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624687,8684,,,,,N,Intermediate,BAO_0000218
11433,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624688,8684,,,,,N,Intermediate,BAO_0000218
11434,Rattus norvegicus,1,A,,1,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL627161,8684,,,,,N,Intermediate,BAO_0000218
11435,Rattus norvegicus,1,A,,1,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL622127,8684,,,,,N,Intermediate,BAO_0000218
11436,Rattus norvegicus,1,A,,1,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL622128,8684,,,,,N,Intermediate,BAO_0000218
11437,Rattus norvegicus,1,A,,1,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL874384,8684,,,,,N,Intermediate,BAO_0000218
11438,Rattus norvegicus,1,A,,1,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624898,8684,,,,,N,Intermediate,BAO_0000218
11439,Rattus norvegicus,1,A,,1,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624899,8684,,,,,N,Intermediate,BAO_0000218
11440,Rattus norvegicus,1,A,,1,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624900,8684,,,,,N,Intermediate,BAO_0000218
11441,Rattus norvegicus,1,A,,1,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624901,8684,,,,,N,Intermediate,BAO_0000218
11442,Rattus norvegicus,1,A,,1,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624902,8684,,,,,N,Intermediate,BAO_0000218
11443,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624903,8684,,,,,N,Intermediate,BAO_0000218
11444,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624904,8684,,,,,N,Intermediate,BAO_0000218
11445,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624905,8684,,,,,N,Intermediate,BAO_0000218
11446,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624906,8684,,,,,N,Intermediate,BAO_0000218
11447,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624907,8684,,,,,N,Intermediate,BAO_0000218
11448,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624908,8684,,,,,N,Intermediate,BAO_0000218
11449,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624909,8684,,,,,N,Intermediate,BAO_0000218
11450,Rattus norvegicus,1,A,,1,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624910,8684,,,,,N,Intermediate,BAO_0000218
11451,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624911,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11452,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL874388,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11453,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL624912,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11454,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL622930,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11455,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623121,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11456,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623122,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11457,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623123,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11458,Rattus norvegicus,1,A,,1,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623124,8684,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11459,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623125,8684,,,,,N,Intermediate,BAO_0000218
11460,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623126,8684,,,,,N,Intermediate,BAO_0000218
11461,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623127,8684,,,,,N,Intermediate,BAO_0000218
11462,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623128,8684,,,,,N,Intermediate,BAO_0000218
11463,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623129,8684,,,,,N,Intermediate,BAO_0000218
11464,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623130,8684,,,,,N,Intermediate,BAO_0000218
11465,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623131,8684,,,,,N,Intermediate,BAO_0000218
11466,Rattus norvegicus,1,A,,1,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL623132,8684,,,,,N,Intermediate,BAO_0000218
11467,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL623133,8319,2107.0,,,Liver,N,Intermediate,BAO_0000218
11468,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL623134,8319,,,,,N,Intermediate,BAO_0000218
11469,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL874389,8319,,,,,N,Intermediate,BAO_0000218
11470,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL623135,8319,,,,,N,Intermediate,BAO_0000218
11471,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL623136,8319,,,,,N,Intermediate,BAO_0000218
11472,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL623137,8319,,,,,N,Intermediate,BAO_0000218
11473,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL623138,8319,,,,,N,Intermediate,BAO_0000218
11474,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL623139,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11475,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL623140,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11476,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL623141,8319,2107.0,,,Liver,N,Intermediate,BAO_0000218
11477,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL623142,8319,2107.0,,,Liver,N,Intermediate,BAO_0000218
11478,Rattus norvegicus,1,A,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL623143,8319,,,,,N,Intermediate,BAO_0000218
11479,Mus musculus,1,A,,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,50594,10090.0,,,CHEMBL623144,14571,1088.0,,,Urine,N,Intermediate,BAO_0000218
11480,Rattus norvegicus,1,A,,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,50597,10116.0,,,CHEMBL623405,14571,1088.0,,,Urine,N,Intermediate,BAO_0000218
11481,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624074,8319,,,,,N,Intermediate,BAO_0000218
11482,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624075,8319,,,,,N,Intermediate,BAO_0000218
11483,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624076,8319,,,,,N,Intermediate,BAO_0000218
11484,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624077,8319,,,,,N,Intermediate,BAO_0000218
11485,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624078,8319,,,,,N,Intermediate,BAO_0000218
11486,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624079,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11487,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624261,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11488,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624262,8319,,,,,N,Intermediate,BAO_0000218
11489,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624263,8319,,,,,N,Intermediate,BAO_0000218
11490,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624264,8319,,,,,N,Intermediate,BAO_0000218
11491,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624265,8319,,,,,N,Intermediate,BAO_0000218
11492,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624266,8319,,,,,N,Intermediate,BAO_0000218
11493,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624267,8319,,,,,N,Intermediate,BAO_0000218
11494,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624268,8319,,,,,N,Intermediate,BAO_0000218
11495,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL875227,8319,,,,,N,Intermediate,BAO_0000218
11496,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624269,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11497,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624270,8319,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11498,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,10116.0,,,CHEMBL624271,8319,,,,,N,Intermediate,BAO_0000218
11499,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624272,8319,,,,,N,Intermediate,BAO_0000218
11500,Rattus norvegicus,1,A,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,10116.0,,,CHEMBL624273,8319,,,,,N,Intermediate,BAO_0000218
11501,Rattus norvegicus,1,A,,1,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,50597,10116.0,,,CHEMBL624274,12064,1088.0,,,Urine,N,Intermediate,BAO_0000218
11502,Rattus norvegicus,1,A,,1,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,50597,10116.0,,,CHEMBL624275,12064,1088.0,,,Urine,N,Intermediate,BAO_0000218
11503,Rattus norvegicus,1,A,,1,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,50597,10116.0,,,CHEMBL624276,12064,1088.0,,,Urine,N,Intermediate,BAO_0000218
11504,Rattus norvegicus,1,A,,1,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,50597,10116.0,,,CHEMBL624277,12038,1088.0,,,Urine,N,Intermediate,BAO_0000218
11505,,0,A,,1,% dose converted to 2-amino-5-chlorophenyl sulfate,22224,,,,CHEMBL624278,14314,,,,,U,Autocuration,BAO_0000019
11506,,0,A,,1,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),22224,,,,CHEMBL624279,14314,,,,,U,Autocuration,BAO_0000019
11507,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",50597,10116.0,,,CHEMBL624280,11488,1988.0,,,Feces,N,Intermediate,BAO_0000218
11508,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",50597,10116.0,,,CHEMBL624281,11488,1988.0,,,Feces,N,Intermediate,BAO_0000218
11509,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",50597,10116.0,,,CHEMBL622933,11488,1988.0,,,Feces,N,Intermediate,BAO_0000218
11510,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",50597,10116.0,,,CHEMBL622934,11488,1988.0,,,Feces,N,Intermediate,BAO_0000218
11511,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL622935,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11512,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 5 minutes of iv administration,50597,10116.0,,,CHEMBL622936,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11513,Rattus norvegicus,1,A,,1,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL875228,8829,2107.0,,,Liver,N,Intermediate,BAO_0000218
11514,Rattus norvegicus,1,A,,1,Biodistribution in Rat lung after 24 hours of iv administration,50597,10116.0,,,CHEMBL622937,8829,2048.0,,,Lung,N,Intermediate,BAO_0000218
11515,Rattus norvegicus,1,A,,1,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,50597,10116.0,,,CHEMBL622938,8829,2048.0,,,Lung,N,Intermediate,BAO_0000218
11516,Rattus norvegicus,1,A,,1,Biodistribution in Rat lung after 30 minutes of iv administration,50597,10116.0,,,CHEMBL619736,8829,2048.0,,,Lung,N,Intermediate,BAO_0000218
11517,Rattus norvegicus,1,A,,1,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL625117,8829,2048.0,,,Lung,N,Intermediate,BAO_0000218
11518,Rattus norvegicus,1,A,,1,Biodistribution in Rat lung after 5 minutes of iv administration,50597,10116.0,,,CHEMBL625118,8829,2048.0,,,Lung,N,Intermediate,BAO_0000218
11519,Rattus norvegicus,1,A,,1,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,50597,10116.0,,,CHEMBL625119,8829,2048.0,,,Lung,N,Intermediate,BAO_0000218
11520,Rattus norvegicus,1,A,,1,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",50597,10116.0,,,CHEMBL625120,14972,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11521,Rattus norvegicus,1,A,,1,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",50597,10116.0,,,CHEMBL625121,14972,,,,,N,Intermediate,BAO_0000218
11522,Rattus norvegicus,1,A,,1,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",50597,10116.0,,,CHEMBL625122,14972,10000006.0,,,Thalamus,N,Intermediate,BAO_0000218
11523,Rattus norvegicus,1,A,,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL622204,14608,178.0,,,Blood,N,Intermediate,BAO_0000218
11524,Rattus norvegicus,1,A,,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL877503,14608,178.0,,,Blood,N,Intermediate,BAO_0000218
11525,Rattus norvegicus,1,A,,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL627127,14608,178.0,,,Blood,N,Intermediate,BAO_0000218
11526,,0,A,,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,22224,,,,CHEMBL627128,14608,10000000.0,,,Hippocampus,U,Autocuration,BAO_0000218
11527,,0,A,,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,22224,,,,CHEMBL627129,14608,10000000.0,,,Hippocampus,U,Autocuration,BAO_0000218
11528,,0,A,,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,22224,,,,CHEMBL627130,14608,10000000.0,,,Hippocampus,U,Autocuration,BAO_0000218
11529,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL627131,14608,955.0,,,Brain,N,Intermediate,BAO_0000218
11530,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL627132,14608,955.0,,,Brain,N,Intermediate,BAO_0000218
11531,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL627133,14608,955.0,,,Brain,N,Intermediate,BAO_0000218
11532,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL627134,14608,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11533,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL627135,14608,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11534,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL627136,14608,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
11535,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL628435,14608,,,,,N,Intermediate,BAO_0000218
11536,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL628436,14608,,,,,N,Intermediate,BAO_0000218
11537,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL628437,14608,,,,,N,Intermediate,BAO_0000218
11538,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL628438,14608,948.0,,,Heart,N,Intermediate,BAO_0000218
11539,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL628439,14608,948.0,,,Heart,N,Intermediate,BAO_0000218
11540,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL628440,14608,948.0,,,Heart,N,Intermediate,BAO_0000218
11541,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL628441,14608,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
11542,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL628442,14608,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
11543,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL628443,14608,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
11544,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL628444,14608,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11545,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL628445,14608,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11546,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL877504,14608,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11547,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL628446,14608,2107.0,,,Liver,N,Intermediate,BAO_0000218
11548,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL626874,14608,2107.0,,,Liver,N,Intermediate,BAO_0000218
11549,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL626875,14608,2107.0,,,Liver,N,Intermediate,BAO_0000218
11550,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL626876,14608,2048.0,,,Lung,N,Intermediate,BAO_0000218
11551,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL626877,14608,2048.0,,,Lung,N,Intermediate,BAO_0000218
11552,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL626878,14608,2048.0,,,Lung,N,Intermediate,BAO_0000218
11553,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL626879,14608,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11554,Simiiformes,0,A,,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,22224,314293.0,,,CHEMBL626880,8918,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11555,Mus musculus,1,A,,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,50594,10090.0,,,CHEMBL626881,8918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11556,Rattus norvegicus,1,A,,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,50597,10116.0,,,CHEMBL626882,8918,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11557,Canis lupus familiaris,1,A,,1,Peak plasma concentration was measured in dogs,50588,9615.0,,,CHEMBL626883,14470,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11558,Rattus norvegicus,1,A,,1,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,10116.0,,,CHEMBL626884,14393,,,,,N,Intermediate,BAO_0000218
11559,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,50597,10116.0,,,CHEMBL626885,14886,,,,,N,Intermediate,BAO_0000218
11560,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,50597,10116.0,,,CHEMBL626886,14886,,,,,N,Intermediate,BAO_0000218
11561,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,50597,10116.0,,,CHEMBL626887,14886,,,,,N,Intermediate,BAO_0000218
11562,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,10116.0,,,CHEMBL626888,14393,,,,,N,Intermediate,BAO_0000218
11563,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,50588,9615.0,,,CHEMBL626889,13465,,,,,N,Intermediate,BAO_0000218
11564,Simiiformes,0,A,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,22224,314293.0,,,CHEMBL626761,13465,,,,,U,Autocuration,BAO_0000218
11565,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,50588,9615.0,,,CHEMBL626762,13465,,,,,N,Intermediate,BAO_0000218
11566,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,50588,9615.0,,,CHEMBL626763,13465,,,,,N,Intermediate,BAO_0000218
11567,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,50597,10116.0,,,CHEMBL626764,13465,,,,,N,Intermediate,BAO_0000218
11568,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,50597,10116.0,,,CHEMBL626765,13465,,,,,N,Intermediate,BAO_0000218
11569,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,50588,9615.0,,,CHEMBL626766,13465,,,,,N,Intermediate,BAO_0000218
11570,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,50597,10116.0,,,CHEMBL626767,13465,,,,,N,Intermediate,BAO_0000218
11571,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,50597,10116.0,,,CHEMBL626768,13465,,,,,N,Intermediate,BAO_0000218
11572,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,50588,9615.0,,,CHEMBL626769,13465,,,,,N,Intermediate,BAO_0000218
11573,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,50588,9615.0,,,CHEMBL874463,13465,,,,,N,Intermediate,BAO_0000218
11574,Simiiformes,0,A,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,22224,314293.0,,,CHEMBL626770,13465,,,,,U,Autocuration,BAO_0000218
11575,Simiiformes,0,A,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,22224,314293.0,,,CHEMBL626771,13465,,,,,U,Autocuration,BAO_0000218
11576,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,50597,10116.0,,,CHEMBL626772,13465,,,,,N,Intermediate,BAO_0000218
11577,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,100710,9541.0,,,CHEMBL626773,14731,,,,,N,Intermediate,BAO_0000218
11578,Mus musculus,1,A,,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,50594,10090.0,,,CHEMBL626774,14731,,,,,N,Intermediate,BAO_0000218
11579,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,50588,9615.0,,,CHEMBL626775,13376,,,,,N,Intermediate,BAO_0000218
11580,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,50588,9615.0,,,CHEMBL626776,13376,,,,,N,Intermediate,BAO_0000218
11581,Rattus norvegicus,1,A,,1,Maximum concentration (Cmax) in rat when administered orally,50597,10116.0,,,CHEMBL626777,14443,,,,,N,Intermediate,BAO_0000218
11582,Simiiformes,0,A,,1,Maximal concentration in monkey plasma after 25 mg/kg oral dose,22224,314293.0,,,CHEMBL626778,13465,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11583,Rattus norvegicus,0,A,,1,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",22224,10116.0,,,CHEMBL626779,16359,,,,,U,Autocuration,BAO_0000218
11584,Rattus norvegicus,0,A,,1,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",22224,10116.0,,,CHEMBL626780,16359,,,,,U,Autocuration,BAO_0000218
11585,,0,A,,1,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,22224,,,,CHEMBL626781,15618,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11586,Rattus norvegicus,1,A,,1,Pharmacokinetic profile Cmax was evaluated in rats,50597,10116.0,,,CHEMBL632164,14554,,,,,N,Intermediate,BAO_0000218
11587,Canis lupus familiaris,1,A,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),50588,9615.0,,,CHEMBL632165,11537,,,,,N,Intermediate,BAO_0000218
11588,Mus musculus,1,A,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),50594,10090.0,,,CHEMBL632166,11537,,,,,N,Intermediate,BAO_0000218
11589,Canis lupus familiaris,1,A,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),50588,9615.0,,,CHEMBL632167,11537,,,,,N,Intermediate,BAO_0000218
11590,Mus musculus,1,A,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),50594,10090.0,,,CHEMBL632168,11537,,,,,N,Intermediate,BAO_0000218
11591,Rattus norvegicus,0,A,,1,Cmax in rat plasma,22224,10116.0,,,CHEMBL632169,2021,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11592,Canis lupus familiaris,1,A,,1,Cmax in dog plasma after 30mg/kg oral dose,50588,9615.0,,,CHEMBL632170,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11593,Rattus norvegicus,1,A,,1,Cmax in rat plasma after 30mg/kg oral dose,50597,10116.0,,,CHEMBL632171,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11594,Rattus norvegicus,1,A,,1,Plasma level in rats at 30 mg/kg,50597,10116.0,,,CHEMBL632172,17320,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11595,Mus musculus,1,A,,1,Tested for maximum plasma concentration in mice,50594,10090.0,,,CHEMBL632173,15831,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11596,Rattus norvegicus,1,A,,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL632174,15078,,,,,N,Intermediate,BAO_0000218
11597,Rattus norvegicus,1,A,,1,The Cmax values in female wistar rats.,50597,10116.0,,,CHEMBL632175,14941,,,,,N,Intermediate,BAO_0000218
11598,Canis lupus familiaris,1,A,,1,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,50588,9615.0,,,CHEMBL632176,15343,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11599,Rattus norvegicus,1,A,,1,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,50597,10116.0,,,CHEMBL632177,15343,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11600,Rattus norvegicus,1,A,,1,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,50597,10116.0,,,CHEMBL632178,14856,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11601,Rattus norvegicus,1,A,,1,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,50597,10116.0,,,CHEMBL632179,13129,,,,,N,Intermediate,BAO_0000218
11602,Rattus norvegicus,1,A,,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,50597,10116.0,,,CHEMBL632180,13098,178.0,,,Blood,N,Intermediate,BAO_0000218
11603,Rattus norvegicus,1,A,,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,50597,10116.0,,,CHEMBL632181,13098,178.0,,,Blood,N,Intermediate,BAO_0000218
11604,Rattus norvegicus,1,A,,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,50597,10116.0,,,CHEMBL632182,13098,178.0,,,Blood,N,Intermediate,BAO_0000218
11605,Mus musculus,0,A,,1,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,22224,10090.0,,,CHEMBL632183,15478,178.0,,,Blood,U,Autocuration,BAO_0000218
11606,Canis lupus familiaris,1,A,,1,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,50588,9615.0,,,CHEMBL632184,15341,,,,,N,Intermediate,BAO_0000218
11607,Rattus norvegicus,1,A,,1,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,50597,10116.0,,,CHEMBL874470,15341,,,,,N,Intermediate,BAO_0000218
11608,Rattus norvegicus,1,A,,1,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL631302,8684,,,,,N,Intermediate,BAO_0000218
11609,Rattus norvegicus,1,A,,1,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL631303,8684,,,,,N,Intermediate,BAO_0000218
11610,Rattus norvegicus,1,A,,1,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL631304,8684,,,,,N,Intermediate,BAO_0000218
11611,Rattus norvegicus,1,A,,1,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL631305,8684,,,,,N,Intermediate,BAO_0000218
11612,Rattus norvegicus,1,A,,1,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL631306,8684,,,,,N,Intermediate,BAO_0000218
11613,Rattus norvegicus,1,A,,1,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL631307,8684,,,,,N,Intermediate,BAO_0000218
11614,Rattus norvegicus,1,A,,1,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL631308,8684,,,,,N,Intermediate,BAO_0000218
11615,Rattus norvegicus,1,A,,1,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625557,8684,,,,,N,Intermediate,BAO_0000218
11616,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625558,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11617,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625559,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11618,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625560,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11619,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625561,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11620,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625562,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11621,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL875320,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11622,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625563,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11623,Rattus norvegicus,1,A,,1,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625564,8684,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11624,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625565,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11625,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625566,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11626,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625567,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11627,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL625568,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11628,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL628217,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11629,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL628218,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11630,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL628219,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11631,Rattus norvegicus,1,A,,1,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",50597,10116.0,,,CHEMBL628220,8684,995.0,,,Uterus,N,Intermediate,BAO_0000218
11632,,0,A,,1,Distribution in the blood after 120 min of intravenous administration,22224,,,,CHEMBL628221,8926,,,,,U,Autocuration,BAO_0000019
11633,,0,A,,1,Distribution in the blood after 15 min of intravenous administration,22224,,,,CHEMBL628222,8926,,,,,U,Autocuration,BAO_0000019
11634,,0,A,,1,Distribution in the blood after 30 min of intravenous administration,22224,,,,CHEMBL628223,8926,,,,,U,Autocuration,BAO_0000019
11635,,0,A,,1,Distribution in the blood after 5 min of intravenous administration,22224,,,,CHEMBL628224,8926,,,,,U,Autocuration,BAO_0000019
11636,,0,A,,1,Distribution in the blood after 60 min of intravenous administration,22224,,,,CHEMBL628225,8926,,,,,U,Autocuration,BAO_0000019
11637,,0,A,,1,Distribution in the blood after 90 min of intravenous administration,22224,,,,CHEMBL628226,8926,,,,,U,Autocuration,BAO_0000019
11638,,0,A,,1,Distribution in the bone after 120 min of intravenous administration,22224,,,,CHEMBL628227,8926,,,,,U,Autocuration,BAO_0000019
11639,,0,A,,1,Distribution in the bone after 15 min of intravenous administration,22224,,,,CHEMBL875481,8926,,,,,U,Autocuration,BAO_0000019
11640,,0,A,,1,Distribution in the bone after 30 min of intravenous administration,22224,,,,CHEMBL628228,8926,,,,,U,Autocuration,BAO_0000019
11641,,0,A,,1,Distribution in the bone after 5 min of intravenous administration,22224,,,,CHEMBL628229,8926,,,,,U,Autocuration,BAO_0000019
11642,,0,A,,1,Distribution in the bone after 60 min of intravenous administration,22224,,,,CHEMBL628230,8926,,,,,U,Autocuration,BAO_0000019
11643,,0,A,,1,Distribution in the bone after 90 min of intravenous administration,22224,,,,CHEMBL628231,8926,,,,,U,Autocuration,BAO_0000019
11644,,0,A,,1,Distribution in the heart after 120 min of intravenous administration,22224,,,,CHEMBL628232,8926,,,,,U,Autocuration,BAO_0000019
11645,,0,A,,1,Distribution in the heart after 15 min of intravenous administration,22224,,,,CHEMBL628233,8926,,,,,U,Autocuration,BAO_0000019
11646,,0,A,,1,Distribution in the heart after 30 min of intravenous administration,22224,,,,CHEMBL628234,8926,,,,,U,Autocuration,BAO_0000019
11647,,0,A,,1,Distribution in the heart after 5 min of intravenous administration,22224,,,,CHEMBL628235,8926,,,,,U,Autocuration,BAO_0000019
11648,,0,A,,1,Distribution in the heart after 60 min of intravenous administration,22224,,,,CHEMBL628236,8926,,,,,U,Autocuration,BAO_0000019
11649,,0,A,,1,Distribution in the heart after 90 min of intravenous administration,22224,,,,CHEMBL628237,8926,,,,,U,Autocuration,BAO_0000019
11650,,0,A,,1,Distribution in the kidneys after 120 min of intravenous administration,22224,,,,CHEMBL628238,8926,,,,,U,Autocuration,BAO_0000019
11651,,0,A,,1,Distribution in the kidneys after 15 min of intravenous administration,22224,,,,CHEMBL628239,8926,,,,,U,Autocuration,BAO_0000019
11652,,0,A,,1,Distribution in the kidneys after 30 min of intravenous administration,22224,,,,CHEMBL628240,8926,,,,,U,Autocuration,BAO_0000019
11653,,0,A,,1,Distribution in the kidneys after 5 min of intravenous administration,22224,,,,CHEMBL628241,8926,,,,,U,Autocuration,BAO_0000019
11654,,0,A,,1,Distribution in the kidneys after 60 min of intravenous administration,22224,,,,CHEMBL628242,8926,,,,,U,Autocuration,BAO_0000019
11655,,0,A,,1,Distribution in the kidneys after 90 min of intravenous administration,22224,,,,CHEMBL875482,8926,,,,,U,Autocuration,BAO_0000019
11656,,0,A,,1,Distribution in the liver after 120 min of intravenous administration,22224,,,,CHEMBL628243,8926,,,,,U,Autocuration,BAO_0000019
11657,,0,A,,1,Distribution in the liver after 15 min of intravenous administration,22224,,,,CHEMBL628244,8926,,,,,U,Autocuration,BAO_0000019
11658,,0,A,,1,Distribution in the liver after 30 min of intravenous administration,22224,,,,CHEMBL628245,8926,,,,,U,Autocuration,BAO_0000019
11659,,0,A,,1,Distribution in the liver after 5 min of intravenous administration,22224,,,,CHEMBL628246,8926,,,,,U,Autocuration,BAO_0000019
11660,,0,A,,1,Distribution in the liver after 60 min of intravenous administration,22224,,,,CHEMBL628247,8926,,,,,U,Autocuration,BAO_0000019
11661,,0,A,,1,Distribution in the liver after 90 min of intravenous administration,22224,,,,CHEMBL628248,8926,,,,,U,Autocuration,BAO_0000019
11662,,0,A,,1,Distribution in the lung after 120 min of intravenous administration,22224,,,,CHEMBL628249,8926,,,,,U,Autocuration,BAO_0000019
11663,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",50594,10090.0,,,CHEMBL625452,14839,,,,,N,Intermediate,BAO_0000218
11664,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",50594,10090.0,,,CHEMBL625453,14839,,,,,N,Intermediate,BAO_0000218
11665,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",50594,10090.0,,,CHEMBL625454,14839,,,,,N,Intermediate,BAO_0000218
11666,Mus musculus,1,A,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",50594,10090.0,,,CHEMBL623844,14839,,,,,N,Intermediate,BAO_0000218
11667,Rattus norvegicus,1,A,,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,50597,10116.0,,,CHEMBL623845,12178,,,,,N,Intermediate,BAO_0000218
11668,Rattus norvegicus,1,A,,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,50597,10116.0,,,CHEMBL623846,12178,,,,,N,Intermediate,BAO_0000218
11669,,0,A,,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,22224,,,,CHEMBL623847,12178,,,,,U,Autocuration,BAO_0000218
11670,Macaca fascicularis,1,A,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,9541.0,,,CHEMBL623848,12186,,,,,N,Intermediate,BAO_0000218
11671,Macaca fascicularis,1,A,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,100710,9541.0,,,CHEMBL623849,12186,,,,,N,Intermediate,BAO_0000218
11672,Macaca fascicularis,1,A,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,9541.0,,,CHEMBL623850,12186,,,,,N,Intermediate,BAO_0000218
11673,Macaca fascicularis,1,A,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,100710,9541.0,,,CHEMBL623851,12186,,,,,N,Intermediate,BAO_0000218
11674,Simiiformes,0,A,,1,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,22224,314293.0,,,CHEMBL623852,12187,,,,,U,Autocuration,BAO_0000218
11675,Mustela putorius furo,1,A,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,50506,9669.0,,,CHEMBL624551,12187,,,,,N,Intermediate,BAO_0000218
11676,Mustela putorius furo,1,A,,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",50506,9669.0,,,CHEMBL624552,12187,,,,,N,Intermediate,BAO_0000218
11677,Simiiformes,0,A,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,22224,314293.0,,,CHEMBL624553,12187,,,,,U,Autocuration,BAO_0000218
11678,Simiiformes,0,A,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,22224,314293.0,,,CHEMBL624554,12187,,,,,U,Autocuration,BAO_0000218
11679,Rattus norvegicus,1,A,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,50597,10116.0,,,CHEMBL624555,12187,,,,,N,Intermediate,BAO_0000218
11680,Rattus norvegicus,1,A,,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,10116.0,,,CHEMBL624741,12187,,,,,N,Intermediate,BAO_0000218
11681,Canis lupus familiaris,1,A,,1,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",50588,9615.0,,,CHEMBL624742,14122,,,,,N,Intermediate,BAO_0000218
11682,Cricetinae,1,A,,1,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",100712,10026.0,,,CHEMBL624743,14122,,,,,N,Intermediate,BAO_0000218
11683,Rattus norvegicus,1,A,,1,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",50597,10116.0,,,CHEMBL877606,14122,,,,,N,Intermediate,BAO_0000218
11684,,0,A,,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,22224,,,,CHEMBL624744,13391,,,,,U,Autocuration,BAO_0000218
11685,,0,A,,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,,CHEMBL624745,13391,178.0,,,Blood,U,Autocuration,BAO_0000218
11686,,0,A,,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,22224,,,,CHEMBL624746,13391,178.0,,,Blood,U,Autocuration,BAO_0000218
11687,,0,A,,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,,CHEMBL624747,13391,178.0,,,Blood,U,Autocuration,BAO_0000218
11688,,0,A,,1,Oral absorption expressed as Area under curve was determined,22224,,,,CHEMBL624748,16360,,,,,U,Autocuration,BAO_0000019
11689,Canis lupus familiaris,1,A,,1,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,50588,9615.0,,,CHEMBL622504,3673,,,,,N,Intermediate,BAO_0000218
11690,Canis lupus familiaris,1,A,,1,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",50588,9615.0,,,CHEMBL622505,14122,,,,,N,Intermediate,BAO_0000218
11691,Cricetinae,1,A,,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",100712,10026.0,,,CHEMBL622506,14122,,,,,N,Intermediate,BAO_0000218
11692,Cricetinae,1,A,,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",100712,10026.0,,,CHEMBL622507,14122,,,,,N,Intermediate,BAO_0000218
11693,Rattus norvegicus,1,A,,1,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",50597,10116.0,,,CHEMBL622508,14122,,,,,N,Intermediate,BAO_0000218
11694,,0,A,,1,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,22224,,,,CHEMBL622509,13889,,,,,U,Autocuration,BAO_0000019
11695,Rattus norvegicus,1,A,,1,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,10116.0,,,CHEMBL622510,14393,,,,,N,Intermediate,BAO_0000218
11696,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),50597,10116.0,,,CHEMBL622511,17279,,,,,N,Intermediate,BAO_0000218
11697,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,100710,9541.0,,,CHEMBL622512,14548,,,,,N,Intermediate,BAO_0000218
11698,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,100710,9541.0,,,CHEMBL622513,14548,,,,,N,Intermediate,BAO_0000218
11699,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,100710,9541.0,,,CHEMBL622514,14548,,,,,N,Intermediate,BAO_0000218
11700,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,50588,9615.0,,,CHEMBL622515,14548,,,,,N,Intermediate,BAO_0000218
11701,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,50588,9615.0,,,CHEMBL622516,14548,,,,,N,Intermediate,BAO_0000218
11702,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,50597,10116.0,,,CHEMBL622517,14548,,,,,N,Intermediate,BAO_0000218
11703,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,50597,10116.0,,,CHEMBL622518,14548,,,,,N,Intermediate,BAO_0000218
11704,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,50597,10116.0,,,CHEMBL622519,14548,,,,,N,Intermediate,BAO_0000218
11705,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL622520,14608,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11706,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL622521,14608,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11707,Mus musculus,1,A,,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,50594,10090.0,,,CHEMBL625113,14608,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
11708,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL625114,14608,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
11709,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL874397,14608,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
11710,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL625115,14608,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11711,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL625116,14608,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11712,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL623932,14608,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11713,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL623933,14608,2435.0,,,Striatum,N,Intermediate,BAO_0000218
11714,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL623934,14608,2435.0,,,Striatum,N,Intermediate,BAO_0000218
11715,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL623935,14608,2435.0,,,Striatum,N,Intermediate,BAO_0000218
11716,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,10116.0,,,CHEMBL623936,14608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
11717,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,10116.0,,,CHEMBL623937,14608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
11718,Rattus norvegicus,1,A,,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,10116.0,,,CHEMBL623938,14608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
11719,Mus musculus,1,A,,1,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL623939,15383,,,,,N,Intermediate,BAO_0000218
11720,Mus musculus,1,A,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,10090.0,,,CHEMBL623940,15383,,,,,N,Intermediate,BAO_0000218
11721,Mus musculus,1,A,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,10090.0,,,CHEMBL623941,15383,,,,,N,Intermediate,BAO_0000218
11722,Mus musculus,1,A,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL627216,15383,,,,,N,Intermediate,BAO_0000218
11723,Mus musculus,1,A,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL623942,15383,,,,,N,Intermediate,BAO_0000218
11724,Mus musculus,1,A,,1,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL618793,15383,955.0,,,Brain,N,Intermediate,BAO_0000218
11725,Mus musculus,1,A,,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL618794,15383,955.0,,,Brain,N,Intermediate,BAO_0000218
11726,Mus musculus,1,A,,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL618795,15383,955.0,,,Brain,N,Intermediate,BAO_0000218
11727,Mus musculus,1,A,,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL618796,15383,,,,,N,Intermediate,BAO_0000218
11728,Mus musculus,1,A,,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL618797,15383,,,,,N,Intermediate,BAO_0000218
11729,Mus musculus,1,A,,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,50594,10090.0,,,CHEMBL618798,15383,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11730,Mus musculus,1,A,,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL618799,15383,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11731,Mus musculus,1,A,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,10090.0,,,CHEMBL618800,15383,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11732,Mus musculus,1,A,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,10090.0,,,CHEMBL618801,15383,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11733,Mus musculus,1,A,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL618802,15383,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11734,Mus musculus,1,A,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL618803,15383,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11735,Mus musculus,1,A,,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,50594,10090.0,,,CHEMBL618804,15383,2107.0,,,Liver,N,Intermediate,BAO_0000218
11736,Mus musculus,1,A,,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL618805,15383,2107.0,,,Liver,N,Intermediate,BAO_0000218
11737,Mus musculus,1,A,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,10090.0,,,CHEMBL618806,15383,2107.0,,,Liver,N,Intermediate,BAO_0000218
11738,Mus musculus,1,A,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,10090.0,,,CHEMBL618807,15383,2107.0,,,Liver,N,Intermediate,BAO_0000218
11739,Mus musculus,1,A,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL618808,15383,2107.0,,,Liver,N,Intermediate,BAO_0000218
11740,Mus musculus,1,A,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL618809,15383,2107.0,,,Liver,N,Intermediate,BAO_0000218
11741,Mus musculus,1,A,,1,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL618810,15383,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11742,Mus musculus,1,A,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,10090.0,,,CHEMBL618811,15383,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11743,Mus musculus,1,A,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,10090.0,,,CHEMBL875844,15383,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11744,Mus musculus,1,A,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL618812,15383,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11745,Mus musculus,1,A,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL618813,15383,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11746,Mus musculus,1,A,,1,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL618814,15383,,,,,N,Intermediate,BAO_0000218
11747,Mus musculus,1,A,,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL618815,15383,,,,,N,Intermediate,BAO_0000218
11748,Mus musculus,1,A,,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL618816,15383,,,,,N,Intermediate,BAO_0000218
11749,Mus musculus,1,A,,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL618817,15383,,,,,N,Intermediate,BAO_0000218
11750,Mus musculus,1,A,,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL620544,15383,,,,,N,Intermediate,BAO_0000218
11751,Rattus norvegicus,1,A,,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,50597,10116.0,,,CHEMBL626230,15341,,,,,N,Intermediate,BAO_0000218
11752,Rattus norvegicus,1,A,,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,50597,10116.0,,,CHEMBL626231,15341,,,,,N,Intermediate,BAO_0000218
11753,Rattus norvegicus,1,A,,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,50597,10116.0,,,CHEMBL626232,15341,,,,,N,Intermediate,BAO_0000218
11754,Canis lupus familiaris,1,A,,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,50588,9615.0,,,CHEMBL626233,14906,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11755,Rattus norvegicus,1,A,,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,50597,10116.0,,,CHEMBL626234,14906,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11756,Rattus norvegicus,1,A,,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,50597,10116.0,,,CHEMBL875341,14906,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11757,Homo sapiens,1,A,,1,The maximum plasma concentration (100 mg/kg) administered orally in human,50587,9606.0,,,CHEMBL626235,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11758,Callithrix,0,A,,1,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,22224,9481.0,,,CHEMBL626236,14215,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11759,Simiiformes,0,A,,1,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,22224,314293.0,,,CHEMBL626237,14215,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11760,Canis lupus familiaris,1,A,,1,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,50588,9615.0,,,CHEMBL626238,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11761,Homo sapiens,1,A,,1,The maximum plasma concentration (200 mg/kg) administered orally in human,50587,9606.0,,,CHEMBL622412,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11762,Rattus norvegicus,1,A,,1,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,50597,10116.0,,,CHEMBL623114,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11763,Callithrix,0,A,,1,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,22224,9481.0,,,CHEMBL623115,14215,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11764,Simiiformes,0,A,,1,The maximum plasma concentration (25 mg/kg) administered orally in monkey,22224,314293.0,,,CHEMBL623116,14215,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11765,Canis lupus familiaris,0,A,,1,The maximum plasma concentration (30 mg/kg) administered orally in dog,22224,9615.0,,,CHEMBL623117,14215,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11766,Homo sapiens,1,A,,1,The maximum plasma concentration (400 mg/kg) administered orally in human,50587,9606.0,,,CHEMBL623118,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11767,Rattus norvegicus,1,A,,1,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,50597,10116.0,,,CHEMBL623119,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11768,Rattus norvegicus,1,A,,1,The maximum plasma concentration (50 mg/kg) administered orally in rat,50597,10116.0,,,CHEMBL623120,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11769,Homo sapiens,1,A,,1,The maximum plasma concentration (800 mg/kg) administered orally in human,50587,9606.0,,,CHEMBL623286,14215,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11770,Rattus norvegicus,1,A,,1,The maximum plasma concentration was measured on rats,50597,10116.0,,,CHEMBL623287,14067,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11771,Rattus norvegicus,1,A,,1,The maximum plasma concentration was measured on rats after oral administration,50597,10116.0,,,CHEMBL623288,12350,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11772,Rattus norvegicus,1,A,,1,Plasma drug Cmax in rat (PO dose),50597,10116.0,,,CHEMBL623289,14813,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11773,,0,A,,1,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,22224,,,,CHEMBL623290,12536,,,,,U,Autocuration,BAO_0000218
11774,Canis lupus familiaris,1,A,,1,maximum Plasma concentration in Dog was determined after Peroral administration,50588,9615.0,,,CHEMBL623291,14169,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11775,Rattus norvegicus,1,A,,1,maximum Plasma concentration in Rats was determined after Peroral administration,50597,10116.0,,,CHEMBL623292,14169,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11776,Canis lupus familiaris,1,A,,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,50588,9615.0,,,CHEMBL623293,15604,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11777,Simiiformes,0,A,,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,22224,314293.0,,,CHEMBL623294,15604,1969.0,,,Plasma,U,Autocuration,BAO_0000218
11778,Rattus norvegicus,1,A,,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,50597,10116.0,,,CHEMBL623295,15604,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11779,Mus musculus,1,A,,1,maximum concentration was measured when administered through oral route in mice,50594,10090.0,,,CHEMBL623296,14387,,,,,N,Intermediate,BAO_0000218
11780,Mus musculus,1,A,,1,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,50594,10090.0,,,CHEMBL875349,15115,,,,,N,Intermediate,BAO_0000218
11781,Simiiformes,0,A,,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,22224,314293.0,,,CHEMBL623297,15115,,,,,U,Autocuration,BAO_0000019
11782,Simiiformes,0,A,,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,22224,314293.0,,,CHEMBL623298,15115,,,,,U,Autocuration,BAO_0000019
11783,Simiiformes,0,A,,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,22224,314293.0,,,CHEMBL623299,15115,,,,,U,Autocuration,BAO_0000019
11784,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter was evaluated in rats,50597,10116.0,,,CHEMBL623300,16359,,,,,N,Intermediate,BAO_0000218
11785,Mus musculus,1,A,,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,50594,10090.0,,,CHEMBL623301,12829,,,,,N,Intermediate,BAO_0000218
11786,Mus musculus,1,A,,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,50594,10090.0,,,CHEMBL623302,12829,,,,,N,Intermediate,BAO_0000218
11787,Mus musculus,1,A,,1,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,50594,10090.0,,,CHEMBL623303,12829,,,,,N,Intermediate,BAO_0000218
11788,Mus musculus,1,A,,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,50594,10090.0,,,CHEMBL623304,12829,,,,,N,Intermediate,BAO_0000218
11789,Mus musculus,1,A,,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,50594,10090.0,,,CHEMBL623305,12829,,,,,N,Intermediate,BAO_0000218
11790,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,50597,10116.0,,,CHEMBL623306,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11791,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,50597,10116.0,,,CHEMBL623307,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11792,Rattus norvegicus,1,A,,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,50597,10116.0,,,CHEMBL623308,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11793,Mus musculus,1,A,,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,50594,10090.0,,,CHEMBL623309,15137,1969.0,,,Plasma,N,Intermediate,BAO_0000218
11794,Mus musculus,1,A,,1,Plasma Concentration after 120 min of oral administration to mice,50594,10090.0,,,CHEMBL623310,13509,,,,,N,Intermediate,BAO_0000218
11795,Mus musculus,1,A,,1,Plasma Concentration after 30 min of oral administration to mice,50594,10090.0,,,CHEMBL623311,13509,,,,,N,Intermediate,BAO_0000218
11796,Macaca fascicularis,1,A,,1,Plasma Concentration after 60 min of oral administration to mice,100710,9541.0,,,CHEMBL623312,13509,,,,,N,Intermediate,BAO_0000218
11797,Mus musculus,1,A,,1,Plasma Concentration after 60 min of oral administration to mice; Not determined,50594,10090.0,,,CHEMBL875350,13509,,,,,N,Intermediate,BAO_0000218
11798,Mus musculus,1,A,,1,Plasma Concentration after 90 min of oral administration to mice,50594,10090.0,,,CHEMBL628635,13509,,,,,N,Intermediate,BAO_0000218
11799,Rattus norvegicus,1,A,,1,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,50597,10116.0,,,CHEMBL628636,12064,,,,,N,Intermediate,BAO_0000218
11800,Rattus norvegicus,1,A,,1,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,50597,10116.0,,,CHEMBL628637,12064,,,,,N,Intermediate,BAO_0000218
11801,Rattus norvegicus,1,A,,1,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,50597,10116.0,,,CHEMBL628058,12064,,,,,N,Intermediate,BAO_0000218
11802,Rattus norvegicus,1,A,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,50597,10116.0,,,CHEMBL628059,10677,,,,,N,Intermediate,BAO_0000218
11803,Rattus norvegicus,1,A,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,50597,10116.0,,,CHEMBL628060,10677,,,,,N,Intermediate,BAO_0000218
11804,,0,A,,1,Distribution in the lung after 15 min of intravenous administration,22224,,,,CHEMBL628061,8926,,,,,U,Autocuration,BAO_0000019
11805,,0,A,,1,Distribution in the lung after 30 min of intravenous administration,22224,,,,CHEMBL628062,8926,,,,,U,Autocuration,BAO_0000019
11806,,0,A,,1,Distribution in the lung after 5 min of intravenous administration,22224,,,,CHEMBL628063,8926,,,,,U,Autocuration,BAO_0000019
11807,,0,A,,1,Distribution in the lung after 60 min of intravenous administration,22224,,,,CHEMBL628064,8926,,,,,U,Autocuration,BAO_0000019
11808,,0,A,,1,Distribution in the lung after 90 min of intravenous administration,22224,,,,CHEMBL628065,8926,,,,,U,Autocuration,BAO_0000019
11809,,0,A,,1,Distribution in the muscle after 120 min of intravenous administration,22224,,,,CHEMBL628066,8926,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000019
11810,,0,A,,1,Distribution in the muscle after 15 min of intravenous administration,22224,,,,CHEMBL628067,8926,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000019
11811,Mus musculus,1,A,,1,Distribution in the muscle after 30 min of intravenous administration,50594,10090.0,,,CHEMBL874646,8926,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11812,,0,A,,1,Distribution in the muscle after 5 min of intravenous administration,22224,,,,CHEMBL628068,8926,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000019
11813,,0,A,,1,Distribution in the muscle after 60 min of intravenous administration,22224,,,,CHEMBL628069,8926,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000019
11814,,0,A,,1,Distribution in the muscle after 90 min of intravenous administration,22224,,,,CHEMBL628070,8926,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000019
11815,,0,A,,1,Distribution in the spleen after 120 min of intravenous administration,22224,,,,CHEMBL628071,8926,2106.0,,,Spleen,U,Autocuration,BAO_0000019
11816,,0,A,,1,Distribution in the spleen after 15 min of intravenous administration,22224,,,,CHEMBL628072,8926,2106.0,,,Spleen,U,Autocuration,BAO_0000019
11817,,0,A,,1,Distribution in the spleen after 30 min of intravenous administration,22224,,,,CHEMBL628073,8926,2106.0,,,Spleen,U,Autocuration,BAO_0000019
11818,,0,A,,1,Distribution in the spleen after 5 min of intravenous administration,22224,,,,CHEMBL628074,8926,2106.0,,,Spleen,U,Autocuration,BAO_0000019
11819,,0,A,,1,Distribution in the spleen after 60 min of intravenous administration,22224,,,,CHEMBL628075,8926,2106.0,,,Spleen,U,Autocuration,BAO_0000019
11820,,0,A,,1,Distribution in the spleen after 90 min of intravenous administration,22224,,,,CHEMBL628076,8926,2106.0,,,Spleen,U,Autocuration,BAO_0000019
11821,Rattus norvegicus,1,A,,1,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,50597,10116.0,,,CHEMBL628077,7570,1235.0,,,Adrenal cortex,N,Intermediate,BAO_0000218
11822,Rattus norvegicus,1,A,,1,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,50597,10116.0,,,CHEMBL628078,7570,178.0,,,Blood,N,Intermediate,BAO_0000218
11823,Rattus norvegicus,1,A,,1,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,50597,10116.0,,,CHEMBL628079,7570,2107.0,,,Liver,N,Intermediate,BAO_0000218
11824,Rattus norvegicus,1,A,,1,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,50597,10116.0,,,CHEMBL628080,7570,992.0,,,Female gonad,N,Intermediate,BAO_0000218
11825,Rattus norvegicus,1,A,,1,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,50597,10116.0,,,CHEMBL628081,7570,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
11826,Rattus norvegicus,1,A,,1,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,50597,10116.0,,,CHEMBL628082,7570,1235.0,,,Adrenal cortex,N,Intermediate,BAO_0000218
11827,Rattus norvegicus,1,A,,1,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,50597,10116.0,,,CHEMBL874647,7570,178.0,,,Blood,N,Intermediate,BAO_0000218
11828,Rattus norvegicus,1,A,,1,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,50597,10116.0,,,CHEMBL626406,7570,2107.0,,,Liver,N,Intermediate,BAO_0000218
11829,Rattus norvegicus,1,A,,1,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,50597,10116.0,,,CHEMBL626407,7570,992.0,,,Female gonad,N,Intermediate,BAO_0000218
11830,Rattus norvegicus,1,A,,1,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,50597,10116.0,,,CHEMBL626408,7570,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
11831,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",50597,10116.0,,,CHEMBL626409,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11832,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",50597,10116.0,,,CHEMBL626410,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11833,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",50597,10116.0,,,CHEMBL626411,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11834,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",50597,10116.0,,,CHEMBL626412,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11835,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",50597,10116.0,,,CHEMBL626413,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11836,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",50597,10116.0,,,CHEMBL626414,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11837,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",50597,10116.0,,,CHEMBL626415,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11838,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",50597,10116.0,,,CHEMBL626416,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11839,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",50597,10116.0,,,CHEMBL627062,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11840,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",50597,10116.0,,,CHEMBL627063,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11841,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",50597,10116.0,,,CHEMBL627064,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11842,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",50597,10116.0,,,CHEMBL627227,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11843,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",50597,10116.0,,,CHEMBL627228,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11844,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",50597,10116.0,,,CHEMBL627229,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11845,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",50597,10116.0,,,CHEMBL625792,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11846,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",50597,10116.0,,,CHEMBL625793,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11847,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",50597,10116.0,,,CHEMBL625794,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11848,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",50597,10116.0,,,CHEMBL625795,8608,178.0,,,Blood,N,Intermediate,BAO_0000218
11849,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,50594,10090.0,,,CHEMBL625796,13792,,,,,N,Intermediate,BAO_0000218
11850,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,50588,9615.0,,,CHEMBL625797,13376,,,,,N,Intermediate,BAO_0000218
11851,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,50588,9615.0,,,CHEMBL625798,13376,,,,,N,Intermediate,BAO_0000218
11852,,0,A,,1,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,,CHEMBL875613,14380,,,,,U,Autocuration,BAO_0000218
11853,,0,A,,1,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,,CHEMBL625799,14380,,,,,U,Autocuration,BAO_0000218
11854,,0,A,,1,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,22224,,,,CHEMBL625800,14380,,,,,U,Autocuration,BAO_0000218
11855,,0,A,,1,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL625801,14380,,,,,U,Autocuration,BAO_0000218
11856,,0,A,,1,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL625802,14380,,,,,U,Autocuration,BAO_0000218
11857,,0,A,,1,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL625803,14380,,,,,U,Autocuration,BAO_0000218
11858,,0,A,,1,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,22224,,,,CHEMBL625804,14380,,,,,U,Autocuration,BAO_0000019
11859,,0,A,,1,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,22224,,,,CHEMBL622530,14380,,,,,U,Autocuration,BAO_0000218
11860,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,50594,10090.0,,,CHEMBL622531,13701,,,,,N,Intermediate,BAO_0000218
11861,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,10090.0,,,CHEMBL622532,13701,,,,,N,Intermediate,BAO_0000218
11862,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL623176,13701,,,,,N,Intermediate,BAO_0000218
11863,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),50594,10090.0,,,CHEMBL623177,13701,,,,,N,Intermediate,BAO_0000218
11864,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,10090.0,,,CHEMBL623178,13701,,,,,N,Intermediate,BAO_0000218
11865,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,50594,10090.0,,,CHEMBL623179,13701,,,,,N,Intermediate,BAO_0000218
11866,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),50594,10090.0,,,CHEMBL623180,13701,,,,,N,Intermediate,BAO_0000218
11867,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL623181,13701,,,,,N,Intermediate,BAO_0000218
11868,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL624131,13701,,,,,N,Intermediate,BAO_0000218
11869,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),50594,10090.0,,,CHEMBL624132,13701,,,,,N,Intermediate,BAO_0000218
11870,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL624133,13701,,,,,N,Intermediate,BAO_0000218
11871,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,50594,10090.0,,,CHEMBL624846,13701,,,,,N,Intermediate,BAO_0000218
11872,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL624847,13701,,,,,N,Intermediate,BAO_0000218
11873,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL624848,13701,,,,,N,Intermediate,BAO_0000218
11874,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,10090.0,,,CHEMBL625012,13701,,,,,N,Intermediate,BAO_0000218
11875,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL625013,13701,,,,,N,Intermediate,BAO_0000218
11876,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,50594,10090.0,,,CHEMBL625014,13701,,,,,N,Intermediate,BAO_0000218
11877,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),50594,10090.0,,,CHEMBL625015,13701,,,,,N,Intermediate,BAO_0000218
11878,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL625016,13701,,,,,N,Intermediate,BAO_0000218
11879,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,50594,10090.0,,,CHEMBL625017,13701,,,,,N,Intermediate,BAO_0000218
11880,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL625018,13701,,,,,N,Intermediate,BAO_0000218
11881,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL625019,13701,,,,,N,Intermediate,BAO_0000218
11882,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL625020,13701,,,,,N,Intermediate,BAO_0000218
11883,Mus musculus,1,A,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,50594,10090.0,,,CHEMBL625021,13701,,,,,N,Intermediate,BAO_0000218
11884,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,10116.0,,,CHEMBL625022,14393,,,,,N,Intermediate,BAO_0000218
11885,Mus musculus,1,A,,1,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,50594,10090.0,,,CHEMBL625023,14731,,,,,N,Intermediate,BAO_0000218
11886,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,100710,9541.0,,,CHEMBL625024,14731,,,,,N,Intermediate,BAO_0000218
11887,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,100710,9541.0,,,CHEMBL627626,14731,,,,,N,Intermediate,BAO_0000218
11888,,0,A,,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,22224,,,,CHEMBL627627,13758,955.0,,,Brain,U,Autocuration,BAO_0000218
11889,,0,A,,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,22224,,,,CHEMBL627628,13758,1977.0,,,Serum,U,Autocuration,BAO_0000218
11890,,0,A,,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,22224,,,,CHEMBL627629,13758,955.0,,,Brain,U,Autocuration,BAO_0000218
11891,,0,A,,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,22224,,,,CHEMBL627630,13758,1977.0,,,Serum,U,Autocuration,BAO_0000218
11892,,0,A,,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),22224,,,,CHEMBL627631,16359,,,,,U,Autocuration,BAO_0000019
11893,,0,A,,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),22224,,,,CHEMBL629515,16359,,,,,U,Autocuration,BAO_0000218
11894,Mus musculus,1,A,,1,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL629516,15383,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11895,Mus musculus,1,A,,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL629517,15383,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11896,Mus musculus,1,A,,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL629518,15383,2106.0,,,Spleen,N,Intermediate,BAO_0000218
11897,Mus musculus,1,A,,1,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,10090.0,,,CHEMBL877499,15383,,,,,N,Intermediate,BAO_0000218
11898,Mus musculus,1,A,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,10090.0,,,CHEMBL629519,15383,,,,,N,Intermediate,BAO_0000218
11899,Mus musculus,1,A,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,10090.0,,,CHEMBL629520,15383,,,,,N,Intermediate,BAO_0000218
11900,Mus musculus,1,A,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,10090.0,,,CHEMBL629521,15383,,,,,N,Intermediate,BAO_0000218
11901,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),50594,10090.0,,,CHEMBL629522,14439,,,,,N,Intermediate,BAO_0000218
11902,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),50594,10090.0,,,CHEMBL629523,14439,,,,,N,Intermediate,BAO_0000218
11903,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),50594,10090.0,,,CHEMBL629524,14439,,,,,N,Intermediate,BAO_0000218
11904,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),50594,10090.0,,,CHEMBL629525,14439,,,,,N,Intermediate,BAO_0000218
11905,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),50594,10090.0,,,CHEMBL629526,14439,,,,,N,Intermediate,BAO_0000218
11906,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),50594,10090.0,,,CHEMBL629527,14439,,,,,N,Intermediate,BAO_0000218
11907,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),50594,10090.0,,,CHEMBL629528,14439,,,,,N,Intermediate,BAO_0000218
11908,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),50594,10090.0,,,CHEMBL629529,14439,,,,,N,Intermediate,BAO_0000218
11909,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),50594,10090.0,,,CHEMBL629530,14439,,,,,N,Intermediate,BAO_0000218
11910,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),50594,10090.0,,,CHEMBL629531,14439,,,,,N,Intermediate,BAO_0000218
11911,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),50594,10090.0,,,CHEMBL628656,14439,,,,,N,Intermediate,BAO_0000218
11912,Mus musculus,1,A,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),50594,10090.0,,,CHEMBL628657,14439,,,,,N,Intermediate,BAO_0000218
11913,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628658,13751,,,,,N,Intermediate,BAO_0000218
11914,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628659,13751,,,,,N,Intermediate,BAO_0000218
11915,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL877500,13751,,,,,N,Intermediate,BAO_0000218
11916,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628660,13751,,,,,N,Intermediate,BAO_0000218
11917,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628661,13751,,,,,N,Intermediate,BAO_0000218
11918,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628662,13751,,,,,N,Intermediate,BAO_0000218
11919,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628663,13751,,,,,N,Intermediate,BAO_0000218
11920,Rattus norvegicus,1,A,,1,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628664,13751,,,,,N,Intermediate,BAO_0000218
11921,Rattus norvegicus,1,A,,1,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628665,13751,178.0,,,Blood,N,Intermediate,BAO_0000218
11922,Rattus norvegicus,1,A,,1,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628666,13751,178.0,,,Blood,N,Intermediate,BAO_0000218
11923,Rattus norvegicus,1,A,,1,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628667,13751,178.0,,,Blood,N,Intermediate,BAO_0000218
11924,Rattus norvegicus,1,A,,1,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628668,13751,178.0,,,Blood,N,Intermediate,BAO_0000218
11925,Rattus norvegicus,1,A,,1,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628669,13751,178.0,,,Blood,N,Intermediate,BAO_0000218
11926,Rattus norvegicus,1,A,,1,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628670,13751,178.0,,,Blood,N,Intermediate,BAO_0000218
11927,Rattus norvegicus,1,A,,1,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628671,13751,178.0,,,Blood,N,Intermediate,BAO_0000218
11928,Rattus norvegicus,1,A,,1,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL628672,13751,10000001.0,,,Bone,N,Intermediate,BAO_0000218
11929,Rattus norvegicus,1,A,,1,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL630300,13751,10000001.0,,,Bone,N,Intermediate,BAO_0000218
11930,Rattus norvegicus,1,A,,1,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629787,13751,10000001.0,,,Bone,N,Intermediate,BAO_0000218
11931,Rattus norvegicus,1,A,,1,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629788,13751,10000001.0,,,Bone,N,Intermediate,BAO_0000218
11932,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629789,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
11933,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629790,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
11934,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629791,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
11935,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629792,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
11936,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629793,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
11937,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629794,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
11938,Rattus norvegicus,1,A,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,50597,10116.0,,,CHEMBL874459,10677,,,,,N,Intermediate,BAO_0000218
11939,Rattus norvegicus,1,A,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,50597,10116.0,,,CHEMBL629795,10677,,,,,N,Intermediate,BAO_0000218
11940,Rattus norvegicus,1,A,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,50597,10116.0,,,CHEMBL629796,10677,,,,,N,Intermediate,BAO_0000218
11941,Rattus norvegicus,1,A,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,50597,10116.0,,,CHEMBL629797,10677,,,,,N,Intermediate,BAO_0000218
11942,Rattus norvegicus,1,A,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,50597,10116.0,,,CHEMBL629798,10677,,,,,N,Intermediate,BAO_0000218
11943,Rattus norvegicus,1,A,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629799,10911,2369.0,,,Adrenal gland,N,Intermediate,BAO_0000218
11944,Rattus norvegicus,1,A,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629800,10911,2369.0,,,Adrenal gland,N,Intermediate,BAO_0000218
11945,Rattus norvegicus,1,A,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629801,10911,2369.0,,,Adrenal gland,N,Intermediate,BAO_0000218
11946,Rattus norvegicus,1,A,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,50597,10116.0,,,CHEMBL629802,10911,2369.0,,,Adrenal gland,N,Intermediate,BAO_0000218
11947,Rattus norvegicus,1,A,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629803,10911,2369.0,,,Adrenal gland,N,Intermediate,BAO_0000218
11948,Rattus norvegicus,1,A,,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629804,10911,178.0,,,Blood,N,Intermediate,BAO_0000218
11949,Rattus norvegicus,1,A,,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629805,10911,178.0,,,Blood,N,Intermediate,BAO_0000218
11950,Rattus norvegicus,1,A,,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629806,10911,178.0,,,Blood,N,Intermediate,BAO_0000218
11951,Rattus norvegicus,1,A,,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629807,10911,178.0,,,Blood,N,Intermediate,BAO_0000218
11952,Rattus norvegicus,1,A,,1,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629808,10911,178.0,,,Blood,N,Intermediate,BAO_0000218
11953,Rattus norvegicus,1,A,,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629809,10911,955.0,,,Brain,N,Intermediate,BAO_0000218
11954,Rattus norvegicus,1,A,,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629810,10911,955.0,,,Brain,N,Intermediate,BAO_0000218
11955,Rattus norvegicus,1,A,,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629811,10911,955.0,,,Brain,N,Intermediate,BAO_0000218
11956,Rattus norvegicus,1,A,,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629812,10911,955.0,,,Brain,N,Intermediate,BAO_0000218
11957,Rattus norvegicus,1,A,,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629813,10911,955.0,,,Brain,N,Intermediate,BAO_0000218
11958,Rattus norvegicus,1,A,,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL874460,10911,955.0,,,Brain,N,Intermediate,BAO_0000218
11959,Rattus norvegicus,1,A,,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629814,10911,,,,,N,Intermediate,BAO_0000218
11960,Rattus norvegicus,1,A,,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629815,10911,,,,,N,Intermediate,BAO_0000218
11961,Rattus norvegicus,1,A,,1,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629816,10911,,,,,N,Intermediate,BAO_0000218
11962,Rattus norvegicus,1,A,,1,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL629817,10911,,,,,N,Intermediate,BAO_0000218
11963,Rattus norvegicus,1,A,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL626643,10911,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11964,Rattus norvegicus,1,A,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL626644,10911,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11965,Rattus norvegicus,1,A,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL626806,10911,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11966,Rattus norvegicus,1,A,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL626807,10911,2113.0,,,Kidney,N,Intermediate,BAO_0000218
11967,Rattus norvegicus,1,A,,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627261,10911,2107.0,,,Liver,N,Intermediate,BAO_0000218
11968,Rattus norvegicus,1,A,,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627262,10911,2107.0,,,Liver,N,Intermediate,BAO_0000218
11969,Rattus norvegicus,1,A,,1,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627263,10911,2107.0,,,Liver,N,Intermediate,BAO_0000218
11970,Rattus norvegicus,1,A,,1,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627264,10911,2107.0,,,Liver,N,Intermediate,BAO_0000218
11971,Rattus norvegicus,1,A,,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627265,10911,2048.0,,,Lung,N,Intermediate,BAO_0000218
11972,Rattus norvegicus,1,A,,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627266,10911,2048.0,,,Lung,N,Intermediate,BAO_0000218
11973,Rattus norvegicus,1,A,,1,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627267,10911,2048.0,,,Lung,N,Intermediate,BAO_0000218
11974,Rattus norvegicus,1,A,,1,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627268,10911,2048.0,,,Lung,N,Intermediate,BAO_0000218
11975,Rattus norvegicus,1,A,,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627269,10911,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11976,Rattus norvegicus,1,A,,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627270,10911,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
11977,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",50597,10116.0,,,CHEMBL627271,8608,,,,,N,Intermediate,BAO_0000218
11978,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",50597,10116.0,,,CHEMBL627946,8608,,,,,N,Intermediate,BAO_0000218
11979,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",50597,10116.0,,,CHEMBL875472,8608,,,,,N,Intermediate,BAO_0000218
11980,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",50597,10116.0,,,CHEMBL627947,8608,,,,,N,Intermediate,BAO_0000218
11981,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",50597,10116.0,,,CHEMBL627948,8608,,,,,N,Intermediate,BAO_0000218
11982,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",50597,10116.0,,,CHEMBL628113,8608,,,,,N,Intermediate,BAO_0000218
11983,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",50597,10116.0,,,CHEMBL628114,8608,,,,,N,Intermediate,BAO_0000218
11984,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",50597,10116.0,,,CHEMBL628115,8608,,,,,N,Intermediate,BAO_0000218
11985,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",50597,10116.0,,,CHEMBL628116,8608,,,,,N,Intermediate,BAO_0000218
11986,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",50597,10116.0,,,CHEMBL628117,8608,,,,,N,Intermediate,BAO_0000218
11987,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",50597,10116.0,,,CHEMBL628118,8608,,,,,N,Intermediate,BAO_0000218
11988,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",50597,10116.0,,,CHEMBL628119,8608,,,,,N,Intermediate,BAO_0000218
11989,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",50597,10116.0,,,CHEMBL628120,8608,,,,,N,Intermediate,BAO_0000218
11990,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",50597,10116.0,,,CHEMBL628121,8608,,,,,N,Intermediate,BAO_0000218
11991,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",50597,10116.0,,,CHEMBL628122,8608,,,,,N,Intermediate,BAO_0000218
11992,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",50597,10116.0,,,CHEMBL627297,8608,,,,,N,Intermediate,BAO_0000218
11993,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",50597,10116.0,,,CHEMBL627298,8608,,,,,N,Intermediate,BAO_0000218
11994,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",50597,10116.0,,,CHEMBL627299,8608,,,,,N,Intermediate,BAO_0000218
11995,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",50597,10116.0,,,CHEMBL627300,8608,,,,,N,Intermediate,BAO_0000218
11996,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",50597,10116.0,,,CHEMBL627301,8608,,,,,N,Intermediate,BAO_0000218
11997,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",50597,10116.0,,,CHEMBL627302,8608,,,,,N,Intermediate,BAO_0000218
11998,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",50597,10116.0,,,CHEMBL627303,8608,,,,,N,Intermediate,BAO_0000218
11999,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",50597,10116.0,,,CHEMBL627304,8608,,,,,N,Intermediate,BAO_0000218
12000,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",50597,10116.0,,,CHEMBL627305,8608,,,,,N,Intermediate,BAO_0000218
12001,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",50597,10116.0,,,CHEMBL627306,8608,,,,,N,Intermediate,BAO_0000218
12002,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",50597,10116.0,,,CHEMBL623982,8608,,,,,N,Intermediate,BAO_0000218
12003,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",50597,10116.0,,,CHEMBL623983,8608,,,,,N,Intermediate,BAO_0000218
12004,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",50597,10116.0,,,CHEMBL623984,8608,,,,,N,Intermediate,BAO_0000218
12005,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",50597,10116.0,,,CHEMBL623985,8608,,,,,N,Intermediate,BAO_0000218
12006,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",50597,10116.0,,,CHEMBL623986,8608,,,,,N,Intermediate,BAO_0000218
12007,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",50597,10116.0,,,CHEMBL623987,8608,,,,,N,Intermediate,BAO_0000218
12008,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",50597,10116.0,,,CHEMBL623988,8608,,,,,N,Intermediate,BAO_0000218
12009,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",50597,10116.0,,,CHEMBL623989,8608,,,,,N,Intermediate,BAO_0000218
12010,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",50597,10116.0,,,CHEMBL622215,8608,,,,,N,Intermediate,BAO_0000218
12011,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",50597,10116.0,,,CHEMBL622216,8608,,,,,N,Intermediate,BAO_0000218
12012,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",50597,10116.0,,,CHEMBL877481,8608,,,,,N,Intermediate,BAO_0000218
12013,,0,A,,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),22224,,,,CHEMBL622217,16359,,,,,U,Autocuration,BAO_0000218
12014,Mus musculus,1,A,,1,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),50594,10090.0,,,CHEMBL622218,13701,,,,,N,Intermediate,BAO_0000218
12015,Rattus norvegicus,1,A,,1,Pharmacokinetic profile AUC was evaluated in rats,50597,10116.0,,,CHEMBL622219,14554,,,,,N,Intermediate,BAO_0000218
12016,,0,A,,1,Pharmacokinetic property (Area under curve),22224,,,,CHEMBL622220,6241,,,,,U,Autocuration,BAO_0000019
12017,Canis lupus familiaris,1,A,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",50588,9615.0,,,CHEMBL622221,11537,,,,,N,Intermediate,BAO_0000218
12018,Mus musculus,1,A,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",50594,10090.0,,,CHEMBL622222,11537,,,,,N,Intermediate,BAO_0000218
12019,Canis lupus familiaris,1,A,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",50588,9615.0,,,CHEMBL622223,11537,,,,,N,Intermediate,BAO_0000218
12020,Mus musculus,1,A,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",50594,10090.0,,,CHEMBL622224,11537,,,,,N,Intermediate,BAO_0000218
12021,,0,A,,1,Plasma concentration (AUC) was determined,22224,,,,CHEMBL622225,13118,,,,,U,Autocuration,BAO_0000019
12022,,0,A,,1,Plasma concentration (AUC) was determined; Not detectable,22224,,,,CHEMBL622226,13118,,,,,U,Autocuration,BAO_0000019
12023,Cavia porcellus,1,A,,1,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),50512,10141.0,,,CHEMBL624154,9562,,,,,N,Intermediate,BAO_0000218
12024,Rattus norvegicus,1,A,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,50597,10116.0,,,CHEMBL624155,10363,,,,,N,Intermediate,BAO_0000218
12025,Rattus norvegicus,1,A,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,10116.0,,,CHEMBL624156,10363,,,,,N,Intermediate,BAO_0000218
12026,Rattus norvegicus,1,A,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,50597,10116.0,,,CHEMBL624157,10363,,,,,N,Intermediate,BAO_0000218
12027,Rattus norvegicus,1,A,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,50597,10116.0,,,CHEMBL624158,10363,,,,,N,Intermediate,BAO_0000218
12028,Rattus norvegicus,1,A,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,50597,10116.0,,,CHEMBL624159,12504,,,,,N,Intermediate,BAO_0000218
12029,Rattus norvegicus,1,A,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,50597,10116.0,,,CHEMBL624160,12504,,,,,N,Intermediate,BAO_0000218
12030,Rattus norvegicus,1,A,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,50597,10116.0,,,CHEMBL624161,12504,,,,,N,Intermediate,BAO_0000218
12031,Rattus norvegicus,1,A,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,50597,10116.0,,,CHEMBL624162,12504,,,,,N,Intermediate,BAO_0000218
12032,Canis lupus familiaris,1,A,,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,50588,9615.0,,,CHEMBL624163,13317,,,,,N,Intermediate,BAO_0000218
12033,Rattus norvegicus,1,A,,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL624164,15078,,,,,N,Intermediate,BAO_0000218
12034,Rattus norvegicus,1,A,,1,The AUC(0-infinity) values in female wistar rats.,50597,10116.0,,,CHEMBL624165,14941,,,,,N,Intermediate,BAO_0000218
12035,Rattus norvegicus,1,A,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL624166,15078,,,,,N,Intermediate,BAO_0000218
12036,Rattus norvegicus,1,A,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",50597,10116.0,,,CHEMBL624167,15078,,,,,N,Intermediate,BAO_0000218
12037,Rattus norvegicus,1,A,,1,The AUC(0-t)values in female wistar rats.,50597,10116.0,,,CHEMBL624168,14941,,,,,N,Intermediate,BAO_0000218
12038,Rattus norvegicus,1,A,,1,The Area under the concentration time curve of compound was measured on rats,50597,10116.0,,,CHEMBL624169,14067,,,,,N,Intermediate,BAO_0000218
12039,Homo sapiens,1,A,,1,The area under curve (100 mg/kg) administered orally in humans,50587,9606.0,,,CHEMBL624170,14215,,,,,N,Intermediate,BAO_0000218
12040,Callithrix,0,A,,1,The area under curve (12.5 mg/kg) administered intravenously in marmoset,22224,9481.0,,,CHEMBL624171,14215,,,,,U,Autocuration,BAO_0000218
12041,Simiiformes,0,A,,1,The area under curve (12.5 mg/kg) administered intravenously in monkey,22224,314293.0,,,CHEMBL624172,14215,,,,,U,Autocuration,BAO_0000218
12042,Canis lupus familiaris,1,A,,1,The area under curve (15 mg/kg) administered intravenously in dog,50588,9615.0,,,CHEMBL624173,14215,,,,,N,Intermediate,BAO_0000218
12043,Homo sapiens,1,A,,1,The area under curve (200 mg/kg) administered orally in humans,50587,9606.0,,,CHEMBL877488,14215,,,,,N,Intermediate,BAO_0000218
12044,Rattus norvegicus,1,A,,1,The area under curve (25 mg/kg) administered intravenously in rat,50597,10116.0,,,CHEMBL624174,14215,,,,,N,Intermediate,BAO_0000218
12045,Callithrix,0,A,,1,The area under curve (25 mg/kg) administered orally in marmoset,22224,9481.0,,,CHEMBL624175,14215,,,,,U,Autocuration,BAO_0000218
12046,Simiiformes,0,A,,1,The area under curve (25 mg/kg) administered orally in monkey,22224,314293.0,,,CHEMBL624176,14215,,,,,U,Autocuration,BAO_0000218
12047,Canis lupus familiaris,1,A,,1,The area under curve (30 mg/kg) administered orally in dog,50588,9615.0,,,CHEMBL624177,14215,,,,,N,Intermediate,BAO_0000218
12048,Homo sapiens,1,A,,1,The area under curve (400 mg/kg) administered orally in humans,50587,9606.0,,,CHEMBL624178,14215,,,,,N,Intermediate,BAO_0000218
12049,Rattus norvegicus,1,A,,1,The area under curve (50 mg/kg) administered orally in fasted rat,50597,10116.0,,,CHEMBL624179,14215,,,,,N,Intermediate,BAO_0000218
12050,Rattus norvegicus,1,A,,1,The area under curve (50 mg/kg) administered orally in rat,50597,10116.0,,,CHEMBL627689,14215,,,,,N,Intermediate,BAO_0000218
12051,Homo sapiens,1,A,,1,The area under curve (800 mg/kg) administered orally in humans,50587,9606.0,,,CHEMBL627690,14215,,,,,N,Intermediate,BAO_0000218
12052,,0,A,,1,The compound was evaluated for area under the curve,22224,,,,CHEMBL627691,11324,,,,,U,Autocuration,BAO_0000019
12053,Callithrix,0,A,,1,The compound was evaluated for area under the curve in marmosets,22224,9481.0,,,CHEMBL627692,11324,,,,,U,Autocuration,BAO_0000019
12054,Callithrix,0,A,,1,The compound was evaluated for area under the curve in marmosets,22224,9481.0,,,CHEMBL627693,11324,,,,,U,Autocuration,BAO_0000019
12055,Rattus norvegicus,1,A,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,10116.0,,,CHEMBL627694,13875,,,,,N,Intermediate,BAO_0000218
12056,Rattus norvegicus,1,A,,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,50597,10116.0,,,CHEMBL627695,13875,,,,,N,Intermediate,BAO_0000218
12057,,0,A,,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),22224,,,,CHEMBL627696,13875,,,,,U,Autocuration,BAO_0000218
12058,Rattus norvegicus,1,A,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,10116.0,,,CHEMBL627697,13875,,,,,N,Intermediate,BAO_0000218
12059,Rattus norvegicus,1,A,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,10116.0,,,CHEMBL627698,13875,,,,,N,Intermediate,BAO_0000218
12060,Rattus norvegicus,1,A,,1,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,50597,10116.0,,,CHEMBL627699,13875,,,,,N,Intermediate,BAO_0000218
12061,Rattus norvegicus,1,A,,1,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,50597,10116.0,,,CHEMBL627700,13807,,,,,N,Intermediate,BAO_0000218
12062,Rattus norvegicus,1,A,,1,Total drug exposure is determined after oral dosing in rats.,50597,10116.0,,,CHEMBL627701,14127,,,,,N,Intermediate,BAO_0000218
12063,,0,A,,1,Total drug exposure (5 mg/kg) when administered intravenously,22224,,,,CHEMBL627702,15116,,,,,U,Autocuration,BAO_0000218
12064,,0,A,,1,Total drug exposure (5 mg/kg) when administered orally,22224,,,,CHEMBL627703,15116,,,,,U,Autocuration,BAO_0000218
12065,Simiiformes,0,A,,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,22224,314293.0,,,CHEMBL626873,15604,,,,,U,Autocuration,BAO_0000218
12066,Rattus norvegicus,1,A,,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,50597,10116.0,,,CHEMBL629583,15604,,,,,N,Intermediate,BAO_0000218
12067,Canis lupus familiaris,1,A,,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,50588,9615.0,,,CHEMBL629584,15604,,,,,N,Intermediate,BAO_0000218
12068,Canis lupus familiaris,1,A,,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,50588,9615.0,,,CHEMBL629585,15604,,,,,N,Intermediate,BAO_0000218
12069,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629586,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
12070,Rattus norvegicus,1,A,,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629587,13751,955.0,,,Brain,N,Intermediate,BAO_0000218
12071,Rattus norvegicus,1,A,,1,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629588,13751,,,,,N,Intermediate,BAO_0000218
12072,Rattus norvegicus,1,A,,1,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629589,13751,,,,,N,Intermediate,BAO_0000218
12073,Rattus norvegicus,1,A,,1,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629590,13751,,,,,N,Intermediate,BAO_0000218
12074,Rattus norvegicus,1,A,,1,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629591,13751,,,,,N,Intermediate,BAO_0000218
12075,Rattus norvegicus,1,A,,1,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629592,13751,,,,,N,Intermediate,BAO_0000218
12076,Rattus norvegicus,1,A,,1,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629593,13751,,,,,N,Intermediate,BAO_0000218
12077,Rattus norvegicus,1,A,,1,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629594,13751,,,,,N,Intermediate,BAO_0000218
12078,Rattus norvegicus,1,A,,1,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL629595,13751,948.0,,,Heart,N,Intermediate,BAO_0000218
12079,Rattus norvegicus,1,A,,1,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL630290,13751,948.0,,,Heart,N,Intermediate,BAO_0000218
12080,Rattus norvegicus,1,A,,1,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627137,13751,948.0,,,Heart,N,Intermediate,BAO_0000218
12081,Rattus norvegicus,1,A,,1,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627138,13751,948.0,,,Heart,N,Intermediate,BAO_0000218
12082,Rattus norvegicus,1,A,,1,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627139,13751,948.0,,,Heart,N,Intermediate,BAO_0000218
12083,Rattus norvegicus,1,A,,1,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627140,13751,948.0,,,Heart,N,Intermediate,BAO_0000218
12084,Rattus norvegicus,1,A,,1,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627141,13751,948.0,,,Heart,N,Intermediate,BAO_0000218
12085,Rattus norvegicus,1,A,,1,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627142,13751,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12086,Rattus norvegicus,1,A,,1,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627143,13751,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12087,Rattus norvegicus,1,A,,1,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL874449,13751,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12088,Rattus norvegicus,1,A,,1,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627144,13751,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12089,Rattus norvegicus,1,A,,1,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627145,13751,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12090,Rattus norvegicus,1,A,,1,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627146,13751,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12091,Rattus norvegicus,1,A,,1,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627147,13751,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12092,Rattus norvegicus,1,A,,1,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627148,13751,2107.0,,,Liver,N,Intermediate,BAO_0000218
12093,Rattus norvegicus,1,A,,1,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627149,13751,2048.0,,,Lung,N,Intermediate,BAO_0000218
12094,Rattus norvegicus,1,A,,1,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL632160,13751,2048.0,,,Lung,N,Intermediate,BAO_0000218
12095,Rattus norvegicus,1,A,,1,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL632161,13751,2048.0,,,Lung,N,Intermediate,BAO_0000218
12096,Rattus norvegicus,1,A,,1,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL632162,13751,2048.0,,,Lung,N,Intermediate,BAO_0000218
12097,Rattus norvegicus,1,A,,1,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL632163,13751,2048.0,,,Lung,N,Intermediate,BAO_0000218
12098,Rattus norvegicus,1,A,,1,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL874469,13751,2048.0,,,Lung,N,Intermediate,BAO_0000218
12099,Rattus norvegicus,1,A,,1,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627182,13751,2048.0,,,Lung,N,Intermediate,BAO_0000218
12100,Rattus norvegicus,1,A,,1,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627183,13751,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12101,Rattus norvegicus,1,A,,1,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627184,13751,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12102,Rattus norvegicus,1,A,,1,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627185,13751,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12103,Rattus norvegicus,1,A,,1,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627186,13751,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12104,Rattus norvegicus,1,A,,1,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627187,13751,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12105,Rattus norvegicus,1,A,,1,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627188,13751,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12106,Rattus norvegicus,1,A,,1,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627189,13751,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12107,Rattus norvegicus,1,A,,1,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627190,13751,,,,,N,Intermediate,BAO_0000218
12108,Rattus norvegicus,1,A,,1,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627191,13751,2107.0,,,Liver,N,Intermediate,BAO_0000218
12109,Rattus norvegicus,1,A,,1,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627192,13751,2107.0,,,Liver,N,Intermediate,BAO_0000218
12110,Rattus norvegicus,1,A,,1,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL627193,13751,2107.0,,,Liver,N,Intermediate,BAO_0000218
12111,Rattus norvegicus,1,A,,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL874590,10911,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12112,Rattus norvegicus,1,A,,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627194,10911,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12113,Rattus norvegicus,1,A,,1,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627195,10911,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12114,Rattus norvegicus,1,A,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627196,10911,992.0,,,Female gonad,N,Intermediate,BAO_0000218
12115,Rattus norvegicus,1,A,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627197,10911,992.0,,,Female gonad,N,Intermediate,BAO_0000218
12116,Rattus norvegicus,1,A,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627198,10911,992.0,,,Female gonad,N,Intermediate,BAO_0000218
12117,Rattus norvegicus,1,A,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,50597,10116.0,,,CHEMBL627199,10911,992.0,,,Female gonad,N,Intermediate,BAO_0000218
12118,Rattus norvegicus,1,A,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627200,10911,992.0,,,Female gonad,N,Intermediate,BAO_0000218
12119,Rattus norvegicus,1,A,,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627201,10911,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12120,Rattus norvegicus,1,A,,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627202,10911,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12121,Rattus norvegicus,1,A,,1,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627203,10911,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12122,Rattus norvegicus,1,A,,1,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627204,10911,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12123,Rattus norvegicus,1,A,,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627205,10911,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12124,Rattus norvegicus,1,A,,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627206,10911,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12125,Rattus norvegicus,1,A,,1,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627207,10911,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12126,Rattus norvegicus,1,A,,1,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627208,10911,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12127,Rattus norvegicus,1,A,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627209,10911,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12128,Rattus norvegicus,1,A,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627210,10911,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12129,Rattus norvegicus,1,A,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627211,10911,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12130,Rattus norvegicus,1,A,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627212,10911,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12131,Rattus norvegicus,1,A,,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL627213,10911,995.0,,,Uterus,N,Intermediate,BAO_0000218
12132,Rattus norvegicus,1,A,,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL626599,10911,995.0,,,Uterus,N,Intermediate,BAO_0000218
12133,Rattus norvegicus,1,A,,1,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL626600,10911,995.0,,,Uterus,N,Intermediate,BAO_0000218
12134,Rattus norvegicus,1,A,,1,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,10116.0,,,CHEMBL626601,10911,995.0,,,Uterus,N,Intermediate,BAO_0000218
12135,,0,A,,1,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,22224,,,,CHEMBL627484,8081,,,,,U,Autocuration,BAO_0000019
12136,Macaca fascicularis,1,A,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),100710,9541.0,,,CHEMBL627485,17248,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12137,Macaca fascicularis,1,A,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,100710,9541.0,,,CHEMBL628147,17248,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12138,Macaca fascicularis,1,A,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,100710,9541.0,,,CHEMBL628148,17248,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12139,Canis lupus familiaris,1,A,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),50588,9615.0,,,CHEMBL628149,17248,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12140,Canis lupus familiaris,1,A,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,50588,9615.0,,,CHEMBL628150,17248,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12141,Canis lupus familiaris,1,A,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,50588,9615.0,,,CHEMBL628318,17248,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12142,Canis lupus familiaris,1,A,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,50588,9615.0,,,CHEMBL628319,17248,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12143,Canis lupus familiaris,1,A,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",50588,9615.0,,,CHEMBL875609,15592,,,,,N,Intermediate,BAO_0000218
12144,,0,A,,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,22224,,,,CHEMBL628320,7040,,,,,U,Autocuration,BAO_0000019
12145,,0,A,,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,22224,,,,CHEMBL628321,7040,,,,,U,Autocuration,BAO_0000019
12146,,0,A,,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,22224,,,,CHEMBL628322,7040,,,,,U,Autocuration,BAO_0000019
12147,,0,A,,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,22224,,,,CHEMBL628323,7040,,,,,U,Autocuration,BAO_0000019
12148,,0,A,,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,22224,,,,CHEMBL628324,7040,,,,,U,Autocuration,BAO_0000019
12149,,0,A,,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,22224,,,,CHEMBL628325,7040,,,,,U,Autocuration,BAO_0000019
12150,,0,A,,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,22224,,,,CHEMBL628326,7040,,,,,U,Autocuration,BAO_0000019
12151,Canis lupus familiaris,1,A,,1,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",50588,9615.0,,,CHEMBL628327,9614,1236.0,,,Adrenal medulla,N,Intermediate,BAO_0000218
12152,Canis lupus familiaris,1,A,,1,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",50588,9615.0,,,CHEMBL628328,9614,1236.0,,,Adrenal medulla,N,Intermediate,BAO_0000218
12153,Canis lupus familiaris,1,A,,1,"Concentration of compound in blood of dog 1, after administering intravenously",50588,9615.0,,,CHEMBL628329,9614,178.0,,,Blood,N,Intermediate,BAO_0000218
12154,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",50597,10116.0,,,CHEMBL628330,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12155,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",50597,10116.0,,,CHEMBL628331,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12156,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",50597,10116.0,,,CHEMBL628332,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12157,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",50597,10116.0,,,CHEMBL628333,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12158,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",50597,10116.0,,,CHEMBL628334,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12159,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",50597,10116.0,,,CHEMBL628335,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12160,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",50597,10116.0,,,CHEMBL628336,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12161,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",50597,10116.0,,,CHEMBL628337,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12162,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",50597,10116.0,,,CHEMBL628338,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12163,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",50597,10116.0,,,CHEMBL875610,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12164,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",50597,10116.0,,,CHEMBL628339,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12165,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",50597,10116.0,,,CHEMBL628340,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12166,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",50597,10116.0,,,CHEMBL628341,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12167,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",50597,10116.0,,,CHEMBL622214,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12168,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",50597,10116.0,,,CHEMBL623167,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12169,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",50597,10116.0,,,CHEMBL623168,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12170,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",50597,10116.0,,,CHEMBL623169,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12171,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",50597,10116.0,,,CHEMBL623170,8608,2107.0,,,Liver,N,Intermediate,BAO_0000218
12172,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",50597,10116.0,,,CHEMBL627224,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12173,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",50597,10116.0,,,CHEMBL875634,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12174,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",50597,10116.0,,,CHEMBL627225,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12175,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",50597,10116.0,,,CHEMBL627226,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12176,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",50597,10116.0,,,CHEMBL626083,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12177,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",50597,10116.0,,,CHEMBL626084,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12178,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",50597,10116.0,,,CHEMBL626085,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12179,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",50597,10116.0,,,CHEMBL626086,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12180,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",50597,10116.0,,,CHEMBL626087,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12181,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",50597,10116.0,,,CHEMBL626088,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12182,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",50597,10116.0,,,CHEMBL626089,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12183,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",50597,10116.0,,,CHEMBL626090,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12184,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",50597,10116.0,,,CHEMBL626091,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12185,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",50597,10116.0,,,CHEMBL626092,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12186,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",50597,10116.0,,,CHEMBL626093,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12187,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",50597,10116.0,,,CHEMBL626094,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12188,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",50597,10116.0,,,CHEMBL626095,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12189,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",50597,10116.0,,,CHEMBL626096,8608,2048.0,,,Lung,N,Intermediate,BAO_0000218
12190,Simiiformes,0,A,,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,22224,314293.0,,,CHEMBL626097,15604,,,,,U,Autocuration,BAO_0000218
12191,Rattus norvegicus,1,A,,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,50597,10116.0,,,CHEMBL626098,15604,,,,,N,Intermediate,BAO_0000218
12192,,0,A,,1,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,22224,,,,CHEMBL626099,1806,1969.0,,,Plasma,U,Autocuration,BAO_0000218
12193,,0,A,,1,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,22224,,,,CHEMBL626100,1806,1969.0,,,Plasma,U,Autocuration,BAO_0000218
12194,Canis lupus familiaris,1,A,,1,AUC 0-inf in dog,50588,9615.0,,,CHEMBL626101,17237,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12195,Cavia porcellus,1,A,,1,AUC 0-inf in guinea pig,50512,10141.0,,,CHEMBL626102,17237,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12196,Canis lupus familiaris,1,A,,1,AUC 0-t in dog,50588,9615.0,,,CHEMBL626103,17237,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12197,Cavia porcellus,1,A,,1,AUC 0-t in guinea pig,50512,10141.0,,,CHEMBL628391,17237,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12198,Rattus norvegicus,1,A,,1,The compound was tested for brain to plasma partition in rat,50597,10116.0,,,CHEMBL628392,15194,,,,,N,Intermediate,BAO_0000218
12199,Rattus norvegicus,1,A,,1,The compound was tested for brain to plasma partition in rat.,50597,10116.0,,,CHEMBL628393,15194,,,,,N,Intermediate,BAO_0000218
12200,,0,A,,1,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,22224,,,,CHEMBL628394,8787,178.0,,,Blood,U,Autocuration,BAO_0000019
12201,Canis lupus familiaris,1,A,,1,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,50588,9615.0,,,CHEMBL628395,17025,,,,,N,Intermediate,BAO_0000218
12202,Simiiformes,0,A,,1,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,22224,314293.0,,,CHEMBL628396,17025,,,,,U,Autocuration,BAO_0000218
12203,Oryctolagus cuniculus,1,A,,1,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,50592,9986.0,,,CHEMBL628397,17025,,,,,N,Intermediate,BAO_0000218
12204,Rattus norvegicus,1,A,,1,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,50597,10116.0,,,CHEMBL628398,17025,,,,,N,Intermediate,BAO_0000218
12205,Macaca mulatta,1,A,,1,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,50797,9544.0,,,CHEMBL628399,4236,,,,,N,Intermediate,BAO_0000218
12206,Canis lupus familiaris,1,A,,1,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,50588,9615.0,,,CHEMBL628400,15343,,,,,N,Intermediate,BAO_0000218
12207,Rattus norvegicus,1,A,,1,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,50597,10116.0,,,CHEMBL874907,15343,,,,,N,Intermediate,BAO_0000218
12208,,0,A,,1,Area under curve of the compound was determined,22224,,,,CHEMBL628401,17720,,,,,U,Autocuration,BAO_0000019
12209,Simiiformes,0,A,,1,AUC in monkeys at a dose of 1 mg/kg,22224,314293.0,,,CHEMBL628402,17788,1969.0,,,Plasma,U,Autocuration,BAO_0000218
12210,Rattus norvegicus,1,A,,1,AUC in rats at a dose of 1 mg/kg,50597,10116.0,,,CHEMBL628403,17788,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12211,,0,A,,1,Compound was evaluated for the overall absorbance loss at pH of 2,22224,,,,CHEMBL628404,8778,,,,,U,Autocuration,BAO_0000019
12212,,0,A,,1,Compound was evaluated for the overall absorbance loss at pH of 4,22224,,,,CHEMBL628405,8778,,,,,U,Autocuration,BAO_0000019
12213,,0,A,,1,Compound was evaluated for the overall absorbance loss at pH of 7,22224,,,,CHEMBL628406,8778,,,,,U,Autocuration,BAO_0000019
12214,Rattus norvegicus,1,A,,1,Compound was evaluated for its absorption in the rats,50597,10116.0,,,CHEMBL628407,2249,,,,,N,Intermediate,BAO_0000218
12215,Rattus norvegicus,1,A,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,50597,10116.0,,,CHEMBL628408,8881,1088.0,,,Urine,N,Intermediate,BAO_0000218
12216,Rattus norvegicus,1,A,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,50597,10116.0,,,CHEMBL629171,8881,1088.0,,,Urine,N,Intermediate,BAO_0000218
12217,Rattus norvegicus,1,A,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,50597,10116.0,,,CHEMBL629172,8881,1088.0,,,Urine,N,Intermediate,BAO_0000218
12218,Rattus norvegicus,1,A,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,50597,10116.0,,,CHEMBL629173,8881,1088.0,,,Urine,N,Intermediate,BAO_0000218
12219,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum,50597,10116.0,,,CHEMBL629174,15286,,,,,N,Intermediate,BAO_0000218
12220,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 10-17,50597,10116.0,,,CHEMBL629175,15286,,,,,N,Intermediate,BAO_0000218
12221,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 10-18,50597,10116.0,,,CHEMBL629176,15286,,,,,N,Intermediate,BAO_0000218
12222,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 10-19,50597,10116.0,,,CHEMBL629177,15286,,,,,N,Intermediate,BAO_0000218
12223,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 12-15,50597,10116.0,,,CHEMBL629178,15286,,,,,N,Intermediate,BAO_0000218
12224,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 13-19,50597,10116.0,,,CHEMBL631869,15286,,,,,N,Intermediate,BAO_0000218
12225,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 14-17,50597,10116.0,,,CHEMBL631870,15286,,,,,N,Intermediate,BAO_0000218
12226,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 15-18,50597,10116.0,,,CHEMBL631871,15286,,,,,N,Intermediate,BAO_0000218
12227,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 2-5,50597,10116.0,,,CHEMBL631872,15286,,,,,N,Intermediate,BAO_0000218
12228,,0,A,,1,In vitro percent permeability into rat ileum; Range is 23-42,22224,,,,CHEMBL875775,15286,2116.0,,,Ileum,U,Autocuration,BAO_0000221
12229,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 28-36,50597,10116.0,,,CHEMBL631873,15286,,,,,N,Intermediate,BAO_0000218
12230,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 29-35,50597,10116.0,,,CHEMBL631874,15286,,,,,N,Intermediate,BAO_0000218
12231,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 46-66,50597,10116.0,,,CHEMBL631875,15286,,,,,N,Intermediate,BAO_0000218
12232,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 50-68,50597,10116.0,,,CHEMBL631876,15286,,,,,N,Intermediate,BAO_0000218
12233,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; Range is 78-81,50597,10116.0,,,CHEMBL631877,15286,,,,,N,Intermediate,BAO_0000218
12234,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,50597,10116.0,,,CHEMBL631878,15286,,,,,N,Intermediate,BAO_0000218
12235,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; nd indicates not detected,50597,10116.0,,,CHEMBL631879,15286,,,,,N,Intermediate,BAO_0000218
12236,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; nt indicates not detected,50597,10116.0,,,CHEMBL631880,15286,,,,,N,Intermediate,BAO_0000218
12237,Rattus norvegicus,1,A,,1,In vitro percent permeability into rat ileum; nt indicates not tested,50597,10116.0,,,CHEMBL631881,15286,,,,,N,Intermediate,BAO_0000218
12238,Rattus norvegicus,1,A,,1,Compound was tested for oral absorption in bile-duct cannulated rats,50597,10116.0,,,CHEMBL631882,13770,,,,,N,Intermediate,BAO_0000218
12239,Rattus norvegicus,1,A,,1,Compound was tested for oral absorption in bile-duct cannulated rats.,50597,10116.0,,,CHEMBL630749,13770,,,,,N,Intermediate,BAO_0000218
12240,Homo sapiens,1,A,,1,Oral absorption using Caco-2 cell monolayers.,50587,9606.0,,,CHEMBL630750,5202,,,,,N,Intermediate,BAO_0000218
12241,Homo sapiens,1,A,,1,Percent of the drug absorbed after administration to humans was determined,50587,9606.0,,,CHEMBL630253,14920,,,,,N,Intermediate,BAO_0000218
12242,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,50597,10116.0,,,CHEMBL630254,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12243,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,50597,10116.0,,,CHEMBL630255,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12244,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,50597,10116.0,,,CHEMBL630256,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12245,Rattus norvegicus,1,A,,1,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL875781,13751,2107.0,,,Liver,N,Intermediate,BAO_0000218
12246,Rattus norvegicus,1,A,,1,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL630257,13751,2107.0,,,Liver,N,Intermediate,BAO_0000218
12247,Rattus norvegicus,1,A,,1,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,10116.0,,,CHEMBL630258,13751,2107.0,,,Liver,N,Intermediate,BAO_0000218
12248,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",50597,10116.0,,,CHEMBL630259,15807,,,,,N,Intermediate,BAO_0000218
12249,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",50597,10116.0,,,CHEMBL630260,15807,2435.0,,,Striatum,N,Intermediate,BAO_0000218
12250,Rattus norvegicus,1,A,,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",50597,10116.0,,,CHEMBL630261,15807,2435.0,,,Striatum,N,Intermediate,BAO_0000218
12251,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,50597,10116.0,,,CHEMBL630262,14950,,,,,N,Intermediate,BAO_0000218
12252,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,50597,10116.0,,,CHEMBL630263,14950,,,,,N,Intermediate,BAO_0000218
12253,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,50597,10116.0,,,CHEMBL630264,14950,,,,,N,Intermediate,BAO_0000218
12254,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,50597,10116.0,,,CHEMBL630265,14950,,,,,N,Intermediate,BAO_0000218
12255,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,50597,10116.0,,,CHEMBL630266,14950,,,,,N,Intermediate,BAO_0000218
12256,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,50597,10116.0,,,CHEMBL630267,14950,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12257,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,50597,10116.0,,,CHEMBL630268,14950,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12258,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,50597,10116.0,,,CHEMBL630269,14950,,,,,N,Intermediate,BAO_0000218
12259,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,50597,10116.0,,,CHEMBL630270,14950,,,,,N,Intermediate,BAO_0000218
12260,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,50597,10116.0,,,CHEMBL630141,14950,2048.0,,,Lung,N,Intermediate,BAO_0000218
12261,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,50597,10116.0,,,CHEMBL630142,14950,2048.0,,,Lung,N,Intermediate,BAO_0000218
12262,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,50597,10116.0,,,CHEMBL630143,14950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12263,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,50597,10116.0,,,CHEMBL630144,14950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12264,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,50597,10116.0,,,CHEMBL630145,14950,2367.0,,,Prostate gland,N,Intermediate,BAO_0000218
12265,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,50597,10116.0,,,CHEMBL630146,14950,2367.0,,,Prostate gland,N,Intermediate,BAO_0000218
12266,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,50597,10116.0,,,CHEMBL630147,14950,,,,,N,Intermediate,BAO_0000218
12267,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,50597,10116.0,,,CHEMBL630148,14950,,,,,N,Intermediate,BAO_0000218
12268,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,50597,10116.0,,,CHEMBL630149,14950,,,,,N,Intermediate,BAO_0000218
12269,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,50597,10116.0,,,CHEMBL630150,14950,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12270,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,50597,10116.0,,,CHEMBL630151,14950,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12271,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,50597,10116.0,,,CHEMBL632031,14950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12272,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,50597,10116.0,,,CHEMBL632032,14950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12273,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,50597,10116.0,,,CHEMBL632033,14950,,,,,N,Intermediate,BAO_0000218
12274,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,50597,10116.0,,,CHEMBL632034,14950,,,,,N,Intermediate,BAO_0000218
12275,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,50597,10116.0,,,CHEMBL632035,14950,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12276,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,50597,10116.0,,,CHEMBL632036,14950,,,,,N,Intermediate,BAO_0000218
12277,Rattus norvegicus,1,A,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,50597,10116.0,,,CHEMBL632037,14950,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12278,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,50597,10116.0,,,CHEMBL632038,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12279,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,50597,10116.0,,,CHEMBL632039,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12280,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,50597,10116.0,,,CHEMBL632040,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12281,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,50597,10116.0,,,CHEMBL632041,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12282,Canis lupus familiaris,1,A,,1,"Concentration of compound in blood of dog 2, after administering intravenously",50588,9615.0,,,CHEMBL632042,9614,178.0,,,Blood,N,Intermediate,BAO_0000218
12283,Canis lupus familiaris,1,A,,1,"Concentration of compound in left ventricle of dog 1, after administering intravenously",50588,9615.0,,,CHEMBL632043,9614,,,,,N,Intermediate,BAO_0000218
12284,Canis lupus familiaris,1,A,,1,"Concentration of compound in left ventricle of dog 2, after administering intravenously",50588,9615.0,,,CHEMBL632044,9614,,,,,N,Intermediate,BAO_0000218
12285,Canis lupus familiaris,1,A,,1,"Concentration of compound in liver of dog 1, after administering intravenously",50588,9615.0,,,CHEMBL632045,9614,2107.0,,,Liver,N,Intermediate,BAO_0000218
12286,Canis lupus familiaris,1,A,,1,"Concentration of compound in liver of dog 2, after administering intravenously",50588,9615.0,,,CHEMBL632046,9614,2107.0,,,Liver,N,Intermediate,BAO_0000218
12287,Canis lupus familiaris,1,A,,1,"Concentration of compound in lung of dog 1, after administering intravenously",50588,9615.0,,,CHEMBL632047,9614,2048.0,,,Lung,N,Intermediate,BAO_0000218
12288,Canis lupus familiaris,1,A,,1,"Concentration of compound in lung of dog 2, after administering intravenously",50588,9615.0,,,CHEMBL632048,9614,2048.0,,,Lung,N,Intermediate,BAO_0000218
12289,Canis lupus familiaris,1,A,,1,"Concentration of compound in muscle of dog 1, after administering intravenously",50588,9615.0,,,CHEMBL632049,9614,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12290,Canis lupus familiaris,1,A,,1,"Concentration of compound in muscle of dog 2, after administering intravenously",50588,9615.0,,,CHEMBL876418,9614,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12291,Canis lupus familiaris,1,A,,1,"Concentration of compound in spleen of dog 1,after administering intravenously",50588,9615.0,,,CHEMBL632050,9614,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12292,Canis lupus familiaris,1,A,,1,"Concentration of compound in spleen of dog 2, after administering intravenously",50588,9615.0,,,CHEMBL632051,9614,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12293,,0,F,,1,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,22224,,,,CHEMBL632052,10353,,,,,U,Autocuration,BAO_0000218
12294,,0,F,,1,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,22224,,,,CHEMBL632053,10353,,,,,U,Autocuration,BAO_0000218
12295,,0,A,,1,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,22224,,,,CHEMBL632054,10353,,,,,U,Autocuration,BAO_0000218
12296,,0,F,,1,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,22224,,,,CHEMBL632055,10353,,,,,U,Autocuration,BAO_0000218
12297,,0,F,,1,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,22224,,,,CHEMBL631181,10353,,,,,U,Autocuration,BAO_0000218
12298,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,22224,,,,CHEMBL631182,9196,,,,,U,Autocuration,BAO_0000218
12299,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,,,,CHEMBL631183,9196,,,,,U,Autocuration,BAO_0000218
12300,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,,CHEMBL631184,9196,,,,,U,Autocuration,BAO_0000218
12301,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,,CHEMBL629774,9196,,,,,U,Autocuration,BAO_0000218
12302,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,,CHEMBL629775,9196,,,,,U,Autocuration,BAO_0000218
12303,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,,CHEMBL876549,9196,,,,,U,Autocuration,BAO_0000218
12304,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL628172,9196,,,,,U,Autocuration,BAO_0000218
12305,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,,,,CHEMBL628173,9196,,,,,U,Autocuration,BAO_0000218
12306,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,22224,,,,CHEMBL628174,9196,,,,,U,Autocuration,BAO_0000218
12307,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,22224,,,,CHEMBL628175,9196,,,,,U,Autocuration,BAO_0000218
12308,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,,,,CHEMBL628176,9196,,,,,U,Autocuration,BAO_0000218
12309,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,,,,CHEMBL628177,9196,,,,,U,Autocuration,BAO_0000218
12310,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL628178,9196,,,,,U,Autocuration,BAO_0000218
12311,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,,,,CHEMBL628179,9196,,,,,U,Autocuration,BAO_0000218
12312,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,22224,,,,CHEMBL628180,9196,,,,,U,Autocuration,BAO_0000218
12313,,0,A,,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,22224,,,,CHEMBL628181,9196,,,,,U,Autocuration,BAO_0000218
12314,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,,CHEMBL628182,9196,,,,,U,Autocuration,BAO_0000218
12315,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,,CHEMBL628183,9196,,,,,U,Autocuration,BAO_0000218
12316,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,22224,,,,CHEMBL628184,9196,,,,,U,Autocuration,BAO_0000218
12317,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,,CHEMBL628185,9196,,,,,U,Autocuration,BAO_0000218
12318,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL875617,9196,,,,,U,Autocuration,BAO_0000218
12319,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,22224,,,,CHEMBL628186,9196,,,,,U,Autocuration,BAO_0000218
12320,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,,CHEMBL628187,9196,,,,,U,Autocuration,BAO_0000218
12321,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,,,,CHEMBL628188,9196,,,,,U,Autocuration,BAO_0000218
12322,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,22224,,,,CHEMBL628189,9196,,,,,U,Autocuration,BAO_0000218
12323,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,22224,,,,CHEMBL628190,9196,,,,,U,Autocuration,BAO_0000218
12324,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,,,,CHEMBL628191,9196,,,,,U,Autocuration,BAO_0000218
12325,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,22224,,,,CHEMBL626513,9196,,,,,U,Autocuration,BAO_0000218
12326,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",50597,10116.0,,,CHEMBL626514,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12327,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",50597,10116.0,,,CHEMBL626515,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12328,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",50597,10116.0,,,CHEMBL626516,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12329,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",50597,10116.0,,,CHEMBL626517,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12330,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",50597,10116.0,,,CHEMBL626518,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12331,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",50597,10116.0,,,CHEMBL626519,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12332,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",50597,10116.0,,,CHEMBL626520,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12333,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",50597,10116.0,,,CHEMBL626521,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12334,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",50597,10116.0,,,CHEMBL626522,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12335,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",50597,10116.0,,,CHEMBL626523,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12336,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",50597,10116.0,,,CHEMBL626524,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12337,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",50597,10116.0,,,CHEMBL626688,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12338,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",50597,10116.0,,,CHEMBL626689,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12339,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",50597,10116.0,,,CHEMBL626690,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12340,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",50597,10116.0,,,CHEMBL626691,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12341,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",50597,10116.0,,,CHEMBL627319,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12342,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",50597,10116.0,,,CHEMBL624052,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12343,Rattus norvegicus,1,A,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",50597,10116.0,,,CHEMBL624053,8608,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12344,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL624054,8085,,,,,N,Intermediate,BAO_0000218
12345,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL624055,8085,,,,,N,Intermediate,BAO_0000218
12346,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL624056,8085,,,,,N,Intermediate,BAO_0000218
12347,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL624057,8085,995.0,,,Uterus,N,Intermediate,BAO_0000218
12348,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL622281,8085,995.0,,,Uterus,N,Intermediate,BAO_0000218
12349,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL622282,8085,995.0,,,Uterus,N,Intermediate,BAO_0000218
12350,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL622283,8085,995.0,,,Uterus,N,Intermediate,BAO_0000218
12351,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL622284,8085,995.0,,,Uterus,N,Intermediate,BAO_0000218
12352,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL622285,8085,995.0,,,Uterus,N,Intermediate,BAO_0000218
12353,Rattus norvegicus,1,A,,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,10116.0,,,CHEMBL622286,8085,995.0,,,Uterus,N,Intermediate,BAO_0000218
12354,,0,P,,1,Distribution coefficient (D %) between octanol and buffer of pH 7.4,22224,,,,CHEMBL622287,7657,,,,,U,Autocuration,BAO_0000100
12355,Mus musculus,1,A,,1,Partition coefficient (logD7.4),50594,10090.0,,,CHEMBL622288,8935,,,,,N,Intermediate,BAO_0000218
12356,Mus musculus,1,A,,1,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",50594,10090.0,,,CHEMBL622289,13792,,,,,N,Intermediate,BAO_0000218
12357,Mus musculus,1,A,,1,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",50594,10090.0,,,CHEMBL622290,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
12358,Mus musculus,1,A,,1,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,50594,10090.0,,,CHEMBL622291,13792,,,,,N,Intermediate,BAO_0000218
12359,Mus musculus,1,A,,1,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,50594,10090.0,,,CHEMBL622292,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
12360,Mus musculus,1,A,,1,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",50594,10090.0,,,CHEMBL622293,13792,,,,,N,Intermediate,BAO_0000218
12361,Mus musculus,1,A,,1,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",50594,10090.0,,,CHEMBL622294,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
12362,Mus musculus,1,A,,1,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,50594,10090.0,,,CHEMBL622295,13792,,,,,N,Intermediate,BAO_0000218
12363,Rattus norvegicus,1,A,,1,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,50597,10116.0,,,CHEMBL622296,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
12364,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,50597,10116.0,,,CHEMBL874409,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12365,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,50597,10116.0,,,CHEMBL622297,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12366,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,50597,10116.0,,,CHEMBL622298,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12367,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,50597,10116.0,,,CHEMBL622299,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12368,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,50597,10116.0,,,CHEMBL622300,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12369,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,50597,10116.0,,,CHEMBL622301,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12370,Rattus norvegicus,1,A,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,50597,10116.0,,,CHEMBL622302,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12371,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,50597,10116.0,,,CHEMBL622303,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12372,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,50597,10116.0,,,CHEMBL622304,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12373,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,50597,10116.0,,,CHEMBL622305,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12374,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,50597,10116.0,,,CHEMBL622306,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12375,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,50597,10116.0,,,CHEMBL626864,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12376,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,50597,10116.0,,,CHEMBL626865,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12377,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,50597,10116.0,,,CHEMBL626866,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12378,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,50597,10116.0,,,CHEMBL626867,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12379,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,50597,10116.0,,,CHEMBL626868,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12380,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,50597,10116.0,,,CHEMBL626869,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12381,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,50597,10116.0,,,CHEMBL626870,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12382,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,50597,10116.0,,,CHEMBL626871,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12383,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,50597,10116.0,,,CHEMBL626872,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12384,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,50597,10116.0,,,CHEMBL632185,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12385,Rattus norvegicus,1,A,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,50597,10116.0,,,CHEMBL632186,14103,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12386,,0,A,,1,Amount of acetic acid produced by the compound,22224,,,,CHEMBL629310,12904,,,,,U,Autocuration,BAO_0000019
12387,,0,A,,1,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,22224,,,,CHEMBL629311,12904,,,,,U,Autocuration,BAO_0000019
12388,Rattus norvegicus,1,A,,1,Log of (Cbrain/Cblood) in rats,50597,10116.0,,,CHEMBL629312,9663,,,,,N,Intermediate,BAO_0000218
12389,,0,A,,1,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),22224,,,,CHEMBL629313,7652,,,,,U,Autocuration,BAO_0000221
12390,,0,A,,1,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,,,,CHEMBL629314,7652,,,,,U,Autocuration,BAO_0000221
12391,,0,A,,1,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),22224,,,,CHEMBL629315,7652,,,,,U,Autocuration,BAO_0000221
12392,,0,B,,1,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),22224,,,,CHEMBL629316,7652,,,,,U,Autocuration,BAO_0000219
12393,,0,A,,1,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,,,,CHEMBL629317,7652,,,,,U,Autocuration,BAO_0000221
12394,,0,A,,1,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),22224,,,,CHEMBL629318,7652,,,,,U,Autocuration,BAO_0000019
12395,,0,A,,1,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),22224,,,,CHEMBL877497,7652,,,,,U,Autocuration,BAO_0000019
12396,,0,A,,1,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),22224,,,,CHEMBL629319,7652,,,,,U,Autocuration,BAO_0000019
12397,,0,A,,1,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,,,,CHEMBL629320,7652,,,,,U,Autocuration,BAO_0000019
12398,,0,A,,1,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),22224,,,,CHEMBL629496,7652,,,,,U,Autocuration,BAO_0000019
12399,,0,A,,1,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),22224,,,,CHEMBL629497,7652,,,,,U,Autocuration,BAO_0000019
12400,,0,A,,1,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),22224,,,,CHEMBL629498,7652,,,,,U,Autocuration,BAO_0000019
12401,,0,A,,1,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),22224,,,,CHEMBL629499,7652,,,,,U,Autocuration,BAO_0000019
12402,,0,A,,1,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),22224,,,,CHEMBL629500,7652,,,,,U,Autocuration,BAO_0000019
12403,,0,A,,1,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),22224,,,,CHEMBL629501,7652,,,,,U,Autocuration,BAO_0000019
12404,,0,A,,1,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),22224,,,,CHEMBL629502,7652,,,,,U,Autocuration,BAO_0000019
12405,,0,F,,1,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,22224,,,,CHEMBL629503,8267,,,,,U,Autocuration,BAO_0000218
12406,Canis lupus familiaris,1,A,,1,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,50588,9615.0,,,CHEMBL629504,8267,,,,,N,Intermediate,BAO_0000218
12407,,0,A,,1,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,22224,,,,CHEMBL629505,14479,,,,,U,Autocuration,BAO_0000019
12408,,0,A,,1,Compound was evaluated for total body clearance,22224,,,,CHEMBL629506,17515,,,,,U,Autocuration,BAO_0000019
12409,,0,A,,1,Compound was evaluated for volume of distribution at steady state,22224,,,,CHEMBL629507,17515,,,,,U,Autocuration,BAO_0000019
12410,,0,A,,1,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,22224,,,,CHEMBL877498,8142,,,,,U,Autocuration,BAO_0000019
12411,,0,A,,1,Percentage of the diamine which is monoprotonated at pH 7.4,22224,,,,CHEMBL629508,14849,,,,,U,Autocuration,BAO_0000019
12412,,0,A,,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,22224,,,,CHEMBL629509,7653,,,,,U,Autocuration,BAO_0000019
12413,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,50597,10116.0,,,CHEMBL629510,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12414,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,10116.0,,,CHEMBL629511,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12415,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,10116.0,,,CHEMBL629512,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12416,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,10116.0,,,CHEMBL629513,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12417,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,50597,10116.0,,,CHEMBL629514,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12418,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,10116.0,,,CHEMBL628447,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12419,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,50597,10116.0,,,CHEMBL628448,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12420,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,50597,10116.0,,,CHEMBL628449,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12421,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,50597,10116.0,,,CHEMBL631119,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12422,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,50597,10116.0,,,CHEMBL631120,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12423,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,50597,10116.0,,,CHEMBL631121,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12424,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,50597,10116.0,,,CHEMBL874458,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12425,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,10116.0,,,CHEMBL631122,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12426,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,10116.0,,,CHEMBL631123,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12427,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,10116.0,,,CHEMBL631124,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12428,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,10116.0,,,CHEMBL631125,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12429,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,10116.0,,,CHEMBL631290,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12430,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,10116.0,,,CHEMBL631291,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12431,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,10116.0,,,CHEMBL631292,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12432,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,10116.0,,,CHEMBL631293,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12433,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,10116.0,,,CHEMBL631294,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12434,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,10116.0,,,CHEMBL631295,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12435,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,50597,10116.0,,,CHEMBL631296,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12436,Rattus norvegicus,1,A,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,10116.0,,,CHEMBL631297,8631,178.0,,,Blood,N,Intermediate,BAO_0000218
12437,,0,A,,1,Maximum biodistribution (Bmax) was determined.,22224,,,,CHEMBL631298,10263,,,,,U,Autocuration,BAO_0000218
12438,Mus musculus,1,A,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,50594,10090.0,,,CHEMBL631299,12364,,,,,N,Intermediate,BAO_0000218
12439,Mus musculus,1,A,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,50594,10090.0,,,CHEMBL631300,12364,,,,,N,Intermediate,BAO_0000218
12440,Mus musculus,1,A,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,50594,10090.0,,,CHEMBL631301,12364,,,,,N,Intermediate,BAO_0000218
12441,Mus musculus,1,A,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,50594,10090.0,,,CHEMBL630291,12364,,,,,N,Intermediate,BAO_0000218
12442,,0,A,,1,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,,CHEMBL630292,14793,,,,,U,Autocuration,BAO_0000218
12443,,0,A,,1,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,22224,,,,CHEMBL630293,14793,,,,,U,Autocuration,BAO_0000218
12444,,0,A,,1,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,22224,,,,CHEMBL630294,14793,,,,,U,Autocuration,BAO_0000218
12445,,0,A,,1,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,22224,,,,CHEMBL630295,14793,,,,,U,Autocuration,BAO_0000218
12446,,0,A,,1,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,22224,,,,CHEMBL630296,14793,,,,,U,Autocuration,BAO_0000218
12447,,0,A,,1,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,22224,,,,CHEMBL626782,14793,,,,,U,Autocuration,BAO_0000218
12448,,0,A,,1,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,22224,,,,CHEMBL626783,14793,,,,,U,Autocuration,BAO_0000218
12449,,0,A,,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,,CHEMBL626784,14793,,,,,U,Autocuration,BAO_0000218
12450,,0,A,,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,22224,,,,CHEMBL626785,14793,,,,,U,Autocuration,BAO_0000218
12451,,0,A,,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,22224,,,,CHEMBL626786,14793,,,,,U,Autocuration,BAO_0000218
12452,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL626787,9196,,,,,U,Autocuration,BAO_0000218
12453,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,22224,,,,CHEMBL626788,9196,,,,,U,Autocuration,BAO_0000218
12454,,0,A,,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,,,,CHEMBL625927,9196,,,,,U,Autocuration,BAO_0000218
12455,Rattus norvegicus,1,A,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL625928,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12456,Rattus norvegicus,1,A,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,10116.0,,,CHEMBL625929,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12457,Rattus norvegicus,1,A,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,50597,10116.0,,,CHEMBL625930,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12458,Rattus norvegicus,1,A,,1,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",50597,10116.0,,,CHEMBL625931,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12459,Rattus norvegicus,1,A,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,50597,10116.0,,,CHEMBL627230,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12460,Rattus norvegicus,1,A,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627231,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12461,Rattus norvegicus,1,A,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,10116.0,,,CHEMBL627232,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12462,Rattus norvegicus,1,A,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,50597,10116.0,,,CHEMBL627233,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12463,Rattus norvegicus,1,A,,1,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL875470,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12464,Rattus norvegicus,1,A,,1,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627234,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12465,Rattus norvegicus,1,A,,1,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627235,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12466,Rattus norvegicus,1,A,,1,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627236,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12467,Rattus norvegicus,1,A,,1,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627237,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12468,Rattus norvegicus,1,A,,1,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627238,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12469,Rattus norvegicus,1,A,,1,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627239,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12470,Rattus norvegicus,1,A,,1,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627240,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12471,Rattus norvegicus,1,A,,1,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627241,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12472,Rattus norvegicus,1,A,,1,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627242,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12473,Rattus norvegicus,1,A,,1,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,50597,10116.0,,,CHEMBL627243,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12474,Rattus norvegicus,1,A,,1,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,10116.0,,,CHEMBL627244,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12475,Rattus norvegicus,1,A,,1,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627245,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12476,Rattus norvegicus,1,A,,1,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627246,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12477,Rattus norvegicus,1,A,,1,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627247,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12478,Rattus norvegicus,1,A,,1,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627248,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12479,Rattus norvegicus,1,A,,1,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627249,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12480,Rattus norvegicus,1,A,,1,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL625569,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12481,Rattus norvegicus,1,A,,1,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL625570,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12482,Rattus norvegicus,1,A,,1,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL625571,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12483,Rattus norvegicus,1,A,,1,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,10116.0,,,CHEMBL625572,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12484,Rattus norvegicus,1,A,,1,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,10116.0,,,CHEMBL625573,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12485,Rattus norvegicus,1,A,,1,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,50597,10116.0,,,CHEMBL625574,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12486,Rattus norvegicus,1,A,,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,10116.0,,,CHEMBL626245,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12487,Rattus norvegicus,1,A,,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL626246,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12488,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,,CHEMBL626247,9196,,,,,U,Autocuration,BAO_0000218
12489,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,,CHEMBL626248,9196,,,,,U,Autocuration,BAO_0000218
12490,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,22224,,,,CHEMBL626249,9196,,,,,U,Autocuration,BAO_0000218
12491,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,,CHEMBL626420,9196,,,,,U,Autocuration,BAO_0000218
12492,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,,,,CHEMBL626421,9196,,,,,U,Autocuration,BAO_0000218
12493,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,,,,CHEMBL626422,9196,,,,,U,Autocuration,BAO_0000218
12494,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,,CHEMBL626423,9196,,,,,U,Autocuration,BAO_0000218
12495,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL626424,9196,,,,,U,Autocuration,BAO_0000218
12496,Canis lupus familiaris,1,A,,1,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,50588,9615.0,,,CHEMBL626425,12023,,,,,N,Intermediate,BAO_0000218
12497,Rattus norvegicus,1,A,,1,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,50597,10116.0,,,CHEMBL875476,12023,,,,,N,Intermediate,BAO_0000218
12498,Macaca fascicularis,1,A,,1,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,100710,9541.0,,,CHEMBL626426,12023,,,,,N,Intermediate,BAO_0000218
12499,,0,P,,1,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,22224,,,,CHEMBL626427,10580,,,,,U,Autocuration,BAO_0000100
12500,,0,P,,1,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,22224,,,,CHEMBL626428,10580,,,,,U,Autocuration,BAO_0000100
12501,,0,A,,1,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,22224,,,,CHEMBL626429,16032,,,,,U,Autocuration,BAO_0000019
12502,,0,A,,1,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,22224,,,,CHEMBL625025,16032,1088.0,,,Urine,U,Autocuration,BAO_0000019
12503,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL625026,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12504,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL625027,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12505,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL874410,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12506,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL625028,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12507,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL625029,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12508,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL625030,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12509,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL625031,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12510,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL625032,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12511,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL625033,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12512,Rattus norvegicus,1,A,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL625034,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12513,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624872,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12514,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624873,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12515,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624874,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12516,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624875,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12517,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624876,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12518,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624877,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12519,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624878,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12520,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624879,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12521,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624880,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12522,Rattus norvegicus,1,A,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624881,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12523,Rattus norvegicus,1,A,,1,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",50597,10116.0,,,CHEMBL624882,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12524,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624883,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12525,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624884,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12526,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624885,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12527,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624886,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12528,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624887,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12529,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624888,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12530,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624889,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12531,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624890,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12532,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL621964,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12533,Rattus norvegicus,1,A,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL621965,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12534,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL621966,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12535,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL621967,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12536,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL622164,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12537,,0,A,,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),22224,,,,CHEMBL623097,7653,,,,,U,Autocuration,BAO_0000019
12538,,0,A,,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),22224,,,,CHEMBL623098,7653,,,,,U,Autocuration,BAO_0000019
12539,,0,A,,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,22224,,,,CHEMBL623099,7653,,,,,U,Autocuration,BAO_0000019
12540,,0,A,,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,22224,,,,CHEMBL623100,7653,,,,,U,Autocuration,BAO_0000019
12541,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",50597,10116.0,,,CHEMBL628673,9104,,,,,N,Intermediate,BAO_0000218
12542,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",50597,10116.0,,,CHEMBL628674,9104,,,,,N,Intermediate,BAO_0000218
12543,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",50597,10116.0,,,CHEMBL628675,9104,,,,,N,Intermediate,BAO_0000218
12544,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",50597,10116.0,,,CHEMBL627644,9104,,,,,N,Intermediate,BAO_0000218
12545,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",50597,10116.0,,,CHEMBL627645,9104,,,,,N,Intermediate,BAO_0000218
12546,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",50597,10116.0,,,CHEMBL627646,9104,,,,,N,Intermediate,BAO_0000218
12547,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",50597,10116.0,,,CHEMBL627647,9104,,,,,N,Intermediate,BAO_0000218
12548,Rattus norvegicus,1,A,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",50597,10116.0,,,CHEMBL627648,9104,,,,,N,Intermediate,BAO_0000218
12549,Rattus norvegicus,1,A,,1,Free level in rat plasma,50597,10116.0,,,CHEMBL627649,12902,,,,,N,Intermediate,BAO_0000218
12550,,0,A,,1,Level reaching in blood plasma of rat or human was determined,22224,,,,CHEMBL628313,6614,,,,,U,Autocuration,BAO_0000019
12551,Rattus norvegicus,1,A,,1,Log (Cbrain/Cblood) in rats,50597,10116.0,,,CHEMBL628314,9663,,,,,N,Intermediate,BAO_0000218
12552,,0,A,,1,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,22224,,,,CHEMBL628315,17658,,,,,U,Autocuration,BAO_0000019
12553,,0,A,,1,Mean percentage of compound transport through membrane; expressed as membrane transport,22224,,,,CHEMBL628316,17658,,,,,U,Autocuration,BAO_0000019
12554,,0,A,,1,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,22224,,,,CHEMBL628317,14314,,,,,U,Autocuration,BAO_0000218
12555,,0,A,,1,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,22224,,,,CHEMBL628473,7385,,,,,U,Autocuration,BAO_0000019
12556,,0,A,,1,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",22224,,,,CHEMBL628474,7385,,,,,U,Autocuration,BAO_0000019
12557,,0,A,,1,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,22224,,,,CHEMBL628475,7385,,,,,U,Autocuration,BAO_0000019
12558,,0,A,,1,Net water uptake by a carrier mediated transport (%cm) mechanism,22224,,,,CHEMBL628476,1329,,,,,U,Autocuration,BAO_0000019
12559,Simiiformes,0,A,,1,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,22224,314293.0,,,CHEMBL628477,12187,,,,,U,Autocuration,BAO_0000218
12560,Mustela putorius furo,1,A,,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,50506,9669.0,,,CHEMBL628478,12187,,,,,N,Intermediate,BAO_0000218
12561,Mustela putorius furo,1,A,,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",50506,9669.0,,,CHEMBL628479,12187,,,,,N,Intermediate,BAO_0000218
12562,Simiiformes,0,A,,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,22224,314293.0,,,CHEMBL628480,12187,,,,,U,Autocuration,BAO_0000218
12563,Simiiformes,0,A,,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",22224,314293.0,,,CHEMBL628481,12187,,,,,U,Autocuration,BAO_0000218
12564,Rattus norvegicus,1,A,,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,50597,10116.0,,,CHEMBL628482,12187,,,,,N,Intermediate,BAO_0000218
12565,Rattus norvegicus,1,A,,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,10116.0,,,CHEMBL628483,12187,,,,,N,Intermediate,BAO_0000218
12566,Rattus norvegicus,1,A,,1,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",50597,10116.0,,,CHEMBL628484,9278,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12567,Rattus norvegicus,1,A,,1,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,10116.0,,,CHEMBL628485,9278,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12568,Macaca fascicularis,1,A,,1,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",100710,9541.0,,,CHEMBL628486,9278,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12569,Homo sapiens,1,A,,1,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",50587,9606.0,,,CHEMBL628487,9278,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12570,Rattus norvegicus,1,A,,1,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",50597,10116.0,,,CHEMBL628488,9278,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12571,Rattus norvegicus,1,A,,1,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,10116.0,,,CHEMBL628489,9278,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12572,Rattus norvegicus,1,A,,1,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,10116.0,,,CHEMBL628490,9278,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12573,Macaca fascicularis,1,A,,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,9541.0,,,CHEMBL628491,12186,,,,,N,Intermediate,BAO_0000218
12574,Macaca fascicularis,1,A,,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,9541.0,,,CHEMBL877507,12186,,,,,N,Intermediate,BAO_0000218
12575,,0,A,,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,22224,,,,CHEMBL628492,12186,,,,,U,Autocuration,BAO_0000218
12576,Simiiformes,0,A,,1,% metabolized in monkey S-9 after 2 hours (10 ug/mL),22224,314293.0,,,CHEMBL628493,12041,,,,,U,Autocuration,BAO_0000019
12577,Simiiformes,0,A,,1,% metabolized in monkey S-9 after 2 hours (1 ug/ml),22224,314293.0,,,CHEMBL628494,12041,,,,,U,Autocuration,BAO_0000019
12578,Simiiformes,0,A,,1,% metabolized in monkey S-9 after 2 hours (10 ug/ml),22224,314293.0,,,CHEMBL628495,12041,,,,,U,Autocuration,BAO_0000019
12579,Homo sapiens,1,A,,1,Permeability in Caco-2 assay at 10E-6,50587,9606.0,,,CHEMBL628496,6737,,,,,N,Intermediate,BAO_0000218
12580,,0,A,,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,22224,,,,CHEMBL628497,13758,955.0,,,Brain,U,Autocuration,BAO_0000218
12581,,0,A,,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,22224,,,,CHEMBL628498,13758,955.0,,,Brain,U,Autocuration,BAO_0000218
12582,,0,A,,1,Plasma protein binding was determined,22224,,,,CHEMBL628499,5676,,,,,U,Autocuration,BAO_0000019
12583,,0,A,,1,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,22224,,,,CHEMBL627656,14793,,,,,U,Autocuration,BAO_0000218
12584,,0,A,,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,,CHEMBL627657,14793,,,,,U,Autocuration,BAO_0000218
12585,,0,A,,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,22224,,,,CHEMBL626808,14793,,,,,U,Autocuration,BAO_0000218
12586,,0,A,,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,22224,,,,CHEMBL626809,14793,,,,,U,Autocuration,BAO_0000218
12587,,0,A,,1,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,22224,,,,CHEMBL626810,14793,,,,,U,Autocuration,BAO_0000218
12588,,0,A,,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,,CHEMBL626811,14793,,,,,U,Autocuration,BAO_0000218
12589,,0,A,,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,22224,,,,CHEMBL874465,14793,,,,,U,Autocuration,BAO_0000218
12590,,0,A,,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,22224,,,,CHEMBL626812,14793,,,,,U,Autocuration,BAO_0000218
12591,,0,A,,1,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,22224,,,,CHEMBL626813,14793,,,,,U,Autocuration,BAO_0000218
12592,,0,A,,1,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,22224,,,,CHEMBL626814,14793,,,,,U,Autocuration,BAO_0000218
12593,,0,A,,1,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,22224,,,,CHEMBL626815,14000,,,,,U,Autocuration,BAO_0000019
12594,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL628566,5948,,,,,U,Autocuration,BAO_0000019
12595,,0,P,,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,,,,CHEMBL628567,13824,,,,,U,Autocuration,BAO_0000100
12596,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL628568,10778,,,,,U,Autocuration,BAO_0000100
12597,Canis lupus familiaris,1,A,,1,C max in dog,50588,9615.0,,,CHEMBL628569,17237,,,,,N,Intermediate,BAO_0000218
12598,Cavia porcellus,1,A,,1,C max in guinea pig,50512,10141.0,,,CHEMBL628570,17237,,,,,N,Intermediate,BAO_0000218
12599,,0,A,,1,C max value was evaluated,22224,,,,CHEMBL628571,2809,,,,,U,Autocuration,BAO_0000218
12600,,0,A,,1,Cmax value after oral dose of 0.1 mg//kg,22224,,,,CHEMBL628572,11954,,,,,U,Autocuration,BAO_0000218
12601,,0,A,,1,Cmax value after oral dose of 0.3 mg/kg,22224,,,,CHEMBL628573,11954,,,,,U,Autocuration,BAO_0000218
12602,,0,A,,1,Cmax value after oral dose of 1 mg/kg,22224,,,,CHEMBL628574,11954,,,,,U,Autocuration,BAO_0000218
12603,,0,A,,1,Cmax value after oral dose of 10 mg/kg,22224,,,,CHEMBL628575,11954,,,,,U,Autocuration,BAO_0000218
12604,,0,A,,1,Cmax value after oral dose of 23.4 mg/kg,22224,,,,CHEMBL628576,11954,,,,,U,Autocuration,BAO_0000218
12605,,0,A,,1,Cmax value after oral dose of 3 mg/kg,22224,,,,CHEMBL628577,11954,,,,,U,Autocuration,BAO_0000218
12606,,0,A,,1,Cmax value after oral dose of 3.87 mg/kg,22224,,,,CHEMBL628578,11954,,,,,U,Autocuration,BAO_0000218
12607,Canis lupus familiaris,1,A,,1,Cmax value in female Beagle dogs,50588,9615.0,,,CHEMBL874466,12768,,,,,N,Intermediate,BAO_0000218
12608,Rattus norvegicus,1,A,,1,Cmax value in male rats,50597,10116.0,,,CHEMBL628579,12768,,,,,N,Intermediate,BAO_0000218
12609,Rattus norvegicus,1,A,,1,Cmax value in rat plasma when administered 20 mg/kg perorally,50597,10116.0,,,CHEMBL628580,12780,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12610,Canis lupus familiaris,1,A,,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,9615.0,,,CHEMBL628581,15592,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12611,Canis lupus familiaris,1,A,,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,9615.0,,,CHEMBL628582,15592,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12612,Canis lupus familiaris,1,A,,1,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,50588,9615.0,,,CHEMBL628583,17025,,,,,N,Intermediate,BAO_0000218
12613,Simiiformes,0,A,,1,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,22224,314293.0,,,CHEMBL625782,17025,,,,,U,Autocuration,BAO_0000218
12614,Oryctolagus cuniculus,1,A,,1,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,50592,9986.0,,,CHEMBL625783,17025,,,,,N,Intermediate,BAO_0000218
12615,Rattus norvegicus,1,A,,1,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,50597,10116.0,,,CHEMBL625784,17025,,,,,N,Intermediate,BAO_0000218
12616,Macaca mulatta,1,A,,1,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,50797,9544.0,,,CHEMBL625785,4236,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12617,Rattus norvegicus,1,A,,1,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,50597,10116.0,,,CHEMBL625786,15791,,,,,N,Intermediate,BAO_0000218
12618,,0,A,,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,22224,,,,CHEMBL874467,11149,,,,,U,Autocuration,BAO_0000019
12619,Canis lupus familiaris,1,A,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",50588,9615.0,,,CHEMBL625787,15592,,,,,N,Intermediate,BAO_0000218
12620,Human immunodeficiency virus,1,A,,1,cytotoxicity against HIV protease enzyme.,50677,12721.0,,,CHEMBL625964,15778,,,,,N,Intermediate,BAO_0000218
12621,Mus musculus,1,A,,1,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,50594,10090.0,,,CHEMBL625965,12745,,,,,N,Intermediate,BAO_0000218
12622,Mus musculus,1,A,,1,Apparent clearance in mice after oral administration of 100 mg/kg of dose,50594,10090.0,,,CHEMBL625966,12745,,,,,N,Intermediate,BAO_0000218
12623,Canis lupus familiaris,1,A,,1,The plasma clearance in dog.,50588,9615.0,,,CHEMBL625967,13941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12624,Rattus norvegicus,1,A,,1,The plasma clearance in rat.,50597,10116.0,,,CHEMBL625968,13941,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12625,Rattus norvegicus,1,A,,1,Clearance from plasma in male Sprague-Dawley rats,50597,10116.0,,,CHEMBL625969,16449,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12626,Macaca fascicularis,1,A,,1,Clearance from plasma in male cynomolgus monkeys,100710,9541.0,,,CHEMBL625970,16449,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12627,Canis lupus familiaris,1,A,,1,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",50588,9615.0,,,CHEMBL625971,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12628,Canis lupus familiaris,1,A,,1,Clearance of compound in dog plasma,50588,9615.0,,,CHEMBL625972,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12629,Homo sapiens,1,A,,1,Clearance of compound in human plasma,50587,9606.0,,,CHEMBL625973,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12630,Canis lupus familiaris,1,A,,1,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,50588,9615.0,,,CHEMBL625974,14317,,,,,N,Intermediate,BAO_0000218
12631,Canis lupus familiaris,1,A,,1,Clearance of compound when administered intravenously as an individual dose to a single dog.,50588,9615.0,,,CHEMBL625975,14317,,,,,N,Intermediate,BAO_0000218
12632,Canis lupus familiaris,1,A,,1,"Clearance (10 mg/kg, intravenously) in dog plasma",50588,9615.0,,,CHEMBL625976,14224,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12633,Canis lupus familiaris,1,A,,1,Clearance value in dog,50588,9615.0,,,CHEMBL625977,17237,,,,,N,Intermediate,BAO_0000218
12634,Cavia porcellus,1,A,,1,Clearance value in guinea pig,50512,10141.0,,,CHEMBL625978,17237,,,,,N,Intermediate,BAO_0000218
12635,Rattus norvegicus,1,A,,1,Clearance values in rats after iv administration.,50597,10116.0,,,CHEMBL874468,14187,,,,,N,Intermediate,BAO_0000218
12636,,0,A,,1,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,22224,,,,CHEMBL625421,4806,1969.0,,,Plasma,U,Autocuration,BAO_0000218
12637,Oryctolagus cuniculus,1,A,,1,In vivo clearance (5 mg/kg) was determined in rabbits,50592,9986.0,,,CHEMBL625422,15025,,,,,N,Intermediate,BAO_0000218
12638,Rattus norvegicus,1,A,,1,Plasma Clearance rate was determined for the compound in rats,50597,10116.0,,,CHEMBL625423,13197,,,,,N,Intermediate,BAO_0000218
12639,Saimiri,0,A,,1,Plasma Clearance rate was determined for the compound in squirrel monkeys,22224,9520.0,,,CHEMBL625424,13197,,,,,U,Autocuration,BAO_0000218
12640,Rattus norvegicus,1,A,,1,Plasma clearance in rat,50597,10116.0,,,CHEMBL625425,13960,,,,,N,Intermediate,BAO_0000218
12641,,0,A,,1,Plasma clearance of the compound,22224,,,,CHEMBL625426,17820,,,,,U,Autocuration,BAO_0000218
12642,Cavia porcellus,1,A,,1,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,50512,10141.0,,,CHEMBL625427,14706,,,,,N,Intermediate,BAO_0000218
12643,Cavia porcellus,1,A,,1,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,50512,10141.0,,,CHEMBL625428,14706,,,,,N,Intermediate,BAO_0000218
12644,,0,A,,1,Plasma clearance was determined,22224,,,,CHEMBL625429,6504,,,,,U,Autocuration,BAO_0000218
12645,Canis lupus familiaris,1,A,,1,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,50588,9615.0,,,CHEMBL625430,14925,,,,,N,Intermediate,BAO_0000218
12646,Rattus norvegicus,1,A,,1,Plasma clearance rate was determined for the compound in rats,50597,10116.0,,,CHEMBL625431,13197,,,,,N,Intermediate,BAO_0000218
12647,Saimiri,0,A,,1,Plasma clearance rate was determined for the compound in squirrel monkeys,22224,9520.0,,,CHEMBL627307,13197,,,,,U,Autocuration,BAO_0000218
12648,,0,A,,1,Slow clearance (CL) was determined,22224,,,,CHEMBL627308,3437,,,,,U,Autocuration,BAO_0000218
12649,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,,,,CHEMBL627309,9196,,,,,U,Autocuration,BAO_0000218
12650,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,22224,,,,CHEMBL627310,9196,,,,,U,Autocuration,BAO_0000218
12651,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,22224,,,,CHEMBL627311,9196,,,,,U,Autocuration,BAO_0000218
12652,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,,,,CHEMBL627312,9196,,,,,U,Autocuration,BAO_0000218
12653,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,22224,,,,CHEMBL627313,9196,,,,,U,Autocuration,BAO_0000218
12654,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,,,,CHEMBL627314,9196,,,,,U,Autocuration,BAO_0000218
12655,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,,,,CHEMBL627315,9196,,,,,U,Autocuration,BAO_0000218
12656,,0,A,,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL627316,9196,,,,,U,Autocuration,BAO_0000218
12657,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,,CHEMBL627317,9196,,,,,U,Autocuration,BAO_0000218
12658,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,,CHEMBL627318,9196,,,,,U,Autocuration,BAO_0000218
12659,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,22224,,,,CHEMBL627999,9196,,,,,U,Autocuration,BAO_0000218
12660,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,,CHEMBL628000,9196,,,,,U,Autocuration,BAO_0000218
12661,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,,,,CHEMBL628001,9196,,,,,U,Autocuration,BAO_0000218
12662,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL628002,9196,,,,,U,Autocuration,BAO_0000218
12663,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,,,,CHEMBL625610,9196,,,,,U,Autocuration,BAO_0000218
12664,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,,CHEMBL625611,9196,,,,,U,Autocuration,BAO_0000218
12665,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,22224,,,,CHEMBL625612,9196,,,,,U,Autocuration,BAO_0000218
12666,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,22224,,,,CHEMBL625613,9196,,,,,U,Autocuration,BAO_0000218
12667,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,,CHEMBL875479,9196,,,,,U,Autocuration,BAO_0000218
12668,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,,,,CHEMBL625614,9196,,,,,U,Autocuration,BAO_0000218
12669,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,,,,CHEMBL625615,9196,,,,,U,Autocuration,BAO_0000218
12670,,0,A,,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,22224,,,,CHEMBL626302,9196,,,,,U,Autocuration,BAO_0000218
12671,Rattus norvegicus,1,A,,1,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL626303,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12672,Rattus norvegicus,1,A,,1,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,10116.0,,,CHEMBL627420,8374,178.0,,,Blood,N,Intermediate,BAO_0000218
12673,Rattus norvegicus,1,A,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,50597,10116.0,,,CHEMBL627421,13477,,,,,N,Intermediate,BAO_0000218
12674,Rattus norvegicus,1,A,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,50597,10116.0,,,CHEMBL625695,13477,,,,,N,Intermediate,BAO_0000218
12675,Rattus norvegicus,1,A,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,50597,10116.0,,,CHEMBL625696,13477,,,,,N,Intermediate,BAO_0000218
12676,Mus musculus,1,A,,1,Distribution of compound in mice brain was measured after 1 hr,50594,10090.0,,,CHEMBL875606,10009,955.0,,,Brain,N,Intermediate,BAO_0000218
12677,Mus musculus,1,A,,1,Distribution of compound in mice brain was measured after 24 hr r,50594,10090.0,,,CHEMBL625697,10009,955.0,,,Brain,N,Intermediate,BAO_0000218
12678,Mus musculus,1,A,,1,Distribution of compound in mice brain was measured after 2 hr,50594,10090.0,,,CHEMBL625698,10009,955.0,,,Brain,N,Intermediate,BAO_0000218
12679,Mus musculus,1,A,,1,Distribution of compound in mice brain was measured after 3 hr,50594,10090.0,,,CHEMBL625699,10009,955.0,,,Brain,N,Intermediate,BAO_0000218
12680,Mus musculus,1,A,,1,Distribution of compound in mice brain was measured after 6 hr,50594,10090.0,,,CHEMBL625700,10009,955.0,,,Brain,N,Intermediate,BAO_0000218
12681,Mus musculus,1,A,,1,Distribution of compound in mice liver was measured after 1 hr,50594,10090.0,,,CHEMBL625701,10009,,,,,N,Intermediate,BAO_0000218
12682,Mus musculus,1,A,,1,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,50594,10090.0,,,CHEMBL625702,10009,,,,,N,Intermediate,BAO_0000218
12683,Mus musculus,1,A,,1,Distribution of compound in mice liver was measured after 2 hr,50594,10090.0,,,CHEMBL625703,10009,,,,,N,Intermediate,BAO_0000218
12684,Mus musculus,1,A,,1,Distribution of compound in mice liver was measured after 3 hr,50594,10090.0,,,CHEMBL625704,10009,,,,,N,Intermediate,BAO_0000218
12685,Mus musculus,1,A,,1,Distribution of compound in mice liver was measured after 6 hr,50594,10090.0,,,CHEMBL625705,10009,,,,,N,Intermediate,BAO_0000218
12686,Canis lupus familiaris,1,A,,1,Distribution in dog adrenal medulla 30 min after administration.,50588,9615.0,,,CHEMBL625706,8170,1236.0,,,Adrenal medulla,N,Intermediate,BAO_0000218
12687,Canis lupus familiaris,1,A,,1,Distribution in dog adrenal medulla 72 hours after administration.,50588,9615.0,,,CHEMBL625707,8170,1236.0,,,Adrenal medulla,N,Intermediate,BAO_0000218
12688,Canis lupus familiaris,1,A,,1,Distribution in female dog Ovary 24 hours after administration.,50588,9615.0,,,CHEMBL625708,8170,,,,,N,Intermediate,BAO_0000218
12689,Canis lupus familiaris,1,A,,1,Distribution in female dog Ovary 72 hours after administration.,50588,9615.0,,,CHEMBL625709,8170,,,,,N,Intermediate,BAO_0000218
12690,Canis lupus familiaris,1,A,,1,Distribution in female dog adipose 24 hours after administration.,50588,9615.0,,,CHEMBL624180,8170,,,,,N,Intermediate,BAO_0000218
12691,Canis lupus familiaris,1,A,,1,Distribution in female dog adipose 72 hours after administration.,50588,9615.0,,,CHEMBL624181,8170,,,,,N,Intermediate,BAO_0000218
12692,Canis lupus familiaris,1,A,,1,Distribution in female dog adrenal cortex 72 hours after administration.,50588,9615.0,,,CHEMBL624182,8170,1235.0,,,Adrenal cortex,N,Intermediate,BAO_0000218
12693,Canis lupus familiaris,1,A,,1,Distribution in female dog adrenal cortex 72 hours after administration.,50588,9615.0,,,CHEMBL624183,8170,1235.0,,,Adrenal cortex,N,Intermediate,BAO_0000218
12694,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624184,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12695,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL877489,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12696,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624185,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12697,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624186,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12698,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624187,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12699,Rattus norvegicus,1,A,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624188,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12700,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624189,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12701,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624190,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12702,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624191,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12703,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624192,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12704,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624193,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12705,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624194,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12706,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624891,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12707,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL624892,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12708,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL624893,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12709,Rattus norvegicus,1,A,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL627632,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12710,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL627633,8594,,,,,N,Intermediate,BAO_0000218
12711,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL627634,8594,,,,,N,Intermediate,BAO_0000218
12712,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL627635,8594,,,,,N,Intermediate,BAO_0000218
12713,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL627636,8594,,,,,N,Intermediate,BAO_0000218
12714,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL626816,8594,,,,,N,Intermediate,BAO_0000218
12715,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626817,8594,,,,,N,Intermediate,BAO_0000218
12716,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL626818,8594,,,,,N,Intermediate,BAO_0000218
12717,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626819,8594,,,,,N,Intermediate,BAO_0000218
12718,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL626820,8594,,,,,N,Intermediate,BAO_0000218
12719,Rattus norvegicus,1,A,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626821,8594,,,,,N,Intermediate,BAO_0000218
12720,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626822,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12721,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626823,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12722,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL626824,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12723,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626825,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12724,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL626826,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12725,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626827,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12726,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL626828,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12727,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626829,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12728,Rattus norvegicus,1,A,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626830,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12729,Rattus norvegicus,1,A,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL627150,8594,,,,,N,Intermediate,BAO_0000218
12730,Rattus norvegicus,1,A,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL627151,8594,,,,,N,Intermediate,BAO_0000218
12731,Rattus norvegicus,1,A,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,10116.0,,,CHEMBL627152,8594,,,,,N,Intermediate,BAO_0000218
12732,Rattus norvegicus,1,A,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL627153,8594,,,,,N,Intermediate,BAO_0000218
12733,,0,A,,1,Rate of acetate production by the compound was determined,22224,,,,CHEMBL627154,12904,,,,,U,Autocuration,BAO_0000019
12734,,0,A,,1,Rate of acetate production by the compound was determined; Not determined,22224,,,,CHEMBL627155,12904,,,,,U,Autocuration,BAO_0000019
12735,,0,A,,1,Rate of hydrolysis of nitrocefin by compound was evaluated in water,22224,,,,CHEMBL627156,3730,,,,,U,Autocuration,BAO_0000019
12736,,0,A,,1,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,22224,,,,CHEMBL627157,3627,,,,,U,Autocuration,BAO_0000019
12737,Oryctolagus cuniculus,1,A,,1,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,50592,9986.0,,,CHEMBL627158,13799,,,,,N,Intermediate,BAO_0000218
12738,Oryctolagus cuniculus,1,A,,1,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,50592,9986.0,,,CHEMBL627159,13799,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12739,Mus musculus,1,A,,1,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,50594,10090.0,,,CHEMBL627160,13799,,,,,N,Intermediate,BAO_0000218
12740,Rattus norvegicus,1,A,,1,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,50597,10116.0,,,CHEMBL628540,13799,,,,,N,Intermediate,BAO_0000218
12741,Rattus norvegicus,1,A,,1,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,50597,10116.0,,,CHEMBL628541,13799,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12742,Rattus norvegicus,1,A,,1,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,50597,10116.0,,,CHEMBL628542,13799,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12743,,0,P,,1,Solubility after at a pH 1.2,22229,,,,CHEMBL628543,6629,,,,,U,Autocuration,BAO_0000100
12744,,0,P,,1,Solubility after at pH 1.2,22229,,,,CHEMBL628544,6629,,,,,U,Autocuration,BAO_0000100
12745,,0,P,,1,Solubility after injection of water,22229,,,,CHEMBL628545,6629,,,,,U,Autocuration,BAO_0000100
12746,,0,A,,1,Statistical significance of IC 50 values; Expressed as R value,22224,,,,CHEMBL628546,14000,,,,,U,Autocuration,BAO_0000019
12747,,0,A,,1,Systemic availability with respect to methyldopa was determined,22224,,,,CHEMBL874455,8267,,,,,U,Autocuration,BAO_0000019
12748,Rattus norvegicus,1,A,,1,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,50597,10116.0,,,CHEMBL628547,13799,,,,,N,Intermediate,BAO_0000218
12749,Rattus norvegicus,1,A,,1,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,50597,10116.0,,,CHEMBL628548,13799,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12750,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL628549,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12751,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL628550,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12752,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",50592,9986.0,,,CHEMBL628551,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12753,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",50592,9986.0,,,CHEMBL628552,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12754,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",50592,9986.0,,,CHEMBL628553,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12755,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",50592,9986.0,,,CHEMBL628554,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12756,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",50592,9986.0,,,CHEMBL628555,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12757,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",50592,9986.0,,,CHEMBL628556,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12758,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL628557,7132,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12759,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL628558,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12760,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",50592,9986.0,,,CHEMBL628559,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12761,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL628560,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12762,Oryctolagus cuniculus,1,A,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",50592,9986.0,,,CHEMBL874456,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12763,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",50592,9986.0,,,CHEMBL628561,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12764,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",50592,9986.0,,,CHEMBL628562,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12765,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",50592,9986.0,,,CHEMBL628563,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12766,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",50592,9986.0,,,CHEMBL628564,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12767,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",50592,9986.0,,,CHEMBL628565,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12768,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",50592,9986.0,,,CHEMBL631248,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12769,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",50592,9986.0,,,CHEMBL631249,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
12770,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL627214,7132,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12771,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL874591,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12772,Oryctolagus cuniculus,1,A,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",50592,9986.0,,,CHEMBL627215,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12773,Oryctolagus cuniculus,1,A,,1,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,50592,9986.0,,,CHEMBL625471,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
12774,Oryctolagus cuniculus,1,A,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,50592,9986.0,,,CHEMBL625472,7132,,,,,N,Intermediate,BAO_0000218
12775,Oryctolagus cuniculus,1,A,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,50592,9986.0,,,CHEMBL625473,7132,,,,,N,Intermediate,BAO_0000218
12776,Canis lupus familiaris,1,A,,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,50588,9615.0,,,CHEMBL625474,13317,,,,,N,Intermediate,BAO_0000218
12777,Canis lupus familiaris,1,A,,1,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,50588,9615.0,,,CHEMBL625475,15341,,,,,N,Intermediate,BAO_0000218
12778,Rattus norvegicus,1,A,,1,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,50597,10116.0,,,CHEMBL625476,15341,,,,,N,Intermediate,BAO_0000218
12779,Rattus norvegicus,1,A,,1,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,50597,10116.0,,,CHEMBL625477,15341,,,,,N,Intermediate,BAO_0000218
12780,Rattus norvegicus,1,A,,1,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,50597,10116.0,,,CHEMBL625478,15341,,,,,N,Intermediate,BAO_0000218
12781,Rattus norvegicus,1,A,,1,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,50597,10116.0,,,CHEMBL625479,12801,,,,esophageal tunica muscularis mucosae,N,Intermediate,BAO_0000218
12782,Rattus norvegicus,1,A,,1,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,50597,10116.0,,,CHEMBL625480,12801,,,,esophageal tunica muscularis mucosae,N,Intermediate,BAO_0000218
12783,Rattus norvegicus,1,A,,1,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,50597,10116.0,,,CHEMBL625481,14856,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12784,Rattus norvegicus,1,A,,1,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,50597,10116.0,,,CHEMBL625482,14062,,,,,N,Intermediate,BAO_0000218
12785,Rattus norvegicus,1,A,,1,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,50597,10116.0,,,CHEMBL625483,14062,,,,,N,Intermediate,BAO_0000218
12786,Rattus norvegicus,1,A,,1,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,50597,10116.0,,,CHEMBL625484,14062,,,,,N,Intermediate,BAO_0000218
12787,Rattus norvegicus,1,A,,1,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,50597,10116.0,,,CHEMBL625485,14062,,,,,N,Intermediate,BAO_0000218
12788,Canis lupus familiaris,1,A,,1,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,50588,9615.0,,,CHEMBL625486,14346,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12789,Rattus norvegicus,1,A,,1,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL625487,14346,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12790,Rattus norvegicus,1,A,,1,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL625488,14346,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12791,Rattus norvegicus,1,A,,1,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL625489,14346,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12792,Rattus norvegicus,1,A,,1,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL625490,14346,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12793,Canis lupus familiaris,1,A,,1,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,50588,9615.0,,,CHEMBL625491,14346,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12794,Rattus norvegicus,1,A,,1,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,50597,10116.0,,,CHEMBL625492,14346,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12795,Homo sapiens,1,A,,1,plasma clearance in human,50587,9606.0,,,CHEMBL625493,15711,1969.0,,,Plasma,N,Intermediate,BAO_0000218
12796,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,50597,10116.0,,,CHEMBL625494,14886,,,,,N,Intermediate,BAO_0000218
12797,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,50597,10116.0,,,CHEMBL625495,14886,,,,,N,Intermediate,BAO_0000218
12798,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,50597,10116.0,,,CHEMBL625496,14886,,,,,N,Intermediate,BAO_0000218
12799,,0,P,,1,1-Octanol/water partition coefficient measured at 7.4,22229,,,,CHEMBL625497,4115,,,,,U,Autocuration,BAO_0000100
12800,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625498,13733,,,,,U,Autocuration,BAO_0000100
12801,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL625499,12102,,,,,U,Autocuration,BAO_0000019
12802,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625500,12676,,,,,U,Autocuration,BAO_0000100
12803,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625501,13733,,,,,U,Autocuration,BAO_0000100
12804,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625502,13740,,,,,U,Autocuration,BAO_0000100
12805,,0,P,,1,Calculated partition coefficient (clogP) (relative to BAY K 8644),22229,,,,CHEMBL625503,12766,,,,,U,Autocuration,BAO_0000100
12806,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625504,2764,,,,,U,Autocuration,BAO_0000100
12807,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625505,12355,,,,,U,Autocuration,BAO_0000100
12808,,0,P,,1,Calculated partition coefficient of the compound,22229,,,,CHEMBL625506,11314,,,,,U,Autocuration,BAO_0000100
12809,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL625507,12706,,,,,U,Autocuration,BAO_0000019
12810,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625508,12645,,,,,U,Autocuration,BAO_0000100
12811,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625509,13668,,,,,U,Autocuration,BAO_0000100
12812,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625510,12819,,,,,U,Autocuration,BAO_0000100
12813,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL883125,13668,,,,,U,Autocuration,BAO_0000100
12814,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625511,13017,,,,,U,Autocuration,BAO_0000100
12815,,0,A,,1,Partition coefficient of the compound,22224,,,,CHEMBL874650,2448,,,,,U,Autocuration,BAO_0000019
12816,,0,A,,1,Partition coefficient of the compound,22224,,,,CHEMBL625512,11526,,,,,U,Autocuration,BAO_0000019
12817,,0,A,,1,Partition coefficient of compound was determined,22224,,,,CHEMBL625513,12426,,,,,U,Autocuration,BAO_0000019
12818,,0,A,,1,Partition coefficient was determined,22224,,,,CHEMBL625514,2448,,,,,U,Autocuration,BAO_0000019
12819,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625515,12001,,,,,U,Autocuration,BAO_0000100
12820,,0,P,,1,partition coefficient of compound was determined,22229,,,,CHEMBL625516,12426,,,,,U,Autocuration,BAO_0000100
12821,Canis lupus familiaris,1,A,,1,The total body administered intravenously in dog,50588,9615.0,,,CHEMBL625517,13204,,,,,N,Intermediate,BAO_0000218
12822,Rattus norvegicus,1,A,,1,The total body administered intravenously in rats,50597,10116.0,,,CHEMBL625518,13204,,,,,N,Intermediate,BAO_0000218
12823,Mus musculus,1,A,,1,Time taken for the administration to female NIH mice weighing 25-30 g.,50594,10090.0,,,CHEMBL625519,13889,,,,,N,Intermediate,BAO_0000218
12824,,0,A,,1,Time taken for the administration,22224,,,,CHEMBL625520,13889,,,,,U,Autocuration,BAO_0000019
12825,Canis lupus familiaris,1,A,,1,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,50588,9615.0,,,CHEMBL874651,17025,,,,,N,Intermediate,BAO_0000218
12826,Simiiformes,0,A,,1,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,22224,314293.0,,,CHEMBL625521,17025,,,,,U,Autocuration,BAO_0000218
12827,Oryctolagus cuniculus,1,A,,1,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,50592,9986.0,,,CHEMBL623171,17025,,,,,N,Intermediate,BAO_0000218
12828,Rattus norvegicus,1,A,,1,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,50597,10116.0,,,CHEMBL623853,17025,,,,,N,Intermediate,BAO_0000218
12829,,0,A,,1,Plasma clearance for the compound was determined.,22224,,,,CHEMBL623854,15067,,,,,U,Autocuration,BAO_0000019
12830,,0,P,,1,CLog P value of the compound,22224,,,,CHEMBL874405,3091,,,,,U,Autocuration,BAO_0000100
12831,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL623855,15592,,,,,U,Autocuration,BAO_0000100
12832,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL623856,14738,,,,,U,Autocuration,BAO_0000100
12833,,0,P,,1,ClogP value of the compound; nd ='no data',22224,,,,CHEMBL623857,14738,,,,,U,Autocuration,BAO_0000100
12834,,0,P,,1,ClogP value of the compound; nd ='not determined',22224,,,,CHEMBL623858,14738,,,,,U,Autocuration,BAO_0000100
12835,,0,P,,1,CLog P was determined,22224,,,,CHEMBL623859,6076,,,,,U,Autocuration,BAO_0000100
12836,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL839829,17840,,,,,U,Autocuration,BAO_0000100
12837,,0,A,,1,CLogP was calculated,22224,,,,CHEMBL623860,13589,,,,,U,Autocuration,BAO_0000019
12838,,0,A,,1,CLogP value was determined,22224,,,,CHEMBL623861,17655,,,,,U,Autocuration,BAO_0000019
12839,,0,A,,1,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,22224,,,,CHEMBL623862,5867,,,,,U,Autocuration,BAO_0000019
12840,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL874406,5867,,,,,U,Autocuration,BAO_0000100
12841,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL623863,10783,,,,,U,Autocuration,BAO_0000100
12842,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624021,14849,,,,,U,Autocuration,BAO_0000100
12843,Canis lupus familiaris,1,A,,1,Distribution in female dog adrenal medulla 24 hours after administration.,50588,9615.0,,,CHEMBL624022,8170,1236.0,,,Adrenal medulla,N,Intermediate,BAO_0000218
12844,Canis lupus familiaris,1,A,,1,Distribution in female dog adrenal medulla 72 hours after administration.,50588,9615.0,,,CHEMBL624023,8170,1236.0,,,Adrenal medulla,N,Intermediate,BAO_0000218
12845,Canis lupus familiaris,1,A,,1,Distribution in female dog bile 24 hours after administration.,50588,9615.0,,,CHEMBL624024,8170,,,,,N,Intermediate,BAO_0000218
12846,Canis lupus familiaris,1,A,,1,Distribution in female dog bile 72 hr after administration.,50588,9615.0,,,CHEMBL624025,8170,,,,,N,Intermediate,BAO_0000218
12847,Canis lupus familiaris,1,A,,1,Distribution in female dog blood 24 hours after administration.,50588,9615.0,,,CHEMBL624026,8170,,,,,N,Intermediate,BAO_0000218
12848,Canis lupus familiaris,1,A,,1,Distribution in female dog blood 72 hours after administration.,50588,9615.0,,,CHEMBL624027,8170,,,,,N,Intermediate,BAO_0000218
12849,Canis lupus familiaris,1,A,,1,Distribution in female dog heart 24 hours after administration.,50588,9615.0,,,CHEMBL624028,8170,,,,,N,Intermediate,BAO_0000218
12850,Canis lupus familiaris,1,A,,1,Distribution in female dog heart 72 hours after administration.,50588,9615.0,,,CHEMBL624029,8170,,,,,N,Intermediate,BAO_0000218
12851,Canis lupus familiaris,1,A,,1,Distribution in female dog kidney 24 hours after administration.,50588,9615.0,,,CHEMBL624030,8170,,,,,N,Intermediate,BAO_0000218
12852,Canis lupus familiaris,1,A,,1,Distribution in female dog kidney 72 hours after administration.,50588,9615.0,,,CHEMBL624031,8170,,,,,N,Intermediate,BAO_0000218
12853,Canis lupus familiaris,1,A,,1,Distribution in female dog large intestine 24 hours after administration.,50588,9615.0,,,CHEMBL624032,8170,160.0,,,Intestine,N,Intermediate,BAO_0000218
12854,Canis lupus familiaris,1,A,,1,Distribution in female dog large intestine 72 hours after administration.,50588,9615.0,,,CHEMBL874407,8170,160.0,,,Intestine,N,Intermediate,BAO_0000218
12855,Canis lupus familiaris,1,A,,1,Distribution in female dog liver 24 hours after administration.,50588,9615.0,,,CHEMBL624033,8170,,,,,N,Intermediate,BAO_0000218
12856,Canis lupus familiaris,1,A,,1,Distribution in female dog liver 72 hours after administration.,50588,9615.0,,,CHEMBL624034,8170,,,,,N,Intermediate,BAO_0000218
12857,Canis lupus familiaris,1,A,,1,Distribution in female dog lung 24 hours after administration.,50588,9615.0,,,CHEMBL624035,8170,,,,,N,Intermediate,BAO_0000218
12858,Canis lupus familiaris,1,A,,1,Distribution in female dog lung 72 hours after administration.,50588,9615.0,,,CHEMBL624036,8170,,,,,N,Intermediate,BAO_0000218
12859,Canis lupus familiaris,1,A,,1,Distribution in female dog muscle 24 hours after administration.,50588,9615.0,,,CHEMBL624037,8170,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12860,Canis lupus familiaris,1,A,,1,Distribution in female dog muscle 72 hours after administration.,50588,9615.0,,,CHEMBL624038,8170,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12861,Canis lupus familiaris,1,A,,1,Distribution in female dog pancreas 24 hours after administration.,50588,9615.0,,,CHEMBL624039,8170,,,,,N,Intermediate,BAO_0000218
12862,Canis lupus familiaris,1,A,,1,Distribution in female dog pancreas 72 hours after administration.,50588,9615.0,,,CHEMBL624040,8170,,,,,N,Intermediate,BAO_0000218
12863,Canis lupus familiaris,1,A,,1,Distribution in female dog small intestine 24 hours after administration.,50588,9615.0,,,CHEMBL624041,8170,160.0,,,Intestine,N,Intermediate,BAO_0000218
12864,Canis lupus familiaris,1,A,,1,Distribution in female dog small intestine 72 hours after administration.,50588,9615.0,,,CHEMBL624042,8170,160.0,,,Intestine,N,Intermediate,BAO_0000218
12865,Canis lupus familiaris,1,A,,1,Distribution in female dog spleen 24 hours after administration.,50588,9615.0,,,CHEMBL624043,8170,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12866,Canis lupus familiaris,1,A,,1,Distribution in female dog spleen 72 hours after administration.,50588,9615.0,,,CHEMBL624044,8170,2106.0,,,Spleen,N,Intermediate,BAO_0000218
12867,Canis lupus familiaris,1,A,,1,Distribution in female dog stomach 24 hours after administration.,50588,9615.0,,,CHEMBL624045,8170,945.0,,,Stomach,N,Intermediate,BAO_0000218
12868,Canis lupus familiaris,1,A,,1,Distribution in female dog stomach 72 hours after administration.,50588,9615.0,,,CHEMBL624046,8170,945.0,,,Stomach,N,Intermediate,BAO_0000218
12869,Canis lupus familiaris,1,A,,1,Distribution in female dog thyroid 24 hours after administration.,50588,9615.0,,,CHEMBL624047,8170,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12870,Canis lupus familiaris,1,A,,1,Distribution in female dog thyroid 72 hours after administration.,50588,9615.0,,,CHEMBL624048,8170,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12871,Canis lupus familiaris,1,A,,1,Distribution in female dog urine 24 hours after administration.,50588,9615.0,,,CHEMBL874408,8170,1088.0,,,Urine,N,Intermediate,BAO_0000218
12872,Canis lupus familiaris,1,A,,1,Distribution in female dog urine 72 hr after administration.,50588,9615.0,,,CHEMBL624049,8170,1088.0,,,Urine,N,Intermediate,BAO_0000218
12873,,0,A,,1,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,22224,,,,CHEMBL624050,14283,1969.0,,,Plasma,U,Autocuration,BAO_0000218
12874,,0,A,,1,Plasma concentration at 7 hr after intravenous dosing,22224,,,,CHEMBL624051,5623,,,,,U,Autocuration,BAO_0000019
12875,Rattus norvegicus,1,A,,1,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,50597,10116.0,,,CHEMBL623278,13477,,,,,N,Intermediate,BAO_0000218
12876,Rattus norvegicus,1,A,,1,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,50597,10116.0,,,CHEMBL623279,13477,,,,,N,Intermediate,BAO_0000218
12877,Rattus norvegicus,1,A,,1,Plasma concentration of 3 mg/kg iv after 1 hr in rats,50597,10116.0,,,CHEMBL623280,13477,,,,,N,Intermediate,BAO_0000218
12878,Rattus norvegicus,1,A,,1,Plasma concentration of 3 mg/kg iv after 2 hr in rats,50597,10116.0,,,CHEMBL623963,13477,,,,,N,Intermediate,BAO_0000218
12879,Rattus norvegicus,1,A,,1,Plasma concentration of 3 mg/kg iv after 4 hr in rats,50597,10116.0,,,CHEMBL623964,13477,,,,,N,Intermediate,BAO_0000218
12880,Rattus norvegicus,1,A,,1,Plasma concentration of 3 mg/kg iv after 6 hr in rats,50597,10116.0,,,CHEMBL623965,13477,,,,,N,Intermediate,BAO_0000218
12881,Rattus norvegicus,1,A,,1,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,50597,10116.0,,,CHEMBL623966,13477,,,,,N,Intermediate,BAO_0000218
12882,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,50597,10116.0,,,CHEMBL874415,13477,,,,,N,Intermediate,BAO_0000218
12883,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,50597,10116.0,,,CHEMBL623967,13477,,,,,N,Intermediate,BAO_0000218
12884,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,50597,10116.0,,,CHEMBL623968,13477,,,,,N,Intermediate,BAO_0000218
12885,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,50597,10116.0,,,CHEMBL623969,13477,,,,,N,Intermediate,BAO_0000218
12886,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,50597,10116.0,,,CHEMBL628409,13477,,,,,N,Intermediate,BAO_0000218
12887,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,50597,10116.0,,,CHEMBL628410,13477,,,,,N,Intermediate,BAO_0000218
12888,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,50597,10116.0,,,CHEMBL628411,13477,,,,,N,Intermediate,BAO_0000218
12889,Rattus norvegicus,1,A,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,50597,10116.0,,,CHEMBL628412,13477,,,,,N,Intermediate,BAO_0000218
12890,,0,A,,1,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,22224,,,,CHEMBL628413,12553,,,,,U,Autocuration,BAO_0000019
12891,,0,A,,1,The concentration in plasmat; Not determined,22224,,,,CHEMBL628414,14548,1969.0,,,Plasma,U,Autocuration,BAO_0000019
12892,Rattus norvegicus,1,A,,1,Tissue level at 10 mg/kg/po in wistar rats in blood,50597,10116.0,,,CHEMBL628415,14393,,,,,N,Intermediate,BAO_0000218
12893,Rattus norvegicus,1,A,,1,Tissue level at 10 mg/kg/po in wistar rats in brown fat,50597,10116.0,,,CHEMBL628416,14393,,,,,N,Intermediate,BAO_0000218
12894,Rattus norvegicus,1,A,,1,Tissue level at 10 mg/kg/po in wistar rats in heart,50597,10116.0,,,CHEMBL628417,14393,,,,,N,Intermediate,BAO_0000218
12895,Rattus norvegicus,1,A,,1,Tissue level at 10 mg/kg/po in wistar rats in liver,50597,10116.0,,,CHEMBL874908,14393,2107.0,,,Liver,N,Intermediate,BAO_0000218
12896,Rattus norvegicus,1,A,,1,Tissue level at 10 mg/kg/po in wistar rats in plasma,50597,10116.0,,,CHEMBL628418,14393,,,,,N,Intermediate,BAO_0000218
12897,Rattus norvegicus,1,A,,1,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,50597,10116.0,,,CHEMBL628419,14393,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
12898,Rattus norvegicus,1,A,,1,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,50597,10116.0,,,CHEMBL628420,14393,,,,,N,Intermediate,BAO_0000218
12899,,0,A,,1,Water solubility at 37 degree C.,22224,,,,CHEMBL628421,1629,,,,,U,Autocuration,BAO_0000019
12900,,0,P,,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,22229,,,,CHEMBL626726,8194,,,,,U,Autocuration,BAO_0000100
12901,,0,P,,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,,,,CHEMBL626727,8194,,,,,U,Autocuration,BAO_0000100
12902,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626728,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12903,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626729,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12904,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626730,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12905,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626731,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12906,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626732,8594,178.0,,,Blood,N,Intermediate,BAO_0000218
12907,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626733,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12908,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626734,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12909,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626735,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12910,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL874909,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12911,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626736,8594,948.0,,,Heart,N,Intermediate,BAO_0000218
12912,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL626737,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12913,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630999,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12914,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631000,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12915,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631001,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12916,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631002,8594,2113.0,,,Kidney,N,Intermediate,BAO_0000218
12917,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631003,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12918,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631004,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12919,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631005,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12920,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631006,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12921,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631007,8594,2107.0,,,Liver,N,Intermediate,BAO_0000218
12922,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631008,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12923,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631009,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12924,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631010,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12925,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631011,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12926,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL631012,8594,2048.0,,,Lung,N,Intermediate,BAO_0000218
12927,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630271,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12928,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630272,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12929,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630273,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12930,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630274,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12931,Rattus norvegicus,1,A,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630275,8594,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
12932,Rattus norvegicus,1,A,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL875782,8594,,,,,N,Intermediate,BAO_0000218
12933,Rattus norvegicus,1,A,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630276,8594,,,,,N,Intermediate,BAO_0000218
12934,Rattus norvegicus,1,A,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630277,8594,,,,,N,Intermediate,BAO_0000218
12935,Rattus norvegicus,1,A,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630278,8594,,,,,N,Intermediate,BAO_0000218
12936,Rattus norvegicus,1,A,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,50597,10116.0,,,CHEMBL630279,8594,,,,,N,Intermediate,BAO_0000218
12937,,0,A,,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,22224,,,,CHEMBL630280,8151,,,,,U,Autocuration,BAO_0000019
12938,,0,A,,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,22224,,,,CHEMBL630281,8151,,,,,U,Autocuration,BAO_0000019
12939,Oryctolagus cuniculus,1,A,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,50592,9986.0,,,CHEMBL630282,7132,,,,,N,Intermediate,BAO_0000218
12940,Oryctolagus cuniculus,1,A,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,50592,9986.0,,,CHEMBL630283,7132,,,,,N,Intermediate,BAO_0000218
12941,,0,A,,1,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),22224,,,,CHEMBL630284,5797,,,,,U,Autocuration,BAO_0000019
12942,,0,A,,1,Alkylating activity was determined,22224,,,,CHEMBL630285,7849,,,,,U,Autocuration,BAO_0000019
12943,,0,A,,1,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),22224,,Microsomes,,CHEMBL630286,14220,,,,,U,Autocuration,BAO_0000251
12944,Oryctolagus cuniculus,1,A,,1,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",50592,9986.0,,,CHEMBL630069,8650,,,,,N,Intermediate,BAO_0000218
12945,Oryctolagus cuniculus,1,A,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",50592,9986.0,,,CHEMBL630070,8650,,,,,N,Intermediate,BAO_0000218
12946,Oryctolagus cuniculus,1,A,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",50592,9986.0,,,CHEMBL630071,8650,,,,,N,Intermediate,BAO_0000218
12947,Oryctolagus cuniculus,1,A,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",50592,9986.0,,,CHEMBL630072,8650,,,,,N,Intermediate,BAO_0000218
12948,Oryctolagus cuniculus,1,A,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",50592,9986.0,,,CHEMBL875110,8650,,,,,N,Intermediate,BAO_0000218
12949,Rattus norvegicus,1,A,,1,Compound was tested for antidiuretic activity in rats,50597,10116.0,,,CHEMBL630073,7116,,,,,N,Intermediate,BAO_0000218
12950,,0,A,,1,Compound was tested for inactivation kinetic values,22224,,,,CHEMBL630074,14131,,,,,U,Autocuration,BAO_0000019
12951,,0,A,,1,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,22224,,,,CHEMBL630075,7415,,,,,U,Autocuration,BAO_0000218
12952,,0,A,,1,Dissociation rate calculated from the first-order equation using the t1/2 value,22224,,,,CHEMBL630076,13178,,,,,U,Autocuration,BAO_0000019
12953,,0,P,,1,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,22229,,,,CHEMBL630077,8815,,,,,U,Autocuration,BAO_0000100
12954,,0,P,,1,Aqueous solubility was measured,22229,,,,CHEMBL630078,1450,,,,,U,Autocuration,BAO_0000100
12955,,0,P,,1,Aqueous solubility was measured at a pH 4,22229,,,,CHEMBL630079,1450,,,,,U,Autocuration,BAO_0000100
12956,,0,P,,1,Aqueous solubility (pH 7),22229,,,,CHEMBL630080,1450,,,,,U,Autocuration,BAO_0000100
12957,,0,P,,1,Aqueous solubility was measured at a pH 9,22229,,,,CHEMBL630081,1450,,,,,U,Autocuration,BAO_0000100
12958,,0,A,,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",22224,,,,CHEMBL630082,12711,,,,,U,Autocuration,BAO_0000019
12959,,0,A,,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",22224,,,,CHEMBL630083,12711,,,,,U,Autocuration,BAO_0000019
12960,,0,A,,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",22224,,,,CHEMBL630084,12711,,,,,U,Autocuration,BAO_0000019
12961,,0,P,,1,Aqueous solubility of the compound,22229,,,,CHEMBL629198,15032,,,,,U,Autocuration,BAO_0000100
12962,,0,P,,1,Aqueous solubility at 37 degree Celsius at pH 7.38,22229,,,,CHEMBL629199,9964,,,,,U,Autocuration,BAO_0000100
12963,,0,P,,1,Aqueous solubility in pH 7.4 phosphate buffer,22229,,,,CHEMBL629200,14962,,,,,U,Autocuration,BAO_0000100
12964,Canis lupus familiaris,1,A,,1,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,50588,9615.0,,,CHEMBL629201,12487,,,,,N,Intermediate,BAO_0000218
12965,Canis lupus familiaris,1,A,,1,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,50588,9615.0,,,CHEMBL629202,12487,,,,,N,Intermediate,BAO_0000218
12966,Homo sapiens,1,A,,1,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,50587,9606.0,,,CHEMBL875111,10026,,,,,N,Intermediate,BAO_0000218
12967,Homo sapiens,1,A,,1,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,50587,9606.0,,,CHEMBL629203,10026,,,,,N,Intermediate,BAO_0000218
12968,Homo sapiens,1,A,,1,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,50587,9606.0,,,CHEMBL629204,10026,,,,,N,Intermediate,BAO_0000218
12969,Homo sapiens,1,A,,1,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,50587,9606.0,,,CHEMBL629205,10026,,,,,N,Intermediate,BAO_0000218
12970,Homo sapiens,1,A,,1,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,50587,9606.0,,,CHEMBL629206,10026,,,,,N,Intermediate,BAO_0000218
12971,,0,A,,1,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,22224,,,,CHEMBL631185,10026,,,,,U,Autocuration,BAO_0000019
12972,Rattus norvegicus,1,A,,1,Compound was evaluated for the average bile flow rat in rats,50597,10116.0,,,CHEMBL631186,7415,,,,,N,Intermediate,BAO_0000218
12973,Oryctolagus cuniculus,1,A,,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",50592,9986.0,,,CHEMBL631187,17025,,,,,N,Intermediate,BAO_0000218
12974,Oryctolagus cuniculus,1,A,,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",50592,9986.0,,,CHEMBL631188,17025,,,,,N,Intermediate,BAO_0000218
12975,,0,A,,1,Average half life period was determined,22224,,,,CHEMBL876419,10184,,,,,U,Autocuration,BAO_0000019
12976,,0,A,,1,Average half life period was determined,22224,,,,CHEMBL631189,10184,,,,,U,Autocuration,BAO_0000019
12977,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,50602,10298.0,,,CHEMBL631190,8613,,,,,N,Intermediate,BAO_0000218
12978,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,50602,10298.0,,,CHEMBL631191,8613,,,,,N,Intermediate,BAO_0000218
12979,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,50602,10298.0,,,CHEMBL631192,8613,,,,,N,Intermediate,BAO_0000218
12980,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,50602,10298.0,,,CHEMBL632400,8613,,,,,N,Intermediate,BAO_0000218
12981,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,50602,10298.0,,,CHEMBL630564,8613,,,,,N,Intermediate,BAO_0000218
12982,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,50602,10298.0,,,CHEMBL630565,8613,,,,,N,Intermediate,BAO_0000218
12983,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,50602,10298.0,,,CHEMBL630566,8613,,,,,N,Intermediate,BAO_0000218
12984,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,50602,10298.0,,,CHEMBL631229,8613,,,,,N,Intermediate,BAO_0000218
12985,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,50602,10298.0,,,CHEMBL631230,8613,,,,,N,Intermediate,BAO_0000218
12986,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL876428,6030,,,,,U,Autocuration,BAO_0000100
12987,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631231,6147,,,,,U,Autocuration,BAO_0000100
12988,,0,P,,1,Calculated partition coefficient (clogP) (MacLogP),22229,,,,CHEMBL631232,14556,,,,,U,Autocuration,BAO_0000100
12989,,0,A,,1,Hydrophilicity was determined,22224,,,,CHEMBL631233,768,,,,,U,Autocuration,BAO_0000019
12990,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631234,14452,,,,,U,Autocuration,BAO_0000100
12991,,0,A,,1,Increased absorption was determined,22224,,,,CHEMBL883126,5237,,,,,U,Autocuration,BAO_0000019
12992,,0,P,,1,Lipophilicity value was evaluated,22224,,,,CHEMBL631235,14378,,,,,U,Autocuration,BAO_0000100
12993,,0,P,,1,Log P value of the compound.,22224,,,,CHEMBL631236,14418,,,,,U,Autocuration,BAO_0000100
12994,,0,A,,1,Partition coefficient of compound was determined,22224,,,,CHEMBL631237,5249,,,,,U,Autocuration,BAO_0000019
12995,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631238,14621,,,,,U,Autocuration,BAO_0000100
12996,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL876429,12542,,,,,U,Autocuration,BAO_0000100
12997,,0,A,,1,Partition coefficient was measured by medchem software; Not calculated,22224,,,,CHEMBL631414,12542,,,,,U,Autocuration,BAO_0000019
12998,,0,P,,1,Partition coefficient was measured by octanol-water using standard shake-flask method,22224,,,,CHEMBL631415,12542,,,,,U,Autocuration,BAO_0000100
12999,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631416,15462,,,,,U,Autocuration,BAO_0000100
13000,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL631417,14884,,,,,U,Autocuration,BAO_0000019
13001,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631418,16526,,,,,U,Autocuration,BAO_0000100
13002,,0,P,,1,The Octanol/Water partition coefficient CLogP,22229,,,,CHEMBL631419,13693,,,,,U,Autocuration,BAO_0000100
13003,,0,A,,1,The pharmacokinetic parameter C Log p was reported,22224,,,,CHEMBL631420,13693,,,,,U,Autocuration,BAO_0000019
13004,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631421,13779,,,,,U,Autocuration,BAO_0000100
13005,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631422,14772,,,,,U,Autocuration,BAO_0000100
13006,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL631423,14393,,,,,U,Autocuration,BAO_0000100
13007,Rattus norvegicus,1,A,,1,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL876430,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13008,Rattus norvegicus,1,A,,1,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL631424,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13009,Canis lupus familiaris,1,A,,1,Compound was administered intravenously in dog to evaluate plasma clearance values,50588,9615.0,,,CHEMBL631425,13744,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13010,Simiiformes,0,A,,1,Compound was administered intravenously in monkey to evaluate plasma clearance values,22224,314293.0,,,CHEMBL631426,13744,1969.0,,,Plasma,U,Autocuration,BAO_0000218
13011,Mus musculus,1,A,,1,Compound was administered intravenously in mouse to evaluate plasma clearance values,50594,10090.0,,,CHEMBL631427,13744,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13012,Canis lupus familiaris,1,A,,1,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,50588,9615.0,,,CHEMBL631428,13207,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13013,Macaca mulatta,1,A,,1,Intrinsic clearance in Rhesus liver microsome,50797,9544.0,Microsomes,,CHEMBL631429,5669,2107.0,,,Liver,N,Intermediate,BAO_0000218
13014,Canis lupus familiaris,1,A,,1,Intrinsic clearance in dog liver microsome,50588,9615.0,Microsomes,,CHEMBL631430,5669,2107.0,,,Liver,N,Intermediate,BAO_0000218
13015,Rattus norvegicus,1,A,,1,Intrinsic clearance in rat liver microsome,50597,10116.0,Microsomes,,CHEMBL631431,5669,2107.0,,,Liver,N,Intermediate,BAO_0000218
13016,Macaca mulatta,1,A,,1,Low plasma clearance was calculated in rhesus monkey,50797,9544.0,,,CHEMBL631432,4853,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13017,Canis lupus familiaris,1,A,,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,9615.0,,,CHEMBL631433,16452,,,,,N,Intermediate,BAO_0000218
13018,,0,A,,1,Plasma clearance after intravenous dose of 0.3 mg/kg,22224,,,,CHEMBL631434,11954,,,,,U,Autocuration,BAO_0000218
13019,,0,A,,1,Plasma clearance after intravenous dose of 1 mg/kg,22224,,,,CHEMBL631435,11954,,,,,U,Autocuration,BAO_0000218
13020,,0,A,,1,Plasma clearance after intravenous dose of 3 mg/kg,22224,,,,CHEMBL631436,11954,,,,,U,Autocuration,BAO_0000218
13021,,0,A,,1,Plasma clearance after intravenous dose of 3.87 mg/kg,22224,,,,CHEMBL631437,11954,,,,,U,Autocuration,BAO_0000218
13022,Rattus norvegicus,1,A,,1,Plasma clearance after peroral administration at 10 mpk in Rat,50597,10116.0,,,CHEMBL631438,5669,,,,,N,Intermediate,BAO_0000218
13023,Macaca mulatta,1,A,,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,50797,9544.0,,,CHEMBL876431,5669,,,,,N,Intermediate,BAO_0000218
13024,Canis lupus familiaris,1,A,,1,Plasma clearance after peroral administration at 10 mpk in dog,50588,9615.0,,,CHEMBL631439,5669,,,,,N,Intermediate,BAO_0000218
13025,Rattus norvegicus,1,A,,1,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,50597,10116.0,,,CHEMBL631440,13662,,,,,N,Intermediate,BAO_0000218
13026,,0,A,,1,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),22224,,,,CHEMBL631441,8272,,,,,U,Autocuration,BAO_0000019
13027,,0,A,,1,Critical Micellar concentration was determined,22224,,,,CHEMBL631442,13410,,,,,U,Autocuration,BAO_0000019
13028,,0,A,,1,Critical Micellar concentration of the compound. was determined,22224,,,,CHEMBL626525,13410,,,,,U,Autocuration,BAO_0000019
13029,,0,A,,1,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,22224,,,,CHEMBL627168,12628,,,,,U,Autocuration,BAO_0000019
13030,,0,A,,1,Critical micellar concentration was measured in water by the dye solubilization method,22224,,,,CHEMBL875618,9675,,,,,U,Autocuration,BAO_0000019
13031,,0,B,,1,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,22224,,,,CHEMBL626612,12628,,,,,U,Autocuration,BAO_0000019
13032,,0,A,,1,CMR value (relative to BAY K 8644),22224,,,,CHEMBL626613,12766,,,,,U,Autocuration,BAO_0000019
13033,,0,A,,1,Carbamoylating activity was determined,22224,,,,CHEMBL626614,7849,,,,,U,Autocuration,BAO_0000019
13034,Simiiformes,0,A,,1,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,22224,314293.0,,,CHEMBL626615,12187,,,,,U,Autocuration,BAO_0000218
13035,,0,A,,1,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,22224,,,,CHEMBL626616,2040,,,,,U,Autocuration,BAO_0000019
13036,,0,A,,1,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,22224,,,,CHEMBL626617,2040,,,,,U,Autocuration,BAO_0000019
13037,Canis lupus familiaris,1,A,,1,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,50588,9615.0,,,CHEMBL626618,14180,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13038,Rattus norvegicus,1,A,,1,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,50597,10116.0,,,CHEMBL626619,14180,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13039,Canis lupus familiaris,1,A,,1,"Clearance rate at 0.46 mg/kg, iv, in dogs",50588,9615.0,,,CHEMBL626620,14474,,,,,N,Intermediate,BAO_0000218
13040,Rattus norvegicus,1,A,,1,"Clearance rate at 5.5 mg/kg, iv, in rat",50597,10116.0,,,CHEMBL626621,14474,,,,,N,Intermediate,BAO_0000218
13041,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,100710,9541.0,,,CHEMBL626622,14548,,,,,N,Intermediate,BAO_0000218
13042,Macaca fascicularis,1,A,,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,100710,9541.0,,,CHEMBL626623,14548,,,,,N,Intermediate,BAO_0000218
13043,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,50588,9615.0,,,CHEMBL626624,14548,,,,,N,Intermediate,BAO_0000218
13044,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,50597,10116.0,,,CHEMBL626625,14548,,,,,N,Intermediate,BAO_0000218
13045,Rattus norvegicus,1,A,,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,10116.0,,,CHEMBL626626,6125,2107.0,,,Liver,N,Intermediate,BAO_0000218
13046,,0,A,,1,Tested for the total clearance of the compound,22224,,,,CHEMBL626627,6874,,,,,U,Autocuration,BAO_0000218
13047,Canis lupus familiaris,1,A,,1,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,50588,9615.0,,,CHEMBL626628,15343,,,,,N,Intermediate,BAO_0000218
13048,,0,A,,1,Total body clearance was determined,22224,,,,CHEMBL626629,6236,,,,,U,Autocuration,BAO_0000218
13049,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,10116.0,,,CHEMBL626630,11510,,,,,N,Intermediate,BAO_0000218
13050,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,10116.0,,,CHEMBL626631,11510,,,,,N,Intermediate,BAO_0000218
13051,,0,P,,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,22229,,,,CHEMBL626632,8194,,,,,U,Autocuration,BAO_0000100
13052,,0,P,,1,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,,,,CHEMBL626633,8194,,,,,U,Autocuration,BAO_0000100
13053,,0,P,,1,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,22229,,,,CHEMBL626634,8194,,,,,U,Autocuration,BAO_0000100
13054,,0,P,,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,22229,,,,CHEMBL626635,8194,,,,,U,Autocuration,BAO_0000100
13055,,0,P,,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,,,,CHEMBL626636,8194,,,,,U,Autocuration,BAO_0000100
13056,,0,P,,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,22229,,,,CHEMBL626637,8194,,,,,U,Autocuration,BAO_0000100
13057,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),50339,4754.0,,,CHEMBL626638,13273,,,,,N,Intermediate,BAO_0000218
13058,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,50339,4754.0,,,CHEMBL626639,13273,,,,,N,Intermediate,BAO_0000218
13059,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,50339,4754.0,,,CHEMBL626640,13273,,,,,N,Intermediate,BAO_0000218
13060,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,50339,4754.0,,,CHEMBL626641,13273,,,,,N,Intermediate,BAO_0000218
13061,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,50339,4754.0,,,CHEMBL627272,13273,,,,,N,Intermediate,BAO_0000218
13062,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,50339,4754.0,,,CHEMBL627273,13273,,,,,N,Intermediate,BAO_0000218
13063,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),50339,4754.0,,,CHEMBL627441,13273,,,,,N,Intermediate,BAO_0000218
13064,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),50339,4754.0,,,CHEMBL628355,13273,,,,,N,Intermediate,BAO_0000218
13065,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),50339,4754.0,,,CHEMBL628356,13273,,,,,N,Intermediate,BAO_0000218
13066,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),50339,4754.0,,,CHEMBL628357,13273,,,,,N,Intermediate,BAO_0000218
13067,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),50339,4754.0,,,CHEMBL628358,13273,,,,,N,Intermediate,BAO_0000218
13068,Pneumocystis carinii,1,A,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),50339,4754.0,,,CHEMBL622307,13273,,,,,N,Intermediate,BAO_0000218
13069,,0,A,,1,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,22224,,,,CHEMBL622527,13118,,,,,U,Autocuration,BAO_0000019
13070,,0,A,,1,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,22224,,,,CHEMBL622528,13118,,,,,U,Autocuration,BAO_0000019
13071,,0,A,,1,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,22224,,,,CHEMBL622529,13118,,,,,U,Autocuration,BAO_0000019
13072,,0,A,,1,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,22224,,,,CHEMBL622992,13118,,,,,U,Autocuration,BAO_0000019
13073,,0,A,,1,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,22224,,,,CHEMBL622993,13118,,,,,U,Autocuration,BAO_0000019
13074,,0,A,,1,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,22224,,,,CHEMBL622994,13118,,,,,U,Autocuration,BAO_0000019
13075,Rattus norvegicus,1,A,,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",50597,10116.0,,,CHEMBL622995,10633,,,,,N,Intermediate,BAO_0000218
13076,Rattus norvegicus,1,A,,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",50597,10116.0,,,CHEMBL622996,10633,,,,,N,Intermediate,BAO_0000218
13077,Rattus norvegicus,1,A,,1,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",50597,10116.0,,,CHEMBL622997,10633,,,,,N,Intermediate,BAO_0000218
13078,Rattus norvegicus,1,A,,1,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",50597,10116.0,,,CHEMBL622998,10633,,,,,N,Intermediate,BAO_0000218
13079,,0,A,,1,Cp max following ip administration at 1 mg/kg,22224,,,,CHEMBL622999,5767,,,,,U,Autocuration,BAO_0000218
13080,,0,A,,1,Maximum concentration in plasma was reported at 0.5 hour,22224,,,,CHEMBL623000,3302,1969.0,,,Plasma,U,Autocuration,BAO_0000218
13081,,0,A,,1,Maximum concentration in plasma was reported at 2 hour,22224,,,,CHEMBL623001,3302,1969.0,,,Plasma,U,Autocuration,BAO_0000218
13082,Mus musculus,1,A,,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,50594,10090.0,,,CHEMBL623002,12467,,,,,N,Intermediate,BAO_0000218
13083,,0,P,,1,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),22229,,,,CHEMBL623003,11778,,,,,U,Autocuration,BAO_0000100
13084,,0,A,,1,Steady state concentration was evaluated,22224,,,,CHEMBL623004,4321,,,,,U,Autocuration,BAO_0000019
13085,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL623005,14884,,,,,U,Autocuration,BAO_0000019
13086,,0,A,,1,Partition coefficient (logD7.4),22224,,,,CHEMBL623006,15234,,,,,U,Autocuration,BAO_0000019
13087,Rattus norvegicus,1,A,,1,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,50597,10116.0,,,CHEMBL623007,14198,2107.0,,,Liver,N,Intermediate,BAO_0000218
13088,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,50597,10116.0,,,CHEMBL623008,14198,10000001.0,,,Bone,N,Intermediate,BAO_0000218
13089,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,50597,10116.0,,,CHEMBL876654,14198,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13090,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,50597,10116.0,,,CHEMBL623009,14198,,,,,N,Intermediate,BAO_0000218
13091,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,50597,10116.0,,,CHEMBL623010,14198,,,,,N,Intermediate,BAO_0000218
13092,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,50597,10116.0,,,CHEMBL623011,14198,948.0,,,Heart,N,Intermediate,BAO_0000218
13093,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,50597,10116.0,,,CHEMBL623012,14198,160.0,,,Intestine,N,Intermediate,BAO_0000218
13094,,0,A,,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,22224,,,,CHEMBL623013,8151,,,,,U,Autocuration,BAO_0000019
13095,,0,A,,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,22224,,,,CHEMBL623014,8151,,,,,U,Autocuration,BAO_0000019
13096,,0,A,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,22224,,,,CHEMBL623015,8151,1088.0,,,Urine,U,Autocuration,BAO_0000019
13097,,0,A,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,22224,,,,CHEMBL623016,8151,1088.0,,,Urine,U,Autocuration,BAO_0000019
13098,,0,A,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,22224,,,,CHEMBL624858,8151,1088.0,,,Urine,U,Autocuration,BAO_0000019
13099,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,50597,10116.0,,,CHEMBL624859,8151,,,,,N,Intermediate,BAO_0000218
13100,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,10116.0,,,CHEMBL624860,8151,,,,,N,Intermediate,BAO_0000218
13101,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,10116.0,,,CHEMBL624861,8151,,,,,N,Intermediate,BAO_0000218
13102,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,50597,10116.0,,,CHEMBL624862,8151,,,,,N,Intermediate,BAO_0000218
13103,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,50597,10116.0,,,CHEMBL624863,8151,,,,,N,Intermediate,BAO_0000218
13104,Rattus norvegicus,1,A,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,10116.0,,,CHEMBL876655,8151,,,,,N,Intermediate,BAO_0000218
13105,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,50588,9615.0,,,CHEMBL624864,6996,,,,,N,Intermediate,BAO_0000218
13106,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,50588,9615.0,,,CHEMBL624865,6996,,,,,N,Intermediate,BAO_0000218
13107,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,9615.0,,,CHEMBL624866,6996,,,,,N,Intermediate,BAO_0000218
13108,Canis lupus familiaris,1,F,,1,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,50588,9615.0,,,CHEMBL624867,6996,,,,,N,Expert,BAO_0000218
13109,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,50588,9615.0,,,CHEMBL624868,6996,,,,,N,Intermediate,BAO_0000218
13110,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,50588,9615.0,,,CHEMBL628450,6996,,,,,N,Intermediate,BAO_0000218
13111,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,50588,9615.0,,,CHEMBL628451,6996,,,,,N,Intermediate,BAO_0000218
13112,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,50588,9615.0,,,CHEMBL628452,6996,,,,,N,Intermediate,BAO_0000218
13113,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,9615.0,,,CHEMBL628453,6996,,,,,N,Intermediate,BAO_0000218
13114,Canis lupus familiaris,1,A,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,50588,9615.0,,,CHEMBL628454,6996,,,,,N,Intermediate,BAO_0000218
13115,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,50588,9615.0,,,CHEMBL628455,6996,,,,,N,Intermediate,BAO_0000218
13116,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,50588,9615.0,,,CHEMBL628456,6996,,,,,N,Intermediate,BAO_0000218
13117,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,9615.0,,,CHEMBL628457,6996,,,,,N,Intermediate,BAO_0000218
13118,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,50588,9615.0,,,CHEMBL877505,6996,,,,,N,Intermediate,BAO_0000218
13119,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,50588,9615.0,,,CHEMBL628458,6996,,,,,N,Intermediate,BAO_0000218
13120,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,50588,9615.0,,,CHEMBL628459,6996,,,,,N,Intermediate,BAO_0000218
13121,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,50588,9615.0,,,CHEMBL628460,6996,,,,,N,Intermediate,BAO_0000218
13122,Canis lupus familiaris,1,A,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,50588,9615.0,,,CHEMBL628461,6996,,,,,N,Intermediate,BAO_0000218
13123,,0,B,,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",22224,,,,CHEMBL628462,6996,,,,,U,Autocuration,BAO_0000218
13124,Canis lupus familiaris,1,A,,1,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50588,9615.0,,,CHEMBL628463,6996,,,,,N,Intermediate,BAO_0000218
13125,Rattus norvegicus,1,F,,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",50597,10116.0,,,CHEMBL625666,6996,,,,,N,Expert,BAO_0000218
13126,,0,B,,1,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,22224,,,,CHEMBL625667,6996,,,,,U,Autocuration,BAO_0000218
13127,Rattus norvegicus,1,A,,1,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50597,10116.0,,,CHEMBL625668,6996,,,,,N,Expert,BAO_0000218
13128,Rattus norvegicus,1,A,,1,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50597,10116.0,,,CHEMBL625669,6996,,,,,N,Intermediate,BAO_0000218
13129,,0,A,,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,22224,,,,CHEMBL625670,7114,,,,,U,Autocuration,BAO_0000019
13130,Rattus norvegicus,1,A,,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,50597,10116.0,,,CHEMBL625671,7114,,,,,N,Intermediate,BAO_0000218
13131,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,50602,10298.0,,,CHEMBL625672,8613,,,,,N,Intermediate,BAO_0000218
13132,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,50602,10298.0,,,CHEMBL625673,8613,,,,,N,Intermediate,BAO_0000218
13133,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,50602,10298.0,,,CHEMBL625674,8613,,,,,N,Intermediate,BAO_0000218
13134,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,50602,10298.0,,,CHEMBL625675,8613,,,,,N,Intermediate,BAO_0000218
13135,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,50602,10298.0,,,CHEMBL627637,8613,,,,,N,Intermediate,BAO_0000218
13136,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,50602,10298.0,,,CHEMBL627638,8613,,,,,N,Intermediate,BAO_0000218
13137,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,50602,10298.0,,,CHEMBL627639,8613,,,,,N,Intermediate,BAO_0000218
13138,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,50602,10298.0,,,CHEMBL627640,8613,,,,,N,Intermediate,BAO_0000218
13139,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,50602,10298.0,,,CHEMBL627641,8613,,,,,N,Intermediate,BAO_0000218
13140,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,50602,10298.0,,,CHEMBL627642,8613,,,,,N,Intermediate,BAO_0000218
13141,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,50602,10298.0,,,CHEMBL877506,8613,,,,,N,Intermediate,BAO_0000218
13142,Mus musculus,1,A,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,50594,10090.0,,,CHEMBL627275,8613,,,,,N,Intermediate,BAO_0000218
13143,Mustela putorius furo,1,A,,1,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",50506,9669.0,,,CHEMBL627643,11219,,,,,N,Intermediate,BAO_0000218
13144,Mustela putorius furo,1,A,,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",50506,9669.0,,,CHEMBL631246,11219,,,,,N,Intermediate,BAO_0000218
13145,Mustela putorius furo,1,A,,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",50506,9669.0,,,CHEMBL631247,11219,,,,,N,Intermediate,BAO_0000218
13146,Mustela putorius furo,1,A,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,50506,9669.0,,,CHEMBL629532,11219,,,,,N,Intermediate,BAO_0000218
13147,Mustela putorius furo,1,A,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,50506,9669.0,,,CHEMBL629533,11219,,,,,N,Intermediate,BAO_0000218
13148,Mustela putorius furo,1,A,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,50506,9669.0,,,CHEMBL629534,11219,,,,,N,Intermediate,BAO_0000218
13149,Mustela putorius furo,1,A,,1,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,50506,9669.0,,,CHEMBL629535,11219,,,,,N,Intermediate,BAO_0000218
13150,,0,A,,1,Pharmacokinetic parameter :drug bound to plasma was reported,22224,,,,CHEMBL625932,14837,,,,,U,Autocuration,BAO_0000019
13151,,0,A,,1,compound was evaluated for drug bound in plasma,22224,,,,CHEMBL625933,14837,,,,,U,Autocuration,BAO_0000019
13152,Rattus norvegicus,1,A,,1,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,50597,10116.0,,,CHEMBL625934,15343,,,,,N,Intermediate,BAO_0000218
13153,Eutheria,0,A,,1,Bioavailability,22224,9347.0,,,CHEMBL625935,13761,,,,,U,Autocuration,BAO_0000218
13154,Rattus norvegicus,1,A,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,50597,10116.0,,,CHEMBL625936,14810,,,,,N,Intermediate,BAO_0000218
13155,Rattus norvegicus,1,A,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,50597,10116.0,,,CHEMBL625937,14810,,,,,N,Intermediate,BAO_0000218
13156,Canis lupus familiaris,1,A,,1,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,50588,9615.0,,,CHEMBL625938,13249,,,,,N,Intermediate,BAO_0000218
13157,Rattus norvegicus,1,A,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,50597,10116.0,,,CHEMBL625939,9267,1970.0,,,Bile,N,Intermediate,BAO_0000218
13158,Rattus norvegicus,1,A,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,50597,10116.0,,,CHEMBL625940,9267,1970.0,,,Bile,N,Intermediate,BAO_0000218
13159,Rattus norvegicus,1,A,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,50597,10116.0,,,CHEMBL874464,9267,1970.0,,,Bile,N,Intermediate,BAO_0000218
13160,Rattus norvegicus,1,A,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,50597,10116.0,,,CHEMBL625941,9267,1970.0,,,Bile,N,Intermediate,BAO_0000218
13161,Rattus norvegicus,1,A,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,50597,10116.0,,,CHEMBL625942,9267,1970.0,,,Bile,N,Intermediate,BAO_0000218
13162,Rattus norvegicus,1,A,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,50597,10116.0,,,CHEMBL625943,9267,1970.0,,,Bile,N,Intermediate,BAO_0000218
13163,Homo sapiens,1,A,,1,In vitro protein binding in human serum at 5 ug/ml,50587,9606.0,,,CHEMBL625944,15549,1977.0,,,Serum,N,Intermediate,BAO_0000218
13164,,0,A,,1,Serum protein binding ability was measured,22224,,,,CHEMBL625945,10929,,,,,U,Autocuration,BAO_0000019
13165,,0,A,,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,,,,CHEMBL625946,15444,,,,,U,Autocuration,BAO_0000019
13166,Canis lupus familiaris,0,A,,1,Oral bioavailability in dog,22224,9615.0,,,CHEMBL625947,12860,,,,,U,Autocuration,BAO_0000218
13167,Rattus norvegicus,1,A,,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,50597,10116.0,,,CHEMBL625948,12170,,,,,N,Intermediate,BAO_0000218
13168,,0,A,,1,Absolute oral bioavailability at an iv dose of 14 mg/kg,22224,,,,CHEMBL625949,15173,,,,,U,Autocuration,BAO_0000218
13169,,0,A,,1,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,22224,,,,CHEMBL625950,15173,,,,,U,Autocuration,BAO_0000218
13170,Eutheria,0,A,,1,Oral bioavailability (dose 15 mg/kg i.v.),22224,9347.0,,,CHEMBL625951,15173,,,,,U,Autocuration,BAO_0000218
13171,,0,A,,1,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,22224,,,,CHEMBL625952,15173,,,,,U,Autocuration,BAO_0000218
13172,,0,A,,1,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,22224,,,,CHEMBL625953,15173,,,,,U,Autocuration,BAO_0000218
13173,,0,A,,1,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,22224,,,,CHEMBL625954,15173,,,,,U,Autocuration,BAO_0000218
13174,,0,A,,1,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,22224,,,,CHEMBL882959,15173,,,,,U,Autocuration,BAO_0000218
13175,Canis lupus familiaris,1,A,,1,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,50588,9615.0,,,CHEMBL625955,11767,,,,,N,Intermediate,BAO_0000218
13176,Mustela putorius furo,0,A,,1,Bioavailability in ferret,22224,9669.0,,,CHEMBL625956,11219,,,,,U,Autocuration,BAO_0000218
13177,Macaca fascicularis,1,A,,1,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,100710,9541.0,,,CHEMBL625957,12186,,,,,N,Intermediate,BAO_0000218
13178,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,10116.0,,,CHEMBL625958,11510,,,,,N,Intermediate,BAO_0000218
13179,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,10116.0,,,CHEMBL625959,11510,,,,,N,Intermediate,BAO_0000218
13180,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,10116.0,,,CHEMBL626642,11510,,,,,N,Intermediate,BAO_0000218
13181,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,10116.0,,,CHEMBL631330,11510,,,,,N,Intermediate,BAO_0000218
13182,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,10116.0,,,CHEMBL631331,11510,,,,,N,Intermediate,BAO_0000218
13183,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,10116.0,,,CHEMBL631332,11510,,,,,N,Intermediate,BAO_0000218
13184,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,10116.0,,,CHEMBL631333,11510,,,,,N,Intermediate,BAO_0000218
13185,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,10116.0,,,CHEMBL632018,11510,,,,,N,Intermediate,BAO_0000218
13186,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,10116.0,,,CHEMBL632019,11510,,,,,N,Intermediate,BAO_0000218
13187,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,10116.0,,,CHEMBL632020,11510,,,,,N,Intermediate,BAO_0000218
13188,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,10116.0,,,CHEMBL632021,11510,,,,,N,Intermediate,BAO_0000218
13189,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,10116.0,,,CHEMBL632022,11510,,,,,N,Intermediate,BAO_0000218
13190,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,10116.0,,,CHEMBL632023,11510,,,,,N,Intermediate,BAO_0000218
13191,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,10116.0,,,CHEMBL632024,11510,,,,,N,Intermediate,BAO_0000218
13192,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,10116.0,,,CHEMBL874472,11510,,,,,N,Intermediate,BAO_0000218
13193,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,10116.0,,,CHEMBL632025,11510,,,,,N,Intermediate,BAO_0000218
13194,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,10116.0,,,CHEMBL632026,11510,,,,,N,Intermediate,BAO_0000218
13195,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,10116.0,,,CHEMBL632027,11510,,,,,N,Intermediate,BAO_0000218
13196,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,10116.0,,,CHEMBL632028,11510,,,,,N,Intermediate,BAO_0000218
13197,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,10116.0,,,CHEMBL626430,11510,,,,,N,Intermediate,BAO_0000218
13198,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,10116.0,,,CHEMBL626431,11510,,,,,N,Intermediate,BAO_0000218
13199,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,10116.0,,,CHEMBL626432,11510,,,,,N,Intermediate,BAO_0000218
13200,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,10116.0,,,CHEMBL626433,11510,,,,,N,Intermediate,BAO_0000218
13201,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,10116.0,,,CHEMBL626434,11510,,,,,N,Intermediate,BAO_0000218
13202,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,10116.0,,,CHEMBL627280,11510,,,,,N,Intermediate,BAO_0000218
13203,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,10116.0,,,CHEMBL627281,11510,,,,,N,Intermediate,BAO_0000218
13204,Rattus norvegicus,1,A,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,10116.0,,,CHEMBL627282,11510,,,,,N,Intermediate,BAO_0000218
13205,,0,A,,1,Total body clearance was measured at given dose,22224,,,,CHEMBL627283,7199,,,,,U,Autocuration,BAO_0000019
13206,,0,A,,1,Total body clearance was measured at given dose.,22224,,,,CHEMBL627284,7199,,,,,U,Autocuration,BAO_0000218
13207,Rattus norvegicus,1,A,,1,Metabolic clearance from the body in rat,50597,10116.0,,,CHEMBL627285,7095,,,,,N,Intermediate,BAO_0000218
13208,,0,A,,1,Renal clearance from the body,22224,,,,CHEMBL627286,7095,,,,,U,Autocuration,BAO_0000218
13209,Rattus norvegicus,1,A,,1,Renal clearance from the body in rat,50597,10116.0,,,CHEMBL875477,7095,,,,,N,Intermediate,BAO_0000218
13210,Rattus norvegicus,1,A,,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,50597,10116.0,,,CHEMBL627287,12528,,,,,N,Intermediate,BAO_0000218
13211,Canis lupus familiaris,1,A,,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,50588,9615.0,,,CHEMBL627288,12528,,,,,N,Intermediate,BAO_0000218
13212,Rattus norvegicus,1,A,,1,Total clearance from the body in rat,50597,10116.0,,,CHEMBL627289,7095,,,,,N,Intermediate,BAO_0000218
13213,Rattus norvegicus,1,A,,1,Clearance into cortex from rat plasma or PBS,50597,10116.0,,,CHEMBL627290,14223,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13214,,0,A,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,22224,,,,CHEMBL627291,13569,,,,,U,Autocuration,BAO_0000218
13215,,0,A,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,22224,,,,CHEMBL627292,13569,,,,,U,Autocuration,BAO_0000218
13216,,0,A,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,22224,,,,CHEMBL627293,13569,,,,,U,Autocuration,BAO_0000218
13217,,0,A,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,22224,,,,CHEMBL627294,13569,,,,,U,Autocuration,BAO_0000218
13218,,0,A,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,22224,,,,CHEMBL875478,13569,,,,,U,Autocuration,BAO_0000218
13219,,0,A,,1,Clearance was determined,22224,,,,CHEMBL627295,13979,,,,,U,Autocuration,BAO_0000218
13220,Mus musculus,1,A,,1,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,50594,10090.0,,,CHEMBL627296,14315,,,,,N,Intermediate,BAO_0000218
13221,Oryctolagus cuniculus,1,A,,1,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,50592,9986.0,,,CHEMBL626119,14315,,,,,N,Intermediate,BAO_0000218
13222,Rattus norvegicus,1,A,,1,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,50597,10116.0,,,CHEMBL626120,14315,,,,,N,Intermediate,BAO_0000218
13223,Rattus norvegicus,1,A,,1,Clearance in rat after iv dose (100 ug/kg),50597,10116.0,,,CHEMBL626121,12174,,,,,N,Intermediate,BAO_0000218
13224,Cavia porcellus,0,A,,1,Clearance in guinea pig,22224,10141.0,,,CHEMBL626122,12797,,,,,U,Autocuration,BAO_0000218
13225,Rattus norvegicus,1,A,,1,Compound was evaluated for clearance in rat,50597,10116.0,,,CHEMBL626123,12797,,,,,N,Intermediate,BAO_0000218
13226,Canis lupus familiaris,1,A,,1,Compound was evaluated for the clearance in dog,50588,9615.0,,,CHEMBL623456,12797,,,,,N,Intermediate,BAO_0000218
13227,Rattus norvegicus,1,A,,1,Compound was evaluated for the clearance in rat,50597,10116.0,,,CHEMBL623457,12797,,,,,N,Intermediate,BAO_0000218
13228,Rattus norvegicus,1,A,,1,Compound was tested in vivo for clearance after iv administration in the rat,50597,10116.0,,,CHEMBL623458,11500,,,,,N,Intermediate,BAO_0000218
13229,,0,A,,1,IV clearance determined at an iv dose of 14 mg/kg,22224,,,,CHEMBL623459,15173,,,,,U,Autocuration,BAO_0000218
13230,,0,A,,1,IV clearance determined at an iv dose of 15.2 mg/kg,22224,,,,CHEMBL875484,15173,,,,,U,Autocuration,BAO_0000218
13231,,0,A,,1,IV clearance determined at an iv dose of 15 mg/kg,22224,,,,CHEMBL623460,15173,,,,,U,Autocuration,BAO_0000218
13232,,0,A,,1,IV clearance determined at an peroral dose of 30 mg/kg.,22224,,,,CHEMBL623461,15173,,,,,U,Autocuration,BAO_0000218
13233,,0,A,,1,IV clearance determined at an peroral dose of 30.2 mg/kg.,22224,,,,CHEMBL623462,15173,,,,,U,Autocuration,BAO_0000218
13234,,0,A,,1,IV clearance determined at an peroral dose of 30.3 mg/kg.,22224,,,,CHEMBL627386,15173,,,,,U,Autocuration,BAO_0000218
13235,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,50597,10116.0,,,CHEMBL627387,14198,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13236,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,50597,10116.0,,,CHEMBL627388,14198,2107.0,,,Liver,N,Intermediate,BAO_0000218
13237,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,50597,10116.0,,,CHEMBL627389,14198,2048.0,,,Lung,N,Intermediate,BAO_0000218
13238,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,50597,10116.0,,,CHEMBL627390,14198,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13239,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,50597,10116.0,,,CHEMBL627391,14198,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13240,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,50597,10116.0,,,CHEMBL627392,14198,,,,,N,Intermediate,BAO_0000218
13241,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,50597,10116.0,,,CHEMBL627393,14198,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13242,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,50597,10116.0,,,CHEMBL627394,14198,3126.0,,,Trachea,N,Intermediate,BAO_0000218
13243,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,50597,10116.0,,,CHEMBL627395,14198,10000001.0,,,Bone,N,Intermediate,BAO_0000218
13244,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,50597,10116.0,,,CHEMBL875485,14198,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13245,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,50597,10116.0,,,CHEMBL627396,14198,,,,,N,Intermediate,BAO_0000218
13246,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,50597,10116.0,,,CHEMBL627397,14198,,,,,N,Intermediate,BAO_0000218
13247,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,50597,10116.0,,,CHEMBL627398,14198,948.0,,,Heart,N,Intermediate,BAO_0000218
13248,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,50597,10116.0,,,CHEMBL627399,14198,10000001.0,,,Bone,N,Intermediate,BAO_0000218
13249,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,50597,10116.0,,,CHEMBL627400,14198,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13250,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,50597,10116.0,,,CHEMBL627401,14198,2107.0,,,Liver,N,Intermediate,BAO_0000218
13251,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,50597,10116.0,,,CHEMBL627402,14198,2048.0,,,Lung,N,Intermediate,BAO_0000218
13252,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,50597,10116.0,,,CHEMBL627403,14198,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13253,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,50597,10116.0,,,CHEMBL627404,14198,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13254,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,50597,10116.0,,,CHEMBL623101,14198,,,,,N,Intermediate,BAO_0000218
13255,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,50597,10116.0,,,CHEMBL877480,14198,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13256,Rattus norvegicus,1,A,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,50597,10116.0,,,CHEMBL623102,14198,3126.0,,,Trachea,N,Intermediate,BAO_0000218
13257,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,50597,10116.0,,,CHEMBL623103,14198,10000001.0,,,Bone,N,Intermediate,BAO_0000218
13258,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,50597,10116.0,,,CHEMBL623104,14198,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13259,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,50597,10116.0,,,CHEMBL623105,14198,,,,,N,Intermediate,BAO_0000218
13260,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,50597,10116.0,,,CHEMBL623106,14198,,,,,N,Intermediate,BAO_0000218
13261,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,50597,10116.0,,,CHEMBL623107,14198,948.0,,,Heart,N,Intermediate,BAO_0000218
13262,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,50597,10116.0,,,CHEMBL623108,14198,160.0,,,Intestine,N,Intermediate,BAO_0000218
13263,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,50597,10116.0,,,CHEMBL623109,14198,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13264,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,50597,10116.0,,,CHEMBL623110,14198,2107.0,,,Liver,N,Intermediate,BAO_0000218
13265,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,50597,10116.0,,,CHEMBL623111,14198,2048.0,,,Lung,N,Intermediate,BAO_0000218
13266,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,50597,10116.0,,,CHEMBL625060,14198,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13267,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,50597,10116.0,,,CHEMBL625061,14198,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13268,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,50597,10116.0,,,CHEMBL625062,14198,,,,,N,Intermediate,BAO_0000218
13269,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,50597,10116.0,,,CHEMBL625063,14198,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13270,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,50597,10116.0,,,CHEMBL625064,14198,3126.0,,,Trachea,N,Intermediate,BAO_0000218
13271,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,50597,10116.0,,,CHEMBL625065,14198,10000001.0,,,Bone,N,Intermediate,BAO_0000218
13272,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,50597,10116.0,,,CHEMBL625066,14198,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13273,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,50597,10116.0,,,CHEMBL625067,14198,,,,,N,Intermediate,BAO_0000218
13274,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,50597,10116.0,,,CHEMBL625068,14198,,,,,N,Intermediate,BAO_0000218
13275,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,50597,10116.0,,,CHEMBL622159,14198,948.0,,,Heart,N,Intermediate,BAO_0000218
13276,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,50597,10116.0,,,CHEMBL622160,14198,160.0,,,Intestine,N,Intermediate,BAO_0000218
13277,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,50597,10116.0,,,CHEMBL622161,14198,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13278,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,50597,10116.0,,,CHEMBL622162,14198,2048.0,,,Lung,N,Intermediate,BAO_0000218
13279,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,50597,10116.0,,,CHEMBL622163,14198,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13280,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,50597,10116.0,,,CHEMBL622313,14198,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13281,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,50597,10116.0,,,CHEMBL622314,14198,,,,,N,Intermediate,BAO_0000218
13282,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,50597,10116.0,,,CHEMBL622315,14198,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13283,Rattus norvegicus,1,A,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,50597,10116.0,,,CHEMBL622316,14198,3126.0,,,Trachea,N,Intermediate,BAO_0000218
13284,Escherichia coli,1,A,,1,Normal diffusion coefficient in water for Escherichia coli,50212,562.0,,,CHEMBL877486,15599,,,,,N,Intermediate,BAO_0000218
13285,,0,A,,1,Average max percent decrease in RVR (renal vascular resistance) was determined,22224,,,,CHEMBL622317,8204,,,,,U,Autocuration,BAO_0000019
13286,,0,A,,1,Average max percent decrease in RVR (renal vascular resistance) was determined.,22224,,,,CHEMBL622318,8204,,,,,U,Autocuration,BAO_0000019
13287,,0,A,,1,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,22224,,,,CHEMBL622319,6154,,,,,U,Autocuration,BAO_0000019
13288,,0,A,,1,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,22224,,,,CHEMBL622320,6154,,,,,U,Autocuration,BAO_0000019
13289,,0,A,,1,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,22224,,,,CHEMBL622321,6154,,,,,U,Autocuration,BAO_0000019
13290,,0,A,,1,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,22224,,,,CHEMBL622322,6154,,,,,U,Autocuration,BAO_0000019
13291,,0,A,,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,22224,,,,CHEMBL622323,7114,,,,,U,Autocuration,BAO_0000019
13292,Rattus norvegicus,1,A,,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,50597,10116.0,,,CHEMBL622324,7114,,,,,N,Intermediate,BAO_0000218
13293,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",50588,9615.0,,,CHEMBL622325,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13294,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,9615.0,,,CHEMBL622326,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13295,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",50588,9615.0,,,CHEMBL877487,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13296,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,9615.0,,,CHEMBL622327,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13297,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",50588,9615.0,,,CHEMBL622328,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13298,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",50588,9615.0,,,CHEMBL622329,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13299,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,9615.0,,,CHEMBL622330,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13300,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",50588,9615.0,,,CHEMBL622331,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13301,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,9615.0,,,CHEMBL622332,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13302,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",50588,9615.0,,,CHEMBL622333,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13303,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,314293.0,,,CHEMBL627658,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13304,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",22224,314293.0,,,CHEMBL630428,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13305,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,314293.0,,,CHEMBL630429,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13306,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",22224,314293.0,,,CHEMBL630430,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13307,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",22224,314293.0,,,CHEMBL630431,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13308,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,10116.0,,,CHEMBL630432,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13309,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",50597,10116.0,,,CHEMBL630433,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13310,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",50597,10116.0,,,CHEMBL630434,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13311,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",50597,10116.0,,,CHEMBL629372,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13312,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",50597,10116.0,,,CHEMBL629553,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13313,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",50597,10116.0,,,CHEMBL629554,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13314,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",50597,10116.0,,,CHEMBL874447,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13315,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",50597,10116.0,,,CHEMBL629555,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13316,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",50597,10116.0,,,CHEMBL629556,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13317,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",50597,10116.0,,,CHEMBL629557,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13318,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",50597,10116.0,,,CHEMBL629558,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13319,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",50597,10116.0,,,CHEMBL629559,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13320,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",50597,10116.0,,,CHEMBL629560,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13321,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",50588,9615.0,,,CHEMBL629561,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13322,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,9615.0,,,CHEMBL629562,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13323,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",50588,9615.0,,,CHEMBL629563,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13324,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,9615.0,,,CHEMBL629564,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13325,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",50588,9615.0,,,CHEMBL629565,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13326,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,9615.0,,,CHEMBL629566,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13327,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,9615.0,,,CHEMBL629567,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13328,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",50588,9615.0,,,CHEMBL629568,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13329,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",50588,9615.0,,,CHEMBL629569,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13330,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",50588,9615.0,,,CHEMBL629570,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13331,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,314293.0,,,CHEMBL629571,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13332,Rattus norvegicus,0,A,,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,22224,10116.0,,,CHEMBL629572,12170,,,,,U,Autocuration,BAO_0000218
13333,Rattus norvegicus,0,A,,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,22224,10116.0,,,CHEMBL629573,12170,,,,,U,Autocuration,BAO_0000218
13334,Eutheria,0,A,,1,Bioavailability (dose 20 mg/kg),22224,9347.0,,,CHEMBL629574,4985,,,,,U,Autocuration,BAO_0000218
13335,Canis lupus familiaris,0,A,,1,Bioavailability in dog,22224,9615.0,,,CHEMBL629575,15145,,,,,U,Autocuration,BAO_0000218
13336,Rattus norvegicus,0,A,,1,Bioavailability in rat (Sprague-Dawley) (male),22224,10116.0,,,CHEMBL874448,14080,,,,,U,Autocuration,BAO_0000218
13337,Primates,0,A,,1,Bioavailability in monkey (dose 10 mg/kg i.d.),22224,9443.0,,,CHEMBL629576,11219,,,,,U,Autocuration,BAO_0000218
13338,Rattus norvegicus,0,A,,1,Bioavailability in rat,22224,10116.0,,,CHEMBL629577,15145,,,,,U,Autocuration,BAO_0000218
13339,Rattus norvegicus,0,A,,1,Bioavailability in rat,22224,10116.0,,,CHEMBL629578,15145,,,,,U,Autocuration,BAO_0000218
13340,Canis lupus familiaris,0,A,,1,Bioavailability in dog (dose 3.0 mg/kg p.o.),22224,9615.0,,,CHEMBL629579,1202,,,,,U,Autocuration,BAO_0000218
13341,Canis lupus familiaris,0,A,,1,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,22224,9615.0,,,CHEMBL882958,1202,,,,,U,Autocuration,BAO_0000218
13342,Pan troglodytes,1,A,,1,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,50505,9598.0,,,CHEMBL629580,1202,,,,,N,Intermediate,BAO_0000218
13343,Eutheria,0,A,,1,Bioavailability,22224,9347.0,,,CHEMBL629581,4026,,,,,U,Autocuration,BAO_0000218
13344,Saimiri,0,A,,1,Bioavailability in squirrel monkey,22224,9520.0,,,CHEMBL629582,1492,,,,,U,Autocuration,BAO_0000218
13345,Canis lupus familiaris,1,A,,1,Bioavailability was evaluated in dog,50588,9615.0,,,CHEMBL628522,12793,,,,,N,Intermediate,BAO_0000218
13346,Cricetinae,1,A,,1,Bioavailability was evaluated in hamster,100712,10026.0,,,CHEMBL625432,12793,,,,,N,Intermediate,BAO_0000218
13347,Rattus norvegicus,0,A,,1,Bioavailability in rat,22224,10116.0,,,CHEMBL625433,12793,,,,,U,Autocuration,BAO_0000218
13348,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL625434,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13349,Rattus norvegicus,1,A,,1,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,50597,10116.0,,,CHEMBL625435,14793,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13350,Rattus norvegicus,0,A,,1,Bioavailability in rat (dose 10 mg/kg p.o.),22224,10116.0,,,CHEMBL625436,14793,,,,,U,Autocuration,BAO_0000218
13351,Macaca fascicularis,1,A,,1,Bioavailability was measured in cynomolgus monkeys.,100710,9541.0,,,CHEMBL874588,14731,,,,,N,Intermediate,BAO_0000218
13352,Mus musculus,1,A,,1,Bioavailability was measured in nude mice.,50594,10090.0,,,CHEMBL625437,14731,,,,,N,Intermediate,BAO_0000218
13353,Mustela putorius furo,0,A,,1,Bioavailability in ferret (dose 10 mg/kg i.d.),22224,9669.0,,,CHEMBL625438,12187,,,,,U,Autocuration,BAO_0000218
13354,Simiiformes,0,A,,1,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),22224,314293.0,,,CHEMBL625439,12187,,,,,U,Autocuration,BAO_0000218
13355,Simiiformes,0,A,,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",22224,314293.0,,,CHEMBL625440,12187,,,,,U,Autocuration,BAO_0000218
13356,Simiiformes,0,A,,1,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),22224,314293.0,,,CHEMBL625441,12187,,,,,U,Autocuration,BAO_0000218
13357,Rattus norvegicus,0,A,,1,Bioavailability in rat (dose 10 mg/kg i.d.),22224,10116.0,,,CHEMBL625442,12187,,,,,U,Autocuration,BAO_0000218
13358,Rattus norvegicus,1,A,,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,10116.0,,,CHEMBL625443,12187,,,,,N,Intermediate,BAO_0000218
13359,,0,A,,1,Bioavailability was determined; extremely poor,22224,,,,CHEMBL625444,17431,,,,,U,Autocuration,BAO_0000218
13360,Mus musculus,1,A,,1,% bioavailability in mice after oral administration of prodrug,50594,10090.0,,,CHEMBL625445,13318,,,,,N,Intermediate,BAO_0000218
13361,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,50588,9615.0,,,CHEMBL625446,9025,,,,,N,Intermediate,BAO_0000218
13362,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,50588,9615.0,,,CHEMBL882960,9025,,,,,N,Intermediate,BAO_0000218
13363,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,50588,9615.0,,,CHEMBL625447,9025,,,,,N,Intermediate,BAO_0000218
13364,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,50588,9615.0,,,CHEMBL625448,9025,,,,,N,Intermediate,BAO_0000218
13365,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,50588,9615.0,,,CHEMBL625449,9025,,,,,N,Intermediate,BAO_0000218
13366,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),50588,9615.0,,,CHEMBL874589,9025,,,,,N,Intermediate,BAO_0000218
13367,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,50588,9615.0,,,CHEMBL625450,9025,,,,,N,Intermediate,BAO_0000218
13368,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,50588,9615.0,,,CHEMBL625451,9025,,,,,N,Intermediate,BAO_0000218
13369,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,50588,9615.0,,,CHEMBL626584,9025,,,,,N,Intermediate,BAO_0000218
13370,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,50588,9615.0,,,CHEMBL626585,9025,,,,,N,Intermediate,BAO_0000218
13371,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,50588,9615.0,,,CHEMBL626586,9025,,,,,N,Intermediate,BAO_0000218
13372,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,50588,9615.0,,,CHEMBL626587,9025,,,,,N,Intermediate,BAO_0000218
13373,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,50588,9615.0,,,CHEMBL626588,9025,,,,,N,Intermediate,BAO_0000218
13374,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,50588,9615.0,,,CHEMBL626589,9025,,,,,N,Intermediate,BAO_0000218
13375,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,50588,9615.0,,,CHEMBL626590,9025,,,,,N,Intermediate,BAO_0000218
13376,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,50588,9615.0,,,CHEMBL626591,9025,,,,,N,Intermediate,BAO_0000218
13377,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,50588,9615.0,,,CHEMBL627181,9025,,,,,N,Intermediate,BAO_0000218
13378,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,50588,9615.0,,,CHEMBL628083,9025,,,,,N,Intermediate,BAO_0000218
13379,,0,A,,1,IV clearance determined at an peroral dose of 15 mg/kg.,22224,,,,CHEMBL628084,15173,,,,,U,Autocuration,BAO_0000218
13380,Hymenolepis nana,1,F,,1,Mouse oral clearance was measured against Hymenolepiasis nana.,50064,102285.0,,,CHEMBL628085,7732,,,,,N,Expert,BAO_0000218
13381,Heligmosomoides polygyrus,1,F,,1,Mouse oral clearance was measured against Nematospiroides dubius,50545,6339.0,,,CHEMBL628086,7732,,,,,N,Expert,BAO_0000218
13382,,0,F,,1,Mouse oral clearance was measured against N. dubius; NT is Not Tested,22224,,,,CHEMBL628087,7732,,,,,U,Autocuration,BAO_0000218
13383,Mus musculus,1,A,,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,50594,10090.0,,,CHEMBL628088,7732,,,,,N,Intermediate,BAO_0000218
13384,,0,B,,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,22224,,,,CHEMBL628089,7732,,,,,U,Autocuration,BAO_0000218
13385,,0,A,,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL628090,8328,,,,,U,Autocuration,BAO_0000218
13386,,0,A,,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL628091,8328,,,,,U,Autocuration,BAO_0000218
13387,,0,A,,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL628092,8328,,,,,U,Autocuration,BAO_0000218
13388,,0,A,,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL628093,8328,,,,,U,Autocuration,BAO_0000218
13389,,0,A,,1,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL875607,8328,,,,,U,Autocuration,BAO_0000218
13390,,0,A,,1,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL625710,8328,,,,,U,Autocuration,BAO_0000218
13391,,0,A,,1,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL625711,8328,,,,,U,Autocuration,BAO_0000218
13392,,0,A,,1,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL625712,8328,,,,,U,Autocuration,BAO_0000218
13393,,0,A,,1,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,22224,,,,CHEMBL625713,8328,,,,,U,Autocuration,BAO_0000218
13394,Canis lupus familiaris,1,A,,1,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,50588,9615.0,,,CHEMBL625714,13376,,,,,N,Intermediate,BAO_0000218
13395,Macaca mulatta,1,A,,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,50797,9544.0,,,CHEMBL625715,13477,,,,,N,Intermediate,BAO_0000218
13396,Rattus norvegicus,1,A,,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,50597,10116.0,,,CHEMBL625716,13477,,,,,N,Intermediate,BAO_0000218
13397,Rattus norvegicus,1,A,,1,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,50597,10116.0,,,CHEMBL625717,13477,,,,,N,Intermediate,BAO_0000218
13398,Rattus norvegicus,1,A,,1,Plasma clearance was determined for the compound in rats,50597,10116.0,,,CHEMBL625718,13313,,,,,N,Intermediate,BAO_0000218
13399,Rattus norvegicus,1,A,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,50597,10116.0,,,CHEMBL625719,12504,,,,,N,Intermediate,BAO_0000218
13400,Rattus norvegicus,1,A,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,50597,10116.0,,,CHEMBL625720,12504,,,,,N,Intermediate,BAO_0000218
13401,Rattus norvegicus,1,A,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,50597,10116.0,,,CHEMBL625721,12504,,,,,N,Intermediate,BAO_0000218
13402,Rattus norvegicus,1,A,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,50597,10116.0,,,CHEMBL625722,12504,,,,,N,Intermediate,BAO_0000218
13403,Rattus norvegicus,1,A,,1,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,50597,10116.0,,,CHEMBL625723,13129,,,,,N,Intermediate,BAO_0000218
13404,Heligmosomoides polygyrus,1,A,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,50545,6339.0,,,CHEMBL625724,7732,,,,,N,Intermediate,BAO_0000218
13405,Heligmosomoides polygyrus,1,A,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,50545,6339.0,,,CHEMBL625725,7732,,,,,N,Intermediate,BAO_0000218
13406,Heligmosomoides polygyrus,1,A,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,50545,6339.0,,,CHEMBL625726,7732,,,,,N,Intermediate,BAO_0000218
13407,Heligmosomoides polygyrus,1,A,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,50545,6339.0,,,CHEMBL875608,7732,,,,,N,Intermediate,BAO_0000218
13408,Heligmosomoides polygyrus,1,A,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,50545,6339.0,,,CHEMBL625727,7732,,,,,N,Intermediate,BAO_0000218
13409,Rattus norvegicus,0,A,,1,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,22224,10116.0,,,CHEMBL625728,9278,1088.0,,,Urine,U,Autocuration,BAO_0000218
13410,Rattus norvegicus,0,A,,1,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,22224,10116.0,,,CHEMBL625729,9278,,,,,U,Autocuration,BAO_0000218
13411,Rattus norvegicus,0,A,,1,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,22224,10116.0,,,CHEMBL625730,9278,,,,,U,Autocuration,BAO_0000218
13412,Rattus norvegicus,0,A,,1,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,22224,10116.0,,,CHEMBL625731,9278,1088.0,,,Urine,U,Autocuration,BAO_0000218
13413,Rattus norvegicus,0,A,,1,Urinary clearance was determined in rat at 25 mg/kg os dosage,22224,10116.0,,,CHEMBL626417,9278,1088.0,,,Urine,U,Autocuration,BAO_0000218
13414,Homo sapiens,1,A,,1,Urinary clearance was determined at 100 mg/kg oral dosage in human,50587,9606.0,,,CHEMBL626418,9278,1088.0,,,Urine,N,Intermediate,BAO_0000218
13415,Canis lupus familiaris,1,A,,1,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,50588,9615.0,,,CHEMBL626419,9278,1088.0,,,Urine,N,Intermediate,BAO_0000218
13416,Canis lupus familiaris,1,A,,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,9615.0,,,CHEMBL626592,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13417,Rattus norvegicus,1,A,,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,10116.0,,,CHEMBL626593,5932,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13418,Rattus norvegicus,1,A,,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,10116.0,,,CHEMBL626594,5182,,,,,N,Intermediate,BAO_0000218
13419,Canis lupus familiaris,1,A,,1,Clearance rate in dogs,50588,9615.0,,,CHEMBL625035,10499,,,,,N,Intermediate,BAO_0000218
13420,,0,A,,1,Compound was measured for intrinsic clearance,22224,,,,CHEMBL625036,6051,,,,,U,Autocuration,BAO_0000019
13421,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625037,17508,,,,,U,Autocuration,BAO_0000100
13422,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625038,6228,,,,,U,Autocuration,BAO_0000100
13423,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625039,6231,,,,,U,Autocuration,BAO_0000100
13424,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625040,17740,,,,,U,Autocuration,BAO_0000100
13425,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625041,6495,,,,,U,Autocuration,BAO_0000100
13426,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625042,2171,,,,,U,Autocuration,BAO_0000100
13427,,0,A,,1,Partition coefficient of the compound,22224,,,,CHEMBL874411,3255,,,,,U,Autocuration,BAO_0000019
13428,,0,A,,1,Permeability,22224,,,,CHEMBL625043,6821,,,,,U,Autocuration,BAO_0000019
13429,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625044,2685,,,,,U,Autocuration,BAO_0000100
13430,,0,A,,1,Partition coefficient (logD),22224,,,,CHEMBL625045,17584,,,,,U,Autocuration,BAO_0000019
13431,,0,P,,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,,,,CHEMBL625046,13824,,,,,U,Autocuration,BAO_0000100
13432,,0,P,,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,,,,CHEMBL625047,13824,,,,,U,Autocuration,BAO_0000100
13433,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625048,16479,,,,,U,Autocuration,BAO_0000100
13434,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625049,11997,,,,,U,Autocuration,BAO_0000100
13435,,0,P,,1,Calculated logarithm of partition coefficient (P) was determined,22229,,,,CHEMBL625050,2988,,,,,U,Autocuration,BAO_0000100
13436,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625051,931,,,,,U,Autocuration,BAO_0000100
13437,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL874412,4381,,,,,U,Autocuration,BAO_0000100
13438,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625052,4397,,,,,U,Autocuration,BAO_0000100
13439,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL625053,5889,,,,,U,Autocuration,BAO_0000100
13440,,0,A,,1,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,22224,,,,CHEMBL623250,6154,,,,,U,Autocuration,BAO_0000019
13441,,0,A,,1,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,22224,,,,CHEMBL623251,6154,,,,,U,Autocuration,BAO_0000019
13442,,0,A,,1,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,22224,,,,CHEMBL623252,6154,,,,,U,Autocuration,BAO_0000019
13443,,0,A,,1,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,22224,,,,CHEMBL623253,6154,,,,,U,Autocuration,BAO_0000019
13444,,0,A,,1,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,22224,,,,CHEMBL623254,6154,,,,,U,Autocuration,BAO_0000019
13445,,0,A,,1,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,22224,,,,CHEMBL623255,6154,,,,,U,Autocuration,BAO_0000019
13446,,0,A,,1,Percent degradation of compound at a pH of 1 over a 18 hr period,22224,,,,CHEMBL626831,6887,,,,,U,Autocuration,BAO_0000019
13447,,0,A,,1,Percent degradation of compound at pH of 1 over an 18 hr period,22224,,,,CHEMBL877494,6887,,,,,U,Autocuration,BAO_0000019
13448,,0,A,,1,Delta Logarithm of Partition Coefficient value was determined.,22224,,,,CHEMBL626832,14116,,,,,U,Autocuration,BAO_0000019
13449,,0,A,,1,Delta logPoct-cyc,22224,,,,CHEMBL626833,11137,,,,,U,Autocuration,BAO_0000019
13450,,0,P,,1,Lipophilicity estimated on reversed phase TLC,22224,,,,CHEMBL626834,7230,,,,,U,Autocuration,BAO_0000100
13451,,0,A,,1,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,22224,,,,CHEMBL626835,15741,,,,,U,Autocuration,BAO_0000019
13452,,0,A,,1,Delta logPoct-cyc,22224,,,,CHEMBL626836,9663,,,,,U,Autocuration,BAO_0000019
13453,,0,P,,1,Change in logarithm of partition coefficient of the compound,22229,,,,CHEMBL626837,9663,,,,,U,Autocuration,BAO_0000100
13454,,0,A,,1,Delta logD (pH 6.5),22224,,,,CHEMBL626838,13807,,,,,U,Autocuration,BAO_0000019
13455,,0,P,,1,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",22224,,,,CHEMBL626839,13807,,,,,U,Autocuration,BAO_0000100
13456,,0,A,,1,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,22224,,,,CHEMBL626840,17425,,,,,U,Autocuration,BAO_0000019
13457,,0,A,,1,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),22224,,,,CHEMBL626841,12143,,,,,U,Autocuration,BAO_0000019
13458,,0,A,,1,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,22224,,,,CHEMBL626842,12608,,,,,U,Autocuration,BAO_0000219
13459,,0,A,,1,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,22224,,,,CHEMBL626843,12608,,,,,U,Autocuration,BAO_0000219
13460,Rattus norvegicus,1,A,,1,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,50597,10116.0,,,CHEMBL626844,8649,,,,,N,Intermediate,BAO_0000218
13461,Rattus norvegicus,1,A,,1,Amount of deuterium retained was reported after normal workup in rats,50597,10116.0,,,CHEMBL877495,8649,,,,,N,Intermediate,BAO_0000218
13462,Rattus norvegicus,1,A,,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,50597,10116.0,,,CHEMBL626845,8649,,,,,N,Intermediate,BAO_0000218
13463,Rattus norvegicus,1,A,,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,50597,10116.0,,,CHEMBL626846,8649,,,,,N,Intermediate,BAO_0000218
13464,Rattus norvegicus,1,A,,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,50597,10116.0,,,CHEMBL626847,8649,,,,,N,Intermediate,BAO_0000218
13465,Rattus norvegicus,1,A,,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,50597,10116.0,,,CHEMBL628677,8649,,,,,N,Intermediate,BAO_0000218
13466,Rattus norvegicus,1,A,,1,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,50597,10116.0,,,CHEMBL628678,8649,,,,,N,Intermediate,BAO_0000218
13467,,0,A,,1,Compound was subjected to electrochemical oxidation,22224,,,,CHEMBL628679,9659,,,,,U,Autocuration,BAO_0000019
13468,,0,A,,1,Compound was subjected to photochemical oxidation,22224,,,,CHEMBL628680,9659,,,,,U,Autocuration,BAO_0000019
13469,,0,A,,1,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,22224,,,,CHEMBL628681,9659,,,,,U,Autocuration,BAO_0000019
13470,,0,A,,1,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,22224,,,,CHEMBL628682,9659,,,,,U,Autocuration,BAO_0000019
13471,,0,A,,1,Oxidation of compound by methemoglobin in presence of hydroperoxide,22224,,,,CHEMBL628683,9659,,,,,U,Autocuration,BAO_0000019
13472,Rattus norvegicus,1,A,,1,Percent diffusion through fuzzy rat skin after 48 h of incubation,50597,10116.0,,,CHEMBL628684,9607,,,,,N,Intermediate,BAO_0000218
13473,,0,P,,1,Dissociation constant (pKa),22229,,,,CHEMBL877501,7057,,,,,U,Autocuration,BAO_0000100
13474,,0,P,,1,Dissociation constant value of the compound; ND means not determined.,22224,,,,CHEMBL628685,7057,,,,,U,Autocuration,BAO_0000100
13475,Rattus norvegicus,1,A,,1,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,50597,10116.0,,,CHEMBL628686,7911,178.0,,,Blood,N,Intermediate,BAO_0000218
13476,Rattus norvegicus,1,A,,1,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,10116.0,,,CHEMBL628687,7911,178.0,,,Blood,N,Intermediate,BAO_0000218
13477,Rattus norvegicus,1,A,,1,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,50597,10116.0,,,CHEMBL628688,7911,,,,,N,Intermediate,BAO_0000218
13478,Rattus norvegicus,1,A,,1,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,10116.0,,,CHEMBL628689,7911,,,,,N,Intermediate,BAO_0000218
13479,Rattus norvegicus,1,A,,1,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,50597,10116.0,,,CHEMBL628690,7911,2107.0,,,Liver,N,Intermediate,BAO_0000218
13480,Rattus norvegicus,1,A,,1,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,50597,10116.0,,,CHEMBL629363,7911,2107.0,,,Liver,N,Intermediate,BAO_0000218
13481,Rattus norvegicus,1,A,,1,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,50597,10116.0,,,CHEMBL629364,7911,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13482,Rattus norvegicus,1,A,,1,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,10116.0,,,CHEMBL629365,7911,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13483,Rattus norvegicus,1,A,,1,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,50597,10116.0,,,CHEMBL629366,7911,,,,,N,Intermediate,BAO_0000218
13484,Rattus norvegicus,1,A,,1,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,50597,10116.0,,,CHEMBL629367,7911,1088.0,,,Urine,N,Intermediate,BAO_0000218
13485,Rattus norvegicus,1,A,,1,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,10116.0,,,CHEMBL629368,7911,1988.0,,,Feces,N,Intermediate,BAO_0000218
13486,Rattus norvegicus,1,A,,1,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,50597,10116.0,,,CHEMBL877502,7911,1088.0,,,Urine,N,Intermediate,BAO_0000218
13487,Mus musculus,1,A,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,50594,10090.0,,,CHEMBL629369,13792,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13488,Mus musculus,1,A,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,50594,10090.0,,,CHEMBL629370,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
13489,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",22224,314293.0,,,CHEMBL629371,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13490,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,314293.0,,,CHEMBL626276,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13491,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",22224,314293.0,,,CHEMBL626277,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13492,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",22224,314293.0,,,CHEMBL631250,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13493,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,10116.0,,,CHEMBL631251,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13494,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",50597,10116.0,,,CHEMBL631252,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13495,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",50597,10116.0,,,CHEMBL631253,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13496,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",50597,10116.0,,,CHEMBL631254,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13497,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",50597,10116.0,,,CHEMBL631255,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13498,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",50597,10116.0,,,CHEMBL631256,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13499,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",50597,10116.0,,,CHEMBL631257,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13500,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",50597,10116.0,,,CHEMBL628009,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13501,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",50597,10116.0,,,CHEMBL628010,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13502,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",50597,10116.0,,,CHEMBL628011,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13503,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",50597,10116.0,,,CHEMBL628012,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13504,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",50597,10116.0,,,CHEMBL628013,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13505,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",50597,10116.0,,,CHEMBL628014,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13506,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",50588,9615.0,,,CHEMBL628015,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13507,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,9615.0,,,CHEMBL628016,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13508,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",50588,9615.0,,,CHEMBL874461,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13509,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,9615.0,,,CHEMBL628017,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13510,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",50588,9615.0,,,CHEMBL628018,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13511,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,9615.0,,,CHEMBL628019,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13512,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,9615.0,,,CHEMBL628020,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13513,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",50588,9615.0,,,CHEMBL628021,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13514,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",50588,9615.0,,,CHEMBL628022,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13515,Canis lupus familiaris,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",50588,9615.0,,,CHEMBL628023,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13516,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,314293.0,,,CHEMBL628024,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13517,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",22224,314293.0,,,CHEMBL628025,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13518,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,314293.0,,,CHEMBL628026,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13519,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",22224,314293.0,,,CHEMBL628027,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13520,Simiiformes,0,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",22224,314293.0,,,CHEMBL628028,8133,1088.0,,,Urine,U,Autocuration,BAO_0000218
13521,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,10116.0,,,CHEMBL628029,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13522,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",50597,10116.0,,,CHEMBL628030,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13523,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",50597,10116.0,,,CHEMBL628031,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13524,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",50597,10116.0,,,CHEMBL628032,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13525,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",50597,10116.0,,,CHEMBL628033,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13526,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",50597,10116.0,,,CHEMBL628034,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13527,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",50597,10116.0,,,CHEMBL628035,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13528,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",50597,10116.0,,,CHEMBL628036,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13529,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",50597,10116.0,,,CHEMBL874462,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13530,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,50588,9615.0,,,CHEMBL628037,9025,,,,,N,Intermediate,BAO_0000218
13531,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,50588,9615.0,,,CHEMBL628123,9025,,,,,N,Intermediate,BAO_0000218
13532,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,50588,9615.0,,,CHEMBL628124,9025,,,,,N,Intermediate,BAO_0000218
13533,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,50588,9615.0,,,CHEMBL628125,9025,,,,,N,Intermediate,BAO_0000218
13534,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,50588,9615.0,,,CHEMBL628126,9025,,,,,N,Intermediate,BAO_0000218
13535,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),50588,9615.0,,,CHEMBL628127,9025,,,,,N,Intermediate,BAO_0000218
13536,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,50588,9615.0,,,CHEMBL628128,9025,,,,,N,Intermediate,BAO_0000218
13537,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,50588,9615.0,,,CHEMBL628129,9025,,,,,N,Intermediate,BAO_0000218
13538,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,50588,9615.0,,,CHEMBL628130,9025,,,,,N,Intermediate,BAO_0000218
13539,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,50588,9615.0,,,CHEMBL628131,9025,,,,,N,Intermediate,BAO_0000218
13540,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,50588,9615.0,,,CHEMBL628132,9025,,,,,N,Intermediate,BAO_0000218
13541,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,50588,9615.0,,,CHEMBL628133,9025,,,,,N,Intermediate,BAO_0000218
13542,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,50588,9615.0,,,CHEMBL628134,9025,,,,,N,Intermediate,BAO_0000218
13543,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,50588,9615.0,,,CHEMBL628135,9025,,,,,N,Intermediate,BAO_0000218
13544,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,50588,9615.0,,,CHEMBL628136,9025,,,,,N,Intermediate,BAO_0000218
13545,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,50588,9615.0,,,CHEMBL628137,9025,,,,,N,Intermediate,BAO_0000218
13546,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,50588,9615.0,,,CHEMBL628138,9025,,,,,N,Intermediate,BAO_0000218
13547,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,50588,9615.0,,,CHEMBL628139,9025,,,,,N,Intermediate,BAO_0000218
13548,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,50588,9615.0,,,CHEMBL628140,9025,,,,,N,Intermediate,BAO_0000218
13549,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,50588,9615.0,,,CHEMBL628141,9025,,,,,N,Intermediate,BAO_0000218
13550,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,50588,9615.0,,,CHEMBL628142,9025,,,,,N,Intermediate,BAO_0000218
13551,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,50588,9615.0,,,CHEMBL628143,9025,,,,,N,Intermediate,BAO_0000218
13552,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,50588,9615.0,,,CHEMBL628144,9025,,,,,N,Intermediate,BAO_0000218
13553,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,50588,9615.0,,,CHEMBL628145,9025,,,,,N,Intermediate,BAO_0000218
13554,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,50588,9615.0,,,CHEMBL628146,9025,,,,,N,Intermediate,BAO_0000218
13555,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,50588,9615.0,,,CHEMBL625355,9025,,,,,N,Intermediate,BAO_0000218
13556,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,50588,9615.0,,,CHEMBL625356,9025,,,,,N,Intermediate,BAO_0000218
13557,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,50588,9615.0,,,CHEMBL625357,9025,,,,,N,Intermediate,BAO_0000218
13558,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,50588,9615.0,,,CHEMBL625527,9025,,,,,N,Intermediate,BAO_0000218
13559,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),50588,9615.0,,,CHEMBL875473,9025,,,,,N,Intermediate,BAO_0000218
13560,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,50588,9615.0,,,CHEMBL625528,9025,,,,,N,Intermediate,BAO_0000218
13561,Rattus norvegicus,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,50597,10116.0,,,CHEMBL626304,9025,,,,,N,Intermediate,BAO_0000218
13562,Canis lupus familiaris,1,A,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,50588,9615.0,,,CHEMBL624138,9025,1637.0,,,Artery,N,Intermediate,BAO_0000218
13563,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624139,6448,,,,,U,Autocuration,BAO_0000100
13564,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624140,17221,,,,,U,Autocuration,BAO_0000100
13565,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624141,6545,,,,,U,Autocuration,BAO_0000100
13566,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624142,577,,,,,U,Autocuration,BAO_0000100
13567,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624143,6285,,,,,U,Autocuration,BAO_0000100
13568,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624144,6500,,,,,U,Autocuration,BAO_0000100
13569,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624145,6716,,,,,U,Autocuration,BAO_0000100
13570,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624146,13658,,,,,U,Autocuration,BAO_0000100
13571,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624147,6549,,,,,U,Autocuration,BAO_0000100
13572,,0,P,,1,Calculated partition coefficient (clogP) (MacLogP),22229,,,,CHEMBL883123,14685,,,,,U,Autocuration,BAO_0000100
13573,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL624148,6893,,,,,U,Autocuration,BAO_0000019
13574,,0,A,,1,Kinetic parameter was determined,22224,,,,CHEMBL874416,3687,,,,,U,Autocuration,BAO_0000019
13575,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624149,4207,,,,,U,Autocuration,BAO_0000100
13576,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL624150,4626,,,,,U,Autocuration,BAO_0000100
13577,,0,P,,1,Lipophilicity was determined,22224,,,,CHEMBL624151,1021,,,,,U,Autocuration,BAO_0000100
13578,,0,P,,1,Lipophilicity was determined,22224,,,,CHEMBL624152,3777,,,,,U,Autocuration,BAO_0000100
13579,,0,P,,1,Lipophilicity was determined,22224,,,,CHEMBL622139,17533,,,,,U,Autocuration,BAO_0000100
13580,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL622140,6524,,,,,U,Autocuration,BAO_0000100
13581,,0,P,,1,Lipophilicity was determined,22224,,,,CHEMBL622141,17533,,,,,U,Autocuration,BAO_0000100
13582,,0,P,,1,Lipophilicity in octanol-water,22224,,,,CHEMBL622142,6480,,,,,U,Autocuration,BAO_0000100
13583,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL622143,17606,,,,,U,Autocuration,BAO_0000100
13584,,0,P,,1,Octanol-water partition coefficient was determined,22229,,,,CHEMBL622144,6863,,,,,U,Autocuration,BAO_0000100
13585,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL877473,1356,,,,,U,Autocuration,BAO_0000019
13586,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL622145,3326,,,,,U,Autocuration,BAO_0000100
13587,,0,A,,1,Partition coefficient was determined; ND means not determined,22224,,,,CHEMBL622146,1356,,,,,U,Autocuration,BAO_0000019
13588,,0,P,,1,Calculated partition coefficient (clogP),22229,,,,CHEMBL622147,12984,,,,,U,Autocuration,BAO_0000100
13589,,0,A,,1,Partition coefficient of the compound,22224,,,,CHEMBL622148,17363,,,,,U,Autocuration,BAO_0000019
13590,,0,A,,1,Permeability was determined,22224,,,,CHEMBL883124,6827,,,,,U,Autocuration,BAO_0000019
13591,,0,P,,1,The compound was evaluated for the partition coefficient,22229,,,,CHEMBL622149,261,,,,,U,Autocuration,BAO_0000100
13592,,0,A,,1,Partition coefficient (logP),22224,,,,CHEMBL622150,2685,,,,,U,Autocuration,BAO_0000019
13593,,0,P,,1,The lipophilicity was reported,22224,,,,CHEMBL622151,414,,,,,U,Autocuration,BAO_0000100
13594,,0,P,,1,logarithm of the octanol-water partition coefficient for the compound,22229,,,,CHEMBL622152,15769,,,,,U,Autocuration,BAO_0000100
13595,,0,A,,1,Clogp value was determined,22224,,,,CHEMBL622153,17248,,,,,U,Autocuration,BAO_0000019
13596,,0,A,,1,Clp at a dose of 1.5 mg/kg,22224,,,,CHEMBL877474,16935,,,,,U,Autocuration,BAO_0000218
13597,,0,A,,1,Clp at a dose of 2.0 mg/kg,22224,,,,CHEMBL622154,16935,,,,,U,Autocuration,BAO_0000218
13598,,0,A,,1,"Clp, plasma clearance at a dose of 10 mg/kg",22224,,,,CHEMBL622155,14832,1969.0,,,Plasma,U,Autocuration,BAO_0000218
13599,,0,A,,1,"Clp, plasma clearance at a dose of 50 mg/kg",22224,,,,CHEMBL622156,14832,1969.0,,,Plasma,U,Autocuration,BAO_0000218
13600,Rattus norvegicus,1,A,,1,Compound was tested for plasma clearance in rat,50597,10116.0,,,CHEMBL622157,2399,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13601,Rattus norvegicus,1,A,,1,Compound was tested for plasma clearance in rat; Not determined,50597,10116.0,,,CHEMBL622158,2399,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13602,Rattus norvegicus,1,A,,1,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,50597,10116.0,,,CHEMBL622807,6227,,,,,N,Intermediate,BAO_0000218
13603,Macaca mulatta,1,A,,1,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,50797,9544.0,,,CHEMBL622808,6227,,,,,N,Intermediate,BAO_0000218
13604,,0,A,,1,Plasma clearance by iv administration at a dose 0.003 ug/mL,22224,,,,CHEMBL622809,5623,,,,,U,Autocuration,BAO_0000218
13605,,0,A,,1,Plasma clearance determined,22224,,,,CHEMBL622810,4854,,,,,U,Autocuration,BAO_0000218
13606,Cricetinae,1,A,,1,Plasma clearance after iv administration at 3 mg/kg in hamster,100712,10026.0,,,CHEMBL876653,4493,,,,,N,Intermediate,BAO_0000218
13607,Cricetinae,1,A,,1,Plasma clearance after iv administration at 4 mg/kg in hamster,100712,10026.0,,,CHEMBL622811,4493,,,,,N,Intermediate,BAO_0000218
13608,Rattus norvegicus,1,A,,1,Rate of clearance in rat was determined,50597,10116.0,,,CHEMBL622986,14956,,,,,N,Intermediate,BAO_0000218
13609,Rattus norvegicus,1,A,,1,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,50597,10116.0,,,CHEMBL622987,15372,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13610,Rattus norvegicus,1,A,,1,Total plasma clearance after iv dose of 5.10 mg/kg in rats,50597,10116.0,,,CHEMBL622988,15372,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13611,Rattus norvegicus,1,A,,1,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,10116.0,,,CHEMBL622989,15372,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13612,Rattus norvegicus,1,A,,1,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,10116.0,,,CHEMBL622990,15372,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13613,Simiiformes,0,A,,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,22224,314293.0,,,CHEMBL622991,15604,1969.0,,,Plasma,U,Autocuration,BAO_0000218
13614,Rattus norvegicus,1,A,,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,50597,10116.0,,,CHEMBL622227,15604,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13615,Canis lupus familiaris,1,A,,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,50588,9615.0,,,CHEMBL622228,15604,1969.0,,,Plasma,N,Intermediate,BAO_0000218
13616,Rattus norvegicus,1,A,,1,Clpl value in rat,50597,10116.0,,,CHEMBL622229,14964,,,,,N,Intermediate,BAO_0000218
13617,Cavia porcellus,1,A,,1,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,50512,10141.0,,,CHEMBL622230,15240,,,,,N,Intermediate,BAO_0000218
13618,Rattus norvegicus,1,A,,1,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,50597,10116.0,,,CHEMBL622231,16449,,,,,N,Intermediate,BAO_0000218
13619,Macaca fascicularis,1,A,,1,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,100710,9541.0,,,CHEMBL622232,16449,,,,,N,Intermediate,BAO_0000218
13620,,0,A,,1,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,22224,,,,CHEMBL622233,12902,,,,,U,Autocuration,BAO_0000218
13621,,0,A,,1,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,22224,,,,CHEMBL622234,12902,,,,,U,Autocuration,BAO_0000218
13622,,0,A,,1,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,22224,,,,CHEMBL622235,12902,,,,,U,Autocuration,BAO_0000218
13623,,0,A,,1,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,22224,,,,CHEMBL622236,12902,,,,,U,Autocuration,BAO_0000218
13624,,0,A,,1,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,22224,,,,CHEMBL622237,12902,,,,,U,Autocuration,BAO_0000218
13625,,0,A,,1,Cmax in minutes at a po dose of 10.0(pmol/g/h).,22224,,,,CHEMBL877482,12902,,,,,U,Autocuration,BAO_0000218
13626,,0,A,,1,Cmax in minutes at a po dose of 20.0(pmol/g/h).,22224,,,,CHEMBL622238,12902,,,,,U,Autocuration,BAO_0000218
13627,,0,A,,1,Cmax in minutes at a po dose of 40.0(pmol/g/h).,22224,,,,CHEMBL622239,12902,,,,,U,Autocuration,BAO_0000218
13628,,0,A,,1,Cmax was calculated as maximum concentration reached in the blood,22224,,,,CHEMBL622240,11149,178.0,,,Blood,U,Autocuration,BAO_0000218
13629,,0,A,,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,22224,,,,CHEMBL622241,11149,178.0,,,Blood,U,Autocuration,BAO_0000218
13630,Rattus norvegicus,1,A,,1,Cmax was determine after peroral administration at 10 mpk in Rat,50597,10116.0,,,CHEMBL631013,5669,,,,,N,Intermediate,BAO_0000218
13631,Macaca mulatta,1,A,,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,50797,9544.0,,,CHEMBL631014,5669,,,,,N,Intermediate,BAO_0000218
13632,Canis lupus familiaris,1,A,,1,Cmax was determine after peroral administration at 10 mpk in dog,50588,9615.0,,,CHEMBL631015,5669,,,,,N,Intermediate,BAO_0000218
13633,Rattus norvegicus,1,A,,1,Cmax was determine after peroral administration at 160 mpk in Rat,50597,10116.0,,,CHEMBL631016,5669,,,,,N,Intermediate,BAO_0000218
13634,Rattus norvegicus,1,A,,1,Cmax was determine after peroral administration at 20 mpk in Rat,50597,10116.0,,,CHEMBL631017,5669,,,,,N,Intermediate,BAO_0000218
13635,Rattus norvegicus,1,A,,1,Cmax was determine after peroral administration at 50 mpk in Rat,50597,10116.0,,,CHEMBL631018,5669,,,,,N,Intermediate,BAO_0000218
13636,,0,A,,1,Cmax was determined,22224,,,,CHEMBL631019,4236,,,,,U,Autocuration,BAO_0000218
13637,Mus musculus,1,A,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,50594,10090.0,,,CHEMBL875761,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
13638,Mus musculus,1,A,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,50594,10090.0,,,CHEMBL631020,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
13639,Mus musculus,1,A,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,50594,10090.0,,,CHEMBL631669,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
13640,Mus musculus,1,A,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,50594,10090.0,,,CHEMBL631670,13792,955.0,,,Brain,N,Intermediate,BAO_0000218
13641,Mus musculus,1,A,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,50594,10090.0,,,CHEMBL631671,13792,2435.0,,,Striatum,N,Intermediate,BAO_0000218
13642,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,50597,10116.0,,,CHEMBL631672,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13643,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,50597,10116.0,,,CHEMBL631673,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13644,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,50597,10116.0,,,CHEMBL631856,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13645,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,50597,10116.0,,,CHEMBL631857,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13646,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,50597,10116.0,,,CHEMBL631858,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13647,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,50597,10116.0,,,CHEMBL631859,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13648,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,50597,10116.0,,,CHEMBL631860,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13649,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,50597,10116.0,,,CHEMBL631861,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13650,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,50597,10116.0,,,CHEMBL631862,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13651,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,50597,10116.0,,,CHEMBL631863,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13652,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,50597,10116.0,,,CHEMBL631864,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13653,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,50597,10116.0,,,CHEMBL631865,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13654,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,50597,10116.0,,,CHEMBL631866,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13655,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,50597,10116.0,,,CHEMBL629360,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13656,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,50597,10116.0,,,CHEMBL629361,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13657,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,50597,10116.0,,,CHEMBL629362,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13658,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,50597,10116.0,,,CHEMBL630740,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13659,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,50597,10116.0,,,CHEMBL630741,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13660,Rattus norvegicus,1,A,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,50597,10116.0,,,CHEMBL630742,8418,178.0,,,Blood,N,Intermediate,BAO_0000218
13661,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,50597,10116.0,,,CHEMBL630743,8418,,,,,N,Intermediate,BAO_0000218
13662,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,50597,10116.0,,,CHEMBL630744,8418,,,,,N,Intermediate,BAO_0000218
13663,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,50597,10116.0,,,CHEMBL630745,8418,,,,,N,Intermediate,BAO_0000218
13664,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,50597,10116.0,,,CHEMBL630746,8418,,,,,N,Intermediate,BAO_0000218
13665,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,50597,10116.0,,,CHEMBL630747,8418,,,,,N,Intermediate,BAO_0000218
13666,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,50597,10116.0,,,CHEMBL630748,8418,,,,,N,Intermediate,BAO_0000218
13667,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,50597,10116.0,,,CHEMBL632056,8418,,,,,N,Intermediate,BAO_0000218
13668,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,50597,10116.0,,,CHEMBL632057,8418,,,,,N,Intermediate,BAO_0000218
13669,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,50597,10116.0,,,CHEMBL632058,8418,,,,,N,Intermediate,BAO_0000218
13670,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,50597,10116.0,,,CHEMBL632059,8418,,,,,N,Intermediate,BAO_0000218
13671,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,50597,10116.0,,,CHEMBL632060,8418,,,,,N,Intermediate,BAO_0000218
13672,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,50597,10116.0,,,CHEMBL632061,8418,,,,,N,Intermediate,BAO_0000218
13673,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,50597,10116.0,,,CHEMBL629207,8418,,,,,N,Intermediate,BAO_0000218
13674,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,50597,10116.0,,,CHEMBL629208,8418,,,,,N,Intermediate,BAO_0000218
13675,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,50597,10116.0,,,CHEMBL629209,8418,,,,,N,Intermediate,BAO_0000218
13676,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,50597,10116.0,,,CHEMBL629210,8418,,,,,N,Intermediate,BAO_0000218
13677,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,50597,10116.0,,,CHEMBL629211,8418,,,,,N,Intermediate,BAO_0000218
13678,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,50597,10116.0,,,CHEMBL629212,8418,,,,,N,Intermediate,BAO_0000218
13679,Rattus norvegicus,1,A,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,50597,10116.0,,,CHEMBL629213,8418,,,,,N,Intermediate,BAO_0000218
13680,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",50597,10116.0,,,CHEMBL629214,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13681,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",50597,10116.0,,,CHEMBL629215,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13682,Rattus norvegicus,1,A,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",50597,10116.0,,,CHEMBL635154,8133,1088.0,,,Urine,N,Intermediate,BAO_0000218
13683,Rattus norvegicus,1,A,,1,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL629216,6996,,,,,N,Intermediate,BAO_0000218
13684,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,50597,10116.0,,,CHEMBL629217,6996,,,,,N,Intermediate,BAO_0000218
13685,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL629218,6996,,,,,N,Intermediate,BAO_0000218
13686,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL629219,6996,,,,,N,Intermediate,BAO_0000218
13687,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL629220,6996,,,,,N,Intermediate,BAO_0000218
13688,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL629221,6996,,,,,N,Intermediate,BAO_0000218
13689,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL631127,6996,,,,,N,Intermediate,BAO_0000218
13690,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,50597,10116.0,,,CHEMBL631128,6996,,,,,N,Intermediate,BAO_0000218
13691,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL631129,6996,,,,,N,Intermediate,BAO_0000218
13692,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL631130,6996,,,,,N,Intermediate,BAO_0000218
13693,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL631131,6996,,,,,N,Intermediate,BAO_0000218
13694,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL631132,6996,,,,,N,Intermediate,BAO_0000218
13695,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL631133,6996,,,,,N,Intermediate,BAO_0000218
13696,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,50597,10116.0,,,CHEMBL631134,6996,,,,,N,Intermediate,BAO_0000218
13697,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL875120,6996,,,,,N,Intermediate,BAO_0000218
13698,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL631135,6996,,,,,N,Intermediate,BAO_0000218
13699,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL631136,6996,,,,,N,Intermediate,BAO_0000218
13700,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL631137,6996,,,,,N,Intermediate,BAO_0000218
13701,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL631138,6996,,,,,N,Intermediate,BAO_0000218
13702,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,50597,10116.0,,,CHEMBL631139,6996,,,,,N,Intermediate,BAO_0000218
13703,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL631140,6996,,,,,N,Intermediate,BAO_0000218
13704,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,10116.0,,,CHEMBL631141,6996,,,,,N,Intermediate,BAO_0000218
13705,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,10116.0,,,CHEMBL631142,6996,,,,,N,Intermediate,BAO_0000218
13706,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,10116.0,,,CHEMBL631143,6996,,,,,N,Intermediate,BAO_0000218
13707,Rattus norvegicus,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,10116.0,,,CHEMBL631144,6996,,,,,N,Intermediate,BAO_0000218
13708,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,50588,9615.0,,,CHEMBL631145,6996,,,,,N,Intermediate,BAO_0000218
13709,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL631146,6996,,,,,N,Intermediate,BAO_0000218
13710,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,50588,9615.0,,,CHEMBL631147,6996,,,,,N,Intermediate,BAO_0000218
13711,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL631148,6996,,,,,N,Intermediate,BAO_0000218
13712,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL631149,6996,,,,,N,Intermediate,BAO_0000218
13713,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL631150,6996,,,,,N,Intermediate,BAO_0000218
13714,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL631151,6996,,,,,N,Intermediate,BAO_0000218
13715,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL631152,6996,,,,,N,Intermediate,BAO_0000218
13716,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL631443,6996,,,,,N,Intermediate,BAO_0000218
13717,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL631444,6996,,,,,N,Intermediate,BAO_0000218
13718,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL631445,6996,,,,,N,Intermediate,BAO_0000218
13719,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,9615.0,,,CHEMBL631446,6996,,,,,N,Intermediate,BAO_0000218
13720,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),50588,9615.0,,,CHEMBL631447,6996,,,,,N,Intermediate,BAO_0000218
13721,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,9615.0,,,CHEMBL631448,6996,,,,,N,Intermediate,BAO_0000218
13722,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,50588,9615.0,,,CHEMBL631449,6996,,,,,N,Intermediate,BAO_0000218
13723,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,9615.0,,,CHEMBL631450,6996,,,,,N,Intermediate,BAO_0000218
13724,Canis lupus familiaris,1,A,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,9615.0,,,CHEMBL629724,6996,,,,,N,Intermediate,BAO_0000218
13725,Mus musculus,1,A,,1,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL629725,9716,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
13726,Mus musculus,1,A,,1,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL629726,9716,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
13727,Mus musculus,1,A,,1,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL629727,9716,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13728,Mus musculus,1,A,,1,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630404,9716,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13729,Mus musculus,1,A,,1,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630405,9716,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13730,Mus musculus,1,A,,1,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630406,9716,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13731,Mus musculus,1,A,,1,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630407,9716,945.0,,,Stomach,N,Intermediate,BAO_0000218
13732,Mus musculus,1,A,,1,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630573,9716,945.0,,,Stomach,N,Intermediate,BAO_0000218
13733,Mus musculus,1,A,,1,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630574,9716,945.0,,,Stomach,N,Intermediate,BAO_0000218
13734,Mus musculus,1,A,,1,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630575,9716,945.0,,,Stomach,N,Intermediate,BAO_0000218
13735,Mus musculus,1,A,,1,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630576,9716,,,,,N,Intermediate,BAO_0000218
13736,Mus musculus,1,A,,1,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630577,9716,,,,,N,Intermediate,BAO_0000218
13737,Mus musculus,1,A,,1,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630578,9716,,,,,N,Intermediate,BAO_0000218
13738,Mus musculus,1,A,,1,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,10090.0,,,CHEMBL630579,9716,,,,,N,Intermediate,BAO_0000218
13739,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),50594,10090.0,,,CHEMBL630580,12192,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13740,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,50594,10090.0,,,CHEMBL630581,12192,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13741,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),50594,10090.0,,,CHEMBL630582,12192,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13742,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,50594,10090.0,,,CHEMBL630583,12192,,,,,N,Intermediate,BAO_0000218
13743,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),50594,10090.0,,,CHEMBL630584,12192,,,,,N,Intermediate,BAO_0000218
13744,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,50594,10090.0,,,CHEMBL630585,12192,,,,,N,Intermediate,BAO_0000218
13745,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),50594,10090.0,,,CHEMBL630586,12192,,,,,N,Intermediate,BAO_0000218
13746,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,50594,10090.0,,,CHEMBL630587,12192,,,,,N,Intermediate,BAO_0000218
13747,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),50594,10090.0,,,CHEMBL630588,12192,,,,,N,Intermediate,BAO_0000218
13748,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,50594,10090.0,,,CHEMBL630589,12192,,,,,N,Intermediate,BAO_0000218
13749,Mus musculus,1,A,,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),50594,10090.0,,,CHEMBL630590,12192,,,,,N,Intermediate,BAO_0000218
13750,,0,A,,1,Removal of 238-Plutonium(IV) in feces at 24 h,22224,,,,CHEMBL630591,12192,1988.0,,,Feces,U,Autocuration,BAO_0000019
13751,,0,A,,1,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),22224,,,,CHEMBL630592,12192,1988.0,,,Feces,U,Autocuration,BAO_0000019
13752,,0,A,,1,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,22224,,,,CHEMBL630593,12192,,,,,U,Autocuration,BAO_0000019
13753,,0,A,,1,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),22224,,,,CHEMBL630594,12192,,,,,U,Autocuration,BAO_0000019
13754,,0,A,,1,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),22224,,,,CHEMBL630595,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13755,,0,A,,1,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),22224,,,,CHEMBL630596,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13756,,0,A,,1,Removal of 238-Plutonium(IV) in urine after 0-24 h,22224,,,,CHEMBL630597,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13757,,0,A,,1,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),22224,,,,CHEMBL630598,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13758,,0,A,,1,Removal of 238-Plutonium(IV) in urine after 0-4 h,22224,,,,CHEMBL630599,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13759,,0,A,,1,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),22224,,,,CHEMBL630600,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13760,,0,A,,1,Removal of 238-Plutonium(IV) in urine after 4-24 h,22224,,,,CHEMBL630601,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13761,,0,A,,1,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),22224,,,,CHEMBL630602,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13762,,0,A,,1,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),22224,,,,CHEMBL630603,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13763,,0,A,,1,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),22224,,,,CHEMBL630604,12192,1088.0,,,Urine,U,Autocuration,BAO_0000019
13764,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL624869,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
13765,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL624870,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
13766,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL623189,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
13767,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623190,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
13768,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623191,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
13769,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623192,12017,,,,,N,Intermediate,BAO_0000218
13770,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623193,12017,,,,,N,Intermediate,BAO_0000218
13771,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL623194,12017,,,,,N,Intermediate,BAO_0000218
13772,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623195,12017,,,,,N,Intermediate,BAO_0000218
13773,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623196,12017,,,,,N,Intermediate,BAO_0000218
13774,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,50597,10116.0,,,CHEMBL623197,11836,,,,,N,Intermediate,BAO_0000218
13775,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623198,11836,,,,,N,Intermediate,BAO_0000218
13776,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,50597,10116.0,,,CHEMBL623199,11836,,,,,N,Intermediate,BAO_0000218
13777,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623200,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13778,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623201,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13779,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623202,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13780,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623203,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13781,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623204,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13782,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,50597,10116.0,,,CHEMBL623205,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13783,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623206,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13784,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,50597,10116.0,,,CHEMBL623207,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13785,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,50597,10116.0,,,CHEMBL623208,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13786,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623209,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13787,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,50597,10116.0,,,CHEMBL623210,11836,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13788,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623211,11836,,,,,N,Intermediate,BAO_0000218
13789,Rattus norvegicus,1,A,,1,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,10116.0,,,CHEMBL623212,11836,995.0,,,Uterus,N,Intermediate,BAO_0000218
13790,,0,A,,1,Tested in vitro for intrinsic activity relative to quinpirole,22224,,,,CHEMBL623213,12640,,,,,U,Autocuration,BAO_0000019
13791,,0,A,,1,"Relative ion enhancement, determined in pulsed ultrafiltration",22224,,,,CHEMBL623214,14218,,,,,U,Autocuration,BAO_0000019
13792,,0,A,,1,% ionization at the pH 7.4 at 37 degree Centigrade,22224,,,,CHEMBL623215,11296,,,,,U,Autocuration,BAO_0000019
13793,,0,A,,1,Percentage ionization was measured,22224,,,,CHEMBL623216,10929,,,,,U,Autocuration,BAO_0000019
13794,Bos taurus,1,A,,1,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,50591,9913.0,,,CHEMBL623217,13841,,,,,N,Intermediate,BAO_0000218
13795,,0,A,,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,22224,,,,CHEMBL623218,10431,,,,,U,Autocuration,BAO_0000019
13796,,0,A,,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,22224,,,,CHEMBL623913,10431,,,,,U,Autocuration,BAO_0000019
13797,,0,A,,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,22224,,,,CHEMBL623914,10431,,,,,U,Autocuration,BAO_0000019
13798,,0,P,,1,Compound was evaluated for the partition coefficient in octanol/water,22229,,,,CHEMBL623915,8826,,,,,U,Autocuration,BAO_0000100
13799,,0,P,,1,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),22229,,,,CHEMBL624080,8826,,,,,U,Autocuration,BAO_0000100
13800,,0,A,,1,Equilibrium constant measured by the pulse radiolysis at pH 7,22224,,,,CHEMBL624081,9884,,,,,U,Autocuration,BAO_0000019
13801,Homo sapiens,1,A,,1,In vitro hydrolytic rate constant determined in human blood,50587,9606.0,,,CHEMBL624082,9827,,,,,N,Intermediate,BAO_0000218
13802,Homo sapiens,1,A,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,50587,9606.0,,,CHEMBL625054,10009,,,,,N,Intermediate,BAO_0000218
13803,,0,A,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,22224,,,,CHEMBL877485,10009,,,,,U,Autocuration,BAO_0000019
13804,Mus musculus,1,A,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,50594,10090.0,,,CHEMBL625055,10009,,,,,N,Intermediate,BAO_0000218
13805,Mus musculus,1,A,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,50594,10090.0,,,CHEMBL625056,10009,,,,,N,Intermediate,BAO_0000218
13806,Homo sapiens,1,A,,1,In vitro oxidation of compound in presence of human plasma,50587,9606.0,,,CHEMBL625057,10009,,,,,N,Intermediate,BAO_0000218
13807,,0,A,,1,In vitro oxidation of compound in presence of hydrogen peroxide,22224,,,,CHEMBL625058,10009,,,,,U,Autocuration,BAO_0000019
13808,Mus musculus,1,A,,1,In vitro oxidation of compound in presence of mouse brain homogenate,50594,10090.0,,,CHEMBL625059,10009,,,,,N,Intermediate,BAO_0000218
13809,Mus musculus,1,A,,1,In vitro oxidation of compound in presence of mouse liver homogenate,50594,10090.0,,,CHEMBL629536,10009,,,,,N,Intermediate,BAO_0000218
13810,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,10116.0,,,CHEMBL629537,11510,,,,,N,Intermediate,BAO_0000218
13811,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,10116.0,,,CHEMBL629538,11510,,,,,N,Intermediate,BAO_0000218
13812,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,10116.0,,,CHEMBL629539,11510,,,,,N,Intermediate,BAO_0000218
13813,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,10116.0,,,CHEMBL874445,11510,,,,,N,Intermediate,BAO_0000218
13814,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,10116.0,,,CHEMBL629540,11510,,,,,N,Intermediate,BAO_0000218
13815,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,10116.0,,,CHEMBL629541,11510,,,,,N,Intermediate,BAO_0000218
13816,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,10116.0,,,CHEMBL629542,11510,,,,,N,Intermediate,BAO_0000218
13817,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,10116.0,,,CHEMBL630243,11510,,,,,N,Intermediate,BAO_0000218
13818,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,10116.0,,,CHEMBL630244,11510,,,,,N,Intermediate,BAO_0000218
13819,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,10116.0,,,CHEMBL630245,11510,,,,,N,Intermediate,BAO_0000218
13820,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,10116.0,,,CHEMBL630246,11510,,,,,N,Intermediate,BAO_0000218
13821,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,10116.0,,,CHEMBL630247,11510,,,,,N,Intermediate,BAO_0000218
13822,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,10116.0,,,CHEMBL630248,11510,,,,,N,Intermediate,BAO_0000218
13823,Rattus norvegicus,1,A,,1,Biodistribution in rat blood at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL630249,13100,178.0,,,Blood,N,Intermediate,BAO_0000218
13824,Rattus norvegicus,1,A,,1,Biodistribution in rat blood at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL630250,13100,178.0,,,Blood,N,Intermediate,BAO_0000218
13825,Rattus norvegicus,1,A,,1,Biodistribution in rat blood at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL630251,13100,178.0,,,Blood,N,Intermediate,BAO_0000218
13826,Rattus norvegicus,1,A,,1,Biodistribution in rat blood at 3 hr after dose administration.,50597,10116.0,,,CHEMBL630252,13100,178.0,,,Blood,N,Intermediate,BAO_0000218
13827,Rattus norvegicus,1,A,,1,Biodistribution in rat blood at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL630408,13100,178.0,,,Blood,N,Intermediate,BAO_0000218
13828,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL630409,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13829,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL874446,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13830,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL630410,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13831,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL630411,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13832,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL630412,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13833,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL630413,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13834,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 3 hr after dose administration.,50597,10116.0,,,CHEMBL630414,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13835,Rattus norvegicus,1,A,,1,Biodistribution in rat cerebellum at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL630415,13100,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
13836,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL630416,13100,,,,,N,Intermediate,BAO_0000218
13837,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL630417,13100,,,,,N,Intermediate,BAO_0000218
13838,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL630418,13100,,,,,N,Intermediate,BAO_0000218
13839,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL630419,13100,,,,,N,Intermediate,BAO_0000218
13840,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL630420,13100,,,,,N,Intermediate,BAO_0000218
13841,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL630421,13100,,,,,N,Intermediate,BAO_0000218
13842,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 3 hr after dose administration.,50597,10116.0,,,CHEMBL630422,13100,,,,,N,Intermediate,BAO_0000218
13843,Rattus norvegicus,1,A,,1,Biodistribution in rat cortex at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL630423,13100,,,,,N,Intermediate,BAO_0000218
13844,Rattus norvegicus,1,A,,1,Biodistribution in rat heart at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL630424,13100,948.0,,,Heart,N,Intermediate,BAO_0000218
13845,Rattus norvegicus,1,A,,1,Biodistribution in rat heart at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL630425,13100,948.0,,,Heart,N,Intermediate,BAO_0000218
13846,Rattus norvegicus,1,A,,1,Biodistribution in rat heart at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL629462,13100,948.0,,,Heart,N,Intermediate,BAO_0000218
13847,Rattus norvegicus,1,A,,1,Biodistribution in rat heart at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL630426,13100,948.0,,,Heart,N,Intermediate,BAO_0000218
13848,Rattus norvegicus,1,A,,1,Biodistribution in rat heart at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL630427,13100,948.0,,,Heart,N,Intermediate,BAO_0000218
13849,Rattus norvegicus,1,A,,1,Biodistribution in rat heart at 3 hr after dose administration.,50597,10116.0,,,CHEMBL625877,13100,948.0,,,Heart,N,Intermediate,BAO_0000218
13850,Rattus norvegicus,1,A,,1,Biodistribution in rat heart at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL625878,13100,948.0,,,Heart,N,Intermediate,BAO_0000218
13851,Rattus norvegicus,1,A,,1,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL625879,13100,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
13852,Rattus norvegicus,1,A,,1,Biodistribution in rat hippocampus at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL625880,13100,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
13853,Rattus norvegicus,1,A,,1,Biodistribution in rat hippocampus at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL625881,13100,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
13854,Rattus norvegicus,1,A,,1,Biodistribution in rat hippocampus at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL625882,13100,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
13855,Rattus norvegicus,1,A,,1,Biodistribution in rat hippocampus at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL625883,13100,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
13856,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL625884,13100,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13857,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL625885,13100,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13858,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL628649,13100,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13859,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL628650,13100,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13860,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL628651,13100,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13861,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL628652,13100,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13862,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL628653,13100,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13863,Rattus norvegicus,1,A,,1,Biodistribution in rat liver at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL628654,13100,2107.0,,,Liver,N,Intermediate,BAO_0000218
13864,Rattus norvegicus,1,A,,1,Biodistribution in rat liver at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL628655,13100,2107.0,,,Liver,N,Intermediate,BAO_0000218
13865,Rattus norvegicus,1,A,,1,Biodistribution in rat liver at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL625238,13100,2107.0,,,Liver,N,Intermediate,BAO_0000218
13866,Rattus norvegicus,1,A,,1,Biodistribution in rat liver at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL625239,13100,2107.0,,,Liver,N,Intermediate,BAO_0000218
13867,Rattus norvegicus,1,A,,1,Biodistribution in rat liver at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL625240,13100,2107.0,,,Liver,N,Intermediate,BAO_0000218
13868,Rattus norvegicus,1,A,,1,Biodistribution in rat liver at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL625241,13100,2107.0,,,Liver,N,Intermediate,BAO_0000218
13869,Rattus norvegicus,1,A,,1,Biodistribution in rat liver at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL625242,13100,2107.0,,,Liver,N,Intermediate,BAO_0000218
13870,Rattus norvegicus,1,A,,1,Biodistribution in rat lung at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL874587,13100,2048.0,,,Lung,N,Intermediate,BAO_0000218
13871,Rattus norvegicus,1,A,,1,Biodistribution in rat lung at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL625405,13100,2048.0,,,Lung,N,Intermediate,BAO_0000218
13872,Rattus norvegicus,1,A,,1,Biodistribution in rat lung at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL625406,13100,2048.0,,,Lung,N,Intermediate,BAO_0000218
13873,Rattus norvegicus,1,A,,1,Biodistribution in rat lung at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL625407,13100,2048.0,,,Lung,N,Intermediate,BAO_0000218
13874,Rattus norvegicus,1,A,,1,Biodistribution in rat lung at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL625408,13100,2048.0,,,Lung,N,Intermediate,BAO_0000218
13875,Rattus norvegicus,1,A,,1,Biodistribution in rat lung at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL625409,13100,2048.0,,,Lung,N,Intermediate,BAO_0000218
13876,Rattus norvegicus,1,A,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,50597,10116.0,,,CHEMBL625410,12361,1515.0,,,Thoracic aorta,N,Intermediate,BAO_0000218
13877,Rattus norvegicus,1,A,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,50597,10116.0,,,CHEMBL625411,12361,1515.0,,,Thoracic aorta,N,Intermediate,BAO_0000218
13878,Rattus norvegicus,1,A,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,50597,10116.0,,,CHEMBL625412,12361,1515.0,,,Thoracic aorta,N,Intermediate,BAO_0000218
13879,Rattus norvegicus,1,A,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,50597,10116.0,,,CHEMBL625413,12361,1515.0,,,Thoracic aorta,N,Intermediate,BAO_0000218
13880,Rattus norvegicus,1,A,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips v,50597,10116.0,,,CHEMBL625414,12361,1515.0,,,Thoracic aorta,N,Intermediate,BAO_0000218
13881,Rattus norvegicus,1,A,,1,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,50597,10116.0,,,CHEMBL625415,12361,1515.0,,,Thoracic aorta,N,Intermediate,BAO_0000218
13882,Rattus norvegicus,1,A,,1,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,50597,10116.0,,,CHEMBL625416,12361,1515.0,,,Thoracic aorta,N,Intermediate,BAO_0000218
13883,Rattus norvegicus,1,A,,1,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,50597,10116.0,,,CHEMBL625417,12712,1088.0,,,Urine,N,Intermediate,BAO_0000218
13884,Rattus norvegicus,1,A,,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,50597,10116.0,,,CHEMBL625418,7415,1988.0,,,Feces,N,Intermediate,BAO_0000218
13885,Rattus norvegicus,1,A,,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,50597,10116.0,,,CHEMBL625419,7415,1088.0,,,Urine,N,Intermediate,BAO_0000218
13886,Rattus norvegicus,1,A,,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,50597,10116.0,,,CHEMBL625420,7415,,,,,N,Intermediate,BAO_0000218
13887,Rattus norvegicus,1,A,,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,50597,10116.0,,,CHEMBL626996,7415,,,,,N,Intermediate,BAO_0000218
13888,Rattus norvegicus,1,A,,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",50597,10116.0,,,CHEMBL626997,7415,1988.0,,,Feces,N,Intermediate,BAO_0000218
13889,Rattus norvegicus,1,A,,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",50597,10116.0,,,CHEMBL626998,7415,1088.0,,,Urine,N,Intermediate,BAO_0000218
13890,Rattus norvegicus,1,A,,1,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",50597,10116.0,,,CHEMBL626999,7415,,,,,N,Intermediate,BAO_0000218
13891,Mus musculus,1,A,,1,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,50594,10090.0,,,CHEMBL627000,8050,,,,,N,Intermediate,BAO_0000218
13892,Mus musculus,1,A,,1,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,50594,10090.0,,,CHEMBL627001,8050,,,,,N,Intermediate,BAO_0000218
13893,Mus musculus,1,A,,1,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,50594,10090.0,,,CHEMBL627002,8050,,,,,N,Intermediate,BAO_0000218
13894,Mus musculus,1,A,,1,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,50594,10090.0,,,CHEMBL627003,8050,,,,,N,Intermediate,BAO_0000218
13895,Mus musculus,1,A,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,50594,10090.0,,,CHEMBL627004,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13896,Mus musculus,1,A,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,50594,10090.0,,,CHEMBL627005,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13897,Mus musculus,1,A,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,50594,10090.0,,,CHEMBL874594,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13898,Mus musculus,1,A,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,50594,10090.0,,,CHEMBL627006,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13899,Mus musculus,1,A,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,50594,10090.0,,,CHEMBL627007,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13900,Mus musculus,1,A,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,50594,10090.0,,,CHEMBL627884,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13901,Mus musculus,1,A,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,50594,10090.0,,,CHEMBL627885,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13902,Mus musculus,1,A,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,50594,10090.0,,,CHEMBL627886,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13903,Mus musculus,1,A,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,50594,10090.0,,,CHEMBL627887,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13904,Mus musculus,1,A,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,50594,10090.0,,,CHEMBL627888,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13905,Mus musculus,1,A,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,50594,10090.0,,,CHEMBL628057,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13906,Mus musculus,1,A,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,50594,10090.0,,,CHEMBL627405,8050,1088.0,,,Urine,N,Intermediate,BAO_0000218
13907,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,9615.0,,,CHEMBL627406,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13908,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,9615.0,,,CHEMBL627407,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13909,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,9615.0,,,CHEMBL627408,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13910,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,9615.0,,,CHEMBL627409,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13911,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,9615.0,,,CHEMBL875486,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13912,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,9615.0,,,CHEMBL627410,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13913,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,9615.0,,,CHEMBL627411,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13914,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,9615.0,,,CHEMBL627412,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13915,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,9615.0,,,CHEMBL627413,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13916,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,9615.0,,,CHEMBL627414,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13917,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,9615.0,,,CHEMBL627415,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13918,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,50588,9615.0,,,CHEMBL627416,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13919,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,9615.0,,,CHEMBL627417,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13920,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,9615.0,,,CHEMBL627418,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13921,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,50588,9615.0,,,CHEMBL627419,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13922,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,50588,9615.0,,,CHEMBL627320,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13923,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,50588,9615.0,,,CHEMBL627321,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
13924,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627322,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13925,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627323,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13926,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL627491,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13927,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627492,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13928,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627493,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
13929,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627494,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
13930,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627495,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
13931,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL627496,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
13932,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627497,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
13933,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627498,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
13934,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627499,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
13935,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL627500,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
13936,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL627501,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
13937,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625616,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
13938,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625617,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
13939,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625618,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13940,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625619,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13941,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL625620,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13942,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625621,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13943,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625622,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
13944,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625788,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13945,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625789,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13946,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL625790,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13947,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL625791,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13948,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL622334,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13949,Rattus norvegicus,1,A,,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL622335,12017,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
13950,Rattus norvegicus,1,A,,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL622336,12017,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
13951,Rattus norvegicus,1,A,,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL622337,12017,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
13952,Rattus norvegicus,1,A,,1,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL622338,12017,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
13953,Rattus norvegicus,1,A,,1,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL622339,12017,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
13954,Rattus norvegicus,1,A,,1,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL624153,12017,,,,,N,Intermediate,BAO_0000218
13955,Rattus norvegicus,1,A,,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL628430,12017,,,,,N,Intermediate,BAO_0000218
13956,Rattus norvegicus,1,A,,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL628431,12017,,,,,N,Intermediate,BAO_0000218
13957,Rattus norvegicus,1,A,,1,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL628432,12017,,,,,N,Intermediate,BAO_0000218
13958,Rattus norvegicus,1,A,,1,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL628433,12017,,,,,N,Intermediate,BAO_0000218
13959,Rattus norvegicus,1,A,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,10116.0,,,CHEMBL628434,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13960,Rattus norvegicus,1,A,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,10116.0,,,CHEMBL626789,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13961,Rattus norvegicus,1,A,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",50597,10116.0,,,CHEMBL626790,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13962,Rattus norvegicus,1,A,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,10116.0,,,CHEMBL626791,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13963,Rattus norvegicus,1,A,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,10116.0,,,CHEMBL626792,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13964,Rattus norvegicus,1,A,,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,10116.0,,,CHEMBL626793,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
13965,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,10116.0,,,CHEMBL627436,11510,,,,,N,Intermediate,BAO_0000218
13966,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,10116.0,,,CHEMBL627437,11510,,,,,N,Intermediate,BAO_0000218
13967,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,10116.0,,,CHEMBL627438,11510,,,,,N,Intermediate,BAO_0000218
13968,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,10116.0,,,CHEMBL627439,11510,,,,,N,Intermediate,BAO_0000218
13969,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,10116.0,,,CHEMBL627440,11510,,,,,N,Intermediate,BAO_0000218
13970,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,10116.0,,,CHEMBL627602,11510,,,,,N,Intermediate,BAO_0000218
13971,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,10116.0,,,CHEMBL627603,11510,,,,,N,Intermediate,BAO_0000218
13972,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,10116.0,,,CHEMBL627604,11510,,,,,N,Intermediate,BAO_0000218
13973,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,10116.0,,,CHEMBL627605,11510,,,,,N,Intermediate,BAO_0000218
13974,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,10116.0,,,CHEMBL627606,11510,,,,,N,Intermediate,BAO_0000218
13975,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,10116.0,,,CHEMBL627607,11510,,,,,N,Intermediate,BAO_0000218
13976,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,10116.0,,,CHEMBL627608,11510,,,,,N,Intermediate,BAO_0000218
13977,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,10116.0,,,CHEMBL627609,11510,,,,,N,Intermediate,BAO_0000218
13978,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,10116.0,,,CHEMBL627610,11510,,,,,N,Intermediate,BAO_0000218
13979,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,10116.0,,,CHEMBL627611,11510,,,,,N,Intermediate,BAO_0000218
13980,Rattus norvegicus,1,A,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,10116.0,,,CHEMBL627612,11510,,,,,N,Intermediate,BAO_0000218
13981,,0,P,,1,Octanol:water partition coefficient is evaluated,22229,,,,CHEMBL627613,8362,,,,,U,Autocuration,BAO_0000100
13982,,0,P,,1,Partition coefficient in 1-octanol/water system,22224,,,,CHEMBL627614,8257,,,,,U,Autocuration,BAO_0000100
13983,,0,P,,1,Partition coefficient in 1-octanol/water system measured using radio active compounds,22224,,,,CHEMBL627615,8257,,,,,U,Autocuration,BAO_0000100
13984,,0,P,,1,Partition coefficient in octanol/water system was determined,22224,,,,CHEMBL627616,9468,,,,,U,Autocuration,BAO_0000100
13985,,0,P,,1,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,22224,,,,CHEMBL627617,9468,,,,,U,Autocuration,BAO_0000100
13986,,0,A,,1,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,22224,,,,CHEMBL627618,10568,,,,,U,Autocuration,BAO_0000019
13987,,0,A,,1,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",22224,,,,CHEMBL627619,10568,,,,,U,Autocuration,BAO_0000019
13988,,0,A,,1,Pseudo-first-order rate constant of the compound,22224,,,,CHEMBL627620,15359,,,,,U,Autocuration,BAO_0000019
13989,,0,A,,1,Pseudo-first-order rate constant with 1-min time point,22224,,,,CHEMBL627621,15359,,,,,U,Autocuration,BAO_0000019
13990,,0,A,,1,Pseudo-first-order rate constant without 1-min time point,22224,,,,CHEMBL627622,15359,,,,,U,Autocuration,BAO_0000019
13991,,0,A,,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,22224,,,,CHEMBL627623,10431,,,,,U,Autocuration,BAO_0000019
13992,,0,A,,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,22224,,,,CHEMBL627624,10431,,,,,U,Autocuration,BAO_0000019
13993,,0,A,,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,22224,,,,CHEMBL627625,10431,,,,,U,Autocuration,BAO_0000019
13994,,0,A,,1,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,22224,,,,CHEMBL628523,15704,,,,,U,Autocuration,BAO_0000019
13995,,0,A,,1,The alkaline hydrolysis second order rate constant(K OH) of the compound,22224,,,,CHEMBL628524,15287,,,,,U,Autocuration,BAO_0000019
13996,,0,A,,1,The efflux rate constant of the compound,22224,,,,CHEMBL628525,7516,,,,,U,Autocuration,BAO_0000019
13997,,0,A,,1,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,,,,CHEMBL625732,12973,,,,,U,Autocuration,BAO_0000019
13998,,0,A,,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,,,,CHEMBL625733,12973,,,,,U,Autocuration,BAO_0000019
13999,,0,F,,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,,,,CHEMBL625734,12973,,,,,U,Autocuration,BAO_0000019
14000,,0,A,,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,22224,,,,CHEMBL625913,12973,,,,,U,Autocuration,BAO_0000019
14001,,0,A,,1,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,22224,,,,CHEMBL625914,8696,,,,,U,Autocuration,BAO_0000019
14002,,0,A,,1,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,22224,,,,CHEMBL625915,15052,,,,,U,Autocuration,BAO_0000019
14003,,0,A,,1,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,22224,,,,CHEMBL625916,15052,,,,,U,Autocuration,BAO_0000019
14004,,0,A,,1,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),22224,,,,CHEMBL625917,10503,,,,,U,Autocuration,BAO_0000019
14005,,0,A,,1,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625918,8354,,,,,U,Autocuration,BAO_0000019
14006,,0,A,,1,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625919,8354,,,,,U,Autocuration,BAO_0000019
14007,,0,A,,1,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625920,8354,,,,,U,Autocuration,BAO_0000019
14008,,0,A,,1,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL874453,8354,,,,,U,Autocuration,BAO_0000019
14009,,0,A,,1,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625921,8354,,,,,U,Autocuration,BAO_0000019
14010,,0,A,,1,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,22224,,,,CHEMBL625922,10503,,,,,U,Autocuration,BAO_0000019
14011,,0,A,,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625923,8354,,,,,U,Autocuration,BAO_0000019
14012,,0,A,,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625924,8354,,,,,U,Autocuration,BAO_0000019
14013,,0,A,,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625925,8354,,,,,U,Autocuration,BAO_0000019
14014,,0,A,,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL625926,8354,,,,,U,Autocuration,BAO_0000019
14015,Rattus norvegicus,1,A,,1,Biodistribution in rat lung at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL627704,13100,2048.0,,,Lung,N,Intermediate,BAO_0000218
14016,Rattus norvegicus,1,A,,1,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL627705,13100,,,,,N,Intermediate,BAO_0000218
14017,Rattus norvegicus,1,A,,1,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL627706,13100,,,,,N,Intermediate,BAO_0000218
14018,Rattus norvegicus,1,A,,1,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL627707,13100,,,,,N,Intermediate,BAO_0000218
14019,Rattus norvegicus,1,A,,1,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL627708,13100,,,,,N,Intermediate,BAO_0000218
14020,Rattus norvegicus,1,A,,1,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL628361,13100,,,,,N,Intermediate,BAO_0000218
14021,Rattus norvegicus,1,A,,1,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL628362,13100,,,,,N,Intermediate,BAO_0000218
14022,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL628363,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14023,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL628364,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14024,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL628365,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14025,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL874454,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14026,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL628531,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14027,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL628532,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14028,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 3 hr after dose administration.,50597,10116.0,,,CHEMBL628533,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14029,Rattus norvegicus,1,A,,1,Biodistribution in rat striatum at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL628534,13100,2435.0,,,Striatum,N,Intermediate,BAO_0000218
14030,Rattus norvegicus,1,A,,1,Biodistribution in rat thyroid at 120 minutes after dose administration.,50597,10116.0,,,CHEMBL628535,13100,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14031,Rattus norvegicus,1,A,,1,Biodistribution in rat thyroid at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL628536,13100,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14032,Rattus norvegicus,1,A,,1,Biodistribution in rat thyroid at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL628537,13100,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14033,Rattus norvegicus,1,A,,1,Biodistribution in rat thyroid at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL628538,13100,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14034,Rattus norvegicus,1,A,,1,Biodistribution in rat thyroid at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL628539,13100,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14035,Rattus norvegicus,1,A,,1,Biodistribution in rat thyroid at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL630297,13100,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14036,Rattus norvegicus,1,A,,1,Biodistribution in rat thyroid at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL630298,13100,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14037,Rattus norvegicus,1,A,,1,Biodistribution in rest of brain of rat 120 minutes after dose administration.,50597,10116.0,,,CHEMBL630299,13100,955.0,,,Brain,N,Intermediate,BAO_0000218
14038,Rattus norvegicus,1,A,,1,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,50597,10116.0,,,CHEMBL628094,13100,955.0,,,Brain,N,Intermediate,BAO_0000218
14039,Rattus norvegicus,1,A,,1,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,50597,10116.0,,,CHEMBL628095,13100,955.0,,,Brain,N,Intermediate,BAO_0000218
14040,Rattus norvegicus,1,A,,1,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,50597,10116.0,,,CHEMBL874648,13100,955.0,,,Brain,N,Intermediate,BAO_0000218
14041,Rattus norvegicus,1,A,,1,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,50597,10116.0,,,CHEMBL628096,13100,955.0,,,Brain,N,Intermediate,BAO_0000218
14042,Rattus norvegicus,1,A,,1,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,50597,10116.0,,,CHEMBL628097,13100,955.0,,,Brain,N,Intermediate,BAO_0000218
14043,Rattus norvegicus,1,A,,1,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,50597,10116.0,,,CHEMBL628098,13100,955.0,,,Brain,N,Intermediate,BAO_0000218
14044,,0,A,,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",22224,,,,CHEMBL628099,13331,,,,,U,Autocuration,BAO_0000019
14045,,0,A,,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",22224,,,,CHEMBL628100,13331,,,,,U,Autocuration,BAO_0000019
14046,,0,A,,1,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),22224,,,,CHEMBL628101,13331,,,,,U,Autocuration,BAO_0000019
14047,,0,A,,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",22224,,,,CHEMBL628102,13331,,,,,U,Autocuration,BAO_0000019
14048,,0,A,,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",22224,,,,CHEMBL628103,13331,,,,,U,Autocuration,BAO_0000019
14049,,0,A,,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",22224,,,,CHEMBL628104,13331,,,,,U,Autocuration,BAO_0000019
14050,,0,A,,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",22224,,,,CHEMBL628105,13331,,,,,U,Autocuration,BAO_0000019
14051,,0,A,,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",22224,,,,CHEMBL628106,13331,,,,,U,Autocuration,BAO_0000019
14052,Rattus norvegicus,1,A,,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,50597,10116.0,,,CHEMBL628107,10086,1088.0,,,Urine,N,Intermediate,BAO_0000218
14053,,0,F,,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,22224,,,,CHEMBL628108,10086,1088.0,,,Urine,U,Autocuration,BAO_0000218
14054,Rattus norvegicus,1,A,,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,50597,10116.0,,,CHEMBL628109,10086,1088.0,,,Urine,N,Intermediate,BAO_0000218
14055,,0,F,,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,22224,,,,CHEMBL625299,10086,1088.0,,,Urine,U,Autocuration,BAO_0000218
14056,Rattus norvegicus,1,A,,1,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,50597,10116.0,,,CHEMBL625300,10086,1088.0,,,Urine,N,Intermediate,BAO_0000218
14057,Rattus norvegicus,1,A,,1,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,50597,10116.0,,,CHEMBL625301,10086,1088.0,,,Urine,N,Intermediate,BAO_0000218
14058,Rattus norvegicus,1,A,,1,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,50597,10116.0,,,CHEMBL625302,10086,1088.0,,,Urine,N,Intermediate,BAO_0000218
14059,Rattus norvegicus,1,A,,1,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,50597,10116.0,,,CHEMBL874649,10086,1088.0,,,Urine,N,Intermediate,BAO_0000218
14060,Rattus norvegicus,1,A,,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,50597,10116.0,,,CHEMBL625303,13248,,,,,N,Intermediate,BAO_0000218
14061,Rattus norvegicus,1,A,,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,50597,10116.0,,,CHEMBL625463,13248,,,,,N,Intermediate,BAO_0000218
14062,Homo sapiens,1,A,,1,In vitro metabolism in human liver microsomes,50587,9606.0,,,CHEMBL625464,14527,2107.0,,,Liver,N,Intermediate,BAO_0000218
14063,Homo sapiens,1,A,,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,50587,9606.0,,,CHEMBL625465,3008,,,,,N,Intermediate,BAO_0000218
14064,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,50588,9615.0,,,CHEMBL625466,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14065,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,9615.0,,,CHEMBL625467,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14066,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,50597,10116.0,,,CHEMBL625468,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14067,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,50597,10116.0,,,CHEMBL625469,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14068,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,10116.0,,,CHEMBL625470,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14069,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,10116.0,,,CHEMBL632418,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14070,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,10116.0,,,CHEMBL627250,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14071,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,50597,10116.0,,,CHEMBL627251,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14072,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,50597,10116.0,,,CHEMBL627252,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14073,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,10116.0,,,CHEMBL627253,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14074,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,50597,10116.0,,,CHEMBL627254,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14075,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,10116.0,,,CHEMBL875471,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14076,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,50597,10116.0,,,CHEMBL627255,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14077,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,10116.0,,,CHEMBL627256,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14078,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,50597,10116.0,,,CHEMBL627257,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14079,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,10116.0,,,CHEMBL627258,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14080,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,50597,10116.0,,,CHEMBL627259,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14081,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,10116.0,,,CHEMBL627260,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14082,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,50597,10116.0,,,CHEMBL623256,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14083,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,10116.0,,,CHEMBL874413,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14084,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,50597,10116.0,,,CHEMBL623257,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14085,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,10116.0,,,CHEMBL623258,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14086,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,50597,10116.0,,,CHEMBL623259,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14087,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,50597,10116.0,,,CHEMBL623260,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14088,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,10116.0,,,CHEMBL623261,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14089,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,50597,10116.0,,,CHEMBL623262,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14090,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,50597,10116.0,,,CHEMBL623263,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14091,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,10116.0,,,CHEMBL623264,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14092,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,50597,10116.0,,,CHEMBL623265,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14093,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,10116.0,,,CHEMBL623266,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14094,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,50597,10116.0,,,CHEMBL623267,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14095,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,50597,10116.0,,,CHEMBL623268,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14096,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,10116.0,,,CHEMBL623269,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14097,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,10116.0,,,CHEMBL623270,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14098,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,50597,10116.0,,,CHEMBL623271,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14099,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,50597,10116.0,,,CHEMBL623272,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14100,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,10116.0,,,CHEMBL623273,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14101,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,50597,10116.0,,,CHEMBL623274,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14102,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,10116.0,,,CHEMBL874414,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14103,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,50597,10116.0,,,CHEMBL623275,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14104,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,10116.0,,,CHEMBL629150,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14105,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,10116.0,,,CHEMBL623276,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14106,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,10116.0,,,CHEMBL623277,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14107,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,50597,10116.0,,,CHEMBL623112,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14108,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,50597,10116.0,,,CHEMBL623113,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14109,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,10116.0,,,CHEMBL623800,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14110,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,10116.0,,,CHEMBL623801,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14111,Rattus norvegicus,1,A,,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,10116.0,,,CHEMBL623802,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14112,Rattus norvegicus,1,A,,1,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623803,12017,995.0,,,Uterus,N,Intermediate,BAO_0000218
14113,Rattus norvegicus,1,A,,1,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623970,12017,995.0,,,Uterus,N,Intermediate,BAO_0000218
14114,Rattus norvegicus,1,A,,1,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL623971,12017,995.0,,,Uterus,N,Intermediate,BAO_0000218
14115,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623972,14045,178.0,,,Blood,N,Intermediate,BAO_0000218
14116,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623973,14045,178.0,,,Blood,N,Intermediate,BAO_0000218
14117,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623974,14045,178.0,,,Blood,N,Intermediate,BAO_0000218
14118,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623975,14045,178.0,,,Blood,N,Intermediate,BAO_0000218
14119,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623976,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14120,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623977,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14121,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623978,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14122,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623979,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14123,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623980,14045,,,,,N,Intermediate,BAO_0000218
14124,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL623981,14045,,,,,N,Intermediate,BAO_0000218
14125,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL626278,14045,,,,,N,Intermediate,BAO_0000218
14126,Rattus norvegicus,1,A,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),50597,10116.0,,,CHEMBL626279,14045,,,,,N,Intermediate,BAO_0000218
14127,Mus musculus,1,A,,1,Biodistribution in mice bladder plus excreted urine was determined,50594,10090.0,,,CHEMBL626280,14045,,,,,N,Intermediate,BAO_0000218
14128,Mus musculus,1,A,,1,"Percentage biodistribution in mouse blood, 10 minutes post injection",50594,10090.0,,,CHEMBL626281,14045,,,,,N,Intermediate,BAO_0000218
14129,Mus musculus,1,A,,1,"Percentage biodistribution in mouse blood, 30 minutes post injection",50594,10090.0,,,CHEMBL626282,14045,,,,,N,Intermediate,BAO_0000218
14130,Mus musculus,1,A,,1,"Percentage biodistribution in mouse blood, 5 minutes post injection",50594,10090.0,,,CHEMBL626283,14045,,,,,N,Intermediate,BAO_0000218
14131,Mus musculus,1,A,,1,"Percentage biodistribution in mouse blood, 60 minutes post injection",50594,10090.0,,,CHEMBL626284,14045,,,,,N,Intermediate,BAO_0000218
14132,Mus musculus,1,A,,1,"Percentage biodistribution in mouse brain, 10 minutes post injection",50594,10090.0,,,CHEMBL626285,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14133,Mus musculus,1,A,,1,"Percentage biodistribution in mouse brain, 30 minutes post injection",50594,10090.0,,,CHEMBL626286,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14134,Mus musculus,1,A,,1,"Percentage biodistribution in mouse brain, 5 minutes post injection",50594,10090.0,,,CHEMBL626287,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14135,Mus musculus,1,A,,1,"Percentage biodistribution in mouse brain, 60 minutes post injection",50594,10090.0,,,CHEMBL626288,14045,955.0,,,Brain,N,Intermediate,BAO_0000218
14136,Mus musculus,1,A,,1,"Percentage biodistribution in mouse heart, 10 minutes post injection",50594,10090.0,,,CHEMBL626289,14045,,,,,N,Intermediate,BAO_0000218
14137,Mus musculus,1,A,,1,"Percentage biodistribution in mouse heart, 30 minutes post injection",50594,10090.0,,,CHEMBL626290,14045,,,,,N,Intermediate,BAO_0000218
14138,Mus musculus,1,A,,1,"Percentage biodistribution in mouse heart, 5 minutes post injection",50594,10090.0,,,CHEMBL626291,14045,,,,,N,Intermediate,BAO_0000218
14139,Mus musculus,1,A,,1,"Percentage biodistribution in mouse heart, 60 minutes post injection",50594,10090.0,,,CHEMBL839888,14045,,,,,N,Intermediate,BAO_0000218
14140,Mus musculus,1,A,,1,"Percentage biodistribution in mouse intestine, 10 minutes post injection",50594,10090.0,,,CHEMBL626292,14045,160.0,,,Intestine,N,Intermediate,BAO_0000218
14141,Mus musculus,1,A,,1,"Percentage biodistribution in mouse intestine, 30 minutes post injection",50594,10090.0,,,CHEMBL626293,14045,160.0,,,Intestine,N,Intermediate,BAO_0000218
14142,Mus musculus,1,A,,1,"Percentage biodistribution in mouse intestine, 5 minutes post injection",50594,10090.0,,,CHEMBL626294,14045,160.0,,,Intestine,N,Intermediate,BAO_0000218
14143,Mus musculus,1,A,,1,"Percentage biodistribution in mouse intestine, 60 minutes post injection",50594,10090.0,,,CHEMBL626295,14045,160.0,,,Intestine,N,Intermediate,BAO_0000218
14144,Mus musculus,1,A,,1,"Percentage biodistribution in mouse liver, 10 minutes post injection",50594,10090.0,,,CHEMBL627659,14045,2107.0,,,Liver,N,Intermediate,BAO_0000218
14145,Mus musculus,1,A,,1,"Percentage biodistribution in mouse liver, 30 minutes of post injection",50594,10090.0,,,CHEMBL627660,14045,2107.0,,,Liver,N,Intermediate,BAO_0000218
14146,Mus musculus,1,A,,1,"Percentage biodistribution in mouse liver, 5 minutes post injection",50594,10090.0,,,CHEMBL627661,14045,2107.0,,,Liver,N,Intermediate,BAO_0000218
14147,Mus musculus,1,A,,1,Biodistribution in mice liver at 60 minutes of post injection,50594,10090.0,,,CHEMBL627662,14045,2107.0,,,Liver,N,Intermediate,BAO_0000218
14148,Mus musculus,1,A,,1,Biodistribution in mice lungs at 10 min of post injection,50594,10090.0,,,CHEMBL627663,14045,2048.0,,,Lung,N,Intermediate,BAO_0000218
14149,Mus musculus,1,A,,1,"Percentage biodistribution in mouse lung, 30 minutes post injection",50594,10090.0,,,CHEMBL627664,14045,,,,,N,Intermediate,BAO_0000218
14150,Mus musculus,1,A,,1,"Percentage biodistribution in mousee lung, 5 minutes post injection",50594,10090.0,,,CHEMBL627665,14045,,,,,N,Intermediate,BAO_0000218
14151,Mus musculus,1,A,,1,Biodistribution in mice lungs at 60 min of post injection,50594,10090.0,,,CHEMBL627666,14045,2048.0,,,Lung,N,Intermediate,BAO_0000218
14152,Mus musculus,1,A,,1,Percentage biodistribution in mouse spleen,50594,10090.0,,,CHEMBL627667,14045,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14153,Mus musculus,1,A,,1,Percentage biodistribution in mouse stomach,50594,10090.0,,,CHEMBL627668,14045,945.0,,,Stomach,N,Intermediate,BAO_0000218
14154,Mus musculus,1,A,,1,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,50594,10090.0,,,CHEMBL627669,11745,1088.0,,,Urine,N,Intermediate,BAO_0000218
14155,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,22224,,,,CHEMBL627670,13257,1255.0,,,Urinary bladder,U,Autocuration,BAO_0000218
14156,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,22224,,,,CHEMBL627671,13257,178.0,,,Blood,U,Autocuration,BAO_0000218
14157,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,22224,,,,CHEMBL627672,13257,1474.0,,,Bone element,U,Autocuration,BAO_0000218
14158,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,22224,,,,CHEMBL627673,13257,,,,,U,Autocuration,BAO_0000218
14159,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,22224,,,,CHEMBL627674,13257,2113.0,,,Kidney,U,Autocuration,BAO_0000218
14160,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,22224,,,,CHEMBL627675,13257,2107.0,,,Liver,U,Autocuration,BAO_0000218
14161,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,22224,,,,CHEMBL627676,13257,2048.0,,,Lung,U,Autocuration,BAO_0000218
14162,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,22224,,,,CHEMBL627677,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14163,,0,A,,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL627678,8354,,,,,U,Autocuration,BAO_0000019
14164,Rattus norvegicus,1,A,,1,Affinity for protein binding expressed as association constant in fresh rat serum,50597,10116.0,,,CHEMBL627679,7095,1977.0,,,Serum,N,Intermediate,BAO_0000218
14165,,0,A,,1,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,22224,,,,CHEMBL627680,12185,,,,,U,Autocuration,BAO_0000019
14166,,0,A,,1,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,22224,,,,CHEMBL627681,12185,,,,,U,Autocuration,BAO_0000019
14167,,0,A,,1,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,22224,,,,CHEMBL627682,12185,,,,,U,Autocuration,BAO_0000019
14168,,0,A,,1,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,22224,,,,CHEMBL627683,12185,,,,,U,Autocuration,BAO_0000019
14169,,0,A,,1,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,22224,,,,CHEMBL627684,12686,,,,,U,Autocuration,BAO_0000019
14170,,0,A,,1,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",22224,,,,CHEMBL874441,12686,,,,,U,Autocuration,BAO_0000019
14171,,0,A,,1,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,22224,,,,CHEMBL627685,12686,,,,,U,Autocuration,BAO_0000019
14172,,0,A,,1,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",22224,,,,CHEMBL627686,12686,,,,,U,Autocuration,BAO_0000019
14173,,0,A,,1,Apparent rate constant Koff for inactivation of dTMP synthase.,22224,,,,CHEMBL627687,8057,,,,,U,Autocuration,BAO_0000019
14174,,0,A,,1,The irreversible inhibitor activity by second order rate equation.,22224,,,,CHEMBL627688,15778,,,,,U,Autocuration,BAO_0000019
14175,Rattus norvegicus,1,A,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,50597,10116.0,,,CHEMBL628038,12375,,,,,N,Intermediate,BAO_0000218
14176,Rattus norvegicus,1,A,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,50597,10116.0,,,CHEMBL628039,12375,,,,,N,Intermediate,BAO_0000218
14177,Rattus norvegicus,1,A,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,50597,10116.0,,,CHEMBL628040,12375,,,,,N,Intermediate,BAO_0000218
14178,,0,A,,1,Dissociation rate calculated from the first-order equation using t1/2 value,22224,,,,CHEMBL628041,13588,,,,,U,Autocuration,BAO_0000019
14179,,0,A,,1,The compound was tested for Binding constant against DNA,22224,,,,CHEMBL630226,15039,,,,,U,Autocuration,BAO_0000019
14180,,0,A,,1,First order rate constant for cyclization of the compound,22224,,,,CHEMBL628042,9500,,,,,U,Autocuration,BAO_0000019
14181,,0,A,,1,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,22224,,,,CHEMBL625232,10014,,,,,U,Autocuration,BAO_0000019
14182,,0,A,,1,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,22224,,,,CHEMBL625233,10014,,,,,U,Autocuration,BAO_0000019
14183,,0,A,,1,Hydrolysis rate constant was determined,22224,,,,CHEMBL625979,568,,,,,U,Autocuration,BAO_0000019
14184,,0,A,,1,Observed first order rate constant,22224,,,,CHEMBL625980,10026,,,,,U,Autocuration,BAO_0000019
14185,,0,A,,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,,,,CHEMBL625981,10281,,,,,U,Autocuration,BAO_0000019
14186,,0,A,,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,,,,CHEMBL625982,10281,,,,,U,Autocuration,BAO_0000019
14187,,0,A,,1,Second-order rate constant for attack on PNPA at 25 degree Centigrade,22224,,,,CHEMBL625983,9680,,,,,U,Autocuration,BAO_0000019
14188,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625984,13028,,,,,U,Autocuration,BAO_0000019
14189,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625985,13028,,,,,U,Autocuration,BAO_0000019
14190,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625986,13028,,,,,U,Autocuration,BAO_0000019
14191,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625987,13028,,,,,U,Autocuration,BAO_0000019
14192,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625988,13028,,,,,U,Autocuration,BAO_0000019
14193,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625989,13028,,,,,U,Autocuration,BAO_0000019
14194,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625990,13028,,,,,U,Autocuration,BAO_0000019
14195,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625991,13028,,,,,U,Autocuration,BAO_0000019
14196,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625992,13028,,,,,U,Autocuration,BAO_0000019
14197,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL625993,13028,,,,,U,Autocuration,BAO_0000019
14198,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL631973,13028,,,,,U,Autocuration,BAO_0000019
14199,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632143,13028,,,,,U,Autocuration,BAO_0000019
14200,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632144,13028,,,,,U,Autocuration,BAO_0000019
14201,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632145,13028,,,,,U,Autocuration,BAO_0000019
14202,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632146,13028,,,,,U,Autocuration,BAO_0000019
14203,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632147,13028,,,,,U,Autocuration,BAO_0000019
14204,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632148,13028,,,,,U,Autocuration,BAO_0000019
14205,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632149,13028,,,,,U,Autocuration,BAO_0000019
14206,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632150,13028,,,,,U,Autocuration,BAO_0000019
14207,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL632151,13028,,,,,U,Autocuration,BAO_0000019
14208,Homo sapiens,1,A,,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,50587,9606.0,,,CHEMBL632152,3008,,,,,N,Intermediate,BAO_0000218
14209,Homo sapiens,1,A,,1,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,50587,9606.0,,,CHEMBL632153,4509,,,,,N,Intermediate,BAO_0000218
14210,Homo sapiens,1,A,,1,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,50587,9606.0,,,CHEMBL632154,4509,,,,,N,Intermediate,BAO_0000218
14211,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL632155,8613,,,,,N,Intermediate,BAO_0000218
14212,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,50602,10298.0,,,CHEMBL632156,8613,,,,,N,Intermediate,BAO_0000218
14213,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL632157,8613,,,,,N,Intermediate,BAO_0000218
14214,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL632158,8613,,,,,N,Intermediate,BAO_0000218
14215,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,50602,10298.0,,,CHEMBL632159,8613,,,,,N,Intermediate,BAO_0000218
14216,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL626305,8613,,,,,N,Intermediate,BAO_0000218
14217,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,50602,10298.0,,,CHEMBL626306,8613,,,,,N,Intermediate,BAO_0000218
14218,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL626307,8613,,,,,N,Intermediate,BAO_0000218
14219,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL626308,8613,,,,,N,Intermediate,BAO_0000218
14220,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL626479,8613,,,,,N,Intermediate,BAO_0000218
14221,Human herpesvirus 1,1,A,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,50602,10298.0,,,CHEMBL626480,8613,,,,,N,Intermediate,BAO_0000218
14222,,0,P,,1,Calculated partition coefficient (clogP) (MlogP),22229,,,,CHEMBL626481,6021,,,,,U,Autocuration,BAO_0000100
14223,,0,A,,1,Equipotent potent ratio relative to carbachol (nicotinic activity),22224,,,,CHEMBL626482,9348,,,,,U,Autocuration,BAO_0000019
14224,Canis lupus familiaris,1,A,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",50588,9615.0,,,CHEMBL626483,15592,,,,,N,Intermediate,BAO_0000218
14225,Canis lupus familiaris,1,A,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",50588,9615.0,,,CHEMBL626484,15592,,,,,N,Intermediate,BAO_0000218
14226,,0,P,,1,Solubility at pH 7.4 in micro g/mL;NA denotes available,22229,,,,CHEMBL626485,15592,,,,,U,Autocuration,BAO_0000100
14227,,0,P,,1,Solubility at pH 7.4 in micro g/mL;NA denotes not available,22229,,,,CHEMBL626486,15592,,,,,U,Autocuration,BAO_0000100
14228,,0,P,,1,Solubility at pH 7.4 in ug/mL;NA denotes not available,22229,,,,CHEMBL626487,15592,,,,,U,Autocuration,BAO_0000100
14229,Canis lupus familiaris,1,A,,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,9615.0,,,CHEMBL626488,15592,1969.0,,,Plasma,N,Intermediate,BAO_0000218
14230,Rattus norvegicus,1,A,,1,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,50597,10116.0,,,CHEMBL626489,7095,1977.0,,,Serum,N,Intermediate,BAO_0000218
14231,,0,A,,1,Area under the MAP curve measured over 5 min; ND means Not determined,22224,,,,CHEMBL626490,16618,,,,,U,Autocuration,BAO_0000019
14232,,0,P,,1,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,22224,,,,CHEMBL626491,16835,,,,,U,Autocuration,BAO_0000100
14233,,0,P,,1,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,22229,,,,CHEMBL626492,15284,,,,,U,Autocuration,BAO_0000100
14234,,0,A,,1,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,22224,,,,CHEMBL626493,15750,,,,,U,Autocuration,BAO_0000019
14235,Rattus norvegicus,1,A,,1,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,50597,10116.0,,,CHEMBL626494,16618,,,,,N,Intermediate,BAO_0000218
14236,,0,A,,1,Half life after oral tested,22224,,,,CHEMBL626495,16618,,,,,U,Autocuration,BAO_0000218
14237,Rattus norvegicus,1,A,,1,Half life was determined in plasma of rat; NT indicates not tested,50597,10116.0,,,CHEMBL626496,15812,1969.0,,,Plasma,N,Intermediate,BAO_0000218
14238,Rattus norvegicus,1,A,,1,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,50597,10116.0,,,CHEMBL626497,16618,,,,,N,Intermediate,BAO_0000218
14239,,0,A,,1,Oral bioavailability after oral tested,22224,,,,CHEMBL626498,16618,,,,,U,Autocuration,BAO_0000218
14240,Rattus norvegicus,1,A,,1,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),50597,10116.0,,,CHEMBL626499,13098,,,,,N,Intermediate,BAO_0000218
14241,Rattus norvegicus,1,A,,1,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),50597,10116.0,,,CHEMBL626500,13098,,,,,N,Intermediate,BAO_0000218
14242,Rattus norvegicus,1,A,,1,half life was determined in plasma of rat; NT indicates not tested,50597,10116.0,,,CHEMBL626501,15812,1969.0,,,Plasma,N,Intermediate,BAO_0000218
14243,Rattus norvegicus,1,A,,1,half life was determined in plasma of rat; NT means not tested,50597,10116.0,,,CHEMBL626502,15812,1969.0,,,Plasma,N,Intermediate,BAO_0000218
14244,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,50597,10116.0,,,CHEMBL626503,11510,,,,,N,Intermediate,BAO_0000218
14245,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); inactive,50597,10116.0,,,CHEMBL626504,11510,,,,,N,Intermediate,BAO_0000218
14246,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,50597,10116.0,,,CHEMBL626505,11510,,,,,N,Intermediate,BAO_0000218
14247,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,50597,10116.0,,,CHEMBL626506,11510,,,,,N,Intermediate,BAO_0000218
14248,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,50597,10116.0,,,CHEMBL626507,11510,,,,,N,Intermediate,BAO_0000218
14249,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,50597,10116.0,,,CHEMBL626508,11510,,,,,N,Intermediate,BAO_0000218
14250,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,50597,10116.0,,,CHEMBL626509,11510,,,,,N,Intermediate,BAO_0000218
14251,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,50597,10116.0,,,CHEMBL875480,11510,,,,,N,Intermediate,BAO_0000218
14252,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,50597,10116.0,,,CHEMBL626510,11510,,,,,N,Intermediate,BAO_0000218
14253,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,50597,10116.0,,,CHEMBL626511,11510,,,,,N,Intermediate,BAO_0000218
14254,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,50597,10116.0,,,CHEMBL626512,11510,,,,,N,Intermediate,BAO_0000218
14255,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,50597,10116.0,,,CHEMBL628208,11510,,,,,N,Intermediate,BAO_0000218
14256,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,50597,10116.0,,,CHEMBL628209,11510,,,,,N,Intermediate,BAO_0000218
14257,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,50597,10116.0,,,CHEMBL628210,11510,,,,,N,Intermediate,BAO_0000218
14258,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,50597,10116.0,,,CHEMBL628211,11510,,,,,N,Intermediate,BAO_0000218
14259,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,50597,10116.0,,,CHEMBL628212,11510,,,,,N,Intermediate,BAO_0000218
14260,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,50597,10116.0,,,CHEMBL628213,11510,,,,,N,Intermediate,BAO_0000218
14261,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,10116.0,,,CHEMBL628214,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14262,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,10116.0,,,CHEMBL628215,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14263,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,10116.0,,,CHEMBL628216,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14264,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,10116.0,,,CHEMBL626595,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14265,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,10116.0,,,CHEMBL626596,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14266,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,10116.0,,,CHEMBL626597,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14267,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,10116.0,,,CHEMBL626598,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14268,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,10116.0,,,CHEMBL622242,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14269,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,10116.0,,,CHEMBL622243,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14270,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,10116.0,,,CHEMBL622244,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14271,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,10116.0,,,CHEMBL622245,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14272,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,10116.0,,,CHEMBL622246,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14273,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,10116.0,,,CHEMBL622247,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14274,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,10116.0,,,CHEMBL622248,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14275,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,10116.0,,,CHEMBL877483,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14276,Rattus norvegicus,1,A,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,10116.0,,,CHEMBL622249,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14277,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,9615.0,,,CHEMBL622250,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14278,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,9615.0,,,CHEMBL622251,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14279,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,9615.0,,,CHEMBL622252,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14280,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,9615.0,,,CHEMBL622253,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14281,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,9615.0,,,CHEMBL622254,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14282,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,9615.0,,,CHEMBL622255,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14283,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,9615.0,,,CHEMBL622256,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14284,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,9615.0,,,CHEMBL622257,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14285,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,9615.0,,,CHEMBL622258,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14286,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,9615.0,,,CHEMBL622259,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14287,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,9615.0,,,CHEMBL622927,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14288,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,9615.0,,,CHEMBL622928,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14289,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,9615.0,,,CHEMBL622929,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14290,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,50588,9615.0,,,CHEMBL623182,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14291,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,9615.0,,,CHEMBL623183,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14292,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,50597,10116.0,,,CHEMBL623184,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14293,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,10116.0,,,CHEMBL623185,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14294,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,10116.0,,,CHEMBL877484,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14295,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,10116.0,,,CHEMBL627274,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14296,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,50597,10116.0,,,CHEMBL623186,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14297,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,50597,10116.0,,,CHEMBL623187,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14298,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,10116.0,,,CHEMBL623188,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14299,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,50597,10116.0,,,CHEMBL628055,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14300,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,10116.0,,,CHEMBL628056,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14301,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,50597,10116.0,,,CHEMBL628200,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14302,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,10116.0,,,CHEMBL628201,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14303,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,50597,10116.0,,,CHEMBL628202,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14304,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,10116.0,,,CHEMBL628203,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14305,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,50597,10116.0,,,CHEMBL628204,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14306,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,10116.0,,,CHEMBL628205,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14307,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,50597,10116.0,,,CHEMBL628206,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14308,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),22224,,,,CHEMBL628207,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14309,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,22224,,,,CHEMBL627220,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14310,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,22224,,,,CHEMBL627221,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14311,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),22224,,,,CHEMBL627222,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14312,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,22224,,,,CHEMBL627223,13257,,,,,U,Autocuration,BAO_0000218
14313,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,22224,,,,CHEMBL632062,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14314,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,22224,,,,CHEMBL632063,13257,2106.0,,,Spleen,U,Autocuration,BAO_0000218
14315,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,22224,,,,CHEMBL632064,13257,1255.0,,,Urinary bladder,U,Autocuration,BAO_0000218
14316,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,22224,,,,CHEMBL632065,13257,178.0,,,Blood,U,Autocuration,BAO_0000218
14317,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,22224,,,,CHEMBL632066,13257,1474.0,,,Bone element,U,Autocuration,BAO_0000218
14318,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,22224,,,,CHEMBL632067,13257,,,,,U,Autocuration,BAO_0000218
14319,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,22224,,,,CHEMBL629188,13257,2113.0,,,Kidney,U,Autocuration,BAO_0000218
14320,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,22224,,,,CHEMBL629189,13257,2107.0,,,Liver,U,Autocuration,BAO_0000218
14321,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,22224,,,,CHEMBL629190,13257,2048.0,,,Lung,U,Autocuration,BAO_0000218
14322,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,22224,,,,CHEMBL629191,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14323,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),22224,,,,CHEMBL629192,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14324,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,22224,,,,CHEMBL629193,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14325,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),22224,,,,CHEMBL629194,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14326,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,22224,,,,CHEMBL629195,13257,,,,,U,Autocuration,BAO_0000218
14327,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,22224,,,,CHEMBL629373,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14328,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,22224,,,,CHEMBL629374,13257,2106.0,,,Spleen,U,Autocuration,BAO_0000218
14329,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,22224,,,,CHEMBL629375,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14330,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,22224,,,,CHEMBL629376,13257,1255.0,,,Urinary bladder,U,Autocuration,BAO_0000218
14331,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,22224,,,,CHEMBL629377,13257,178.0,,,Blood,U,Autocuration,BAO_0000218
14332,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,22224,,,,CHEMBL629378,13257,1474.0,,,Bone element,U,Autocuration,BAO_0000218
14333,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,22224,,,,CHEMBL629379,13257,,,,,U,Autocuration,BAO_0000218
14334,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,22224,,,,CHEMBL629151,13257,2113.0,,,Kidney,U,Autocuration,BAO_0000218
14335,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,22224,,,,CHEMBL629152,13257,2107.0,,,Liver,U,Autocuration,BAO_0000218
14336,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,22224,,,,CHEMBL629153,13257,2048.0,,,Lung,U,Autocuration,BAO_0000218
14337,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,22224,,,,CHEMBL629154,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14338,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),22224,,,,CHEMBL629155,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14339,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,22224,,,,CHEMBL629156,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14340,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,22224,,,,CHEMBL629157,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14341,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),22224,,,,CHEMBL629158,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14342,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,22224,,,,CHEMBL629159,13257,,,,,U,Autocuration,BAO_0000218
14343,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,22224,,,,CHEMBL629160,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14344,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,22224,,,,CHEMBL629161,13257,2106.0,,,Spleen,U,Autocuration,BAO_0000218
14345,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,22224,,,,CHEMBL629162,13257,1255.0,,,Urinary bladder,U,Autocuration,BAO_0000218
14346,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,22224,,,,CHEMBL629163,13257,178.0,,,Blood,U,Autocuration,BAO_0000218
14347,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,22224,,,,CHEMBL629164,13257,1474.0,,,Bone element,U,Autocuration,BAO_0000218
14348,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,22224,,,,CHEMBL629165,13257,,,,,U,Autocuration,BAO_0000218
14349,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,22224,,,,CHEMBL629166,13257,2107.0,,,Liver,U,Autocuration,BAO_0000218
14350,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,22224,,,,CHEMBL629167,13257,2048.0,,,Lung,U,Autocuration,BAO_0000218
14351,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,22224,,,,CHEMBL629168,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14352,,0,A,,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,22224,,,,CHEMBL629169,2193,,,,,U,Autocuration,BAO_0000019
14353,,0,A,,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,22224,,,,CHEMBL629170,2193,,,,,U,Autocuration,BAO_0000019
14354,,0,A,,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,22224,,,,CHEMBL631153,2193,,,,,U,Autocuration,BAO_0000019
14355,,0,A,,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,22224,,,,CHEMBL875121,2193,,,,,U,Autocuration,BAO_0000019
14356,,0,A,,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,22224,,,,CHEMBL631154,2193,,,,,U,Autocuration,BAO_0000019
14357,,0,A,,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,22224,,,,CHEMBL631155,2193,,,,,U,Autocuration,BAO_0000019
14358,,0,A,,1,Hydrolysis rate constant was determined,22224,,,,CHEMBL631156,568,,,,,U,Autocuration,BAO_0000019
14359,,0,A,,1,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",22224,,,,CHEMBL631157,9680,,,,,U,Autocuration,BAO_0000019
14360,,0,A,,1,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",22224,,,,CHEMBL631158,9680,,,,,U,Autocuration,BAO_0000019
14361,,0,A,,1,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",22224,,,,CHEMBL631159,9680,,,,,U,Autocuration,BAO_0000019
14362,,0,A,,1,Observed second order rate constant,22224,,,,CHEMBL631160,10026,,,,,U,Autocuration,BAO_0000019
14363,,0,A,,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,,,,CHEMBL631161,10281,,,,,U,Autocuration,BAO_0000019
14364,,0,A,,1,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,22224,,,,CHEMBL631162,10014,,,,,U,Autocuration,BAO_0000019
14365,,0,A,,1,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,22224,,,,CHEMBL630313,10014,,,,,U,Autocuration,BAO_0000019
14366,,0,A,,1,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",22224,,,,CHEMBL630314,9680,,,,,U,Autocuration,BAO_0000019
14367,,0,A,,1,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",22224,,,,CHEMBL630315,9680,,,,,U,Autocuration,BAO_0000019
14368,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630316,13028,,,,,U,Autocuration,BAO_0000019
14369,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630986,13028,,,,,U,Autocuration,BAO_0000019
14370,,0,A,,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630987,13028,,,,,U,Autocuration,BAO_0000019
14371,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630988,13028,,,,,U,Autocuration,BAO_0000019
14372,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630989,13028,,,,,U,Autocuration,BAO_0000019
14373,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630990,13028,,,,,U,Autocuration,BAO_0000019
14374,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630991,13028,,,,,U,Autocuration,BAO_0000019
14375,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630992,13028,,,,,U,Autocuration,BAO_0000019
14376,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630993,13028,,,,,U,Autocuration,BAO_0000019
14377,,0,A,,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,,CHEMBL630994,13028,,,,,U,Autocuration,BAO_0000019
14378,Rattus norvegicus,1,A,,1,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,50597,10116.0,,,CHEMBL630995,10014,,,,,N,Intermediate,BAO_0000218
14379,,0,A,,1,Association constant for compound at 31 degree C was determined,22224,,,,CHEMBL629252,9962,,,,,U,Autocuration,BAO_0000019
14380,,0,A,,1,Calculated antagonist equilibrium dissociation constant of the compound,22224,,,,CHEMBL629253,12029,,,,,U,Autocuration,BAO_0000019
14381,,0,A,,1,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,22224,,,,CHEMBL629944,12029,,,,,U,Autocuration,BAO_0000019
14382,Cavia porcellus,1,A,,1,Dissociation constants vs LTE4 on guinea pig trachea,50512,10141.0,,,CHEMBL629945,10583,3126.0,,,Trachea,N,Intermediate,BAO_0000218
14383,,0,A,,1,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",22224,,,,CHEMBL629946,568,,,,,U,Autocuration,BAO_0000019
14384,,0,A,,1,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",22224,,,,CHEMBL629947,568,,,,,U,Autocuration,BAO_0000019
14385,,0,A,,1,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",22224,,,,CHEMBL629948,568,,,,,U,Autocuration,BAO_0000019
14386,,0,A,,1,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",22224,,,,CHEMBL856024,568,,,,,U,Autocuration,BAO_0000019
14387,,0,A,,1,Affinity constant KD value was derived from TMP,22224,,,,CHEMBL629949,7493,,,,,U,Autocuration,BAO_0000019
14388,,0,A,,1,Apparent dissociation (binding) rate constant was evaluated,22224,,,,CHEMBL629950,8371,,,,,U,Autocuration,BAO_0000019
14389,,0,P,,1,Dissociation constant (KD) of the compound,22224,,,,CHEMBL630127,13114,,,,,U,Autocuration,BAO_0000100
14390,,0,P,,1,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,22224,,,,CHEMBL630128,15515,,,,,U,Autocuration,BAO_0000100
14391,,0,P,,1,Dissociation constant from ESR titration experiments,22224,,,,CHEMBL630129,522,,,,,U,Autocuration,BAO_0000100
14392,,0,,,1,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),22224,,,,CHEMBL630130,13888,,,,,U,Autocuration,BAO_0000019
14393,,0,P,,1,Dissociation constant was evaluated.,22224,,,,CHEMBL875234,2616,,,,,U,Autocuration,BAO_0000100
14394,,0,P,,1,Dissociation constant was reported,22224,,,,CHEMBL630131,3798,,,,,U,Autocuration,BAO_0000100
14395,Rattus norvegicus,1,A,,1,Dissociation constant was determined in rat pituitary cells.,50597,10116.0,,,CHEMBL630132,8731,,,,,N,Intermediate,BAO_0000218
14396,,0,A,,1,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,22224,,,,CHEMBL630133,11892,,,,,U,Autocuration,BAO_0000019
14397,,0,A,,1,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,22224,,,,CHEMBL630134,11892,,,,,U,Autocuration,BAO_0000019
14398,,0,A,,1,Equilibrium dissociation constant of the compound,22224,,,,CHEMBL630135,2582,,,,,U,Autocuration,BAO_0000019
14399,,0,A,,1,Equilibrium dissociation constant was determined,22224,,,,CHEMBL630136,11892,,,,,U,Autocuration,BAO_0000019
14400,,0,A,,1,Kinetic constant KD was evaluated,22224,,,,CHEMBL630137,13396,,,,,U,Autocuration,BAO_0000019
14401,,0,A,,1,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,22224,,,,CHEMBL630138,603,,,,,U,Autocuration,BAO_0000019
14402,,0,A,,1,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,22224,,,,CHEMBL630139,15673,,,,,U,Autocuration,BAO_0000019
14403,,0,A,,1,Rate constant for hydrolysis in aqueous acetone.,22224,,,,CHEMBL630140,10368,,,,,U,Autocuration,BAO_0000019
14404,,0,A,,1,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,22224,,,,CHEMBL875235,14228,,,,,U,Autocuration,BAO_0000019
14405,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,50597,10116.0,,,CHEMBL876439,11510,,,,,N,Intermediate,BAO_0000218
14406,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,50597,10116.0,,,CHEMBL630605,11510,,,,,N,Intermediate,BAO_0000218
14407,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,50597,10116.0,,,CHEMBL630606,11510,,,,,N,Intermediate,BAO_0000218
14408,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,50597,10116.0,,,CHEMBL630607,11510,,,,,N,Intermediate,BAO_0000218
14409,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,50597,10116.0,,,CHEMBL630608,11510,,,,,N,Intermediate,BAO_0000218
14410,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,50597,10116.0,,,CHEMBL630609,11510,,,,,N,Intermediate,BAO_0000218
14411,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,50597,10116.0,,,CHEMBL630610,11510,,,,,N,Intermediate,BAO_0000218
14412,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,50597,10116.0,,,CHEMBL630611,11510,,,,,N,Intermediate,BAO_0000218
14413,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,50597,10116.0,,,CHEMBL629552,11510,,,,,N,Intermediate,BAO_0000218
14414,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,10116.0,,,CHEMBL629733,11510,,,,,N,Intermediate,BAO_0000218
14415,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,10116.0,,,CHEMBL629734,11510,,,,,N,Intermediate,BAO_0000218
14416,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,10116.0,,,CHEMBL629735,11510,,,,,N,Intermediate,BAO_0000218
14417,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,10116.0,,,CHEMBL629736,11510,,,,,N,Intermediate,BAO_0000218
14418,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,10116.0,,,CHEMBL629737,11510,,,,,N,Intermediate,BAO_0000218
14419,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,10116.0,,,CHEMBL629738,11510,,,,,N,Intermediate,BAO_0000218
14420,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,10116.0,,,CHEMBL629739,11510,,,,,N,Intermediate,BAO_0000218
14421,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,10116.0,,,CHEMBL629740,11510,,,,,N,Intermediate,BAO_0000218
14422,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,10116.0,,,CHEMBL629741,11510,,,,,N,Intermediate,BAO_0000218
14423,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,10116.0,,,CHEMBL629742,11510,,,,,N,Intermediate,BAO_0000218
14424,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,10116.0,,,CHEMBL629743,11510,,,,,N,Intermediate,BAO_0000218
14425,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,10116.0,,,CHEMBL629744,11510,,,,,N,Intermediate,BAO_0000218
14426,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,10116.0,,,CHEMBL629745,11510,,,,,N,Intermediate,BAO_0000218
14427,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,10116.0,,,CHEMBL629746,11510,,,,,N,Intermediate,BAO_0000218
14428,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,10116.0,,,CHEMBL629747,11510,,,,,N,Intermediate,BAO_0000218
14429,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,10116.0,,,CHEMBL629748,11510,,,,,N,Intermediate,BAO_0000218
14430,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,10116.0,,,CHEMBL629749,11510,,,,,N,Intermediate,BAO_0000218
14431,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,10116.0,,,CHEMBL629750,11510,,,,,N,Intermediate,BAO_0000218
14432,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,10116.0,,,CHEMBL629751,11510,,,,,N,Intermediate,BAO_0000218
14433,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,10116.0,,,CHEMBL629752,11510,,,,,N,Intermediate,BAO_0000218
14434,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,10116.0,,,CHEMBL629753,11510,,,,,N,Intermediate,BAO_0000218
14435,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,10116.0,,,CHEMBL629754,11510,,,,,N,Intermediate,BAO_0000218
14436,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,10116.0,,,CHEMBL629755,11510,,,,,N,Intermediate,BAO_0000218
14437,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,10116.0,,,CHEMBL629756,11510,,,,,N,Intermediate,BAO_0000218
14438,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,10116.0,,,CHEMBL629757,11510,,,,,N,Intermediate,BAO_0000218
14439,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,10116.0,,,CHEMBL629758,11510,,,,,N,Intermediate,BAO_0000218
14440,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,10116.0,,,CHEMBL629759,11510,,,,,N,Intermediate,BAO_0000218
14441,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,10116.0,,,CHEMBL629760,11510,,,,,N,Intermediate,BAO_0000218
14442,Rattus norvegicus,1,A,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,10116.0,,,CHEMBL876443,11510,,,,,N,Intermediate,BAO_0000218
14443,Canis lupus familiaris,1,A,,1,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,50588,9615.0,,,CHEMBL629761,8310,,,,,N,Intermediate,BAO_0000218
14444,Canis lupus familiaris,1,A,,1,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,50588,9615.0,,,CHEMBL629762,8310,,,,,N,Intermediate,BAO_0000218
14445,Mus musculus,1,A,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,10090.0,,,CHEMBL629763,8310,,,,,N,Intermediate,BAO_0000218
14446,Mus musculus,1,A,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,10090.0,,,CHEMBL629764,8310,,,,,N,Intermediate,BAO_0000218
14447,Mus musculus,1,A,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,10090.0,,,CHEMBL629765,8310,,,,,N,Intermediate,BAO_0000218
14448,Mus musculus,1,A,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,50594,10090.0,,,CHEMBL629766,8310,,,,,N,Intermediate,BAO_0000218
14449,Mus musculus,1,A,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,10090.0,,,CHEMBL629767,8310,,,,,N,Intermediate,BAO_0000218
14450,Canis lupus familiaris,1,A,,1,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,50588,9615.0,,,CHEMBL629768,8310,,,,,N,Intermediate,BAO_0000218
14451,Mus musculus,1,A,,1,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,50594,10090.0,,,CHEMBL629769,8310,,,,,N,Intermediate,BAO_0000218
14452,Canis lupus familiaris,1,A,,1,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,50588,9615.0,,,CHEMBL629770,8310,,,,,N,Intermediate,BAO_0000218
14453,Canis lupus familiaris,1,A,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,50588,9615.0,,,CHEMBL629771,8310,,,,,N,Intermediate,BAO_0000218
14454,Mus musculus,1,A,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,10090.0,,,CHEMBL629772,8310,,,,,N,Intermediate,BAO_0000218
14455,Mus musculus,1,A,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,10090.0,,,CHEMBL629773,8310,,,,,N,Intermediate,BAO_0000218
14456,Mus musculus,1,A,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,10090.0,,,CHEMBL625455,8310,,,,,N,Intermediate,BAO_0000218
14457,Mus musculus,1,A,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,50594,10090.0,,,CHEMBL625456,8310,,,,,N,Intermediate,BAO_0000218
14458,Mus musculus,1,A,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,50594,10090.0,,,CHEMBL625457,8310,,,,,N,Intermediate,BAO_0000218
14459,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,10116.0,,,CHEMBL625458,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14460,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,50597,10116.0,,,CHEMBL625459,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14461,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,10116.0,,,CHEMBL875483,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14462,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,50597,10116.0,,,CHEMBL634779,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14463,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,50597,10116.0,,,CHEMBL625460,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14464,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,10116.0,,,CHEMBL626117,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14465,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,50597,10116.0,,,CHEMBL626118,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14466,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,50597,10116.0,,,CHEMBL628342,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14467,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,10116.0,,,CHEMBL628343,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14468,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,50597,10116.0,,,CHEMBL628344,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14469,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,10116.0,,,CHEMBL628345,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14470,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,50597,10116.0,,,CHEMBL628346,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14471,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,50597,10116.0,,,CHEMBL628347,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14472,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,10116.0,,,CHEMBL628348,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14473,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,10116.0,,,CHEMBL628349,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14474,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,50597,10116.0,,,CHEMBL875611,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14475,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,50597,10116.0,,,CHEMBL628350,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14476,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,10116.0,,,CHEMBL628351,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14477,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,50597,10116.0,,,CHEMBL628352,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14478,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,10116.0,,,CHEMBL628353,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14479,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,50597,10116.0,,,CHEMBL628354,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14480,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,10116.0,,,CHEMBL626667,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14481,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,10116.0,,,CHEMBL626668,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14482,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,10116.0,,,CHEMBL626669,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14483,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,50597,10116.0,,,CHEMBL626670,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14484,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,50597,10116.0,,,CHEMBL626671,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14485,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,10116.0,,,CHEMBL626672,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14486,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,50597,10116.0,,,CHEMBL626673,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14487,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,10116.0,,,CHEMBL626674,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14488,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,10116.0,,,CHEMBL626675,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14489,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,50597,10116.0,,,CHEMBL626676,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14490,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,50597,10116.0,,,CHEMBL626677,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14491,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,10116.0,,,CHEMBL626678,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14492,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,10116.0,,,CHEMBL626679,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14493,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,10116.0,,,CHEMBL875612,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14494,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,10116.0,,,CHEMBL626680,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14495,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,10116.0,,,CHEMBL626681,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14496,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,10116.0,,,CHEMBL626682,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14497,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,10116.0,,,CHEMBL626683,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14498,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,10116.0,,,CHEMBL626684,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14499,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,10116.0,,,CHEMBL626685,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14500,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,10116.0,,,CHEMBL626686,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14501,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,10116.0,,,CHEMBL626687,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14502,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,10116.0,,,CHEMBL624978,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14503,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,10116.0,,,CHEMBL624979,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14504,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,10116.0,,,CHEMBL624980,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14505,Rattus norvegicus,1,A,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,10116.0,,,CHEMBL624981,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14506,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,9615.0,,,CHEMBL624982,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14507,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),22224,,,,CHEMBL627564,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14508,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),22224,,,,CHEMBL627565,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14509,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,22224,,,,CHEMBL627566,13257,,,,,U,Autocuration,BAO_0000218
14510,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,22224,,,,CHEMBL627567,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14511,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,22224,,,,CHEMBL627568,13257,2106.0,,,Spleen,U,Autocuration,BAO_0000218
14512,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,22224,,,,CHEMBL627569,13257,2113.0,,,Kidney,U,Autocuration,BAO_0000218
14513,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,22224,,,,CHEMBL627570,13257,1255.0,,,Urinary bladder,U,Autocuration,BAO_0000218
14514,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,22224,,,,CHEMBL627571,13257,178.0,,,Blood,U,Autocuration,BAO_0000218
14515,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,22224,,,,CHEMBL627572,13257,1474.0,,,Bone element,U,Autocuration,BAO_0000218
14516,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,22224,,,,CHEMBL627573,13257,,,,,U,Autocuration,BAO_0000218
14517,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,22224,,,,CHEMBL627574,13257,2113.0,,,Kidney,U,Autocuration,BAO_0000218
14518,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,22224,,,,CHEMBL627575,13257,2107.0,,,Liver,U,Autocuration,BAO_0000218
14519,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,22224,,,,CHEMBL627576,13257,2048.0,,,Lung,U,Autocuration,BAO_0000218
14520,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,22224,,,,CHEMBL627577,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14521,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),22224,,,,CHEMBL627578,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14522,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,22224,,,,CHEMBL627579,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14523,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,22224,,,,CHEMBL627580,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14524,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),22224,,,,CHEMBL627581,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14525,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,22224,,,,CHEMBL627582,13257,,,,,U,Autocuration,BAO_0000218
14526,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,22224,,,,CHEMBL627583,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14527,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,22224,,,,CHEMBL627584,13257,2106.0,,,Spleen,U,Autocuration,BAO_0000218
14528,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,22224,,,,CHEMBL627585,13257,2367.0,,,Prostate gland,U,Autocuration,BAO_0000218
14529,,0,A,,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,22224,,,,CHEMBL627586,13257,2385.0,,,Muscle tissue,U,Autocuration,BAO_0000218
14530,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,50597,10116.0,,,CHEMBL627587,15413,,,,,N,Intermediate,BAO_0000218
14531,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL627588,15413,,,,,N,Intermediate,BAO_0000218
14532,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,50597,10116.0,,,CHEMBL628250,15413,,,,,N,Intermediate,BAO_0000218
14533,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628251,15413,,,,,N,Intermediate,BAO_0000218
14534,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,50597,10116.0,,,CHEMBL628252,15413,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
14535,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628253,15413,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
14536,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,50597,10116.0,,,CHEMBL628254,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14537,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL877493,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14538,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628255,15413,,,,,N,Intermediate,BAO_0000218
14539,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628256,15413,,,,,N,Intermediate,BAO_0000218
14540,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628257,15413,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
14541,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628258,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14542,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628259,15413,,,,,N,Intermediate,BAO_0000218
14543,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL628429,15413,,,,,N,Intermediate,BAO_0000218
14544,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,10116.0,,,CHEMBL626862,15413,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
14545,Rattus norvegicus,1,A,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,50597,10116.0,,,CHEMBL626863,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14546,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,50597,10116.0,,,CHEMBL625886,15413,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
14547,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,50597,10116.0,,,CHEMBL625887,15413,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
14548,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex,50597,10116.0,,,CHEMBL625888,15413,,,,,N,Intermediate,BAO_0000218
14549,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,50597,10116.0,,,CHEMBL625889,15413,,,,,N,Intermediate,BAO_0000218
14550,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,50597,10116.0,,,CHEMBL625890,15413,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
14551,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,50597,10116.0,,,CHEMBL625891,15413,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
14552,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,50597,10116.0,,,CHEMBL625892,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14553,Rattus norvegicus,1,A,,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,50597,10116.0,,,CHEMBL625893,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14554,Rattus norvegicus,1,A,,1,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,50597,10116.0,,,CHEMBL625894,15413,2037.0,,,Cerebellum,N,Intermediate,BAO_0000218
14555,Rattus norvegicus,1,A,,1,Biodistribution of the [18F]-radiolabeled compound in rat cortex,50597,10116.0,,,CHEMBL625895,15413,,,,,N,Intermediate,BAO_0000218
14556,,0,A,,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,,,,CHEMBL625896,12404,,,,,U,Autocuration,BAO_0000019
14557,,0,A,,1,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",22224,,,,CHEMBL625897,568,,,,,U,Autocuration,BAO_0000019
14558,,0,A,,1,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",22224,,,,CHEMBL625898,568,,,,,U,Autocuration,BAO_0000019
14559,,0,A,,1,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",22224,,,,CHEMBL625899,568,,,,,U,Autocuration,BAO_0000019
14560,,0,A,,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,,,,CHEMBL626124,12404,,,,,U,Autocuration,BAO_0000019
14561,Escherichia coli,1,A,,1,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,50212,562.0,,,CHEMBL628500,7624,,,,,N,Intermediate,BAO_0000218
14562,Rattus norvegicus,1,A,,1,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",50597,10116.0,,,CHEMBL857856,7624,,,,,N,Intermediate,BAO_0000218
14563,Rattus norvegicus,1,A,,1,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",50597,10116.0,,,CHEMBL628501,7624,,,,,N,Intermediate,BAO_0000218
14564,,0,A,,1,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",22224,,,,CHEMBL628502,4643,,,,,U,Autocuration,BAO_0000019
14565,,0,A,,1,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,22224,,,,CHEMBL628503,11532,,,,,U,Autocuration,BAO_0000019
14566,,0,A,,1,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,22224,,,,CHEMBL628504,11018,,,,,U,Autocuration,BAO_0000019
14567,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",22224,,,,CHEMBL628505,2276,,,,,U,Autocuration,BAO_0000019
14568,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",22224,,,,CHEMBL874452,2276,,,,,U,Autocuration,BAO_0000019
14569,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",22224,,,,CHEMBL628506,2276,,,,,U,Autocuration,BAO_0000019
14570,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",22224,,,,CHEMBL628507,2276,,,,,U,Autocuration,BAO_0000019
14571,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",22224,,,,CHEMBL628508,2276,,,,,U,Autocuration,BAO_0000019
14572,,0,A,,1,Michaelis constant (KM) was evaluated,22224,,,,CHEMBL628509,8949,,,,,U,Autocuration,BAO_0000019
14573,,0,A,,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,,,,CHEMBL628510,12404,,,,,U,Autocuration,BAO_0000019
14574,,0,B,,1,Substrate concentration for half maximal velocity was reported for rat hexokinase I,22224,,,,CHEMBL628511,7625,,,,,U,Autocuration,BAO_0000019
14575,,0,B,,1,Substrate concentration for half maximal velocity was reported for rat hexokinase II,22224,,,,CHEMBL628512,7625,,,,,U,Autocuration,BAO_0000019
14576,,0,B,,1,Substrate concentration for half maximal velocity was reported for rat hexokinase III,22224,,,,CHEMBL628513,7625,,,,,U,Autocuration,BAO_0000019
14577,,0,B,,1,Substrate concentration for half maximal velocity was reported for yeast hexokinase,22224,,,,CHEMBL628514,7625,,,,,U,Autocuration,BAO_0000019
14578,,0,A,,1,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,22224,,,,CHEMBL628515,12908,,,,,U,Autocuration,BAO_0000019
14579,,0,A,,1,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,22224,,,,CHEMBL628516,10368,,,,,U,Autocuration,BAO_0000019
14580,,0,A,,1,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),22224,,,,CHEMBL628517,13108,,,,,U,Autocuration,BAO_0000019
14581,,0,A,,1,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),22224,,,,CHEMBL628518,13108,,,,,U,Autocuration,BAO_0000019
14582,,0,A,,1,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,22224,,,,CHEMBL628519,15217,,,,,U,Autocuration,BAO_0000019
14583,,0,A,,1,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,22224,,,,CHEMBL628520,15217,,,,,U,Autocuration,BAO_0000019
14584,,0,A,,1,Binding constant was determined,22224,,,,CHEMBL628521,10933,,,,,U,Autocuration,BAO_0000019
14585,,0,A,,1,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,22224,,,,CHEMBL630443,2363,,,,,U,Autocuration,BAO_0000019
14586,,0,A,,1,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,22224,,,,CHEMBL630444,2363,,,,,U,Autocuration,BAO_0000019
14587,,0,A,,1,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,22224,,,,CHEMBL857732,2276,,,,,U,Autocuration,BAO_0000019
14588,,0,P,,1,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,22224,,,,CHEMBL630445,14915,,,,,U,Autocuration,BAO_0000100
14589,,0,A,,1,Catalytic rate constant of the compound,22224,,,,CHEMBL630446,8847,,,,,U,Autocuration,BAO_0000019
14590,,0,B,,1,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,22224,,,,CHEMBL630447,15357,,,,,U,Autocuration,BAO_0000019
14591,,0,A,,1,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),22224,,,,CHEMBL630448,2869,,,,,U,Autocuration,BAO_0000019
14592,,0,A,,1,Catalytic rate constant against phospholipase A2 was determined,22224,,,,CHEMBL630449,3484,,,,,U,Autocuration,BAO_0000019
14593,,0,A,,1,"Compound was evaluated for catalytic constant, Kcat",22224,,,,CHEMBL630450,1373,,,,,U,Autocuration,BAO_0000019
14594,,0,A,,1,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,22224,,,,CHEMBL630451,8142,,,,,U,Autocuration,BAO_0000019
14595,,0,A,,1,Kcat calculated from 0.693/T1/2,22224,,,,CHEMBL630452,14131,,,,,U,Autocuration,BAO_0000019
14596,,0,A,,1,Kcat was determined,22224,,,,CHEMBL630453,17269,,,,,U,Autocuration,BAO_0000019
14597,,0,A,,1,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,22224,,,,CHEMBL630454,3485,,,,,U,Autocuration,BAO_0000019
14598,,0,A,,1,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,22224,,,,CHEMBL630455,3485,,,,,U,Autocuration,BAO_0000019
14599,,0,A,,1,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,22224,,,,CHEMBL631487,3485,,,,,U,Autocuration,BAO_0000019
14600,,0,A,,1,Kcat value was determined,22224,,,,CHEMBL631488,5962,,,,,U,Autocuration,BAO_0000019
14601,,0,A,,1,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,22224,,,,CHEMBL876440,3133,,,,,U,Autocuration,BAO_0000019
14602,,0,A,,1,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,22224,,,,CHEMBL631489,3133,,,,,U,Autocuration,BAO_0000019
14603,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",22224,,,,CHEMBL857742,2276,,,,,U,Autocuration,BAO_0000019
14604,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",22224,,,,CHEMBL631490,2276,,,,,U,Autocuration,BAO_0000019
14605,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",22224,,,,CHEMBL631491,2276,,,,,U,Autocuration,BAO_0000019
14606,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",22224,,,,CHEMBL631492,2276,,,,,U,Autocuration,BAO_0000019
14607,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",22224,,,,CHEMBL631493,2276,,,,,U,Autocuration,BAO_0000019
14608,,0,A,,1,Kinetic parameter for rate of conversion to PABA was determined,22224,,,,CHEMBL631494,4892,,,,,U,Autocuration,BAO_0000019
14609,,0,A,,1,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,22224,,,,CHEMBL631495,3133,,,,,U,Autocuration,BAO_0000019
14610,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",50597,10116.0,,,CHEMBL631496,11488,1988.0,,,Feces,N,Intermediate,BAO_0000218
14611,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",50597,10116.0,,,CHEMBL631497,11488,1088.0,,,Urine,N,Intermediate,BAO_0000218
14612,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",50597,10116.0,,,CHEMBL631498,11488,1088.0,,,Urine,N,Intermediate,BAO_0000218
14613,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",50597,10116.0,,,CHEMBL629776,11488,1088.0,,,Urine,N,Intermediate,BAO_0000218
14614,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",50597,10116.0,,,CHEMBL629777,11488,1088.0,,,Urine,N,Intermediate,BAO_0000218
14615,Rattus norvegicus,1,A,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",50597,10116.0,,,CHEMBL629778,11488,1088.0,,,Urine,N,Intermediate,BAO_0000218
14616,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,50597,10116.0,,,CHEMBL630456,11488,,,,,N,Intermediate,BAO_0000218
14617,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,50597,10116.0,,,CHEMBL630457,11488,,,,,N,Intermediate,BAO_0000218
14618,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,50597,10116.0,,,CHEMBL630458,11488,,,,,N,Intermediate,BAO_0000218
14619,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,50597,10116.0,,,CHEMBL630459,11488,,,,,N,Intermediate,BAO_0000218
14620,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,50597,10116.0,,,CHEMBL630460,11488,,,,,N,Intermediate,BAO_0000218
14621,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,50597,10116.0,,,CHEMBL876550,11488,,,,,N,Intermediate,BAO_0000218
14622,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,50597,10116.0,,,CHEMBL630461,11488,,,,,N,Intermediate,BAO_0000218
14623,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,50597,10116.0,,,CHEMBL630462,11488,,,,,N,Intermediate,BAO_0000218
14624,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,50597,10116.0,,,CHEMBL630463,11488,,,,,N,Intermediate,BAO_0000218
14625,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,50597,10116.0,,,CHEMBL630464,11488,,,,,N,Intermediate,BAO_0000218
14626,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,50597,10116.0,,,CHEMBL630465,11488,,,,,N,Intermediate,BAO_0000218
14627,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,50597,10116.0,,,CHEMBL630466,11488,,,,,N,Intermediate,BAO_0000218
14628,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,50597,10116.0,,,CHEMBL630467,11488,,,,,N,Intermediate,BAO_0000218
14629,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,50597,10116.0,,,CHEMBL630633,11488,,,,,N,Intermediate,BAO_0000218
14630,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,50597,10116.0,,,CHEMBL630634,11488,,,,,N,Intermediate,BAO_0000218
14631,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,50597,10116.0,,,CHEMBL630635,11488,,,,,N,Intermediate,BAO_0000218
14632,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,50597,10116.0,,,CHEMBL630636,11488,,,,,N,Intermediate,BAO_0000218
14633,Rattus norvegicus,1,A,,1,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,50597,10116.0,,,CHEMBL630637,11488,,,,,N,Intermediate,BAO_0000218
14634,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",50592,9986.0,,,CHEMBL630638,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14635,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",50592,9986.0,,,CHEMBL630639,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14636,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",50592,9986.0,,,CHEMBL630640,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14637,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",50592,9986.0,,,CHEMBL876551,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14638,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",50592,9986.0,,,CHEMBL630641,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14639,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",50592,9986.0,,,CHEMBL630642,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14640,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",50592,9986.0,,,CHEMBL630643,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14641,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",50592,9986.0,,,CHEMBL630644,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14642,Oryctolagus cuniculus,1,A,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",50592,9986.0,,,CHEMBL630645,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14643,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",50592,9986.0,,,CHEMBL625599,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14644,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",50592,9986.0,,,CHEMBL625600,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14645,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",50592,9986.0,,,CHEMBL625601,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14646,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",50592,9986.0,,,CHEMBL625602,7132,1988.0,,,Feces,N,Intermediate,BAO_0000218
14647,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",50592,9986.0,,,CHEMBL627470,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14648,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",50592,9986.0,,,CHEMBL627471,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14649,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",50592,9986.0,,,CHEMBL627472,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14650,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",50592,9986.0,,,CHEMBL627473,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14651,Oryctolagus cuniculus,1,A,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",50592,9986.0,,,CHEMBL627474,7132,1088.0,,,Urine,N,Intermediate,BAO_0000218
14652,Rattus norvegicus,1,A,,1,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL627475,13925,178.0,,,Blood,N,Intermediate,BAO_0000218
14653,Rattus norvegicus,1,A,,1,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL627476,13925,178.0,,,Blood,N,Intermediate,BAO_0000218
14654,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,9615.0,,,CHEMBL627477,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14655,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,9615.0,,,CHEMBL627478,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14656,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,9615.0,,,CHEMBL627479,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14657,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,9615.0,,,CHEMBL627480,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14658,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,9615.0,,,CHEMBL627481,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14659,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,9615.0,,,CHEMBL627482,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14660,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,9615.0,,,CHEMBL627483,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14661,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,9615.0,,,CHEMBL875636,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14662,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,9615.0,,,CHEMBL625764,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14663,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,9615.0,,,CHEMBL625765,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14664,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,50588,9615.0,,,CHEMBL625766,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14665,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,9615.0,,,CHEMBL625767,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14666,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,9615.0,,,CHEMBL625768,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14667,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,50588,9615.0,,,CHEMBL625769,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14668,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,50588,9615.0,,,CHEMBL625770,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14669,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,50588,9615.0,,,CHEMBL625771,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14670,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,50588,9615.0,,,CHEMBL625772,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14671,Canis lupus familiaris,1,A,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,9615.0,,,CHEMBL625773,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14672,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,50597,10116.0,,,CHEMBL625774,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14673,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,50597,10116.0,,,CHEMBL625775,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14674,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,10116.0,,,CHEMBL625776,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14675,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,10116.0,,,CHEMBL625777,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14676,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,10116.0,,,CHEMBL625778,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14677,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,50597,10116.0,,,CHEMBL625779,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14678,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,50597,10116.0,,,CHEMBL625780,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14679,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,10116.0,,,CHEMBL625781,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14680,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,50597,10116.0,,,CHEMBL875637,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14681,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,10116.0,,,CHEMBL626473,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14682,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,50597,10116.0,,,CHEMBL626474,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14683,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,10116.0,,,CHEMBL626475,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14684,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,50597,10116.0,,,CHEMBL626476,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14685,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,10116.0,,,CHEMBL634397,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14686,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,50597,10116.0,,,CHEMBL626477,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14687,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,10116.0,,,CHEMBL631069,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14688,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,50597,10116.0,,,CHEMBL631070,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14689,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,10116.0,,,CHEMBL631071,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14690,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,50597,10116.0,,,CHEMBL631072,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14691,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,10116.0,,,CHEMBL631073,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14692,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,50597,10116.0,,,CHEMBL631074,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14693,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,50597,10116.0,,,CHEMBL631075,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14694,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,10116.0,,,CHEMBL631725,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14695,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,50597,10116.0,,,CHEMBL631726,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14696,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,50597,10116.0,,,CHEMBL631727,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14697,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,10116.0,,,CHEMBL631728,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14698,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,10116.0,,,CHEMBL631729,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14699,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,50597,10116.0,,,CHEMBL631730,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14700,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,50597,10116.0,,,CHEMBL631731,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14701,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,10116.0,,,CHEMBL631910,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14702,Rattus norvegicus,1,A,,1,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,50597,10116.0,,,CHEMBL631911,15413,10000000.0,,,Hippocampus,N,Intermediate,BAO_0000218
14703,Rattus norvegicus,1,A,,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,50597,10116.0,,,CHEMBL631912,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14704,Rattus norvegicus,1,A,,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,50597,10116.0,,,CHEMBL631913,15413,1898.0,,,Hypothalamus,N,Intermediate,BAO_0000218
14705,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631914,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14706,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631915,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14707,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL875778,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14708,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631916,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14709,Rattus norvegicus,1,A,,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631917,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14710,Rattus norvegicus,1,A,,1,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631918,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14711,Rattus norvegicus,1,A,,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631919,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14712,Rattus norvegicus,1,A,,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL631920,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14713,Rattus norvegicus,1,A,,1,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631921,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14714,Rattus norvegicus,1,A,,1,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631922,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14715,Rattus norvegicus,1,A,,1,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL631923,12017,178.0,,,Blood,N,Intermediate,BAO_0000218
14716,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631924,12017,,,,,N,Intermediate,BAO_0000218
14717,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630234,12017,,,,,N,Intermediate,BAO_0000218
14718,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630235,12017,,,,,N,Intermediate,BAO_0000218
14719,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630236,12017,,,,,N,Intermediate,BAO_0000218
14720,Rattus norvegicus,1,A,,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630237,12017,,,,,N,Intermediate,BAO_0000218
14721,Rattus norvegicus,1,A,,1,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630238,12017,,,,,N,Intermediate,BAO_0000218
14722,Rattus norvegicus,1,A,,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630239,12017,,,,,N,Intermediate,BAO_0000218
14723,Rattus norvegicus,1,A,,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630303,12017,,,,,N,Intermediate,BAO_0000218
14724,Rattus norvegicus,1,A,,1,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630304,12017,,,,,N,Intermediate,BAO_0000218
14725,Rattus norvegicus,1,A,,1,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630305,12017,,,,,N,Intermediate,BAO_0000218
14726,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630306,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14727,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630307,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14728,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630308,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14729,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630309,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14730,Rattus norvegicus,1,A,,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL629309,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14731,Rattus norvegicus,1,A,,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL629993,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14732,Rattus norvegicus,1,A,,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL629994,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14733,Rattus norvegicus,1,A,,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL629995,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14734,Rattus norvegicus,1,A,,1,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631993,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14735,Rattus norvegicus,1,A,,1,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631994,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14736,Rattus norvegicus,1,A,,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631995,12017,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14737,Rattus norvegicus,1,A,,1,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL631996,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14738,Rattus norvegicus,1,A,,1,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631997,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14739,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631998,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14740,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631999,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14741,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL632000,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14742,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL632001,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14743,Rattus norvegicus,1,A,,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL874424,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14744,Rattus norvegicus,1,A,,1,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL632002,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14745,Rattus norvegicus,1,A,,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL632003,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14746,,0,A,,1,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,22224,,,,CHEMBL632004,3133,,,,,U,Autocuration,BAO_0000019
14747,,0,A,,1,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,22224,,,,CHEMBL632005,2742,,,,,U,Autocuration,BAO_0000019
14748,,0,A,,1,Compound was tested for amidase rate in the presence of N62C screen enzyme,22224,,,,CHEMBL632006,2742,,,,,U,Autocuration,BAO_0000019
14749,,0,A,,1,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,22224,,,,CHEMBL632007,2742,,,,,U,Autocuration,BAO_0000019
14750,,0,A,,1,Compound was tested for amidase rate in the presence of S166C screen enzyme,22224,,,,CHEMBL632008,2742,,,,,U,Autocuration,BAO_0000019
14751,,0,A,,1,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,22224,,,,CHEMBL632009,2742,,,,,U,Autocuration,BAO_0000019
14752,,0,A,,1,Compound was tested for esterase rate in the presence of N62C screen enzyme,22224,,,,CHEMBL632010,2742,,,,,U,Autocuration,BAO_0000019
14753,,0,A,,1,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,22224,,,,CHEMBL857750,2742,,,,,U,Autocuration,BAO_0000019
14754,,0,A,,1,Compound was tested for esterase rate in the presence of S166C screen enzyme,22224,,,,CHEMBL632011,2742,,,,,U,Autocuration,BAO_0000019
14755,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,,CHEMBL632012,2276,,,,,U,Autocuration,BAO_0000019
14756,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,,CHEMBL632013,2276,,,,,U,Autocuration,BAO_0000019
14757,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",22224,,,,CHEMBL632014,2276,,,,,U,Autocuration,BAO_0000019
14758,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,,CHEMBL629622,2276,,,,,U,Autocuration,BAO_0000019
14759,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,,CHEMBL629623,2276,,,,,U,Autocuration,BAO_0000019
14760,,0,A,,1,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",22224,,,,CHEMBL629624,2276,,,,,U,Autocuration,BAO_0000019
14761,,0,A,,1,Ratio of Kcat to that of Km was determined,22224,,,,CHEMBL629625,17269,,,,,U,Autocuration,BAO_0000019
14762,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",22224,,,,CHEMBL629626,2276,,,,,U,Autocuration,BAO_0000019
14763,,0,A,,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",22224,,,,CHEMBL629627,2276,,,,,U,Autocuration,BAO_0000019
14764,,0,A,,1,"Compound was evaluated for constant, Kd",22224,,,,CHEMBL629628,15917,,,,,U,Autocuration,BAO_0000019
14765,,0,A,,1,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,22224,,,,CHEMBL629629,10933,,,,,U,Autocuration,BAO_0000019
14766,,0,A,,1,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,22224,,,,CHEMBL629630,10933,,,,,U,Autocuration,BAO_0000019
14767,,0,A,,1,Dissociation Constant of compound determined,22224,,,,CHEMBL856030,14293,,,,,U,Autocuration,BAO_0000019
14768,,0,B,,1,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,22224,,,,CHEMBL629631,6698,,,,,U,Autocuration,BAO_0000019
14769,,0,B,,1,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,22224,,,,CHEMBL629632,6698,,,,,U,Autocuration,BAO_0000019
14770,,0,P,,1,Dissociation constant of compound with Fructose was determined,22224,,,,CHEMBL629633,4318,,,,,U,Autocuration,BAO_0000100
14771,,0,P,,1,Dissociation constant of compound with Fructose was determined; Not determined,22224,,,,CHEMBL629634,4318,,,,,U,Autocuration,BAO_0000100
14772,,0,P,,1,Dissociation constant of compound with Lactulose was determined,22224,,,,CHEMBL629635,4318,,,,,U,Autocuration,BAO_0000100
14773,,0,P,,1,Dissociation constant of compound with Lactulose was determined; Not determined,22224,,,,CHEMBL629636,4318,,,,,U,Autocuration,BAO_0000100
14774,,0,P,,1,Dissociation constant of the Compound,22224,,,,CHEMBL629637,14959,,,,,U,Autocuration,BAO_0000100
14775,,0,P,,1,Dissociation constant by non-linear regression analysis,22224,,,,CHEMBL629638,5913,,,,,U,Autocuration,BAO_0000100
14776,,0,P,,1,Dissociation constant was determined,22224,,,,CHEMBL629639,14218,,,,,U,Autocuration,BAO_0000100
14777,,0,P,,1,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,22224,,,,CHEMBL629640,10689,,,,,U,Autocuration,BAO_0000100
14778,,0,P,,1,Dissociation constant was determined,22224,,,,CHEMBL629641,13925,,,,,U,Autocuration,BAO_0000100
14779,,0,P,,1,Dissociation constant was determined,22224,,,,CHEMBL631344,16359,,,,,U,Autocuration,BAO_0000100
14780,Rattus norvegicus,1,A,,1,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,50597,10116.0,,,CHEMBL631345,10944,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14781,,0,A,,1,The dissociation constant determined by fluorescence displacement assay,22224,,,,CHEMBL631346,11080,,,,,U,Autocuration,BAO_0000019
14782,,0,A,,1,kd value surface plasmon resonance (SPR) method,22224,,,,CHEMBL631524,17805,,,,,U,Autocuration,BAO_0000019
14783,Rattus norvegicus,1,A,,1,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,50597,10116.0,,,CHEMBL631525,10944,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14784,,0,F,,1,First dissociation constant of the binding of compound to V30M TTR,22224,,,,CHEMBL631526,16645,,,,,U,Autocuration,BAO_0000019
14785,,0,F,,1,Second dissociation constant of the binding of compound to V30M TTR,22224,,,,CHEMBL631527,16645,,,,,U,Autocuration,BAO_0000019
14786,,0,A,,1,"Compound was evaluated for equilibrium constant, Ke",22224,,,,CHEMBL631528,7793,,,,,U,Autocuration,BAO_0000019
14787,,0,A,,1,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,22224,,,,CHEMBL631529,12199,1898.0,,,Hypothalamus,U,Autocuration,BAO_0000019
14788,,0,A,,1,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,22224,,,,CHEMBL631530,12199,1898.0,,,Hypothalamus,U,Autocuration,BAO_0000019
14789,,0,A,,1,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,,CHEMBL631531,9680,,,,,U,Autocuration,BAO_0000019
14790,,0,A,,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,,CHEMBL631532,9680,,,,,U,Autocuration,BAO_0000019
14791,,0,A,,1,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,,CHEMBL631533,9680,,,,,U,Autocuration,BAO_0000019
14792,Mus musculus,1,A,,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,10090.0,,,CHEMBL876552,13758,,,,,N,Intermediate,BAO_0000218
14793,Mus musculus,1,A,,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,50594,10090.0,,,CHEMBL631534,13758,,,,,N,Intermediate,BAO_0000218
14794,Mus musculus,1,A,,1,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,10090.0,,,CHEMBL631535,13758,,,,,N,Intermediate,BAO_0000218
14795,Mus musculus,1,A,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,10090.0,,,CHEMBL631536,13758,,,,,N,Intermediate,BAO_0000218
14796,Mus musculus,1,A,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,50594,10090.0,,,CHEMBL631537,13758,,,,,N,Intermediate,BAO_0000218
14797,Mus musculus,1,A,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,50594,10090.0,,,CHEMBL631538,13758,,,,,N,Intermediate,BAO_0000218
14798,Mus musculus,1,A,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,50594,10090.0,,,CHEMBL631539,13758,,,,,N,Intermediate,BAO_0000218
14799,Mus musculus,1,A,,1,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,10090.0,,,CHEMBL631540,13758,,,,,N,Intermediate,BAO_0000218
14800,Rattus norvegicus,1,A,,1,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,10116.0,,,CHEMBL625637,14393,,,,,N,Intermediate,BAO_0000218
14801,Rattus norvegicus,1,A,,1,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,10116.0,,,CHEMBL625638,14393,,,,,N,Intermediate,BAO_0000218
14802,Rattus norvegicus,1,A,,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,10116.0,,,CHEMBL625639,15078,,,,,N,Intermediate,BAO_0000218
14803,Rattus norvegicus,1,A,,1,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625640,13925,955.0,,,Brain,N,Intermediate,BAO_0000218
14804,Rattus norvegicus,1,A,,1,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625641,13925,955.0,,,Brain,N,Intermediate,BAO_0000218
14805,Rattus norvegicus,1,A,,1,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625642,13925,948.0,,,Heart,N,Intermediate,BAO_0000218
14806,Rattus norvegicus,1,A,,1,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625643,13925,948.0,,,Heart,N,Intermediate,BAO_0000218
14807,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625644,13925,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14808,Rattus norvegicus,1,A,,1,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625645,13925,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14809,Rattus norvegicus,1,A,,1,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625646,13925,2107.0,,,Liver,N,Intermediate,BAO_0000218
14810,Rattus norvegicus,1,A,,1,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625647,13925,2107.0,,,Liver,N,Intermediate,BAO_0000218
14811,Rattus norvegicus,1,A,,1,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625648,13925,2048.0,,,Lung,N,Intermediate,BAO_0000218
14812,Rattus norvegicus,1,A,,1,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625649,13925,2048.0,,,Lung,N,Intermediate,BAO_0000218
14813,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625650,13925,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14814,Rattus norvegicus,1,A,,1,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625651,13925,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14815,Rattus norvegicus,1,A,,1,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625652,13925,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
14816,Rattus norvegicus,1,A,,1,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625653,13925,14.0,,,Zone of skin,N,Intermediate,BAO_0000218
14817,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625654,13925,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14818,Rattus norvegicus,1,A,,1,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,10116.0,,,CHEMBL625655,13925,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14819,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat blood after 15 minutes of administration,50597,10116.0,,,CHEMBL625656,9712,178.0,,,Blood,N,Intermediate,BAO_0000218
14820,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat blood after 2 minutes of administration,50597,10116.0,,,CHEMBL625657,9712,178.0,,,Blood,N,Intermediate,BAO_0000218
14821,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat brain after 15 minutes of administration,50597,10116.0,,,CHEMBL625658,9712,955.0,,,Brain,N,Intermediate,BAO_0000218
14822,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat brain after 2 minutes of administration,50597,10116.0,,,CHEMBL625659,9712,955.0,,,Brain,N,Intermediate,BAO_0000218
14823,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat heart after 15 minutes of administration,50597,10116.0,,,CHEMBL625660,9712,948.0,,,Heart,N,Intermediate,BAO_0000218
14824,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat heart after 2 minutes of administration,50597,10116.0,,,CHEMBL625661,9712,948.0,,,Heart,N,Intermediate,BAO_0000218
14825,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat liver after 15 minutes of administration,50597,10116.0,,,CHEMBL625662,9712,2107.0,,,Liver,N,Intermediate,BAO_0000218
14826,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat liver after 2 minutes of administration,50597,10116.0,,,CHEMBL625663,9712,2107.0,,,Liver,N,Intermediate,BAO_0000218
14827,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat lung after 15 minutes of administration,50597,10116.0,,,CHEMBL875621,9712,2048.0,,,Lung,N,Intermediate,BAO_0000218
14828,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat lung after 2 minutes of administration,50597,10116.0,,,CHEMBL628382,9712,2048.0,,,Lung,N,Intermediate,BAO_0000218
14829,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat muscle after 15 minutes of administration,50597,10116.0,,,CHEMBL628383,9712,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14830,Rattus norvegicus,1,A,,1,Biodistribution of Compound in rat muscle after 2 minutes of administration,50597,10116.0,,,CHEMBL628384,9712,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14831,Rattus norvegicus,1,A,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,50597,10116.0,,,CHEMBL628385,13925,,,,,N,Intermediate,BAO_0000218
14832,Rattus norvegicus,1,A,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,50597,10116.0,,,CHEMBL875753,13925,,,,,N,Intermediate,BAO_0000218
14833,Rattus norvegicus,1,A,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,50597,10116.0,,,CHEMBL628386,13925,,,,,N,Intermediate,BAO_0000218
14834,Rattus norvegicus,1,A,,1,Organ distribution in rat blood 2 minutes after intravenous injection,50597,10116.0,,,CHEMBL628387,6941,,,,,N,Intermediate,BAO_0000218
14835,Rattus norvegicus,1,A,,1,Organ distribution in rat blood 2 hr after intravenous injection,50597,10116.0,,,CHEMBL628388,6941,,,,,N,Intermediate,BAO_0000218
14836,Rattus norvegicus,1,A,,1,Organ distribution in rat blood 30 minutes after intravenous injection,50597,10116.0,,,CHEMBL628389,6941,,,,,N,Intermediate,BAO_0000218
14837,Rattus norvegicus,1,A,,1,Organ distribution in rat blood 30 min after intravenous injection,50597,10116.0,,,CHEMBL632756,6941,,,,,N,Intermediate,BAO_0000218
14838,Rattus norvegicus,1,A,,1,Organ distribution in rat brain 2 minutes after intravenous injection,50597,10116.0,,,CHEMBL628390,6941,,,,,N,Intermediate,BAO_0000218
14839,Rattus norvegicus,1,A,,1,Organ distribution in rat brain 2 hr after intravenous injection,50597,10116.0,,,CHEMBL631811,6941,,,,,N,Intermediate,BAO_0000218
14840,Rattus norvegicus,1,A,,1,Organ distribution in rat brain 30 minutes after intravenous injection,50597,10116.0,,,CHEMBL631812,6941,,,,,N,Intermediate,BAO_0000218
14841,Rattus norvegicus,1,A,,1,Organ distribution in rat heart 2 minutes after intravenous injection,50597,10116.0,,,CHEMBL631813,6941,,,,,N,Intermediate,BAO_0000218
14842,Rattus norvegicus,1,A,,1,Organ distribution in rat heart 2 hr after intravenous injection,50597,10116.0,,,CHEMBL631814,6941,,,,,N,Intermediate,BAO_0000218
14843,Rattus norvegicus,1,A,,1,Organ distribution in rat heart 30 minutes after intravenous injection,50597,10116.0,,,CHEMBL631815,6941,,,,,N,Intermediate,BAO_0000218
14844,Rattus norvegicus,1,A,,1,Organ distribution in rat kidney 2 minutes after intravenous injection,50597,10116.0,,,CHEMBL631816,6941,,,,,N,Intermediate,BAO_0000218
14845,Rattus norvegicus,1,A,,1,Organ distribution in rat kidney 2 hr after intravenous injection,50597,10116.0,,,CHEMBL875758,6941,,,,,N,Intermediate,BAO_0000218
14846,Rattus norvegicus,1,A,,1,Organ distribution in rat kidney 30 minutes after intravenous injection,50597,10116.0,,,CHEMBL631817,6941,,,,,N,Intermediate,BAO_0000218
14847,Rattus norvegicus,1,A,,1,Organ distribution in rat liver 2 minutes after intravenous injection,50597,10116.0,,,CHEMBL631818,6941,2107.0,,,Liver,N,Intermediate,BAO_0000218
14848,Rattus norvegicus,1,A,,1,Organ distribution in rat liver 2 hr after intravenous injection,50597,10116.0,,,CHEMBL631819,6941,2107.0,,,Liver,N,Intermediate,BAO_0000218
14849,Rattus norvegicus,1,A,,1,Organ distribution in rat liver 30 minutes after intravenous injection,50597,10116.0,,,CHEMBL631820,6941,2107.0,,,Liver,N,Intermediate,BAO_0000218
14850,Rattus norvegicus,1,A,,1,Organ distribution in rat lung 2 minutes after intravenous injection,50597,10116.0,,,CHEMBL631821,6941,,,,,N,Intermediate,BAO_0000218
14851,Rattus norvegicus,1,A,,1,Organ distribution in rat lung 2 hr after intravenous injection,50597,10116.0,,,CHEMBL631822,6941,,,,,N,Intermediate,BAO_0000218
14852,Rattus norvegicus,1,A,,1,Organ distribution in rat lung 30 minutes after intravenous injection,50597,10116.0,,,CHEMBL631823,6941,,,,,N,Intermediate,BAO_0000218
14853,Rattus norvegicus,1,A,,1,Organ distribution in rat muscle 2 minutes after intravenous injection,50597,10116.0,,,CHEMBL631824,6941,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14854,Rattus norvegicus,1,A,,1,Organ distribution in rat muscle 2 hr after intravenous injection,50597,10116.0,,,CHEMBL631825,6941,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14855,Rattus norvegicus,1,A,,1,Organ distribution in rat muscle 30 minutes after intravenous injection,50597,10116.0,,,CHEMBL631826,6941,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14856,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),50594,10090.0,,,CHEMBL631827,14439,,,,,N,Intermediate,BAO_0000218
14857,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),50594,10090.0,,,CHEMBL631828,14439,,,,,N,Intermediate,BAO_0000218
14858,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),50594,10090.0,,,CHEMBL631829,14439,,,,,N,Intermediate,BAO_0000218
14859,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,10116.0,,,CHEMBL875759,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14860,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,50597,10116.0,,,CHEMBL631830,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14861,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,50597,10116.0,,,CHEMBL631831,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14862,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,10116.0,,,CHEMBL631832,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14863,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,50597,10116.0,,,CHEMBL631833,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14864,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,10116.0,,,CHEMBL631834,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14865,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,50597,10116.0,,,CHEMBL631835,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14866,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,10116.0,,,CHEMBL631836,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14867,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,10116.0,,,CHEMBL631837,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14868,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,10116.0,,,CHEMBL631838,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14869,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,50597,10116.0,,,CHEMBL631839,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14870,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,50597,10116.0,,,CHEMBL631840,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14871,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,10116.0,,,CHEMBL631841,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14872,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,10116.0,,,CHEMBL631842,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14873,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,10116.0,,,CHEMBL631843,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14874,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,10116.0,,,CHEMBL631844,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14875,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,10116.0,,,CHEMBL631845,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14876,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,10116.0,,,CHEMBL631846,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14877,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,10116.0,,,CHEMBL875760,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14878,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,10116.0,,,CHEMBL632199,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14879,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,10116.0,,,CHEMBL631847,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14880,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,10116.0,,,CHEMBL631848,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14881,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,10116.0,,,CHEMBL628707,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14882,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,10116.0,,,CHEMBL628708,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14883,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,10116.0,,,CHEMBL628709,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14884,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,10116.0,,,CHEMBL628710,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14885,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,10116.0,,,CHEMBL628711,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14886,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,10116.0,,,CHEMBL628712,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14887,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,10116.0,,,CHEMBL628713,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14888,Rattus norvegicus,1,A,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,10116.0,,,CHEMBL628714,12582,1088.0,,,Urine,N,Intermediate,BAO_0000218
14889,Rattus norvegicus,1,A,,1,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",50597,10116.0,,,CHEMBL628715,7415,,,,,N,Intermediate,BAO_0000218
14890,,0,A,,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,22224,,,,CHEMBL629179,7313,,,,,U,Autocuration,BAO_0000019
14891,,0,A,,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,22224,,,,CHEMBL629180,7313,,,,,U,Autocuration,BAO_0000019
14892,,0,A,,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,22224,,,,CHEMBL875108,7313,,,,,U,Autocuration,BAO_0000019
14893,,0,A,,1,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,22224,,,,CHEMBL629181,7570,1235.0,,,Adrenal cortex,U,Autocuration,BAO_0000019
14894,,0,A,,1,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,22224,,,,CHEMBL629182,7570,1235.0,,,Adrenal cortex,U,Autocuration,BAO_0000019
14895,,0,A,,1,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,22224,,,,CHEMBL629183,7570,,,,,U,Autocuration,BAO_0000019
14896,,0,A,,1,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,22224,,,,CHEMBL629184,7570,,,,,U,Autocuration,BAO_0000019
14897,,0,A,,1,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,22224,,,,CHEMBL629185,7570,1235.0,,,Adrenal cortex,U,Autocuration,BAO_0000019
14898,,0,A,,1,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,22224,,,,CHEMBL629186,7570,1235.0,,,Adrenal cortex,U,Autocuration,BAO_0000019
14899,,0,A,,1,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,22224,,,,CHEMBL629187,7570,,,,,U,Autocuration,BAO_0000019
14900,,0,A,,1,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,22224,,,,CHEMBL629887,7570,,,,,U,Autocuration,BAO_0000019
14901,,0,A,,1,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,22224,,,,CHEMBL629888,7570,,,,,U,Autocuration,BAO_0000019
14902,,0,A,,1,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,22224,,,,CHEMBL629889,7570,,,,,U,Autocuration,BAO_0000019
14903,,0,A,,1,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,22224,,,,CHEMBL629890,7570,1235.0,,,Adrenal cortex,U,Autocuration,BAO_0000019
14904,,0,A,,1,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,22224,,,,CHEMBL629891,7570,,,,,U,Autocuration,BAO_0000019
14905,,0,A,,1,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,22224,,,,CHEMBL629892,7570,,,,,U,Autocuration,BAO_0000019
14906,,0,A,,1,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,22224,,,,CHEMBL629893,7570,1235.0,,,Adrenal cortex,U,Autocuration,BAO_0000019
14907,,0,A,,1,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,22224,,,,CHEMBL629894,7570,,,,,U,Autocuration,BAO_0000019
14908,,0,A,,1,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,22224,,,,CHEMBL629895,7570,,,,,U,Autocuration,BAO_0000019
14909,Canis lupus familiaris,0,A,,1,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",22224,9615.0,,,CHEMBL875109,14122,,,,,U,Autocuration,BAO_0000218
14910,Macaca fascicularis,0,A,,1,Absolute bioavailability in male cynomolgus monkeys,22224,9541.0,,,CHEMBL629896,16449,,,,,U,Autocuration,BAO_0000218
14911,Rattus norvegicus,0,A,,1,Absolute bioavailability in maleSprague-Dawley rats,22224,10116.0,,,CHEMBL629897,16449,,,,,U,Autocuration,BAO_0000218
14912,Rattus norvegicus,1,A,,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL629898,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14913,Rattus norvegicus,1,A,,1,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630057,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14914,Rattus norvegicus,1,A,,1,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630058,12017,2107.0,,,Liver,N,Intermediate,BAO_0000218
14915,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630059,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14916,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630060,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14917,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630061,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14918,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630062,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14919,Rattus norvegicus,1,A,,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630063,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14920,Rattus norvegicus,1,A,,1,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630064,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14921,Rattus norvegicus,1,A,,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630065,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14922,Rattus norvegicus,1,A,,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630066,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14923,Rattus norvegicus,1,A,,1,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630067,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14924,Rattus norvegicus,1,A,,1,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630068,12017,2048.0,,,Lung,N,Intermediate,BAO_0000218
14925,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631113,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14926,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631114,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14927,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL631115,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14928,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL631116,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14929,Rattus norvegicus,1,A,,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630528,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14930,Rattus norvegicus,1,A,,1,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630529,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14931,Rattus norvegicus,1,A,,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630530,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14932,Rattus norvegicus,1,A,,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630531,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14933,Rattus norvegicus,1,A,,1,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630532,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14934,Rattus norvegicus,1,A,,1,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630533,12017,2385.0,,,Muscle tissue,N,Intermediate,BAO_0000218
14935,Mus musculus,1,A,,1,Biodistribution in normal mice blood after 120 hr,50594,10090.0,,,CHEMBL630534,15045,178.0,,,Blood,N,Intermediate,BAO_0000218
14936,Mus musculus,1,A,,1,Biodistribution in normal mice blood after 24 hr,50594,10090.0,,,CHEMBL630535,15045,178.0,,,Blood,N,Intermediate,BAO_0000218
14937,Mus musculus,1,A,,1,Biodistribution in normal mice blood after 4 hr,50594,10090.0,,,CHEMBL630536,15045,178.0,,,Blood,N,Intermediate,BAO_0000218
14938,Mus musculus,1,A,,1,Biodistribution in normal mice bone after 120 hr,50594,10090.0,,,CHEMBL630537,15045,10000001.0,,,Bone,N,Intermediate,BAO_0000218
14939,Mus musculus,1,A,,1,Biodistribution in normal mice bone after 24 hr,50594,10090.0,,,CHEMBL630538,15045,10000001.0,,,Bone,N,Intermediate,BAO_0000218
14940,Mus musculus,1,A,,1,Biodistribution in normal mice bone after 4 hr,50594,10090.0,,,CHEMBL630539,15045,10000001.0,,,Bone,N,Intermediate,BAO_0000218
14941,Mus musculus,1,A,,1,Biodistribution in normal mice heart after 120 hr,50594,10090.0,,,CHEMBL630540,15045,948.0,,,Heart,N,Intermediate,BAO_0000218
14942,Mus musculus,1,A,,1,Biodistribution in normal mice heart after 24 hr,50594,10090.0,,,CHEMBL630541,15045,948.0,,,Heart,N,Intermediate,BAO_0000218
14943,Mus musculus,1,A,,1,Biodistribution in normal mice heart after 4 hr,50594,10090.0,,,CHEMBL630542,15045,948.0,,,Heart,N,Intermediate,BAO_0000218
14944,Mus musculus,1,A,,1,Biodistribution in normal mice kidney after 120 hr,50594,10090.0,,,CHEMBL630543,15045,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14945,Mus musculus,1,A,,1,Biodistribution in normal mice kidney after 24 hr,50594,10090.0,,,CHEMBL630544,15045,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14946,Mus musculus,1,A,,1,Biodistribution in normal mice kidney after 4 hr,50594,10090.0,,,CHEMBL630545,15045,2113.0,,,Kidney,N,Intermediate,BAO_0000218
14947,Mus musculus,1,A,,1,Biodistribution in normal mice liver after 120 hr,50594,10090.0,,,CHEMBL630546,15045,2107.0,,,Liver,N,Intermediate,BAO_0000218
14948,Mus musculus,1,A,,1,Biodistribution in normal mice liver after 24 hr,50594,10090.0,,,CHEMBL630547,15045,2107.0,,,Liver,N,Intermediate,BAO_0000218
14949,Mus musculus,1,A,,1,Biodistribution in normal mice liver after 4 hr,50594,10090.0,,,CHEMBL630548,15045,2107.0,,,Liver,N,Intermediate,BAO_0000218
14950,Mus musculus,1,A,,1,Biodistribution in normal mice spleen after 120 hr,50594,10090.0,,,CHEMBL630549,15045,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14951,Mus musculus,1,A,,1,Biodistribution in normal mice spleen after 24 hr,50594,10090.0,,,CHEMBL630550,15045,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14952,Mus musculus,1,A,,1,Biodistribution in normal mice spleen after 4 hr,50594,10090.0,,,CHEMBL876426,15045,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14953,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630551,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14954,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630552,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14955,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630553,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14956,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630554,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14957,Rattus norvegicus,1,A,,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630555,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14958,Rattus norvegicus,1,A,,1,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630556,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14959,Rattus norvegicus,1,A,,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630557,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14960,Rattus norvegicus,1,A,,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,10116.0,,,CHEMBL630558,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14961,Rattus norvegicus,1,A,,1,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630559,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14962,Rattus norvegicus,1,A,,1,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL630560,12017,2106.0,,,Spleen,N,Intermediate,BAO_0000218
14963,Rattus norvegicus,1,A,,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,10116.0,,,CHEMBL876427,12017,2046.0,,,Thyroid gland,N,Intermediate,BAO_0000218
14964,Rattus norvegicus,1,A,,1,The Kel values in female wistar rats.,50597,10116.0,,,CHEMBL630561,14941,,,,,N,Intermediate,BAO_0000218
14965,,0,A,,1,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,22224,,,,CHEMBL630562,4646,,,,,U,Autocuration,BAO_0000019
14966,,0,A,,1,Hydrolysis rate constant of the compound,22224,,,,CHEMBL630563,8847,,,,,U,Autocuration,BAO_0000019
14967,,0,P,,1,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,22229,,,,CHEMBL629673,11778,,,,,U,Autocuration,BAO_0000100
14968,,0,A,,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",22224,,,,CHEMBL629674,2363,,,,,U,Autocuration,BAO_0000019
14969,,0,A,,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",22224,,,,CHEMBL629675,2363,,,,,U,Autocuration,BAO_0000019
14970,,0,A,,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",22224,,,,CHEMBL629676,2363,,,,,U,Autocuration,BAO_0000019
14971,,0,A,,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",22224,,,,CHEMBL629677,2363,,,,,U,Autocuration,BAO_0000019
14972,,0,A,,1,Apparent inactivation rate constant was evaluated,22224,,,,CHEMBL629678,8371,,,,,U,Autocuration,BAO_0000019
14973,,0,A,,1,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,22224,,,,CHEMBL629679,14883,,,,,U,Autocuration,BAO_0000019
14974,,0,A,,1,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,22224,,,,CHEMBL629680,14883,,,,,U,Autocuration,BAO_0000019
14975,,0,A,,1,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,22224,,,,CHEMBL629681,4643,,,,,U,Autocuration,BAO_0000019
14976,,0,A,,1,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,22224,,,,CHEMBL629682,3519,,,,,U,Autocuration,BAO_0000019
14977,,0,A,,1,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,22224,,,,CHEMBL629683,10600,,,,,U,Autocuration,BAO_0000019
14978,,0,F,,1,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,22224,,,,CHEMBL629684,8501,,,,,U,Autocuration,BAO_0000019
14979,,0,P,,1,Dissociation constant was determined,22224,,,,CHEMBL629685,8505,,,,,U,Autocuration,BAO_0000100
14980,,0,P,,1,Dissociation constant was determined,22224,,,,CHEMBL629686,9778,,,,,U,Autocuration,BAO_0000100
14981,,0,P,,1,Dissociation constant at pH 7.4,22224,,,,CHEMBL872932,9778,,,,,U,Autocuration,BAO_0000100
14982,,0,P,,1,Dissociation constant in presence of 1 mM dithiothreitol,22224,,,,CHEMBL629687,9778,,,,,U,Autocuration,BAO_0000100
14983,,0,A,,1,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,22224,,,,CHEMBL872931,13007,,,,,U,Autocuration,BAO_0000019
14984,,0,A,,1,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,22224,,,,CHEMBL628151,13007,,,,,U,Autocuration,BAO_0000019
14985,,0,A,,1,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,22224,,,,CHEMBL628152,13007,,,,,U,Autocuration,BAO_0000019
14986,,0,A,,1,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,22224,,,,CHEMBL628153,13007,,,,,U,Autocuration,BAO_0000019
14987,,0,A,,1,Kinetic constant for aromatization of androstenedione,22224,,,,CHEMBL628154,11482,,,,,U,Autocuration,BAO_0000019
14988,,0,A,,1,Kinetic constant for aromatization of testosterone,22224,,,,CHEMBL628155,11482,,,,,U,Autocuration,BAO_0000019
14989,,0,A,,1,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,22224,,,,CHEMBL628156,2303,,,,,U,Autocuration,BAO_0000019
14990,,0,A,,1,Local inhibition constant was determined,22224,,,,CHEMBL628157,11964,,,,,U,Autocuration,BAO_0000019
14991,Saccharomyces cerevisiae,1,A,,1,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,50347,4932.0,,,CHEMBL857533,3140,,,,,N,Intermediate,BAO_0000218
14992,,0,P,,1,Dissociation constant value of the compound,22224,,,,CHEMBL628158,10650,,,,,U,Autocuration,BAO_0000100
14993,,0,A,,1,In vitro permeability through cornea without epithelium,22224,,,,CHEMBL628159,4667,964.0,,,Cornea,U,Autocuration,BAO_0000019
14994,,0,A,,1,In vitro permeability through intact cornea,22224,,,,CHEMBL875616,4667,964.0,,,Cornea,U,Autocuration,BAO_0000019
14995,Oryctolagus cuniculus,1,A,,1,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,50592,9986.0,,,CHEMBL628160,9199,964.0,,,Cornea,N,Intermediate,BAO_0000218
14996,,0,A,,1,Rate of enzyme inactivation for the compound was determined,22224,,,,CHEMBL628161,11966,,,,,U,Autocuration,BAO_0000019
14997,,0,A,,1,In vitro permeability through cornea without epithelium,22224,,,,CHEMBL628162,4667,964.0,,,Cornea,U,Autocuration,BAO_0000019
14998,,0,A,,1,In vitro permeability through intact cornea,22224,,,,CHEMBL628163,4667,964.0,,,Cornea,U,Autocuration,BAO_0000019
14999,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628164,8354,,,,,U,Autocuration,BAO_0000019
15000,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628165,8354,,,,,U,Autocuration,BAO_0000019
15001,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628166,8354,,,,,U,Autocuration,BAO_0000019
15002,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628167,8354,,,,,U,Autocuration,BAO_0000019
15003,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628168,8354,,,,,U,Autocuration,BAO_0000019
15004,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628169,8354,,,,,U,Autocuration,BAO_0000019
15005,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628170,8354,,,,,U,Autocuration,BAO_0000019
15006,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628171,8354,,,,,U,Autocuration,BAO_0000019
15007,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL627434,8354,,,,,U,Autocuration,BAO_0000019
15008,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL627435,8354,,,,,U,Autocuration,BAO_0000019
15009,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628110,8354,,,,,U,Autocuration,BAO_0000019
15010,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628111,8354,,,,,U,Autocuration,BAO_0000019
15011,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628112,8354,,,,,U,Autocuration,BAO_0000019
15012,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628260,8354,,,,,U,Autocuration,BAO_0000019
15013,,0,A,,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,,CHEMBL628261,8354,,,,,U,Autocuration,BAO_0000019
15014,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),50594,10090.0,,,CHEMBL628262,14439,,,,,N,Intermediate,BAO_0000218
15015,Homo sapiens,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,50587,9606.0,,,CHEMBL628263,14439,,,,,N,Intermediate,BAO_0000218
15016,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),50594,10090.0,,,CHEMBL628264,14439,,,,,N,Intermediate,BAO_0000218
15017,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),50594,10090.0,,,CHEMBL628265,14439,,,,,N,Intermediate,BAO_0000218
15018,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),50594,10090.0,,,CHEMBL628266,14439,,,,,N,Intermediate,BAO_0000218
15019,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),50594,10090.0,,,CHEMBL628267,14439,,,,,N,Intermediate,BAO_0000218
15020,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,50594,10090.0,,,CHEMBL628268,14439,,,,,N,Intermediate,BAO_0000218
15021,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),50594,10090.0,,,CHEMBL628269,14439,,,,,N,Intermediate,BAO_0000218
15022,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),50594,10090.0,,,CHEMBL628270,14439,,,,,N,Intermediate,BAO_0000218
15023,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),50594,10090.0,,,CHEMBL628271,14439,,,,,N,Intermediate,BAO_0000218
15024,Mus musculus,1,A,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),50594,10090.0,,,CHEMBL628272,14439,,,,,N,Intermediate,BAO_0000218
